Document

Description

Effective Date

Effect on the financial statements or other significant matters

Accounting Standards Update 2016-02, Leases

This standard was issued to increase transparency and comparability among organizations by recognizing lease assets and lease liabilities, including leases classified as operating leases under current GAAP, on the balance sheet and requiring additional disclosures about leasing arrangements. An entity can apply the new leases standard retrospectively to each prior reporting period presented or with the cumulative effect of initially applying the standard recognized at the date of initial application in retained earnings. We plan to use the latter approach.

This standard was effective January 1, 2019, and we adopted on that date.

We expect to record a right-of-use asset and lease liability for operating leases of approximately $575 million on our consolidated balance sheet as of January 1, 2019. Our accounting for capital leases will remain substantially unchanged. This standard will not have a material impact on our consolidated statement of operations.

0000059478-19-000274.txt : 20191024 0000059478-19-000274.hdr.sgml : 20191024 20191024100012 ACCESSION NUMBER: 0000059478-19-000274 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 119 CONFORMED PERIOD OF REPORT: 20191024 ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20191024 DATE AS OF CHANGE: 20191024 FILER: COMPANY DATA: COMPANY CONFORMED NAME: LILLY ELI & CO CENTRAL INDEX KEY: 0000059478 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 350470950 STATE OF INCORPORATION: IN FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-06351 FILM NUMBER: 191165040 BUSINESS ADDRESS: STREET 1: LILLY CORPORATE CTR STREET 2: DROP CODE 1094 CITY: INDIANAPOLIS STATE: IN ZIP: 46285 BUSINESS PHONE: 3172762000 MAIL ADDRESS: STREET 1: LILLY CORPORATE CENTER STREET 2: DROP CODE 1094 CITY: INDIANAPOLIS STATE: IN ZIP: 46285 8-K 1 a20198-kfor201810xkrec.htm 8-K Document

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

________________

FORM 8-K

Current Report

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

________________

Date of Report (Date of earliest event reported): October 24, 2019

ELI LILLY AND COMPANY

(Exact name of registrant as specified in its charter)



Indiana	001-06351	35-0470950
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(I.R.S. Employer Identification No.)

Lilly Corporate Center

Indianapolis, Indiana 46285

(Address of Principal Executive Offices, and Zip Code)

(317) 276-2000

Registrant’s Telephone Number, Including Area Code

Not Applicable

Former Name or Former Address, if Changed Since Last Report

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Securities registered pursuant to Section 12(b) of the Exchange Act:



Title of Each Class	Trading Symbol	Name of Each Exchange On Which Registered
Common Stock (no par value)	LLY	New York Stock Exchange
1.000% Notes Due June 2, 2022	LLY22	New York Stock Exchange
7 1/8% Notes Due June 1, 2025	LLY25	New York Stock Exchange
1.625% Notes Due June 2, 2026	LLY26	New York Stock Exchange
2.125% Notes Due June 3, 2030	LLY30	New York Stock Exchange
6.77% Notes Due January 1, 2036	LLY36	New York Stock Exchange

Item 8.01 Other Events

On March 11, 2019, we completed the disposition of our remaining 80.2 percent ownership of Elanco Animal Health (Elanco) common stock through a tax-free exchange offer. As a result, beginning in our Quarterly Report on Form 10-Q for the first quarter of 2019, we presented Elanco as discontinued operations in our consolidated condensed financial statements for all periods presented. We are issuing this Current Report on Form 8-K to recast Elanco as discontinued operations as of and for each of the periods covered by our 2018 Annual Report on Form 10-K (Form 10-K).

Exhibit 99.1 of this current report on Form 8-K, which is incorporated herein by reference, presents a recast of the following sections of our Form 10-K to present Elanco as discontinued operations: Item 6. Selected Financial Data, Item 7. Management's Discussion and Analysis of Results of Operations and Financial Condition, Item 7A. Quantitative and Qualitative Disclosures About Market Risk, and Item 8. Financial Statements and Supplementary Data. Except as specifically set forth herein, no revisions have been made to the Company's Form 10-K to update for other information, developments, or events that have occurred since our Form 10-K was filed on February 19, 2019.

This Current Report on Form 8-K should be read in conjunction with our Form 10-K and subsequent filings with the Securities and Exchange Commission (SEC), including our Quarterly Reports on Form 10-Q and our Current Reports on Form 8-K. These subsequent SEC filings contain important information regarding events, developments, and updates affecting us and our expectations that have occurred since the filing of the Form 10-K.

We are also providing the following update regarding Trulicity. Revenue of Trulicity, a treatment for type 2 diabetes, increased 17 percent and 24 percent in the United States (U.S.) during the three and nine months ended September 30, 2019, respectively, primarily driven by increased demand, partially offset by lower realized prices resulting from the following negative price dynamics: higher contracted rebates, changes in segment mix, and increased coverage gap funding requirements in Medicare Part D. We expect these negative price dynamics to moderate by the end of 2019 and into 2020. Revenue outside the U.S. increased 50 percent and 45 percent during the three and nine months ended September 30, 2019, respectively, primarily driven by increased volume.

This Current Report on Form 8-K contains management’s current intentions and expectations for the future, which are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Actual results may differ materially due to various factors, including due to competitive developments affecting current products and the impact of actions of governmental and private payers affecting the pricing of, reimbursement for, and access to pharmaceuticals. For additional information, refer to our latest Form 10-K and 10-Q and any 8-Ks filed with the SEC. You should not place undue reliance on forward-looking statements, which speak only as of the date of this report. Except as is required by law, we expressly disclaim any obligation to publicly release any revisions to forward-looking statements to reflect events after the date of this report.

Item 9.01. Financial Statements and Exhibits

(d) Exhibits. The following Exhibits are filed as part of this Report on Form 8-K:



Exhibit Number			Description of Exhibit
23.1			Consent of Independent Registered Public Accounting Firm
99.1			Recast of Eli Lilly and Company's Selected Financial Data, Consolidated Financial Statements and notes thereto as of December 31, 2018 and for each of the years ended December 31, 2018, 2017, and 2016, and the related Management's Discussion and Analysis of Results of Operations and Financial Condition.
101			Interactive Data Files (embedded within the Inline XBRL document)
104			Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

ELI LILLY AND COMPANY

(Registrant)

By: /s/ Donald A. Zakrowski

Name: Donald A. Zakrowski

Title: Vice President, Finance and

Chief Accounting Officer

Dated: October 24, 2019

EX-23.1 2 ex-231xeyconsent.htm CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM Exhibit

Exhibit 23.1

Consent of Independent Registered Public Accounting Firm

We consent to the incorporation by reference in the Registration Statements (Form S-3 ASR No. 333-229735; and Form S-8 Nos. 333-104057 and 333-172422) of Eli Lilly and Company and in the related Prospectus of our report dated February 19, 2019 (except for the effects of discontinued operations discussed in Note 20, as to which the date is October 24, 2019), with respect to the consolidated financial statements of Eli Lilly and Company and subsidiaries and our report dated February 19, 2019, with respect to the effectiveness of internal control over financial reporting of Eli Lilly and Company and subsidiaries, included in this Current Report on Form 8-K.

/s/ Ernst and Young LLP

Indianapolis, Indiana

October 24, 2019

EX-99.1 3 ex-991xllyx20181231x10.htm EXHIBIT 99.1 Exhibit

Exhibit 99.1

The information provided in each Item contained in this Exhibit is presented only in connection with the reporting changes described in the accompanying Current Report on Form 8-K. It does not reflect information, developments, or events occurring after February 19, 2019, the date on which we filed our Form 10-K, and does not update the disclosures therein in any way other than as required to reflect Elanco as discontinued operations. Accordingly, this Current Report on Form 8-K should be read in conjunction with our Form 10-K and subsequent filings with the SEC, including our Quarterly Reports on Form 10-Q.

Item 6. Selected Financial Data (unaudited)



ELI LILLY AND COMPANY AND SUBSIDIARIES (Dollars in millions, except revenue per employee and per-share data)	2018			2017			2016			2015			2014
Operations
Revenue	$	21,493.3		$	19,973.8		$	18,312.8		$	17,050.5		$	17,553.2
Cost of sales	4,681.7			4,447.7			4,160.5			3,373.1			3,957.0
Research and development	5,051.2			5,096.2			5,040.0			4,514.2			4,528.7
Marketing, selling, and administrative	5,975.1			5,982.4			5,841.9			5,732.4			6,146.0
Other⁽¹⁾	2,105.2			2,142.7			(5.9		)	538.9			288.2
Income before income taxes	3,680.1			2,304.8			3,276.3			2,891.9			2,633.3
Income taxes⁽²⁾	529.5			2,391.2			551.4			379.7			480.9
Net income (loss) from continuing operations	3,150.6			(86.4		)	2,724.9			2,512.2			2,152.4
Net income (loss) from discontinued operations	81.4			(117.7		)	12.7			(103.8		)	238.1
Net income (loss)	3,232.0			(204.1		)	2,737.6			2,408.4			2,390.5
Net income (loss) from continuing operations as a percent of revenue	14.7		%	(0.4		)%	14.9		%	14.7		%	12.3		%
Net income (loss) per share from continuing operations—diluted	$	3.05		$	(0.08	)	$	2.57		$	2.36		$	2.01
Net income (loss) per share from discontinued operations—diluted	0.08			(0.11		)	0.01			(0.10		)	0.22
Net income (loss) per share—diluted	3.13			(0.19		)	2.58			2.26			2.23
Dividends declared per share	2.33			2.12			2.05			2.01			1.97
Weighted-average number of shares outstanding—diluted (thousands)	1,033,667			1,052,023			1,061,825			1,065,720			1,074,286

Financial Position
Current assets	$	20,549.6		$	19,202.1		$	15,101.4		$	12,573.6		$	11,928.3
Current liabilities	11,888.1			14,535.9			10,986.6			8,229.6			9,741.0
Property and equipment—net	7,996.1			7,885.1			7,492.6			7,216.4			7,274.0
Total assets	43,908.4			44,981.0			38,805.9			35,568.9			36,307.6
Long-term debt	9,196.4			9,940.0			8,367.4			7,971.4			5,330.7
Total equity	10,909.1			11,667.9			14,080.5			14,590.3			15,388.1

Supplementary Data
Return on total equity	25.7		%	(1.5		)%	18.5		%	16.1		%	13.7		%
Return on assets	7.3		%	(0.5		)%	7.5		%	6.8		%	6.8		%
Capital expenditures	$	1,210.6		$	1,076.8		$	1,037.0		$	1,066.2		$	1,162.6
Depreciation and amortization	1,609.0			1,567.3			1,496.6			1,427.7			1,379.0
Effective tax rate⁽²⁾	14.4		%	103.7		%	16.8		%	13.1		%	18.3		%
Revenue per employee	$	650,000		$	575,000		$	510,000		$	490,000		$	477,000
Number of employees	33,090			34,750			35,910			34,790			36,765
Number of shareholders of record	24,000			25,300			26,800			28,000			29,300

⁽¹⁾Other includes acquired in-process research and development, asset impairment, restructuring, and other special charges, and other—net, (income) expense; See Note 3 to the consolidated financial statements for discussion regarding in-process research and development charges; See Note 5 to the consolidated financial statements for discussion regarding asset impairment, restructuring, and other special charges.

⁽²⁾See Note 13 to the consolidated financial statements for discussion regarding income taxes.


Item 7.	Management’s Discussion and Analysis of Results of Operations and Financial Condition

RESULTS OF OPERATIONS

(Tables present dollars in millions, except per-share data)

General

Management’s discussion and analysis of results of operations and financial condition is intended to assist the reader in understanding and assessing significant changes and trends related to the results of operations and financial position of our consolidated company. This discussion and analysis should be read in conjunction with the consolidated financial statements and accompanying footnotes included herein. Certain statements in this Item 7 constitute forward-looking statements. Various risks and uncertainties, including those discussed in "Forward-Looking Statements" and Item 1A, “Risk Factors” in Part I of our Form 10-K, may cause our actual results, financial position, and cash generated from operations to differ materially from these forward-looking statements.

Executive Overview

This section provides an overview of our financial results, recent product and late-stage pipeline developments, and other matters affecting our company and the pharmaceutical industry. Earnings per share data are presented on a diluted basis.

Financial Results

The following table summarizes our key operating results:



	Year Ended December 31,						Percent Change
	2018			2017			Percent Change
Revenue	$	21,493.3		$	19,973.8		8
Gross margin	16,811.6			15,526.1			8
Gross margin as a percent of revenue	78.2		%	77.7		%
Operating expense	$	11,026.3		$	11,078.6		—
Acquired in-process research and development	1,983.9			1,112.6			78
Asset impairment, restructuring, and other special charges	266.9			1,331.6			(80)
Income before income taxes	3,680.1			2,304.8			60
Income taxes	529.5			2,391.2			(78)
Net income (loss) from continuing operations	3,150.6			(86.4		)	NM
Net income (loss) from discontinued operations	81.4			(117.7		)	NM
Net income	3,232.0			(204.1		)	NM
Earnings (loss) per share from continuing operations	3.05			(0.08		)	NM
Earnings (loss) per share from discontinued operations	0.08			(0.11		)	NM
Earnings (loss) per share	3.13			(0.19		)	NM

NM - not meaningful

Revenue and gross margin increased in 2018. Income before income taxes increased in 2018 as a higher gross margin, lower asset impairment, restructuring, and other special charges were partially offset by higher acquired in-process research and development (IPR&D) charges. Income taxes decreased in 2018 as we recognized an income tax benefit primarily related to measurement period adjustments to the one-time repatriation transition tax (also known as the ‘Toll Tax’) and the global intangible low-taxed income (GILTI) provision due to the Tax Cuts and Jobs Act (2017 Tax Act).

The following highlighted items affect comparisons of our 2018 and 2017 financial results:

2018

Acquired IPR&D (Note 3 to the consolidated financial statements)


•	We recognized acquired IPR&D charges of $1.98 billion primarily related to the acquisition of ARMO Biosciences Inc. (ARMO) and the collaboration with Dicerna Pharmaceuticals (Dicerna).

Asset Impairment, Restructuring, and Other Special Charges (Note 5 to the consolidated financial statements)


•	We recognized charges of $266.9 million primarily associated with asset impairments related to the sale of the Posilac^® (rbST) brand and the related sale of the Augusta, Georgia manufacturing site and with expenses related to our efforts to reduce our cost structure.

Income Tax Expense (Note 13 to the consolidated financial statements)


•	We recognized $313.3 million of income tax benefit primarily due to measurement period adjustments to the Toll Tax and GILTI.

2017

Acquired IPR&D (Note 3 to the consolidated financial statements)


•	We recognized acquired IPR&D charges of $1.11 billion primarily related to the acquisition of CoLucid Pharmaceuticals, Inc. (CoLucid).

Asset Impairment, Restructuring, and Other Special Charges (Note 5 to the consolidated financial statements).


•	We recognized charges of $1.33 billion primarily associated with efforts to reduce our cost structure, including the United States (U.S.) voluntary early retirement program.

Income Tax Expense (Note 13 to the consolidated financial statements)


•	We recognized a provisional tax expense of $1.91 billion due to the 2017 Tax Act.

Late-Stage Pipeline

Our long-term success depends to a great extent on our ability to continue to discover and develop innovative pharmaceutical products and acquire or collaborate on molecules currently in development by other biotechnology or pharmaceutical companies. We currently have approximately 45 potential new drugs in human testing or under regulatory review and a larger number of projects in preclinical research.

The following new molecular entities (NMEs) have been approved by regulatory authorities in at least one of the major geographies for use in the diseases described. The first quarter in which each NME initially was approved in any major geography for any indication is shown in parentheses:

Abemaciclib (Verzenio^®) (Q3 2017)—a small molecule cell-cycle inhibitor, selective for cyclin-dependent kinases 4 and 6 for the treatment of metastatic breast cancer.

Baricitinib (Olumiant^®) (Q1 2017)—a Janus tyrosine kinase (JAK) inhibitor for the treatment of moderate-to-severe active rheumatoid arthritis (in collaboration with Incyte Corporation).

Galcanezumab* (Emgality^®) (Q3 2018)—a once-monthly subcutaneously injected calcitonin gene-related peptide (CGRP) antibody for the treatment of migraine prevention. Refer to Item 3, "Legal Proceedings - Other Patent Litigation" in Part I of our Form 10-K for discussion of the lawsuit filed by Teva Pharmaceuticals International GMBH.

The following NME had received advanced approval by regulatory authorities in at least one of the major geographies for use in the diseases described, however in January 2019 we announced the phase III trial did not meet the primary endpoint of overall survival. As the trial did not confirm clinical benefit, we are suspending promotion and are working with global regulators to determine the appropriate next steps:

Olaratumab* (Lartruvo^®) (Q4 2016)—a lgG1 monoclonal antibody for the treatment of advanced soft tissue sarcoma. See the "Results of Operations - Executive Overview - Other Matters" for more information.

The following NMEs have been submitted for regulatory review in at least one of the major geographies for potential use in the disease described. The first quarter in which each NME initially was submitted in any major geography for any indication is shown in parentheses:

Lasmiditan (Q4 2018)—an oral 5-HT_1F agonist for the acute treatment of migraine. In the U.S., Lasmiditan is protected by a compound patent (2025).

Nasal glucagon* (Q2 2018)—a glucagon nasal powder formulation for the treatment of severe hypoglycemia in patients with diabetes treated with insulin. In the U.S., nasal glucagon is protected by a delivery device patent (2034), with data protection (3.5 years) expected upon approval. In Europe, nasal glucagon is protected by a delivery device patent (2034), with data protection (6 years) expected upon approval.

The following NMEs and diagnostic agent are currently in Phase III clinical trial testing for potential use in the diseases described but have not yet been submitted for approval for any indication. The first quarter in which each NME and the diagnostic agent initially entered Phase III for any indication is shown in parentheses:

Flortaucipir** (Q3 2015)—a positron emission tomography (PET) tracer intended to image tau (or neurofibrillary) tangles in the brain, which are an indicator of Alzheimer's disease.

Mirikizumab* (Q2 2018)—a monoclonal antibody designed for the treatment of autoimmune diseases.

Pegilodecakin* (Q1 2017)—a PEGylated IL-10, which has demonstrated clinical benefit as a single agent, and in combination with both chemotherapy and checkpoint inhibitor therapy, across several tumor types.

Solanezumab* (Q2 2009)—an anti-amyloid beta monoclonal antibody for the treatment of preclinical Alzheimer’s disease.

Tanezumab* (Q3 2008)—an anti-nerve growth factor monoclonal antibody for the treatment of osteoarthritis pain, chronic low back pain, and cancer pain (in collaboration with Pfizer Inc.).

Tirzepatide* (Q4 2018)—a long-acting, combination therapy of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide 1 for the treatment of type 2 diabetes.

Ultra-rapid Lispro* (Q3 2017)—an ultra-rapid insulin for the treatment of type 1 and type 2 diabetes.


*	Biologic molecule subject to the U.S. Biologics Price Competition and Innovation Act


**	Diagnostic agent

The following table reflects the status of the recently approved products, NMEs, and diagnostic agent set forth above, as well as certain other developments to our late-stage pipeline since January 1, 2018:



Compound	Indication	U.S.	Europe	Japan	Developments
Endocrinology
Nasal glucagon	Severe hypoglycemia	Submitted		Phase III	Submitted to U.S. Food and Drug Administration (FDA) in second quarter of 2018. Submitted to European regulatory authorities in third quarter of 2018.
Tirzepatide	Type 2 diabetes	Phase III			Phase III trials were initiated during the fourth quarter of 2018.
Ultra-rapid Lispro	Type 1 and 2 diabetes	Phase III			In the fourth quarter of 2018, announced Phase III trials met primary efficacy endpoint. Submission to regulatory authorities expected in 2019.
Immunology
Mirikizumab	Psoriasis	Phase III			Phase III trials were initiated during the second quarter of 2018.
Mirikizumab	Ulcerative colitis	Phase III			Phase III trial was initiated during the second quarter of 2018.



Compound	Indication	U.S.	Europe	Japan	Developments
Olumiant	Rheumatoid arthritis	Launched			Granted approval of 2mg dose by FDA and launched in U.S. in second quarter of 2018.
	Atopic dermatitis	Phase III			In the first quarter of 2019, announced Phase III trials met primary endpoint. Additional Phase III trials are ongoing.
	Systemic lupus erythematosus	Phase III			Phase III trials were initiated during the third quarter of 2018. Granted Fast Track designation⁽¹⁾ from the FDA in fourth quarter of 2018.
Neuroscience
Emgality	Cluster headache	Submitted		Phase III	In the second quarter of 2018, announced Phase III trial met primary endpoint for episodic cluster headache. Received Breakthrough Therapy Designation⁽²⁾in the third quarter of 2018. Submitted to FDA in fourth quarter of 2018 and to European regulatory authorities in first quarter of 2019. Granted Priority Review⁽³⁾ from FDA in first quarter of 2019. A separate Phase III trial did not meet primary endpoint for chronic cluster headache.
Emgality	Migraine prevention	Launched		Phase III	Approved and launched in the U.S. in the third and fourth quarters of 2018, respectively. Approved and launched in Europe in the fourth quarter of 2018 and first quarter of 2019, respectively.
Flortaucipir	Alzheimer's disease	Phase III			In the third quarter of 2018, announced Phase III trial met primary endpoints. In discussions with regulatory authorities to determine next steps.
Lanabecestat	Early and mild Alzheimer's disease	Discontinued			Phase III trials discontinued in second quarter of 2018.
Lasmiditan	Migraine	Submitted	Phase III		Submitted to FDA in fourth quarter of 2018. Phase III trials are ongoing.
Solanezumab	Preclinical Alzheimer's disease	Phase III			Phase III trial is ongoing.
Tanezumab	Osteoarthritis pain	Phase III			In the third quarter of 2018 and the first quarter of 2019, announced multiple Phase III trials met primary endpoints. We anticipate additional readouts from the program to be available in 2019.
	Chronic low back pain	Phase III			In the first quarter of 2019, announced Phase III trial met primary endpoint for the 10mg dose and did not meet primary endpoint on the 5mg dose. We anticipate additional readouts from the program to be available in 2019.
	Cancer pain	Phase III			Phase III trial is ongoing.



Compound	Indication	U.S.	Europe	Japan	Developments
Oncology
Lartruvo	Soft tissue sarcoma	Launched		Phase III	Granted accelerated approval by the FDA based on Phase II data and launched in the U.S. in 2016. Granted conditional approval and launched in Europe in 2016. In the first quarter of 2019, announced confirmatory phase III trial did not meet primary endpoint. As trial did not confirm clinical benefit, we are suspending promotion and are in discussions with global regulators to determine next steps.
Pegilodecakin	Pancreatic cancer	Phase III			Acquired with ARMO in the second quarter of 2018. Phase III trial is ongoing. See Note 3 to the consolidated financial statements for information on the acquisition.
Verzenio	Adjuvant breast cancer	Phase III			Phase III trial is ongoing.
Verzenio	Metastatic breast cancer	Launched	Approved		Approved in Europe and Japan in the fourth quarter of 2018.

⁽¹⁾The FDA's fast track designation is designed to expedite the development and review of new therapies to treat serious conditions and address unmet medical needs.

⁽²⁾The Breakthrough Therapy Designation is designed to expedite the development and review of potential medicines that are intended to treat a serious condition where preliminary clinical evidence indicates that the treatment may demonstrate substantial improvement over available therapy on a clinically significant endpoint.

⁽³⁾ Priority Review is designed to expedite the review of potential medicines that, if approved, would be significant improvements in the safety or effectiveness of the treatment, diagnosis, or prevention of serious conditions when compared to standard applications.

There are many difficulties and uncertainties inherent in human pharmaceutical research and development and the introduction of new products. There is a high rate of failure inherent in new drug discovery and development. To bring a drug from the discovery phase to market can take over a decade and often costs in excess of $2 billion. Failure can occur at any point in the process, including in later stages after substantial investment. As a result, most funds invested in research programs will not generate financial returns. New product candidates that appear promising in development may fail to reach the market or may have only limited commercial success because of efficacy or safety concerns, inability to obtain or maintain necessary regulatory approvals or payer reimbursement or coverage, limited scope of approved uses, changes in the relevant treatment standards or the availability of new or better competitive products, difficulty or excessive costs to manufacture, or infringement of the patents or intellectual property rights of others. Regulatory agencies continue to establish increasingly high hurdles for the efficacy and safety of new products. Delays and uncertainties in drug approval processes can result in delays in product launches and lost market opportunity. In addition, it can be very difficult to predict revenue growth rates of new products.

We manage research and development spending across our portfolio of molecules, and a delay in, or termination of, any one project will not necessarily cause a significant change in our total research and development spending. Due to the risks and uncertainties involved in the research and development process, we cannot reliably estimate the nature, timing, and costs of the efforts necessary to complete the development of our research and development projects, nor can we reliably estimate the future potential revenue that will be generated from a successful research and development project. Each project represents only a portion of the overall pipeline, and none is individually material to our consolidated research and development expense. While we do accumulate certain research and development costs on a project level for internal reporting purposes, we must make significant cost estimations and allocations, some of which rely on data that are neither reproducible nor validated through accepted control mechanisms. Therefore, we do not have sufficiently reliable data to report on total research and development costs by project, by preclinical versus clinical spend, or by therapeutic category.

Other Matters

Elanco Animal Health

On September 24, 2018, Elanco Animal Health Incorporated (Elanco), a subsidiary, completed its IPO of 72.3 million shares of its common stock, which represents 19.8 percent of Elanco's outstanding shares, at $24 per share. In addition, Elanco completed a debt offering and entered into a term loan facility during the third quarter of 2018. See Note 20 to the consolidated financial statements for additional details.

On March 11, 2019, we completed the disposition of our remaining 293.3 million shares of Elanco common stock, which represented 80.2 percent ownership of Elanco's outstanding shares, through a tax-free exchange offer. As a result, in the first quarter of 2019, we presented Elanco as discontinued operations in our consolidated condensed financial statements. Accordingly, all prior periods have been recast to conform to this presentation.

Lartruvo

In January 2019, we announced that we are suspending promotion of Lartruvo because the ANNOUNCE study did not meet the primary endpoint of overall survival. We are working with global regulators to determine the appropriate next steps. We expect to incur a charge in the first quarter of 2019 related to the suspension of promotion for Lartruvo. The exact amount of the charge has not yet been determined, but is estimated to be approximately $80 million (pre-tax), or approximately $0.13 per share (after tax). Revenue related to Lartruvo was $304.7 million in 2018.

Patent Matters

We depend on patents or other forms of intellectual-property protection for most of our revenue, cash flows, and earnings.

We lost patent exclusivity for the bipolar mania indication for Zyprexa^® in Japan in April 2016. Generic versions of Zyprexa launched in Japan in June 2016. The loss of exclusivity for Zyprexa in Japan has caused a rapid and severe decline in revenue for the product.

We lost our patent exclusivity for Strattera^® in the U.S. in May 2017, and generic versions of Strattera were approved in the same month. Following a settlement related to the compound patent challenge for Effient^®, generic products launched in the U.S. in the third quarter of 2017. The entry of generic competition for these products has caused a rapid and severe decline in revenue, which, in the aggregate, has had a material adverse effect on our consolidated results of operations and cash flows.

Our compound patent protection for Cialis^® (tadalafil) and Adcirca^® (tadalafil) expired in major European markets and the U.S. in November 2017; however, in the U.S., we were granted pediatric exclusivity through May 2018. Pursuant to a settlement agreement related to our unit dose patent in the U.S., generic tadalafil entered the U.S. market in September 2018. We expect that the entry of additional generic competition into these markets following the loss of exclusivity will continue to cause a rapid and severe decline in revenue, which will, in the aggregate, have a material adverse effect on our consolidated results of operations and cash flows.

Our formulation patents for Forteo^®expired in December 2018 and use patents will expire in August 2019 in major European markets and the U.S. Both the formulation patent and the use patent expire in 2019 in Japan. While it is difficult to estimate the severity of the impact of generic and/or biosimilar competition in these markets, we expect a rapid and severe decline in revenue in the U.S. as a result of generic competition when the U.S. patents expire. Outside the U.S., we expect a decline in revenue following patent expirations; however the decline may not be rapid and severe. In the aggregate, we expect that the decline in revenue will have a material adverse effect on our consolidated results of operations and cash flows.

The Alimta^® vitamin regimen patents, which provide us with patent protection for Alimta through June 2021 in Japan and major European countries, and through May 2022 in the U.S., have been challenged in each of these jurisdictions. Our vitamin regimen patents have also been challenged in other smaller European jurisdictions. Our compound patent for Alimta expired in the U.S. in January 2017, and expired in major European countries and Japan in December 2015. We expect that the entry of generic competition for Alimta following the loss of effective patent protection will cause a rapid and severe decline in revenue for the product, which will, in the aggregate, have a material adverse effect on our consolidated results of operations and cash flows. See Note 15 to the consolidated financial statements for a more detailed account of the legal proceedings currently pending in the U.S., Europe, and Japan regarding our Alimta patents.

The compound patent for Humalog^® (insulin lispro) has expired in major markets. Global regulators have different legal pathways to approve similar versions of insulin lispro. A similar version of insulin lispro launched in the U.S. in the second quarter of 2018 and in certain European markets in 2017. While it is difficult to estimate the severity of the impact of similar insulin lispro products entering the market, we do not expect and have not experienced a rapid and severe decline in revenue; however, we expect additional pricing pressure and some loss of market share that would continue over time.

Foreign Currency Exchange Rates

As a global company with substantial operations outside the U.S., we face foreign currency risk exposure from fluctuating currency exchange rates, primarily the U.S. dollar against the euro and Japanese yen. While we manage a portion of these exposures through hedging and other risk management techniques, significant fluctuations in currency rates can have a substantial impact, either positive or negative, on our revenue, cost of sales, and operating expenses. While there is uncertainty in the future movements in foreign exchange rates, fluctuations in these rates could negatively impact our future consolidated results of operations and cash flows.

The impact of the Venezuelan financial crisis, including the significant deterioration of the bolívar, resulted in a charge of $203.9 million in 2016. See Note 17 to the consolidated financial statements for additional information related to the charge. As of December 31, 2018, our Venezuelan subsidiaries represented a de minimis portion of our consolidated assets and liabilities. We continue to monitor other deteriorating economies and it is possible that additional charges may be recorded in the future. Any additional charges are not expected to have a material adverse effect on our future consolidated results of operations.

Trends Affecting Pharmaceutical Pricing, Reimbursement, and Access

United States

In the U.S., public concern over access to and affordability of pharmaceuticals continues to drive the regulatory and legislative debate. These policy and political issues increase the risk that taxes, fees, rebates, or other cost control measures may be enacted to manage federal and state budgets. Key health policy proposals affecting biopharmaceuticals include a reduction in biologic data exclusivity, modifications to Medicare Parts B and D, language that would allow the Department of Health and Human Services to negotiate prices for biologics and drugs in Medicare, proposals that would require biopharmaceutical manufacturers to disclose proprietary drug pricing information, and state-level proposals related to prescription drug prices and reducing the cost of pharmaceuticals purchased by government health care programs. California and several other states have enacted legislation related to prescription drug pricing transparency and it is unclear the effect this legislation will have on our business. The Bipartisan Budget Act, enacted in February 2018, requires manufacturers of brand-name drugs, biologics, and biosimilars to pay a 70 percent discount in the Medicare Part D Coverage Gap, up from the previous 50 percent discount. This increase in Coverage Gap discounts became effective at the beginning of 2019. We expect this increase in the Coverage Gap discounts to negatively impact our results of operations by approximately $200 million in 2019. In May 2018, the White House released "American Patients First: The Trump Administration Blueprint to Lower Drug Prices and Reduce Out-of-Pocket Costs" (Blueprint). The Administration’s corresponding request for information included more than 30 proposed policy changes. We believe the effect of certain of these proposals would be positive for our business while others would have negative consequences to our business. The effect of these proposals, and those that extend beyond the Blueprint, will depend on the details and timing of the final legislation, regulation, or guidance and could lead to a wide range of outcomes. Some of these outcomes could have a material adverse effect on our consolidated results of operations and cash flows. In January 2019, the Department of Health and Human Services released a proposed rule to reform the system of rebates paid to Medicare Part D plans, Medicaid Managed Care organizations, and pharmacy benefit managers. We are currently reviewing the proposed rule, the impact of which is uncertain at this time.

In the private sector, consolidation and integration among healthcare providers is also a major factor in the competitive marketplace for human pharmaceuticals. Health plans, pharmacy benefit managers, wholesalers, and other supply chain stakeholders have been consolidating into fewer, larger entities, increasingly through vertical integration, thus enhancing their purchasing strength and importance. Payers typically maintain formularies which specify coverage (the conditions under which drugs are included on a plan's formulary) and reimbursement (the associated out-of-pocket cost to the consumer). Formulary placement can lead to reduced usage of a drug for the relevant patient population due to coverage restrictions, such as prior authorizations and formulary exclusions, or due to reimbursement limitations that result in higher consumer out-of-pocket cost, such as non-preferred co-pay tiers, increased co-insurance levels and higher deductibles. Consequently, pharmaceutical companies compete for formulary placement not only on the basis of product attributes such as greater efficacy, fewer side effects, or greater patient ease of use, but also by providing rebates. Value-based agreements are another tool which may be utilized between payers and pharmaceutical companies as formulary placement and pricing are negotiated. Price is an increasingly important factor in formulary decisions, particularly in treatment areas in which the payer has taken the position that multiple branded products are therapeutically comparable. These downward pricing pressures could continue to negatively affect future consolidated results of operations and cash flows.

The main coverage expansion provisions of the Affordable Care Act (ACA) are currently in effect through both state-based exchanges and the expansion of Medicaid. A trend has been the prevalence of benefit designs containing high out-of-pocket costs for patients, particularly for pharmaceuticals. In addition to the coverage expansions, many employers in the commercial market, driven in part by ACA changes such as the 2022 implementation of the excise tax on employer-sponsored health care coverage for which there is an excess benefit (the so-called "Cadillac tax"), continue to evaluate strategies such as private exchanges and wider use of consumer-driven health plans to reduce their healthcare liabilities over time. Federal legislation, litigation, or administrative actions to repeal or modify some or all of the provisions of the ACA could have a material adverse effect on our consolidated results of operations and cash flows. At the same time, the broader paradigm shift towards performance-based reimbursement and the launch of several value-based purchasing initiatives have placed demands on the pharmaceutical industry to offer products with proven real-world outcomes data and a favorable economic profile.

International

International operations also are generally subject to extensive price and market regulations. Cost-containment measures exist in a number of countries, including additional price controls and mechanisms to limit reimbursement for our products. Such policies are expected to increase in impact and reach, given the pressures on national and regional health care budgets that come from a growing aging population and ongoing economic challenges. As additional reforms are finalized, we will assess their impact on future revenues. In addition, governments in many emerging markets are becoming increasingly active in expanding health care system offerings. Given the budget challenges of increasing health care coverage for citizens, policies may be proposed that promote generics and biosimilars only and reduce current and future access to branded human pharmaceutical products.

Tax Matters

We are subject to income taxes in the U.S. and numerous foreign jurisdictions. Changes in the relevant tax laws, regulations, administrative practices, and interpretations could adversely affect our future effective tax rates. The U.S. recently enacted tax reform legislation, including the 2017 Tax Act, significantly revising U.S. tax law, and other countries are actively considering or enacting tax law changes. Further, organizations such as the Organisation for Economic Co-operation and Development and the European Commission are active regarding tax-related matters, which could influence international tax policy in countries in which we operate. While outcomes of these initiatives continue to develop and remain uncertain, modifications to key elements of the U.S. or international tax framework could have a material adverse effect on our consolidated results of operations and cash flows.

Our accounting for the effects of the 2017 Tax Act, signed into law in December 2017, is complete (see Note 13 to the consolidated financial statements for further information related to the 2017 Tax Act); however, we expect that additional guidance will be issued in 2019 which may materially affect our assumptions and estimates used to record our U.S. federal and state income tax expense resulting from the 2017 Tax Act. Refer to “Results of Operations - Financial Condition” for discussion of the impact of the 2017 Tax Act on our liquidity.

Acquisitions

We strategically invest in external research and technologies that we believe to complement and strengthen our own efforts. These investments can take many forms, including licensing arrangements, collaborations, and acquisitions. We view our business development activity as an important way to achieve our strategies, as we seek to bolster our pipeline and enhance shareholder value. We continue to evaluate business development transactions that have the potential to strengthen our business. Since January 1, 2019, we have acquired Loxo Oncology, Inc. (Loxo). for a purchase price of $235 per share, or approximately $8 billion. We also entered into a license and collaboration agreement with AC Immune SA for an upfront fee of CHF80.0 million and $50.0 million in exchange for a note, convertible to equity at a premium. See Note 3 to the consolidated financial statements for further discussion regarding our recent acquisitions of businesses and assets.

Operating Results—2018

Revenue

The following table summarizes our revenue activity by region:



	Year Ended December 31,
	2018		2017		Percent Change
U.S.⁽¹⁾	$	12,391.9	$	11,414.4	9
Outside U.S.	9,101.4		8,559.4		6
Revenue	$	21,493.3	$	19,973.8	8

Numbers may not add due to rounding.

⁽¹⁾U.S. revenue includes revenue in Puerto Rico.

The following are components of the change in revenue compared with the prior year:



	2018 vs. 2017
	U.S.		Outside U.S.		Consolidated
Volume	9	%	8	%	9	%
Price	(1	)%	(4	)%	(2	)%
Foreign exchange rates	—	%	2	%	1	%
Percent change	9	%	6	%	8	%

Numbers may not add due to rounding.

In the U.S., the revenue increase in 2018 was driven by increased volume for newer products, including Trulicity^®, Basaglar^®, Taltz^®, Verzenio, and Jardiance^®. The increase in revenue was partially offset by decreased volume for products that have lost exclusivity, including Cialis, Effient, and Strattera, as well as lower realized prices for several products, including Trulicity, Basaglar, Forteo, and Taltz.

Outside the U.S., the revenue increase in 2018 was due to increased volume for several newer products, primarily driven by Trulicity, Olumiant, and Taltz and, to a lesser extent, the favorable impact of foreign exchange rates. The increase in revenue was partially offset by lower realized prices for several products.

The following table summarizes our revenue activity in 2018 compared with 2017:



	Year Ended December 31,
	2018						2017
Product	U.S.⁽¹⁾		Outside U.S.		Total		Total		Percent Change
Trulicity	$	2,515.8	$	683.3	$	3,199.1	$	2,029.8	58
Humalog	1,787.8		1,208.7		2,996.5		2,865.2		5
Alimta	1,131.0		1,001.9		2,132.9		2,062.5		3
Cialis	1,129.2		722.7		1,851.8		2,323.1		(20)
Forteo	757.9		817.7		1,575.6		1,749.0		(10)
Humulin^®	910.2		421.2		1,331.4		1,335.4		—
Taltz	738.7		198.7		937.5		559.2		68
Cyramza^®	291.5		529.9		821.4		758.3		8
Basaglar	622.8		178.5		801.2		432.1		85
Cymbalta^®	54.3		653.7		708.0		757.2		(6)
Jardiance⁽²⁾	400.2		258.1		658.3		447.5		47
Erbitux^®	531.6		103.8		635.3		645.9		(2)
Trajenta^®(3)	224.2		350.5		574.7		537.9		7
Zyprexa	36.2		435.1		471.3		581.2		(19)
Strattera	89.7		361.1		450.8		618.2		(27)
Other products	1,170.8		1,176.5		2,347.5		2,271.3		3
Revenue	$	12,391.9	$	9,101.4	$	21,493.3	$	19,973.8	8

Numbers may not add due to rounding.


⁽¹⁾	U.S. revenue includes revenue in Puerto Rico.


⁽²⁾	Jardiance revenue includes Glyxambi^® and Synjardy^®.


⁽³⁾	Trajenta revenue includes Jentadueto^®.

Revenue of Trulicity, a treatment for type 2 diabetes, increased 56 percent in the U.S., driven by higher demand. Revenue outside the U.S. increased 63 percent primarily driven by increased volume and, to a lesser extent, the favorable impact of foreign exchange rates, partially offset by lower realized prices.

Revenue of Humalog, our injectable human insulin analog for the treatment of diabetes, increased 4 percent in the U.S., primarily driven by increased demand and, to a lesser extent, higher realized prices due to changes in estimates to rebates and discounts. Revenue outside the U.S. increased 5 percent, driven by increased volume and, to a lesser extent, the favorable impact of foreign exchange rates, partially offset by lower realized prices. A similar version of insulin lispro launched in the U.S. in the second quarter of 2018 and in certain European markets in 2017. While it is difficult to estimate the severity of the impact of similar insulin lispro products entering the market, we do not expect and have not experienced a rapid severe decline in revenue; however, we expect additional pricing pressure and some loss of market share that would continue over time.

Revenue of Alimta, a treatment for various cancers, increased 9 percent in the U.S., driven by increased demand and higher realized prices. Revenue outside the U.S. decreased 3 percent, driven by lower volume due to competitive pressure and the loss of exclusivity in certain European countries, including Germany, and lower realized prices, partially offset by the favorable impact of foreign exchange rates. We have faced and remain exposed to generic entry in multiple countries, which has eroded revenue and is likely to continue to erode revenue in those countries from current levels.

Revenue of Cialis, a treatment for erectile dysfunction and benign prostatic hyperplasia, decreased 17 percent in the U.S., driven by decreased demand primarily due to the entry of generic tadalafil, partially offset by higher realized prices. Revenue outside the U.S. decreased 25 percent, driven by the loss of exclusivity in Europe. We lost our compound patent protection for Cialis in major European markets in November 2017 and U.S. exclusivity ended in late September 2018. See "Results of Operations - Executive Overview - Other Matters - Patent Matters" for more information. In addition to competition from generic tadalafil, we also currently face competition from generic sildenafil, which accelerated during 2018. We expect that the entry of generic competition due to the loss of exclusivity will continue to cause a rapid and severe decline in revenue.

Revenue of Forteo, an injectable treatment for osteoporosis in postmenopausal women and men at high risk for fracture and for glucocorticoid-induced osteoporosis in men and postmenopausal women, decreased 21 percent in the U.S., driven by decreased demand, and, to a lesser extent, lower realized prices. Revenue outside the U.S. increased 4 percent, driven by increased volume and the favorable impact of foreign exchange rates, partially offset by lower realized prices. Our formulation patent for Forteo expired in December 2018 in major European markets and the U.S. Our use patent for Forteo expires in August 2019 in major European markets and the U.S. Both the formulation patent and the use patent expire in 2019 in Japan. While it is difficult to estimate the severity of the impact of generic and/or biosimilar competition in these markets, we expect a rapid and severe decline in revenue in the U.S. as a result of generic competition when the U.S. patents expire. Outside the U.S., we expect a decline in revenue following patent expirations, however the decline may not be rapid and severe. See "Executive Overview - Other Matters - Patent Matters" for more information.

Revenue of Humulin, an injectable human insulin for the treatment of diabetes, increased 3 percent in the U.S., driven by increased volume, partially offset by lower realized prices primarily due to changes in segment mix and, to a lesser extent, the impact of patient affordability programs. Revenue outside the U.S. decreased 7 percent, primarily driven by decreased volume and, to a lesser extent, lower realized prices.

Revenue of Taltz, a treatment for moderate-to-severe plaque psoriasis and active psoriatic arthritis, increased 52 percent in the U.S., primarily driven by increased demand, partially offset by lower realized prices. Revenue outside the U.S. increased $125.6 million, driven by increased volume from recent launches, partially offset by lower realized prices.

Revenue of Cyramza, a treatment for various cancers, increased 5 percent in the U.S., driven by increased demand and, to a lesser extent, higher realized prices. Revenue outside the U.S. increased 10 percent, primarily due to increased volume and, to a lesser extent, the favorable impact of foreign exchange rates, partially offset by lower realized prices.

Revenue of Basaglar, a long-acting human insulin analog for the treatment of diabetes, increased $311.7 million in the U.S., driven by increased demand, partially offset by lower realized prices due to increased volume in Medicare Part D. Revenue outside the U.S. increased $57.5 million primarily driven by increased volume.

Revenue of Cymbalta, a product for the treatment of major depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, chronic musculoskeletal pain, and the management of fibromyalgia, decreased 53 percent in the U.S. driven by decreased volume, partially offset by higher realized prices. Revenue outside the U.S. increased 2 percent, driven by increased volume in Japan.

Gross Margin, Costs, and Expenses

Gross margin as a percent of total revenue was 78.2 percent in 2018, an increase of 0.5 percentage points compared with 2017, primarily due to manufacturing efficiencies and lower amortization expenses, offset by the impact of foreign exchange rates on international inventories sold, the timing of manufacturing production, and the negative impact of price on revenue.

Research and development expenses decreased 1 percent to $5.05 billion in 2018 driven by lower development expenses for lanabecestat, partially offset by higher expenses for other late-stage assets.

Marketing, selling, and administrative expenses remained flat in 2018 compared to 2017.

Both research and development expenses and marketing, selling, and administrative expenses benefited during 2018 from actions taken to reduce our cost structure.

We recognized acquired IPR&D charges of $1.98 billion in 2018 primarily related to the acquisition of ARMO and the collaboration with Dicerna. In 2017, we recognized acquired IPR&D charges of $1.11 billion primarily related to the acquisition of CoLucid.

We recognized asset impairment, restructuring, and other special charges of $266.9 million in 2018. The charges are primarily associated with asset impairments related to the sale of the Posilac(rbST) brand and the related sale of the Augusta, Georgia manufacturing site and with expenses associated with efforts to reduce our cost structure. In 2017, we recognized $1.33 billion of asset impairment, restructuring, and other special charges primarily associated with efforts to reduce our cost structure, including the U.S. voluntary early retirement program, and asset impairments related to lower projected revenue for Posilac (rbST).

Other—net, (income) expense was income of $145.6 million in 2018 compared to income of $301.5 million in 2017 driven by lower net gains on sales of investments.

During 2018, we recorded income tax expense of $529.5 million while earning $3.68 billion of income before income taxes. We recognized $313.3 million of income tax benefit primarily due to measurement period adjustments to the Toll Tax and GILTI. During 2017, we recorded income tax expense of $2.40 billion, which included a provisional tax charge of $1.91 billion, despite earning $2.30 billion of income before income taxes. The provisional tax charge was a result of the 2017 Tax Act, including the Toll Tax.

Operating Results—2017

Financial Results

The following table summarizes our key operating results:



	Year Ended December 31,						Percent Change
	2017			2016			Percent Change
Revenue	$	19,973.8		$	18,312.8		9
Gross margin	15,526.1			14,152.3			10
Gross margin as a percent of revenue	77.7		%	77.3		%
Operating expense	$	11,078.6		$	10,881.9		2
Acquired in-process research and development	1,112.6			30.0			NM
Asset impairment, restructuring, and other special charges	1,331.6			72.9			NM
Income before income taxes	2,304.8			3,276.3			(30)
Income taxes	2,391.2			551.4			NM
Net income (loss) from continuing operations	(86.4		)	2,724.9			NM
Net income (loss) from discontinued operations	(117.7		)	12.7			NM
Net income (loss)	(204.1		)	2,737.6			NM
Earnings (loss) per share from continuing operations	(0.08		)	2.57			NM
Earnings (loss) per share from discontinued operations	(0.11		)	0.01			NM
Earnings (loss) per share	(0.19		)	2.58			NM

NM - not meaningful

Revenue and gross margin increased in 2017. The increase in operating expense in 2017 was primarily due to an increase in marketing, selling, and administrative expense. Income before income taxes decreased in 2017 as higher asset impairment, restructuring, and other special charges, acquired IPR&D charges and, to a lesser extent, higher operating expense were partially offset by a higher gross margin. Tax expense exceeded income before income taxes in 2017 as a result of the 2017 Tax Act, resulting in a net loss for the year.

Certain items affect the comparisons of our 2017 and 2016 results. The 2017 highlighted items are summarized in the "Results of Operations - Executive Overview" section. The 2016 highlighted items are summarized as follows:

Acquired IPR&D (Note 3 to the consolidated financial statements)


•	We recognized acquired IPR&D charges of $30.0 million related to upfront fees paid in connection with a collaboration agreement with AstraZeneca to co-develop MEDI1814, a potential disease-modifying treatment for Alzheimer's disease.

Asset Impairment, Restructuring, and Other Special Charges (Note 5 to the consolidated financial statements)


•	We recognized charges of $72.9 million primarily related to global severance costs.

Other-Net, (Income) Expense (Note 17 to the consolidated financial statements)


•	We recognized charges of $203.9 million related to the impact of the Venezuelan financial crisis, including the significant deterioration of the bolívar.

Revenue

The following table summarizes our revenue activity by region:



	Year Ended December 31,
	2017		2016		Percent Change
U.S. ⁽¹⁾	$	11,414.4	$	10,147.0	12
Outside U.S.	8,559.4		8,165.8		5
Revenue	$	19,973.8	$	18,312.8	9

Numbers may not add due to rounding.

⁽¹⁾U.S. revenue includes revenue in Puerto Rico.

The following are components of the change in revenue compared to the prior year:



	2017 vs. 2016
	U.S.		Outside U.S.		Consolidated
Volume	7	%	7	%	7	%
Price	6	%	(1	)%	3	%
Foreign exchange rates	—	%	(1	)%	—	%
Percent change	12	%	5	%	9	%

Numbers may not add due to rounding.

In the U.S., the revenue increase in 2017 was driven by increased volume for newer products, including Trulicity, Taltz, Basaglar, Lartruvo, and Jardiance, and higher realized prices for several products, primarily Forteo and Cialis. The increase in revenue was partially offset by decreased volume due to loss of exclusivity for Strattera and Effient, as well as decreased demand for Cialis. Cymbalta revenue declined, as 2016 revenue benefited from reductions to the reserve for expected product returns of approximately $175 million.

Outside the U.S., the revenue increase in 2017 was due to increased volume for several new products, primarily driven by Trulicity and Cyramza. The increase in revenue was partially offset by competitive pressure and the loss of exclusivity for Alimta in several countries and lower volume from the loss of exclusivity for Zyprexa in Japan.

The following table summarizes our revenue activity in 2017 compared with 2016:



	Year Ended December 31,
	2017						2016
Product	U.S.⁽¹⁾		Outside U.S.		Total		Total		Percent Change
Humalog	$	1,717.8	$	1,147.4	$	2,865.2	$	2,768.8	3
Cialis	1,358.6		964.5		2,323.1		2,471.6		(6	)
Alimta	1,034.3		1,028.2		2,062.5		2,283.3		(10	)
Trulicity	1,609.8		419.9		2,029.8		925.5		NM
Forteo	965.2		783.8		1,749.0		1,500.0		17
Humulin	884.6		450.7		1,335.4		1,365.9		(2	)
Cyramza	278.8		479.6		758.3		614.1		23
Cymbalta	114.9		642.2		757.2		930.5		(19	)
Erbitux	541.7		104.2		645.9		687.0		(6	)
Strattera	284.9		333.3		618.2		854.7		(28	)
Zyprexa	75.5		505.7		581.2		725.3		(20	)
Taltz	486.0		73.2		559.2		113.1		NM
Trajenta⁽²⁾	213.2		324.7		537.9		436.6		23
Jardiance⁽³⁾	290.4		157.0		447.5		201.9		NM
Basaglar	311.1		121.0		432.1		86.1		NM
Effient	340.1		48.8		388.9		535.2		(27	)
Other products	907.5		975.2		1,882.4		1,813.2		4
Revenue	$	11,414.4	$	8,559.4	$	19,973.8	$	18,312.8	9

Numbers may not add due to rounding.

⁽¹⁾U.S. revenue includes revenue in Puerto Rico.

⁽²⁾Trajenta revenue includes Jentadueto.

⁽³⁾Jardiance revenue includes Glyxambi and Synjardy.

NM - not meaningful

Revenue of Humalog increased 2 percent in the U.S., primarily driven by higher realized prices due to changes in estimates for rebates and discounts, which decreased revenue in 2016 and increased revenue in 2017. Revenue outside the U.S. increased 6 percent, driven by increased volume and, to a lesser extent, higher realized prices, partially offset by the unfavorable impact of foreign exchange rates.

Revenue of Cialis decreased 8 percent in the U.S., driven by decreased demand partially offset by higher realized prices. Revenue outside the U.S. decreased 4 percent, driven by decreased volume, partially offset by higher realized prices.

Revenue of Alimta decreased 6 percent in the U.S., driven by decreased demand due to competitive pressure. Revenue outside the U.S. decreased 13 percent, driven by competitive pressure and the loss of exclusivity in several countries.

Revenue of Trulicity increased 118 percent in the U.S., driven by increased share of market for Trulicity and growth in the GLP-1 class. Revenue outside the U.S. increased 123 percent.

Revenue of Forteo increased 25 percent in the U.S., driven by higher realized prices and increased volume, primarily due to wholesaler buying patterns. Revenue outside the U.S. increased 7 percent, driven by increased volume, partially offset by the unfavorable impact of foreign exchange rates and lower realized prices.

Revenue of Humulin increased 3 percent in the U.S., driven by higher realized prices. Revenue outside the U.S. decreased 11 percent, driven primarily by decreased volume and lower realized prices.

Revenue of Cyramza increased 3 percent in the U.S., driven by increased volume. Revenue outside the U.S. increased 39 percent, primarily due to strong volume growth in Japan, partially offset by lower realized prices and, to a lesser extent, the unfavorable impact of foreign exchange rates.

Revenue of Cymbalta decreased 57 percent in the U.S., driven by reductions to the reserve for expected product returns, which increased revenue by approximately $175 million in 2016. Revenue outside the U.S. decreased 3 percent driven by the loss of exclusivity in Canada and Europe, partially offset by increased volume in Japan.

Revenue of Erbitux, a treatment for various cancers, decreased 7 percent in the U.S. in 2017. The decrease was due to increased competition from immuno-oncology products.

Revenue of Strattera, a treatment for attention-deficit hyperactivity disorder, decreased 47 percent in the U.S., driven by the loss of exclusivity in the second quarter of 2017, partially offset by higher realized prices. The entry of generic competition following the loss of effective patent protection has caused a rapid and severe decline in revenue. Revenue outside the U.S. increased 4 percent, driven by increased volume in Japan, partially offset by lower realized prices and the unfavorable impact of foreign exchange rates, primarily the Japanese yen.

Gross Margin, Costs, and Expenses

Gross margin as a percent of total revenue was 77.7 percent in 2017, an increase of 0.4 percentage points compared with 2016.

Research and development expenses increased 1 percent to $5.10 billion in 2017.

Marketing, selling, and administrative expenses increased 2 percent to $5.98 billion in 2017, driven by increased marketing expenses for new products that were partially offset by decreased expenses related to late life-cycle products.

We recognized acquired IPR&D charges of $1.11 billion in 2017 resulting from business development activity, primarily related to the acquisition of CoLucid. In 2016, we recognized acquired IPR&D charges of $30.0 million associated with the agreement with AstraZeneca to co-develop MEDI1814. See Note 3 to the consolidated financial statements for additional information.

We recognized asset impairment, restructuring, and other special charges of $1.33 billion in 2017. The charges are primarily associated with efforts to reduce our cost structure, including the U.S. voluntary early retirement program and asset impairments related to lower projected revenue for Posilac (rbST). In 2016, we recognized $72.9 million of asset impairment, restructuring, and other special charges primarily associated with global severance costs associated with actions taken to reduce cost structure. See Note 5 to the consolidated financial statements for additional information.

Other-net, (income) expense was income of $301.5 million in 2017, compared with income of $108.8 million in 2016. Other-net, (income) expense in 2016 included a $203.9 million charge related to the impact of the Venezuelan financial crisis, including the significant deterioration of the bolívar. See Note 17 to the consolidated financial statements for additional information.

During 2017, we recorded income tax expense of $2.39 billion, which included a provisional tax charge of $1.91 billion, despite earning $2.30 billion of income before income taxes. The provisional tax charge was a result of the 2017 Tax Act. The effective tax rate in 2016 was 16.8 percent.

FINANCIAL CONDITION

As of December 31, 2018, cash and cash equivalents were $7.32 billion, an increase of $1.11 billion, compared with $6.21 billion at December 31, 2017. Refer to the Consolidated Statements of Cash Flows for additional details on the significant sources and uses of cash for the years ended December 31, 2018 and December 31, 2017.

In addition to our cash and cash equivalents, we held total investments of $2.09 billion and $7.16 billion as of December 31, 2018 and December 31, 2017, respectively. See Note 7 to the consolidated financial statements for additional details.

As of December 31, 2018, total debt was $10.30 billion, a decrease of $3.35 billion compared with $13.65 billion at December 31, 2017. The decrease was primarily due to the net decrease in the balance of commercial paper outstanding of $2.20 billion and the repayment of $1.01 billion of long term debt. See Note 10 to the consolidated financial statements for additional details.

As of December 31, 2018, we had a total of $5.42 billion of unused committed bank credit facilities, $5.00 billion of which is available to support our commercial paper program. See Note 10 to the consolidated financial statements for additional details. In January 2019, we entered into a $4.00 billion credit facility to support our commercial paper program. We believe that amounts accessible through existing commercial paper markets should be adequate to fund short-term borrowing needs.

For the 133^rd consecutive year, we distributed dividends to our shareholders. Dividends of $2.25 per share and $2.08 per share were paid in 2018 and 2017, respectively. In the fourth quarter of 2018, effective for the dividend to be paid in the first quarter of 2019, the quarterly dividend was increased to $0.645 per share, resulting in an indicated annual rate for 2019 of $2.58 per share.

Capital expenditures of $1.21 billion during 2018 were $133.8 million more than in 2017.

In 2018, we repurchased $4.15 billion of shares. We completed the $5.00 billion share repurchase program announced in October 2013, and the board authorized a new $8.00 billion share repurchase program. There were $2.10 billion of shares repurchased under the $8.00 billion program during 2018. See Note 12 to the consolidated financial statements for additional details. In January 2019, we initiated $3.50 billion of share repurchases that will conclude in the first half of 2019. These purchases are part of the $8.00 billion program previously authorized by the Board.

On March 11, 2019, we completed the disposition of our remaining 80.2 percent ownership of Elanco common stock through a tax-free exchange offer, which resulted in a reduction in shares of our common stock outstanding by approximately 65 million as of that date.

In February 2019, we completed our acquisition of Loxo for $235 per share or approximately $8 billion, which will be funded through a mixture of cash and debt. See Note 3 to the consolidated financial statements for additional information.

See "Results of Operations - Executive Overview - Other Matters - Patent Matters" for information regarding recent and upcoming losses of patent protection.

Pursuant to the 2017 Tax Act, the U.S. transitioned to a territorial tax system effective January 1, 2018; therefore, repatriations of cash from our foreign subsidiaries to the U.S. provides us with additional liquidity in the U.S. without the requirement to pay U.S. taxes as existed prior to the enactment of the new tax law. We believe cash provided by operating activities, along with available cash and cash equivalents, should be sufficient to fund our normal operating needs, including installment payments of the Toll Tax, dividends paid to shareholders, share repurchases, and capital expenditures.

Both domestically and abroad, we continue to monitor the potential impacts of the economic environment; the creditworthiness of our wholesalers and other customers, including foreign government-backed agencies and suppliers; the uncertain impact of health care legislation; and various international government funding levels.

In the normal course of business, our operations are exposed to fluctuations in interest rates and currency values. These fluctuations can vary the costs of financing, investing, and operating. We seek to address a portion of these risks through a controlled program of risk management that includes the use of derivative financial instruments. The objective of controlling these risks is to limit the impact on earnings of fluctuations in interest and currency exchange rates. All derivative activities are for purposes other than trading.

Our primary interest rate risk exposure results from changes in short-term U.S. dollar interest rates. In an effort to manage interest rate exposures, we strive to achieve an acceptable balance between fixed and floating rate debt positions and may enter into interest rate derivatives to help maintain that balance. Based on our overall interest rate exposure at December 31, 2018 and 2017, including derivatives and other interest rate risk-sensitive instruments, a hypothetical 10 percent change in interest rates applied to the fair value of the instruments as of December 31, 2018 and 2017, respectively, would not have a material impact on earnings, cash flows, or fair values of interest rate risk-sensitive instruments over a one-year period.

Our foreign currency risk exposure results from fluctuating currency exchange rates, primarily the U.S. dollar against the euro and Japanese yen. We face foreign currency exchange exposures when we enter into transactions arising from subsidiary trade and loan payables and receivables denominated in foreign currencies. We also face currency exposure that arises from translating the results of our global operations to the U.S. dollar at exchange rates that have fluctuated from the beginning of the period. We may enter into foreign currency forward or option derivative contracts to reduce the effect of fluctuating currency exchange rates (principally the euro and the Japanese yen). Our corporate risk-management policy outlines the minimum and maximum hedge coverage of such exposures. Gains and losses on these derivative contracts offset, in part, the impact of currency fluctuations on the existing assets and liabilities. We periodically analyze the fair values of the outstanding foreign currency derivative contracts to determine their sensitivity to changes in foreign exchange rates. A hypothetical 10 percent change in exchange rates (primarily against the U.S. dollar) applied to the fair values of our outstanding foreign currency derivative contracts as of December 31, 2018 and 2017, would not have a material impact on earnings, cash flows, or financial position over a one-year period. This sensitivity analysis does not consider the impact that hypothetical changes in exchange rates would have on the underlying foreign currency denominated transactions.

Off-Balance Sheet Arrangements and Contractual Obligations

We have no off-balance sheet arrangements that have a material current effect or that are reasonably likely to have a material future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures, or capital resources. We acquire and collaborate on potential products still in development and enter into research and development arrangements with third parties that often require milestone and royalty payments to the third party contingent upon the occurrence of certain future events linked to the success of the asset in development. Milestone payments may be required contingent upon the successful achievement of an important point in the development life cycle of the pharmaceutical product (e.g., approval for marketing by the appropriate regulatory agency or upon the achievement of certain sales levels). If required by the arrangement, we may make royalty payments based upon a percentage of the sales of the pharmaceutical product in the event that regulatory approval for marketing is obtained. Because of the contingent nature of these payments, they are not included in the table of contractual obligations below.

Individually, these arrangements are generally not material in any one annual reporting period. However, if milestones for multiple products covered by these arrangements were reached in the same reporting period, the aggregate charge to expense or aggregate milestone payments made could be material to the results of operations or cash flows, respectively, in that period. See Note 4 to the consolidated financial statements for additional details. These arrangements often give us the discretion to unilaterally terminate development of the product, which would allow us to avoid making the contingent payments; however, we are unlikely to cease development if the compound successfully achieves milestone objectives. We also note that, from a business perspective, we view these payments as positive because they signify that the product is successfully moving through development and is now generating or is more likely to generate cash flows from sales of products.

Our current noncancelable contractual obligations that will require future cash payments are as follows:



	Payments Due by Period
(Dollars in millions)	Total		Less Than 1 Year		1-3 Years		3-5 Years		More Than 5 Years
Long-term debt, including interest payments⁽¹⁾	$	13,647.3	$	847.8	$	552.6	$	1,970.5	$	10,276.4
Capital lease obligations	11.8		4.5		5.9		1.4		—
Operating leases	709.6		130.6		183.4		114.6		281.0
Purchase obligations⁽²⁾	15,930.7		15,716.6		204.5		9.6		—
2017 Tax Act one-time Toll Tax⁽³⁾	2,836.5		159.8		509.8		732.9		1,434.0
Other long-term liabilities reflected on our balance sheet⁽⁴⁾	1,559.8		—		401.6		190.8		967.4
Total	$	34,695.7	$	16,859.3	$	1,857.8	$	3,019.8	$	12,958.8

⁽¹⁾Our long-term debt obligations include both our expected principal and interest obligations and our interest rate swaps. We used the interest rate forward curve at December 31, 2018, to compute the amount of the contractual obligation for interest on the variable rate debt instruments and swaps.

⁽²⁾We have included the following:


•	Purchase obligations consisting primarily of all open purchase orders as of December 31, 2018. Some of these purchase orders may be cancelable; however, for purposes of this disclosure, we have not distinguished between cancelable and noncancelable purchase obligations.


•	Contractual payment obligations with each of our significant vendors, which are noncancelable and are not contingent.

⁽³⁾The 2017 Tax Act provided an election to taxpayers subject to the Toll Tax to make payments over an eight-year period. We made this election; therefore, we have included future Toll Tax payments accordingly.

⁽⁴⁾We have included long-term liabilities consisting primarily of our nonqualified supplemental pension funding requirements and other post-employment benefit liabilities. We excluded long-term income taxes payable of $1.02 billion, because we cannot reasonably estimate the timing of future cash outflows associated with those liabilities.

The contractual obligations table is current as of December 31, 2018. We expect the amount of these obligations to change materially over time as new contracts are initiated and existing contracts are completed, terminated, or modified.

APPLICATION OF CRITICAL ACCOUNTING ESTIMATES

In preparing our financial statements in accordance with accounting principles generally accepted in the U.S. (GAAP), we must often make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues, expenses, and related disclosures. Some of those judgments can be subjective and complex, and consequently actual results could differ from those estimates. For any given individual estimate or assumption we make, it is possible that other people applying reasonable judgment to the same facts and circumstances could develop different estimates. We believe that, given current facts and circumstances, it is unlikely that applying any such other reasonable judgment would cause a material adverse effect on our consolidated results of operations, financial position, or liquidity for the periods presented in this report. Our most critical accounting estimates have been discussed with our audit committee and are described below.

Revenue Recognition and Sales Return, Rebate, and Discount Accruals

We recognize revenue primarily from two different types of contracts, product sales to customers (net product revenue) and collaborations and other arrangements. Revenue recognized from collaborations and other arrangements will include our share of profits from the collaboration, as well as royalties, upfront and milestone payments we receive under these types of contracts. Refer to Note 1 to the consolidated financial statements for further information on revenue recognition and sales return, rebate, and discount accruals.

Financial Statement Impact

We believe that our accruals for sales returns, rebates, and discounts are reasonable and appropriate based on current facts and circumstances. Our global rebate and discount liabilities are included in sales rebates and discounts on our consolidated balance sheet. Our global sales return liability is included in other current liabilities and other noncurrent liabilities on our consolidated balance sheet. As of December 31, 2018, a 5 percent change in our global sales return, rebate, and discount liability would have led to an approximate $265 million effect on our income before income taxes.

The portion of our global sales return, rebate, and discount liability resulting from sales of our products in the U.S. was approximately 90 percent as of December 31, 2018 and December 31, 2017.

The following represents a roll-forward of our most significant U.S. sales return, rebate, and discount liability balances, including managed care, Medicare, and Medicaid:



(Dollars in millions)	2018			2017
Sales return, rebate, and discount liabilities, beginning of year	$	4,172.0		$	3,601.8
Reduction of net sales due to sales returns, discounts, and rebates⁽¹⁾	12,529.6			10,603.4
Cash payments of discounts and rebates	(12,023.4		)	(10,033.2		)
Sales return, rebate, and discount liabilities, end of year	$	4,678.2		$	4,172.0

⁽¹⁾Adjustments of the estimates for these returns, rebates, and discounts to actual results were approximately 1 percent of consolidated net sales for each of the years presented.

Product Litigation Liabilities and Other Contingencies

Background and Uncertainties

Product litigation liabilities and other contingencies are, by their nature, uncertain and based upon complex judgments and probabilities. The factors we consider in developing our product litigation liability reserves and other contingent liability amounts include the merits and jurisdiction of the litigation, the nature and the number of other similar current and past matters, the nature of the product and the current assessment of the science subject to the litigation, and the likelihood of settlement and current state of settlement discussions, if any. In addition, we accrue for certain product liability claims incurred, but not filed, to the extent we can formulate a reasonable estimate of their costs based primarily on historical claims experience and data regarding product usage. We accrue legal defense costs expected to be incurred in connection with significant product liability contingencies when both probable and reasonably estimable.

We also consider the insurance coverage we have to diminish the exposure for periods covered by insurance. In assessing our insurance coverage, we consider the policy coverage limits and exclusions, the potential for denial of coverage by the insurance company, the financial condition of the insurers, and the possibility of and length of time for collection. Due to a very restrictive market for product liability insurance, we are self-insured for product liability losses for all our currently marketed products. In addition to insurance coverage, we also consider any third-party indemnification to which we are entitled or under which we are obligated. With respect to our third-party indemnification rights, these considerations include the nature of the indemnification, the financial condition of the indemnifying party, and the possibility of and length of time for collection.

The litigation accruals and environmental liabilities and the related estimated insurance recoverables have been reflected on a gross basis as liabilities and assets, respectively, on our consolidated balance sheets.

Impairment of Indefinite-Lived and Long-Lived Assets

Background and Uncertainties

We review the carrying value of long-lived assets (both intangible and tangible) for potential impairment on a periodic basis and whenever events or changes in circumstances indicate the carrying value of an asset (or asset group) may not be recoverable. We identify impairment by comparing the projected undiscounted cash flows to be generated by the asset (or asset group) to its carrying value. If an impairment is identified, a loss is recorded equal to the excess of the asset’s net book value over its fair value, and the cost basis is adjusted.

Goodwill and indefinite-lived intangible assets are reviewed for impairment at least annually and when certain impairment indicators are present. When required, a comparison of fair value to the carrying amount of assets is performed to determine the amount of any impairment.

Several methods may be used to determine the estimated fair value of acquired IPR&D, all of which require multiple assumptions. We utilize the “income method,” as described in Note 8 to the consolidated financial statements.

For acquired IPR&D assets, the risk of failure has been factored into the fair value measure and there can be no certainty that these assets ultimately will yield a successful product, as discussed previously in “Results of Operations - Executive Overview - Late-Stage Pipeline." The nature of the pharmaceutical business is high-risk and requires that we invest in a large number of projects to maintain a successful portfolio of approved products. As such, it is likely that some acquired IPR&D assets will become impaired in the future.

Estimates of future cash flows, based on what we believe to be reasonable and supportable assumptions and projections, require management’s judgment. Actual results could vary materially from these estimates.

Retirement Benefits Assumptions

Background and Uncertainties

Defined benefit pension plan and retiree health benefit plan costs include assumptions for the discount rate, expected return on plan assets, and retirement age. These assumptions have a significant effect on the amounts reported. In addition to the analysis below, see Note 14 to the consolidated financial statements for additional information regarding our retirement benefits.

Annually, we evaluate the discount rate and the expected return on plan assets in our defined benefit pension and retiree health benefit plans. We use an actuarially determined, plan-specific yield curve of high quality, fixed income debt instruments to determine the discount rates. In evaluating the expected return on plan assets, we consider many factors, with a primary analysis of current and projected market conditions, asset returns and asset allocations (approximately 70 percent of which are growth investments); and the views of leading financial advisers and economists. We may also review our historical assumptions compared with actual results, as well as the discount rates and expected return on plan assets of other companies, where applicable. In evaluating our expected retirement age assumption, we consider the retirement ages of our past employees eligible for pension and medical benefits together with our expectations of future retirement ages.

Financial Statement Impact

If the 2018 discount rate for the U.S. defined benefit pension and retiree health benefit plans (U.S. plans) were to change by a quarter percentage point, income before income taxes would change by $33.7 million. If the 2018 expected return on plan assets for U.S. plans were to change by a quarter percentage point, income before income taxes would change by $25.6 million. If our assumption regarding the 2018 expected age of future retirees for U.S. plans were adjusted by one year, our income before income taxes would be affected by $49.1 million. The U.S. plans, including Puerto Rico, represent approximately 75 percent and 80 percent of the total projected benefit obligation and total plan assets, respectively, at December 31, 2018.

Income Taxes

Background and Uncertainties

We prepare and file tax returns based upon our interpretation of tax laws and regulations and record estimates based on these judgments and interpretations. In the normal course of business, our tax returns are subject to examination by various taxing authorities, which may result in future tax, interest, and penalty assessments by these authorities. Inherent uncertainties exist in estimates of many tax positions due to changes in tax law resulting from legislation and regulation as concluded through the various jurisdictions’ tax court systems. We recognize the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by the taxing authorities, based on the technical merits of the position. The tax benefits recognized in the financial statements from such a position are measured based on the largest benefit that has a greater than 50 percent likelihood of being realized upon ultimate resolution. The amount of unrecognized tax benefits is adjusted for changes in facts and circumstances. For example, adjustments could result from significant amendments to existing tax law, the issuance of regulations or interpretations by the taxing authorities, new information obtained during a tax examination, or resolution of a tax examination. We believe our estimates for uncertain tax positions are appropriate and sufficient to pay assessments that may result from examinations of our tax returns. We recognize both accrued interest and penalties related to unrecognized tax benefits in income tax expense.

We have recorded valuation allowances against certain of our deferred tax assets, primarily those that have been generated from net operating losses and tax credit carryforwards in certain taxing jurisdictions. In evaluating whether we would more likely than not recover these deferred tax assets, we have not assumed any future taxable income or tax planning strategies in the jurisdictions associated with these carryforwards where history does not support such an assumption. Implementation of tax planning strategies to recover these deferred tax assets or future income generation in these jurisdictions could lead to the reversal of these valuation allowances and a reduction of income tax expense.

The 2017 Tax Act was enacted in December 2017 and introduced significant changes to the U.S. corporate income tax system. In accordance with GAAP, our accounting for the effects of the 2017 Tax Act is complete

(refer to "Results of Operations - Executive Overview - Other Matters - Tax Matters" and Note 13 to the consolidated financial statements for further discussion on the 2017 Tax Act). Subsequent to the enactment of the 2017 Tax Act, numerous items of additional guidance were issued, including Notices, Proposed Regulations, and Final Regulations. We expect that further guidance will be issued in 2019 which may change our interpretations of the new tax laws and could materially affect the estimates used to record U.S. federal and state income tax expense.

Financial Statement Impact

As of December 31, 2018, a 5 percent change in the amount of uncertain tax positions and the valuation allowance would result in a change in net income of $74.0 million and $28.7 million, respectively.

Acquisitions

Background and Uncertainties

To determine whether acquisitions or licensing transactions should be accounted for as a business combination or as an asset acquisition, we make certain judgments, which include assessing whether the acquired set of activities and assets would meet the definition of a business under the relevant accounting rules.

If the acquired set of activities and assets meets the definition of a business, assets acquired and liabilities assumed are required to be recorded at their respective fair values as of the acquisition date. The excess of the purchase price over the fair value of the acquired net assets, where applicable, is recorded as goodwill. If the acquired set of activities and assets does not meet the definition of a business, the transaction is recorded as an acquisition of assets and, therefore, any acquired IPR&D that does not have an alternative future use is charged to expense at the acquisition date, and goodwill is not recorded. Refer to Note 3 to the consolidated financial statements for additional information.

The judgments made in determining estimated fair values assigned to assets acquired and liabilities assumed in a business combination, as well as estimated asset lives, can materially affect our consolidated results of operations. The fair values of intangible assets, including acquired IPR&D, are determined using information available near the acquisition date based on expectations and assumptions that are deemed reasonable by management. Depending on the facts and circumstances, we may deem it necessary to engage an independent valuation expert to assist in valuing significant assets and liabilities.

The fair values of identifiable intangible assets are primarily determined using an "income method," as described in Note 8 to the consolidated financial statements.

LEGAL AND REGULATORY MATTERS

Information relating to certain legal proceedings can be found in Note 15 to the consolidated financial statements and is incorporated here by reference.


Item 7A.	Quantitative and Qualitative Disclosures About Market Risk

You can find quantitative and qualitative disclosures about market risk (e.g., interest rate risk) at Item 7, “Management’s Discussion and Analysis - Financial Condition.” That information is incorporated in this report by reference.


Item 8.	Financial Statements and Supplementary Data

Consolidated Statements of Operations



ELI LILLY AND COMPANY AND SUBSIDIARIES (Dollars in millions and shares in thousands, except per-share data)	Year Ended December 31	2018			2017			2016
Revenue		$	21,493.3		$	19,973.8		$	18,312.8
Costs, expenses, and other:
Cost of sales		4,681.7			4,447.7			4,160.5
Research and development		5,051.2			5,096.2			5,040.0
Marketing, selling, and administrative		5,975.1			5,982.4			5,841.9
Acquired in-process research and development (Note 3)		1,983.9			1,112.6			30.0
Asset impairment, restructuring, and other special charges (Note 5)		266.9			1,331.6			72.9
Other—net, (income) expense (Note 17)		(145.6		)	(301.5		)	(108.8		)
		17,813.2			17,669.0			15,036.5
Income before income taxes		3,680.1			2,304.8			3,276.3
Income taxes (Note 13)		529.5			2,391.2			551.4
Net income (loss) from continuing operations		3,150.6			(86.4		)	2,724.9
Net Income (loss) from discontinued operations (Note 20)		81.4			(117.7		)	12.7
Net income (loss)		$	3,232.0		$	(204.1	)	$	2,737.6

Earnings (loss) per share:
Earnings (loss) from continuing operations - basic		3.07			(0.08		)	2.57
Earnings (loss) from discontinued operations - basic		0.07			(0.11		)	0.02
Earnings (loss) per share - basic		$	3.14		$	(0.19	)	$	2.59

Earnings (loss) from continuing operations - diluted		3.05			(0.08		)	2.57
Earnings (loss) from discontinued operations - diluted		0.08			(0.11		)	0.01
Earnings (loss) per share - diluted		$	3.13		$	(0.19	)	$	2.58

Shares used in calculation of earnings (loss) per share:
Basic		1,027,721			1,052,023			1,058,324
Diluted		1,033,667			1,052,023			1,061,825

See notes to consolidated financial statements.

Consolidated Statements of Comprehensive Income (Loss)



ELI LILLY AND COMPANY AND SUBSIDIARIES (Dollars in millions)	Year Ended December 31	2018			2017			2016
Net income (loss)		$	3,232.0		$	(204.1	)	$	2,737.6
Other comprehensive income (loss) from continuing operations:
Change in foreign currency translation gains (losses)		(429.6		)	362.9			(300.0		)
Change in net unrealized gains (losses) on securities		(8.8		)	(181.3		)	303.0
Change in defined benefit pension and retiree health benefit plans (Note 14)		544.0			(566.8		)	(508.5		)
Change in effective portion of cash flow hedges		(6.0		)	27.8			11.7
Other comprehensive income (loss) from continuing operations before income taxes		99.6			(357.4		)	(493.8		)
Benefit (provision) for income taxes related to other comprehensive income (loss) from continuing operations		(30.3		)	402.7			(10.6		)
Other comprehensive income (loss) from continuing operations, net of tax (Note 16)		69.3			45.3			(504.4		)
Other comprehensive income (loss) from discontinuing operations, net of tax (Note 16)		14.3			129.2			(140.7		)
Other comprehensive income (loss), net of tax (Note 16)⁽¹⁾		83.6			174.5			(645.1		)
Comprehensive income (loss)		$	3,315.6		$	(29.6	)	$	2,092.5

⁽¹⁾Other comprehensive income in 2018 consists of $72.6 million of other comprehensive income attributable to controlling interest and $11.0 million of other comprehensive income attributable to noncontrolling interest. Other comprehensive income in 2017 consists of $199.0 million of other comprehensive income attributable to controlling interest and $24.5 million of other comprehensive loss attributable to noncontrolling interest. Other comprehensive loss in 2016 consists of $693.3 million of other comprehensive loss attributable to controlling interest and $48.2 million of other comprehensive income attributable to noncontrolling interest.

See notes to consolidated financial statements.

Consolidated Balance Sheets



ELI LILLY AND COMPANY AND SUBSIDIARIES (Dollars in millions, shares in thousands)	December 31	2018			2017
Assets
Current Assets
Cash and cash equivalents (Note 7)		$	7,320.7		$	6,211.8
Short-term investments (Note 7)		88.2			1,497.9
Accounts receivable, net of allowances of $24.1 (2018) and $28.9 (2017)		4,593.9			3,977.0
Other receivables		1,182.9			689.5
Inventories (Note 6)		3,098.1			3,396.0
Prepaid expenses and other		2,036.7			1,319.9
Current assets of discontinued operations (Note 20)		2,229.1			2,110.0
Total current assets		20,549.6			19,202.1
Investments (Note 7)		2,005.4			5,666.5
Goodwill (Note 8)		1,366.6			1,378.0
Other intangibles, net (Note 8)		1,068.0			1,354.4
Deferred tax assets (Note 13)		2,613.7			1,216.9
Sundry		1,824.9			1,609.3
Property and equipment, net (Note 9)		7,996.1			7,885.1
Noncurrent assets of discontinued operations (Note 20)		6,484.1			6,668.7
Total assets		$	43,908.4		$	44,981.0
Liabilities and Equity
Current Liabilities
Short-term borrowings and current maturities of long-term debt (Note 10)		$	1,102.2		$	3,706.5
Accounts payable		1,207.1			1,206.9
Employee compensation		955.6			911.8
Sales rebates and discounts		4,849.5			4,310.1
Dividends payable		650.8			590.6
Income taxes payable (Note 13)		393.4			522.5
Other current liabilities		2,036.7			2,650.0
Current liabilities of discontinued operations (Note 20)		692.8			637.5
Total current liabilities		11,888.1			14,535.9
Other Liabilities
Long-term debt (Note 10)		9,196.4			9,940.0
Accrued retirement benefits (Note 14)		2,802.2			3,376.0
Long-term income taxes payable (Note 13)		3,700.0			3,747.0
Other noncurrent liabilities		2,670.3			1,362.6
Noncurrent liabilities of discontinued operations (Note 20)		2,742.3			351.6
Total other liabilities		21,111.2			18,777.2
Commitments and Contingencies (Note 15)
Eli Lilly and Company Shareholders' Equity (Notes 11 and 12)
Common stock—no par value Authorized shares: 3,200,000 Issued shares: 1,057,639 (2018) and 1,100,672 (2017)		661.0			687.9
Additional paid-in capital		6,583.6			5,817.8
Retained earnings		11,395.9			13,894.1
Employee benefit trust		(3,013.2		)	(3,013.2		)
Accumulated other comprehensive loss (Note 16)		(5,729.2		)	(5,718.6		)
Cost of common stock in treasury		(69.4		)	(75.8		)
Total Eli Lilly and Company shareholders' equity		9,828.7			11,592.2
Noncontrolling interests		1,080.4			75.7
Total equity		10,909.1			11,667.9
Total liabilities and equity		$	43,908.4		$	44,981.0

See notes to consolidated financial statements.

Consolidated Statements of Shareholders' Equity



	Equity of Eli Lilly and Company Shareholders
ELI LILLY AND COMPANY AND SUBSIDIARIES (Dollars in millions, shares in thousands)	Common Stock					Additional Paid-in Capital			Retained Earnings			Employee Benefit Trust			Accumulated Other Comprehensive Loss			Common Stock in Treasury					Noncontrolling Interest
	Shares		Amount															Shares		Amount
Balance at January 1, 2016	1,106,063		$	691.3		$	5,552.1		$	16,011.8		$	(3,013.2	)	$	(4,580.7	)	796		$	(90.0	)	$	19.0
Net income									2,737.6														16.3
Other comprehensive income (loss), net of tax															(693.3		)						48.2
Cash dividends declared per share: $2.05									(2,167.6		)
Retirement of treasury shares	(7,306	)	(4.6		)				(535.5		)							(7,306	)	540.1
Purchase of treasury shares						(60.0		)										7,306		(540.1		)
Issuance of stock under employee stock plans, net	2,829		1.8			(106.8		)										(85	)	9.5
Stock-based compensation						255.3
Other																							(10.7		)
Balance at December 31, 2016	1,101,586		688.5			5,640.6			16,046.3			(3,013.2		)	(5,274.0		)	711		(80.5		)	72.8
Net income (loss)									(204.1		)												30.5
Other comprehensive income (loss), net of tax															199.0								(24.5		)
Cash dividends declared per share: $2.12									(2,234.6		)
Retirement of treasury shares	(4,390	)	(2.7		)				(357.1		)							(4,390	)	359.8
Purchase of treasury shares						60.0												4,390		(359.8		)
Issuance of stock under employee stock plans, net	3,476		2.1			(164.1		)										(47	)	4.7
Stock-based compensation						281.3
Reclassification of stranded tax effects (Note 2)									643.6						(643.6		)
Other																							(3.1		)
Balance at December 31, 2017	1,100,672		687.9			5,817.8			13,894.1			(3,013.2		)	(5,718.6		)	664		(75.8		)	75.7
Net income									3,232.0														3.7
Other comprehensive income (loss), net of tax															85.6								(2.0		)
Cash dividends declared per share: $2.33									(2,372.0		)
Retirement of treasury shares	(45,882	)	(28.7		)				(4,122.0		)							(45,882	)	4,150.7
Purchase of treasury shares																		45,882		(4,150.7		)
Issuance of stock under employee stock plans, net	2,849		1.8			(139.0		)										(60	)	6.4
Stock-based compensation						279.5
Adoption of new accounting standards (Note 2)									763.8						(105.2		)
Sale of Elanco Stock (Note 20)						629.2									9.0								1,017.2
Other						(3.9		)															(14.2		)
Balance at December 31, 2018	1,057,639		$	661.0		$	6,583.6		$	11,395.9		$	(3,013.2	)	$	(5,729.2	)	604		$	(69.4	)	$	1,080.4

See notes to consolidated financial statements.

Consolidated Statements of Cash Flows



ELI LILLY AND COMPANY AND SUBSIDIARIES (Dollars in millions)	Year Ended December 31	2018			2017			2016
Cash Flows from Operating Activities
Net income (loss)		$	3,232.0		$	(204.1	)	$	2,737.6
Adjustments to Reconcile Net Income (Loss) to Cash Flows from Operating Activities:
Depreciation and amortization		1,609.0			1,567.3			1,496.6
Change in deferred income taxes		326.8			(787.9		)	439.5
Stock-based compensation expense		279.5			281.3			255.3
Acquired in-process research and development		1,983.9			1,112.6			30.0
Other non-cash operating activities, net		472.0			441.5			376.1
Other changes in operating assets and liabilities, net of acquisitions and divestitures:
Receivables—(increase) decrease		(996.7		)	(357.0		)	(709.4		)
Inventories—(increase) decrease		7.8			(253.9		)	(328.2		)
Other assets—(increase) decrease		(980.0		)	(590.1		)	(265.5		)
Income taxes payable—increase (decrease)		(125.3		)	3,489.6			(304.8		)
Accounts payable and other liabilities—increase (decrease)		(284.5		)	916.3			1,123.8
Net Cash Provided by Operating Activities		5,524.5			5,615.6			4,851.0
Cash Flows from Investing Activities
Purchases of property and equipment		(1,210.6		)	(1,076.8		)	(1,037.0		)
Proceeds from disposals of property and equipment		3.6			40.7			73.4
Proceeds from sales and maturities of short-term investments		2,552.5			4,852.5			1,642.0
Purchases of short-term investments		(112.2		)	(3,389.7		)	(1,327.4		)
Proceeds from sales of noncurrent investments		3,509.5			2,586.0			2,086.0
Purchases of noncurrent investments		(837.9		)	(4,611.6		)	(4,346.0		)
Purchases of in-process research and development		(1,807.6		)	(1,086.8		)	(55.0		)
Cash paid for acquisitions, net of cash acquired (Note 3 and 20)		—			(882.1		)	(45.0		)
Other investing activities, net		(191.3		)	(215.8		)	(130.1		)
Net Cash Provided by (Used for) Investing Activities		1,906.0			(3,783.6		)	(3,139.1		)
Cash Flows from Financing Activities
Dividends paid		(2,311.8		)	(2,192.1		)	(2,158.5		)
Net change in short-term borrowings		(2,197.9		)	1,397.5			1,293.2
Proceeds from issuance of long-term debt		2,477.7			2,232.0			1,206.6
Repayments of long-term debt		(1,009.1		)	(630.6		)	(0.2		)
Purchases of common stock		(4,150.7		)	(299.8		)	(600.1		)
Net proceeds from Elanco initial public offering (Note 20)		1,659.7			—			—
Other financing activities, net		(372.8		)	(364.4		)	(300.8		)
Net Cash Provided by (Used for) Financing Activities		(5,904.9		)	142.6			(559.8		)
Effect of exchange rate changes on cash and cash equivalents		(63.6		)	(20.5		)	(236.4		)
Net increase in cash and cash equivalents		1,462.0			1,954.1			915.7
Cash and cash equivalents at beginning of year (includes $324.4 (2018), $258.8 (2017), and $460.6 (2016) of discontinued operations)		6,536.2			4,582.1			3,666.4
Cash and Cash Equivalents at End of Year (includes $677.5 (2018), $324.4 (2017), and $258.8 (2016) of discontinued operations)		$	7,998.2		$	6,536.2		$	4,582.1

See notes to consolidated financial statements.

Notes to Consolidated Financial Statements

ELI LILLY AND COMPANY AND SUBSIDIARIES

(Tables present dollars in millions, except per-share data)

Note 1: Summary of Significant Accounting Policies

Basis of presentation

The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (GAAP). The accounts of all wholly-owned and majority-owned subsidiaries are included in the consolidated financial statements. Where our ownership of consolidated subsidiaries is less than 100 percent, the noncontrolling shareholders’ interests are reflected as a separate component of equity. All intercompany balances and transactions have been eliminated.

The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues, expenses, and related disclosures at the date of the financial statements and during the reporting period. Actual results could differ from those estimates. We issued our financial statements by filing with the Securities and Exchange Commission (SEC) and have evaluated subsequent events up to the time of the filing of our Form 10-K.

On September 24, 2018, Elanco Animal Health Incorporated (Elanco), one of our subsidiaries, completed its initial public offering (IPO) of 72.3 million shares of its common stock, which represents 19.8 percent of Elanco's outstanding shares, at $24 per share. On March 11, 2019, we completed the disposition of our remaining 80.2 percent ownership of Elanco common stock through a tax-free exchange offer. As a result, in the first quarter of 2019, we presented Elanco as discontinued operations in our consolidated condensed financial statements for all periods presented. Accordingly, all prior periods have been recast to conform to this presentation.

Certain reclassifications have been made to prior periods in the consolidated financial statements and accompanying notes to conform with the current presentation.

All per-share amounts, unless otherwise noted in the footnotes, are presented on a diluted basis.

Adoption of Revenue Accounting Standard

Effective January 1, 2018, we adopted Accounting Standards Update 2014-09, Revenue from Contracts with Customers and other related updates (see Note 2 for additional discussion). The new standard has been applied to contracts for which performance was not substantially complete as of the date of adoption. For those contracts that were modified prior to the date of adoption, we reflected the aggregate effect of those modifications when determining the appropriate accounting under the new standard. We don’t believe the effect of applying this practical expedient resulted in material differences. Revenue presented for periods prior to 2018 was accounted for under previous standards and has not been adjusted. Revenue and net income for 2018 do not differ materially from amounts that would have resulted from application of the previous standards.

The following table summarizes our revenue recognized in our consolidated statements of operations:



	2018		2017		2016
Net product revenue	$	19,866.4	$	18,776.5	$	17,480.0
Collaboration and other revenue⁽¹⁾	1,626.9		1,197.3		832.8
Revenue	$	21,493.3	$	19,973.8	$	18,312.8

⁽¹⁾Collaboration and other revenue associated with prior year transfers of intellectual property was $303.2 million, $144.9 million, and $145.3 million during the years ended 2018, 2017, and 2016, respectively.

We recognize revenue primarily from two different types of contracts, product sales to customers (net product revenue) and collaborations and other arrangements. Revenue recognized from collaborations and other arrangements will include our share of profits from the collaboration, as well as royalties, upfront and milestone payments we receive under these types of contracts. See Note 4 for additional information related to our collaborations and other arrangements. Collaboration and other revenue disclosed above includes the revenue from the Trajenta^® and Jardiance^® families of products resulting from our collaboration with

Boehringer Ingelheim discussed in Note 4. Substantially all of the remainder of collaboration and other revenue is related to contracts accounted for as contracts with customers.

Net Product Revenue

Revenue from sales of products is recognized at the point where the customer obtains control of the goods and we satisfy our performance obligation, which generally is at the time we ship the product to the customer. Payment terms differ by jurisdiction and customer, but payment terms in most of our major jurisdictions typically range from 30 to 70 days from date of shipment. Revenue for our product sales has not been adjusted for the effects of a financing component as we expect, at contract inception, that the period between when we transfer control of the product and when we receive payment will be one year or less. Any exceptions are either not material or we collect interest for payments made after the due date. Provisions for rebates and discounts, and returns are established in the same period the related sales are recognized. We generally ship product shortly after orders are received; therefore, we generally only have a few days of orders received but not yet shipped at the end of any reporting period. Shipping and handling activities are considered to be fulfillment activities and are not considered to be a separate performance obligation. We exclude from the measurement of the transaction price all taxes assessed by a governmental authority that are imposed on our sales of product and collected from a customer.

Significant judgments must be made in determining the transaction price for our sales of products related to anticipated rebates and discounts and returns. The following describe the most significant of these judgments:

Sales Rebates and Discounts - Background and Uncertainties

•

Most of our products are sold to wholesalers that serve pharmacies, physicians and other health care professionals, and hospitals. We initially invoice our customers at contractual list prices. Contracts with direct and indirect customers may provide for various rebates and discounts that may differ in each contract. As a consequence, to determine the appropriate transaction price for our product sales at the time we recognize a sale to a direct customer, we must estimate any rebates or discounts that ultimately will be due to the direct customer and other customers in the distribution chain under the terms of our contracts. Significant judgments are required in making these estimates.


•	The rebate and discount amounts are recorded as a deduction to arrive at our net product revenue. Sales rebates and discounts that require the use of judgment in the establishment of the accrual include managed care, Medicare, Medicaid, chargebacks, long-term care, hospital, patient assistance programs, and various other programs. We estimate these accruals using an expected value approach.

•

The largest of our sales rebate and discount amounts are rebates associated with sales covered by managed care, Medicare, Medicaid, and chargeback contracts in the United States (U.S.) In determining the appropriate accrual amount, we consider our historical rebate payments for these programs by product as a percentage of our historical sales as well as any significant changes in sales trends (e.g., patent expiries and product launches), an evaluation of the current contracts for these programs, the percentage of our products that are sold via these programs, and our product pricing. Although we accrue a liability for rebates related to these programs at the time we record the sale, the rebate related to that sale is typically paid up to six months later. Because of this time lag, in any particular period our rebate adjustments may incorporate revisions of accruals for several periods.

•

Most of our rebates outside the U.S. are contractual or legislatively mandated and are estimated and recognized in the same period as the related sales. In some large European countries, government rebates are based on the anticipated budget for pharmaceutical payments in the country. An estimate of these rebates, updated as governmental authorities revise budgeted deficits, is recognized in the same period as the related sale.

Sales Returns - Background and Uncertainties

•

When product sales occur, to determine the appropriate transaction price for our sales, we estimate a reserve for future product returns related to those sales using an expected value approach. This estimate is based on several factors, including: historical return rates, expiration date by product (on average, approximately 24 months after the initial sale of a product to our customer), and estimated levels of inventory in the wholesale and retail channels, as well as any other specifically-identified anticipated returns due to known factors such as the loss of patent exclusivity, product recalls and

discontinuances, or a changing competitive environment. We maintain a returns policy that allows U.S. customers to return product for dating issues within a specified period prior to and subsequent to the product's expiration date. Following the loss of exclusivity for a patent-dependent product, we expect to experience an elevated level of product returns as product inventory remaining in the wholesale and retail channels expires. Adjustments to the returns reserve have been and may in the future be required based on revised estimates to our assumptions. We record the return amounts as a deduction to arrive at our net product revenue. Once the product is returned, it is destroyed; we do not record a right of return asset. Our returns policies outside the U.S. are generally more restrictive than in the U.S. as returns are not allowed for reasons other than failure to meet product specifications in many countries. Our reserve for future product returns for product sales outside the U.S. is not material.

•

As a part of our process to estimate a reserve for product returns, we regularly review the supply levels of our significant products sold to major wholesalers in the U.S. and in major markets outside the U.S., primarily by reviewing periodic inventory reports supplied by our major wholesalers and available prescription volume information for our products, or alternative approaches. We attempt to maintain U.S. wholesaler inventory levels at an average of approximately one month or less on a consistent basis across our product portfolio. Causes of unusual wholesaler buying patterns include actual or anticipated product-supply issues, weather patterns, anticipated changes in the transportation network, redundant holiday stocking, and changes in wholesaler business operations. In the U.S., the current structure of our arrangements provides us with data on inventory levels at our wholesalers; however, our data on inventory levels in the retail channel is more limited. Wholesaler stocking and destocking activity historically has not caused any material changes in the rate of actual product returns.


•	Actual product returns have been less than 2 percent of our net revenue over each of the past three years and have not fluctuated significantly as a percentage of revenue, although fluctuations are more likely in periods following loss of patent exclusivity for major products in the U.S. market.

Adjustments to Revenue

Adjustments to revenue recognized as a result of changes in estimates for the judgments described above during 2018 for product shipped in previous years were approximately 1 percent of revenue.

Disaggregation of Revenue

Our disaggregated revenue is disclosed in Note 18.

Collaborations and Other Arrangements

We recognize several types of revenue from our collaborations and other arrangements, which we discuss in general terms immediately below and more specifically in Note 4 for each of our material collaborations and other arrangements. Our collaborations and other arrangements are not contracts with customers but are evaluated to determine whether any aspects of the arrangements are contracts with customers.


•	Revenue related to products we sell pursuant to these arrangements is included in net product revenue, while other sources of revenue (e.g., royalties and profit sharing from our partner) are included in collaboration and other revenue.


•	Initial fees and developmental milestones we receive in collaborative and other similar arrangements from the partnering of our compounds under development are generally deferred and amortized into income through the expected product approval date.


•	Profit-sharing due from our collaboration partners, which is based upon gross margins reported to us by our partners, is recognized as collaboration and other revenue as earned.


•	Royalty revenue from licensees, which is based on sales to third-parties of licensed products and technology, is recorded when the third-party sale occurs and the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). This royalty revenue is included in collaboration and other revenue.


•	For arrangements involving multiple goods or services (e.g., research and development, marketing and selling, manufacturing, and distribution), each required good or service is evaluated to determine whether it is distinct. If a good or service does not qualify as distinct, it is combined with the other non-distinct goods or services within the arrangement and these combined goods or services are

treated as a single performance obligation for accounting purposes. The arrangement's transaction price is then allocated to each performance obligation based on the relative standalone selling price of each performance obligation. For arrangements that involve variable consideration where we have sold intellectual property, we recognize revenue based on estimates of the amount of consideration we believe we will be entitled to receive from the other party, subject to a constraint. These estimates are adjusted to reflect the actual amounts to be collected when those facts and circumstances become known.


•	Significant judgments must be made in determining the transaction price for our sales of intellectual property. Because of the risk that products in development will not receive regulatory approval, we generally do not recognize any contingent payments that would be due to us upon or after regulatory approval.


•	We have entered into arrangements whereby we transferred rights to products and committed to supply for a period of time. For those arrangements for which we concluded that the obligations were not distinct, any amounts received upfront are being amortized to revenue as net product revenue over the period of the supply arrangement as the performance obligation is satisfied.

Contract Liabilities

Our contract liabilities result from arrangements where we have received payment in advance of performance under the contract and do not include sales rebates, discounts, and returns. Changes in contract liabilities are generally due to either receipt of additional advance payments or our performance under the contract.

We have the following amounts recorded for contract liabilities:



	2018		2017
Contract liabilities	$	294.9	$	330.9

The contract liabilities amount disclosed above as of December 31, 2018 and 2017, are primarily related to:


•	The remaining license period of symbolic intellectual property, and


•	Obligations to supply product for a defined period of time.

Revenue recognized from contract liabilities as of January 1, 2018, during the year ended December 31, 2018 was not material. Revenue expected to be recognized in the future from contract liabilities as the related performance obligations are satisfied is not expected to be material in any one year.

Research and development expenses and acquired in-process research and development

Research and development expenses include the following:


•	Research and development costs, which are expensed as incurred.


•	Milestone payment obligations incurred prior to regulatory approval of the product, which are accrued when the event requiring payment of the milestone occurs.

Acquired in-process research and development (IPR&D) expense includes the initial costs of IPR&D projects, acquired directly in a transaction other than a business combination, that do not have an alternative future use.

Earnings per share

We calculate basic earnings per share (EPS) based on the weighted-average number of common shares outstanding and incremental shares from potential participating securities. We calculate diluted EPS based on the weighted-average number of common shares outstanding, including incremental shares from our stock-based compensation programs.

Foreign Currency Translation

Operations in our subsidiaries outside the U.S. are recorded in the functional currency of each subsidiary which is determined by a review of the environment where each subsidiary primarily generates and expends cash. The results of operations for our subsidiaries outside the U.S. are translated from functional currencies into U.S. dollars using the weighted average currency rate for the period. Assets and liabilities are translated

using the period end exchange rates. The U.S. dollar effects that arise from translating the net assets of these subsidiaries are recorded in other comprehensive income (loss).

Other significant accounting policies

Our other significant accounting policies are described in the remaining appropriate notes to the consolidated financial statements.

Note 2: Implementation of New Financial Accounting Pronouncements

The following table provides a brief description of accounting standards that were effective January 1, 2018 and were adopted on that date:



Standard	Description	Effect on the financial statements or other significant matters
Accounting Standards Update 2014-09 and various other related updates, Revenue from Contracts with Customers	This standard replaced existing revenue recognition standards and requires entities to recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. An entity can apply the new revenue standard retrospectively to each prior reporting period presented or with the cumulative effect of initially applying the standard recognized at the date of initial application in retained earnings. We applied the latter approach.	Application of the new standard to applicable contracts resulted in an increase of approximately $5 million to retained earnings as of January 1, 2018. Disclosures required by the new standard are included in Note 1, Note 4, and Note 18.
Accounting Standards Update 2016-01, Financial Instruments - Overall: Recognition and Measurement of Financial Assets and Financial Liabilities	This standard requires entities to recognize changes in the fair value of equity investments with readily determinable fair values in net income (except for investments accounted for under the equity method of accounting or those that result in consolidation of the investee). An entity should apply the new standard through a cumulative effect adjustment to retained earnings as of the beginning of the fiscal year of adoption.	Upon adoption, we reclassified from accumulated other comprehensive loss the after-tax amount of net unrealized gains resulting in an increase to retained earnings of approximately $105 million. Adoption of this standard did not result in a material change in net income in 2018.
Accounting Standards Update 2016-16, Income Taxes: Intra-Entity Transfers of Assets Other Than Inventory	This standard requires entities to recognize the income tax consequences of intra-entity transfers of assets other than inventory at the time of transfer. This standard requires a modified retrospective approach to adoption.	Upon adoption, the cumulative effect of applying the standard resulted in an increase of approximately $700 million to retained earnings, $2.5 billion to deferred tax assets, and $1.8 billion to deferred tax liabilities. Adoption of this standard did not result in a material change in net income in 2018.



Accounting Standards Update 2017-07, Compensation-Retirement Benefits: Improving the Presentation of Net Periodic Pension Cost and Net Periodic Postretirement Benefit Cost	This standard was issued to improve the transparency and comparability among organizations by requiring entities to separate their net periodic pension cost and net periodic postretirement benefit cost into a service cost component and other components. Previously, the costs of the other components along with the service cost component were classified based upon the function of the employee. This standard requires entities to classify the service cost component in the same financial statement line item or items as other compensation costs arising from services rendered by pertinent employees. The other components of net benefit cost are now presented separately from the line items that include the service cost component. When applicable, the service cost component is now the only component eligible for capitalization. An entity should apply the new standard retrospectively for the classification of the service cost and other components and prospectively for the capitalization of the service cost component.	Upon adoption of this standard, pension and postretirement benefit cost components other than service costs are presented in other–net, (income) expense. The application of the new standard resulted in reclassification to other income of $249.0 million for the year ended December 31, 2017, while increasing cost of sales by $80.8 million, research and development expenses by $75.8 million, and marketing, selling, and administrative expenses by $92.4 million for the same period. The application of the new standard resulted in reclassification to other income of $197.1 million for the year ended December 31, 2016, while increasing cost of sales by $54.2 million, research and development expenses by $66.4 million, and marketing, selling, and administrative expenses by $76.5 million for the same period. We do not expect application of the new standard to have a material impact on an ongoing basis.

We elected to early adopt Accounting Standards Update 2018-02, Income Statement-Reporting Comprehensive Income: Reclassification of Certain Tax Effects from Accumulated Other Comprehensive Income as of December 31, 2017, which allowed a reclassification from accumulated other comprehensive loss to retained earnings for stranded tax effects resulting from the Tax Cuts and Jobs Act (2017 Tax Act - see Note 13). This standard allowed us to reclassify the effect of remeasuring deferred tax liabilities and assets related to items within accumulated other comprehensive loss using the then newly enacted 21 percent federal corporate income tax rate. The provisional effect of this early adoption was a reclassification from accumulated other comprehensive loss, which resulted in an increase to retained earnings of $643.6 million as of December 31, 2017.

The following table provides a brief description of the accounting standard that had not yet been adopted as of December 31, 2018:

Note 3: Acquisitions

We acquired assets in development in 2018, 2017, and 2016 which are further discussed in this note below in Asset Acquisitions. Upon acquisition, the acquired IPR&D charges related to these products were immediately expensed because the products had no alternative future use. For the years ended December 31, 2018, 2017, and 2016, we recorded acquired IPR&D charges of $1.98 billion, $1.11 billion, and $30.0 million, respectively. The acquired IPR&D charges in 2018 were primarily related to the acquisition of ARMO Biosciences, Inc. (ARMO). Substantially all of the value of ARMO was related to pegilodecakin, its only significant asset.

Acquisition of a Business

Subsequent Event - Loxo Oncology, Inc. (Loxo) Acquisition

Overview of transaction

On February 15, 2019, we acquired Loxo for a purchase price of $235 per share, or approximately $8 billion. Under the terms of the agreement, we acquired a pipeline of highly selective potential medicines for patients with genomically defined cancers. Loxo's pipeline includes LOXO-292, an oral RET inhibitor being studied across multiple tumor types, which recently was granted Breakthrough Therapy designation by the U.S. Food and Drug Administration. The accounting impact of this acquisition and the results of the operations for Loxo will be included in our consolidated financial statements beginning in the first quarter of 2019.

Assets Acquired and Liabilities Assumed

The initial accounting for this acquisition is incomplete. Significant, relevant information needed to complete the initial accounting is not available because the valuation of assets acquired and liabilities assumed is not complete. As a result, determining these values is not practicable and we are unable to disclose these values or provide other related disclosures at this time.

Asset Acquisitions

The following table and narrative summarize our asset acquisitions during 2018, 2017, and 2016.



Counterparty	Compound(s),Therapy, or Asset	Acquisition Month	Phase of Development⁽¹⁾	Acquired IPR&D Expense
Sigilon Therapeutics	Encapsulated cell therapies for the potential treatment of type 1 diabetes	April 2018	Pre-clinical	$	66.9
AurKa Pharma, Inc.	AK-01, an Aurora kinase A inhibitor	June 2018	Phase I	81.8
ARMO	Cancer therapy - pegilodecakin	June 2018	Phase III	1,475.8
Anima Biotech	Translation inhibitors for selected neuroscience targets	July 2018	Pre-clinical	30.0
SIGA Technologies, Inc.	Priority Review Voucher	October 2018	Not applicable	80.0
Chugai Pharmaceutical Company	OWL833, an oral non-peptidic GLP-1 receptor agonist	October 2018	Pre-clinical	50.0
NextCure, Inc.	Immuno-oncology cancer therapies	November 2018	Pre-clinical	28.1
Dicerna Pharmaceuticals	Cardio-metabolic disease, neurodegeneration, and pain	December 2018	Pre-clinical	148.7
Hydra Biosciences	TRPA1 antagonists program for the potential treatment of chronic pain syndromes	December 2018	Pre-clinical	22.6

CoLucid Pharmaceuticals, Inc. (CoLucid)	Oral therapy for the acute treatment of migraine - lasmiditan	March 2017	Phase III	857.6
KeyBioscience AG	Multiple molecules for treatment of metabolic disorders	July 2017	Phase II	55.0
Nektar Therapeutics	Immunological therapy - NKTR-358	August 2017	Phase I	150.0
CureVac AG	Cancer vaccines	November 2017	Pre-clinical	50.0

AstraZeneca	Antibody selective for amyloid-beta 42 (Aβ42) - MEDI1814	December 2016	Phase I	30.0

⁽¹⁾The phase of development presented is as of the date of the arrangement and represents the phase of development of the most advanced asset acquired, where applicable.

In connection with these arrangements, our partners may be entitled to future royalties and/or commercial milestones based on sales should products be approved for commercialization and/or milestones based on the successful progress of compounds through the development process.

Subsequent Event - AC Immune SA

In January 2019, we entered into a license and collaboration agreement with AC Immune SA for the discovery and development of tau aggregation inhibitor small molecules for the potential treatment of Alzheimer's disease and other neurodegenerative diseases. Under terms of the agreement, we paid an upfront fee of CHF80.0 million and we will pay $50.0 million in exchange for a note, convertible to equity at a premium. As a result of this transaction, we will record an acquired IPR&D expense of $96.9 million in the first quarter of 2019.

Note 4: Collaborations and Other Arrangements

We often enter into collaborative and other similar arrangements to develop and commercialize drug candidates. Collaborative activities may include research and development, marketing and selling (including promotional activities and physician detailing), manufacturing, and distribution. These arrangements often require milestone and royalty or profit-share payments, contingent upon the occurrence of certain future events linked to the success of the asset in development, as well as expense reimbursements or payments to the collaboration partner. See Note 1 for amounts of collaboration and other revenue recognized from these types of arrangements.

Operating expenses for costs incurred pursuant to these arrangements are reported in their respective expense line item, net of any payments due to or reimbursements due from our collaboration partners, with such reimbursements being recognized at the time the party becomes obligated to pay. Each collaboration is unique in nature, and our more significant arrangements are discussed below.

Boehringer Ingelheim Diabetes Collaboration

We and Boehringer Ingelheim have a global agreement to jointly develop and commercialize a portfolio of diabetes compounds. Currently, included in the collaboration are Boehringer Ingelheim’s oral diabetes products: Trajenta, Jentadueto^®, Jardiance, Glyxambi^®, and Synjardy^®, as well as our basal insulin: Basaglar^®.

The table below summarizes significant milestones (deferred) capitalized for the compounds included in this collaboration:



Product Family	Milestones (Deferred) Capitalized⁽¹⁾
Product Family	Year	Amount
Trajenta⁽²⁾	Cumulative⁽⁴⁾	$	446.4
Jardiance⁽³⁾	Cumulative⁽⁴⁾	289.0
Basaglar	2018	—
	2017	—
	2016	(187.5		)
	Cumulative⁽⁴⁾	(250.0		)

⁽¹⁾In connection with the regulatory approvals of Basaglar in the U.S., Europe, and Japan, milestone payments received were recorded as contract liabilities and are being amortized through the term of the collaboration (2029) to collaboration and other revenue. In connection with the regulatory approvals of Trajenta and Jardiance, milestone payments made were capitalized as intangible assets and are being amortized to cost of sales through the term of the collaboration.

⁽²⁾Jentadueto is included in the Trajenta product family. The collaboration agreement with Boehringer Ingelheim for Trajenta ends upon expiration of the compound patent and any supplementary protection certificates or extensions thereto.

⁽³⁾Glyxambi and Synjardyare included in the Jardiance product family. The collaboration agreement with Boehringer Ingelheim for Jardiance ends upon expiration of the compound patent and any supplementary protection certificates or extensions thereto.

⁽⁴⁾The cumulative amount represents the total amounts that have been (deferred) or capitalized from the start of this collaboration through the end of the reporting period.

In the most significant markets, we and Boehringer Ingelheim share equally the ongoing development costs, commercialization costs, and agreed upon gross margin for any product resulting from the collaboration. We record our portion of the gross margin associated with Boehringer Ingelheim's products as collaboration and other revenue. We record our sales of Basaglar to third parties as net product revenue with the payments made to Boehringer Ingelheim for their portion of the gross margin recorded as cost of sales. For all compounds under this collaboration, we record our portion of the development and commercialization costs as research and development expense and marketing, selling, and administrative expense, respectively. Each company is entitled to potential performance payments depending on the sales of the molecules it contributes to the collaboration. These performance payments result in the owner of the molecule retaining a greater share of the agreed upon gross margin of that product. Subject to achieving these thresholds, in a given period, our reported revenue for Trajenta and Jardiance may be reduced by any performance payments we make related to these products. Similarly, performance payments we may receive related to Basaglar effectively reduce Boehringer Ingelheim's share of the gross margin, which reduces our cost of sales.

The following table summarizes our collaboration and other revenue recognized with respect to the Trajenta and Jardiance families of products and net product revenue recognized with respect to Basaglar:



	2018		2017		2016
Basaglar	$	801.2	$	432.1	$	86.1
Jardiance	658.3		447.5		201.9
Trajenta	574.7		537.9		436.6

Erbitux^®

We have several collaborations with respect to Erbitux. The most significant collaborations are or, where applicable, were in Japan, and prior to the transfer of commercialization rights in the fourth quarter of 2015, the U.S. and Canada (Bristol-Myers Squibb Company); and worldwide except the U.S. and Canada (Merck KGaA). Certain rights to Erbitux outside the U.S. and Canada (North America) will remain with Merck KGaA (Merck) upon expiration of that agreement.

The following table summarizes our revenue recognized with respect to Erbitux:



	2018		2017		2016
Net product revenue	$	536.1	$	548.2	$	587.0
Collaboration and other revenue	99.2		97.7		100.0
Revenue	$	635.3	$	645.9	$	687.0

Bristol-Myers Squibb Company

Pursuant to commercial agreements with Bristol-Myers Squibb Company and E.R. Squibb (collectively, BMS), we had been co-developing Erbitux in North America exclusively with BMS. On October 1, 2015, BMS transferred their commercialization rights to us with respect to Erbitux in North America pursuant to a modification of our existing arrangement, and we began selling Erbitux at that time. This modification did not affect our rights with respect to Erbitux in other jurisdictions. In connection with the modification of terms, we provided consideration to BMS based upon a tiered percentage of net sales of Erbitux in North America estimated to average 38 percent through September 2018. The transfer of the commercialization rights was accounted for as an acquisition of a business. The consideration to be paid to BMS was accounted for as contingent consideration liability.

Merck KGaA

A development and license agreement granted Merck exclusive rights to market Erbitux outside of North America until December 2018. A separate agreement grants co-exclusive rights among Merck, BMS, and us in Japan and expires in 2032. This agreement was amended in 2015 to grant Merck exclusive commercialization rights in Japan but did not result in any other changes to our rights.

Merck manufactures Erbitux for supply in its territory, including Japan. We receive a royalty on the sales of Erbitux outside of North America, which is included in collaboration and other revenue as the underlying sales occur. Royalties due to third parties are recorded as a reduction of collaboration and other revenue, net of any royalty reimbursements due from third parties.

Olumiant^®

We have a worldwide license and collaboration agreement with Incyte Corporation (Incyte) which provides us the development and commercialization rights to its Janus tyrosine kinase (JAK) inhibitor compound, now known as Olumiant, and certain follow-on compounds, for the treatment of inflammatory and autoimmune diseases. Incyte has the right to receive tiered, double-digit royalty payments on future global sales with rates ranging up to 20 percent if the product is successfully commercialized. The agreement provides Incyte with options to co-develop these compounds on an indication-by-indication basis by funding 30 percent of the associated development costs from the initiation of a Phase IIb trial through regulatory approval in exchange for increased tiered royalties ranging up to percentages in the high twenties. Incyte exercised its option to co-develop Olumiant in rheumatoid arthritis in 2010 and psoriatic arthritis, atopic dermatitis, alopecia areata, and systemic lupus erythematosus (SLE) in 2017. The agreement calls for payments by us to Incyte associated with certain development, success-based regulatory, and sales-based milestones. The following table summarizes our milestones achieved:



Year	Event	Classification	Amount
2018	Regulatory approval in the U.S.	Intangible asset	$	100.0
2018	Began Phase III testing for SLE	R&D Expense	20.0
2017	Regulatory approval in Europe	Intangible asset	65.0
	Regulatory approval in Japan	Intangible asset	15.0
	Began Phase III testing for atopic dermatitis	R&D expense	30.0
2016	Regulatory submissions in the U.S. and Europe	R&D expense	55.0

As of December 31, 2018, Incyte is eligible to receive up to $130.0 million of additional payments from us contingent upon certain development and success-based regulatory milestones. Incyte is also eligible to receive up to $150.0 million of potential sales-based milestones.

Effient^®

We are in a collaborative arrangement with Daiichi Sankyo Co., Ltd. (Daiichi Sankyo) to develop, market, and promote Effient. Marketing rights for major territories are shown below. We and Daiichi Sankyo each have exclusive marketing rights in certain other territories.



Territory	Marketing Rights	Selling Party
U.S.	Co-promotion	Lilly
Major European markets	Co-promotion	Daiichi Sankyo
Japan	Exclusive	Daiichi Sankyo

The parties share approximately 50/50 in the profits, as well as in the costs of development and marketing in the co-promotion territories. A third party manufactures bulk product, and we produce the finished product for our exclusive and co-promotion territories, including the major European markets.

We record net product revenue in our exclusive and co-promotion territories where we are the selling party. Profit-share payments due to Daiichi Sankyo for co-promotion countries where we are the selling party are recorded as marketing, selling, and administrative expenses. Any profit-share payments due to us from Daiichi Sankyo for the major European markets are recorded as collaboration and other revenue. We also record our share of the expenses in these co-promotion territories as marketing, selling, and administrative expenses. In our exclusive territories, we pay Daiichi Sankyo a royalty specific to these territories. All royalties due to Daiichi Sankyo and the third-party manufacturer are recorded in cost of sales. Generic versions of Effient launched in the U.S. in the third quarter of 2017.

The following table summarizes our revenue recognized with respect to Effient:



	2018		2017		2016
Revenue	$	122.2	$	388.9	$	535.2

Tanezumab

We have a collaboration agreement with Pfizer Inc. (Pfizer) to jointly develop and globally commercialize tanezumab for the treatment of osteoarthritis pain, chronic low back pain and cancer pain. Under the agreement, the companies share equally the ongoing development costs and, if successful, in gross margins and certain commercialization expenses. As of December 31, 2018, Pfizer is eligible to receive up to $350.0 million in success-based regulatory milestones and up to $1.23 billion in a series of sales-based milestones, contingent upon the commercial success of tanezumab.

Note 5: Asset Impairment, Restructuring, and Other Special Charges

The components of the charges included in asset impairment, restructuring, and other special charges in our consolidated statements of operations are described below:



	2018		2017		2016
Severance	$	127.8	$	601.0	$	85.9
Pension and post-retirement medical charges associated with U.S. voluntary early retirement program (see Note 14)	—		446.7		—
Asset impairment (gains from facility sales) and other special charges	139.1		283.9		(13.0		)
Total asset impairment, restructuring, and other special charges	$	266.9	$	1,331.6	$	72.9

Severance costs recognized during the years ended December 31, 2018, 2017 and 2016 were incurred as a result of actions taken to reduce our cost structure. Severance costs recognized in 2017 were associated with the U.S. voluntary early retirement program. During 2017, severance costs recognized in the U.S. and outside the U.S. were $368.3 million and $232.7 million, respectively. Substantially all of the severance costs incurred in 2016 and 2017 have been paid. Of the severance costs incurred during the year ended December 31, 2018, approximately half will be paid in 2019 and half will be paid in 2020.

Asset impairment and other special charges recognized during the year ended December 31, 2018 resulted primarily from asset impairment and other special charges related to the sale of the Posilac^® (rbST) brand and the associated Augusta, Georgia manufacturing site.

Asset impairment and other special charges recognized during the year ended December 31, 2017 resulted primarily from asset impairments related to lower projected revenue for Posilac (rbST). The assets associated with Posilac (rbST) were written down to their fair values, which were determined based upon a discounted cash flow valuation. Impairment charges were recorded for the associated fixed assets and intangible asset of $151.5 million and $50.0 million, respectively (refer to Note 8 for further detail relating to intangible asset impairments). In addition, we incurred approximately $43.4 million of costs associated with the temporary shut down of our Puerto Rico facility following Hurricane Maria.

Note 6: Inventories

We use the last-in, first-out (LIFO) method for the majority of our inventories located in the continental U.S. Other inventories are valued by the first-in, first-out (FIFO) method. FIFO cost approximates current replacement cost. Inventories measured using LIFO must be valued at the lower of cost or market. Inventories measured using FIFO must be valued at the lower of cost or net realizable value.

Inventories at December 31 consisted of the following:



	2018		2017
Finished products	$	577.8	$	759.4
Work in process	2,057.8		2,117.7
Raw materials and supplies	426.1		418.4
Total (approximates replacement cost)	3,061.7		3,295.5
Increase (reduction) to LIFO cost	36.4		100.5
Inventories	$	3,098.1	$	3,396.0

Inventories valued under the LIFO method comprised $1.37 billion and $1.33 billion of total inventories at December 31, 2018 and 2017, respectively.

Note 7: Financial Instruments

Financial instruments that potentially subject us to credit risk consist principally of trade receivables and interest-bearing investments. Wholesale distributors of life-science products account for a substantial portion of our trade receivables; collateral is generally not required. We seek to mitigate the risk associated with this concentration through our ongoing credit-review procedures and insurance. A large portion of our cash is held by a few major financial institutions. We monitor our exposures with these institutions and do not expect any of these institutions to fail to meet their obligations. Major financial institutions represent the largest component of our investments in corporate debt securities. In accordance with documented corporate risk-management policies, we monitor the amount of credit exposure to any one financial institution or corporate issuer. We are exposed to credit-related losses in the event of nonperformance by counterparties to risk-management instruments but do not expect any counterparties to fail to meet their obligations given their high credit ratings.

We consider all highly liquid investments with a maturity of three months or less from the date of purchase to be cash equivalents. The cost of these investments approximates fair value.

Our equity investments are accounted for using three different methods depending on the type of equity investment:


•	Investments in companies over which we have significant influence but not a controlling interest are accounted for using the equity method, with our share of earnings or losses reported in other-net, (income) expense.


•	For equity investments that do not have readily determinable fair values, we measure these investments at cost, less any impairment, plus or minus changes resulting from observable price changes in orderly transactions for the identical or similar investment of the same issuer. Any change in recorded value is recorded in other-net, (income) expense.


•	Our public equity investments are measured and carried at fair value. Any change in fair value is recognized in other-net, (income) expense.

We review equity investments other than public equity investments for indications of impairment on a regular basis.

Our derivative activities are initiated within the guidelines of documented corporate risk-management policies and are intended to offset losses and gains on the assets, liabilities, and transactions being hedged. Management reviews the correlation and effectiveness of our derivatives on a quarterly basis.

For derivative instruments that are designated and qualify as fair value hedges, the derivative instrument is marked to market with gains and losses recognized currently in income to offset the respective losses and gains recognized on the underlying exposure. For derivative instruments that are designated and qualify as cash flow hedges, gains and losses are reported as a component of accumulated other comprehensive loss and reclassified into earnings in the same period the hedged transaction affects earnings. For derivative and non-derivative instruments that are designated and qualify as net investment hedges, the foreign currency translation gains or losses due to spot rate fluctuations are reported as a component of accumulated other comprehensive loss. Derivative contracts that are not designated as hedging instruments are recorded at fair value with the gain or loss recognized in earnings during the period of change.

We may enter into foreign currency forward or option contracts to reduce the effect of fluctuating currency exchange rates (principally the euro, British pound, and the Japanese yen). Foreign currency derivatives used for hedging are put in place using the same or like currencies and duration as the underlying exposures. Forward and option contracts are principally used to manage exposures arising from subsidiary trade and loan payables and receivables denominated in foreign currencies. These contracts are recorded at fair value with the gain or loss recognized in other–net, (income) expense. We may enter into foreign currency forward and option contracts and currency swaps as fair value hedges of firm commitments. Forward contracts generally have maturities not exceeding 12 months. At December 31, 2018, we had outstanding foreign currency forward commitments to purchase 785.5 million U.S. dollars and sell 685.3 million euro; commitments to purchase 2.05 billion euro and sell 2.35 billion U.S. dollars; commitments to purchase 435.1 million U.S. dollars and sell 48.85 billion Japanese yen, commitments to purchase 255.6 million Swiss francs and sell 259.7 million U.S. dollars, commitments to purchase 388.3 million U.S. dollars and sell 306.7 million

British pounds, and commitments to purchase 354.0 million British pounds and sell 448.1 million U.S. dollars which will all settle within 30 days.

Foreign currency exchange risk is also managed through the use of foreign currency debt and cross-currency interest rate swaps. Our foreign currency-denominated notes had carrying amounts of $3.40 billion and $3.70 billion as of December 31, 2018 and 2017, respectively, of which $2.65 billion and $3.70 billion have been designated as, and are effective as, economic hedges of net investments in certain of our euro-denominated and Swiss franc-denominated foreign operations as of December 31, 2018 and 2017, respectively. Our cross-currency interest rate swaps, for which a majority convert a portion of our U.S. dollar-denominated floating rate debt to foreign-denominated floating rate debt, have also been designated as, and are effective as, economic hedges of net investments. At December 31, 2018, we had outstanding cross currency swaps with notional amounts of $2.46 billion swapping U.S. dollars to euro, $754.0 million swapping Swiss francs to U.S. dollars, and $350.0 million swapping U.S. dollars to British pounds, which have settlement dates ranging through 2028.

In the normal course of business, our operations are exposed to fluctuations in interest rates which can vary the costs of financing, investing, and operating. We seek to address a portion of these risks through a controlled program of risk management that includes the use of derivative financial instruments. The objective of controlling these risks is to limit the impact of fluctuations in interest rates on earnings. Our primary interest-rate risk exposure results from changes in short-term U.S. dollar interest rates. In an effort to manage interest-rate exposures, we strive to achieve an acceptable balance between fixed- and floating-rate debt and investment positions and may enter into interest rate swaps or collars to help maintain that balance.

Interest rate swaps or collars that convert our fixed-rate debt to a floating rate are designated as fair value hedges of the underlying instruments. Interest rate swaps or collars that convert floating-rate debt to a fixed rate are designated as cash flow hedges. Interest expense on the debt is adjusted to include the payments made or received under the swap agreements. Cash proceeds from or payments to counterparties resulting from the termination of interest rate swaps are classified as operating activities in our consolidated statements of cash flows. At December 31, 2018, substantially all of our total long-term debt is at a fixed rate. We have converted approximately 25 percent of our long-term fixed-rate notes to floating rates through the use of interest rate swaps.

We may enter into forward contracts and designate them as cash flow hedges to limit the potential volatility of earnings and cash flow associated with forecasted sales of available-for-sale securities.

We also may enter into forward-starting interest rate swaps, which we designate as cash flow hedges, as part of any anticipated future debt issuances in order to reduce the risk of cash flow volatility from future changes in interest rates. Upon completion of a debt issuance and termination of the swap, the change in fair value of these instruments is recorded as part of other comprehensive income (loss) and is amortized to interest expense over the life of the underlying debt.

The Effect of Risk Management Instruments on the Consolidated Statements of Operations

The following effects of risk-management instruments were recognized in other–net, (income) expense:



	2018			2017			2016
Fair value hedges:
Effect from hedged fixed-rate debt	$	(40.9	)	$	(14.1	)	$	(30.8	)
Effect from interest rate contracts	40.9			14.1			30.8
Cash flow hedges:
Effective portion of losses on interest rate contracts reclassified from accumulated other comprehensive loss	14.8			14.8			15.0
Net losses on foreign currency exchange contracts not designated as hedging instruments	100.0			97.9			78.8
Total	$	114.8		$	112.7		$	93.8

During the years ended December 31, 2018, the amortization of losses related to the portion of our risk management hedging instruments, fair value hedges, and cash flow hedges that were excluded from the assessment of effectiveness were not material.

During the years ended December 31, 2017, and 2016, net losses related to ineffectiveness, as well as net losses related to the portion of our risk-management hedging instruments, fair value hedges, and cash flow hedges that were excluded from the assessment of effectiveness, were not material.

The Effect of Risk-Management Instruments on Other Comprehensive Income (Loss)

The effective portion of risk-management instruments that was recognized in other comprehensive income (loss) is as follows:



	2018		2017			2016
Net investment hedges:
Foreign currency-denominated notes	$	110.4	$	(361.5	)	$	137.5
Cross-currency interest rate swaps	96.8		(126.6		)	32.5
Foreign currency exchange contracts	5.7		—			31.9
Cash flow hedges:
Forward-starting interest rate swaps	—		13.0			(3.4		)

During the next 12 months, we expect to reclassify $15.0 million of pretax net losses on cash flow hedges from accumulated other comprehensive loss to other–net, (income) expense. During the year ended December 31, 2018, the amounts excluded from the assessment of hedge effectiveness recognized in other comprehensive income (loss) was not material.

Fair Value of Financial Instruments

The following tables summarize certain fair value information at December 31 for assets and liabilities measured at fair value on a recurring basis, as well as the carrying amount and amortized cost of certain other investments:



					Fair Value Measurements Using
Description	Carrying Amount		Cost⁽¹⁾		Quoted Prices in Active Markets for Identical Assets (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)		Fair Value
December 31, 2018
Cash equivalents	$	5,727.1	$	5,727.1	$	5,727.1	$	—	$	—	$	5,727.1
Short-term investments:
U.S. government and agency securities	$	16.9	$	17.1	$	16.9	$	—	$	—	$	16.9
Corporate debt securities	62.2		62.6		—		62.2		—		62.2
Asset-backed securities	7.6		7.7		—		7.6		—		7.6
Other securities	1.5		1.5		—		1.5		—		1.5
Short-term investments	$	88.2
Noncurrent investments:
U.S. government and agency securities	$	149.1	$	153.6	$	149.1	$	—	$	—	$	149.1
Corporate debt securities	568.0		587.8		—		568.0		—		568.0
Mortgage-backed securities	111.4		114.5		—		111.4		—		111.4
Asset-backed securities	27.7		27.9		—		27.7		—		27.7
Other securities	87.8		29.7		—		—		87.8		87.8
Marketable equity securities	357.5		238.3		357.5		—		—		357.5
Equity investments without readily determinable fair values⁽²⁾	414.7
Equity method investments⁽²⁾	289.2
Noncurrent investments	$	2,005.4

December 31, 2017
Cash equivalents	$	4,763.9	$	4,763.9	$	4,712.4	$	51.5	$	—	$	4,763.9
Short-term investments:
U.S. government and agency securities	$	217.8	$	218.2	$	217.8	$	—	$	—	$	217.8
Corporate debt securities	1,182.3		1,183.2		—		1,182.3		—		1,182.3
Asset-backed securities	94.2		94.3		—		94.2		—		94.2
Other securities	3.6		3.6		—		3.6		—		3.6
Short-term investments	$	1,497.9
Noncurrent investments:
U.S. government and agency securities	$	360.0	$	365.0	$	360.0	$	—	$	—	$	360.0
Corporate debt securities	3,464.3		3,473.5		—		3,464.3		—		3,464.3
Mortgage-backed securities	202.4		204.2		—		202.4		—		202.4
Asset-backed securities	653.9		656.0		—		653.9		—		653.9
Other securities	132.1		66.4		—		—		132.1		132.1
Marketable equity securities	281.3		131.0		281.3		—		—		281.3
Cost and equity method investments⁽²⁾	572.5
Noncurrent investments	$	5,666.5

⁽¹⁾For available-for-sale debt securities, amounts disclosed represent the securities' amortized cost.

⁽²⁾Fair value disclosures are not applicable for equity method investments, investments accounted for under the measurement alternative for equity investments, and cost method investments that do not have readily determinable fair values.



				Fair Value Measurements Using
Description	Carrying Amount			Quoted Prices in Active Markets for Identical Assets (Level 1)		Significant Other Observable Inputs (Level 2)			Significant Unobservable Inputs (Level 3)		Fair Value
Short-term commercial paper borrowings
December 31, 2018	$	(498.9	)	$	—	$	(497.6	)	$	—	$	(497.6	)
December 31, 2017	(2,696.8		)	—		(2,690.6		)	—		(2,690.6		)

Long-term debt, including current portion
December 31, 2018	$	(9,799.7	)	$	—	$	(9,989.4	)	$	—	$	(9,989.4	)
December 31, 2017	(10,950.3		)	—		(11,529.9		)	—		(11,529.9		)



				Fair Value Measurements Using
Description	Carrying Amount			Quoted Prices in Active Markets for Identical Assets (Level 1)		Significant Other Observable Inputs (Level 2)			Significant Unobservable Inputs (Level 3)			Fair Value
December 31, 2018
Risk-management instruments
Interest rate contracts designated as fair value hedges:
Sundry	$	4.5		$	—	$	4.5		$	—		$	4.5
Other current liabilities	(22.3		)	—		(22.3		)	—			(22.3		)
Other noncurrent liabilities	(19.0		)	—		(19.0		)	—			(19.0		)
Cross-currency interest rate contracts designated as net investment hedges:
Other receivables	69.2			—		69.2			—			69.2
Sundry	8.2			—		8.2			—			8.2
Other current liabilities	(9.2		)	—		(9.2		)	—			(9.2		)
Cross-currency interest rate contracts not designated as hedging instruments:
Other noncurrent liabilities	(25.8		)	—		(25.8		)	—			(25.8		)
Foreign exchange contracts not designated as hedging instruments:
Other receivables	11.3			—		11.3			—			11.3
Other current liabilities	(16.3		)	—		(16.3		)	—			(16.3		)

December 31, 2017
Risk-management instruments
Interest rate contracts designated as fair value hedges:
Other receivables	$	0.8		$	—	$	0.8		$	—		$	0.8
Sundry	35.1			—		35.1			—			35.1
Other current liabilities	(0.2		)	—		(0.2		)	—			(0.2		)
Other noncurrent liabilities	(10.5		)	—		(10.5		)	—			(10.5		)
Cross-currency interest rate contracts designated as net investment hedges:
Other current liabilities	(33.4		)	—		(33.4		)	—			(33.4		)
Other noncurrent liabilities	(26.0		)	—		(26.0		)	—			(26.0		)
Foreign exchange contracts not designated as hedging instruments:
Other receivables	26.8			—		26.8			—			26.8
Other current liabilities	(36.0		)	—		(36.0		)	—			(36.0		)
Contingent consideration liabilities
Other current liabilities	(206.7		)	—		—			(206.7		)	(206.7		)

Risk-management instruments above are disclosed on a gross basis. There are various rights of setoff associated with certain of the risk-management instruments above that are subject to an enforceable master netting arrangement or similar agreements. Although various rights of setoff and master netting arrangements or similar agreements may exist with the individual counterparties to the risk-management instruments above, individually, these financial rights are not material.

We determine our Level 1 and Level 2 fair value measurements based on a market approach using quoted market values, significant other observable inputs for identical or comparable assets or liabilities, or discounted cash flow analyses. Level 3 fair value measurements for other investment securities are determined using unobservable inputs, including the investments' cost adjusted for impairments and price changes from orderly transactions. The fair values of equity method investments and investments measured under the measurement alternative for equity investments that do not have readily determinable fair values are not readily available.

Contingent consideration liabilities were recorded at fair value and were estimated using a discounted cash flow analysis and Level 3 inputs, including projections representative of a market participant view for net sales and an estimated discount rate. The decrease in the fair value of the contingent consideration liabilities during the years ended December 31, 2018 and 2017 was due primarily to cash payments of $199.7 million and $203.1 million, which related to Erbitux (see Note 4). The change in the fair value of the contingent consideration liabilities recognized in earnings during the years ended December 31, 2018, 2017, and 2016 due to changes in time value of money was not material.

The table below summarizes the contractual maturities of our investments in debt securities measured at fair value as of December 31, 2018:



	Maturities by Period
	Total		Less Than 1 Year		1-5 Years		6-10 Years		More Than 10 Years
Fair value of debt securities	$	943.0	$	86.8	$	604.8	$	97.0	$	154.4

A summary of the fair value of available-for-sale securities in an unrealized gain or loss position and the amount of unrealized gains and losses (pretax) in accumulated other comprehensive loss follows:



	2018		2017
Unrealized gross gains	$	0.8	$	184.7
Unrealized gross losses	29.0		47.5
Fair value of securities in an unrealized gain position	84.3		1,434.2
Fair value of securities in an unrealized loss position	858.6		4,692.8

The unrealized losses (pretax) recognized in our consolidated statement of operations for equity securities held as of December 31, 2018 was $20.1 million.

We periodically assess our investment in available-for-sale securities for other-than-temporary impairment losses. There were no other-than-temporary impairment losses recognized in 2018 or 2017. Other-than-temporary impairment losses recognized during the year ended December 31, 2016 totaled $53.0 million. Other-than-temporary impairment losses recognized during 2016 related primarily to our cost and equity method investments.

We periodically assess our investments in equity securities other than public equity securities for impairment losses. Impairment losses recognized on these equity securities in 2018 were immaterial.

For fixed-income securities, the amount of credit losses are determined by comparing the difference between the present value of future cash flows expected to be collected on these securities and the amortized cost. Factors considered in assessing credit losses include the position in the capital structure, vintage and amount of collateral, delinquency rates, current credit support, and geographic concentration.

For equity securities, factors considered in assessing impairment losses include the financial condition and near term prospects of the issuer and general market conditions and industry specific factors.

As of December 31, 2018, the available-for-sale securities in an unrealized loss position include primarily fixed-rate debt securities of varying maturities, which are sensitive to changes in the yield curve and other market conditions. Approximately 55 percent of the fixed-rate debt securities in a loss position are investment-grade debt securities. As of December 31, 2018, we do not intend to sell, and it is not more likely than not that we will be required to sell, the securities in a loss position before the market values recover or the underlying cash flows have been received, and there is no indication of default on interest or principal payments for any of our debt securities.

Activity related to our investment portfolio, substantially all of which related to equity and available-for-sale securities, was as follows:



	2018		2017		2016
Proceeds from sales	$	5,668.0	$	5,769.3	$	3,240.5
Realized gross gains on sales	11.8		176.0		30.7
Realized gross losses on sales	51.3		5.8		14.6

Realized gains and losses on sales of available-for-sale investments are computed based upon specific identification of the initial cost adjusted for any other-than-temporary declines in fair value that were recorded in earnings.

Adjustments recorded to our equity investments without readily determinable fair values are based upon changes in the equity instrument's value resulting from observable price changes in orderly transactions for an identical or similar investment of the same issuer. Downward adjustments resulting from an impairment are recorded based upon the impairment considerations mentioned above. Adjustments recorded during 2018 were not material.

Accounts Receivable Factoring Arrangements

We have entered into accounts receivable factoring agreements with financial institutions to sell certain of our non-U.S. accounts receivable. These transactions are accounted for as sales and result in a reduction in accounts receivable because the agreements transfer effective control over and risk related to the receivables to the buyers. Our factoring agreements do not allow for recourse in the event of uncollectibility, and we do not retain any interest in the underlying accounts receivable once sold. We derecognized $696.2 million and $723.2 million of accounts receivable as of December 31, 2018 and 2017, respectively, under these factoring arrangements. The costs of factoring such accounts receivable on our consolidated results of operations for the years ended December 31, 2018, 2017, and 2016 were not material.

Note 8: Goodwill and Other Intangibles

Goodwill

Goodwill results from excess consideration in a business combination over the fair value of identifiable net assets acquired. Goodwill is not amortized but is reviewed for impairment at least annually and when impairment indicators are present. When required, a comparison of the fair value of the reporting unit to its carrying amount including goodwill is used to determine the amount of any impairment.

No impairments occurred with respect to the carrying value of goodwill for the years ended December 31, 2018, 2017, and 2016.

Other Intangibles

The components of intangible assets other than goodwill at December 31 were as follows:



	2018							2017
Description	Carrying Amount, Gross		Accumulated Amortization			Carrying Amount, Net		Carrying Amount, Gross		Accumulated Amortization			Carrying Amount, Net
Finite-lived intangible assets:
Marketed products	$	2,077.2	$	(1,069.0	)	$	1,008.2	$	4,528.8	$	(3,251.3	)	$	1,277.5
Other	89.5		(29.7		)	59.8		117.1		(40.2		)	76.9
Other intangibles	$	2,166.7	$	(1,098.7	)	$	1,068.0	$	4,645.9	$	(3,291.5	)	$	1,354.4

Marketed products consist of the amortized cost of the rights to assets acquired in business combinations and approved for marketing in a significant global jurisdiction (U.S., Europe, and Japan) and capitalized milestone payments. For transactions other than a business combination, we capitalize milestone payments incurred at or after the product has obtained regulatory approval for marketing.

Other finite-lived intangibles consist primarily of the amortized cost of licensed platform technologies that have alternative future uses in research and development, manufacturing technologies, and customer relationships from business combinations.

Acquired IPR&D consists of the related costs capitalized, adjusted for subsequent impairments, if any. The costs of acquired IPR&D projects acquired directly in a transaction other than a business combination are capitalized if the projects have an alternative future use; otherwise, they are expensed immediately. The fair values of acquired IPR&D projects acquired in business combinations, if any, are capitalized as other intangible assets. As of December 31, 2018 and 2017, we had no acquired IPR&D indefinite-lived intangible assets.

Several methods may be used to determine the estimated fair value of other intangibles acquired in a business combination. We utilize the “income method,” which is a Level 3 fair value measurement and applies a probability weighting that considers the risk of development and commercialization to the estimated future net cash flows that are derived from projected revenues and estimated costs. These projections are based on factors such as relevant market size, patent protection, historical pricing of similar products, and expected industry trends. The estimated future net cash flows are then discounted to the present value using an appropriate discount rate. This analysis is performed for each asset independently. The acquired IPR&D assets are treated as indefinite-lived intangible assets until completion or abandonment of the projects, at which time the assets are tested for impairment and amortized over the remaining useful life or written off, as appropriate.

See Note 4 for additional discussion of recent capitalized milestone payments.

Other indefinite-lived intangible assets are reviewed for impairment at least annually and when impairment indicators are present. Finite-lived intangible assets are reviewed for impairment when an indicator of impairment is present. When required, a comparison of fair value to the carrying amount of assets is performed to determine the amount of any impairment. When determining the fair value of indefinite-lived acquired IPR&D as well as the fair value of finite-lived intangible assets for impairment testing purposes, we utilize the "income method" discussed above. During 2018, we had finite-lived intangible impairment charges of $46.9 million which were recorded in asset impairment, restructuring and other special charges on the consolidated statements of operations. These impairments were primarily related to the sale of the Posilac (rbST) brand. During 2017, we had finite-lived intangible impairment charges of $50.0 million which were recorded in asset impairment, restructuring and other special charges on the consolidated statements of operations. These impairments were related to lower projected revenue for Posilac (rbST). No material impairments occurred with respect to the carrying value of other intangible assets for the year ended December 31, 2016.

Intangible assets with finite lives are capitalized and are amortized over their estimated useful lives, ranging from three to 20 years. As of December 31, 2018, the remaining weighted-average amortization period for finite-lived intangible assets was approximately 10 years.

Amortization expense related to finite-lived intangible assets was as follows:



	2018		2017		2016
Amortization expense	$	361.3	$	462.2	$	517.2

The estimated amortization expense for each of the next five years associated with our finite-lived intangible assets as of December 31, 2018 is as follows:



	2019		2020		2021		2022		2023
Estimated amortization expense	$	145.4	$	144.0	$	141.6	$	133.8	$	122.6

Amortization expense is included in either cost of sales, marketing, selling, and administrative or research and development depending on the nature of the intangible asset being amortized.

Note 9: Property and Equipment

Property and equipment is stated on the basis of cost. Provisions for depreciation of buildings and equipment are computed generally by the straight-line method at rates based on their estimated useful lives (12 to 50 years for buildings and three to 25 years for equipment). We review the carrying value of long-lived assets for potential impairment on a periodic basis and whenever events or changes in circumstances indicate the carrying value of an asset may not be recoverable. Impairment is determined by comparing projected undiscounted cash flows to be generated by the asset to its carrying value. If an impairment is identified, a loss is recorded equal to the excess of the asset’s net book value over its fair value, and the cost basis is adjusted.

At December 31, property and equipment consisted of the following:



	2018			2017
Land	$	165.5		$	167.7
Buildings	7,116.6			6,826.9
Equipment	7,792.3			7,684.1
Construction in progress	1,588.6			1,600.6
	16,663.0			16,279.3
Less accumulated depreciation	(8,666.9		)	(8,394.2		)
Property and equipment, net	$	7,996.1		$	7,885.1

Depreciation expense related to property and equipment and rental expense for all leases, including contingent rentals (not material), was as follows:



	2018		2017		2016
Depreciation expense	$	797.1	$	681.7	$	638.8
Rental expense	175.7		177.4		179.2

The future minimum rental commitments under non-cancelable operating leases are as follows:



	2019		2020		2021		2022		2023		After 2023
Lease commitments	$	130.6	$	107.9	$	75.5	$	64.7	$	49.9	$	281.0

Capitalized interest costs were not material for the years ended December 31, 2018, 2017, and 2016.

Assets under capital leases included in property and equipment, net on the consolidated balance sheets, capital lease obligations entered into, and future minimum rental commitments are not material.

Note 10: Borrowings

Debt at December 31 consisted of the following:



	2018			2017
Short-term commercial paper borrowings	$	498.9		$	2,696.8
0.15 to 7.13 percent long-term notes (due 2019-2047)	9,640.8			10,756.7
Other long-term debt	10.1			13.0
Unamortized debt issuance costs	(28.4		)	(49.0		)
Fair value adjustment on hedged long-term notes	177.2			229.0
Total debt	10,298.6			13,646.5
Less current portion	(1,102.2		)	(3,706.5		)
Long-term debt	$	9,196.4		$	9,940.0

The weighted-average effective borrowing rate on outstanding commercial paper at December 31, 2018 was 2.36 percent.

At December 31, 2018, we had a total of $5.42 billion of unused committed bank credit facilities, which consisted primarily of a $3.00 billion credit facility that expires in December 2023 and a $2.00 billion 364-day facility that expires in December 2019, both of which are available to support our commercial paper program. We have not drawn against the $3.00 billion and $2.00 billion facilities. Of the remaining facilities, there was $25.9 million outstanding under the revolving credit facilities as of December 31, 2018, and $6.0 million was outstanding under these facilities as of December 31, 2017. Compensating balances and commitment fees are not material, and there are no conditions that are probable of occurring under which the lines may be withdrawn.

In May 2017, we issued $750.0 million of 2.35 percent fixed-rate notes due in May 2022, $750.0 million of 3.10 percent fixed-rate notes due in May 2027, and $750.0 million of 3.95 percent fixed-rate notes due in May 2047, with interest to be paid semi-annually. We are using the net proceeds of $2.23 billion from the sale of these notes for general corporate purposes, which included the repayment of notes due in 2018 and may include the repayment of notes due in 2019. Prior to such uses, we may temporarily invest the net proceeds in investment securities.

The aggregate amounts of maturities on long-term debt for the next five years are as follows:



	2019		2020		2021		2022		2023
Maturities on long-term debt	$	604.5	$	3.5	$	2.3	$	1,439.0	$	0.3

We have converted approximately 25 percent of our long-term fixed-rate notes to floating rates through the use of interest rate swaps. The weighted-average effective borrowing rates based on long-term debt obligations and interest rates at December 31, 2018 and 2017, including the effects of interest rate swaps for hedged debt obligations, were 3.13 percent and 2.65 percent, respectively.

The aggregate amount of cash payments for interest on borrowings, net of capitalized interest, are as follows:



	2018		2017		2016
Cash payments for interest on borrowings	$	223.8	$	192.7	$	146.4

In accordance with the requirements of derivatives and hedging guidance, the portion of our fixed-rate debt obligations that is hedged as a fair value hedge is reflected in the consolidated balance sheets as an amount equal to the sum of the debt’s carrying value plus the fair value adjustment representing changes in fair value of the hedged debt attributable to movements in market interest rates subsequent to the inception of the hedge.

Note 11: Stock-Based Compensation

Our stock-based compensation expense consists of performance awards (PAs), shareholder value awards (SVAs), and restricted stock units (RSUs). We recognize the fair value of stock-based compensation as expense over the requisite service period of the individual grantees, which generally equals the vesting period. We provide newly issued shares of our common stock and treasury stock to satisfy the issuance of PA, SVA, and RSU shares.

Stock-based compensation expense and the related tax benefits were as follows:



	2018		2017		2016
Stock-based compensation expense	$	253.5	$	256.3	$	234.9
Tax benefit	53.2		64.1		82.2

At December 31, 2018, stock-based compensation awards may be granted under the 2002 Lilly Stock Plan for not more than 53.3 million additional shares.

Performance Award Program

PAs are granted to officers and management and are payable in shares of our common stock. The number of PA shares actually issued, if any, varies depending on the achievement of certain pre-established earnings-per-share targets over a two-year period. PA shares are accounted for at fair value based upon the closing stock price on the date of grant and fully vest at the end of the measurement period. The fair values of PAs granted for the years ended December 31, 2018, 2017, and 2016 were $71.63, $73.54, and $72.00, respectively. The number of shares ultimately issued for the PA program is dependent upon the EPS achieved during the vesting period. Pursuant to this program, approximately 0.9 million shares, 1.3 million shares, and 0.5 million shares were issued during the years ended December 31, 2018, 2017, and 2016, respectively. Approximately 1.2 million shares are expected to be issued in 2019. As of December 31, 2018, the total remaining unrecognized compensation cost related to nonvested PAs was $57.9 million, which will be amortized over the weighted-average remaining requisite service period of 12 months.

Shareholder Value Award Program

SVAs are granted to officers and management and are payable in shares of our common stock. The number of shares actually issued, if any, varies depending on our stock price at the end of the three-year vesting period compared to pre-established target stock prices. We measure the fair value of the SVA unit on the grant date using a Monte Carlo simulation model. The model utilizes multiple input variables that determine the probability of satisfying the market condition stipulated in the award grant and calculates the fair value of the award. Expected volatilities utilized in the model are based on implied volatilities from traded options on our stock, historical volatility of our stock price, and other factors. Similarly, the dividend yield is based on historical experience and our estimate of future dividend yields. The risk-free interest rate is derived from the U.S. Treasury yield curve in effect at the time of grant. The weighted-average fair values of the SVA units granted during the years ended December 31, 2018, 2017, and 2016 were $48.51, $66.25, and $48.68, respectively, determined using the following assumptions:



(Percents)	2018		2017		2016
Expected dividend yield	2.50	%	2.50	%	2.00	%
Risk-free interest rate	2.31		1.38		0.92
Volatility	22.26		22.91		21.68

Pursuant to this program, approximately 0.7 million shares, 1.1 million shares, and 1.0 million shares were issued during the years ended December 31, 2018, 2017, and 2016, respectively. Approximately 1.0 million shares are expected to be issued in 2019. As of December 31, 2018, the total remaining unrecognized compensation cost related to nonvested SVAs was $52.2 million, which will be amortized over the weighted-average remaining requisite service period of 20 months.

Restricted Stock Units

RSUs are granted to certain employees and are payable in shares of our common stock. RSU shares are accounted for at fair value based upon the closing stock price on the date of grant. The corresponding expense is amortized over the vesting period, typically three years. The fair values of RSU awards granted during the years ended December 31, 2018, 2017, and 2016 were $70.95, $72.47, and $71.46, respectively. The number of shares ultimately issued for the RSU program remains constant with the exception of forfeitures. Pursuant to this program, 1.3 million, 1.4 million, and 1.3 million shares were granted and approximately 1.0 million, 0.9 million, and 0.6 million shares were issued during the years ended December 31, 2018, 2017, and 2016, respectively. Approximately 0.8 million shares are expected to be issued in 2019. As of December 31, 2018, the total remaining unrecognized compensation cost related to nonvested RSUs was $99.7 million, which will be amortized over the weighted-average remaining requisite service period of 21 months.

Note 12: Shareholders' Equity

During 2018, 2017, and 2016, we repurchased $4.15 billion, $359.8 million and $540.1 million, respectively, of shares associated with our share repurchase programs. A payment of $60.0 million was made in 2016 for shares repurchased in 2017.

During 2018, we repurchased $2.05 billion of shares, which completed the $5.00 billion share repurchase program announced in October 2013 and our board authorized an $8.00 billion share repurchase program.

There were $2.10 billion repurchased under the $8.00 billion program in 2018. As of December 31, 2018, there were $5.90 billion of shares remaining under the 2018 program.

We have 5.0 million authorized shares of preferred stock. As of December 31, 2018 and 2017, no preferred stock was issued.

We have an employee benefit trust that held 50.0 million shares of our common stock at both December 31, 2018 and 2017, to provide a source of funds to assist us in meeting our obligations under various employee benefit plans. The cost basis of the shares held in the trust was $3.01 billion at both December 31, 2018 and 2017, and is shown as a reduction of shareholders’ equity. Any dividend transactions between us and the trust are eliminated. Stock held by the trust is not considered outstanding in the computation of EPS. The assets of the trust were not used to fund any of our obligations under these employee benefit plans during the years ended December 31, 2018, 2017, and 2016.

Note 13: Income Taxes

2017 Tax Act

In December 2017, the President of the U.S. signed into law the 2017 Tax Act. The 2017 Tax Act included significant changes to the U.S. corporate income tax system, such as the reduction in the corporate income tax rate from 35 percent to 21 percent, transition to a territorial tax system, changes to business related exclusions, deductions and credits, and modifications to international tax provisions, including a one-time repatriation transition tax (also known as the ‘Toll Tax’) on unremitted foreign earnings.

GAAP requires that the income tax accounting effects from a change in tax laws or tax rates be recognized in continuing operations in the reporting period that includes the enactment date of the change. These effects include, among other things, re-measuring deferred tax assets and liabilities, evaluating deferred tax assets for valuation allowances, and assessing the impact of the Toll Tax and certain other provisions of the 2017 Tax Act. Our accounting for the tax effects of the enactment of the 2017 Tax Act was not complete as of December 31, 2017; however, in certain cases we made a reasonable estimate. In other cases, we were not able to make a reasonable estimate and continued to account for those items based on our existing accounting model under ASC 740, Income Taxes, and the provisions of the tax laws that were in effect immediately prior to enactment. For the items for which we were able to determine a reasonable estimate, we recognized a provisional amount of $1.91 billion, which was included as a component of income tax expense from continuing operations. Our accounting for the effects of the 2017 Tax Act was completed in the current period, and we recorded $313.3 million of income tax benefit in 2018, mainly attributable to measurement period adjustments to the Toll Tax and the global intangible low-taxed income (GILTI) provision, the new U.S. minimum tax on the earnings of our foreign subsidiaries. Related to GILTI, we elected to establish deferred taxes in the amount of $1.74 billion for the reversal of temporary items in future years.

Subsequent to the enactment of the 2017 Tax Act, additional guidance was issued, including Notices, Proposed Regulations, and Final Regulations. We expect that further guidance will continue to be issued in 2019 which may impact our interpretations of the 2017 Tax Act and could materially affect the estimates used.

Deferred taxes are recognized for the future tax effects of temporary differences between financial and income tax reporting based on enacted tax laws and rates.

We recognize the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by the taxing authorities, based on the technical merits of the position. The tax benefits recognized in the financial statements from such a position are measured based on the largest benefit that has a greater than 50 percent likelihood of being realized upon ultimate resolution.

Following is the composition of income tax expense:



	2018			2017			2016
Current:
Federal	$	(31.9	)	$	(66.5	)	$	20.0
Foreign	106.8			47.5			397.0
State	4.7			(5.4		)	(134.4		)
2017 Tax Act	201.5			3,247.5			—
Total current tax expense	281.1			3,223.1			282.6
Deferred:
Federal	22.5			732.3			410.0
Foreign	248.7			(230.9		)	(136.3		)
State	3.4			0.2			(4.9		)
2017 Tax Act	(26.2		)	(1,333.5		)	—
Total deferred tax (benefit) expense	248.4			(831.9		)	268.8
Income taxes	$	529.5		$	2,391.2		$	551.4

Significant components of our deferred tax assets and liabilities as of December 31 are as follows:



	2018			2017
Deferred tax assets:
Purchases of intangible assets	$	2,627.7		$	441.9
Compensation and benefits	781.6			995.3
Tax credit carryforwards and carrybacks	359.4			467.5
Tax loss carryforwards and carrybacks	248.2			471.3
Product return reserves	95.3			83.4
Other comprehensive loss on hedging transactions	68.9			68.9
Debt	40.3			53.5
Contingent consideration	11.7			32.1
Other	680.1			524.3
Total gross deferred tax assets	4,913.2			3,138.2
Valuation allowances	(574.8		)	(681.8		)
Total deferred tax assets	4,338.4			2,456.4
Deferred tax liabilities:
Earnings of foreign subsidiaries	(1,745.3		)	(16.6		)
Inventories	(681.3		)	(649.5		)
Property and equipment	(260.9		)	(247.5		)
Prepaid employee benefits	(240.1		)	(231.5		)
Intangibles	(86.9		)	(120.7		)
Financial instruments	(22.8		)	(41.6		)
Total deferred tax liabilities	(3,037.3		)	(1,307.4		)
Deferred tax assets - net	$	1,301.1		$	1,149.0

Our accounting for the effects of the 2017 Tax Act was completed in the current period; therefore, deferred tax assets and liabilities reflect re-measurement resulting from the 2017 Tax Act.

The deferred tax asset and related valuation allowance amounts for U.S. federal and state net operating losses and tax credits shown above have been reduced for differences between financial reporting and tax return filings.

At December 31, 2018, based on filed tax returns we have tax credit carryforwards and carrybacks of $729.5 million available to reduce future income taxes; $150.5 million, if unused, will expire by 2027. The remaining portion of the tax credit carryforwards is related to federal tax credits of $122.9 million, international tax credits of $119.3 million, and state tax credits of $336.9 million, all of which are substantially reserved.

At December 31, 2018, based on filed tax returns we had net operating losses and other carryforwards for international and U.S. federal income tax purposes of $773.2 million: $12.1 million will expire by 2023; $462.2 million will expire between 2024 and 2038; and $298.9 million of the carryforwards will never expire. Net operating losses and other carryforwards for international and U.S. federal income tax purposes are partially reserved. Deferred tax assets related to state net operating losses of $99.7 million and other state carryforwards of $2.6 million are fully reserved.

Domestic and Puerto Rican companies contributed approximately 15 percent, 16 percent, and 63 percent for the years ended December 31, 2018, 2017, and 2016, respectively, to consolidated income before income taxes. We have a subsidiary operating in Puerto Rico under a tax incentive grant effective through the end of 2031.

The 2017 Tax Act introduced international tax provisions that fundamentally change the U.S. taxation of foreign earnings. As a result, substantially all of the unremitted earnings of our foreign subsidiaries are considered to not be indefinitely reinvested for continued use in our foreign operations. At December 31, 2018, we have accrued an immaterial amount of foreign withholding taxes and state income taxes that would be owed upon future distributions of unremitted earnings of our foreign subsidiaries that are not indefinitely reinvested. For the amount considered to be indefinitely reinvested, it is not practicable to determine the amount of the related deferred income tax liability due to the complexities in the tax laws and assumptions we would have to make.

Cash payments of income taxes were as follows:



	2018		2017		2016
Cash payments of income taxes	$	1,076.7	$	221.5	$	686.4

The 2017 Tax Act provided an election to taxpayers subject to the Toll Tax to make payments over an eight-year period. We made this election; therefore, we have included Toll Tax payments accordingly.

Following is a reconciliation of the income tax expense applying the U.S. federal statutory rate to income before income taxes to reported income tax expense:



	2018			2017			2016
Income tax at the U.S. federal statutory tax rate	$	772.8		$	806.7		$	1,146.7
Add (deduct):
International operations, including Puerto Rico	(627.1		)	(480.8		)	(357.2		)
General business credits	(87.4		)	(66.8		)	(57.0		)
Non-deductible acquired IPR&D⁽¹⁾	309.9			300.1			—
2017 Tax Act	175.3			1,914.0			—
Other	(14.0		)	(82.0		)	(181.1		)
Income taxes	$	529.5		$	2,391.2		$	551.4

⁽¹⁾Non-deductible acquired IPR&D was related to ARMO in 2018 and CoLucid in 2017. See Note 3 for additional information related to acquisitions.

A reconciliation of the beginning and ending amount of gross unrecognized tax benefits is as follows:



	2018			2017			2016
Beginning balance at January 1	$	1,000.8		$	843.3		$	1,057.2
Additions based on tax positions related to the current year	798.2			133.8			73.4
Additions for tax positions of prior years	410.9			93.8			11.0
Reductions for tax positions of prior years	(115.4		)	(59.3		)	(12.1		)
Settlements	(33.2		)	(2.4		)	(171.9		)
Lapses of statutes of limitation	(20.5		)	(19.3		)	(110.0		)
Changes related to the impact of foreign currency translation	(6.2		)	10.9			(4.3		)
Ending balance at December 31	$	2,034.6		$	1,000.8		$	843.3

The total amount of unrecognized tax benefits that, if recognized, would affect our effective tax rate was $1.48 billion and $657.1 million at December 31, 2018 and 2017, respectively.

We file income tax returns in the U.S. federal jurisdiction and various state, local, and non-U.S. jurisdictions. We are no longer subject to U.S. federal, state and local, or non-U.S. income tax examinations in most major taxing jurisdictions for years before 2010.

The U.S. examination of tax years 2010-2012 commenced during the fourth quarter of 2013. In December 2015, we executed a closing agreement with the Internal Revenue Service which effectively settled certain matters for tax years 2010-2012. Accordingly, we reduced our gross uncertain tax positions by approximately $320 million in 2015. During 2016, we effectively settled the remaining matters related to tax years

2010-2012. As a result of this resolution, our gross uncertain tax positions were further reduced by approximately $140 million, and our consolidated results of operations benefited from an immaterial reduction in income tax expense. During 2016, we made cash payments of approximately $150 million related to tax years 2010-2012 after application of available tax credit carryforwards and carrybacks. The U.S. examination of tax years 2013-2015 began in 2016, and we believe it is reasonably possible that this examination could reach resolution within the next 12 months for tax years 2013-2014 and certain matters under examination for tax year 2015, for which the audit remains ongoing. As a result, we currently estimate that gross uncertain tax positions may be reduced by approximately $450 million within the next 12 months. Additionally, we anticipate up to $150 million of cash payments will be due upon resolution.

We recognize both accrued interest and penalties related to unrecognized tax benefits in income tax expense. We recognized income tax (benefit) expense related to interest and penalties as follows:



	2018		2017		2016
Income tax expense (benefit)	$	25.1	$	22.8	$	(63.8	)

At December 31, 2018 and 2017, our accruals for the payment of interest and penalties totaled $183.9 million and $155.0 million, respectively.

Note 14: Retirement Benefits

We use a measurement date of December 31 to develop the change in benefit obligation, change in plan assets, funded status, and amounts recognized in the consolidated balance sheets at December 31 for our defined benefit pension and retiree health benefit plans, which were as follows:



	Defined Benefit Pension Plans						Retiree Health Benefit Plans
	2018			2017			2018			2017
Change in benefit obligation:
Benefit obligation at beginning of year	$	14,839.7		$	12,230.9		$	1,718.7		$	1,494.6
Service cost	292.7			320.8			41.5			46.4
Interest cost	458.5			411.6			57.3			52.9
Actuarial (gain) loss	(1,386.5		)	1,556.0			(176.9		)	30.2
Benefits paid	(579.4		)	(467.8		)	(82.8		)	(60.1		)
Plan amendments	17.6			—			(14.1		)	—
Curtailment (gain) loss	(43.9		)	90.4			2.5			105.2
Special termination benefit	—			317.2			—			37.5
Foreign currency exchange rate changes and other adjustments	(171.6		)	380.6			(6.2		)	12.0
Benefit obligation at end of year	13,427.1			14,839.7			1,540.0			1,718.7



Change in plan assets:
Fair value of plan assets at beginning of year	11,713.0		10,056.0		2,372.4		1,961.2
Actual return on plan assets	(360.1	)	1,434.3		32.6		462.0
Employer contribution	319.0		410.4		75.9		9.1
Benefits paid	(579.4	)	(467.8	)	(82.8	)	(60.1	)
Foreign currency exchange rate changes and other adjustments	(159.9	)	280.1		—		0.2
Fair value of plan assets at end of year	10,932.6		11,713.0		2,398.1		2,372.4



Funded status	(2,494.5		)	(3,126.7		)	858.1			653.7
Unrecognized net actuarial loss	5,011.3			5,616.4			140.6			182.0
Unrecognized prior service (benefit) cost	25.0			14.5			(299.9		)	(395.0		)
Net amount recognized	$	2,541.8		$	2,504.2		$	698.8		$	440.7



Amounts recognized in the consolidated balance sheet consisted of:
Sundry	$	193.7		$	104.5		$	1,043.6		$	870.1
Other current liabilities	(64.2		)	(64.5		)	(7.3		)	(7.1		)
Accrued retirement benefits	(2,624.0		)	(3,166.7		)	(178.2		)	(209.3		)
Accumulated other comprehensive (income) loss before income taxes	5,036.3			5,630.9			(159.3		)	(213.0		)
Net amount recognized	$	2,541.8		$	2,504.2		$	698.8		$	440.7

The unrecognized net actuarial loss and unrecognized prior service cost (benefit) have not yet been recognized in net periodic pension costs and are included in accumulated other comprehensive loss at December 31, 2018.

In July 2018, we announced that we would amend our defined benefit pension and retiree health benefit plans to freeze or reduce benefits for certain employees effective January 1, 2019. We remeasured the impacted pension and retiree health plans’ benefit obligations as of July 31, 2018, which resulted in a net curtailment gain of $28.0 million, which was recorded in asset impairment, restructuring, and other special charges. Market variables associated with this remeasurement, specifically an increase in the discount rate, were the primary driver for the $1.59 billion decrease in the benefit obligations in 2018.

The workforce reduction plan initiated in 2017 included a curtailment loss of $159.0 million and a special termination benefit of $354.7 million, which $446.7 million was recorded in asset impairment, restructuring, and other special charges and $67.0 million was recorded in discontinued operations, as a result of a remeasurement as of October 31, 2017. The special termination benefits related to early retirement incentives

offered as part of a voluntary early retirement program for the U.S. plan in the fourth quarter of 2017. This program allowed certain employees the opportunity to voluntarily leave the Company. Market variables associated with this remeasurement, specifically a decrease in the discount rate, were the primary driver for the $2.83 billion increase in the benefit obligations in 2017.

The following represents our weighted-average assumptions as of December 31:



	Defined Benefit Pension Plans						Retiree Health Benefit Plans
(Percents)	2018		2017		2016		2018		2017		2016
Discount rate for benefit obligation	4.0	%	3.4	%	3.9	%	4.4	%	3.7	%	4.3	%
Discount rate for net benefit costs	3.4		3.9		4.3		3.7		4.3		4.5
Rate of compensation increase for benefit obligation	3.4		3.4		3.4
Rate of compensation increase for net benefit costs	3.4		3.4		3.4
Expected return on plan assets for net benefit costs	7.4		7.4		7.4		8.0		8.0		8.0

We annually evaluate the expected return on plan assets in our defined benefit pension and retiree health benefit plans. In evaluating the expected rate of return, we consider many factors, with a primary analysis of current and projected market conditions; asset returns and asset allocations; and the views of leading financial advisers and economists. We may also review our historical assumptions compared with actual results, as well as the assumptions and trend rates utilized by similar plans, where applicable.

Given the design of our retiree health benefit plans, healthcare-cost trend rates do not have a material impact on our financial condition or results of operations.

The following benefit payments, which reflect expected future service, as appropriate, are expected to be paid as follows:



	2019		2020		2021		2022		2023		2024-2028
Defined benefit pension plans	$	604.1	$	607.2	$	616.5	$	632.1	$	641.6	$	3,524.7
Retiree health benefit plans	98.0		99.1		100.7		99.9		98.5		505.3

Amounts relating to defined benefit pension plans with projected benefit obligations in excess of plan assets were as follows at December 31:



	2018		2017
Projected benefit obligation	$	11,584.2	$	12,773.4
Fair value of plan assets	8,895.6		9,542.5

Amounts relating to defined benefit pension plans and retiree health benefit plans with accumulated benefit obligations in excess of plan assets were as follows at December 31:



	Defined Benefit Pension Plans				Retiree Health Benefit Plans
	2018		2017		2018		2017
Accumulated benefit obligation	$	10,837.8	$	11,733.6	$	189.4	$	225.1
Fair value of plan assets	8,895.6		9,517.6		—		—

The total accumulated benefit obligation for our defined benefit pension plans was $12.57 billion and $13.67 billion at December 31, 2018 and 2017, respectively.

Net pension and retiree health benefit expense included the following components:



	Defined Benefit Pension Plans									Retiree Health Benefit Plans
	2018			2017			2016			2018			2017			2016
Components of net periodic (benefit) cost:
Service cost	$	292.7		$	320.8		$	268.4		$	41.5		$	46.4		$	39.1
Interest cost	458.5			411.6			419.0			57.3			52.9			53.2
Expected return on plan assets	(842.1		)	(773.6		)	(748.7		)	(177.9		)	(160.7		)	(150.2		)
Amortization of prior service (benefit) cost	4.6			5.6			11.7			(79.5		)	(90.0		)	(85.8		)
Recognized actuarial loss	332.5			286.8			284.6			6.1			18.4			19.1
Curtailment (gain) loss	1.3			93.5			—			(29.3		)	65.5			—
Special termination benefit	—			317.2			—			—			37.5			—
Net periodic (benefit) cost	$	247.5		$	661.9		$	235.0		$	(181.8	)	$	(30.0	)	$	(124.6	)

The following represents the amounts recognized in other comprehensive income (loss) for the years ended December 31, 2018, 2017, and 2016:



	Defined Benefit Pension Plans									Retiree Health Benefit Plans
	2018			2017			2016			2018			2017			2016
Actuarial gain (loss) arising during period	$	182.8		$	(898.1	)	$	(719.1	)	$	37.5		$	261.3		$	(132.2	)
Plan amendments during period	(17.6		)	—			—			14.1			—			35.8
Curtailment gain (loss)	45.2			3.2			—			(31.8		)	(39.7		)	—
Amortization of prior service (benefit) cost included in net income	4.6			5.6			11.7			(79.5		)	(90.0		)	(85.8		)
Amortization of net actuarial loss included in net income	332.5			286.8			284.6			6.1			18.4			19.1
Foreign currency exchange rate changes and other	47.1			(108.8		)	72.6			(0.1		)	(3.3		)	2.5
Total other comprehensive income (loss) during period	$	594.6		$	(711.3	)	$	(350.2	)	$	(53.7	)	$	146.7		$	(160.6	)

We have defined contribution savings plans that cover our eligible employees worldwide. The purpose of these plans is generally to provide additional financial security during retirement by providing employees with an incentive to save. Our contributions to the plans are based on employee contributions and the level of our match. Expenses under the plans totaled $132.6 million, $147.0 million, and $155.4 million for the years ended December 31, 2018, 2017, and 2016, respectively.

We provide certain other postemployment benefits primarily related to disability benefits and accrue for the related cost over the service lives of employees. Expenses associated with these benefit plans for the years ended December 31, 2018, 2017, and 2016 were not material.

Benefit Plan Investments

Our benefit plan investment policies are set with specific consideration of return and risk requirements in relationship to the respective liabilities. U.S. and Puerto Rico plans represent approximately 80 percent of our global investments. Given the long-term nature of our liabilities, these plans have the flexibility to manage an above-average degree of risk in the asset portfolios. At the investment-policy level, there are no specifically prohibited investments. However, within individual investment manager mandates, restrictions and limitations are contractually set to align with our investment objectives, ensure risk control, and limit concentrations.

We manage our portfolio to minimize concentration of risk by allocating funds within asset categories. In addition, within a category we use different managers with various management objectives to eliminate any significant concentration of risk.

Our global benefit plans may enter into contractual arrangements (derivatives) to implement the local investment policy or manage particular portfolio risks. Derivatives are principally used to increase or decrease exposure to a particular public equity, fixed income, commodity, or currency market more rapidly or less expensively than could be accomplished through the use of the cash markets. The plans utilize both exchange-traded and over-the-counter instruments. The maximum exposure to either a market or counterparty credit loss is limited to the carrying value of the receivable, and is managed within contractual limits. We expect all of our counterparties to meet their obligations. The gross values of these derivative receivables and payables are not material to the global asset portfolio, and their values are reflected within the tables below.

The defined benefit pension and retiree health benefit plan allocation for the U.S. and Puerto Rico currently comprises approximately 70 percent growth investments and 30 percent fixed-income investments. The growth investment allocation encompasses U.S. and international public equity securities, hedge funds, private equity-like investments, and real estate. These portfolio allocations are intended to reduce overall risk by providing diversification, while seeking moderate to high returns over the long term.

Public equity securities are well diversified and invested in U.S. and international small-to-large companies across various asset managers and styles. The remaining portion of the growth portfolio is invested in private alternative investments.

Fixed-income investments primarily consist of fixed-income securities in U.S. treasuries and agencies, emerging market debt obligations, corporate bonds, mortgage-backed securities, commercial mortgage-backed obligations, and any related repurchase agreements.

Hedge funds are privately owned institutional investment funds that generally have moderate liquidity. Hedge funds seek specified levels of absolute return regardless of overall market conditions, and generally have low correlations to public equity and debt markets. Hedge funds often invest substantially in financial market instruments (stocks, bonds, commodities, currencies, derivatives, etc.) using a very broad range of trading activities to manage portfolio risks. Hedge fund strategies focus primarily on security selection and seek to be neutral with respect to market moves. Common groupings of hedge fund strategies include relative value, tactical, and event driven. Relative value strategies include arbitrage, when the same asset can simultaneously be bought and sold at different prices, achieving an immediate profit. Tactical strategies often take long and short positions to reduce or eliminate overall market risks while seeking a particular investment opportunity. Event strategy opportunities can evolve from specific company announcements such as mergers and acquisitions, and typically have little correlation to overall market directional movements. Our hedge fund investments are made through limited partnership interests primarily in fund-of-funds structures to ensure diversification across many strategies and many individual managers. Plan holdings in hedge funds are valued based on net asset values (NAVs) calculated by each fund or general partner, as applicable, and we have the ability to redeem these investments at NAV.

Private equity-like investment funds typically have low liquidity and are made through long-term partnerships or joint ventures that invest in pools of capital invested in primarily non-publicly traded entities. Underlying investments include venture capital (early stage investing), buyout, and special situation investing. Private equity management firms typically acquire and then reorganize private companies to create increased long term value. Private equity-like funds usually have a limited life of approximately 10-15 years, and require a minimum investment commitment from their limited partners. Our private investments are made both directly into funds and through fund-of-funds structures to ensure broad diversification of management styles and assets across the portfolio. Plan holdings in private equity-like investments are valued using the value reported by the partnership, adjusted for known cash flows and significant events through our reporting date. Values provided by the partnerships are primarily based on analysis of and judgments about the underlying investments. Inputs to these valuations include underlying NAVs, discounted cash flow valuations, comparable market valuations, and may also include adjustments for currency, credit, liquidity and other risks as applicable. The vast majority of these private partnerships provide us with annual audited financial statements including their compliance with fair valuation procedures consistent with applicable accounting standards.

Real estate is composed of both public and private holdings. Real estate investments in registered investment companies that trade on an exchange are classified as Level 1 on the fair value hierarchy. Real estate investments in funds measured at fair value on the basis of NAV provided by the fund manager are classified as such. These NAVs are developed with inputs including discounted cash flow, independent appraisal, and market comparable analyses.

Other assets include cash and cash equivalents and mark-to-market value of derivatives.

The cash value of the trust-owned insurance contract is primarily invested in investment-grade publicly traded equity and fixed-income securities.

Other than hedge funds, private equity-like investments, and real estate, which are discussed above, we determine fair values based on a market approach using quoted market values, significant other observable inputs for identical or comparable assets or liabilities, or discounted cash flow analyses.

The fair values of our defined benefit pension plan and retiree health plan assets as of December 31, 2018 by asset category were as follows:



				Fair Value Measurements Using
Asset Class	Total			Quoted Prices in Active Markets for Identical Assets (Level 1)		Significant Observable Inputs (Level 2)			Significant Unobservable Inputs (Level 3)		Investments Valued at Net Asset Value⁽¹⁾
Defined Benefit Pension Plans
Public equity securities:
U.S.	$	617.7		$	409.1	$	—		$	—	$	208.6
International	2,117.8			828.8		—			1.8		1,287.2
Fixed income:
Developed markets	2,933.4			17.2		2,173.3			—		742.9
Developed markets - repurchase agreements	(1,225.5		)	—		(1,225.5		)	—		—
Emerging markets	565.2			3.4		255.8			6.1		299.9
Private alternative investments:
Hedge funds	2,795.3			—		—			—		2,795.3
Equity-like funds	1,893.5			—		—			16.8		1,876.7
Real estate	505.7			147.1		—			—		358.6
Other	729.5			213.0		83.7			—		432.8
Total	$	10,932.6		$	1,618.6	$	1,287.3		$	24.7	$	8,002.0

Retiree Health Benefit Plans
Public equity securities:
U.S.	$	59.9		$	41.0	$	—		$	—	$	18.9
International	127.0			50.5		—			0.2		76.3
Fixed income:
Developed markets	69.1			—		61.5			—		7.6
Emerging markets	53.5			—		25.5			0.6		27.4
Private alternative investments:
Hedge funds	245.8			—		—			—		245.8
Equity-like funds	169.2			—		—			1.7		167.5
Cash value of trust owned insurance contract	1,574.7			—		1,574.7			—		—
Real estate	27.7			14.7		—			—		13.0
Other	71.2			38.1		(3.8		)	—		36.9
Total	$	2,398.1		$	144.3	$	1,657.9		$	2.5	$	593.4

⁽¹⁾Certain investments that are measured at fair value using the NAV per share (or its equivalent) as a practical expedient have not been classified in the fair value hierarchy.

No material transfers between Level 1, Level 2, or Level 3 occurred during the year ended December 31, 2018. The activity in the Level 3 investments during the year ended December 31, 2018 was not material.

The fair values of our defined benefit pension plan and retiree health plan assets as of December 31, 2017 by asset category were as follows:



				Fair Value Measurements Using
Asset Class	Total			Quoted Prices in Active Markets for Identical Assets (Level 1)		Significant Observable Inputs (Level 2)			Significant Unobservable Inputs (Level 3)		Investments Valued at Net Asset Value⁽¹⁾
Defined Benefit Pension Plans
Public equity securities:
U.S.	$	465.4		$	199.0	$	—		$	—	$	266.4
International	2,934.2			955.1		—			—		1,979.1
Fixed income:
Developed markets	3,153.0			20.5		2,468.1			—		664.4
Developed markets - repurchase agreements	(1,372.9		)	—		(1,372.9		)	—		—
Emerging markets	577.5			3.6		251.7			3.1		319.1
Private alternative investments:
Hedge funds	2,977.8			—		—			—		2,977.8
Equity-like funds	1,586.9			—		—			16.8		1,570.1
Real estate	543.7			338.6		—			—		205.1
Other	847.4			119.1		602.7			2.2		123.4
Total	$	11,713.0		$	1,635.9	$	1,949.6		$	22.1	$	8,105.4

Retiree Health Benefit Plans
Public equity securities:
U.S.	$	43.0		$	19.4	$	—		$	—	$	23.6
International	182.5			61.3		—			—		121.2
Fixed income:
Developed markets	71.2			—		63.5			—		7.7
Emerging markets	53.1			—		24.4			0.3		28.4
Private alternative investments:
Hedge funds	256.0			—		—			—		256.0
Equity-like funds	137.0			—		—			1.6		135.4
Cash value of trust owned insurance contract	1,524.6			—		1,524.6			—		—
Real estate	33.0			33.0		—			—		—
Other	72.0			15.0		50.5			0.2		6.3
Total	$	2,372.4		$	128.7	$	1,663.0		$	2.1	$	578.6

⁽¹⁾Certain investments that are measured at fair value using the NAV per share (or its equivalent) as a practical expedient have not been classified in the fair value hierarchy.

No material transfers between Level 1, Level 2, or Level 3 occurred during the year ended December 31, 2017. The activity in the Level 3 investments during the year ended December 31, 2017 was not material.

In 2019, we expect to contribute approximately $45 million to our defined benefit pension plans to satisfy minimum funding requirements for the year. Additional discretionary contributions are not expected to be significant.

Note 15: Contingencies

We are a party to various legal actions and government investigations. The most significant of these are described below. It is not possible to determine the outcome of these matters, and we cannot reasonably estimate the maximum potential exposure or the range of possible loss in excess of amounts accrued for any of these matters; however, we believe that, except as noted below with respect to the Alimta^® patent litigation and administrative proceedings, the resolution of all such matters will not have a material adverse effect on our consolidated financial position or liquidity, but could possibly be material to our consolidated results of operations in any one accounting period.

Litigation accruals, environmental liabilities, and the related estimated insurance recoverables are reflected on a gross basis as liabilities and assets, respectively, on our consolidated balance sheets. With respect to the product liability claims currently asserted against us, we have accrued for our estimated exposures to the extent they are both probable and reasonably estimable based on the information available to us. We accrue for certain product liability claims incurred but not filed to the extent we can formulate a reasonable estimate of their costs. We estimate these expenses based primarily on historical claims experience and data regarding product usage. Legal defense costs expected to be incurred in connection with significant product liability loss contingencies are accrued when both probable and reasonably estimable.

Alimta Patent Litigation and Administrative Proceedings

A number of generic manufacturers are seeking approvals in the U.S., Japan, and a number of countries in Europe to market generic forms of Alimta prior to the expiration of our vitamin regimen patents, alleging that those patents are invalid, not infringed, or both. We believe our Alimta vitamin regimen patents are valid and enforceable against these generic manufacturers. However, it is not possible to determine the ultimate outcome of the proceedings, and accordingly, we can provide no assurance that we will prevail. An unfavorable outcome could have a material adverse impact on our future consolidated results of operations, liquidity, and financial position. We expect that a loss of exclusivity for Alimta in one or more of the below jurisdictions would result in a rapid and severe decline in future revenue for the product in the relevant market.

U.S. Patent Litigation and Administrative Proceedings

In the U.S., more than 10 Abbreviated New Drug Applications (ANDAs) seeking approval to market generic versions of Alimta prior to the expiration of our vitamin regimen patent (expiring in 2021 plus pediatric exclusivity expiring in 2022) have been filed by a number of companies, including Teva Parenteral Medicines, Inc. (Teva) and APP Pharmaceuticals, LLC (APP) pursuant to procedures set out in the Drug Price Competition and Patent Term Restoration Act of 1984 (the Hatch-Waxman Act). We have received favorable decisions from the U.S. Court of Appeals for the Federal Circuit (affirming the U.S. District Court for the Southern District of Indiana's decisions finding our U.S. vitamin regimen patent valid and infringed) against Teva, APP, and two other defendants' proposed products, and similar favorable judgments have been entered by the U.S. District Court for the Southern District of Indiana against five other companies. The remaining ANDA applicants have agreed to a preliminary injunction or stay pending the appeal of the inter partes review (IPR) described in the following sentence. In October 2017, the U.S. Patent and Trademark Office issued written decisions in our favor following IPR of our vitamin regimen patent, finding that the generic company petitioners failed to show that the claims in our patent are unpatentable. A number of these challengers have appealed. A hearing on the appeal was held in the first quarter of 2019, and we expect a decision in the second quarter of 2019.

We also currently have pending lawsuits in the U.S. District Court for the Southern District of Indiana alleging infringement against Actavis LLC (Actavis) and Apotex Inc. in response to their applications to market alternative forms of pemetrexed (the active ingredient in Alimta) products, and we filed a similar lawsuit in the U.S. District Court for the District of Delaware against Eagle Pharmaceuticals, Inc. In June 2018, the U.S. District Court for the Southern District of Indiana ruled in our favor in two similar cases, finding Dr. Reddy's Laboratories' (Dr. Reddy) and Hospira, Inc.'s (Hospira) proposed products would infringe our patent. Dr. Reddy and Hospira have appealed those rulings. The lawsuit against Actavis has been stayed, pending a decision in Dr. Reddy’s appeal.

European Patent Litigation and Administrative Proceedings

In July 2017, the United Kingdom (U.K.) Supreme Court ruled that commercialization of certain salt forms of pemetrexed by Actavis Group ehf and other Actavis companies directly infringes our vitamin regimen patents in the U.K., Italy, France, and Spain. This litigation in the U.K. is now concluded.

Hexal AG, Stada Arzneimittel AG (Stada), and Fresenius Kabi Deutschland GmbH have each challenged the validity of our vitamin regimen patent before the German Federal Patent Court. At a hearing in July 2018, the German Federal Patent Court held that our vitamin regimen patent is invalid. We have appealed this decision. Under German law, the patent remains in force pending appeal. A number of generic competitors have received approval to market generic versions of pemetrexed in Germany. Injunctions are in place against four of these companies, but in two cases the injunctions have been temporarily suspended pending the validity appeal at the German Supreme Court. Stada has recently launched at risk in Germany and we are seeking an injunction. We are pursuing injunctions against others who have launched or are preparing to launch at

risk. Whether the existing injunctions remain in effect, the suspended injunctions are reinstated pending the appeal or further injunctions are granted, or whether additional generic competitors choose to launch at risk, makes the timing of further generic entry and market erosion in Germany unpredictable.

Additional legal proceedings are ongoing in various national courts throughout Europe. We are aware that several companies have received approval to market generic versions of pemetrexed in major European markets and that additional generic competitors may choose to launch at risk (including one generic product currently on the market in France). We will continue to seek to remove any generic pemetrexed products launched at risk in European markets, including Germany, seek damages in respect of such launches, and defend our patents against validity challenges.

Japanese Administrative Proceedings

Three separate sets of demands for invalidation of our two vitamin regimen patents, involving several companies, have been filed with the Japanese Patent Office (JPO). The JPO rejected a demand for invalidation by Sawai Pharmaceutical Co., Ltd., which was affirmed on appeal in 2017. In July 2018, the JPO issued written decisions dismissing demands brought by Nipro Corporation (Nipro) for invalidation of our two Japanese vitamin regimen patents. Nipro filed an appeal, and we anticipate decisions by the Japan Intellectual Property High Court in the third quarter of 2019. We anticipate decisions by the JPO with respect to another set of demands, brought by Hospira, in the third quarter of 2019. If upheld through all challenges, these patents would provide intellectual property protection for Alimta until June 2021. Notwithstanding our patents, generic versions of Alimta received regulatory approval in Japan starting in February 2016. We do not currently anticipate that generic versions of Alimta will proceed to pricing approval.

Cymbalta^® Product Liability Litigation

We were named as a defendant in a purported class-action lawsuit in the U.S. District Court for the Central District of California (now called Strafford et al. v. Eli Lilly and Company) involving Cymbalta. The plaintiffs, purporting to represent a class of all persons within the U.S. who purchased and/or paid for Cymbalta, asserted claims under the consumer protection statutes of four states, California, Massachusetts, Missouri, and New York, and sought declaratory, injunctive, and monetary relief for various alleged economic injuries arising from discontinuing treatment with Cymbalta. The district court denied the plaintiffs' motions for class certification. The district court dismissed the suits and plaintiffs appealed to the U.S. Court of Appeals for the Ninth Circuit. In November 2017, the U.S. Court of Appeals for the Ninth Circuit dismissed the suit. In July 2018, the U.S. District Court for the District of California denied plaintiffs’ motion to reopen the case. Plaintiffs’ appeal of this denial is currently pending before the U.S. Court of Appeals for the Ninth Circuit.

Brazil–Employee Litigation

Our subsidiary in Brazil, Eli Lilly do Brasil Limitada (Lilly Brasil), is named in a lawsuit brought by the Labor Attorney for the 15th Region in the Labor Court of Paulinia, State of Sao Paulo, Brazil, alleging possible harm to employees and former employees caused by exposure to heavy metals at a former Lilly Brasil manufacturing facility in Cosmopolis, Brazil, operated by the company between 1977 and 2003. In May 2014, the labor court judge ruled against Lilly Brasil, ordering it to undertake several actions of unspecified financial impact, including paying lifetime medical insurance for the employees and contractors who worked at the Cosmopolis facility more than six months during the affected years and their children born during and after this period. We appealed this decision. In July 2018, the appeals court affirmed the labor court's ruling with the total financial impact of the ruling estimated to be approximately 500.0 million Brazilian real (approximately $130.0 million as of December 31, 2018). The appeals court restricted the broad health coverage awarded by the labor court to health problems that claimants could show arose from exposure to the alleged contamination. We strongly disagree with the appeals court's decision. Lilly Brasil has taken an initial step in the appeal process by filing a Motion for Clarification; a decision on that motion is expected in the first quarter of 2019.

We are also named in approximately 30 lawsuits filed in the same labor court by individual former employees making similar claims. These lawsuits are each at various stages in the litigation process, with judgments being handed down in approximately half of the lawsuits, nearly all of which are on appeal in the labor courts.

Lilly Brasil and Elanco Quimica Ltda. have also been named in two similar lawsuits in the same labor court involving approximately 410 individual plaintiffs. As part of the disposition of Elanco, we agreed to indemnify Elanco Quimica Ltda. in this litigation. The plaintiffs’ claims in these lawsuits relate only to mental anguish attributable to the possibility of illness due to alleged exposure to heavy metals or other contaminants. In

2017, the labor court dismissed the claims brought by all but the first named plaintiff in each of the lawsuits. The plaintiffs in both lawsuits are appealing.

We believe all of these lawsuits are without merit and are defending against them vigorously.

Adocia, S.A.

We have been named as a respondent in an arbitration filed by Adocia, S.A. (Adocia), with which we entered into agreements for the co-development of an ultra-rapid insulin product. Adocia alleges that we misappropriated and misused Adocia's confidential information and intellectual property and is seeking approximately $1.30 billion in damages and other specific relief. We have asserted several counterclaims relating to fraudulent misrepresentation and are seeking approximately $188.0 million in damages. An arbitration hearing was held on Adocia’s claims and our counterclaims in December 2018, and we expect a decision in the third quarter of 2019. We believe Adocia's claims are without merit and have defended against them vigorously.

Throughout the arbitrations described above, Adocia has made statements alleging that Adocia employees should be listed as inventors on two of our patents related to our ultra-rapid insulin product currently in development. We strongly contest this allegation. While inventorship of these two patents is not at issue in the arbitrations, in October 2018 we filed a declaratory judgment action against Adocia in the U.S. District Court for the Southern District of Indiana to confirm our inventorship.

Insulin and Glucagon Pricing Litigation and Proceedings

We, along with Sanofi and Novo Nordisk, are named as defendants in a consolidated purported class action lawsuit, In re. Insulin Pricing Litigation, in the U.S. District Court of New Jersey relating to insulin pricing. Plaintiffs seek damages under various state consumer protection laws and the Federal Racketeer Influenced and Corrupt Organization Act (Federal RICO Act). In February 2019, the court dismissed without prejudice the federal RICO Act claim as well as certain state consumer protection claims. Separately, we, along with Sanofi and Novo Nordisk, are named as defendants in a purported class action lawsuit, MSP Recovery Claims, Series, LLC et al. v. Sanofi Aventis U.S. LLC et al., in the same court, seeking damages under various state consumer protection laws, common law fraud, unjust enrichment, and the federal RICO Act. Finally, the Minnesota Attorney General’s Office filed a complaint against us, Sanofi, and Novo Nordisk, State of Minnesota v. Sanofi-Aventis U.S. LLC et al., in the U.S. District Court of New Jersey, alleging unjust enrichment, and violations of various Minnesota state consumer protection laws and the Federal RICO Act. We believe these claims are without merit and are defending against them vigorously.

We have received civil investigative demands from the Offices of the Attorney General from Washington and New Mexico relating to the pricing and sale of our insulin products. We are cooperating with these investigations. The Offices of the Attorney General in Mississippi, Washington D.C., California, Florida, Hawaii, and Nevada have requested information relating to the pricing and sale of our insulin products. We are cooperating with these requests. We received interrogatories from the California Attorney General's Office regarding our competition in the long-acting insulin market. We are cooperating with this investigation. Finally, we received a request from the House of Representatives’ Committee on Oversight and Reform; two requests from its Committee on Energy and Commerce; as well as a request from the Senate Committee on Health, Education, Labor, and Pensions, seeking certain information related to the pricing of insulin products, among other issues. We are cooperating with these investigations.

We, along with Novo Nordisk and various pharmacy benefit managers, are named as defendants in a lawsuit seeking class action status in the U.S. District Court of New Jersey relating to glucagon pricing. The plaintiffs are seeking damages under various state consumer protection laws, the Federal RICO Act, the Sherman Act, and other state and federal laws. We believe this lawsuit is without merit and are defending against it vigorously.

Product Liability Insurance

Because of the nature of pharmaceutical products, it is possible that we could become subject to large numbers of additional product liability and related claims in the future. Due to a very restrictive market for product liability insurance, we are self-insured for product liability losses for all our currently marketed products.

Note 16: Other Comprehensive Income (Loss)

The following table summarizes the activity related to each component of other comprehensive income (loss):



	Continuing Operations
(Amounts presented net of taxes)	Foreign Currency Translation Gains (Losses)			Unrealized Net Gains (Losses) on Securities			Defined Benefit Pension and Retiree Health Benefit Plans			Effective Portion of Cash Flow Hedges			Discontinued Operations			Accumulated Other Comprehensive Loss
Beginning balance at January 1, 2016	$	(1,315.9	)	$	10.1		$	(2,996.8	)	$	(218.5	)	$	(59.6	)	$	(4,580.7	)

Other comprehensive income (loss) before reclassifications	(445.2		)	206.7			(514.3		)	(2.2		)	(140.8		)	(895.8		)
Net amount reclassified from accumulated other comprehensive loss	74.5			7.2			159.1			9.8			0.1			250.7
Net other comprehensive income (loss)	(370.7		)	213.9			(355.2		)	7.6			(140.7		)	(645.1		)

Balance at December 31, 2016⁽¹⁾	(1,686.6		)	224.0			(3,352.0		)	(210.9		)	(200.3		)	(5,225.8		)

Other comprehensive income (loss) before reclassifications	525.6			(15.7		)	(532.1		)	8.5			127.7			114.0
Net amount reclassified from accumulated other comprehensive loss	8.1			(110.6		)	151.9			9.6			1.5			60.5
Net other comprehensive income (loss)	533.7			(126.3		)	(380.2		)	18.1			129.2			174.5

Reclassifications of stranded tax effects (Note 2)	(38.8		)	15.8			(579.1		)	(41.5		)	—			(643.6		)

Balance at December 31, 2017⁽²⁾	(1,191.7		)	113.5			(4,311.3		)	(234.3		)	(71.1		)	(5,694.9		)

Reclassification due to adoption of new accounting standard⁽³⁾	—			(128.9		)	—			—			—			(128.9		)
Other comprehensive income (loss) before reclassifications	(378.0		)	24.5			250.7			(16.3		)	12.2			(106.9		)
Net amount reclassified from accumulated other comprehensive loss	—			(31.2		)	207.9			11.7			2.1			190.5
Net other comprehensive income (loss)	(378.0		)	(6.7		)	458.6			(4.6		)	14.3			83.6

Ending balance at December 31, 2018⁽⁴⁾	$	(1,569.7	)	$	(22.1	)	$	(3,852.7	)	$	(238.9	)	$	(56.8	)	$	(5,740.2	)

⁽¹⁾Accumulated other comprehensive loss as of December 31, 2016 consists of $5.27 billion of accumulated other comprehensive loss attributable to controlling interest and $48.2 million of accumulated other comprehensive income attributable to noncontrolling interest.

⁽²⁾Accumulated other comprehensive loss as of December 31, 2017 consists of $5.72 billion of accumulated other comprehensive loss attributable to controlling interest and $23.7 million of accumulated other comprehensive income attributable to noncontrolling interest.

⁽³⁾This reclassification consists of $105.2 million of accumulated other comprehensive loss attributable to controlling interest and $23.7 million of accumulated other comprehensive loss attributable to noncontrolling interest. Refer to Note 2 for further details regarding the reclassification due to the adoption of Accounting Standards Update 2016-01, Financial Instruments - Overall: Recognition and Measurement of Financial Assets and Financial Liabilities.

⁽⁴⁾Accumulated other comprehensive loss as of December 31, 2018 consists of $5.73 billion of accumulated other comprehensive loss attributable to controlling interest and $11.0 million of accumulated other comprehensive loss attributable to noncontrolling interest.

The tax effects on the net activity related to each component of other comprehensive income (loss) for the years ended December 31, were as follows:



Tax benefit (expense)	2018			2017			2016
Foreign currency translation gains/losses	$	51.6		$	170.8		$	(70.6	)
Unrealized net gains/losses on securities	2.1			55.0			(89.2		)
Defined benefit pension and retiree health benefit plans	(85.3		)	186.6			153.3
Effective portion of cash flow hedges	1.3			(9.7		)	(4.1		)
Benefit/(provision) for income taxes allocated to other comprehensive income (loss) items	$	(30.3	)	$	402.7		$	(10.6	)

Except for the tax effects of foreign currency translation gains and losses related to our foreign currency-denominated notes, cross-currency interest rate swaps, and other foreign currency exchange contracts designated as net investment hedges (see Note 7), income taxes were not provided for foreign currency translation. Generally, the assets and liabilities of foreign operations are translated into U.S. dollars using the current exchange rate. For those operations, changes in exchange rates generally do not affect cash flows; therefore, resulting translation adjustments are made in shareholders' equity rather than in the consolidated statements of operations.

Reclassifications out of accumulated other comprehensive loss were as follows:



Details about Accumulated Other Comprehensive Loss Components	Year Ended December 31,									Affected Line Item in the Consolidated Statements of Operations
	2018			2017			2016
Amortization of retirement benefit items:
Prior service benefits, net	$	(74.9	)	$	(84.4	)	$	(74.1	)	Other—net, (income) expense
Actuarial losses	338.6			305.2			304.7			Other—net, (income) expense
Total before tax	263.7			220.8			230.6
Tax benefit	(55.8		)	(68.9		)	(71.5		)	Income taxes
Net of tax	207.9			151.9			159.1

Unrealized gains/losses on available-for-sale securities:
Realized gains, net	(39.5		)	(170.2		)	(16.1		)	Other—net, (income) expense
Impairment losses	—			—			27.3			Other—net, (income) expense
Total before tax	(39.5		)	(170.2		)	11.2
Tax (benefit) expense	8.3			59.6			(4.0		)	Income taxes
Net of tax	(31.2		)	(110.6		)	7.2

Other, net of tax⁽¹⁾	13.8			19.2			84.4			Other—net, (income) expense
Total reclassifications for the period (net of tax)	$	190.5		$	60.5		$	250.7

⁽¹⁾Amount for year ended December 31, 2016 included primarily $74.5 million of foreign currency translation losses.

Note 17: Other–Net, (Income) Expense

Other–net, (income) expense consisted of the following:



	2018			2017			2016
Interest expense	$	242.5		$	225.0		$	185.2
Interest income	(159.3		)	(166.4		)	(107.9		)
Venezuela charge	—			—			203.9
Retirement benefit	(240.5		)	(249.0		)	(197.1		)
Other (income) expense	11.7			(111.1		)	(192.9		)
Other–net, (income) expense	$	(145.6	)	$	(301.5	)	$	(108.8	)

Due to the financial crisis in Venezuela and the significant deterioration of the bolívar, we changed the exchange rate used to translate the assets and liabilities of our subsidiaries in Venezuela in 2016, which resulted in a charge of $203.9 million for the year ended December 31, 2016. Prior to this change, we used the Supplementary Foreign Currency Administration System (SICAD) rate; however, this official rate was discontinued in the first quarter of 2016. After considering several factors, including the future uncertainty of the Venezuelan economy, published exchange rates, and the limited amount of foreign currency exchanged, we changed to the Divisa Complementaria (DICOM) rate.

As discussed in Note 2, upon adoption of Accounting Standards Update 2017-07, Compensation-Retirement Benefits: Improving the Presentation of Net Periodic Pension Cost and Net Periodic Postretirement Benefit Cost, pension and postretirement benefit cost components other than service costs are presented in other–net, (income) expense. Results for the years ended December 31, 2017 and 2016 have been reclassified to reflect the adoption of this standard.

For the years ended December 31, 2017, and 2016, other income is primarily related to net gains on investments (Note 7).

Note 18: Segment Information

On March 11, 2019, we completed the disposition of our remaining 80.2 percent ownership of Elanco common stock through a tax-free exchange offer. As a result, Elanco has been presented as discontinued operations in our consolidated financial statements for all periods presented. Following the completion of the disposition of Elanco, we now operate as a single operating segment engaged in the discovery, development, manufacturing, marketing, and sales of pharmaceutical products worldwide. A global research and development organization and a supply chain organization are responsible for the discovery, development, manufacturing, and supply of our products. Regional commercial organizations market, distribute, and sell the products. The business is also supported by global corporate staff functions. Our determination that we operate as a single segment is consistent with the financial information regularly reviewed by the chief operating decision maker for purposes of evaluating performance, allocating resources, setting incentive compensation targets, and planning and forecasting for future periods.

We lost our compound patent protection for Cialis^® (tadalafil) and Adcirca^® (tadalafil) in major European markets in November 2017, and in the U.S., pediatric exclusivity expired in May 2018. Pursuant to a settlement agreement related to our unit dose patent in the U.S., generic tadalafil entered the U.S. market in September 2018. Entry of generic competition into these markets following the loss of exclusivity will continue to cause a rapid and severe decline in revenue. Our formulation patents for Forteo^®expired in December 2018 and use patents will expire in August 2019 in major European markets and the U.S. Both the formulation patent and the use patent expire in 2019 in Japan.

Most of our products are distributed through wholesalers that serve pharmacies, physicians and other health care professionals, and hospitals. For the years ended December 31, 2018, 2017, and 2016, our three largest wholesalers each accounted for between 13 percent and 21 percent of consolidated total revenue. Further, they each accounted for between 16 percent and 25 percent of accounts receivable as of December 31, 2018 and 2017.

We are exposed to the risk of changes in social, political, and economic conditions inherent in foreign operations, and our results of operations and the value of our foreign assets are affected by fluctuations in foreign currency exchange rates.

The following table summarizes our revenue activity:



	U.S.⁽¹⁾						Outside U.S.
	2018		2017		2016		2018		2017		2016
Revenue—to unaffiliated customers:
Endocrinology:
Trulicity^®	$	2,515.8	$	1,609.8	$	737.6	$	683.3	$	419.9	$	187.9
Humalog^®	1,787.8		1,717.8		1,685.2		1,208.7		1,147.4		1,083.6
Humulin^®	910.2		884.6		861.8		421.2		450.7		504.1
Forteo	757.9		965.2		770.5		817.7		783.8		729.4
Basaglar	622.8		311.1		15.8		178.5		121.0		70.3
Jardiance	400.2		290.4		144.5		258.1		157.0		57.4
Trajenta	224.2		213.2		165.9		350.5		324.7		270.7
Other Endocrinology	292.7		380.9		450.6		272.5		307.7		347.5
Total Endocrinology	7,511.6		6,373.0		4,831.9		4,190.5		3,712.2		3,250.9

Oncology:
Alimta	1,131.0		1,034.3		1,101.0		1,001.9		1,028.2		1,182.3
Erbitux	531.6		541.7		581.1		103.8		104.2		105.9
Cyramza^®	291.5		278.8		270.1		529.9		479.6		344.0
Other Oncology	449.1		195.6		22.9		221.7		149.6		114.6
Total Oncology	2,403.2		2,050.4		1,975.1		1,857.3		1,761.6		1,746.8

Cardiovascular:
Cialis	1,129.2		1,358.6		1,469.5		722.7		964.5		1,002.1
Effient	68.1		340.1		465.6		54.1		48.8		69.6
Other Cardiovascular	158.4		24.0		56.3		121.8		135.2		162.3
Total Cardiovascular	1,355.7		1,722.7		1,991.4		898.6		1,148.5		1,234.0

Neuroscience:
Strattera^®	89.7		284.9		534.9		361.1		333.3		319.8
Cymbalta⁽²⁾	54.3		114.9		269.3		653.7		642.2		661.2
Zyprexa^®	36.2		75.5		69.8		435.1		505.7		655.5
Other Neuroscience	97.2		115.7		115.9		93.4		98.9		93.9
Total Neuroscience	277.4		591.0		989.9		1,543.3		1,580.1		1,730.4

Immunology:
Taltz^®	738.7		486.0		110.8		198.7		73.2		2.3
Other Immunology	6.7		—		—		195.9		45.8		—
Total Immunology	745.4		486.0		110.8		394.6		119.0		2.3

Other	98.5		191.3		247.9		217.0		238.0		201.3
Revenue	$	12,391.9	$	11,414.4	$	10,147.0	$	9,101.4	$	8,559.4	$	8,165.8

Numbers may not add due to rounding.

⁽¹⁾ U.S. revenue includes revenue in Puerto Rico.

⁽²⁾Cymbalta revenues benefited from reductions to the reserve for expected product returns of approximately $175 million during the year ended December 31, 2016.



	2018		2017		2016
Geographic Information
Revenue—to unaffiliated customers⁽¹⁾:
United States	$	12,391.9	$	11,414.4	$	10,147.0
Europe	3,663.1		3,390.6		3,214.4
Japan	2,407.4		2,339.5		2,253.0
Other foreign countries	3,030.9		2,829.3		2,698.3
Revenue	$	21,493.3	$	19,973.8	$	18,312.8

Long-lived assets⁽²⁾:
United States	$	4,344.0	$	4,408.7	$	4,520.8
Europe	2,413.5		2,246.4		1,864.8
Japan	180.2		153.4		91.0
Other foreign countries	1,608.5		1,672.5		1,690.4
Long-lived assets	$	8,546.2	$	8,481.0	$	8,167.0

Numbers may not add due to rounding.

⁽¹⁾Revenue is attributed to the countries based on the location of the customer.

⁽²⁾Long-lived assets consist of property and equipment, net, and certain sundry assets.

Note 19: Selected Quarterly Data (unaudited)



2018	Fourth			Third		Second			First
Revenue	$	5,637.6		$	5,306.9	$	5,585.0		$	4,963.8
Cost of sales	1,129.9			1,152.9		1,234.3			1,164.6
Operating expenses⁽¹⁾	3,085.5			2,738.1		2,756.6			2,446.2
Acquired in-process research and development⁽²⁾	329.4			30.0		1,624.5			—
Asset impairment, restructuring, and other special charges	192.7			42.9		(25.5		)	56.8
Income before income taxes	931.6			1,341.1		41.7			1,365.7
Income taxes⁽³⁾	(189.8		)	247.5		273.3			198.5
Net income (loss) from continuing operations	1,121.4			1,093.6		(231.6		)	1,167.2
Net income (loss) from discontinued operations	3.7			55.9		(28.3		)	50.2
Net income (loss)	1,125.1			1,149.5		(259.9		)	1,217.4
Earnings (loss) from continuing operations - basic	1.11			1.07		(0.22		)	1.11
Earnings (loss) from discontinued operations - basic	—			0.06		(0.03		)	0.05
Earnings (loss) per share—basic	1.11			1.13		(0.25		)	1.16
Earnings (loss) from continuing operations - diluted	1.10			1.07		(0.22		)	1.11
Earnings (loss) from discontinued operations - diluted	—			0.05		(0.03		)	0.05
Earnings (loss) per share—diluted	1.10			1.12		(0.25		)	1.16
Dividends paid per share	0.5625			0.5625		0.5625			0.5625

2017	Fourth			Third		Second			First
Revenue	$	5,406.4		$	4,961.0	$	5,091.6		$	4,514.9
Cost of sales⁽⁴⁾	1,186.4			1,163.5		1,140.1			957.7
Operating expenses⁽¹⁾⁽⁴⁾	3,054.0			2,678.2		2,763.8			2,582.5
Acquired in-process research and development⁽²⁾	50.0			205.0		—			857.6
Asset impairment, restructuring, and other special charges⁽⁵⁾	830.7			389.2		0.3			111.4
Income before income taxes	397.0			573.1		1,249.4			85.2
Income taxes⁽³⁾	1,947.5			29.0		244.3			170.3
Net income (loss) from continuing operations	(1,550.5		)	544.1		1,005.1			(85.1		)
Net income (loss) from discontinued operations	(106.4		)	11.5		2.9			(25.7		)
Net income (loss)	(1,656.9		)	555.6		1,008.0			(110.8		)
Earnings (loss) from continuing operations - basic	(1.48		)	0.52		0.96			(0.08		)
Earnings (loss) from discontinued operations - basic	(0.10		)	0.01		—			(0.02		)
Earnings (loss) per share—basic	(1.58		)	0.53		0.96			(0.10		)
Earnings (loss) from continuing operations - diluted	(1.48		)	0.52		0.95			(0.08		)
Earnings (loss) from discontinued operations - diluted	(0.10		)	0.01		—			(0.02		)
Earnings (loss) per share—diluted	(1.58		)	0.53		0.95			(0.10		)
Dividends paid per share	0.52			0.52		0.52			0.52

⁽¹⁾Includes research and development and marketing, selling, and administrative expenses.

⁽²⁾ Acquired IPR&D charges in the second quarter of 2018 were primarily due to the ARMO acquisition. Acquired IPR&D charges in the first quarter of 2017 were due to the CoLucid acquisition. See Note 3 for further discussion.

⁽³⁾Income taxes in the fourth quarter of 2018 were a tax benefit primarily due to adjustments associated with U.S. tax reform. Income taxes in the fourth quarter of 2017 were due to the provisional charge resulting from the 2017 Tax Act. See Note 13 for further discussion.

⁽⁴⁾As discussed in Note 2, upon adoption of Accounting Standards Update 2017-07, Compensation-Retirement Benefits: Improving the Presentation of Net Periodic Pension Cost and Net Periodic Postretirement Benefit Cost, pension and postretirement benefit cost components other than service costs are presented in other–net, (income) expense. Results for the quarters in 2017 have been reclassified to reflect the adoption of this standard.

⁽⁵⁾Asset impairment, restructuring, and other special charges in the third quarter 2017 were primarily from asset impairments related to lower projected revenue for Posilac (rbST). In the fourth quarter of 2017, restructuring charges were primarily due to severance costs resulting from the U.S. voluntary early retirement program. See Note 5 for further discussion.

Our common stock is listed under the ticker symbol LLY on the New York Stock Exchange (NYSE) and the NYSE Euronext.

Note 20: Discontinued Operations

On September 24, 2018, Elanco completed its IPO resulting in the issuance of 72.3 million shares of its common stock, which represented 19.8 percent of Elanco's outstanding shares, at $24 per share. Elanco shares began trading on the New York Stock Exchange under the symbol "ELAN" in September 2018.

In connection with the completion of the IPO, through a series of equity and other transactions, we transferred to Elanco the animal health businesses that formed its business. In exchange, Elanco transferred to us consideration of approximately $4.2 billion, which consisted primarily of the net proceeds from the IPO and the net proceeds from a $2.00 billion debt offering and a $500.0 million three-year term loan facility entered into by Elanco in August 2018. The consideration that we received was used for debt repayment, dividends, and/or share repurchases. The excess of the net proceeds from the IPO over the net book value of our divested interest was $629.2 million and was recorded in additional paid-in capital.

Through March 11, 2019, we continued to consolidate Elanco, as we retained control over Elanco. The earnings attributable to the divested, noncontrolling interest for the period from the IPO until December 31, 2018 were not material. As of December 31, 2018, the noncontrolling interest of $1.02 billion associated with Elanco was reflected in noncontrolling interests in the consolidated balance sheet.

On March 11, 2019, we completed the disposition of our remaining 80.2 percent ownership of Elanco common stock through a tax-free exchange offer. As a result, in the first quarter of 2019, we recognized a gain related to the disposition of approximately $3.7 billion, and we presented Elanco, including the gain related to the disposition, as discontinued operations in our consolidated condensed financial statements for all periods presented.

The following table sets forth details of revenue and net income (loss) from discontinued operations:



	2018		2017			2016
Revenue from discontinued operations	$	3,062.4	$	2,897.5		$	2,909.3
Net income (loss) from discontinued operations	81.4		(117.7		)	12.7

The following table presents the major classes of assets and liabilities from discontinued operations at December 31:



	2018		2017
Inventories	$	1,013.7	$	1,062.3
Other current assets	1,215.4		1,047.7
Current assets of discontinued operations	$	2,229.1	$	2,110.0

Goodwill	$	2,980.9	$	2,992.1
Other intangibles, net	2,453.0		2,674.8
Property and equipment, net	923.4		941.4
Other assets	126.8		60.4
Noncurrent assets of discontinued operations	$	6,484.1	$	6,668.7

Current liabilities of discontinued operations	$	692.8	$	637.5

Long-term debt	$	2,443.3	$	0.5
Other liabilities	299.0		351.1
Noncurrent liabilities of discontinued operations	$	2,742.3	$	351.6

Net cash provided by operating activities related to our discontinued operations was approximately $500 million, $300 million, and $300 million for the years ended December 31, 2018, 2017, and 2016, respectively. Net cash used by investing activities related to our discontinued operations was approximately $130 million, $960 million, and $180 million for the years ended December 31, 2018, 2017, and 2016, respectively.

We entered into a transitional services agreement (TSA) with Elanco that is designed to facilitate the orderly transfer of various services to Elanco. The TSA relates primarily to administrative services, which are

generally to be provided over 24 months from March 11, 2019, the disposition date. This agreement is not material and does not confer upon us the ability to influence the operating and/or financial policies of Elanco subsequent to the disposition date.

Management’s Reports

Management’s Report for Financial Statements—Eli Lilly and Company and Subsidiaries

Management of Eli Lilly and Company and subsidiaries is responsible for the accuracy, integrity, and fair presentation of the financial statements. The statements have been prepared in accordance with generally accepted accounting principles in the United States and include amounts based on judgments and estimates by management. In management’s opinion, the consolidated financial statements present fairly our financial position, results of operations, and cash flows.

In addition to the system of internal accounting controls, we maintain a code of conduct (known as "The Red Book") that applies to all employees worldwide, requiring proper overall business conduct, avoidance of conflicts of interest, compliance with laws, and confidentiality of proprietary information. All employees must take training annually on The Red Book and are required to report suspected violations. A hotline number is published in The Red Book to enable employees to report suspected violations anonymously. Employees who report suspected violations are protected from discrimination or retaliation by the company. In addition to The Red Book, the chief executive officer and all financial management must sign a financial code of ethics, which further reinforces their ethical and fiduciary responsibilities.

The consolidated financial statements have been audited by Ernst & Young LLP, an independent registered public accounting firm. Their responsibility is to examine our consolidated financial statements in accordance with generally accepted auditing standards of the Public Company Accounting Oversight Board (United States). Ernst & Young’s opinion with respect to the fairness of the presentation of the statements is included in Item 8 of this Form 8-K. Ernst & Young reports directly to the audit committee of the board of directors.

Our audit committee includes six nonemployee members of the board of directors, all of whom are independent from our company. The committee charter, which is available on our website, outlines the members’ roles and responsibilities and is consistent with enacted corporate reform laws and regulations. It is the audit committee’s responsibility to appoint an independent registered public accounting firm subject to shareholder ratification, approve both audit and non-audit services performed by the independent registered public accounting firm, and review the reports submitted by the firm. The audit committee meets several times during the year with management, the internal auditors, and the independent public accounting firm to discuss audit activities, internal controls, and financial reporting matters, including reviews of our externally published financial results. The internal auditors and the independent registered public accounting firm have full and free access to the committee.

We are dedicated to ensuring that we maintain the high standards of financial accounting and reporting that we have established. We are committed to providing financial information that is transparent, timely, complete, relevant, and accurate. Our culture demands integrity and an unyielding commitment to strong internal practices and policies. Finally, we have the highest confidence in our financial reporting, our underlying system of internal controls, and our people, who are objective in their responsibilities and operate under a code of conduct and the highest level of ethical standards.

Management’s Report on Internal Control Over Financial Reporting—Eli Lilly and Company and Subsidiaries

Management of Eli Lilly and Company and subsidiaries is responsible for establishing and maintaining adequate internal control over financial reporting as defined in Rules 13a-15(f) and 15d-15(f) under the Securities Exchange Act of 1934. We have global financial policies that govern critical areas, including internal controls, financial accounting and reporting, fiduciary accountability, and safeguarding of corporate assets. Our internal accounting control systems are designed to provide reasonable assurance that assets are safeguarded, that transactions are executed in accordance with management’s authorization and are properly recorded, and that accounting records are adequate for preparation of financial statements and other financial information. A staff of internal auditors regularly monitors, on a worldwide basis, the adequacy and effectiveness of internal accounting controls. The general auditor reports directly to the audit committee of the board of directors.

We conducted an evaluation of the effectiveness of our internal control over financial reporting based on the framework in "2013 Internal Control—Integrated Framework" issued by the Committee of Sponsoring Organizations of the Treadway Commission.

Based on our evaluation under this framework, we concluded that our internal control over financial reporting was effective as of December 31, 2018. However, because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

The internal control over financial reporting has been assessed by Ernst & Young LLP as of December 31, 2018. Their responsibility is to evaluate whether internal control over financial reporting was designed and operating effectively.



David A. Ricks		Joshua L. Smiley
Chairman, President and Chief Executive Officer		Senior Vice President and Chief Financial Officer

February 19, 2019

Report of Independent Registered Public Accounting Firm

To the Board of Directors and Shareholders of Eli Lilly and Company

Opinion on the Financial Statements

We have audited the accompanying consolidated balance sheets of Eli Lilly and Company and subsidiaries (the Company) as of December 31, 2018 and 2017, the related consolidated statements of operations, comprehensive income (loss), shareholders’ equity and cash flows for each of the three years in the period ended December 31, 2018, and the related notes (collectively referred to as the “consolidated financial statements”). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company at December 31, 2018 and 2017, and the results of its operations and its cash flows for each of the three years in the period ended December 31, 2018, in conformity with U.S. generally accepted accounting principles.

We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the Company's internal control over financial reporting as of December 31, 2018, based on criteria established in Internal Control-Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework), and our report dated February 19, 2019 expressed an unqualified opinion thereon.

Adoption of Accounting Standards Update ("ASU") No. 2016-16

As discussed in Note 2 to the consolidated financial statements, the Company changed its method of accounting for the recognition of income tax consequences of intra-entity transfers of assets other than inventory in 2018 due to the adoption of ASU No. 2016-16, Intra-Entity Transfers of Assets Other Than Inventory (Topic 740), using the modified retrospective adoption method.

Basis for Opinion

These financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on the Company’s financial statements based on our audits. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.

We have served as the Company‘s auditor since 1940.

Indianapolis, Indiana

February 19, 2019, except for the effects of discontinued operations discussed in Note 20, as to which the date is October 24, 2019

Report of Independent Registered Public Accounting Firm

To the Board of Directors and Shareholders of Eli Lilly and Company

Opinion on Internal Control Over Financial Reporting

We have audited Eli Lilly and Company and subsidiaries’ internal control over financial reporting as of December 31, 2018, based on criteria established in Internal Control - Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework) (the COSO criteria). In our opinion, Eli Lilly and Company and subsidiaries (the Company) maintained, in all material respects, effective internal control over financial reporting as of December 31, 2018, based on the COSO criteria.

We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the consolidated balance sheets of the Company as of December 31, 2018 and 2017, the related consolidated statements of operations, comprehensive income (loss), shareholders‘ equity and cash flows for each of the three years in the period ended December 31, 2018, and the related notes and our report dated February 19, 2019 expressed an unqualified opinion thereon.

Basis for Opinion

The Company’s management is responsible for maintaining effective internal control over financial reporting and for its assessment of the effectiveness of internal control over financial reporting included in the accompanying Management’s Report on Internal Control Over Financial Reporting. Our responsibility is to express an opinion on the Company’s internal control over financial reporting based on our audit. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether effective internal control over financial reporting was maintained in all material respects.

Our audit included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, testing and evaluating the design and operating effectiveness of internal control based on the assessed risk, and performing such other procedures as we considered necessary in the circumstances. We believe that our audit provides a reasonable basis for our opinion.

Definition and Limitations of Internal Control Over Financial Reporting

A company’s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company’s internal control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company’s assets that could have a material effect on the financial statements.

Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

Indianapolis, Indiana

February 19, 2019

EX-101.SCH 4 lly-20191024.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 2105100 - Disclosure - Acquisitions link:presentationLink link:calculationLink link:definitionLink 2305301 - Disclosure - Acquisitions (Tables) link:presentationLink link:calculationLink link:definitionLink 2107100 - Disclosure - Asset Impairment, Restructuring, and Other Special Charges link:presentationLink link:calculationLink link:definitionLink 2407402 - Disclosure - Asset Impairment, Restructuring, and Other Special Charges (Details) link:presentationLink link:calculationLink link:definitionLink 2407403 - Disclosure - Asset Impairment, Restructuring, and Other Special Charges (Narrative) (Details) link:presentationLink link:calculationLink link:definitionLink 2307301 - Disclosure - Asset Impairment, Restructuring, and Other Special Charges (Tables) link:presentationLink link:calculationLink link:definitionLink 2112100 - Disclosure - Borrowings link:presentationLink link:calculationLink link:definitionLink 2412404 - Disclosure - Borrowings (Debt maturities) (Details) link:presentationLink link:calculationLink link:definitionLink 2412402 - Disclosure - Borrowings (Long-term Debt) (Details) link:presentationLink link:calculationLink link:definitionLink 2412402 - Disclosure - Borrowings (Long-term Debt) (Details) link:presentationLink link:calculationLink link:definitionLink 2412403 - Disclosure - Borrowings (narrative) (Details) link:presentationLink link:calculationLink link:definitionLink 2312301 - Disclosure - Borrowings (Tables) link:presentationLink link:calculationLink link:definitionLink 2106100 - Disclosure - Collaborations and Other Arrangements link:presentationLink link:calculationLink link:definitionLink 2406402 - Disclosure - Collaborations and Other Arrangements (Details) link:presentationLink link:calculationLink link:definitionLink 2306301 - Disclosure - Collaborations and Other Arrangements (Tables) link:presentationLink link:calculationLink link:definitionLink 1003000 - Statement - Consolidated Balance Sheets link:presentationLink link:calculationLink link:definitionLink 1003501 - Statement - Consolidated Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 1005000 - Statement - Consolidated Statements of Cash Flows link:presentationLink link:calculationLink link:definitionLink 1005001 - Statement - Consolidated Statements of Cash Flows Consolidated Statements of Cash Flows (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 1002000 - Statement - Consolidated Statements of Comprehensive Income (Loss) link:presentationLink link:calculationLink link:definitionLink 1002001 - Statement - Consolidated Statements of Comprehensive Income (Loss) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 1001000 - Statement - Consolidated Statements of Operations link:presentationLink link:calculationLink link:definitionLink 1004001 - Statement - Consolidated Statements of Shareholders' Equity (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 1004000 - Statement - Consolidated Statements of Shareholders' Equity Statement link:presentationLink link:calculationLink link:definitionLink 2121100 - Disclosure - Contingencies link:presentationLink link:calculationLink link:definitionLink 2421402 - Disclosure - Contingencies (Details) link:presentationLink link:calculationLink link:definitionLink 2221201 - Disclosure - Contingencies (Policies) link:presentationLink link:calculationLink link:definitionLink 0001000 - Document - Cover Page link:presentationLink link:calculationLink link:definitionLink 2426402 - Disclosure - Discontinued Operations (Details) link:presentationLink link:calculationLink link:definitionLink 2426403 - Disclosure - Discontinued Operations (Discontinued Operations in Financial Statements) (Details) link:presentationLink link:calculationLink link:definitionLink 2426404 - Disclosure - Discontinued Operations (Major Classes of Assets and Liabilities) (Details) link:presentationLink link:calculationLink link:definitionLink 2126100 - Disclosure - Discontinued Operations (Notes) link:presentationLink link:calculationLink link:definitionLink 2326301 - Disclosure - Discontinued Operations (Tables) link:presentationLink link:calculationLink link:definitionLink 2109100 - Disclosure - Financial Instruments link:presentationLink link:calculationLink link:definitionLink 2409406 - Disclosure - Financial Instruments (Contractual Maturities) (Details) link:presentationLink link:calculationLink link:definitionLink 2409403 - Disclosure - Financial Instruments (Effect of Risk Management) (Details) link:presentationLink link:calculationLink link:definitionLink 2409404 - Disclosure - Financial Instruments (Fair Value Measurement) (Details) link:presentationLink link:calculationLink link:definitionLink 2409408 - Disclosure - Financial Instruments (Investment Portfolio Activity) (Details) link:presentationLink link:calculationLink link:definitionLink 2409409 - Disclosure - Financial Instruments (Narrative) (Details) link:presentationLink link:calculationLink link:definitionLink 2209201 - Disclosure - Financial Instruments (Policies) link:presentationLink link:calculationLink link:definitionLink 2409405 - Disclosure - Financial Instruments (Short-term and Long-term Classification) (Details) link:presentationLink link:calculationLink link:definitionLink 2409407 - Disclosure - Financial Instruments (Summary of AFS Unrealized Gain(Loss)) (Details) link:presentationLink link:calculationLink link:definitionLink 2309302 - Disclosure - Financial Instruments (Tables) link:presentationLink link:calculationLink link:definitionLink 2110100 - Disclosure - Goodwill and Other Intangibles link:presentationLink link:calculationLink link:definitionLink 2410406 - Disclosure - Goodwill and Other Intangibles (Amortization Expense) (Details) link:presentationLink link:calculationLink link:definitionLink 2410404 - Disclosure - Goodwill and Other Intangibles (Intangibles) (Details) link:presentationLink link:calculationLink link:definitionLink 2410405 - Disclosure - Goodwill and Other Intangibles (Narrative) (Details) link:presentationLink link:calculationLink link:definitionLink 2210201 - Disclosure - Goodwill and Other Intangibles (Policies) link:presentationLink link:calculationLink link:definitionLink 2310302 - Disclosure - Goodwill and Other Intangibles (Tables) link:presentationLink link:calculationLink link:definitionLink 2104100 - Disclosure - Implementation of New Financial Accounting Pronouncements link:presentationLink link:calculationLink link:definitionLink 2404402 - Disclosure - Implementation of New Financial Accounting Pronouncements (Details) link:presentationLink link:calculationLink link:definitionLink 2304301 - Disclosure - Implementation of New Financial Accounting Pronouncements (Tables) link:presentationLink link:calculationLink link:definitionLink 2119100 - Disclosure - Income Taxes link:presentationLink link:calculationLink link:definitionLink 2419404 - Disclosure - Income Taxes (Current and Deferred) (Details) link:presentationLink link:calculationLink link:definitionLink 2419405 - Disclosure - Income Taxes (Deferred tax asset and liabilities) (Details) link:presentationLink link:calculationLink link:definitionLink 2419403 - Disclosure - Income Taxes (Narrative) (Details) link:presentationLink link:calculationLink link:definitionLink 2219201 - Disclosure - Income Taxes (Policies) link:presentationLink link:calculationLink link:definitionLink 2419407 - Disclosure - Income Taxes (Reconciliation of Income Taxes) (Details) link:presentationLink link:calculationLink link:definitionLink 2319302 - Disclosure - Income Taxes (Tables) link:presentationLink link:calculationLink link:definitionLink 2419406 - Disclosure - Income Taxes (Unrecognized benefits) (Details) link:presentationLink link:calculationLink link:definitionLink 2108100 - Disclosure - Inventories link:presentationLink link:calculationLink link:definitionLink 2408403 - Disclosure - Inventories (Details) link:presentationLink link:calculationLink link:definitionLink 2208201 - Disclosure - Inventories (Policies) link:presentationLink link:calculationLink link:definitionLink 2308302 - Disclosure - Inventories (Tables) link:presentationLink link:calculationLink link:definitionLink 2405403 - Disclosure - (Narrative) (Details) link:presentationLink link:calculationLink link:definitionLink 2122100 - Disclosure - Other Comprehensive Income (Loss) link:presentationLink link:calculationLink link:definitionLink 2422404 - Disclosure - Other Comprehensive Income (Loss) (Reclassification) (Details) link:presentationLink link:calculationLink link:definitionLink 2422402 - Disclosure - Other Comprehensive Income (Loss) (Roll-forward) (Details) link:presentationLink link:calculationLink link:definitionLink 2322301 - Disclosure - Other Comprehensive Income (Loss) (Tables) link:presentationLink link:calculationLink link:definitionLink 2422403 - Disclosure - Other Comprehensive Income (Loss) (Tax effect) (Details) link:presentationLink link:calculationLink link:definitionLink 2123100 - Disclosure - Other-Net, (Income) Expense link:presentationLink link:calculationLink link:definitionLink 2423402 - Disclosure - Other - Net, (Income) Expense (Details) link:presentationLink link:calculationLink link:definitionLink 2323301 - Disclosure - Other - Net, (Income) Expense (Tables) link:presentationLink link:calculationLink link:definitionLink 2111100 - Disclosure - Property and Equipment link:presentationLink link:calculationLink link:definitionLink 2411403 - Disclosure - Property and Equipment (Details) link:presentationLink link:calculationLink link:definitionLink 2211201 - Disclosure - Property and Equipment (Policies) link:presentationLink link:calculationLink link:definitionLink 2311302 - Disclosure - Property and Equipment (Tables) link:presentationLink link:calculationLink link:definitionLink 2120100 - Disclosure - Retirement Benefits link:presentationLink link:calculationLink link:definitionLink 2420406 - Disclosure - Retirement Benefits (Fair Value Disclosures) (Details) link:presentationLink link:calculationLink link:definitionLink 2420407 - Disclosure - Retirement Benefits (Narrative) (Details) link:presentationLink link:calculationLink link:definitionLink 2420402 - Disclosure - Retirement Benefits (Schedule of Benefit Obligations and Plan Assets) (Details) link:presentationLink link:calculationLink link:definitionLink 2420403 - Disclosure - Retirement Benefits (Schedule of Components in Consolidated Balance Sheets) (Details) link:presentationLink link:calculationLink link:definitionLink 2420405 - Disclosure - Retirement Benefits (Schedule of Expected Benefit Payments, Contributions and Expense) (Details) link:presentationLink link:calculationLink link:definitionLink 2420404 - Disclosure - Retirement Benefits (Schedule of Weighted Average Assumptions) (Details) link:presentationLink link:calculationLink link:definitionLink 2320301 - Disclosure - Retirement Benefits (Tables) link:presentationLink link:calculationLink link:definitionLink 2124100 - Disclosure - Segment Information link:presentationLink link:calculationLink link:definitionLink 2424402 - Disclosure - Segment Information (Details) link:presentationLink link:calculationLink link:definitionLink 2324301 - Disclosure - Segment Information (Tables) link:presentationLink link:calculationLink link:definitionLink 2125100 - Disclosure - Selected Quarterly Data (Unaudited) link:presentationLink link:calculationLink link:definitionLink 2425402 - Disclosure - Selected Quarterly Data (Unaudited) (Details) link:presentationLink link:calculationLink link:definitionLink 2325301 - Disclosure - Selected Quarterly Data (Unaudited) (Tables) link:presentationLink link:calculationLink link:definitionLink 2117100 - Disclosure - Shareholders' Equity link:presentationLink link:calculationLink link:definitionLink 2417401 - Disclosure - Shareholders' Equity (Details) link:presentationLink link:calculationLink link:definitionLink 2116100 - Disclosure - Stock-Based Compensation link:presentationLink link:calculationLink link:definitionLink 2416403 - Disclosure - Stock-Based Compensation (Details) link:presentationLink link:calculationLink link:definitionLink 2216201 - Disclosure - Stock-Based Compensation (Policies) link:presentationLink link:calculationLink link:definitionLink 2316302 - Disclosure - Stock-Based Compensation (Tables) link:presentationLink link:calculationLink link:definitionLink 2101100 - Disclosure - Summary of Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 2401403 - Disclosure - Summary of Significant Accounting Policies (Acquisitions) (Details) link:presentationLink link:calculationLink link:definitionLink 2401405 - Disclosure - Summary of Significant Accounting Policies (Contract Liabilities) (Details) link:presentationLink link:calculationLink link:definitionLink 2201201 - Disclosure - Summary of Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 2401404 - Disclosure - Summary of Significant Accounting Policies (Revenue) (Details) link:presentationLink link:calculationLink link:definitionLink 2301302 - Disclosure - Summary of Significant Accounting Policies (Tables) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 5 lly-20191024_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 6 lly-20191024_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 7 lly-20191024_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Cover page. Entities [Table] Entities [Table] Class of Stock [Axis] Class of Stock [Axis] Class of Stock [Domain] Class of Stock [Domain] Common Stock (no par value) Common Class A [Member] 1.000% Notes Due June 2, 2022 1.000% Notes Due June 2, 2022 [Member] 1.000% Notes Due June 2, 2022 [Member] 7 1/8% Notes Due June 1, 2025 7 1/8% Notes Due June 1, 2025 [Member] 7 1/8% Notes Due June 1, 2025 [Member] 1.625% Notes Due June 2, 2026 1.625% Notes Due June 2, 2026 [Member] 1.625% Notes Due June 2, 2026 [Member] 2.125% Notes Due June 3, 2030 2.125% Notes Due June 3, 2030 [Member] 2.125% Notes Due June 3, 2030 [Member] 6.77% Notes Due January 1, 2036 6.77% Notes Due January 1, 2036 [Member] 6.77% Notes Due January 1, 2036 [Member] Entity Information [Line Items] Entity Information [Line Items] Document Type Document Type Document Period End Date Document Period End Date Entity Registrant Name Entity Registrant Name Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Entity File Number Entity File Number Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line One Entity Address, City or Town Entity Address, City or Town Entity Address, State or Province Entity Address, State or Province Entity Address, Postal Zip Code Entity Address, Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Written Communications Written Communications Soliciting Material Soliciting Material Pre-commencement Tender Offer Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Pre-commencement Issuer Tender Offer Entity Emerging Growth Company Entity Emerging Growth Company Title of 12(b) Security Title of 12(b) Security Trading Symbol Trading Symbol Security Exchange Name Security Exchange Name Entity Central Index Key Entity Central Index Key Amendment Flag Amendment Flag Document Fiscal Period Focus Document Fiscal Period Focus Document Fiscal Year Focus Document Fiscal Year Focus Equity [Abstract] Accumulated Other Comprehensive Income (Loss) [Table] Accumulated Other Comprehensive Income (Loss) [Table] Operating Activities [Axis] Operating Activities [Axis] Operating Activities [Domain] Operating Activities [Domain] Continuing Operations Continuing Operations [Member] Discontinued Operations Discontinued Operations [Member] Equity Components [Axis] Equity Components [Axis] Equity Component [Domain] Equity Component [Domain] Accumulated Other Comprehensive Loss AOCI Including Portion Attributable to Noncontrolling Interest [Member] Foreign Currency Translation Gains (Losses) Accumulated Foreign Currency Adjustment Including Portion Attributable to Noncontrolling Interest [Member] Unrealized Net Gains (Losses) on Securities AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-sale, Including Noncontrolling Interest [Member] Defined Benefit Pension and Retiree Health Benefit Plans Accumulated Defined Benefit Plans Adjustment Including Portion Attributable to Noncontrolling Interest [Member] Effective Portion of Cash Flow Hedges Accumulated Net Gain (Loss) from Cash Flow Hedges Including Portion Attributable to Noncontrolling Interest [Member] Accumulated Other Comprehensive Loss AOCI Attributable to Parent [Member] AOCI Attributable to Noncontrolling Interest AOCI Attributable to Noncontrolling Interest [Member] Accumulated Other Comprehensive Income (Loss) [Line Items] Accumulated Other Comprehensive Income (Loss) [Line Items] AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward] AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward] Beginning balance Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest Reclassification due to adoption of new accounting standard(3) Cumulative Effect of New Accounting Principle in Period of Adoption Other comprehensive income (loss) before reclassifications Other Comprehensive Income (Loss), before Reclassifications, Net of Tax Net amount reclassified from accumulated other comprehensive loss Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax Net other comprehensive income (loss) Other Comprehensive Income (Loss), Net of Tax Reclassifications of stranded tax effects (Note 2) Tax Cuts and Jobs Act, Reclassification from AOCI to Retained Earnings, Tax Effect Tax Cuts and Jobs Act, Reclassification from AOCI to Retained Earnings, Tax Effect Ending balance Accumulated other comprehensive loss Accumulated Other Comprehensive Income (Loss), Net of Tax Goodwill and Intangible Assets Disclosure [Abstract] Goodwill and Intangible Assets Goodwill and Intangible Assets, Policy [Policy Text Block] Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Abstract] Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Table] Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Table] Retirement Plan Type [Axis] Retirement Plan Type [Axis] Retirement Plan Type [Domain] Retirement Plan Type [Domain] Defined Benefit Pension Plans Pension Plan [Member] Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items] [Line Items] Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items] Schedule of Changes in Accumulated Postemployment Benefit Obligations Schedule of Changes in Accumulated Postemployment Benefit Obligations [Table Text Block] Schedule of Changes in Fair Value of Plan Assets Schedule of Changes in Fair Value of Plan Assets [Table Text Block] Schedule of Net Funded Status Schedule of Net Funded Status [Table Text Block] Schedule of Amounts Recognized in Balance Sheet Schedule of Amounts Recognized in Balance Sheet [Table Text Block] Schedule of Assumptions Used Defined Benefit Plan, Assumptions [Table Text Block] Schedule of Expected Benefit Payments Schedule of Expected Benefit Payments [Table Text Block] Schedule of Net Benefit Costs Schedule of Net Benefit Costs [Table Text Block] Schedule of Amounts Recognized in Other Comprehensive Income (Loss) Schedule of Amounts Recognized in Other Comprehensive Income (Loss) [Table Text Block] Schedule of Allocation of Plan Assets Schedule of Allocation of Plan Assets [Table Text Block] Schedule of Benefit Obligations in Excess of Fair Value of Plan Assets Defined Benefit Plan, Plan with Projected Benefit Obligation in Excess of Plan Assets [Table Text Block] Schedule of Accumulated Benefit Obligations in Excess of Fair Value of Plan Assets Defined Benefit Plan, Plan with Accumulated Benefit Obligation in Excess of Plan Assets [Table Text Block] Segment Reporting [Abstract] Reconciliation of Operating Profit (Loss) from Segments to Consolidated Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table Text Block] Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas [Table Text Block] Derivative Instruments and Hedging Activities Disclosure [Abstract] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table] Short-term Debt, Type [Axis] Short-term Debt, Type [Axis] Short-term Debt, Type [Domain] Short-term Debt, Type [Domain] Commercial Paper Commercial Paper [Member] Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Domain] Fair Value Hierarchy and NAV [Domain] Quoted Prices in Active Markets for Identical Assets (Level 1) Fair Value, Inputs, Level 1 [Member] Significant Other Observable Inputs (Level 2) Fair Value, Inputs, Level 2 [Member] Significant Unobservable Inputs (Level 3) Fair Value, Inputs, Level 3 [Member] Measurement Basis [Axis] Measurement Basis [Axis] Fair Value Measurement [Domain] Fair Value Measurement [Domain] Portion at Fair Value Measurement Portion at Fair Value Measurement [Member] Carrying Amount Reported Value Measurement [Member] Fair Value Estimate of Fair Value Measurement [Member] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items] Short-term commercial paper borrowings Commercial Paper Long-term debt, including current portion Long-term Debt Nonoperating Income (Expense) [Abstract] Schedule of Other Nonoperating Income (Expense) Schedule of Other Nonoperating Income (Expense) [Table Text Block] Income Tax Disclosure [Abstract] Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward] Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward] Unrecognized Tax Benefits Unrecognized Tax Benefits Additions based on tax positions related to the current year Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions Additions for tax positions of prior years Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions Reductions for tax positions of prior years Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions Settlements Unrecognized Tax Benefits, Decrease Resulting from Settlements with Taxing Authorities Lapses of statutes of limitation Unrecognized Tax Benefits, Reduction Resulting from Lapse of Applicable Statute of Limitations Changes related to the impact of foreign currency translation, increase Unrecognized Tax Benefits, Increase Resulting from Foreign Currency Translation Changes related to the impact of foreign currency translation, decrease Unrecognized Tax Benefits, Decrease Resulting from Foreign Currency Translation Unrecognized Tax Benefits Schedule of Intangible Assets and Goodwill Schedule of Finite-Lived Intangible Assets [Table Text Block] Finite-lived Intangible Assets Amortization Expense Finite-lived Intangible Assets Amortization Expense [Table Text Block] Schedule of Finite-Lived Intangible Assets, Future Amortization Expense Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block] Retirement Benefits [Abstract] Schedule of Defined Benefit Plans Disclosures [Table] Schedule of Defined Benefit Plans Disclosures [Table] Income Statement Location [Axis] Income Statement Location [Axis] Income Statement Location [Domain] Income Statement Location [Domain] Restructuring, Settlement and Impairment Provisions Restructuring, Settlement And Impairment Provisions [Member] Restructuring, Settlement And Impairment Provisions [Member] Defined Benefit Plan, Plan Assets, Category [Axis] Defined Benefit Plan, Plan Assets, Category [Axis] Defined Benefit Plan, Plan Assets, Category [Domain] Defined Benefit Plan, Plan Assets, Category [Domain] Marketable equity securities Defined Benefit Plan, Equity Securities [Member] Developed markets Fixed Income Funds [Member] Defined Benefit Plan Disclosure [Line Items] Defined Benefit Plan Disclosure [Line Items] Curtailment (gain) loss Defined Benefit Plan, Net Periodic Benefit Cost (Credit), Gain (Loss) Due to Curtailment Defined benefit obligation, increase (decrease) Defined Benefit Plan, Benefit Obligation, Period Increase (Decrease) Curtailment (gain) loss Defined Benefit Plan, Benefit Obligation, (Increase) Decrease for Curtailment Special termination benefit Defined Benefit Plan, Benefit Obligation, Special and Contractual Termination Benefits Total accumulated benefit obligation for our defined benefit pension plans Defined Benefit Plan, Accumulated Benefit Obligation Expense under the plans Defined Contribution Plan, Cost Percentage of global investments in plan assets (in percentage) Defined Benefit Plan, Percentage of Global Investments in Plan Assets Percentage description of US defined benefit and other postretirement plan assets as compared to the total global investment balance Plan assets, target allocation (in percentage) Defined Benefit Plan, Plan Assets, Target Allocation, Percentage Expected contribution Defined Benefit Plan, Estimated Future Employer Contributions in Next Fiscal Year, Minimum Defined Benefit Plan, Estimated Future Employer Contributions in Next Fiscal Year, Minimum Statement of Financial Position [Abstract] Assets Assets [Abstract] Current Assets Assets, Current [Abstract] Cash and cash equivalents (Note 7) Cash and Cash Equivalents, at Carrying Value Short-term investments (Note 7) Short-term Investments Accounts receivable, net of allowances of $24.1 (2018) and $28.9 (2017) Accounts Receivable, after Allowance for Credit Loss, Current Other receivables Other Receivables Inventories (Note 6) Inventory, Net Prepaid expenses and other Prepaid Expense, Current Current assets of discontinued operations Disposal Group, Including Discontinued Operation, Assets, Current Total current assets Assets, Current Other Assets Assets, Noncurrent [Abstract] Investments (Note 7) Long-term Investments Goodwill (Note 8) Goodwill Other intangibles, net (Note 8) Intangible Assets, Net (Excluding Goodwill) Deferred tax assets (Note 13) Deferred Income Tax Assets, Net Sundry Other Assets, Noncurrent Property and equipment, net (Note 9) Property, Plant and Equipment, Net Noncurrent assets of discontinued operations Disposal Group, Including Discontinued Operation, Assets, Noncurrent Total assets Assets Liabilities and Equity Liabilities and Equity [Abstract] Current Liabilities Liabilities, Current [Abstract] Short-term borrowings and current maturities of long-term debt (Note 10) Debt, Current Accounts payable Accounts Payable, Current Employee compensation Employee-related Liabilities, Current Sales rebates and discounts Sales rebates and discounts Sales rebates and discounts Dividends payable Dividends Payable, Current Income taxes payable (Note 13) Taxes Payable, Current Other current liabilities Other Liabilities, Current Current liabilities of discontinued operations Disposal Group, Including Discontinued Operation, Liabilities, Current Total current liabilities Liabilities, Current Other Liabilities Liabilities, Noncurrent [Abstract] Long-term debt (Note 10) Long-term Debt, Excluding Current Maturities Accrued retirement benefits (Note 14) Liability, Defined Benefit Plan, Noncurrent Long-term income taxes payable (Note 13) Accrued Income Taxes, Noncurrent Other noncurrent liabilities Other Liabilities, Noncurrent Noncurrent liabilities of discontinued operations Disposal Group, Including Discontinued Operation, Liabilities, Noncurrent Total other liabilities Liabilities, Noncurrent Commitments and Contingencies (Note 15) Commitments and Contingencies Eli Lilly and Company Shareholders' Equity (Notes 11 and 12) Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract] Common stock—no par value Authorized shares: 3,200,000 Issued shares: 1,057,639 (2018) and 1,100,672 (2017) Common Stock, Value, Issued Additional paid-in capital Additional Paid in Capital, Common Stock Retained earnings Retained Earnings (Accumulated Deficit) Employee benefit trust Common Stock, Shares Held in Employee Trust Accumulated other comprehensive loss (Note 16) Cost of common stock in treasury Treasury Stock, Value Total Eli Lilly and Company shareholders' equity Stockholders' Equity Attributable to Parent Noncontrolling interests Stockholders' Equity Attributable to Noncontrolling Interest Total equity Total liabilities and equity Liabilities and Equity Restructuring and Related Activities [Abstract] Schedule of Other Operating Cost and Expense, by Component Restructuring and Related Costs [Table Text Block] Statement of Stockholders' Equity [Abstract] Statement [Table] Statement [Table] Common Stock Common Stock [Member] Additional Paid-in Capital Additional Paid-in Capital [Member] Retained Earnings Retained Earnings [Member] EX-101.PRE 8 lly-20191024_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT GRAPHIC 9 g266023g32y59a012015a17.jpg begin 644 g266023g32y59a012015a17.jpg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htm IDEA: XBRL DOCUMENT

Contingencies (Details) R$ in Millions, $ in Millions	1 Months Ended		12 Months Ended
Contingencies (Details) R$ in Millions, $ in Millions	Jul. 31, 2018 company product	Jun. 30, 2018 case	Dec. 31, 2018 USD ($) individual application company patent lawsuit demand defendant	Dec. 31, 2018 BRL (R$) individual lawsuit defendant
Loss Contingencies [Line Items]
Number of companies \| company	4
Number of generic products \| product	1
Dr Reddy's Lab
Loss Contingencies [Line Items]
Claims settled and dismissed \| case		2
Adocia S.A
Loss Contingencies [Line Items]
Number of patents \| patent			2
Amount of claim \| $			$ 1,300.0
Gain contingency, unrecorded amount \| $			$ 188.0
Japanese Administrative Proceedings
Loss Contingencies [Line Items]
Number of demands \| demand			3
Number of patents \| patent			2
United States \| Alimta
Loss Contingencies [Line Items]
Number of new application \| application			10
Number of defendants \| defendant			2	2
Number of companies \| company			5
Brazil \| Employee Litigation
Loss Contingencies [Line Items]
Number of lawsuits \| lawsuit			30	30
Damages awarded, value			$ 130.0	R$ 500.0
Plaintiff Appealing Decision of Court \| Brazil \| Employee Litigation
Loss Contingencies [Line Items]
Number of similar lawsuits \| lawsuit			2	2
Number of individuals \| individual			410	410

XML 11 R63.htm IDEA: XBRL DOCUMENT

Asset Impairment, Restructuring, and Other Special Charges (Details) - USD ($) $ in Millions	3 Months Ended								12 Months Ended
	Dec. 31, 2018	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018	Dec. 31, 2017	Sep. 30, 2017	Jun. 30, 2017	Mar. 31, 2017	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Restructuring and Related Activities [Abstract]
Severance									$ 127.8	$ 601.0	$ 85.9
Pension and post-retirement medical charges associated with U.S. voluntary early retirement program (see Note 14)									0.0	446.7	0.0
Asset impairment (gains from facility sales) and other special charges									139.1	283.9	(13.0)
Asset impairment, restructuring, and other special charges	$ 192.7	$ 42.9	$ (25.5)	$ 56.8	$ 830.7	$ 389.2	$ 0.3	$ 111.4	$ 266.9	$ 1,331.6	$ 72.9

XML 12 R67.htm IDEA: XBRL DOCUMENT

Financial Instruments (Fair Value Measurement) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Noncurrent investments:
Equity investments without readily determinable fair values	$ 414.7
Investments (Note 7)	2,005.4	$ 5,666.5
Contingent consideration liabilities:
Change on the fair value of contingent consideration	199.7	203.1
Quoted Prices in Active Markets for Identical Assets (Level 1) \| Designated as Hedging Instrument \| Interest Rate Contract
Risk-management instruments
Other current liabilities		0.0
Quoted Prices in Active Markets for Identical Assets (Level 1) \| Designated as Hedging Instrument \| Cross-currency interest rate swaps
Risk-management instruments
Other receivables	0.0
Sundry	0.0
Significant Other Observable Inputs (Level 2) \| Designated as Hedging Instrument \| Interest Rate Contract
Risk-management instruments
Other current liabilities		(0.2)
Significant Other Observable Inputs (Level 2) \| Designated as Hedging Instrument \| Cross-currency interest rate swaps
Risk-management instruments
Other receivables	69.2
Sundry	8.2
Significant Unobservable Inputs (Level 3) \| Designated as Hedging Instrument \| Interest Rate Contract
Risk-management instruments
Other current liabilities		0.0
Significant Unobservable Inputs (Level 3) \| Designated as Hedging Instrument \| Cross-currency interest rate swaps
Risk-management instruments
Other receivables	0.0
Sundry	0.0
Portion at Other than Fair Value Measurement
Statement [Line Items]
Cash equivalents	5,727.1	4,763.9
Carrying Amount
Statement [Line Items]
Cash equivalents	5,727.1	4,763.9
Short-term investments:
Short-term investments	88.2	1,497.9
Noncurrent investments:
Investments (Note 7)	2,005.4
Available-for-sale Securities, Noncurrent, Total		5,666.5
Contingent consideration liabilities:
Other current liabilities		(206.7)
Carrying Amount \| Designated as Hedging Instrument \| Interest Rate Contract
Risk-management instruments
Other receivables		0.8
Sundry	4.5	35.1
Other current liabilities	(22.3)	(0.2)
Other noncurrent liabilities	(19.0)	(10.5)
Carrying Amount \| Designated as Hedging Instrument \| Cross-currency interest rate swaps
Risk-management instruments
Other receivables	69.2
Sundry	8.2
Other current liabilities	(9.2)	(33.4)
Other noncurrent liabilities	(25.8)	(26.0)
Carrying Amount \| Not Designated as Hedging Instrument \| Foreign Exchange Contract
Risk-management instruments
Other receivables	11.3	26.8
Other current liabilities	(16.3)	(36.0)
Fair Value
Statement [Line Items]
Cash equivalents	5,727.1	4,763.9
Contingent consideration liabilities:
Other current liabilities		(206.7)
Fair Value \| Designated as Hedging Instrument \| Interest Rate Contract
Risk-management instruments
Other receivables		0.8
Sundry	4.5	35.1
Other current liabilities	(22.3)	(0.2)
Other noncurrent liabilities	(19.0)	(10.5)
Fair Value \| Designated as Hedging Instrument \| Cross-currency interest rate swaps
Risk-management instruments
Other receivables	69.2
Sundry	8.2
Other current liabilities	(9.2)	(33.4)
Other noncurrent liabilities	(25.8)	(26.0)
Fair Value \| Not Designated as Hedging Instrument \| Foreign Exchange Contract
Risk-management instruments
Other receivables	11.3	26.8
Other current liabilities	(16.3)	(36.0)
Fair Value \| Quoted Prices in Active Markets for Identical Assets (Level 1)
Statement [Line Items]
Cash equivalents	5,727.1	4,712.4
Contingent consideration liabilities:
Other current liabilities		0.0
Fair Value \| Quoted Prices in Active Markets for Identical Assets (Level 1) \| Designated as Hedging Instrument \| Interest Rate Contract
Risk-management instruments
Other receivables		0.0
Sundry	0.0	0.0
Other current liabilities	0.0
Other noncurrent liabilities	0.0	0.0
Fair Value \| Quoted Prices in Active Markets for Identical Assets (Level 1) \| Designated as Hedging Instrument \| Cross-currency interest rate swaps
Risk-management instruments
Other current liabilities	0.0	0.0
Other noncurrent liabilities	0.0	0.0
Fair Value \| Quoted Prices in Active Markets for Identical Assets (Level 1) \| Not Designated as Hedging Instrument \| Foreign Exchange Contract
Risk-management instruments
Other receivables	0.0	0.0
Other current liabilities	0.0	0.0
Fair Value \| Significant Other Observable Inputs (Level 2)
Statement [Line Items]
Cash equivalents	0.0	51.5
Contingent consideration liabilities:
Other current liabilities		0.0
Fair Value \| Significant Other Observable Inputs (Level 2) \| Designated as Hedging Instrument \| Interest Rate Contract
Risk-management instruments
Other receivables		0.8
Sundry	4.5	35.1
Other current liabilities	(22.3)
Other noncurrent liabilities	(19.0)	(10.5)
Fair Value \| Significant Other Observable Inputs (Level 2) \| Designated as Hedging Instrument \| Cross-currency interest rate swaps
Risk-management instruments
Other current liabilities	(9.2)	(33.4)
Other noncurrent liabilities	(25.8)	(26.0)
Fair Value \| Significant Other Observable Inputs (Level 2) \| Not Designated as Hedging Instrument \| Foreign Exchange Contract
Risk-management instruments
Other receivables	11.3	26.8
Other current liabilities	(16.3)	(36.0)
Fair Value \| Significant Unobservable Inputs (Level 3)
Statement [Line Items]
Cash equivalents	0.0	0.0
Contingent consideration liabilities:
Other current liabilities		(206.7)
Fair Value \| Significant Unobservable Inputs (Level 3) \| Designated as Hedging Instrument \| Interest Rate Contract
Risk-management instruments
Other receivables		0.0
Sundry	0.0	0.0
Other current liabilities	0.0
Other noncurrent liabilities	0.0	0.0
Fair Value \| Significant Unobservable Inputs (Level 3) \| Designated as Hedging Instrument \| Cross-currency interest rate swaps
Risk-management instruments
Other current liabilities	0.0	0.0
Other noncurrent liabilities	0.0	0.0
Fair Value \| Significant Unobservable Inputs (Level 3) \| Not Designated as Hedging Instrument \| Foreign Exchange Contract
Risk-management instruments
Other receivables	0.0	0.0
Other current liabilities	0.0	0.0
U.S. government and agency securities \| Portion at Other than Fair Value Measurement
Short-term investments:
Short-term investments, debt securities	17.1	218.2
Noncurrent investments:
Noncurrent investments, debt securities	153.6	365.0
U.S. government and agency securities \| Carrying Amount
Short-term investments:
Short-term investments, debt securities	16.9	217.8
Noncurrent investments:
Noncurrent investments, debt securities	149.1	360.0
U.S. government and agency securities \| Fair Value
Short-term investments:
Short-term investments, debt securities	16.9	217.8
Noncurrent investments:
Noncurrent investments, debt securities	149.1	360.0
U.S. government and agency securities \| Fair Value \| Quoted Prices in Active Markets for Identical Assets (Level 1)
Short-term investments:
Short-term investments, debt securities	16.9	217.8
Noncurrent investments:
Noncurrent investments, debt securities	149.1	360.0
U.S. government and agency securities \| Fair Value \| Significant Other Observable Inputs (Level 2)
Short-term investments:
Short-term investments, debt securities	0.0	0.0
Noncurrent investments:
Noncurrent investments, debt securities	0.0	0.0
U.S. government and agency securities \| Fair Value \| Significant Unobservable Inputs (Level 3)
Short-term investments:
Short-term investments, debt securities	0.0	0.0
Noncurrent investments:
Noncurrent investments, debt securities	0.0	0.0
Corporate debt securities \| Portion at Other than Fair Value Measurement
Short-term investments:
Short-term investments, debt securities	62.6	1,183.2
Noncurrent investments:
Noncurrent investments, debt securities	587.8	3,473.5
Corporate debt securities \| Carrying Amount
Short-term investments:
Short-term investments, debt securities	62.2	1,182.3
Noncurrent investments:
Noncurrent investments, debt securities	568.0	3,464.3
Corporate debt securities \| Fair Value
Short-term investments:
Short-term investments, debt securities	62.2	1,182.3
Noncurrent investments:
Noncurrent investments, debt securities	568.0	3,464.3
Corporate debt securities \| Fair Value \| Quoted Prices in Active Markets for Identical Assets (Level 1)
Short-term investments:
Short-term investments, debt securities	0.0	0.0
Noncurrent investments:
Noncurrent investments, debt securities	0.0	0.0
Corporate debt securities \| Fair Value \| Significant Other Observable Inputs (Level 2)
Short-term investments:
Short-term investments, debt securities	62.2	1,182.3
Noncurrent investments:
Noncurrent investments, debt securities	568.0	3,464.3
Corporate debt securities \| Fair Value \| Significant Unobservable Inputs (Level 3)
Short-term investments:
Short-term investments, debt securities	0.0	0.0
Noncurrent investments:
Noncurrent investments, debt securities	0.0	0.0
Mortgage-backed securities \| Portion at Other than Fair Value Measurement
Noncurrent investments:
Noncurrent investments, debt securities	114.5	204.2
Mortgage-backed securities \| Carrying Amount
Noncurrent investments:
Noncurrent investments, debt securities	111.4	202.4
Mortgage-backed securities \| Fair Value
Noncurrent investments:
Noncurrent investments, debt securities	111.4	202.4
Mortgage-backed securities \| Fair Value \| Quoted Prices in Active Markets for Identical Assets (Level 1)
Noncurrent investments:
Noncurrent investments, debt securities	0.0	0.0
Mortgage-backed securities \| Fair Value \| Significant Other Observable Inputs (Level 2)
Noncurrent investments:
Noncurrent investments, debt securities	111.4	202.4
Mortgage-backed securities \| Fair Value \| Significant Unobservable Inputs (Level 3)
Noncurrent investments:
Noncurrent investments, debt securities	0.0	0.0
Asset-backed securities \| Portion at Other than Fair Value Measurement
Short-term investments:
Short-term investments, debt securities	7.7	94.3
Noncurrent investments:
Noncurrent investments, debt securities	27.9	656.0
Asset-backed securities \| Carrying Amount
Short-term investments:
Short-term investments, debt securities	7.6	94.2
Noncurrent investments:
Noncurrent investments, debt securities	27.7	653.9
Asset-backed securities \| Fair Value
Short-term investments:
Short-term investments, debt securities	7.6	94.2
Noncurrent investments:
Noncurrent investments, debt securities	27.7	653.9
Asset-backed securities \| Fair Value \| Quoted Prices in Active Markets for Identical Assets (Level 1)
Short-term investments:
Short-term investments, debt securities	0.0	0.0
Noncurrent investments:
Noncurrent investments, debt securities	0.0	0.0
Asset-backed securities \| Fair Value \| Significant Other Observable Inputs (Level 2)
Short-term investments:
Short-term investments, debt securities	7.6	94.2
Noncurrent investments:
Noncurrent investments, debt securities	27.7	653.9
Asset-backed securities \| Fair Value \| Significant Unobservable Inputs (Level 3)
Short-term investments:
Short-term investments, debt securities	0.0	0.0
Noncurrent investments:
Noncurrent investments, debt securities	0.0	0.0
Other securities \| Portion at Other than Fair Value Measurement
Noncurrent investments:
Equity Securities, FV-NI	29.7
Other securities \| Carrying Amount
Noncurrent investments:
Equity Securities, FV-NI	87.8
Other securities \| Fair Value
Noncurrent investments:
Equity Securities, FV-NI	87.8
Other securities \| Fair Value \| Quoted Prices in Active Markets for Identical Assets (Level 1)
Noncurrent investments:
Equity Securities, FV-NI	0.0
Other securities \| Fair Value \| Significant Other Observable Inputs (Level 2)
Noncurrent investments:
Equity Securities, FV-NI	0.0
Other securities \| Fair Value \| Significant Unobservable Inputs (Level 3)
Noncurrent investments:
Equity Securities, FV-NI	87.8
Marketable equity securities \| Portion at Other than Fair Value Measurement
Noncurrent investments:
Equity Securities, FV-NI	238.3
Marketable equity securities \| Carrying Amount
Noncurrent investments:
Equity Securities, FV-NI	357.5
Marketable equity securities \| Fair Value
Noncurrent investments:
Equity Securities, FV-NI	357.5
Marketable equity securities \| Fair Value \| Quoted Prices in Active Markets for Identical Assets (Level 1)
Noncurrent investments:
Equity Securities, FV-NI	357.5
Marketable equity securities \| Fair Value \| Significant Other Observable Inputs (Level 2)
Noncurrent investments:
Equity Securities, FV-NI	0.0
Marketable equity securities \| Fair Value \| Significant Unobservable Inputs (Level 3)
Noncurrent investments:
Equity Securities, FV-NI	0.0
Other securities \| Portion at Other than Fair Value Measurement
Short-term investments:
Short-term investments, debt securities	1.5	3.6
Noncurrent investments:
Noncurrent investments, debt securities		66.4
Other securities \| Carrying Amount
Short-term investments:
Short-term investments, debt securities	1.5	3.6
Noncurrent investments:
Noncurrent investments, debt securities		132.1
Other securities \| Fair Value
Short-term investments:
Short-term investments, debt securities	1.5	3.6
Noncurrent investments:
Noncurrent investments, debt securities		132.1
Other securities \| Fair Value \| Quoted Prices in Active Markets for Identical Assets (Level 1)
Short-term investments:
Short-term investments, debt securities	0.0	0.0
Noncurrent investments:
Noncurrent investments, debt securities		0.0
Other securities \| Fair Value \| Significant Other Observable Inputs (Level 2)
Short-term investments:
Short-term investments, debt securities	1.5	3.6
Noncurrent investments:
Noncurrent investments, debt securities		0.0
Other securities \| Fair Value \| Significant Unobservable Inputs (Level 3)
Short-term investments:
Short-term investments, debt securities	0.0	0.0
Noncurrent investments:
Noncurrent investments, debt securities		132.1
Marketable equity securities \| Portion at Other than Fair Value Measurement
Noncurrent investments:
Marketable equity securities		131.0
Marketable equity securities \| Carrying Amount
Noncurrent investments:
Marketable equity securities		281.3
Marketable equity securities \| Fair Value
Noncurrent investments:
Marketable equity securities		281.3
Marketable equity securities \| Fair Value \| Quoted Prices in Active Markets for Identical Assets (Level 1)
Noncurrent investments:
Marketable equity securities		281.3
Marketable equity securities \| Fair Value \| Significant Other Observable Inputs (Level 2)
Noncurrent investments:
Marketable equity securities		0.0
Marketable equity securities \| Fair Value \| Significant Unobservable Inputs (Level 3)
Noncurrent investments:
Marketable equity securities		0.0
Cost and equity method investments \| Carrying Amount
Noncurrent investments:
Cost and equity method investments	$ 289.2	$ 572.5

XML 13 R97.htm IDEA: XBRL DOCUMENT

Other - Net, (Income) Expense (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Nonoperating Income (Expense) [Abstract]
Interest expense	$ 242.5	$ 225.0	$ 185.2
Interest income	(159.3)	(166.4)	(107.9)
Venezuela charge	0.0	0.0	203.9
Retirement benefit	(240.5)	(249.0)	(197.1)
Other (income) expense	11.7	(111.1)	(192.9)
Other–net, (income) expense	$ (145.6)	$ (301.5)	$ (108.8)

XML 14 R44.htm IDEA: XBRL DOCUMENT

Inventories (Tables)

12 Months Ended

Dec. 31, 2018

Inventory Disclosure [Abstract]

Schedule of Inventory

Inventories at December 31 consisted of the following:



	2018		2017
Finished products	$	577.8	$	759.4
Work in process	2,057.8		2,117.7
Raw materials and supplies	426.1		418.4
Total (approximates replacement cost)	3,061.7		3,295.5
Increase (reduction) to LIFO cost	36.4		100.5
Inventories	$	3,098.1	$	3,396.0

XML 15 R40.htm IDEA: XBRL DOCUMENT

Implementation of New Financial Accounting Pronouncements (Tables)

12 Months Ended

Dec. 31, 2018

New Accounting Pronouncements and Changes in Accounting Principles [Abstract]

Schedule of New Accounting Pronouncements and Changes in Accounting Principles

The following table provides a brief description of accounting standards that were effective January 1, 2018 and were adopted on that date:



Standard	Description	Effect on the financial statements or other significant matters
Accounting Standards Update 2014-09 and various other related updates, Revenue from Contracts with Customers	This standard replaced existing revenue recognition standards and requires entities to recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. An entity can apply the new revenue standard retrospectively to each prior reporting period presented or with the cumulative effect of initially applying the standard recognized at the date of initial application in retained earnings. We applied the latter approach.	Application of the new standard to applicable contracts resulted in an increase of approximately $5 million to retained earnings as of January 1, 2018. Disclosures required by the new standard are included in Note 1, Note 4, and Note 18.
Accounting Standards Update 2016-01, Financial Instruments - Overall: Recognition and Measurement of Financial Assets and Financial Liabilities	This standard requires entities to recognize changes in the fair value of equity investments with readily determinable fair values in net income (except for investments accounted for under the equity method of accounting or those that result in consolidation of the investee). An entity should apply the new standard through a cumulative effect adjustment to retained earnings as of the beginning of the fiscal year of adoption.	Upon adoption, we reclassified from accumulated other comprehensive loss the after-tax amount of net unrealized gains resulting in an increase to retained earnings of approximately $105 million. Adoption of this standard did not result in a material change in net income in 2018.
Accounting Standards Update 2016-16, Income Taxes: Intra-Entity Transfers of Assets Other Than Inventory	This standard requires entities to recognize the income tax consequences of intra-entity transfers of assets other than inventory at the time of transfer. This standard requires a modified retrospective approach to adoption.	Upon adoption, the cumulative effect of applying the standard resulted in an increase of approximately $700 million to retained earnings, $2.5 billion to deferred tax assets, and $1.8 billion to deferred tax liabilities. Adoption of this standard did not result in a material change in net income in 2018.



Accounting Standards Update 2017-07, Compensation-Retirement Benefits: Improving the Presentation of Net Periodic Pension Cost and Net Periodic Postretirement Benefit Cost	This standard was issued to improve the transparency and comparability among organizations by requiring entities to separate their net periodic pension cost and net periodic postretirement benefit cost into a service cost component and other components. Previously, the costs of the other components along with the service cost component were classified based upon the function of the employee. This standard requires entities to classify the service cost component in the same financial statement line item or items as other compensation costs arising from services rendered by pertinent employees. The other components of net benefit cost are now presented separately from the line items that include the service cost component. When applicable, the service cost component is now the only component eligible for capitalization. An entity should apply the new standard retrospectively for the classification of the service cost and other components and prospectively for the capitalization of the service cost component.	Upon adoption of this standard, pension and postretirement benefit cost components other than service costs are presented in other–net, (income) expense. The application of the new standard resulted in reclassification to other income of $249.0 million for the year ended December 31, 2017, while increasing cost of sales by $80.8 million, research and development expenses by $75.8 million, and marketing, selling, and administrative expenses by $92.4 million for the same period. The application of the new standard resulted in reclassification to other income of $197.1 million for the year ended December 31, 2016, while increasing cost of sales by $54.2 million, research and development expenses by $66.4 million, and marketing, selling, and administrative expenses by $76.5 million for the same period. We do not expect application of the new standard to have a material impact on an ongoing basis.

The following table provides a brief description of the accounting standard that had not yet been adopted as of December 31, 2018:

XML 16 R48.htm IDEA: XBRL DOCUMENT

Borrowings (Tables)

12 Months Ended

Dec. 31, 2018

Long-term Debt, Current and Noncurrent [Abstract]

Schedule of Additional Borrowings Disclosures

The aggregate amount of cash payments for interest on borrowings, net of capitalized interest, are as follows:



	2018		2017		2016
Cash payments for interest on borrowings	$	223.8	$	192.7	$	146.4

Schedule of Maturities of Long-term Debt

The aggregate amounts of maturities on long-term debt for the next five years are as follows:



	2019		2020		2021		2022		2023
Maturities on long-term debt	$	604.5	$	3.5	$	2.3	$	1,439.0	$	0.3

Schedule of Debt

Debt at December 31 consisted of the following:



	2018			2017
Short-term commercial paper borrowings	$	498.9		$	2,696.8
0.15 to 7.13 percent long-term notes (due 2019-2047)	9,640.8			10,756.7
Other long-term debt	10.1			13.0
Unamortized debt issuance costs	(28.4		)	(49.0		)
Fair value adjustment on hedged long-term notes	177.2			229.0
Total debt	10,298.6			13,646.5
Less current portion	(1,102.2		)	(3,706.5		)
Long-term debt	$	9,196.4		$	9,940.0

XML 17 R29.htm IDEA: XBRL DOCUMENT

Selected Quarterly Data (Unaudited)

12 Months Ended

Dec. 31, 2018

Quarterly Financial Information Disclosure [Abstract]

Selected Quarterly Data (Unaudited)

Selected Quarterly Data (unaudited)



2018	Fourth			Third		Second			First
Revenue	$	5,637.6		$	5,306.9	$	5,585.0		$	4,963.8
Cost of sales	1,129.9			1,152.9		1,234.3			1,164.6
Operating expenses⁽¹⁾	3,085.5			2,738.1		2,756.6			2,446.2
Acquired in-process research and development⁽²⁾	329.4			30.0		1,624.5			—
Asset impairment, restructuring, and other special charges	192.7			42.9		(25.5		)	56.8
Income before income taxes	931.6			1,341.1		41.7			1,365.7
Income taxes⁽³⁾	(189.8		)	247.5		273.3			198.5
Net income (loss) from continuing operations	1,121.4			1,093.6		(231.6		)	1,167.2
Net income (loss) from discontinued operations	3.7			55.9		(28.3		)	50.2
Net income (loss)	1,125.1			1,149.5		(259.9		)	1,217.4
Earnings (loss) from continuing operations - basic	1.11			1.07		(0.22		)	1.11
Earnings (loss) from discontinued operations - basic	—			0.06		(0.03		)	0.05
Earnings (loss) per share—basic	1.11			1.13		(0.25		)	1.16
Earnings (loss) from continuing operations - diluted	1.10			1.07		(0.22		)	1.11
Earnings (loss) from discontinued operations - diluted	—			0.05		(0.03		)	0.05
Earnings (loss) per share—diluted	1.10			1.12		(0.25		)	1.16
Dividends paid per share	0.5625			0.5625		0.5625			0.5625

2017	Fourth			Third		Second			First
Revenue	$	5,406.4		$	4,961.0	$	5,091.6		$	4,514.9
Cost of sales⁽⁴⁾	1,186.4			1,163.5		1,140.1			957.7
Operating expenses⁽¹⁾⁽⁴⁾	3,054.0			2,678.2		2,763.8			2,582.5
Acquired in-process research and development⁽²⁾	50.0			205.0		—			857.6
Asset impairment, restructuring, and other special charges⁽⁵⁾	830.7			389.2		0.3			111.4
Income before income taxes	397.0			573.1		1,249.4			85.2
Income taxes⁽³⁾	1,947.5			29.0		244.3			170.3
Net income (loss) from continuing operations	(1,550.5		)	544.1		1,005.1			(85.1		)
Net income (loss) from discontinued operations	(106.4		)	11.5		2.9			(25.7		)
Net income (loss)	(1,656.9		)	555.6		1,008.0			(110.8		)
Earnings (loss) from continuing operations - basic	(1.48		)	0.52		0.96			(0.08		)
Earnings (loss) from discontinued operations - basic	(0.10		)	0.01		—			(0.02		)
Earnings (loss) per share—basic	(1.58		)	0.53		0.96			(0.10		)
Earnings (loss) from continuing operations - diluted	(1.48		)	0.52		0.95			(0.08		)
Earnings (loss) from discontinued operations - diluted	(0.10		)	0.01		—			(0.02		)
Earnings (loss) per share—diluted	(1.58		)	0.53		0.95			(0.10		)
Dividends paid per share	0.52			0.52		0.52			0.52

⁽¹⁾Includes research and development and marketing, selling, and administrative expenses.

Our common stock is listed under the ticker symbol LLY on the New York Stock Exchange (NYSE) and the NYSE Euronext.

XML 18 R21.htm IDEA: XBRL DOCUMENT

Stock-Based Compensation

12 Months Ended

Dec. 31, 2018

Share-based Payment Arrangement [Abstract]

Stock-Based Compensation

Stock-based compensation expense and the related tax benefits were as follows:



	2018		2017		2016
Stock-based compensation expense	$	253.5	$	256.3	$	234.9
Tax benefit	53.2		64.1		82.2

At December 31, 2018, stock-based compensation awards may be granted under the 2002 Lilly Stock Plan for not more than 53.3 million additional shares.

Performance Award Program

Shareholder Value Award Program



(Percents)	2018		2017		2016
Expected dividend yield	2.50	%	2.50	%	2.00	%
Risk-free interest rate	2.31		1.38		0.92
Volatility	22.26		22.91		21.68

Restricted Stock Units

XML 19 R25.htm IDEA: XBRL DOCUMENT

Contingencies	12 Months Ended
Contingencies	Dec. 31, 2018
Commitments and Contingencies Disclosure [Abstract]
Contingencies	Contingencies We are a party to various legal actions and government investigations. The most significant of these are described below. It is not possible to determine the outcome of these matters, and we cannot reasonably estimate the maximum potential exposure or the range of possible loss in excess of amounts accrued for any of these matters; however, we believe that, except as noted below with respect to the Alimta^® patent litigation and administrative proceedings, the resolution of all such matters will not have a material adverse effect on our consolidated financial position or liquidity, but could possibly be material to our consolidated results of operations in any one accounting period. Litigation accruals, environmental liabilities, and the related estimated insurance recoverables are reflected on a gross basis as liabilities and assets, respectively, on our consolidated balance sheets. With respect to the product liability claims currently asserted against us, we have accrued for our estimated exposures to the extent they are both probable and reasonably estimable based on the information available to us. We accrue for certain product liability claims incurred but not filed to the extent we can formulate a reasonable estimate of their costs. We estimate these expenses based primarily on historical claims experience and data regarding product usage. Legal defense costs expected to be incurred in connection with significant product liability loss contingencies are accrued when both probable and reasonably estimable. Alimta Patent Litigation and Administrative Proceedings A number of generic manufacturers are seeking approvals in the U.S., Japan, and a number of countries in Europe to market generic forms of Alimta prior to the expiration of our vitamin regimen patents, alleging that those patents are invalid, not infringed, or both. We believe our Alimta vitamin regimen patents are valid and enforceable against these generic manufacturers. However, it is not possible to determine the ultimate outcome of the proceedings, and accordingly, we can provide no assurance that we will prevail. An unfavorable outcome could have a material adverse impact on our future consolidated results of operations, liquidity, and financial position. We expect that a loss of exclusivity for Alimta in one or more of the below jurisdictions would result in a rapid and severe decline in future revenue for the product in the relevant market. U.S. Patent Litigation and Administrative Proceedings In the U.S., more than 10 Abbreviated New Drug Applications (ANDAs) seeking approval to market generic versions of Alimta prior to the expiration of our vitamin regimen patent (expiring in 2021 plus pediatric exclusivity expiring in 2022) have been filed by a number of companies, including Teva Parenteral Medicines, Inc. (Teva) and APP Pharmaceuticals, LLC (APP) pursuant to procedures set out in the Drug Price Competition and Patent Term Restoration Act of 1984 (the Hatch-Waxman Act). We have received favorable decisions from the U.S. Court of Appeals for the Federal Circuit (affirming the U.S. District Court for the Southern District of Indiana's decisions finding our U.S. vitamin regimen patent valid and infringed) against Teva, APP, and two other defendants' proposed products, and similar favorable judgments have been entered by the U.S. District Court for the Southern District of Indiana against five other companies. The remaining ANDA applicants have agreed to a preliminary injunction or stay pending the appeal of the inter partes review (IPR) described in the following sentence. In October 2017, the U.S. Patent and Trademark Office issued written decisions in our favor following IPR of our vitamin regimen patent, finding that the generic company petitioners failed to show that the claims in our patent are unpatentable. A number of these challengers have appealed. A hearing on the appeal was held in the first quarter of 2019, and we expect a decision in the second quarter of 2019. We also currently have pending lawsuits in the U.S. District Court for the Southern District of Indiana alleging infringement against Actavis LLC (Actavis) and Apotex Inc. in response to their applications to market alternative forms of pemetrexed (the active ingredient in Alimta) products, and we filed a similar lawsuit in the U.S. District Court for the District of Delaware against Eagle Pharmaceuticals, Inc. In June 2018, the U.S. District Court for the Southern District of Indiana ruled in our favor in two similar cases, finding Dr. Reddy's Laboratories' (Dr. Reddy) and Hospira, Inc.'s (Hospira) proposed products would infringe our patent. Dr. Reddy and Hospira have appealed those rulings. The lawsuit against Actavis has been stayed, pending a decision in Dr. Reddy’s appeal. European Patent Litigation and Administrative Proceedings In July 2017, the United Kingdom (U.K.) Supreme Court ruled that commercialization of certain salt forms of pemetrexed by Actavis Group ehf and other Actavis companies directly infringes our vitamin regimen patents in the U.K., Italy, France, and Spain. This litigation in the U.K. is now concluded. Hexal AG, Stada Arzneimittel AG (Stada), and Fresenius Kabi Deutschland GmbH have each challenged the validity of our vitamin regimen patent before the German Federal Patent Court. At a hearing in July 2018, the German Federal Patent Court held that our vitamin regimen patent is invalid. We have appealed this decision. Under German law, the patent remains in force pending appeal. A number of generic competitors have received approval to market generic versions of pemetrexed in Germany. Injunctions are in place against four of these companies, but in two cases the injunctions have been temporarily suspended pending the validity appeal at the German Supreme Court. Stada has recently launched at risk in Germany and we are seeking an injunction. We are pursuing injunctions against others who have launched or are preparing to launch at risk. Whether the existing injunctions remain in effect, the suspended injunctions are reinstated pending the appeal or further injunctions are granted, or whether additional generic competitors choose to launch at risk, makes the timing of further generic entry and market erosion in Germany unpredictable. Additional legal proceedings are ongoing in various national courts throughout Europe. We are aware that several companies have received approval to market generic versions of pemetrexed in major European markets and that additional generic competitors may choose to launch at risk (including one generic product currently on the market in France). We will continue to seek to remove any generic pemetrexed products launched at risk in European markets, including Germany, seek damages in respect of such launches, and defend our patents against validity challenges. Japanese Administrative Proceedings Three separate sets of demands for invalidation of our two vitamin regimen patents, involving several companies, have been filed with the Japanese Patent Office (JPO). The JPO rejected a demand for invalidation by Sawai Pharmaceutical Co., Ltd., which was affirmed on appeal in 2017. In July 2018, the JPO issued written decisions dismissing demands brought by Nipro Corporation (Nipro) for invalidation of our two Japanese vitamin regimen patents. Nipro filed an appeal, and we anticipate decisions by the Japan Intellectual Property High Court in the third quarter of 2019. We anticipate decisions by the JPO with respect to another set of demands, brought by Hospira, in the third quarter of 2019. If upheld through all challenges, these patents would provide intellectual property protection for Alimta until June 2021. Notwithstanding our patents, generic versions of Alimta received regulatory approval in Japan starting in February 2016. We do not currently anticipate that generic versions of Alimta will proceed to pricing approval. Cymbalta^® Product Liability Litigation We were named as a defendant in a purported class-action lawsuit in the U.S. District Court for the Central District of California (now called Strafford et al. v. Eli Lilly and Company) involving Cymbalta. The plaintiffs, purporting to represent a class of all persons within the U.S. who purchased and/or paid for Cymbalta, asserted claims under the consumer protection statutes of four states, California, Massachusetts, Missouri, and New York, and sought declaratory, injunctive, and monetary relief for various alleged economic injuries arising from discontinuing treatment with Cymbalta. The district court denied the plaintiffs' motions for class certification. The district court dismissed the suits and plaintiffs appealed to the U.S. Court of Appeals for the Ninth Circuit. In November 2017, the U.S. Court of Appeals for the Ninth Circuit dismissed the suit. In July 2018, the U.S. District Court for the District of California denied plaintiffs’ motion to reopen the case. Plaintiffs’ appeal of this denial is currently pending before the U.S. Court of Appeals for the Ninth Circuit. Brazil–Employee Litigation Our subsidiary in Brazil, Eli Lilly do Brasil Limitada (Lilly Brasil), is named in a lawsuit brought by the Labor Attorney for the 15th Region in the Labor Court of Paulinia, State of Sao Paulo, Brazil, alleging possible harm to employees and former employees caused by exposure to heavy metals at a former Lilly Brasil manufacturing facility in Cosmopolis, Brazil, operated by the company between 1977 and 2003. In May 2014, the labor court judge ruled against Lilly Brasil, ordering it to undertake several actions of unspecified financial impact, including paying lifetime medical insurance for the employees and contractors who worked at the Cosmopolis facility more than six months during the affected years and their children born during and after this period. We appealed this decision. In July 2018, the appeals court affirmed the labor court's ruling with the total financial impact of the ruling estimated to be approximately 500.0 million Brazilian real (approximately $130.0 million as of December 31, 2018). The appeals court restricted the broad health coverage awarded by the labor court to health problems that claimants could show arose from exposure to the alleged contamination. We strongly disagree with the appeals court's decision. Lilly Brasil has taken an initial step in the appeal process by filing a Motion for Clarification; a decision on that motion is expected in the first quarter of 2019. We are also named in approximately 30 lawsuits filed in the same labor court by individual former employees making similar claims. These lawsuits are each at various stages in the litigation process, with judgments being handed down in approximately half of the lawsuits, nearly all of which are on appeal in the labor courts. Lilly Brasil and Elanco Quimica Ltda. have also been named in two similar lawsuits in the same labor court involving approximately 410 individual plaintiffs. As part of the disposition of Elanco, we agreed to indemnify Elanco Quimica Ltda. in this litigation. The plaintiffs’ claims in these lawsuits relate only to mental anguish attributable to the possibility of illness due to alleged exposure to heavy metals or other contaminants. In 2017, the labor court dismissed the claims brought by all but the first named plaintiff in each of the lawsuits. The plaintiffs in both lawsuits are appealing. We believe all of these lawsuits are without merit and are defending against them vigorously. Adocia, S.A. We have been named as a respondent in an arbitration filed by Adocia, S.A. (Adocia), with which we entered into agreements for the co-development of an ultra-rapid insulin product. Adocia alleges that we misappropriated and misused Adocia's confidential information and intellectual property and is seeking approximately $1.30 billion in damages and other specific relief. We have asserted several counterclaims relating to fraudulent misrepresentation and are seeking approximately $188.0 million in damages. An arbitration hearing was held on Adocia’s claims and our counterclaims in December 2018, and we expect a decision in the third quarter of 2019. We believe Adocia's claims are without merit and have defended against them vigorously. Throughout the arbitrations described above, Adocia has made statements alleging that Adocia employees should be listed as inventors on two of our patents related to our ultra-rapid insulin product currently in development. We strongly contest this allegation. While inventorship of these two patents is not at issue in the arbitrations, in October 2018 we filed a declaratory judgment action against Adocia in the U.S. District Court for the Southern District of Indiana to confirm our inventorship. Insulin and Glucagon Pricing Litigation and Proceedings We, along with Sanofi and Novo Nordisk, are named as defendants in a consolidated purported class action lawsuit, In re. Insulin Pricing Litigation, in the U.S. District Court of New Jersey relating to insulin pricing. Plaintiffs seek damages under various state consumer protection laws and the Federal Racketeer Influenced and Corrupt Organization Act (Federal RICO Act). In February 2019, the court dismissed without prejudice the federal RICO Act claim as well as certain state consumer protection claims. Separately, we, along with Sanofi and Novo Nordisk, are named as defendants in a purported class action lawsuit, MSP Recovery Claims, Series, LLC et al. v. Sanofi Aventis U.S. LLC et al., in the same court, seeking damages under various state consumer protection laws, common law fraud, unjust enrichment, and the federal RICO Act. Finally, the Minnesota Attorney General’s Office filed a complaint against us, Sanofi, and Novo Nordisk, State of Minnesota v. Sanofi-Aventis U.S. LLC et al., in the U.S. District Court of New Jersey, alleging unjust enrichment, and violations of various Minnesota state consumer protection laws and the Federal RICO Act. We believe these claims are without merit and are defending against them vigorously. We have received civil investigative demands from the Offices of the Attorney General from Washington and New Mexico relating to the pricing and sale of our insulin products. We are cooperating with these investigations. The Offices of the Attorney General in Mississippi, Washington D.C., California, Florida, Hawaii, and Nevada have requested information relating to the pricing and sale of our insulin products. We are cooperating with these requests. We received interrogatories from the California Attorney General's Office regarding our competition in the long-acting insulin market. We are cooperating with this investigation. Finally, we received a request from the House of Representatives’ Committee on Oversight and Reform; two requests from its Committee on Energy and Commerce; as well as a request from the Senate Committee on Health, Education, Labor, and Pensions, seeking certain information related to the pricing of insulin products, among other issues. We are cooperating with these investigations. We, along with Novo Nordisk and various pharmacy benefit managers, are named as defendants in a lawsuit seeking class action status in the U.S. District Court of New Jersey relating to glucagon pricing. The plaintiffs are seeking damages under various state consumer protection laws, the Federal RICO Act, the Sherman Act, and other state and federal laws. We believe this lawsuit is without merit and are defending against it vigorously. Product Liability Insurance Because of the nature of pharmaceutical products, it is possible that we could become subject to large numbers of additional product liability and related claims in the future. Due to a very restrictive market for product liability insurance, we are self-insured for product liability losses for all our currently marketed products.

ZIP 20 0000059478-19-000274-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0000059478-19-000274-xbrl.zip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׆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�,2!1,%$P7WH""I*2@@1SYHR@H#9C1"G!)4 ME@&W +I3&_:.K\7VWJ#7IR#&-__Y[F:^6%W$ZO/- B+?#]Q[GR(Q>C76OH\O MK65_QI?6LC_C2VO9G_$-9BW;C%P\ZWKROUZ^NQQ]BE,_BT+Q:#R['HT_9;.K M;Z-EU<]T^]YHX&JXMH8J UGW%@N@6$*EE9.K)EZJ-^K+^/)-._B-5^\ M&S>; ]KLPZK^R11%&T\3N;BU"GWY][^^^VNU_57<^1OC:*_:'N27HM=V@V3O M3#P\2QZ*1DM78X GR&,KF/6*:LH)K *!I-TH"'H:'NX3SMA-*(IV.W0D*"8H M)BBV D54AP0IQ3!3F%AB);,:2E"[PBE4]&A0['*,9#?YFH3.Q-?$UR[RE=1\ M18)C$AAKB=906&D$5%45^@##SO/U&(&7G>!KBF!*<$UP[3Y<61W!9*DS4A(@ ME:< !L8""=X"IJN$*M@0(*6\LP$!(YX%%I M+G4,;03)G\9<>G8D')P:WZ>6=6:^N)TOPG8+2_UAM=65?M[ME7;AA105+[ P M!%LI+.4J_!%:146IZ2('-[J;]\O=7.V, W$"OH4"7>(62=%9Z:@'0E#O#[Z$ MO#KX#"AEG./<.L$1MQZC^N #?CP7PNG\JLGT[W_Z<1UE)AQ$ M '/MB=:<8Q3./"]M,-Q)V'D;3*<T<2#KE$$K"2&+(0!@B&_4B&8#"(^D404 @PH#QI=]#2GL\AO3@P/=7KWN\.T(,"V)! J,>,"V,@0A2@((L06JHRPH*. M>$T/Y07)-XS.]\L!\"%)RBCI;=S(@/&!:^$#(VR1@$1923'G0%!DJJ +Z#>* M[??0EW)PAK0I?R2&)(9T@B&T#MS21GJE#7!"8Z*XT@17'AD:M)G.&T$ZY9%I M&4!",(81TZQRS0X;= M$JP#B80%E:*&&?'=,/:< SF&)LCT*:8PJZ<> /ZO9)ISZ=^B&<>@ZJ4T^P8XI:@R4&'@(#N:*ELQ="=#SYOQ>. MFE8!DB)5$S^ZR0]9\X-Q3I1R"GB'&3,6$EQ)#< QUGE^=,JWD@20!) ! 0! MV0AU%PPKK"GQ)J@>/D@?K@1(4#RZ[YSME#(Z6S3&,EK.IY/KT;^! M_)^]>/'DW*YO%K\*-^YTX!G;JZ[BELEY3=W%_>;BF,2E=7Z ]!)*8@ #'D(L M#/*ZJI1@#7E!3Z^3^H):R24DDK?;KGO?37:4T]1^?,EKS]3KI+073%I71;CS M"DYI.PRINQM["(%3VSJY]GD2!COPM/II]=/J#W/@22KIME2RW=IQ0"-GZTKZ MC_/95:$@-LT:WP^\O?R0[-=I+<]^?&DM^S.^M);]&5]:R_Z,;S!K>0[>O,V; MY)^8S,+DK+Z_R'_S:M'XU\MWEZ-/57^HT7AV/1K')E'?MB8QM;Y!4F^TX[GA MB*RK_'D,K160&XBXPPYJI4B51N[,9(I+".3!#&,2*ME X)B!@SAN(2B59)U!DD'C2+[:A15\ 2 1FS%)9)?L2ZO9/\]N%B+_+\DNB9$)L0.WC$-@K>2H<5$%I8 M88VW&%*&195';=S>:0C'1&RG4B$/B=A4Y"WQ-?&U^WSE=3DJ1[6VG$.OI9!8 M>F6M+)(.K$66[YUG?DR^=BI3-/$U\37Q==A\;10EMMH2XI5P2E$IPRLT5+%6!L$!4P8L!P"RC0N M<\ AEKPS9_^@GM8C (#C2YH D #0"0"0.OK, 2\8-YQA%-[^T%,)J[X!!.Q? MMFNP+L74Z#YA9" 8835&,(88(T\4Q]Y CZ0Q19K3^-/V<6'O%%>>QZ0 M\RH1LPM#4"V*(&P8M!0:#STFDFM%?"F**"SV;IYV-JZ1HNV%X):CW&2H9_-$;4N:J?)5?0 MG@.5.N5$2H)20E)"THN1A.H6NTYB(B"'.FAJ.BAUC!E4(BF&X'?&#'0F_!B< M5-.GA!RU7&:KUIU19XL)TLC@LXP :5'X);9>:LBQJC*D-3AJD9^3^)SRK7$P M3#"*6^WTUEF!8DARP]F>>];06*@TFG"J.90 .LR9TJ67B$'3G>&*2)I(X,A2.0%E'O3(6:*&Y$Y0" MXX#SA%0UA(P^"V&D4[Z3)(PDB P"(EC4E44LXEQZ&\-=&?:4:21+C89*U)W0 M^7,X\7V5' :1>I.;R5+"S=/4H+7H8;#7BFNJ8]9O>+?!\'-)C>@_[0PU#N7\ MR#?+@7+V($:7L-<>TA1D,4B <-'07327&+,@8P#)(-9!#BFC41DGW>FF=U O MRB$IPEC/PRP21 8)$5E71$744TV]BO4#H*>$(U090"B0ZAP,()WRQK3*HQ0W MFFC4&^JH^L];RJ#I1+]PZB4:)1HE&+Z$1KBM& M0T6)018Y*@*4B,1>RU+!,L">A6S4*>=0LO@D("4@O1!(M"X]:ZCPG KF0=#7 MI(?&TRKJQ0)YU$R_1(_SHD>?,FK^/E[\EJWBQAYE_[R;K+X-/JV& 5[++18I MJ8&P7$F D FBBG:5%@7E"PS#+I_=,_0M/7SP]E+O!.Q'*<@4A-*#0R\;LH$@ MUDC*(*3*2& E6Y>2=LH)AUY0EO[@A_Z@_J"#G7R(84JH22>_&R$'[6QLGOA1,GB0\)(@. "*XA0K'V$L-8L4,S:KRQ M!%8IN12?"40ZY7MI#R(I"CX1I)L$H77I9TF]-@90Y@#EQ%B-J:Q2\A1^@;?D ME 3IE+\D$201I.\$X74Y($B55@0:A:G *)QM G$I@TB NF2W[/AQ[ZO6L=V) M\2(WX*$<')LWR3\QF05BK+Z_R'_SZM-EYLO5:#R[+ET@G[/5S?QZ-)E]R9:K MN+]NG]A8NWMR MYXOK;%$N [S]?;2<3R?7HW\#^3_]\_3"AC57 AUUTTRGW]:T^WN^:]7L.A]!X\E;@Q_EJ-5^Y'OO MR\[*22EPY.P"1]I>Z;0W3[DW\3'W9LU[;]4";:@6^RSZ^IKQ$YNZRH$GY@\'G(/6AWQ$31\W6B48Y "G3C/'+ "2 MHUB#K,SBM^X%M9!/'9S9AJ[^EC%V0&U]C+7OXTMKV9_QI;7LS_@&LY:Y;OOG/#^M_'T;[^+&:#9\ ML,T9(O>\R^)E,DKY\7U=P#1W <,_C4;WG< ONW_0;4;C4M&Y" K#Q3)H#T&C M^+!JI/J]'8USC60YNBY4D>QZM,AN%]DRJN*KFZSQV7^/GPT#^5<6-^)R=;G? MW(K&5MO-NW^2^4>OG?^@XXV^1"6OG-J@Y2U'XT4VFLU7H_'M[30\4LR_#&OS M= #"V^8/H_'555RML #Q2W=ANA;Y(GVN==#1>+K*%K/Q:O+EWJ7O73/&/,0E M?.2&X7KCU>AZGC_ES3A<9)&-K\,XP]8)%_X\F14/70UO^6 ?K!7/'^\^AV-Y M5?P<=>G)[&Y<:*+YQXK#6>Z35;CP5?&;K\4]/\RGU^&B MA#P86/[OFT5YG]OQI^SB0YB=WR[&'\/4?#^>?AU_6X:G^?/-8H=1'4C=J*>T M,<7WUN2^:<,B ,4_R/^^W\A]K\P4?YN,/TRFZX"J?*==_S3[)8)A$4YQ;O5X M'ZZGI_.KW][DAIKXX[MLFN6VAPL@#/",0^BIS_Y',#U8_9U],O\ M\WCCO?]YO/@TF16/-[Y;S/.TZ;NX!X%__,N;#7EP??]G_@KL][6]_HH?\5Y''9CLW+UV M#G8\A+S\]%MK+X$FZ04#T_$@?&5X9ZN6VXU7%7_9)N:EV'5?R,K%Y%S(< M*"UNYAZ ?8Y/M/0CN;W@89=C&YC>+E:X,;3CL[!X)" MZ35]TL!P^$$J#ZN3O_<3>/%IB?@R8=]*+);*2N?\/RVSQ)5I)3O@011YU1W"!$BX2+KJ*BU]G\W1@'QQ8G YL.K"/&UE.N$-S M\TZ;_1Q%_-]1-/^7.:KWBF9\#+ W\\7J(GI;P\[]_#E;Q/S?T>WX-EN,P@Y= MS+^&9]I6IG>/O(C#S6N7;,1]'GA:_;3Z:?6'.?"T^FGUA[SZ'77VMR44VNPJ MSQ%;:WKP[2@&;AW)17KLP>Z3]OB:8;22E_3(.(I4QN^>SV44I"X!:04VR@F. MB7 00@LLP55+,^^_W6;WKWK_ M65M+>2127,H6$QXWSWH'3\@^EIYS)WPB6]?(M@5LK 8;T(I[ZSQC7LN -FH- M+\'FK=D(/MX;;&=1/?](H$PU:Q/E$N4.+K^)N@ OMM0 ZB1R6'DKM-#&EI@S M"O"38^ZH]?U/)0_R2Y;DP43*1,INR8,2U/*@$I0JB3C!G$/$#<%.EZ!D3N*3 M@_*H;0R2/)CDP42Y)!(JK"RU1%F-E"0$5(UD!5'MR8-GRZ0D MO#TNO+VF4.1>U6V.T]FCP]HN0[S\;A^7+KCC!HL*)-E!+QI&'6DO, M*-8:5%8TO0].CMG+X#1$06^99)?BL*WI[^^Q[L!F/\6PMS[BGI-D"TAH#1+H MH&9:6Z^$9"2\=#TG)4BXD:PUD"1S_''4KR=W:V?UL@29\X3,-G&%\XHRB"IN M/ -< *H ,T)848DK"NT1S7#.W6Y/)_Z 5E6J)/XD,G623%O )&OQ!RB-,!98 M"BLAT%HA(DLP*6')R<&4K,])_$F0Z2)DGA=_>"!!+?YPSH5$U !O%'#$0(Y* MRD@LX'&L-5U&0I)5MLDJ)XUJ?XB-=95)%$M*=B6?H6?C'M)8TQKW?ZQIC?L_ MUK3&_1_K(-_52D(@6UG]2-L6=0.T>D]FMP03FF4C+L,*?" M$84JOX;B7#ST:T1MH?0EG*9"10N^"?F62WG)4VAZ-TP?YV;:27 Z6%XA1ZQF M$P->&^@@M]QQY"B2DI9LTE:B=MC4Y:C6KH5F=#8"(V$J8>JX,I1@-:>P4HH# MRI0!4F(C :@"\"4%&_5PCLNI8\3%MB*322$O29+)$NP2[+HEDV%0RV2&6@(Y MT4@@CYPP",DJ#8!(K4_+NF.$VB:9+&$J8:J+,AE&K)$4R2W3AC'%N%<.*N>K M&H5.PXV:- >P:R4!*M5;2/46#H.(78E ZO(M4!DH#//,.L(Q==#J*D\(4O]2 M:](1BBVT 4(W@8-]!*G,/SDM>T["[:@@-4H0(PRS+S208^17CL/:X.-8<2T M@X)D6$XY?XD27:/$-HE!P+I"DR6< <0(1L!C1"64L,2$E6BCL,IQ,7$F=ET( MWU(D6VWJD"20Q)9.LN5YM!!02R# $D$)(-1+IQSE4'!8FR?L1O&WXZ)EB&;4 M)($D2G1" B&HED ,0X@*0X#7T$NBG655=!['!AS!9I'$A9.+"[DY\\^KV!V] M_'T;D&D,8SJ991?K3#R(P!_O382X?77:V>.0"RL+W&QYC_>?0Z# MN,J?L/QB^<3//_8KCNP3,U?\&#_^_605KGSUF V:T #J>767O;K)L]==P]F\G$8R_K_1T?O7;FT<&)9T3#C-J!; X M(%^&66!E+<1 M+HN[[,UKSVGCV_=>B3'?MIE>&G]N7GX6&3V]=P,("O[E)!I=9=/I^F__WYOP M)HH_A^UU5?[\R.Y\/_F<+4<_9E]'O\P_CS>$B*^3Z]5-^&,8UX?YXCI;1%Y/ MQ[?+[/OR#W]Y"-PWE:.G%AG FZ?]0,4]"/SC7]YLO#[6]W_ZK^1>WTKWZO:] M.IK'PU_VGN7GE?9_;H$;'1M?M980;E.0"I*NAP)O?Q\MY]/)]>C?0/Y/NWK2 M57B39(O7;>)'Y*OX8A_E;_910U=9CGY=A@<;^ 8XQ6$^%K1VC^,XP"8_ZB0\ MLNEM$ ,7D]LV*F^<=G8.!(4RF.))I?;PCU#$;^QCDCC!BG054/W'5]G"]&/T3%*T[(2"V7X949_BIU58N5/>_\,R6WR)!I 3/D3AJNL( M+E#"1<)%5W'QZVR>#FQU8$.[_V%CN8R>[ M/,SX>*(<4ZK-E6)GTNH/<^!I]=/JI]4?YL#3ZN\F,A[7';1GQ-POD^5O%Y_' ML_&GW-LYFLR6J\5=[OCLH$NP2T>\!^-+:]F?\:6U[,_XTEKV9WR#6)7E4=HQNV0YNLZ6X4'&T6$_7HX^QFBS+WFT MV4UV_2E;?I^D[:1KI=5/JY]6/ZU^6OVT^D-?_7VL;**C9K9W87D6WU+YSS,H M__ELWKP F-9=;8C1 '&BC"$,.F.,+7),G7'4Z8W,41L.P)=Q#- M(G%_G,_6 MS2^WU *MO_A#99Z-AMM[*?2EVO%+T##,6NG8L\+&"RL(5M_[KZ#(A*_9M:(3 M9N_>96VE *GE^J/U>%K+[2>7--4][C[=$_C.#'R4U*THO,;>8:88$!PC*)&P M!?BL=5!LM//J$OBZ7"_QQ"!-]>,31Q-'#\U1CNO"2]A83YU0S@I!,/" FHJC M'OH^=F T?H$C*:3\8?)=+*:9-M"J7M4?OA)"#U?CUA 5'=_))118KGQPB'. M$;$$P%*:0QRYIRGTMWK*32%82&VN+ID5V=.BX,&&9;6$9JEGEH %4, M TIC'SA!D28ERQ05STA476!9&:00J%,1@';1'1DD%!DB*= M9U#R!:0XM42DSA-IFUC4,. [194&1 *C& 5!QR/K+J'.60+M;K[)9V-Z?D.3(MV=Z3F)6(U!4Q M"S<,YII;RJ4WB'CNM5'4(U\BB0AO.H^DOO CR42O,(T/H'"G6<68(%F7D>,"8(ZDMT9#+)BRKLJ-LA*#;=GF+0:1Y:*_ M64O^*3:C4)"9O$3)Q-9]N X3)$34A7B9@YX9*(0Q0#,)'.:EA4VB;W(\C(-(4D=B1V+'L^QH MA!HH [ 23E IB<7"<%E7;Y5(/A-JT =V/(PW2%)'(D0!HE(*Y]+067;&,G8V7"HIR;MOHM&'8HN;BER.%5V>X8\ MJ): #"..TLA1XE-G6?3-DF)-70T8IV7!$9# MD06<<")MF6Q%(58#@-/PRKXER2O1[7SIM@5N#4,X$%AS@ 1A@.BL60.5?W? MM3IZ*ZH.F,)["+24V=85-6R0OWK".0RR!(A;%[GA,:2L8K$I2"@N.W@LJ MV<>3F)0*P;50"&XV7STH!G=3;-'PC7*/IE)PJ2!06OVT^FGUT^JGU4^KGU:_ M0\$:1Q$F4[>^'?1ET4@^]$XCIHQPT&&-((+.LBKY$ MX@GKI*:SCL9ZC]%(D MM3E9\,Z42%N 1!I 4M1H8(TCG%+F&9; E]X%)N S8?9=!%(*[4@.AH2GSN-I MF\#$ZKQH9PV50A@(K)7",$*9*QT,#N[H8#A[/@TONB,)8(EP9TRX+8 3C7(T MD%GE>0 :-(1ZB"UPI0 F*#Y%4[\4X9$$L"2 ]1E/6P0P"6H!C!ACN-$&.B.5 MH9!X#$H!3"G2)XO5&<$D24LIRN,YP[R?+\)DS4;9[UWB)DYVL^W@<)BY(W3"'66*X,IYKJ"%% M$D%7)4(9(Y])03\]+OH0-=$2?I*1/L'G3.##:A^BTHAC(;33VEC&$.%"EE&E M2$C91_AT*20BR3X)/T/#3R.$@2.G,=3,!0Y)YAP@I(HAQ=)O[5UQCOCI4L!" MDGT2? 8%']B(3P <6PZ05MA!@!4G$K&J H7PMLOP.5=2]%10.8>N@BT9?]O/ MU^M#5?CGPZ(D1#5VE'"<,0NH9]8&UC!E:8D=X/4S*M=A"M\,V4;,6L7/UHU\ M=E%1R7,Y$'YMP5>CW2!DGF JK <:0F,)49Z7%B,FO.X\OI+-.K7H23#K,\RV M"6.-IH5>4LT1QUK[H!I23)# 9:\P1PGN+HO#9)1/PEV"V3G ;(MPAT MW"F,-0+8"D@T=A)[ M+E3I7>2&=I]FYXJ>)(FUG7QX1)_C3?&XD+THF_"PR0$]&_>0QIK6N/]C36O< M_[&F->[_6 >YQJW&;G0R=.,1*=1F5[ET/\+P[2CH,CQE;Z;%4K-4&S7I6FGU MT^JGU4^KGU8_K7Y:_0'61FU=03CPL/[PBF&<+'IXM\P'AD4C5M@(KX @V$H@ MD4! T:H0FK7/I+5N*P;"7QHFG#KI%F'#H-7.))W-3#AWAB>F=8IIM*XLJPS0 MS%DC*+% .RZ\E&4V%V7RF09Q)V9:'U+T4R^XA,B$R$XBDM<%*)'2 C--J2%4 MA+_PUKM2[#->/],D^$P1V:6\_R1&)D8F1G:3D;+19U@Y9["GVG""%?:0N$J, M%%2ZWC&R2\4 DAB9$)D0V45$RR8YTP;"BBW .8VH1]TH;:H&EKJK*9 CGN3NW/$V/#L_$D>2R#K(\A$ M#3((8SMQI06$%"+BH#?K=GD"($5A'T&6C/$)8PEC9X\Q >I86\ZQ!,0Y!K'$ MUE#!?=7Q7&&UU5K>67O6&3%G:,)3_S(-VF_$UUVV;"GZ+5 -%V 1H99X";BE MR!LF9&6SXHZK5Q;]3N;RO5URJ$7 ;)ZYT_NZ]^FQ,B29IKMXV4(74M-%*^L= MM1AIKQE10FAA2M%%"_U,+%07Z-*63?Q(0 $I9BD!HA. V"9_L#KIAB (M<78 M*A[^B GUW%;*C86@GX1X:&Y.(D<2.1)1]A&P-E,I!HC#S2E,H9-5P M%SK>3Z \-/OVSS*;1(X$B/U%#@EJD0,C!;G#0?T(RHBCGC$ 2I'#*?R,6Z@+ MA.BI1768PL<@(I8+^^NL\D*T:((]0[_/-E U;+/4"(2%@E0*ZC22B)>99,XZ MRW9KR-A9[\]9FV''029)+]!L"_;; KV%!A\H#8ADSAA/"/48>X=(^!JBWO85?BIU.DEQB MV1FP['E)#@+0L/8'@CD#)'*:>PLDP A7E8HU\[L%&'36B'9&Z$ER5PNN@'MG M\JQ[ IG%?+F\*$[5U;?19*<60;,L]F/\$CZ7MV9LITU0#V#?]_&EM>S/^-): M]F=\:2W[,[[!K&5JRWAOAC;_?:B$N1YJFA#7Y9^$P H#*QF6"D)+=:QEN=8T MPU_M%J[18EQ9+F&;M8"= C?6F;OXDB2U,YG(^@ZN;=QJE*USV# )!3=8(>HT MADQ5]GYG^-%3<%[!K13#D2S_"6L]QMI6>:Q1QPXJ:KACS&ID))6<8(ZJ@(E0Y2AQCTR"!(JL@.;-!N<6K=X%I?()2$L13C ML;.#X2 9H6>,MH8K 4NOI!%0:*&\L=HAPTJ3'$)F-]6UW:"UY$UX!'"(78(! MIJT/R1M^OL#9QIN&"T )3 . %!%4 A\KY8"*-Q;14V2:)R_ N6F)G54&$XZZ M@*.M\D_3=.^44S8H=,A!X* F'/G2=*^1]L/@T?"L]TF>2@#K+,"V\:MA< MQ%Q)BZW6WDC(O-!5"U(+3Y%"F:SN29Y*\E2/<+1-GL(-4SGF4B$E"&4,8R\0 MU;AR 1KR7$N_+O*H+_!(PD\*QV]\WL\76;CC*/O]ZF8\^]3,@IS-5P\R(6^* M;3B:5/OPU7F0??:9#G;@:?73ZJ?5'^; T^JGU1_RZO>OB>$BN\J":O5AVN,X MB2UJ+<&H-K,AJ#04D!&CH8%(405*M5:JYS(NB\ZH+09_K85WMY;=NQD4$33X M6HMH4V\5R>S5?1P. P\4UO7SD7;*>NZY4M AK1AP5?=!XY^)HCH]'OH0P] 2 M;I*-/<&FH[#AC>H/P C+-# . P:Y4-CAJI&R\%N[M)\C;+H4H)!DFX2;ON.F M$6'@12Q)+R1"GD#K*-?*EKB)C0_[B)LNQ1,DV2;!IM>PH8WP :.EUYI#C#ED M(OP/"%\J4DRI9]JXGQXVYTJ&G@HB ^IXF KH[1"E1%&-&0J5M9!A2XS$!A!' M3(49X0$Z=D+O@&VZN-U8I+//W$V.Q'[B:1N=2".&DBC".4?6:0,A]I C5VI< M0EG=>3HEDW(JEI+@U2-X;96M6-W4RP,"#0%*6&ZH, B3L@B4LQ0=OSAQLE$G M62W):@EW+/;RXA\,-HWD^ MG(_EY#J\9?-CN;NQON]MDH;DQ4UK>?;C2VO9G_&EM>S/^ :SEJU&-H".RDTI MLF%GC8[C.A/%*:2=#LH<,DH3PHSALDI4,QP^U.CTW7(RRY9+,__\85+H.[7$ M:IH":ZGQ?=M-WSM0L$(; 4Z 7?*D;25+4-^YL0T;C00VQ1D!#",$/7>6&NF$ M*[%!%-I(8#L&-KH<19#,R\F\G*#R&%0:B6J6&A1N/1Y]BI6>1Q_BSK\IF=!4VWG@RBY]8W63A\]N> M874S7N6W6-Y]^+\PWM%J/@KSE\W"N;C*XDJ//H^7J]B"+EO%HQX^O(B1+?GU MYHO1[R\0N';WP;90$(JV*P M<8236=@MD^N[\30@YBZ6QKX=+Z*1/0YDIREXV[C&]-O;^*5E-OH8 #<+,SLM MGSW.42PM'/D3=]+E_3U\U#W[/V'?9.$Q/H<[C>9WBU$NBHU@/JW%G]'H8R!C M6(" QM'G&JKYYBIWV^?QXK8&],(-1((PL#<1M_CD<@7[KP9@YZX"A* F$DX^FW918V4S$>_.1XXDV+!YK,OF3+5;[* MR^SJ;I'?HCAEY6Q=K\=X-]MX^K@/KJ9W<:76.ZN\VO+?PT#"IAM?_]_=,CYF M/LXPLLEBO8_"M-\&=&6C(NHK/-1B_CF,+;P/I]]&J["QE\7;HSC5C;'DAR+[ MYUUX5X9AA6-SW;QQ?N7FS^N1AV',PK7SYVQ,QF@\#>.7'QQ_&8>#&3YUN8GQ>P3\C_S7!>_+ M0_+\26E=$2]^C!__?K(*%[XJ?O.UN.>'^?0Z7)2P!P/)_WVS*.]S&]AQ\2$, M_[>+\<+'49U('-"/:6-*=[^-F,>4,\$E$Y238FF;IV; MYQ6&BM +7DAKX1+9M5J]^.OBS9%IN$M\VNAK?)4NLJMX)J]'X0@T$%F-TNPFMEMBK.9CCS%7WS]]75Y#:" M]+$,4D"[?C;VOAZ..^#U;HB'_8IB.R1K=+ M*54XY^&TA\,NL,)&K$NU:2?D9G>YW75$U9#W3/[:_&%6N,Y_^KA-K80/%$H; MM]8_R/^^MRVH?5#*1]2^49C7:?C# _7OI,IAB3=JT9QN\7A;BX< OH0'6KRWHZ\WDR F+[)I3N)P,-WBPV1U]_OH MNV66C7X,N('%]80>S^5Q:EP%%@\BQ\I>.@?GL":KY]S;D* M]V7['N=(ZLCGM=@?5WOR.:M7^O-\EGW+F?Z,[GC/_/$TV.Z?U1[D]"G1Z.K_Z[KF^_C^UD2A 43&").^1__\B'7M:-9=3J^76;?EW_8T"C?5'&G MM1< O'DZ++6X(X%__,N;#2MO\7?/_)7E0"K56'V546[;R-H8B7C5R4AJ'[9J"_UV^!#]]& M/X>7\?SZ*2?(+LM_B#DYT?9HIW?.:>?C0+OF_7PUGN[C##S!;'0UG:6?.^-O M09,.JN!X]J2GZ/#/ $?_&Q3$M#W3]MS<&A=TE/\3=\@3.4F=FY:T18ZY1=@% M!&F'I!WRC,P\7V3Y.VX4=LI3VV1WB?F808>MB\K^GHWW@OOE M1IJ-O7?@B?G#(6+EGIN$O<9ZQ!P3" FNK*C((V"X<,HY2K3"'IIU=!DT$FTF MKJDR_,+/%^_&T^Q=M<=LV'+U3X_$7(I_D!9<+)+@X]3Z.31D<+WC;'8]7 M/4-2-ZC#ZG:PTO/<=R.%DLI[(RRIJ,,LWGL?R:KF\GLIUD6A8'* M1W4P%HEV6WVD?+%$FT2;EF@CZN1\0KW#QCK,C>$*8,((*VF#!)?[TD;%<,P MF_!D@B3R)/(D\'R1,.>=WVGCB@D8),"01CUWNPSK4- MY*%.;<0OOH@\D3=K]+S/9D!)X$GA>!A[4*!UB/>!66,BI\%(: M#P OP:.-D'7RF2<>*7PD6_NUUDJ_'O?\JO?G5U]_FN" HO4A%CXN,BN\EFRYCN MD]_GXWP:WB/+%':Y=IB)K5&7G.X7X >.&#*XX\TZ'31V[B[3#L40-N.QDZ-\ M0*O.]_)[OZ#*<4>=WK\V7I%Y[8K\17EJY>9TWNY'=L> W-^/C'XGQ0E#5F>< M>BN9]$H9CBU6A A<*$Y.> 'L1M+B0ZGX@#'+T M[P?3G\!QK,3)5=ZU]]T08#!G(A36"1%BE&+ ERJ3>;*UX M*)3Q=DQ!@ARG'%HW8=:CCEX;0EMATWAEM<16<[Q.*X[0VB[F),-""N*LY-A0 MC!2KS[ B&R:[?<_PW\)/AQ='D&S5>=19R:(' L09G[M=CQFKNQ!;B"P6U"($ M""?:&DY@>E >[VEXB"><7N&X1/U,[=W[3W'/.]$X_W?:$2)!KMSG0XH8X#CC!0T"/#*RLYL6;#2OY\),E] M^?CP+U4J+ED?Y..DAG;YG.UZK BODS$!E[WES$!@!6*$>(ZH MHL"9LNPM"%KIPT/L\NFKC['_\N,DRJ_QT+ZZT'#LFQ!^MZ5H[<%JUIZX3<5M M7D4M@B4V#H@;?OF@OF8N_#T;OEDU>+A8W8QG%^$4W,X7,12T;L&P/DQERY2\ MF/MLON.W'IR\_:O([GTZP@"/7S/W'A==WA$A6C2(D3%.%=Q1)L M^]<_WA$PLB[9H)6QB#AI'#1$0N:XXV6LM+>$/03,#]6<_O3QA[JR["-L86W5 MP::/U6AH"2G[;YPXPJI\]KT*]\7[+C99F5T_W0_E_9]<7 MD]G5_'/SG?+V0:#_U2*[GE3S^Z!CT(=OZSY&)?JN)Q\_AF'.KF)IZ=77+"MJ MO*\[?-06CH]WJ[MPJ:IQR'*4_7Z;7:U+QW^(-:BGT^+G:AV;C8OJ?(0@F\?5 MC@?D\/INA'DA5/6*8ZK*O27XUO8U><4>R(=16? M]>WHRV2V&G\J>J(TYB?&]8<)&4_?AID)2_?/NS#\;WD+DC"95T67O_+.R[O; MP(15493]4S;_M!C?WA1)+S$ MY!<3[TS-@[,V]''+1.[2;CFY-8=P\+WK^N4 MDEE\4<;-%!O"+./Z+\LDELER>1>P4$S3+$YOV12FND39 NKZ+BQ2>-SP_=B% MJWS64\ZBZHQZL3[.+TL"NI_\4ZYD_5(JT!%W^$;Y]S#L+^&5%_=$73J^[ Z1 M-].+B3]YIY\'S0&BX#2)NEFXUI?BE!6OAHUUOQRIV);M][SK3WB%ZLV MW?I1*(A/],K&,&5>V].[+N[@AREKBV:?NHL VNN-[X6-U*&#^C4KF\^%%TTV MR]^$RVPZ+5X6X>4Q6;?*B(4%IY/?XM;/Q:;XR[QW7;C"UR#&QO?G(D)\D34N M$J?P^2G[D =_%)WSFAT.:FY]5;>]AZDRUX/NMA?3(/?*#2XM5#_-&BKEL]G MR@CK8BJPUT)Z!XAWI.QCJ\/3-+*!2;AQ^# E"N$P ,ZEJ+*!->3LQ-G 83Q? MHO36Z,3TP*H4!="/\Z#LOHV=;9>K<5BE0FL+Z @G;*.3TUH>S.7>YP2)M[DM M<]R#?%X(P.LR>"':FL++4&]2>%.^\*D]D/W,'$WYPD-<]-C8>;-?G(UAA0&N6^P6\,-\J).B(HT():)ARSFF*U M5JJ8(H*09L!JN?7BSHLQ.?./A;L_"/I-N]3]DEN';"],WS(F4@'U84:<#X%O M@\+9KO1J9)02"""0Q DD!0<2,[WNRAWHI1&TAZ!7:_VUZ5O.Y'%28A*]$KT2 MO3I!KT:B+@662X,%XM(ZYZD45)?T4HJA0]"KM:@H_!81T&IJ[IG1JT?91+\\ M4GMF>T2[/.)=A;[5)U.5HJ'4: .^ME,)#8H4'J#RZ&!'7/+I/G\]P>#<" MIO_[QQ]^:23^'5)]@K ?&0XI=:C+QVW'T\5!G77@J$!88,>!%EHKSDAIE.#* M(,P/>;I:$^\A9ZE 3#I>73E>"#?D3BVM8@)R8:T"RE!,RI>7!$P?\GBU)W^" M5BNH=5R,/&^?Q2^/E4AK2\ \HX(2^TJ>G-3O1DTPP)!)#0SUW%EN/2\/+[0< M/'5XER\YO*VDZSUG^H*I%$QO35M]/+F['E36:$:,/(,80VTY](PA*[ M#RJC M$A[RH+9GHTZ=^=(Y[>$Y%:@1GXN<5YI:YX' #&-76V&Q9>*0Y[0U:1B25JO M=.^@]K&*Q2]/=D0J1>,G&C(UL8]>9,?IVL;N9WJ_#1\77,6BOS5O/( M\7K Q90W9OI!4EIUY9@*&J_\[\OU3"VRY=W_S]Z;-C>2(VG"?X56,SU;9:;4 MX#ZR=M8,0 1Z9M_#U6^<\*7M"X43#]^ODR73O%#GJJNE MW%"GL[[Y)1^[%4CNU>N7.YP[U"K;(L\'T>QV>IMDHW*KJS6Y]SS^TDU;9M+> MT-;;!N%I/E8U>)84*OYW[A_NP\F%,V?G@Y5[4+:POU1/=6B*>O&NZN)'_^&J MP\=W8PQ]GW ^^!Q:HH)L%#W*?KU4EGD!"8OY],>NZCO9 SO=54-_Z.<*Y9X! M 9R>)=7;9,W;7-9ODWS+TK31O%;3KU>=\7Q12%39CS88.D,59LT5+5T.M-_] M[?S+^:J;!.Z2/+VO/%Z>R\]60)>7(.N!M]"%HLO-O-B=GX_R/=J^,OT1SY;SZU<7B+LWR M\\%']ZHKEZSL_$M\XTQX&Z]^/'%>.*0J>BR:YH'/6=2 MZ.B]:[KJRFNT&O=6+8/O0?>GL:/SP3]\KV2+3.&@_"&B-1O49RGVJ,U>A:3]JO=?A9J!+MH)\ MLQN2D;#?!]Z0)C\%B.:>S 41/RP3,X64K!BC" 5+M&^=;T@W!' ==NA5(=$=/8'G*S!YG2F#'3N99[.1;^E7T]&'Z=QIR-B)>X&G#?G#HYW-)A+ 2*880\@J @P7M.JR MMEK 5F&6JV2H*-AI;I8!-:.+/T^3F_+,*4=D\\'DS0)S&YNLT(+OG?EK])[D7M)FN'I MEWS04W)I.1_]*G!M%$_AL+RBXLJ;K-#]-REB$]_^[XVI=ZE\>#)V[S)TYK<( M"PI>JX+RQ__B6^O=%GD1X]0$8 ^HPD+(43_W-IC^?!+R:!J9 (1!2FG#(1X# MK9D+0[A'0:$$T3JJH-#_N ZG&T:ZKH]*GFN5F M[YS7- S,9:,BEB\]N"J:K<6E%JU:3'K_JA/_:BMVJCU=[2PQV(([8L?X"P(X*, M3LH@CHL=YS65N;R5?5[%AW/4)%B=*OV*-8F<&Y6-;[88@-4552JK7CV7A;$8@OZR*^"QALA[&CFYK>C'M M8?RY'^&W=-YK1Z\=O7;T3DZO'[V3TXOIZQ+3'L;7.SEOH96\.)M[-_&'<\L' M4N_WU9E7W.[W9E^\W_U^]_O=?YLOWN]^O_O][K_-%^]W?P>*4GBLCO^O8<)@ MF'4]\^V9SS7UXJ"OM2*TVX4R>9_7>!%BJZ* &H+6( H!*&90"D$B@)F(-8N+ MNLG81D)!_K!<\Y$BS9#D7-VJ^7OY]=\?^;J^^S7YYRPS$Q=3JC_'>?V=*/V> M3F8WZ>AK.KR:.J3X=O?9OW+^:UI,0=V[ZQ"= (*_=&Z@LZK'FJ+#F MQPU@TYH;H1W( &PB!2,C+54&T8)@-I;6 H.? #:MO'D[>7V2\ // ).=DM8N M:^P1JL%//7SU\/7B\+4!O7B#7@931:+(*D@UI@0A"4B%7AJSI:'QCX#-;^G\ M5)$*B-Y1ZI'F(+'F20++EC@B&QR!A",E,0!&<,0$U+:BE_9J(&YUU2O-J8DI (K;2$!D21T= 2GLWM'1 M\<,./$.<=SJ;[\5\FBYKVH[V;"O06;P=DO8=4R"0-//WK,: &&-$ MC*R5G!EY!*=%85,??KHS%1?R>69O'FTP\VH/[=^:TF^*,EC#+0'N>QS6%Q ,E.QZ!M%*CCB3LZ.LCI<>25X,@&&!$-C!@5LUA8 MC0B,A)%22&DK&/'#$%_\_.2PD$%E/]2I5_E-[6$G! G;(0!J#1AFQD+#I#0& M(*H(L0R1BJ0>&7T,)Q^'Q0 (^3GL$@1VE:;C!8GGU(\>1(X&1#:$(Z@U1UDB MYTCPB&D3*8*Q@(#;"D4T5(<)1XX;5PCHM"AC;_DZGG!EQ^BD1Z$WB4(;0(@T M(&2 LA Q]R0R <^0'),]R#K)\DS:'\[LN MR, KZN^F\W]_-AO4"35&>E9+L'Y?VH-J#ZIL$U<EMB'&J*,K46D"A,8LV\ MOZB% *RJJ^ F7J+PV#F [F;$-SECA!XP>]BC7(]R/.O*SSNH^$>(7N$W,4/9 U ,JB, MBC@@5C.* #.6\"+6)9I%8*D9>,=8MQM(A&>8DG/RYKW <([\GV%Z;O7[3JY] M;Q;S,X\P7N*,]$*4C_-Y-=T^*8QNZHM-FM\&MYV%P=W+C;N-IZ?U,\^MP:_YE?PK_'"8W8?2U?U#W MOFD^GTW3P4UR%V:OGP]V&WA=J9::+ODEGYQ,#N\>G7.-(T"8ALPZWXA;!*&, M3#7G&@*'!DU'+N""1(K!6!&*!941$:":Z# M@D&I ;"45??QG /OP,,QV=:/E,^2:5YH\KTIUW6S[*Z4BF1R7RK.EQ1CI_GJ MG6A)45%QN7JP0J,R-YD#S,Q=9[WR.*%)I[G7-_?R'G,'\ZK%>>RNY'; K]-W M]]6)6SZ_]N[?EXOY(DL'BSSUJ^R6+D^3;'@5!']4M$K[+3ASBS==7+H]=7KC MU*I]Y4)AA@NW9VXUW24FA5I>C6_RP64VNUZMM>>#9:PJ)3$I;$#X=0%JU;X\ MOCF= W;QH__X^R"=PU7):/)PM&_X[U56W>#\:63\;L"ZC>L#U.*H\B!)E=*46(AM:!"3&PT>_3],QVV+>?(_7C\R#)TGLF<'Q9(6]Q MDP)2IFM0Y>?B#K?CW!E6]Z^[<+WTSYL"JL;7U^EH[/9FXE;7O]>E6_2! ^Q% MNOW;K?,+JGT[6WJ'I#)+2S-LS@1*!V&FL^B MXA?#LT%[)/D3+Q;PWH< P7)?):/!CA>:SG9^@F6Y\(6.:\QHM;/+:U@!+$,4)<(,*8;UB@JOXZ9MZ=>F;P_.)L?.;\H^MT?C4;Y<[,WPTN M@N:.O L^<@Y\=NV>(NB\<\N<%Q+ LE93KRP/=>F^;J[&E?/!/]QMYN/@\OF+ M_\>_"83 S\[5#PFH'[\6[0L%&N% P+Z.._ __*BV?IW!K9@ZALN'8 M TH#"O,;:(<=RE+A*_+>X9O",V+[RKEGO[EG[WT4WAX@[\#I\Y]WGN M7\-=95Y_OG]>MT]39GGSH1[85 E68#O=R[L&*S?.R\2T8$.^KNZ=R%ZV_ M-,C<3_Z&?NNGR>3.F74O!C=IYCWRGBT8NW&K-ID%D9O>-XYD/6 K9=:M5R'G[ MWFGM>33N1B'!M7?OVSY*'^;:A3=^K9QR7BXFSM^_3/W];YW+YS;:W?ORS+]& M:QVW\K&?$VS2P6].& _1&X=;N&6K+^VWKGW+O+G-/_QGL[101">E085ZI_U+)JKU\>E=ZVG*1Z@^7%B!]($=6]J)E=#A#,EDXO]W M^0(;MO'! GKU]P]RL\AN9KD/I&_OF\0?[AG#'RHM\0]VX7#A?%F?!U$1GWOO MKO;.UCY6ZUF&5TGV+2U=WYU\LB)/_>^/)ZH):8JRJ*"&46HLHA'A,<-1;!@Q M$06(,2G%4J*Z?MJ/EP]39H48AQ?\87T&;O^BA57]3AZ;)NV)N;NYM(69N$V# MQ@U]EKKPG@JS5K_[F<_1S+-%E8GQRE[X7[DSU^[2S59."TURWH-/<@^W.46JDC&%Q]&*>HM':?).50Q=*FCNEJLR=Y]FN?,?AH,?LXLO7W\: M7+CX$L4F4#@B2:3M%"DCS&B$.14Q0EI@!]G$: Z-!0Z^GR*)'VH,"2^Y MZ2@E*HY2NA%/"E:4#;YJ\6P)I?,ZTVS9P0Z@>U] SYT3,O"^JW_5>]><#&1T-J@!\X&/O'?? B0K;\:L/'<%G M]98^+"U06-Y"2P9>3?+E#(UW@K-TA2/L[&T3>]2N\'=O/C-_&[=!(=3:<:7F M5UF:[JHD3E+VPJP'1TD/$(LUQ7Y2Q1I1" SW17X(2PYY=:B##%OJEEM?!?.W ML(*_N%ABK>'\/<_FOW]V7TI#:['_Z=?DS_'UXKIJ)&YATKL\';X?+3(O^UYD MUQZU[+;"_K*M)-T.%RD[A\L3WW!D,/* %I#&/VG:=;[L[$'\5B0BTM&[Q.=> MOM5"7H02#O3&L\+9WN!.WE;!WI]!&YR-/J#P\:;"P)E$J;%SV:!@ROT@F'/@ M2N&+Y9/F-WVN%J5=@/4IK !\Q)%;*V]P2=X*B=E/ZAZBYTX'OH\5HK5>/BY2 MXU]]*<"C1\!&44(T,2JV2'$06XA@?30K &T= 0N,0!1C(JF2L0'8?;6U85@^ M/,-]YO.;MO27)P-MP[Z-%GB;._%YIWH&?>L5[E4Y@0>-\?[G]CM.O6A-[KTE M!$7S?2C/& Q=]%?^];]^\(,5R 8O!>,7C!6"09;L3#;VY3G9!GKO&1[E7?W3!-=UB[\R'9,?;;[(%-Q]!+0V5#2L9QA F+;&S\J1#"C&-:D Y24!A4+2&A[.8:L0(50(9BBV1L&(Y M% 2"O0&%=7:6#/DK!Y1GZKG;Z;#@R_ J'2TFZ>SRD6,#&PHO=SH\X#&-!$(Q MC@G&G',+4-7%01C0^E[_& (6QA@R2>.8.V-8M8!A#8 D+WMX<+\4-5EUE%!7 MB);5*E.W$H-+WZ80CH;\.<)L. [?#^?2L\7&D[=DG_*4;FOQQ_WI1\@M(;#Q M](/N=D; G_$\HK_7<]VK/]+I$[1-@E;VF?M>,%8(AJ]?Z@6C%XQEP8"]8/2" ML4HP4"\8O6"L$@S\=@^!XT9X1[^JM[T*M58T0[(O0FM%N*L_XD^%2L M7G]P<\('-[Z(OI[*$G.$L2):0PMC#9%JH(@#NW02_#0H^N\TR;[>S@Z(0*3; M@0)'=YC3@TP/,J<),J@9C*X-(#PF$73_GS/D,$>4K(Z"0XF?--)X#3 M\(] 3#+R%&+Y/"O8;F?96M[L0<%&./8\BP7?S30);(EE+=K#TK+!13HN2,\* MUI/SY;7MCB/[J<"P%TGVPPJ+'4BRDX V.6(4J5C$FFI 922$)[BW$!@^WW%DP2<_'B&;WWV: M)-.YFH[B?RW&0*3K5 M&N*(.U.;#,Z @L##:($ ::P!FZ)=?E4%'"C6KN M2#0:1N#P-EOJAEVX4*Y"Y%1 M9N?27XBZ /9[NY962^"A/?"(C2K(O4@\:ZQ#7 _OYP/WM>_C/)#J^M)@A]"9 M9R:;E^2C%XOQQ#]H_N"R@:%J=GVS\%?^EDX];?+D;G!Q5]#A.6/@W_6=?^^2 ML-%3;:B&FAL52&TD1YM:2B%>;:@U= MHEU<*VL[,DWN3WM3?1=U_O;HIO5Y_5Y09M))^"J&/RJ8/0>]5; MU 3H2&-%D60"N!VQEC+JXO=RBW <+W6)=+U%;7*OPVX1[9@?K+!P15V_5^[[ MROQJ*.$JF2&HQ?&$8\XD("[8@H)C(S6IPBU.HNU-R$O)3/VWS:1R]!"D W[XV3F,Q$%3W##^W@S\Z3K]XDE/?(G);&;V\/"'E4LS9Z M?^"Y*CW_9.;I,:??BF$\PW$V7%P[6S8=AE\$FN5TS=,D%1>G9_"?SGPD$8@Z M/<6<"R_.!Q_N,3/7K,DC;\%*-F;/15SS9[I(M6%N;Q/;S_RE"P,X+[Y>TYK[ M/X[#A)7VX[E[A^>[SPT]]@THX\MQP0?MW,= [5QSB[J=<&M8D>W_.?3C ZK1 M1_Y6?C( Y#_G@7?^8C;[HUH*OYS^&1IFYB)HFY=34\KE]SM0CGY9$63MW<"U M5O(?]02KVMVAF)C;U- MG/9D:WW5[.:UV"6!W#.I];M^:)JTS4KOWN'$JZ!_<7;OI0^]>NJKDZ"^*@,\ MAF'3AR]<@!=;9'%L5&PPB%1)X@N,46:I M%+V^%.QQCM=I!]7])\F%GTK_;T MOF_:.(*FC0JF6K-4. "1009CYH\+%'6/*"JZ$!C9I4!Y#4QU-%Z>\7/^=F%J M.Z?J)'RG*J.<;_"8T0:/>9>7/4K/H#4,1/LV*4[\F8%57,98D](S@,8PL51I M4Z^EGSU_[0>D%S-W_IK-\L-U0?$S"%FG)35':_Y?4PAZ>@JUG?Z(YKA-8:*Y MP10R)B25D!C)*L\ZDG+)LWZJ_G1CR]B90*O&SYV@_KR%8+]51;*7?G6Z"L=H MR3AH-!$+C;$5A#!#(P0 !,)6EHQ"N73P_6LRO!I/T^RN?<)R:#/&)7H>8N>C MM6^ON?[\-2KF=GJ(6A.^)(*Q)HA2%6..6"1 4;L=FQ@[J[B7'G9C#OF9,^'G M\%7KX2N*W\QL6HP%#7(W]6?!W[(TWS><.\1AT%$:2=(H9\RAC2G%F#!-)(=( M2EPII[%ZR5UM+_V'Z:=RX0]K)>$9%:+;_HD-.WV\QO(-G5>^/G7=3CM9JPY/ M<^?1:A4K1F-$;10Q69M.3.1^VME16O2, ? VM/,X";:.5C]/QZ?=T8Z*1E,Q M)%8;Y!162B91) %05; )Z3*ER]J2O@.;4G;&&.[I6WKM['01COU,48"F] '3 MR$H81438B%,1Q1$L#SB(IE0OA:-/UM2N3AO/$)=O>>C7*PI8?_$%Y\EPN+A> M%).HVWUB;\X-7FMM?WQ&!3E>WJ3=TA2"\1HJF8T MP P'6MIL!&& MZ2KX488ML;6MQ;[?TL/Y0OQ,2M;M:=RN6WZ\.8Q]A?B$G9\W G=O#=VV [,6 MHS_CC H7!7*(+::QE=26#+=,$:2V;Z->#69=E18(0=\XF)W"<-2/EY^=)&P] M\U2;V$^-@(P29)CA4 E<-=<+S5"KN3Z63%FL140(QU9YOO>X:JZGU#C0$]!#]L#[4*=OS7\O8S'Y$YPMGC][J^*R> M*Z 7C-6"L8I.H!>,7C @.YEZH,[#T%4NXMOMV.XJ"WF:+=R[I2"=5]R4'+,X MQH@K F1$<80)0JCNRQ$Q7CJN:8O?6A;!+B)UR9^G!> XRRV."L..*:/X2G#K M3<'4EJB$F@+.F$88&2@QAY0R99E0M$(EP,42D_$&5.)=H1(3\"VS3O2HU$^O M.<5S"@A:!2H&,4%U9!7BQ!(* :OHE*&)-%_*26_ %M89MF#QRH=?;1VAG40@ M]OE>POW5<6WL&EO0IKX!(4Z9X 8P:HW64"M>MV%@#9:L^"_^K$)-1\7*EJ<_ MAPPR(*>=FO.C-L"IMJ3F\.4SG@L;&2 4@%=8%Z!%O-">*P%)ET+:: MTYDC##GO=/!]KSF]YNRN.;+%F&:EL)HHS*"T6@*I#:HTAS&X-&AY6\WIS,V# M7'9:3-S7D3Q:1V(7?BA?.9JHV.1/R5T@];*S[..-'W7A1#J(0;ZYT@1 JV"$ MI&!<:TXMM7$U^(M2:MLCMIC4C##*&,5&061C\0AY+04=_;U.ZUY] 4Y_G-XL%8)1BP%XQ>,%8)!NH%HQ>,58*!>\'H!6-),-2EN^I@C7B\D8K.D'MJIUU> MN@"A+XLZHK(H)&1#M!-KH$5$A4!&JLAR4$T/!P9(OL1K]R"]>2\76F5!HT5J M%EEV2#H=B#NFI.RKIOJ18CVBG2JB82 :_C^- (ZY S1N$(U]15:-:(A(NB.B M?9A^O9W]MY_]?CA0 [Q;AK >U'I0ZT'M9$$--75O EN(DV A)Y^0"#)805J M<U7I4ZU&M0#72H%J,E: \BA"-L*0 40YIA6I, MFR66UZU1SE +H,::0FL:$\Q=J&F% ")VWAF$J@(U MCJ3>'=3&WP_LJ1'9QY\]J/6@UH-: +46%6-D,)<1%C%A?E*55+H:J@&,)'N MVN?99.(^%@[M/+AYD#L8OB$!GV MG.9S)S[Y/!_I@AQ\XD/8"[/ Q M8$H@\;Q()KZ38I!?I>[Z9_#_8K3DH2B_FT3@?3F:Y6\Y'VWT@0Q!@9"D D5 F8K'2 M5;L/L RWVGUD+"Q@F+AGE@RZD +(@O_8_5X9@7XHB5<7Z4C-GWP?^+!;2,^R M;';K1#Y?@O1[6_Y@QW=Y1[C?HWL*U3V;N/R.;>[-DH 8KF)K46RHIA2"2%9/ M(K6)6YME$21 2F*QDH(9J27"U6;%EHN=>[/"L(Z]P<>_[R"9#QX:I0 EX]SC MR.PR8$O1<^7N?M)=5UP2Y!Q8@2'BE._7=24V-EUQNEO/#7C&+IXM;]:W\1RP MDG*7KN>>)+??]2YW?14#[EN8NO3E:I;-W[E%O0[^;9H-?4AXXTQR-KAHN3XO MFP$[Z"*L$(C71=VUX@4?S70)"05*68N\5''L8I.86.%\/,RH8KH\DL0ZHIPL M3V2O1.F3EZ0#IN;%\^3FWVKZ_8UDV%]9$OU%\^0E>K1(1AGC$7)1AV0\]O7T ML=!1/;;6_?AT].AF2!$Z8Y*]>2K DQDG#K%FJ/'V(\Z[7)"C MM%DMFDY&%%0H-B &A$$"C2:\\B"5AG:IT,*O][,8+@B>9WK&T9JSUQR OD9E MW$[W6D2?BKG?"$RY10316%G94.1:K)8,X#:ZUY$5Q,]3MW3DIO$D+.#?G)#, MW*/[BB1O_0;C/%^$ HU0EO3J_,RU-N_'1Q6/PY;BP8@QQ & ,,(:Q)3B6O%< M;+O4W=9:8G^N_:%/ M >*V/K)@D-9S(2;N$7YQV_#5[8+7>K]E?_<[INH-.USHR7FG!/<["\#QQJ;/ M*=*G:JM?D=YOI^:\L?&40:N5(#:FC&CC_LE09>-!S.!^:M[1*27JUL*?GIJ_ MHC#XZ\QW$G20_CT^Y=O1Z+8R3=1R!B(=(0&<(2DZ)=P[6DOZE@SB3I5%1]NV6JB9 M@*16,P*=TOZ1Y M/A@6-*B#&Y\NF4U[_W7/I+' C7*;B!E).>2&"Q)3J;CBU3"LB&*Y2KD/3DM[ M!@$ZCE#U^-);'667^U#W;4'%ELA &V1@6DM)%8E!Q BA@(8F6H\,5.E8+U7A M/HX,W=AV?,;!04S[:T"&?1+?I^$,;%$/]83-1IVTW;TZ=S*Z_TVFPX/[ S),RA9IR?F MFS;\.*.=E]#M(_-;GOW]C['-:7^T.H;TBFQFAV#((")0 Q4;H*4E@IHJB\D0 M6V+:WQI_NG&YY)E#PP,>*"QOXES.!!64N.RG95Z_J-<>%6L^X>26>VS6^J-_H)3PPO? MR]BH+*DU]AUZ_ 3P'"\?,E0=< _T]HFK]Y .; UQ5:$$%1_5XR+?N8(7/_J/ MOP^D=L-53B)].$$U_/YI_O,JV^*M M#@13S9*VEK@#*BGTPW:X5(*V>. _=,/L=AS@7^V'- MOS\.-KAI?":QP0;&5@%EC(TLX(355&6:+-$F_.*VZ>.ER=+1>.XN,)Z,YW>? MT^MD/'4;4Q.1F<2303-K9^MV0WBW^8KK( MTU%)IU=0]4W_& S#6P\NB]<>I[G;MZOQ\*I%Q763N>?+W-7]59+#;F*K%(P8 MX6)))!#1L8%4*0.J3301-MMLXJ_)GYY)<,LM_+V\U.^ACG2:S[.%KS#YG([2 MZQO_L)\@H#/P;*CV)$@ MW-_ON\'\RCDCZ9\WXRP0/]:4;&%F96!E/.R.DR:# (DQ#' 1,>)3!E)I6C,, M4FF6,P@OO.-0=K;CZ( [WH6#5S$;/MB[)LO-%8J=MII8(DPACC1$,9.:*V"U MT(BMRG(W"^X=O0<[U- F=K5)K>5_EZ?#]Z-%-DKNG+8QLI9B5>^ MTGXOJ%%'67(['23?G/7*YX%#\:#J*WO /BQ@[TQIO.4.4MP#\&$!N/&MS@OH,SW3\HW[3A#2<)5"8F%"N.G,(JC1!KHG(BS5)4OFK#ZYK< MCY=%1=+')O-QN.8WNH)_;'#=C:OW!\_*^=FW(1_!GWRK.A3[0W*U.X/5[!?*XD=Y>^&UPX#!S/KX(CLPMO?F>9 ME _3P:_N>?SJAFR&[YW>=4C#ENK%6U,V+>("./^9R@A@$DL1BTJ]W&\WN-3N M$NFJ"M%"BY![+PS76-_:V@8V@6B1CJ?NXU]OW9_J_\XV6M[M!W*N.A;I"LOW MS#D]OEFBR6]#9SBYUI$1AD(# ,1E<:_'PD@O#0^\O^+MC/:7N9^C\*G(,B?? MTF?:OOWRY,NE1-WDR0>7XS_3T;MPJ%(0S7F>N7&EEPCM.(ED2VT4C;'C2#&) ME%$*.EO':2QPDU-TGO(+:N.7]'LZ[?71;5<3C')L$:#*0FLD%=9MD?-TJ^VR M9NDT^$7U!=4XI:-E!J[(%4R$CF-Q +I)N<0JY5E MUX?2RF(O[2SK-;+9*M',CT$NO(R!QI'UYE$!).I8$ZQ(+CRO1F[;W6N=#.,;#[S[O5-,AX-\O1Z_"Z93A>)6XJ00_3.^B+WSKEWR/V$)^>Z M#]-TM$^TLHU*0P!0&[JQC U3'-"(6^Q^K&?7V$@LN5*?RF>TV>RZ8O_X>/DE M=8%&00ER7SZB6CXZ21LA?+"TD7N?L!%Y4L1.1119;+,?'O&5 MT$*HUZVJN MT8%:;@XW^D@>H,VJ%XS3%PSTL*2R%XQ>,()@P%XP>L%8)1BH%XQ>,%8)!MZI MD_DE*.8[[XK[]9'0]IF8F-8NX,LU.S__4+1CIVB"L%40)8Q!#$I,;&RQ0 1X M]OV0\0&&8/5H$V$C<)^KM%G^\?)3-IX.QS?)Y,/T-_=Z7V_3R??T5_><5_G! MJJ,8(-V2.[RH'/>C,YY@\IX/PUX93!T%$K5&[W!*8L"!C4"D%*-8*F$K)**$ MB+V0Z+_3)/MZ.SL8 .'G@9\>87J$Z1'F20C3HGT5U#=&&J2H 8*AF I3^SHV M%OOY.@%AKK+T@/-/SI=/7GN,Z3&FQY@7QA@$V]32)#(86@DBR3@@%C)984S, MV=( P2=CC)TM#C?F'IX1W#$)? \S/85 MS# %ES@VGPXSX^^'\V3 *_=D7B,?5-5Q[43";T,Z&B0W-]GLS['OC9K<[58L M6>Y7F3\+.^2$Q)?V.9'P[YINJQNMMFRG#()RCHUS\Y%!D9&,5I5ISA;?&ZD4 MI?DP&X?&VX^7D5O6[XFGMU*>Y&H\O_O[;.(6NRR\W8%Y"6W=47*P>EG?@K9H MCX1>*J"=SP;.!!7=-GPQOTUN\O/!DSC"\L%% MXNE8ELON9A=.*Y.BA\X79=Z[5[XS=]A6PM4MO=C.C0!;/>L>38]G995K5>I< M;%*^9F=#(60Y^^WA#OEZUVQ'BH7NU)TUC6@:1AA'G&B)M$%,.>\;5>HNHFAI M;/#Z,ONXDMQUE?;=LJWA<[BBE+H;K3^L(&ZW14U0%!O.F&9<2&FIYBKB@E1; MQ"W$76\1[XX0CQT*F,\&[IUNBI>9W.U3 .[M6%7\/;M4HZ(=.9G4C!1Y-,Z' MDUF^<'?<7 ,>$64HUI$FD%E$N59 537@+KI5K1IP*#C&6F!B!*8P4BZ^576' MBXK)\=6 >\ ;)OG5H')\ ]35$.BDN#9:#NE\[7[XPDW@ _0CI:N/GO5%X56M M"40;B\(9VJW^&#QC1?,QWJROG^YKFYKZ:;%+<-P+QNL7#-X+1B\8JP2#O=UJ M2+.EE_?2B?+3'P-SFJ62*]Y^F[ 6\Z9O&UMFJ5 V4@CJ""" 8U(EX7%,E_B* MJD#V4S(>_98^S">V [L.9CGC<]$71!X%M/5G?/T9W[9G?%@VB4V, ;$J9H)I MX--F3!M:P8O@>JD@"[9]:&K=RY=G!>X-DHD_'@^<1(OKDI(H/,I__)M D/^<#X9)EMWY%REN M>S-9Y.%#K4=)1O]Z>W]^S?(&Q>\V;:G'K.YPO2]>*L4Q) M )F<.1<"V!A& G */24K(UQ&P"ID)4#A'""I+M7-D*/'#BF'PQ!EK(CD/,W9 M ,+W@]VHE)KSLH^7#5GP;/HYG7BA,;-\GG^Y2K)4^XJ&3V62X=%3-2&QC1ER MSEPL!!' (,VJ4S6WH''K5(V0F,1"^1D"#&@:,6E+)D?I5AFK I;=#J4C-7_R M?>##0[DO<_?([\*;#-HONW9$Q):CH[9YDGU>9-O)4R$T15T@W<>%G_+E5ZNH M9!FV5LL/O'#_3JLI0@'S;IS;YDV@!YCD-LE&^>#'3RK_Z*R>L:0T2 MY=^__#U\P$.D5V>W\AZFPFV#U74?^?SE;_E/YSO*=B.W[&XN C8R.%),54QCS:9"6/&/,200%,UAB;# B M%A8\B!;KXO3_OD#^PQN/X>S;U"W]0RAUB[IV!QQV5YO@'>;&"N5C7]B29M_' M;A]NPGR%"@/'4R="XY''^6]9XA:PH9(KR>8F=X4=*%#=<[=YZ"ZN$C@$;[*9 MNX(G#;OUS&\%8W;8W[PR8YY6?#8M-S$PB&=IXN#EKOR5YY-S[Y!?WA4/57+Z M^:]_4F<#)Q*%0+B-+Z]\OE$[]Z\?","P)"E/JB6 5DO$*$,:8A1;RV)@:REQ MGFE+2A2'&L382,&5DRO*N"RGF3*%-+4[UQ)TH_M?-NE]20SO)"[8B,$\^7-P MX43HTJML*)GJBP7Z8H&^6* _^NN+!7K!Z(L%>L$X-L%XP\4"F[R[5YTG/X(Z M@.,ZZI=8()HRTF)HUP@PX,D#K(X,C".(RJ,XJF(,EQC:E7/SASX,6!UMQX54 M';0 @/:4)/T)W9$CSVL#FNUPI=6[)(P L3'8&(NEE%9C!BI<$9HN-<;LC"N= MG?PCREYY\VZ/*SVNG"2NB":9&BEA(Z8C9)V; I2B7+#:7U%HB85D9USIK!X M8;)BP.UKPI6M0ZF3B)B^-NGM#?$TVA!/[_*Z1QDOR(;+4$"H@?NUQDI!HC' M#%?ZA[!=8AJ+KV\FL[LT_5(<4JW60K?DNEAQ/_CIF>,)%TZ@#M7S:*W[*S#B M)ZQY6RD:;]-M15@:3:R-.#.1Q$;%NE(T)N7S*5IG#C8CY[!7M%[1CD'16H13 M$564QI@0HB/!I.5:RTK1G)5;*D8_F*)UYG$*]#HLVA'5F7964ZI.AO+G[)%Z MI**BR\^&O$C+\J*1D]M169N$ $"#7\:^PBB:KG]QO M#C&MME1PVK!F62JU,98:Q;A O@(Q+KD\XL@R;+:K(U-9YFM:?3VDOELJD51^ M17X+="P?+\-?<_4]&4^\[-I9]E>_1!L9=XH"J%V=V!6,.]V,%4[JNJFJ1&NP MK% K2FL+S:LJ9A_7LSVLP!K5+W[T'W\?*$Z&JX(?^G ,4_CO5=:4+GU+WUUD M:?+'N^1RGF;OD\EMW/\G+4[C0ID"'\Z#]ZD]R%:K7Q M])&"R8)FKB!Q*BHBJP\[!0ZCG,NBR[/!^-)=^NYL\#W)_!2<4>IPR;^D[_CV MB)L,K\9I43H?>'V<(4_PLZSJ_]NTNQ=N-=@GF3? M?'] *"Q-=H7D^>ULQV^^\X-HZZK3UA+XNL+AT+PU^4?GO1FN3>K^7C_I[N.W7NYM4_3G. MZ]^V3$3A:?V:%C1X[<#)?2C\<35G*7C4F>+PG&T\"3PB/=M*8F1SA@(B)&04 M0THXM!&T2AI6M>%H"^0I20P_#HG!YW1CS^>10>!V4D-:.&,H$TII?[2/(@HH MQI74,,N7\B3'+#7L.*0&G8.-$PF>+#7WR#)BE;[68S"MRZ[*KI_)@G/]U M4_C;OL&T<#.](U3[6?&G+Y6S.1J,%MFXI-U]V#[T:9'Y5I^R1]-=J[SLV7&0 M:U?B+1IN;4Z<$$><<1PQ*K05K 9%K-42YP[I4,'\X4[I%3 "N. MK3M**11/=7B;^.CN.Q1K3"*)8JU!#"TDB$&@%"R2P+&-B!#=F<0M=[\CL[;' M[L/#)92JW7]!*N=* IJ#;4H$5P9H&$-!$-= :%A)@,"$/[<$=&2B]M+_%0S1 M74I $4F5%JAE2_HP^@V$T0\=%;6_6["=SB/<1OU(1%',L8TUHDPS!6L^ H<# M]_J(=W9G_[P))!V%@GZ=Z;30_:.T^7#%R6&W.N_S>FFY)-XYO*@18+SS@9!; M.KGC5YW@A73>R>",!\CY;)Y,G/Y<)V.?SG4[7],*/#BI&\X\;TK5N#T;3/V, MF]S_X/.7MTG^P@&FP(T%5B2R7%-DM(HC8I$2N+; $I&E<1=;'<3_5KUP4":G M?F[EVG_WC">_S>;_G3K5J99P]4%=%]'B;F=[_&".>,4(<>LNYC4QN?8L15Z* M:IZ)I2DXC=@]1D'Q3'Y=101Q7ZA(BR@,R\A&EA'BPC@D*.1QG;6@,%YR[ \F M5(6C9V=9^2O_.=BY#6B)T;L\';YW7M6UN\.50W:TEEAC-SP/U\T?L"R]\.GA MEQ;Y3,C]',T9HB>_>99#Q%U.$&<5_4]Y<+9\*'8X=9[[R<)[G1W>3ST%^^>6 M(*SPP_//XK"S_:YY8+HIS_Q6'2@6!XGA6'$1#AV3P:]>C0+^=A/6\D'USX'=Q,V]V8Q#[OB][HD?QNE M?H:8$\J".BZ;7207[HOSN[##!:%.%2V5+&D.2(HR#?=VXYM%8?%+7KA0K],Z M_W169Q@^L43H5KYQ^,+YH')=!]]G_H4F8;1B]0[UU8LW\P);CT$;.Q0=/_S> M93:['LRSQ(=ULR*3>T_XS@978_>/S%>@-=^\JX2^M6E%6#/S:6'W\$/W';>- M7\9.5-P&W!4^4F _\A)\-TXG(Y_-K)^N=1OOB3I]"#16_I+N/EZ:KLLCX\O% MW(O%_6N5X^&RG%8_E0JK#E0NE@*58*GJG+ARJ'!=[,'?W">WF)T$;0R08%Q! MS! G"FE3\1TA3'&;Y2WFW)@H)A'4D"HL8V$K/PX3$S]*CK;Q/DLL;RM']3TX MK&]K<7-LOS;EL-I.;BZPV>;A]WEWM".=8)\(.>)$R#'4$PC>G//%!" I)((T M$AQSA;6U=;DDTEO2[AW'.=^CSK0#R]];#F.!BP$FNS[H(^*<;FQ].")%VTYD MF@I;X.1'<2H\%8*1B[,4VZMSIQFLDZ M4WP_5?K2)%0G-(6Q"(]DJV\U8I!*%D6"8@ 5$5;KJ(JJ%5T>PKAS>+0J*UQM M:%3NYV<7_QPPP5*<7[4C'E)'/,[%?Y1?Z9QN+*+N4OX:G3J8 !Z(^_0O+ZV. M1V:NW@0.;0<[K?POCP0'A %$)9%(8HBEJ&#'*GL4L--5DJZ'G>Y=@1YE>I19 M@S*B<6Z(\(->D:;&,J1C"(V(*Y0!D'9'RK$'RG25T]T+939WB/4H\Z1 ZR3B MJ<^KBTN>B8WL&",C"$#3\\XB(@A70MB801UQ&46F0@^$17ZC/RE@_/C]*E)BP!#@LA%Y$!!BRW!U&!5:[N(-7B6B+S9 MKR/VJM$Y8J]ZH$.?KCM]1-@2 %C#@1(+ ZP$VCGFDEJN$%6H @ .X%+_[G%/\*#GGMMU5A%DRD2*QT3Y(CU%**GY4-V.'Q5AW'-M\/)A M]6DPQAU'%_1+M3B?))$;A*@Y$.:4((*%4HACKAGGSH!63^9WM[(MM;H!]Z>;HW"#&O=59B9+'34>)4-E8:,V/CRH"ZSRT9T./@ M>WM:+^]NA&^KYK?UA&_K"=\@),WD>6NH(!8H%CL#@30#7.(JJD((+$55Q\WX MMEG1-QM_R,X<#MS.)%.2Y*](DKJ%A)6CL;R,EF.B-Q(M74B?EA/ M:O7$$.$(2*T@9+)5,VU521YQ(<=$Z6<_VG3W#EA*?) M$1/.2<08UU:[B-9X1G-:"T_$3HH8;:N!),\E//"<;"S!VC./^<3)6=[IJ49G M%1%S[MRRL^PR'7N&V?RQ@5G/Y#2O$V?15 @9 M3B!0V! 2.>\9$0ZQJ G;U,L1MAW:1A[E&*67%XRF&-F58+SX8"T(6^-&/3((J2,1*QX[/US$H/:@N* O M-F[TT#;N*%'CWD%J%9V'G-/QC&5TTM/XW]8*XTLG$%8Q@Y+&@M?'["Z4Z\[_ M[G(NX[.(R*&.]U[0S6 X$F4\LL1(A!I&(3(Z2HCJ)B,J=EBD'<75%JEW,9GT4"E@.@TZBUZ?.W MQY^_/4!13W?H@%J^)<.1-=RY"%I3A@SEJNPJQUI2:8^J[N=9T6&Y/KTO_GFC MQ3_AX/D(BG\01NT#6!Q#HQ5C#!!-N&!U*DEQM)0Q.([BGQW2G#NIKY0'JX,_ ML@J@K4[N46M*J,6* 22!M5:A2#H74-.JO(="O92#/.[RGMW/]JL:']CM@?[J ML8XK^W;^S_].PC[E1KN8S&)C8XFIE)&6+DXG7&HK%08L]FS[R39E.'N6V)1( M-1P&I%I1)N2V,"VP&:+W90_@D^:KU4&&WZ2B(BLOLD[^TM$X]T4UB^SQ46H: M$X6IVSS%/B_QE/D?752?.2M?Q$*[5]KW705;F2EO M=VX6V? JU*WM95W6.R82L)3B)N&$4.3[!YRPL1A@H94@I@HH,)%+1 M"$5UYM#I3>;M2S[_-9U?/9)%?,13X+6G(!\?^',.E\LO!A[=W!MFG=F^H$&4%G M1")!D/.X.:8"<5"Y4C862PH*ASC MAUFT_D\M>*H.ZW,78_K*W3#&>5^7>,-&TB:8TD0 A+2"2A@44RDXC2K0XJ@) MIGP6I$QLY,%QK9[_XZ4)5<5A9S],?W/[]_4VG7Q/?PW>X"$WE8'#]2GYF/U?:U!D[$T+GKDA!%D $ M2JEC6(F1\SZ7^-[VLGUUZ!.UHBBW;#!Z$NSYW@O\_\N6H]I:N8M#N:&_7F0%GQ*=N?88%M'P^BLR_ M;#UE_&+F1[(G]8*Z/QQ6%IJ^.X"M)B9F ")&C23&XIIZ79H5Q3J[R,)2(FT+ M41"'DP+Q E+PT)RL2:(4+"F5P7GY3_M<95N\U=YOL9IKIEG2UA)WD+#8 M?^+H$R7LZY4_B=V]HV)+B&C/ ,<@ID8Q: T20KJ(#*HZ,N#LY3R! T($.H<' M@XBV,[>8CLH\^T$W4_1X?Z#-K(Q\$36(ZEBQ.OP;5.=^X0#O.12W7:%-H6>B MD8;&1%LC" .B?.87MI^?R8-O?9 ;:I[*53OOW M6N< /*O1^$EE MFF7EB5A1>]'(XVKQZZ9X@AXN(]%R^)NN[IOJ3:NF[I.J4SA\$=/N9Q5X/IAGB]S]]RJ9#Z[2R0M6 MQQ9BU>)L9Q8XY]Q8"[21L952U^?#"N(E3&UE>0N9^K_N=3Y,JQJ)K_X]OY3R M/J_K@ZGWD?QP_/&R2#W*WT,/"%7#H_*/=_3/)\ M[#1FD7LG^3I- QV(WY#9Q63\+3Q'7CI-WY-L/',?7%*ZFTDRS2OR$7>QB\1= MT]_%NUGE-@=M'!>D)862OFR96]#/5GFJ!A&-)4=6 \NMT!;(FE(]PG2I6&D; M_=RHF;LZS?@<+)^N%:+?<*V"GA>-.&_*KV>W4:9O30F=C%\.JLSAO%?+\ MQ[\)!/G/@S24\SCG;-;]-TZM767[]1JE#K.QE?CZ?^ M&/2\Y%@*RG=QU_J<>Z+I;![:GMWEO=6?+>:^ SJ0!I5ZZL\_%O.D>M3XTY=" MR1UFI/-:P4MM]J&SO^0B+XI:/<*XA[NK 'X93]R7\W0-FO1M#&^LC>%)98R6 M0DN4P1A)0Z4+4Z6E$NJ86,RYL&+K,L:.?=.GE#7B][L5-'Z8.K5,OR9_;EG# M2+D@Q"C*7" /&6(7/#K[4=10N-_\;=S9R/R\;=I.%!U9F"2W%;9MOJQ"RO2 M_HW[['"R\ #OOSN^' \]O\;PRO?[Y 7/1GEM!SDW'G5\I4@0G+F[0GZ7S]/K MLT&^&%YY&^L_W5C9VIJM^&;X^3*;70\P]07RP[3@]4"P^NFLL+RA:#PXS(.Y M"Y/'\YE?IWMW;SWNQ2)W.Y#G=9='^J=[O]P;OS/G\)5/5ACOH7O2\;QD1+^> MC<+;%W]V5PI#A:?AY_)VP9TO+U4LFS>4RWGWY M1^=HS@9_3$MGQ*]+\#K8SU]GDXG?CM()^MH(VB"=X+*9RR_>.9[/?S]_+&$YYAQ"^[+WMY=A\,[?[M1E:T);ULX9%Z M)N/DPL]D&?LREM0S_27S=9_W-5;E)]QF)Y/)[#:9#BMR?O^A/*^J5J'\7K-P*RX4PL?"A2V* M=+PXKSC;<>ZT\[S3[VEV%C:S?-9ADH>^V:+HS/OD2>XTS--X>@9(WSUY/OA0 MO5/X=*CUJMW<\%&GG]?)'VN^7ZQ-96T"=!2O7;[SS+-R.N#(2[I/[V2[M4G_ M'!>_EK-@FH4KJ-/Q_84CR*A?(+5_9$E5M1;U'6Z=5J MG33/Z5 U">=DAZH")0 P0%**&P[\"&-*.33N=P HHZ'DJFJIDT MG?VYK3$N M/%/3T?^;7>1.^C]>>M$.&Q>$7]6R8@*N?)BZK_BI3)^:UZP=Q[B@A-5%O+5+ M^?6V>0JX:OI:5R7OI2 D>>,\A/#:KXFSA<6&MDQ"Q80;[,!*4%\+3@^ :0F' MFD+!RM=8.*QU3U#QZGKM*"4PVV/RQ79RUASD828)QU1#]W^-L R9LD#&#S[A M$&\I9P]D:GM!VM@[<2\/[5T_][O',U\0'XYPY[Z\5/F(LGC@;."/D!U,)7/G M7%TLYK4%"#8YM*573D R^NAUL$> QA4/%+!YON[<;YU3VW(:V]GNH(R(OBW&(^^TMLXKVV'1;[/Y.'BT;D-O M9M[-^IQ^6TP*O"]PV8[]=5J_/A_\HR),*'R6RT46W,#F7KXCNW+MEB@5//%! M:9VND[O:(V+B8L%G8[Z!?.84WA+86E*ER8/F=:' M8=A^*:5/,^<1WCV:3K+:UZ;'BC(BM--3;I&L:BZ-,+"53@+(*$:!UC*R!!K& M9,P;#DK?I' _'_39U(=-=5;^TDG4 M=.C3 R'YW\HVU-%B[?('22_#LN E^Z^$2/0E-?(?K;6HG?C*(!:!M,\.5-%4 M2$O,RC3#S!O)L3.EX93AVAD@%Y3^X1U\ITS3$#S5$?N]+U8\![FSG>ZJY?K\ MF83##/^!Z@0C^3/$1T6!3A'IUNL9/I .KZ9^CL' JT'CMU5W*O)/K5?*'X3\ M8>/K371/,T\+8QY>O<@R-<_M):=T D;W'V229-]2?R!:52>$NH3@I7YS4G;\ENK9M\@_[Y6^QC_L:""^#*_2T6)2-!\6P57^\7)-'/#5.\:/ MVI 8(B6@%,A9#(6)<4&*K6R(%A%MV1 JB$&*V@A'$8VUGT!5X M!T-_^;GZT,._P4?^!';[VJNYV8H%73.^NMB_JCSOYL^!,R'CT: ZUWT%0^%K M><,_=+,6NXR%]Z8\S5H/+IZ&+^)FY?"L=D7"4X:6][M^XKO.^UU_@[O.5KSU M9JAW[_#S13+\XULV6TQ'[\J:E%'X/P?9]-U;7=>X5:;(GK_?=].?6?+? M[(OWN]_O_EO>_>WP_]Y;PF/%>9LZHYQ,=I#Q77;QH"^SPH#_^Q[OMQ4":"7BAM*:U\*PTL=*Z^8 MTO#@$&Z';6PTZ0CE\Z=GTKMC0L^3PY43A9$M48,VJ,$!(<8HBI4RG& 6R2IY M396$:&D6_--1XVFDDMN@!F/G&P>JGC1J]"#1@\3A0>)QC."MV87,N121P09; MIF-E!#"\ZM&,T?* L:=C1&==6VBA@PUG#J!5:"ALS ;U60D%JSM@X(AUH8V>,[(1W MZC/WRM@KXS$H(VY*EB#5."(^?D442,EBRVNF'T+ ,I/(DY6Q,R\52]ZIFWI\ MVOB:TN5??!WJGHIW?/JUFR\J:,OZR=@"7UO.8FRIAI&4JAZ]I)8G#Y<*%Y93 M34>_S(:'2#L_.@EF>63<"<:&;R /=,)ZM5T*5O 6_0MBWH0SSA,+"W=Q6"9L4JA"1(#1& M0FJG^) J%=6S]*B(XT=[FG]MFLZ+Z;:J;CD_5'O^HZ<=L-NLSJYR'18!7ORV&(7K9.))VA MKA.[/03T$/ &(("V_'_ .(1*1 83!A 1[G\J" 8\8- P.ZYY/])L]DHR:_\ MS@L$T<]O6OMW2#0C<:0>_]?9/)G4'%:M[N57%Z3OZ,7SQFY##54<:6:Q8 [_ MN(' 5$H+G4*O"=I?PDD7<,5,YC[O?-+V\OA4:CL-:J6]%*4Q9XP+ZQ0GQEA* M(>OS4MN!!G7IY2+A0Q" ANE188 X5RJVB$K(%79N9*U$,$)[*U%W ME;$"G;/7H$)OH1.[XDCK6['[9MQ^]_O=[W?_E=:6/=J*?<*>U&X!/@2M5@<* M3"PABZQD(@)8(BQPY5IA2)8FK%I^#Y(Z8.4G8,4V&I3(#** M&158<8:PYI&Q3:%F)#7K3),ZB_@Y1BOHYGM5ZE7I)52IU60@J?9M=D A9XRT MC 14N.Z_0U!VIDJ=Q?T$]BVQIU/TU;?$;JF3K3X$@:2"$1? Z:!51A**:YTD M%"WU(=0Z6:SU2SB*1'3:BG!\Q[)]A/ZZU'2[JFH(6VT-0AC#O"9BH[5!VEA: MMZI3\XC7^52U[+ZO 6'0*2_5QHT^]H+K7IW?ICK?ZY(@% BGS5B[X!%K86-= MJ3.0R_1R.ZOS(=HD6*?1Y,FK\VO*H/;=N2V%1:T^!QTI2R-HB4$($"PAJ>H[ MJ'+ZNM;^WNMK>@'G&'?:TG2T'O!;LHS'IU];JE.K4< @$ZN86H4UB!&GUB)1 M)5$EIFOMWX[JU%DJ%9RC7IUZ=3H*?Q*UJNZ=(B$:*T(90 PYGQ(27HT6A5RM MS:3NJ$_=>Y7DE5,7]ZVW?>OM=C[I)JWGS4!A!B5CR H<^:QM)(7G2:NB2*[, MH\VWQ3SL\89YV*&+XEG8RQ'KU+;N+2K'@QTK1&6GM%+?NO>F$&9;0)$-H$@B MH)5:1":6V$001*;N8C 17:H2*D%%U:#R,4PI?Z'6WJVR5V<8X^/H\3T^H.EQ MI<>5KJ)]#!M8,<9W1G%+H8& :B2*LGBIIZO*3+Q0 M(4F7V?)-^WVTZ;^W-'3U]2GMEGX_IHV!IE%,.!4$*<\[:SE"O&;Q0E3:_96T M>T]>=#SN;-N-?NWN>J_/H XY5773@FR4EI.+(J1L.2B4 M4A-K$V&M%#5&Q64& 1C+#7P(8B\0/5 D#YA7?,)^GTA8L8,$G[!+\D:P[JU! MVW9(1J!H\B$2<$DH(E91J6-(8A!7E1J:D25^]!5ED')QPJS]-P^/?+ M.+D83\;S<9I_]8__U5U13V;#/WX(,NE__)).TK"E[X#!@ "C4*RT)K'AL2Q+ M%Q2G-++O6K/MB ':XMB3DT?W[C)>)J^ MNRIB&8C 7^ZIK3_;VK\%PPG%^-))WG0^\.>=LVDZG>>#V>5@MLCN'U E8:4& MR70TF#1KY7[M/QVEP_3Z(LT*),=PD&2I_]/E;.),15Z3H;5>[AXV _Y]_X0%" 5A&TP3">3\J__]0/X(?SL;CFL?EZQ)%_'U^[Y M?TMO!Y]GU\F2(;L=C^97[Z4\=QX4PH()#!&G_"^55CJ-FR0W>?J^^L?/#_7L MASKM4N<(Q0_KDS+%#3G]R\\_+.%#\3?XR)_ ;E\[Y,TV)Y[>8)9X(_?7EFNQ MB^4>.M5*L]:#BZ>!AEB=7_&(VY\-O,%=YV\TVQPMV\6>[K,G?.QWOXNBK:-M M+?FTR(9729X&AW<\G2?3;V/O>A8 \$R-;Z=P>/3BR84=SX H;RK)H)*"1!8C M;;GP,V84+;M=H-$Q7Z+87PHI_SJ;C6['DXD++3_4LE+\Z4$*XD,1L7:22V6( M]Y.23P$83PX;3A0*MM3\5EL*UYQ!A#'44"IAX\A&LM)\0_':[M8=-9]WHOF$ M=%N?]BJ*58[6DS"S:Y^23H(D^H1:6?N]QHEXC31&.YIH!IK#3QS?@4 ?_KTNO=U2 M35%S;@E->^4/9C\QE3WEV&NSAL>G65LJ$F.-;PHC#"G@P#*$#,9, M-8I$ !?=*5)'\2/K=A;YD1NR$X\?O86;S/+\D/;MA'S270V?:/15T C'<<0( M$9#SB$22\5I?(5_;DUCKZ\>;-$L\1\ O;E^>Q_CY#N).ZV:/SBOM@\?7I:C; MZ24'M#F&H9 J*")HE8UCC@QE<9V,)6AS,O9)>MF1+>6PCQ9/)EK\E,U&B^%\ MD*7S139U_Y.GV?=U380G[,/N:"0Y:I2142:D1@98:"E4 !E4.[661&NGM3R2 MR?E<+K>:CM1PF"V/3MRW5BS0E!Q*:6&G,@286 M19& ,&YB1@XVV[I]U:L;\R=>"0O\FX@D/\[=JH3*_RR])=.\V,<^J-RHT*Q1: J9-)I(Y\$"RF.K(U0'E;%:9J);=E[][ICV MYG@O]F"&D8GG&9UTM!:SCR=/2T>W5$F!6]3U3A4%9A8A(H617*'Z,)(#L?DP M[,LY?WPZMJ,=%*!1.F"C6$54H(A)XF>Q('\(4BB= M(%RWF>,?*IQ-QMG?D\DB5:-_+O+YM6]//)@!)*"/#%^;.3L^C=I2@5 S#PQI M&$NNH8HU$1&/&*&L.4TTI ,%ZL9!WC<:UWJ6Y;D;2IMVHX/F!B%,)^M'4? M_YV0_FZIKJP9!1A!0B/L!XYH8JR&@-LZ_H- ;D[)=**NW1A;C,[AJU;7UQ0; MAKS!FR,0WM7 BD9C*28:1H1#'D44\!C )HD:.:.[7<;F@#E3T*T6'BN+<,_F M\9H5=3N]E* U!!1Q'EDD-*019QI0+&J]A,8NT;%MK9<=1:*(=%N$K2,G>CL>[HT&5J#&H&L0QLE&,D&4N0&7 8%(KK@6;VR;_FAWR M$)*<28C[NM8^#CTAK=Q2"4F+%1+J*(J!LYDQH=(8HJ.FUD?1S?TAZY2PH]#R M#.+77ES^FJ)+G^ OV00\WV8R'>Y=P7IZ/NQ:V[AA-I5DC5YR0[!BFL0DQAB! MF$2TKC=W_V]S#5Z]$ZK:B(-92LK)LPZP69;J?;;\A&95ORFK>W)JOZV6BT;+ MM8DBC2RD3 F L>:0U-:7&[69W&LK+>^J @B^<2U?K=1O*.[M(]XG1[P(@";B MY9 :$TGN#+NFED* ;*WN& "S4=U_2Q^.#>@RWL6XXTFP1^=J]_'NZ]+)+540 M-197BE@Q"FC$C.%0QS2RN*E@(IO]ZM4JV(V)16>$LE>N@KM,3S]2HWB/?;LU MBF)?"NY7 #;_/WMOVMQ&2;Z.^>2 M@*((&P0X6*2F?_V;685:2' I@@6@ %1/C$R" *HJ\SQ/GOV<^O.=S5Z>10*B M&\RGX8)9/^U ST''"Y]>?5V,1^/!?/QV#];Q'*A;NJX0J"5*,!T,60*P<$ B M+RCU!)5:+B?/&;6UV4=_FX[&B^5\_'6U3$<^WY1BGW:7>'C!R9XZ['7/O&W+ MB=7KT$<%^88(AS4[U@LE%<>482L(DI8B2ZHF11+M!.'MJ-B0[:?/;??@_1;O MU7$/M=4LP;; MARUP![?C97C0?Z>C8OWOS&RQP^*XZ(AN\XCN'E1;.HG/Z<#M'F*; K16PX,H M!X8&+=DY9*SU7(BJR1A[-I6Q'8"V%"DBLM7JN^X!=/>1H,X>LA_GL]OP4'=9 MD\_T?U?CVUC)>3[J\M8',:LU?R#A]"600\\\U5890&AI(=MGBW]J."]VXN-D M,%VJZ<@5F[&[1I\,[*<+1/<0WQO'O7'\#+AKG5V(94IPJ1V!P!L)J8>J-(Z= M:F@#<3BP;VXGL[LT;6O04_<0N^WYC$#5 M+TT1[)"6 !KJB6,">%WU%]7TN3R->Q#.UGRMAN^R_7:[E7_=PV=O#Y\ ,)OB M$%4X%)YA39'QS,:C$P/,2SW9 -K0'GX9ART=H!CV9N^IFKW5 ,T^&OPRADG5 MJYLSI%&PV1#GHBX]J8RR52>/RT'7R=I\7HKWYVO MW"^KF_"1X;V'FXRGZ?OK_-"""/S^GB!'U]";Q?+7U3P9#(=!2XV3'^)&)\OK M-$FOKM+A,JMPC[]&:4F"9"5JN$Q^#!;9Y-5)N@PZTWB:O6.X"L(W72:WX1EF MHY_C:_,T%L=?/-8&*JL&J/F+DO#>29I-,W]_DPX6JWD:8S!QJOEJDM_8?':S M<2N7]Q=RKPOW)=S+YI-E#S9/)X.X--\WNULF@YNXU(MLH?]V^?DRN4KC_*)) M]L'%,GPN*IY)S.8=9 \>I]JF^8+%JPS#Y<;A\XOKV8_PO5_#89-<#[['#,TT M3H$?K8;ARO';1^.PAV%/AN'37]/EC_CWJS+0-4]O9_/L L4WKP?)7X4MF7Y; M'')IU3(IKOYJ37Z8WGQ-Y_EYB>%%%!>QY9==)%\'B["8LVQ1TOHJ+9(?ZV6O M]B09#N;SN[#R/P;S4;YAV2O1#,R M.5MY ?'[YX_.4BM;E.'1'I/EK,UEI*K5=CP--!<]%7$[4X7 M/^]X*ZM8C\'2 <8!]1)XK33V1A=;J1C?:#^UJZUTO]V.\R%KXZG\GW0P7[2V MH9""G6WH13*^"G>X"BB^2&+&2)+&!PED>;?M%B* ^)8?O4SBF1%.ML$X-BU( M,@(.V[\^8Y]DDO&B/%&"6!;G1?TPV#6YX,H&EA@IA2$VF#B!I ]*:2F1U+(6 MR:7T#JK5\GH6E*F[3!RK/R_3^70P^91^3Z>K]',Z_SX>IA\^?XMG\+8A*AWYY@(_1(0F!K@IT_?OS.?0N#K%KW6"H\AEY[RYGP##GE2GK" M9*/P86?"L&X'8N(WS>\Z(P%0/A+S:DL"*H5QG[M/*@L5(0T$U1*ZL%=(< \5 M+*E V(UT^YWM_N>X"FHZ^LLL[,I_K^;CQ6B)X-PNL5>9,M!,.C"7^ZB#17G_(UZC;Z!1C]ZVOJ:19/VP=$<[:S[3!S? M><^NJQ3'Y'8UOYW%K]LU2&FM-LV'H]I RZT&V 8S03)1@%0BM)%Q^VOQZ'\) M3U['R1/) 0>U!?AC W?:@=5/.]XA4>GX0#BG%7'>&H8)-8288H< 8QLTNJ,= MJE3\'^/E]7A*[]I5\Q\;^MF2V=::9H^W_.B.#4)6&80L2 [4#@(@."#("BY\ M(2S"VXVIDCL7%KJ<(="N14@8>@36^0&P X%9N\:VEQJRM;LAG!5;7Q9O>PC^ M_);K-A-87ID($@&%,+) "N P4U1J4BJ)#.Y+8'^952+;FJ B*7:FUA5>@?OZ M1B:XTV#QSM?B>YG\L@=])2J5MX/Y0X4R>2QQHN:J>,:=O6L-J-9@@^DXY1YS MK"!EWCKIG"HDT.!G2Q;6 S^?%,E[AL>)VS!2/E+_U);?M1377&3N"^W.9:7* M9*,8V'DO.?XUO_REKJC=\+ V)D@8.GVE%$O%K2VA(_V(,,:E_"JGY. M8W@WO/*>3KY/XV'XCA@D'TQC>#L^T+IS<3*XO9W/?@N@6::3K8V5)MDD M1%9N (XU@AA8JVRT&)#'Z\+;Z 9@H.SE&O#U4_% X7GRQ\F>QA2/$"ZTG.5L M]36+\)?,M9&]:W..^Y\OMD8P@3>U]O>"M;@7[)$(0RM[4>8"98Z@))V.TJVWIF4O M[M9&,]PV=OLFP8P[OO5U@[9S&\^^[^&TN(A659"F+!]ND&=?9=9:+G3WDA0N MD[^O4U0&U7"2NYHE-I[63JM9D,5@_X7W1E,N?$\0GW#)Y-M\,%VNL\'B[\OK M^6SU[3K/$8M:^]:Z.0(8;AM(WSZ2T7X=Y,/LN&!>SV=Y%M9FC#:<_-_'B_#[ M(JS@8!D4VNEH$#/=,L-Z>#V8?DNSMSR=8+< MQ8.0SSHB%+]H-9VG-^-EE)6T-K9FMIH_.KHF4[.CA(V#-.16_'2V#/(5'F:4 M7HT#8:69"CZ>?@^$N$XU*_6U9+6([[SW]6N)"]\9[GF9%%20%"QP4>92#8;# M>?R2L 'CFZ@?Q25?9\S5UR ZJ*^#[ARE.)/U6BRT#H%\C7_,5I-1?(+9CWB# MMS'XD^?TE/,DL@V97;UZL;+OCRL6U^B)!;I,_)I'UP]R?W6?7MF+9+R,N1_Q MNV\S:A\6J4FC-*S-39#U^O>N-[SPOY2YB36'3I%Q>9>,5MD791ZF+)7SMSP/ M^FL3RN$U>'Z>7B= MCE:3=':E EISN)0'J!TOAI-9S @-QG5X_F@.Z,EL^*]WCQ@72F$**"-!HZ50 MR7"J([.V#EBP[='[:K(?XLX#ZRRVD$&'!9,@G^SGE(.:D'=)&@[@VYAA'(1R MWT:%&2RND]O!7=:))&[M/;G^$:0G;$L0RIA7NJAB5;5[O)?9#PKJB[(VS7^O M/\0TZA>3>X\!09X4GZ4[)\-T,EG_]3_?@7?9[^&2P^+W1Y[LRSBH3,DOZ8_D MT^QFL%$&\6,\6EZ''\/JK1.^A^%I!K>+]*?BAPVV?E=6G)5EFQ"]>[H@+;\& M0[__N7C3P[_!9_X$MOO8R5SLY0J_,YQ#_M( OT.L10TF46]+Y[5G$Z^C'_%X MI5Q=6^\'U/>"41<,W@M&+QB/"09[9&&:GRF;Q?,B_M]Q5)0_J[[MJ4G7DRO8 MJ68F6U5[OB0;W>RL\,NG2]B..B?L6_%.I;R93:99)]>1T9J M-F#,V8U?$Q_I?0RIKUME9'':F\$HQG+&B_(R]SIH% &R8$5.5O%^RNN4WQ][ M>,SC!3A&1^O7)%[+=$U*?!,OV4AB\:CB?C+++WLXTL%H# MH[7@D KNB\ ,44C7 C-80*:M]XP2;PC6QAM0!&8 1&*KP$SA7<&/R$W[[>2S ML$P68\]CM/6U*N)TM;!?I=/T0(YXGQ!D<4 MO_E0J4V#Y7/J6-9 (*AD)^U]Z$#8II.1&2ZJR(S30A,47A(.<02)=P[E5HOP MR$+ZI'_BOB55OKP>/ZKSN]&[Q_M S=G M%K@1H-9_A%LMC$&*:4-C)W-E;<%W=-:3VMG1&NUN5A6 M"4@X!-8YJ*!"W@!6T!ITU.^;UEH+-\6&ZV=-;"4:-1LD?1K'1\/*//[W1 MP]#3=N>?K]_+TWF^L]G+-OU]G9T _N%>J6Y5LGJQCKG'J&RM6OH%D7AQEF"; MJO>!7&,OS >4@-::CW! I<*6.\BY%,Y04:AB0M*--M%/J&)E:Z/%NMWS+MU> M#/%V)VB]M.7=F6K\R)9O-7+TA.W+4T1Z4V"C"MB>$Z6@ 1S(P2F =^EC26X M>#KG]_7 ;LTK1 38CS^[>\#N<=SCN,(QJ7 ,$13* $ MUU+CF5:6*FG#R0P%M$QS*POTKU[O4J\6[<[@[AXX6]*>S^EP[1XLFZ*P MUCH84F)%+%&AE!OGPL_6%2C$7&Z,<=@&A:TIP8RUJ@-W#X4]Z$X5=!B "G3( M.H0AT(HQ[PRSD*$R=T$JL=&O>QO0M::Q!H6US3')QP*Z+OJ/W_R@O\RF[_.X MW3B6O R&_[L:QV9['SY^^C^#F]N?[=8];%>WSZS2,[V]V>WRW7_] <8=6-T^ M(4^G:.YNE[N) 8955PTB%-=4*P6MPDP91TL6@4PV5:"#3%0BL4X7^)0NTL%\ M>*VF(YM^3R>SVUBNMTL%&P/YR%"2/E^S=UAU%<$- 4MK):+8:X&-9%)( KD' M')6Z-G&Z:6[/FP#;FBX>%)K]1)IZP/: W2=@654=@80S0C&E"-;..* DQ 5@ MM:5/=V]H$;#;Z_'_3N>ST6!Q'7=:((A^/FFTGI(?N=[-X>3LY6TU7UD=I,PI MACG7,?X#K=9*XQ*7PN-[(S":-8+XS:R6B\%T]-^SKXNPZ(^.=VZW[QRGCPS9 MWAZ0G3TES^DP[![8FF$+@NK,8P@1K2%R2E%M(>6.V.K,,QN3E]?8425V?KV* M])6A[7:2+E,U'$8PA<DE@@(K7=!=G93 W*^63*Z$TQJ*PMYGU@YUK/^A BE*7_4G%/:<*<=AUH* MQ25RG/B2/Q@5HCW^>)W.W80_!.KYH]5DYYXN>KIXA"YJG7X@"!:]CO/DC%7( M02V@*3O]!%.C/;IXG7W02-T0L-U8TZGSQ0G5FG^H]8A]\U:C5IKY[5N!W*IA M1L/G[IX)]3RE(!PXXI(J?%0R=*.PU9!E=59DH"+@E%Q"LJM8/$ 5,/-TB M<7^Q#'2!)6RWK*SGF9YG>I[9.<]04K6;$)1H3Z%GCCHC@#.8%3QCV3.5.#L, MV#S49BAL=V1,5UEF1Y-C:@_SXBSVS;A0?;K%^^R5ZII;M,Y^2]8^76?M)\G] MO/W77?_%:H3DQV"1S-/)(,X$6FOOR;C:9QV(Y+!=)28V5]6P_%H_1J_ M3#ZG:?++;)DF.,IQ$M=PW1QG/,T%.X*P]I7911?9FQ8/)M \G/.SW42:U-LL;H7W,B761C3P728QCDT_SV8KH(*G(L#/'3G\Z,(WIS8R!F,156VS*7# M1$-F-8-02BL]7B>8>RLQV6A^\+>:?A[,I[6;XV'@^4/N3VTE,3SP2C\[YF3S M14Z$:DZ-69H12?C?*@%.,N8-Y(A9:;""2&%4$(FUF^'?YD3"6B$207"K)5X] MC?0TTM-(.S0":P5OA$E")5/>:DJ45U#2@D8\-F![&J%MZ2/[ZAG:\1J:HS"! MU#KDL @FT"(=)4'VHE/Y=K8.,M2##]%'/5S-Y\$.3>[2P5L+;+J7I[JEN4!J MZ1?8:869D(H2'!NE,8U( 4\CW$8QW!/P_# =SM.P(8M/Z6(UB0$8/Y_=F'SQ M/P9IG<5W?RQV::>C*:5H%JAM#S6.J[G+Q'I-A;2":2B4$A"74), ;Z01 M[ QJK>4&<=QJ:E#'5='C=M-7.FI,DKFOGLZNDML@-_-,(7UKY_HC*JG:5E65 MU?GIG5&"020\M5IPZA K00TU;6I)/@[JCW%3]JNH$@CZGIPGZ\ Z11 WPRR% MU4$,H;#2&":U\AA[AJ0HGLCUD.P%9C"K(:FU$ #$W MV @FN+6J#" C"M&>(-O>9&S8;C.$SD'VA+R[G_)T]3VHSMU#ZI,:\@M=""BM MCEOBI."><@2X!TQR(!THL(N1VVA:\@1V;=H1%1E"V@^&ZAU478=N4Z36/%3( M8BZ%I8!("R0V@"E?9E=@VU0Q?BM26U.,J6PU&:-[0.UQ>;JXE+@VO%@+!0TG M0!&FD')$E-HO09O#BW>$R_:T7]1J:Y]CP>4YN)D_I\OE),W:1)V//;NMELQ@ M;4 YU5(::Z1VQF/+L8*R.GL;YSP\CO':KOQ]O+P.[P]_4*OE]2PP[SC=J;J, M\;D./VY)C>Z]6\?%!DW!7TMX(L09+"FF#@JGG:7"E"8R5'2C4=^NP=]>EYIV M>T<<#_9[J/=0KZ!.:6N8T ;+:6VC74VU/J.=Q/Y/A8 MP'Y"+O"_Q+81F;-[L1PL5\O\Y\GX9KS,FF^,P^%9LH) M)@01O$(Z;FJU5^&'>U#/MN37*W5[.PD+^G62?LYWYM>KOY3;LE.]'H%6NUQV M#]6]%_P$@-P4M[+"K84<40N8$=0!"Z#R3)3>-L;E87#;7GYT[Q3O87JD,.6P M@BE1'B-CD<%60^(U-Y05,&4.-LV\;!FF+6:(@%931(X%I^?@),\GLFV4!8YO M;L,V1\TZR$70.Z;K0L'A7;*<#Z:+21NZ]@E-Q-A62>=8UOK)(Z@(8$QJ2Y32 M!*S[+48E_9$1&:\RQWV^C6:]BU^J3=RE8LYVV!7ZJ.=FM.6/[P?OG!7--,M6 MY;0V0QYI;9"&WFJL&*3>NI)4D)!OJ_1Z%:FT9S6T7!:RK7AT-P>]9X6S9(67 M= U>S?C57B-@'64*>",P QJ574>H9QO=WG>G:[1FI9!VNQV=CJYQ\B$!EW?6 MKO5\#'*9WGQ-YSE3X&VZ/A[=)(M'5,J3'&WQI*GU//L)4$MP"M07N[P(*C26 MV#"C=,%^G)FF[/=(SR712L\E= $PN63G,.JB'ZAS8C1THJS3D&00.>=&LSW) M]"33D\S.28;@\VU"VU6*V='(KH=#H&H/]^+@HS<+XY?K-%G.EH-);6C1T^.* MEM>#Y44RODJJ-UPD/V:KR2@97%VE,9JTFB=I]N/X>S92.9D/EFDV9>NU$[SN MP>5W+^"%5<7[BA,CM*26,&J\)L*QM=]#>BH:%P!_"<_Z]_AH'[(XF2L>*LXK M#X_T:L. EW"2SY_9EV3SP,YI_^MX,JF'Y+9:SVQ0U6[WHIJ?S!#BEFII%..8 M82M)D7XJ/2*-N>OU>]&._L0H?Z1T++EI9Q^6VV[#0]?'15(?_K-'>:A/GWGE M1R\"ARQN\VV%4"CSYS]5\O!B-<\F/:_=],!_/5HLL5S6]2":S(%D7V5^"T+S//EO_S.(R M"5<MB_P[L^]:?^UL7GUK[8;3W\(C3O,T MD7C7-[/%,KD9_#-O(!$]9_=N(>LLD;60"-P>H_]1@, A-^%+L]_^$^_W; M-.Q@[;7[%!6=XB!WBD<,@0T=X$W,\GZ72R5K;9,E@< 9+0 G#&.@$"B6RF&M MVUFJ+(" JK5"[:Y5N-;-33H=!DUG%! 2@!(!?Q74F.5U\K^KP7P9X!GD,%P9 M7R8?IJ7;.;Y"@_*3!HE-AZN85S-(AI/9(G['X-L\S>HBDA_C\#WQ*S_$05!Q M2NBG]'LZ7:7)YW3^?3P,JM'U>'A=Z4R3NV21E56,DF%0CP<1S(-E^&S5#F;G M>*C5@O=X>&&I^&GAX3)1PV$PP((43^XR\9['C,7893YH]L4XTT(R[S$Z$@-F]WVC$',=3>BW+EL49[+V:FV?;\8WVY M?\0^!UG# _7;>/&/R>0NOA)W>A%E/>[A7S-*>49A94VKG]%F$F=+ZFH^ )E> M)C;GR>@_R/GO$>J*C#=/;X*,Q+<6!%9/0-S@L&R>,-OS7^/;?QH'4WD\?"Q 1>F#)\G^O9X7U[D=?$O??PT"]J_W@ZNP M'#\-)C\&=XMP-W^ZGC=XK!TY-JHUK:WQ@TUX9' TY8(0HRCCAL>1"1RONVS% M@ "$5/ZN32F&TTJB^/MP_2I M!,!P\ T6L^G@Z^3N8UB'\=?)8ZX5]O^1?RSFRW]\BEGEV9$6?_MK.!=O5C>M MG60!E3LZR7+;/.YV>+3,M9P=2KED9)6FL]M@?:]UFGQMPM^O@BX0/IF,;^(^ MQZ_.12#?I>E]:_PVG2[2S:/R9C!*D^%@<9W<#NXRE2)>;I_B4Z6',:"-$YH@ MCJT&A@#$34F QF[4BY:H3AAU![(-V9VO.LSK(#WD6H/Z*:+A4[ MK2,JR?3"2 >Q"*SP@ V^#\:3&'/*Y"]0^&B\#!PRG]\%0/P8S$>+C,^R5V+& MXN(R.:0S3>+*+C/."R.(%PY+X8,@>4,C(C1RL-^P*KG8%'X\$UWKR:!@$ M6BN($ EF+-,4&%FNE7<;I_D;UHI6:T5;EN"OZ;?!=&TJLOR@#UW0R3K^G M21#<3./_PNJ:I93ZUM6=^&AXL@2BY"7=R MO3\/F:R5=/5"_L):U5(9@&9>,6.0A%9RS2V%I9 SA9[6.5Z_5J1:*](V34\W M?;.K>$?WA+(1XH-5//!R9U)0EZ??9D&EOF?-9:KU M>LAE()5TL6$F8-= P5N^>=+7$7;K3"W,?< E3E33\TJ=K;GQV:1T&KO&_/_@A? M&R$U6L5=",M6'=P/XLLO.QF!#PO*""(J*/2.4:F4*)V,G(CWH*&3L2CQ80_R M&MO*'R@AF(0K72>#X7"^"G0RCC&_0$?9B7&;!DF- 8.Z2?ETJM43'H7ZQ4;U M=_QA_* MXO'RK7J"6HLEFKU@G(!@\%XP>L%X3##85C7-AVANW'KMRX<-W:_2\/;4;N[) M!5S+6Z;C[:PZ8Z?USR^)QG.KLM7#'[ JF@!6<\!Q325B7F+A'43&2;;V$!GG ME7C%+-*U$5O8$FHZ^K V,EPNKSMM!DM;G>AR6$GOYY.^XE \!Y8[*U)KR&&B MYBO5%%GC >::Q\.>S$:*H++;8(K"6> M6ZTE5!A2!['T0 2:<@45,4B:-IG9DHI>UU9K$18JO/9\O>.>1KL?50.MW51\ M;R2Y'S:(HB*"DI7.ISNMIR:PEN>&++"< M"JV5M](K3#DH4P*5L4UKVY\E')5'KW;6^0H*_$ASS[:*JG=;W$X@KO+BN=$& M:D$0,PY3AU398%%ZZ6S3V4I;;D9+'8(H?:3O>UN)UL^4>+=;Z-..NIK_^E*= MST.OY!9U/H-,JA96>PNA=)(H1B5G4D(JH(!6!:M&ZQC=_M.@\7+L2%M_M$"H MG?MX5&[6FL)PF!DHCVS +[-EFD#RTUK%OI\<]:3/Z3X4 ]060>@"T'Z-Q1P? M9XOE/%V.YUF=7UD/.%[$@M[5/(UI"7HR&_[KW2-9"H(+C:+J!S7#EFFB"2ZR M%'AX[7W%&"JPMS( >2B(,,IYX7+WF^<*:P1SF =(I".U?/5UPL?3 /K;J!T% MTGCW7Y_*1TJ*9WHR5ZMA2D:3FWC+,Z!7E(U!]*CFLY5 ?!Y>IZ/5)/WU:CTM MX<,T4._J9I7E4$3Y2&]N)[.[FGS\^C503UXF\B5JB,\*"=4X]H<3UC-*A:!< MTN+!@RAH7Q,2BIB2DD@2:$!P#Y7CI! 2@*%ZN,M;Y*NL%FDR2&[2013N3#YB M#4S4QHL%NER<9%< MQ>S(:"L,EJM%GA6<=QM:W$]FR:]0+\HI^KTNKM/P38^U?UV])7QYN)\\US K[JIEQ)1JQ!FFQ+ 74V(HWBIQ M1.XQ2>6\K]4X3KK?<.@6L>&&47)^@"CYOF/B=LUQZQ/HR7X]N[^3M0*5?(P4 MNB9_6)^C_S4[0 PK>6O2?%+Q.YQR^V4UW7QYWP*+=R#7:+F9U MCJF+KUBI\TY?ZYI(]4F/O=3T1-2+U,%%ZC$BZL14U$,F8)EGW%P_O57,.K-L M76FEYMCEINS%8U^]P^Z"%L,-X1=K?;1&TI&#'5]3;^-IUD#U=E5 MUD9D3W[68RCA.7BVZ"//\6PB.\$J> \(8B0;0'RE.]CO,2S27: M2!Y=.__7LA+]GQN!Z,?3A,J.?%4^0/STE[O;O'UC\>>U3S_SK-Z_V(N-^AJG M&Y$+@>4E;S')M+,I[,=.L$='+4?*),V(@U0%,!8;C1 D.OR_TMPAO&[S%(E# MJ9:(@W6+.- %PNT.A>^)HR>.7B<)U,*J@I9@U3H(H(8T=K3BP@)""VHAM4Y6 M>]-)'ES@7IYF'HLV4;0'W]+VJ.:"0]&K*#W3]"K*ZU0442N,H]HKX P6S$E@ MA7"XM&T(TQL367:NHAR$1XAL=\+[P7BDS7A09YTPQ4"N81".%YQN:)].MT[J M#)+5>HI("BQPCDK#G2?<*E5@W3JW,>-S$^OKE3=AX9_L&M(A6P1)U*IZL//R M[;XZ?QO/^@F!O!&F):RZT2./L:/*:J(X\;&CM+$%IJ$S#>R YS'-NX9IC,!^ M2M][3/>8/N#!+7$U0,IQZXBQW$/.E/2.60@+D-. ^?T>W ?0T F\I#WF>\P? M#>:;09Q6$.=..$@XQX0A[J6B@OH\VT5RL\+&8VH2*5H_H MSI[$YW3@=@^:S9 HJ]P=K03DG $&%==6.NCL.@0?-&FB&OB\7D!BYPQD N%I M^+)[)'89B=L=DA! 5!O(QX3 C!AF@9) ">Y!H?,JY39F@>[XE#R TDOY)>ZA MVD.U XO_#M\%X^L=D,EL\T>OD%)U-3Q[%3S5(+A!?GVLI,1"",^VD448KH+TJSF)+ M20,]N=R$/XY:>% M\JV5 EDEAPH.@")404>$QA9#H"H#G>H&<>?VE8)#Y(=RUJHQT*L(/7ETFSR: MJ0BPYLL37A!E46RN;Z71T$AI"A7!.-\@C[Q]%6%75-%$9<#@$IVTOG!*X>RB MYWIR.QB/3L[]MZTF &L.06,,)$)B+#!#P +O?!G0YEXTL VRD2*1?\8UOP8 M7 64RU8S5$[VL#^G,[U[:&\*[IKOCQI. ;',,,$4!BX.G"USR WG[8.[>T%S MQEO-*N\>N'LL'Q^6MSZY:[X[AR4$'% K/";"<@M$62!B,#CXR7T >UZT.]"U M>UCO#_(3 ']3K->3W8#EP@I,(,;$&@M]I:4CS=VA#_(#8)V!5@?0=P_KS\Q# M/?6P_\=L=%40GE$4H#[@_Y*_#L$J0YTY%VO(C CZ =<26&]!016*:?8R560^ MNW+Q.V/!-XKG\58S9+OGG.O]\:<%^(;XQI4J (G"UDAJL-+,0>4U+4/V!HH& MH;L7\7UX(_[?Z7PV&BRNHT (!-'//:A[4!\-J+>U[E'-=0)ZVJ^'UTOB>.;A-'0VV 5]J HIHQ8:5Q1A.G@8&R M[/RDD#=[UP;V01/GI1UT*!Z_>9'Z].7W3TP#?R4$S&J^'(PGV4SL]K+^NP?V MK;6$FE\0.< @8P@X"17@+ABF#M56ML&Y3RUU3XN4Y_@5E/W3E8'.*>COGL@ M;W:B8UA!FFB,I'>80> !=X)C[XH376+:P+Y_ =*'M^X?(%F"5M-O.FO&]TCL MY''[ C3KQ;-("HN,EHQSI,/Y:ATI2^D,;]#*J=73]@ 6.>I;P?1([4*QY)@#83@R2D->=67"3($]GYF'<)4!VFI:>L>MW2./;W^^#?LVF"3+='XS MGN;3YM93;L_'V;7M@5Q+@;,,28-AK& %GC//N&/E@>R:Z,KKG?A2;421%],9 M8_A\/5^]>_NT$-\0X+4Z52.X\L(8H142'EGCN"L S@!JD,SR*H!WSC3&D)]X MM5F/\=/"^):G.H&@TN:5=]!8Q#WUA&%(O2T[UD!O&X2^=WBJ]_&MG@%Z!GC[ M*4]P!7@09!PYS ERE"C*)+%E)8L'JD&9V@Y/^0,8\YB?^%"$#Z;?TF0^6*9)_O,B&4Q'R6P9UC(9C/ZY6BS;2'[O'C]L M&_03]8 \XC*2CU#@LFN&)E$,YIW: 4KAWH M=\]7(,!YM(?_.IN/TGDAH_#VMV0QFXQ'R7^ [+^S0O0NUJ*CQ[^L# 9C%058 M6,.=!H@)RF4Y4XE T:"G[2&._T-VK6+MNA$;2MW)*0L]]1PS]313-BBLE W) MJ9/8&48Q,%XBXW$YGY&()D/4#Z%L'"+_ +7;1?<%V>JXY^+(TQ/6@I/,2I%, M!LLDC=Z)J^0N'TB%#!>(+@OA^2ONVDXZ#6SB[#7F\8E$ZJWR<"(4T9 Q:V3[2 M.P6$-Q2)+#KBJ29EPTZ)6F(,WBW&(!<"RTO>,T8?)#T#4MA6KV"RFOIC)3"2 M$6\$X( Q[94H!\LWFE/;LEYQ")OD@A*PG^$>/6GT:D:7&:4A@8B*0,(].0B@ MAI0@I;BP@%2# IUMD%K=LIIQ$ +A4)RSUI%Y._ZT''R=I.7K^5K\LKH)7S4L M!&K]ZU,>\H?"\GEXG8Y6D_37J[4/[,/4#\;S_S>8K,)K64>*Q2)=+K[$*W\) M7Z@GL^&_WF7B&G_]G$[2;"O>I8IY:S"%PTCFBUU.@E0!>JO>5XBRT9%@P MIX@*!Z. S(.UXLSC>\&[) U2<1M7>+Y*[Z_Y/;B#!TDB\?=)D,WWU_F1/8T2 M-;G'"!#D2E2VE,DPG4S6?_W/=^&Z\?>P]L/B]T>V[LOX)ETDOZ0_DD^SF\$& M0?X8CY;7X4?P^T*2@GA-!K>+]*?BAY\?RLV[TI%5TB%$[Y[V<^77H/CW/[_; MD/;B^L_\;;L_GZ?YX/WN]^A_.>WYS8'Q3WY'C7W&!VLG?LQ9O@U_3:>3L/]/!\Y/+*DQ2W] M.W:6 M.CY@-L0AJN+O'F%@*,?<<,FQI5CS?$*6,\ZY1@D^#7'(NH5#< %:GGS=X[#' MX1L/2$QKE?_40@RUX+$L4"CL6>Y_=LX:IAKXGW=P0!ZBX]8%YJCOC]?C](#G M):G"0G%J)"-$<&$0AK% ?SUT+IR7 ![HO#Q(:$@RV'?<.IJ4UFP&^20)M]:R!M9JO_Z=L^7^= M/@G\;M?4XI9GSO4#*4[&HW="A-%0*1"U_AT242C2 M]0IZZ%S=+;P@F%SBDV[8T>/Z^'&]K5$NJ]F2G% ?;'''H%8:&4.8X@70!6<- M&O7L3 \X1)L>U ^;[%'?<=0W [D HM9,6S$8H.T%,,I0;JDL08ZI$P<\S0\ M E6G-\!2*\F8= P9 MS"PP2!7 1LXT\-V9VJHN]%VQVITQXI_MI"O[:-\>L MY58CA0P' )<&LP.Z0?^:YDCLG+U,8#_OJ4=BIP[)^B@9QFR04*V=Y)YX(+VD MI?9+I#S<(7D Y9?35F[.C,/ $S9:ARJXZ;GD8>>BT[DR>U@/#IM9].VL68AJ@,8<6Y,UN$5*2&( MD+S"N;>Z07^3RN%4+/W'L/+'8*12+EM5C?L <^^2[AY+-"4%695+>.Z\5-9; MJ" E&&O2]<5 TU<5XU)H7OV,N.7XCQ)H>> 4^6 ;34%"2M-@3F . K6N9=" M(P4X)K#(2B.,-+ (=J0I', @$.A<.:)7',Z&-)IR!*H4!^XTUM1*Z*@4CGM MA"L4!R6U.ICB< "..-_LU<<(<4T(* MC(C$R/J"4RBA#=)=*TYYT![^RSS8$9.L6]J?!^/I7V:+X\J0AU2V&C'H'I6T MI&Z0WBSA(6NNA2H47CAF)%= $*^\M+$.! +W*Z; 5SCOGBD"B716B MLP'!,YCSLO?G[V3H7W)$?B5;;"'L[UHY]$W=49 M+STYG!HY-.0"4?D-((2<,N QL5 !S.*S_X#>!/ 7B?*]2D* M!^OA]N+4_@ M0NZK5JZ;?=3[00P'CTQT??A"//+[[I#M=X?LF>)$C(X3(8-M]8C:S$C##=,6 M&^*)%\0P:GFI1U!.&LQVVH$><9C6>%+T8R1[M>(\F:0A<9"^I^;N>VH>&7'L M?J[3+^G2A]5(1Y^7@^6JP2 G!YFUR@K/$6 62NA+08Y4:5A;9 3-IYYZ81P MR!+OC03K$CW/E>:<]8.!43E'A ]$ MDNC2M) N6@C/IR@A"*K4:"P9 M8*@H&EBA%L]9I-1?0F-&G36V/O_+#OAI^Q M2182NB"27-+.YCKN12DXXF3I[AH69T=&3;D'U3HH*"(5=QAZP" 40A@'UMQC M4?A32]QS ,]EHQ[!%Q"Q_$8A0;7^I) RXB@3''$+$>3( M%VJ/()3N7^TY1"D8[9VB/:'TA-*4/UC%'Q9#08@ACCMH$9+8P%)UX4YN^+MV MK[H?^Z=JA=]:[\;3I/A[-OT_#2*)FFRV00&_/&]R:3V>*M_I;N MI7ENJT'4NL\XR;@S@DMHO:+<2*4*!I!**]VD^?%P=;.:#);IZ-=80F=F-[?S M]#J:(-_3#]/A[";])5W&S,]%3/U,%SH-8$R_#'X['@<+O0 0MCKRH+/JP@GD M51PQHIL!. "E,@%P.+6E9[$*'#KL,<9N#6"-*6W@^6P5P!WU4M +!EG?A;4' M<$>/Y #I$M%"4F>\0!902ST&P*ZS%KPP#H$&2OFACN1=*>^-*K$):#7CNL=W MC^_M#VA2&Q:&.- "0N\UT,9:J-;C10*3H:+SMFI3^7_4!/?.==(G"(W-*0"7G5F M,9[18 AX[*%0%'),L2F,?$! @Q[1NZ*"CM53[2D+JKM4\$)9>4\5^UZD;N9. M(ED-9T+26N"9,% R3X'Q@A8&BI34-&@KVP$]XY"V"I+M-H%[LWR>7/>XGM;. MB]8:LAB&E8J$+=70*QS_WS(E$2,BK_42(/SE.%2D0[(8EBW;4:?#8MNVTSV: MQ(E?8J[$3=B+95)Y,2TB*+#/->!-'5B:;BT^E;'Z8ZD%X?9A^OD[39?==5!>4P'8'%KP@5-W, M-3L$?QQ3RNH9D>LY?\;S!X.374V>W M7'J!.@'98>O%GCJ/QA(^(W;L5<\WJ)ZB:D'I+=!02BR9DM(&M5-B521?$.6: M^#9WJ7H>HMI!BEX1[0B;]HIH!ZCV')FU&9&26B]?XCT5DB"AK804(*:#6KI. M1D%4\@,KH@<@4D) NV5C1TFDN^^L]8+5:8Z\$X(R%']:=MH(] MA4BMTQ8R'!H05 2I$=#<6:50T6E+.0S[3EM]IZT3N-81Y*3>N\:NI@.NJ:46 M\TC&TV1YG4:6R@@V!@.3KSG=)(O(-]F?QHOP>JX_S:Y^>B%NB_>9N794)OL) M/WB_^_WN][M_G@_>[_X6J1&=G17T.6S/_.[0(T$[Y%0^>';8EGYA6DM)4-)J M3[WDD#& *-0>YP-'/-:4FB9M+XI19_&78E+Z+[-I/FFZ^RD)4+;;]::SKMQC MY]*CHYDC996&)%(/S@LH8JD^(98 8IW%FA@G8+;GH2 MZ4FDUU4BS=1BV)(#IJSQ4%'N,0OOX"7-2*SD@765 X1>X 4@N._VT1-/K[V\ M3GMAM8@NE2"PB@@JBQ%< PAE$>L*)I!HU)=DE]K+(1H)<]!J(^'#!F5/?89S M5J.5K&4MF8P'7\>3\7*<=FJLRH&4BQ?JYABL5_\JQ^+X542#_<((*-L38>T8 MV)B1MK8JU#0ODKL/S$V.6.13X)=_J?:G\ZX1UG*^\?$4NCTB4!V<8= -Y_X) M\4A3VL 5;7"M?+ ]M/;:0& $H( 5M $0W@]M=,L9PKH\@FG'AW'/$J?/$EMK M&[2B#6FE))YR)TQ0-PQ"'%:^# 8VNA4?6MLX@!7"6^TS?D0LTBL?9TDK35FD MU@Z-2H,@X,<'\*W/^/J0!>.ACJ-0M=#4,DD!EP7BD10;J5@=..,/ MD3?!1:N1C>[AOS_Q3X 0FN*?55/0*((",V\E9DII1+0IRM.QME:_V:^X@Q/_ M /A'0+;J7.P>_M]B_1\V'V+S(KLH>*U:W":S/'^BWN0V^<,X:W/[QVQ<:O(U M:VJ;Y*\ER\%O?6[%BQE6O#9;U2)@'"#0*0\YTXR3*L/*>[T1(]VJ)?'QS&FA M%P"S_00W.IO.V0U.:Q6J.,8MHCXBBRR@EH:0%ZXE$[?RZ-]W@ MH',@:;LFRQ%%,OM\B+-DEZ9D0BJ=0XE8PZY<-#@L]L;KBDRF8' &;]HIH!ZCV')FU(9$B MVL\PZ6>8O-PNY_X,DS=^]X,)*/EWUAZN/@H$(O#[A] 2#PA'M)'\]>4Z#1)3 MFW4PC1[3X7(UB._/4[X&T]']]]S&<>?)(I]W'L1[L4S^L*XV^V-R/?B>)M/9 M,KE+8PU:.GTP22%>X#8LP6PT'H8?,CLK^X[\0H,\N6RR&N5O'[R0G9;?X3(I MEOF5SV_388:;_,S \"*)BLZ67W9Y7XZ>V]O6N?[#-/GOU>0NN_V+Y$<:%G,: M>&D8EFUY'=8GO/)CMIJ$!0[4$99R-0_1KX),+)+95;XFQ;:&=;D>#Z_#5RU6D^5:OC*!'*[B#4^RNLEO\<[# M1[<4@OP ^MT+)Q"M!>J4EMA[CBPPEG!ED#7%?"$N#'WY!*J.GE_2Y9_#[?\E M@,*NTB\S4SW7@W+E?,H2CNO3AC-#/!)#2\(R3<(/#XZ.5ZYGL6D_!OE,EGE! M#+'17"8JXWE\OHNXKK7C5NIH[([71E!F#@HF( M.,*D$"^!R4;=VZ9XK7_\M037QXR^/ZR?/U!H]K\/%)WZ&*\GY8N7\B4;IGY< MTLV\L>1K&X(6[^O>AC[&*N%/\;E>P?0[.;)_S.;_"JLT3'/ZS40@,F*XO_$R ME^/\3GEUF [NL5QV;NZ:Y5B5]XR0L$ #K31R'GD4-&Z1BR%3RDCQLA@^S669 MK/&79*UQ0125.R.S7,4I"6F9SF_&TTRT*FG;]9Y43G@&J6+(*)AEH<<>?XX6 M>T(H;T -G_,'^5(]1]'R'(6P2E%)%?@^T6/CO]IJ(ZGQ6_?4Z_94)1]UNL7[-1)YJ& MMZ_2T?J3;S\,R% M*<(ODWB,/W,.Q(OG5F^PMM+!/.B)+LW^MY<9W;P;?T_=>@ MH/WK_> J+-A/@\F/P=TBW,V?KN<-'FM'OJ)J36MK_& 3'ID_*[C02(!@OFJ& M+=-$$US,G^7AM?Q#WV\%\C83OLTDPB*+Q MLR'!M_/9M_G@IC2'_G;Y^;)08;,7KF:KK:"[F7]YE?T7[G$>++O_786["T , M]Y?A,'?\?(GV7G%+P<";_0B/LNG%B/1NNXB-(M'#/>33-+H^XIO MBJFR@^E=*Y;FAEWR.D.S[47<[L![Y@N;G82BYK*''&A*.#"00J -!U05%BT% M=J.NNTV+]D4=]IY%^YS'Y%)LEC"T8ND">MICY XOYK?._%XO5S6UV M@;\MTM'+\[X-1P)#HXVU$!$F?1"9@C"5=J8V[ULP')1QB[T*:I;15"!19'42 MIYA^;M[W?JS_JUEDJ/"U@3AN@^81+>+,HYN?J.GH_2"/"46V*=9IK8@\='B7 M@XIK3W$OSGG"4\O%NZ=3WM=3RY^9G4W;GM/=?^&^OO#E$H<=]GQY.O0C7L<( MHGDIE'BI%.J%:M16*Z*BZ9+.W_;9_6H. @K<6_2<%KS'O-=V5-@HBVWGT/P05/J[JXHERV.95H3M\ M]!UM>SUEH<46!*=$0Z>YZP]=9OVNG\.NLW[7SW#7>X8_QUWO&?X<=_TQAC^& M?I5O]F[:>F@CBV!LNI0/W>ZFB[5A&-7&\%F. 04 6VXPT!A2H$F1UF,,WG"K M/SK$M^Y>-X/),*9@AX78B)P4._8I;-C>VA5,5_D+5=P%EV&7&#E]+K7D7)N] M/")8OS\TE#IVJIP*AS2D#(IKXW L]]YY8:&&AD'FY9HRJ!+.-NE*VQIE[*9, M_PV4@2_)>5)&SQ!GSA"L4BI\X =##!5,:$FA=(2QDB&\;Y"_W1Y#L.XQQ%Z: MV?8,T3-$U^T042D5#@-%-? :HXEPTZ?%S"#OD#277;[)+SE3) MZ.V2L^&4AA0BJZ&^%A,O/0-.><^HP-X)5[@RD,9[I9#]=&UXDQ;2:MN&XZ&0 MGC'.FS$PK,JDO$%:22TUM-(X#0DBMG1^"6DUM'$6L4]$XHA M#+SS3L("KU" -[DBM\(K[R1>VW1)]GCM\?HZO%)1:[%(HRH>U'*)':/6 EFV M&1&V2>>"EO'*.HC7=E7Q'J\]7M^H(/.J=Y/CE&K(K!? $FH]0+H\<"4CK.,* M\BEXXWI ]X!^W0$LJCE%G&GOO;..(8B4,$*8,A"'N7^33VP/"O,I^,9Z_/;X M?15^26U\M/$$ <()Q,'>)=Q29749!7--^O0=5($^%'[I*>#W+-+^HYC%YB2Q MM7>PMM9-LXKF,GT90&.MG<"JNZ<'D%I%4=#:&9-085BXM:D"CK0;"8L[^.N5 MJ>U?T4SI&(H"]I3AVUDEH ^%=Y\1&A) +:ZEB70T*/Y48N>!TI*)L@Y(4-UD M O2.".!<4_Q[ N@)8-<$4 N4 * HZ]],H97KARL$1O MJH-J ;W=3(#LT=NC]W#HQ;A68$#"?X(+JY47 $)@5&W.FCPP>KN8#MFC]UC0 MV]C".H%G/?7GZ_?R=)[O;/;R+#)DW&^W:382?9XN5_-I4LS[S897+EIS?1Q1 M.&Q;GXBLQ<<$D9X"YZR@"%L.#3>E527T#O2R8AO_,IM^BW,X/V6[^6O\GO31 M,9Q=](OP/E9VFJ[B$V*'9F3 0%6E)H#TD$,FD2+,((3*J8+A?PTP'2"#+KI9 M>C+HR>!$R !5%6_ $8X,9HI:&70#AHAAA6; D>,=((,N>FUZ,NC)H.MDL*7= MP'"56>\T]$9C9@'62 NLF-:%JB ][@(['$.%K-A/*_Z>+7JVV+7J0*MBO6@^ M("LXA=QS;A@+%D6A.G@#NT .QU!^VY-#3PXG0@ZLRL*R$CGLK<<06D:(,^IDT,6TOC3>[A)V,7WU[E6 M#!'X_3UPB8"D-T/E[VDRF$Y7@\GD+DF_#R:KF,NYO$Z3]/G0QCB\LIH'*Q<1CMOUC.W!-/M@-G_Y.A.XZBW1V+U,/DR+ZX7G>7#%=3YI?N6+Y$<:\; 8 MC])YC[>)'.\Z](PQ5F-^/%,CQI6.*;0;BYR6(6+A._(5NZ MZ_#7V3S*?;Q@P1Y9$NU@'FXU?[;A,NQ-^-AB-5F&!QXLPFI,XB>RVZE_,+O% M\,CY^BV2U7(\"1L=]N8N68R## SF^=J'90O"&3Y\>SL)EP_2?)D\.1U[]Q+X MY_'W=)H]S2A=!!C'U8WK\YSX7*Q?'8:5>A^C:O>>?#1+IK-EGAF?A]?I M:#5)?[TJN+]@Y\%=I.7%E[@37\(WZ2!W_WJ7'5?QU\_I),VX]#UBBCI(O7#0 M,:<%869MX"J!@6/OJR)3X9BTS#@),!3AR//.K_LM"PJ,@>^2-'#Z;>3/^2I] MM^)AF8 @R M/)\%^(<]#K_/:R2RG(4O#M\YCGA>7VWQ4[&1M<>]I\" \'C9B3*>!HTK_[V^ M'M-X^DWNK0@$N4:3G0O),*!S_=?_? ?>9;^'2PZ+WQ]9I"_CFR"TOP1:^#0+ M]/9PN7Z,1\OK\&/8B/78S' <3@:WB_2GXH>?'QZ"[\K0>Y5O0-X]'9G/KX'D M[W]^MW$ZKZ__])^V^]1V?^JO=8K7>CE7I- )SVB&+C[)&;JRGYQ\?KN.0+_K M9[CKL-_U,]QUU._Z&>XZ[G?]#'>=O __B!UG?WOTP(+2[;HVKQ:@>^GE/R]@/>S;TPP"YA"<=_.DCPSUM M'2=M"5IK.<\,PU) A( "Q#BUSH()M$6A:M!NY%G:^I]T,/_R8W8$;,4O4<]6 M/5OU;-4UMI*@*@34<4(&5LH#P03&7#'J"[92VC1(RWF9K:[GZ?YZ86_-5Y"U MVC:_YZN>KWJ^:H>O4,57T#D /1$:8BVIQEH@6/ 5L$V&7+_(5WZVFG>?KC#J MC<&>KGJZZB!=D:K_E9/<(X,X4YA!P SUB!9TQ0##;=#5^/L1:%<$7K*>KGJZ MZNFJ-K#%5/5_X??;*F['QZ9G<]P/T%>L$%?"J M*4RPI9@EB!MIC.=$(8A%206:OY4*VHV^O:$6:UM&D.U68G56;SD!]>3T<2NK MB[#3X> JVS57=+#M8?KMG EH#:JU"F) ML? \O :X<=A8P JX0MAD4N$^XB\' "P$H%5]NT=LC]CM$8OK:6G*:P8-<083 MASQ'1)7Y'=*T@=BW1R .<\+*'J\]7CN!5UKE8VF@#">4F/"OQ=X"ITN?%G%- M1H'NP05_& .VS7R''J\]7K?'*Z\B_,0YS9B53D+%@-+"6%XZGK!^*UYWY(,^ M ( IH)?X%!"\IYX_;VPILC'V>?$A2-HP72Q^O?*#\?S_#2:K\+9UIZJT4;,1 M!X'$7###N(0&:*%%V6R$45!K-D*,%<% M(ABBI43V/,\[\5S131!6S<;:<>9 MKFYFJP"N9)Y.ULV&9D_V+SJ6DU^"\[Z?Q>XK()\FSRW* O=<_;BC==A= MNXO':B.[*!3'7A9[=(+!S[1H]N,SI^I))_ \(@:GE='SR ,V,:]@S;RRUAB M,"-$2H.9]#BU'"XNHF=6,MW/:HC5XJQ^O9MGH:_ MIZ6@;GSN<6.LC; "O*""])5I?2YBMZGLU)BK(5')*A=1, 1<9Y%32.@&[I./;0%MC6##6(H;:'[4=]=SO3/\2%D+354HC.:ADG MH$P<,4H;@A)5F8.(*: M'EU8Y:6A$,7(@W+]^\A+*Y$7R%X,O5!\(J&74[U6XY#2*6DV_ #1@7W' HHN MDNNSYLE!++N_D[6&E'S<8__*7O(.)WE%D6&> O3T"*#=W\E:]I^4O#Z>WH=- M^WAZ+QBOC*?W@M$UP5A?);.=-B[1T\EV*]6+5)=$ZEP3>]2S;IM#Q\.WDY(3 MR?O9[N$/&8\C#)5N4 P]@H K:2FEFA* _7IR.]$48+%/U_]SG^Q\GR (+@3F MEV(?4?N]X*W//>ID[M'AN/:LJ+4ADPI8,BD#VB$@L(18<\@$I\ 53*H8WFMZ MY2N9E'>+2>$%QW@_32-[)CTJZ^@<:+97:;=0:2FH(OM6 :,PL=!SB .[*09P MJ=(*V&4B[G;9,11R/UFI/2OWK-PQ5CXK$F[(N0C4>@\*XRB'@ *I')2.4%MP M+D:Z0<_08U!^#\"Y"-']3'OH)N?V90)'F("\K0Z'J]9-$,?Z'^NQL@CQR"5( M%'P".$-=S$CNEC^R+SW#VXNWJ4\ZJ:EU%-I4(."14L >>$6'=U"V@/;S_VHWP? M-L&_T_EL-%A<1S$3"**?>^#WP._$J5ZKVC<"&0D5 RRRZB+. M.V;[GR3.]U27N-_RO"_7:;*<+0>3%PKJXO8FL]7\I9:(@T59(?"J.UG[<-9N MFFQ7@Z#-YMG%X_JD)9)_]SR4&:RL;Z0M@\@#835T&!@@_1K*3#&C-\H[-Z'\ M^KC',WCA)5[D"XTS+NGFX(#DZW@RJ2?);;',[_XK*Z\\^!;)_!(*;S@0B,!@AH1:,(R'8VM=2D\Y^&U]S@'>?B*=*26 MK_XX>??F7@"_I,LU\YB@3C4I[S=(&$8]L-+#<"X1YWQ1WH\4(;7R?B[B$V D MK ><2>J1< 4_:BGYUN7]H@WU(3QYJ0$\4[>?_A;?E";CZ7"R&@7M81G4CKP M/[8$&,YN;@/6I\O%&9??(_)B^3W9KG1\NW[)_;7Z:STCD?OS=1RBN"^'KA]D>IN8X)> MI(Y4I%AG1:J7FNY*37^V]2+5GVV]2'5;I!X[V\ZA?8HI/>4Q]WZ:>=_GX]EH M/$S^L':V_S'(SF+YTUO%ZEQ[')SR@_>[W^]^O_OG^>#][O>[W^_^>3YXO_M; ME-_"KMH G]/Y]_$PS=3\/<52=_I$CUAXV[0H.'BEP2//T:#T@ )6E1X +BFP MP#DJ#7>><*M447I@G8,O)\.NA2/FH;U[*I&M0_5_2*++S33:(RP..(,,AN-B ME2,ED8:<(:K&I\AC[*BRFBA.O(((F;)C"72F00+]\YS!N\89&(%6NY/VG-%S MQAEP!@15BT^*N-8 8*\LLQ@;#\U:SP!&*M6@<<'SG,&ZQAF(B58[OO6\B9DMXQ"V'9KS(H)ONU7@[0XXS TYC VI-,QTCF2#FE M(8606K6;$PX2SC%AB'NIJ*#KPCBJI !TO\;,(2B$]7I*3R$]A;R20EA%(326 M]7(DC93( ^X59ZRP;91XNS_D=;;- 2@$RU8;K1Z,0MK,Y^IL,.=#S)!+%\MG MHCF-FR^U&KWKIK7!J]XNWJ" <"B\,4IC)HB6K+ VM/#D99P7:W\LP1)"1:OV MQ9/RTEFMX63CTR<*\X:HEE5+5:T$Y)P!!A775CKHK"PZ-DFB&D1 7T!UY$9 M!,+]C CJ4=VC>H^H1K#*:W#68$&--%P98('!KH@W0&.E>?M9W;F X'R$O2H M[E%]-*C>4B5'N-8YU3$A,".&6: D4()[4'COE')ZSRKY 6QORB]QC_H>]4># M^H8@IU6^D=4.0&J!]\H:P+RTF)9MT&T+=G?G??047Y#W(3PWDO#8#&'M( M)<,(>X$<&ZRTPL@:A#6@'A7(9LPU M&!O]*F1WSJ'..6[5H=X]9/= /ET@XPK(DBL6DUB80%AB@!UFL@ R;>0U?Q60 M.^=#YT2T6AS8 [D'\N&4;TQK=;[&&0X4HT)(S!2G2I='M!&X@:-\A\KW 8QM MR'FK+K7N(;U7QD\ ^DV17AL:"@VWFGF#M=: .>"=I072L;?^H,KX(9#.0'^F M]\ ^4F#7IH1:1*0"TE(!)(0:**%% 6S J3BHI MC]!ZW\XD474S"X_][WR,V^PJN9V/9_-DL6Y6=+\[Z?F$WK;,JB&U(::Q0I]Z MP)2Q$"K-$2"\3)[SK,D0T]K6_'KU,6Y,K<;%S-/1^#@2X/M$V3[N?D3@;XAU M7*6_ \R4%T1#*ST@1$FM7:E5:-[ ,; EUCOGQ:<]UGNLGQ[6:T[ 8#M(;8D$ MV ;8$RT]*Y/B$0,-7 -;8KUSCGX(6_4)]&#OP=[-& "I>085D@H+3RQG7%C( MI.>^C.YYT63P_3[4^EVY$A9A,$KSP< Y7[J7;OG:V@I7-#SRG'Q2E,:J?DA MC;78>8BMU$0!JP" 91Z?9KY!P>Q>+(9#TH@$^RG%ZQZ-]*S1LT;)&K16D&LA MY=19334D5'K,(2Q3BQ3T#:(7>[$]#LD:@K;:9?CH6>.4Z@4^I//@_%T\9>P MV&EW"@6:$ +&J&_O>6K'?/<0VQ"@M H:,,2%)U!+++2SQE'#6>%(%%HT*.5Y M#4 /$REH E D6#\8H =H1P!:<_49*0W76&/. W 9Q(*Z J">\5='\)\'Z&'< M^\T VFX$OP=H#] 6==Z:5TT#IZPT6%-%(9+>.&E*Y[QJ4O^^.YWWD$8Q.XW6 MLCU^NXS?9G!E\%Y/&@(APL8*IP7W3DM0SK.!31I/[4X#/B1<83_UIL=K5_"* MJ_8RBCHO-3.$.2.H MS"UNUF-5\.QI,H%\D?O@4) M_&,;+N0CBCMMJ6>S6C,YKS1"3#)JG.6 4!PLXL(R-LRJEXF@'HN*(A-0A9R^;C &'#C#!2 M"T8)P+R@!L09/P0U=*[A#H:\W8DW/3OT[-!5=A! E.Q "./4HF!'8$69T<8 M4K(#8O(0['#BT8J>&GIJ.!HC0Z"**S#&AFJHN'6 &\&%9U4O3JE!]XV,H_=) M]-S1R-R<'$O M(7"O9T\&1 9$!D2. Y&=Y&,FK,IB+&3"-#<(,"F;.MM6*]HC(E\_^+>K15+> M;P7M@,B R'U#9##%[S+%O[,#3/.6H@I3FMA,IT3&F)K49K@Y-56DZ!YUQY_) M%G_=*DVXWU+C3Q6Q\>T-"W@>.YX/C<;WA6\G0QY9H2452,0QS0Q&K',6?8*R M/E78802:[U75O>?#8<;#WH#:@-J V@>@5K<.5:YH(E5,L>:<(R8RP4634ZR3 M>]0U>R9OP:OJN:3G [S'SEH?^O_3)C^9%_7[O7@TRA'XL+V GTQJ'UCU\BY# M:E=B/T[.B^EV7OQ\:BZ@BS?K=D_M^\7/&WB:9'EQN2K.G7OJ2_%^,5E>%"X1 MY9-KSB>X0SQ?3CZ_\9/(O?Q8S LO$>^$S9355EF2$)LF0B)>!6R-0@:K=UV5 M)D89,8B2U&J%I+#U(9K29(R 2E. C%ZZ 5MMB^M#.(>)\.Z\M"TP07^\)@0* M1OS)8_KIO(#Y,(<%""X;K0KHCK7;6!Q!]T1YV6WP=G,6T6P1+5W/P1ATN@[> M=GT7O775)7]P$\S__JK(5^NH6$SAA_7X/NCYJCE1318OT#!5ERN?%^0DHH F MI,7$,>]1?GBD5WD[RL>^=,?Z]]U M9.[:(H] QGRWSV 0%^7KKE N'$KGU\02HY)$G@G1I)C/JT__[0UZXU_#+2?U MZUN>]=/LHEA''XJOT:_+B_R&1O1U-MVF M24]J4_K8F[NSE\I[4/['/[^Y ?KJ_G=_I![UJ\=]%.XUQGM]/Y^N4B]&8) T M$Q+C(2793H!VQ:K3%/6PY57=[AFL=-NR0RH-UZL_58@L\C&R R\O?Q"24!I! M1=DAI5GC!:$2BCL%X=YL.*3\?/H* G.S+ZJ[>"7H_LG9SR1?71UX<+LZ'M!3 M0:2&)%(RB%00J7Y%2@Q6I(+4#%=JPMH61"JL;4&DABU2MZUMCZ@/V=,*UGM MR$PVV]Q]%+FSI6KO/[RS=L&$Z7;E_E/NF7PAE\8^I%>^>K#XSBS);P:/!26= M2I;49@@C00Q%6&,K!6V#6MS8W5#O++*;^6]<#OIUP\_I#L?D-+NM/ MU2NF]:YQ4XI;ZJ6MC$?'Q>ER57S*?]^'_8]8D7 D_)XHY;VW[W$+UNMER#Q; MDUXP"T90VM;=-#&.29):PS&W5J6*$5R#3"A]X[R/X8!LN*>$*:UZ/2/T4;DP MKSFS'I.4&.@XK#$\7#KRSC$&B4UQC!.F4Q8KA(UBM*2CTL;J&SF"PZ'CZVQ0 MO \=9<\G* E"-$#=N$-8^?> MMXI1"-SO29DO,54"] +T]A1ZW[%H&6ZI)U%LJ,(F,\1D/),Q5XV_+Q/BQ@&= MPZ'>'FVBHZ378WI&8>'V62-WJ/%@)XD13)_%U!].>9\(\!B/"[W3YOP>IRAO MM3,1QT)P)235:1S'3'%2<\H@+>[+J=MW[<)XK#X6JR^S2=&6X=[[0*KL=^ON M_FS-O47@PO'DX^?,_6P^QENJ9$HK@A.:Q-1:;5.1)+2)=EJ5O3Y57K_VZF&= M5AR8<)!,D*S-@! WU(#"/6=2_W".LU_A_X$?@Q!)V"8]KJ M%":-,QX;E!I%4LR!$(WW O.8O3XNAA=#"CI&8,3H&4';,Z]HQI(L)D1PH;&R M%BG4R;Q& _!%[$_$A?)^JW,/#A;?#9W8M'=-O=$5 R/"(^T.CBG MW6K0+$$\L]*@),D2:ZFH$<&(O7'FT[>"M=EL 8W[/U\Y\.?3-G3[8;FH/0;7 MIJR;X_^5S[?5$:1[% =AO-?HZV!5A$/2!(8WO>\YFV6[X%M,+9&24\HE1RC) MTAA5/@3.8HT',9M?/_ZPN[2'R1PF\T FS!KT M]V$LS>,.'(2Y'.9RC]E'HG/8*HU5RA FF286Q8DUFK!ZJ8X-?]"NZ($HWJ]J MGO=[>-9H$Y ".(:@!'R/$[2C!0AC*:=IQH6B4ADAI:P-=)+9>_OP!J32ORHG M]+$<-2<"%O87"]^A F^I@&+$1S#ESAXO$RIN#G-Q>E.>)40T/1H\,14G="469 M!"%$J-*QS9BURE#5),!0=<.9?'.S&@S'=K%9_UI,EF<+5Q[P_>);! /NU/4# M]RJN1"D)I9['IG@,;TK?;P:K3JHKXCQ529:EJ#!Q5>(ZC>[(\S@ M,(/[4ZM5Q_=H4VYC+3,WI74FF4U8LR@C@6_8_,-4JU_AY '1:VFI,,'#!'_\ M$BW:JOLHPXE&2<9P$L?4R$1FO,JY,HE$-^I!#5/)?H7YC-4Q"Q,Z3.A!3&BE MVGJ0AG)BK 4#.7;UZ+&V]?9O9C"YL4%TF#KW:TSH?@]_#/LZGM%3GH&8P=6B MR7:U*A:3JZCX?7*>+\Z*:)5OBJC\>QWEBVFT=*)[.&&\1ZKX&K4J 4V2E,N$ M,TU%3*1@2C0JOJ3V09LXJH%*JG'ZM (;NGP LYCZ5_.=D-]>^Q/!^^;>K.$?&/Z:S7.W/^%M7T#\_8*;WWP2M&I22B M[3F'DB+"$LYQS!1&FETKZJT^(5/,.<]EMS=%P,[ROB':!^*% _1(;?S\V, M<4ML*C$B.-5"6I09)#6B2>MF9OOC^7C-! ',Q(NR.[B= WL#>P?*WN^HR[@3 MX\NXH2*1BB@4*Y8D,>=-85M#!-D;'\=K;%\5Z$5#?7NF+W^C>.2?-OG)O*C? M[P7_Y2A\V%[ 3R;7FC4'N7AW7NKMF* _7NLU!5WTY';^HXC.\R\%R)"702_* MJ]G)UL^]=?X%;K:.+IWD1YOS? .?@P!$R^TJ*J"W9] 547%Q.5]>%<4Z^KI< MS:=?9]/B./IT7D27V]7E"/\CJS=70&HK[*Y_.K:+.,+E?++_"; MR#7-W3:?1_ L^6+BZEBNB\D6.O*JSA-I9T9T8C9YCR"/I@M)O M MEW "]X"6P$/]O%U=:^#:?;0YKQ\L7Q712;Z&7H"VUQ?<^8';).Q^,2^^%'/7 M,M<5,,LFY\>1_?T2, */L%V W'8NO'&Y,'#9>MP?1<8_?(>,O"4C%SIC:285 M8]H5UY54Q75 +E4"W;&K/^FTU('*%<-M]_7?Z17H T?TMDTL$73*'/[8P=(# M>^_H<=U>9815M/%\@<==KGPZG7O,XOXCT^;^"7@KR[(D=F:#0M1B6QVI*0Q& MM+>1D;V-#).W5#+O:V3<;'KMT1%M%5B5;X!*855?3I;YR>SN=,3S]7H)*HK[M5-+K%X5^9EY%;H:+W"Y!L;\:N7W&J.WV\.V% 9Z\?"V;[?#:9 M%:56OBXVY21SB)J=SB9N35T#(E9-^7LP#+:KA9>.U6S]&5[_[[:R%%PA_'*F M.Q7^?'99J_TM\F"JE[B8N3G^V_''8W^E7[9 H&7TZVRRK&;TJKB$7[D'S"\! M4[_/W%@#>IZDVG];0R&H+YDAV SI_K:& :75+K:Y? MBI6SB?*SXN?3O\Z7)_F\(P?OO>YBUM#7Z_OH^J"*>%]$J[:01FMY1[Y]*L4M M&N5E^6Q/U%DJ@^S,-ZXC3C"H?X5A7I2VV]()<;&Z@,X"H2GJ7W5DX.B:Q>HM M9/?+TWGQ^ZQ:5D N+O(%]*4S-O,36#S>Y:67!KKD;%7XRWI1G)6WS5W7@ERO M-J<@VTMX)+/Q'[2/^.3S(QI_MT&GD3\NO M\-/5D9\M,S>A8$+/IMMKG5$]M[-;%U,0W[5?_$&%G;0V[GQV,=ODU>M5907[ MXR7<[5U#H/W>X5).3-=_G3LL3_Y93BRX-BR7KI-]5_C++.='[3W<6V[@RYF\ M?F7-HQI1UYIFH/Q(SQ;PL/]77'_:9H1/KJ OYLL)O+LXBT[!_E_7(U"..GQ2 MG"U7GB[O%XVKHQFGO/[&%:PBT18D;SH[/871;T>K\FQ\ 55GN5U7[^YTMGO4 MPG7KPA4VRQ=7/@#CI6:QN?W9CV\ZH]P@S1;;O/0)^K=+KU4])-\>ER>XAN]P MFY4OW==_!*&$&7+;^L;U3DO\O\]7]7TNH;O>G:R*_/.[_!1F_X_Y_&M^M8:G M^=/YZA[->J;83]NGG3[>&02_('R";OU8S L_2=\IJ6*BD"(X%C05,8OK8NE& MNJ-MW[&2X7")8FHV#_XY?_,*ND"%[>LZ]$5^!0B! 0.^@'AW0 1@6KG2?>4: M_Q:T@=F7W,^#']Q$F('27DZ0$OJ3ZQ"L4+M>[>T\[\Y]-T5@SJ;M MM3T.P>983&:7'H;;=6ERP#L@7<[?N7*+8OEW\3N8+0Y_#I?7;K$]@?M'3DO9 M7!U%I[/?/6O&8*7VS0)_U>77Y=>6\ M]9V_W]=#UU%$W\$5W6(T;I<*,I.+A]VM;IRH/V2S[=- M$U9@_< 8G[-@+=0.K>;"C,!S5SF=X MB.IN[@*KXM3-ZK:9[@J;\@8GQ7SY]3675-<_=6BAF=9EK*U4U;T[OXC.?9CK MNC%0KZCPU=J.OE4Q+Z?'!N3>[S.=>>/\Q91SW"9=6TF(53PQ. 4=760Q25B[ ML?MF[;M;%/1& _^4K\Z*C6FZH%7==W3S]Z5N?EPON._RR+7VHTB2C4E)*5"HX MEE2DC6\_QC M2X?7=8N4F4/^(J\BD->6YSH*Z0U#6$5!6? Z_I'3 [XX5;O\WKOY[/.U9SFJ M( <7A+?@B_[AG%W9*!CM8Y4X=X_A_82 -U@%MY/"K[%N=:I-C3;J"2P'P\#K M]Y4Y<3Z;.W=)\=E]##I$X4LCJ=*1PY4_@U%XE?[NAKWQ]? M"VAYT\Y*ZRB[N#S8$X!7(/XS>$9W\W=5/)+0[[P%YU4ZW5I1Y6+;&-CN0OY M)Z_D:%5VQ:LF =:U\JB_7I?05^SN[8^9T M/.G>O>9W) MJ;FKRZ47T).EGT[N2,LS;Z?ED\_0C]UYYW1B (=3DW:_=NVB_B$6;3!@55QN M5Z"XPJS+G5OFU;O_IQ8@M2WQI=13EE\77GC6F]EF6\EQAV#E3WP:1IM X7U3 MS42?SV 2.Q@&A=B#!';Q[R>NJ^>IJ.H1&]76^6D\_P6)43_[MB((*";R?$/8 4Y M&-&":X/-MNBV,(5YJ7+IW)3E[>N+, O#E"):^;"H6A[ MZ1-UX)'/;WV(ZB38R@L.@^4-B".P$R8^FZL<4! +$+/IRGE*CZ-?KWWWMJOE MJY/9QGD\W<)3.5?7H.,T3B]H*MA^=71>.C%PFA),.>O[KWJFJ\YG[OE<;Q1? MEG/HT-/5\J(;RG!+DYL="[ [)Y4[8[V=G$,_1@ZB]<*43V >K;M3<'-U67F$ MRRDXVVSF17<6NB;O-&\*%M>DHHL3I$IK<@Z8CO!<4Z)7SHR?%HWWH#;(79\ M WQ,Q2^_$.NK+MYZ\HK+4_?52""*3MQ/O?255EZAG>TF'J%OO#^RW: 77O] M>QVG=KUN'Y=AK7,0*#\1X,;G.YCU4CQM$[S\>3BMC^NT'\U_K'V"1LJ +&#I:?R#5SKVTT$ M]WU5]>N;.FR]ZNP(&K"^66M*V;PA(TV4I2,E:]>-_UR"K$1NKI2"X!:T"OM. M<5HNR[5IDE\Z;^^N5E6)%E@4[\K5Q3F\2H>4R_>K(G@N V_NG43=SJ[!5=V[ MN<7;(E^YL(8SL*H?P$]_@/5D>[7<;LJ1]1/6,0<6Y\HM6W\3Q.]:)W:]\Z>S MU46W__PD=F&=TIGCUMSEZBQWN4*-TMAJJ\[C"0K6IFC8E[D*M>%2/6H9_]A>=.7"K;&S2D0NOO =&RK5[%R;0RLY@E*I]*;#>T*YA MXY,UZP7]%II\Q]#K$J94*-P%RX43%%"X<(D3?YMV.D W^WQR^-"YN#XO0 ,L M?;%N9T5EC70B.'Z!7C>=XGR5Y=6],>CMR_\J85:ET-QVTT;KK&920T3HIOD5 MJ/U>,N#._]Q.SZK6P:)=NM&WMTXL%]2ZW&[J?-IUV?1*#:PG7>>GCK1'+D>G M]+1.VS9W?GA43H.58VN]=G4_+=<#%WE;+UN5I,G/+[-O:M_Y4>53/MK!5IE: M5*[XUVA>FG]?\K735O^Y].I:F\A<2<.U7JVSEK9-#O+"!RFV4S\C.CG-SA/0 M!5(E+[.R4MY\!M\KRFN'YM_1_.2G9M7'J1.RWG?F4D>-=XU;'UU'-::.?'UU#NC!77 ZMK M0? N.]W"XI>&4KK;_P*#-8\\& O/KF MLY1 MUAEHLW(.MC)UVP0[E\3%422SY;UP9 8^@U\ZYD0K$K/_V&B?O96W>O M*+% (4I\+/$H<1DW+)?NFOE>MIWX^C_<"@W3KO'^.YEV?L#."N)U MGXXKX+4C9/ZYKP4S0;]9;]XU_J#MRB\)=0#34;1K9+7Z<2>5Z,R#[X:*W'IB M[G#LO69GE,/KP]=/:[%<74-L M*8<_@2)J79P0L_.\\MU\6/]QXW%_TU3]KJM M$>_$\:ZJV.4]*/[CG^LO[7[VK8\>^;-PL\'?[/L%U/L[J!H]H(BZ>A@?U?V/ M4J#/<$KUXXO%]][.%V_;:QV)@?'WSL2XML7^YH;X7H_&F/B,RTY3Y,,&5MZ^ M!R5SB[WW4$5_+TWETH#^S:E7!RX KS&17[*M]T;S.EY:?&P?.;9WVHH]6!M:Z M,DR"# <9_KX,_[;HN"%O2A$-4A2DZ#;_V_]?;RCCYVQ]Q]([;&+S=O_O+6+^;;R]OJU=W?V'C)XS:?OZISM?TC:HH] M5*YS7[OPJ0(_XI-)#[;A8?3#Z(?1/\R&A]$/HW_(HS^BTY;OVD+YXX$''4( M:51M'7O[PEB.IWUA+,?3OH,9R_NI1/?3"/%0E257MN"%Y/C.GGKF)C[J )GO MC>IC$HE>\& NV3F82TI$;282+FB:P@L;"U[F.G.C,WM7G?U.V1R7JN2=W3^? MWED7]65J+_U6%>09T)&Y LM^C^QZ[FG2_W%<8S6* P7WG(*T+4@7*Y%H:S(F M,<$T4?!_4E/0J"3;:PHVCQ9?-7_^5._5]#'NZT7.ZN^4H7#_!3PXL#*DCW$ M:P!K .O@P,K;@X(PPUF<82LMQY;&&:&)J,'*%+YQ[NNA@96\/EC_KU@MI_GZ MW,U(13#Y\F?S,8I*E-I&Q1H" C"J2^+5>;C,:18RT&3LOOB DH"2QZ-$M"@QJ616&P%J M22HSQ#*ATUHQ20W! 25#<$#O*"8XJ"6!)0-AB6H3KU2F*4<:9U3'AI,LXZR) M9*5,W.,DT /WN0[3K8*/B)+'9 S$Z3/1?ZA^UZQSIO93-T(>;*AOS T/HQ]& M/XS^838\C'X8_4,>_3$%V-/F'*SJ8.'#-$$50FV<32*39()DDDN)E1#4)K8V M045&['#<65Y-?^^U],P=]S,XLX\<:4J/V1C,ON!H&L$L)ZW36AEDJ.&,I9Q; ME2F:J6:6I\H,:"/*=V;Y*,/F>"3.HD"-$5"#M>YIQC-,$J!&G- 8:<6TH4T" M'F4#2L![?FH,(#Q^,WE/TF,:P!' ,0APB!8UNN$*C=]&JN-S"NI:OBR@_6Q7EF8M/)%.O?O&70=;;;S,+ M(]+)!:0)T0EAE,0$RY1EJM%S$J79Z^LY'EP[Z/BU&>>I:<;Y=7CBSD2'][Z7 M34/X,7^);8P[TQ ]42S[F:J/.H!IK.&HD;/G.^@A+7JH%)G +#,V3A!B1F*L MFIIM::SW%SWCVW/] MB#T#TBMYCX-Z%=2K@+-[JU>B5:\2%F>*DDQ2B12"_\(D:0+F23J 75ZO2+.1 MN[2#>A5X- @>J5:[2B1-#&6:DMAR*BSC&-6>)BSB0]TI-G#WUN$2:TQIP_:B M6)W!'0\\:QC8T!:VEBJA-N4,QYA*Q5&6-/4T#*$#.#'@-C+4 _GW=#:!\SL.G^SC8\5,H)!!D( M07A+$&O2U!J:""R31/'4QJ@Q.&36=W;@WA!D )[8W2,?>SV7+/ C\./Q_)"J MX8?6 A$=6P3J1TJ4-APUF7J$DYX=%GOM/QVZEX1H'1*-]Z6VUB^KV1<0N2B? M5V<;?"FB62O/H=Q6*+H21C^,?AC],/IA],/H'_SHCREN_E,Q/2NB4V=3'*@% MRCHA<\Z-2$T68R;B!+YAI&D.M$EB,@ ?>/T;/V[#W&1*CJ3FH>;%/I#L(.9W M)T:>V@QCE6J>$IRPV,UN6^]?1XP.J%C.G?-['"'Q4.TBT&*8M.A$Q(VQJ=52 M9)PCA865BJDFHP;U?=KN4&DQ@ !XH$6@Q3!IT8E^,V(QP]8FF*6I481E5M3Y M,RIER6'08@#![D"+0(MATJ(3ZTY3HC!/XY@DA"I!2$:;7!F&5<]5:?8FUAW< M&_L:W!ZLA[,\CNS=?/:Y'S_GZ+8P,MUBB25$TE0@Q-,D95(S&>-:B8FM'M") MWN6P#A,1^$AI^C+E&@:KD(PV^G/0K.!8MNEZ4N@DX=10F:48"Y$Q4[,B,7VG MZST/*X(W-9 GD&4;NF0WD">09 M!'EX2QXID$92$6YC03EGUF9QG2!B6#*@!)%G)<\ O+R[)I?H=4]D8$]@SR#8 M(]M3('5BD03\9,08B<'$0K+9'F65[/D4R+US&0_<(23%L1PUH!Z1%3M4E_&O M13Z/0%Y!T XT5,5URYT,5)L4U!TAN#)8I7$B=7/"'%=D.#K/S=^XD;1^( ?' M!(YXKT08K&9R2 K(OLYW@=MS:*E.!)$)YSQC-B$2R=:O*PT=4 SH ?-]'([> M7;6"R5#)(2!D( BA[=F20 EB9$P)LB+)4H6MD35"J+4##P_>,L/BH6U1AN%8BH2@KA):>WJ$"P>4.;]R_)C '[7P(_ CV'R0[8G@R!) M5$8R3&-!A.124)4U!Z_Q]-"S:_?*3T*Y.A9C@,PAE)+Z>0.=\M0@SG(U+59U M,_#E[]%Z.9]-HW]!_I_Q!7F$[IRPC5)-$;XW"_>QDCE8Q29$C0\1.!+CCJLFR90%!IE4LM2D&>/-&;72BH&< M47LOX(S2QTLP/4:!88%A@6'7&4;;LBY9EJ2QQ&E$+\:;G) MYT_6; MZV,)HR,-9.HS1/<]Z1BN&O4,L_-6 TNLC6ATA1)XQ#W!?*/W]"-$0 M MKGA?^B@B^^5&Q[T(=QOEQ_A#X(,A%D(LA$D(D@$T$F@DP\J3_NK6SN04:2 M?_FU[+>3Y7SZ9U?ET%DU1?13D<\WYU%ELD3>C'FB=(P@:W3L[0MC.9[VA;$< M3_O"6(ZG?03+?31K%C_N,^:],&:5$.9^6/N MA(-M>!C],/IA] ^SX6'T'[&+;["'1_]V_/'XA6R7 ::T/.6I7RXK16/='DIK MTLQFJ< J8W$F,4N,('5:($\2_/IU%N[^37F"TOEM_"] @,9[C4Q+S P,/ 0&$C;$^:8H%(G$F3_OWM0G M')6W$*MQ> O[3'<9;.CC/4R;U2)W8W17)<.#K:RJB6HKJUJ;26NQ4)AC; G7 M"6_.1T?RN2H1/ ]$/BP7^\ 1(OO="SNX2J@A@GZ(5*%(M0>!44)32K(T3M(T M2U6,5=P>!(;EOE/E($(#'/5[_EC@5.#4$#A%VH0+I%&,$TRQTEHQF@@E4:W] M,,WV*N'BF3AU8.[[0*E J4%0BK642JSEJ12,Q8QRI03EPC011F('<,KAJU-J M@"[V'6T*'9. J8"IL6%*M,E@-A6&QQPAE&;:(,JL:I0I36,4G."C\%])T6]1 MX\&1;$0'^62SWXMI-%M,EA?%4[=ZCH#38V]?&,OQM"^,Y7C:%\9R/.T[F+$\ MB#R!U#D/EI>@)%WDJ\]@;00#[[J!QSJY E3%/-6ILBA)L4PYQJ+)\U2&V.'X MH;S>^]ZKO1F,Q?"-*J&/\:B-JN >.D1Z\$Y. ,9,IBZJIJQ*TE@J+6A-#PQD MV1MZC#/X'X)J 4>CQU$G](]URK 2J4[CW+IJ_=QXFV>^Y[8,CUI@*]]F+8G4&=^S)*;VW M.%*=Y"+),$.I0"Q)LT00G3#1:$=4I*^O'7DF[5"A'LB_E^,X>$APVJN9-5CU MY9"TE'V=_0*U%4:HR5!&8Y9@C2U\()AM(D]IK.)]G/W!C1QP$G#R@ MJR2Q0JCF"36ZYXJ*>^-\'8.+A:O9%Y# " 2AK";VI8AFK7B' MP_/"$4IA],/HA]$/HQ]&/XS^P8_^F&+P/Q73LR(Z=2;&@1JD4K4!.,PSPY(4 M,:T(P2PF7,?-Y@V3#2@YT8_;?J3D$,:/U1ALP>!^VO_9KE#'G8U2JQB*F@1ZO!P]2.N\EC$V5F?&2F8LQU2S5-?%G[G"!T*/ M 0;3 ST"/89)#T8[12:8HI+%6-M8Z(2Y3-_F#&Q"![0O\SGI,<#(>:!'H,

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�[=5;\Y!?+=;XXGL3@H38_ M;UD&1EFI)86>$XX$T]!LJ#4(X_MX]+O8_.4.#=NAY[3;7JS^9093 <&X<&)' M6) MQAU!D5/8">N)TU9I:%W=TX 9VJ=Q'80RP(%DJ6TZP,#Y88"TF0"LM M4L X;C"6ACN#:5E^Z)&F5I&.O8TQP +GX)0F6$BP,!A8.-"K8+CAP^*(0!/ M04' B)36.*OK,N7PTWUPHF.O8AA!"0%Y:F5(H#$@T-@1(VC##:,Q5UY%)+M4_DH6,78Q@8P05.#=0)(\:'$2TN.T*9]M9*[!7VA$*(JW8G M3[3S0KV>OS$0C$!RY+U.Q]/$H+-5]FF6+4>7]#S0W^"@P8E8JZ2IEUIIQK'D ME(C*WQ">4]$U_VZ]%<..3#"$4F'BV,R!_JGWCMH,97/J,^Z0I!Y203#Q7 "E MZOX?@G773<[CT&8,X3CJ&)(VCT";<:/-!A'+G>?..(^0T9A!6VJSL-9IV+$- M/PYM3D/+DC+WU_*FHC6<,'CF3BDE/;<\Z+1B9C.:Q[E]VOLZM[R'X:-#+CI- M$"9=3[I^^,'-&\9C(;'@"FEKB1 4 .EK4E$G+9==^Z.4;41/ 5)M9-J]T*U M)6\1DP**#((:Q7'"X>06U;PJYRW6I.N!>B-4;0[&,:O>;Q@),B )1IZJ3\APE,C 6&N& M$E5&(T!0!5;> M2,6(HU0B7><5M-N+P;A[]V(8(0I$1:<5 0DW$F[TP:*0+T6\ZQI.U)VP\]O1%H\8(93,,![C%%DG&$-&((U\JM)=MGLM\S6.,#4>[@ M:J=1!$FY^Z'64HXTKTUS+J%]7=-\&,J-^$CFC*2^@I_> MK\.:3=S\?'&VG,[#*WWZ]M0,#H&0# M'15 [8A'5+9&2>AHZUAL(!!,(N'AAL[&6HSZX88- X\PZ'CT3,*CA$?'@$>\ MP2-'B;+(&0LM $1I@BRIQU\)8KJFO!TW'A%^Y/;1$QM3:$=(TW'&[,U/OR_6 MV:S3_-@AV%')0_S$MC#TTA-#H$$:[ EB'BJ" < &88BXW]#O6K8/D=\NGMB( M C_\A$+X'*&?/27IM:V9;HR2/=Z]KQ;+P,!C1ZQ HN4E$-<$J4Y!$;7'=A. M@'T8(78I"!H',$"0+(8$#$,"AD-]"];BLH(684(\9PY C&&P&L2&.T89_WJ^ MQ3!J!H,] 3KN=TJPD6"C#_9$B]%%$^FLPL0Z[8%&$CG+:Y0 C.[#L]"QHS$8 ME$"BVY:$A!())?J $K)!"2(")"@K!./",HVHYJ9N0R":\-?S.H:"$E"@D<!]J^YTZB4>AS *> MPJ3,29G[:7>+AIF("D25IXP1+SSV' =OO=1NHKFGKVEW#\1#!_A4)%5/JMZ' ML M@)!+ C2-%DG%ILPE['I>7B4DPPXJ( F[Y3[M728PU0N,"RAVQ 7.6]-;N!3! MKC&>:TTEIP:BNJK(:]=UYF NE82-C$1BAB7&.,% '.2JXD$;H>_R84 MWZ?@L&O'8ABQ$8IDZEU(J#$@U-@1)#!M9CFI\!^DL(+:2VT((54 U4,#I>VZ M27I\($&X['909 *)!!)] G:@ 2C '!!+80,"\*=4ZB:V<05(V8?D.C:Y1@& M2 0/;>3-T\?3N5 ,5)_4?*6CR\$>ZGB(!BZ0\C^&':<@1*9BR;&9!OW3\9U4&@- &I(U;<*ASS!BP0YPR$GBS*;% M>;\ZBUWZ)2J-&I:D2F$;W7P/#)(<."E=W)D'@0,=&_8A4 M&J%QE$PEC6YY5.4LNNI-ML?1]4_C#S/4,2"X*3TR2G%.M<3A'%="4V\K"##. M2[@/<-!.\*2CK,/;W[Z?;'.9EWE&CI-4;[B!/@#'1\(&^!! M"AMI'%604"H=P(C0FF)),<2Z=GS&$?8X(0"_#$UC/R?#OW(AQ!Z+TENC9B00 MM"/BX(9S7B@%C;<,*LT\0P KP3?15FJ[;D$?"^( "DY)0IR$. EQ=D(4(R=J,F!+-2OZG,-!7XXZY98.\%/@I\1PP\"LM5_&_"'?JZ(,B>>I*+MQ$[;7XMSCU9IL>3Y= M?,E69]>S;/G#$T5CS%P@1_OB:??3[J?=/\X73[N?=C_M_G&^>-K]XV&U,N%S MT]7H:#$.+&*BK>%A5C%AN9)"(\\X0%(37)/?(P?89\[L1W.PIMQE0D#JNDS3W1 M9M)H,P;* 2G">8TE@D0@;7U=8&S=7C-R=B*F'84V$R8['9Z5M#EIF-VLH MZK#TU!@C.69""&R0C\,LRL,:&M5UF_8>ZCV,^CF.4*?$5$G3DZ8??FZ+%O$< MQ0IKAY!@)BB\P]3:BG]!<&&0-(*0*!0BM";0=>PRC@ 5,TM3;A LCQ 7>X *E%$($C+64V.!P M2 5U32%+!>G:X1@%+A#6[4B:A L)%_KI5\B&#LUR0#AW 'ECJ'<\F!.TID.C MP0-Y1;]B&*$)2I(QD4!C0*"Q&T9PV/"5&6$U1)933%2P)P) R-K),%RSKN=9 MC \CB'@9MHZ$$0DC7A(C<(,1%CG-#?M_[+UY<^-&EB_Z51!UN^?9$2IU[HM[ M;D?D.K?N<]L>5TU,S/MG@J*@$ML4J>92RWSZEPD0!"2J2EQ "033X7:+&X#, M/+]?GBW/L=2I\+:6@H!UVSQF$'I%@^,T.(*UW.RF&< MM(3N(7U+8/.ZQ!\ @!.K - (6>4D"JI!!6QEF#]& [P^ 1N12Y!PG7#="5S+ M1N5@X;QW5D.(A9:.$BQ(E9_(,&];R>\=KBEKM69YPG4'<'UZ#2GWU-P%%'6C M.*DU,P0%(!MM%<'$K:,& IG6&\7M202G8?E#!-MU#W:U3V7J<]MG6MF213!O ML(AS@F L%2($8@>=EA6+6(1WL?^/:2:<"(M@VFX3RL0BB44ZRR*T9A&&N,2, M&$NEII9#@LC*V>"LU>WW$^@WBS#4;ENEKK+(F?;,;C4HT9<>)OL:1*(F(2!$ M>%/'GMDJA[[Q+J9I&9*G8=RK[EEF%!% M. =6:P2JE% *O&S[0'NO>$=*V&K>1N*=Q#LGR3M[&EZR4>J.*$6H % ["H77 MG@N[RDV'AABF7]_P.@W'3S!?4T/;Q$F)D[:DH$8Y/L.(!=@9A@R#G#KEE*R* M^W"HVLYVZRT%P0M(1*OUNQ())1+J,PF)FH0($]1 C)5'6A !,8>VTH."PK1+ MZ< C&62G0D((MYM]>V(DE'IKG^NPSVBH:87[/M2TPGT?:EKAO@\UK7#?AWJ. M*[R7@KV=88M91Y//?LF7L^E\.,HGPSSUTDX]-=/JI]5/JY]6/ZU^6OVT^FGU MSWCUSZ IT.QIPWL[-&-0U_4&T%",(6'("$*9421@>-4CU'N_2ZF>;9*2>H)F M),BE3'!.<.X$G%$-9R$=)%AI9CQ3@B@!T>JL+;/6_0$SA0G."Q'A] $]BZ#?4MLT[IJ MIC-(26V5\U!H!RG"R*_+7$G;=H^^7F(;XU0Y,V&[(]AN5+J6G#'FK 0<<"HP MT[2J="T]$G:7UCCMZ^4G@FTH6RU_>2*9\[WL[&V^WET-QHM7\O#_@'YLQ;U_ M0HUZ]C0]"*Q="XI!)9@5L7\HA)AY!LJBWLY;R>DN%+;5">J5B)RX9X&T6R:O M<]UZ4E"Z7T2Q)2\T.GH)1"T53#/BJ7$($8YP%4&P1M.VCS7W@A<@;-?CF(@A M$4,GB('6Q,"XTH(1JHW&3!$0[!Q8*@S"*TQV:1F\U5'C7A #8C)I#(D83H@8 M]C4M6.T=@8XB*2V@%!#IL5->Z%*%X KPG:*6K9L6I^$<812_3(G*1!N)-EY2 MGQ!U,R'!K8 8&6<L\3YG*7X_[[>S_(OZ21% M9\P>VDCF(H@B'][P1'.FF?! VRKA Q&H6C9[5K)PVOX1S%KEILXJ*N>DCW0/ MW%MBN9&\)8!B4E/*B * @$=JDOO8UQT@LL<]IJ%=>$Y83E_;'< M2-82TE%N;/B'>B80,L_0/*6J68 MP]8:PJ77,JC>5;J"%+SM1A"[@/LTW ,$TW1^(D&]&]LV@W5O32P1M1IAB[SD M2!DM *@2%#T#;;<)[Q^R*6BWOV9"=D+V_LC&-;*-%)!#X$RPI0.>L2#(53Y] MI&#;K;O[AVQ&>V)JI[,3?RL:RV?-2JGG$P[<4_]GK.82SXA5#G(-$#:*&84A MKLH780O;UO^+U6HNUFF;^9+W/#28$@CZQ1A;$H2H6]9ZZ*CB5AD!#6+6<")E MY0RD ,.L3 M$(KNXKL\GE5R&KX.B2])F_2RKYQVEWY>$GF)GEZ=GK9D(U(WB552&R8(]R#\ M'W>,8;5.3&2 M1U)Z34;B7:5G<1&B8W.@8U8S49<,>7$F&,[ MHA 0U^GA3C"M(/( <&$!MX2PRE?#D6^[X%5_B()*> D2422BZ#-1X)HHD#,, M"6T(-(HAXRSBNBI8 ;2'+1LN_2$**>0Q[)1$%(DHNFN+"%KWV)-28&JL-E S MJP&'$+'*Y0$LWN4$VE%LD=/P=L +2MKM!Y"(Y,AC_];.^^V1]Y5%MB0-7I>3 M4,@QPIPC%B!))'64TBJSU5'-7]LN.1G2$*#5 VZ)-!)I=(LT1'W6'7-IK = M4.V8%M);OFH8"(V5X-5ME%,A#8[!&3A!=PN?="'=;56>BH8OOI0YD^:CXRF0 M22:23"29Z,I\I#E(,I%D(LE$DHDD$SO-QX&Y7)AU-)?KW=W=/7GPZ4 M@AZDR/9]?&DM^S.^M);]&5]:R_Z,+ZUE?\9W-FN9*EW][<-@O/B?O5I7/'6U M[C2S.*'36OOE,E'8:-O%',>>,(NH%9XC;!6U5821$M/VT?9":$X[_9%CD6KH MI$.?)T03V[$" G49/NNHP0#AP (D_(MIE:P46 %PLLNASFV2E7K "D2P=D]/ M)%9(K- %5D U*RBL!<*(:< TI)H[0U')"D13MU,9G&VRD7K "A""5AMO)%9( MK-!)DP*1N@ ?%0@(J!U2@#"@M%&4E)G.QF''VCX>L3U-G$BVHDSV1>*,4^*, M+2F"U07U*!(,"6P$M\XK:;%"<-7#BSCNVBYAU3>*X#C5^4X,T3^&$#5#2, P M() R B'SA E3^R6Q;KU1>-\8 K5[L+)S!'$^/<++AB)UUM&1:]5UCSOVM$@P MI(WVOX0PASPFA',%M2Z:XYH% R!2VO:L0H)$@'[)33<'] V7(7HT0IB5(ZJX3( MNC2=!P 3!+C%" (L+)JU8M96*=IV]5O^\L@A+:;N)$()!%(5PF$P)I +," M&,>E$LZ%\Y-^1[] MXHHMJ8'!VGL*N:7 22P@(!YQ01A>NSX3 M<6V=<0 [I=$J;11K8%S;;0+[X;EX1!Q8DDN6B",1Q\D0QY8\ >O"^DAC[*A! MA@O(.0.& %7I% [NQ!-',#=.@R<@E,GV2#S1/Y[ -4] (KB$ "@&.;14@4 6 MZZ0N!G;AB2/8'J?!$^DLRBL50%O5RQ+WW:E\W*]AG]%0TPKW?:AIA?L^U+3" M?1]J6N&^#_4<5_A824:=[3%19,4=.5GQA,SV/>,"'-291X!XJ9U WCO-(/$8 M6%ME'DF\T^&LK4]6/#2KYZ<=393BDKY@0F/WK/RCC>BL?(7](:4M.0C5>0S8 M.X^HEX!8AHCR6EM2E;3AN\4FMSZ;T2L.@A*VZTI,))1(Z!Q(B-0D9(4% '.K M,?:$.@^5U*4BY*T00![C?$>O2 @1_J)'2Q,))1+J-@GM:YXQT*P'2K334F ' ML"#*8%#6 W4NV&D:=L4\.Y& *^3M)F8DBDH4==(4M24C\3KQ0P@MD*>(>V&, M]][9JHAY("2G=G$8'=58.Q%&PB(Q4G? EACI5!A)UHR$-?!2(!"T).",080! MO"KM$6RWXYS,[S$C@7/W)1U80KDEJFD]=K82^X.7$!VWO$=KY:(?&EY_.N*X M3\W %(URKM@0"(3W1EA#E( ,*EV1)PNB M)[4#THZI0_TBJ9YRTI841.OBCAP:X"2R'#BJC4900E6%_XBA>_;4?"D*@A<$ MDG:KD"0*2A24*.CH%-2H+XN"WH.8Y I*)KV5@K&ROJQ'VF.[BYN=O3P%@0M( MCNG83A1TUA2TNF;\QO$*['7[J\%X M,:CF;IY=Y9/\9K3(K[.;V?0NO!\S*@(3S:-P+F[S\,X\GWW*(YEE^9?[?!B_ M>U]F7H0/%\M9^.[T)AO_!'9;Y..OV7Z/5^X'?WIF0Z"-QA2,4DH\@-@; M[ %E%-IU0A[7;1]ZT(XJOEW&""J'ZF@^"- 5<76KSN%/^-,X>#2PXK^WL^H^]X./^=NK63[XX^W@)JA"/PW&GP=?Y^%I M_G([VV)41YK^>DH;4_Q@!;[EOWO,">^'MX'TQOFO-Q4[^,"$[DNA]HU-@.XT M7&^N)M<_3R;@KGBR_?Y M."^@]!;%8U:*0,&HP%YJ"ORJ=IR2##+_MC[_X!%6& 'AF%4B:&D6"5B1FS2$ MO,GR@.C[J+#-EOF;8OA-D7SB[LH9R+G"07.&6@N H%@U,%9*$B'?XC=M@ZUQ MM0?[*WBTO<;7S=M-(D6-']P0@M(B+=3%;)B/QZM/__<;\*9X'41D6+U^0L(^ MC.["EO=+_CG[?1J8]/'3?AY=+V[#GV&<*VUY.!V/!_?S_*?JCXT!O]E,EX/T MS1/9=*O'*>^!Q9__^F9#L2\_0]_Y"'[[LST_ JU?\;1N]L02G6W/LS3^-/YS M'O_6991>8RX:&\\PCSZIPTS1)S3!J"$EP4B"\91@\"0823">$@SV@J79NGFZ MY(EYJ>W"[-VD]+4TO2<[0.@<#O@]BYT>3\+9#CRM?EK]7UK(_XSN;M3R6"0F[:4.^^=M_3(HDC"('8)ZTQ>.B^NAU-XYZHN>YE3ZQ MD@P,"91*,IQ,8[-$1"=/1'WCG>UH!@.8RBXDFDDTDVCFJ#33:.Z02BMTG68. MK'?767/2+6?3^WWJW?6 /K>N'+K/6#MI06':. GLF706&!I,*.(1$P*LCD2( M2#FX;0LJ?EI*6VN'X_ %8_@2MD@\G55C$MQ.8$?G=4Z^P$!08PGU&&NFXBYN MJI9Q!,/6#8>CH M+<,D2NA*Z.H$N6:-+B6![*ZL5)I0[PV0\W5=Z_Z(";=K6 MEX^"+M2R;7Y"NO&)QV#^[R!\/_DB]N.?$RJSOZ>631"M*U$88RFSR@LNM84: M:+&*4V#MO-RE;>-.<8K_^UL;9>XO".#)?Y@P>T*8W1*BI*[NKIR2TGMH!*0X MMNLA#E3.-\")/Y:/OR6(8BS;;:Z<()H@V@6(LAJBR!GA4( CL SI[VK^FE) M+ZS;LWS'BT$449S.W=?W@0CQ]*9VF$LX6710 @Q=M5]Q=%>., MCJCV#]W;@9E"L08S,9Y[#H2SU#. E0(:5PH'-FZ7=GE;E\D]+IC1A4#R19O6 M)3 G,+\>F'$-9BH)YI )BA4WTFJU3N(3@DF^2Z1[ZVJPQP8SD^(\P'Q>-0(. MZD#98S?(#K*+VJGP?=(G/YXK\=S9U,D][3#*:[;'7%#I!'/, R*0UU"7N91. M.^]V4MVJ.I"'\S6\(!(?D;!W6.,34C;6M,;] M'VM:X_Z/]2S7>*_-ZD7UZX,5J]@AY.TXM@C)!D6/D%>J>H=>ONI=GPVA;DIK MIZS!'@\\K7Y:_7->_;XF@1Y:NC(J^9'D96LP]/>"[K]TB:KM%,D49Q$)YXJGT#M'PUXJI(+#D*';+$7$4M"+" M4L&;A-;>H35 LMY;-=30*PX44T #HK$H?8(>&*>Q.HH5< 2TP@O!2+N)?9U# M:U]C*ON6T#LG$NH>U^RIV$M:E_*A@7>@%H1IYK$BC.$J19@I:-U&M:U6 Q*M MU/.! ERB/C@@$M:ZC+4MH<7Q&EI0." <-89C"'A"FFU+EJA-FM-MNKD;P=: M%/>C)&Z"5@^@)6MH<2<1!0@Y)YGPB&.@:>TX-_N$T;=WG+<"+0G[$4,_.Z]Y M>R7HDF6_1:&3$[+\]]/&.4!UL03FE(0"X6#X&RA-K*K)*VVO MCP,O&!#M>MWW%9O.JB O"H3$%J_.%EN2 ZE/\P*/L1#.*J\,]4ARX7AE3P A M-JKNMF)/O @Y<)3(H3MRG\CA5,B!-0J5.">LQ]0P2KPEVC /UR6YM=Y' M(GH15Y^FQV$%1VW'&B'CGIL.^Y3L_4@X(V4 MJJ*=,&6<&(B "73M*L9FFKG];+T6.%=<4,):#:D\MYPGHG>U@[_$/YU+'>\\ MW6S)+HC5+5J,LY(B91A@ "))/5]YR+DRVN]YPJ05=B&B7=]W8I?$+HE=CL\N MI&:7P"U(2FRT-0@;AHT'ZV.L0K*-LIC;69NML MD_#S8I3 +_[(87(WSZOTV MKMT8S$:YFJ:DDH:DUA&[8ORC26"6Q4]OBW?J>XK=1+/\^B_+Z$F89W>#K]ED MNLC"';/K99XMIEEAI(?;7^XW /'D Y\W/T+ -&B !#\,#>7@[0#R^/9X.!P7>IS?EUY;S(.KYK$_S MB@Z7_7([NH[?L(IODX3_QO6'X=# * MMPL"._NZNL*CZ8V,%4EQ-%D.5I15%3AC"'CT96_/=V5MWG?O Q?WLURP=_O!W<+/+93X/QY\'7>7B: MO]S.5L,:%)O/W'H.J2.&<^HIX%HQ2CT"&B#%%04J_F:P]7P^W?*S_E<%AL2$^LR"_319Y!^5/VKP]$ZML5]A_NWO^^',S".HV_^M%D M,!F&)W@W*??@(*V^Q=(*Y"61D"N)?;B'6%DA M2C%'P-OZA!G$B! G)07,6X\L=8)5M6J=QZY4&0(Z\FNUV/D^\$V6!P7B/F[1 MLV7^YF_E;P.PAX)H)3C4K#I80$#4 MTKXWI<_=9V-*__41@^TC#_"P948/M;$'VQ!XI)[$UTUH3N(:C!^"$Y2Z=Z%D M!18?CU>?_N\WX$WQ.DC$L'K]!%P_C.[";OM+_CG[?7HWV+"V/H^N%[?AS\ ) M*S4S0'D\N)_G/U5__/6Q1OEF,Q8 ^9LG0@6KQRGO0=F?__IF0^-=W7^OCT3; M%TSW^L:OGEC4[C12^[;!LX>>]\36%0DU]93[;ES\V0)WKRL6PT"V^:QUP?#3 MY6QQFT0CB<:&:'RX'&(_&R;[[M@$I- M+ON7>-AZYM$W)VN%J,+D/%J X:CY.@%V-1C!". ,,&D 88IQYM2I-BS1P>+=^O;@M1L. 76@+_+:+ =1B,7DK72=<3FE/?L$UOQ"CG.$^L(M$4DLA+*WK!SN-'O-+E)=?;_YM.KV> MJ\GU^WSV:33,Y^_#O8_IYX(7$,E6K<+.:D,)4"<(*%J?]:30 2"==]QH2:T' M1))JPR;6;I@@.P*J)3=+ !1%"5 )4!T%%*\/(!DK"1+6:PB0D5C'1-#*IB?$ M;'@I=P142U8^O$"87.($J 2H3@)*-@!%.0-(844X4-R3\#]=J7R.B/5A9@0VZNJMI=RMA/R8 M1BZ^ (*FAE4)DOV')$%K2'JM@H:/B7&(0LV=@@I7D(S-*O:#9$MF,KK@6%S" M!,D$R;Y#DL&ZIQR45$!%$"76.Q ,!*4K%Q:W:"/3<3M(MF1H!TA2]C(ICPF2 M"9*O"4E10Q)9"YSES%IA'78*8&ZK7=+HS3#-=I!LR51'%Z3M*H*=@^3KA7P? M7//9RCM[FO-J^,_E:)9?9Z/)V_O9=)C/Y]DLG^>#V?"VJ&MRG7_*Q].BVLDK M&?IH?T/_G&BQ+^PG01VD-L@X@ FD!E%OG04$^XK]J$>T8K]Q?(25)+^;_%;* M\>\K,5:3:UL+\5$->213+ZV$JX[B"C5BU80[9X@PEBA*O8%8K;4*Q3%K"U,8]*.15H)5#V'5*)DIF-02"L>\T]X:(P20%:RXEJHM6+46NF:(M.IW3LA* MR&H/68PU^B(AIB1B6'-C*$,.RG4Q6N2%;PM9^QK&_Y//IM>#^6U<0H$@^FL? M0-7!\/7CT;^,C1QK>6:CN_O!:%96_0P6\F*V'"Z6LW#SLO[GM.@9.;_/8[6_ M;'@[F'U,'2-WIK"[\!SCO/\N/BEA,W&42HUPL'0!(RPHXE451JR-)AOMV7]O M"M_[?+$8%YV; KN]6XMH8+Y/HWFX[5$#UX&$+WFOO7\)K0FM,H< UN5 A 24 M XM%H8"H $3:R5?42:. ->6S&C2;N)W0FM"ZRNA]8=GX(KJD^&62Q.SR DT M'HI@E$-9G7,"!JHGSE$>#-==S/-YF*SPWO?#;"TEAVTK +5$'R(!1SI$_&/" M_?GB_AG8TWJ75H)B"XBTPG JH5*6FGJ7UNH(L&\IJ$[9RYRP[KA;X26\!P=[ M!MY-AM.[/+O*PWKFV:A\M1A\22>JS\1'"0&G=7L+*(@55!KN/3%48$]E=;X& M8;R1JU-*S\_3^=S/IG=F6O1$"(->Y? $GM&%8)7?^Q#%ZN^CR32LRM=WL3YJ MH*S(3P^NXOZY#!__/5_<3L,GG\)7(G,=U0L@,>S'<9T$T#X"5))&%$$3RIAQ M# +B),:T3CE73FXX)H@FA[$(6P<5#+8&2Y-Y0H SRU M6KKJC"K WF^DH+\V1%L*Q0=\MNE(3_A,^&P1G[C&)Y160V M1U8:"2%58ET, MFUM&NX;/U@ZE8T;[ =$.1O7;LL,?6-XOG*6.TW'T@]BR#^[)9$2L-%40'GM M8V:[=$Y09GU@%5ZCI-D(XJXYL?5N1Z=3_*;T>'9[-O$'Z"0+^.23 &(A/!N M(_P9@(L:X(93;K$W3DM!D54!Y>L4>TGHQO'V70#>UB%WPE/5B83+,\!EHU(\ MY!(1RCG3ECC /$!RG6V'E-G(MML%EVV==.>XU8)R"9<)EYW$)8(U+JDT%#GI MC.%<<6(L0KY2B(G:[+*U"R[;<@)(T?/]LD>A^5]BRG[I%OAA/)W/?\QN9M.[ MJO-\>)1LNG9!)4?F>3@R$:EC@4J'G5_$$E1":VL5XIHP:;SGU!J-P>Z.S/"- M\3+.PV_367Q#+1:ST=5R,;@:YQ^FOTPG4?9FT_$X?*7R;1Z[=CI,Y]$3&KN* M1H8;[C F,0<$(A> J1$D&!5H%(8(HO<(*[2&QM:"\$#BE">3T-A5[S02=6U& M'#1PXH.I'/"'C?:*0%[ 47'*+-LC"M\:'%M/KF\Y>ZVW/NR$ZDZB^ON@Q@ W M#JXAX(#4RD:WES'*8%V VB+"-'2O".K6HO20\5;KT77<$N__V?MOF/'7H_G* MDL^O#S/DDZOQ+%R-&-55Y5PP_#FBVC#'(!4:(DT+(G0::>N>(4+;$+V:"H.< M_GKS8?#EJ.7ETF'[!-4S@"JI"]4QX2'E4$&*!,>$<.1+OX!W# ?KI'6HMM7- MGJ:C]@FK?<#J,UX#W"C2I113PEO(K.+,8N 5ETQ: "#F/FCFK8.U=5^ >)FX M>V]]! GU/4'],Z 7]0Y-E :648,0D(1*9XGF!>BQ1L0<09ENZY@]2(7K3S:6 MG]R7Y^&^)+".2>A@LT/*"-#":>;$(^TIV(CJ/8.@]CJ2$YFJ4"<$==7$ M)?3!J0XF.(4<(!Y XW'8CJI-R%.ZZR;4?J4XV:K?J;>&:D)B)Y'X#!!YO9=Q MY1VTDAH*'#<(*VI)!40@--X1B*T%H!'D_4BY3 'H\OMN,)N$F\R?SR+/WF97 M@_EHF/QFR6_V#0*3O%$L3DFM#>/0:D69,=H6?C,OD;%([I%B]UL^TU'^WM\. M9OF6-F_XS>KK-=NA-=F![Y/=)4P-DA-J>X]:"NL0%Q$: 6L1TM929[CP#A2H M5=H:A3:J2;>!VDT[^S#4@I1%DE#; ]0^8[937%=F95@2YSWT4%I*@(<6P@*V MVBE ^1['2YZ'[:9M_RQLMS'QP25ZD;A5;TW_A/^>X/\9^--&]SB-G//& J@Y M=A8S05T!?\L\AN0HNO:F1R'IVN<1K7[28_"-A/4#? ;G1%?]8271",^W@>)["2QP*+S492NV3.'-T7T,N&EPER/80< Z"10V* "Z9[T >L MA]PH"J/Y#@%2#L!O%7]J"W+M&O+@$J33Y ET';6^6:.TD[5&8>JX #@8W]H0 MHEB!.L* E_ 9I]FAJ#N:'0[:S!7OK;F=X-M)^#Z#7@(:@2I/D1;,.00L!@8K MB KT,NP\91N1]G;1VZX9'4#;BT2S$PC.MVY&W\?VZG'A5P9'BK4G_]_W*(S5 M[G] &2%48P^)5@)K[R6H$E\UYAL*2"5Z%=44')4BZBDVE[#9#C9%HR>;,$H9 MX8PWT%G*O7>N2N33%F_42=\>FVW'S6&JR9RPV0-L/F.Y\T;)*(R- %(" XWU MFA(#V;IA(M%HXW#G]N \7G3\12HT]]9<3RCO" M>,IMU;:8>&CV!WGK,? V'=[=VX'['@/_5M;\]6B\7.37R;EX'LY%3AK=6*QG M5EDAF).28\$?MU\:W+-@ZW3Z>@); EN;MG.C,)(D@ AMD8": .:X ML$ 5:/,0((">2>_:%VVGD77>6_,YP;:3L/T^:@40#874"L:)82*V[L2*A2TS MHE8"11&C1U)(.YTLWG%[^$R/H'\[H7Q_'WAOI =B(6:\6< M&ZQED9L7M!?DI3\T(_;8IO@QT]"[YR!,^$WXC?BE=55$;@6FD C+-&?1BC<$ M%_BEG!%L#BJ_^O+6?0G!"<'==!2(1BDKS!0D"F M$ .*<:XY+R#,G"<" M'9I@^WHN@U83Y%,H/G'!B7+!,U0@Z]U5; XF -] H#+%4Y6XN!/& P&-3 M0:>S[;NWF_/\ MH!7KI$A\"@Z>-:1PHR -DDXA#[!TE@+&,=.KZK7*22]%-- MD#I)2#UC1DM:'_)",3PG*-8: ^TT$$SDZ" M\QEL\F8!-J,0X$HC)H,Q"Y0BLL*FY*W$ "-$FT262 9)S&>ICCT5*P[)H4_[6/>,M.[N^GD_6(Z M_&,M>!4;F<'\]K<@@P?8P>]^\5N[WBA[F9-PG=7H$US/ ZZH+E7C$1: .:2, M,-H"0B" E5E-#$>MP74[&SO!-<$UP?417'%]^$LRZ[D42!H'G9'2$+GNZ(G" MR];@NIWYGN":X)K@^@BNM(9KV%RMX M[F3NOZ K[;84,[J3_;X74L]HJ&M2PD=P('9WV&-J.KO.9]6(X/V7;#X=CZZS_P6*?UXX44[LID6+IY7HH+#R?33(5YB*U[*B MGH/"*XO%, \&R*QUP?#3Y6QQFT0CB<:&:'RX':T'OF PN_YIWRRW"=OHP>R_W(98^TLUI\.&,:K MN64R7]]^9D/%H MDK]=A>$@ G]N7(#=+][\[0<2C\,M[U,&7O\S\+;D-((;?9.Q#_]3S@,!*;;( M4%R[%YY*N)LO?KWYM^GT>JXFU^_SV:?1,)^_GXZ?2K-KS>$ +Z!HU^'0O?2Z MA,6SQ")##2Q:IBFEPH6/K(HEW==-DK"%\D LMN0C"%AD^++?J:X)BV>)15'K M^L93ZZ1A1@L!N/!J79!(.KGF[#8-RR2Q@EI280R MRCFDK$)*6(&M79_A0O)0';4E2UQ2?MEFVZ#N(?'U2A$>+'*K4I63CUG^Y3Z? MS%_-&(<_'F*/GQ.EG2QSH?HXF]-:,$, -X(J 8DR&%;'V>+9\;EHQ5=,$9OA0) M-PDWG.6Y O MZM%Y<,UC50A4PW\N1[/\.AM-WM[/IL-\/L]F^3P?S(:WV6!R'<3B4SZ>WM^% M>[Z288I2E#AYX)K\2"&I]0I","4(8VR],%X0)%!EQ_KP0<6/XWC+E:R_F_Q6 M2OKO*T%7DVM;B_E1\]-!JV9M]SQQ"9%GB.7,?+G M\WR1C>[N!Z-9%):+:.(O9LOA8CD+-[\H#/WIXC:V![@/JSX89\/;P>SCJ\6B M:0I$]]G!264=B#; "\6]A099'-01@XVHN) M-$,[/>FY+[/%XMQ'D4ZL.&[ MM7P'IOPTFL?VG\>TY04&K:;5=%8A29#J/J08K&/42 N.' /06QH02F$U2XE 3T&I%J* M;8/+-OO0)T E0.T/*,H;:I^41OG8P 8)@HS PE2 @H@_48K@8$"U9 U#"/M1 M8*B#(>_6S_^_FPRG=WEVE8<%S;-1^6HQ^%);MLDQ=^:..=:H?&0I=1 A(2#V M EAFM5VSDJ-V8YLOQ>OGZ7SN9],[$VX_FBS#&%=9.(&)="%YY?<^1+G[^V@R M#:OS]5VLDQA(+3+8@ZNX?R[#QW_/%[?3\,FG\)7(;2>#N'[A) ]P 6:054H0QC:!CU*W '17T MS0-7KPWNUF+NK3K"NX?L$SZR_>X)-\(+!\AQ"I#WV5/*&R?G, (*4PTE ))Q M@07BM,JG%7(SFKH >P>K G63 $$"< ML\A9BHPUZSH'6*F-.@>[H*>M#'292ATDZ'0#.@+0-72 U\(H(;3CQB#.B?%U MB(Z9C>)&NT"GK8/;A*3P=L).1["#:NP80I6E%GI,/1)>8XO6WF:OK#H$.VW% ML7E/4D/.(8[]2\S?+LW.'\;3^?S'[&8VO2NDHW1O9-.U?R.YT<[&C?;#,XQ$ M0:-;%Q.2*,$5Y=@!A*CW3%J @]@8.SN?K3PC?$RCONWZ2R^H1:+V>AJN1A< MC?,/TU^FDRB=L^EX'+Y2N=8.MD+G80[#>\^8HY2"EZD#O"GKA\A&.USQ8R* MLR& 9_#/:_Q["1ET1(N@DCA'E8D.]8A_HCTP;J.IUPOBOZU0=S &4J@[H;AW M*!:-LIU2(LNQ98(9P[&@(D WHEAP&PR+C4+\+XCBUJ+: -"$XX3C$\3Q,^JX M!#60"9<6:N@4\U( X+B@I "RUMP"LD?.2FM WL6_L(TZ+EX(SJ>BB[]>Y/NE MW!+7H_G*,Y%?'^:8."?".UU>P[31.QA01S!B\4R/0E"90'&1UPPSWJ%G,NAM M0W!J9@M2]NO-A\&7EW$>M-P__%18*2'Q%)#X#!!I XC2>^,DUM J$6!( "W] M?980AK^5-G( $-MJX@53(DG"4T?PQ.M"HT)PS0&#U!N(O=+2*UC@R2D8+'+? M.I[:"I'WHP5O@M,IP.DY15'6>$(JEE%@5 !NO!&$"F4*/'F/A%"@=3RU;=8B MVFKUGU/1$\\RVIY\>,F'5U 8!HUS9U0&70!@2*A%!#*#+%_W-*%,;*@$O\VF M-Z-%I+ 7"H,SREK=_4_>]99 VT_0/H/9QG$RJYEWT,*@>%CLK.$(^.HTA7-Z M5\RV%;JFM.<55A/RSA)YM(YX^=BA0PN"/R6@PWBU3\ M)&'O!+'WG*K*&^%FA8 P "G*B->&0Z'73>.5VCS+\0SXVK:E(02MMM\[>46U M1S%B-YA-P@WGSR>N9V^SJ\%\-$SNOUZZ_S!L'"Z# GBH;?C72Z4)=L!Q)BU$ M" F.Z1Z);+_E,QVEY_WM8)9O:6"'WZR^7K,76I,7V)*\+DF;W'4J%)4@>0J0 M? :1C2-KA".DI8$<.^,(T(PX5B 24^4MWN. R/.(W#2?GT7D=TL=TU0\/"&K M&\@B=:A+:>$E5LYY*;7%@"FM"F01)I14>Y0P>AY9F^;Q8<(YYXA(2RG& ED9:E&4DZ#4;G15KX-:&T:OZVHD> 2G*,:>0[QY"=- MX&\D21]@!"<_7B_]>%""1ET)AXVCG@H!K?5"BQ7?L5CH5#RCI'\_:^;5#&AP M"5_$ 7\JE)APWD^24X%<$4S/2R MD7%ZCB[-!+Q3 -XSN),U[K367AAMF?$V* Z.V:I%O?"0J@V%87O%4ZM,/L56;90>W!X_*0*6@+TU#*OB'-,,@VB'TYY;+0">Y1 #-QE2XD[]23P MD_>_)7SW$]_/P%O4\';6*"8),EX:18A2"!59KQH:(9'[1ON@0^'=Z8SR% Y+ M,.T"3 FH4TT@\49*K(D3!'+LG2I3330RC!IR))BV;KB_2+>/!-,$TY?4EDFC MV)#A2&,#63#W)>6:XK"U%CC%1CIM]^C?L0U.3R/7_>2UY1Y'JY_)==_?0W!. MU':Z#$;J5KS:(^DI\I##8/%+ZJ@J&8PHB(0Z-'?]M2S_,_5U)GB> CR?02>K MT6FYDY8)! 76TG(+C(4%.IG&A&X61FL;G9U..N^LXI]0=@(H$W4J"3*.6&.4 M, XP0'RPLG&!LJ##8^<.S10_MMU]S%SQA+&$L?T53=JH+408\LQQ[ZQTT"O@ M\,I4]E8S1_2Q078:*=ZGHFB>8U#]<8IWBJ,GS^!#NL.-.+K67$@-J': $"^4 M [+*#@(*;!P6?9P=M.*S$TX,/WG_7T)Q/U'\#(@I;)SMH(90[!TC!$$KI)!\ MG2,+^$$@[G26>0JV)3!V HR\CK5I:3A@4EH/A/<0&N-T!48AO3L$C"GRG<"8 MP/BL?MNH>83B04<*L0(48RG#_[0ICSUB30@]"(VGD?]^\OIMC^+;=O1I%+!_ M/<_N!Z/KVE)/CL43=2Q^GX@8K$-DTCCLA8WUF""31'BH?'4.U%JW$< VT[N[ MZ>3]8CK\8RTU%;V8P?SVMR! !UC=[W[QJ3!R M2I :K1+!Y+ 2EG4..PQP/J M+5"N\EQ!1#>,WKT!M9T%G "5 '6"@*+U05'F?"Q,YB$1E#"BJ-9KPQ5QU1Z@ MMK-B$Z 2H$X04(VN[T "9"$@E&#,#:<6>U;M4 HZW!J@MC-$SP]0A>7XE\7@ M:IQ7[Q]X[3 GJ_C^8#4IY2S]LKP+/Q]6=WGTM4)&/H1QO\_'>3&;07NQ GE) M).1*8A\6,I!NX9=0B@4]YBUZL]5EO" L_-2 (@,/&<14=1G(K7@+WV3KA 2U MV/GGZ.':C4>3_.UM7G )1.#/#U I @3KZ1.[0:SZ^O+^.S;^QNWKW]/[Q9N_ M_0!_S+*P5LO[]8KM=O]WD^%X>9W/LUD^SP>SX6TVF%P'"'W*Q]/[NWRR*%[? M#69_Y&%*/UYD\WP\+OZ([P^N[T:3T7P1LSX^Y5G^Y3Z?S//YY4/)/*'I1#\> M,IF9&OYS.9KEU]F[WW[_E\'=_5]M-@RD]#',[VB2+6[S,'U!.*^S?RX'LT4^ MRZ8W6> SD7W.9WEV/PMD- N7SZZ7>;:8%C]0O__]UVP0KSL?10F^W.(F-Z/9 M?/'H'KR\1^/*9OKS_3)=Y!F.=)G=+&?AJ[/B1,)R/B^^#>;SZ7 T M6(15_3P*U_N/R_>7Q:]G>=RU+K.M[[VYSO>SZ:=17+K!>"4H$>S+<<1S>=XD M?JOXZ8=P1S5<-,0 ?E,.3E8,R(%BH.;5-(35"DM1S!.ZR);W8<,:7$_OBYTK MK(8:#J?+23'-[Q>!+@>SZWGV'_?7@T4YW6\!O\CV>8;R5?SN3Z-%&/DP/%50 MI2+Y%MOFV]\#6<_R@KYU*7[SG[)W=X4DA*>)Z_U;)/S)8E ]["_Y(@LZU&AZ M/1J&/R9QC0-%S,L-X.&GX=W9QAV*+^\WGC=_NU_=,-[K_N'E*_P,X[,$$(19 M+B S+01R<1MOD\\^C89Y\96 I8)*B]&5"U1\LT@-@W^=Y.$9?Q@5:/JQVK N ML]\+0,P+68^SL\)4 ;4"&;>#L+]=Y?DD8&ZGBQ9Z,%KF079&=_>#T2RNYT4DG\5L.5PL9VL]HES+^7U0Q]L>L*:XFU(+$!H]N%%6:<<&H89&"O1=^&^3_'V&IPENSH. $!;%8 M[R#.H_%@F/TPNWK_X<=(M=]AUT>/OW[6IS?P>;C-;#!9B^83O%LP_:?I.!#% M8/8U"SI8^'E#_,,S?YP-[AJ43+=CY$W-?1NI6QF7D#TR0"%Z((K[VI,MZ/=1 M0=\8VZ_+6>2&8$R&IPG69!:P-PZ*:5CJY>0Z+T$=9/^/*&9?[ZZFX^SGG_\K MFY9+_4O^.?NOZ>R/K+!$,_@=3-Q/!E+\]W96W>=^\#%_>S7+!W^\ M'=P$(/PT&'\>?)W'1;B=K48U*-9QCF_P%;O"P?JGF, ;+A"F,D> ##K:?C2%9R??.':]/"STMK+F#VZ:S\^.YX.E_.\H@Y/0["_N8)"$J", ;4 M<$R<9119*P&1AEJ&@0+0OJV3#;PEXF";3HGFFC]/.ML\R2$#V=:IL&)?\8A\11O< M^^LD;"'WB_SN*NZBY*(P5"XR-P[[T[10K,9YH3"%?>K=;[\V]JK5/CR:SY?% M7A:VPEUU@6W\B2#,EL@I%&OIHE)C ZQ%,O8#%4H"O2KDZ*U6>./XU_O!./_U MIB#Q( EAG.%%] G.WX5'SZ_?33Z$S7A>WO6A6[$$&(X3A,A_7^>C__XY_S@8 MN[#DBZ_JRVC^W^/QU_\NYTI-HL_P_^2#\>(VFF6S^^DLZAE_+Z;VOU=F&_IVH?)ONO#Y.AR,],T"\LQ M#G\\\F7NN&YESL8\KGP4C^9.>Y%]OAT-;X.XU#KW$:4#H3IZHR!$+/SK$/-. M46PMK:0# +MV-H>5:TI&,&.&T?#Y6+WQ/O#PL:2AL;*39?E&O;)XO;"!(+Z; M_R\O-_/_8RY-',B!*QN6M!S(_Q.6=[DH#)8(^G+%@WJ^.&PY__3,>M;Y(H1P M&=:-.<$4\, @'G>7STNQ<36GA&BAD*[LMA"N[6L[#>(/%.H\>C$6Q\*N] MM_IHM2KAJ?/5-*\WZT=W6<[W%8$]?Q>F,0!@I7S%B1G8;^5V^ M(9>; ='LJ@UEHM(8"BDJ3/3:;[)"X"0O'!_#/+^>UZZ2J)56MOCF-P9'E3M2 MGSWRW#@@M23.*22\H5K[('?*<*><=QMR]]OJ,>-IZ778#,ENYWU#X]SM0@K'0@L;BU%'/&X:U>GT$GHA;7!7!/0!@O-&2D MDYXY"SF"?M.\#H_Z;A(=?A'6X1*YNHL^_2A3C-$-YF'7#7]$3VPASL'\&7PM_=O7529+X=O^RW2E9<6O+&=A)X\!\N(F M85\/^_SSG!^RVR&-(/K7+ MMH.\R*M1$(+03F?7921LL)ZDXCC&V_#6L%R =L+Z>VKF'U:Z]M^+!!0("]^4 M+!3JVMNWF!:HG(Y'10"U7*( L7F)S,4@/.9U\?U9,$ *S)3?68&MJADQ6"QF MHZMED2-5A<@K"%UD82%6EQB7KJ\5I*K X'T1!'V(SQCC'>\+.!LX)8I3J>WC MVE89A$^5TFE) M&7R<^;+:E$OF*B+K)75]0VS64>(&-UQG5^6V#U5]_"[K14PJU_'<8Y@3"Q>T:60] 8E99 M&,,"$P_<;]^,?H5?AW=N=.&X>Z1T=Q>V!WB.!7A*P6C)#R!D9=S M2XDZ)$J1D(9H2J$A/OR?P#AHQ()#J26G8D,C_KTD:T@"8(4\Z(AH*0:&*%P^*I" M3C)+-?END!\$X]8+9J3R CBEB93Q/K$7%PW7$6_!XVR%+FH:'XK,MO%X^KF0 MR<((FN>EK 3MZSK:4>/"8JA2Y*)H1\=#F3.Y39WZGXZE;PT+#\X3D]"XQ8-C M5*#Z_2CBI'S=?(9)9(OQPT0W4)ZK*J=FF(_'JT^+ %U\'<8VK%X_,?$?1G?Y MO(B4_3Z]&VR<+[L;S#Z.)N7C#9:+:?5&>5RM>.?SZ'IQ&[X=YN@],]_K;[T^#/XG8_0?C\[@9OA MK7[V?(&.JA1)N7Y55N7]EZP@[^Q_@>*?7AUPQ,^5W7F%N?@>>>R13OU$^E[3 M'[)+C9HD&/T7#)X$(PG&4X+!]BKZ].WR5L4_IU$0ZO?JY,5W%,@7JA3PS8E< MR5VA#FX(W5'GYPEQ^5,[%= >BLCW9F6OP;=2<.")T6_AH62B48 22_/8AEU)XU/.EM+H32/@V2;IRND@) 8Q6 R"MOJ11*B8*DE67: MZHT&RM\A:99(^B"2ED ^<;+O;$AZ:\?(2?@_?MDIE-:[FH+[F?@"/7$* M,B8E,DQ#3[P607MTVC/AI70;24B[M*O[IAN@!1P+V*HYW%F=J4\.ZM/#5P6G M;S6,6.&)UL?H.&4>:T5Y+&"@@UDF$"KPQ(V$F&RXS [$$]\)3UMU1X/\B M_G=Z3$ \!2!^'X>\<9P5.D,X]LQ!@#SEU%!>X% R+JS9\(H+T6R1:'8RJ66KC,-YD>EX-_C'=)85U?/*\_1%R;9YD6$V M'@VNXBF]>-+^>PIQK$=1'4K),$RI9IU(-1//9YJ)_?*QY$LF?VWWC"GY*Z5R MI.2O)!A[)'\=DN-S0OW9WTT^A6F=QK(YKQ=>*.>KCZD\#R6AF_&&_?Q\@M6E M.HB/!=TTHL$F$L(AK[DDTA*DB! (;P0@=BCO4\GG5[.<;1X^W#C0FP(6NQF$ M%P ^==;J" T]NQFP>&5R/^^H\FO3_EFQ_':DWLC/=%H2[JE#@DDAJ<'&@T#J MF!H''2;?+V]\,*GS1.H'D#I[JK[LV9!ZOZ+0OQ;E*X5>,E;H6(Y[S,Q&0+]M M4DI:UB%:%FDWF:&SI'0FKE#S0,6*0<_VSCP^7%O4"I=]<[9/PE?ZS(0<8F5W M4165I#Y4HQD/-C7%WC@##20 D])=ZA0'A/&-0JR%0#ZJW?-,5?3D+3U&>C=" M\A(>C?)W0$%G%=07W0*ZY!/M#\.?&Z%OQ]^L/F\C@ ,$ BNP)I"%/U2L:&8Q M PA*Q,E1^3NI[ ?P-X1/U<\_)_Y^5=_H8[Y>Y=NAF%S7E227GHW[G,9ZEFM\ M)L;YOTVGUY]'X_%K1ZM/PK;NK*JUG^T, :J-9XJU)%^T:Z6W(L08WF$0IB MCQ7&%#'J8E4)61BXB''EZ"'YG%MQ;+)Q#^%8B=KU47:.8_N8WS.:+ :3CZ.K M<6SD/,D7!\;.NQ<;WU?U:QQ_#XQ$N/#<.>.Y,@I@J@O5#WMFF#A$]7NWGO[2 M69=4P&/1$Z&X51=<9S6]'BAT)TPW6[)+LV,6\TA[ZK!BT@L"J5:N4'H(D#R\ M]U+LDI2? ]B%<7(I^L N9^+6^VT6TVH67XO" OD_EZ/[LC'OX1I0J_/23=5( MUN2%,0,2*"J$%HZ10MJBRR/J-SHM'YZND=>W/ M5Z3="N.8F)XT34$C'A!*$ 1M4JD*7"F8@!0<= M?"VFON:A=%CL".1]VAC*BJ3W2PH$#]H04QSSJ=G!!!.G&4;!NUF#IU/;2I3RX,]DZTDZQ MN[$@Z\(0Q"#-+<< 2\[#_PFHRV"T<%IRJ8Z[,20[X8"-@3%QQ+(0)[\QI -H M9W0X*:UQ_\=])AZ%JCI,L_O%Z?H4SMUMT$G/ &*@/N8&'-+>IG9,6E->[_N,_$ M4O]Y&A\HG]T%VK_ZQC&2UM?\M"WMSBI=>UK2F-26M$8: 6D\0(Y20IT$%$9+ MFD!ME.#K&'O0+78)H]@@6RFZ?K13P@2_3 >39"%WS4(^'?;M&]ENR:U4-HIQ M<:)]=$P*!B#RU(CR&(_E.OR+CL6MR:[=FUM!NU9MYWBUCV=U&C&GWB72[ZOA M\3JSW@K%I*%(>ADXAUJ(BW)5)/QCH3&'U(5YE%G?\- EC:]5C4_*5!7F1+2W M$R:;+;E%UN5&@1086"PP@10R1IVP11=,YJ%D]/"V<=MR2])X]N863&&KF=K= M5VU.VW_7.+O3CV2;=("GFVG9>ZJ>I-' SQ-%& * L& $$\J""HH+U9,)ACG' M;85XDZ?Q6)Y&3EKNE=RO=.U.;35=R0Z2-HR=S0>"ZY*U5 &-M88,"T]< MV""L+\[Q<* -PIR^R/Z0;(>#; >6=H?O6B1_60RNQGGU?BO7#O.]6OQ!.>&- MX8U'D_SM*F4"(O#GQQPA'G%M?-V^C9(OLN%@?IO=SZ:?1M?!'+GZ6EDDDX]9 ME)-/I=DRR\=1(K/%-)LN9]\R8;+/@WDVN ]7^Q($;Y&/OV;5E.S%4']ZAJ)( MXZ@A-]1S0Z2RX4,O '1"68L9LU)JO%&7Q(1A_[8:M?[Z'X$-WDU^K4:NU@-_ M&K^/V,F6VNM_?; M8)6"30]B%J9J'/YXA-@=Y_3BN(M!&ZT%'6.46FR =-;% M['_NRL4PG&E_],7@;2T&/N)BQ%JQQUV0NK J8=X I123X6.AL%$5.CQ%GP::-._[!=7PB=(JJR.$E'.H K4BZYSEV%,C?;DJU#EG-MPT M;:_*;K2ZS:I(=L+\RNH,$B01M%@RK+F7A#CE %WAA7/)Q+%79C=^W0HOHMM$ MFSW4M;NF6?]G'@:VR&=A:*-)H/E!MI@-)O.5Y9C-\]FGT3#L!(./L[RP,K,? M/KQ7/V:?1XO;K+0*PQP-%MEH'I8Q+EBY7=P,AM&P#KM!,86%.17VA>+B-V'Z MIC?9I\%L-%W.ZWN$GY57O,P^A-^$^ZPVH'G0^\-JST;Q"N$9K^]&D]%\$<7L M4[[^_47V^78TO,T&LSS;PL"I+*%J6;Z_-@?X-KYABI4OX]=_"O,T'@V?X?2L)PAA0PS%QEE%DK01$&AHM)06@?8O>= ]!'_-) M(+QQ*9I7>6VB1O?I8<2^XO5?EG=AZH>/:5W4:I 'C'&(C?$4"FJ!"?\P*830 M5$/,Q9Z)@1\:5/!^A3)5$<&'?';WD.$CPSNW#1VS=_0^N*EJL%#?M4_&1^Z#8UF]YE8=(#]<%R4Y(7!>E>%\,L)B"[ M#L\8:774I/+P8C)=9%%GC]_9X' M&GM>-QXW4'>V,L#_% M/F=K4V4P'"Z#%?3U(FKS^<<@I%]+T^1F,)H%U22?A]N4ZE>X5_Q%S=3S]GW<;TMSH-:$PB?Y?70]A_+ZX_EHQ2= MJX+Y>5?\Z.IKV+VJZ;O,WDT:+]=R,KT/YL)T4FZ*81\IHCF%7^NIP5>S5$Q9 M&$MT?#6WLW*;*LR\Y;BL=%R[PLK)+AQK,7(^OWQ%N0J3,5CI/]4^._\Z#Z., MCQS%8Q8MO,8*Q2UV-AU'0RH/\QA[I,95#N^')0F_"9]?+X?! OQC,OT;C&HDC >?*U$(/PAW#!,\*%2G\+-XQX#AQ6 6O:ZEOAC6Z#)3 M#Y[V;CD/^M'@CSP:S4& "^4J*$ 17V%%CS+S^ZJ@<:31["ZGM?0 S$IVGB\+ M;TAX[]-H.BY1$H::W4X7$0+99%FX4P*?W2^OQJ/Y;&$T^B5'7QO)\ M?X1A1J:3KX'%YM$'Y&H1O'WF9[/"@%R4'Q2:?72ZST9W@8%*VIZ%"\3!E2\# M 9:L5NP3!0,V0=^E:5SQ[^THO\GR+_EP67AOIC?!&(P-8F% MZ%P*;%1_H>*E?'$[&J[=/S?+67&*9Y87X"H<2X%G9^775E9.P.0R7",@<+V+ MKO) 7I.Q/VRU/]6;\2"8K8LR?.-FD_FBS*[ZE\'=_5^S_PJL_C'[^>??(@\% M1%WG]]&#&29SEG\UR*(9/A%]D.I3913 M4*H4/UY^8UH>:P;E@ZW\MM5>&;?_8B=8/RGXZUUXO[RO*+\< M/O>!ZC/Q]O_]UF.MF&$>(#\+#U)ZE JM+LY/Q/C=:+'(\^KN5\7 BT3M^/WI M[%6%]]<@$(\?=#4C\X#=+UE@Q(H^L[O"6S+_]D@N"C(([P3&O"MHL2G"!3&6 M$KCBO1(ZU7V'MX-9D/"*$J+3X]-@-"XH/*Y>^.7G/&C3BZ *3)?%1E1Z.%;/ MM1*0+&A#*\WT,4V4ZFJA)LPCFL)#%4(4]HF"NM>.H?#+N,47*L'J2A^7ZWWP M7>&$>6*-UR+Z"(11J;F_GXYBIXT=81T-B'^L!'P>)BB_#995),KP,)5#[J*, MXT:"F8;1E \5GSHLWMORU=I=']2F.+*2?^(0=GJ:B]5D?!KEGXM?5\(?GK*8 M@O5EUY2T(5YW>6PU,L\+W2T+-D%XJNMEH=95<9MR5>JMY&+UI)7V&Z]8BEMX MFL>#^,8\AOF+F_(R<,-J@M:!L(OZTK4V76XX%3N6XXP7"WI?^&[QFY4'1LC.G)(3TO)<7V1H8=A@5?%@,/,GT]K\W\\KN3;#GY.LK'UZ4]%Y_M M;N5GG0=I#&^NQ>2^B)8.5U16N6DO"U?*.#Y0->QJ\L+PU^;,,$K5(]-X/6L7 MQ0?+21'R*[;U3;/S(3KB]^_S:1C_1:$BQYF=%F055<1R 1\K)!4)E\9W7M[O M"6NU0D$UA#"W^7BM-I;J2BD3>\KS*[N_@ER]JV;5E+-:*$<-G]COU>Q4):1NZ<8>Q"#W.L?[?1FT@U*+@WCP%M(?;GXL M[@+I]>I5*911_-X'@V=62JW[$O23R<<\J+/%^*#$I""4 FX?Q].KP?BI"$I! M'Q_CPTVR8;Q680)B#U/=!<-BVCUG56PIP3H?' 3U)8 DOC+ ER5 M>E/V^RK)Z3M.I14'S%>L72<*K,*E61S&M#2RPR4#XY6QI<&ZHUC\X?HQ\NN+ M\L."2LNTC_(KI67YM(/R"=_@8+FXG3J:E_I.^7##$C3YS4U)K)5U\SU?8*E;K&RVZO:G;:C\9U[M M#7FQ8X:]=KQ\8-9MS-"T*=S/LL3::UUHK[/!71X6Y8\HD&\0@+@]I\QCWE_1 M^[M")RBT(E_=?5^?:F#5^;+6Q4US:=]'KIT6&M>OLX^#R0I%:ZON0\#T]>?! MU_)7\WDAU2<:M*3]R<-Y4;#I"@N%.5,CK=H8PZ:]1DBA<@9TK;PH!=ONAKR8 MB+P&;]RM@R3N*?A5HE^YOU?9?GM>[#+[/]//T4R]R*[RX6 Y+_ S*AQD83G+ ML_=WHT451-I^Q'TM]#ZHN)?,O"W@C;X6BZVNH:?H3"[7V$A M50<2H>8=-VTE"(G44U6J0NX^&]@$K@[.86B3?]^=F7TSV$#,BR'E6ZD)'L_N MSL[.\SQCN6F@5?Q!_0=(KM3.:#PZ)4!8'X18/!;/C2@F[.K "6' 4Z%D(XRN M8#5.T4I@M_4'; C4'KPQ/#\W=KK,(SEX,7?S<1SQR4HU79[M!,&ZHNY1S>U5 MU6*:7'S@1@QSG9>M994HZH,>7%*3U'O>Z0@;?QW2$]N2,C3&(@I^-G]^ DF; M%SX4VB2G1K&>-6">)ZY^R-@9_,S-'LC/$=[N837K"_MI??-YWKIH+<_P9J-W M3J-0KU4KY9+M-/ ?;Z1RD1\H/?7,HO M+5XKQE^JVOK:Z^H8UW;YZ<5J%JQOX\'W)*U1#ON4+R04-0S1_E'U,M_Y./[M M!Z.Y:WTN6%W^-?:-JHH\35R!WS(#;)6U]Y($?& E5;$*Z]5G!M MA^#:HY\&!YWH)SSN73;AJ9+U#Q]4/?+D 3W\NI(8/_P1VO04DJX;UI_.W>FS MJ,HY1(=.>O;=W5EU-YT!-CNJUG;&K[6=2KM:YJFAW;ZN.LY5LVC76LU&\ZIY M5;RN737._-K(-24+\W?6)P-Y^Z:1-\%J,-@,-SSX)LMD56Z:(IU][_;TZ*39 MDG7$MJPC$FBAP>P@%B_8F0P/X9[]-X[K"&J**"-&$9PW?Z1]R 81K) ,),$] M)E>+^K&F!O5)E6,%(P3L-X=TLJ+F"%=SXLR[I,"4TLMZ7O (2+,>LL"HNR_P M=<%F/GL8/[DBU(A%BZSG!T$N;](D%"<$*(X";M4\7T*;W,%(UCYG(RA>D')4 M -!40HG7D4J@4C[ Q >&((V!7R;Y4#1KJ)<970>0@C M0!4I@&%@E+'>=%OH%C8FM[^@('$L8=L(=/L(%*X7^*%HD8_"Y@2=;DOZGQ 3 MY*SLUZMFIY7+FU/NK^!E4&]4L,EK= <@6)CZ)B\$J7\+J,Q%%!ZS8US%RB*R MI$KI.;3#"37C";7%[XI M6"5-Q5H3M4/S7U3=*6H^L-G(QV3*)( )&1$ V_<3%;;%KCASG_".J-T<,(D= M3]T+T#?,M+J?L 6"[0GBGHV0K0@0A8^R!PKWPSE3T+$Y7-U;F#N)V5NML<7P\"J5^Q<8NX[Z$J(EOC@#VF%31D/#[)7 MA'8 C2XG' M$ H!U ]G[8L_%VE1WX1(<8L,%+W0C6-I&CQ.M7WBEA>IQ>F'2:!1='<9(V*V M9LR![M@0:2"!YC(I6C.N85!>#1#QF,XU"4!7G1E,C#JO?D/L"OR@PX,)-!.8[QJ2\Z;!%$\"O%"V&M,3 _VA*P>K.!R/SR^IQ M2%Q#%%H@<\V L"IX7.R'(-[R!26(>#A&0BJ+O1MTDPMYW(F6]QJNQ.Q<&R#( M /+'(^6[\T @L@#.HG2 NU%K0@HO-]'(U6*A4K'+T!VL4;1KCE/; M#D@NK062&W8\6EQ*&RW^^'[\<&\%T\&'S'VI5K-+Y?MRZ;GJN#:?$,6J6ZP7 M_GN\S_"U,UOS#6&R&-]:E=]"/&.U3+=[RV^5.HX6\XIDIW*(5R1O"QJEO>4? MHD<;ED] >061-UC*+6N7@>+F\G,&WR2*3L6.(%L>#HG[-!F.^08 /"V^>8E/ M*=JS4V20[\9/4 14!V9B)*UZ:T[4,=[&C9%G!R131-8;"A+X.70P\Z'N5*J$ M#3TQVFQ]9UADL56QVWQ6MQKM9I8Y(II_@JP MR;U$P]\;"]Q8ZG5T,$ (+UPY+-NZ*RDM=A%^E(A?&J"!=6&E 1ND/00$^':Z M'>6H"+PR$7@LE7\2?HJ&+K5X8(>#GK93EWR:9CWM* #!->R$$$R=/NF@=G#2 MP>^.'6Z!9:31?;2W$KF($D:;.NA$,0]:0_#?P0HBEEK-6FJ\PG3M#YL]=)9( M1;L1P>\$R4F@!E5URC.ZDQ3=2:E#?@0 1'C)&:A%8^N=M-/YG['>,>>^-H%YH5\G\YD M"5#J8/X"7!FP5UB*AEF _6$NZVW\;>GR,54>(SUJ:2X630QS!][Y82!2YYQCEW-OHC+,D3KO;7M-# 7?I*]C>93>&G QOT'(XF< MUE8>DIWO"/A5+-FY:K^2M*T[V>L+''!I94NY#5JU+'5C MD?U3(/+H6 ,3A0'!=J.1W6(,C;8MW!(V?I0-I)\@61K/< S"CXIF]QEIZZ&3 MU,2+3)M"C6,$O4!EW.1<69=<]"5/.^1MSX\^ MFW@V\6SBV<2M33P))6EC>_3VE$#80\Z*UKD-T$FT 7J-9+]RH>+4X5U[C5JC M7"PU]LWUJ]=7N7'IOD5=/43K79HA.QH__Q_FW?'SY__),G%[,' M[^,O4$L#!!0 ( 106$] @B3K&QH !0= ; 9S(V-C R,V=[W^UW?^\?O/M=>9Z^]SMISKW7F MNNY]4%]09R*NY,L#KX' 1 5U8[-]9OU:R4E+_K A<6=,+^]>*\)7E_M?*U9X_ MK^:N%Y7^K\!8O0S__X]=U8S[NXM7=:/?^S5^QYC^=.V73W_E._]A_PO\%Z/M M:NTA('A1\].+*L5_[?Z+\P^OJG6 27KHX0K_W MO^@CP'@QU08 ]HNZ<&@!6@ -]<__E?+%!:"V >+[=F ;>\#NV64NZBL0 A#B MXN+BX1+BX1&2$> 3D%&1$!*24-%24%!14-"2$5[A]^U_!QH1 0$1,1$I,3$I M)3$Q,>6E(:;\E4+VWVR ^@"0X5X4X(J!=@- )T/#($-#35\4BX/J1I.Y8(F% M=H7?W<&X* <3"QL'%P^? .W?@V@ .L9?05( #1,- QT3'0L'&Q<+@U#P(DB& M@7F=G!_KOHXUQ0VW( %LRKBL2MF;K%2Z'3:"0N[/A^5PV.+UOL__L/40ILZN M"F:73]"W4^C,\12A&3'X9K];'=(UZK6PI\CQ.O=%36+WV.)^7FT/? EIZ. = MFI1?UXM8/A!5,GKH$Y9<4 \=7SDD ]#1+]AB7G'"P<82OJ)PG9\<\X*!VPT* M+(&@.,I+!AVZP]\%66WFW9_'R^E1V7H(_6##OB2 PR[<.7)!(H?&3L% Q-/^ MVQ\*_V\&'/^B@)H$"#&N?I,,D &VI"N]IE(W'ZJN6D] =! (@>),X0/;A0;? MI)F5V>-H::5<&;V'VG5%VWXHH+-8QK!BUZV22]SX<,'\L-MN648$6EOJ:'\@ MM0T1.YC81M[J/2-?.!8AT>_+GZI\X:.S>C0A;O1M/.S-E!K;$8E/*?S-^+Q) M0M+6R_+9E,")HN*A$VZC'3/:0,/S"E/>+EC[YC0)KVW&:*_!A&AMJ0.,[^V8 M -WZ>$SJ5H;3_M89!B=$+&,$]%%%ZP$N"ZD=XWV\<;(@I,_&BS2)W*K-KE'G M#GLAD2(0L;/^N)E)G%<_H=C14:,$A/YQ;9WUO"T**&@?:_JR!-$[GK>8YEM MLGO1^T+*_4Q2[&M;T!S[\D_<4PX*ENR^WJLN6!1'^@K/SSI(BPA*F96K:"F, M25?OE_#DA(VFQ:FT8G0RYBRK:]RI&YB%[:\7912XH("I_*6BPZJZN[!K MM+WH*^*] (:1^"#GJU5+0X^[)(AKS>MK8TNBA9$<(I6:PK1;X-*#)KM R'>##[^O>]U6P4H!D4NJ,S MD4*MBP)L2R:.97YJ9:U.QJ?G]\>[IB6&#+_14)SRYM]"GW4Y?FLQ>$:SUBXR MNXR@T3B>@#18F!4B08J>FYKQ"WK!8/L=CPUP<>P W#G'#Z)ZR][@Z\.-!Z7, M&F ;FVH*^A8':1B#\;.3] V0S*>JC7TZ/12BLNAT&9J84FS=/#B?6?0.RA\PI G*04^:2?I7N]![2HS'> M+CAE\U$^.<55[E4:S$Y]L&9.9'^Q]WAK1K&OR-E;IC$_Z;(SMP :@_S-W1-N MKZ0%DQCK;-AV94DY/5:W?Z49C[3\L+#"0/CGBUNCVF_'DH%E\.3J2T4\,,R3[^I?)PI;<0WKJ,? MVF=+BS!QL+*%8 M 1>)LWX%H[M99.!L8'Q=6V\Y4:\D=3_8SQ80C/&%*BJWE M)>*'M>5%J=+0J.9](ZE&8F1Y\QDC23'S$0KP;52"%]A#[*6Y\>4QJO<_4@VUYD%)S'G4[JH8:0=S?**LS,Y.C5WLG=P_"( M\)LN6)':GD&RQJNHJK#&Z\:KL+Y>.'LTV$Z1Y_ND+E)@;Z< A^D;A^TNR$&F M#!$F.*N@5;6. N8Y]0-*/3?IFZ"Z 50&XQ$C7[54.FU9-YUHITZG1\_)-]\A M?'?.W;_RMRN7GKE2IH?.'9K"!GXNX.V+U$\*M/JV=:\7?X+HF]3?'$4:GSB= M62+.;H2-#0V/E)-X,*8<;,[6IZ::?JXYR]ZQ''6:MCUC/Y$BVIY=]34;T6NY MH%@0%+[[93N_W^E/G+HG:E8QE$ MQOZ9\.2%IKE2T03TGC5,S\1L950S5C.U3]2C@(S5X_5C5=V+PC-0$U?Z>?U* M+0Q^*2P D #W 3L #-@ ]@ +H TX7LP]+X;'U>Q27BG^CR=8 !& !^ #_IRL M?IT7< #HD%5"6J=S==^UA6GRJ YCN M&BR)GL1)1TL:<89&"33F4@1U9V2.;U5P6-6H/Z7 ]4+#@XOIL;!N6 4WPD'< MK[:VEL4H$';/&MD#F!SS4P-I1F5B[Y)\<+V&@[$D-O<6G;_O8X?9U[<]+ N? MQ4)"<$E#U 3P^3K#!X2P*>TH8,*4G[E6V"^4IUW&?['T_DGPJ0DBE-^)VH/TH1B(2U*#"(*L5WXJ#C MP9B.M8CW3JIWRM?&_8FT0WTEL@\,H;7K"K8UPFPY%2Z5C>;E10<5"==MN89& M\3:9 R:=8<9],1EU)I<_+3$07P1O&XB+'/O]729.98 M\&X3*YV4 <^.FT!\YWRG<- N^WMI2%!#%7DGJ[UCH "X*5/@D0;.LV21'&J\ M#.?Z]!_W#BT@\/KZ>]-XZUAT+P2Y!$N;O?.#;1I8:9RL1J86PE28GX=;V3P/ MX\F<-#C^C!#Q/X:T,O05O6UMK'YO.U:V7\]+%/Q,\_']L_<%J6G[28PVI&?7U]A+ M-KWG-WGB1T8*;B.+BRL-5;"@K-94)9\Z@M:FD4^.O+[H=C^HYOX&H9%BJGQR MS=4#KS%@ETRV71S]Q3T1[@4[X6,IKQ[AQH.-8I,#;,_.I5NANH-Z;^:\_;,E MA\05&B7Y.Y-=.^\MXF8]4YU>CJ?SFD0O*[ T)S7BPK@5;>9EWO.M*T:^I) P M[3C'6R$4;A\#6]@AKLV9(%)I(QZ6 E]\238$Q_?#; QO-5C=32&9[1NW!%L< M?EC! -?2,T@6U86.CS_-/7'!'(L0,F5^*.OE7IYLFL39=3KACA;I9=X[C/?^ M=K<70\\>?WIBU=037P)A6 M<=";KPP"J[F:86654&$,$NB(C+1^G'$EI0_8(#EQ[$WCDFUO:!NGK&6VB4"T M"8EC8\WUF]HHX)/]*M8H/V6"C@ZNFI !%*MRA_BYU)[?D'%RIE"45%WX=]\# M.3$!'Y'G>GC&_2-J( L?ZBY(N'Y27AR! E_:O(,)2$/Y[KZH2CSI6OKS)]1% M*?;1:-+.@V^=% _U-.E10)VPF46[;J.T@$K22S')3[:L$=>C>;(W=T CX7*; M#A;,GA1Y"*7:#Y+V5)0OPO1:ABST]_#7?V(4IK::/#C/]:4PUM>6"LRL:.4B M,D+8Z#_Q[T@5+* L#+BY M$O9=[X\-IJY_^S76A3NQ_P5@6G2!QK*I^HB'B1/&>@HY#^PO[7UN]RYP,I:H#"E4HZ M71.VB:MEWQ#DFUELXSIJBI#]O$SH9O.P M>@6>P)C/1L$X-6SH[\]O7P&EQ(%*5I[\.&E+LQ\?DZ:V>#.^QG;(#6] =J#Y M?0DG9&6@!VO6*LM*^Y"'-+Y!X)+LLNN\UO$.4K'89_K1$5@)#I]_O4.<%W_FS*=XI9!!(\),\P,+E4G# [ EB\4^Q7GB- MW^K@:"OE*>E^QW MY1U>9K57,*D)#F4VU7'I/>I;B>?,37WC,SO:UG M+FJS==S]Y,C!R9P=<@.$ ML! >RL=QJL+ED5MAB =!CD1C^C+%6]@2C!Y;>7@I9]MCER_M9P?B_V2+,>;2 M,L%,:VFF<:KP)5G,S]:K6KC)O/&BO"+98B-!=2ME>4%AH_3:CPC2";'NV,;; MT)5J,Q;BGF.LY'X/7E5657R\V1GZY!-!B?KQ !])2_;-P9X1'#URQ4/:--MR M&G;/K*]TXJF- ATVP[=;(@K)V:*U?]Z.>:JL0=1JYZ=-&K&S$22%JYW5T13= M#?;./E9[-7-$N>PNR*;I*+!:*&PZ@+#YB,5MMSJ]'!G#=#\=/J?.24UV*C^>QK@T$J;6-LQ< MR(JEU;N8UAYBT(5HTV P&CEKWS, M-PW\X,\.*G="JJ]9DY3"2CBLGJ?"Y@H?:R4VM9XP&,34L4I)/2IQI/.=G-9: MPX+4U[_,;\=F+G]=U_P11/XU)D)[B##7I7[KY7?UL>?TS%.R!BE>/2IZAL;N MB7U6Z<(S)9FG',CSN220V?+,IL:+"E-N&D,2"*>V*0T\N,:,0JAIRH[&WY : M9JAH]XSOH[E?A&(W".QN@OF!4)WO>MW?M;9]2_X1/ M56X>]+F)?<9+%$]R[970^:)LI>_P[_5.L@^6/,IVBE)F:[PQV,@8-A%R*S+2 MFSE]98MW43%KPR*E+(DILY,+\2IK=CHTI;I C5^F1GR,5]/X8$0^JY?YFJ?S MNA9-LLJFGWB$$";C>,,N+D\;'BZ36-ZXM>\6SMZ&T>E*+OW[UH?O;R KEK$_ M>KW\.=;\=C&U)Q5](ARJPC:J0I^GLACI;=J]2"]_^]FKU?+X^R_O2)V*A>Y\ MEY'(4!06(%L0*6E^W#MV'.9G25_+XUVS-%F\_$J*.%K?PTS^O5#>!)*#,;UE M I]=?4N+OR^&SF>J:O-!6G1'0$HO([A12&YH?'8<##[]5MNR-&6J9&'BLSU@ MV!@0.TVI42X>":^ /)XT45>0+6Y<;_TH$Z-S@&'0(!$1\<4G""S5#/7@G%FK!(+]R>U[G/6@8C%TX,W*4"GQ!,\3V6,TC>O MK&5\>Q8&.\U\A6\W\+ _'=P[7JL2030;N3XU\!M[3R^C;)JQ%;ZPL6@3$8$] MQVEOJZ!P\Q5F3;OZ+!G7@I'@D2"<(B^QCP5F]#UX2(/@R^2AB7%(O[]66.%[D3$: IDC?%VB5*2K7T\U[&3LPWC:M#$VU@'I0+Y MF"UW_,T[2PVI7HU#.*D>=JV5P?4(<5#^%J+B55@32 )7PL.1 RY"'-SR63^[ M6#597.AN:?[:I[7Z;R;8+7)^MS]4W'?^+ *7 ,O+W.-6V,=?G1@IIJU+?YK@ M#J?W[7FI*L!]5@?F;S6+$#'0V31#ZVI2C'(&5W$[X1I<[W ( ;<$V=D-@+2[ MJ^64-CXL:);JS58L<3CB8+&.D+SK-)AUQFLD^VZ:)-IL+Y:>T M6PEY9Q@TE<'( IJ_U>Y[SQ'W=Y1]:;*K67@W:J6'I3:CK.V M7$%X=Y$F8RY=Z$*=#8%1(5/^3>!K_C]7Z3::O4+>U8?4JC[4!S/XC%,!) M:+ J@QJISTA/I:5)K_A:EQ,RT:.QIK+<8>SS2@[/)SR[_U"YSI2-Y?!623L, M*ZZ!1.)E,,>:>VKX0&5))2F'D/+'_O.H[W<)_OJ:P,& NL;P28A5M=SEKVZ4 M4/QXJV$C)]A*4:R"\DFDZ#NUV[DL6=SRM.B-+&6.=NFJ-Y.?V,\^.9PU)[$- MRID)<]F7^'SF$#<3CWN2&"3D$1 -?RTLR@1KW_TZ:@62370L+E+.QLN]SRFN M/*TWX%YUGYR&JE"@KX.J6>Y;_YW2@*?5;^T_K[R@J#$6V(06/DC;5F/J![/- MF;'L;,$-R]9WN0Y>1=P?&<06)4^TUH2&TT6\:N=OIE+:[# AK.Z6# +X6HPN M:\!E.\LP_[2J%Y=,CLZB/(IX M)L:I6Z=C2@$FS\987%@=LZ>^=/#\"'B, MPM]LL@R\\@](-RT7T!'4S!7[<) M[)9PAR"F69Z(6N4079T&NE)DK!F&DU0ML8D%]>P-"A$ANCYA,K?5V.:?OF8+ MT+9$ O0K%O.SI:O!8%!Y#+W+Z4].?9[O,\EJG1] 7"U#Y(^H1E1MG"NN=\PH M;F%AN46W:SZS.QHVXO+MSU7<6)NU6$I"VW*\;;QU\-.E/?=ZXFGBW5Y$WPHB MO0TGV/?EZ..FQ(2W/%_\=-*&O-1U#F1$O^Q%/'YT^UHXVG[5TQN, M17_U9NS?>Z.P'K?+>U=*> SLT-YC3\YM9?@F<)CQ2)J RC-!TI"**]M&_:"T MZ8&9L>(MN,V/$Z'ANT]X61/-:NB[P,Q4:D)"QW@^R*6U-L2X<]7,\&2D"VP( M@X\EJ7)2*QWZN)DR"T MUPSJ9&=EZZ24JT#(C]V%>0SC7<_^9(\T\-H;,!#H4]^%5<0V7#%@1L'_K2\W M3MK/86:S6_XHX/RU]YPL/1H*R#/M.Q^2#USDGW-& ?]X6@8U\3]02P,$% M @ !%!83^%D'-D[5U;<]LX MLG[?7\'CEY.M&MF2'.=6D]F2[3BK6=^.Y'AD06P3!^'EQZ,O ML\%D=C&='OWMI[_\^#^#P3_/'ZZM2V(''L3,NJ 0,.A8SXBMK%\=Z'^U%I1X MUJ^$?D5/8# (B2SYX\5W/OCV"GK HQ1- \8O"+4NX0+$+CLXU& ?PN BQ8( M.EP$%XHBB*2Y\"'279WTY Q)A@'GIJUP^@) MVZSA"<\TX+D@179"5T^4)Q 9');09.4_.PD3LUF11EN$?0:PG6C[4K+.\ZG, M/7K__OV)3$VR^HXJ(V<[.OGGS?5,HGSTTU\L2Z*.O#6AS,(EM!; GTM*G[*! M4->7EAT,1X/3T9$5UI9K8@,FZV96Z2RI)#J!+O-31H.4T3&7X<@Z:2?.+@39 M1H3 'RP!6+<7(TL8BA)]V58<2MPN^"CED;RV%:ACA5$*U+G.Z-I5A3AE$O'7 M(*8;B$^#T7@[*=*^K)T4,=TNI'A_ J@MH.:PV6P 7]8NP( 1NKGB?S>3S*4T MQ^53RD2(^%Z(.'JSA8B2,X9+,9 U%RE+M5,Y6I@EIMBZ?/4(U42,+.5M2+A# M:;I)TET,]6C:L/W$!*+@LW9%^M ^7I*G$YL$F-&-Z)G>ZKHT7T<8_S%(N724 M)J"4.X*;VAZV+$Z6,OFK2^^:8^M U%Z6F$C\V%H"^&*OVHN04,E?6PN!\!/T MI:MQVF3<4Y!%OPNJ#ZR!;M1&R%B&O%CD!)W%("M MJ>#VKE6U2*CDKT%*7Q0"8$R8Y"0^Q1_7:X07)/S"OXEQ^T,\>#_ A24=]@_1 MT*EWZT_6E*PA98B[4YDYD&2PHG#Q\8C/>P;QG.<_-G"/^3P@SE'BG_S E3I(D""-S57+!O*U*G 2Z9FJS MIK"M-IS$AYAUJG6"P2//8"$^TYW8OP7(EU#[1Y9(^O(PK5@9D"7G"&+&,>NT MWOPT'@W/1L.A-; ND6^[Q \HY']DR7\\*1(5V 4^=.[P3_)W4>.(.,JB(2RT MS\9T^3:@)(L^Q@9M:.9',.T,!F 45X.<'.'5M!.EM#&P'W8B76WAIBTYZMOKF\534748B5 MEO*#E2OG!PM@QY)%65%95E38 6 -$I>0 >1^*YQC[CJX7P_?OAZ.=P>W]2HJ M]="R==#< DJYT$_PV]: 4C&U5>%TEU4A*?ZOAVK1"*\V0W)7YOJ!^ZUJX-ZB M"O1OF#\GE))G;I=F.&:R:X?ET5@Q+*?$O33P)9RS&R!JH9CBM.E*ZWAH^\D1 M[RI?5T,A^KHYL[R$:3][O]0@UP0O'Z'89)ZS;B"I.-1"5/)JLA )C@/&65J" MYP&ADGTON(3C[6$*V1RPVAU6G5Q'#7DM-B67,(L-[K>+EYJBA>M6(M*Z9*.Q MPB7+0M _%^N"N"Z8$RK%\&-O=\)K(E[*D*9F.#1@HU\I>:-PR?),,ZYQEN\! MJXPQVO1CS;GI9[IO%$-.(^1ZV8F7ZB^D;1*S9$L(\=)O:)BQP1 M2G,.7!$"-5M!V+B?K*+60,2[QM.A[!YGW&K2]!*AE)45\;)"9@/=UW:46,N_6UP ?W7EDN?V[4G-10_764V[ M2GE:9&$)KI9D>P J-7%MANV:XB[*K*T$VC9;50D:YCJT\1)*Q..*K2#V^6QW MBCGL\)KX6[;X"IYZZ,?MVG^V#"LL1*RI^+WU@!H@L,/6WZ2 6KS;-/5JO ^M MN@3/W1I&TX6M4,ZPT6,Y:M5V4[8'J!:S%:^\*^(ZD/J??@L0V^RNE=;QUH/Z MNE4#S9;UOU98VJ%E-H D2=TQU"G?6IA;M%TES$F6?@',$%Y";*/&2T19"NT: M['BD7(/-T/?5TNV6516$VA74\4BY@IIAT].5THP%[GG/T*W.)Y0Z#,:\]JO6 M0',8Q)SZ!<(3I/=@"1L:/LZM,?8P\=R2@_G"U)S2$J0],JZH;+**!9P^<4_; M=#9Z#OI>1[5OD^67\9A[V?]4V%;Y=8JO$ 98Q.NEGLL.@&Q?6"WFI1"$:LPK M$A"V$@$RCEH_HQ;4$-V _Q)ZX0+?A]Q-ED&?8GON&H$YL]=U7T1"6&DN$!EQ;[[%H& MVKWUL6IOO1*9_NVF)P/)%(LP^.8!1TI"?8C1>T4C20>R#)^>VU],>RBP60#< M;A'AK9GJ XS>OQZ^:82;]2I3BG73\Z!Q%0J?%@MHL[O% _*_W@ ,PCB>;;'5 M&ZG0NH1&C6B3?-T2RY^=15<9NM4:M9:!=JAZ^5RQ55Z#4QR5KE65G M*][;B.-48H$D.EDE%S'0 H6W'FW;TIJ74-L$SQJ"*XL,#W/)Y9?D:%>^W$,# M33 */ _0S=UBLO"_8 J!BWZ'SF> ,#?UUC.<9MQKT7_;%/VP.+D&=S6STA(M M4608I'2 /K97B\4>#;EVJ6?X_K2\H5(!7O\6>CX3XCQS0\>'5*9<$[Q$C5'1 MT6N7?49#Q;)/S"USKB7#\ "+L,+$X\,+^ET*^.EE#;'?RAWMQEG;/8Z&BI4@ M/936JVQA5E1:/_M%#2*9GSO"6,&Q%MO28D$=MID_#I 6 .@TAVS#KQ;.DA]; M!V?/YY0:X[>:6C;AHYUACH:*&68=>'V<:FHLW<+AK.>B]3M'0X7?68=6_QS0 MJ;@XU8OEOUO_EZ-D%FQ:=]!;L]:L&KQ4!(EL@ MW\..71[+>P0O39',Y->O'*@"1J)#@)*\GT:^D ]D,.ZM7,(%Y+^=5EUH$T;Z MJ85J6SD+B_4JXBR=GYAW/^<4&7/'AN!_R*#-[O&HK9G6XEF:*N;QC$NQ&'BQ M@+Q"54#K]CW@- -$I^F^CKX6LU+83AZSGD_F,Z9M-7E7T>DGZZKMX#P4?9R: M9^SX &W"_2;>6X2N6Z[[ZM18&G"L;3ZE?;X\9ODBA N83>]]FVKCN9>H],LI MJFV\/#:]]K'%1K--EEAL-9]#S$MI.8=NQJJV_90V@O(897E;\XAY7YO-$Q>> MT.9#4)I?OT[U3CE!2JC[:>-VC:%$IE\G>J?TNQ(F?:_?+5VM,IW6U1J^4[I: M&>OWT]-*#-!J5"Y2Z9?)WBE'Y8SI^S'VWN%NNCIL^)2J<\AO%[[:EC56/7Q2BZ2<%QZB>_4P$]>](O09 MT%8+TRU9UH);&JV:@,O+&2S"@@[ %E%HX5TT8*-U-\:JAR(: -@_)T1OZ9?P MS.:NVF&)86TK+#DOC4!\L: LIL=M\!:RT"Q1R&QS[$J4>H_FM,JC&7!&/X@8 M3\'KKW'H;M]Q:-V4JACHF\YIY0 VL)2X'%I*;."VPU0%O7Y\.JTK$T8]!Z!-!Z:CUV\0C!1#OQJ. M7G9<*L.V6CO5,M#O5ZMNVJR"IH_KJ2K3MAA3-.3Z?<^18H6U"I?^C24/D*'P M4I)XI[(1&@HRO3NL.JV8,K%B+KVV?'(C36JE5KMN[3CJ'675D40%7KD;;C*% M]'.&60:@TUY& S:UX)7"<)3@]7S'HVSHF;V"3N#"NT7TY6[NHJ444UQ">N\" M'-X,NAV>K8NIQ;LTQ"GQCLL5<5?15RM3M!P.1>'1]:>'6E&$2RRP$1Q>+U7Y MKMZNZD:KPFIK2&G>4%M#TO+%WQ V] MP^+7[DNMK3FE*/;:FA,+DG0RL2@_6#EA0O^[SY<7Z.#\%:+EBEMQ\@0I6$+> M)P?>6MIM5Q6FOH3:RE':[*VM''&A5E2JE2GV4 E"B[68&%<2ZU=:AXJ55B5T M_9L3S^!2V&"*%X1Z4I9&0"C(]'-BU7'HB(F5X=)KR[?IZ:JI];V8ZI"R H=> M=DUEF[;HFBJ)]5V3ZNBP$H\^=DVN=*S^+P"40>IN+@$#7S (',2_-@1%RT+? M99TINZR0H95PM 1+<58A8GI *+9$N^ZL"2=]UW:F[-IJ\>II5Z>S=ZMNKP$C M?1=XINP"&^#6PRZQ]%AG,Y#*9/J=\+>JKD_Q@&>O3=^J?ZNDUN^!OWVM:!O* M!W/[V(DQ8G\]!YQ:K-Y![+>8OZA)]:U"]4*39#20G*PLJ][#T*IU:#GH6XCJ M.;PJ4 ZM)#%%JTB1&A;Z6)$WBEB1:H#Z&"VB-F\;)TS'0!\Q\D81,5*-3@\] MKOA&^!E:8GEB![/,76&M6E$S5MHQ:*B*4&U7F5+[.G,MA$R\2-S'6_/VKJ0VEI0VH=L4POB@@_/ MN38#ZAMTXPUO(U %TK9!NI?N4B, 'N 3Q$&K<(-.C&M;!X=X .$I M3Q#:'5EAQC6DB#B/,J,3T&C9Z:2-5F_&9T6!WY2TTF8R3ZOQ\2@OL(R\*&A5 MD\E K7A;ETNN#W =4'O%I\7WE"PI\(J:U6?X[ M=);0!]BY(A1R_R:\H=O>3)S_!N&#P%Q#-W"D*T5%^1,6AK\*31FY)=@6$U/B ML/T&71&>@ M8X,US=Y%L_"+1S"??-!-4;5Y&!C/]8)SQ'97$9,E+/$ JUQ%X4AQ$A&5CQP8 MLBS6FW9$YC4_A\/E!#:;1!D2S10)W:'D+$2MW[GP<=MCY &R@&)1"^D3+(!4 MF\U 6(B-P.RX.#R5/ILGN8L\!@IBY[^9)S-&'N C)H/VJB"Y*L5,^=V_0^"R M%>^.1:OU%7I4Y3!/'_'YWQ!#NUB1% GF21_0K^">3\B\HO2*A/V/^T\ 21$6 MA,Z "V?0#JA*%GV3I=F'PO'M0Y\,'2!31?ZTM?C6NPY\'F4T#)#+KN%_^2.^@E%3093-3F M\_F]E'5V6=)#D62B!K-G)*9?O)+ZH;B.&I:Z?";J%@LI!#X7C=Y?K4F G9)R MM1E-U^YGL :8N]K_@EBKG"J?D;KYCA!7] 5E?11IQNEP :B#R!/PQ;9,H355 MI)FH ]U$%]V6-"BG&"A_9D&I..NN2C1MYGVQ"I8 A;ZL#;D<-G!%R![ FP(F M#3*:!Q'B_E=A!E7X9I[,Y#JPD9.W=%$'?1X#=1(2D9 01$]<1Z$)1VHVTD\99DD52\29D+G2H-"&8E\C1:J>S^X68A' OUM+2?$RNGW$CU^IOX49W9IF M_V[P#2C\!=B3SX4>JO39O.YVXW&3%!=O2U\-E)L"[_>2V/F/>^_\+^&9M,NFW*,K8I?LMU/^F MMMV7-7=<;:-)!EC"N\5GE_!BQ)-Z48<\Q>GUFM4F:\-BSS.92Y[_2G&><27?&H(F3@)EED6*:BCS6*@1C:D&&B7MVKR M[-]Q0OZ:<(==EI9$"XJC''*"'T GF@*+.PCF3$0,RB##M'UMP<#8N4!SG1XI MP.'):L77-(1X?%\6Q'N<^@)21!_$[ MZPHS$C[:,Q>30IAY*#VQR58L]C3\5O8&] $ZSL:_!O-"%Z!(V'N[#]^=2UZC MXS9]X,.(< .PC5P479KP.+P5JS7=BQ,\RJK8.5:(IZ> MA[3XT;BAZ9,P!,V[RJ7"F]"DFZ<+=@AW M4S%QR;*P6ZE.,D\#&3-V ]F*./$B>6;J5-"I86;SM*2\:PE>FF\"MB$P55NE M1L9+'844*X4OIIFGP\L:A51GC(R'8AVQV(1T.0S6!^'W6FU*Z0;K\HS8"N&S MC4X?91[C=$IV,)010)6IIH4 )8*6+\?/#"^3%^275&M"T4Q=AWUPD"?>8@XG M6>8H?BGK3CO5$QISZZQ6?IG# >P6,KEP*__.-]9=,#+/.NA%G(04,[.K #O^ M)P_2):]Y-X!^A45_K&EFX[5,C^8[R8I)C:YZ$O,TSA_UO828R#T;<3/XO.#M M-,QKHHX,DI(NV6_&R2R'1D=6+K$,4@9#E\$\;0(/\/EF08/"1R.EQOFE=O71 MPR893=0N"S,T/!?&K4HW30][!H5B>47S?^^+NU%MS#0@. MEUF(#&4D"_5M#PC/N'S(08!N4ITZTQN[=YPL4D=/TDTP;_9H#5BZ0Z[/8NIF ME91Z[4(&,]>W4?*$?+F!E"@51;!&GFU.YR[4W\OZO:RG84P+< M-5YED7,\3 MGT2;.-QY0R*/V'215YQ L8=8Z%*;9S=04\K[$5X'BAH5/QLG^3_@)C.*70; MG7@;WDU> -=&3*QJ/4 ;KAFADR41J!1 VX)^[Z/--<%+L2LM/%I%)&RL8GTV M4WM8$2"5G'>P-^$6)EECMX7=:E(-5R/\:E.CTRJ>7H@E\\=^= 6/Q">N9]O@IT'N!07'Q): MF&RW)_NN- =9%2[ &K'P"-5%> \D*EXBMR->?PH;Q6>RMK=0B=.?PC[;V^5/ M8(]H%:.K,4KDYEM"GF*6SU?5Z*S(:)QVM_ KGPKY]V*S;IHLO(K5^\<5I&!= M&"V:9S=0TX#&RP%%I10I!LK_PL3I\K(/K$PQ3WZ21O 4Y%>E&"A_>.TYPC=@ M\_C,LT;_ST3,85&C1GF_'QT?GTE##;,Y#=8O%%;L@.OQJ\RW]S7"> H?7K.$ MTB,@JH1]+U;$,DVQ@YZ0$P"W)&X^:>^K1+%8M_!YLEZ[?(@+*?)"EU)-,?0] MGZ]FKE\R!C87ZN M@0BH1E3\D<36^B5UN]#NO49'9]CEJX0B.)R;)1J@1:S?#7C)7JC8-//^+[>I MD31_3V33S/M3J[+&(O_K#< @O,DZ33]/'J&]"G?]BOYQ M9>K>FY08O^\6TI/-WD8H/\R(FQQ7:)!OSS<4RCWE!S@7DP_1CXO+KH+,0J\F MW=18X)F]@DX@?*^)XT1W=)T32LFS"*T7&KC$#RCTY:/VCWP>B-I4U65+DR$38O<*8C^\Y:Z+'=JS,L(HPKLN29UY M&^%\DV:)#U6)EW!$((TMUB5$JO](SJ&8UZ4GL;X%XRV&)\EL)\::EW024OOI M>0@NK2,=) J%<9M?1[C)@4SM$0N MP6'$D5Q7+"JDR6">-N(X&>.2%G0H?39/\F>PEB_S7\+K/\>>\>>>D6RXN5&(@0CNZ\K#@E^T@8 M<%.UMN)AVAI>I6EN(! .BUROD+S2(WXU1Y%WP^J[,=0#M%W@^V@1Q>.(Y8/) MW<54O@19W T>7^R2K9956VY:K88%+P1LO?OSCI/[Q1 CMVROH@9_^\O]02P,$% @ !%!8 M3R*YMQPI-P "&0" !0 !L;'DM,C Q.3$P,C1?8V%L+GAM;.U]67=CMW+N M>WZ%K_-3ZKS_^ M\1XNWK^\O/SQ7__E'_[Y_P#\YXMWO_SP:AJ6']-D\+FGW[ZZ?/GSW_YXF?COTQGUS\Q0OA/=ZV>_*+\!K>?0?D34 :< M_N7+//[X W(XF:_&KC'([>=?'GW_F:^^IM;:GU;_]^[3^6C7A]@M_>D_?_WE M_8I/&$WF"S<)Z<=_^8[RV\Z&8_&XZ]_"=.//Y7_ M^]-%^._E:#XJDIKCN*OF'V8I__5'_ PYII82)@J__[CKT\77F_37'^>CCS=C MY/"GQB3\[OPX'4/(MPU:(6<^3XO+CS=N-"MH?)?FB]DR+)8S1.[%)%XM/J39 M^YL41F[\\H.;71\F]^0.AV'G55JXT;A]KA[T.PQSO[G9#/7"I]05ET\-, R[ M]=93PV[;8.W%=#:;?L8!#Q'[^,-VAW^5_.)75YA?C.JNA9JMVR7TE^GD^O8?WHRG MGX^1[=[VO1![\(-3)Z/%T3H5Q/3CS2Q]2),Y[AF7Z!=_3+],YR?/X?[>!F"D ME>D[HNLN6;RZ21OM>2(CCSOHDMSW:**G#]-Q3+/Y:W24%U_;F(R:O?;+V-W_ M;8VI1SVVQ- "[;$T":,:V_6.;ULGHJ[9\W23UDEZBQ-TK'P>MFF'J$]I]M9= MIX.$//BNC<%?C>9AQ> RQ7NM46^V:K7MD,B=?[V?)U0JJVA*,;1_&3D_&A\11FBI]^X8_6VZ.+A :[3LCL!: M'E&=IFV0> ?)RTD)J-5QC_:G57U?,O'&CV7^X\3+]FMQ\.6O(2HW>NF+DG?J==L75DK/"8+KHBN::-5:=I5R2^_X#360*^98O; MQ'Y7F]\HC]8'NJ>+^^B^.V-R^?&CFWW%W3S/_YC,DAN/_I[BSVXT&:.#VX#! M8_KMBKE:>_#AAFV0]_-T&C_CGVZCGI>3A9M?$2PCOZ^@N7K M+S=I,J^I:!KUV3%36S\V9N;IOCIFXDC%?T)/'3-0.":ZE4FJW;X/8 MR]*X:*W56KK*OZ7/=RKM(H3I#N;3O#'4.MHK$F70[%4;P6TT/-0#-9" M7O..6V%O%2'_W7TY3._C+ULFX.5R5H+#N!1?I9SPYU@3*4=TT3+)MZ/@+ZL8 MRRD!G%.[:YF5(S>H&BU;)K#F!K2G1*H3MHA^Q-JFNFL#B(??=DR 75E]%2# MELFIO5*?;-$R035!_L3W;1!SI';M4J6N[-S34@GJ-.V:1-24)T1V&O38.4/3 M\?C-=/;9S6K:.Z=UUC4;M=98_0ZZ)_?+.E#?7.9/==4:"[^EQ7JT3?BE#JU/ MM>F,J"/D>*!I9R36A^C^EFT0B([=39HMOJ*)7Y)(;FHDI.QKTA5)]6:U1LNN M"*QI:]1IVA6)M6!WN&$;Y+U+B]'Z&._6,CY UM,-NB'G[L2QG+>/I^70L:9U M>U)?W3!QI+%7OX-NR"U7 N-RG*[RYB]7?CRZODO]?CMVDW4"R:GLG#I U^R6 M_7PZ61\,/YF;W9SI4X;IFO6RKX7%G8/\UGV]S\,8^>7MU!RUMW;(Y+H6NF[&R9K[3V'FK5!VOMT70:XG.3I[.-JZ1\@ MZND&W9!3;ZH/MNN&N%K3>*A9.Z2-5^OXWY=NMDBS\==7;N'^F+AE'.%?#Q)8 MIW'W9-:=ZB/ZZ)[HFA"HWT4K)#_*A3]$X),-NB&GYE0?:M<*<8MI^/.%FZ=8 M# +KKLA*Z>9"&X<5B.5]KP%_Q]\WDA^=@*1>LATI=%FL1B;K8ZR"YN MVARJ83F@04G9B=8[B@H]MQ2-I^$;:&VH6!7'RF[N5Z6LEG.X=N[FIX*YG])X M,;_]RPJ%0.BFUM8_;OYIA"0F(;V< MSA=SNH?M!U]6BK 0$A,@0U)@+8O@J> 0*"/"\:1LR'7XVL+?Q2S\,)VA_?W7 M'Y&2SZN@R>K'=2]N%A[!\MN*:9LO?IH7W5-Z!/1X/MZV+Y7@^IO*:=OB0^9Z M@<2#I?U D^Q QNX&E9?"2L8H!,LYLFD,2"H21*8Y%5188E@Y/=@A.>-QO.=CWM8__-/NPR7_BV:_0=T@QI;'1NB3U72ZV2(&H7Q M.AGW8*6['HW70D.A9[&^@KBZCEA^?CG]Z,M:O?A8_*H]>W2]#BK!20HY!0B1 M>PA)$P@B=A]\664?/ DV I5>0NJ]%S^W!P?9G%4K=,^4,)%H8 MX5I!-DF#)LR)E!CC6IZ[0=H#"!K*K"\$K%/TZL'@T;>5"41XE]#]2MR!UX*" MI4'C/Y$Q)GV(@K=B#SYO++0AN+X \VP&$(COT.*7ZK5\394RZK72EJD+S0A.R MJ7K#7%\:>N4M0N-S<]ST@B\U7AQFF M@FK.201FLT5>DP7GT?QEQAHT>GE6I(&^/RM?H=W)G_8J]+[,BFW-\-MT$@Z" M;7>#PR)PCB7- X5(> *=T=3FDC#03DF2K55$GWV\_!QPUY_\^]N>>@LU[G\" MH,6!CBWGW^O074OYM,KZK1)0JUQ^C_;.5L9141PE$6YGAN@NA7N@:15UI@Y7 M-:@4!6BB'%"9 R274)7$E- U&IZO9;G)AKL-K1V> M]=T-*AN,L<@):"\R!(-"\MYS8#[8[*V+-I]]7+ME +0FJ;ZP\/KCS7CZ-:5W M:5SVY*/VA(-M*\>\XH)]XA]>OHL MB^!VSA-(R1+DUM(<&0W9-K !]'.$0GNB MZBT8?4_L5<8=[68Z=^.?9]/ES>4DC)?EB?2=;Y0<%5@XI>=*Z4PHI:)X6 XI M5P9XPI\4M8[PZE^D \"PWI'(KN^K& 5-6C'(V@6(&<6*.IB! MM"0%AXZY$[5.%L_$;^TT<-5(;,_MJ*S;D[#>(UJGSEV]SNR(SCR\9S(_5*JWT7TE!M$1+O]RMD1#Q9\ -GH(P4GF3A=2N M0?BT=RW4$MB&DFV/L=<9[KG;!A<0.8=1:>2 M1"&,?D91MI:0U++(AG*\:L'CZ4:5P15 5A<\(PE ,JX'2WC)J[;1!)&U(0V, MG=Z#6^32$8/N"Y&/'XXZI\LAAF<'%NL9B"7O]/BU,E5(OTS&2JHT5A%;PB5?A+G!6VG.YG%C)N"J[!/MJ/;SC$)!_$V0F2[0LSY5KB=+(B>76G M8 ]B'GY:92*=9T("\Y&"-DI"TBD"%8HZZ125\NQO?C:=K!VW/!O*J#,CDZDUA=>WI7$W4F*K]UL4I*8T?E.E$:@/L+*ORK_-_2V/$_&UR MT.^SY5ZKN$[SBG"ID_04DJ2Q."T!@D\!6*)92T:5D@ULWI[NCW:W!;4IN!ZC MA[<8W_1FG Y40@1R^LTV2YS_(3-\D2K2D3+A2<1I/4H MKB0#Y.PM>!52-"QGFY_3(47[X;EVA=>;N;)Z5VF?%;+ZH*(Z99X%!<&R!LD" M08/+4; \Z402I50->$]N362-6S+;WU7$R_<1_3IF>7=5%&PBE-YWFYA_*RL+_E.7ZR8U7:VWQTLUF7W&M'8S_U6E? MT9BT(2% R8Z!Z!P'XE,$PH,Q+EFA58.]LD]0G#2C#Y5:1S+K[4BA5!DHF5'E M\>9UK9E]RF[7YQ6U*1%E% AN+,B8'<3D<)>/T4LC+6X3Y-RMI_80T9*(^KY( M^2Z%A/!%TQ"=O?K7*7O((/I2/#=8"EH2:="%I$&?_4EE>X!H M651] >/V-?>O2.T>(&Q_5H6@&2G7P42P!*0+)>"D$WACDB&9N?5LPK;11:U9FXXKNQ"$9Q!;C)&1ME9,ZI5B)G MSV+F6Q!/OZYMRW>A3N^T4LQ[+C.'K'B$)*4%%3D%IQC'V6#,Z09 ZN>678MF M0Y^"[/N62SUO8\?7E:$NYW(!W<^;Z]I.*:R\$20R45*%LD@+0)WFE2E%9XCR8 SZS"S*!+P$AADW M/H28+?K.S\.C:(2&CF356VV.E!-N3?<76>ZXV(./IQM5R*44V7$P+##@B1L( M"=>$X,J%Z#3E[NP+2K> BE8EU*NKL2&T]KV@A]]7/AHI9$P0,O*GR@THG[." M%$D4A++ 90.]T*?3T0@!;0FGOUC#%(W5Q==R[[&\O55BYC?%>MFO"O8UJP03 M*@56:A") -26:C0Z6. L"F<206$VB#STZ38T@D++,NIM:ZCOWARA-!KT6F7/ MK0G1@'0$-T^!7GO268"(/H=D?6:\@6KIIQI'&YM+KR*\AULWY:"?+-K[UA6* M/Z3%"#O^EJ:.:@:_7^"_*X_M*I=SPS?CZ>?A:@?O/L!A&(N5T!ME8/0:)<_#B MZQ_S8F)MT#ZYO@B+T:=5CLP>>=3OI J)1%V2I!Q7Z+L'ZT';5.Z2$'3MDF F MI]/U33\'ZMU-_\,'MKJ4:W^.\[<2N9S<'A7M!]7>=E5FGHML(NI;(8&RE( % M92 [$J0@%OW!!L?PM)\,UJ[F]Y$_W:XDAT/.@VJ]N @W12.VL<;EXEGS(3QD%TC(+B.H*-S "/HB2#DF32V1==[@E?'Y)FLP/X6=W@RH3;Z-A$CS^ %SGB-X&_FJ910]76F-L@]VO MGT!Q3XAI38*]A@QW2.'6>[KSJ Z%$>OT45&I:=)1050H6H$K [B5&522)CFI M>,P-BIKU$USN"4E="G5XD^JV@%N]O)BC^JFLC=QJR4 K2T$(1X 82<$D2:T2 M6G+>0%WU=-UL< NJ'@8"NZOI=$*J4\[2!T62_!Z.I6W$.:BX]*%*Z"6P< M:RSM[J52EG-/M 6A6< -G5A -P6]6*%29#%IS9J\T4>^!VSU(]>^,(;"NJ\] ML?^0Y?Z[*E%-0J() G<&DDD)C/$$/=ED(DJ4QB;UA6@_!RD]X:2IY'I$PBYQ MK+->&Y[%[>BD(KE45"8*'(L.5"P%"[3#A:&YR*X$7OW97V4<^BRN';GVEI'D MOJX?#9YN]N9US?:GDFGV)2D=UU.E97B1)$6!1A-!)K7*S;%@ M LF^W$%,34J4#'IJUSK@NI?M<(@[\M)_O0ZJD)-E)I6DPH"[B-8!I$=[) KI M@B#4*-L@#W/0,[ONT=621/O>-=],9]_P1XD:NYR=N ]6!H$9#1R MT621'-5YL(&W\T#K=[1;=B/7H?06JMM?W6)9"HQMM/%IZFMO/Q5#:00K.$0E M.=!,"'@3.9 L=,["Y)#/ODCD0%JL;<$.ZP(;%L)PS7E$?UJ65@NAPB1 M:@[*R\24H"HW>5%DV).^?LS\9M(<#$4OEO/1),WG:5T^=>66;\*_QP!J3S>5 MGK'%OM"G9@RVMKH=0-BQW94^5E MR$IX!<;8\LI8>AST#[,D":U&V@ZFUX\\13^VJ,DH( M96R)1CL&UC"#[K2(0)F*:)_JX$R#K=-^EXCK4+@#!_W?C"9N$AH&_7=T4M&4 MH^4!S0EO"3"G!#AK-7"GBNLC3>&X4;N9<, B<9M.>NG'5%GC271C6P MD@:-NW<)I=:DV1>.MK%?$SU/-:DD"59%;D%):4"5IQX\CPITBC3@GPS1#=3/ ML-'TMD'3HA '"!(@]4LT_M'LN\KUGOX[W+CBV1#!4'Z6.AS(R1,)0VC]0!2XJ!I*I4,C&1 M&1)Y]F=?57: 7:T;T9Z8>GY+6-[:;J>SL'9;_T\U$I)K7WKJ=KA719D 8H MZ^?&<6]AHXXEZWHL'[6S?M/!#P:N,[7[7<B""C$-KRLP]TGA.V.A+Z.4#N1"/@>(OBU_6%7J6M\LF'NHSY#HOGGN5_ M#BB_^.1&XV(,O5E'EMZG4!+$RP/3K<'ZJ#'0^'*!248AH9( M,)0HLX(2-I& M$O:86OO\]P1;JP*:NX^FT][3^[T>1> MXN]2&+OY?)1'P=U^>Q*DVQR^4M)S7>XAJO( A)>KX&UYBTP;Y9CRZ)PV>"FE MGR#E<&@?>"J&7@B%I=/5C3-*IA0\;7!0? 9& M0^>>V&E2'"P>_H3A,VCP^^Z=BN'BWGQ:?BYG$%J?,0XL3,.\#RR:-6PEBOJ%>@ R]5* B:0UD9H(&B ME'UPW#=XP*@?0)\##(]>&7U.67]9IY_29+DWM>OVDTHPZ:)#!C*U AQ;U99S M 4TB@N(VUF9_]N>(9S/+C[)03Q;RB=E;+Z=SM&V+@S^_*S^W>=#^KO#R[F?[ MCFA=)_3 M[-,HI/G[Z7C?_?FG&U5<"AMH(,!R.785Z*<1]+O!"R(8E3RAJ,]5/74VH],. MQ=??'K7KANM&-'LWKCWMJH1L!IL,$*(RAU4QN80N.! +<=_DM8@ M#8I:F4@#R]01<;9WL_K"4&>B/-'N^1X*IG<;F.\:&=]'I70D>#%;AE(0:W+] M/BT6XU5 $NF__'CC1K/RRRJ]?[X=FMR]31W14:6L5-H*A[X!0:M1,():EWFP M(A!C @N1-JB7WFT%LQ[WK6Y%VENMC.ED>BNDM7=Q>.]ZLDU52H9K[1(DRAB4 M$N(0=:E"DG$GCT*@N]$@QZ/C6F5]8:=-\?4;Y$3'@%F$P!9>70"Y )N&*,&6+JOMU\YO[Z0-'%-N0]3.!\Y\/P=;+(C^FFLC$S M44XV1$::@@P:@B9H">;H@C'4L281QM[*9G1R5M.ZZ(8Z1%Z]3_EA.L8YF:_O M(0Y[?OR8GD%&XYX&>XN"[IBU3VGVUEVGSD;8 MO=ZZEN(3H^[\Z]UU83>^Q_,P!/[J_FLZ>UG2HM RR^M7]= @VWKQ>ABZ?ILN M.@3A[C%__^8IT=8'O9OSRTEQ3EHM MM5SN?]MCJ=3MHDI2L2",!YZL!1:D!K/*3.3>4"*5EZ96TN40DKB?L;^-%A]& MDZM)^G_)S=Z@4_P?;KSG",2CGF) WH MWAM2RD.7VG,Q4(@L)8^RY)0T2*WNQQAB56C81@$\4%;>,W;*^W,]ECI?Z+8L\K.$;F=X?2RQF!Q75C/0 M)#JPTF3PD0I@EC'A4PQ>-CA_[^?JROF!M TY=QT8VN54W!80>C>:__FKFZ!C M7_Y\NE>Q\^CW_L+QULBWEWO>I3"]GHS^OO/YCB-:5XJR9 FQD*378(7@D.7M MD261)FI1ZV)X1UE7J_I,EY,_)K/DQH7@6Q:N)JN;U[%DJUU.[@"T^B/=HP=. M[+$*2O"4LH1(O -'I0.&H 1)C->,!6UE@](AW>=K=8*'A_E:OK@'FZV/ M57$7E+,.3/PI$LD,2T2$!FFNO/M#_#Y0>PYB[PO.6^OQV_O, M.X7PVQ2MJCE^55A>%UOY=N7N 7/+(U5*I<3#RM\W$G1&?RDG%\L_.G%G)/[Y M7%V OI \O,R'< ?N=I9?DYLO9PV=@:X=Z9(OLIJ5?1DW=9I7.5CC;/$.B[/& MN!"EW#P!Z65 K]'PJ&M5+QGVD*6A/)[JK!*9&I5= AD"!<,(PE:C9VM4""@8 MHXENYU6>04(&I\+@J'!!2W(=/GBUR=1H"W-/=U1:-#D\+^0^OWDV;_1.5^ MND2'L/;N7X NWE:>CD?3S?L'7[M.&]I%SF]NMKZ;-,3@G6?.[1KT[JVUDK.U M>0/IY3=%KH80Q?NRY&9?K_)%GG\;?AJOJH?V3U''J5WE7NYG_-/M58;+R<)- MKD=#C7GQL<0^_K[J<9.VWK70]U"S]>/0GN ]*>M,Q]_2XO67S86"6P[VIL0? M;EX98ZPBRH,Q&8VQ6.X$E%V"<>/1*L]6VEJQZ7XD\/,,5V03&>SNH'*_1CXTE/',.M%L&< MN=U%;^HUK)+1Q7'%14:8@A).A2Q*G4^7W>*T,JH"&$5X7JJ<; MSW>/;5O3X^S!KKN['G^5'TKZ*//NF'XJ&87W/GG0(49P*LARNUJCH6*3)I[2 M3 9\=&L?+VM@C@LP3Y3&5@^58,(&GAFDD"W8\CH>+HL,FA+I4WFZ6I[]DR(= MSOQ#L[XXO,]%VTMOD/=5D)R+:74H+S7P!/.B PI(_592ZH, ML?ELRV*=%P8[$/6 6U3G<'636\RK^ESW?!/S0OILO5Q>:W ML^D$?PRIVQN7IQ#3=53N%)JZGK/[4IM]C+$Y3UD5I\H)?XZ#6VIG5_*EHWSA MM>2/9W=_P\I%HV,P&G2I^22C1I^$N@0JI!('(9+1LW=76YG1A_F^;8NMM\3R M->%O4BQU!D] RE,M*TJ(CC8CD]%P""HH2"F73&9K"/=4I'#V!=?;G-;=B&E1 M?'U#9IU8>0IDGFA91>\)UX$!$8% =E2 DDF!"2%2%IDS32ZW]?0L;O>0:4]\ M/4-F56]E=5@>3M(U^]M7.G/M//=@+2OEYKPK"<.F7!PD7#)1/]P7GT[IJ6>*UQ!(4CA0:UJ M($]$V8H ],,0\MLNU[J&:3"6#^>6*NS_ 2"6A=C[T!:>P8-@+2W M@\H$E[*Q')P1%)A/Y;(+SY 8\9(3IC)I<-+6CPKJ!4AMB[%O('WC(YP.ISK= M5,')0#6ZJ50Y CXE U10#I%3%0U*W=8K_#&DU]8'J#H29EO>V[KBP:B$)=XA MH4\0^/MTX78=PC;MLI(V6X8Z&*A1%'+D:(H&$]<6H4;FA6_@^_?CKW6!H@$$ MVY>RVK!U<7R?C5#HH[AAZ2DP0#L:CNV2X9:!$UHS'S*AN4-"S M'V>P2W4WM+2[3A;8.AZ]%2/^LLI].*;TFI M=L0W&(3N7ADL)=A.AM'3O50^R$@(2V (RVB T@0ZZ@@VTTB=EA+_>2[1GBZA MU*H(S\B^*L_>SCZM7J^\"&&V=./YSK?!3C.T#O5>^9)I18D!K:( $XG$54C+ M&Z@FIT""8^;L#_2'L;@Z$.UYP_+V3ZTC\O9/E2&>:%G>UY3HC.LL/7"#ID5D M+ NG==*LP;,5ZG\6&!M(=;C=MMS[*:[,+'U MD:?5H]?'K73[NRA2IR3R*P! M2I1!8P/]>RZYABPRX2Z'[$*#DSG]W2"K-?&=>!;WD*"[,K#W>7B[X%"W*;K# M:"-XJT$9)H$8YD%*G>Z.@ CR=CH.S'/#08=R&U:''*TR*F>TUS8JH"D:<)I& M0"^$@PQ$*ZLISZS!899];LAH75J#X:%@>3T=X_'TLYN$?4\:U6A=2>FUB3E M=LX #^7-)\E*2,U(S:F)DC8X$>FI5D?WL>]6)#=8KNO6"=$QB:Y;S2I:!)@" M@RB9!B$E^J8L1" ^Z6R9LSFV3@#.SJ13V38[X_Q;,ZJG^#S+H-LOG&4 MCP?DHRXJ12RUB00@N#& 1$L4I$(C(_)DI%):1-[.Y=]NR_WW!K8V)'@V.&H" MH"J('),7"H1+J3RFGL 1'\!Q3RGZ.$RV=,/WNT/.":(;&#*_38MAL@R+$C;9 MRK-!LCZLZH!^2N/IH1A$X[XKP8SB)8-?QB21=!HA!B- :&MIRE%0VB IJI^H M1(^(ZU2R R-R=?:^/Q/FR!XJ]*IQ)1I@>:]MO;L=??"SWBY](F&K08T5S)@G7#FC"*"AC(K"R MB-;Y0)D&)AMM+.?4>*H!ERX' M;\M!;GD:AF3+F1$N2MX@@Z>?;- NE-Z9";W'L%Q_Q>K+.Z9A>CTI20:WMS2[ MCP6NDQFZC0'>C3%\H&^3N[&_W,'V9U4(FI$LT/@+M@2-<0MG22?P!G=WDIFK MF?[9,4>';NM_^V'%(A>**@'HJAM@7#F@7B)KQG*?LY4^-DC.Z"NH=NHT/3+I M&LJF/^M_0VAYQ&C^(<5RD%]KUK]I4 GTMFW4'$A$ ]5D&R!9XT I]&XTL8&H M!BG-/<_^"9/VU/PWE5+O./C;=/;GY03WV)#JK?YO&E2$!6Z8*M4>200;6$;Q M.0T*71=NI+61-(@@]%5NM7T<-)52[SAXYS[_BL;6;.3&M6"P_7V5@U(L> &, M(5?)H74H=2G\Z20W+FLMZCU,.F0"51"X=\,@(4)>ST+D\C]F@;$%OYQYMVP/-1-2]EW)G6/=PD'\W5L<> M46]Y$(]O-*Z=L>V+I;T.^BZ%L9O/1WD45MT.[2WA_H<^Z(%[MODL M;7GDK[\L9@YUV&CB9E\O4??,?YOB_YTL<"J1ONO+">X.:7[XE*>342MAK%?4 M*]"!VU+\,8#.R@ -5&GI45OYLW]\ZE3X[ S*GXN8>S\,.IN\I4'W_U:QU(:, MNC8 ]FXFB.(WZSHX0^\C^\A$4^TJHZSW8+9.\XJFR)0S#&(4'H0E&:(J3\@3 M$6040EN>AMM[]K&P5DP/]_ZF@CG0:Z5-MHX; =&@91P0PN"(C6C<>HT&LF"J MR5O._>P=[0-C.J2 ^]HU'M)<=LR+$)8?RSRF^!33F\>1UH]?U4!GF\-4G.>H M0U!@(U7 O>/@(BVJ6'G4\R2GEIX>[W)_ZARO XM\R.VN8Z=T_]!?U@?\O3BL M.#_KH3?62;^C#6U*H(D^O2WWMU,,.Q31DVTJ-.22UJZ\ (GJ.0EF(&J*1F/. MS.%:0^-^P*.]]02

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�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~~~~'I=NCP-U<67Q!F03EWK$LIJ1V&;?*U.K7Q+FO+N M]WE1?$C*V_LORQ^+R'4??Z?(1!%H4[_FZ39;';/A\M<(&( M1~~~~

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end XML 21 R34.htm IDEA: XBRL DOCUMENT v3.19.3

Goodwill and Other Intangibles (Policies)
12 Months Ended

Dec. 31, 2018

Goodwill and Intangible Assets Disclosure [Abstract]

Goodwill and Intangible Assets For transactions other than a business combination, we capitalize milestone payments incurred at or after the product has obtained regulatory approval for marketing.
Goodwill results from excess consideration in a business combination over the fair value of identifiable net assets acquired. Goodwill is not amortized but is reviewed for impairment at least annually and when impairment indicators are present. When required, a comparison of the fair value of the reporting unit to its carrying amount including goodwill is used to determine the amount of any impairment.
The costs of acquired IPR&D projects acquired directly in a transaction other than a business combination are capitalized if the projects have an alternative future use; otherwise, they are expensed immediately. The fair values of acquired IPR&D projects acquired in business combinations, if any, are capitalized as other intangible assets. As of December 31, 2018 and 2017, we had no acquired IPR&D indefinite-lived intangible assets.
Several methods may be used to determine the estimated fair value of other intangibles acquired in a business combination. We utilize the “income method,” which is a Level 3 fair value measurement and applies a probability weighting that considers the risk of development and commercialization to the estimated future net cash flows that are derived from projected revenues and estimated costs. These projections are based on factors such as relevant market size, patent protection, historical pricing of similar products, and expected industry trends. The estimated future net cash flows are then discounted to the present value using an appropriate discount rate. This analysis is performed for each asset independently. The acquired IPR&D assets are treated as indefinite-lived intangible assets until completion or abandonment of the projects, at which time the assets are tested for impairment and amortized over the remaining useful life or written off, as appropriate.
Other indefinite-lived intangible assets are reviewed for impairment at least annually and when impairment indicators are present. Finite-lived intangible assets are reviewed for impairment when an indicator of impairment is present. When required, a comparison of fair value to the carrying amount of assets is performed to determine the amount of any impairment. When determining the fair value of indefinite-lived acquired IPR&D as well as the fair value of finite-lived intangible assets for impairment testing purposes, we utilize the "income method" discussed above.

XML 22 R4.htm IDEA: XBRL DOCUMENT v3.19.3

Consolidated Statements of Comprehensive Income (Loss) (Parenthetical) - USD ($)
$ in Millions
12 Months Ended

Dec. 31, 2018

Dec. 31, 2017

Dec. 31, 2016

Statement of Other Comprehensive Income [Abstract]

Other comprehensive income (loss), attributed to parent $ 72.6 $ 199.0 $ (693.3)

Other comprehensive income (loss), non-controlling interest $ 11.0 $ (24.5) $ 48.2

X

- Definition
Amount after tax of other comprehensive income (loss) attributable to noncontrolling interests.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 45
-Paragraph 20
-URI http://asc.fasb.org/extlink&oid=108774443&loc=SL4569643-111683

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 1A
-Subparagraph (c)(3)
-URI http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=118930883&loc=SL7669625-108580

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=118930883&loc=SL7669619-108580

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 45
-Paragraph 19
-URI http://asc.fasb.org/extlink&oid=108774443&loc=SL4569616-111683
+ Details

Name: us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount after tax of other comprehensive income (loss) attributable to parent entity.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=118930883&loc=SL7669625-108580

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 1A
-Subparagraph (c)(3)
-URI http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 45
-Paragraph 20
-URI http://asc.fasb.org/extlink&oid=108774443&loc=SL4569643-111683

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=118930883&loc=SL7669619-108580

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 45
-Paragraph 19
-URI http://asc.fasb.org/extlink&oid=108774443&loc=SL4569616-111683
+ Details

Name: us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_StatementOfOtherComprehensiveIncomeAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 23 R102.htm IDEA: XBRL DOCUMENT v3.19.3

Discontinued Operations (Major Classes of Assets and Liabilities) (Details) - USD ($)
$ in Millions

Dec. 31, 2018

Dec. 31, 2017

Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]

Current assets of discontinued operations $ 2,229.1 $ 2,110.0

Noncurrent assets of discontinued operations 6,484.1 6,668.7

Current liabilities of discontinued operations 692.8 637.5

Noncurrent liabilities of discontinued operations 2,742.3 351.6

Elanco Animal Health Incorporated | Discontinued Operations, Disposed of by Sale

Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]

Inventories 1,013.7 1,062.3

Other current assets 1,215.4 1,047.7

Current assets of discontinued operations 2,229.1 2,110.0

Goodwill 2,980.9 2,992.1

Other intangibles, net 2,453.0 2,674.8

Property and equipment, net 923.4 941.4

Other assets 126.8 60.4

Noncurrent assets of discontinued operations 6,484.1 6,668.7

Current liabilities of discontinued operations 692.8 637.5

Long-term debt 2,443.3 0.5

Other liabilities 299.0 351.1

Noncurrent liabilities of discontinued operations $ 2,742.3 $ 351.6

X

- Definition
Disposal Group, Including Discontinued Operation, Debt, Noncurrent
+ References
No definition available.
+ Details

Name: lly_DisposalGroupIncludingDiscontinuedOperationDebtNoncurrent

Namespace Prefix: lly_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount classified as assets attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 45
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=109222160&loc=d3e1107-107759

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5C
-Subparagraph (a)(2)
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5B
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 45
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=109226348&loc=d3e2473-110228

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 45
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=109222160&loc=SL51721533-107759

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230
+ Details

Name: us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount classified as assets attributable to disposal group held for sale or disposed of, expected to be disposed of after one year or the normal operating cycle, if longer.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 45
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=109226348&loc=d3e2510-110228

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 45
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=109222160&loc=SL51721533-107759

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5B
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5C
-Subparagraph (a)(2)
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 45
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=109222160&loc=d3e1107-107759
+ Details

Name: us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount classified as goodwill attributable to disposal group held for sale or disposed of, expected to be disposed of after one year or the normal operating cycle, if longer.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 45
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=109222160&loc=d3e1107-107759

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 45
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=109222160&loc=SL51721533-107759

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 45
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=109226348&loc=d3e2510-110228

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5B
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760
+ Details

Name: us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwillNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount classified as intangible assets, excluding goodwill, attributable to disposal group held for sale or disposed of, expected to be disposed of beyond one year or the normal operating cycle, if longer.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 45
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=109222160&loc=SL51721533-107759

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 45
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=109226348&loc=d3e2510-110228

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5B
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 45
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=109222160&loc=d3e1107-107759
+ Details

Name: us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount classified as inventory attributable to disposal group, expected to be disposed of within one year or the normal operating cycle, if longer.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 45
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=109222160&loc=SL51721533-107759

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5B
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 45
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=109226348&loc=d3e2473-110228

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 45
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=109222160&loc=d3e1107-107759
+ Details

Name: us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount classified as other assets attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 45
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=109222160&loc=d3e1107-107759

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 45
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=109222160&loc=SL51721533-107759

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5B
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 45
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=109226348&loc=d3e2473-110228
+ Details

Name: us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentAssets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount classified as other assets attributable to disposal group held for sale or disposed of, expected to be disposed of after one year or the normal operating cycle, if longer.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 45
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=109226348&loc=d3e2510-110228

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5B
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 45
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=109222160&loc=SL51721533-107759

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 45
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=109222160&loc=d3e1107-107759

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230
+ Details

Name: us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentAssets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount classified as other liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of beyond one year or the normal operating cycle, if longer.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 45
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=109222160&loc=SL51721533-107759

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 45
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=109222160&loc=d3e1107-107759

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 45
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=109226348&loc=d3e2510-110228

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5B
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760
+ Details

Name: us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount classified as property, plant and equipment attributable to disposal group held for sale or disposed of, expected to be disposed of after one year or the normal operating cycle, if longer.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 45
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=109222160&loc=SL51721533-107759

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 45
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=109222160&loc=d3e1107-107759

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 45
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=109226348&loc=d3e2510-110228

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5B
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760
+ Details

Name: us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount classified as liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 45
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=109222160&loc=d3e1107-107759

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5B
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 45
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=109222160&loc=SL51721533-107759

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 45
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=109226348&loc=d3e2473-110228

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5C
-Subparagraph (a)(2)
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760
+ Details

Name: us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount classified as liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of beyond one year or the normal operating cycle, if longer.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 45
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=109222160&loc=d3e1107-107759

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5C
-Subparagraph (a)(2)
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5B
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 45
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=109226348&loc=d3e2510-110228

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 45
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=109222160&loc=SL51721533-107759
+ Details

Name: us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Details

Name: us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=lly_ElancoAnimalHealthIncorporatedMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_DisposalGroupClassificationAxis=us-gaap_DiscontinuedOperationsDisposedOfBySaleMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 24 R30.htm IDEA: XBRL DOCUMENT v3.19.3

Discontinued Operations (Notes)
12 Months Ended

Dec. 31, 2018

Discontinued Operations and Disposal Groups [Abstract]

Disposal Groups, Including Discontinued Operations, Disclosure Discontinued Operations
On September 24, 2018, Elanco completed its IPO resulting in the issuance of 72.3 million shares of its common stock, which represented 19.8 percent of Elanco's outstanding shares, at $24 per share. Elanco shares began trading on the New York Stock Exchange under the symbol "ELAN" in September 2018.
In connection with the completion of the IPO, through a series of equity and other transactions, we transferred to Elanco the animal health businesses that formed its business. In exchange, Elanco transferred to us consideration of approximately $4.2 billion, which consisted primarily of the net proceeds from the IPO and the net proceeds from a $2.00 billion debt offering and a $500.0 million three-year term loan facility entered into by Elanco in August 2018. The consideration that we received was used for debt repayment, dividends, and/or share repurchases. The excess of the net proceeds from the IPO over the net book value of our divested interest was $629.2 million and was recorded in additional paid-in capital.
Through March 11, 2019, we continued to consolidate Elanco, as we retained control over Elanco. The earnings attributable to the divested, noncontrolling interest for the period from the IPO until December 31, 2018 were not material. As of December 31, 2018, the noncontrolling interest of $1.02 billion associated with Elanco was reflected in noncontrolling interests in the consolidated balance sheet.
On March 11, 2019, we completed the disposition of our remaining 80.2 percent ownership of Elanco common stock through a tax-free exchange offer. As a result, in the first quarter of 2019, we recognized a gain related to the disposition of approximately $3.7 billion, and we presented Elanco, including the gain related to the disposition, as discontinued operations in our consolidated condensed financial statements for all periods presented.
The following table sets forth details of revenue and net income (loss) from discontinued operations:

2018

2017

2016
Revenue from discontinued operations
$
3,062.4

$
2,897.5

$
2,909.3

Net income (loss) from discontinued operations
81.4

(117.7
)

12.7

The following table presents the major classes of assets and liabilities from discontinued operations at December 31:

2018

2017
Inventories
$
1,013.7

$
1,062.3

Other current assets
1,215.4

1,047.7

Current assets of discontinued operations
$
2,229.1

$
2,110.0

Goodwill
$
2,980.9

$
2,992.1

Other intangibles, net
2,453.0

2,674.8

Property and equipment, net
923.4

941.4

Other assets
126.8

60.4

Noncurrent assets of discontinued operations
$
6,484.1

$
6,668.7

Current liabilities of discontinued operations
$
692.8

$
637.5

Long-term debt
$
2,443.3

$
0.5

Other liabilities
299.0

351.1

Noncurrent liabilities of discontinued operations
$
2,742.3

$
351.6

Net cash provided by operating activities related to our discontinued operations was approximately $500 million, $300 million, and $300 million for the years ended December 31, 2018, 2017, and 2016, respectively. Net cash used by investing activities related to our discontinued operations was approximately $130 million, $960 million, and $180 million for the years ended December 31, 2018, 2017, and 2016, respectively.
We entered into a transitional services agreement (TSA) with Elanco that is designed to facilitate the orderly transfer of various services to Elanco. The TSA relates primarily to administrative services, which are
generally to be provided over 24 months from March 11, 2019, the disposition date. This agreement is not material and does not confer upon us the ability to influence the operating and/or financial policies of Elanco subsequent to the disposition date.

X

- References
No definition available.
+ Details

Name: us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-URI http://asc.fasb.org/topic&trid=2155823

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-URI http://asc.fasb.org/subtopic&trid=2122178
+ Details

Name: us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 25 R8.htm IDEA: XBRL DOCUMENT v3.19.3

Consolidated Statements of Shareholders' Equity (Parenthetical) - $ / shares
12 Months Ended

Dec. 31, 2018

Dec. 31, 2017

Dec. 31, 2016

Statement of Stockholders' Equity [Abstract]

Cash dividend declared per share (usd per share) $ 2.33 $ 2.12 $ 2.05

X

- Definition
Aggregate dividends declared during the period for each share of common stock outstanding.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770
+ Details

Name: us-gaap_CommonStockDividendsPerShareDeclared

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_StatementOfStockholdersEquityAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 26 R38.htm IDEA: XBRL DOCUMENT v3.19.3

Contingencies (Policies)
12 Months Ended

Dec. 31, 2018

Commitments and Contingencies Disclosure [Abstract]

Commitments and Contingencies
Litigation accruals, environmental liabilities, and the related estimated insurance recoverables are reflected on a gross basis as liabilities and assets, respectively, on our consolidated balance sheets. With respect to the product liability claims currently asserted against us, we have accrued for our estimated exposures to the extent they are both probable and reasonably estimable based on the information available to us. We accrue for certain product liability claims incurred but not filed to the extent we can formulate a reasonable estimate of their costs. We estimate these expenses based primarily on historical claims experience and data regarding product usage. Legal defense costs expected to be incurred in connection with significant product liability loss contingencies are accrued when both probable and reasonably estimable.

X

- References
No definition available.
+ Details

Name: us-gaap_CommitmentsAndContingenciesDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for commitments and contingencies, which may include policies for recognizing and measuring loss and gain contingencies.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 954
-SubTopic 450
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6491354&loc=d3e6052-115624

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 954
-SubTopic 450
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6491354&loc=d3e6049-115624

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 460
-SubTopic 10
-Section 50
-Paragraph 8
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=68068213&loc=d3e12565-110249

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790
+ Details

Name: us-gaap_CommitmentsAndContingenciesPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 27 R13.htm IDEA: XBRL DOCUMENT v3.19.3

Acquisitions
12 Months Ended

Dec. 31, 2018

Business Combinations [Abstract]

Acquisitions Acquisitions
We acquired assets in development in 2018, 2017, and 2016 which are further discussed in this note below in Asset Acquisitions. Upon acquisition, the acquired IPR&D charges related to these products were immediately expensed because the products had no alternative future use. For the years ended December 31, 2018, 2017, and 2016, we recorded acquired IPR&D charges of $1.98 billion, $1.11 billion, and $30.0 million, respectively. The acquired IPR&D charges in 2018 were primarily related to the acquisition of ARMO Biosciences, Inc. (ARMO). Substantially all of the value of ARMO was related to pegilodecakin, its only significant asset.
Acquisition of a Business
Subsequent Event - Loxo Oncology, Inc. (Loxo) Acquisition
Overview of transaction
On February 15, 2019, we acquired Loxo for a purchase price of $235 per share, or approximately $8 billion. Under the terms of the agreement, we acquired a pipeline of highly selective potential medicines for patients with genomically defined cancers. Loxo's pipeline includes LOXO-292, an oral RET inhibitor being studied across multiple tumor types, which recently was granted Breakthrough Therapy designation by the U.S. Food and Drug Administration. The accounting impact of this acquisition and the results of the operations for Loxo will be included in our consolidated financial statements beginning in the first quarter of 2019.
Assets Acquired and Liabilities Assumed
The initial accounting for this acquisition is incomplete. Significant, relevant information needed to complete the initial accounting is not available because the valuation of assets acquired and liabilities assumed is not complete. As a result, determining these values is not practicable and we are unable to disclose these values or provide other related disclosures at this time.

Asset Acquisitions
The following table and narrative summarize our asset acquisitions during 2018, 2017, and 2016.
Counterparty
Compound(s),Therapy, or Asset
Acquisition Month

Phase of Development⁽¹⁾

Acquired IPR&D Expense
Sigilon Therapeutics
Encapsulated cell therapies for the potential treatment of type 1 diabetes
April 2018

Pre-clinical

$
66.9

AurKa Pharma, Inc.
AK-01, an Aurora kinase A inhibitor
June 2018

Phase I

81.8

ARMO
Cancer therapy - pegilodecakin
June 2018

Phase III

1,475.8

Anima Biotech
Translation inhibitors for selected neuroscience targets
July 2018

Pre-clinical

30.0

SIGA Technologies, Inc.
Priority Review Voucher
October 2018

Not applicable

80.0

Chugai Pharmaceutical Company
OWL833, an oral non-peptidic GLP-1 receptor agonist
October 2018

Pre-clinical

50.0

NextCure, Inc.
Immuno-oncology cancer therapies
November 2018

Pre-clinical

28.1

Dicerna Pharmaceuticals
Cardio-metabolic disease, neurodegeneration, and pain
December 2018

Pre-clinical

148.7

Hydra Biosciences
TRPA1 antagonists program for the potential treatment of chronic pain syndromes
December 2018

Pre-clinical

22.6

CoLucid Pharmaceuticals, Inc. (CoLucid)
Oral therapy for the acute treatment of migraine - lasmiditan
March 2017

Phase III

857.6

KeyBioscience AG
Multiple molecules for treatment of metabolic disorders
July 2017

Phase II

55.0

Nektar Therapeutics
Immunological therapy - NKTR-358
August 2017

Phase I

150.0

CureVac AG
Cancer vaccines
November 2017

Pre-clinical

50.0

AstraZeneca
Antibody selective for amyloid-beta 42 (Aβ42) - MEDI1814
December 2016

Phase I

30.0

⁽¹⁾The phase of development presented is as of the date of the arrangement and represents the phase of development of the most advanced asset acquired, where applicable.
In connection with these arrangements, our partners may be entitled to future royalties and/or commercial milestones based on sales should products be approved for commercialization and/or milestones based on the successful progress of compounds through the development process.
Subsequent Event - AC Immune SA
In January 2019, we entered into a license and collaboration agreement with AC Immune SA for the discovery and development of tau aggregation inhibitor small molecules for the potential treatment of Alzheimer's disease and other neurodegenerative diseases. Under terms of the agreement, we paid an upfront fee of CHF80.0 million and we will pay $50.0 million in exchange for a note, convertible to equity at a premium. As a result of this transaction, we will record an acquired IPR&D expense of $96.9 million in the first quarter of 2019.

X

- References
No definition available.
+ Details

Name: us-gaap_BusinessCombinationsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for business combinations, including leverage buyout transactions (as applicable), and divestitures. This may include a description of a business combination or divestiture (or series of individually immaterial business combinations or divestitures) completed during the period, including background, timing, and assets and liabilities recognized and reclassified or sold. This element does not include fixed asset sales and plant closings.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-URI http://asc.fasb.org/subtopic&trid=2122178

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-URI http://asc.fasb.org/topic&trid=2303972
+ Details

Name: us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 28 R17.htm IDEA: XBRL DOCUMENT v3.19.3

Financial Instruments
12 Months Ended

Dec. 31, 2018

Derivative Instruments and Hedging Activities Disclosure [Abstract]

Financial Instruments Financial Instruments
Financial instruments that potentially subject us to credit risk consist principally of trade receivables and interest-bearing investments. Wholesale distributors of life-science products account for a substantial portion of our trade receivables; collateral is generally not required. We seek to mitigate the risk associated with this concentration through our ongoing credit-review procedures and insurance. A large portion of our cash is held by a few major financial institutions. We monitor our exposures with these institutions and do not expect any of these institutions to fail to meet their obligations. Major financial institutions represent the largest component of our investments in corporate debt securities. In accordance with documented corporate risk-management policies, we monitor the amount of credit exposure to any one financial institution or corporate issuer. We are exposed to credit-related losses in the event of nonperformance by counterparties to risk-management instruments but do not expect any counterparties to fail to meet their obligations given their high credit ratings.
We consider all highly liquid investments with a maturity of three months or less from the date of purchase to be cash equivalents. The cost of these investments approximates fair value.
Our equity investments are accounted for using three different methods depending on the type of equity investment:
•
Investments in companies over which we have significant influence but not a controlling interest are accounted for using the equity method, with our share of earnings or losses reported in other-net, (income) expense.
•
For equity investments that do not have readily determinable fair values, we measure these investments at cost, less any impairment, plus or minus changes resulting from observable price changes in orderly transactions for the identical or similar investment of the same issuer. Any change in recorded value is recorded in other-net, (income) expense.
•
Our public equity investments are measured and carried at fair value. Any change in fair value is recognized in other-net, (income) expense.
We review equity investments other than public equity investments for indications of impairment on a regular basis.
Our derivative activities are initiated within the guidelines of documented corporate risk-management policies and are intended to offset losses and gains on the assets, liabilities, and transactions being hedged. Management reviews the correlation and effectiveness of our derivatives on a quarterly basis.
For derivative instruments that are designated and qualify as fair value hedges, the derivative instrument is marked to market with gains and losses recognized currently in income to offset the respective losses and gains recognized on the underlying exposure. For derivative instruments that are designated and qualify as cash flow hedges, gains and losses are reported as a component of accumulated other comprehensive loss and reclassified into earnings in the same period the hedged transaction affects earnings. For derivative and non-derivative instruments that are designated and qualify as net investment hedges, the foreign currency translation gains or losses due to spot rate fluctuations are reported as a component of accumulated other comprehensive loss. Derivative contracts that are not designated as hedging instruments are recorded at fair value with the gain or loss recognized in earnings during the period of change.
We may enter into foreign currency forward or option contracts to reduce the effect of fluctuating currency exchange rates (principally the euro, British pound, and the Japanese yen). Foreign currency derivatives used for hedging are put in place using the same or like currencies and duration as the underlying exposures. Forward and option contracts are principally used to manage exposures arising from subsidiary trade and loan payables and receivables denominated in foreign currencies. These contracts are recorded at fair value with the gain or loss recognized in other–net, (income) expense. We may enter into foreign currency forward and option contracts and currency swaps as fair value hedges of firm commitments. Forward contracts generally have maturities not exceeding 12 months. At December 31, 2018, we had outstanding foreign currency forward commitments to purchase 785.5 million U.S. dollars and sell 685.3 million euro; commitments to purchase 2.05 billion euro and sell 2.35 billion U.S. dollars; commitments to purchase 435.1 million U.S. dollars and sell 48.85 billion Japanese yen, commitments to purchase 255.6 million Swiss francs and sell 259.7 million U.S. dollars, commitments to purchase 388.3 million U.S. dollars and sell 306.7 million
British pounds, and commitments to purchase 354.0 million British pounds and sell 448.1 million U.S. dollars which will all settle within 30 days.
Foreign currency exchange risk is also managed through the use of foreign currency debt and cross-currency interest rate swaps. Our foreign currency-denominated notes had carrying amounts of $3.40 billion and $3.70 billion as of December 31, 2018 and 2017, respectively, of which $2.65 billion and $3.70 billion have been designated as, and are effective as, economic hedges of net investments in certain of our euro-denominated and Swiss franc-denominated foreign operations as of December 31, 2018 and 2017, respectively. Our cross-currency interest rate swaps, for which a majority convert a portion of our U.S. dollar-denominated floating rate debt to foreign-denominated floating rate debt, have also been designated as, and are effective as, economic hedges of net investments. At December 31, 2018, we had outstanding cross currency swaps with notional amounts of $2.46 billion swapping U.S. dollars to euro, $754.0 million swapping Swiss francs to U.S. dollars, and $350.0 million swapping U.S. dollars to British pounds, which have settlement dates ranging through 2028.
In the normal course of business, our operations are exposed to fluctuations in interest rates which can vary the costs of financing, investing, and operating. We seek to address a portion of these risks through a controlled program of risk management that includes the use of derivative financial instruments. The objective of controlling these risks is to limit the impact of fluctuations in interest rates on earnings. Our primary interest-rate risk exposure results from changes in short-term U.S. dollar interest rates. In an effort to manage interest-rate exposures, we strive to achieve an acceptable balance between fixed- and floating-rate debt and investment positions and may enter into interest rate swaps or collars to help maintain that balance.
Interest rate swaps or collars that convert our fixed-rate debt to a floating rate are designated as fair value hedges of the underlying instruments. Interest rate swaps or collars that convert floating-rate debt to a fixed rate are designated as cash flow hedges. Interest expense on the debt is adjusted to include the payments made or received under the swap agreements. Cash proceeds from or payments to counterparties resulting from the termination of interest rate swaps are classified as operating activities in our consolidated statements of cash flows. At December 31, 2018, substantially all of our total long-term debt is at a fixed rate. We have converted approximately 25 percent of our long-term fixed-rate notes to floating rates through the use of interest rate swaps.
We may enter into forward contracts and designate them as cash flow hedges to limit the potential volatility of earnings and cash flow associated with forecasted sales of available-for-sale securities.
We also may enter into forward-starting interest rate swaps, which we designate as cash flow hedges, as part of any anticipated future debt issuances in order to reduce the risk of cash flow volatility from future changes in interest rates. Upon completion of a debt issuance and termination of the swap, the change in fair value of these instruments is recorded as part of other comprehensive income (loss) and is amortized to interest expense over the life of the underlying debt.
The Effect of Risk Management Instruments on the Consolidated Statements of Operations
The following effects of risk-management instruments were recognized in other–net, (income) expense:

2018

2017

2016
Fair value hedges:

Effect from hedged fixed-rate debt
$
(40.9
)

$
(14.1
)

$
(30.8
)
Effect from interest rate contracts
40.9

14.1

30.8

Cash flow hedges:

Effective portion of losses on interest rate contracts reclassified from accumulated other comprehensive loss
14.8

14.8

15.0

Net losses on foreign currency exchange contracts not designated as hedging instruments
100.0

97.9

78.8

Total
$
114.8

$
112.7

$
93.8

During the years ended December 31, 2018, the amortization of losses related to the portion of our risk management hedging instruments, fair value hedges, and cash flow hedges that were excluded from the assessment of effectiveness were not material.
During the years ended December 31, 2017, and 2016, net losses related to ineffectiveness, as well as net losses related to the portion of our risk-management hedging instruments, fair value hedges, and cash flow hedges that were excluded from the assessment of effectiveness, were not material.
The Effect of Risk-Management Instruments on Other Comprehensive Income (Loss)
The effective portion of risk-management instruments that was recognized in other comprehensive income (loss) is as follows:

2018

2017

2016
Net investment hedges:

    Foreign currency-denominated notes
$
110.4

$
(361.5
)

$
137.5

    Cross-currency interest rate swaps
96.8

(126.6
)

32.5

    Foreign currency exchange contracts
5.7

—

31.9

Cash flow hedges:

    Forward-starting interest rate swaps
—

13.0

(3.4
)

During the next 12 months, we expect to reclassify $15.0 million of pretax net losses on cash flow hedges from accumulated other comprehensive loss to other–net, (income) expense. During the year ended December 31, 2018, the amounts excluded from the assessment of hedge effectiveness recognized in other comprehensive income (loss) was not material.
Fair Value of Financial Instruments
The following tables summarize certain fair value information at December 31 for assets and liabilities measured at fair value on a recurring basis, as well as the carrying amount and amortized cost of certain other investments:

Fair Value Measurements Using

Description
Carrying
Amount

Cost⁽¹⁾

Quoted Prices in Active Markets for Identical Assets
(Level 1)

Significant
Other
Observable
Inputs
(Level 2)

Significant
Unobservable
Inputs
(Level 3)

Fair
Value
December 31, 2018

Cash equivalents
$
5,727.1

$
5,727.1

$
5,727.1

$
—

$
—

$
5,727.1

Short-term investments:

U.S. government and agency securities
$
16.9

$
17.1

$
16.9

$
—

$
—

$
16.9

Corporate debt securities
62.2

62.6

—

62.2

—

62.2

Asset-backed securities
7.6

7.7

—

7.6

—

7.6

Other securities
1.5

1.5

—

1.5

—

1.5

Short-term investments
$
88.2

Noncurrent investments:
U.S. government and agency securities
$
149.1

$
153.6

$
149.1

$
—

$
—

$
149.1

Corporate debt securities
568.0

587.8

—

568.0

—

568.0

Mortgage-backed securities
111.4

114.5

—

111.4

—

111.4

Asset-backed securities
27.7

27.9

—

27.7

—

27.7

Other securities
87.8

29.7

—

—

87.8

87.8

Marketable equity securities
357.5

238.3

357.5

—

—

357.5

Equity investments without readily determinable fair values⁽²⁾
414.7

Equity method investments⁽²⁾
289.2

Noncurrent investments
$
2,005.4

December 31, 2017

Cash equivalents
$
4,763.9

$
4,763.9

$
4,712.4

$
51.5

$
—

$
4,763.9

Short-term investments:

U.S. government and agency securities
$
217.8

$
218.2

$
217.8

$
—

$
—

$
217.8

Corporate debt securities
1,182.3

1,183.2

—

1,182.3

—

1,182.3

Asset-backed securities
94.2

94.3

—

94.2

—

94.2

Other securities
3.6

3.6

—

3.6

—

3.6

Short-term investments
$
1,497.9

Noncurrent investments:

U.S. government and agency securities
$
360.0

$
365.0

$
360.0

$
—

$
—

$
360.0

Corporate debt securities
3,464.3

3,473.5

—

3,464.3

—

3,464.3

Mortgage-backed securities
202.4

204.2

—

202.4

—

202.4

Asset-backed securities
653.9

656.0

—

653.9

—

653.9

Other securities
132.1

66.4

—

—

132.1

132.1

Marketable equity securities
281.3

131.0

281.3

—

—

281.3

Cost and equity method investments⁽²⁾
572.5

Noncurrent investments
$
5,666.5

⁽¹⁾For available-for-sale debt securities, amounts disclosed represent the securities' amortized cost.
⁽²⁾Fair value disclosures are not applicable for equity method investments, investments accounted for under the measurement alternative for equity investments, and cost method investments that do not have readily determinable fair values.

Fair Value Measurements Using

Description
Carrying
Amount

Quoted Prices in Active Markets for Identical Assets
(Level 1)

Significant
Other
Observable
Inputs
(Level 2)

Significant
Unobservable
Inputs
(Level 3)

Fair
Value
Short-term commercial paper borrowings

December 31, 2018
$
(498.9
)

$
—

$
(497.6
)

$
—

$
(497.6
)
December 31, 2017
(2,696.8
)

—

(2,690.6
)

—

(2,690.6
)

Long-term debt, including current portion

December 31, 2018
$
(9,799.7
)

$
—

$
(9,989.4
)

$
—

$
(9,989.4
)
December 31, 2017
(10,950.3
)

—

(11,529.9
)

—

(11,529.9
)

Fair Value Measurements Using

Description
Carrying
Amount

Quoted Prices in Active Markets for Identical Assets
(Level 1)

Significant
Other
Observable
Inputs
(Level 2)

Significant
Unobservable
Inputs
(Level 3)

Fair
Value
December 31, 2018

Risk-management instruments

Interest rate contracts designated as fair value hedges:

Sundry
$
4.5

$
—

$
4.5

$
—

$
4.5

Other current liabilities
(22.3
)

—

(22.3
)

—

(22.3
)
Other noncurrent liabilities
(19.0
)

—

(19.0
)

—

(19.0
)
Cross-currency interest rate contracts designated as net investment hedges:

Other receivables
69.2

—

69.2

—

69.2

Sundry
8.2

—

8.2

—

8.2

Other current liabilities
(9.2
)

—

(9.2
)

—

(9.2
)
Cross-currency interest rate contracts not designated as hedging instruments:

Other noncurrent liabilities
(25.8
)

—

(25.8
)

—

(25.8
)
Foreign exchange contracts not designated as hedging instruments:

Other receivables
11.3

—

11.3

—

11.3

Other current liabilities
(16.3
)

—

(16.3
)

—

(16.3
)

December 31, 2017

Risk-management instruments

Interest rate contracts designated as fair value hedges:

Other receivables
$
0.8

$
—

$
0.8

$
—

$
0.8

Sundry
35.1

—

35.1

—

35.1

Other current liabilities
(0.2
)

—

(0.2
)

—

(0.2
)
Other noncurrent liabilities
(10.5
)

—

(10.5
)

—

(10.5
)
Cross-currency interest rate contracts designated as net investment hedges:

    Other current liabilities
(33.4
)

—

(33.4
)

—

(33.4
)
    Other noncurrent liabilities
(26.0
)

—

(26.0
)

—

(26.0
)
Foreign exchange contracts not designated as hedging instruments:

Other receivables
26.8

—

26.8

—

26.8

Other current liabilities
(36.0
)

—

(36.0
)

—

(36.0
)
Contingent consideration liabilities

Other current liabilities
(206.7
)

—

—

(206.7
)

(206.7
)

Risk-management instruments above are disclosed on a gross basis. There are various rights of setoff associated with certain of the risk-management instruments above that are subject to an enforceable master netting arrangement or similar agreements. Although various rights of setoff and master netting arrangements or similar agreements may exist with the individual counterparties to the risk-management instruments above, individually, these financial rights are not material.
We determine our Level 1 and Level 2 fair value measurements based on a market approach using quoted market values, significant other observable inputs for identical or comparable assets or liabilities, or discounted cash flow analyses. Level 3 fair value measurements for other investment securities are determined using unobservable inputs, including the investments' cost adjusted for impairments and price changes from orderly transactions. The fair values of equity method investments and investments measured under the measurement alternative for equity investments that do not have readily determinable fair values are not readily available.
Contingent consideration liabilities were recorded at fair value and were estimated using a discounted cash flow analysis and Level 3 inputs, including projections representative of a market participant view for net sales and an estimated discount rate. The decrease in the fair value of the contingent consideration liabilities during the years ended December 31, 2018 and 2017 was due primarily to cash payments of $199.7 million and $203.1 million, which related to Erbitux (see Note 4). The change in the fair value of the contingent consideration liabilities recognized in earnings during the years ended December 31, 2018, 2017, and 2016 due to changes in time value of money was not material.
The table below summarizes the contractual maturities of our investments in debt securities measured at fair value as of December 31, 2018:

Maturities by Period

Total

Less Than
1 Year

1-5 Years

6-10 Years

More Than 10 Years
Fair value of debt securities
$
943.0

$
86.8

$
604.8

$
97.0

$
154.4

A summary of the fair value of available-for-sale securities in an unrealized gain or loss position and the amount of unrealized gains and losses (pretax) in accumulated other comprehensive loss follows:

2018

2017
Unrealized gross gains
$
0.8

$
184.7

Unrealized gross losses
29.0

47.5

Fair value of securities in an unrealized gain position
84.3

1,434.2

Fair value of securities in an unrealized loss position
858.6

4,692.8

The unrealized losses (pretax) recognized in our consolidated statement of operations for equity securities held as of December 31, 2018 was $20.1 million.
We periodically assess our investment in available-for-sale securities for other-than-temporary impairment losses. There were no other-than-temporary impairment losses recognized in 2018 or 2017. Other-than-temporary impairment losses recognized during the year ended December 31, 2016 totaled $53.0 million. Other-than-temporary impairment losses recognized during 2016 related primarily to our cost and equity method investments.
We periodically assess our investments in equity securities other than public equity securities for impairment losses. Impairment losses recognized on these equity securities in 2018 were immaterial.
For fixed-income securities, the amount of credit losses are determined by comparing the difference between the present value of future cash flows expected to be collected on these securities and the amortized cost. Factors considered in assessing credit losses include the position in the capital structure, vintage and amount of collateral, delinquency rates, current credit support, and geographic concentration.
For equity securities, factors considered in assessing impairment losses include the financial condition and near term prospects of the issuer and general market conditions and industry specific factors.
As of December 31, 2018, the available-for-sale securities in an unrealized loss position include primarily fixed-rate debt securities of varying maturities, which are sensitive to changes in the yield curve and other market conditions. Approximately 55 percent of the fixed-rate debt securities in a loss position are investment-grade debt securities. As of December 31, 2018, we do not intend to sell, and it is not more likely than not that we will be required to sell, the securities in a loss position before the market values recover or the underlying cash flows have been received, and there is no indication of default on interest or principal payments for any of our debt securities.
Activity related to our investment portfolio, substantially all of which related to equity and available-for-sale securities, was as follows:

2018

2017

2016
Proceeds from sales
$
5,668.0

$
5,769.3

$
3,240.5

Realized gross gains on sales
11.8

176.0

30.7

Realized gross losses on sales
51.3

5.8

14.6

Realized gains and losses on sales of available-for-sale investments are computed based upon specific identification of the initial cost adjusted for any other-than-temporary declines in fair value that were recorded in earnings.
Adjustments recorded to our equity investments without readily determinable fair values are based upon changes in the equity instrument's value resulting from observable price changes in orderly transactions for an identical or similar investment of the same issuer. Downward adjustments resulting from an impairment are recorded based upon the impairment considerations mentioned above. Adjustments recorded during 2018 were not material.
Accounts Receivable Factoring Arrangements
We have entered into accounts receivable factoring agreements with financial institutions to sell certain of our non-U.S. accounts receivable. These transactions are accounted for as sales and result in a reduction in accounts receivable because the agreements transfer effective control over and risk related to the receivables to the buyers. Our factoring agreements do not allow for recourse in the event of uncollectibility, and we do not retain any interest in the underlying accounts receivable once sold. We derecognized $696.2 million and $723.2 million of accounts receivable as of December 31, 2018 and 2017, respectively, under these factoring arrangements. The costs of factoring such accounts receivable on our consolidated results of operations for the years ended December 31, 2018, 2017, and 2016 were not material.

X

- References
No definition available.
+ Details

Name: us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 820
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258
+ Details

Name: us-gaap_FairValueDisclosuresTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 29 R86.htm IDEA: XBRL DOCUMENT v3.19.3

Income Taxes (Reconciliation of Income Taxes) (Details) - USD ($)
$ in Millions
3 Months Ended 12 Months Ended

Dec. 31, 2018

Sep. 30, 2018

Jun. 30, 2018

Mar. 31, 2018

Dec. 31, 2017

Sep. 30, 2017

Jun. 30, 2017

Mar. 31, 2017

Dec. 31, 2018

Dec. 31, 2017

Dec. 31, 2016

Income Tax Disclosure [Abstract]

Income tax at the U.S. federal statutory tax rate $ 772.8 $ 806.7 $ 1,146.7

Add (deduct):

International operations, including Puerto Rico (627.1) (480.8) (357.2)

General business credits (87.4) (66.8) (57.0)

Non-deductible acquired IPR&D 309.9 300.1 0.0

2017 Tax Act 1,914.0 0.0

2017 Tax Act 175.3

Other (14.0) (82.0) (181.1)

Income taxes $ (189.8) $ 247.5 $ 273.3 $ 198.5 $ 1,947.5 $ 29.0 $ 244.3 $ 170.3 $ 529.5 $ 2,391.2 $ 551.4

X

- Definition
Add (Deduct) [Abstract]
+ References
No definition available.
+ Details

Name: lly_AddDeductAbstract

Namespace Prefix: lly_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Effective Income Tax Rate Reconciliation, Tax Cuts and Jobs Act, Amount
+ References
No definition available.
+ Details

Name: lly_EffectiveIncomeTaxRateReconciliationTaxCutsandJobsActAmount

Namespace Prefix: lly_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_IncomeTaxDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (h)
-URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(h))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 20
-Section 45
-Paragraph 2
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109238882&loc=d3e38679-109324
+ Details

Name: us-gaap_IncomeTaxExpenseBenefit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 13
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32698-109319

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32687-109319

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(h)(2))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690
+ Details

Name: us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible research and development expense.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 13
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32698-109319

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32687-109319
+ Details

Name: us-gaap_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32687-109319
+ Details

Name: us-gaap_IncomeTaxReconciliationOtherAdjustments

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax credits. Including, but not limited to, research credit, foreign tax credit, investment tax credit, and other tax credits.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32687-109319

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 13
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32698-109319
+ Details

Name: us-gaap_IncomeTaxReconciliationTaxCredits

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to foreign tax credit.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32687-109319

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 13
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32698-109319
+ Details

Name: us-gaap_IncomeTaxReconciliationTaxCreditsForeign

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of reasonable estimate for income tax expense (benefit) for which accounting for tax effect for remeasurement of deferred tax from change in tax rate is incomplete pursuant to Tax Cuts and Jobs Act.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section S99
-Paragraph 2A
-Subparagraph (SAB Topic 5.EE.Q2(b))
-URI http://asc.fasb.org/extlink&oid=116825942&loc=SL116722634-122817
+ Details

Name: us-gaap_TaxCutsAndJobsActOf2017IncompleteAccountingChangeInTaxRateProvisionalIncomeTaxExpenseBenefit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

XML 30 R76.htm IDEA: XBRL DOCUMENT v3.19.3

Property and Equipment (Details) - USD ($)
$ in Millions
12 Months Ended

Dec. 31, 2018

Dec. 31, 2017

Dec. 31, 2016

Property, Plant and Equipment [Abstract]

Land $ 165.5 $ 167.7

Buildings 7,116.6 6,826.9

Equipment 7,792.3 7,684.1

Construction in progress 1,588.6 1,600.6

Property and equipment, gross 16,663.0 16,279.3

Less accumulated depreciation (8,666.9) (8,394.2)

Property and equipment, net 7,996.1 7,885.1

Depreciation expense 797.1 681.7 $ 638.8

Rental expense 175.7 $ 177.4 $ 179.2

Property, Plant and Equipment [Line Items]

2019 130.6

2020 107.9

2021 75.5

2022 64.7

2023 49.9

After 2023 $ 281.0

Building | Minimum

Property, Plant and Equipment [Line Items]

Estimated useful life (in years) 12 years

Building | Maximum

Property, Plant and Equipment [Line Items]

Estimated useful life (in years) 50 years

Equipment | Minimum

Property, Plant and Equipment [Line Items]

Estimated useful life (in years) 3 years

Equipment | Maximum

Property, Plant and Equipment [Line Items]

Estimated useful life (in years) 25 years

X

- Definition
Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.14)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount before accumulated depreciation of building structures held for productive use including addition, improvement, or renovation to the structure, including, but not limited to, interior masonry, interior flooring, electrical, and plumbing.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 4
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=118951113&loc=d3e6812-107765

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229
+ Details

Name: us-gaap_BuildingsAndImprovementsGross

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229
+ Details

Name: us-gaap_ConstructionInProgressGross

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585
+ Details

Name: us-gaap_Depreciation

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount before accumulated depletion of real estate held for productive use, excluding land held for sale.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.13)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 4
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=118951113&loc=d3e6812-107765
+ Details

Name: us-gaap_Land

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of rent expense incurred for leased assets, including but not limited to, furniture and equipment, that is not directly or indirectly associated with the manufacture, sale or creation of a product or product line.
+ References
No definition available.
+ Details

Name: us-gaap_LeaseAndRentalExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount before accumulated depreciation of tangible personal property used to produce goods and services, including, but is not limited to, tools, dies and molds, computer and office equipment.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 4
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=118951113&loc=d3e6812-107765

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229
+ Details

Name: us-gaap_MachineryAndEquipmentGross

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 840
-SubTopic 20
-Section 50
-Paragraph 2
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=77902758&loc=d3e41502-112717

Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 840
-SubTopic 10
-Section 55
-Paragraph 40
-Subparagraph (Note 3)
-URI http://asc.fasb.org/extlink&oid=82846649&loc=d3e38371-112697
+ Details

Name: us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 840
-SubTopic 20
-Section 50
-Paragraph 2
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=77902758&loc=d3e41502-112717

Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 840
-SubTopic 10
-Section 55
-Paragraph 40
-Subparagraph (Note 3)
-URI http://asc.fasb.org/extlink&oid=82846649&loc=d3e38371-112697
+ Details

Name: us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 840
-SubTopic 20
-Section 50
-Paragraph 2
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=77902758&loc=d3e41502-112717

Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 840
-SubTopic 10
-Section 55
-Paragraph 40
-Subparagraph (Note 3)
-URI http://asc.fasb.org/extlink&oid=82846649&loc=d3e38371-112697
+ Details

Name: us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due after the fifth rolling twelve months following the latest balance sheet. For interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.
+ References
No definition available.
+ Details

Name: us-gaap_OperatingLeasesFutureMinimumPaymentsDueInRollingAfterYearFive

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 840
-SubTopic 10
-Section 55
-Paragraph 40
-Subparagraph (Note 3)
-URI http://asc.fasb.org/extlink&oid=82846649&loc=d3e38371-112697

Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 840
-SubTopic 20
-Section 50
-Paragraph 2
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=77902758&loc=d3e41502-112717
+ Details

Name: us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 840
-SubTopic 20
-Section 50
-Paragraph 2
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=77902758&loc=d3e41502-112717

Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 840
-SubTopic 10
-Section 55
-Paragraph 40
-Subparagraph (Note 3)
-URI http://asc.fasb.org/extlink&oid=82846649&loc=d3e38371-112697
+ Details

Name: us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_PropertyPlantAndEquipmentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.13)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_PropertyPlantAndEquipmentGross

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_PropertyPlantAndEquipmentLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(14))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(8))
-URI http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(13))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_PropertyPlantAndEquipmentNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.
+ References
No definition available.
+ Details

Name: us-gaap_PropertyPlantAndEquipmentUsefulLife

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_RangeAxis=srt_MinimumMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_RangeAxis=srt_MaximumMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 31 R72.htm IDEA: XBRL DOCUMENT v3.19.3

Financial Instruments (Narrative) (Details)
€ in Millions, ¥ in Millions, £ in Millions, SFr in Millions, $ in Millions
12 Months Ended

Dec. 31, 2018

USD ($)

Dec. 31, 2017

USD ($)

Dec. 31, 2016

USD ($)

Dec. 31, 2018

EUR (€)

Dec. 31, 2018

CHF (SFr)

Dec. 31, 2018

GBP (£)

Dec. 31, 2018

USD ($)

Dec. 31, 2018

JPY (¥)

Derivative [Line Items]

Average remaining maturity of foreign currency derivatives 12 months

Maximum remaining maturity of foreign currency derivatives (in days) 30 days

Foreign currency-denominated notes, designated as hedge $ 3,700.0 $ 2,650.0

Variable rate (in percentage) 25.00% 25.00% 25.00% 25.00% 25.00%

Losses expected to be reclassified in the next 12 months $ 15.0

Change on the fair value of contingent consideration $ 199.7 203.1

Unrealized losses from equity securities 20.1

Other-than-temporary impairment losses recognized during the year $ 0.0 0.0 $ 53.0

Percentage of nonperforming assets (in percentage) 55.00%

Amount derecognized 723.2 696.2

Buy USD Sell Euro

Derivative [Line Items]

Derivative liability, notional amount 785.5

Derivative asset, notional amount | € € 685.3

Buy euro Sell US dollar

Derivative [Line Items]

Derivative liability, notional amount | € € 2,050.0

Derivative asset, notional amount 2,350.0

Buy USD Sell Japanese Yen

Derivative [Line Items]

Derivative liability, notional amount 435.1

Derivative asset, notional amount | ¥ ¥ 48,850

Buy Swiss francs Sell US dollar

Derivative [Line Items]

Derivative liability, notional amount | SFr SFr 255.6

Derivative asset, notional amount 259.7

Buy US dollar Sell British pound

Derivative [Line Items]

Derivative liability, notional amount 388.3

Derivative asset, notional amount | £ £ 306.7

Buy GBP Sell USD

Derivative [Line Items]

Derivative liability, notional amount | £ £ 354.0

Derivative asset, notional amount 448.1

Currency Swap

Derivative [Line Items]

Derivative liability, notional amount 2,460.0

Swap Swiss Francs to U.S. Dollars

Derivative [Line Items]

Derivative liability, notional amount 754.0

Interest rate swap

Derivative [Line Items]

Derivative asset, notional amount 350.0

Foreign Currency Denominated Debt

Derivative [Line Items]

Long-term debt $ 3,700.0 $ 3,400.0

X

- Definition
This item represents the percentage of nonperforming assets that the underlying assets in the security represent and which were considered as one of the potential factors in reaching a conclusion that the available-for-sale investments are not other-than-temporarily impaired.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=118939692&loc=d3e27290-111563
+ Details

Name: us-gaap_AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureOtherPercentageOfNonperformingAssets

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
Average period remaining before foreign currency exchange rate derivatives mature or expire, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.
+ References
No definition available.
+ Details

Name: us-gaap_AverageRemainingMaturityOfForeignCurrencyDerivatives1

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 4
-Subparagraph (a)(1)
-URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e7008-128479
+ Details

Name: us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Nominal or face amount used to calculate payments on the derivative asset.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 1A
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=109980867&loc=SL5579245-113959

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 1B
-URI http://asc.fasb.org/extlink&oid=109980867&loc=SL5580258-113959

Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 1A
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109980867&loc=SL5579245-113959
+ Details

Name: us-gaap_DerivativeAssetNotionalAmount

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: na

Period Type: instant

X

- Definition
Nominal or face amount used to calculate payments on the derivative liability.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 1A
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109980867&loc=SL5579245-113959

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 1B
-URI http://asc.fasb.org/extlink&oid=109980867&loc=SL5580258-113959

Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 1A
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=109980867&loc=SL5579245-113959
+ Details

Name: us-gaap_DerivativeLiabilityNotionalAmount

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: na

Period Type: instant

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_DerivativeLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of unrealized and realized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 321
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=116654751&loc=SL75117546-209714
+ Details

Name: us-gaap_EquitySecuritiesFvNiGainLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The amount by which the fair value of an investment is less than the amortized cost basis or carrying amount of that investment at the balance sheet date and the decline in fair value is deemed to be other than temporary, before considering whether or not such amount is recognized in earnings or other comprehensive income.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-SubTopic 10
-Section 45
-Paragraph 8A
-URI http://asc.fasb.org/extlink&oid=118954083&loc=SL6284422-111562
+ Details

Name: us-gaap_ImpairmentOfInvestments

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The estimated net amount of unrealized gains or losses on interest rate cash flow hedges as of the balance sheet date expected to be reclassified to earnings within the next twelve months.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 30
-Section 50
-Paragraph 1
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=112277219&loc=d3e80748-113994
+ Details

Name: us-gaap_InterestRateCashFlowHedgeGainLossToBeReclassifiedDuringNext12MonthsNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 4
-Subparagraph (b)(3)
-URI http://asc.fasb.org/extlink&oid=109500613&loc=SL6031897-161870

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(16))
-URI http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(16))
-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(22))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_LongTermDebt

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
The interest rate applicable to the portion of the carrying amount of long-term borrowings outstanding as of the balance sheet date, including current maturities, which accrues interest at a rate subject to change from time to time.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.22(a)(1))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_LongTermDebtPercentageBearingVariableInterestRate

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: instant

X

- Definition
Maximum amount of time remaining before foreign currency exchange rate derivatives mature or expire, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.
+ References
No definition available.
+ Details

Name: us-gaap_MaximumRemainingMaturityOfForeignCurrencyDerivatives1

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of derecognized financial assets from transactions which comprise an initial transfer and an agreement entered into in contemplation of the initial transfer resulting in retention of substantially all of the exposure to the economic return throughout the term of the transaction, at the date of derecognition.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 860
-SubTopic 20
-Section 50
-Paragraph 4D
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118948506&loc=SL51823488-111719
+ Details

Name: us-gaap_TransferOfFinancialAssetsAccountedForAsSalesAmountDerecognized

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount, after tax, of cumulative translation adjustment attributable to gain (loss) on foreign currency derivatives that are designated as, and are effective as, economic hedges of a net investment in a foreign entity.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 830
-SubTopic 30
-Section 45
-Paragraph 20
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900
+ Details

Name: us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Details

Name: us-gaap_DerivativeInstrumentRiskAxis=lly_BuyUsdSellEuroMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_DerivativeInstrumentRiskAxis=lly_BuyEuroSellUsDollarMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_DerivativeInstrumentRiskAxis=lly_BuyUSdollarSellJapaneseYenMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_DerivativeInstrumentRiskAxis=lly_BuySwissfrancsSellUSdollarMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_DerivativeInstrumentRiskAxis=lly_BuyUSdollarSellBritishpoundMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_DerivativeInstrumentRiskAxis=lly_BuyGBPSellUSDMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_DerivativeInstrumentRiskAxis=us-gaap_CurrencySwapMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_DerivativeInstrumentRiskAxis=lly_SwapSwissFrancsToU.S.DollarsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_LongtermDebtTypeAxis=lly_ForeignCurrencyDenominatedDebtMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 32 R82.htm IDEA: XBRL DOCUMENT v3.19.3

Income Taxes (Narrative) (Details) - USD ($)
$ in Millions
12 Months Ended

Dec. 31, 2018

Dec. 31, 2017

Dec. 31, 2016

Dec. 31, 2015

Dec. 31, 2014

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2010

Operating Loss Carryforwards [Line Items]

2017 Tax Act provision $ 1,914.0 $ 0.0

2017 Tax Act benefit $ 313.3

2017 Tax Act, deferred taxes related to GILTI $ 1,740.0

Domestic and Puerto Rican companies contribution 15.00% 16.00% 63.00%

Unrecognized tax benefits that would impact effective tax rate $ 1,480.0 $ 657.1

Year under examination 2015 2014 2013 2012 2010

Settlements 33.2 2.4 $ 171.9

Cash payments of income taxes 1,076.7 221.5 686.4

Decrease in unrecognized tax benefits is reasonably possible 450.0

Income tax payment, anticipated 150.0

Income tax expense (benefit) 25.1 22.8 (63.8)

Accruals for the payment of interest and penalties 183.9 $ 155.0

Carryforward

Operating Loss Carryforwards [Line Items]

Tax credit carryforward 729.5

Operating loss carryforwards 773.2

Expiration in 9 Years

Operating Loss Carryforwards [Line Items]

Tax credit carryforward 150.5

Designated Unusable | Internal Revenue Service (IRS)

Operating Loss Carryforwards [Line Items]

Tax credit carryforward 122.9

Designated Unusable | Foreign Tax Authority

Operating Loss Carryforwards [Line Items]

Tax credit carryforward 119.3

Designated Unusable | State and Local Jurisdiction

Operating Loss Carryforwards [Line Items]

Tax credit carryforward 336.9

Deferred tax assets related to state net operating losses 99.7

Other state carryforwards 2.6

Expiration within 5 years

Operating Loss Carryforwards [Line Items]

Operating loss carryforwards 12.1

Expiration 5 to 20 Years

Operating Loss Carryforwards [Line Items]

Operating loss carryforwards 462.2

No Expiration

Operating Loss Carryforwards [Line Items]

Operating loss carryforwards $ 298.9

Tax Years 2010-2012

Operating Loss Carryforwards [Line Items]

Settlements $ 320.0

Cash payments of income taxes 150.0

Maximum

Operating Loss Carryforwards [Line Items]

Decrease in unrecognized tax benefits is reasonably possible $ 140.0

X

- Definition
Percent contribution of most significant (domestic, including Puerto Rico) areas that contributed to the consolidated income (loss) before income taxes.
+ References
No definition available.
+ Details

Name: lly_DomesticandPuertoRicanContributiontoIncomebeforeIncomeTaxes

Namespace Prefix: lly_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
Income Tax Payment, Anticipated
+ References
No definition available.
+ Details

Name: lly_IncomeTaxPaymentAnticipated

Namespace Prefix: lly_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Tax Cuts and Jobs Act of 2017, Deferred Tax Asset, Global Intangible Low-Taxed Income Provision
+ References
No definition available.
+ Details

Name: lly_TaxCutsandJobsActof2017DeferredTaxAssetGlobalIntangibleLowTaxedIncomeProvision

Namespace Prefix: lly_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of decrease reasonably possible in the next twelve months for the unrecognized tax benefit.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 15
-Subparagraph (d)(3)
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32718-109319
+ Details

Name: us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount before allocation of valuation allowances of deferred tax asset attributable to deductible state and local operating loss carryforwards.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 25
-Paragraph 20
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=117330534&loc=d3e28680-109314

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32632-109319

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32621-109319
+ Details

Name: us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible tax credit carryforwards, classified as other.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32632-109319

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32621-109319

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32559-109319
+ Details

Name: us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsOther

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Tax year being audited in the income tax examination, in CCYY format.
+ References
No definition available.
+ Details

Name: us-gaap_IncomeTaxExaminationYearUnderExamination

Namespace Prefix: us-gaap_

Data Type: us-types:gYearListItemType

Balance Type: na

Period Type: duration

X

- Definition
The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=98513485&loc=d3e4297-108586

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 25
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3536-108585
+ Details

Name: us-gaap_IncomeTaxesPaid

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32559-109319
+ Details

Name: us-gaap_OperatingLossCarryforwards

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_OperatingLossCarryforwardsLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32559-109319
+ Details

Name: us-gaap_TaxCreditCarryforwardAmount

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of income tax expense (benefit) for remeasurement of deferred tax from change in tax rate pursuant to Tax Cuts and Jobs Act.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319
+ Details

Name: us-gaap_TaxCutsAndJobsActOf2017ChangeInTaxRateIncomeTaxExpenseBenefit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of reasonable estimate for income tax expense (benefit) for which accounting for tax effect for remeasurement of deferred tax from change in tax rate is incomplete pursuant to Tax Cuts and Jobs Act.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section S99
-Paragraph 2A
-Subparagraph (SAB Topic 5.EE.Q2(b))
-URI http://asc.fasb.org/extlink&oid=116825942&loc=SL116722634-122817
+ Details

Name: us-gaap_TaxCutsAndJobsActOf2017IncompleteAccountingChangeInTaxRateProvisionalIncomeTaxExpenseBenefit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of decrease in unrecognized tax benefits resulting from settlements with taxing authorities.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 15A
-Subparagraph (a)(3)
-URI http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319
+ Details

Name: us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 15
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32718-109319
+ Details

Name: us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of expense for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 15
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32718-109319
+ Details

Name: us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The total amount of unrecognized tax benefits that, if recognized, would affect the effective tax rate.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 15A
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319
+ Details

Name: us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Details

Name: us-gaap_TaxCreditCarryforwardAxis=lly_CarryforwardMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_TaxCreditCarryforwardAxis=lly_Expirationin9YearsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_TaxCreditCarryforwardAxis=lly_DesignatedUnusableMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_IncomeTaxAuthorityAxis=us-gaap_InternalRevenueServiceIRSMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_TaxCreditCarryforwardAxis=lly_Expirationwithin5yearsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_TaxCreditCarryforwardAxis=lly_Expiration5to20YearsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_TaxCreditCarryforwardAxis=lly_NoExpirationMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_TaxPeriodAxis=lly_TaxYears20102012Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_RangeAxis=srt_MaximumMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 33 R59.htm IDEA: XBRL DOCUMENT v3.19.3

Summary of Significant Accounting Policies (Contract Liabilities) (Details) - USD ($)
$ in Millions

Dec. 31, 2018

Dec. 31, 2017

Accounting Policies [Abstract]

Contract liabilities $ 294.9 $ 330.9

X

- References
No definition available.
+ Details

Name: us-gaap_AccountingPoliciesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=118944033&loc=SL49130531-203044

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 8
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118956577&loc=SL49130549-203045

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=118944033&loc=SL49130532-203044
+ Details

Name: us-gaap_ContractWithCustomerLiability

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

XML 34 R51.htm IDEA: XBRL DOCUMENT v3.19.3

Retirement Benefits (Tables)
12 Months Ended

Dec. 31, 2018

Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items] [Line Items]

Schedule of Changes in Accumulated Postemployment Benefit Obligations We use a measurement date of December 31 to develop the change in benefit obligation, change in plan assets, funded status, and amounts recognized in the consolidated balance sheets at December 31 for our defined benefit pension and retiree health benefit plans, which were as follows:

Defined Benefit
Pension Plans

Retiree Health
Benefit Plans

2018

2017

2018

2017
Change in benefit obligation:

Benefit obligation at beginning of year
$
14,839.7

$
12,230.9

$
1,718.7

$
1,494.6

Service cost
292.7

320.8

41.5

46.4

Interest cost
458.5

411.6

57.3

52.9

Actuarial (gain) loss
(1,386.5
)

1,556.0

(176.9
)

30.2

Benefits paid
(579.4
)

(467.8
)

(82.8
)

(60.1
)
Plan amendments
17.6

—

(14.1
)

—

Curtailment (gain) loss
(43.9
)

90.4

2.5

105.2

Special termination benefit
—

317.2

—

37.5

Foreign currency exchange rate changes and other adjustments
(171.6
)

380.6

(6.2
)

12.0

Benefit obligation at end of year
13,427.1

14,839.7

1,540.0

1,718.7

Schedule of Changes in Fair Value of Plan Assets
Change in plan assets:

Fair value of plan assets at beginning of year
11,713.0

10,056.0

2,372.4

1,961.2

Actual return on plan assets
(360.1
)

1,434.3

32.6

462.0

Employer contribution
319.0

410.4

75.9

9.1

Benefits paid
(579.4
)

(467.8
)

(82.8
)

(60.1
)
Foreign currency exchange rate changes and other adjustments
(159.9
)

280.1

—

0.2

Fair value of plan assets at end of year
10,932.6

11,713.0

2,398.1

2,372.4

Schedule of Net Funded Status
Funded status
(2,494.5
)

(3,126.7
)

858.1

653.7

Unrecognized net actuarial loss
5,011.3

5,616.4

140.6

182.0

Unrecognized prior service (benefit) cost
25.0

14.5

(299.9
)

(395.0
)
Net amount recognized
$
2,541.8

$
2,504.2

$
698.8

$
440.7

Schedule of Amounts Recognized in Balance Sheet
Amounts recognized in the consolidated balance sheet consisted of:

Sundry
$
193.7

$
104.5

$
1,043.6

$
870.1

Other current liabilities
(64.2
)

(64.5
)

(7.3
)

(7.1
)
Accrued retirement benefits
(2,624.0
)

(3,166.7
)

(178.2
)

(209.3
)
Accumulated other comprehensive (income) loss before income taxes
5,036.3

5,630.9

(159.3
)

(213.0
)
Net amount recognized
$
2,541.8

$
2,504.2

$
698.8

$
440.7

Schedule of Assumptions Used
The following represents our weighted-average assumptions as of December 31:

Defined Benefit
Pension Plans

Retiree Health
Benefit Plans
(Percents)
2018

2017

2016

2018

2017

2016
Discount rate for benefit obligation
4.0
%

3.4
%

3.9
%

4.4
%

3.7
%

4.3
%
Discount rate for net benefit costs
3.4

3.9

4.3

3.7

4.3

4.5

Rate of compensation increase for benefit obligation
3.4

3.4

3.4

Rate of compensation increase for net benefit costs
3.4

3.4

3.4

Expected return on plan assets for net benefit costs
7.4

7.4

7.4

8.0

8.0

8.0

Schedule of Expected Benefit Payments
The following benefit payments, which reflect expected future service, as appropriate, are expected to be paid as follows:

2019

2020

2021

2022

2023

2024-2028
Defined benefit pension plans
$
604.1

$
607.2

$
616.5

$
632.1

$
641.6

$
3,524.7

Retiree health benefit plans
98.0

99.1

100.7

99.9

98.5

505.3

Schedule of Net Benefit Costs
Net pension and retiree health benefit expense included the following components:

Defined Benefit
Pension Plans

Retiree Health
Benefit Plans

2018

2017

2016

2018

2017

2016
Components of net periodic (benefit) cost:

Service cost
$
292.7

$
320.8

$
268.4

$
41.5

$
46.4

$
39.1

Interest cost
458.5

411.6

419.0

57.3

52.9

53.2

Expected return on plan assets
(842.1
)

(773.6
)

(748.7
)

(177.9
)

(160.7
)

(150.2
)
Amortization of prior service (benefit) cost
4.6

5.6

11.7

(79.5
)

(90.0
)

(85.8
)
Recognized actuarial loss
332.5

286.8

284.6

6.1

18.4

19.1

Curtailment (gain) loss
1.3

93.5

—

(29.3
)

65.5

—

Special termination benefit
—

317.2

—

—

37.5

—

Net periodic (benefit) cost
$
247.5

$
661.9

$
235.0

$
(181.8
)

$
(30.0
)

$
(124.6
)

Schedule of Amounts Recognized in Other Comprehensive Income (Loss)
The following represents the amounts recognized in other comprehensive income (loss) for the years ended December 31, 2018, 2017, and 2016:

Defined Benefit
Pension Plans

Retiree Health
Benefit Plans

2018

2017

2016

2018

2017

2016
Actuarial gain (loss) arising during period
$
182.8

$
(898.1
)

$
(719.1
)

$
37.5

$
261.3

$
(132.2
)
Plan amendments during period
(17.6
)

—

—

14.1

—

35.8

Curtailment gain (loss)
45.2

3.2

—

(31.8
)

(39.7
)

—

Amortization of prior service (benefit) cost included in net income
4.6

5.6

11.7

(79.5
)

(90.0
)

(85.8
)
Amortization of net actuarial loss included in net income
332.5

286.8

284.6

6.1

18.4

19.1

Foreign currency exchange rate changes and other
47.1

(108.8
)

72.6

(0.1
)

(3.3
)

2.5

Total other comprehensive income (loss) during period
$
594.6

$
(711.3
)

$
(350.2
)

$
(53.7
)

$
146.7

$
(160.6
)

Schedule of Allocation of Plan Assets
The fair values of our defined benefit pension plan and retiree health plan assets as of December 31, 2017 by asset category were as follows:

Fair Value Measurements Using

Asset Class
Total

Quoted Prices in Active Markets for Identical Assets
(Level 1)

Significant Observable Inputs
(Level 2)

Significant Unobservable Inputs
(Level 3)

Investments Valued at Net Asset Value⁽¹⁾
Defined Benefit Pension Plans

Public equity securities:

U.S.
$
465.4

$
199.0

$
—

$
—

$
266.4

International
2,934.2

955.1

—

—

1,979.1

Fixed income:

Developed markets
3,153.0

20.5

2,468.1

—

664.4

Developed markets - repurchase agreements
(1,372.9
)

—

(1,372.9
)

—

—

Emerging markets
577.5

3.6

251.7

3.1

319.1

Private alternative investments:

Hedge funds
2,977.8

—

—

—

2,977.8

Equity-like funds
1,586.9

—

—

16.8

1,570.1

Real estate
543.7

338.6

—

—

205.1

Other
847.4

119.1

602.7

2.2

123.4

Total
$
11,713.0

$
1,635.9

$
1,949.6

$
22.1

$
8,105.4

Retiree Health Benefit Plans

Public equity securities:

U.S.
$
43.0

$
19.4

$
—

$
—

$
23.6

International
182.5

61.3

—

—

121.2

Fixed income:

Developed markets
71.2

—

63.5

—

7.7

Emerging markets
53.1

—

24.4

0.3

28.4

Private alternative investments:

Hedge funds
256.0

—

—

—

256.0

Equity-like funds
137.0

—

—

1.6

135.4

Cash value of trust owned insurance contract
1,524.6

—

1,524.6

—

—

Real estate
33.0

33.0

—

—

—

Other
72.0

15.0

50.5

0.2

6.3

Total
$
2,372.4

$
128.7

$
1,663.0

$
2.1

$
578.6

⁽¹⁾Certain investments that are measured at fair value using the NAV per share (or its equivalent) as a practical expedient have not been classified in the fair value hierarchy.
The fair values of our defined benefit pension plan and retiree health plan assets as of December 31, 2018 by asset category were as follows:

Fair Value Measurements Using

Asset Class
Total

Quoted Prices in Active Markets for
Identical Assets
(Level 1)

Significant
Observable
Inputs
(Level 2)

Significant
Unobservable Inputs
(Level 3)

Investments Valued at Net Asset Value⁽¹⁾
Defined Benefit Pension Plans

Public equity securities:

U.S.
$
617.7

$
409.1

$
—

$
—

$
208.6

International
2,117.8

828.8

—

1.8

1,287.2

Fixed income:

Developed markets
2,933.4

17.2

2,173.3

—

742.9

Developed markets - repurchase agreements
(1,225.5
)

—

(1,225.5
)

—

—

Emerging markets
565.2

3.4

255.8

6.1

299.9

Private alternative investments:

Hedge funds
2,795.3

—

—

—

2,795.3

Equity-like funds
1,893.5

—

—

16.8

1,876.7

Real estate
505.7

147.1

—

—

358.6

Other
729.5

213.0

83.7

—

432.8

Total
$
10,932.6

$
1,618.6

$
1,287.3

$
24.7

$
8,002.0

Retiree Health Benefit Plans

Public equity securities:

U.S.
$
59.9

$
41.0

$
—

$
—

$
18.9

International
127.0

50.5

—

0.2

76.3

Fixed income:

Developed markets
69.1

—

61.5

—

7.6

Emerging markets
53.5

—

25.5

0.6

27.4

Private alternative investments:

Hedge funds
245.8

—

—

—

245.8

Equity-like funds
169.2

—

—

1.7

167.5

Cash value of trust owned insurance contract
1,574.7

—

1,574.7

—

—

Real estate
27.7

14.7

—

—

13.0

Other
71.2

38.1

(3.8
)

—

36.9

Total
$
2,398.1

$
144.3

$
1,657.9

$
2.5

$
593.4

⁽¹⁾Certain investments that are measured at fair value using the NAV per share (or its equivalent) as a practical expedient have not been classified in the fair value hierarchy.

Schedule of Benefit Obligations in Excess of Fair Value of Plan Assets
Amounts relating to defined benefit pension plans with projected benefit obligations in excess of plan assets were as follows at December 31:

2018

2017
Projected benefit obligation
$
11,584.2

$
12,773.4

Fair value of plan assets
8,895.6

9,542.5

Schedule of Accumulated Benefit Obligations in Excess of Fair Value of Plan Assets
Amounts relating to defined benefit pension plans and retiree health benefit plans with accumulated benefit obligations in excess of plan assets were as follows at December 31:

Defined Benefit
Pension Plans

Retiree Health
Benefit Plans

2018

2017

2018

2017
Accumulated benefit obligation
$
10,837.8

$
11,733.6

$
189.4

$
225.1

Fair value of plan assets
8,895.6

9,517.6

—

—

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of benefit obligation and plan assets of defined benefit plan with accumulated benefit obligation in excess of plan assets.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 3
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=118255775&loc=d3e2417-114920

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 3
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118255775&loc=d3e2417-114920

Reference 3: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 55
-Paragraph 17
-URI http://asc.fasb.org/extlink&oid=118257860&loc=d3e4179-114921
+ Details

Name: us-gaap_ScheduleOfAccumulatedBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of the major categories of plan assets of pension plans and/or other employee benefit plans. This information may include, but is not limited to, the target allocation of plan assets, the fair value of each major category of plan assets, and the level within the fair value hierarchy in which the fair value measurements fall.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (d)(5)
-URI http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920
+ Details

Name: us-gaap_ScheduleOfAllocationOfPlanAssetsTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of the amounts that are recognized in the balance sheet (or statement of financial position) for pension plans and/or other employee benefit plans, showing separately the assets and current and noncurrent liabilities (if applicable) recognized.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920
+ Details

Name: us-gaap_ScheduleOfAmountsRecognizedInBalanceSheetTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of the net gain (loss) and net prior service cost or credit recognized in other comprehensive income (loss) for the period for pension plans and/or other employee benefit plans, and reclassification adjustments of other comprehensive income (loss) for the period, as those amounts, including amortization of the net transition asset or obligation, are recognized as components of net periodic benefit cost.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (i)
-URI http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920
+ Details

Name: us-gaap_ScheduleOfAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of assumption used to determine benefit obligation and net periodic benefit cost of defined benefit plan. Includes, but is not limited to, discount rate, rate of compensation increase, expected long-term rate of return on plan assets and interest crediting rate.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (k)
-URI http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920
+ Details

Name: us-gaap_ScheduleOfAssumptionsUsedTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of benefit obligation and plan assets for defined benefit pension plan with projected benefit obligation in excess of plan assets.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 3
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118255775&loc=d3e2417-114920

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 55
-Paragraph 17
-URI http://asc.fasb.org/extlink&oid=118257860&loc=d3e4179-114921
+ Details

Name: us-gaap_ScheduleOfBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of the change in the accumulated postemployment benefit obligation from the beginning to the end of the period, showing separately, if applicable, the effects of the following: service cost, interest cost, contributions by plan participants, actuarial gains and losses, foreign currency exchange rate changes, benefits paid, plan amendments, business combinations, divestitures, curtailments, settlements, and special and contractual termination benefits.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920
+ Details

Name: us-gaap_ScheduleOfChangesInAccumulatedPostemploymentBenefitObligationsTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of the reconciliation of beginning and ending balances of the fair value of plan assets of pension plans and/or other employee benefit plans showing separately, if applicable, the effects during the period attributable to each of the following: actual return on plan assets, foreign currency exchange rate changes, contributions by the employer, contributions by plan participants, benefits paid, business combinations, divestitures, and settlements.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920
+ Details

Name: us-gaap_ScheduleOfChangesInFairValueOfPlanAssetsTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of benefits expected to be paid by pension plans and/or other employee benefit plans in each of the next five fiscal years and in the aggregate for the five fiscal years thereafter.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920
+ Details

Name: us-gaap_ScheduleOfExpectedBenefitPaymentsTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of the components of net benefit costs for pension plans and/or other employee benefit plans including service cost, interest cost, expected return on plan assets, gain (loss), prior service cost or credit, transition asset or obligation, and gain (loss) recognized due to settlements or curtailments.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (h)
-URI http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920
+ Details

Name: us-gaap_ScheduleOfNetBenefitCostsTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of net funded status of pension plans and/or other employee benefit plans.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920
+ Details

Name: us-gaap_ScheduleOfNetFundedStatusTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 35 R55.htm IDEA: XBRL DOCUMENT v3.19.3

Selected Quarterly Data (Unaudited) (Tables)
12 Months Ended

Dec. 31, 2018

Quarterly Financial Information Disclosure [Abstract]

Schedule of Quarterly Financial Information
2018

Fourth

Third

Second

First
Revenue

$
5,637.6

$
5,306.9

$
5,585.0

$
4,963.8

Cost of sales

1,129.9

1,152.9

1,234.3

1,164.6

Operating expenses⁽¹⁾

3,085.5

2,738.1

2,756.6

2,446.2

Acquired in-process research and development⁽²⁾

329.4

30.0

1,624.5

—

Asset impairment, restructuring, and other special charges

192.7

42.9

(25.5
)

56.8

Income before income taxes

931.6

1,341.1

41.7

1,365.7

Income taxes⁽³⁾

(189.8
)

247.5

273.3

198.5

Net income (loss) from continuing operations

1,121.4

1,093.6

(231.6
)

1,167.2

Net income (loss) from discontinued operations

3.7

55.9

(28.3
)

50.2

Net income (loss)

1,125.1

1,149.5

(259.9
)

1,217.4

Earnings (loss) from continuing operations - basic

1.11

1.07

(0.22
)

1.11

Earnings (loss) from discontinued operations - basic

—

0.06

(0.03
)

0.05

Earnings (loss) per share—basic

1.11

1.13

(0.25
)

1.16

Earnings (loss) from continuing operations - diluted

1.10

1.07

(0.22
)

1.11

Earnings (loss) from discontinued operations - diluted

—

0.05

(0.03
)

0.05

Earnings (loss) per share—diluted

1.10

1.12

(0.25
)

1.16

Dividends paid per share

0.5625

0.5625

0.5625

0.5625

2017

Fourth

Third

Second

First
Revenue

$
5,406.4

$
4,961.0

$
5,091.6

$
4,514.9

Cost of sales⁽⁴⁾

1,186.4

1,163.5

1,140.1

957.7

Operating expenses⁽¹⁾⁽⁴⁾

3,054.0

2,678.2

2,763.8

2,582.5

Acquired in-process research and development⁽²⁾

50.0

205.0

—

857.6

Asset impairment, restructuring, and other special charges⁽⁵⁾

830.7

389.2

0.3

111.4

Income before income taxes

397.0

573.1

1,249.4

85.2

Income taxes⁽³⁾

1,947.5

29.0

244.3

170.3

Net income (loss) from continuing operations

(1,550.5
)

544.1

1,005.1

(85.1
)
Net income (loss) from discontinued operations

(106.4
)

11.5

2.9

(25.7
)
Net income (loss)

(1,656.9
)

555.6

1,008.0

(110.8
)
Earnings (loss) from continuing operations - basic

(1.48
)

0.52

0.96

(0.08
)
Earnings (loss) from discontinued operations - basic

(0.10
)

0.01

—

(0.02
)
Earnings (loss) per share—basic

(1.58
)

0.53

0.96

(0.10
)
Earnings (loss) from continuing operations - diluted

(1.48
)

0.52

0.95

(0.08
)
Earnings (loss) from discontinued operations - diluted

(0.10
)

0.01

—

(0.02
)
Earnings (loss) per share—diluted

(1.58
)

0.53

0.95

(0.10
)
Dividends paid per share

0.52

0.52

0.52

0.52

⁽¹⁾Includes research and development and marketing, selling, and administrative expenses.
⁽²⁾ Acquired IPR&D charges in the second quarter of 2018 were primarily due to the ARMO acquisition. Acquired IPR&D charges in the first quarter of 2017 were due to the CoLucid acquisition. See Note 3 for further discussion.
⁽³⁾Income taxes in the fourth quarter of 2018 were a tax benefit primarily due to adjustments associated with U.S. tax reform. Income taxes in the fourth quarter of 2017 were due to the provisional charge resulting from the 2017 Tax Act. See Note 13 for further discussion.
⁽⁴⁾As discussed in Note 2, upon adoption of Accounting Standards Update 2017-07, Compensation-Retirement Benefits: Improving the Presentation of Net Periodic Pension Cost and Net Periodic Postretirement Benefit Cost, pension and postretirement benefit cost components other than service costs are presented in other–net, (income) expense. Results for the quarters in 2017 have been reclassified to reflect the adoption of this standard.
⁽⁵⁾Asset impairment, restructuring, and other special charges in the third quarter 2017 were primarily from asset impairments related to lower projected revenue for Posilac (rbST). In the fourth quarter of 2017, restructuring charges were primarily due to severance costs resulting from the U.S. voluntary early retirement program. See Note 5 for further discussion.

X

- References
No definition available.
+ Details

Name: us-gaap_QuarterlyFinancialInformationDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of quarterly financial data. Includes, but is not limited to, financial information for fiscal quarters, cumulative effect of a change in accounting principle and earnings per share data.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 270
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=118952077&loc=d3e1280-108306
+ Details

Name: us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 36 R9.htm IDEA: XBRL DOCUMENT v3.19.3

Consolidated Statements of Cash Flows - USD ($)
$ in Millions
12 Months Ended

Dec. 31, 2018

Dec. 31, 2017

Dec. 31, 2016

Cash Flows from Operating Activities

Net income (loss) $ 3,232.0 $ (204.1) $ 2,737.6

Adjustments to Reconcile Net Income (Loss) to Cash Flows from Operating Activities:

Depreciation and amortization 1,609.0 1,567.3 1,496.6

Change in deferred income taxes 326.8 (787.9) 439.5

Stock-based compensation expense 279.5 281.3 255.3

Acquired in-process research and development 1,983.9 1,112.6 30.0

Other non-cash operating activities, net 472.0 441.5 376.1

Other changes in operating assets and liabilities, net of acquisitions and divestitures:

Receivables—(increase) decrease (996.7) (357.0) (709.4)

Inventories—(increase) decrease 7.8 (253.9) (328.2)

Other assets—(increase) decrease (980.0) (590.1) (265.5)

Income taxes payable—increase (decrease) (125.3) 3,489.6 (304.8)

Accounts payable and other liabilities—increase (decrease) (284.5) 916.3 1,123.8

Net Cash Provided by Operating Activities 5,524.5 5,615.6 4,851.0

Cash Flows from Investing Activities

Purchases of property and equipment (1,210.6) (1,076.8) (1,037.0)

Proceeds from disposals of property and equipment 3.6 40.7 73.4

Proceeds from sales and maturities of short-term investments 2,552.5 4,852.5 1,642.0

Purchases of short-term investments (112.2) (3,389.7) (1,327.4)

Proceeds from sales of noncurrent investments 3,509.5 2,586.0 2,086.0

Purchases of noncurrent investments (837.9) (4,611.6) (4,346.0)

Purchases of in-process research and development (1,807.6) (1,086.8) (55.0)

Cash paid for acquisitions, net of cash acquired (Note 3 and 20) 0.0 (882.1) (45.0)

Other investing activities, net (191.3) (215.8) (130.1)

Net Cash Provided by (Used for) Investing Activities 1,906.0 (3,783.6) (3,139.1)

Cash Flows from Financing Activities

Dividends paid (2,311.8) (2,192.1) (2,158.5)

Net change in short-term borrowings (2,197.9) 1,397.5 1,293.2

Proceeds from issuance of long-term debt 2,477.7 2,232.0 1,206.6

Repayments of long-term debt (1,009.1) (630.6) (0.2)

Purchases of common stock (4,150.7) (299.8) (600.1)

Net proceeds from Elanco initial public offering (Note 20) 1,659.7 0.0 0.0

Other financing activities, net (372.8) (364.4) (300.8)

Net Cash Provided by (Used for) Financing Activities (5,904.9) 142.6 (559.8)

Effect of exchange rate changes on cash and cash equivalents (63.6) (20.5) (236.4)

Net increase in cash and cash equivalents 1,462.0 1,954.1 915.7

Cash and cash equivalents at beginning of year (includes $324.4 (2018), $258.8 (2017), and $460.6 (2016) of discontinued operations) 6,536.2 4,582.1 3,666.4

Cash and Cash Equivalents at End of Year (includes $677.5 (2018), $324.4 (2017), and $258.8 (2016) of discontinued operations) $ 7,998.2 $ 6,536.2 $ 4,582.1

X

- Definition
The amount of EXPENSE related to research and development assets that are acquired in a business combination (pre-141R) and/or licensing arrangement that have no alternative future use and are therefore written off in the period of acquisition (INCOME STATEMENT)
+ References
No definition available.
+ Details

Name: lly_AcquiredInProcessResearchAndDevelopment

Namespace Prefix: lly_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Proceeds from Issuance or Sale of Equity from Subsidiary
+ References
No definition available.
+ Details

Name: lly_ProceedsfromIssuanceorSaleofEquityfromSubsidiary

Namespace Prefix: lly_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
For the entity and the disposal group, cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the Entity may deposit additional funds at any time and also effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Compensating balance arrangements that do not legally restrict the withdrawal or usage of cash amounts may be reported as Cash and Cash Equivalents, while legally restricted deposits held as compensating balances against borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits are not generally reported as cash and cash equivalents.
+ References
No definition available.
+ Details

Name: us-gaap_CashAndCashEquivalentsAtCarryingValueIncludingDiscontinuedOperations

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of increase (decrease) in cash and cash equivalents. Cash and cash equivalents are the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Includes effect from exchange rate changes.
+ References
No definition available.
+ Details

Name: us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585
+ Details

Name: us-gaap_DepreciationDepletionAndAmortization

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of increase (decrease) from the effect of exchange rate changes on cash and cash equivalent balances held in foreign currencies.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 830
-SubTopic 230
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=98513438&loc=d3e33268-110906
+ Details

Name: us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The increase (decrease) during the reporting period in the amount due from customers for the credit sale of goods and services; includes accounts receivable and other types of receivables.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585
+ Details

Name: us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585
+ Details

Name: us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The increase (decrease) during the period in the amount due for taxes based on the reporting entity's earnings or attributable to the entity's income earning process (business presence) within a given jurisdiction.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585
+ Details

Name: us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The increase (decrease) during the reporting period in the account that represents the temporary difference that results from Income or Loss that is recognized for accounting purposes but not for tax purposes and vice versa.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585
+ Details

Name: us-gaap_IncreaseDecreaseInDeferredIncomeTaxes

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585
+ Details

Name: us-gaap_IncreaseDecreaseInInventories

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_IncreaseDecreaseInOperatingCapitalAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of increase (decrease) in operating assets classified as other.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585
+ Details

Name: us-gaap_IncreaseDecreaseInOtherOperatingAssets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 24
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3521-108585
+ Details

Name: us-gaap_NetCashProvidedByUsedInFinancingActivities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 24
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3521-108585
+ Details

Name: us-gaap_NetCashProvidedByUsedInInvestingActivities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 25
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3536-108585

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 24
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3521-108585

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585
+ Details

Name: us-gaap_NetCashProvidedByUsedInOperatingActivities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118930883&loc=SL7669619-108580

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(22))
-URI http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118930883&loc=SL7669625-108580

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(18))
-URI http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(20))
-URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585

Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257
+ Details

Name: us-gaap_NetIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Other cash or noncash adjustments to reconcile net income to cash provided by (used in) operating activities that are not separately disclosed in the statement of cash flows (for example, cash received or cash paid during the current period for miscellaneous operating activities, net change during the reporting period in other assets or other liabilities).
+ References
No definition available.
+ Details

Name: us-gaap_OtherOperatingActivitiesCashFlowStatement

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of cash (inflow) outflow from investing activities classified as other.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 3
-Subparagraph (SX 210.12-04(a))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e24072-122690

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 13
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3213-108585

Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3179-108585
+ Details

Name: us-gaap_PaymentsForProceedsFromOtherInvestingActivities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The net amount paid (received) by the reporting entity through acquisition or sale and maturities of short-term investments with an original maturity that is three months or less which qualify for treatment as an investing activity based on management's intention and intended by management to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 13
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3213-108585

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 9
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3098-108585

Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 12
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3179-108585
+ Details

Name: us-gaap_PaymentsForProceedsFromShortTermInvestments

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The cash outflow to reacquire common stock during the period.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 15
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3291-108585
+ Details

Name: us-gaap_PaymentsForRepurchaseOfCommonStock

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Cash outflow in the form of capital distributions and dividends to common shareholders, preferred shareholders and noncontrolling interests.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 15
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3291-108585
+ Details

Name: us-gaap_PaymentsOfDividends

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 13
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3213-108585
+ Details

Name: us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The cash outflows from the purchase of net carrying value allocated to in-process research and development costs and materials acquired in a business combination.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 13
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3213-108585
+ Details

Name: us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of cash outflow to acquire investments classified as other.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 13
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3213-108585
+ Details

Name: us-gaap_PaymentsToAcquireOtherInvestments

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of cash outflow from the acquisition of or improvements to long-lived, physical assets used to produce goods and services and not intended for resale, classified as other.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 13
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3213-108585
+ Details

Name: us-gaap_PaymentsToAcquireOtherPropertyPlantAndEquipment

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 14
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3255-108585
+ Details

Name: us-gaap_ProceedsFromIssuanceOfLongTermDebt

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of cash inflow (outflow) from financing activities classified as other.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 3
-Subparagraph (SX 210.12-04(a))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e24072-122690

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 14
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3255-108585

Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 15
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3291-108585
+ Details

Name: us-gaap_ProceedsFromPaymentsForOtherFinancingActivities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The net cash inflow or outflow for borrowing having initial term of repayment within one year or the normal operating cycle, if longer.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 3
-Subparagraph (SX 210.12-04(a))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e24072-122690
+ Details

Name: us-gaap_ProceedsFromRepaymentsOfShortTermDebt

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The cash inflow associated with the sale and maturity (principal being due) of other investments, prepayment and call (request of early payment) of other investments not otherwise defined in the taxonomy.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3179-108585
+ Details

Name: us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of cash inflow for the sale of long-lived, physical assets used to produce goods and services and not intended for resale, classified as other.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 12
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3179-108585
+ Details

Name: us-gaap_ProceedsFromSaleOfOtherPropertyPlantAndEquipment

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The cash inflow from sales of all investments, including securities and other assets, having ready marketability and intended by management to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3179-108585
+ Details

Name: us-gaap_ProceedsFromSaleOfShortTermInvestments

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 15
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3291-108585
+ Details

Name: us-gaap_RepaymentsOfLongTermDebt

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of noncash expense for share-based payment arrangement.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585
+ Details

Name: us-gaap_ShareBasedCompensation

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

XML 37 R39.htm IDEA: XBRL DOCUMENT v3.19.3

Summary of Significant Accounting Policies (Tables)
12 Months Ended

Dec. 31, 2018

Accounting Policies [Abstract]

Schedule of Revenue Recognized
The following table summarizes our revenue recognized in our consolidated statements of operations:

2018

2017

2016
Net product revenue
$
19,866.4

$
18,776.5

$
17,480.0

Collaboration and other revenue⁽¹⁾
1,626.9

1,197.3

832.8

Revenue
$
21,493.3

$
19,973.8

$
18,312.8

⁽¹⁾Collaboration and other revenue associated with prior year transfers of intellectual property was $303.2 million, $144.9 million, and $145.3 million during the years ended 2018, 2017, and 2016, respectively.

Schedule of Contract Liabilities
We have the following amounts recorded for contract liabilities:

2018

2017
Contract liabilities
$
294.9

$
330.9

X

- References
No definition available.
+ Details

Name: us-gaap_AccountingPoliciesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of contract balances and changes in contract balances.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=118956577&loc=SL49130551-203045
+ Details

Name: us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=118956577&loc=SL49130545-203045
+ Details

Name: us-gaap_DisaggregationOfRevenueTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 38 R35.htm IDEA: XBRL DOCUMENT v3.19.3

Property and Equipment (Policies)
12 Months Ended

Dec. 31, 2018

Property, Plant and Equipment [Abstract]

Property, Plant and Equipment
Property and equipment is stated on the basis of cost. Provisions for depreciation of buildings and equipment are computed generally by the straight-line method at rates based on their estimated useful lives (12 to 50 years for buildings and three to 25 years for equipment). We review the carrying value of long-lived assets for potential impairment on a periodic basis and whenever events or changes in circumstances indicate the carrying value of an asset may not be recoverable. Impairment is determined by comparing projected undiscounted cash flows to be generated by the asset to its carrying value. If an impairment is identified, a loss is recorded equal to the excess of the asset’s net book value over its fair value, and the cost basis is adjusted.

X

- References
No definition available.
+ Details

Name: us-gaap_PropertyPlantAndEquipmentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, basis of assets, depreciation and depletion methods used, including composite deprecation, estimated useful lives, capitalization policy, accounting treatment for costs incurred for repairs and maintenance, capitalized interest and the method it is calculated, disposals and impairments.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.13(a))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790
+ Details

Name: us-gaap_PropertyPlantAndEquipmentPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 39 R5.htm IDEA: XBRL DOCUMENT v3.19.3

Consolidated Balance Sheets - USD ($)
$ in Millions

Dec. 31, 2018

Dec. 31, 2017

Current Assets

Cash and cash equivalents (Note 7) $ 7,320.7 $ 6,211.8

Short-term investments (Note 7) 88.2 1,497.9

Accounts receivable, net of allowances of $24.1 (2018) and $28.9 (2017) 4,593.9 3,977.0

Other receivables 1,182.9 689.5

Inventories (Note 6) 3,098.1 3,396.0

Prepaid expenses and other 2,036.7 1,319.9

Current assets of discontinued operations 2,229.1 2,110.0

Total current assets 20,549.6 19,202.1

Other Assets

Investments (Note 7) 2,005.4 5,666.5

Goodwill (Note 8) 1,366.6 1,378.0

Other intangibles, net (Note 8) 1,068.0 1,354.4

Deferred tax assets (Note 13) 2,613.7 1,216.9

Sundry 1,824.9 1,609.3

Property and equipment, net (Note 9) 7,996.1 7,885.1

Noncurrent assets of discontinued operations 6,484.1 6,668.7

Total assets 43,908.4 44,981.0

Current Liabilities

Short-term borrowings and current maturities of long-term debt (Note 10) 1,102.2 3,706.5

Accounts payable 1,207.1 1,206.9

Employee compensation 955.6 911.8

Sales rebates and discounts 4,849.5 4,310.1

Dividends payable 650.8 590.6

Income taxes payable (Note 13) 393.4 522.5

Other current liabilities 2,036.7 2,650.0

Current liabilities of discontinued operations 692.8 637.5

Total current liabilities 11,888.1 14,535.9

Other Liabilities

Long-term debt (Note 10) 9,196.4 9,940.0

Accrued retirement benefits (Note 14) 2,802.2 3,376.0

Long-term income taxes payable (Note 13) 3,700.0 3,747.0

Other noncurrent liabilities 2,670.3 1,362.6

Noncurrent liabilities of discontinued operations 2,742.3 351.6

Total other liabilities 21,111.2 18,777.2

Commitments and Contingencies (Note 15)

Eli Lilly and Company Shareholders' Equity (Notes 11 and 12)

Common stock—no par value Authorized shares: 3,200,000 Issued shares: 1,057,639 (2018) and 1,100,672 (2017) 661.0 687.9

Additional paid-in capital 6,583.6 5,817.8

Retained earnings 11,395.9 13,894.1

Employee benefit trust (3,013.2) (3,013.2)

Accumulated other comprehensive loss (Note 16) (5,729.2) (5,718.6)

Cost of common stock in treasury (69.4) (75.8)

Total Eli Lilly and Company shareholders' equity 9,828.7 11,592.2

Noncontrolling interests 1,080.4 75.7

Total equity 10,909.1 11,667.9

Total liabilities and equity $ 43,908.4 $ 44,981.0

X

- Definition
Sales rebates and discounts
+ References
No definition available.
+ Details

Name: lly_SalesRebatesAndDiscounts

Namespace Prefix: lly_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.19(a))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_AccountsPayableCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 8
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118956577&loc=SL49130549-203045

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=118952595&loc=d3e4428-111522

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(3))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 1
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section 45
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=118952595&loc=d3e4531-111522
+ Details

Name: us-gaap_AccountsReceivableNetCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all domestic and foreign income tax obligations due beyond one year or the operating cycle, whichever is longer. Alternate captions include income taxes payable, noncurrent.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(15)(b)(1))
-URI http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(15)(1))
-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(24))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_AccruedIncomeTaxesNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=118930883&loc=d3e637-108580

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 14A
-URI http://asc.fasb.org/extlink&oid=118930883&loc=SL7669686-108580

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 14
-URI http://asc.fasb.org/extlink&oid=118930883&loc=d3e681-108580
+ Details

Name: us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30)(a)(1))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_AdditionalPaidInCapitalCommonStock

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(11))
-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(12))
-URI http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910
+ Details

Name: us-gaap_Assets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=118951113&loc=d3e6801-107765

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.9)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765
+ Details

Name: us-gaap_AssetsCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_AssetsCurrentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_AssetsNoncurrentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount classified as assets attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 45
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=109222160&loc=d3e1107-107759

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5C
-Subparagraph (a)(2)
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5B
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 45
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=109226348&loc=d3e2473-110228

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 45
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=109222160&loc=SL51721533-107759

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230
+ Details

Name: us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3044-108585

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.1)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_CashAndCashEquivalentsAtCarryingValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.25)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03.(a),19)
-URI http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03.17)
-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 450
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=118942415&loc=d3e14326-108349
+ Details

Name: us-gaap_CommitmentsAndContingencies

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Value of common stock issued to a trust (for example, but not limited to, rabbi trust) set up specifically to accumulate stock for the sole purpose of distribution to participating employees.
+ References
No definition available.
+ Details

Name: us-gaap_CommonStockSharesHeldInEmployeeTrust

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_CommonStockValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of short-term debt and current maturity of long-term debt and capital lease obligations due within one year or the normal operating cycle, if longer.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.19,20)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_DebtCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319
+ Details

Name: us-gaap_DeferredIncomeTaxAssetsNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount classified as assets attributable to disposal group held for sale or disposed of, expected to be disposed of after one year or the normal operating cycle, if longer.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 45
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=109226348&loc=d3e2510-110228

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 45
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=109222160&loc=SL51721533-107759

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5B
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5C
-Subparagraph (a)(2)
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 45
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=109222160&loc=d3e1107-107759
+ Details

Name: us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Carrying value as of the balance sheet date of dividends declared but unpaid on equity securities issued by the entity and outstanding. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.20)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=118951113&loc=d3e6935-107765
+ Details

Name: us-gaap_DividendsPayableCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.20)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_EmployeeRelatedLiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 45
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=77989000&loc=SL49117168-202975

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266
+ Details

Name: us-gaap_Goodwill

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph ((a)(1),(b))
-URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274
+ Details

Name: us-gaap_IntangibleAssetsNetExcludingGoodwill

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 330
-SubTopic 10
-Section 35
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=116846819&loc=d3e3927-108312

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.6(a))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_InventoryNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(23))
-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(25))
-URI http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(32))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_LiabilitiesAndStockholdersEquity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.21)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_LiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_LiabilitiesCurrentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of obligation due after one year or beyond the normal operating cycle, if longer.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 201.5-02(25))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(23))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(22))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 201.5-02(26))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 201.5-02(24))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_LiabilitiesNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_LiabilitiesNoncurrentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount classified as liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 45
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=109222160&loc=d3e1107-107759

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5B
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 45
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=109222160&loc=SL51721533-107759

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 45
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=109226348&loc=d3e2473-110228

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5C
-Subparagraph (a)(2)
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760
+ Details

Name: us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount classified as liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of beyond one year or the normal operating cycle, if longer.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 45
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=109222160&loc=d3e1107-107759

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5C
-Subparagraph (a)(2)
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5B
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 45
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=109226348&loc=d3e2510-110228

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 45
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=109222160&loc=SL51721533-107759
+ Details

Name: us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.22)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_LongTermDebtNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
The total amount of investments that are intended to be held for an extended period of time (longer than one operating cycle).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.12)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_LongTermInvestments

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(24))
-URI http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.31)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(22))
-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878
+ Details

Name: us-gaap_MinorityInterest

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of noncurrent assets classified as other.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.17)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_OtherAssetsNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=118951113&loc=d3e6904-107765

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=118951113&loc=d3e6911-107765

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.20)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_OtherLiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.24)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_OtherLiabilitiesNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount due from parties in nontrade transactions, classified as other.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.8)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_OtherReceivables

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of liability, recognized in statement of financial position, for defined benefit pension and other postretirement plans, classified as noncurrent.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109237824&loc=d3e1703-114919

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 45
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=109237824&loc=d3e1731-114919

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(24))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=118951113&loc=d3e6787-107765

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 1
-Subparagraph (g)
-URI http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 340
-SubTopic 10
-Section 05
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=68074540&loc=d3e5879-108316
+ Details

Name: us-gaap_PrepaidExpenseCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(14))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(8))
-URI http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(13))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_PropertyPlantAndEquipmentNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
The cumulative amount of the reporting entity's undistributed earnings or deficit.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30)(a)(3))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(23)(a)(4))
-URI http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770
+ Details

Name: us-gaap_RetainedEarningsAccumulatedDeficit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(4))
-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(6))
-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(5))
-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(1)(g))
-URI http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(2))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_ShortTermInvestments

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 4.E)
-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(31))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_StockholdersEquity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 45
-Paragraph 16
-URI http://asc.fasb.org/extlink&oid=108774443&loc=SL4568740-111683

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 55
-Paragraph 4I
-URI http://asc.fasb.org/extlink&oid=116874947&loc=SL4590271-111686

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 45
-Paragraph 15
-URI http://asc.fasb.org/extlink&oid=108774443&loc=SL4568447-111683
+ Details

Name: us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.19,20)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_TaxesPayableCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 30
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6405834&loc=d3e23315-112656

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.29,30)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 30
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6405813&loc=d3e23239-112655
+ Details

Name: us-gaap_TreasuryStockValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

XML 40 R1.htm IDEA: XBRL DOCUMENT v3.19.3

Cover Page

Oct. 24, 2019

Entity Information [Line Items]

Document Type 8-K

Document Period End Date Oct. 24, 2019

Entity Registrant Name Lilly Eli & Co

Entity Incorporation, State or Country Code IN

Entity File Number 001-06351

Entity Tax Identification Number 35-0470950

Entity Address, Address Line One Lilly Corporate Center

Entity Address, City or Town Indianapolis

Entity Address, State or Province IN

Entity Address, Postal Zip Code 46285

City Area Code 317

Local Phone Number 276-2000

Written Communications false

Soliciting Material false

Pre-commencement Tender Offer false

Pre-commencement Issuer Tender Offer false

Entity Emerging Growth Company false

Entity Central Index Key 0000059478

Amendment Flag false

Document Fiscal Period Focus FY

Document Fiscal Year Focus 2018

Common Stock (no par value)

Entity Information [Line Items]

Title of 12(b) Security Common Stock (no par value)

Trading Symbol LLY

Security Exchange Name NYSE

1.000% Notes Due June 2, 2022

Entity Information [Line Items]

Title of 12(b) Security 1.000% Notes Due June 2, 2022

Trading Symbol LLY22

Security Exchange Name NYSE

7 1/8% Notes Due June 1, 2025

Entity Information [Line Items]

Title of 12(b) Security 7 1/8% Notes Due June 1, 2025

Trading Symbol LLY25

Security Exchange Name NYSE

1.625% Notes Due June 2, 2026

Entity Information [Line Items]

Title of 12(b) Security 1.625% Notes Due June 2, 2026

Trading Symbol LLY26

Security Exchange Name NYSE

2.125% Notes Due June 3, 2030

Entity Information [Line Items]

Title of 12(b) Security 2.125% Notes Due June 3, 2030

Trading Symbol LLY30

Security Exchange Name NYSE

6.77% Notes Due January 1, 2036

Entity Information [Line Items]

Title of 12(b) Security 6.77% Notes Due January 1, 2036

Trading Symbol LLY36

Security Exchange Name NYSE

X

- Definition
Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.
+ References
No definition available.
+ Details

Name: dei_AmendmentFlag

Namespace Prefix: dei_

Data Type: xbrli:booleanItemType

Balance Type: na

Period Type: duration

X

- Definition
Area code of city
+ References
No definition available.
+ Details

Name: dei_CityAreaCode

Namespace Prefix: dei_

Data Type: xbrli:normalizedStringItemType

Balance Type: na

Period Type: duration

X

- Definition
Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.
+ References
No definition available.
+ Details

Name: dei_DocumentFiscalPeriodFocus

Namespace Prefix: dei_

Data Type: dei:fiscalPeriodItemType

Balance Type: na

Period Type: duration

X

- Definition
This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.
+ References
No definition available.
+ Details

Name: dei_DocumentFiscalYearFocus

Namespace Prefix: dei_

Data Type: xbrli:gYearItemType

Balance Type: na

Period Type: duration

X

- Definition
The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.
+ References
No definition available.
+ Details

Name: dei_DocumentPeriodEndDate

Namespace Prefix: dei_

Data Type: xbrli:dateItemType

Balance Type: na

Period Type: duration

X

- Definition
The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.
+ References
No definition available.
+ Details

Name: dei_DocumentType

Namespace Prefix: dei_

Data Type: dei:submissionTypeItemType

Balance Type: na

Period Type: duration

X

- Definition
Address Line 1 such as Attn, Building Name, Street Name
+ References
No definition available.
+ Details

Name: dei_EntityAddressAddressLine1

Namespace Prefix: dei_

Data Type: xbrli:normalizedStringItemType

Balance Type: na

Period Type: duration

X

- Definition
Name of the City or Town
+ References
No definition available.
+ Details

Name: dei_EntityAddressCityOrTown

Namespace Prefix: dei_

Data Type: xbrli:normalizedStringItemType

Balance Type: na

Period Type: duration

X

- Definition
Code for the postal or zip code
+ References
No definition available.
+ Details

Name: dei_EntityAddressPostalZipCode

Namespace Prefix: dei_

Data Type: xbrli:normalizedStringItemType

Balance Type: na

Period Type: duration

X

- Definition
Name of the state or province.
+ References
No definition available.
+ Details

Name: dei_EntityAddressStateOrProvince

Namespace Prefix: dei_

Data Type: dei:stateOrProvinceItemType

Balance Type: na

Period Type: duration

X

- Definition
A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation 12B
-Number 240
-Section 12
-Subsection b-2
+ Details

Name: dei_EntityCentralIndexKey

Namespace Prefix: dei_

Data Type: dei:centralIndexKeyItemType

Balance Type: na

Period Type: duration

X

- Definition
Indicate if registrant meets the emerging growth company criteria.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation 12B
-Number 240
-Section 12
-Subsection b-2
+ Details

Name: dei_EntityEmergingGrowthCompany

Namespace Prefix: dei_

Data Type: xbrli:booleanItemType

Balance Type: na

Period Type: duration

X

- Definition
Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.
+ References
No definition available.
+ Details

Name: dei_EntityFileNumber

Namespace Prefix: dei_

Data Type: dei:fileNumberItemType

Balance Type: na

Period Type: duration

X

- Definition
Two-character EDGAR code representing the state or country of incorporation.
+ References
No definition available.
+ Details

Name: dei_EntityIncorporationStateCountryCode

Namespace Prefix: dei_

Data Type: dei:edgarStateCountryItemType

Balance Type: na

Period Type: duration

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: dei_EntityInformationLineItems

Namespace Prefix: dei_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation 12B
-Number 240
-Section 12
-Subsection b-2
+ Details

Name: dei_EntityRegistrantName

Namespace Prefix: dei_

Data Type: xbrli:normalizedStringItemType

Balance Type: na

Period Type: duration

X

- Definition
The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation 12B
-Number 240
-Section 12
-Subsection b-2
+ Details

Name: dei_EntityTaxIdentificationNumber

Namespace Prefix: dei_

Data Type: dei:employerIdItemType

Balance Type: na

Period Type: duration

X

- Definition
Local phone number for entity.
+ References
No definition available.
+ Details

Name: dei_LocalPhoneNumber

Namespace Prefix: dei_

Data Type: xbrli:normalizedStringItemType

Balance Type: na

Period Type: duration

X

- Definition
Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 13e
-Subsection 4c
+ Details

Name: dei_PreCommencementIssuerTenderOffer

Namespace Prefix: dei_

Data Type: xbrli:booleanItemType

Balance Type: na

Period Type: duration

X

- Definition
Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 14d
-Subsection 2b
+ Details

Name: dei_PreCommencementTenderOffer

Namespace Prefix: dei_

Data Type: xbrli:booleanItemType

Balance Type: na

Period Type: duration

X

- Definition
Title of a 12(b) registered security.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b
+ Details

Name: dei_Security12bTitle

Namespace Prefix: dei_

Data Type: dei:securityTitleItemType

Balance Type: na

Period Type: duration

X

- Definition
Name of the Exchange on which a security is registered.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection d1-1
+ Details

Name: dei_SecurityExchangeName

Namespace Prefix: dei_

Data Type: dei:edgarExchangeCodeItemType

Balance Type: na

Period Type: duration

X

- Definition
Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Section 14a
-Number 240
-Subsection 12
+ Details

Name: dei_SolicitingMaterial

Namespace Prefix: dei_

Data Type: xbrli:booleanItemType

Balance Type: na

Period Type: duration

X

- Definition
Trading symbol of an instrument as listed on an exchange.
+ References
No definition available.
+ Details

Name: dei_TradingSymbol

Namespace Prefix: dei_

Data Type: dei:tradingSymbolItemType

Balance Type: na

Period Type: duration

X

- Definition
Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Securities Act
-Number 230
-Section 425
+ Details

Name: dei_WrittenCommunications

Namespace Prefix: dei_

Data Type: xbrli:booleanItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementClassOfStockAxis=lly_A1.000NotesDueJune22022Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementClassOfStockAxis=lly_A718NotesDueJune12025Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementClassOfStockAxis=lly_A1.625NotesDueJune22026Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementClassOfStockAxis=lly_A2.125NotesDueJune32030Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementClassOfStockAxis=lly_A6.77NotesDueJanuary12036Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 41 R31.htm IDEA: XBRL DOCUMENT v3.19.3

Summary of Significant Accounting Policies (Policies)
12 Months Ended

Dec. 31, 2018

Accounting Policies [Abstract]

Inventory We use the last-in, first-out (LIFO) method for the majority of our inventories located in the continental U.S. Other inventories are valued by the first-in, first-out (FIFO) method. FIFO cost approximates current replacement cost.

Investment
We consider all highly liquid investments with a maturity of three months or less from the date of purchase to be cash equivalents. The cost of these investments approximates fair value.
Our equity investments are accounted for using three different methods depending on the type of equity investment:
•
Investments in companies over which we have significant influence but not a controlling interest are accounted for using the equity method, with our share of earnings or losses reported in other-net, (income) expense.
•
For equity investments that do not have readily determinable fair values, we measure these investments at cost, less any impairment, plus or minus changes resulting from observable price changes in orderly transactions for the identical or similar investment of the same issuer. Any change in recorded value is recorded in other-net, (income) expense.
•
Our public equity investments are measured and carried at fair value. Any change in fair value is recognized in other-net, (income) expense.
We review equity investments other than public equity investments for indications of impairment on a regular basis.

Derivatives
In the normal course of business, our operations are exposed to fluctuations in interest rates which can vary the costs of financing, investing, and operating. We seek to address a portion of these risks through a controlled program of risk management that includes the use of derivative financial instruments. The objective of controlling these risks is to limit the impact of fluctuations in interest rates on earnings. Our primary interest-rate risk exposure results from changes in short-term U.S. dollar interest rates. In an effort to manage interest-rate exposures, we strive to achieve an acceptable balance between fixed- and floating-rate debt and investment positions and may enter into interest rate swaps or collars to help maintain that balance.
Interest rate swaps or collars that convert our fixed-rate debt to a floating rate are designated as fair value hedges of the underlying instruments. Interest rate swaps or collars that convert floating-rate debt to a fixed rate are designated as cash flow hedges. Interest expense on the debt is adjusted to include the payments made or received under the swap agreements. Cash proceeds from or payments to counterparties resulting from the termination of interest rate swaps are classified as operating activities in our consolidated statements of cash flows.
We may enter into forward contracts and designate them as cash flow hedges to limit the potential volatility of earnings and cash flow associated with forecasted sales of available-for-sale securities.
We also may enter into forward-starting interest rate swaps, which we designate as cash flow hedges, as part of any anticipated future debt issuances in order to reduce the risk of cash flow volatility from future changes in interest rates. Upon completion of a debt issuance and termination of the swap, the change in fair value of these instruments is recorded as part of other comprehensive income (loss) and is amortized to interest expense over the life of the underlying debt.
Our derivative activities are initiated within the guidelines of documented corporate risk-management policies and are intended to offset losses and gains on the assets, liabilities, and transactions being hedged. Management reviews the correlation and effectiveness of our derivatives on a quarterly basis.
For derivative instruments that are designated and qualify as fair value hedges, the derivative instrument is marked to market with gains and losses recognized currently in income to offset the respective losses and gains recognized on the underlying exposure. For derivative instruments that are designated and qualify as cash flow hedges, gains and losses are reported as a component of accumulated other comprehensive loss and reclassified into earnings in the same period the hedged transaction affects earnings. For derivative and non-derivative instruments that are designated and qualify as net investment hedges, the foreign currency translation gains or losses due to spot rate fluctuations are reported as a component of accumulated other comprehensive loss. Derivative contracts that are not designated as hedging instruments are recorded at fair value with the gain or loss recognized in earnings during the period of change.
We may enter into foreign currency forward or option contracts to reduce the effect of fluctuating currency exchange rates (principally the euro, British pound, and the Japanese yen). Foreign currency derivatives used for hedging are put in place using the same or like currencies and duration as the underlying exposures. Forward and option contracts are principally used to manage exposures arising from subsidiary trade and loan payables and receivables denominated in foreign currencies. These contracts are recorded at fair value with the gain or loss recognized in other–net, (income) expense. We may enter into foreign currency forward and option contracts and currency swaps as fair value hedges of firm commitments.

Goodwill and Intangible Assets For transactions other than a business combination, we capitalize milestone payments incurred at or after the product has obtained regulatory approval for marketing.
Goodwill results from excess consideration in a business combination over the fair value of identifiable net assets acquired. Goodwill is not amortized but is reviewed for impairment at least annually and when impairment indicators are present. When required, a comparison of the fair value of the reporting unit to its carrying amount including goodwill is used to determine the amount of any impairment.
The costs of acquired IPR&D projects acquired directly in a transaction other than a business combination are capitalized if the projects have an alternative future use; otherwise, they are expensed immediately. The fair values of acquired IPR&D projects acquired in business combinations, if any, are capitalized as other intangible assets. As of December 31, 2018 and 2017, we had no acquired IPR&D indefinite-lived intangible assets.
Several methods may be used to determine the estimated fair value of other intangibles acquired in a business combination. We utilize the “income method,” which is a Level 3 fair value measurement and applies a probability weighting that considers the risk of development and commercialization to the estimated future net cash flows that are derived from projected revenues and estimated costs. These projections are based on factors such as relevant market size, patent protection, historical pricing of similar products, and expected industry trends. The estimated future net cash flows are then discounted to the present value using an appropriate discount rate. This analysis is performed for each asset independently. The acquired IPR&D assets are treated as indefinite-lived intangible assets until completion or abandonment of the projects, at which time the assets are tested for impairment and amortized over the remaining useful life or written off, as appropriate.
Other indefinite-lived intangible assets are reviewed for impairment at least annually and when impairment indicators are present. Finite-lived intangible assets are reviewed for impairment when an indicator of impairment is present. When required, a comparison of fair value to the carrying amount of assets is performed to determine the amount of any impairment. When determining the fair value of indefinite-lived acquired IPR&D as well as the fair value of finite-lived intangible assets for impairment testing purposes, we utilize the "income method" discussed above.

Property, Plant and Equipment
Property and equipment is stated on the basis of cost. Provisions for depreciation of buildings and equipment are computed generally by the straight-line method at rates based on their estimated useful lives (12 to 50 years for buildings and three to 25 years for equipment). We review the carrying value of long-lived assets for potential impairment on a periodic basis and whenever events or changes in circumstances indicate the carrying value of an asset may not be recoverable. Impairment is determined by comparing projected undiscounted cash flows to be generated by the asset to its carrying value. If an impairment is identified, a loss is recorded equal to the excess of the asset’s net book value over its fair value, and the cost basis is adjusted.

Commitments and Contingencies
Litigation accruals, environmental liabilities, and the related estimated insurance recoverables are reflected on a gross basis as liabilities and assets, respectively, on our consolidated balance sheets. With respect to the product liability claims currently asserted against us, we have accrued for our estimated exposures to the extent they are both probable and reasonably estimable based on the information available to us. We accrue for certain product liability claims incurred but not filed to the extent we can formulate a reasonable estimate of their costs. We estimate these expenses based primarily on historical claims experience and data regarding product usage. Legal defense costs expected to be incurred in connection with significant product liability loss contingencies are accrued when both probable and reasonably estimable.

Revenue Recognition
Adoption of Revenue Accounting Standard
Effective January 1, 2018, we adopted Accounting Standards Update 2014-09, Revenue from Contracts with Customers and other related updates (see Note 2 for additional discussion). The new standard has been applied to contracts for which performance was not substantially complete as of the date of adoption. For those contracts that were modified prior to the date of adoption, we reflected the aggregate effect of those modifications when determining the appropriate accounting under the new standard. We don’t believe the effect of applying this practical expedient resulted in material differences. Revenue presented for periods prior to 2018 was accounted for under previous standards and has not been adjusted. Revenue and net income for 2018 do not differ materially from amounts that would have resulted from application of the previous standards.
The following table summarizes our revenue recognized in our consolidated statements of operations:

2018

2017

2016
Net product revenue
$
19,866.4

$
18,776.5

$
17,480.0

Collaboration and other revenue⁽¹⁾
1,626.9

1,197.3

832.8

Revenue
$
21,493.3

$
19,973.8

$
18,312.8

⁽¹⁾Collaboration and other revenue associated with prior year transfers of intellectual property was $303.2 million, $144.9 million, and $145.3 million during the years ended 2018, 2017, and 2016, respectively.
We recognize revenue primarily from two different types of contracts, product sales to customers (net product revenue) and collaborations and other arrangements. Revenue recognized from collaborations and other arrangements will include our share of profits from the collaboration, as well as royalties, upfront and milestone payments we receive under these types of contracts. See Note 4 for additional information related to our collaborations and other arrangements. Collaboration and other revenue disclosed above includes the revenue from the Trajenta^® and Jardiance^® families of products resulting from our collaboration with
Boehringer Ingelheim discussed in Note 4. Substantially all of the remainder of collaboration and other revenue is related to contracts accounted for as contracts with customers.
Net Product Revenue
Revenue from sales of products is recognized at the point where the customer obtains control of the goods and we satisfy our performance obligation, which generally is at the time we ship the product to the customer. Payment terms differ by jurisdiction and customer, but payment terms in most of our major jurisdictions typically range from 30 to 70 days from date of shipment. Revenue for our product sales has not been adjusted for the effects of a financing component as we expect, at contract inception, that the period between when we transfer control of the product and when we receive payment will be one year or less. Any exceptions are either not material or we collect interest for payments made after the due date. Provisions for rebates and discounts, and returns are established in the same period the related sales are recognized. We generally ship product shortly after orders are received; therefore, we generally only have a few days of orders received but not yet shipped at the end of any reporting period. Shipping and handling activities are considered to be fulfillment activities and are not considered to be a separate performance obligation. We exclude from the measurement of the transaction price all taxes assessed by a governmental authority that are imposed on our sales of product and collected from a customer.
Significant judgments must be made in determining the transaction price for our sales of products related to anticipated rebates and discounts and returns. The following describe the most significant of these judgments:
Sales Rebates and Discounts - Background and Uncertainties
•
Most of our products are sold to wholesalers that serve pharmacies, physicians and other health care professionals, and hospitals. We initially invoice our customers at contractual list prices. Contracts with direct and indirect customers may provide for various rebates and discounts that may differ in each contract. As a consequence, to determine the appropriate transaction price for our product sales at the time we recognize a sale to a direct customer, we must estimate any rebates or discounts that ultimately will be due to the direct customer and other customers in the distribution chain under the terms of our contracts. Significant judgments are required in making these estimates.
•
The rebate and discount amounts are recorded as a deduction to arrive at our net product revenue. Sales rebates and discounts that require the use of judgment in the establishment of the accrual include managed care, Medicare, Medicaid, chargebacks, long-term care, hospital, patient assistance programs, and various other programs. We estimate these accruals using an expected value approach.
•
The largest of our sales rebate and discount amounts are rebates associated with sales covered by managed care, Medicare, Medicaid, and chargeback contracts in the United States (U.S.) In determining the appropriate accrual amount, we consider our historical rebate payments for these programs by product as a percentage of our historical sales as well as any significant changes in sales trends (e.g., patent expiries and product launches), an evaluation of the current contracts for these programs, the percentage of our products that are sold via these programs, and our product pricing. Although we accrue a liability for rebates related to these programs at the time we record the sale, the rebate related to that sale is typically paid up to six months later. Because of this time lag, in any particular period our rebate adjustments may incorporate revisions of accruals for several periods.
•
Most of our rebates outside the U.S. are contractual or legislatively mandated and are estimated and recognized in the same period as the related sales. In some large European countries, government rebates are based on the anticipated budget for pharmaceutical payments in the country. An estimate of these rebates, updated as governmental authorities revise budgeted deficits, is recognized in the same period as the related sale.
Sales Returns - Background and Uncertainties
•
When product sales occur, to determine the appropriate transaction price for our sales, we estimate a reserve for future product returns related to those sales using an expected value approach. This estimate is based on several factors, including: historical return rates, expiration date by product (on average, approximately 24 months after the initial sale of a product to our customer), and estimated levels of inventory in the wholesale and retail channels, as well as any other specifically-identified anticipated returns due to known factors such as the loss of patent exclusivity, product recalls and
discontinuances, or a changing competitive environment. We maintain a returns policy that allows U.S. customers to return product for dating issues within a specified period prior to and subsequent to the product's expiration date. Following the loss of exclusivity for a patent-dependent product, we expect to experience an elevated level of product returns as product inventory remaining in the wholesale and retail channels expires. Adjustments to the returns reserve have been and may in the future be required based on revised estimates to our assumptions. We record the return amounts as a deduction to arrive at our net product revenue. Once the product is returned, it is destroyed; we do not record a right of return asset. Our returns policies outside the U.S. are generally more restrictive than in the U.S. as returns are not allowed for reasons other than failure to meet product specifications in many countries. Our reserve for future product returns for product sales outside the U.S. is not material.
•
As a part of our process to estimate a reserve for product returns, we regularly review the supply levels of our significant products sold to major wholesalers in the U.S. and in major markets outside the U.S., primarily by reviewing periodic inventory reports supplied by our major wholesalers and available prescription volume information for our products, or alternative approaches. We attempt to maintain U.S. wholesaler inventory levels at an average of approximately one month or less on a consistent basis across our product portfolio. Causes of unusual wholesaler buying patterns include actual or anticipated product-supply issues, weather patterns, anticipated changes in the transportation network, redundant holiday stocking, and changes in wholesaler business operations. In the U.S., the current structure of our arrangements provides us with data on inventory levels at our wholesalers; however, our data on inventory levels in the retail channel is more limited. Wholesaler stocking and destocking activity historically has not caused any material changes in the rate of actual product returns.
•
Actual product returns have been less than 2 percent of our net revenue over each of the past three years and have not fluctuated significantly as a percentage of revenue, although fluctuations are more likely in periods following loss of patent exclusivity for major products in the U.S. market.
Adjustments to Revenue
Adjustments to revenue recognized as a result of changes in estimates for the judgments described above during 2018 for product shipped in previous years were approximately 1 percent of revenue.
Disaggregation of Revenue
Our disaggregated revenue is disclosed in Note 18.
Collaborations and Other Arrangements
We recognize several types of revenue from our collaborations and other arrangements, which we discuss in general terms immediately below and more specifically in Note 4 for each of our material collaborations and other arrangements. Our collaborations and other arrangements are not contracts with customers but are evaluated to determine whether any aspects of the arrangements are contracts with customers.
•
Revenue related to products we sell pursuant to these arrangements is included in net product revenue, while other sources of revenue (e.g., royalties and profit sharing from our partner) are included in collaboration and other revenue.
•
Initial fees and developmental milestones we receive in collaborative and other similar arrangements from the partnering of our compounds under development are generally deferred and amortized into income through the expected product approval date.
•
Profit-sharing due from our collaboration partners, which is based upon gross margins reported to us by our partners, is recognized as collaboration and other revenue as earned.
•
Royalty revenue from licensees, which is based on sales to third-parties of licensed products and technology, is recorded when the third-party sale occurs and the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). This royalty revenue is included in collaboration and other revenue.
•
For arrangements involving multiple goods or services (e.g., research and development, marketing and selling, manufacturing, and distribution), each required good or service is evaluated to determine whether it is distinct. If a good or service does not qualify as distinct, it is combined with the other non-distinct goods or services within the arrangement and these combined goods or services are
treated as a single performance obligation for accounting purposes. The arrangement's transaction price is then allocated to each performance obligation based on the relative standalone selling price of each performance obligation. For arrangements that involve variable consideration where we have sold intellectual property, we recognize revenue based on estimates of the amount of consideration we believe we will be entitled to receive from the other party, subject to a constraint. These estimates are adjusted to reflect the actual amounts to be collected when those facts and circumstances become known.
•
Significant judgments must be made in determining the transaction price for our sales of intellectual property. Because of the risk that products in development will not receive regulatory approval, we generally do not recognize any contingent payments that would be due to us upon or after regulatory approval.
•
We have entered into arrangements whereby we transferred rights to products and committed to supply for a period of time. For those arrangements for which we concluded that the obligations were not distinct, any amounts received upfront are being amortized to revenue as net product revenue over the period of the supply arrangement as the performance obligation is satisfied.
Contract Liabilities
Our contract liabilities result from arrangements where we have received payment in advance of performance under the contract and do not include sales rebates, discounts, and returns. Changes in contract liabilities are generally due to either receipt of additional advance payments or our performance under the contract.
We have the following amounts recorded for contract liabilities:

2018

2017
Contract liabilities
$
294.9

$
330.9

The contract liabilities amount disclosed above as of December 31, 2018 and 2017, are primarily related to:
•
The remaining license period of symbolic intellectual property, and
•
Obligations to supply product for a defined period of time.
Revenue recognized from contract liabilities as of January 1, 2018, during the year ended December 31, 2018 was not material. Revenue expected to be recognized in the future from contract liabilities as the related performance obligations are satisfied is not expected to be material in any one year.

Research and Development Expense
Research and development expenses and acquired in-process research and development
Research and development expenses include the following:
•
Research and development costs, which are expensed as incurred.
•
Milestone payment obligations incurred prior to regulatory approval of the product, which are accrued when the event requiring payment of the milestone occurs.
Acquired in-process research and development (IPR&D) expense includes the initial costs of IPR&D projects, acquired directly in a transaction other than a business combination, that do not have an alternative future use.

Income Tax
Deferred taxes are recognized for the future tax effects of temporary differences between financial and income tax reporting based on enacted tax laws and rates.
We recognize the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by the taxing authorities, based on the technical merits of the position. The tax benefits recognized in the financial statements from such a position are measured based on the largest benefit that has a greater than 50 percent likelihood of being realized upon ultimate resolution.

Earnings Per Share
Earnings per share
We calculate basic earnings per share (EPS) based on the weighted-average number of common shares outstanding and incremental shares from potential participating securities. We calculate diluted EPS based on the weighted-average number of common shares outstanding, including incremental shares from our stock-based compensation programs.

Share-based Compensation, Option and Incentive Plans We recognize the fair value of stock-based compensation as expense over the requisite service period of the individual grantees, which generally equals the vesting period. We provide newly issued shares of our common stock and treasury stock to satisfy the issuance of PA, SVA, and RSU shares.

Foreign Currency Translation
Foreign Currency Translation
Operations in our subsidiaries outside the U.S. are recorded in the functional currency of each subsidiary which is determined by a review of the environment where each subsidiary primarily generates and expends cash. The results of operations for our subsidiaries outside the U.S. are translated from functional currencies into U.S. dollars using the weighted average currency rate for the period. Assets and liabilities are translated
using the period end exchange rates. The U.S. dollar effects that arise from translating the net assets of these subsidiaries are recorded in other comprehensive income (loss).

New Accounting Pronouncements, Policy
The following table provides a brief description of accounting standards that were effective January 1, 2018 and were adopted on that date:
Standard

Description

Effect on the financial statements or other significant matters
Accounting Standards Update 2014-09 and various other related updates, Revenue from Contracts with Customers

This standard replaced existing revenue recognition standards and requires entities to recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. An entity can apply the new revenue standard retrospectively to each prior reporting period presented or with the cumulative effect of initially applying the standard recognized at the date of initial application in retained earnings. We applied the latter approach.

Application of the new standard to applicable contracts resulted in an increase of approximately $5 million to retained earnings as of January 1, 2018. Disclosures required by the new standard are included in Note 1, Note 4, and Note 18.
Accounting Standards Update 2016-01, Financial Instruments - Overall: Recognition and Measurement of Financial Assets and Financial Liabilities

This standard requires entities to recognize changes in the fair value of equity investments with readily determinable fair values in net income (except for investments accounted for under the equity method of accounting or those that result in consolidation of the investee). An entity should apply the new standard through a cumulative effect adjustment to retained earnings as of the beginning of the fiscal year of adoption.

Upon adoption, we reclassified from accumulated other comprehensive loss the after-tax amount of net unrealized gains resulting in an increase to retained earnings of approximately $105 million. Adoption of this standard did not result in a material change in net income in 2018.
Accounting Standards Update 2016-16, Income Taxes: Intra-Entity Transfers of Assets Other Than Inventory

This standard requires entities to recognize the income tax consequences of intra-entity transfers of assets other than inventory at the time of transfer. This standard requires a modified
retrospective approach to adoption.

Upon adoption, the cumulative effect of applying the standard resulted in an increase of approximately $700 million to retained earnings, $2.5 billion to deferred tax assets, and $1.8 billion to deferred tax liabilities. Adoption of this standard did not result in a material change in net income in 2018.
Accounting Standards Update 2017-07, Compensation-Retirement Benefits: Improving the Presentation of Net Periodic Pension Cost and Net Periodic Postretirement Benefit Cost

This standard was issued to improve the transparency and comparability among organizations by requiring entities to separate their net periodic pension cost and net periodic postretirement benefit cost into a service cost component and other components. Previously, the costs of the other components along with the service cost component were classified based upon the function of the employee. This standard requires entities to classify the service cost component in the same financial statement line item or items as other compensation costs arising from services rendered by pertinent employees. The other components of net benefit cost are now presented separately from the line items that include the service cost component. When applicable, the service cost component is now the only component eligible for capitalization. An entity should apply the new standard retrospectively for the classification of the service cost and other components and prospectively for the capitalization of the service cost component.

Upon adoption of this standard, pension and postretirement benefit cost components other than service costs are presented in other–net, (income) expense. The application of the new standard resulted in reclassification to other income of $249.0 million for the year ended December 31, 2017, while increasing cost of sales by $80.8 million, research and development expenses by $75.8 million, and marketing, selling, and administrative expenses by $92.4 million for the same period. The application of the new standard resulted in reclassification to other income of $197.1 million for the year ended December 31, 2016, while increasing cost of sales by $54.2 million, research and development expenses by $66.4 million, and marketing, selling, and administrative expenses by $76.5 million for the same period. We do not expect application of the new standard to have a material impact on an ongoing basis.

We elected to early adopt Accounting Standards Update 2018-02, Income Statement-Reporting Comprehensive Income: Reclassification of Certain Tax Effects from Accumulated Other Comprehensive Income as of December 31, 2017, which allowed a reclassification from accumulated other comprehensive loss to retained earnings for stranded tax effects resulting from the Tax Cuts and Jobs Act (2017 Tax Act - see Note 13). This standard allowed us to reclassify the effect of remeasuring deferred tax liabilities and assets related to items within accumulated other comprehensive loss using the then newly enacted 21 percent federal corporate income tax rate. The provisional effect of this early adoption was a reclassification from accumulated other comprehensive loss, which resulted in an increase to retained earnings of $643.6 million as of December 31, 2017.
The following table provides a brief description of the accounting standard that had not yet been adopted as of December 31, 2018:
Standard

Description

Effective Date

Effect on the financial statements or other significant matters
Accounting Standards Update 2016-02, Leases

This standard was issued to increase transparency and comparability among organizations by recognizing lease assets and lease liabilities, including leases classified as operating leases under current GAAP, on the balance sheet and requiring additional disclosures about leasing arrangements. An entity can apply the new leases standard retrospectively to each prior reporting period presented or with the cumulative effect of initially applying the standard recognized at the date of initial application in retained earnings. We plan to use the latter approach.

This standard was effective January 1, 2019, and we adopted on that date.

We expect to record a right-of-use asset and lease liability for operating leases of approximately $575 million on our consolidated balance sheet as of January 1, 2019. Our accounting for capital leases will remain substantially unchanged. This standard will not have a material impact on our consolidated statement of operations.

X

- References
No definition available.
+ Details

Name: us-gaap_AccountingPoliciesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for commitments and contingencies, which may include policies for recognizing and measuring loss and gain contingencies.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 954
-SubTopic 450
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6491354&loc=d3e6052-115624

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 954
-SubTopic 450
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6491354&loc=d3e6049-115624

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 460
-SubTopic 10
-Section 50
-Paragraph 8
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=68068213&loc=d3e12565-110249

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790
+ Details

Name: us-gaap_CommitmentsAndContingenciesPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for its derivative instruments and hedging activities.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109980867&loc=d3e41620-113959

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=109980867&loc=d3e41638-113959

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 1A
-URI http://asc.fasb.org/extlink&oid=109980867&loc=SL5579245-113959

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=109980867&loc=d3e41675-113959

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(n))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=109980867&loc=SL5579240-113959
+ Details

Name: us-gaap_DerivativesPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3630-109257
+ Details

Name: us-gaap_EarningsPerSharePolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 830
-SubTopic 30
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 830
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6450222&loc=d3e30840-110895
+ Details

Name: us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for goodwill and intangible assets. This accounting policy also may address how an entity assesses and measures impairment of goodwill and intangible assets.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=108376223&loc=d3e13816-109267

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275
+ Details

Name: us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 20
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32847-109319

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 954
-SubTopic 740
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6491622&loc=d3e9504-115650

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 17
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32809-109319

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=116657188&loc=SL116659661-227067

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 19
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32840-109319

Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 45
-Paragraph 25
-URI http://asc.fasb.org/extlink&oid=116821951&loc=d3e32247-109318

Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=116821951&loc=d3e32280-109318

Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 30
-Section 05
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=65884525&loc=d3e40913-109327
+ Details

Name: us-gaap_IncomeTaxPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 330
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=116847112&loc=d3e4556-108314

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 270
-SubTopic 10
-Section 45
-Paragraph 6
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=116846552&loc=d3e543-108305

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 330
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=116847112&loc=d3e4492-108314

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.6(b))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_InventoryPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for investment in financial asset.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (a)(2)
-URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571
+ Details

Name: us-gaap_InvestmentPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.
+ References
No definition available.
+ Details

Name: us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, basis of assets, depreciation and depletion methods used, including composite deprecation, estimated useful lives, capitalization policy, accounting treatment for costs incurred for repairs and maintenance, capitalized interest and the method it is calculated, disposals and impairments.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.13(a))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790
+ Details

Name: us-gaap_PropertyPlantAndEquipmentPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 730
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373
+ Details

Name: us-gaap_ResearchAndDevelopmentExpensePolicy

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.
+ References
Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 4
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=84158767&loc=d3e18823-107790

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 4
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=84158767&loc=d3e18823-107790
+ Details

Name: us-gaap_RevenueRecognitionPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (b),(f)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5047-113901
+ Details

Name: us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 42 R12.htm IDEA: XBRL DOCUMENT v3.19.3

Implementation of New Financial Accounting Pronouncements
12 Months Ended

Dec. 31, 2018

New Accounting Pronouncements and Changes in Accounting Principles [Abstract]

Implementation of New Financial Accounting Pronouncements Implementation of New Financial Accounting Pronouncements
The following table provides a brief description of accounting standards that were effective January 1, 2018 and were adopted on that date:
Standard

Description

Effect on the financial statements or other significant matters
Accounting Standards Update 2014-09 and various other related updates, Revenue from Contracts with Customers

This standard replaced existing revenue recognition standards and requires entities to recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. An entity can apply the new revenue standard retrospectively to each prior reporting period presented or with the cumulative effect of initially applying the standard recognized at the date of initial application in retained earnings. We applied the latter approach.

Application of the new standard to applicable contracts resulted in an increase of approximately $5 million to retained earnings as of January 1, 2018. Disclosures required by the new standard are included in Note 1, Note 4, and Note 18.
Accounting Standards Update 2016-01, Financial Instruments - Overall: Recognition and Measurement of Financial Assets and Financial Liabilities

This standard requires entities to recognize changes in the fair value of equity investments with readily determinable fair values in net income (except for investments accounted for under the equity method of accounting or those that result in consolidation of the investee). An entity should apply the new standard through a cumulative effect adjustment to retained earnings as of the beginning of the fiscal year of adoption.

Upon adoption, we reclassified from accumulated other comprehensive loss the after-tax amount of net unrealized gains resulting in an increase to retained earnings of approximately $105 million. Adoption of this standard did not result in a material change in net income in 2018.
Accounting Standards Update 2016-16, Income Taxes: Intra-Entity Transfers of Assets Other Than Inventory

This standard requires entities to recognize the income tax consequences of intra-entity transfers of assets other than inventory at the time of transfer. This standard requires a modified
retrospective approach to adoption.

Upon adoption, the cumulative effect of applying the standard resulted in an increase of approximately $700 million to retained earnings, $2.5 billion to deferred tax assets, and $1.8 billion to deferred tax liabilities. Adoption of this standard did not result in a material change in net income in 2018.
Accounting Standards Update 2017-07, Compensation-Retirement Benefits: Improving the Presentation of Net Periodic Pension Cost and Net Periodic Postretirement Benefit Cost

This standard was issued to improve the transparency and comparability among organizations by requiring entities to separate their net periodic pension cost and net periodic postretirement benefit cost into a service cost component and other components. Previously, the costs of the other components along with the service cost component were classified based upon the function of the employee. This standard requires entities to classify the service cost component in the same financial statement line item or items as other compensation costs arising from services rendered by pertinent employees. The other components of net benefit cost are now presented separately from the line items that include the service cost component. When applicable, the service cost component is now the only component eligible for capitalization. An entity should apply the new standard retrospectively for the classification of the service cost and other components and prospectively for the capitalization of the service cost component.

Upon adoption of this standard, pension and postretirement benefit cost components other than service costs are presented in other–net, (income) expense. The application of the new standard resulted in reclassification to other income of $249.0 million for the year ended December 31, 2017, while increasing cost of sales by $80.8 million, research and development expenses by $75.8 million, and marketing, selling, and administrative expenses by $92.4 million for the same period. The application of the new standard resulted in reclassification to other income of $197.1 million for the year ended December 31, 2016, while increasing cost of sales by $54.2 million, research and development expenses by $66.4 million, and marketing, selling, and administrative expenses by $76.5 million for the same period. We do not expect application of the new standard to have a material impact on an ongoing basis.

We elected to early adopt Accounting Standards Update 2018-02, Income Statement-Reporting Comprehensive Income: Reclassification of Certain Tax Effects from Accumulated Other Comprehensive Income as of December 31, 2017, which allowed a reclassification from accumulated other comprehensive loss to retained earnings for stranded tax effects resulting from the Tax Cuts and Jobs Act (2017 Tax Act - see Note 13). This standard allowed us to reclassify the effect of remeasuring deferred tax liabilities and assets related to items within accumulated other comprehensive loss using the then newly enacted 21 percent federal corporate income tax rate. The provisional effect of this early adoption was a reclassification from accumulated other comprehensive loss, which resulted in an increase to retained earnings of $643.6 million as of December 31, 2017.
The following table provides a brief description of the accounting standard that had not yet been adopted as of December 31, 2018:
Standard

Description

Effective Date

Effect on the financial statements or other significant matters
Accounting Standards Update 2016-02, Leases

This standard was issued to increase transparency and comparability among organizations by recognizing lease assets and lease liabilities, including leases classified as operating leases under current GAAP, on the balance sheet and requiring additional disclosures about leasing arrangements. An entity can apply the new leases standard retrospectively to each prior reporting period presented or with the cumulative effect of initially applying the standard recognized at the date of initial application in retained earnings. We plan to use the latter approach.

This standard was effective January 1, 2019, and we adopted on that date.

We expect to record a right-of-use asset and lease liability for operating leases of approximately $575 million on our consolidated balance sheet as of January 1, 2019. Our accounting for capital leases will remain substantially unchanged. This standard will not have a material impact on our consolidated statement of operations.

X

- References
No definition available.
+ Details

Name: us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure of changes in accounting principles, including adoption of new accounting pronouncements, that describes the new methods, amount and effects on financial statement line items.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-URI http://asc.fasb.org/topic&trid=2122394
+ Details

Name: us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 43 R16.htm IDEA: XBRL DOCUMENT v3.19.3

Inventories
12 Months Ended

Dec. 31, 2018

Inventory Disclosure [Abstract]

Inventories Inventories
We use the last-in, first-out (LIFO) method for the majority of our inventories located in the continental U.S. Other inventories are valued by the first-in, first-out (FIFO) method. FIFO cost approximates current replacement cost. Inventories measured using LIFO must be valued at the lower of cost or market. Inventories measured using FIFO must be valued at the lower of cost or net realizable value.
Inventories at December 31 consisted of the following:

2018

2017
Finished products
$
577.8

$
759.4

Work in process
2,057.8

2,117.7

Raw materials and supplies
426.1

418.4

Total (approximates replacement cost)
3,061.7

3,295.5

Increase (reduction) to LIFO cost
36.4

100.5

Inventories
$
3,098.1

$
3,396.0

Inventories valued under the LIFO method comprised $1.37 billion and $1.33 billion of total inventories at December 31, 2018 and 2017, respectively.

X

- References
No definition available.
+ Details

Name: us-gaap_InventoryDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 330
-URI http://asc.fasb.org/topic&trid=2126998
+ Details

Name: us-gaap_InventoryDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 44 R87.htm IDEA: XBRL DOCUMENT v3.19.3

Retirement Benefits (Schedule of Benefit Obligations and Plan Assets) (Details) - USD ($)
$ in Millions
12 Months Ended

Dec. 31, 2018

Dec. 31, 2017

Dec. 31, 2016

Change in benefit obligation:

Curtailment (gain) loss $ 159.0

Special termination benefit 354.7

Defined Benefit Pension Plans

Change in benefit obligation:

Benefit obligation at beginning of year $ 14,839.7 12,230.9

Service cost 292.7 320.8 $ 268.4

Interest cost 458.5 411.6 419.0

Actuarial (gain) loss (1,386.5) 1,556.0

Benefits paid (579.4) (467.8)

Plan amendments 17.6 0.0

Curtailment (gain) loss (43.9) 90.4

Special termination benefit 0.0 317.2

Foreign currency exchange rate changes and other adjustments (171.6) 380.6

Benefit obligation at end of year 13,427.1 14,839.7 12,230.9

Defined Benefit Plan, Change in Fair Value of Plan Assets [Roll Forward]

Fair value of plan assets at beginning of year 11,713.0 10,056.0

Actual return on plan assets (360.1) 1,434.3

Employer contribution 319.0 410.4

Benefits paid (579.4) (467.8)

Foreign currency exchange rate changes and other adjustments (159.9) 280.1

Fair value of plan assets at end of year 10,932.6 11,713.0 10,056.0

Funded status (2,494.5) (3,126.7)

Unrecognized net actuarial loss 5,011.3 5,616.4

Unrecognized prior service (benefit) cost 25.0 14.5

Net amount recognized 2,541.8 2,504.2

Retiree Health Benefit Plans

Change in benefit obligation:

Benefit obligation at beginning of year 1,718.7 1,494.6

Service cost 41.5 46.4 39.1

Interest cost 57.3 52.9 53.2

Actuarial (gain) loss (176.9) 30.2

Benefits paid (82.8) (60.1)

Plan amendments (14.1) 0.0

Curtailment (gain) loss 2.5 105.2

Special termination benefit 0.0 37.5

Foreign currency exchange rate changes and other adjustments (6.2) 12.0

Benefit obligation at end of year 1,540.0 1,718.7 1,494.6

Defined Benefit Plan, Change in Fair Value of Plan Assets [Roll Forward]

Fair value of plan assets at beginning of year 2,372.4 1,961.2

Actual return on plan assets 32.6 462.0

Employer contribution 75.9 9.1

Benefits paid (82.8) (60.1)

Foreign currency exchange rate changes and other adjustments 0.0 0.2

Fair value of plan assets at end of year 2,398.1 2,372.4 $ 1,961.2

Funded status 858.1 653.7

Unrecognized net actuarial loss 140.6 182.0

Unrecognized prior service (benefit) cost (299.9) (395.0)

Net amount recognized $ 698.8 $ 440.7

X

- Definition
Amount, before tax, of accumulated other comprehensive income (loss) for gain (loss) of defined benefit plan, that has not been recognized in net periodic benefit (cost) credit.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (j)
-URI http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 14A
-URI http://asc.fasb.org/extlink&oid=118930883&loc=SL7669686-108580
+ Details

Name: us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount, before tax, of accumulated other comprehensive (income) loss for cost (credit) of benefit change attributable to participants' prior service from plan amendment or plan initiation of defined benefit plan, that has not been recognized in net periodic benefit cost (credit).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 14A
-URI http://asc.fasb.org/extlink&oid=118930883&loc=SL7669686-108580

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (j)
-URI http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920
+ Details

Name: us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of increase (decrease) in plan assets of defined benefit plan from actual return (loss) determined by change in fair value of plan assets adjusted for contributions, benefit payments, and other expenses.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (b)(1)
-URI http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 55
-Paragraph 17
-URI http://asc.fasb.org/extlink&oid=118257860&loc=d3e4179-114921
+ Details

Name: us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of gain (loss) from change in actuarial assumptions which (increases) decreases benefit obligation of defined benefit plan. Assumptions include, but are not limited to, interest, mortality, employee turnover, salary, and temporary deviation from substantive plan.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (a)(4)
-URI http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920
+ Details

Name: us-gaap_DefinedBenefitPlanActuarialGainLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of asset (liability), recognized in statement of financial position, for defined benefit pension and other postretirement plans.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109237824&loc=d3e1703-114919
+ Details

Name: us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of actuarial present value of benefits attributed to service rendered by employee for defined benefit plan.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920
+ Details

Name: us-gaap_DefinedBenefitPlanBenefitObligation

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of payment to participant of defined benefit plan which decreases benefit obligation. For pension plan, payment includes, but is not limited to, pension benefits and death benefits. For other postretirement plan, payment includes, but is not limited to, prescription drug benefits, health care benefits, life insurance benefits, and legal, educational and advisory services.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (a)(6)
-URI http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 60
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6414203&loc=d3e39716-114964
+ Details

Name: us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.
+ References
No definition available.
+ Details

Name: us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.
+ References
No definition available.
+ Details

Name: us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of contribution received by defined benefit plan from employer which increases plan assets.
+ References
Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 55
-Paragraph 17
-URI http://asc.fasb.org/extlink&oid=118257860&loc=d3e4179-114921

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (d)(iv)(01)
-URI http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920

Reference 3: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (d)(ii)
-URI http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920

Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 6
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=118255775&loc=d3e2709-114920

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (b)(3)
-URI http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920
+ Details

Name: us-gaap_DefinedBenefitPlanContributionsByEmployer

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of (increase) decrease in benefit obligation of defined benefit plan from event reducing expected years of future service of present employees or eliminating accrual of benefits for some or all future services of present employees.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (a)(10)
-URI http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920
+ Details

Name: us-gaap_DefinedBenefitPlanCurtailments

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of asset segregated and restricted to provide benefit under defined benefit plan. Asset includes, but is not limited to, stock, bond, other investment, earning from investment, and contribution by employer and employee.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (d)(iv)(01)
-URI http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (d)(iv)(01)
-URI http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (d)(ii)
-URI http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920

Reference 4: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 55
-Paragraph 17
-URI http://asc.fasb.org/extlink&oid=118257860&loc=d3e4179-114921

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920

Reference 6: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (d)(ii)
-URI http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920
+ Details

Name: us-gaap_DefinedBenefitPlanFairValueOfPlanAssets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of foreign currency translation gain (loss) which (increases) decreases benefit obligation of defined benefit plan.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (a)(5)
-URI http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920
+ Details

Name: us-gaap_DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of funded (unfunded) status of defined benefit plan, measured as difference between fair value of plan assets and benefit obligation. Includes, but is not limited to, overfunded (underfunded) status.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109237824&loc=d3e1703-114919
+ Details

Name: us-gaap_DefinedBenefitPlanFundedStatusOfPlan

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of cost recognized for passage of time related to defined benefit plan.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (h)(2)
-URI http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 55
-Paragraph 17
-URI http://asc.fasb.org/extlink&oid=118257860&loc=d3e4179-114921

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (a)(2)
-URI http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 6
-Subparagraph (a)(2)
-URI http://asc.fasb.org/extlink&oid=118255775&loc=d3e2709-114920
+ Details

Name: us-gaap_DefinedBenefitPlanInterestCost

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of increase (decrease) in benefit obligation of defined benefit plan from change in terms of existing plan or initiation of new plan.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (a)(7)
-URI http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920
+ Details

Name: us-gaap_DefinedBenefitPlanPlanAmendments

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of payment to participant under defined benefit plan which decreases plan assets. For pension plan, payment includes, but is not limited to, pension benefits and death benefits. For other postretirement plan, payment includes, but is not limited to, prescription drug benefits, health care benefits, life insurance benefits, and legal, educational and advisory services.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 60
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6414203&loc=d3e39716-114964

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (b)(5)
-URI http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920
+ Details

Name: us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of foreign currency translation gain (loss) which increases (decreases) plan assets of defined benefit plan.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (b)(2)
-URI http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920
+ Details

Name: us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of cost for actuarial present value of benefits attributed to service rendered by employee for defined benefit plan.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (h)(1)
-URI http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 55
-Paragraph 17
-URI http://asc.fasb.org/extlink&oid=118257860&loc=d3e4179-114921

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 6
-Subparagraph (a)(1)
-URI http://asc.fasb.org/extlink&oid=118255775&loc=d3e2709-114920

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (a)(1)
-URI http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920
+ Details

Name: us-gaap_DefinedBenefitPlanServiceCost

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of increase in benefit obligation for benefits provided to employees payable from defined benefit plan or payable upon retirement.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (a)(10)
-URI http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920
+ Details

Name: us-gaap_DefinedBenefitPlanSpecialTerminationBenefits

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Details

Name: us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_RetirementPlanTypeAxis=us-gaap_DefinedBenefitPostretirementHealthCoverageMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 45 FilingSummary.xml IDEA: XBRL DOCUMENT 3.19.3 html 890 601 1 true 193 0 false 20 false false R1.htm 0001000 - Document - Cover Page Sheet http://www.lilly.com/role/CoverPage Cover Page Cover 1 false false R2.htm 1001000 - Statement - Consolidated Statements of Operations Sheet http://www.lilly.com/role/ConsolidatedStatementsOfOperations Consolidated Statements of Operations Statements 2 false false R3.htm 1002000 - Statement - Consolidated Statements of Comprehensive Income (Loss) Sheet http://www.lilly.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss Consolidated Statements of Comprehensive Income (Loss) Statements 3 false false R4.htm 1002001 - Statement - Consolidated Statements of Comprehensive Income (Loss) (Parenthetical) Sheet http://www.lilly.com/role/ConsolidatedStatementsOfComprehensiveIncomeLossParenthetical Consolidated Statements of Comprehensive Income (Loss) (Parenthetical) Statements 4 false false R5.htm 1003000 - Statement - Consolidated Balance Sheets Sheet http://www.lilly.com/role/ConsolidatedBalanceSheets Consolidated Balance Sheets Statements 5 false false R6.htm 1003501 - Statement - Consolidated Balance Sheets (Parenthetical) Sheet http://www.lilly.com/role/ConsolidatedBalanceSheetsParenthetical Consolidated Balance Sheets (Parenthetical) Statements 6 false false R7.htm 1004000 - Statement - Consolidated Statements of Shareholders' Equity Statement Sheet http://www.lilly.com/role/ConsolidatedStatementsOfShareholdersEquityStatement Consolidated Statements of Shareholders' Equity Statement Statements 7 false false R8.htm 1004001 - Statement - Consolidated Statements of Shareholders' Equity (Parenthetical) Sheet http://www.lilly.com/role/ConsolidatedStatementsOfShareholdersEquityParenthetical Consolidated Statements of Shareholders' Equity (Parenthetical) Statements 8 false false R9.htm 1005000 - Statement - Consolidated Statements of Cash Flows Sheet http://www.lilly.com/role/ConsolidatedStatementsOfCashFlows Consolidated Statements of Cash Flows Statements 9 false false R10.htm 1005001 - Statement - Consolidated Statements of Cash Flows Consolidated Statements of Cash Flows (Parenthetical) Sheet http://www.lilly.com/role/ConsolidatedStatementsOfCashFlowsConsolidatedStatementsOfCashFlowsParenthetical Consolidated Statements of Cash Flows Consolidated Statements of Cash Flows (Parenthetical) Statements 10 false false R11.htm 2101100 - Disclosure - Summary of Significant Accounting Policies Sheet http://www.lilly.com/role/SummaryOfSignificantAccountingPolicies Summary of Significant Accounting Policies Notes 11 false false R12.htm 2104100 - Disclosure - Implementation of New Financial Accounting Pronouncements Sheet http://www.lilly.com/role/ImplementationOfNewFinancialAccountingPronouncements Implementation of New Financial Accounting Pronouncements Notes 12 false false R13.htm 2105100 - Disclosure - Acquisitions Sheet http://www.lilly.com/role/Acquisitions Acquisitions Notes 13 false false R14.htm 2106100 - Disclosure - Collaborations and Other Arrangements Sheet http://www.lilly.com/role/CollaborationsAndOtherArrangements Collaborations and Other Arrangements Notes 14 false false R15.htm 2107100 - Disclosure - Asset Impairment, Restructuring, and Other Special Charges Sheet http://www.lilly.com/role/AssetImpairmentRestructuringAndOtherSpecialCharges Asset Impairment, Restructuring, and Other Special Charges Notes 15 false false R16.htm 2108100 - Disclosure - Inventories Sheet http://www.lilly.com/role/Inventories Inventories Notes 16 false false R17.htm 2109100 - Disclosure - Financial Instruments Sheet http://www.lilly.com/role/FinancialInstruments Financial Instruments Notes 17 false false R18.htm 2110100 - Disclosure - Goodwill and Other Intangibles Sheet http://www.lilly.com/role/GoodwillAndOtherIntangibles Goodwill and Other Intangibles Notes 18 false false R19.htm 2111100 - Disclosure - Property and Equipment Sheet http://www.lilly.com/role/PropertyAndEquipment Property and Equipment Notes 19 false false R20.htm 2112100 - Disclosure - Borrowings Sheet http://www.lilly.com/role/Borrowings Borrowings Notes 20 false false R21.htm 2116100 - Disclosure - Stock-Based Compensation Sheet http://www.lilly.com/role/StockBasedCompensation Stock-Based Compensation Notes 21 false false R22.htm 2117100 - Disclosure - Shareholders' Equity Sheet http://www.lilly.com/role/ShareholdersEquity Shareholders' Equity Notes 22 false false R23.htm 2119100 - Disclosure - Income Taxes Sheet http://www.lilly.com/role/IncomeTaxes Income Taxes Notes 23 false false R24.htm 2120100 - Disclosure - Retirement Benefits Sheet http://www.lilly.com/role/RetirementBenefits Retirement Benefits Notes 24 false false R25.htm 2121100 - Disclosure - Contingencies Sheet http://www.lilly.com/role/Contingencies Contingencies Notes 25 false false R26.htm 2122100 - Disclosure - Other Comprehensive Income (Loss) Sheet http://www.lilly.com/role/OtherComprehensiveIncomeLoss Other Comprehensive Income (Loss) Notes 26 false false R27.htm 2123100 - Disclosure - Other-Net, (Income) Expense Sheet http://www.lilly.com/role/OtherNetIncomeExpense Other-Net, (Income) Expense Notes 27 false false R28.htm 2124100 - Disclosure - Segment Information Sheet http://www.lilly.com/role/SegmentInformation Segment Information Notes 28 false false R29.htm 2125100 - Disclosure - Selected Quarterly Data (Unaudited) Sheet http://www.lilly.com/role/SelectedQuarterlyDataUnaudited Selected Quarterly Data (Unaudited) Notes 29 false false R30.htm 2126100 - Disclosure - Discontinued Operations (Notes) Notes http://www.lilly.com/role/DiscontinuedOperationsNotes Discontinued Operations (Notes) Notes 30 false false R31.htm 2201201 - Disclosure - Summary of Significant Accounting Policies (Policies) Sheet http://www.lilly.com/role/SummaryOfSignificantAccountingPoliciesPolicies Summary of Significant Accounting Policies (Policies) Policies http://www.lilly.com/role/SummaryOfSignificantAccountingPolicies 31 false false R32.htm 2208201 - Disclosure - Inventories (Policies) Sheet http://www.lilly.com/role/InventoriesPolicies Inventories (Policies) Policies http://www.lilly.com/role/SummaryOfSignificantAccountingPolicies 32 false false R33.htm 2209201 - Disclosure - Financial Instruments (Policies) Sheet http://www.lilly.com/role/FinancialInstrumentsPolicies Financial Instruments (Policies) Policies http://www.lilly.com/role/SummaryOfSignificantAccountingPolicies 33 false false R34.htm 2210201 - Disclosure - Goodwill and Other Intangibles (Policies) Sheet http://www.lilly.com/role/GoodwillAndOtherIntangiblesPolicies Goodwill and Other Intangibles (Policies) Policies http://www.lilly.com/role/SummaryOfSignificantAccountingPolicies 34 false false R35.htm 2211201 - Disclosure - Property and Equipment (Policies) Sheet http://www.lilly.com/role/PropertyAndEquipmentPolicies Property and Equipment (Policies) Policies http://www.lilly.com/role/SummaryOfSignificantAccountingPolicies 35 false false R36.htm 2216201 - Disclosure - Stock-Based Compensation (Policies) Sheet http://www.lilly.com/role/StockBasedCompensationPolicies Stock-Based Compensation (Policies) Policies http://www.lilly.com/role/SummaryOfSignificantAccountingPolicies 36 false false R37.htm 2219201 - Disclosure - Income Taxes (Policies) Sheet http://www.lilly.com/role/IncomeTaxesPolicies Income Taxes (Policies) Policies http://www.lilly.com/role/SummaryOfSignificantAccountingPolicies 37 false false R38.htm 2221201 - Disclosure - Contingencies (Policies) Sheet http://www.lilly.com/role/ContingenciesPolicies Contingencies (Policies) Policies http://www.lilly.com/role/SummaryOfSignificantAccountingPolicies 38 false false R39.htm 2301302 - Disclosure - Summary of Significant Accounting Policies (Tables) Sheet http://www.lilly.com/role/SummaryOfSignificantAccountingPoliciesTables Summary of Significant Accounting Policies (Tables) Tables http://www.lilly.com/role/SummaryOfSignificantAccountingPolicies 39 false false R40.htm 2304301 - Disclosure - Implementation of New Financial Accounting Pronouncements (Tables) Sheet http://www.lilly.com/role/ImplementationOfNewFinancialAccountingPronouncementsTables Implementation of New Financial Accounting Pronouncements (Tables) Tables http://www.lilly.com/role/ImplementationOfNewFinancialAccountingPronouncements 40 false false R41.htm 2305301 - Disclosure - Acquisitions (Tables) Sheet http://www.lilly.com/role/AcquisitionsTables Acquisitions (Tables) Tables http://www.lilly.com/role/Acquisitions 41 false false R42.htm 2306301 - Disclosure - Collaborations and Other Arrangements (Tables) Sheet http://www.lilly.com/role/CollaborationsAndOtherArrangementsTables Collaborations and Other Arrangements (Tables) Tables http://www.lilly.com/role/CollaborationsAndOtherArrangements 42 false false R43.htm 2307301 - Disclosure - Asset Impairment, Restructuring, and Other Special Charges (Tables) Sheet http://www.lilly.com/role/AssetImpairmentRestructuringAndOtherSpecialChargesTables Asset Impairment, Restructuring, and Other Special Charges (Tables) Tables http://www.lilly.com/role/AssetImpairmentRestructuringAndOtherSpecialCharges 43 false false R44.htm 2308302 - Disclosure - Inventories (Tables) Sheet http://www.lilly.com/role/InventoriesTables Inventories (Tables) Tables http://www.lilly.com/role/Inventories 44 false false R45.htm 2309302 - Disclosure - Financial Instruments (Tables) Sheet http://www.lilly.com/role/FinancialInstrumentsTables Financial Instruments (Tables) Tables http://www.lilly.com/role/FinancialInstruments 45 false false R46.htm 2310302 - Disclosure - Goodwill and Other Intangibles (Tables) Sheet http://www.lilly.com/role/GoodwillAndOtherIntangiblesTables Goodwill and Other Intangibles (Tables) Tables http://www.lilly.com/role/GoodwillAndOtherIntangibles 46 false false R47.htm 2311302 - Disclosure - Property and Equipment (Tables) Sheet http://www.lilly.com/role/PropertyAndEquipmentTables Property and Equipment (Tables) Tables http://www.lilly.com/role/PropertyAndEquipment 47 false false R48.htm 2312301 - Disclosure - Borrowings (Tables) Sheet http://www.lilly.com/role/BorrowingsTables Borrowings (Tables) Tables http://www.lilly.com/role/Borrowings 48 false false R49.htm 2316302 - Disclosure - Stock-Based Compensation (Tables) Sheet http://www.lilly.com/role/StockBasedCompensationTables Stock-Based Compensation (Tables) Tables http://www.lilly.com/role/StockBasedCompensation 49 false false R50.htm 2319302 - Disclosure - Income Taxes (Tables) Sheet http://www.lilly.com/role/IncomeTaxesTables Income Taxes (Tables) Tables http://www.lilly.com/role/IncomeTaxes 50 false false R51.htm 2320301 - Disclosure - Retirement Benefits (Tables) Sheet http://www.lilly.com/role/RetirementBenefitsTables Retirement Benefits (Tables) Tables http://www.lilly.com/role/RetirementBenefits 51 false false R52.htm 2322301 - Disclosure - Other Comprehensive Income (Loss) (Tables) Sheet http://www.lilly.com/role/OtherComprehensiveIncomeLossTables Other Comprehensive Income (Loss) (Tables) Tables http://www.lilly.com/role/OtherComprehensiveIncomeLoss 52 false false R53.htm 2323301 - Disclosure - Other - Net, (Income) Expense (Tables) Sheet http://www.lilly.com/role/OtherNetIncomeExpenseTables Other - Net, (Income) Expense (Tables) Tables 53 false false R54.htm 2324301 - Disclosure - Segment Information (Tables) Sheet http://www.lilly.com/role/SegmentInformationTables Segment Information (Tables) Tables http://www.lilly.com/role/SegmentInformation 54 false false R55.htm 2325301 - Disclosure - Selected Quarterly Data (Unaudited) (Tables) Sheet http://www.lilly.com/role/SelectedQuarterlyDataUnauditedTables Selected Quarterly Data (Unaudited) (Tables) Tables http://www.lilly.com/role/SelectedQuarterlyDataUnaudited 55 false false R56.htm 2326301 - Disclosure - Discontinued Operations (Tables) Sheet http://www.lilly.com/role/DiscontinuedOperationsTables Discontinued Operations (Tables) Tables http://www.lilly.com/role/DiscontinuedOperationsNotes 56 false false R57.htm 2401403 - Disclosure - Summary of Significant Accounting Policies (Acquisitions) (Details) Sheet http://www.lilly.com/role/SummaryOfSignificantAccountingPoliciesAcquisitionsDetails Summary of Significant Accounting Policies (Acquisitions) (Details) Details http://www.lilly.com/role/SummaryOfSignificantAccountingPoliciesTables 57 false false R58.htm 2401404 - Disclosure - Summary of Significant Accounting Policies (Revenue) (Details) Sheet http://www.lilly.com/role/SummaryOfSignificantAccountingPoliciesRevenueDetails Summary of Significant Accounting Policies (Revenue) (Details) Details http://www.lilly.com/role/SummaryOfSignificantAccountingPoliciesTables 58 false false R59.htm 2401405 - Disclosure - Summary of Significant Accounting Policies (Contract Liabilities) (Details) Sheet http://www.lilly.com/role/SummaryOfSignificantAccountingPoliciesContractLiabilitiesDetails Summary of Significant Accounting Policies (Contract Liabilities) (Details) Details http://www.lilly.com/role/SummaryOfSignificantAccountingPoliciesTables 59 false false R60.htm 2404402 - Disclosure - Implementation of New Financial Accounting Pronouncements (Details) Sheet http://www.lilly.com/role/ImplementationOfNewFinancialAccountingPronouncementsDetails Implementation of New Financial Accounting Pronouncements (Details) Details http://www.lilly.com/role/ImplementationOfNewFinancialAccountingPronouncementsTables 60 false false R61.htm 2405403 - Disclosure - (Narrative) (Details) Sheet http://www.lilly.com/role/NarrativeDetails (Narrative) (Details) Details 61 false false R62.htm 2406402 - Disclosure - Collaborations and Other Arrangements (Details) Sheet http://www.lilly.com/role/CollaborationsAndOtherArrangementsDetails Collaborations and Other Arrangements (Details) Details http://www.lilly.com/role/CollaborationsAndOtherArrangementsTables 62 false false R63.htm 2407402 - Disclosure - Asset Impairment, Restructuring, and Other Special Charges (Details) Sheet http://www.lilly.com/role/AssetImpairmentRestructuringAndOtherSpecialChargesDetails Asset Impairment, Restructuring, and Other Special Charges (Details) Details http://www.lilly.com/role/AssetImpairmentRestructuringAndOtherSpecialChargesTables 63 false false R64.htm 2407403 - Disclosure - Asset Impairment, Restructuring, and Other Special Charges (Narrative) (Details) Sheet http://www.lilly.com/role/AssetImpairmentRestructuringAndOtherSpecialChargesNarrativeDetails Asset Impairment, Restructuring, and Other Special Charges (Narrative) (Details) Details http://www.lilly.com/role/AssetImpairmentRestructuringAndOtherSpecialChargesTables 64 false false R65.htm 2408403 - Disclosure - Inventories (Details) Sheet http://www.lilly.com/role/InventoriesDetails Inventories (Details) Details http://www.lilly.com/role/InventoriesTables 65 false false R66.htm 2409403 - Disclosure - Financial Instruments (Effect of Risk Management) (Details) Sheet http://www.lilly.com/role/FinancialInstrumentsEffectOfRiskManagementDetails Financial Instruments (Effect of Risk Management) (Details) Details http://www.lilly.com/role/FinancialInstrumentsTables 66 false false R67.htm 2409404 - Disclosure - Financial Instruments (Fair Value Measurement) (Details) Sheet http://www.lilly.com/role/FinancialInstrumentsFairValueMeasurementDetails Financial Instruments (Fair Value Measurement) (Details) Details http://www.lilly.com/role/FinancialInstrumentsTables 67 false false R68.htm 2409405 - Disclosure - Financial Instruments (Short-term and Long-term Classification) (Details) Sheet http://www.lilly.com/role/FinancialInstrumentsShortTermAndLongTermClassificationDetails Financial Instruments (Short-term and Long-term Classification) (Details) Details http://www.lilly.com/role/FinancialInstrumentsTables 68 false false R69.htm 2409406 - Disclosure - Financial Instruments (Contractual Maturities) (Details) Sheet http://www.lilly.com/role/FinancialInstrumentsContractualMaturitiesDetails Financial Instruments (Contractual Maturities) (Details) Details http://www.lilly.com/role/FinancialInstrumentsTables 69 false false R70.htm 2409407 - Disclosure - Financial Instruments (Summary of AFS Unrealized Gain(Loss)) (Details) Sheet http://www.lilly.com/role/FinancialInstrumentsSummaryOfAfsUnrealizedGainlossDetails Financial Instruments (Summary of AFS Unrealized Gain(Loss)) (Details) Details http://www.lilly.com/role/FinancialInstrumentsTables 70 false false R71.htm 2409408 - Disclosure - Financial Instruments (Investment Portfolio Activity) (Details) Sheet http://www.lilly.com/role/FinancialInstrumentsInvestmentPortfolioActivityDetails Financial Instruments (Investment Portfolio Activity) (Details) Details http://www.lilly.com/role/FinancialInstrumentsTables 71 false false R72.htm 2409409 - Disclosure - Financial Instruments (Narrative) (Details) Sheet http://www.lilly.com/role/FinancialInstrumentsNarrativeDetails Financial Instruments (Narrative) (Details) Details http://www.lilly.com/role/FinancialInstrumentsTables 72 false false R73.htm 2410404 - Disclosure - Goodwill and Other Intangibles (Intangibles) (Details) Sheet http://www.lilly.com/role/GoodwillAndOtherIntangiblesIntangiblesDetails Goodwill and Other Intangibles (Intangibles) (Details) Details http://www.lilly.com/role/GoodwillAndOtherIntangiblesTables 73 false false R74.htm 2410405 - Disclosure - Goodwill and Other Intangibles (Narrative) (Details) Sheet http://www.lilly.com/role/GoodwillAndOtherIntangiblesNarrativeDetails Goodwill and Other Intangibles (Narrative) (Details) Details http://www.lilly.com/role/GoodwillAndOtherIntangiblesTables 74 false false R75.htm 2410406 - Disclosure - Goodwill and Other Intangibles (Amortization Expense) (Details) Sheet http://www.lilly.com/role/GoodwillAndOtherIntangiblesAmortizationExpenseDetails Goodwill and Other Intangibles (Amortization Expense) (Details) Details http://www.lilly.com/role/GoodwillAndOtherIntangiblesTables 75 false false R76.htm 2411403 - Disclosure - Property and Equipment (Details) Sheet http://www.lilly.com/role/PropertyAndEquipmentDetails Property and Equipment (Details) Details http://www.lilly.com/role/PropertyAndEquipmentTables 76 false false R77.htm 2412402 - Disclosure - Borrowings (Long-term Debt) (Details) Sheet http://www.lilly.com/role/BorrowingsLongTermDebtDetails Borrowings (Long-term Debt) (Details) Details http://www.lilly.com/role/BorrowingsTables 77 false false R78.htm 2412403 - Disclosure - Borrowings (narrative) (Details) Sheet http://www.lilly.com/role/BorrowingsNarrativeDetails Borrowings (narrative) (Details) Details http://www.lilly.com/role/BorrowingsTables 78 false false R79.htm 2412404 - Disclosure - Borrowings (Debt maturities) (Details) Sheet http://www.lilly.com/role/BorrowingsDebtMaturitiesDetails Borrowings (Debt maturities) (Details) Details http://www.lilly.com/role/BorrowingsTables 79 false false R80.htm 2416403 - Disclosure - Stock-Based Compensation (Details) Sheet http://www.lilly.com/role/StockBasedCompensationDetails Stock-Based Compensation (Details) Details http://www.lilly.com/role/StockBasedCompensationTables 80 false false R81.htm 2417401 - Disclosure - Shareholders' Equity (Details) Sheet http://www.lilly.com/role/ShareholdersEquityDetails Shareholders' Equity (Details) Details http://www.lilly.com/role/ShareholdersEquity 81 false false R82.htm 2419403 - Disclosure - Income Taxes (Narrative) (Details) Sheet http://www.lilly.com/role/IncomeTaxesNarrativeDetails Income Taxes (Narrative) (Details) Details http://www.lilly.com/role/IncomeTaxesTables 82 false false R83.htm 2419404 - Disclosure - Income Taxes (Current and Deferred) (Details) Sheet http://www.lilly.com/role/IncomeTaxesCurrentAndDeferredDetails Income Taxes (Current and Deferred) (Details) Details http://www.lilly.com/role/IncomeTaxesTables 83 false false R84.htm 2419405 - Disclosure - Income Taxes (Deferred tax asset and liabilities) (Details) Sheet http://www.lilly.com/role/IncomeTaxesDeferredTaxAssetAndLiabilitiesDetails Income Taxes (Deferred tax asset and liabilities) (Details) Details http://www.lilly.com/role/IncomeTaxesTables 84 false false R85.htm 2419406 - Disclosure - Income Taxes (Unrecognized benefits) (Details) Sheet http://www.lilly.com/role/IncomeTaxesUnrecognizedBenefitsDetails Income Taxes (Unrecognized benefits) (Details) Details http://www.lilly.com/role/IncomeTaxesTables 85 false false R86.htm 2419407 - Disclosure - Income Taxes (Reconciliation of Income Taxes) (Details) Sheet http://www.lilly.com/role/IncomeTaxesReconciliationOfIncomeTaxesDetails Income Taxes (Reconciliation of Income Taxes) (Details) Details http://www.lilly.com/role/IncomeTaxesTables 86 false false R87.htm 2420402 - Disclosure - Retirement Benefits (Schedule of Benefit Obligations and Plan Assets) (Details) Sheet http://www.lilly.com/role/RetirementBenefitsScheduleOfBenefitObligationsAndPlanAssetsDetails Retirement Benefits (Schedule of Benefit Obligations and Plan Assets) (Details) Details http://www.lilly.com/role/RetirementBenefitsTables 87 false false R88.htm 2420403 - Disclosure - Retirement Benefits (Schedule of Components in Consolidated Balance Sheets) (Details) Sheet http://www.lilly.com/role/RetirementBenefitsScheduleOfComponentsInConsolidatedBalanceSheetsDetails Retirement Benefits (Schedule of Components in Consolidated Balance Sheets) (Details) Details http://www.lilly.com/role/RetirementBenefitsTables 88 false false R89.htm 2420404 - Disclosure - Retirement Benefits (Schedule of Weighted Average Assumptions) (Details) Sheet http://www.lilly.com/role/RetirementBenefitsScheduleOfWeightedAverageAssumptionsDetails Retirement Benefits (Schedule of Weighted Average Assumptions) (Details) Details http://www.lilly.com/role/RetirementBenefitsTables 89 false false R90.htm 2420405 - Disclosure - Retirement Benefits (Schedule of Expected Benefit Payments, Contributions and Expense) (Details) Sheet http://www.lilly.com/role/RetirementBenefitsScheduleOfExpectedBenefitPaymentsContributionsAndExpenseDetails Retirement Benefits (Schedule of Expected Benefit Payments, Contributions and Expense) (Details) Details http://www.lilly.com/role/RetirementBenefitsTables 90 false false R91.htm 2420406 - Disclosure - Retirement Benefits (Fair Value Disclosures) (Details) Sheet http://www.lilly.com/role/RetirementBenefitsFairValueDisclosuresDetails Retirement Benefits (Fair Value Disclosures) (Details) Details http://www.lilly.com/role/RetirementBenefitsTables 91 false false R92.htm 2420407 - Disclosure - Retirement Benefits (Narrative) (Details) Sheet http://www.lilly.com/role/RetirementBenefitsNarrativeDetails Retirement Benefits (Narrative) (Details) Details http://www.lilly.com/role/RetirementBenefitsTables 92 false false R93.htm 2421402 - Disclosure - Contingencies (Details) Sheet http://www.lilly.com/role/ContingenciesDetails Contingencies (Details) Details http://www.lilly.com/role/ContingenciesPolicies 93 false false R94.htm 2422402 - Disclosure - Other Comprehensive Income (Loss) (Roll-forward) (Details) Sheet http://www.lilly.com/role/OtherComprehensiveIncomeLossRollForwardDetails Other Comprehensive Income (Loss) (Roll-forward) (Details) Details http://www.lilly.com/role/OtherComprehensiveIncomeLossTables 94 false false R95.htm 2422403 - Disclosure - Other Comprehensive Income (Loss) (Tax effect) (Details) Sheet http://www.lilly.com/role/OtherComprehensiveIncomeLossTaxEffectDetails Other Comprehensive Income (Loss) (Tax effect) (Details) Details http://www.lilly.com/role/OtherComprehensiveIncomeLossTables 95 false false R96.htm 2422404 - Disclosure - Other Comprehensive Income (Loss) (Reclassification) (Details) Sheet http://www.lilly.com/role/OtherComprehensiveIncomeLossReclassificationDetails Other Comprehensive Income (Loss) (Reclassification) (Details) Details http://www.lilly.com/role/OtherComprehensiveIncomeLossTables 96 false false R97.htm 2423402 - Disclosure - Other - Net, (Income) Expense (Details) Sheet http://www.lilly.com/role/OtherNetIncomeExpenseDetails Other - Net, (Income) Expense (Details) Details http://www.lilly.com/role/OtherNetIncomeExpenseTables 97 false false R98.htm 2424402 - Disclosure - Segment Information (Details) Sheet http://www.lilly.com/role/SegmentInformationDetails Segment Information (Details) Details http://www.lilly.com/role/SegmentInformationTables 98 false false R99.htm 2425402 - Disclosure - Selected Quarterly Data (Unaudited) (Details) Sheet http://www.lilly.com/role/SelectedQuarterlyDataUnauditedDetails Selected Quarterly Data (Unaudited) (Details) Details http://www.lilly.com/role/SelectedQuarterlyDataUnauditedTables 99 false false R100.htm 2426402 - Disclosure - Discontinued Operations (Details) Sheet http://www.lilly.com/role/DiscontinuedOperationsDetails Discontinued Operations (Details) Details http://www.lilly.com/role/DiscontinuedOperationsTables 100 false false R101.htm 2426403 - Disclosure - Discontinued Operations (Discontinued Operations in Financial Statements) (Details) Sheet http://www.lilly.com/role/DiscontinuedOperationsDiscontinuedOperationsInFinancialStatementsDetails Discontinued Operations (Discontinued Operations in Financial Statements) (Details) Details http://www.lilly.com/role/DiscontinuedOperationsTables 101 false false R102.htm 2426404 - Disclosure - Discontinued Operations (Major Classes of Assets and Liabilities) (Details) Sheet http://www.lilly.com/role/DiscontinuedOperationsMajorClassesOfAssetsAndLiabilitiesDetails Discontinued Operations (Major Classes of Assets and Liabilities) (Details) Details http://www.lilly.com/role/DiscontinuedOperationsTables 102 false false R9999.htm Uncategorized Items - _IXDS Sheet http://xbrl.sec.gov/role/uncategorizedFacts Uncategorized Items - _IXDS Cover 103 false false All Reports Book All Reports a20198-kfor201810xkrec.htm ex-991xllyx20181231x10.htm ex-231xeyconsent.htm lly-20191024.xsd lly-20191024_cal.xml lly-20191024_def.xml lly-20191024_lab.xml lly-20191024_pre.xml g266023g32y59a012015a17.jpg http://fasb.org/srt/2019-01-31 http://xbrl.sec.gov/dei/2019-01-31 http://fasb.org/us-gaap/2019-01-31 http://xbrl.sec.gov/country/2017-01-31 true true XML 46 R77.htm IDEA: XBRL DOCUMENT v3.19.3

Borrowings (Long-term Debt) (Details) - USD ($)
$ in Millions

Dec. 31, 2018

Dec. 31, 2017

Debt Disclosure [Abstract]

Short-term commercial paper borrowings $ 498.9 $ 2,696.8

0.15 to 7.13 percent long-term notes (due 2019-2047) 9,640.8 10,756.7

Other long-term debt 10.1 13.0

Unamortized debt issuance costs (28.4) (49.0)

Fair value adjustment on hedged long-term notes 177.2 229.0

Total debt 10,298.6 13,646.5

Less current portion (1,102.2) (3,706.5)

Long-term debt $ 9,196.4 $ 9,940.0

X

- Definition
Fair value adjustment to carrying value of long term debt to arrive at total fair value.
+ References
No definition available.
+ Details

Name: lly_LongTermDebtFairValueAdjustment

Namespace Prefix: lly_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Carrying value as of the balance sheet date of short-term borrowings using unsecured obligations issued by banks, corporations and other borrowers to investors. The maturities of these money market securities generally do not exceed 270 days.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(13)(2))
-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(16))
-URI http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(19)(a)(3))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_CommercialPaper

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of short-term debt and current maturity of long-term debt and capital lease obligations due within one year or the normal operating cycle, if longer.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.19,20)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_DebtCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_DebtDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Represents the aggregate of total long-term debt, including current maturities and short-term debt.
+ References
No definition available.
+ Details

Name: us-gaap_DebtLongtermAndShorttermCombinedAmount

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.22)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_LongTermDebtNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Including the current and noncurrent portions, aggregate carrying amount of all types of notes payable, as of the balance sheet date, with initial maturities beyond one year or beyond the normal operating cycle, if longer.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(16))
-URI http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(22))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(16))
-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878
+ Details

Name: us-gaap_NotesPayable

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of long-term notes payable classified as other.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(16))
-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(22))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(16))
-URI http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910
+ Details

Name: us-gaap_OtherNotesPayable

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
The remaining balance of debt issuance expenses that were capitalized and are being amortized against income over the lives of the respective bond issues. This does not include the amounts capitalized as part of the cost of the utility plant or asset.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.17)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_UnamortizedDebtIssuanceExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

XML 47 R73.htm IDEA: XBRL DOCUMENT v3.19.3

Goodwill and Other Intangibles (Intangibles) (Details) - USD ($)
$ in Millions
12 Months Ended

Dec. 31, 2018

Dec. 31, 2017

Dec. 31, 2016

Finite-lived intangible assets:

Accumulated Amortization $ (1,098.7) $ (3,291.5)

Other Intangibles, gross 2,166.7 4,645.9

Other intangibles, net 1,068.0 1,354.4

Amortization expense 361.3 462.2 $ 517.2

Marketed products

Finite-lived intangible assets:

Carrying Amount, Gross 2,077.2 4,528.8

Accumulated Amortization (1,069.0) (3,251.3)

Carrying Amount, Net 1,008.2 1,277.5

Other

Finite-lived intangible assets:

Carrying Amount, Gross 89.5 117.1

Accumulated Amortization (29.7) (40.2)

Carrying Amount, Net $ 59.8 $ 76.9

X

- Definition
The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph (a)(2)
-URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274
+ Details

Name: us-gaap_AmortizationOfIntangibleAssets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph (a)(1)
-URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275
+ Details

Name: us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 928
-SubTopic 340
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph (a)(1)
-URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275
+ Details

Name: us-gaap_FiniteLivedIntangibleAssetsGross

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_FiniteLivedIntangibleAssetsLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph (a)(1)
-URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275
+ Details

Name: us-gaap_FiniteLivedIntangibleAssetsNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount before accumulated amortization of intangible assets, excluding goodwill.
+ References
No definition available.
+ Details

Name: us-gaap_IntangibleAssetsGrossExcludingGoodwill

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph ((a)(1),(b))
-URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274
+ Details

Name: us-gaap_IntangibleAssetsNetExcludingGoodwill

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Details

Name: us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_OtherIntangibleAssetsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 48 R83.htm IDEA: XBRL DOCUMENT v3.19.3

Income Taxes (Current and Deferred) (Details) - USD ($)
$ in Millions
3 Months Ended 12 Months Ended

Dec. 31, 2018

Sep. 30, 2018

Jun. 30, 2018

Mar. 31, 2018

Dec. 31, 2017

Sep. 30, 2017

Jun. 30, 2017

Mar. 31, 2017

Dec. 31, 2018

Dec. 31, 2017

Dec. 31, 2016

Current:

Federal $ (31.9) $ (66.5) $ 20.0

Foreign 106.8 47.5 397.0

State 4.7 (5.4) (134.4)

Tax Cuts and Jobs Act, Measurement Period Adjustment, Income Tax Expense (Benefit) 201.5

2017 Tax Act 3,247.5 0.0

Total current tax expense 281.1 3,223.1 282.6

Deferred:

Federal 22.5 732.3 410.0

Foreign 248.7 (230.9) (136.3)

State 3.4 0.2 (4.9)

Tax Cuts and Jobs Act, Change in Tax Rate, Income Tax Expense (Benefit), Total (26.2)

2017 Tax Act (1,333.5) 0.0

Total deferred tax (benefit) expense 248.4 (831.9) 268.8

Income taxes $ (189.8) $ 247.5 $ 273.3 $ 198.5 $ 1,947.5 $ 29.0 $ 244.3 $ 170.3 $ 529.5 $ 2,391.2 $ 551.4

X

- Definition
Incomplete Accounting, Provisional Income Tax Expense (Benefit)
+ References
No definition available.
+ Details

Name: lly_IncompleteAccountingProvisionalIncomeTaxExpenseBenefit

Namespace Prefix: lly_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Tax Cuts and Jobs Act, Change in Tax Rate, Income Tax Expense (Benefit), Total
+ References
No definition available.
+ Details

Name: lly_TaxCutsandJobsActChangeinTaxRateIncomeTaxExpenseBenefitTotal

Namespace Prefix: lly_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Tax Cuts and Jobs Act, Measurement Period Adjustment, Income Tax Expense (Benefit)
+ References
No definition available.
+ Details

Name: lly_TaxCutsandJobsActMeasurementPeriodAdjustmentIncomeTaxExpenseBenefit

Namespace Prefix: lly_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of current federal tax expense (benefit) pertaining to income (loss) from continuing operations.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 6.I.7)
-URI http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(h))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 9
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319
+ Details

Name: us-gaap_CurrentFederalTaxExpenseBenefit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(h))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690
+ Details

Name: us-gaap_CurrentForeignTaxExpenseBenefit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 6.I.7)
-URI http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 9
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(h))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690
+ Details

Name: us-gaap_CurrentIncomeTaxExpenseBenefit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of current state and local tax expense (benefit) pertaining to income (loss) from continuing operations.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(h))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 6.I.7)
-URI http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 9
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319
+ Details

Name: us-gaap_CurrentStateAndLocalTaxExpenseBenefit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of deferred federal income tax expense (benefit) pertaining to income (loss) from continuing operations.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 9
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(h))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 6.I.7)
-URI http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817
+ Details

Name: us-gaap_DeferredFederalIncomeTaxExpenseBenefit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of deferred foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 6.I.7)
-URI http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 9
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(h))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690
+ Details

Name: us-gaap_DeferredForeignIncomeTaxExpenseBenefit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 6.I.7)
-URI http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(h))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 9
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319
+ Details

Name: us-gaap_DeferredIncomeTaxExpenseBenefit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of deferred state and local tax expense (benefit) pertaining to income (loss) from continuing operations.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 6.I.7)
-URI http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(h))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 9
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319
+ Details

Name: us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (h)
-URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(h))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 20
-Section 45
-Paragraph 2
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109238882&loc=d3e38679-109324
+ Details

Name: us-gaap_IncomeTaxExpenseBenefit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of reasonable estimate for income tax expense (benefit) for which accounting for tax effect is incomplete pursuant to Tax Cuts and Jobs Act.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section S99
-Paragraph 2A
-Subparagraph (SAB Topic 5.EE.Q2(b))
-URI http://asc.fasb.org/extlink&oid=116825942&loc=SL116722634-122817
+ Details

Name: us-gaap_TaxCutsAndJobsActOf2017IncompleteAccountingProvisionalIncomeTaxExpenseBenefit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

XML 49 R50.htm IDEA: XBRL DOCUMENT v3.19.3

Income Taxes (Tables)
12 Months Ended

Dec. 31, 2018

Income Tax Disclosure [Abstract]

Schedule of Components of Income Tax Expense (Benefit)
Following is the composition of income tax expense:

2018

2017

2016
Current:

Federal
$
(31.9
)

$
(66.5
)

$
20.0

Foreign
106.8

47.5

397.0

State
4.7

(5.4
)

(134.4
)
2017 Tax Act
201.5

3,247.5

—

Total current tax expense
281.1

3,223.1

282.6

Deferred:

Federal
22.5

732.3

410.0

Foreign
248.7

(230.9
)

(136.3
)
State
3.4

0.2

(4.9
)
2017 Tax Act
(26.2
)

(1,333.5
)

—

Total deferred tax (benefit) expense
248.4

(831.9
)

268.8

Income taxes
$
529.5

$
2,391.2

$
551.4

Schedule of Deferred Tax Assets and Liabilities
Significant components of our deferred tax assets and liabilities as of December 31 are as follows:

2018

2017
Deferred tax assets:

Purchases of intangible assets
$
2,627.7

$
441.9

Compensation and benefits
781.6

995.3

Tax credit carryforwards and carrybacks
359.4

467.5

Tax loss carryforwards and carrybacks
248.2

471.3

Product return reserves
95.3

83.4

Other comprehensive loss on hedging transactions
68.9

68.9

Debt
40.3

53.5

Contingent consideration
11.7

32.1

Other
680.1

524.3

Total gross deferred tax assets
4,913.2

3,138.2

Valuation allowances
(574.8
)

(681.8
)
Total deferred tax assets
4,338.4

2,456.4

Deferred tax liabilities:

Earnings of foreign subsidiaries
(1,745.3
)

(16.6
)
Inventories
(681.3
)

(649.5
)
Property and equipment
(260.9
)

(247.5
)
Prepaid employee benefits
(240.1
)

(231.5
)
Intangibles
(86.9
)

(120.7
)
Financial instruments
(22.8
)

(41.6
)
Total deferred tax liabilities
(3,037.3
)

(1,307.4
)
Deferred tax assets - net
$
1,301.1

$
1,149.0

Schedule of Additional Income Tax Disclosures
Cash payments of income taxes were as follows:

2018

2017

2016
Cash payments of income taxes
$
1,076.7

$
221.5

$
686.4

Schedule of Effective Income Tax Rate Reconciliation
Following is a reconciliation of the income tax expense applying the U.S. federal statutory rate to income before income taxes to reported income tax expense:

2018

2017

2016
Income tax at the U.S. federal statutory tax rate
$
772.8

$
806.7

$
1,146.7

Add (deduct):

International operations, including Puerto Rico
(627.1
)

(480.8
)

(357.2
)
General business credits
(87.4
)

(66.8
)

(57.0
)
Non-deductible acquired IPR&D⁽¹⁾
309.9

300.1

—

2017 Tax Act
175.3

1,914.0

—

Other
(14.0
)

(82.0
)

(181.1
)
Income taxes
$
529.5

$
2,391.2

$
551.4

⁽¹⁾Non-deductible acquired IPR&D was related to ARMO in 2018 and CoLucid in 2017. See Note 3 for additional information related to acquisitions.

Summary of Income Tax Contingencies
A reconciliation of the beginning and ending amount of gross unrecognized tax benefits is as follows:

2018

2017

2016
Beginning balance at January 1
$
1,000.8

$
843.3

$
1,057.2

Additions based on tax positions related to the current year
798.2

133.8

73.4

Additions for tax positions of prior years
410.9

93.8

11.0

Reductions for tax positions of prior years
(115.4
)

(59.3
)

(12.1
)
Settlements
(33.2
)

(2.4
)

(171.9
)
Lapses of statutes of limitation
(20.5
)

(19.3
)

(110.0
)
Changes related to the impact of foreign currency translation
(6.2
)

10.9

(4.3
)
Ending balance at December 31
$
2,034.6

$
1,000.8

$
843.3

We recognize both accrued interest and penalties related to unrecognized tax benefits in income tax expense. We recognized income tax (benefit) expense related to interest and penalties as follows:

2018

2017

2016
Income tax expense (benefit)
$
25.1

$
22.8

$
(63.8
)

X

- Definition
Schedule of Additional Income Tax Disclosures [Table Text Block]
+ References
No definition available.
+ Details

Name: lly_ScheduleofAdditionalIncomeTaxDisclosuresTableTextBlock

Namespace Prefix: lly_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_IncomeTaxDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319
+ Details

Name: us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319
+ Details

Name: us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32687-109319
+ Details

Name: us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure for tax positions taken in the tax returns filed or to be filed for which it is more likely than not that the tax position will not be sustained upon examination by taxing authorities and other income tax contingencies. Includes, but is not limited to, interest and penalties, reconciliation of unrecognized tax benefits, unrecognized tax benefits that would affect the effective tax rate, tax years that remain subject to examination by tax jurisdictions, and information about positions for which it is reasonably possible that amounts unrecognized will significantly change within 12 months.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 15A
-URI http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 15
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32718-109319

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 19
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32840-109319
+ Details

Name: us-gaap_SummaryOfIncomeTaxContingenciesTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 50 R54.htm IDEA: XBRL DOCUMENT v3.19.3

Segment Information (Tables)
12 Months Ended

Dec. 31, 2018

Segment Reporting [Abstract]

Reconciliation of Operating Profit (Loss) from Segments to Consolidated
The following table summarizes our revenue activity:

U.S.⁽¹⁾

Outside U.S.

2018

2017

2016

2018

2017

2016
Revenue—to unaffiliated customers:

Endocrinology:

Trulicity^®
$
2,515.8

$
1,609.8

$
737.6

$
683.3

$
419.9

$
187.9

Humalog^®
1,787.8

1,717.8

1,685.2

1,208.7

1,147.4

1,083.6

Humulin^®
910.2

884.6

861.8

421.2

450.7

504.1

Forteo
757.9

965.2

770.5

817.7

783.8

729.4

Basaglar
622.8

311.1

15.8

178.5

121.0

70.3

Jardiance
400.2

290.4

144.5

258.1

157.0

57.4

Trajenta
224.2

213.2

165.9

350.5

324.7

270.7

Other Endocrinology
292.7

380.9

450.6

272.5

307.7

347.5

Total Endocrinology
7,511.6

6,373.0

4,831.9

4,190.5

3,712.2

3,250.9

Oncology:

Alimta
1,131.0

1,034.3

1,101.0

1,001.9

1,028.2

1,182.3

Erbitux
531.6

541.7

581.1

103.8

104.2

105.9

Cyramza^®
291.5

278.8

270.1

529.9

479.6

344.0

Other Oncology
449.1

195.6

22.9

221.7

149.6

114.6

Total Oncology
2,403.2

2,050.4

1,975.1

1,857.3

1,761.6

1,746.8

Cardiovascular:

Cialis
1,129.2

1,358.6

1,469.5

722.7

964.5

1,002.1

Effient
68.1

340.1

465.6

54.1

48.8

69.6

Other Cardiovascular
158.4

24.0

56.3

121.8

135.2

162.3

Total Cardiovascular
1,355.7

1,722.7

1,991.4

898.6

1,148.5

1,234.0

Neuroscience:

Strattera^®
89.7

284.9

534.9

361.1

333.3

319.8

Cymbalta⁽²⁾
54.3

114.9

269.3

653.7

642.2

661.2

Zyprexa^®
36.2

75.5

69.8

435.1

505.7

655.5

Other Neuroscience
97.2

115.7

115.9

93.4

98.9

93.9

Total Neuroscience
277.4

591.0

989.9

1,543.3

1,580.1

1,730.4

Immunology:

Taltz^®
738.7

486.0

110.8

198.7

73.2

2.3

Other Immunology
6.7

—

—

195.9

45.8

—

Total Immunology
745.4

486.0

110.8

394.6

119.0

2.3

Other
98.5

191.3

247.9

217.0

238.0

201.3

Revenue
$
12,391.9

$
11,414.4

$
10,147.0

$
9,101.4

$
8,559.4

$
8,165.8

Numbers may not add due to rounding.
⁽¹⁾ U.S. revenue includes revenue in Puerto Rico.
⁽²⁾Cymbalta revenues benefited from reductions to the reserve for expected product returns of approximately $175 million during the year ended December 31, 2016.

Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas

2018

2017

2016
Geographic Information

Revenue—to unaffiliated customers⁽¹⁾:

United States

$
12,391.9

$
11,414.4

$
10,147.0

Europe

3,663.1

3,390.6

3,214.4

Japan

2,407.4

2,339.5

2,253.0

Other foreign countries

3,030.9

2,829.3

2,698.3

Revenue

$
21,493.3

$
19,973.8

$
18,312.8

Long-lived assets⁽²⁾:

United States

$
4,344.0

$
4,408.7

$
4,520.8

Europe

2,413.5

2,246.4

1,864.8

Japan

180.2

153.4

91.0

Other foreign countries

1,608.5

1,672.5

1,690.4

Long-lived assets

$
8,546.2

$
8,481.0

$
8,167.0

Numbers may not add due to rounding.
⁽¹⁾Revenue is attributed to the countries based on the location of the customer.
⁽²⁾Long-lived assets consist of property and equipment, net, and certain sundry assets.

X

- Definition
Tabular disclosure of the reconciliation of profit (loss) from reportable segments to the consolidated income (loss) before income tax expense (benefit) and discontinued operations. Includes, but is not limited to, reconciliation after income tax if income tax is allocated to the reportable segment.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8924-108599

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8906-108599
+ Details

Name: us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of information concerning material long-lived assets (excluding financial instruments, customer relationships with financial institutions, mortgage and other servicing rights, deferred policy acquisition costs, and deferred taxes assets) located in identified geographic areas and/or the amount of revenue from external customers attributed to that country from which revenue is material. An entity may also provide subtotals of geographic information about groups of countries.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 41
-URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e9038-108599

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.1)
-URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227
+ Details

Name: us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_SegmentReportingAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 51 R9999.htm IDEA: XBRL DOCUMENT v3.19.3

Label Element Value

Retained Earnings [Member]

Cumulative Effect of New Accounting Principle in Period of Adoption us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption $ 643,600,000

Cumulative Effect of New Accounting Principle in Period of Adoption us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption $ 763,800,000

X

- Definition
Amount after tax of increase (decrease) to equity or (increase) decrease to net assets, resulting from the cumulative effect adjustment of a new accounting principle applied in the period of adoption.
+ References
No definition available.
+ Details

Name: us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Details

Name: us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 52 R58.htm IDEA: XBRL DOCUMENT v3.19.3

Summary of Significant Accounting Policies (Revenue) (Details) - USD ($)
$ in Millions
3 Months Ended 12 Months Ended

Dec. 31, 2018

Sep. 30, 2018

Jun. 30, 2018

Mar. 31, 2018

Dec. 31, 2017

Sep. 30, 2017

Jun. 30, 2017

Mar. 31, 2017

Dec. 31, 2018

Dec. 31, 2017

Dec. 31, 2016

Disaggregation of Revenue [Line Items]

Revenue from contract, payment term, minimum (in days) 30 days

Revenue from contract, payment term, maximum (in days) 70 days

Revenue $ 5,637.6 $ 5,306.9 $ 5,585.0 $ 4,963.8 $ 5,406.4 $ 4,961.0 $ 5,091.6 $ 4,514.9 $ 21,493.3 $ 19,973.8 $ 18,312.8

Net product revenue

Disaggregation of Revenue [Line Items]

Revenue 19,866.4 18,776.5 17,480.0

Collaboration and other revenue

Disaggregation of Revenue [Line Items]

Revenue 1,626.9 1,197.3 832.8

Royalty

Disaggregation of Revenue [Line Items]

Revenue $ 303.2 $ 144.9 $ 145.3

X

- Definition
Revenue from Contract, Payment Term, Maximum
+ References
No definition available.
+ Details

Name: lly_RevenuefromContractPaymentTermMaximum

Namespace Prefix: lly_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Revenue from Contract, Payment Term
+ References
No definition available.
+ Details

Name: lly_RevenuefromContractPaymentTermMinimum

Namespace Prefix: lly_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_DisaggregationOfRevenueLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8933-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(1))
-URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227
+ Details

Name: us-gaap_Revenues

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Details

Name: srt_ProductOrServiceAxis=us-gaap_ProductMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_ProductOrServiceAxis=lly_CollaborationandOtherRevenueMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_ProductOrServiceAxis=us-gaap_RoyaltyMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 53 R92.htm IDEA: XBRL DOCUMENT v3.19.3

Retirement Benefits (Narrative) (Details) - USD ($)
$ in Millions
1 Months Ended 12 Months Ended

Jul. 31, 2018

Dec. 31, 2018

Dec. 31, 2017

Dec. 31, 2016

Defined Benefit Plan Disclosure [Line Items]

Curtailment (gain) loss $ (28.0)

Defined benefit obligation, increase (decrease) $ (1,590.0) $ 2,830.0

Curtailment (gain) loss 159.0

Special termination benefit 354.7

Total accumulated benefit obligation for our defined benefit pension plans 12,570.0 13,670.0

Expense under the plans $ 132.6 147.0 $ 155.4

Percentage of global investments in plan assets (in percentage) 80.00%

Expected contribution $ 45.0

Marketable equity securities

Defined Benefit Plan Disclosure [Line Items]

Plan assets, target allocation (in percentage) 70.00%

Developed markets

Defined Benefit Plan Disclosure [Line Items]

Plan assets, target allocation (in percentage) 30.00%

Discontinued Operations

Defined Benefit Plan Disclosure [Line Items]

Special termination benefit 67.0

Restructuring, Settlement and Impairment Provisions

Defined Benefit Plan Disclosure [Line Items]

Special termination benefit $ 446.7

X

- Definition
Defined Benefit Plan, Estimated Future Employer Contributions in Next Fiscal Year, Minimum
+ References
No definition available.
+ Details

Name: lly_DefinedBenefitPlanEstimatedFutureEmployerContributionsinNextFiscalYearMinimum

Namespace Prefix: lly_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Percentage description of US defined benefit and other postretirement plan assets as compared to the total global investment balance
+ References
No definition available.
+ Details

Name: lly_DefinedBenefitPlanPercentageOfGlobalInvestmentsInPlanAssets

Namespace Prefix: lly_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of actuarial present value of benefits attributed to employee service rendered, excluding assumptions about future compensation level.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920
+ Details

Name: us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of increase (decrease) in benefit obligation of defined benefit plan.
+ References
No definition available.
+ Details

Name: us-gaap_DefinedBenefitPlanBenefitObligationPeriodIncreaseDecrease

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of (increase) decrease in benefit obligation of defined benefit plan from event reducing expected years of future service of present employees or eliminating accrual of benefits for some or all future services of present employees.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (a)(10)
-URI http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920
+ Details

Name: us-gaap_DefinedBenefitPlanCurtailments

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_DefinedBenefitPlanDisclosureLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Percentage of target investment allocation to total plan assets. Includes, but is not limited to, percentage on weighted-average basis if more than one plan.
+ References
Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 55
-Paragraph 17
-URI http://asc.fasb.org/extlink&oid=118257860&loc=d3e4179-114921

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (d)(i)
-URI http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920
+ Details

Name: us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: instant

X

- Definition
Amount of gain (loss) recognized in net periodic benefit (cost) credit from event reducing expected years of future service of present employees or eliminating accrual of defined benefits for some or all future services of present employees.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (h)(7)
-URI http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 6
-Subparagraph (a)(7)
-URI http://asc.fasb.org/extlink&oid=118255775&loc=d3e2709-114920
+ Details

Name: us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of increase in benefit obligation for benefits provided to employees payable from defined benefit plan or payable upon retirement.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (a)(10)
-URI http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920
+ Details

Name: us-gaap_DefinedBenefitPlanSpecialTerminationBenefits

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of cost for defined contribution plan.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 70
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=49170846&loc=d3e28014-114942
+ Details

Name: us-gaap_DefinedContributionPlanCostRecognized

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_DefinedBenefitPlanEquitySecuritiesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_FixedIncomeFundsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementOperatingActivitiesSegmentAxis=us-gaap_SegmentDiscontinuedOperationsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_IncomeStatementLocationAxis=lly_RestructuringSettlementAndImpairmentProvisionsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 54 R62.htm IDEA: XBRL DOCUMENT v3.19.3

Collaborations and Other Arrangements (Details) - USD ($)
$ in Millions
1 Months Ended 3 Months Ended 12 Months Ended 36 Months Ended

Oct. 01, 2015

Dec. 31, 2009

Dec. 31, 2018

Sep. 30, 2018

Jun. 30, 2018

Mar. 31, 2018

Dec. 31, 2017

Sep. 30, 2017

Jun. 30, 2017

Mar. 31, 2017

Dec. 31, 2018

Dec. 31, 2017

Dec. 31, 2016

Dec. 31, 2018

Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]

Revenue $ 5,637.6 $ 5,306.9 $ 5,585.0 $ 4,963.8 $ 5,406.4 $ 4,961.0 $ 5,091.6 $ 4,514.9 $ 21,493.3 $ 19,973.8 $ 18,312.8

Research and development 5,051.2 5,096.2 5,040.0

Europe

Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]

Revenue 3,663.1 3,390.6 3,214.4

JAPAN

Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]

Revenue 2,407.4 2,339.5 2,253.0

United States

Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]

Revenue 12,391.9 11,414.4 10,147.0

Trajenta

Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]

Revenue 574.7 537.9 436.6

Trajenta | United States | Human pharmaceutical products

Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]

Revenue 224.2 213.2 165.9

Trajenta | Milestone Payments, Development and Regulatory, Capitalized, Cumulative [Member]

Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]

Collaborative arrangement, rights and obligations, terms 446.4

Jardiance

Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]

Revenue 658.3 447.5 201.9

Jardiance | United States | Human pharmaceutical products

Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]

Revenue 400.2 290.4 144.5

Jardiance | Milestone Payments, Development and Regulatory, Capitalized, Cumulative [Member]

Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]

Collaborative arrangement, rights and obligations, terms 289.0

Basaglar

Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]

Revenue 801.2 432.1 86.1

Basaglar | United States | Human pharmaceutical products

Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]

Revenue 622.8 311.1 15.8

Basaglar | Milestone Payments, Development and Regulatory, Capitalized, Cumulative [Member]

Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]

Collaborative arrangement, rights and obligations, terms $ (250.0)

Basaglar | Milestone Payments, Development and Regulatory, Capitalized

Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]

Collaborative arrangement, rights and obligations, terms 0.0 0.0 (187.5)

Erbitux

Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]

Revenue 635.3 645.9 687.0

Erbitux | United States | Human pharmaceutical products

Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]

Revenue 531.6 541.7 581.1

Erbitux | Sales Reported

Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]

Collaborative arrangement, rights and obligations percent (in percentage) 38.00%

Erbitux, Product

Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]

Revenue 536.1 548.2 587.0

Erbitux, Collaboration and Other Revenue

Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]

Revenue 99.2 97.7 100.0

Effient | Human pharmaceutical products

Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]

Revenue 122.2 388.9 535.2

Effient | United States | Human pharmaceutical products

Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]

Revenue $ 68.1 340.1 465.6

Effient | Profit And Development And Marketing Share

Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]

Collaborative arrangement, rights and obligations percent (in percentage) 50.00%

Olumiant | Research And Development Exp

Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]

Collaborative arrangement, rights and obligations percent (in percentage) 30.00%

Olumiant | Milestone Payments, Development and Regulatory, Expensed

Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]

Research and development $ 20.0 30.0

Olumiant | Milestone Payments, Development and Regulatory, Expensed | United States and Europe [Member]

Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]

Research and development $ 55.0

Olumiant | Milestone Payments, Development and Regulatory, Capitalized (Deferred) | Europe

Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]

Collaborative arrangement, rights and obligations, terms 65.0

Olumiant | Milestone Payments, Development and Regulatory, Capitalized (Deferred) | JAPAN

Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]

Collaborative arrangement, rights and obligations, terms $ 15.0

Olumiant | Milestone Payments, Development and Regulatory, Capitalized (Deferred) | United States

Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]

Collaborative arrangement, rights and obligations, terms 100.0

Olumiant | Milestone Payments, Development and Regulatory

Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]

Collaborative arrangement, rights and obligations, terms 130.0

Olumiant | Royalty Payments Received

Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]

Collaborative arrangement, rights and obligations percent (in percentage) 20.00%

Olumiant | Milestone Payments, Sales-based

Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]

Collaborative arrangement, rights and obligations, terms 150.0

Tanezumab | Milestone Payments, Development and Regulatory

Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]

Collaborative arrangement, rights and obligations, terms 350.0

Tanezumab | Milestone Payments, Sales-based

Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]

Collaborative arrangement, rights and obligations, terms $ 1,230.0

X

- Definition
Description of rights and obligations under the collaborative arrangements, including but not limited to - percent share in various revenues and costs, percent interest earned on related party notes.
+ References
No definition available.
+ Details

Name: lly_CollaborativeArrangementRightsAndObligationsPercent

Namespace Prefix: lly_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
Terms or rights and obligations under collaborative arrangements.
+ References
No definition available.
+ Details

Name: lly_CollaborativeArrangementRightsAndObligationsTerms

Namespace Prefix: lly_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 985
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 730
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373
+ Details

Name: us-gaap_ResearchAndDevelopmentExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8933-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(1))
-URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227
+ Details

Name: us-gaap_Revenues

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Details

Name: srt_StatementGeographicalAxis=srt_EuropeMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_StatementGeographicalAxis=country_JP

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_StatementGeographicalAxis=country_US

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_ProductOrServiceAxis=lly_TrajentaBIMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementBusinessSegmentsAxis=lly_HumanPharmaceuticalProductsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_TypeOfArrangementAxis=lly_MilestonePaymentsDevelopmentandRegulatoryCapitalizedCumulativeMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_ProductOrServiceAxis=lly_JardianceMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_ProductOrServiceAxis=lly_BasaglarMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_TypeOfArrangementAxis=lly_MilestonePaymentsDevelopmentandRegulatoryCapitalizedMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_ProductOrServiceAxis=lly_ErbituxMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_TypeOfArrangementAxis=lly_AcquisitionTermsContingentConsiderationMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_ProductOrServiceAxis=lly_ErbituxProductMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_ProductOrServiceAxis=lly_ErbituxCollaborationandOtherRevenueMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_ProductOrServiceAxis=lly_EffientMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_TypeOfArrangementAxis=lly_ProfitAndDevelopmentAndMarketingShareMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_ProductOrServiceAxis=lly_OlumiantMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_TypeOfArrangementAxis=lly_ResearchAndDevelopmentExpMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_TypeOfArrangementAxis=lly_MilestonePaymentsDevelopmentandRegulatoryExpensedMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_StatementGeographicalAxis=lly_UnitedStatesandEuropeMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_TypeOfArrangementAxis=lly_MilestonePaymentsDevelopmentandRegulatoryCapitalizedDeferredMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_TypeOfArrangementAxis=lly_MilestonePaymentsDevelopmentAndRegulatoryMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_TypeOfArrangementAxis=us-gaap_RoyaltyAgreementTermsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_TypeOfArrangementAxis=lly_MilestonePaymentsSalesBasedMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_ProductOrServiceAxis=lly_TanezumabMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 55 R66.htm IDEA: XBRL DOCUMENT v3.19.3

Financial Instruments (Effect of Risk Management) (Details) - USD ($)
$ in Millions
12 Months Ended

Dec. 31, 2018

Dec. 31, 2017

Dec. 31, 2016

Cash Flow Hedge [Abstract]

Total $ 114.8 $ 112.7 $ 93.8

Cash flow hedges: | Interest rate swap

Cash Flow Hedge [Abstract]

Effective portion of risk-management instruments that was recognized in other comprehensive income (loss) is 0.0 13.0 (3.4)

Net investment hedges:

Cash Flow Hedge [Abstract]

Effective portion of risk-management instruments that was recognized in other comprehensive income (loss) is 110.4 (361.5) 137.5

Net investment hedges: | Foreign Exchange Contract

Cash Flow Hedge [Abstract]

Effective portion of risk-management instruments that was recognized in other comprehensive income (loss) is 5.7 0.0 31.9

Net investment hedges: | Cross-currency interest rate swaps

Cash Flow Hedge [Abstract]

Effective portion of risk-management instruments that was recognized in other comprehensive income (loss) is 96.8 (126.6) 32.5

Designated as Hedging Instrument | Hedged Fixed Rate Debt

Fair Value Hedge [Abstract]

Effect from hedged fixed-rate debt (40.9) (14.1) (30.8)

Designated as Hedging Instrument | Interest Rate Contract

Fair Value Hedge [Abstract]

Effect from interest rate contracts 40.9 14.1 30.8

Cash Flow Hedge [Abstract]

Effective portion of losses on interest rate contracts reclassified from accumulated other comprehensive loss 14.8 14.8 15.0

Not Designated as Hedging Instrument | Foreign Exchange Contract

Cash Flow Hedge [Abstract]

Net losses on foreign currency exchange contracts not designated as hedging instruments $ 100.0 $ 97.9 $ 78.8

X

- Definition
Cash Flow Hedge [Abstract]
+ References
No definition available.
+ Details

Name: lly_CashFlowHedgeAbstract

Namespace Prefix: lly_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Derivative Instruments, Gain(loss) Recognized
+ References
No definition available.
+ Details

Name: lly_DerivativeInstrumentsGainLossRecognized

Namespace Prefix: lly_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Fair Value Hedge [Abstract]
+ References
No definition available.
+ Details

Name: lly_FairValueHedgeAbstract

Namespace Prefix: lly_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of gain (loss) from the increase (decrease) in fair value of derivative and nonderivative instruments designated as fair value hedging instruments recognized in the income statement.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 25
-Section 50
-Paragraph 1
-Subparagraph (a)(1)
-URI http://asc.fasb.org/extlink&oid=109977999&loc=d3e76258-113986
+ Details

Name: us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of the increase (decrease) in fair value of the hedged item in a fair value hedge recognized in the income statement.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 25
-Section 50
-Paragraph 1
-Subparagraph (a)(1)
-URI http://asc.fasb.org/extlink&oid=109977999&loc=d3e76258-113986
+ Details

Name: us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The effective portion of loss reclassified from accumulated other comprehensive income into income on derivative instruments designated and qualifying as hedging instruments.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4C
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=109980867&loc=SL5624171-113959
+ Details

Name: us-gaap_DerivativeInstrumentsLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortion

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of gain (loss) recognized in earnings in the period from the increase (decrease) in fair value of foreign currency derivatives not designated as hedging instruments.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4A
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109980867&loc=SL5618551-113959

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4C
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=109980867&loc=SL5624171-113959
+ Details

Name: us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount before tax of increase (decrease) in accumulated gain (loss) from derivative instruments designated and qualifying as the effective portion of cash flow hedges and an entity's share of an equity investee's increase (decrease) in deferred hedging gain (loss).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=118930883&loc=d3e637-108580

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 30
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=109978405&loc=d3e80720-113993

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 10A
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580
+ Details

Name: us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodBeforeTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Details

Name: us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_NetInvestmentHedgingMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_DerivativeInstrumentRiskAxis=us-gaap_CrossCurrencyInterestRateContractMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_DerivativeInstrumentRiskAxis=lly_HedgedFixedRateDebtMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateContractMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 56 R96.htm IDEA: XBRL DOCUMENT v3.19.3

Other Comprehensive Income (Loss) (Reclassification) (Details) - USD ($)
$ in Millions
3 Months Ended 12 Months Ended

Dec. 31, 2018

Sep. 30, 2018

Jun. 30, 2018

Mar. 31, 2018

Dec. 31, 2017

Sep. 30, 2017

Jun. 30, 2017

Mar. 31, 2017

Dec. 31, 2018

Dec. 31, 2017

Dec. 31, 2016

Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]

Other, net (income) expense $ 11.7 $ (111.1) $ (192.9)

Total before tax (3,680.1) (2,304.8) (3,276.3)

Tax (benefit) expense $ 189.8 $ (247.5) $ (273.3) $ (198.5) $ (1,947.5) $ (29.0) $ (244.3) $ (170.3) (529.5) (2,391.2) (551.4)

Net of tax $ (1,125.1) $ (1,149.5) $ 259.9 $ (1,217.4) $ 1,656.9 $ (555.6) $ (1,008.0) $ 110.8

Reclassification out of Accumulated Other Comprehensive Income

Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]

Net of tax 190.5 60.5 250.7

Prior service benefits, net | Reclassification out of Accumulated Other Comprehensive Income

Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]

Other, net (income) expense (74.9) (84.4) (74.1)

Amortization of retirement benefit items: | Reclassification out of Accumulated Other Comprehensive Income

Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]

Other, net (income) expense 338.6 305.2 304.7

Defined Benefit Pension and Retiree Health Benefit Plans | Reclassification out of Accumulated Other Comprehensive Income

Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]

Total before tax 263.7 220.8 230.6

Tax (benefit) expense 55.8 68.9 71.5

Net of tax 207.9 151.9 159.1

Unrealized Net Gains (Losses) on Securities | Reclassification out of Accumulated Other Comprehensive Income

Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]

Other, net (income) expense (39.5) (170.2) (16.1)

Total before tax (39.5) (170.2) 11.2

Tax (benefit) expense (8.3) (59.6) 4.0

Net of tax (31.2) (110.6) 7.2

Impairment losses | Reclassification out of Accumulated Other Comprehensive Income

Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]

Other, net (income) expense 0.0 0.0 27.3

Other, net of tax | Reclassification out of Accumulated Other Comprehensive Income

Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]

Other, net (income) expense $ 13.8 $ 19.2 84.4

Foreign Currency Translation Gains (Losses) | Reclassification out of Accumulated Other Comprehensive Income

Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]

Other, net (income) expense $ (74.5)

X

- Definition
Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 940
-SubTopic 20
-Section 25
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=68072869&loc=d3e41242-110953

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(10))
-URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(8))
-URI http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(15))
-URI http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260
+ Details

Name: us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (h)
-URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(h))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 20
-Section 45
-Paragraph 2
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109238882&loc=d3e38679-109324
+ Details

Name: us-gaap_IncomeTaxExpenseBenefit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of income (expense) related to nonoperating activities, classified as other.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.9)
-URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227
+ Details

Name: us-gaap_OtherNonoperatingIncomeExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118930883&loc=SL7669619-108580

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 1A
-Subparagraph (a)(1)
-URI http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118930883&loc=SL7669625-108580

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 1A
-Subparagraph (c)(1)
-URI http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599

Reference 6: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 55
-Paragraph 4J
-URI http://asc.fasb.org/extlink&oid=116874947&loc=SL4591551-111686

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3000-108585

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 45
-Paragraph 19
-URI http://asc.fasb.org/extlink&oid=108774443&loc=SL4569616-111683

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8933-108599

Reference 10: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 55
-Paragraph 4K
-URI http://asc.fasb.org/extlink&oid=116874947&loc=SL4591552-111686
+ Details

Name: us-gaap_ProfitLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis=us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceIncludingPortionAttributableToNoncontrollingInterestMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetGainLossIncludingPortionAttributableToNoncontrollingInterestMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherthanTemporaryImpairmentIncludingPortionAttributableToNoncontrollingInterestMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementEquityComponentsAxis=lly_AccumulatedNetGainLossfromCashFlowHedgesandForeignCurrencyAdjustmentIncludingPortionAttributabletoNoncontrollingInterestMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 57 R49.htm IDEA: XBRL DOCUMENT v3.19.3

Stock-Based Compensation (Tables)
12 Months Ended

Dec. 31, 2018

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Schedule of Additional Stock-Based Compensation Disclosures
Stock-based compensation expense and the related tax benefits were as follows:

2018

2017

2016
Stock-based compensation expense
$
253.5

$
256.3

$
234.9

Tax benefit
53.2

64.1

82.2

Share-based Compensation Awards, Fair Value Assumptions Used The weighted-average fair values of the SVA units granted during the years ended December 31, 2018, 2017, and 2016 were $48.51, $66.25, and $48.68, respectively, determined using the following assumptions:
(Percents)
2018

2017

2016
Expected dividend yield
2.50
%

2.50
%

2.00
%
Risk-free interest rate
2.31

1.38

0.92

Volatility
22.26

22.91

21.68

X

- Definition
Schedule of Additional Stock-Based Compensation Disclosures [Table Text Block]
+ References
No definition available.
+ Details

Name: lly_ScheduleofAdditionalStockBasedCompensationDisclosuresTableTextBlock

Namespace Prefix: lly_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Share-based Compensation Awards, Fair Value Assumptions Used [Table Text Block]
+ References
No definition available.
+ Details

Name: lly_SharebasedCompensationAwardsFairValueAssumptionsUsedTableTextBlock

Namespace Prefix: lly_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 58 a20198-kfor201810xkrec_htm.xml IDEA: XBRL DOCUMENT 0000059478 2018-01-01 2018-12-31 0000059478 lly:EffientMember 2018-01-01 2018-12-31 0000059478 lly:ErbituxMember 2018-01-01 2018-12-31 0000059478 lly:DiabetesCollaborationMember 2018-01-01 2018-12-31 0000059478 2019-10-24 2019-10-24 0000059478 lly:A718NotesDueJune12025Member 2019-10-24 2019-10-24 0000059478 lly:A1.625NotesDueJune22026Member 2019-10-24 2019-10-24 0000059478 lly:A6.77NotesDueJanuary12036Member 2019-10-24 2019-10-24 0000059478 lly:A2.125NotesDueJune32030Member 2019-10-24 2019-10-24 0000059478 lly:A1.000NotesDueJune22022Member 2019-10-24 2019-10-24 0000059478 us-gaap:CommonClassAMember 2019-10-24 2019-10-24 0000059478 2017-01-01 2017-12-31 0000059478 2016-01-01 2016-12-31 0000059478 us-gaap:SegmentContinuingOperationsMember 2017-01-01 2017-12-31 0000059478 us-gaap:SegmentContinuingOperationsMember 2016-01-01 2016-12-31 0000059478 us-gaap:SegmentContinuingOperationsMember 2018-01-01 2018-12-31 0000059478 us-gaap:SegmentDiscontinuedOperationsMember 2016-01-01 2016-12-31 0000059478 us-gaap:SegmentDiscontinuedOperationsMember 2017-01-01 2017-12-31 0000059478 us-gaap:SegmentDiscontinuedOperationsMember 2018-01-01 2018-12-31 0000059478 2017-12-31 0000059478 2018-12-31 0000059478 us-gaap:RetainedEarningsMember 2016-01-01 2016-12-31 0000059478 us-gaap:CommonStockMember 2017-01-01 2017-12-31 0000059478 us-gaap:TreasuryStockMember 2016-01-01 2016-12-31 0000059478 us-gaap:TreasuryStockMember 2018-01-01 2018-12-31 0000059478 us-gaap:CommonStockMember 2018-12-31 0000059478 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2016-01-01 2016-12-31 0000059478 us-gaap:CommonStockMember 2017-12-31 0000059478 us-gaap:CommonStockMember 2016-01-01 2016-12-31 0000059478 us-gaap:TreasuryStockMember 2017-01-01 2017-12-31 0000059478 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-01-01 2018-12-31 0000059478 us-gaap:NoncontrollingInterestMember 2018-01-01 2018-12-31 0000059478 us-gaap:NoncontrollingInterestMember 2017-01-01 2017-12-31 0000059478 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-01-01 0000059478 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-12-31 0000059478 us-gaap:AdditionalPaidInCapitalMember 2016-01-01 2016-12-31 0000059478 us-gaap:CommonStockMember 2018-01-01 2018-12-31 0000059478 us-gaap:RetainedEarningsMember 2018-01-01 2018-12-31 0000059478 us-gaap:RetainedEarningsMember 2017-01-01 2017-12-31 0000059478 us-gaap:TreasuryStockMember 2017-12-31 0000059478 us-gaap:AdditionalPaidInCapitalMember 2018-12-31 0000059478 us-gaap:NoncontrollingInterestMember 2018-12-31 0000059478 us-gaap:CommonStockMember 2015-12-31 0000059478 us-gaap:RetainedEarningsMember 2018-01-01 0000059478 us-gaap:RetainedEarningsMember 2016-12-31 0000059478 us-gaap:AdditionalPaidInCapitalMember 2017-12-31 0000059478 us-gaap:RetainedEarningsMember 2017-12-31 0000059478 us-gaap:AdditionalPaidInCapitalMember 2018-01-01 2018-12-31 0000059478 us-gaap:AdditionalPaidInCapitalMember 2017-01-01 2017-12-31 0000059478 us-gaap:TreasuryStockMember 2018-12-31 0000059478 us-gaap:CommonStockMember 2016-12-31 0000059478 us-gaap:TreasuryStockMember 2015-12-31 0000059478 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2015-12-31 0000059478 us-gaap:AdditionalPaidInCapitalMember 2016-12-31 0000059478 us-gaap:TrustForBenefitOfEmployeesMember 2015-12-31 0000059478 us-gaap:NoncontrollingInterestMember 2017-12-31 0000059478 us-gaap:RetainedEarningsMember 2015-12-31 0000059478 us-gaap:NoncontrollingInterestMember 2016-12-31 0000059478 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2017-01-01 2017-12-31 0000059478 us-gaap:TrustForBenefitOfEmployeesMember 2017-12-31 0000059478 us-gaap:NoncontrollingInterestMember 2016-01-01 2016-12-31 0000059478 us-gaap:AdditionalPaidInCapitalMember 2015-12-31 0000059478 us-gaap:TrustForBenefitOfEmployeesMember 2016-12-31 0000059478 us-gaap:TreasuryStockMember 2016-12-31 0000059478 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2017-12-31 0000059478 us-gaap:TrustForBenefitOfEmployeesMember 2018-12-31 0000059478 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2017-01-01 0000059478 us-gaap:RetainedEarningsMember 2017-01-01 0000059478 us-gaap:NoncontrollingInterestMember 2015-12-31 0000059478 us-gaap:RetainedEarningsMember 2018-12-31 0000059478 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2016-12-31 0000059478 2016-12-31 0000059478 2015-12-31 0000059478 us-gaap:IPOMember lly:ElancoAnimalHealthIncorporatedMember 2018-09-24 0000059478 us-gaap:RoyaltyMember 2017-01-01 2017-12-31 0000059478 us-gaap:IPOMember lly:ElancoAnimalHealthIncorporatedMember 2018-09-24 2018-09-24 0000059478 lly:ElancoAnimalHealthIncorporatedMember 2018-09-24 2018-09-24 0000059478 us-gaap:RoyaltyMember 2018-01-01 2018-12-31 0000059478 us-gaap:RoyaltyMember 2016-01-01 2016-12-31 0000059478 us-gaap:DiscontinuedOperationsDisposedOfBySaleMember lly:ElancoAnimalHealthIncorporatedMember 2019-03-11 0000059478 lly:CollaborationandOtherRevenueMember 2017-01-01 2017-12-31 0000059478 lly:CollaborationandOtherRevenueMember 2016-01-01 2016-12-31 0000059478 us-gaap:ProductMember 2016-01-01 2016-12-31 0000059478 us-gaap:ProductMember 2017-01-01 2017-12-31 0000059478 us-gaap:ProductMember 2018-01-01 2018-12-31 0000059478 lly:CollaborationandOtherRevenueMember 2018-01-01 2018-12-31 0000059478 us-gaap:AccountingStandardsUpdate201802Member 2017-12-31 0000059478 us-gaap:AccountingStandardsUpdate201616Member 2018-01-01 0000059478 us-gaap:AccountingStandardsUpdate201707Member 2016-01-01 2016-12-31 0000059478 us-gaap:AccountingStandardsUpdate201601Member 2018-01-01 0000059478 us-gaap:AccountingStandardsUpdate201602Member 2019-01-01 0000059478 us-gaap:AccountingStandardsUpdate201409Member us-gaap:DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member 2018-01-01 0000059478 us-gaap:AccountingStandardsUpdate201707Member 2017-01-01 2017-12-31 0000059478 lly:LoxoOncologyInc.Member 2019-02-15 2019-02-15 0000059478 lly:ACImmuneSAMember 2019-01-01 2019-01-31 0000059478 lly:LoxoOncologyInc.Member 2019-02-15 0000059478 lly:CoLucidPharmaceuticalsMember 2017-03-01 2017-03-31 0000059478 lly:SIGATechnologiesMember 2018-10-01 2018-10-31 0000059478 lly:ARMOBiosciencesInc.Member 2018-06-01 2018-06-30 0000059478 lly:NektarsPhaseIImmunologicalTherapyMember 2017-08-01 2017-08-31 0000059478 lly:CureVacAGMember 2017-11-01 2017-11-30 0000059478 lly:KeyBiosciencesDualAmylinCalcitoninReceptorAgonistsMember 2017-07-01 2017-07-31 0000059478 lly:SigilonTherapeuticsMember 2018-04-01 2018-04-30 0000059478 lly:AstraZenecaMember 2016-12-01 2016-12-31 0000059478 lly:AurkaPharmaMember 2018-06-01 2018-06-30 0000059478 lly:NextCureInc.Member 2018-11-01 2018-11-30 0000059478 lly:DicernaPharmaceuticalsMember 2018-12-01 2018-12-31 0000059478 lly:AnimaBiotechMember 2018-07-01 2018-07-31 0000059478 lly:ChugaiPharmaceuticalCompanyMember 2018-10-01 2018-10-31 0000059478 lly:HydraBiosciencesMember 2018-12-01 2018-12-31 0000059478 lly:EffientMember lly:HumanPharmaceuticalProductsMember 2017-01-01 2017-12-31 0000059478 lly:EffientMember lly:HumanPharmaceuticalProductsMember 2018-01-01 2018-12-31 0000059478 lly:EffientMember lly:HumanPharmaceuticalProductsMember 2016-01-01 2016-12-31 0000059478 lly:ErbituxCollaborationandOtherRevenueMember 2017-01-01 2017-12-31 0000059478 lly:ErbituxMember 2016-01-01 2016-12-31 0000059478 lly:ErbituxMember 2017-01-01 2017-12-31 0000059478 lly:ErbituxCollaborationandOtherRevenueMember 2018-01-01 2018-12-31 0000059478 lly:ErbituxCollaborationandOtherRevenueMember 2016-01-01 2016-12-31 0000059478 lly:ErbituxProductMember 2016-01-01 2016-12-31 0000059478 lly:ErbituxProductMember 2018-01-01 2018-12-31 0000059478 lly:ErbituxProductMember 2017-01-01 2017-12-31 0000059478 lly:OlumiantMember lly:MilestonePaymentsDevelopmentAndRegulatoryMember 2018-01-01 2018-12-31 0000059478 lly:TanezumabMember lly:MilestonePaymentsSalesBasedMember 2018-01-01 2018-12-31 0000059478 lly:ErbituxMember lly:AcquisitionTermsContingentConsiderationMember 2015-10-01 2015-10-01 0000059478 lly:EffientMember lly:ProfitAndDevelopmentAndMarketingShareMember 2018-01-01 2018-12-31 0000059478 lly:OlumiantMember lly:MilestonePaymentsSalesBasedMember 2018-01-01 2018-12-31 0000059478 lly:OlumiantMember lly:ResearchAndDevelopmentExpMember 2009-12-01 2009-12-31 0000059478 lly:OlumiantMember us-gaap:RoyaltyAgreementTermsMember 2009-12-01 2009-12-31 0000059478 lly:TanezumabMember lly:MilestonePaymentsDevelopmentAndRegulatoryMember 2018-01-01 2018-12-31 0000059478 lly:JardianceMember 2018-01-01 2018-12-31 0000059478 lly:BasaglarMember 2018-01-01 2018-12-31 0000059478 lly:TrajentaBIMember 2017-01-01 2017-12-31 0000059478 lly:JardianceMember 2017-01-01 2017-12-31 0000059478 lly:TrajentaBIMember 2016-01-01 2016-12-31 0000059478 lly:TrajentaBIMember 2018-01-01 2018-12-31 0000059478 lly:BasaglarMember 2016-01-01 2016-12-31 0000059478 lly:JardianceMember 2016-01-01 2016-12-31 0000059478 lly:BasaglarMember 2017-01-01 2017-12-31 0000059478 lly:OlumiantMember lly:MilestonePaymentsDevelopmentandRegulatoryExpensedMember 2018-01-01 2018-12-31 0000059478 lly:OlumiantMember country:US lly:MilestonePaymentsDevelopmentandRegulatoryCapitalizedDeferredMember 2018-01-01 2018-12-31 0000059478 lly:OlumiantMember country:JP lly:MilestonePaymentsDevelopmentandRegulatoryCapitalizedDeferredMember 2017-01-01 2017-12-31 0000059478 lly:OlumiantMember lly:MilestonePaymentsDevelopmentandRegulatoryExpensedMember 2017-01-01 2017-12-31 0000059478 lly:OlumiantMember srt:EuropeMember lly:MilestonePaymentsDevelopmentandRegulatoryCapitalizedDeferredMember 2017-01-01 2017-12-31 0000059478 lly:OlumiantMember lly:UnitedStatesandEuropeMember lly:MilestonePaymentsDevelopmentandRegulatoryExpensedMember 2016-01-01 2016-12-31 0000059478 lly:BasaglarMember lly:MilestonePaymentsDevelopmentandRegulatoryCapitalizedCumulativeMember 2016-01-01 2018-12-31 0000059478 lly:BasaglarMember lly:MilestonePaymentsDevelopmentandRegulatoryCapitalizedMember 2018-01-01 2018-12-31 0000059478 lly:TrajentaBIMember lly:MilestonePaymentsDevelopmentandRegulatoryCapitalizedCumulativeMember 2018-01-01 2018-12-31 0000059478 lly:BasaglarMember lly:MilestonePaymentsDevelopmentandRegulatoryCapitalizedMember 2017-01-01 2017-12-31 0000059478 lly:BasaglarMember lly:MilestonePaymentsDevelopmentandRegulatoryCapitalizedMember 2016-01-01 2016-12-31 0000059478 lly:JardianceMember lly:MilestonePaymentsDevelopmentandRegulatoryCapitalizedCumulativeMember 2018-01-01 2018-12-31 0000059478 country:PR 2017-01-01 2017-12-31 0000059478 lly:OutsideUnitedStatesMember 2017-01-01 2017-12-31 0000059478 country:US 2017-01-01 2017-12-31 0000059478 us-gaap:InterestRateSwapMember us-gaap:CashFlowHedgingMember 2016-01-01 2016-12-31 0000059478 us-gaap:ForeignExchangeContractMember us-gaap:NetInvestmentHedgingMember 2016-01-01 2016-12-31 0000059478 us-gaap:ForeignExchangeContractMember us-gaap:NetInvestmentHedgingMember 2017-01-01 2017-12-31 0000059478 us-gaap:CrossCurrencyInterestRateContractMember us-gaap:NetInvestmentHedgingMember 2016-01-01 2016-12-31 0000059478 us-gaap:CrossCurrencyInterestRateContractMember us-gaap:NetInvestmentHedgingMember 2018-01-01 2018-12-31 0000059478 us-gaap:NetInvestmentHedgingMember 2017-01-01 2017-12-31 0000059478 us-gaap:CrossCurrencyInterestRateContractMember us-gaap:NetInvestmentHedgingMember 2017-01-01 2017-12-31 0000059478 us-gaap:InterestRateSwapMember us-gaap:CashFlowHedgingMember 2017-01-01 2017-12-31 0000059478 us-gaap:ForeignExchangeContractMember us-gaap:NetInvestmentHedgingMember 2018-01-01 2018-12-31 0000059478 us-gaap:NetInvestmentHedgingMember 2018-01-01 2018-12-31 0000059478 us-gaap:InterestRateSwapMember us-gaap:CashFlowHedgingMember 2018-01-01 2018-12-31 0000059478 us-gaap:NetInvestmentHedgingMember 2016-01-01 2016-12-31 0000059478 lly:HedgedFixedRateDebtMember us-gaap:DesignatedAsHedgingInstrumentMember 2018-01-01 2018-12-31 0000059478 us-gaap:InterestRateContractMember us-gaap:DesignatedAsHedgingInstrumentMember 2018-01-01 2018-12-31 0000059478 us-gaap:ForeignExchangeContractMember us-gaap:NondesignatedMember 2018-01-01 2018-12-31 0000059478 us-gaap:InterestRateContractMember us-gaap:DesignatedAsHedgingInstrumentMember 2017-01-01 2017-12-31 0000059478 us-gaap:InterestRateContractMember us-gaap:DesignatedAsHedgingInstrumentMember 2016-01-01 2016-12-31 0000059478 lly:HedgedFixedRateDebtMember us-gaap:DesignatedAsHedgingInstrumentMember 2016-01-01 2016-12-31 0000059478 us-gaap:ForeignExchangeContractMember us-gaap:NondesignatedMember 2016-01-01 2016-12-31 0000059478 lly:HedgedFixedRateDebtMember us-gaap:DesignatedAsHedgingInstrumentMember 2017-01-01 2017-12-31 0000059478 us-gaap:ForeignExchangeContractMember us-gaap:NondesignatedMember 2017-01-01 2017-12-31 0000059478 us-gaap:InterestRateContractMember us-gaap:FairValueInputsLevel3Member us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:DesignatedAsHedgingInstrumentMember 2017-12-31 0000059478 us-gaap:CrossCurrencyInterestRateContractMember us-gaap:FairValueInputsLevel2Member us-gaap:DesignatedAsHedgingInstrumentMember 2018-12-31 0000059478 us-gaap:InterestRateContractMember us-gaap:FairValueInputsLevel3Member us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:DesignatedAsHedgingInstrumentMember 2018-12-31 0000059478 us-gaap:CrossCurrencyInterestRateContractMember us-gaap:CarryingReportedAmountFairValueDisclosureMember us-gaap:DesignatedAsHedgingInstrumentMember 2018-12-31 0000059478 us-gaap:CarryingReportedAmountFairValueDisclosureMember 2017-12-31 0000059478 us-gaap:InterestRateContractMember us-gaap:CarryingReportedAmountFairValueDisclosureMember us-gaap:DesignatedAsHedgingInstrumentMember 2018-12-31 0000059478 us-gaap:InterestRateContractMember us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:DesignatedAsHedgingInstrumentMember 2017-12-31 0000059478 us-gaap:InterestRateContractMember us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:DesignatedAsHedgingInstrumentMember 2018-12-31 0000059478 us-gaap:ForeignExchangeContractMember us-gaap:FairValueInputsLevel1Member us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:NondesignatedMember 2018-12-31 0000059478 us-gaap:FairValueInputsLevel1Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2017-12-31 0000059478 us-gaap:InterestRateContractMember us-gaap:FairValueInputsLevel2Member us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:DesignatedAsHedgingInstrumentMember 2018-12-31 0000059478 us-gaap:ForeignExchangeContractMember us-gaap:FairValueInputsLevel2Member us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:NondesignatedMember 2018-12-31 0000059478 us-gaap:ForeignExchangeContractMember us-gaap:CarryingReportedAmountFairValueDisclosureMember us-gaap:NondesignatedMember 2017-12-31 0000059478 us-gaap:CrossCurrencyInterestRateContractMember us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:DesignatedAsHedgingInstrumentMember 2017-12-31 0000059478 us-gaap:InterestRateContractMember us-gaap:FairValueInputsLevel2Member us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:DesignatedAsHedgingInstrumentMember 2017-12-31 0000059478 us-gaap:InterestRateContractMember us-gaap:FairValueInputsLevel3Member us-gaap:DesignatedAsHedgingInstrumentMember 2017-12-31 0000059478 us-gaap:CrossCurrencyInterestRateContractMember us-gaap:FairValueInputsLevel3Member us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:DesignatedAsHedgingInstrumentMember 2017-12-31 0000059478 us-gaap:CrossCurrencyInterestRateContractMember us-gaap:CarryingReportedAmountFairValueDisclosureMember us-gaap:DesignatedAsHedgingInstrumentMember 2017-12-31 0000059478 us-gaap:InterestRateContractMember us-gaap:CarryingReportedAmountFairValueDisclosureMember us-gaap:DesignatedAsHedgingInstrumentMember 2017-12-31 0000059478 us-gaap:CrossCurrencyInterestRateContractMember us-gaap:FairValueInputsLevel1Member us-gaap:DesignatedAsHedgingInstrumentMember 2018-12-31 0000059478 us-gaap:InterestRateContractMember us-gaap:FairValueInputsLevel1Member us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:DesignatedAsHedgingInstrumentMember 2017-12-31 0000059478 us-gaap:ForeignExchangeContractMember us-gaap:FairValueInputsLevel1Member us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:NondesignatedMember 2017-12-31 0000059478 us-gaap:CrossCurrencyInterestRateContractMember us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:DesignatedAsHedgingInstrumentMember 2018-12-31 0000059478 us-gaap:ForeignExchangeContractMember us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:NondesignatedMember 2018-12-31 0000059478 us-gaap:CrossCurrencyInterestRateContractMember us-gaap:FairValueInputsLevel1Member us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:DesignatedAsHedgingInstrumentMember 2017-12-31 0000059478 us-gaap:InterestRateContractMember us-gaap:FairValueInputsLevel1Member us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:DesignatedAsHedgingInstrumentMember 2018-12-31 0000059478 us-gaap:ForeignExchangeContractMember us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:NondesignatedMember 2017-12-31 0000059478 us-gaap:CrossCurrencyInterestRateContractMember us-gaap:FairValueInputsLevel3Member us-gaap:DesignatedAsHedgingInstrumentMember 2018-12-31 0000059478 us-gaap:FairValueInputsLevel2Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2017-12-31 0000059478 us-gaap:InterestRateContractMember us-gaap:FairValueInputsLevel1Member us-gaap:DesignatedAsHedgingInstrumentMember 2017-12-31 0000059478 us-gaap:InterestRateContractMember us-gaap:FairValueInputsLevel2Member us-gaap:DesignatedAsHedgingInstrumentMember 2017-12-31 0000059478 us-gaap:CrossCurrencyInterestRateContractMember us-gaap:FairValueInputsLevel1Member us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:DesignatedAsHedgingInstrumentMember 2018-12-31 0000059478 us-gaap:CrossCurrencyInterestRateContractMember us-gaap:FairValueInputsLevel2Member us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:DesignatedAsHedgingInstrumentMember 2018-12-31 0000059478 us-gaap:ForeignExchangeContractMember us-gaap:CarryingReportedAmountFairValueDisclosureMember us-gaap:NondesignatedMember 2018-12-31 0000059478 us-gaap:ForeignExchangeContractMember us-gaap:FairValueInputsLevel3Member us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:NondesignatedMember 2018-12-31 0000059478 us-gaap:ForeignExchangeContractMember us-gaap:FairValueInputsLevel2Member us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:NondesignatedMember 2017-12-31 0000059478 us-gaap:CrossCurrencyInterestRateContractMember us-gaap:FairValueInputsLevel3Member us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:DesignatedAsHedgingInstrumentMember 2018-12-31 0000059478 us-gaap:ForeignExchangeContractMember us-gaap:FairValueInputsLevel3Member us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:NondesignatedMember 2017-12-31 0000059478 us-gaap:CrossCurrencyInterestRateContractMember us-gaap:FairValueInputsLevel2Member us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:DesignatedAsHedgingInstrumentMember 2017-12-31 0000059478 us-gaap:FairValueInputsLevel3Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2017-12-31 0000059478 us-gaap:EstimateOfFairValueFairValueDisclosureMember 2017-12-31 0000059478 lly:BuyEuroSellUsDollarMember 2018-12-31 0000059478 us-gaap:CurrencySwapMember 2018-12-31 0000059478 lly:BuyGBPSellUSDMember 2018-12-31 0000059478 us-gaap:InterestRateSwapMember 2018-12-31 0000059478 lly:BuySwissfrancsSellUSdollarMember 2018-12-31 0000059478 lly:BuyUsdSellEuroMember 2018-12-31 0000059478 lly:ForeignCurrencyDenominatedDebtMember 2017-12-31 0000059478 lly:SwapSwissFrancsToU.S.DollarsMember 2018-12-31 0000059478 lly:BuyUSdollarSellBritishpoundMember 2018-12-31 0000059478 lly:ForeignCurrencyDenominatedDebtMember 2018-12-31 0000059478 lly:BuyUSdollarSellJapaneseYenMember 2018-12-31 0000059478 us-gaap:CarryingReportedAmountFairValueDisclosureMember lly:MarketableSecuritiesMember 2018-12-31 0000059478 us-gaap:FairValueInputsLevel1Member us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2018-12-31 0000059478 us-gaap:FairValueInputsLevel2Member us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:AssetBackedSecuritiesMember 2018-12-31 0000059478 us-gaap:FairValueInputsLevel3Member us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:AssetBackedSecuritiesMember 2018-12-31 0000059478 us-gaap:CarryingReportedAmountFairValueDisclosureMember us-gaap:OtherDebtSecuritiesMember 2017-12-31 0000059478 us-gaap:PortionAtOtherThanFairValueFairValueDisclosureMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2018-12-31 0000059478 us-gaap:FairValueInputsLevel3Member us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:CorporateDebtSecuritiesMember 2018-12-31 0000059478 us-gaap:FairValueInputsLevel2Member us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:MortgageBackedSecuritiesMember 2018-12-31 0000059478 us-gaap:FairValueInputsLevel3Member us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:OtherDebtSecuritiesMember 2017-12-31 0000059478 us-gaap:PortionAtOtherThanFairValueFairValueDisclosureMember us-gaap:CorporateDebtSecuritiesMember 2018-12-31 0000059478 us-gaap:EstimateOfFairValueFairValueDisclosureMember lly:OtherEquitySecuritiesMember 2018-12-31 0000059478 us-gaap:PortionAtOtherThanFairValueFairValueDisclosureMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2017-12-31 0000059478 us-gaap:FairValueInputsLevel2Member us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2018-12-31 0000059478 us-gaap:FairValueInputsLevel1Member us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:CorporateDebtSecuritiesMember 2017-12-31 0000059478 us-gaap:FairValueInputsLevel3Member us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:MortgageBackedSecuritiesMember 2017-12-31 0000059478 us-gaap:FairValueInputsLevel1Member us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:AssetBackedSecuritiesMember 2018-12-31 0000059478 us-gaap:CarryingReportedAmountFairValueDisclosureMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2017-12-31 0000059478 us-gaap:FairValueInputsLevel3Member us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:CorporateDebtSecuritiesMember 2017-12-31 0000059478 us-gaap:CarryingReportedAmountFairValueDisclosureMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2018-12-31 0000059478 us-gaap:FairValueInputsLevel1Member us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:OtherDebtSecuritiesMember 2017-12-31 0000059478 us-gaap:FairValueInputsLevel2Member us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2017-12-31 0000059478 us-gaap:PortionAtOtherThanFairValueFairValueDisclosureMember us-gaap:AssetBackedSecuritiesMember 2017-12-31 0000059478 us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:CorporateDebtSecuritiesMember 2017-12-31 0000059478 us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2017-12-31 0000059478 us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:EquitySecuritiesMember 2017-12-31 0000059478 us-gaap:PortionAtOtherThanFairValueFairValueDisclosureMember us-gaap:MortgageBackedSecuritiesMember 2017-12-31 0000059478 us-gaap:FairValueInputsLevel2Member us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:EquitySecuritiesMember 2017-12-31 0000059478 us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2018-12-31 0000059478 us-gaap:FairValueInputsLevel1Member us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2017-12-31 0000059478 us-gaap:PortionAtOtherThanFairValueFairValueDisclosureMember us-gaap:EquitySecuritiesMember 2017-12-31 0000059478 us-gaap:FairValueInputsLevel2Member us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:CorporateDebtSecuritiesMember 2017-12-31 0000059478 us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:CorporateDebtSecuritiesMember 2018-12-31 0000059478 us-gaap:FairValueInputsLevel3Member us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:AssetBackedSecuritiesMember 2017-12-31 0000059478 us-gaap:FairValueInputsLevel1Member us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:MortgageBackedSecuritiesMember 2018-12-31 0000059478 us-gaap:CarryingReportedAmountFairValueDisclosureMember us-gaap:MortgageBackedSecuritiesMember 2018-12-31 0000059478 us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:OtherDebtSecuritiesMember 2017-12-31 0000059478 us-gaap:FairValueInputsLevel1Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2018-12-31 0000059478 us-gaap:FairValueInputsLevel3Member us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2017-12-31 0000059478 us-gaap:EstimateOfFairValueFairValueDisclosureMember lly:MarketableSecuritiesMember 2018-12-31 0000059478 us-gaap:PortionAtOtherThanFairValueFairValueDisclosureMember us-gaap:AssetBackedSecuritiesMember 2018-12-31 0000059478 us-gaap:FairValueInputsLevel2Member us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:AssetBackedSecuritiesMember 2017-12-31 0000059478 us-gaap:FairValueInputsLevel3Member us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:EquitySecuritiesMember 2017-12-31 0000059478 us-gaap:CarryingReportedAmountFairValueDisclosureMember us-gaap:CorporateDebtSecuritiesMember 2018-12-31 0000059478 us-gaap:FairValueInputsLevel3Member us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2018-12-31 0000059478 us-gaap:CarryingReportedAmountFairValueDisclosureMember us-gaap:AssetBackedSecuritiesMember 2017-12-31 0000059478 us-gaap:CarryingReportedAmountFairValueDisclosureMember 2018-12-31 0000059478 us-gaap:PortionAtOtherThanFairValueFairValueDisclosureMember us-gaap:MortgageBackedSecuritiesMember 2018-12-31 0000059478 us-gaap:CarryingReportedAmountFairValueDisclosureMember lly:EquityMethodAndOtherInvestmentsMember 2018-12-31 0000059478 us-gaap:PortionAtOtherThanFairValueFairValueDisclosureMember 2017-12-31 0000059478 us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:AssetBackedSecuritiesMember 2018-12-31 0000059478 us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:MortgageBackedSecuritiesMember 2018-12-31 0000059478 us-gaap:PortionAtOtherThanFairValueFairValueDisclosureMember us-gaap:CorporateDebtSecuritiesMember 2017-12-31 0000059478 us-gaap:FairValueInputsLevel1Member us-gaap:EstimateOfFairValueFairValueDisclosureMember lly:OtherEquitySecuritiesMember 2018-12-31 0000059478 us-gaap:FairValueInputsLevel2Member us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:CorporateDebtSecuritiesMember 2018-12-31 0000059478 us-gaap:FairValueInputsLevel2Member us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:MortgageBackedSecuritiesMember 2017-12-31 0000059478 us-gaap:PortionAtOtherThanFairValueFairValueDisclosureMember us-gaap:OtherDebtSecuritiesMember 2018-12-31 0000059478 us-gaap:FairValueInputsLevel1Member us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:CorporateDebtSecuritiesMember 2018-12-31 0000059478 us-gaap:PortionAtOtherThanFairValueFairValueDisclosureMember us-gaap:OtherDebtSecuritiesMember 2017-12-31 0000059478 us-gaap:CarryingReportedAmountFairValueDisclosureMember lly:EquityMethodAndOtherInvestmentsMember 2017-12-31 0000059478 us-gaap:EstimateOfFairValueFairValueDisclosureMember 2018-12-31 0000059478 us-gaap:CarryingReportedAmountFairValueDisclosureMember us-gaap:AssetBackedSecuritiesMember 2018-12-31 0000059478 us-gaap:FairValueInputsLevel1Member us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:MortgageBackedSecuritiesMember 2017-12-31 0000059478 us-gaap:PortionAtOtherThanFairValueFairValueDisclosureMember lly:OtherEquitySecuritiesMember 2018-12-31 0000059478 us-gaap:CarryingReportedAmountFairValueDisclosureMember lly:OtherEquitySecuritiesMember 2018-12-31 0000059478 us-gaap:CarryingReportedAmountFairValueDisclosureMember us-gaap:CorporateDebtSecuritiesMember 2017-12-31 0000059478 us-gaap:FairValueInputsLevel1Member us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:EquitySecuritiesMember 2017-12-31 0000059478 us-gaap:FairValueInputsLevel3Member us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:MortgageBackedSecuritiesMember 2018-12-31 0000059478 us-gaap:PortionAtOtherThanFairValueFairValueDisclosureMember lly:MarketableSecuritiesMember 2018-12-31 0000059478 us-gaap:FairValueInputsLevel1Member us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:OtherDebtSecuritiesMember 2018-12-31 0000059478 us-gaap:PortionAtOtherThanFairValueFairValueDisclosureMember 2018-12-31 0000059478 us-gaap:FairValueInputsLevel3Member us-gaap:EstimateOfFairValueFairValueDisclosureMember lly:MarketableSecuritiesMember 2018-12-31 0000059478 us-gaap:FairValueInputsLevel1Member us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:AssetBackedSecuritiesMember 2017-12-31 0000059478 us-gaap:FairValueInputsLevel3Member us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:OtherDebtSecuritiesMember 2018-12-31 0000059478 us-gaap:FairValueInputsLevel2Member us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:OtherDebtSecuritiesMember 2017-12-31 0000059478 us-gaap:CarryingReportedAmountFairValueDisclosureMember us-gaap:EquitySecuritiesMember 2017-12-31 0000059478 us-gaap:CarryingReportedAmountFairValueDisclosureMember us-gaap:OtherDebtSecuritiesMember 2018-12-31 0000059478 us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:AssetBackedSecuritiesMember 2017-12-31 0000059478 us-gaap:FairValueInputsLevel2Member us-gaap:EstimateOfFairValueFairValueDisclosureMember lly:MarketableSecuritiesMember 2018-12-31 0000059478 us-gaap:FairValueInputsLevel3Member us-gaap:EstimateOfFairValueFairValueDisclosureMember lly:OtherEquitySecuritiesMember 2018-12-31 0000059478 us-gaap:FairValueInputsLevel2Member us-gaap:EstimateOfFairValueFairValueDisclosureMember lly:OtherEquitySecuritiesMember 2018-12-31 0000059478 us-gaap:CarryingReportedAmountFairValueDisclosureMember us-gaap:MortgageBackedSecuritiesMember 2017-12-31 0000059478 us-gaap:FairValueInputsLevel3Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2018-12-31 0000059478 us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:MortgageBackedSecuritiesMember 2017-12-31 0000059478 us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:OtherDebtSecuritiesMember 2018-12-31 0000059478 us-gaap:FairValueInputsLevel1Member us-gaap:EstimateOfFairValueFairValueDisclosureMember lly:MarketableSecuritiesMember 2018-12-31 0000059478 us-gaap:FairValueInputsLevel2Member us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:OtherDebtSecuritiesMember 2018-12-31 0000059478 us-gaap:FairValueInputsLevel2Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2018-12-31 0000059478 us-gaap:FairValueInputsLevel2Member us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:CommercialPaperMember 2018-12-31 0000059478 us-gaap:FairValueInputsLevel1Member us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:CommercialPaperMember 2017-12-31 0000059478 us-gaap:FairValueInputsLevel3Member us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:CommercialPaperMember 2018-12-31 0000059478 us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:CommercialPaperMember 2017-12-31 0000059478 us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:CommercialPaperMember 2018-12-31 0000059478 us-gaap:FairValueInputsLevel3Member us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:CommercialPaperMember 2017-12-31 0000059478 us-gaap:CarryingReportedAmountFairValueDisclosureMember us-gaap:CommercialPaperMember 2017-12-31 0000059478 us-gaap:FairValueInputsLevel2Member us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:CommercialPaperMember 2017-12-31 0000059478 us-gaap:FairValueInputsLevel1Member us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:CommercialPaperMember 2018-12-31 0000059478 us-gaap:CarryingReportedAmountFairValueDisclosureMember us-gaap:CommercialPaperMember 2018-12-31 0000059478 srt:MaximumMember 2018-01-01 2018-12-31 0000059478 us-gaap:OtherIntangibleAssetsMember 2018-12-31 0000059478 us-gaap:DevelopedTechnologyRightsMember 2018-12-31 0000059478 us-gaap:DevelopedTechnologyRightsMember 2017-12-31 0000059478 us-gaap:OtherIntangibleAssetsMember 2017-12-31 0000059478 srt:MinimumMember 2018-01-01 2018-12-31 0000059478 lly:AnimalHealthProductsMember 2017-01-01 2017-12-31 0000059478 lly:AnimalHealthProductsMember 2018-01-01 2018-12-31 0000059478 srt:MaximumMember us-gaap:BuildingMember 2018-01-01 2018-12-31 0000059478 srt:MinimumMember us-gaap:BuildingMember 2018-01-01 2018-12-31 0000059478 srt:MaximumMember us-gaap:EquipmentMember 2018-01-01 2018-12-31 0000059478 srt:MinimumMember us-gaap:EquipmentMember 2018-01-01 2018-12-31 0000059478 lly:MaturityDate2019Member 2018-12-31 0000059478 lly:NotesDueinTwentyFortySevenMember 2017-05-31 0000059478 lly:NotesDueinMayTwentyTwentyTwoMember 2017-05-31 0000059478 lly:NotesDueinMayTwentyTwentySevenMember 2017-05-31 0000059478 2017-05-01 2017-05-31 0000059478 lly:MaturityDate2019Member 2018-01-01 2018-12-31 0000059478 lly:MaturityDate2023Member 2018-12-31 0000059478 srt:MaximumMember 2018-12-31 0000059478 srt:MinimumMember 2018-12-31 0000059478 lly:ShareholderValueAwardsMember 2018-01-01 2018-12-31 0000059478 lly:ShareholderValueAwardsMember 2017-01-01 2017-12-31 0000059478 lly:ShareholderValueAwardsMember 2016-01-01 2016-12-31 0000059478 us-gaap:PerformanceSharesMember 2018-01-01 2018-12-31 0000059478 us-gaap:PerformanceSharesMember 2018-12-31 0000059478 us-gaap:RestrictedStockUnitsRSUMember 2017-01-01 2017-12-31 0000059478 us-gaap:PerformanceSharesMember 2017-01-01 2017-12-31 0000059478 us-gaap:RestrictedStockUnitsRSUMember 2018-01-01 2018-12-31 0000059478 lly:ShareholderValueAwardsMember 2018-12-31 0000059478 us-gaap:RestrictedStockUnitsRSUMember 2016-01-01 2016-12-31 0000059478 us-gaap:RestrictedStockUnitsRSUMember 2018-12-31 0000059478 us-gaap:PerformanceSharesMember 2016-01-01 2016-12-31 0000059478 lly:A2013ShareRepurchaseProgramMember 2013-10-31 0000059478 lly:A2018RepurchaseProgramMember 2018-12-31 0000059478 lly:A2013ShareRepurchaseProgramMember 2018-01-01 2018-12-31 0000059478 lly:A2018RepurchaseProgramMember 2018-01-01 2018-12-31 0000059478 us-gaap:StateAndLocalJurisdictionMember lly:DesignatedUnusableMember 2018-12-31 0000059478 lly:Expirationwithin5yearsMember 2018-12-31 0000059478 lly:Expiration5to20YearsMember 2018-12-31 0000059478 2014-01-01 2014-12-31 0000059478 2012-01-01 2012-12-31 0000059478 2015-01-01 2015-12-31 0000059478 2010-01-01 2010-12-31 0000059478 us-gaap:ForeignCountryMember lly:DesignatedUnusableMember 2018-12-31 0000059478 lly:NoExpirationMember 2018-12-31 0000059478 lly:CarryforwardMember 2018-12-31 0000059478 srt:MaximumMember 2016-12-31 0000059478 lly:TaxYears20102012Member 2015-01-01 2015-12-31 0000059478 lly:Expirationin9YearsMember 2018-12-31 0000059478 2013-01-01 2013-12-31 0000059478 us-gaap:InternalRevenueServiceIRSMember lly:DesignatedUnusableMember 2018-12-31 0000059478 lly:TaxYears20102012Member 2016-01-01 2016-12-31 0000059478 us-gaap:PensionPlansDefinedBenefitMember 2018-12-31 0000059478 us-gaap:DefinedBenefitPostretirementHealthCoverageMember 2017-12-31 0000059478 us-gaap:PensionPlansDefinedBenefitMember 2017-12-31 0000059478 us-gaap:DefinedBenefitPostretirementHealthCoverageMember 2018-12-31 0000059478 lly:FixedIncomeFundsEmergingMarketsMember us-gaap:FairValueInputsLevel1Member us-gaap:PensionPlansDefinedBenefitMember 2017-12-31 0000059478 us-gaap:HedgeFundsMember us-gaap:FairValueInputsLevel2Member us-gaap:DefinedBenefitPostretirementHealthCoverageMember 2017-12-31 0000059478 us-gaap:EquityFundsMember us-gaap:FairValueInputsLevel2Member us-gaap:PensionPlansDefinedBenefitMember 2017-12-31 0000059478 lly:FixedIncomeFundsEmergingMarketsMember us-gaap:PensionPlansDefinedBenefitMember 2017-12-31 0000059478 us-gaap:FixedIncomeFundsMember us-gaap:FairValueInputsLevel3Member us-gaap:PensionPlansDefinedBenefitMember 2017-12-31 0000059478 us-gaap:DefinedBenefitPlanEquitySecuritiesUsMember us-gaap:FairValueInputsLevel1Member us-gaap:PensionPlansDefinedBenefitMember 2017-12-31 0000059478 lly:FixedIncomeFundsEmergingMarketsMember us-gaap:FairValueInputsLevel3Member us-gaap:DefinedBenefitPostretirementHealthCoverageMember 2017-12-31 0000059478 us-gaap:DefinedBenefitPlanRealEstateMember us-gaap:FairValueInputsLevel1Member us-gaap:DefinedBenefitPostretirementHealthCoverageMember 2017-12-31 0000059478 lly:FixedIncomeFundsEmergingMarketsMember us-gaap:DefinedBenefitPostretirementHealthCoverageMember 2017-12-31 0000059478 lly:FixedIncomeFundsEmergingMarketsMember us-gaap:FairValueInputsLevel3Member us-gaap:PensionPlansDefinedBenefitMember 2017-12-31 0000059478 us-gaap:HedgeFundsMember us-gaap:DefinedBenefitPostretirementHealthCoverageMember 2017-12-31 0000059478 us-gaap:OtherContractMember us-gaap:FairValueInputsLevel2Member us-gaap:DefinedBenefitPostretirementHealthCoverageMember 2017-12-31 0000059478 us-gaap:DefinedBenefitPlanRealEstateMember us-gaap:FairValueInputsLevel1Member us-gaap:PensionPlansDefinedBenefitMember 2017-12-31 0000059478 us-gaap:DefinedBenefitPlanEquitySecuritiesUsMember us-gaap:FairValueInputsLevel2Member us-gaap:DefinedBenefitPostretirementHealthCoverageMember 2017-12-31 0000059478 us-gaap:DefinedBenefitPlanRealEstateMember us-gaap:FairValueInputsLevel2Member us-gaap:PensionPlansDefinedBenefitMember 2017-12-31 0000059478 lly:FixedIncomeFundsRepurchasedAgreementsMember us-gaap:FairValueInputsLevel2Member us-gaap:PensionPlansDefinedBenefitMember 2017-12-31 0000059478 us-gaap:HedgeFundsMember us-gaap:FairValueInputsLevel1Member us-gaap:DefinedBenefitPostretirementHealthCoverageMember 2017-12-31 0000059478 lly:FixedIncomeFundsEmergingMarketsMember us-gaap:PensionPlansDefinedBenefitMember lly:FairValueRetirementBenefitsInvestmentsValuedatNetAssetValueMember 2017-12-31 0000059478 us-gaap:FairValueInputsLevel1Member us-gaap:PensionPlansDefinedBenefitMember 2017-12-31 0000059478 lly:FixedIncomeFundsRepurchasedAgreementsMember us-gaap:FairValueInputsLevel3Member us-gaap:PensionPlansDefinedBenefitMember 2017-12-31 0000059478 us-gaap:DefinedBenefitPlanEquitySecuritiesUsMember us-gaap:PensionPlansDefinedBenefitMember lly:FairValueRetirementBenefitsInvestmentsValuedatNetAssetValueMember 2017-12-31 0000059478 us-gaap:FairValueInputsLevel3Member us-gaap:DefinedBenefitPostretirementHealthCoverageMember 2017-12-31 0000059478 us-gaap:DefinedBenefitPlanEquitySecuritiesNonUsMember us-gaap:FairValueInputsLevel1Member us-gaap:DefinedBenefitPostretirementHealthCoverageMember 2017-12-31 0000059478 us-gaap:DefinedBenefitPlanEquitySecuritiesNonUsMember us-gaap:PensionPlansDefinedBenefitMember lly:FairValueRetirementBenefitsInvestmentsValuedatNetAssetValueMember 2017-12-31 0000059478 us-gaap:FixedIncomeFundsMember us-gaap:DefinedBenefitPostretirementHealthCoverageMember lly:FairValueRetirementBenefitsInvestmentsValuedatNetAssetValueMember 2017-12-31 0000059478 lly:FixedIncomeFundsRepurchasedAgreementsMember us-gaap:PensionPlansDefinedBenefitMember lly:FairValueRetirementBenefitsInvestmentsValuedatNetAssetValueMember 2017-12-31 0000059478 lly:FixedIncomeFundsEmergingMarketsMember us-gaap:DefinedBenefitPostretirementHealthCoverageMember lly:FairValueRetirementBenefitsInvestmentsValuedatNetAssetValueMember 2017-12-31 0000059478 us-gaap:DefinedBenefitPlanEquitySecuritiesNonUsMember us-gaap:FairValueInputsLevel2Member us-gaap:DefinedBenefitPostretirementHealthCoverageMember 2017-12-31 0000059478 us-gaap:DefinedBenefitPlanEquitySecuritiesNonUsMember us-gaap:FairValueInputsLevel1Member us-gaap:PensionPlansDefinedBenefitMember 2017-12-31 0000059478 us-gaap:EquityFundsMember us-gaap:FairValueInputsLevel1Member us-gaap:PensionPlansDefinedBenefitMember 2017-12-31 0000059478 us-gaap:FixedIncomeFundsMember us-gaap:PensionPlansDefinedBenefitMember lly:FairValueRetirementBenefitsInvestmentsValuedatNetAssetValueMember 2017-12-31 0000059478 lly:FixedIncomeFundsRepurchasedAgreementsMember us-gaap:PensionPlansDefinedBenefitMember 2017-12-31 0000059478 us-gaap:HedgeFundsMember us-gaap:DefinedBenefitPostretirementHealthCoverageMember lly:FairValueRetirementBenefitsInvestmentsValuedatNetAssetValueMember 2017-12-31 0000059478 us-gaap:FairValueInputsLevel2Member us-gaap:DefinedBenefitPostretirementHealthCoverageMember 2017-12-31 0000059478 us-gaap:DefinedBenefitPlanRealEstateMember us-gaap:FairValueInputsLevel2Member us-gaap:DefinedBenefitPostretirementHealthCoverageMember 2017-12-31 0000059478 us-gaap:FixedIncomeFundsMember us-gaap:FairValueInputsLevel2Member us-gaap:PensionPlansDefinedBenefitMember 2017-12-31 0000059478 us-gaap:OtherContractMember us-gaap:DefinedBenefitPostretirementHealthCoverageMember 2017-12-31 0000059478 us-gaap:OtherContractMember us-gaap:DefinedBenefitPostretirementHealthCoverageMember lly:FairValueRetirementBenefitsInvestmentsValuedatNetAssetValueMember 2017-12-31 0000059478 lly:DefineBenefitPlanOtherMember us-gaap:FairValueInputsLevel3Member us-gaap:DefinedBenefitPostretirementHealthCoverageMember 2017-12-31 0000059478 us-gaap:DefinedBenefitPlanEquitySecuritiesNonUsMember us-gaap:DefinedBenefitPostretirementHealthCoverageMember 2017-12-31 0000059478 us-gaap:PensionPlansDefinedBenefitMember lly:FairValueRetirementBenefitsInvestmentsValuedatNetAssetValueMember 2017-12-31 0000059478 us-gaap:HedgeFundsMember us-gaap:PensionPlansDefinedBenefitMember 2017-12-31 0000059478 us-gaap:DefinedBenefitPlanEquitySecuritiesUsMember us-gaap:FairValueInputsLevel2Member us-gaap:PensionPlansDefinedBenefitMember 2017-12-31 0000059478 us-gaap:DefinedBenefitPlanEquitySecuritiesUsMember us-gaap:DefinedBenefitPostretirementHealthCoverageMember lly:FairValueRetirementBenefitsInvestmentsValuedatNetAssetValueMember 2017-12-31 0000059478 us-gaap:DefinedBenefitPlanRealEstateMember us-gaap:FairValueInputsLevel3Member us-gaap:PensionPlansDefinedBenefitMember 2017-12-31 0000059478 us-gaap:EquityFundsMember us-gaap:DefinedBenefitPostretirementHealthCoverageMember lly:FairValueRetirementBenefitsInvestmentsValuedatNetAssetValueMember 2017-12-31 0000059478 lly:DefineBenefitPlanOtherMember us-gaap:DefinedBenefitPostretirementHealthCoverageMember lly:FairValueRetirementBenefitsInvestmentsValuedatNetAssetValueMember 2017-12-31 0000059478 us-gaap:DefinedBenefitPlanRealEstateMember us-gaap:DefinedBenefitPostretirementHealthCoverageMember 2017-12-31 0000059478 lly:FixedIncomeFundsEmergingMarketsMember us-gaap:FairValueInputsLevel2Member us-gaap:PensionPlansDefinedBenefitMember 2017-12-31 0000059478 us-gaap:FairValueInputsLevel2Member us-gaap:PensionPlansDefinedBenefitMember 2017-12-31 0000059478 us-gaap:HedgeFundsMember us-gaap:FairValueInputsLevel3Member us-gaap:DefinedBenefitPostretirementHealthCoverageMember 2017-12-31 0000059478 us-gaap:DefinedBenefitPlanRealEstateMember us-gaap:PensionPlansDefinedBenefitMember 2017-12-31 0000059478 us-gaap:FixedIncomeFundsMember us-gaap:FairValueInputsLevel2Member us-gaap:DefinedBenefitPostretirementHealthCoverageMember 2017-12-31 0000059478 us-gaap:DefinedBenefitPlanEquitySecuritiesUsMember us-gaap:FairValueInputsLevel3Member us-gaap:DefinedBenefitPostretirementHealthCoverageMember 2017-12-31 0000059478 us-gaap:DefinedBenefitPlanEquitySecuritiesUsMember us-gaap:FairValueInputsLevel3Member us-gaap:PensionPlansDefinedBenefitMember 2017-12-31 0000059478 us-gaap:DefinedBenefitPlanEquitySecuritiesNonUsMember us-gaap:PensionPlansDefinedBenefitMember 2017-12-31 0000059478 lly:DefineBenefitPlanOtherMember us-gaap:PensionPlansDefinedBenefitMember lly:FairValueRetirementBenefitsInvestmentsValuedatNetAssetValueMember 2017-12-31 0000059478 us-gaap:EquityFundsMember us-gaap:PensionPlansDefinedBenefitMember 2017-12-31 0000059478 lly:DefineBenefitPlanOtherMember us-gaap:DefinedBenefitPostretirementHealthCoverageMember 2017-12-31 0000059478 lly:DefineBenefitPlanOtherMember us-gaap:FairValueInputsLevel1Member us-gaap:DefinedBenefitPostretirementHealthCoverageMember 2017-12-31 0000059478 us-gaap:EquityFundsMember us-gaap:FairValueInputsLevel3Member us-gaap:DefinedBenefitPostretirementHealthCoverageMember 2017-12-31 0000059478 us-gaap:HedgeFundsMember us-gaap:FairValueInputsLevel2Member us-gaap:PensionPlansDefinedBenefitMember 2017-12-31 0000059478 us-gaap:EquityFundsMember us-gaap:FairValueInputsLevel3Member us-gaap:PensionPlansDefinedBenefitMember 2017-12-31 0000059478 us-gaap:DefinedBenefitPlanEquitySecuritiesUsMember us-gaap:FairValueInputsLevel1Member us-gaap:DefinedBenefitPostretirementHealthCoverageMember 2017-12-31 0000059478 us-gaap:EquityFundsMember us-gaap:FairValueInputsLevel1Member us-gaap:DefinedBenefitPostretirementHealthCoverageMember 2017-12-31 0000059478 lly:FixedIncomeFundsRepurchasedAgreementsMember us-gaap:FairValueInputsLevel1Member us-gaap:PensionPlansDefinedBenefitMember 2017-12-31 0000059478 us-gaap:HedgeFundsMember us-gaap:FairValueInputsLevel1Member us-gaap:PensionPlansDefinedBenefitMember 2017-12-31 0000059478 lly:DefineBenefitPlanOtherMember us-gaap:FairValueInputsLevel3Member us-gaap:PensionPlansDefinedBenefitMember 2017-12-31 0000059478 lly:DefineBenefitPlanOtherMember us-gaap:FairValueInputsLevel1Member us-gaap:PensionPlansDefinedBenefitMember 2017-12-31 0000059478 us-gaap:DefinedBenefitPlanRealEstateMember us-gaap:DefinedBenefitPostretirementHealthCoverageMember lly:FairValueRetirementBenefitsInvestmentsValuedatNetAssetValueMember 2017-12-31 0000059478 us-gaap:DefinedBenefitPlanEquitySecuritiesUsMember us-gaap:PensionPlansDefinedBenefitMember 2017-12-31 0000059478 us-gaap:EquityFundsMember us-gaap:FairValueInputsLevel2Member us-gaap:DefinedBenefitPostretirementHealthCoverageMember 2017-12-31 0000059478 us-gaap:HedgeFundsMember us-gaap:FairValueInputsLevel3Member us-gaap:PensionPlansDefinedBenefitMember 2017-12-31 0000059478 us-gaap:FixedIncomeFundsMember us-gaap:DefinedBenefitPostretirementHealthCoverageMember 2017-12-31 0000059478 us-gaap:FixedIncomeFundsMember us-gaap:FairValueInputsLevel1Member us-gaap:PensionPlansDefinedBenefitMember 2017-12-31 0000059478 us-gaap:OtherContractMember us-gaap:FairValueInputsLevel3Member us-gaap:DefinedBenefitPostretirementHealthCoverageMember 2017-12-31 0000059478 us-gaap:FairValueInputsLevel1Member us-gaap:DefinedBenefitPostretirementHealthCoverageMember 2017-12-31 0000059478 us-gaap:DefinedBenefitPlanEquitySecuritiesNonUsMember us-gaap:DefinedBenefitPostretirementHealthCoverageMember lly:FairValueRetirementBenefitsInvestmentsValuedatNetAssetValueMember 2017-12-31 0000059478 lly:FixedIncomeFundsEmergingMarketsMember us-gaap:FairValueInputsLevel2Member us-gaap:DefinedBenefitPostretirementHealthCoverageMember 2017-12-31 0000059478 us-gaap:DefinedBenefitPlanEquitySecuritiesNonUsMember us-gaap:FairValueInputsLevel2Member us-gaap:PensionPlansDefinedBenefitMember 2017-12-31 0000059478 us-gaap:HedgeFundsMember us-gaap:PensionPlansDefinedBenefitMember lly:FairValueRetirementBenefitsInvestmentsValuedatNetAssetValueMember 2017-12-31 0000059478 lly:DefineBenefitPlanOtherMember us-gaap:PensionPlansDefinedBenefitMember 2017-12-31 0000059478 lly:DefineBenefitPlanOtherMember us-gaap:FairValueInputsLevel2Member us-gaap:DefinedBenefitPostretirementHealthCoverageMember 2017-12-31 0000059478 us-gaap:DefinedBenefitPlanEquitySecuritiesNonUsMember us-gaap:FairValueInputsLevel3Member us-gaap:PensionPlansDefinedBenefitMember 2017-12-31 0000059478 us-gaap:EquityFundsMember us-gaap:DefinedBenefitPostretirementHealthCoverageMember 2017-12-31 0000059478 lly:DefineBenefitPlanOtherMember us-gaap:FairValueInputsLevel2Member us-gaap:PensionPlansDefinedBenefitMember 2017-12-31 0000059478 us-gaap:FixedIncomeFundsMember us-gaap:PensionPlansDefinedBenefitMember 2017-12-31 0000059478 us-gaap:OtherContractMember us-gaap:FairValueInputsLevel1Member us-gaap:DefinedBenefitPostretirementHealthCoverageMember 2017-12-31 0000059478 lly:FixedIncomeFundsEmergingMarketsMember us-gaap:FairValueInputsLevel1Member us-gaap:DefinedBenefitPostretirementHealthCoverageMember 2017-12-31 0000059478 us-gaap:DefinedBenefitPostretirementHealthCoverageMember lly:FairValueRetirementBenefitsInvestmentsValuedatNetAssetValueMember 2017-12-31 0000059478 us-gaap:EquityFundsMember us-gaap:PensionPlansDefinedBenefitMember lly:FairValueRetirementBenefitsInvestmentsValuedatNetAssetValueMember 2017-12-31 0000059478 us-gaap:DefinedBenefitPlanEquitySecuritiesNonUsMember us-gaap:FairValueInputsLevel3Member us-gaap:DefinedBenefitPostretirementHealthCoverageMember 2017-12-31 0000059478 us-gaap:FairValueInputsLevel3Member us-gaap:PensionPlansDefinedBenefitMember 2017-12-31 0000059478 us-gaap:FixedIncomeFundsMember us-gaap:FairValueInputsLevel1Member us-gaap:DefinedBenefitPostretirementHealthCoverageMember 2017-12-31 0000059478 us-gaap:DefinedBenefitPlanRealEstateMember us-gaap:PensionPlansDefinedBenefitMember lly:FairValueRetirementBenefitsInvestmentsValuedatNetAssetValueMember 2017-12-31 0000059478 us-gaap:DefinedBenefitPlanRealEstateMember us-gaap:FairValueInputsLevel3Member us-gaap:DefinedBenefitPostretirementHealthCoverageMember 2017-12-31 0000059478 us-gaap:FixedIncomeFundsMember us-gaap:FairValueInputsLevel3Member us-gaap:DefinedBenefitPostretirementHealthCoverageMember 2017-12-31 0000059478 us-gaap:DefinedBenefitPlanEquitySecuritiesUsMember us-gaap:DefinedBenefitPostretirementHealthCoverageMember 2017-12-31 0000059478 us-gaap:DefinedBenefitPostretirementHealthCoverageMember 2017-01-01 2017-12-31 0000059478 us-gaap:PensionPlansDefinedBenefitMember 2017-01-01 2017-12-31 0000059478 us-gaap:DefinedBenefitPostretirementHealthCoverageMember 2018-01-01 2018-12-31 0000059478 us-gaap:DefinedBenefitPostretirementHealthCoverageMember 2016-12-31 0000059478 us-gaap:PensionPlansDefinedBenefitMember 2016-12-31 0000059478 us-gaap:PensionPlansDefinedBenefitMember 2018-01-01 2018-12-31 0000059478 us-gaap:DefinedBenefitPostretirementHealthCoverageMember 2016-01-01 2016-12-31 0000059478 us-gaap:PensionPlansDefinedBenefitMember 2016-01-01 2016-12-31 0000059478 us-gaap:EquityFundsMember us-gaap:DefinedBenefitPostretirementHealthCoverageMember 2018-12-31 0000059478 us-gaap:DefinedBenefitPlanRealEstateMember us-gaap:DefinedBenefitPostretirementHealthCoverageMember 2018-12-31 0000059478 lly:FixedIncomeFundsEmergingMarketsMember us-gaap:FairValueInputsLevel3Member us-gaap:DefinedBenefitPostretirementHealthCoverageMember 2018-12-31 0000059478 lly:FixedIncomeFundsRepurchasedAgreementsMember us-gaap:PensionPlansDefinedBenefitMember 2018-12-31 0000059478 us-gaap:HedgeFundsMember us-gaap:FairValueInputsLevel1Member us-gaap:DefinedBenefitPostretirementHealthCoverageMember 2018-12-31 0000059478 us-gaap:EquityFundsMember us-gaap:PensionPlansDefinedBenefitMember lly:FairValueRetirementBenefitsInvestmentsValuedatNetAssetValueMember 2018-12-31 0000059478 lly:FixedIncomeFundsEmergingMarketsMember us-gaap:DefinedBenefitPostretirementHealthCoverageMember lly:FairValueRetirementBenefitsInvestmentsValuedatNetAssetValueMember 2018-12-31 0000059478 lly:DefineBenefitPlanOtherMember us-gaap:PensionPlansDefinedBenefitMember lly:FairValueRetirementBenefitsInvestmentsValuedatNetAssetValueMember 2018-12-31 0000059478 us-gaap:DefinedBenefitPlanRealEstateMember us-gaap:FairValueInputsLevel3Member us-gaap:PensionPlansDefinedBenefitMember 2018-12-31 0000059478 us-gaap:EquityFundsMember us-gaap:FairValueInputsLevel2Member us-gaap:PensionPlansDefinedBenefitMember 2018-12-31 0000059478 us-gaap:HedgeFundsMember us-gaap:PensionPlansDefinedBenefitMember lly:FairValueRetirementBenefitsInvestmentsValuedatNetAssetValueMember 2018-12-31 0000059478 us-gaap:EquityFundsMember us-gaap:DefinedBenefitPostretirementHealthCoverageMember lly:FairValueRetirementBenefitsInvestmentsValuedatNetAssetValueMember 2018-12-31 0000059478 lly:FixedIncomeFundsEmergingMarketsMember us-gaap:DefinedBenefitPostretirementHealthCoverageMember 2018-12-31 0000059478 lly:DefineBenefitPlanOtherMember us-gaap:FairValueInputsLevel3Member us-gaap:PensionPlansDefinedBenefitMember 2018-12-31 0000059478 lly:DefineBenefitPlanOtherMember us-gaap:FairValueInputsLevel2Member us-gaap:DefinedBenefitPostretirementHealthCoverageMember 2018-12-31 0000059478 us-gaap:HedgeFundsMember us-gaap:FairValueInputsLevel2Member us-gaap:PensionPlansDefinedBenefitMember 2018-12-31 0000059478 us-gaap:FixedIncomeFundsMember us-gaap:FairValueInputsLevel2Member us-gaap:DefinedBenefitPostretirementHealthCoverageMember 2018-12-31 0000059478 us-gaap:DefinedBenefitPostretirementHealthCoverageMember lly:FairValueRetirementBenefitsInvestmentsValuedatNetAssetValueMember 2018-12-31 0000059478 us-gaap:FixedIncomeFundsMember us-gaap:FairValueInputsLevel3Member us-gaap:DefinedBenefitPostretirementHealthCoverageMember 2018-12-31 0000059478 us-gaap:DefinedBenefitPlanEquitySecuritiesNonUsMember us-gaap:FairValueInputsLevel2Member us-gaap:PensionPlansDefinedBenefitMember 2018-12-31 0000059478 lly:FixedIncomeFundsRepurchasedAgreementsMember us-gaap:PensionPlansDefinedBenefitMember lly:FairValueRetirementBenefitsInvestmentsValuedatNetAssetValueMember 2018-12-31 0000059478 lly:DefineBenefitPlanOtherMember us-gaap:FairValueInputsLevel2Member us-gaap:PensionPlansDefinedBenefitMember 2018-12-31 0000059478 us-gaap:EquityFundsMember us-gaap:FairValueInputsLevel3Member us-gaap:DefinedBenefitPostretirementHealthCoverageMember 2018-12-31 0000059478 lly:FixedIncomeFundsEmergingMarketsMember us-gaap:FairValueInputsLevel3Member us-gaap:PensionPlansDefinedBenefitMember 2018-12-31 0000059478 us-gaap:DefinedBenefitPlanRealEstateMember us-gaap:FairValueInputsLevel2Member us-gaap:DefinedBenefitPostretirementHealthCoverageMember 2018-12-31 0000059478 lly:DefineBenefitPlanOtherMember us-gaap:DefinedBenefitPostretirementHealthCoverageMember lly:FairValueRetirementBenefitsInvestmentsValuedatNetAssetValueMember 2018-12-31 0000059478 us-gaap:HedgeFundsMember us-gaap:DefinedBenefitPostretirementHealthCoverageMember lly:FairValueRetirementBenefitsInvestmentsValuedatNetAssetValueMember 2018-12-31 0000059478 us-gaap:FairValueInputsLevel2Member us-gaap:DefinedBenefitPostretirementHealthCoverageMember 2018-12-31 0000059478 lly:FixedIncomeFundsEmergingMarketsMember us-gaap:PensionPlansDefinedBenefitMember lly:FairValueRetirementBenefitsInvestmentsValuedatNetAssetValueMember 2018-12-31 0000059478 us-gaap:FixedIncomeFundsMember us-gaap:FairValueInputsLevel3Member us-gaap:PensionPlansDefinedBenefitMember 2018-12-31 0000059478 lly:FixedIncomeFundsEmergingMarketsMember us-gaap:FairValueInputsLevel2Member us-gaap:DefinedBenefitPostretirementHealthCoverageMember 2018-12-31 0000059478 lly:DefineBenefitPlanOtherMember us-gaap:FairValueInputsLevel1Member us-gaap:PensionPlansDefinedBenefitMember 2018-12-31 0000059478 lly:FixedIncomeFundsEmergingMarketsMember us-gaap:FairValueInputsLevel1Member us-gaap:PensionPlansDefinedBenefitMember 2018-12-31 0000059478 us-gaap:DefinedBenefitPlanEquitySecuritiesUsMember us-gaap:PensionPlansDefinedBenefitMember 2018-12-31 0000059478 lly:FixedIncomeFundsEmergingMarketsMember us-gaap:PensionPlansDefinedBenefitMember 2018-12-31 0000059478 us-gaap:FairValueInputsLevel3Member us-gaap:PensionPlansDefinedBenefitMember 2018-12-31 0000059478 us-gaap:DefinedBenefitPlanEquitySecuritiesUsMember us-gaap:FairValueInputsLevel1Member us-gaap:PensionPlansDefinedBenefitMember 2018-12-31 0000059478 us-gaap:DefinedBenefitPlanEquitySecuritiesUsMember us-gaap:FairValueInputsLevel1Member us-gaap:DefinedBenefitPostretirementHealthCoverageMember 2018-12-31 0000059478 us-gaap:DefinedBenefitPlanEquitySecuritiesNonUsMember us-gaap:FairValueInputsLevel3Member us-gaap:DefinedBenefitPostretirementHealthCoverageMember 2018-12-31 0000059478 us-gaap:DefinedBenefitPlanEquitySecuritiesUsMember us-gaap:DefinedBenefitPostretirementHealthCoverageMember 2018-12-31 0000059478 us-gaap:FixedIncomeFundsMember us-gaap:DefinedBenefitPostretirementHealthCoverageMember 2018-12-31 0000059478 us-gaap:OtherContractMember us-gaap:DefinedBenefitPostretirementHealthCoverageMember 2018-12-31 0000059478 us-gaap:DefinedBenefitPlanEquitySecuritiesUsMember us-gaap:FairValueInputsLevel2Member us-gaap:DefinedBenefitPostretirementHealthCoverageMember 2018-12-31 0000059478 us-gaap:EquityFundsMember us-gaap:FairValueInputsLevel1Member us-gaap:PensionPlansDefinedBenefitMember 2018-12-31 0000059478 us-gaap:FixedIncomeFundsMember us-gaap:FairValueInputsLevel1Member us-gaap:DefinedBenefitPostretirementHealthCoverageMember 2018-12-31 0000059478 us-gaap:DefinedBenefitPlanEquitySecuritiesNonUsMember us-gaap:DefinedBenefitPostretirementHealthCoverageMember lly:FairValueRetirementBenefitsInvestmentsValuedatNetAssetValueMember 2018-12-31 0000059478 us-gaap:DefinedBenefitPlanEquitySecuritiesUsMember us-gaap:FairValueInputsLevel2Member us-gaap:PensionPlansDefinedBenefitMember 2018-12-31 0000059478 us-gaap:DefinedBenefitPlanEquitySecuritiesUsMember us-gaap:DefinedBenefitPostretirementHealthCoverageMember lly:FairValueRetirementBenefitsInvestmentsValuedatNetAssetValueMember 2018-12-31 0000059478 us-gaap:DefinedBenefitPlanEquitySecuritiesNonUsMember us-gaap:PensionPlansDefinedBenefitMember 2018-12-31 0000059478 lly:FixedIncomeFundsRepurchasedAgreementsMember us-gaap:FairValueInputsLevel1Member us-gaap:PensionPlansDefinedBenefitMember 2018-12-31 0000059478 us-gaap:DefinedBenefitPlanEquitySecuritiesUsMember us-gaap:PensionPlansDefinedBenefitMember lly:FairValueRetirementBenefitsInvestmentsValuedatNetAssetValueMember 2018-12-31 0000059478 us-gaap:DefinedBenefitPlanEquitySecuritiesNonUsMember us-gaap:FairValueInputsLevel2Member us-gaap:DefinedBenefitPostretirementHealthCoverageMember 2018-12-31 0000059478 lly:DefineBenefitPlanOtherMember us-gaap:DefinedBenefitPostretirementHealthCoverageMember 2018-12-31 0000059478 us-gaap:OtherContractMember us-gaap:DefinedBenefitPostretirementHealthCoverageMember lly:FairValueRetirementBenefitsInvestmentsValuedatNetAssetValueMember 2018-12-31 0000059478 lly:FixedIncomeFundsEmergingMarketsMember us-gaap:FairValueInputsLevel2Member us-gaap:PensionPlansDefinedBenefitMember 2018-12-31 0000059478 us-gaap:HedgeFundsMember us-gaap:FairValueInputsLevel1Member us-gaap:PensionPlansDefinedBenefitMember 2018-12-31 0000059478 us-gaap:HedgeFundsMember us-gaap:FairValueInputsLevel3Member us-gaap:PensionPlansDefinedBenefitMember 2018-12-31 0000059478 us-gaap:FixedIncomeFundsMember us-gaap:FairValueInputsLevel1Member us-gaap:PensionPlansDefinedBenefitMember 2018-12-31 0000059478 us-gaap:DefinedBenefitPlanEquitySecuritiesNonUsMember us-gaap:PensionPlansDefinedBenefitMember lly:FairValueRetirementBenefitsInvestmentsValuedatNetAssetValueMember 2018-12-31 0000059478 us-gaap:DefinedBenefitPlanRealEstateMember us-gaap:DefinedBenefitPostretirementHealthCoverageMember lly:FairValueRetirementBenefitsInvestmentsValuedatNetAssetValueMember 2018-12-31 0000059478 lly:FixedIncomeFundsRepurchasedAgreementsMember us-gaap:FairValueInputsLevel3Member us-gaap:PensionPlansDefinedBenefitMember 2018-12-31 0000059478 us-gaap:FairValueInputsLevel2Member us-gaap:PensionPlansDefinedBenefitMember 2018-12-31 0000059478 us-gaap:OtherContractMember us-gaap:FairValueInputsLevel1Member us-gaap:DefinedBenefitPostretirementHealthCoverageMember 2018-12-31 0000059478 us-gaap:DefinedBenefitPlanRealEstateMember us-gaap:FairValueInputsLevel2Member us-gaap:PensionPlansDefinedBenefitMember 2018-12-31 0000059478 us-gaap:HedgeFundsMember us-gaap:DefinedBenefitPostretirementHealthCoverageMember 2018-12-31 0000059478 us-gaap:DefinedBenefitPlanRealEstateMember us-gaap:PensionPlansDefinedBenefitMember 2018-12-31 0000059478 us-gaap:DefinedBenefitPlanEquitySecuritiesNonUsMember us-gaap:DefinedBenefitPostretirementHealthCoverageMember 2018-12-31 0000059478 us-gaap:HedgeFundsMember us-gaap:FairValueInputsLevel3Member us-gaap:DefinedBenefitPostretirementHealthCoverageMember 2018-12-31 0000059478 us-gaap:FairValueInputsLevel1Member us-gaap:DefinedBenefitPostretirementHealthCoverageMember 2018-12-31 0000059478 us-gaap:DefinedBenefitPlanEquitySecuritiesUsMember us-gaap:FairValueInputsLevel3Member us-gaap:DefinedBenefitPostretirementHealthCoverageMember 2018-12-31 0000059478 us-gaap:DefinedBenefitPlanRealEstateMember us-gaap:FairValueInputsLevel1Member us-gaap:PensionPlansDefinedBenefitMember 2018-12-31 0000059478 us-gaap:EquityFundsMember us-gaap:PensionPlansDefinedBenefitMember 2018-12-31 0000059478 lly:DefineBenefitPlanOtherMember us-gaap:FairValueInputsLevel1Member us-gaap:DefinedBenefitPostretirementHealthCoverageMember 2018-12-31 0000059478 us-gaap:DefinedBenefitPlanRealEstateMember us-gaap:PensionPlansDefinedBenefitMember lly:FairValueRetirementBenefitsInvestmentsValuedatNetAssetValueMember 2018-12-31 0000059478 us-gaap:FairValueInputsLevel1Member us-gaap:PensionPlansDefinedBenefitMember 2018-12-31 0000059478 us-gaap:FixedIncomeFundsMember us-gaap:PensionPlansDefinedBenefitMember 2018-12-31 0000059478 lly:FixedIncomeFundsRepurchasedAgreementsMember us-gaap:FairValueInputsLevel2Member us-gaap:PensionPlansDefinedBenefitMember 2018-12-31 0000059478 us-gaap:OtherContractMember us-gaap:FairValueInputsLevel3Member us-gaap:DefinedBenefitPostretirementHealthCoverageMember 2018-12-31 0000059478 us-gaap:FixedIncomeFundsMember us-gaap:FairValueInputsLevel2Member us-gaap:PensionPlansDefinedBenefitMember 2018-12-31 0000059478 us-gaap:DefinedBenefitPlanEquitySecuritiesUsMember us-gaap:FairValueInputsLevel3Member us-gaap:PensionPlansDefinedBenefitMember 2018-12-31 0000059478 us-gaap:EquityFundsMember us-gaap:FairValueInputsLevel2Member us-gaap:DefinedBenefitPostretirementHealthCoverageMember 2018-12-31 0000059478 us-gaap:FixedIncomeFundsMember us-gaap:DefinedBenefitPostretirementHealthCoverageMember lly:FairValueRetirementBenefitsInvestmentsValuedatNetAssetValueMember 2018-12-31 0000059478 lly:FixedIncomeFundsEmergingMarketsMember us-gaap:FairValueInputsLevel1Member us-gaap:DefinedBenefitPostretirementHealthCoverageMember 2018-12-31 0000059478 us-gaap:FixedIncomeFundsMember us-gaap:PensionPlansDefinedBenefitMember lly:FairValueRetirementBenefitsInvestmentsValuedatNetAssetValueMember 2018-12-31 0000059478 us-gaap:OtherContractMember us-gaap:FairValueInputsLevel2Member us-gaap:DefinedBenefitPostretirementHealthCoverageMember 2018-12-31 0000059478 us-gaap:HedgeFundsMember us-gaap:PensionPlansDefinedBenefitMember 2018-12-31 0000059478 us-gaap:DefinedBenefitPlanEquitySecuritiesNonUsMember us-gaap:FairValueInputsLevel3Member us-gaap:PensionPlansDefinedBenefitMember 2018-12-31 0000059478 lly:DefineBenefitPlanOtherMember us-gaap:PensionPlansDefinedBenefitMember 2018-12-31 0000059478 lly:DefineBenefitPlanOtherMember us-gaap:FairValueInputsLevel3Member us-gaap:DefinedBenefitPostretirementHealthCoverageMember 2018-12-31 0000059478 us-gaap:EquityFundsMember us-gaap:FairValueInputsLevel3Member us-gaap:PensionPlansDefinedBenefitMember 2018-12-31 0000059478 us-gaap:DefinedBenefitPlanRealEstateMember us-gaap:FairValueInputsLevel3Member us-gaap:DefinedBenefitPostretirementHealthCoverageMember 2018-12-31 0000059478 us-gaap:PensionPlansDefinedBenefitMember lly:FairValueRetirementBenefitsInvestmentsValuedatNetAssetValueMember 2018-12-31 0000059478 us-gaap:HedgeFundsMember us-gaap:FairValueInputsLevel2Member us-gaap:DefinedBenefitPostretirementHealthCoverageMember 2018-12-31 0000059478 us-gaap:FairValueInputsLevel3Member us-gaap:DefinedBenefitPostretirementHealthCoverageMember 2018-12-31 0000059478 us-gaap:DefinedBenefitPlanEquitySecuritiesNonUsMember us-gaap:FairValueInputsLevel1Member us-gaap:PensionPlansDefinedBenefitMember 2018-12-31 0000059478 us-gaap:DefinedBenefitPlanRealEstateMember us-gaap:FairValueInputsLevel1Member us-gaap:DefinedBenefitPostretirementHealthCoverageMember 2018-12-31 0000059478 us-gaap:DefinedBenefitPlanEquitySecuritiesNonUsMember us-gaap:FairValueInputsLevel1Member us-gaap:DefinedBenefitPostretirementHealthCoverageMember 2018-12-31 0000059478 us-gaap:EquityFundsMember us-gaap:FairValueInputsLevel1Member us-gaap:DefinedBenefitPostretirementHealthCoverageMember 2018-12-31 0000059478 2018-07-01 2018-07-31 0000059478 lly:RestructuringSettlementAndImpairmentProvisionsMember 2017-01-01 2017-12-31 0000059478 us-gaap:DefinedBenefitPlanEquitySecuritiesMember 2018-12-31 0000059478 us-gaap:FixedIncomeFundsMember 2018-12-31 0000059478 lly:EmployeeLitigationMember country:BR 2018-01-01 2018-12-31 0000059478 lly:EmployeeLitigationMember country:BR lly:PlaintiffAppealingDecisionofCourtMember 2018-01-01 2018-12-31 0000059478 lly:AdociaS.AMember 2018-12-31 0000059478 2018-07-31 0000059478 lly:AlimtaMember country:US 2018-12-31 0000059478 lly:DrReddysLabMember 2018-06-01 2018-06-30 0000059478 lly:JapaneseAdministrativeProceedingsMember 2018-12-31 0000059478 lly:AlimtaMember country:US 2018-01-01 2018-12-31 0000059478 us-gaap:AociAttributableToNoncontrollingInterestMember 2018-12-31 0000059478 us-gaap:AociAttributableToNoncontrollingInterestMember 2016-12-31 0000059478 us-gaap:AociAttributableToNoncontrollingInterestMember 2017-12-31 0000059478 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember 2016-01-01 2016-12-31 0000059478 us-gaap:AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember 2018-01-01 2018-12-31 0000059478 us-gaap:AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember 2018-01-01 2018-12-31 0000059478 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember 2016-01-01 2016-12-31 0000059478 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember 2018-01-01 2018-12-31 0000059478 us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember 2016-01-01 2016-12-31 0000059478 us-gaap:AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember 2017-01-01 2017-12-31 0000059478 us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember 2017-01-01 2017-12-31 0000059478 us-gaap:AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember 2017-01-01 2017-12-31 0000059478 us-gaap:AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember 2016-01-01 2016-12-31 0000059478 us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember 2018-01-01 2018-12-31 0000059478 us-gaap:AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember 2016-01-01 2016-12-31 0000059478 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember 2017-01-01 2017-12-31 0000059478 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember 2016-01-01 2016-12-31 0000059478 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember 2018-01-01 2018-12-31 0000059478 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember 2018-01-01 2018-12-31 0000059478 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceIncludingPortionAttributableToNoncontrollingInterestMember 2018-01-01 2018-12-31 0000059478 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedOtherthanTemporaryImpairmentIncludingPortionAttributableToNoncontrollingInterestMember 2017-01-01 2017-12-31 0000059478 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember 2016-01-01 2016-12-31 0000059478 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember 2017-01-01 2017-12-31 0000059478 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetGainLossIncludingPortionAttributableToNoncontrollingInterestMember 2016-01-01 2016-12-31 0000059478 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedOtherthanTemporaryImpairmentIncludingPortionAttributableToNoncontrollingInterestMember 2016-01-01 2016-12-31 0000059478 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember 2017-01-01 2017-12-31 0000059478 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetGainLossIncludingPortionAttributableToNoncontrollingInterestMember 2018-01-01 2018-12-31 0000059478 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember 2016-01-01 2016-12-31 0000059478 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember lly:AccumulatedNetGainLossfromCashFlowHedgesandForeignCurrencyAdjustmentIncludingPortionAttributabletoNoncontrollingInterestMember 2018-01-01 2018-12-31 0000059478 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember lly:AccumulatedNetGainLossfromCashFlowHedgesandForeignCurrencyAdjustmentIncludingPortionAttributabletoNoncontrollingInterestMember 2017-01-01 2017-12-31 0000059478 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceIncludingPortionAttributableToNoncontrollingInterestMember 2017-01-01 2017-12-31 0000059478 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember lly:AccumulatedNetGainLossfromCashFlowHedgesandForeignCurrencyAdjustmentIncludingPortionAttributabletoNoncontrollingInterestMember 2016-01-01 2016-12-31 0000059478 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember 2018-01-01 2018-12-31 0000059478 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetGainLossIncludingPortionAttributableToNoncontrollingInterestMember 2017-01-01 2017-12-31 0000059478 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember 2017-01-01 2017-12-31 0000059478 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceIncludingPortionAttributableToNoncontrollingInterestMember 2016-01-01 2016-12-31 0000059478 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedOtherthanTemporaryImpairmentIncludingPortionAttributableToNoncontrollingInterestMember 2018-01-01 2018-12-31 0000059478 us-gaap:AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember us-gaap:SegmentContinuingOperationsMember 2016-01-01 2016-12-31 0000059478 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember us-gaap:SegmentContinuingOperationsMember 2015-12-31 0000059478 us-gaap:AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember us-gaap:SegmentContinuingOperationsMember 2017-01-01 2017-12-31 0000059478 us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember us-gaap:SegmentContinuingOperationsMember 2016-01-01 2016-12-31 0000059478 us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember us-gaap:SegmentContinuingOperationsMember 2017-01-01 2017-12-31 0000059478 us-gaap:AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember us-gaap:SegmentContinuingOperationsMember 2018-01-01 2018-12-31 0000059478 us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember us-gaap:SegmentContinuingOperationsMember 2018-12-31 0000059478 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember us-gaap:SegmentContinuingOperationsMember 2018-12-31 0000059478 us-gaap:AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember us-gaap:SegmentContinuingOperationsMember 2018-01-01 2018-12-31 0000059478 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember us-gaap:SegmentContinuingOperationsMember 2017-01-01 2017-12-31 0000059478 us-gaap:AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember us-gaap:SegmentContinuingOperationsMember 2017-01-01 2017-12-31 0000059478 us-gaap:AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember us-gaap:SegmentContinuingOperationsMember 2018-12-31 0000059478 us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember us-gaap:SegmentDiscontinuedOperationsMember 2016-01-01 2016-12-31 0000059478 us-gaap:AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember us-gaap:SegmentContinuingOperationsMember 2016-01-01 2016-12-31 0000059478 us-gaap:AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember us-gaap:SegmentContinuingOperationsMember 2016-12-31 0000059478 us-gaap:AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember us-gaap:SegmentContinuingOperationsMember 2017-12-31 0000059478 us-gaap:AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember us-gaap:SegmentContinuingOperationsMember 2017-12-31 0000059478 us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember 2018-12-31 0000059478 us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember us-gaap:SegmentDiscontinuedOperationsMember 2017-01-01 2017-12-31 0000059478 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember us-gaap:SegmentContinuingOperationsMember 2018-01-01 2018-12-31 0000059478 us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember us-gaap:SegmentContinuingOperationsMember 2015-12-31 0000059478 us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember us-gaap:SegmentContinuingOperationsMember 2017-12-31 0000059478 us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember us-gaap:SegmentDiscontinuedOperationsMember 2015-12-31 0000059478 us-gaap:AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember us-gaap:SegmentContinuingOperationsMember 2015-12-31 0000059478 us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember us-gaap:SegmentDiscontinuedOperationsMember 2018-01-01 2018-12-31 0000059478 us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember us-gaap:SegmentDiscontinuedOperationsMember 2018-12-31 0000059478 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember us-gaap:SegmentContinuingOperationsMember 2016-01-01 2016-12-31 0000059478 us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember us-gaap:SegmentContinuingOperationsMember 2018-01-01 2018-12-31 0000059478 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember us-gaap:SegmentContinuingOperationsMember 2016-12-31 0000059478 us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember us-gaap:SegmentDiscontinuedOperationsMember 2017-12-31 0000059478 us-gaap:AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember us-gaap:SegmentContinuingOperationsMember 2016-12-31 0000059478 us-gaap:AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember us-gaap:SegmentContinuingOperationsMember 2015-12-31 0000059478 us-gaap:AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember us-gaap:SegmentContinuingOperationsMember 2018-12-31 0000059478 us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember us-gaap:SegmentDiscontinuedOperationsMember 2016-12-31 0000059478 us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember 2016-12-31 0000059478 us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember 2017-12-31 0000059478 us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember 2015-12-31 0000059478 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember us-gaap:SegmentContinuingOperationsMember 2017-12-31 0000059478 us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember us-gaap:SegmentContinuingOperationsMember 2016-12-31 0000059478 lly:AlimtaMember country:US lly:HumanPharmaceuticalProductsMember 2016-01-01 2016-12-31 0000059478 lly:OtherNeuroscienceMember country:US lly:HumanPharmaceuticalProductsMember 2018-01-01 2018-12-31 0000059478 lly:EffientMember country:US lly:HumanPharmaceuticalProductsMember 2018-01-01 2018-12-31 0000059478 lly:ForteoMember lly:InternationalMember lly:HumanPharmaceuticalProductsMember 2018-01-01 2018-12-31 0000059478 lly:StratteraMember country:US lly:HumanPharmaceuticalProductsMember 2018-01-01 2018-12-31 0000059478 lly:OtherEndocrinologyMember lly:InternationalMember lly:HumanPharmaceuticalProductsMember 2016-01-01 2016-12-31 0000059478 lly:ErbituxMember lly:InternationalMember lly:HumanPharmaceuticalProductsMember 2016-01-01 2016-12-31 0000059478 lly:OtherPharmaceuticalsMember lly:InternationalMember lly:HumanPharmaceuticalProductsMember 2018-01-01 2018-12-31 0000059478 lly:OtherCardiovascularMember country:US lly:HumanPharmaceuticalProductsMember 2017-01-01 2017-12-31 0000059478 lly:OtherOncologyMember lly:InternationalMember lly:HumanPharmaceuticalProductsMember 2018-01-01 2018-12-31 0000059478 lly:OtherCardiovascularMember lly:InternationalMember lly:HumanPharmaceuticalProductsMember 2016-01-01 2016-12-31 0000059478 lly:NeuroscienceMember lly:InternationalMember lly:HumanPharmaceuticalProductsMember 2017-01-01 2017-12-31 0000059478 lly:HumalogMember lly:InternationalMember lly:HumanPharmaceuticalProductsMember 2017-01-01 2017-12-31 0000059478 lly:OncologyMember lly:InternationalMember lly:HumanPharmaceuticalProductsMember 2017-01-01 2017-12-31 0000059478 lly:ImmunologyMember country:US lly:HumanPharmaceuticalProductsMember 2017-01-01 2017-12-31 0000059478 lly:TrulicityMemberMember country:US lly:HumanPharmaceuticalProductsMember 2018-01-01 2018-12-31 0000059478 lly:OtherImmunologyMember lly:InternationalMember lly:HumanPharmaceuticalProductsMember 2018-01-01 2018-12-31 0000059478 lly:ErbituxMember lly:InternationalMember lly:HumanPharmaceuticalProductsMember 2017-01-01 2017-12-31 0000059478 lly:OtherCardiovascularMember country:US lly:HumanPharmaceuticalProductsMember 2018-01-01 2018-12-31 0000059478 lly:AlimtaMember country:US lly:HumanPharmaceuticalProductsMember 2017-01-01 2017-12-31 0000059478 lly:ErbituxMember country:US lly:HumanPharmaceuticalProductsMember 2017-01-01 2017-12-31 0000059478 lly:OncologyMember country:US lly:HumanPharmaceuticalProductsMember 2017-01-01 2017-12-31 0000059478 lly:TrajentaBIMember lly:InternationalMember lly:HumanPharmaceuticalProductsMember 2017-01-01 2017-12-31 0000059478 lly:AlimtaMember lly:InternationalMember lly:HumanPharmaceuticalProductsMember 2016-01-01 2016-12-31 0000059478 lly:StratteraMember lly:InternationalMember lly:HumanPharmaceuticalProductsMember 2016-01-01 2016-12-31 0000059478 lly:OtherOncologyMember lly:InternationalMember lly:HumanPharmaceuticalProductsMember 2017-01-01 2017-12-31 0000059478 lly:TrajentaBIMember lly:InternationalMember lly:HumanPharmaceuticalProductsMember 2018-01-01 2018-12-31 0000059478 lly:OncologyMember lly:InternationalMember lly:HumanPharmaceuticalProductsMember 2016-01-01 2016-12-31 0000059478 lly:OtherNeuroscienceMember country:US lly:HumanPharmaceuticalProductsMember 2017-01-01 2017-12-31 0000059478 lly:EndocrinologyMember country:US lly:HumanPharmaceuticalProductsMember 2017-01-01 2017-12-31 0000059478 lly:OtherPharmaceuticalsMember country:US lly:HumanPharmaceuticalProductsMember 2018-01-01 2018-12-31 0000059478 lly:ImmunologyMember country:US lly:HumanPharmaceuticalProductsMember 2018-01-01 2018-12-31 0000059478 lly:CyramzaMember country:US lly:HumanPharmaceuticalProductsMember 2018-01-01 2018-12-31 0000059478 lly:CymbaltaMember country:US lly:HumanPharmaceuticalProductsMember 2016-01-01 2016-12-31 0000059478 lly:EndocrinologyMember country:US lly:HumanPharmaceuticalProductsMember 2016-01-01 2016-12-31 0000059478 lly:OtherImmunologyMember lly:InternationalMember lly:HumanPharmaceuticalProductsMember 2016-01-01 2016-12-31 0000059478 lly:ForteoMember country:US lly:HumanPharmaceuticalProductsMember 2016-01-01 2016-12-31 0000059478 lly:OtherEndocrinologyMember country:US lly:HumanPharmaceuticalProductsMember 2018-01-01 2018-12-31 0000059478 lly:HumulinMember country:US lly:HumanPharmaceuticalProductsMember 2016-01-01 2016-12-31 0000059478 lly:TaltzMember country:US lly:HumanPharmaceuticalProductsMember 2017-01-01 2017-12-31 0000059478 lly:TaltzMember lly:InternationalMember lly:HumanPharmaceuticalProductsMember 2016-01-01 2016-12-31 0000059478 lly:ForteoMember lly:InternationalMember lly:HumanPharmaceuticalProductsMember 2017-01-01 2017-12-31 0000059478 lly:CyramzaMember lly:InternationalMember lly:HumanPharmaceuticalProductsMember 2017-01-01 2017-12-31 0000059478 lly:AlimtaMember country:US lly:HumanPharmaceuticalProductsMember 2018-01-01 2018-12-31 0000059478 lly:OtherEndocrinologyMember country:US lly:HumanPharmaceuticalProductsMember 2017-01-01 2017-12-31 0000059478 lly:TrulicityMemberMember country:US lly:HumanPharmaceuticalProductsMember 2017-01-01 2017-12-31 0000059478 lly:NeuroscienceMember lly:InternationalMember lly:HumanPharmaceuticalProductsMember 2016-01-01 2016-12-31 0000059478 lly:CyramzaMember lly:InternationalMember lly:HumanPharmaceuticalProductsMember 2018-01-01 2018-12-31 0000059478 lly:EndocrinologyMember lly:InternationalMember lly:HumanPharmaceuticalProductsMember 2018-01-01 2018-12-31 0000059478 lly:OtherEndocrinologyMember country:US lly:HumanPharmaceuticalProductsMember 2016-01-01 2016-12-31 0000059478 lly:CyramzaMember lly:InternationalMember lly:HumanPharmaceuticalProductsMember 2016-01-01 2016-12-31 0000059478 lly:OtherCardiovascularMember country:US lly:HumanPharmaceuticalProductsMember 2016-01-01 2016-12-31 0000059478 country:US 2018-01-01 2018-12-31 0000059478 lly:HumalogMember lly:InternationalMember lly:HumanPharmaceuticalProductsMember 2018-01-01 2018-12-31 0000059478 lly:NeuroscienceMember country:US lly:HumanPharmaceuticalProductsMember 2016-01-01 2016-12-31 0000059478 lly:CymbaltaMember lly:InternationalMember lly:HumanPharmaceuticalProductsMember 2017-01-01 2017-12-31 0000059478 lly:HumulinMember lly:InternationalMember lly:HumanPharmaceuticalProductsMember 2017-01-01 2017-12-31 0000059478 lly:CialisMember country:US lly:HumanPharmaceuticalProductsMember 2016-01-01 2016-12-31 0000059478 lly:ZyprexaMember country:US lly:HumanPharmaceuticalProductsMember 2016-01-01 2016-12-31 0000059478 lly:CialisMember lly:InternationalMember lly:HumanPharmaceuticalProductsMember 2017-01-01 2017-12-31 0000059478 lly:ImmunologyMember lly:InternationalMember lly:HumanPharmaceuticalProductsMember 2017-01-01 2017-12-31 0000059478 lly:HumalogMember country:US lly:HumanPharmaceuticalProductsMember 2016-01-01 2016-12-31 0000059478 lly:BasaglarMember lly:InternationalMember lly:HumanPharmaceuticalProductsMember 2017-01-01 2017-12-31 0000059478 lly:OtherNeuroscienceMember country:US lly:HumanPharmaceuticalProductsMember 2016-01-01 2016-12-31 0000059478 lly:CialisMember lly:InternationalMember lly:HumanPharmaceuticalProductsMember 2018-01-01 2018-12-31 0000059478 lly:StratteraMember country:US lly:HumanPharmaceuticalProductsMember 2017-01-01 2017-12-31 0000059478 lly:JardianceMember country:US lly:HumanPharmaceuticalProductsMember 2016-01-01 2016-12-31 0000059478 lly:CialisMember country:US lly:HumanPharmaceuticalProductsMember 2017-01-01 2017-12-31 0000059478 lly:CymbaltaMember country:US lly:HumanPharmaceuticalProductsMember 2017-01-01 2017-12-31 0000059478 lly:OtherNeuroscienceMember lly:InternationalMember lly:HumanPharmaceuticalProductsMember 2017-01-01 2017-12-31 0000059478 lly:AlimtaMember lly:InternationalMember lly:HumanPharmaceuticalProductsMember 2018-01-01 2018-12-31 0000059478 lly:InternationalMember 2018-01-01 2018-12-31 0000059478 lly:NeuroscienceMember lly:InternationalMember lly:HumanPharmaceuticalProductsMember 2018-01-01 2018-12-31 0000059478 lly:OtherNeuroscienceMember lly:InternationalMember lly:HumanPharmaceuticalProductsMember 2016-01-01 2016-12-31 0000059478 lly:AlimtaMember lly:InternationalMember lly:HumanPharmaceuticalProductsMember 2017-01-01 2017-12-31 0000059478 lly:ForteoMember country:US lly:HumanPharmaceuticalProductsMember 2018-01-01 2018-12-31 0000059478 lly:OtherEndocrinologyMember lly:InternationalMember lly:HumanPharmaceuticalProductsMember 2017-01-01 2017-12-31 0000059478 lly:JardianceMember country:US lly:HumanPharmaceuticalProductsMember 2017-01-01 2017-12-31 0000059478 lly:HumulinMember country:US lly:HumanPharmaceuticalProductsMember 2017-01-01 2017-12-31 0000059478 lly:OtherImmunologyMember country:US lly:HumanPharmaceuticalProductsMember 2017-01-01 2017-12-31 0000059478 lly:OtherPharmaceuticalsMember lly:InternationalMember lly:HumanPharmaceuticalProductsMember 2017-01-01 2017-12-31 0000059478 lly:NeuroscienceMember country:US lly:HumanPharmaceuticalProductsMember 2018-01-01 2018-12-31 0000059478 lly:TaltzMember lly:InternationalMember lly:HumanPharmaceuticalProductsMember 2018-01-01 2018-12-31 0000059478 lly:CardiovascularMember country:US lly:HumanPharmaceuticalProductsMember 2018-01-01 2018-12-31 0000059478 lly:EffientMember lly:InternationalMember lly:HumanPharmaceuticalProductsMember 2016-01-01 2016-12-31 0000059478 lly:OtherOncologyMember country:US lly:HumanPharmaceuticalProductsMember 2016-01-01 2016-12-31 0000059478 lly:HumalogMember country:US lly:HumanPharmaceuticalProductsMember 2017-01-01 2017-12-31 0000059478 lly:JardianceMember country:US lly:HumanPharmaceuticalProductsMember 2018-01-01 2018-12-31 0000059478 lly:EndocrinologyMember lly:InternationalMember lly:HumanPharmaceuticalProductsMember 2016-01-01 2016-12-31 0000059478 lly:ForteoMember country:US lly:HumanPharmaceuticalProductsMember 2017-01-01 2017-12-31 0000059478 lly:ZyprexaMember country:US lly:HumanPharmaceuticalProductsMember 2017-01-01 2017-12-31 0000059478 lly:OtherImmunologyMember country:US lly:HumanPharmaceuticalProductsMember 2018-01-01 2018-12-31 0000059478 lly:BasaglarMember country:US lly:HumanPharmaceuticalProductsMember 2018-01-01 2018-12-31 0000059478 lly:OtherImmunologyMember lly:InternationalMember lly:HumanPharmaceuticalProductsMember 2017-01-01 2017-12-31 0000059478 lly:BasaglarMember country:US lly:HumanPharmaceuticalProductsMember 2016-01-01 2016-12-31 0000059478 lly:OtherPharmaceuticalsMember lly:InternationalMember lly:HumanPharmaceuticalProductsMember 2016-01-01 2016-12-31 0000059478 lly:OncologyMember country:US lly:HumanPharmaceuticalProductsMember 2018-01-01 2018-12-31 0000059478 lly:EndocrinologyMember lly:InternationalMember lly:HumanPharmaceuticalProductsMember 2017-01-01 2017-12-31 0000059478 lly:TrajentaBIMember country:US lly:HumanPharmaceuticalProductsMember 2016-01-01 2016-12-31 0000059478 lly:CialisMember lly:InternationalMember lly:HumanPharmaceuticalProductsMember 2016-01-01 2016-12-31 0000059478 lly:CardiovascularMember lly:InternationalMember lly:HumanPharmaceuticalProductsMember 2017-01-01 2017-12-31 0000059478 lly:ImmunologyMember lly:InternationalMember lly:HumanPharmaceuticalProductsMember 2018-01-01 2018-12-31 0000059478 lly:OtherOncologyMember country:US lly:HumanPharmaceuticalProductsMember 2018-01-01 2018-12-31 0000059478 lly:HumalogMember lly:InternationalMember lly:HumanPharmaceuticalProductsMember 2016-01-01 2016-12-31 0000059478 country:US 2016-01-01 2016-12-31 0000059478 lly:InternationalMember 2017-01-01 2017-12-31 0000059478 lly:ZyprexaMember lly:InternationalMember lly:HumanPharmaceuticalProductsMember 2018-01-01 2018-12-31 0000059478 lly:JardianceMember lly:InternationalMember lly:HumanPharmaceuticalProductsMember 2016-01-01 2016-12-31 0000059478 lly:ErbituxMember country:US lly:HumanPharmaceuticalProductsMember 2016-01-01 2016-12-31 0000059478 lly:TrulicityMemberMember lly:InternationalMember lly:HumanPharmaceuticalProductsMember 2016-01-01 2016-12-31 0000059478 lly:CardiovascularMember country:US lly:HumanPharmaceuticalProductsMember 2017-01-01 2017-12-31 0000059478 lly:ImmunologyMember lly:InternationalMember lly:HumanPharmaceuticalProductsMember 2016-01-01 2016-12-31 0000059478 lly:JardianceMember lly:InternationalMember lly:HumanPharmaceuticalProductsMember 2018-01-01 2018-12-31 0000059478 lly:TrajentaBIMember country:US lly:HumanPharmaceuticalProductsMember 2017-01-01 2017-12-31 0000059478 lly:CyramzaMember country:US lly:HumanPharmaceuticalProductsMember 2017-01-01 2017-12-31 0000059478 lly:OtherPharmaceuticalsMember country:US lly:HumanPharmaceuticalProductsMember 2016-01-01 2016-12-31 0000059478 lly:CyramzaMember country:US lly:HumanPharmaceuticalProductsMember 2016-01-01 2016-12-31 0000059478 lly:ZyprexaMember lly:InternationalMember lly:HumanPharmaceuticalProductsMember 2017-01-01 2017-12-31 0000059478 lly:BasaglarMember lly:InternationalMember lly:HumanPharmaceuticalProductsMember 2016-01-01 2016-12-31 0000059478 lly:OtherOncologyMember country:US lly:HumanPharmaceuticalProductsMember 2017-01-01 2017-12-31 0000059478 lly:CymbaltaMember country:US lly:HumanPharmaceuticalProductsMember 2018-01-01 2018-12-31 0000059478 lly:EffientMember lly:InternationalMember lly:HumanPharmaceuticalProductsMember 2017-01-01 2017-12-31 0000059478 lly:StratteraMember country:US lly:HumanPharmaceuticalProductsMember 2016-01-01 2016-12-31 0000059478 lly:TaltzMember lly:InternationalMember lly:HumanPharmaceuticalProductsMember 2017-01-01 2017-12-31 0000059478 lly:CardiovascularMember country:US lly:HumanPharmaceuticalProductsMember 2016-01-01 2016-12-31 0000059478 lly:ErbituxMember country:US lly:HumanPharmaceuticalProductsMember 2018-01-01 2018-12-31 0000059478 lly:NeuroscienceMember country:US lly:HumanPharmaceuticalProductsMember 2017-01-01 2017-12-31 0000059478 lly:EffientMember country:US lly:HumanPharmaceuticalProductsMember 2017-01-01 2017-12-31 0000059478 lly:CialisMember country:US lly:HumanPharmaceuticalProductsMember 2018-01-01 2018-12-31 0000059478 lly:BasaglarMember country:US lly:HumanPharmaceuticalProductsMember 2017-01-01 2017-12-31 0000059478 lly:TrulicityMemberMember lly:InternationalMember lly:HumanPharmaceuticalProductsMember 2018-01-01 2018-12-31 0000059478 lly:HumalogMember country:US lly:HumanPharmaceuticalProductsMember 2018-01-01 2018-12-31 0000059478 lly:OncologyMember lly:InternationalMember lly:HumanPharmaceuticalProductsMember 2018-01-01 2018-12-31 0000059478 lly:TrulicityMemberMember lly:InternationalMember lly:HumanPharmaceuticalProductsMember 2017-01-01 2017-12-31 0000059478 lly:OtherPharmaceuticalsMember country:US lly:HumanPharmaceuticalProductsMember 2017-01-01 2017-12-31 0000059478 lly:TaltzMember country:US lly:HumanPharmaceuticalProductsMember 2018-01-01 2018-12-31 0000059478 lly:CardiovascularMember lly:InternationalMember lly:HumanPharmaceuticalProductsMember 2016-01-01 2016-12-31 0000059478 lly:HumulinMember lly:InternationalMember lly:HumanPharmaceuticalProductsMember 2016-01-01 2016-12-31 0000059478 lly:CardiovascularMember lly:InternationalMember lly:HumanPharmaceuticalProductsMember 2018-01-01 2018-12-31 0000059478 lly:TrulicityMemberMember country:US lly:HumanPharmaceuticalProductsMember 2016-01-01 2016-12-31 0000059478 lly:EndocrinologyMember country:US lly:HumanPharmaceuticalProductsMember 2018-01-01 2018-12-31 0000059478 lly:OtherImmunologyMember country:US lly:HumanPharmaceuticalProductsMember 2016-01-01 2016-12-31 0000059478 lly:BasaglarMember lly:InternationalMember lly:HumanPharmaceuticalProductsMember 2018-01-01 2018-12-31 0000059478 lly:OtherCardiovascularMember lly:InternationalMember lly:HumanPharmaceuticalProductsMember 2017-01-01 2017-12-31 0000059478 lly:OtherCardiovascularMember lly:InternationalMember lly:HumanPharmaceuticalProductsMember 2018-01-01 2018-12-31 0000059478 lly:StratteraMember lly:InternationalMember lly:HumanPharmaceuticalProductsMember 2017-01-01 2017-12-31 0000059478 lly:EffientMember lly:InternationalMember lly:HumanPharmaceuticalProductsMember 2018-01-01 2018-12-31 0000059478 lly:ZyprexaMember country:US lly:HumanPharmaceuticalProductsMember 2018-01-01 2018-12-31 0000059478 lly:OncologyMember country:US lly:HumanPharmaceuticalProductsMember 2016-01-01 2016-12-31 0000059478 lly:TrajentaBIMember country:US lly:HumanPharmaceuticalProductsMember 2018-01-01 2018-12-31 0000059478 lly:JardianceMember lly:InternationalMember lly:HumanPharmaceuticalProductsMember 2017-01-01 2017-12-31 0000059478 lly:ImmunologyMember country:US lly:HumanPharmaceuticalProductsMember 2016-01-01 2016-12-31 0000059478 lly:HumulinMember country:US lly:HumanPharmaceuticalProductsMember 2018-01-01 2018-12-31 0000059478 lly:InternationalMember 2016-01-01 2016-12-31 0000059478 lly:StratteraMember lly:InternationalMember lly:HumanPharmaceuticalProductsMember 2018-01-01 2018-12-31 0000059478 lly:CymbaltaMember lly:InternationalMember lly:HumanPharmaceuticalProductsMember 2016-01-01 2016-12-31 0000059478 lly:TrajentaBIMember lly:InternationalMember lly:HumanPharmaceuticalProductsMember 2016-01-01 2016-12-31 0000059478 lly:OtherNeuroscienceMember lly:InternationalMember lly:HumanPharmaceuticalProductsMember 2018-01-01 2018-12-31 0000059478 lly:CymbaltaMember lly:InternationalMember lly:HumanPharmaceuticalProductsMember 2018-01-01 2018-12-31 0000059478 lly:OtherEndocrinologyMember lly:InternationalMember lly:HumanPharmaceuticalProductsMember 2018-01-01 2018-12-31 0000059478 lly:ZyprexaMember lly:InternationalMember lly:HumanPharmaceuticalProductsMember 2016-01-01 2016-12-31 0000059478 lly:TaltzMember country:US lly:HumanPharmaceuticalProductsMember 2016-01-01 2016-12-31 0000059478 lly:ErbituxMember lly:InternationalMember lly:HumanPharmaceuticalProductsMember 2018-01-01 2018-12-31 0000059478 lly:ForteoMember lly:InternationalMember lly:HumanPharmaceuticalProductsMember 2016-01-01 2016-12-31 0000059478 lly:HumulinMember lly:InternationalMember lly:HumanPharmaceuticalProductsMember 2018-01-01 2018-12-31 0000059478 lly:OtherOncologyMember lly:InternationalMember lly:HumanPharmaceuticalProductsMember 2016-01-01 2016-12-31 0000059478 lly:EffientMember country:US lly:HumanPharmaceuticalProductsMember 2016-01-01 2016-12-31 0000059478 srt:EuropeMember 2017-01-01 2017-12-31 0000059478 lly:OtherForeignCountriesMember 2016-12-31 0000059478 lly:OtherForeignCountriesMember 2017-01-01 2017-12-31 0000059478 country:JP 2016-01-01 2016-12-31 0000059478 country:US 2018-12-31 0000059478 country:JP 2017-12-31 0000059478 srt:EuropeMember 2018-01-01 2018-12-31 0000059478 lly:OtherForeignCountriesMember 2017-12-31 0000059478 srt:EuropeMember 2017-12-31 0000059478 country:US 2016-12-31 0000059478 country:JP 2018-01-01 2018-12-31 0000059478 srt:EuropeMember 2018-12-31 0000059478 country:JP 2016-12-31 0000059478 country:JP 2017-01-01 2017-12-31 0000059478 lly:OtherForeignCountriesMember 2016-01-01 2016-12-31 0000059478 lly:OtherForeignCountriesMember 2018-01-01 2018-12-31 0000059478 srt:EuropeMember 2016-01-01 2016-12-31 0000059478 lly:OtherForeignCountriesMember 2018-12-31 0000059478 country:JP 2018-12-31 0000059478 country:US 2017-12-31 0000059478 srt:EuropeMember 2016-12-31 0000059478 srt:MaximumMember us-gaap:SalesRevenueNetMember 2018-01-01 2018-12-31 0000059478 srt:MaximumMember us-gaap:AccountsReceivableMember 2018-01-01 2018-12-31 0000059478 lly:CymbaltaMember lly:AdjustmenttoReturnReserveMember lly:HumanPharmaceuticalProductsMember 2016-01-01 2016-12-31 0000059478 srt:MinimumMember us-gaap:AccountsReceivableMember 2018-01-01 2018-12-31 0000059478 srt:MinimumMember us-gaap:SalesRevenueNetMember 2018-01-01 2018-12-31 0000059478 srt:MinimumMember us-gaap:SalesRevenueNetMember 2017-01-01 2017-12-31 0000059478 srt:MaximumMember us-gaap:SalesRevenueNetMember 2016-01-01 2016-12-31 0000059478 srt:MaximumMember us-gaap:SalesRevenueNetMember 2017-01-01 2017-12-31 0000059478 srt:MinimumMember us-gaap:AccountsReceivableMember 2017-01-01 2017-12-31 0000059478 srt:MinimumMember us-gaap:SalesRevenueNetMember 2016-01-01 2016-12-31 0000059478 srt:MaximumMember us-gaap:AccountsReceivableMember 2017-01-01 2017-12-31 0000059478 2018-07-01 2018-09-30 0000059478 2017-01-01 2017-03-31 0000059478 2018-01-01 2018-03-31 0000059478 2017-04-01 2017-06-30 0000059478 2017-10-01 2017-12-31 0000059478 2018-10-01 2018-12-31 0000059478 2017-07-01 2017-09-30 0000059478 2018-04-01 2018-06-30 0000059478 lly:TermFacilityMember lly:ElancoAnimalHealthIncorporatedMember 2018-08-31 0000059478 lly:ElancoAnimalHealthIncorporatedMember 2018-12-31 0000059478 lly:ElancoAnimalHealthIncorporatedMember 2018-09-24 0000059478 us-gaap:DiscontinuedOperationsDisposedOfBySaleMember lly:ElancoAnimalHealthIncorporatedMember 2019-03-11 2019-03-11 0000059478 us-gaap:DiscontinuedOperationsDisposedOfBySaleMember lly:ElancoAnimalHealthIncorporatedMember 2019-01-01 2019-03-31 0000059478 us-gaap:DiscontinuedOperationsDisposedOfBySaleMember lly:ElancoAnimalHealthIncorporatedMember 2018-12-31 0000059478 us-gaap:DiscontinuedOperationsDisposedOfBySaleMember lly:ElancoAnimalHealthIncorporatedMember 2017-12-31 0000059478 us-gaap:DiscontinuedOperationsDisposedOfBySaleMember lly:ElancoAnimalHealthIncorporatedMember 2018-01-01 2018-12-31 0000059478 us-gaap:DiscontinuedOperationsDisposedOfBySaleMember lly:ElancoAnimalHealthIncorporatedMember 2017-01-01 2017-12-31 0000059478 us-gaap:DiscontinuedOperationsDisposedOfBySaleMember lly:ElancoAnimalHealthIncorporatedMember 2016-01-01 2016-12-31 0000059478 lly:TermFacilityMember lly:ElancoAnimalHealthIncorporatedMember 2018-08-01 2018-08-31 iso4217:EUR iso4217:CHF iso4217:GBP iso4217:USD pure shares iso4217:JPY iso4217:USD shares lly:individual lly:wholesaler iso4217:BRL lly:case lly:application lly:company lly:patent lly:lawsuit lly:demand lly:segment lly:defendant lly:product false FY 2018 0000059478 Lilly Eli & Co -643600000 -105000000 28900000 24100000 2.05 2.12 2.33 3200000000 3200000000 3010000000 50000000 1100672000 1057639000 0.20 0.13 0.25 0.21 0.16 0.14 54200000 80800000 0.0713 0.0015 P3Y 2500000000 1800000000 460600000 258800000 324400000 677500000 P3Y 0 0 135500000 68900000 97500000 55900000 38000000 13000000 0 0 197100000 249000000 1 600000000 530000000 0 P3Y 66400000 75800000 5000000 105000000 700000000 76500000 92400000 P3Y P2Y 8-K 2019-10-24 IN 001-06351 35-0470950 Lilly Corporate Center Indianapolis IN 46285 317 276-2000 false false false false false Common Stock (no par value) LLY NYSE 1.000% Notes Due June 2, 2022 LLY22 NYSE 7 1/8% Notes Due June 1, 2025 LLY25 NYSE 1.625% Notes Due June 2, 2026 LLY26 NYSE 2.125% Notes Due June 3, 2030 LLY30 NYSE 6.77% Notes Due January 1, 2036 LLY36 NYSE 21493300000 19973800000 18312800000 4681700000 4447700000 4160500000 5051200000 5096200000 5040000000.0 5975100000 5982400000 5841900000 1983900000 1112600000 30000000.0 266900000 1331600000 72900000 145600000 301500000 108800000 17813200000 17669000000.0 15036500000 3680100000 2304800000 3276300000 529500000 2391200000 551400000 3150600000 -86400000 2724900000 81400000 -117700000 12700000 3232000000.0 -204100000 2737600000 3.07 -0.08 2.57 0.07 -0.11 0.02 3.14 -0.19 2.59 3.05 -0.08 2.57 0.08 -0.11 0.01 3.13 -0.19 2.58 1027721000 1052023000 1058324000 1033667000 1052023000 1061825000 3232000000.0 -204100000 2737600000 -429600000 362900000 -300000000.0 -8800000 -181300000 303000000.0 -544000000.0 566800000 508500000 -6000000.0 27800000 11700000 99600000 -357400000 -493800000 30300000 -402700000 10600000 69300000 45300000 -504400000 14300000 129200000 -140700000 83600000 174500000 -645100000 3315600000 -29600000 2092500000 72600000 11000000.0 199000000.0 -24500000 -693300000 48200000 7320700000 6211800000 88200000 1497900000 4593900000 3977000000.0 1182900000 689500000 3098100000 3396000000.0 2036700000 1319900000 2229100000 2110000000.0 20549600000 19202100000 2005400000 5666500000 1366600000 1378000000.0 1068000000.0 1354400000 2613700000 1216900000 1824900000 1609300000 7996100000 7885100000 6484100000 6668700000 43908400000 44981000000.0 1102200000 3706500000 1207100000 1206900000 955600000 911800000 4849500000 4310100000 650800000 590600000 393400000 522500000 2036700000 2650000000.0 692800000 637500000 11888100000 14535900000 9196400000 9940000000.0 2802200000 3376000000.0 3700000000.0 3747000000.0 2670300000 1362600000 2742300000 351600000 21111200000 18777200000 661000000.0 687900000 6583600000 5817800000 11395900000 13894100000 3013200000 3013200000 -5729200000 -5718600000 69400000 75800000 9828700000 11592200000 1080400000 75700000 10909100000 11667900000 43908400000 44981000000.0 1106063000 691300000 5552100000 16011800000 -3013200000 -4580700000 796000 -90000000.0 19000000.0 2737600000 16300000 -693300000 48200000 2167600000 7306000 4600000 535500000 7306000 -540100000 60000000.0 7306000 540100000 2829000 1800000 -106800000 -85000 9500000 255300000 10700000 1101586000 688500000 5640600000 16046300000 -3013200000 -5274000000.0 711000 -80500000 72800000 -204100000 30500000 199000000.0 -24500000 2234600000 4390000 2700000 357100000 4390000 -359800000 -60000000.0 4390000 359800000 3476000 2100000 -164100000 -47000 4700000 281300000 643600000 -643600000 3100000 1100672000 687900000 5817800000 13894100000 -3013200000 -5718600000 664000 -75800000 75700000 3232000000.0 3700000 85600000 -2000000.0 2372000000.0 45882000 28700000 4122000000.0 45882000 -4150700000 45882000 4150700000 2849000 1800000 -139000000.0 -60000 6400000 279500000 763800000 -105200000 629200000 9000000.0 1017200000 3900000 14200000 1057639000 661000000.0 6583600000 11395900000 -3013200000 -5729200000 604000 -69400000 1080400000 3232000000.0 -204100000 2737600000 1609000000.0 1567300000 1496600000 -326800000 787900000 -439500000 279500000 281300000 255300000 1983900000 1112600000 30000000.0 472000000.0 441500000 376100000 996700000 357000000.0 709400000 -7800000 253900000 328200000 980000000.0 590100000 265500000 -125300000 3489600000 -304800000 -284500000 916300000 1123800000 5524500000 5615600000 4851000000.0 1210600000 1076800000 1037000000.0 3600000 40700000 73400000 2552500000 4852500000 1642000000.0 112200000 3389700000 1327400000 3509500000 2586000000.0 2086000000.0 837900000 4611600000 4346000000.0 1807600000 1086800000 55000000.0 0 882100000 45000000.0 191300000 215800000 130100000 1906000000.0 -3783600000 -3139100000 2311800000 2192100000 2158500000 -2197900000 1397500000 1293200000 2477700000 2232000000.0 1206600000 1009100000 630600000 200000 4150700000 299800000 600100000 1659700000 0 0 -372800000 -364400000 -300800000 -5904900000 142600000 -559800000 -63600000 -20500000 -236400000 1462000000.0 1954100000 915700000 6536200000 4582100000 3666400000 7998200000 6536200000 4582100000 Summary of Significant Accounting Policies<div style="line-height:120%;padding-bottom:8px;padding-top:12px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">Basis of presentation</span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (GAAP). The accounts of all wholly-owned and majority-owned subsidiaries are included in the consolidated financial statements. Where our ownership of consolidated subsidiaries is less than 100 percent, the noncontrolling shareholders’ interests are reflected as a separate component of equity. All intercompany balances and transactions have been eliminated.</span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues, expenses, and related disclosures at the date of the financial statements and during the reporting period. Actual results could differ from those estimates. We issued our financial statements by filing with the Securities and Exchange Commission (SEC) and have evaluated subsequent events up to the time of the filing of our Form 10-K.</span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">On September 24, 2018, Elanco Animal Health Incorporated (Elanco), one of our subsidiaries, completed its initial public offering (IPO) of </span><span style="font-family:Arial;font-size:10pt;"><span>72.3 million</span></span><span style="font-family:Arial;font-size:10pt;"> shares of its common stock, which represents </span><span style="font-family:Arial;font-size:10pt;"><span>19.8 percent</span></span><span style="font-family:Arial;font-size:10pt;"> of Elanco's outstanding shares, at </span><span style="font-family:Arial;font-size:10pt;"><span>$24</span></span><span style="font-family:Arial;font-size:10pt;"> per share. On March 11, 2019, we completed the disposition of our remaining </span><span style="font-family:Arial;font-size:10pt;"><span>80.2 percent</span></span><span style="font-family:Arial;font-size:10pt;"> ownership of Elanco common stock through a tax-free exchange offer. As a result, in the first quarter of 2019, we presented Elanco as discontinued operations in our consolidated condensed financial statements for all periods presented. Accordingly, all prior periods have been recast to conform to this presentation.</span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Certain reclassifications have been made to prior periods in the consolidated financial statements and accompanying notes to conform with the current presentation.</span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">All per-share amounts, unless otherwise noted in the footnotes, are presented on a diluted basis.</span></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">Adoption of Revenue Accounting Standard</span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Effective January 1, 2018, we adopted Accounting Standards Update 2014-09, </span><span style="font-family:Arial;font-size:10pt;font-style:italic;">Revenue from Contracts with Customers</span><span style="font-family:Arial;font-size:10pt;"> and other related updates (see Note 2 for additional discussion). The new standard has been applied to contracts for which performance was not substantially complete as of the date of adoption. For those contracts that were modified prior to the date of adoption, we reflected the aggregate effect of those modifications when determining the appropriate accounting under the new standard. We don’t believe the effect of applying this practical expedient resulted in material differences. Revenue presented for periods prior to 2018 was accounted for under previous standards and has not been adjusted. Revenue and net income for </span><span style="font-family:Arial;font-size:10pt;">2018</span><span style="font-family:Arial;font-size:10pt;"> do not differ materially from amounts that would have resulted from application of the previous standards.</span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">The following table summarizes our revenue recognized in our consolidated statements of operations:</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:53%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">2017</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">2016</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Net product revenue</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d8d8d8;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>19,866.4</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>18,776.5</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d8d8d8;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>17,480.0</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Collaboration and other revenue</span><span style="font-family:Arial;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(1)</sup></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>1,626.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>1,197.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>832.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Revenue</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d8d8d8;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#d8d8d8;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>21,493.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#d8d8d8;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d8d8d8;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#d8d8d8;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>19,973.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#d8d8d8;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d8d8d8;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#d8d8d8;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>18,312.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#d8d8d8;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;padding-top:8px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(1) </sup></span><span style="font-family:Arial;font-size:8pt;">Collaboration and other revenue associated with prior year transfers of intellectual property was </span><span style="font-family:Arial;font-size:8pt;"><span>$303.2 million</span></span><span style="font-family:Arial;font-size:8pt;">, </span><span style="font-family:Arial;font-size:8pt;"><span>$144.9 million</span></span><span style="font-family:Arial;font-size:8pt;">, and </span><span style="font-family:Arial;font-size:8pt;"><span>$145.3 million</span></span><span style="font-family:Arial;font-size:8pt;"> during the years ended </span><span style="font-family:Arial;font-size:8pt;">2018</span><span style="font-family:Arial;font-size:8pt;">, </span><span style="font-family:Arial;font-size:8pt;">2017</span><span style="font-family:Arial;font-size:8pt;">, and </span><span style="font-family:Arial;font-size:8pt;">2016</span><span style="font-family:Arial;font-size:8pt;">, respectively.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">We recognize revenue primarily from two different types of contracts, product sales to customers (net product revenue) and collaborations and other arrangements. Revenue recognized from collaborations and other arrangements will include our share of profits from the collaboration, as well as royalties, upfront and milestone payments we receive under these types of contracts. See Note 4 for additional information related to our collaborations and other arrangements. Collaboration and other revenue disclosed above includes the revenue from the Trajenta</span><span style="font-family:Arial;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">®</sup></span><span style="font-family:Arial;font-size:10pt;"> and Jardiance</span><span style="font-family:Arial;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">®</sup></span><span style="font-family:Arial;font-size:10pt;"> families of products resulting from our collaboration with </span></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Boehringer Ingelheim discussed in Note 4. Substantially all of the remainder of collaboration and other revenue is related to contracts accounted for as contracts with customers.</span></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">Net Product Revenue</span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Revenue from sales of products is recognized at the point where the customer obtains control of the goods and we satisfy our performance obligation, which generally is at the time we ship the product to the customer. Payment terms differ by jurisdiction and customer, but payment terms in most of our major jurisdictions typically range from </span><span style="font-family:Arial;font-size:10pt;"><span>30</span></span><span style="font-family:Arial;font-size:10pt;"> to </span><span style="font-family:Arial;font-size:10pt;"><span>70</span></span><span style="font-family:Arial;font-size:10pt;"> days from date of shipment. Revenue for our product sales has not been adjusted for the effects of a financing component as we expect, at contract inception, that the period between when we transfer control of the product and when we receive payment will be one year or less. Any exceptions are either not material or we collect interest for payments made after the due date. Provisions for rebates and discounts, and returns are established in the same period the related sales are recognized. We generally ship product shortly after orders are received; therefore, we generally only have a few days of orders received but not yet shipped at the end of any reporting period. Shipping and handling activities are considered to be fulfillment activities and are not considered to be a separate performance obligation. We exclude from the measurement of the transaction price all taxes assessed by a governmental authority that are imposed on our sales of product and collected from a customer.</span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Significant judgments must be made in determining the transaction price for our sales of products related to anticipated rebates and discounts and returns. The following describe the most significant of these judgments:</span></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;text-decoration:underline;">Sales Rebates and Discounts - Background and Uncertainties</span></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Arial;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Most of our products are sold to wholesalers that serve pharmacies, physicians and other health care professionals, and hospitals. We initially invoice our customers at contractual list prices. Contracts with direct and indirect customers may provide for various rebates and discounts that may differ in each contract. As a consequence, to determine the appropriate transaction price for our product sales at the time we recognize a sale to a direct customer, we must estimate any rebates or discounts that ultimately will be due to the direct customer and other customers in the distribution chain under the terms of our contracts. Significant judgments are required in making these estimates.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Arial;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">The rebate and discount amounts are recorded as a deduction to arrive at our net product revenue. Sales rebates and discounts that require the use of judgment in the establishment of the accrual include managed care, Medicare, Medicaid, chargebacks, long-term care, hospital, patient assistance programs, and various other programs. We estimate these accruals using an expected value approach.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Arial;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">The largest of our sales rebate and discount amounts are rebates associated with sales covered by managed care, Medicare, Medicaid, and chargeback contracts in the United States (U.S.) In determining the appropriate accrual amount, we consider our historical rebate payments for these programs by product as a percentage of our historical sales as well as any significant changes in sales trends (e.g., patent expiries and product launches), an evaluation of the current contracts for these programs, the percentage of our products that are sold via these programs, and our product pricing. Although we accrue a liability for rebates related to these programs at the time we record the sale, the rebate related to that sale is typically paid up to six months later. Because of this time lag, in any particular period our rebate adjustments may incorporate revisions of accruals for several periods.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Arial;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Most of our rebates outside the U.S. are contractual or legislatively mandated and are estimated and recognized in the same period as the related sales. In some large European countries, government rebates are based on the anticipated budget for pharmaceutical payments in the country. An estimate of these rebates, updated as governmental authorities revise budgeted deficits, is recognized in the same period as the related sale.</span></div></td></tr></table><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;text-decoration:underline;">Sales Returns - Background and Uncertainties</span></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Arial;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">When product sales occur, to determine the appropriate transaction price for our sales, we estimate a reserve for future product returns related to those sales using an expected value approach. This estimate is based on several factors, including: historical return rates, expiration date by product (on average, approximately 24 months after the initial sale of a product to our customer), and estimated levels of inventory in the wholesale and retail channels, as well as any other specifically-identified anticipated returns due to known factors such as the loss of patent exclusivity, product recalls and </span></div></td></tr></table><div style="line-height:120%;padding-left:48px;padding-top:8px;text-align:left;"><span style="font-family:Arial;font-size:10pt;">discontinuances, or a changing competitive environment. We maintain a returns policy that allows U.S. customers to return product for dating issues within a specified period prior to and subsequent to the product's expiration date. Following the loss of exclusivity for a patent-dependent product, we expect to experience an elevated level of product returns as product inventory remaining in the wholesale and retail channels expires. Adjustments to the returns reserve have been and may in the future be required based on revised estimates to our assumptions. We record the return amounts as a deduction to arrive at our net product revenue. Once the product is returned, it is destroyed; we do not record a right of return asset. Our returns policies outside the U.S. are generally more restrictive than in the U.S. as returns are not allowed for reasons other than failure to meet product specifications in many countries. Our reserve for future product returns for product sales outside the U.S. is not material.</span></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Arial;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">As a part of our process to estimate a reserve for product returns, we regularly review the supply levels of our significant products sold to major wholesalers in the U.S. and in major markets outside the U.S., primarily by reviewing periodic inventory reports supplied by our major wholesalers and available prescription volume information for our products, or alternative approaches. We attempt to maintain U.S. wholesaler inventory levels at an average of approximately one month or less on a consistent basis across our product portfolio. Causes of unusual wholesaler buying patterns include actual or anticipated product-supply issues, weather patterns, anticipated changes in the transportation network, redundant holiday stocking, and changes in wholesaler business operations. In the U.S., the current structure of our arrangements provides us with data on inventory levels at our wholesalers; however, our data on inventory levels in the retail channel is more limited. Wholesaler stocking and destocking activity historically has not caused any material changes in the rate of actual product returns.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Arial;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Actual product returns have been less than 2 percent of our net revenue over each of the past three years and have not fluctuated significantly as a percentage of revenue, although fluctuations are more likely in periods following loss of patent exclusivity for major products in the U.S. market. </span></div></td></tr></table><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;text-decoration:underline;">Adjustments to Revenue</span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Adjustments to revenue recognized as a result of changes in estimates for the judgments described above during </span><span style="font-family:Arial;font-size:10pt;">2018</span><span style="font-family:Arial;font-size:10pt;"> for product shipped in previous years were approximately </span><span style="font-family:Arial;font-size:10pt;">1 percent</span><span style="font-family:Arial;font-size:10pt;"> of revenue.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;text-decoration:underline;">Disaggregation of Revenue</span><span style="font-family:Arial;font-size:10pt;"> </span></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Our disaggregated revenue is disclosed in Note 18.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">Collaborations and Other Arrangements</span></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">We recognize several types of revenue from our collaborations and other arrangements, which we discuss in general terms immediately below and more specifically in Note 4 for each of our material collaborations and other arrangements. Our collaborations and other arrangements are not contracts with customers but are evaluated to determine whether any aspects of the arrangements are contracts with customers. </span></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Arial;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Revenue related to products we sell pursuant to these arrangements is included in net product revenue, while other sources of revenue (e.g., royalties and profit sharing from our partner) are included in collaboration and other revenue.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Arial;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Initial fees and developmental milestones we receive in collaborative and other similar arrangements from the partnering of our compounds under development are generally deferred and amortized into income through the expected product approval date. </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Arial;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Profit-sharing due from our collaboration partners, which is based upon gross margins reported to us by our partners, is recognized as collaboration and other revenue as earned.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Arial;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Royalty revenue from licensees, which is based on sales to third-parties of licensed products and technology, is recorded when the third-party sale occurs and the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). This royalty revenue is included in collaboration and other revenue.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Arial;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">For arrangements involving multiple goods or services (e.g., research and development, marketing and selling, manufacturing, and distribution), each required good or service is evaluated to determine whether it is distinct. If a good or service does not qualify as distinct, it is combined with the other non-distinct goods or services within the arrangement and these combined goods or services are </span></div></td></tr></table><div style="line-height:120%;padding-left:48px;padding-top:8px;text-align:left;"><span style="font-family:Arial;font-size:10pt;">treated as a single performance obligation for accounting purposes. The arrangement's transaction price is then allocated to each performance obligation based on the relative standalone selling price of each performance obligation. For arrangements that involve variable consideration where we have sold intellectual property, we recognize revenue based on estimates of the amount of consideration we believe we will be entitled to receive from the other party, subject to a constraint. These estimates are adjusted to reflect the actual amounts to be collected when those facts and circumstances become known.</span></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Arial;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Significant judgments must be made in determining the transaction price for our sales of intellectual property. Because of the risk that products in development will not receive regulatory approval, we generally do not recognize any contingent payments that would be due to us upon or after regulatory approval. </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Arial;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">We have entered into arrangements whereby we transferred rights to products and committed to supply for a period of time. For those arrangements for which we concluded that the obligations were not distinct, any amounts received upfront are being amortized to revenue as net product revenue over the period of the supply arrangement as the performance obligation is satisfied.</span></div></td></tr></table><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;text-decoration:underline;">Contract Liabilities</span></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Our contract liabilities result from arrangements where we have received payment in advance of performance under the contract and do not include sales rebates, discounts, and returns. Changes in contract liabilities are generally due to either receipt of additional advance payments or our performance under the contract. </span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">We have the following amounts recorded for contract liabilities:</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:51%;"/><td style="width:1%;"/><td style="width:22%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:22%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#d1d1d1;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Contract liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d1d1d1;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#d1d1d1;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>294.9</span></span></div></td><td style="vertical-align:bottom;background-color:#d1d1d1;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d1d1d1;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d1d1d1;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#d1d1d1;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>330.9</span></span></div></td><td style="vertical-align:bottom;background-color:#d1d1d1;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">The contract liabilities amount disclosed above as of </span><span style="font-family:Arial;font-size:10pt;">December 31, 2018</span><span style="font-family:Arial;font-size:10pt;"> and 2017, are primarily related to:</span></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Arial;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">The remaining license period of symbolic intellectual property, and </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Arial;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Obligations to supply product for a defined period of time.</span></div></td></tr></table><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Revenue recognized from contract liabilities as of January 1, </span><span style="font-family:Arial;font-size:10pt;">2018</span><span style="font-family:Arial;font-size:10pt;">, during the year ended </span><span style="font-family:Arial;font-size:10pt;">December 31, 2018</span><span style="font-family:Arial;font-size:10pt;"> was not material. Revenue expected to be recognized in the future from contract liabilities as the related performance obligations are satisfied is not expected to be material in any one year.</span></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">Research and development expenses and acquired in-process research and development</span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Research and development expenses include the following:</span></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Arial;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Research and development costs, which are expensed as incurred.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Arial;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Milestone payment obligations incurred prior to regulatory approval of the product, which are accrued when the event requiring payment of the milestone occurs.</span></div></td></tr></table><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Acquired in-process research and development (IPR&D) expense includes the initial costs of IPR&D projects, acquired directly in a transaction other than a business combination, that do not have an alternative future use.</span></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">Earnings per share</span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">We calculate basic earnings per share (EPS) based on the weighted-average number of common shares outstanding and incremental shares from potential participating securities. We calculate diluted EPS based on the weighted-average number of common shares outstanding, including incremental shares from our stock-based compensation programs. </span></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">Foreign Currency Translation</span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Operations in our subsidiaries outside the U.S. are recorded in the functional currency of each subsidiary which is determined by a review of the environment where each subsidiary primarily generates and expends cash. The results of operations for our subsidiaries outside the U.S. are translated from functional currencies into U.S. dollars using the weighted average currency rate for the period. Assets and liabilities are translated </span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">using the period end exchange rates. The U.S. dollar effects that arise from translating the net assets of these subsidiaries are recorded in other comprehensive income (loss).</span></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">Other significant accounting policies</span></div><div style="line-height:120%;padding-bottom:16px;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Our other significant accounting policies are described in the remaining appropriate notes to the consolidated financial statements.</span></div> 72300000 0.198 24 0.802 <div style="line-height:120%;padding-top:12px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">Adoption of Revenue Accounting Standard</span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Effective January 1, 2018, we adopted Accounting Standards Update 2014-09, </span><span style="font-family:Arial;font-size:10pt;font-style:italic;">Revenue from Contracts with Customers</span><span style="font-family:Arial;font-size:10pt;"> and other related updates (see Note 2 for additional discussion). The new standard has been applied to contracts for which performance was not substantially complete as of the date of adoption. For those contracts that were modified prior to the date of adoption, we reflected the aggregate effect of those modifications when determining the appropriate accounting under the new standard. We don’t believe the effect of applying this practical expedient resulted in material differences. Revenue presented for periods prior to 2018 was accounted for under previous standards and has not been adjusted. Revenue and net income for </span><span style="font-family:Arial;font-size:10pt;">2018</span><span style="font-family:Arial;font-size:10pt;"> do not differ materially from amounts that would have resulted from application of the previous standards.</span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">The following table summarizes our revenue recognized in our consolidated statements of operations:</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:53%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">2017</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">2016</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Net product revenue</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d8d8d8;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>19,866.4</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>18,776.5</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d8d8d8;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>17,480.0</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Collaboration and other revenue</span><span style="font-family:Arial;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(1)</sup></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>1,626.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>1,197.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>832.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Revenue</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d8d8d8;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#d8d8d8;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>21,493.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#d8d8d8;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d8d8d8;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#d8d8d8;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>19,973.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#d8d8d8;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d8d8d8;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#d8d8d8;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>18,312.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#d8d8d8;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;padding-top:8px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(1) </sup></span><span style="font-family:Arial;font-size:8pt;">Collaboration and other revenue associated with prior year transfers of intellectual property was </span><span style="font-family:Arial;font-size:8pt;"><span>$303.2 million</span></span><span style="font-family:Arial;font-size:8pt;">, </span><span style="font-family:Arial;font-size:8pt;"><span>$144.9 million</span></span><span style="font-family:Arial;font-size:8pt;">, and </span><span style="font-family:Arial;font-size:8pt;"><span>$145.3 million</span></span><span style="font-family:Arial;font-size:8pt;"> during the years ended </span><span style="font-family:Arial;font-size:8pt;">2018</span><span style="font-family:Arial;font-size:8pt;">, </span><span style="font-family:Arial;font-size:8pt;">2017</span><span style="font-family:Arial;font-size:8pt;">, and </span><span style="font-family:Arial;font-size:8pt;">2016</span><span style="font-family:Arial;font-size:8pt;">, respectively.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">We recognize revenue primarily from two different types of contracts, product sales to customers (net product revenue) and collaborations and other arrangements. Revenue recognized from collaborations and other arrangements will include our share of profits from the collaboration, as well as royalties, upfront and milestone payments we receive under these types of contracts. See Note 4 for additional information related to our collaborations and other arrangements. Collaboration and other revenue disclosed above includes the revenue from the Trajenta</span><span style="font-family:Arial;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">®</sup></span><span style="font-family:Arial;font-size:10pt;"> and Jardiance</span><span style="font-family:Arial;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">®</sup></span><span style="font-family:Arial;font-size:10pt;"> families of products resulting from our collaboration with </span></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Boehringer Ingelheim discussed in Note 4. Substantially all of the remainder of collaboration and other revenue is related to contracts accounted for as contracts with customers.</span></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">Net Product Revenue</span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Revenue from sales of products is recognized at the point where the customer obtains control of the goods and we satisfy our performance obligation, which generally is at the time we ship the product to the customer. Payment terms differ by jurisdiction and customer, but payment terms in most of our major jurisdictions typically range from </span><span style="font-family:Arial;font-size:10pt;"><span>30</span></span><span style="font-family:Arial;font-size:10pt;"> to </span><span style="font-family:Arial;font-size:10pt;"><span>70</span></span><span style="font-family:Arial;font-size:10pt;"> days from date of shipment. Revenue for our product sales has not been adjusted for the effects of a financing component as we expect, at contract inception, that the period between when we transfer control of the product and when we receive payment will be one year or less. Any exceptions are either not material or we collect interest for payments made after the due date. Provisions for rebates and discounts, and returns are established in the same period the related sales are recognized. We generally ship product shortly after orders are received; therefore, we generally only have a few days of orders received but not yet shipped at the end of any reporting period. Shipping and handling activities are considered to be fulfillment activities and are not considered to be a separate performance obligation. We exclude from the measurement of the transaction price all taxes assessed by a governmental authority that are imposed on our sales of product and collected from a customer.</span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Significant judgments must be made in determining the transaction price for our sales of products related to anticipated rebates and discounts and returns. The following describe the most significant of these judgments:</span></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;text-decoration:underline;">Sales Rebates and Discounts - Background and Uncertainties</span></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Arial;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Most of our products are sold to wholesalers that serve pharmacies, physicians and other health care professionals, and hospitals. We initially invoice our customers at contractual list prices. Contracts with direct and indirect customers may provide for various rebates and discounts that may differ in each contract. As a consequence, to determine the appropriate transaction price for our product sales at the time we recognize a sale to a direct customer, we must estimate any rebates or discounts that ultimately will be due to the direct customer and other customers in the distribution chain under the terms of our contracts. Significant judgments are required in making these estimates.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Arial;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">The rebate and discount amounts are recorded as a deduction to arrive at our net product revenue. Sales rebates and discounts that require the use of judgment in the establishment of the accrual include managed care, Medicare, Medicaid, chargebacks, long-term care, hospital, patient assistance programs, and various other programs. We estimate these accruals using an expected value approach.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Arial;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">The largest of our sales rebate and discount amounts are rebates associated with sales covered by managed care, Medicare, Medicaid, and chargeback contracts in the United States (U.S.) In determining the appropriate accrual amount, we consider our historical rebate payments for these programs by product as a percentage of our historical sales as well as any significant changes in sales trends (e.g., patent expiries and product launches), an evaluation of the current contracts for these programs, the percentage of our products that are sold via these programs, and our product pricing. Although we accrue a liability for rebates related to these programs at the time we record the sale, the rebate related to that sale is typically paid up to six months later. Because of this time lag, in any particular period our rebate adjustments may incorporate revisions of accruals for several periods.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Arial;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Most of our rebates outside the U.S. are contractual or legislatively mandated and are estimated and recognized in the same period as the related sales. In some large European countries, government rebates are based on the anticipated budget for pharmaceutical payments in the country. An estimate of these rebates, updated as governmental authorities revise budgeted deficits, is recognized in the same period as the related sale.</span></div></td></tr></table><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;text-decoration:underline;">Sales Returns - Background and Uncertainties</span></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Arial;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">When product sales occur, to determine the appropriate transaction price for our sales, we estimate a reserve for future product returns related to those sales using an expected value approach. This estimate is based on several factors, including: historical return rates, expiration date by product (on average, approximately 24 months after the initial sale of a product to our customer), and estimated levels of inventory in the wholesale and retail channels, as well as any other specifically-identified anticipated returns due to known factors such as the loss of patent exclusivity, product recalls and </span></div></td></tr></table><div style="line-height:120%;padding-left:48px;padding-top:8px;text-align:left;"><span style="font-family:Arial;font-size:10pt;">discontinuances, or a changing competitive environment. We maintain a returns policy that allows U.S. customers to return product for dating issues within a specified period prior to and subsequent to the product's expiration date. Following the loss of exclusivity for a patent-dependent product, we expect to experience an elevated level of product returns as product inventory remaining in the wholesale and retail channels expires. Adjustments to the returns reserve have been and may in the future be required based on revised estimates to our assumptions. We record the return amounts as a deduction to arrive at our net product revenue. Once the product is returned, it is destroyed; we do not record a right of return asset. Our returns policies outside the U.S. are generally more restrictive than in the U.S. as returns are not allowed for reasons other than failure to meet product specifications in many countries. Our reserve for future product returns for product sales outside the U.S. is not material.</span></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Arial;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">As a part of our process to estimate a reserve for product returns, we regularly review the supply levels of our significant products sold to major wholesalers in the U.S. and in major markets outside the U.S., primarily by reviewing periodic inventory reports supplied by our major wholesalers and available prescription volume information for our products, or alternative approaches. We attempt to maintain U.S. wholesaler inventory levels at an average of approximately one month or less on a consistent basis across our product portfolio. Causes of unusual wholesaler buying patterns include actual or anticipated product-supply issues, weather patterns, anticipated changes in the transportation network, redundant holiday stocking, and changes in wholesaler business operations. In the U.S., the current structure of our arrangements provides us with data on inventory levels at our wholesalers; however, our data on inventory levels in the retail channel is more limited. Wholesaler stocking and destocking activity historically has not caused any material changes in the rate of actual product returns.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Arial;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Actual product returns have been less than 2 percent of our net revenue over each of the past three years and have not fluctuated significantly as a percentage of revenue, although fluctuations are more likely in periods following loss of patent exclusivity for major products in the U.S. market. </span></div></td></tr></table><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;text-decoration:underline;">Adjustments to Revenue</span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Adjustments to revenue recognized as a result of changes in estimates for the judgments described above during </span><span style="font-family:Arial;font-size:10pt;">2018</span><span style="font-family:Arial;font-size:10pt;"> for product shipped in previous years were approximately </span><span style="font-family:Arial;font-size:10pt;">1 percent</span><span style="font-family:Arial;font-size:10pt;"> of revenue.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;text-decoration:underline;">Disaggregation of Revenue</span><span style="font-family:Arial;font-size:10pt;"> </span></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Our disaggregated revenue is disclosed in Note 18.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">Collaborations and Other Arrangements</span></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">We recognize several types of revenue from our collaborations and other arrangements, which we discuss in general terms immediately below and more specifically in Note 4 for each of our material collaborations and other arrangements. Our collaborations and other arrangements are not contracts with customers but are evaluated to determine whether any aspects of the arrangements are contracts with customers. </span></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Arial;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Revenue related to products we sell pursuant to these arrangements is included in net product revenue, while other sources of revenue (e.g., royalties and profit sharing from our partner) are included in collaboration and other revenue.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Arial;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Initial fees and developmental milestones we receive in collaborative and other similar arrangements from the partnering of our compounds under development are generally deferred and amortized into income through the expected product approval date. </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Arial;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Profit-sharing due from our collaboration partners, which is based upon gross margins reported to us by our partners, is recognized as collaboration and other revenue as earned.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Arial;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Royalty revenue from licensees, which is based on sales to third-parties of licensed products and technology, is recorded when the third-party sale occurs and the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). This royalty revenue is included in collaboration and other revenue.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Arial;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">For arrangements involving multiple goods or services (e.g., research and development, marketing and selling, manufacturing, and distribution), each required good or service is evaluated to determine whether it is distinct. If a good or service does not qualify as distinct, it is combined with the other non-distinct goods or services within the arrangement and these combined goods or services are </span></div></td></tr></table><div style="line-height:120%;padding-left:48px;padding-top:8px;text-align:left;"><span style="font-family:Arial;font-size:10pt;">treated as a single performance obligation for accounting purposes. The arrangement's transaction price is then allocated to each performance obligation based on the relative standalone selling price of each performance obligation. For arrangements that involve variable consideration where we have sold intellectual property, we recognize revenue based on estimates of the amount of consideration we believe we will be entitled to receive from the other party, subject to a constraint. These estimates are adjusted to reflect the actual amounts to be collected when those facts and circumstances become known.</span></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Arial;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Significant judgments must be made in determining the transaction price for our sales of intellectual property. Because of the risk that products in development will not receive regulatory approval, we generally do not recognize any contingent payments that would be due to us upon or after regulatory approval. </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Arial;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">We have entered into arrangements whereby we transferred rights to products and committed to supply for a period of time. For those arrangements for which we concluded that the obligations were not distinct, any amounts received upfront are being amortized to revenue as net product revenue over the period of the supply arrangement as the performance obligation is satisfied.</span></div></td></tr></table><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;text-decoration:underline;">Contract Liabilities</span></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Our contract liabilities result from arrangements where we have received payment in advance of performance under the contract and do not include sales rebates, discounts, and returns. Changes in contract liabilities are generally due to either receipt of additional advance payments or our performance under the contract. </span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">We have the following amounts recorded for contract liabilities:</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:51%;"/><td style="width:1%;"/><td style="width:22%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:22%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#d1d1d1;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Contract liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d1d1d1;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#d1d1d1;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>294.9</span></span></div></td><td style="vertical-align:bottom;background-color:#d1d1d1;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d1d1d1;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d1d1d1;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#d1d1d1;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>330.9</span></span></div></td><td style="vertical-align:bottom;background-color:#d1d1d1;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">The contract liabilities amount disclosed above as of </span><span style="font-family:Arial;font-size:10pt;">December 31, 2018</span><span style="font-family:Arial;font-size:10pt;"> and 2017, are primarily related to:</span></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Arial;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">The remaining license period of symbolic intellectual property, and </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Arial;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Obligations to supply product for a defined period of time.</span></div></td></tr></table><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Revenue recognized from contract liabilities as of January 1, </span><span style="font-family:Arial;font-size:10pt;">2018</span><span style="font-family:Arial;font-size:10pt;">, during the year ended </span><span style="font-family:Arial;font-size:10pt;">December 31, 2018</span><span style="font-family:Arial;font-size:10pt;"> was not material. Revenue expected to be recognized in the future from contract liabilities as the related performance obligations are satisfied is not expected to be material in any one year.</span></div> <div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">The following table summarizes our revenue recognized in our consolidated statements of operations:</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:53%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">2017</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">2016</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Net product revenue</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d8d8d8;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>19,866.4</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>18,776.5</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d8d8d8;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>17,480.0</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Collaboration and other revenue</span><span style="font-family:Arial;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(1)</sup></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>1,626.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>1,197.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>832.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Revenue</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d8d8d8;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#d8d8d8;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>21,493.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#d8d8d8;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d8d8d8;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#d8d8d8;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>19,973.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#d8d8d8;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d8d8d8;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#d8d8d8;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>18,312.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#d8d8d8;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;padding-top:8px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(1) </sup></span><span style="font-family:Arial;font-size:8pt;">Collaboration and other revenue associated with prior year transfers of intellectual property was </span><span style="font-family:Arial;font-size:8pt;"><span>$303.2 million</span></span><span style="font-family:Arial;font-size:8pt;">, </span><span style="font-family:Arial;font-size:8pt;"><span>$144.9 million</span></span><span style="font-family:Arial;font-size:8pt;">, and </span><span style="font-family:Arial;font-size:8pt;"><span>$145.3 million</span></span><span style="font-family:Arial;font-size:8pt;"> during the years ended </span><span style="font-family:Arial;font-size:8pt;">2018</span><span style="font-family:Arial;font-size:8pt;">, </span><span style="font-family:Arial;font-size:8pt;">2017</span><span style="font-family:Arial;font-size:8pt;">, and </span><span style="font-family:Arial;font-size:8pt;">2016</span><span style="font-family:Arial;font-size:8pt;">, respectively.</span></div> 19866400000 18776500000 17480000000.0 1626900000 1197300000 832800000 21493300000 19973800000 18312800000 303200000 144900000 145300000 P30D P70D <div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">We have the following amounts recorded for contract liabilities:</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:51%;"/><td style="width:1%;"/><td style="width:22%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:22%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#d1d1d1;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Contract liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d1d1d1;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#d1d1d1;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>294.9</span></span></div></td><td style="vertical-align:bottom;background-color:#d1d1d1;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d1d1d1;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d1d1d1;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#d1d1d1;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>330.9</span></span></div></td><td style="vertical-align:bottom;background-color:#d1d1d1;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 294900000 330900000 <div style="line-height:120%;padding-top:12px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">Research and development expenses and acquired in-process research and development</span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Research and development expenses include the following:</span></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Arial;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Research and development costs, which are expensed as incurred.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Arial;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Milestone payment obligations incurred prior to regulatory approval of the product, which are accrued when the event requiring payment of the milestone occurs.</span></div></td></tr></table><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Acquired in-process research and development (IPR&D) expense includes the initial costs of IPR&D projects, acquired directly in a transaction other than a business combination, that do not have an alternative future use.</span></div> <div style="line-height:120%;padding-top:12px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">Earnings per share</span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">We calculate basic earnings per share (EPS) based on the weighted-average number of common shares outstanding and incremental shares from potential participating securities. We calculate diluted EPS based on the weighted-average number of common shares outstanding, including incremental shares from our stock-based compensation programs. </span></div> <div style="line-height:120%;padding-top:12px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">Foreign Currency Translation</span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Operations in our subsidiaries outside the U.S. are recorded in the functional currency of each subsidiary which is determined by a review of the environment where each subsidiary primarily generates and expends cash. The results of operations for our subsidiaries outside the U.S. are translated from functional currencies into U.S. dollars using the weighted average currency rate for the period. Assets and liabilities are translated </span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">using the period end exchange rates. The U.S. dollar effects that arise from translating the net assets of these subsidiaries are recorded in other comprehensive income (loss).</span></div> Implementation of New Financial Accounting Pronouncements<div style="line-height:120%;padding-top:12px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">The following table provides a brief description of accounting standards that were effective January 1, 2018 and were adopted on that date:</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"/></tr><tr><td style="width:30%;"/><td style="width:1%;"/><td style="width:35%;"/><td style="width:1%;"/><td style="width:33%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Standard</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Description</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Effect on the financial statements or other significant matters</span></div></td></tr><tr><td style="vertical-align:top;background-color:#d1d1d1;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Accounting Standards Update 2014-09 and various other related updates, </span><span style="font-family:Arial;font-size:10pt;font-style:italic;">Revenue from Contracts with Customers</span></div></td><td style="vertical-align:bottom;background-color:#d1d1d1;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;background-color:#d1d1d1;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">This standard replaced existing revenue recognition standards and requires entities to recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. An entity can apply the new revenue standard retrospectively to each prior reporting period presented or with the cumulative effect of initially applying the standard recognized at the date of initial application in retained earnings. We applied the latter approach.</span></div></td><td style="vertical-align:bottom;background-color:#d1d1d1;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;background-color:#d1d1d1;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Application of the new standard to applicable contracts resulted in an increase of approximately $5 million to retained earnings as of January 1, 2018. Disclosures required by the new standard are included in Note 1, Note 4, and Note 18.</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Accounting Standards Update 2016-01, </span><span style="font-family:Arial;font-size:10pt;font-style:italic;">Financial Instruments - Overall: Recognition and Measurement of Financial Assets and Financial Liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">This standard requires entities to recognize changes in the fair value of equity investments with readily determinable fair values in net income (except for investments accounted for under the equity method of accounting or those that result in consolidation of the investee). An entity should apply the new standard through a cumulative effect adjustment to retained earnings as of the beginning of the fiscal year of adoption.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Upon adoption, we reclassified from accumulated other comprehensive loss the after-tax amount of net unrealized gains resulting in an increase to retained earnings of approximately $105 million. Adoption of this standard did not result in a material change in net income in 2018.</span></div></td></tr><tr><td style="vertical-align:top;background-color:#d1d1d1;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Accounting Standards Update 2016-16, </span><span style="font-family:Arial;font-size:10pt;font-style:italic;">Income Taxes: Intra-Entity Transfers of Assets Other Than Inventory</span></div></td><td style="vertical-align:bottom;background-color:#d1d1d1;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;background-color:#d1d1d1;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:13px;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">This standard requires entities to recognize the income tax consequences of intra-entity transfers of assets other than inventory at the time of transfer. This standard requires a modified<br/>retrospective approach to adoption.</span></div></td><td style="vertical-align:bottom;background-color:#d1d1d1;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;background-color:#d1d1d1;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Upon adoption, the cumulative effect of applying the standard resulted in an increase of approximately $700 million to retained earnings, $2.5 billion to deferred tax assets, and $1.8 billion to deferred tax liabilities. Adoption of this standard did not result in a material change in net income in 2018.</span></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"/></tr><tr><td style="width:30%;"/><td style="width:1%;"/><td style="width:35%;"/><td style="width:1%;"/><td style="width:33%;"/></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Accounting Standards Update 2017-07, </span><span style="font-family:Arial;font-size:10pt;font-style:italic;">Compensation-Retirement Benefits: Improving the Presentation of Net Periodic Pension Cost and Net Periodic Postretirement Benefit Cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:13px;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">This standard was issued to improve the transparency and comparability among organizations by requiring entities to separate their net periodic pension cost and net periodic postretirement benefit cost into a service cost component and other components. Previously, the costs of the other components along with the service cost component were classified based upon the function of the employee. This standard requires entities to classify the service cost component in the same financial statement line item or items as other compensation costs arising from services rendered by pertinent employees. The other components of net benefit cost are now presented separately from the line items that include the service cost component. When applicable, the service cost component is now the only component eligible for capitalization. An entity should apply the new standard retrospectively for the classification of the service cost and other components and prospectively for the capitalization of the service cost component. </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Upon adoption of this standard, pension and postretirement benefit cost components other than service costs are presented in other–net, (income) expense. The application of the new standard resulted in reclassification to other income of $249.0 million for the year ended December 31, 2017, while increasing cost of sales by $80.8 million, research and development expenses by $75.8 million, and marketing, selling, and administrative expenses by $92.4 million for the same period. The application of the new standard resulted in reclassification to other income of $197.1 million for the year ended December 31, 2016, while increasing cost of sales by $54.2 million, research and development expenses by $66.4 million, and marketing, selling, and administrative expenses by $76.5 million for the same period. We do not expect application of the new standard to have a material impact on an ongoing basis.</span></div><div style="font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">We elected to early adopt Accounting Standards Update 2018-02, </span><span style="font-family:Arial;font-size:10pt;font-style:italic;">Income Statement-Reporting Comprehensive Income: Reclassification of Certain Tax Effects from Accumulated Other Comprehensive Income </span><span style="font-family:Arial;font-size:10pt;">as of December 31, 2017, which allowed a reclassification from accumulated other comprehensive loss to retained earnings for stranded tax effects resulting from the Tax Cuts and Jobs Act (2017 Tax Act - see Note 13). This standard allowed us to reclassify the effect of remeasuring deferred tax liabilities and assets related to items within accumulated other comprehensive loss using the then newly enacted 21 percent federal corporate income tax rate. The provisional effect of this early adoption was a reclassification from accumulated other comprehensive loss, which resulted in an increase to retained earnings of </span><span style="font-family:Arial;font-size:10pt;"><span>$643.6 million</span></span><span style="font-family:Arial;font-size:10pt;"> as of December 31, 2017.</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">The following table provides a brief description of the accounting standard that had not yet been adopted as of December 31, 2018:</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="7"/></tr><tr><td style="width:12%;"/><td style="width:1%;"/><td style="width:39%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/><td style="width:31%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Standard</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Description</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Effective Date</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Effect on the financial statements or other significant matters</span></div></td></tr><tr><td style="vertical-align:top;background-color:#d1d1d1;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Accounting Standards Update 2016-02, </span><span style="font-family:Arial;font-size:10pt;font-style:italic;">Leases</span></div></td><td style="vertical-align:bottom;background-color:#d1d1d1;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;background-color:#d1d1d1;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:13px;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">This standard was issued to increase transparency and comparability among organizations by recognizing lease assets and lease liabilities, including leases classified as operating leases under current GAAP, on the balance sheet and requiring additional disclosures about leasing arrangements. An entity can apply the new leases standard retrospectively to each prior reporting period presented or with the cumulative effect of initially applying the standard recognized at the date of initial application in retained earnings. We plan to use the latter approach.</span></div></td><td style="vertical-align:bottom;background-color:#d1d1d1;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;background-color:#d1d1d1;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">This standard was effective January 1, 2019, and we adopted on that date.</span></div></td><td style="vertical-align:bottom;background-color:#d1d1d1;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;background-color:#d1d1d1;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">We expect to record a right-of-use asset and lease liability for operating leases of approximately $575 million on our consolidated balance sheet as of January 1, 2019. Our accounting for capital leases will remain substantially unchanged. This standard will not have a material impact on our consolidated statement of operations. </span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> <div style="line-height:120%;padding-top:12px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">The following table provides a brief description of accounting standards that were effective January 1, 2018 and were adopted on that date:</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"/></tr><tr><td style="width:30%;"/><td style="width:1%;"/><td style="width:35%;"/><td style="width:1%;"/><td style="width:33%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Standard</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Description</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Effect on the financial statements or other significant matters</span></div></td></tr><tr><td style="vertical-align:top;background-color:#d1d1d1;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Accounting Standards Update 2014-09 and various other related updates, </span><span style="font-family:Arial;font-size:10pt;font-style:italic;">Revenue from Contracts with Customers</span></div></td><td style="vertical-align:bottom;background-color:#d1d1d1;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;background-color:#d1d1d1;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">This standard replaced existing revenue recognition standards and requires entities to recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. An entity can apply the new revenue standard retrospectively to each prior reporting period presented or with the cumulative effect of initially applying the standard recognized at the date of initial application in retained earnings. We applied the latter approach.</span></div></td><td style="vertical-align:bottom;background-color:#d1d1d1;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;background-color:#d1d1d1;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Application of the new standard to applicable contracts resulted in an increase of approximately $5 million to retained earnings as of January 1, 2018. Disclosures required by the new standard are included in Note 1, Note 4, and Note 18.</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Accounting Standards Update 2016-01, </span><span style="font-family:Arial;font-size:10pt;font-style:italic;">Financial Instruments - Overall: Recognition and Measurement of Financial Assets and Financial Liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">This standard requires entities to recognize changes in the fair value of equity investments with readily determinable fair values in net income (except for investments accounted for under the equity method of accounting or those that result in consolidation of the investee). An entity should apply the new standard through a cumulative effect adjustment to retained earnings as of the beginning of the fiscal year of adoption.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Upon adoption, we reclassified from accumulated other comprehensive loss the after-tax amount of net unrealized gains resulting in an increase to retained earnings of approximately $105 million. Adoption of this standard did not result in a material change in net income in 2018.</span></div></td></tr><tr><td style="vertical-align:top;background-color:#d1d1d1;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Accounting Standards Update 2016-16, </span><span style="font-family:Arial;font-size:10pt;font-style:italic;">Income Taxes: Intra-Entity Transfers of Assets Other Than Inventory</span></div></td><td style="vertical-align:bottom;background-color:#d1d1d1;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;background-color:#d1d1d1;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:13px;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">This standard requires entities to recognize the income tax consequences of intra-entity transfers of assets other than inventory at the time of transfer. This standard requires a modified<br/>retrospective approach to adoption.</span></div></td><td style="vertical-align:bottom;background-color:#d1d1d1;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;background-color:#d1d1d1;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Upon adoption, the cumulative effect of applying the standard resulted in an increase of approximately $700 million to retained earnings, $2.5 billion to deferred tax assets, and $1.8 billion to deferred tax liabilities. Adoption of this standard did not result in a material change in net income in 2018.</span></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"/></tr><tr><td style="width:30%;"/><td style="width:1%;"/><td style="width:35%;"/><td style="width:1%;"/><td style="width:33%;"/></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Accounting Standards Update 2017-07, </span><span style="font-family:Arial;font-size:10pt;font-style:italic;">Compensation-Retirement Benefits: Improving the Presentation of Net Periodic Pension Cost and Net Periodic Postretirement Benefit Cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:13px;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">This standard was issued to improve the transparency and comparability among organizations by requiring entities to separate their net periodic pension cost and net periodic postretirement benefit cost into a service cost component and other components. Previously, the costs of the other components along with the service cost component were classified based upon the function of the employee. This standard requires entities to classify the service cost component in the same financial statement line item or items as other compensation costs arising from services rendered by pertinent employees. The other components of net benefit cost are now presented separately from the line items that include the service cost component. When applicable, the service cost component is now the only component eligible for capitalization. An entity should apply the new standard retrospectively for the classification of the service cost and other components and prospectively for the capitalization of the service cost component. </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Upon adoption of this standard, pension and postretirement benefit cost components other than service costs are presented in other–net, (income) expense. The application of the new standard resulted in reclassification to other income of $249.0 million for the year ended December 31, 2017, while increasing cost of sales by $80.8 million, research and development expenses by $75.8 million, and marketing, selling, and administrative expenses by $92.4 million for the same period. The application of the new standard resulted in reclassification to other income of $197.1 million for the year ended December 31, 2016, while increasing cost of sales by $54.2 million, research and development expenses by $66.4 million, and marketing, selling, and administrative expenses by $76.5 million for the same period. We do not expect application of the new standard to have a material impact on an ongoing basis.</span></div><div style="font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">We elected to early adopt Accounting Standards Update 2018-02, </span><span style="font-family:Arial;font-size:10pt;font-style:italic;">Income Statement-Reporting Comprehensive Income: Reclassification of Certain Tax Effects from Accumulated Other Comprehensive Income </span><span style="font-family:Arial;font-size:10pt;">as of December 31, 2017, which allowed a reclassification from accumulated other comprehensive loss to retained earnings for stranded tax effects resulting from the Tax Cuts and Jobs Act (2017 Tax Act - see Note 13). This standard allowed us to reclassify the effect of remeasuring deferred tax liabilities and assets related to items within accumulated other comprehensive loss using the then newly enacted 21 percent federal corporate income tax rate. The provisional effect of this early adoption was a reclassification from accumulated other comprehensive loss, which resulted in an increase to retained earnings of </span><span style="font-family:Arial;font-size:10pt;"><span>$643.6 million</span></span><span style="font-family:Arial;font-size:10pt;"> as of December 31, 2017.</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">The following table provides a brief description of the accounting standard that had not yet been adopted as of December 31, 2018:</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="7"/></tr><tr><td style="width:12%;"/><td style="width:1%;"/><td style="width:39%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/><td style="width:31%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Standard</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Description</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Effective Date</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Effect on the financial statements or other significant matters</span></div></td></tr><tr><td style="vertical-align:top;background-color:#d1d1d1;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Accounting Standards Update 2016-02, </span><span style="font-family:Arial;font-size:10pt;font-style:italic;">Leases</span></div></td><td style="vertical-align:bottom;background-color:#d1d1d1;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;background-color:#d1d1d1;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:13px;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">This standard was issued to increase transparency and comparability among organizations by recognizing lease assets and lease liabilities, including leases classified as operating leases under current GAAP, on the balance sheet and requiring additional disclosures about leasing arrangements. An entity can apply the new leases standard retrospectively to each prior reporting period presented or with the cumulative effect of initially applying the standard recognized at the date of initial application in retained earnings. We plan to use the latter approach.</span></div></td><td style="vertical-align:bottom;background-color:#d1d1d1;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;background-color:#d1d1d1;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">This standard was effective January 1, 2019, and we adopted on that date.</span></div></td><td style="vertical-align:bottom;background-color:#d1d1d1;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;background-color:#d1d1d1;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">We expect to record a right-of-use asset and lease liability for operating leases of approximately $575 million on our consolidated balance sheet as of January 1, 2019. Our accounting for capital leases will remain substantially unchanged. This standard will not have a material impact on our consolidated statement of operations. </span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> <div style="line-height:120%;padding-top:12px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">The following table provides a brief description of accounting standards that were effective January 1, 2018 and were adopted on that date:</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"/></tr><tr><td style="width:30%;"/><td style="width:1%;"/><td style="width:35%;"/><td style="width:1%;"/><td style="width:33%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Standard</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Description</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Effect on the financial statements or other significant matters</span></div></td></tr><tr><td style="vertical-align:top;background-color:#d1d1d1;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Accounting Standards Update 2014-09 and various other related updates, </span><span style="font-family:Arial;font-size:10pt;font-style:italic;">Revenue from Contracts with Customers</span></div></td><td style="vertical-align:bottom;background-color:#d1d1d1;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;background-color:#d1d1d1;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">This standard replaced existing revenue recognition standards and requires entities to recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. An entity can apply the new revenue standard retrospectively to each prior reporting period presented or with the cumulative effect of initially applying the standard recognized at the date of initial application in retained earnings. We applied the latter approach.</span></div></td><td style="vertical-align:bottom;background-color:#d1d1d1;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;background-color:#d1d1d1;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Application of the new standard to applicable contracts resulted in an increase of approximately $5 million to retained earnings as of January 1, 2018. Disclosures required by the new standard are included in Note 1, Note 4, and Note 18.</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Accounting Standards Update 2016-01, </span><span style="font-family:Arial;font-size:10pt;font-style:italic;">Financial Instruments - Overall: Recognition and Measurement of Financial Assets and Financial Liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">This standard requires entities to recognize changes in the fair value of equity investments with readily determinable fair values in net income (except for investments accounted for under the equity method of accounting or those that result in consolidation of the investee). An entity should apply the new standard through a cumulative effect adjustment to retained earnings as of the beginning of the fiscal year of adoption.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Upon adoption, we reclassified from accumulated other comprehensive loss the after-tax amount of net unrealized gains resulting in an increase to retained earnings of approximately $105 million. Adoption of this standard did not result in a material change in net income in 2018.</span></div></td></tr><tr><td style="vertical-align:top;background-color:#d1d1d1;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Accounting Standards Update 2016-16, </span><span style="font-family:Arial;font-size:10pt;font-style:italic;">Income Taxes: Intra-Entity Transfers of Assets Other Than Inventory</span></div></td><td style="vertical-align:bottom;background-color:#d1d1d1;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;background-color:#d1d1d1;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:13px;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">This standard requires entities to recognize the income tax consequences of intra-entity transfers of assets other than inventory at the time of transfer. This standard requires a modified<br/>retrospective approach to adoption.</span></div></td><td style="vertical-align:bottom;background-color:#d1d1d1;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;background-color:#d1d1d1;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Upon adoption, the cumulative effect of applying the standard resulted in an increase of approximately $700 million to retained earnings, $2.5 billion to deferred tax assets, and $1.8 billion to deferred tax liabilities. Adoption of this standard did not result in a material change in net income in 2018.</span></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"/></tr><tr><td style="width:30%;"/><td style="width:1%;"/><td style="width:35%;"/><td style="width:1%;"/><td style="width:33%;"/></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Accounting Standards Update 2017-07, </span><span style="font-family:Arial;font-size:10pt;font-style:italic;">Compensation-Retirement Benefits: Improving the Presentation of Net Periodic Pension Cost and Net Periodic Postretirement Benefit Cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:13px;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">This standard was issued to improve the transparency and comparability among organizations by requiring entities to separate their net periodic pension cost and net periodic postretirement benefit cost into a service cost component and other components. Previously, the costs of the other components along with the service cost component were classified based upon the function of the employee. This standard requires entities to classify the service cost component in the same financial statement line item or items as other compensation costs arising from services rendered by pertinent employees. The other components of net benefit cost are now presented separately from the line items that include the service cost component. When applicable, the service cost component is now the only component eligible for capitalization. An entity should apply the new standard retrospectively for the classification of the service cost and other components and prospectively for the capitalization of the service cost component. </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Upon adoption of this standard, pension and postretirement benefit cost components other than service costs are presented in other–net, (income) expense. The application of the new standard resulted in reclassification to other income of $249.0 million for the year ended December 31, 2017, while increasing cost of sales by $80.8 million, research and development expenses by $75.8 million, and marketing, selling, and administrative expenses by $92.4 million for the same period. The application of the new standard resulted in reclassification to other income of $197.1 million for the year ended December 31, 2016, while increasing cost of sales by $54.2 million, research and development expenses by $66.4 million, and marketing, selling, and administrative expenses by $76.5 million for the same period. We do not expect application of the new standard to have a material impact on an ongoing basis.</span></div><div style="font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">We elected to early adopt Accounting Standards Update 2018-02, </span><span style="font-family:Arial;font-size:10pt;font-style:italic;">Income Statement-Reporting Comprehensive Income: Reclassification of Certain Tax Effects from Accumulated Other Comprehensive Income </span><span style="font-family:Arial;font-size:10pt;">as of December 31, 2017, which allowed a reclassification from accumulated other comprehensive loss to retained earnings for stranded tax effects resulting from the Tax Cuts and Jobs Act (2017 Tax Act - see Note 13). This standard allowed us to reclassify the effect of remeasuring deferred tax liabilities and assets related to items within accumulated other comprehensive loss using the then newly enacted 21 percent federal corporate income tax rate. The provisional effect of this early adoption was a reclassification from accumulated other comprehensive loss, which resulted in an increase to retained earnings of </span><span style="font-family:Arial;font-size:10pt;"><span>$643.6 million</span></span><span style="font-family:Arial;font-size:10pt;"> as of December 31, 2017.</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">The following table provides a brief description of the accounting standard that had not yet been adopted as of December 31, 2018:</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="7"/></tr><tr><td style="width:12%;"/><td style="width:1%;"/><td style="width:39%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/><td style="width:31%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Standard</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Description</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Effective Date</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Effect on the financial statements or other significant matters</span></div></td></tr><tr><td style="vertical-align:top;background-color:#d1d1d1;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Accounting Standards Update 2016-02, </span><span style="font-family:Arial;font-size:10pt;font-style:italic;">Leases</span></div></td><td style="vertical-align:bottom;background-color:#d1d1d1;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;background-color:#d1d1d1;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:13px;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">This standard was issued to increase transparency and comparability among organizations by recognizing lease assets and lease liabilities, including leases classified as operating leases under current GAAP, on the balance sheet and requiring additional disclosures about leasing arrangements. An entity can apply the new leases standard retrospectively to each prior reporting period presented or with the cumulative effect of initially applying the standard recognized at the date of initial application in retained earnings. We plan to use the latter approach.</span></div></td><td style="vertical-align:bottom;background-color:#d1d1d1;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;background-color:#d1d1d1;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">This standard was effective January 1, 2019, and we adopted on that date.</span></div></td><td style="vertical-align:bottom;background-color:#d1d1d1;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;background-color:#d1d1d1;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">We expect to record a right-of-use asset and lease liability for operating leases of approximately $575 million on our consolidated balance sheet as of January 1, 2019. Our accounting for capital leases will remain substantially unchanged. This standard will not have a material impact on our consolidated statement of operations. </span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 643600000 Acquisitions<div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">We acquired assets in development in </span><span style="font-family:Arial;font-size:10pt;">2018</span><span style="font-family:Arial;font-size:10pt;">, </span><span style="font-family:Arial;font-size:10pt;">2017</span><span style="font-family:Arial;font-size:10pt;">, and </span><span style="font-family:Arial;font-size:10pt;">2016</span><span style="font-family:Arial;font-size:10pt;"> which are further discussed in this note below in Asset Acquisitions. Upon acquisition, the acquired IPR&D charges related to these products were immediately expensed because the products had no alternative future use. For the years ended </span><span style="font-family:Arial;font-size:10pt;">December 31, 2018</span><span style="font-family:Arial;font-size:10pt;">, </span><span style="font-family:Arial;font-size:10pt;">2017</span><span style="font-family:Arial;font-size:10pt;">, and </span><span style="font-family:Arial;font-size:10pt;">2016</span><span style="font-family:Arial;font-size:10pt;">, we recorded acquired IPR&D charges of </span><span style="font-family:Arial;font-size:10pt;"><span>$1.98 billion</span></span><span style="font-family:Arial;font-size:10pt;">, </span><span style="font-family:Arial;font-size:10pt;"><span>$1.11 billion</span></span><span style="font-family:Arial;font-size:10pt;">, and </span><span style="font-family:Arial;font-size:10pt;"><span>$30.0 million</span></span><span style="font-family:Arial;font-size:10pt;">, respectively. The acquired IPR&D charges in 2018 were primarily related to the acquisition of ARMO Biosciences, Inc. (ARMO). Substantially all of the value of ARMO was related to pegilodecakin, its only significant asset.</span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">Acquisition of a Business</span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-style:italic;text-decoration:underline;">Subsequent Event - Loxo Oncology, Inc. (Loxo) Acquisition</span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-style:italic;">Overview of transaction</span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">On February 15, 2019, we acquired Loxo for a purchase price of </span><span style="font-family:Arial;font-size:10pt;"><span>$235</span></span><span style="font-family:Arial;font-size:10pt;"> per share, or approximately </span><span style="font-family:Arial;font-size:10pt;"><span>$8 billion</span></span><span style="font-family:Arial;font-size:10pt;">. Under the terms of the agreement, we acquired a pipeline of highly selective potential medicines for patients with genomically defined cancers. Loxo's pipeline includes LOXO-292, an oral RET inhibitor being studied across multiple tumor types, which recently was granted Breakthrough Therapy designation by the U.S. Food and Drug Administration. The accounting impact of this acquisition and the results of the operations for Loxo will be included in our consolidated financial statements beginning in the first quarter of 2019.</span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-style:italic;">Assets Acquired and Liabilities Assumed</span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">The initial accounting for this acquisition is incomplete. Significant, relevant information needed to complete the initial accounting is not available because the valuation of assets acquired and liabilities assumed is not complete. As a result, determining these values is not practicable and we are unable to disclose these values or provide other related disclosures at this time.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">Asset Acquisitions</span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">The following table and narrative summarize our asset acquisitions during </span><span style="font-family:Arial;font-size:10pt;">2018</span><span style="font-family:Arial;font-size:10pt;">, </span><span style="font-family:Arial;font-size:10pt;">2017</span><span style="font-family:Arial;font-size:10pt;">, and </span><span style="font-family:Arial;font-size:10pt;">2016</span><span style="font-family:Arial;font-size:10pt;">. </span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"/></tr><tr><td style="width:30%;"/><td style="width:29%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Counterparty</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Compound(s),Therapy, or Asset</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Acquisition Month</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Phase of Development</span><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(1)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Acquired IPR&D Expense</span></div></td></tr><tr><td style="vertical-align:middle;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Sigilon Therapeutics</span></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Encapsulated cell therapies for the potential treatment of type 1 diabetes</span></div></td><td style="vertical-align:middle;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">April 2018</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Pre-clinical</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d8d8d8;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#d8d8d8;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>66.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d8d8d8;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">AurKa Pharma, Inc.</span></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">AK-01, an Aurora kinase A inhibitor</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">June 2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Phase I</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>81.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">ARMO</span></div></td><td style="vertical-align:middle;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Cancer therapy - pegilodecakin</span></div></td><td style="vertical-align:middle;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">June 2018</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Phase III</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:middle;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>1,475.8</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Anima Biotech</span></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Translation inhibitors for selected neuroscience targets</span></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">July 2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Pre-clinical</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>30.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">SIGA Technologies, Inc.</span></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Priority Review Voucher</span></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">October 2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Not applicable</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>80.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d8d8d8;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Chugai Pharmaceutical Company</span></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">OWL833, an oral non-peptidic GLP-1 receptor agonist</span></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">October 2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Pre-clinical</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>50.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">NextCure, Inc.</span></div></td><td style="vertical-align:middle;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Immuno-oncology cancer therapies</span></div></td><td style="vertical-align:middle;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">November 2018</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Pre-clinical</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>28.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d8d8d8;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Dicerna Pharmaceuticals</span></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Cardio-metabolic disease, neurodegeneration, and pain</span></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">December 2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Pre-clinical</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>148.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Hydra Biosciences</span></div></td><td style="vertical-align:middle;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">TRPA1 antagonists program for the potential treatment of chronic pain syndromes</span></div></td><td style="vertical-align:middle;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">December 2018</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Pre-clinical</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:middle;border-bottom:2px solid #000000;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>22.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;height:13px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;height:13px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;height:13px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;height:13px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;height:13px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;height:13px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;height:13px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:middle;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">CoLucid Pharmaceuticals, Inc. (CoLucid)</span></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Oral therapy for the acute treatment of migraine - lasmiditan</span></div></td><td style="vertical-align:middle;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">March 2017</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Phase III</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>857.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">KeyBioscience AG</span></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Multiple molecules for treatment of metabolic disorders</span></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">July 2017</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Phase II</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>55.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Nektar Therapeutics</span></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Immunological therapy - NKTR-358</span></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">August 2017</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Phase I</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>150.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">CureVac AG</span></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Cancer vaccines</span></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">November 2017</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Pre-clinical</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:middle;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>50.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;height:13px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;height:13px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;height:13px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;height:13px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;height:13px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;height:13px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;height:13px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:middle;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">AstraZeneca</span></div></td><td style="vertical-align:middle;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Antibody selective for amyloid-beta 42 (Aβ42) - MEDI1814</span></div></td><td style="vertical-align:middle;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">December 2016</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Phase I</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:middle;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>30.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;padding-top:8px;padding-left:12px;text-indent:-12px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(1) </sup></span><span style="font-family:Arial;font-size:8pt;">The phase of development presented is as of the date of the arrangement and represents the phase of development of the most advanced asset acquired, where applicable.</span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">In connection with these arrangements, our partners may be entitled to future royalties and/or commercial milestones based on sales should products be approved for commercialization and/or milestones based on the successful progress of compounds through the development process.</span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-style:italic;text-decoration:underline;">Subsequent Event - AC Immune SA</span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">In January 2019, we entered into a license and collaboration agreement with AC Immune SA for the discovery and development of tau aggregation inhibitor small molecules for the potential treatment of Alzheimer's disease and other neurodegenerative diseases. Under terms of the agreement, we paid an upfront fee of CHF</span><span style="font-family:Arial;font-size:10pt;"><span>80.0 million</span></span><span style="font-family:Arial;font-size:10pt;"> and we will pay </span><span style="font-family:Arial;font-size:10pt;"><span>$50.0 million</span></span><span style="font-family:Arial;font-size:10pt;"> in exchange for a note, convertible to equity at a premium. As a result of this transaction, we will record an acquired IPR&D expense of </span><span style="font-family:Arial;font-size:10pt;"><span>$96.9 million</span></span><span style="font-family:Arial;font-size:10pt;"> in the first quarter of 2019.</span></div> 1980000000 1110000000 30000000.0 235 8000000000 <div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">The following table and narrative summarize our asset acquisitions during </span><span style="font-family:Arial;font-size:10pt;">2018</span><span style="font-family:Arial;font-size:10pt;">, </span><span style="font-family:Arial;font-size:10pt;">2017</span><span style="font-family:Arial;font-size:10pt;">, and </span><span style="font-family:Arial;font-size:10pt;">2016</span><span style="font-family:Arial;font-size:10pt;">. </span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"/></tr><tr><td style="width:30%;"/><td style="width:29%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Counterparty</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Compound(s),Therapy, or Asset</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Acquisition Month</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Phase of Development</span><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(1)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Acquired IPR&D Expense</span></div></td></tr><tr><td style="vertical-align:middle;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Sigilon Therapeutics</span></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Encapsulated cell therapies for the potential treatment of type 1 diabetes</span></div></td><td style="vertical-align:middle;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">April 2018</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Pre-clinical</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d8d8d8;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#d8d8d8;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>66.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d8d8d8;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">AurKa Pharma, Inc.</span></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">AK-01, an Aurora kinase A inhibitor</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">June 2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Phase I</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>81.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">ARMO</span></div></td><td style="vertical-align:middle;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Cancer therapy - pegilodecakin</span></div></td><td style="vertical-align:middle;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">June 2018</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Phase III</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:middle;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>1,475.8</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Anima Biotech</span></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Translation inhibitors for selected neuroscience targets</span></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">July 2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Pre-clinical</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>30.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">SIGA Technologies, Inc.</span></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Priority Review Voucher</span></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">October 2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Not applicable</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>80.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d8d8d8;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Chugai Pharmaceutical Company</span></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">OWL833, an oral non-peptidic GLP-1 receptor agonist</span></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">October 2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Pre-clinical</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>50.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">NextCure, Inc.</span></div></td><td style="vertical-align:middle;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Immuno-oncology cancer therapies</span></div></td><td style="vertical-align:middle;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">November 2018</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Pre-clinical</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>28.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d8d8d8;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Dicerna Pharmaceuticals</span></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Cardio-metabolic disease, neurodegeneration, and pain</span></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">December 2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Pre-clinical</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>148.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Hydra Biosciences</span></div></td><td style="vertical-align:middle;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">TRPA1 antagonists program for the potential treatment of chronic pain syndromes</span></div></td><td style="vertical-align:middle;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">December 2018</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Pre-clinical</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:middle;border-bottom:2px solid #000000;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>22.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;height:13px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;height:13px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;height:13px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;height:13px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;height:13px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;height:13px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;height:13px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:middle;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">CoLucid Pharmaceuticals, Inc. (CoLucid)</span></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Oral therapy for the acute treatment of migraine - lasmiditan</span></div></td><td style="vertical-align:middle;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">March 2017</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Phase III</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>857.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">KeyBioscience AG</span></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Multiple molecules for treatment of metabolic disorders</span></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">July 2017</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Phase II</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>55.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Nektar Therapeutics</span></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Immunological therapy - NKTR-358</span></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">August 2017</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Phase I</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>150.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">CureVac AG</span></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Cancer vaccines</span></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">November 2017</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Pre-clinical</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:middle;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>50.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;height:13px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;height:13px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;height:13px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;height:13px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;height:13px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;height:13px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;height:13px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:middle;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">AstraZeneca</span></div></td><td style="vertical-align:middle;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Antibody selective for amyloid-beta 42 (Aβ42) - MEDI1814</span></div></td><td style="vertical-align:middle;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">December 2016</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Phase I</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:middle;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>30.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;padding-top:8px;padding-left:12px;text-indent:-12px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(1) </sup></span><span style="font-family:Arial;font-size:8pt;">The phase of development presented is as of the date of the arrangement and represents the phase of development of the most advanced asset acquired, where applicable.</span></div> 66900000 81800000 1475800000 30000000.0 80000000.0 50000000.0 28100000 148700000 22600000 857600000 55000000.0 150000000.0 50000000.0 30000000.0 80000000.0 50000000.0 96900000 Collaborations and Other Arrangements<div style="line-height:120%;padding-top:12px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">We often enter into collaborative and other similar arrangements to develop and commercialize drug candidates. Collaborative activities may include research and development, marketing and selling (including promotional activities and physician detailing), manufacturing, and distribution. These arrangements often require milestone and royalty or profit-share payments, contingent upon the occurrence of certain future events linked to the success of the asset in development, as well as expense reimbursements or payments to the collaboration partner. See Note 1 for amounts of collaboration and other revenue recognized from these types of arrangements.</span></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Operating expenses for costs incurred pursuant to these arrangements are reported in their respective expense line item, net of any payments due to or reimbursements due from our collaboration partners, with such reimbursements being recognized at the time the party becomes obligated to pay. Each collaboration is unique in nature, and our more significant arrangements are discussed below.</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:12px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">Boehringer Ingelheim Diabetes Collaboration</span></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">We and Boehringer Ingelheim have a global agreement to jointly develop and commercialize a portfolio of diabetes compounds. Currently, included in the collaboration are Boehringer Ingelheim’s oral diabetes products: Trajenta, Jentadueto</span><span style="font-family:Arial;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">®</sup></span><span style="font-family:Arial;font-size:10pt;">, Jardiance, Glyxambi</span><span style="font-family:Arial;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">®</sup></span><span style="font-family:Arial;font-size:10pt;">, and Synjardy</span><span style="font-family:Arial;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">®</sup></span><span style="font-family:Arial;font-size:10pt;">, as well as our basal insulin: Basaglar</span><span style="font-family:Arial;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">®</sup></span><span style="font-family:Arial;font-size:10pt;">.</span></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">The table below summarizes significant milestones (deferred) capitalized for the compounds included in this collaboration: </span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="6"/></tr><tr><td style="width:35%;"/><td style="width:1%;"/><td style="width:49%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/></tr><tr><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Product Family</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="4" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Milestones </span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">(Deferred) Capitalized</span><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(1)</sup></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Year</span></div></td><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Amount</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Trajenta</span><span style="font-family:Arial;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(2)</sup></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Cumulative</span><span style="font-family:Arial;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(4)</sup></span></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>446.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Jardiance</span><span style="font-family:Arial;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(3)</sup></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Cumulative</span><span style="font-family:Arial;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(4)</sup></span></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>289.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td rowspan="4" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Basaglar</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">2018</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">2017</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">2016</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(187.5</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Cumulative</span><span style="font-family:Arial;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(4)</sup></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(250.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:12px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(1) </sup></span><span style="font-family:Arial;font-size:8pt;">In connection with the regulatory approvals of Basaglar in the U.S., Europe, and Japan, milestone payments received were recorded as contract liabilities and are being amortized through the term of the collaboration (2029) to collaboration and other revenue. In connection with the regulatory approvals of Trajenta and Jardiance, milestone payments made were capitalized as intangible assets and are being amortized to cost of sales through the term of the collaboration. </span></div><div style="line-height:120%;padding-top:12px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(2) </sup></span><span style="font-family:Arial;font-size:8pt;">Jentadueto is included in the Trajenta product family. The collaboration agreement with Boehringer Ingelheim for Trajenta ends upon expiration of the compound patent and any supplementary protection certificates or extensions thereto.</span></div><div style="line-height:120%;padding-top:12px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(3) </sup></span><span style="font-family:Arial;font-size:8pt;">Glyxambi and Synjardy</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt"> </sup></span><span style="font-family:Arial;font-size:8pt;">are included in the Jardiance product family. The collaboration agreement with Boehringer Ingelheim for Jardiance ends upon expiration of the compound patent and any supplementary protection certificates or extensions thereto.</span></div><div style="line-height:120%;padding-top:12px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(4) </sup></span><span style="font-family:Arial;font-size:8pt;">The cumulative amount represents the total amounts that have been (deferred) or capitalized from the start of this collaboration through the end of the reporting period.</span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">In the most significant markets, we and Boehringer Ingelheim share equally the ongoing development costs, commercialization costs, and agreed upon gross margin for any product resulting from the collaboration. We record our portion of the gross margin associated with Boehringer Ingelheim's products as collaboration and other revenue. We record our sales of Basaglar to third parties as net product revenue with the payments made to Boehringer Ingelheim for their portion of the gross margin recorded as cost of sales. For all compounds under this collaboration, we record our portion of the development and commercialization costs as research and development expense and marketing, selling, and administrative expense, respectively. Each company is entitled to potential performance payments depending on the sales of the molecules it contributes to the collaboration. These performance payments result in the owner of the molecule retaining a greater share of the agreed upon gross margin of that product. Subject to achieving these thresholds, in a given period, our reported revenue for Trajenta and Jardiance may be reduced by any performance payments we make related to these products. Similarly, performance payments we may receive related to Basaglar effectively reduce Boehringer Ingelheim's share of the gross margin, which reduces our cost of sales.</span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">The following table summarizes our collaboration and other revenue recognized with respect to the Trajenta and Jardiance families of products and net product revenue recognized with respect to Basaglar:</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:62%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2017</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2016</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Basaglar</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d8d8d8;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>801.2</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d8d8d8;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>432.1</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d8d8d8;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>86.1</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Jardiance</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>658.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>447.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>201.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Trajenta</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>574.7</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>537.9</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>436.6</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">Erbitux</span><span style="font-family:Arial;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">®</sup> </span></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">We have several collaborations with respect to Erbitux. The most significant collaborations are or, where applicable, were in Japan, and prior to the transfer of commercialization rights in the fourth quarter of 2015, the U.S. and Canada (Bristol-Myers Squibb Company); and worldwide except the U.S. and Canada (Merck KGaA). Certain rights to Erbitux outside the U.S. and Canada (North America) will remain with Merck KGaA (Merck) upon expiration of that agreement.</span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">The following table summarizes our revenue recognized with respect to Erbitux:</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:62%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2017</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2016</span></div></td></tr><tr><td style="vertical-align:top;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Net product revenue</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d8d8d8;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>536.1</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d8d8d8;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>548.2</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d8d8d8;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>587.0</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Collaboration and other revenue</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>99.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>97.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>100.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Revenue</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#d8d8d8;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>635.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#d8d8d8;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>645.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#d8d8d8;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>687.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:12px;font-size:9.75pt;"><span style="font-family:Arial;font-size:9.75pt;font-style:italic;">Bristol-Myers Squibb Company</span></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Pursuant to commercial agreements with Bristol-Myers Squibb Company and E.R. Squibb (collectively, BMS), we had been co-developing Erbitux in North America exclusively with BMS. On October 1, 2015, BMS transferred their commercialization rights to us with respect to Erbitux in North America pursuant to a modification of our existing arrangement, and we began selling Erbitux at that time. This modification did not affect our rights with respect to Erbitux in other jurisdictions. In connection with the modification of terms, we provided consideration to BMS based upon a tiered percentage of net sales of Erbitux in North America estimated to average </span><span style="font-family:Arial;font-size:10pt;"><span>38 percent</span></span><span style="font-family:Arial;font-size:10pt;"> through September 2018. The transfer of the commercialization rights was accounted for as an acquisition of a business. The consideration to be paid to BMS was accounted for as contingent consideration liability.</span></div><div style="line-height:120%;padding-top:12px;font-size:9.75pt;"><span style="font-family:Arial;font-size:9.75pt;font-style:italic;">Merck KGaA</span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">A development and license agreement granted Merck exclusive rights to market Erbitux outside of North America until December 2018. A separate agreement grants co-exclusive rights among Merck, BMS, and us in Japan and expires in 2032. This agreement was amended in 2015 to grant Merck exclusive commercialization rights in Japan but did not result in any other changes to our rights.</span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Merck manufactures Erbitux for supply in its territory, including Japan. We receive a royalty on the sales of Erbitux outside of North America, which is included in collaboration and other revenue as the underlying sales occur. Royalties due to third parties are recorded as a reduction of collaboration and other revenue, net of any royalty reimbursements due from third parties.</span></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">Olumiant</span><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">®</sup> </span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">We have a worldwide license and collaboration agreement with Incyte Corporation (Incyte) which provides us the development and commercialization rights to its Janus tyrosine kinase (JAK) inhibitor compound, now known as Olumiant, and certain follow-on compounds, for the treatment of inflammatory and autoimmune diseases. Incyte has the right to receive tiered, double-digit royalty payments on future global sales with rates ranging up to </span><span style="font-family:Arial;font-size:10pt;"><span>20 percent</span></span><span style="font-family:Arial;font-size:10pt;"> if the product is successfully commercialized. The agreement provides Incyte with options to co-develop these compounds on an indication-by-indication basis by funding </span><span style="font-family:Arial;font-size:10pt;"><span>30 percent</span></span><span style="font-family:Arial;font-size:10pt;"> of the associated development costs from the initiation of a Phase IIb trial through regulatory approval in exchange for increased tiered royalties ranging up to percentages in the high twenties. Incyte exercised its option to co-develop Olumiant in rheumatoid arthritis in 2010 and psoriatic arthritis, atopic dermatitis, alopecia areata, and systemic lupus erythematosus (SLE) in 2017. The agreement calls for payments by us to Incyte associated with certain development, success-based regulatory, and sales-based milestones. The following table summarizes our milestones achieved:</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="6"/></tr><tr><td style="width:18%;"/><td style="width:50%;"/><td style="width:20%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Year</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Event</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Classification</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Amount</span></div></td></tr><tr><td rowspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">2018</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Regulatory approval in the U.S.</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Intangible asset</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>100.0</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Began Phase III testing for SLE</span></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">R&D Expense</span></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>20.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td rowspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">2017</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Regulatory approval in Europe</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Intangible asset</span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>65.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Regulatory approval in Japan</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Intangible asset</span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>15.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Began Phase III testing for atopic dermatitis</span></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">R&D expense</span></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>30.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">2016</span></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Regulatory submissions in the U.S. and Europe</span></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">R&D expense</span></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>55.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">As of December 31, 2018, Incyte is eligible to receive up to </span><span style="font-family:Arial;font-size:10pt;"><span>$130.0 million</span></span><span style="font-family:Arial;font-size:10pt;"> of additional payments from us contingent upon certain development and success-based regulatory milestones. Incyte is also eligible to receive up to </span><span style="font-family:Arial;font-size:10pt;"><span>$150.0 million</span></span><span style="font-family:Arial;font-size:10pt;"> of potential sales-based milestones.</span></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">Effient</span><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">®</sup> </span></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">We are in a collaborative arrangement with Daiichi Sankyo Co., Ltd. (Daiichi Sankyo) to develop, market, and promote Effient. Marketing rights for major territories are shown below. We and Daiichi Sankyo each have exclusive marketing rights in certain other territories.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"/></tr><tr><td style="width:26%;"/><td style="width:1%;"/><td style="width:27%;"/><td style="width:1%;"/><td style="width:45%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Territory</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Marketing Rights</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Selling Party</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">U.S.</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Co-promotion</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Lilly</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Major European markets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Co-promotion</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Daiichi Sankyo</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Japan</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Exclusive</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Daiichi Sankyo</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">The parties share approximately </span><span style="font-family:Arial;font-size:10pt;"><span>50</span></span><span style="font-family:Arial;font-size:10pt;">/50 in the profits, as well as in the costs of development and marketing in the co-promotion territories. A third party manufactures bulk product, and we produce the finished product for our exclusive and co-promotion territories, including the major European markets. </span></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">We record net product revenue in our exclusive and co-promotion territories where we are the selling party. Profit-share payments due to Daiichi Sankyo for co-promotion countries where we are the selling party are recorded as marketing, selling, and administrative expenses. Any profit-share payments due to us from Daiichi Sankyo for the major European markets are recorded as collaboration and other revenue. We also record our share of the expenses in these co-promotion territories as marketing, selling, and administrative expenses. In our exclusive territories, we pay Daiichi Sankyo a royalty specific to these territories. All royalties due to Daiichi Sankyo and the third-party manufacturer are recorded in cost of sales. Generic versions of Effient launched in the U.S. in the third quarter of 2017.</span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">The following table summarizes our revenue recognized with respect to Effient:</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:62%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2017</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2016</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Revenue</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d8d8d8;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>122.2</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>388.9</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>535.2</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">Tanezumab</span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">We have a collaboration agreement with Pfizer Inc. (Pfizer) to jointly develop and globally commercialize tanezumab for the treatment of osteoarthritis pain, chronic low back pain and cancer pain. Under the agreement, the companies share equally the ongoing development costs and, if successful, in gross margins and certain commercialization expenses. As of </span><span style="font-family:Arial;font-size:10pt;">December 31, 2018</span><span style="font-family:Arial;font-size:10pt;">, Pfizer is eligible to receive up to </span><span style="font-family:Arial;font-size:10pt;"><span>$350.0 million</span></span><span style="font-family:Arial;font-size:10pt;"> in success-based regulatory milestones and up to </span><span style="font-family:Arial;font-size:10pt;"><span>$1.23 billion</span></span><span style="font-family:Arial;font-size:10pt;"> in a series of sales-based milestones, contingent upon the commercial success of tanezumab.</span></div> 446400000 289000000.0 0 0 -187500000 -250000000.0 <div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">The following table summarizes our collaboration and other revenue recognized with respect to the Trajenta and Jardiance families of products and net product revenue recognized with respect to Basaglar:</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:62%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2017</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2016</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Basaglar</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d8d8d8;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>801.2</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d8d8d8;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>432.1</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d8d8d8;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>86.1</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Jardiance</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>658.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>447.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>201.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Trajenta</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>574.7</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>537.9</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>436.6</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">The table below summarizes significant milestones (deferred) capitalized for the compounds included in this collaboration: </span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="6"/></tr><tr><td style="width:35%;"/><td style="width:1%;"/><td style="width:49%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/></tr><tr><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Product Family</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="4" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Milestones </span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">(Deferred) Capitalized</span><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(1)</sup></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Year</span></div></td><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Amount</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Trajenta</span><span style="font-family:Arial;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(2)</sup></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Cumulative</span><span style="font-family:Arial;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(4)</sup></span></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>446.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Jardiance</span><span style="font-family:Arial;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(3)</sup></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Cumulative</span><span style="font-family:Arial;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(4)</sup></span></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>289.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td rowspan="4" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Basaglar</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">2018</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">2017</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">2016</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(187.5</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Cumulative</span><span style="font-family:Arial;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(4)</sup></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(250.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:12px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(1) </sup></span><span style="font-family:Arial;font-size:8pt;">In connection with the regulatory approvals of Basaglar in the U.S., Europe, and Japan, milestone payments received were recorded as contract liabilities and are being amortized through the term of the collaboration (2029) to collaboration and other revenue. In connection with the regulatory approvals of Trajenta and Jardiance, milestone payments made were capitalized as intangible assets and are being amortized to cost of sales through the term of the collaboration. </span></div><div style="line-height:120%;padding-top:12px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(2) </sup></span><span style="font-family:Arial;font-size:8pt;">Jentadueto is included in the Trajenta product family. The collaboration agreement with Boehringer Ingelheim for Trajenta ends upon expiration of the compound patent and any supplementary protection certificates or extensions thereto.</span></div><div style="line-height:120%;padding-top:12px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(3) </sup></span><span style="font-family:Arial;font-size:8pt;">Glyxambi and Synjardy</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt"> </sup></span><span style="font-family:Arial;font-size:8pt;">are included in the Jardiance product family. The collaboration agreement with Boehringer Ingelheim for Jardiance ends upon expiration of the compound patent and any supplementary protection certificates or extensions thereto.</span></div><div style="line-height:120%;padding-top:12px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(4) </sup></span><span style="font-family:Arial;font-size:8pt;">The cumulative amount represents the total amounts that have been (deferred) or capitalized from the start of this collaboration through the end of the reporting period.</span></div> 801200000 432100000 86100000 658300000 447500000 201900000 574700000 537900000 436600000 <div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">The following table summarizes our revenue recognized with respect to Erbitux:</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:62%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2017</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2016</span></div></td></tr><tr><td style="vertical-align:top;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Net product revenue</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d8d8d8;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>536.1</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d8d8d8;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>548.2</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d8d8d8;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>587.0</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Collaboration and other revenue</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>99.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>97.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>100.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Revenue</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#d8d8d8;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>635.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#d8d8d8;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>645.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#d8d8d8;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>687.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 536100000 548200000 587000000.0 99200000 97700000 100000000.0 635300000 645900000 687000000.0 0.38 0.20 0.30 The following table summarizes our milestones achieved:<div style="line-height:120%;padding-bottom:8px;padding-top:8px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="6"/></tr><tr><td style="width:18%;"/><td style="width:50%;"/><td style="width:20%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Year</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Event</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Classification</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Amount</span></div></td></tr><tr><td rowspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">2018</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Regulatory approval in the U.S.</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Intangible asset</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>100.0</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Began Phase III testing for SLE</span></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">R&D Expense</span></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>20.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td rowspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">2017</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Regulatory approval in Europe</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Intangible asset</span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>65.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Regulatory approval in Japan</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Intangible asset</span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>15.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Began Phase III testing for atopic dermatitis</span></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">R&D expense</span></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>30.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">2016</span></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Regulatory submissions in the U.S. and Europe</span></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">R&D expense</span></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>55.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 100000000.0 20000000.0 65000000.0 15000000.0 30000000.0 55000000.0 130000000.0 150000000.0 0.50 <div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">The following table summarizes our revenue recognized with respect to Effient:</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:62%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2017</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2016</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Revenue</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d8d8d8;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>122.2</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>388.9</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>535.2</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">We are in a collaborative arrangement with Daiichi Sankyo Co., Ltd. (Daiichi Sankyo) to develop, market, and promote Effient. Marketing rights for major territories are shown below. We and Daiichi Sankyo each have exclusive marketing rights in certain other territories.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"/></tr><tr><td style="width:26%;"/><td style="width:1%;"/><td style="width:27%;"/><td style="width:1%;"/><td style="width:45%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Territory</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Marketing Rights</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Selling Party</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">U.S.</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Co-promotion</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Lilly</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Major European markets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Co-promotion</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Daiichi Sankyo</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Japan</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Exclusive</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Daiichi Sankyo</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 122200000 388900000 535200000 350000000.0 1230000000 Asset Impairment, Restructuring, and Other Special Charges<div style="line-height:120%;padding-top:12px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">The components of the charges included in asset impairment, restructuring, and other special charges in our consolidated statements of operations are described below: </span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:62%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2017</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2016</span></div></td></tr><tr><td style="vertical-align:top;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Severance</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>127.8</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d8d8d8;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>601.0</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d8d8d8;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>85.9</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Pension and post-retirement medical charges associated with U.S. voluntary early retirement program (see Note 14)</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>446.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Asset impairment (gains from facility sales) and other special charges</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>139.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>283.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(13.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d8d8d8;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Total asset impairment, restructuring, and other special charges</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>266.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>1,331.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>72.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Severance costs recognized during the years ended </span><span style="font-family:Arial;font-size:10pt;">December 31, 2018</span><span style="font-family:Arial;font-size:10pt;">, </span><span style="font-family:Arial;font-size:10pt;">2017</span><span style="font-family:Arial;font-size:10pt;"> and </span><span style="font-family:Arial;font-size:10pt;">2016</span><span style="font-family:Arial;font-size:10pt;"> were incurred as a result of actions taken to reduce our cost structure. Severance costs recognized in 2017 were associated with the U.S. voluntary early retirement program. During 2017, severance costs recognized in the U.S. and outside the U.S. were </span><span style="font-family:Arial;font-size:10pt;"><span>$368.3 million</span></span><span style="font-family:Arial;font-size:10pt;"> and </span><span style="font-family:Arial;font-size:10pt;"><span>$232.7 million</span></span><span style="font-family:Arial;font-size:10pt;">, respectively. Substantially all of the severance costs incurred in 2016 and 2017 have been paid. Of the severance costs incurred during the year ended December 31, 2018, approximately half will be paid in </span><span style="font-family:Arial;font-size:10pt;">2019</span><span style="font-family:Arial;font-size:10pt;"> and half will be paid in </span><span style="font-family:Arial;font-size:10pt;">2020</span><span style="font-family:Arial;font-size:10pt;">.</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Asset impairment and other special charges recognized during the year ended December 31, 2018 resulted primarily from asset impairment and other special charges related to the sale of the Posilac</span><span style="font-family:Arial;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">®</sup></span><span style="font-family:Arial;font-size:10pt;"> (rbST) brand and the associated Augusta, Georgia manufacturing site.</span></div><span style="font-family:Arial;font-size:10pt;">Asset impairment and other special charges recognized during the year ended December 31, 2017 resulted primarily from asset impairments related to lower projected revenue for Posilac (rbST). The assets associated with Posilac (rbST) were written down to their fair values, which were determined based upon a discounted cash flow valuation. Impairment charges were recorded for the associated fixed assets and intangible asset of </span><span style="font-family:Arial;font-size:10pt;"><span>$151.5 million</span></span><span style="font-family:Arial;font-size:10pt;"> and </span><span style="font-family:Arial;font-size:10pt;"><span>$50.0 million</span></span><span style="font-family:Arial;font-size:10pt;">, respectively (refer to Note 8 for further detail relating to intangible asset impairments). In addition, we incurred approximately </span><span style="font-family:Arial;font-size:10pt;"><span>$43.4 million</span></span> of costs associated with the temporary shut down of our Puerto Rico facility following Hurricane Maria. <div style="line-height:120%;padding-top:12px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">The components of the charges included in asset impairment, restructuring, and other special charges in our consolidated statements of operations are described below: </span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:62%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2017</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2016</span></div></td></tr><tr><td style="vertical-align:top;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Severance</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>127.8</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d8d8d8;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>601.0</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d8d8d8;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>85.9</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Pension and post-retirement medical charges associated with U.S. voluntary early retirement program (see Note 14)</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>446.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Asset impairment (gains from facility sales) and other special charges</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>139.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>283.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(13.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d8d8d8;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Total asset impairment, restructuring, and other special charges</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>266.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>1,331.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>72.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 127800000 601000000.0 85900000 0 446700000 0 139100000 283900000 -13000000.0 266900000 1331600000 72900000 368300000 232700000 151500000 50000000.0 43400000 Inventories<div style="line-height:120%;padding-top:12px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">We use the last-in, first-out (LIFO) method for the majority of our inventories located in the continental U.S. Other inventories are valued by the first-in, first-out (FIFO) method. FIFO cost approximates current replacement cost. Inventories measured using LIFO must be valued at the lower of cost or market. Inventories measured using FIFO must be valued at the lower of cost or net realizable value. </span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Inventories at December 31 consisted of the following:</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.79423868312757%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:75%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:top;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Finished products</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d8d8d8;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>577.8</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d8d8d8;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>759.4</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Work in process</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>2,057.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>2,117.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Raw materials and supplies</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>426.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>418.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Total (approximates replacement cost)</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>3,061.7</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>3,295.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Increase (reduction) to LIFO cost</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>36.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>100.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Inventories</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>3,098.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>3,396.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:16px;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Inventories valued under the LIFO method comprised </span><span style="font-family:Arial;font-size:10pt;color:#000000;text-decoration:none;"><span>$1.37 billion</span></span><span style="font-family:Arial;font-size:10pt;"> and </span><span style="font-family:Arial;font-size:10pt;color:#000000;text-decoration:none;"><span>$1.33 billion</span></span><span style="font-family:Arial;font-size:10pt;"> of total inventories at </span><span style="font-family:Arial;font-size:10pt;color:#000000;text-decoration:none;">December 31, 2018</span><span style="font-family:Arial;font-size:10pt;"> and </span><span style="font-family:Arial;font-size:10pt;color:#000000;text-decoration:none;">2017</span><span style="font-family:Arial;font-size:10pt;">, respectively.</span></div> We use the last-in, first-out (LIFO) method for the majority of our inventories located in the continental U.S. Other inventories are valued by the first-in, first-out (FIFO) method. FIFO cost approximates current replacement cost. <div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Inventories at December 31 consisted of the following:</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.79423868312757%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:75%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:top;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Finished products</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d8d8d8;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>577.8</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d8d8d8;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>759.4</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Work in process</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>2,057.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>2,117.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Raw materials and supplies</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>426.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>418.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Total (approximates replacement cost)</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>3,061.7</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>3,295.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Increase (reduction) to LIFO cost</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>36.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>100.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Inventories</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>3,098.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>3,396.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 577800000 759400000 2057800000 2117700000 426100000 418400000 3061700000 3295500000 -36400000 -100500000 3098100000 3396000000.0 1370000000 1330000000 Financial Instruments<div style="line-height:120%;padding-top:12px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Financial instruments that potentially subject us to credit risk consist principally of trade receivables and interest-bearing investments. Wholesale distributors of life-science products account for a substantial portion of our trade receivables; collateral is generally not required. We seek to mitigate the risk associated with this concentration through our ongoing credit-review procedures and insurance. A large portion of our cash is held by a few major financial institutions. We monitor our exposures with these institutions and do not expect any of these institutions to fail to meet their obligations. Major financial institutions represent the largest component of our investments in corporate debt securities. In accordance with documented corporate risk-management policies, we monitor the amount of credit exposure to any one financial institution or corporate issuer. We are exposed to credit-related losses in the event of nonperformance by counterparties to risk-management instruments but do not expect any counterparties to fail to meet their obligations given their high credit ratings.</span></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">We consider all highly liquid investments with a maturity of three months or less from the date of purchase to be cash equivalents. The cost of these investments approximates fair value.</span></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Our equity investments are accounted for using three different methods depending on the type of equity investment:</span></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Arial;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Investments in companies over which we have significant influence but not a controlling interest are accounted for using the equity method, with our share of earnings or losses reported in other-net, (income) expense. </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Arial;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">For equity investments that do not have readily determinable fair values, we measure these investments at cost, less any impairment, plus or minus changes resulting from observable price changes in orderly transactions for the identical or similar investment of the same issuer. Any change in recorded value is recorded in other-net, (income) expense. </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Arial;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Our public equity investments are measured and carried at fair value. Any change in fair value is recognized in other-net, (income) expense. </span></div></td></tr></table><div style="line-height:120%;padding-top:12px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">We review equity investments other than public equity investments for indications of impairment on a regular basis.</span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Our derivative activities are initiated within the guidelines of documented corporate risk-management policies and are intended to offset losses and gains on the assets, liabilities, and transactions being hedged. Management reviews the correlation and effectiveness of our derivatives on a quarterly basis.</span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">For derivative instruments that are designated and qualify as fair value hedges, the derivative instrument is marked to market with gains and losses recognized currently in income to offset the respective losses and gains recognized on the underlying exposure. For derivative instruments that are designated and qualify as cash flow hedges, gains and losses are reported as a component of accumulated other comprehensive loss and reclassified into earnings in the same period the hedged transaction affects earnings. For derivative and non-derivative instruments that are designated and qualify as net investment hedges, the foreign currency translation gains or losses due to spot rate fluctuations are reported as a component of accumulated other comprehensive loss. Derivative contracts that are not designated as hedging instruments are recorded at fair value with the gain or loss recognized in earnings during the period of change.</span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">We may enter into foreign currency forward or option contracts to reduce the effect of fluctuating currency exchange rates (principally the euro, British pound, and the Japanese yen). Foreign currency derivatives used for hedging are put in place using the same or like currencies and duration as the underlying exposures. Forward and option contracts are principally used to manage exposures arising from subsidiary trade and loan payables and receivables denominated in foreign currencies. These contracts are recorded at fair value with the gain or loss recognized in other–net, (income) expense. We may enter into foreign currency forward and option contracts and currency swaps as fair value hedges of firm commitments. Forward contracts generally have maturities not exceeding </span><span style="font-family:Arial;font-size:10pt;"><span>12</span></span><span style="font-family:Arial;font-size:10pt;"> months. At </span><span style="font-family:Arial;font-size:10pt;">December 31, 2018</span><span style="font-family:Arial;font-size:10pt;">, we had outstanding foreign currency forward commitments to purchase </span><span style="font-family:Arial;font-size:10pt;"><span>785.5 million</span></span><span style="font-family:Arial;font-size:10pt;"> U.S. dollars and sell </span><span style="font-family:Arial;font-size:10pt;"><span>685.3 million</span></span><span style="font-family:Arial;font-size:10pt;"> euro; commitments to purchase </span><span style="font-family:Arial;font-size:10pt;"><span>2.05 billion</span></span><span style="font-family:Arial;font-size:10pt;"> euro and sell </span><span style="font-family:Arial;font-size:10pt;"><span>2.35 billion</span></span><span style="font-family:Arial;font-size:10pt;"> U.S. dollars; commitments to purchase </span><span style="font-family:Arial;font-size:10pt;"><span>435.1 million</span></span><span style="font-family:Arial;font-size:10pt;"> U.S. dollars and sell </span><span style="font-family:Arial;font-size:10pt;"><span>48.85 billion</span></span><span style="font-family:Arial;font-size:10pt;"> Japanese yen, commitments to purchase </span><span style="font-family:Arial;font-size:10pt;"><span>255.6 million</span></span><span style="font-family:Arial;font-size:10pt;"> Swiss francs and sell </span><span style="font-family:Arial;font-size:10pt;"><span>259.7 million</span></span><span style="font-family:Arial;font-size:10pt;"> U.S. dollars, commitments to purchase </span><span style="font-family:Arial;font-size:10pt;"><span>388.3 million</span></span><span style="font-family:Arial;font-size:10pt;"> U.S. dollars and sell </span><span style="font-family:Arial;font-size:10pt;"><span>306.7 million</span></span><span style="font-family:Arial;font-size:10pt;"> </span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">British pounds, and commitments to purchase </span><span style="font-family:Arial;font-size:10pt;"><span>354.0 million</span></span><span style="font-family:Arial;font-size:10pt;"> British pounds and sell </span><span style="font-family:Arial;font-size:10pt;"><span>448.1 million</span></span><span style="font-family:Arial;font-size:10pt;"> U.S. dollars which will all settle within </span><span style="font-family:Arial;font-size:10pt;"><span>30 days</span></span><span style="font-family:Arial;font-size:10pt;">.</span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Foreign currency exchange risk is also managed through the use of foreign currency debt and cross-currency interest rate swaps. Our foreign currency-denominated notes had carrying amounts of </span><span style="font-family:Arial;font-size:10pt;"><span>$3.40 billion</span></span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:Arial;font-size:10pt;">and</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:Arial;font-size:10pt;"><span>$3.70 billion</span></span><span style="font-family:Arial;font-size:10pt;"> as of </span><span style="font-family:Arial;font-size:10pt;">December 31, 2018</span><span style="font-family:Arial;font-size:10pt;"> and </span><span style="font-family:Arial;font-size:10pt;">2017</span><span style="font-family:Arial;font-size:10pt;">, respectively, of which $</span><span style="font-family:Arial;font-size:10pt;"><span>2.65 billion</span></span><span style="font-family:Arial;font-size:10pt;"> and </span><span style="font-family:Arial;font-size:10pt;"><span>$3.70 billion</span></span><span style="font-family:Arial;font-size:10pt;"> have been designated as, and are effective as, economic hedges of net investments in certain of our euro-denominated and Swiss franc-denominated foreign operations as of </span><span style="font-family:Arial;font-size:10pt;">December 31, 2018</span><span style="font-family:Arial;font-size:10pt;"> and </span><span style="font-family:Arial;font-size:10pt;">2017</span><span style="font-family:Arial;font-size:10pt;">, respectively. Our cross-currency interest rate swaps, for which a majority convert a portion of our U.S. dollar-denominated floating rate debt to foreign-denominated floating rate debt, have also been designated as, and are effective as, economic hedges of net investments. At </span><span style="font-family:Arial;font-size:10pt;">December 31, 2018</span><span style="font-family:Arial;font-size:10pt;">, we had outstanding cross currency swaps with notional amounts of </span><span style="font-family:Arial;font-size:10pt;"><span>$2.46 billion</span></span><span style="font-family:Arial;font-size:10pt;"> swapping U.S. dollars to euro, </span><span style="font-family:Arial;font-size:10pt;"><span>$754.0 million</span></span><span style="font-family:Arial;font-size:10pt;"> swapping Swiss francs to U.S. dollars, and </span><span style="font-family:Arial;font-size:10pt;"><span>$350.0 million</span></span><span style="font-family:Arial;font-size:10pt;"> swapping U.S. dollars to British pounds, which have settlement dates ranging through </span><span style="font-family:Arial;font-size:10pt;">2028</span><span style="font-family:Arial;font-size:10pt;">.</span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">In the normal course of business, our operations are exposed to fluctuations in interest rates which can vary the costs of financing, investing, and operating. We seek to address a portion of these risks through a controlled program of risk management that includes the use of derivative financial instruments. The objective of controlling these risks is to limit the impact of fluctuations in interest rates on earnings. Our primary interest-rate risk exposure results from changes in short-term U.S. dollar interest rates. In an effort to manage interest-rate exposures, we strive to achieve an acceptable balance between fixed- and floating-rate debt and investment positions and may enter into interest rate swaps or collars to help maintain that balance. </span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Interest rate swaps or collars that convert our fixed-rate debt to a floating rate are designated as fair value hedges of the underlying instruments. Interest rate swaps or collars that convert floating-rate debt to a fixed rate are designated as cash flow hedges. Interest expense on the debt is adjusted to include the payments made or received under the swap agreements. Cash proceeds from or payments to counterparties resulting from the termination of interest rate swaps are classified as operating activities in our consolidated statements of cash flows. At </span><span style="font-family:Arial;font-size:10pt;">December 31, 2018</span><span style="font-family:Arial;font-size:10pt;">, substantially all of our total long-term debt is at a fixed rate. We have converted approximately </span><span style="font-family:Arial;font-size:10pt;"><span>25 percent</span></span><span style="font-family:Arial;font-size:10pt;"> of our long-term fixed-rate notes to floating rates through the use of interest rate swaps.</span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">We may enter into forward contracts and designate them as cash flow hedges to limit the potential volatility of earnings and cash flow associated with forecasted sales of available-for-sale securities.</span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">We also may enter into forward-starting interest rate swaps, which we designate as cash flow hedges, as part of any anticipated future debt issuances in order to reduce the risk of cash flow volatility from future changes in interest rates. Upon completion of a debt issuance and termination of the swap, the change in fair value of these instruments is recorded as part of other comprehensive income (loss) and is amortized to interest expense over the life of the underlying debt. </span></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">The Effect of Risk Management Instruments on the Consolidated Statements of Operations</span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">The following effects of risk-management instruments were recognized in other–net, (income) expense:</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:62%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2017</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2016</span></div></td></tr><tr><td style="vertical-align:top;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Fair value hedges:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Effect from hedged fixed-rate debt</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>(40.9</span></span></div></td><td style="vertical-align:bottom;padding-right:20px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(14.1</span></span></div></td><td style="vertical-align:bottom;padding-right:20px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(30.8</span></span></div></td><td style="vertical-align:bottom;padding-right:20px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#d8d8d8;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Effect from interest rate contracts</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>40.9</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>14.1</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>30.8</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Cash flow hedges:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#d8d8d8;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Effective portion of losses on interest rate contracts reclassified from accumulated other comprehensive loss</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>14.8</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>14.8</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>15.0</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Net losses on foreign currency exchange contracts not designated as hedging instruments</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>100.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>97.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>78.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Total </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#d8d8d8;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>114.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#d8d8d8;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>112.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#d8d8d8;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>93.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">During the years ended </span><span style="font-family:Arial;font-size:10pt;">December 31, 2018</span><span style="font-family:Arial;font-size:10pt;">, the amortization of losses related to the portion of our risk management hedging instruments, fair value hedges, and cash flow hedges that were excluded from the assessment of effectiveness were not material.</span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">During the years ended December 31, </span><span style="font-family:Arial;font-size:10pt;">2017</span><span style="font-family:Arial;font-size:10pt;">, and </span><span style="font-family:Arial;font-size:10pt;">2016</span><span style="font-family:Arial;font-size:10pt;">, net losses related to ineffectiveness, as well as net losses related to the portion of our risk-management hedging instruments, fair value hedges, and cash flow hedges that were excluded from the assessment of effectiveness, were not material.</span></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">The Effect of Risk-Management Instruments on Other Comprehensive Income (Loss)</span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">The effective portion of risk-management instruments that was recognized in other comprehensive income (loss) is as follows:</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:62%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2017</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2016</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Net investment hedges:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">    Foreign currency-denominated notes</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>110.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(361.5</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>137.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">    Cross-currency interest rate swaps</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>96.8</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(126.6</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>32.5</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">    Foreign currency exchange contracts</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>5.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>31.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#d1d1d1;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Cash flow hedges:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d1d1d1;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d1d1d1;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d1d1d1;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d1d1d1;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d1d1d1;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">    Forward-starting interest rate swaps</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>13.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(3.4</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">During the next 12 months, we expect to reclassify </span><span style="font-family:Arial;font-size:10pt;"><span>$15.0 million</span></span><span style="font-family:Arial;font-size:10pt;"> of pretax net losses on cash flow hedges from accumulated other comprehensive loss to other–net, (income) expense. During the year ended </span><span style="font-family:Arial;font-size:10pt;">December 31, 2018</span><span style="font-family:Arial;font-size:10pt;">, the amounts excluded from the assessment of hedge effectiveness recognized in other comprehensive income (loss) was not material. </span></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">Fair Value of Financial Instruments</span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">The following tables summarize certain fair value information at December 31 for assets and liabilities measured at fair value on a recurring basis, as well as the carrying amount and amortized cost of certain other investments:</span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="24"/></tr><tr><td style="width:29%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Fair Value Measurements Using</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Description</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Carrying</span></div><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Amount</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Cost</span><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:5pt"> (1)</sup></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Quoted Prices in Active Markets for Identical Assets</span></div><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">(Level 1)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Significant</span></div><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Other</span></div><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Observable</span></div><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Inputs</span></div><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">(Level 2)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Significant</span></div><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Unobservable</span></div><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Inputs</span></div><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">(Level 3)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Fair</span></div><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Value</span></div></td></tr><tr><td style="vertical-align:top;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">December 31, 2018</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Cash equivalents</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>5,727.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>5,727.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>5,727.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>5,727.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Short-term investments:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">U.S. government and agency securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>16.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>17.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>16.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>16.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#d8d8d8;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Corporate debt securities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>62.2</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>62.6</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>62.2</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>62.2</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Asset-backed securities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>7.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>7.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>7.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>7.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#d8d8d8;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Other securities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>1.5</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>1.5</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>1.5</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>1.5</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Short-term investments</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>88.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td colspan="24" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Noncurrent investments:</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">U.S. government and agency securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>149.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>153.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>149.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>149.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#d8d8d8;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Corporate debt securities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>568.0</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>587.8</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>568.0</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>568.0</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Mortgage-backed securities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>111.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>114.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>111.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>111.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#d8d8d8;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Asset-backed securities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>27.7</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>27.9</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>27.7</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>27.7</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Other securities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>87.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>29.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>87.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>87.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#d8d8d8;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Marketable equity securities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>357.5</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>238.3</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>357.5</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>357.5</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Equity investments without readily determinable fair values</span><span style="font-family:Arial;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(2)</sup></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>414.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#d1d1d1;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Equity method investments</span><span style="font-family:Arial;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(2)</sup></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d1d1d1;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>289.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d1d1d1;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d1d1d1;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d1d1d1;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d1d1d1;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d1d1d1;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d1d1d1;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d1d1d1;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d1d1d1;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d1d1d1;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d1d1d1;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d1d1d1;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Noncurrent investments</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>2,005.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#d1d1d1;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d1d1d1;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d1d1d1;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d1d1d1;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d1d1d1;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d1d1d1;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d1d1d1;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d1d1d1;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d1d1d1;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d1d1d1;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d1d1d1;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d1d1d1;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">December 31, 2017</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#d1d1d1;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Cash equivalents</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d1d1d1;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#d1d1d1;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>4,763.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#d1d1d1;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#d1d1d1;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d1d1d1;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#d1d1d1;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>4,763.9</span></span></div></td><td style="vertical-align:bottom;background-color:#d1d1d1;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d1d1d1;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d1d1d1;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#d1d1d1;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>4,712.4</span></span></div></td><td style="vertical-align:bottom;background-color:#d1d1d1;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d1d1d1;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d1d1d1;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#d1d1d1;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>51.5</span></span></div></td><td style="vertical-align:bottom;background-color:#d1d1d1;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d1d1d1;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d1d1d1;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#d1d1d1;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#d1d1d1;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d1d1d1;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d1d1d1;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#d1d1d1;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>4,763.9</span></span></div></td><td style="vertical-align:bottom;background-color:#d1d1d1;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Short-term investments:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#d1d1d1;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">U.S. government and agency securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d1d1d1;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#d1d1d1;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>217.8</span></span></div></td><td style="vertical-align:bottom;background-color:#d1d1d1;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d1d1d1;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d1d1d1;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#d1d1d1;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>218.2</span></span></div></td><td style="vertical-align:bottom;background-color:#d1d1d1;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d1d1d1;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d1d1d1;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#d1d1d1;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>217.8</span></span></div></td><td style="vertical-align:bottom;background-color:#d1d1d1;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d1d1d1;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d1d1d1;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#d1d1d1;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#d1d1d1;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d1d1d1;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d1d1d1;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#d1d1d1;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#d1d1d1;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d1d1d1;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d1d1d1;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#d1d1d1;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>217.8</span></span></div></td><td style="vertical-align:bottom;background-color:#d1d1d1;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Corporate debt securities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>1,182.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>1,183.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>1,182.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>1,182.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#d1d1d1;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Asset-backed securities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d1d1d1;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>94.2</span></span></div></td><td style="vertical-align:bottom;background-color:#d1d1d1;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d1d1d1;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d1d1d1;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>94.3</span></span></div></td><td style="vertical-align:bottom;background-color:#d1d1d1;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d1d1d1;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d1d1d1;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#d1d1d1;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d1d1d1;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d1d1d1;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>94.2</span></span></div></td><td style="vertical-align:bottom;background-color:#d1d1d1;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d1d1d1;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d1d1d1;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#d1d1d1;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d1d1d1;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d1d1d1;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>94.2</span></span></div></td><td style="vertical-align:bottom;background-color:#d1d1d1;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Other securities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>3.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>3.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>3.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>3.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#d1d1d1;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Short-term investments</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d1d1d1;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#d1d1d1;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>1,497.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#d1d1d1;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#d1d1d1;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d1d1d1;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d1d1d1;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d1d1d1;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d1d1d1;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d1d1d1;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d1d1d1;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d1d1d1;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d1d1d1;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d1d1d1;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d1d1d1;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d1d1d1;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Noncurrent investments:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#d1d1d1;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">U.S. government and agency securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d1d1d1;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#d1d1d1;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>360.0</span></span></div></td><td style="vertical-align:bottom;background-color:#d1d1d1;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d1d1d1;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d1d1d1;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#d1d1d1;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>365.0</span></span></div></td><td style="vertical-align:bottom;background-color:#d1d1d1;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d1d1d1;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d1d1d1;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#d1d1d1;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>360.0</span></span></div></td><td style="vertical-align:bottom;background-color:#d1d1d1;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d1d1d1;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d1d1d1;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#d1d1d1;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#d1d1d1;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d1d1d1;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d1d1d1;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#d1d1d1;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#d1d1d1;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d1d1d1;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d1d1d1;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#d1d1d1;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>360.0</span></span></div></td><td style="vertical-align:bottom;background-color:#d1d1d1;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Corporate debt securities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>3,464.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>3,473.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>3,464.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>3,464.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#d1d1d1;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Mortgage-backed securities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d1d1d1;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>202.4</span></span></div></td><td style="vertical-align:bottom;background-color:#d1d1d1;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d1d1d1;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d1d1d1;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>204.2</span></span></div></td><td style="vertical-align:bottom;background-color:#d1d1d1;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d1d1d1;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d1d1d1;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#d1d1d1;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d1d1d1;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d1d1d1;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>202.4</span></span></div></td><td style="vertical-align:bottom;background-color:#d1d1d1;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d1d1d1;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d1d1d1;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#d1d1d1;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d1d1d1;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d1d1d1;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>202.4</span></span></div></td><td style="vertical-align:bottom;background-color:#d1d1d1;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Asset-backed securities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>653.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>656.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>653.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>653.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#d1d1d1;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Other securities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d1d1d1;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>132.1</span></span></div></td><td style="vertical-align:bottom;background-color:#d1d1d1;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d1d1d1;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d1d1d1;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>66.4</span></span></div></td><td style="vertical-align:bottom;background-color:#d1d1d1;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d1d1d1;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d1d1d1;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#d1d1d1;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d1d1d1;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d1d1d1;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#d1d1d1;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d1d1d1;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d1d1d1;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>132.1</span></span></div></td><td style="vertical-align:bottom;background-color:#d1d1d1;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d1d1d1;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d1d1d1;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>132.1</span></span></div></td><td style="vertical-align:bottom;background-color:#d1d1d1;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Marketable equity securities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>281.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>131.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>281.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>281.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#d1d1d1;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Cost and equity method investments</span><span style="font-family:Arial;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(2)</sup></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d1d1d1;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>572.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d1d1d1;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d1d1d1;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d1d1d1;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d1d1d1;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d1d1d1;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d1d1d1;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d1d1d1;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d1d1d1;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d1d1d1;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d1d1d1;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d1d1d1;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d1d1d1;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Noncurrent investments</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>5,666.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:4px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(1) </sup></span><span style="font-family:Arial;font-size:8pt;">For available-for-sale debt securities, amounts disclosed represent the securities' amortized cost.</span></div><div style="line-height:120%;padding-top:8px;padding-left:12px;text-indent:-12px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(2) </sup></span><span style="font-family:Arial;font-size:8pt;">Fair value disclosures are not applicable for equity method investments, investments accounted for under the measurement alternative for equity investments, and cost method investments that do not have readily determinable fair values.</span></div><div style="line-height:120%;padding-top:8px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="20"/></tr><tr><td style="width:41%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Fair Value Measurements Using</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Description</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Carrying</span></div><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Amount</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Quoted Prices in Active Markets for Identical Assets</span></div><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">(Level 1)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Significant</span></div><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Other</span></div><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Observable</span></div><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Inputs</span></div><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">(Level 2)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Significant</span></div><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Unobservable</span></div><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Inputs</span></div><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">(Level 3)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Fair</span></div><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Value</span></div></td></tr><tr><td style="vertical-align:top;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">Short-term commercial paper borrowings</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">December 31, 2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>(498.9</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>(497.6</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>(497.6</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">December 31, 2017</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(2,696.8</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(2,690.6</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(2,690.6</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">Long-term debt, including current portion</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">December 31, 2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>(9,799.7</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>(9,989.4</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>(9,989.4</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">December 31, 2017</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(10,950.3</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(11,529.9</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(11,529.9</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="20"/></tr><tr><td style="width:41%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Fair Value Measurements Using</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Description</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Carrying</span></div><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Amount</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Quoted Prices in Active Markets for Identical Assets</span></div><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">(Level 1)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Significant</span></div><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Other</span></div><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Observable</span></div><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Inputs</span></div><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">(Level 2)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Significant</span></div><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Unobservable</span></div><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Inputs</span></div><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">(Level 3)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Fair</span></div><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Value</span></div></td></tr><tr><td style="vertical-align:top;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">December 31, 2018</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Risk-management instruments</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#d8d8d8;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Interest rate contracts designated as fair value hedges:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Sundry</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>4.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>4.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>4.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#d8d8d8;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Other current liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>(22.3</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>(22.3</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>(22.3</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Other noncurrent liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>(19.0</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>(19.0</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>(19.0</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#d8d8d8;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Cross-currency interest rate contracts designated as net investment hedges:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Other receivables</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>69.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>69.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>69.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#d8d8d8;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Sundry</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>8.2</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>8.2</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>8.2</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Other current liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>(9.2</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>(9.2</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>(9.2</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#d8d8d8;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Cross-currency interest rate contracts not designated as hedging instruments:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Other noncurrent liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>(25.8</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>(25.8</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>(25.8</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#d8d8d8;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Foreign exchange contracts not designated as hedging instruments:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Other receivables</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>11.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>11.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>11.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#d8d8d8;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Other current liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>(16.3</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>(16.3</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>(16.3</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">December 31, 2017</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Risk-management instruments</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#d8d8d8;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Interest rate contracts designated as fair value hedges:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Other receivables</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>0.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>0.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>0.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#d8d8d8;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Sundry</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>35.1</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>35.1</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>35.1</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Other current liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(0.2</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(0.2</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(0.2</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#d8d8d8;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Other noncurrent liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(10.5</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(10.5</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(10.5</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Cross-currency interest rate contracts designated as net investment hedges:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#d8d8d8;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">    Other current liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(33.4</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(33.4</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(33.4</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">    Other noncurrent liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(26.0</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(26.0</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(26.0</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#d8d8d8;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Foreign exchange contracts not designated as hedging instruments:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Other receivables</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>26.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>26.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>26.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#d8d8d8;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Other current liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(36.0</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(36.0</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(36.0</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Contingent consideration liabilities</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#d8d8d8;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Other current liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(206.7</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(206.7</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(206.7</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Risk-management instruments above are disclosed on a gross basis. There are various rights of setoff associated with certain of the risk-management instruments above that are subject to an enforceable master netting arrangement or similar agreements. Although various rights of setoff and master netting arrangements or similar agreements may exist with the individual counterparties to the risk-management instruments above, individually, these financial rights are not material.</span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">We determine our Level 1 and Level 2 fair value measurements based on a market approach using quoted market values, significant other observable inputs for identical or comparable assets or liabilities, or discounted cash flow analyses. Level 3 fair value measurements for other investment securities are determined using unobservable inputs, including the investments' cost adjusted for impairments and price changes from orderly transactions. The fair values of equity method investments and investments measured under the measurement alternative for equity investments that do not have readily determinable fair values are not readily available.</span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Contingent consideration liabilities were recorded at fair value and were estimated using a discounted cash flow analysis and Level 3 inputs, including projections representative of a market participant view for net sales and an estimated discount rate. The decrease in the fair value of the contingent consideration liabilities during the years ended </span><span style="font-family:Arial;font-size:10pt;">December 31, 2018</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:Arial;font-size:10pt;">and</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:Arial;font-size:10pt;">2017</span><span style="font-family:Arial;font-size:10pt;"> was due primarily to cash payments of </span><span style="font-family:Arial;font-size:10pt;"><span>$199.7 million</span></span><span style="font-family:Arial;font-size:10pt;"> and </span><span style="font-family:Arial;font-size:10pt;"><span>$203.1 million</span></span><span style="font-family:Arial;font-size:10pt;">, which related to Erbitux (see Note 4). The change in the fair value of the contingent consideration liabilities recognized in earnings during the years ended </span><span style="font-family:Arial;font-size:10pt;">December 31, 2018</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:Arial;font-size:10pt;">2017</span><span style="font-family:Arial;font-size:10pt;">, and </span><span style="font-family:Arial;font-size:10pt;">2016</span><span style="font-family:Arial;font-size:10pt;"> due to changes in time value of money was not material.</span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">The table below summarizes the contractual maturities of our investments in debt securities measured at fair value as of </span><span style="font-family:Arial;font-size:10pt;color:#000000;text-decoration:none;">December 31, 2018</span><span style="font-family:Arial;font-size:10pt;">:</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.79423868312757%;border-collapse:collapse;text-align:left;"><tr><td colspan="20"/></tr><tr><td style="width:41%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"> </span></div></td><td colspan="19" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Maturities by Period</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">  </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Less Than</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">1 Year</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">1-5 Years</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">6-10 Years</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">More Than 10 Years</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Fair value of debt securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d8d8d8;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>943.0</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>86.8</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>604.8</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>97.0</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>154.4</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">A summary of the fair value of available-for-sale securities in an unrealized gain or loss position and the amount of unrealized gains and losses (pretax) in accumulated other comprehensive loss follows:</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.79423868312757%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:75%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:top;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Unrealized gross gains</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d8d8d8;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>0.8</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d8d8d8;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>184.7</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Unrealized gross losses</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>29.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>47.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Fair value of securities in an unrealized gain position</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>84.3</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>1,434.2</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Fair value of securities in an unrealized loss position</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>858.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>4,692.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">The unrealized losses (pretax) recognized in our consolidated statement of operations for equity securities held as of </span><span style="font-family:Arial;font-size:10pt;">December 31, 2018</span><span style="font-family:Arial;font-size:10pt;"> was </span><span style="font-family:Arial;font-size:10pt;"><span>$20.1 million</span></span><span style="font-family:Arial;font-size:10pt;">.</span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">We periodically assess our investment in available-for-sale securities for other-than-temporary impairment losses. There were no other-than-temporary impairment losses recognized in </span><span style="font-family:Arial;font-size:10pt;">2018</span><span style="font-family:Arial;font-size:10pt;"> or </span><span style="font-family:Arial;font-size:10pt;">2017</span><span style="font-family:Arial;font-size:10pt;">. Other-than-temporary impairment losses recognized during the year ended December 31, </span><span style="font-family:Arial;font-size:10pt;">2016</span><span style="font-family:Arial;font-size:10pt;"> totaled </span><span style="font-family:Arial;font-size:10pt;"><span>$53.0 million</span></span><span style="font-family:Arial;font-size:10pt;">. Other-than-temporary impairment losses recognized during 2016 related primarily to our cost and equity method investments. </span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">We periodically assess our investments in equity securities other than public equity securities for impairment losses. Impairment losses recognized on these equity securities in </span><span style="font-family:Arial;font-size:10pt;">2018</span><span style="font-family:Arial;font-size:10pt;"> were immaterial.</span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">For fixed-income securities, the amount of credit losses are determined by comparing the difference between the present value of future cash flows expected to be collected on these securities and the amortized cost. Factors considered in assessing credit losses include the position in the capital structure, vintage and amount of collateral, delinquency rates, current credit support, and geographic concentration.</span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">For equity securities, factors considered in assessing impairment losses include the financial condition and near term prospects of the issuer and general market conditions and industry specific factors.</span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">As of </span><span style="font-family:Arial;font-size:10pt;">December 31, 2018</span><span style="font-family:Arial;font-size:10pt;">, the available-for-sale securities in an unrealized loss position include primarily fixed-rate debt securities of varying maturities, which are sensitive to changes in the yield curve and other market conditions. Approximately </span><span style="font-family:Arial;font-size:10pt;color:#000000;text-decoration:none;"><span>55 percent</span></span><span style="font-family:Arial;font-size:10pt;"> of the fixed-rate debt securities in a loss position are investment-grade debt securities. As of </span><span style="font-family:Arial;font-size:10pt;">December 31, 2018</span><span style="font-family:Arial;font-size:10pt;">, we do not intend to sell, and it is not more likely than not that we will be required to sell, the securities in a loss position before the market values recover or the underlying cash flows have been received, and there is no indication of default on interest or principal payments for any of our debt securities.</span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Activity related to our investment portfolio, substantially all of which related to equity and available-for-sale securities, was as follows:</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:62%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2017</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2016</span></div></td></tr><tr><td style="vertical-align:top;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Proceeds from sales</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d8d8d8;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>5,668.0</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d8d8d8;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>5,769.3</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d8d8d8;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>3,240.5</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Realized gross gains on sales</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>11.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>176.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>30.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Realized gross losses on sales</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>51.3</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>5.8</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>14.6</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Realized gains and losses on sales of available-for-sale investments are computed based upon specific identification of the initial cost adjusted for any other-than-temporary declines in fair value that were recorded in earnings.</span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Adjustments recorded to our equity investments without readily determinable fair values are based upon changes in the equity instrument's value resulting from observable price changes in orderly transactions for an identical or similar investment of the same issuer. Downward adjustments resulting from an impairment are recorded based upon the impairment considerations mentioned above. Adjustments recorded during </span><span style="font-family:Arial;font-size:10pt;">2018</span><span style="font-family:Arial;font-size:10pt;"> were not material.</span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-style:italic;">Accounts Receivable Factoring Arrangements</span></div><div style="line-height:120%;padding-bottom:16px;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">We have entered into accounts receivable factoring agreements with financial institutions to sell certain of our non-U.S. accounts receivable. These transactions are accounted for as sales and result in a reduction in accounts receivable because the agreements transfer effective control over and risk related to the receivables to the buyers. Our factoring agreements do not allow for recourse in the event of uncollectibility, and we do not retain any interest in the underlying accounts receivable once sold. We derecognized </span><span style="font-family:Arial;font-size:10pt;"><span>$696.2 million</span></span><span style="font-family:Arial;font-size:10pt;"> and </span><span style="font-family:Arial;font-size:10pt;"><span>$723.2 million</span></span><span style="font-family:Arial;font-size:10pt;"> of accounts receivable as of </span><span style="font-family:Arial;font-size:10pt;">December 31, 2018</span><span style="font-family:Arial;font-size:10pt;"> and </span><span style="font-family:Arial;font-size:10pt;">2017</span><span style="font-family:Arial;font-size:10pt;">, respectively, under these factoring arrangements. The costs of factoring such accounts receivable on our consolidated results of operations for the years ended </span><span style="font-family:Arial;font-size:10pt;">December 31, 2018</span><span style="font-family:Arial;font-size:10pt;">, </span><span style="font-family:Arial;font-size:10pt;">2017</span><span style="font-family:Arial;font-size:10pt;">, and </span><span style="font-family:Arial;font-size:10pt;">2016</span><span style="font-family:Arial;font-size:10pt;"> were not material.</span></div> <div style="line-height:120%;padding-top:12px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Financial instruments that potentially subject us to credit risk consist principally of trade receivables and interest-bearing investments. Wholesale distributors of life-science products account for a substantial portion of our trade receivables; collateral is generally not required. We seek to mitigate the risk associated with this concentration through our ongoing credit-review procedures and insurance. A large portion of our cash is held by a few major financial institutions. We monitor our exposures with these institutions and do not expect any of these institutions to fail to meet their obligations. Major financial institutions represent the largest component of our investments in corporate debt securities. In accordance with documented corporate risk-management policies, we monitor the amount of credit exposure to any one financial institution or corporate issuer. We are exposed to credit-related losses in the event of nonperformance by counterparties to risk-management instruments but do not expect any counterparties to fail to meet their obligations given their high credit ratings.</span></div> <div style="line-height:120%;padding-top:12px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">We consider all highly liquid investments with a maturity of three months or less from the date of purchase to be cash equivalents. The cost of these investments approximates fair value.</span></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Our equity investments are accounted for using three different methods depending on the type of equity investment:</span></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Arial;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Investments in companies over which we have significant influence but not a controlling interest are accounted for using the equity method, with our share of earnings or losses reported in other-net, (income) expense. </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Arial;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">For equity investments that do not have readily determinable fair values, we measure these investments at cost, less any impairment, plus or minus changes resulting from observable price changes in orderly transactions for the identical or similar investment of the same issuer. Any change in recorded value is recorded in other-net, (income) expense. </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Arial;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Our public equity investments are measured and carried at fair value. Any change in fair value is recognized in other-net, (income) expense. </span></div></td></tr></table><div style="line-height:120%;padding-top:12px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">We review equity investments other than public equity investments for indications of impairment on a regular basis.</span></div> P12M 785500000 685300000 2050000000.00 2350000000 435100000 48850000000 255600000 259700000 388300000 306700000 354000000.0 448100000 P30D 3400000000 3700000000 2650000000 3700000000 2460000000 754000000.0 350000000.0 <div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">In the normal course of business, our operations are exposed to fluctuations in interest rates which can vary the costs of financing, investing, and operating. We seek to address a portion of these risks through a controlled program of risk management that includes the use of derivative financial instruments. The objective of controlling these risks is to limit the impact of fluctuations in interest rates on earnings. Our primary interest-rate risk exposure results from changes in short-term U.S. dollar interest rates. In an effort to manage interest-rate exposures, we strive to achieve an acceptable balance between fixed- and floating-rate debt and investment positions and may enter into interest rate swaps or collars to help maintain that balance. </span></div>Interest rate swaps or collars that convert our fixed-rate debt to a floating rate are designated as fair value hedges of the underlying instruments. Interest rate swaps or collars that convert floating-rate debt to a fixed rate are designated as cash flow hedges. Interest expense on the debt is adjusted to include the payments made or received under the swap agreements. Cash proceeds from or payments to counterparties resulting from the termination of interest rate swaps are classified as operating activities in our consolidated statements of cash flows.<div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">We may enter into forward contracts and designate them as cash flow hedges to limit the potential volatility of earnings and cash flow associated with forecasted sales of available-for-sale securities.</span></div>We also may enter into forward-starting interest rate swaps, which we designate as cash flow hedges, as part of any anticipated future debt issuances in order to reduce the risk of cash flow volatility from future changes in interest rates. Upon completion of a debt issuance and termination of the swap, the change in fair value of these instruments is recorded as part of other comprehensive income (loss) and is amortized to interest expense over the life of the underlying debt.<div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Our derivative activities are initiated within the guidelines of documented corporate risk-management policies and are intended to offset losses and gains on the assets, liabilities, and transactions being hedged. Management reviews the correlation and effectiveness of our derivatives on a quarterly basis.</span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">For derivative instruments that are designated and qualify as fair value hedges, the derivative instrument is marked to market with gains and losses recognized currently in income to offset the respective losses and gains recognized on the underlying exposure. For derivative instruments that are designated and qualify as cash flow hedges, gains and losses are reported as a component of accumulated other comprehensive loss and reclassified into earnings in the same period the hedged transaction affects earnings. For derivative and non-derivative instruments that are designated and qualify as net investment hedges, the foreign currency translation gains or losses due to spot rate fluctuations are reported as a component of accumulated other comprehensive loss. Derivative contracts that are not designated as hedging instruments are recorded at fair value with the gain or loss recognized in earnings during the period of change.</span></div>We may enter into foreign currency forward or option contracts to reduce the effect of fluctuating currency exchange rates (principally the euro, British pound, and the Japanese yen). Foreign currency derivatives used for hedging are put in place using the same or like currencies and duration as the underlying exposures. Forward and option contracts are principally used to manage exposures arising from subsidiary trade and loan payables and receivables denominated in foreign currencies. These contracts are recorded at fair value with the gain or loss recognized in other–net, (income) expense. We may enter into foreign currency forward and option contracts and currency swaps as fair value hedges of firm commitments. 0.25 <div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">The following effects of risk-management instruments were recognized in other–net, (income) expense:</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:62%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2017</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2016</span></div></td></tr><tr><td style="vertical-align:top;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Fair value hedges:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Effect from hedged fixed-rate debt</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>(40.9</span></span></div></td><td style="vertical-align:bottom;padding-right:20px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(14.1</span></span></div></td><td style="vertical-align:bottom;padding-right:20px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(30.8</span></span></div></td><td style="vertical-align:bottom;padding-right:20px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#d8d8d8;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Effect from interest rate contracts</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>40.9</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>14.1</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>30.8</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Cash flow hedges:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#d8d8d8;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Effective portion of losses on interest rate contracts reclassified from accumulated other comprehensive loss</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>14.8</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>14.8</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>15.0</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Net losses on foreign currency exchange contracts not designated as hedging instruments</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>100.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>97.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>78.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Total </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#d8d8d8;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>114.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#d8d8d8;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>112.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#d8d8d8;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>93.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> -40900000 -14100000 -30800000 40900000 14100000 30800000 14800000 14800000 15000000.0 100000000.0 97900000 78800000 114800000 112700000 93800000 <div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">The effective portion of risk-management instruments that was recognized in other comprehensive income (loss) is as follows:</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:62%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2017</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2016</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Net investment hedges:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">    Foreign currency-denominated notes</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>110.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(361.5</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>137.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">    Cross-currency interest rate swaps</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>96.8</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(126.6</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>32.5</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">    Foreign currency exchange contracts</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>5.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>31.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#d1d1d1;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Cash flow hedges:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d1d1d1;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d1d1d1;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d1d1d1;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d1d1d1;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d1d1d1;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">    Forward-starting interest rate swaps</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>13.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(3.4</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 110400000 -361500000 137500000 96800000 -126600000 32500000 5700000 0 31900000 0 13000000.0 -3400000 -15000000.0 <div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">The following tables summarize certain fair value information at December 31 for assets and liabilities measured at fair value on a recurring basis, as well as the carrying amount and amortized cost of certain other investments:</span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="24"/></tr><tr><td style="width:29%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Fair Value Measurements Using</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Description</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Carrying</span></div><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Amount</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Cost</span><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:5pt"> (1)</sup></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Quoted Prices in Active Markets for Identical Assets</span></div><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">(Level 1)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Significant</span></div><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Other</span></div><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Observable</span></div><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Inputs</span></div><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">(Level 2)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Significant</span></div><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Unobservable</span></div><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Inputs</span></div><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">(Level 3)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Fair</span></div><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Value</span></div></td></tr><tr><td style="vertical-align:top;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">December 31, 2018</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Cash equivalents</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>5,727.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>5,727.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>5,727.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>5,727.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Short-term investments:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">U.S. government and agency securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>16.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>17.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>16.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>16.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#d8d8d8;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Corporate debt securities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>62.2</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>62.6</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>62.2</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>62.2</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Asset-backed securities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>7.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>7.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>7.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>7.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#d8d8d8;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Other securities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>1.5</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>1.5</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>1.5</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>1.5</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Short-term investments</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>88.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td colspan="24" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Noncurrent investments:</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">U.S. government and agency securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>149.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>153.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>149.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>149.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#d8d8d8;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Corporate debt securities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>568.0</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>587.8</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>568.0</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>568.0</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Mortgage-backed securities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>111.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>114.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>111.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>111.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#d8d8d8;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Asset-backed securities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>27.7</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>27.9</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>27.7</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>27.7</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Other securities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>87.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>29.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>87.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>87.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#d8d8d8;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Marketable equity securities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>357.5</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>238.3</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>357.5</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>357.5</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Equity investments without readily determinable fair values</span><span style="font-family:Arial;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(2)</sup></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>414.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#d1d1d1;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Equity method investments</span><span style="font-family:Arial;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(2)</sup></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d1d1d1;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>289.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d1d1d1;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d1d1d1;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d1d1d1;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d1d1d1;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d1d1d1;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d1d1d1;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d1d1d1;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d1d1d1;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d1d1d1;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d1d1d1;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d1d1d1;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Noncurrent investments</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>2,005.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#d1d1d1;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d1d1d1;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d1d1d1;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d1d1d1;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d1d1d1;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d1d1d1;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d1d1d1;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d1d1d1;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d1d1d1;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d1d1d1;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d1d1d1;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d1d1d1;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">December 31, 2017</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#d1d1d1;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Cash equivalents</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d1d1d1;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#d1d1d1;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>4,763.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#d1d1d1;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#d1d1d1;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d1d1d1;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#d1d1d1;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>4,763.9</span></span></div></td><td style="vertical-align:bottom;background-color:#d1d1d1;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d1d1d1;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d1d1d1;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#d1d1d1;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>4,712.4</span></span></div></td><td style="vertical-align:bottom;background-color:#d1d1d1;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d1d1d1;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d1d1d1;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#d1d1d1;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>51.5</span></span></div></td><td style="vertical-align:bottom;background-color:#d1d1d1;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d1d1d1;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d1d1d1;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#d1d1d1;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#d1d1d1;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d1d1d1;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d1d1d1;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#d1d1d1;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>4,763.9</span></span></div></td><td style="vertical-align:bottom;background-color:#d1d1d1;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Short-term investments:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#d1d1d1;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">U.S. government and agency securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d1d1d1;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#d1d1d1;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>217.8</span></span></div></td><td style="vertical-align:bottom;background-color:#d1d1d1;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d1d1d1;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d1d1d1;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#d1d1d1;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>218.2</span></span></div></td><td style="vertical-align:bottom;background-color:#d1d1d1;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d1d1d1;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d1d1d1;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#d1d1d1;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>217.8</span></span></div></td><td style="vertical-align:bottom;background-color:#d1d1d1;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d1d1d1;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d1d1d1;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#d1d1d1;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#d1d1d1;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d1d1d1;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d1d1d1;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#d1d1d1;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#d1d1d1;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d1d1d1;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d1d1d1;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#d1d1d1;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>217.8</span></span></div></td><td style="vertical-align:bottom;background-color:#d1d1d1;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Corporate debt securities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>1,182.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>1,183.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>1,182.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>1,182.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#d1d1d1;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Asset-backed securities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d1d1d1;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>94.2</span></span></div></td><td style="vertical-align:bottom;background-color:#d1d1d1;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d1d1d1;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d1d1d1;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>94.3</span></span></div></td><td style="vertical-align:bottom;background-color:#d1d1d1;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d1d1d1;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d1d1d1;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#d1d1d1;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d1d1d1;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d1d1d1;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>94.2</span></span></div></td><td style="vertical-align:bottom;background-color:#d1d1d1;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d1d1d1;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d1d1d1;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#d1d1d1;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d1d1d1;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d1d1d1;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>94.2</span></span></div></td><td style="vertical-align:bottom;background-color:#d1d1d1;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Other securities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>3.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>3.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>3.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>3.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#d1d1d1;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Short-term investments</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d1d1d1;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#d1d1d1;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>1,497.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#d1d1d1;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#d1d1d1;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d1d1d1;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d1d1d1;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d1d1d1;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d1d1d1;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d1d1d1;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d1d1d1;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d1d1d1;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d1d1d1;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d1d1d1;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d1d1d1;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d1d1d1;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Noncurrent investments:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#d1d1d1;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">U.S. government and agency securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d1d1d1;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#d1d1d1;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>360.0</span></span></div></td><td style="vertical-align:bottom;background-color:#d1d1d1;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d1d1d1;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d1d1d1;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#d1d1d1;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>365.0</span></span></div></td><td style="vertical-align:bottom;background-color:#d1d1d1;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d1d1d1;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d1d1d1;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#d1d1d1;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>360.0</span></span></div></td><td style="vertical-align:bottom;background-color:#d1d1d1;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d1d1d1;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d1d1d1;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#d1d1d1;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#d1d1d1;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d1d1d1;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d1d1d1;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#d1d1d1;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#d1d1d1;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d1d1d1;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d1d1d1;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#d1d1d1;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>360.0</span></span></div></td><td style="vertical-align:bottom;background-color:#d1d1d1;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Corporate debt securities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>3,464.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>3,473.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>3,464.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>3,464.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#d1d1d1;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Mortgage-backed securities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d1d1d1;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>202.4</span></span></div></td><td style="vertical-align:bottom;background-color:#d1d1d1;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d1d1d1;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d1d1d1;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>204.2</span></span></div></td><td style="vertical-align:bottom;background-color:#d1d1d1;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d1d1d1;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d1d1d1;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#d1d1d1;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d1d1d1;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d1d1d1;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>202.4</span></span></div></td><td style="vertical-align:bottom;background-color:#d1d1d1;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d1d1d1;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d1d1d1;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#d1d1d1;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d1d1d1;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d1d1d1;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>202.4</span></span></div></td><td style="vertical-align:bottom;background-color:#d1d1d1;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Asset-backed securities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>653.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>656.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>653.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>653.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#d1d1d1;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Other securities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d1d1d1;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>132.1</span></span></div></td><td style="vertical-align:bottom;background-color:#d1d1d1;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d1d1d1;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d1d1d1;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>66.4</span></span></div></td><td style="vertical-align:bottom;background-color:#d1d1d1;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d1d1d1;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d1d1d1;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#d1d1d1;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d1d1d1;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d1d1d1;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#d1d1d1;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d1d1d1;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d1d1d1;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>132.1</span></span></div></td><td style="vertical-align:bottom;background-color:#d1d1d1;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d1d1d1;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d1d1d1;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>132.1</span></span></div></td><td style="vertical-align:bottom;background-color:#d1d1d1;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Marketable equity securities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>281.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>131.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>281.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>281.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#d1d1d1;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Cost and equity method investments</span><span style="font-family:Arial;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(2)</sup></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d1d1d1;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>572.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d1d1d1;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d1d1d1;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d1d1d1;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d1d1d1;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d1d1d1;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d1d1d1;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d1d1d1;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d1d1d1;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d1d1d1;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d1d1d1;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d1d1d1;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d1d1d1;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Noncurrent investments</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>5,666.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:4px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(1) </sup></span><span style="font-family:Arial;font-size:8pt;">For available-for-sale debt securities, amounts disclosed represent the securities' amortized cost.</span></div><div style="line-height:120%;padding-top:8px;padding-left:12px;text-indent:-12px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(2) </sup></span><span style="font-family:Arial;font-size:8pt;">Fair value disclosures are not applicable for equity method investments, investments accounted for under the measurement alternative for equity investments, and cost method investments that do not have readily determinable fair values.</span></div> 5727100000 5727100000 5727100000 0 0 5727100000 16900000 17100000 16900000 0 0 16900000 62200000 62600000 0 62200000 0 62200000 7600000 7700000 0 7600000 0 7600000 1500000 1500000 0 1500000 0 1500000 88200000 149100000 153600000 149100000 0 0 149100000 568000000.0 587800000 0 568000000.0 0 568000000.0 111400000 114500000 0 111400000 0 111400000 27700000 27900000 0 27700000 0 27700000 87800000 29700000 0 0 87800000 87800000 357500000 238300000 357500000 0 0 357500000 414700000 289200000 2005400000 4763900000 4763900000 4712400000 51500000 0 4763900000 217800000 218200000 217800000 0 0 217800000 1182300000 1183200000 0 1182300000 0 1182300000 94200000 94300000 0 94200000 0 94200000 3600000 3600000 0 3600000 0 3600000 1497900000 360000000.0 365000000.0 360000000.0 0 0 360000000.0 3464300000 3473500000 0 3464300000 0 3464300000 202400000 204200000 0 202400000 0 202400000 653900000 656000000.0 0 653900000 0 653900000 132100000 66400000 0 0 132100000 132100000 281300000 131000000.0 281300000 0 0 281300000 572500000 5666500000 <div style="line-height:120%;padding-top:8px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="20"/></tr><tr><td style="width:41%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Fair Value Measurements Using</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Description</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Carrying</span></div><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Amount</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Quoted Prices in Active Markets for Identical Assets</span></div><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">(Level 1)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Significant</span></div><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Other</span></div><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Observable</span></div><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Inputs</span></div><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">(Level 2)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Significant</span></div><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Unobservable</span></div><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Inputs</span></div><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">(Level 3)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Fair</span></div><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Value</span></div></td></tr><tr><td style="vertical-align:top;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">Short-term commercial paper borrowings</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">December 31, 2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>(498.9</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>(497.6</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>(497.6</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">December 31, 2017</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(2,696.8</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(2,690.6</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(2,690.6</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">Long-term debt, including current portion</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">December 31, 2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>(9,799.7</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>(9,989.4</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>(9,989.4</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">December 31, 2017</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(10,950.3</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(11,529.9</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(11,529.9</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><br/></span></div> 498900000 0 497600000 0 497600000 2696800000 0 2690600000 0 2690600000 9799700000 0 9989400000 0 9989400000 10950300000 0 11529900000 0 11529900000 <div style="line-height:120%;padding-top:8px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="20"/></tr><tr><td style="width:41%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Fair Value Measurements Using</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Description</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Carrying</span></div><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Amount</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Quoted Prices in Active Markets for Identical Assets</span></div><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">(Level 1)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Significant</span></div><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Other</span></div><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Observable</span></div><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Inputs</span></div><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">(Level 2)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Significant</span></div><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Unobservable</span></div><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Inputs</span></div><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">(Level 3)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Fair</span></div><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Value</span></div></td></tr><tr><td style="vertical-align:top;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">December 31, 2018</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Risk-management instruments</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#d8d8d8;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Interest rate contracts designated as fair value hedges:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Sundry</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>4.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>4.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>4.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#d8d8d8;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Other current liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>(22.3</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>(22.3</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>(22.3</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Other noncurrent liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>(19.0</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>(19.0</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>(19.0</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#d8d8d8;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Cross-currency interest rate contracts designated as net investment hedges:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Other receivables</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>69.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>69.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>69.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#d8d8d8;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Sundry</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>8.2</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>8.2</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>8.2</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Other current liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>(9.2</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>(9.2</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>(9.2</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#d8d8d8;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Cross-currency interest rate contracts not designated as hedging instruments:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Other noncurrent liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>(25.8</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>(25.8</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>(25.8</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#d8d8d8;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Foreign exchange contracts not designated as hedging instruments:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Other receivables</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>11.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>11.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>11.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#d8d8d8;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Other current liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>(16.3</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>(16.3</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>(16.3</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">December 31, 2017</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Risk-management instruments</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#d8d8d8;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Interest rate contracts designated as fair value hedges:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Other receivables</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>0.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>0.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>0.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#d8d8d8;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Sundry</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>35.1</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>35.1</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>35.1</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Other current liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(0.2</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(0.2</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(0.2</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#d8d8d8;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Other noncurrent liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(10.5</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(10.5</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(10.5</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Cross-currency interest rate contracts designated as net investment hedges:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#d8d8d8;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">    Other current liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(33.4</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(33.4</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(33.4</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">    Other noncurrent liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(26.0</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(26.0</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(26.0</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#d8d8d8;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Foreign exchange contracts not designated as hedging instruments:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Other receivables</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>26.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>26.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>26.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#d8d8d8;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Other current liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(36.0</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(36.0</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(36.0</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Contingent consideration liabilities</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#d8d8d8;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Other current liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(206.7</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(206.7</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(206.7</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 4500000 0 4500000 0 4500000 22300000 0 22300000 0 22300000 19000000.0 0 19000000.0 0 19000000.0 69200000 0 69200000 0 69200000 8200000 0 8200000 0 8200000 9200000 0 9200000 0 9200000 25800000 0 25800000 0 25800000 11300000 0 11300000 0 11300000 16300000 0 16300000 0 16300000 800000 0 800000 0 800000 35100000 0 35100000 0 35100000 200000 0 200000 0 200000 10500000 0 10500000 0 10500000 33400000 0 33400000 0 33400000 26000000.0 0 26000000.0 0 26000000.0 26800000 0 26800000 0 26800000 36000000.0 0 36000000.0 0 36000000.0 206700000 0 0 206700000 206700000 199700000 203100000 <div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">The table below summarizes the contractual maturities of our investments in debt securities measured at fair value as of </span><span style="font-family:Arial;font-size:10pt;color:#000000;text-decoration:none;">December 31, 2018</span><span style="font-family:Arial;font-size:10pt;">:</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.79423868312757%;border-collapse:collapse;text-align:left;"><tr><td colspan="20"/></tr><tr><td style="width:41%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"> </span></div></td><td colspan="19" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Maturities by Period</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">  </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Less Than</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">1 Year</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">1-5 Years</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">6-10 Years</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">More Than 10 Years</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Fair value of debt securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d8d8d8;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>943.0</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>86.8</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>604.8</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>97.0</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>154.4</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 943000000.0 86800000 604800000 97000000.0 154400000 <div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">A summary of the fair value of available-for-sale securities in an unrealized gain or loss position and the amount of unrealized gains and losses (pretax) in accumulated other comprehensive loss follows:</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.79423868312757%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:75%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:top;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Unrealized gross gains</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d8d8d8;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>0.8</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d8d8d8;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>184.7</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Unrealized gross losses</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>29.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>47.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Fair value of securities in an unrealized gain position</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>84.3</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>1,434.2</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Fair value of securities in an unrealized loss position</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>858.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>4,692.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 800000 184700000 29000000.0 47500000 84300000 1434200000 858600000 4692800000 -20100000 53000000.0 0.55 <div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Activity related to our investment portfolio, substantially all of which related to equity and available-for-sale securities, was as follows:</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:62%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2017</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2016</span></div></td></tr><tr><td style="vertical-align:top;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Proceeds from sales</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d8d8d8;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>5,668.0</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d8d8d8;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>5,769.3</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d8d8d8;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>3,240.5</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Realized gross gains on sales</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>11.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>176.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>30.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Realized gross losses on sales</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>51.3</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>5.8</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>14.6</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 5668000000.0 5769300000 3240500000 11800000 176000000.0 30700000 51300000 5800000 14600000 696200000 723200000 Goodwill and Other Intangibles<div style="line-height:120%;padding-top:12px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-style:italic;">Goodwill</span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Goodwill results from excess consideration in a business combination over the fair value of identifiable net assets acquired. Goodwill is not amortized but is reviewed for impairment at least annually and when impairment indicators are present. When required, a comparison of the fair value of the reporting unit to its carrying amount including goodwill is used to determine the amount of any impairment.</span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>No</span></span><span style="font-family:Arial;font-size:10pt;"> impairments occurred with respect to the carrying value of goodwill for the years ended </span><span style="font-family:Arial;font-size:10pt;">December 31, 2018</span><span style="font-family:Arial;font-size:10pt;">, </span><span style="font-family:Arial;font-size:10pt;">2017</span><span style="font-family:Arial;font-size:10pt;">, and </span><span style="font-family:Arial;font-size:10pt;color:#000000;text-decoration:none;">2016</span><span style="font-family:Arial;font-size:10pt;">.</span></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-style:italic;">Other Intangibles</span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">The components of intangible assets other than goodwill at December 31 were as follows:</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="24"/></tr><tr><td style="width:23%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Description</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Carrying</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Amount, </span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Gross</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Accumulated</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Amortization</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Carrying</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Amount, </span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Net</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Carrying</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Amount, </span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Gross</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Accumulated</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Amortization</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Carrying</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Amount, </span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Net</span></div></td></tr><tr><td style="vertical-align:top;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Finite-lived intangible assets:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Marketed products</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>2,077.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>(1,069.0</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>1,008.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>4,528.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(3,251.3</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>1,277.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#d8d8d8;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Other</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>89.5</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>(29.7</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>59.8</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>117.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(40.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d8d8d8;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>76.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Other intangibles</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>2,166.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>(1,098.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>1,068.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>4,645.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(3,291.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>1,354.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Marketed products consist of the amortized cost of the rights to assets acquired in business combinations and approved for marketing in a significant global jurisdiction (U.S., Europe, and Japan) and capitalized milestone payments. For transactions other than a business combination, we capitalize milestone payments incurred at or after the product has obtained regulatory approval for marketing.</span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Other finite-lived intangibles consist primarily of the amortized cost of licensed platform technologies that have alternative future uses in research and development, manufacturing technologies, and customer relationships from business combinations. </span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Acquired IPR&D consists of the related costs capitalized, adjusted for subsequent impairments, if any. The costs of acquired IPR&D projects acquired directly in a transaction other than a business combination are capitalized if the projects have an alternative future use; otherwise, they are expensed immediately. The fair values of acquired IPR&D projects acquired in business combinations, if any, are capitalized as other intangible assets. As of </span><span style="font-family:Arial;font-size:10pt;">December 31, 2018</span><span style="font-family:Arial;font-size:10pt;"> and 2017, we had </span><span style="font-family:Arial;font-size:10pt;">no</span><span style="font-family:Arial;font-size:10pt;"> acquired IPR&D indefinite-lived intangible assets.</span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Several methods may be used to determine the estimated fair value of other intangibles acquired in a business combination. We utilize the “income method,” which is a Level 3 fair value measurement and applies a probability weighting that considers the risk of development and commercialization to the estimated future net cash flows that are derived from projected revenues and estimated costs. These projections are based on factors such as relevant market size, patent protection, historical pricing of similar products, and expected industry trends. The estimated future net cash flows are then discounted to the present value using an appropriate discount rate. This analysis is performed for each asset independently. The acquired IPR&D assets are treated as indefinite-lived intangible assets until completion or abandonment of the projects, at which time the assets are tested for impairment and amortized over the remaining useful life or written off, as appropriate. </span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">See Note 4 for additional discussion of recent capitalized milestone payments.</span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Other indefinite-lived intangible assets are reviewed for impairment at least annually and when impairment indicators are present. Finite-lived intangible assets are reviewed for impairment when an indicator of impairment is present. When required, a comparison of fair value to the carrying amount of assets is performed to determine the amount of any impairment. When determining the fair value of indefinite-lived acquired IPR&D as well as the fair value of finite-lived intangible assets for impairment testing purposes, we utilize the "income method" discussed above. During 2018, we had finite-lived intangible impairment charges of </span><span style="font-family:Arial;font-size:10pt;"><span>$46.9 million</span></span><span style="font-family:Arial;font-size:10pt;"> which were recorded in asset impairment, restructuring and other special charges on the consolidated statements of operations. These impairments were primarily related to the sale of the Posilac (rbST) brand. During 2017, we had finite-lived intangible impairment charges of </span><span style="font-family:Arial;font-size:10pt;"><span>$50.0 million</span></span><span style="font-family:Arial;font-size:10pt;"> which were recorded in asset impairment, restructuring and other special charges on the consolidated statements of operations. These impairments were related to lower projected revenue for Posilac (rbST). No material impairments occurred with respect to the carrying value of other intangible assets for the year ended December 31, </span><span style="font-family:Arial;font-size:10pt;">2016</span><span style="font-family:Arial;font-size:10pt;">. </span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Intangible assets with finite lives are capitalized and are amortized over their estimated useful lives, ranging from </span><span style="font-family:Arial;font-size:10pt;">three</span><span style="font-family:Arial;font-size:10pt;"> to </span><span style="font-family:Arial;font-size:10pt;"><span>20</span></span><span style="font-family:Arial;font-size:10pt;"> years. As of </span><span style="font-family:Arial;font-size:10pt;color:#000000;text-decoration:none;">December 31, 2018</span><span style="font-family:Arial;font-size:10pt;">, the remaining weighted-average amortization period for finite-lived intangible assets was approximately </span><span style="font-family:Arial;font-size:10pt;"><span>10 years</span></span><span style="font-family:Arial;font-size:10pt;">. </span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Amortization expense related to finite-lived intangible assets was as follows:</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:62%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2017</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2016</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Amortization expense</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d8d8d8;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>361.3</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>462.2</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>517.2</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">The estimated amortization expense for each of the next five years associated with our finite-lived intangible assets as of </span><span style="font-family:Arial;font-size:10pt;">December 31, 2018</span><span style="font-family:Arial;font-size:10pt;"> is as follows:</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="20"/></tr><tr><td style="width:51%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2021</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2022</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2023</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Estimated amortization expense</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d8d8d8;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>145.4</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>144.0</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>141.6</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>133.8</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>122.6</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:16px;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Amortization expense is included in either cost of sales, marketing, selling, and administrative or research and development depending on the nature of the intangible asset being amortized.</span></div> 0 <div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">The components of intangible assets other than goodwill at December 31 were as follows:</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="24"/></tr><tr><td style="width:23%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Description</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Carrying</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Amount, </span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Gross</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Accumulated</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Amortization</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Carrying</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Amount, </span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Net</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Carrying</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Amount, </span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Gross</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Accumulated</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Amortization</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Carrying</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Amount, </span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Net</span></div></td></tr><tr><td style="vertical-align:top;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Finite-lived intangible assets:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Marketed products</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>2,077.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>(1,069.0</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>1,008.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>4,528.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(3,251.3</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>1,277.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#d8d8d8;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Other</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>89.5</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>(29.7</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>59.8</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>117.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(40.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d8d8d8;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>76.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Other intangibles</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>2,166.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>(1,098.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>1,068.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>4,645.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(3,291.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>1,354.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 2077200000 1069000000.0 1008200000 4528800000 3251300000 1277500000 89500000 29700000 59800000 117100000 40200000 76900000 2166700000 1098700000 1068000000.0 4645900000 3291500000 1354400000 For transactions other than a business combination, we capitalize milestone payments incurred at or after the product has obtained regulatory approval for marketing.<div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Goodwill results from excess consideration in a business combination over the fair value of identifiable net assets acquired. Goodwill is not amortized but is reviewed for impairment at least annually and when impairment indicators are present. When required, a comparison of the fair value of the reporting unit to its carrying amount including goodwill is used to determine the amount of any impairment.</span></div>The costs of acquired IPR&D projects acquired directly in a transaction other than a business combination are capitalized if the projects have an alternative future use; otherwise, they are expensed immediately. The fair values of acquired IPR&D projects acquired in business combinations, if any, are capitalized as other intangible assets. As of <span style="font-family:Arial;font-size:10pt;">December 31, 2018</span><span style="font-family:Arial;font-size:10pt;"> and 2017, we had </span><span style="font-family:Arial;font-size:10pt;">no</span><span style="font-family:Arial;font-size:10pt;"> acquired IPR&D indefinite-lived intangible assets.</span><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Several methods may be used to determine the estimated fair value of other intangibles acquired in a business combination. We utilize the “income method,” which is a Level 3 fair value measurement and applies a probability weighting that considers the risk of development and commercialization to the estimated future net cash flows that are derived from projected revenues and estimated costs. These projections are based on factors such as relevant market size, patent protection, historical pricing of similar products, and expected industry trends. The estimated future net cash flows are then discounted to the present value using an appropriate discount rate. This analysis is performed for each asset independently. The acquired IPR&D assets are treated as indefinite-lived intangible assets until completion or abandonment of the projects, at which time the assets are tested for impairment and amortized over the remaining useful life or written off, as appropriate. </span></div>Other indefinite-lived intangible assets are reviewed for impairment at least annually and when impairment indicators are present. Finite-lived intangible assets are reviewed for impairment when an indicator of impairment is present. When required, a comparison of fair value to the carrying amount of assets is performed to determine the amount of any impairment. When determining the fair value of indefinite-lived acquired IPR&D as well as the fair value of finite-lived intangible assets for impairment testing purposes, we utilize the "income method" discussed above. 46900000 50000000.0 P20Y P10Y <div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Amortization expense related to finite-lived intangible assets was as follows:</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:62%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2017</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2016</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Amortization expense</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d8d8d8;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>361.3</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>462.2</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>517.2</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 361300000 462200000 517200000 <div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">The estimated amortization expense for each of the next five years associated with our finite-lived intangible assets as of </span><span style="font-family:Arial;font-size:10pt;">December 31, 2018</span><span style="font-family:Arial;font-size:10pt;"> is as follows:</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="20"/></tr><tr><td style="width:51%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2021</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2022</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2023</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Estimated amortization expense</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d8d8d8;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>145.4</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>144.0</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>141.6</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>133.8</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>122.6</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 145400000 144000000.0 141600000 133800000 122600000 Property and Equipment<div style="line-height:120%;padding-top:12px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Property and equipment is stated on the basis of cost. Provisions for depreciation of buildings and equipment are computed generally by the straight-line method at rates based on their estimated useful lives (</span><span style="font-family:Arial;font-size:10pt;"><span>12</span></span><span style="font-family:Arial;font-size:10pt;"> to </span><span style="font-family:Arial;font-size:10pt;"><span>50</span></span><span style="font-family:Arial;font-size:10pt;"> years for buildings and </span><span style="font-family:Arial;font-size:10pt;">three</span><span style="font-family:Arial;font-size:10pt;"> to </span><span style="font-family:Arial;font-size:10pt;"><span>25</span></span><span style="font-family:Arial;font-size:10pt;"> years for equipment). We review the carrying value of long-lived assets for potential impairment on a periodic basis and whenever events or changes in circumstances indicate the carrying value of an asset may not be recoverable. Impairment is determined by comparing projected undiscounted cash flows to be generated by the asset to its carrying value. If an impairment is identified, a loss is recorded equal to the excess of the asset’s net book value over its fair value, and the cost basis is adjusted.</span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">At December 31, property and equipment consisted of the following:</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.79423868312757%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:75%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:top;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Land</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d8d8d8;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>165.5</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d8d8d8;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>167.7</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Buildings</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>7,116.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>6,826.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Equipment</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>7,792.3</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>7,684.1</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Construction in progress</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>1,588.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>1,600.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>16,663.0</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>16,279.3</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Less accumulated depreciation</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>(8,666.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:12px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(8,394.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:12px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Property and equipment, net</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#d8d8d8;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>7,996.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#d8d8d8;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>7,885.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Depreciation expense related to property and equipment and rental expense for all leases, including contingent rentals (not material), was as follows:</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:71%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2017</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2016</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Depreciation expense</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d8d8d8;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>797.1</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d8d8d8;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>681.7</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>638.8</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Rental expense</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>175.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>177.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>179.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">The future minimum rental commitments under non-cancelable operating leases are as follows:</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.58847736625515%;border-collapse:collapse;text-align:left;"><tr><td colspan="24"/></tr><tr><td style="width:41%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2021</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2022</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2023</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">After 2023</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Lease commitments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d8d8d8;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>130.6</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d8d8d8;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>107.9</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d8d8d8;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>75.5</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d8d8d8;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>64.7</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d8d8d8;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>49.9</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d8d8d8;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>281.0</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Capitalized interest costs were not material for the years ended </span><span style="font-family:Arial;font-size:10pt;color:#000000;text-decoration:none;">December 31, 2018</span><span style="font-family:Arial;font-size:10pt;">, </span><span style="font-family:Arial;font-size:10pt;color:#000000;text-decoration:none;">2017</span><span style="font-family:Arial;font-size:10pt;">, and </span><span style="font-family:Arial;font-size:10pt;color:#000000;text-decoration:none;">2016</span><span style="font-family:Arial;font-size:10pt;">. </span></div><div style="line-height:120%;padding-bottom:16px;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Assets under capital leases included in property and equipment, net on the consolidated balance sheets, capital lease obligations entered into, and future minimum rental commitments are not material.</span></div> <div style="line-height:120%;padding-top:12px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Property and equipment is stated on the basis of cost. Provisions for depreciation of buildings and equipment are computed generally by the straight-line method at rates based on their estimated useful lives (</span><span style="font-family:Arial;font-size:10pt;"><span>12</span></span><span style="font-family:Arial;font-size:10pt;"> to </span><span style="font-family:Arial;font-size:10pt;"><span>50</span></span><span style="font-family:Arial;font-size:10pt;"> years for buildings and </span><span style="font-family:Arial;font-size:10pt;">three</span><span style="font-family:Arial;font-size:10pt;"> to </span><span style="font-family:Arial;font-size:10pt;"><span>25</span></span><span style="font-family:Arial;font-size:10pt;"> years for equipment). We review the carrying value of long-lived assets for potential impairment on a periodic basis and whenever events or changes in circumstances indicate the carrying value of an asset may not be recoverable. Impairment is determined by comparing projected undiscounted cash flows to be generated by the asset to its carrying value. If an impairment is identified, a loss is recorded equal to the excess of the asset’s net book value over its fair value, and the cost basis is adjusted.</span></div> P12Y P50Y P25Y <div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">At December 31, property and equipment consisted of the following:</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.79423868312757%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:75%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:top;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Land</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d8d8d8;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>165.5</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d8d8d8;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>167.7</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Buildings</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>7,116.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>6,826.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Equipment</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>7,792.3</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>7,684.1</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Construction in progress</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>1,588.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>1,600.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>16,663.0</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>16,279.3</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Less accumulated depreciation</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>(8,666.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:12px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(8,394.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:12px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Property and equipment, net</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#d8d8d8;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>7,996.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#d8d8d8;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>7,885.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 165500000 167700000 7116600000 6826900000 7792300000 7684100000 1588600000 1600600000 16663000000.0 16279300000 8666900000 8394200000 7996100000 7885100000 <div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Depreciation expense related to property and equipment and rental expense for all leases, including contingent rentals (not material), was as follows:</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:71%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2017</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2016</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Depreciation expense</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d8d8d8;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>797.1</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d8d8d8;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>681.7</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>638.8</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Rental expense</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>175.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>177.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>179.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 797100000 681700000 638800000 175700000 177400000 179200000 <div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">The future minimum rental commitments under non-cancelable operating leases are as follows:</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.58847736625515%;border-collapse:collapse;text-align:left;"><tr><td colspan="24"/></tr><tr><td style="width:41%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2021</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2022</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2023</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">After 2023</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Lease commitments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d8d8d8;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>130.6</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d8d8d8;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>107.9</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d8d8d8;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>75.5</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d8d8d8;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>64.7</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d8d8d8;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>49.9</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d8d8d8;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>281.0</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 130600000 107900000 75500000 64700000 49900000 281000000.0 Borrowings<div style="line-height:120%;padding-top:12px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Debt at December 31 consisted of the following:</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.79423868312757%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:75%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:top;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Short-term commercial paper borrowings</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>498.9</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>2,696.8</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">0.15 to 7.13 percent long-term notes (due 2019-2047)</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>9,640.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>10,756.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Other long-term debt</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>10.1</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>13.0</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Unamortized debt issuance costs</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>(28.4</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(49.0</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Fair value adjustment on hedged long-term notes</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>177.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>229.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Total debt</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>10,298.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>13,646.5</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Less current portion</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>(1,102.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d8d8d8;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(3,706.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d8d8d8;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Long-term debt</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>9,196.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>9,940.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">The weighted-average effective borrowing rate on outstanding commercial paper at </span><span style="font-family:Arial;font-size:10pt;">December 31, 2018</span><span style="font-family:Arial;font-size:10pt;"> was </span><span style="font-family:Arial;font-size:10pt;"><span>2.36 percent</span></span><span style="font-family:Arial;font-size:10pt;">. </span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">At </span><span style="font-family:Arial;font-size:10pt;">December 31, 2018</span><span style="font-family:Arial;font-size:10pt;">, we had a total of </span><span style="font-family:Arial;font-size:10pt;"><span>$5.42 billion</span></span><span style="font-family:Arial;font-size:10pt;"> of unused committed bank credit facilities, which consisted primarily of a </span><span style="font-family:Arial;font-size:10pt;"><span>$3.00 billion</span></span><span style="font-family:Arial;font-size:10pt;"> credit facility that expires in December 2023 and a </span><span style="font-family:Arial;font-size:10pt;"><span>$2.00 billion</span></span><span style="font-family:Arial;font-size:10pt;"> </span><span style="font-family:Arial;font-size:10pt;"><span>364</span></span><span style="font-family:Arial;font-size:10pt;">-day facility that expires in December 2019, both of which are available to support our commercial paper program. We have not drawn against the </span><span style="font-family:Arial;font-size:10pt;"><span>$3.00 billion</span></span><span style="font-family:Arial;font-size:10pt;"> and </span><span style="font-family:Arial;font-size:10pt;"><span>$2.00 billion</span></span><span style="font-family:Arial;font-size:10pt;"> facilities. Of the remaining facilities, there was </span><span style="font-family:Arial;font-size:10pt;"><span>$25.9 million</span></span><span style="font-family:Arial;font-size:10pt;"> outstanding under the revolving credit facilities as of </span><span style="font-family:Arial;font-size:10pt;">December 31, 2018</span><span style="font-family:Arial;font-size:10pt;">, and </span><span style="font-family:Arial;font-size:10pt;"><span>$6.0 million</span></span><span style="font-family:Arial;font-size:10pt;"> was outstanding under these facilities as of </span><span style="font-family:Arial;font-size:10pt;">December 31, 2017</span><span style="font-family:Arial;font-size:10pt;">. Compensating balances and commitment fees are not material, and there are no conditions that are probable of occurring under which the lines may be withdrawn. </span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">In May 2017, we issued </span><span style="font-family:Arial;font-size:10pt;"><span>$750.0 million</span></span><span style="font-family:Arial;font-size:10pt;"> of </span><span style="font-family:Arial;font-size:10pt;"><span>2.35 percent</span></span><span style="font-family:Arial;font-size:10pt;"> fixed-rate notes due in May 2022, </span><span style="font-family:Arial;font-size:10pt;"><span>$750.0 million</span></span><span style="font-family:Arial;font-size:10pt;"> of </span><span style="font-family:Arial;font-size:10pt;"><span>3.10 percent</span></span><span style="font-family:Arial;font-size:10pt;"> fixed-rate notes due in May 2027, and </span><span style="font-family:Arial;font-size:10pt;"><span>$750.0 million</span></span><span style="font-family:Arial;font-size:10pt;"> of </span><span style="font-family:Arial;font-size:10pt;"><span>3.95 percent</span></span><span style="font-family:Arial;font-size:10pt;"> fixed-rate notes due in May 2047, with interest to be paid semi-annually. We are using the net proceeds of </span><span style="font-family:Arial;font-size:10pt;"><span>$2.23 billion</span></span><span style="font-family:Arial;font-size:10pt;"> from the sale of these notes for general corporate purposes, which included the repayment of notes due in 2018 and may include the repayment of notes due in 2019. Prior to such uses, we may temporarily invest the net proceeds in investment securities.</span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">The aggregate amounts of maturities on long-term debt for the next five years are as follows:</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="20"/></tr><tr><td style="width:51%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2021</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2022</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2023</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Maturities on long-term debt</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d8d8d8;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>604.5</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>3.5</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>2.3</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>1,439.0</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>0.3</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">We have converted approximately </span><span style="font-family:Arial;font-size:10pt;color:#000000;text-decoration:none;"><span>25 percent</span></span><span style="font-family:Arial;font-size:10pt;"> of our long-term fixed-rate notes to floating rates through the use of interest rate swaps. The weighted-average effective borrowing rates based on long-term debt obligations and interest rates at </span><span style="font-family:Arial;font-size:10pt;color:#000000;text-decoration:none;">December 31, 2018</span><span style="font-family:Arial;font-size:10pt;"> and </span><span style="font-family:Arial;font-size:10pt;color:#000000;text-decoration:none;">2017</span><span style="font-family:Arial;font-size:10pt;">, including the effects of interest rate swaps for hedged debt obligations, were </span><span style="font-family:Arial;font-size:10pt;color:#000000;text-decoration:none;"><span>3.13 percent</span></span><span style="font-family:Arial;font-size:10pt;"> and </span><span style="font-family:Arial;font-size:10pt;color:#000000;text-decoration:none;"><span>2.65 percent</span></span><span style="font-family:Arial;font-size:10pt;">, respectively.</span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">The aggregate amount of cash payments for interest on borrowings, net of capitalized interest, are as follows:</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:62%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2017</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2016</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Cash payments for interest on borrowings</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d8d8d8;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>223.8</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>192.7</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>146.4</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:16px;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">In accordance with the requirements of derivatives and hedging guidance, the portion of our fixed-rate debt obligations that is hedged as a fair value hedge is reflected in the consolidated balance sheets as an amount equal to the sum of the debt’s carrying value plus the fair value adjustment representing changes in fair value of the hedged debt attributable to movements in market interest rates subsequent to the inception of the hedge.</span></div> <div style="line-height:120%;padding-top:12px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Debt at December 31 consisted of the following:</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.79423868312757%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:75%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:top;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Short-term commercial paper borrowings</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>498.9</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>2,696.8</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">0.15 to 7.13 percent long-term notes (due 2019-2047)</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>9,640.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>10,756.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Other long-term debt</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>10.1</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>13.0</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Unamortized debt issuance costs</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>(28.4</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(49.0</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Fair value adjustment on hedged long-term notes</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>177.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>229.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Total debt</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>10,298.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>13,646.5</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Less current portion</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>(1,102.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d8d8d8;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(3,706.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d8d8d8;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Long-term debt</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>9,196.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>9,940.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 498900000 2696800000 9640800000 10756700000 10100000 13000000.0 28400000 49000000.0 177200000 229000000.0 10298600000 13646500000 1102200000 3706500000 9196400000 9940000000.0 0.0236 5420000000 3000000000.00 2000000000.00 P364D 3000000000.00 2000000000.00 25900000 6000000.0 750000000.0 0.0235 750000000.0 0.0310 750000000.0 0.0395 2230000000 <div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">The aggregate amounts of maturities on long-term debt for the next five years are as follows:</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="20"/></tr><tr><td style="width:51%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2021</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2022</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2023</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Maturities on long-term debt</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d8d8d8;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>604.5</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>3.5</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>2.3</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>1,439.0</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>0.3</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 604500000 3500000 2300000 1439000000.0 300000 0.25 0.0313 0.0265 <div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">The aggregate amount of cash payments for interest on borrowings, net of capitalized interest, are as follows:</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:62%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2017</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2016</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Cash payments for interest on borrowings</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d8d8d8;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>223.8</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>192.7</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>146.4</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 223800000 192700000 146400000 Stock-Based Compensation<div style="line-height:120%;padding-top:12px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Our stock-based compensation expense consists of performance awards (PAs), shareholder value awards (SVAs), and restricted stock units (RSUs). We recognize the fair value of stock-based compensation as expense over the requisite service period of the individual grantees, which generally equals the vesting period. We provide newly issued shares of our common stock and treasury stock to satisfy the issuance of PA, SVA, and RSU shares.</span></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Stock-based compensation expense and the related tax benefits were as follows:</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:62%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2017</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2016</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Stock-based compensation expense</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>253.5</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>256.3</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>234.9</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Tax benefit</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>53.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>64.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>82.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">At </span><span style="font-family:Arial;font-size:10pt;color:#000000;text-decoration:none;">December 31, 2018</span><span style="font-family:Arial;font-size:10pt;">, stock-based compensation awards may be granted under the 2002 Lilly Stock Plan for not more than </span><span style="font-family:Arial;font-size:10pt;"><span>53.3 million</span></span><span style="font-family:Arial;font-size:10pt;"> additional shares. </span></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">Performance Award Program</span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">PAs are granted to officers and management and are payable in shares of our common stock. The number of PA shares actually issued, if any, varies depending on the achievement of certain pre-established earnings-per-share targets over a </span><span style="font-family:Arial;font-size:10pt;">two</span><span style="font-family:Arial;font-size:10pt;">-year period. PA shares are accounted for at fair value based upon the closing stock price on the date of grant and fully vest at the end of the measurement period. The fair values of PAs granted for the years ended </span><span style="font-family:Arial;font-size:10pt;color:#000000;text-decoration:none;">December 31, 2018</span><span style="font-family:Arial;font-size:10pt;">, </span><span style="font-family:Arial;font-size:10pt;color:#000000;text-decoration:none;">2017</span><span style="font-family:Arial;font-size:10pt;">, and </span><span style="font-family:Arial;font-size:10pt;color:#000000;text-decoration:none;">2016</span><span style="font-family:Arial;font-size:10pt;"> were </span><span style="font-family:Arial;font-size:10pt;color:#000000;text-decoration:none;"><span>$71.63</span></span><span style="font-family:Arial;font-size:10pt;">, </span><span style="font-family:Arial;font-size:10pt;color:#000000;text-decoration:none;"><span>$73.54</span></span><span style="font-family:Arial;font-size:10pt;">, and </span><span style="font-family:Arial;font-size:10pt;color:#000000;text-decoration:none;"><span>$72.00</span></span><span style="font-family:Arial;font-size:10pt;">, respectively. The number of shares ultimately issued for the PA program is dependent upon the EPS achieved during the vesting period. Pursuant to this program, approximately </span><span style="font-family:Arial;font-size:10pt;color:#000000;text-decoration:none;"><span>0.9 million</span></span><span style="font-family:Arial;font-size:10pt;"> shares, </span><span style="font-family:Arial;font-size:10pt;color:#000000;text-decoration:none;"><span>1.3 million</span></span><span style="font-family:Arial;font-size:10pt;"> shares, and </span><span style="font-family:Arial;font-size:10pt;color:#000000;text-decoration:none;"><span>0.5 million</span></span><span style="font-family:Arial;font-size:10pt;"> shares were issued during the years ended </span><span style="font-family:Arial;font-size:10pt;color:#000000;text-decoration:none;">December 31, 2018</span><span style="font-family:Arial;font-size:10pt;">, </span><span style="font-family:Arial;font-size:10pt;color:#000000;text-decoration:none;">2017</span><span style="font-family:Arial;font-size:10pt;">, and </span><span style="font-family:Arial;font-size:10pt;color:#000000;text-decoration:none;">2016</span><span style="font-family:Arial;font-size:10pt;">, respectively. Approximately </span><span style="font-family:Arial;font-size:10pt;"><span>1.2 million</span></span><span style="font-family:Arial;font-size:10pt;"> shares are expected to be issued in </span><span style="font-family:Arial;font-size:10pt;">2019</span><span style="font-family:Arial;font-size:10pt;">. As of </span><span style="font-family:Arial;font-size:10pt;color:#000000;text-decoration:none;">December 31, 2018</span><span style="font-family:Arial;font-size:10pt;">, the total remaining unrecognized compensation cost related to nonvested PAs was </span><span style="font-family:Arial;font-size:10pt;color:#000000;text-decoration:none;"><span>$57.9 million</span></span><span style="font-family:Arial;font-size:10pt;">, which will be amortized over the weighted-average remaining requisite service period of </span><span style="font-family:Arial;font-size:10pt;color:#000000;text-decoration:none;"><span>12</span></span><span style="font-family:Arial;font-size:10pt;"> months.</span></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">Shareholder Value Award Program</span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">SVAs are granted to officers and management and are payable in shares of our common stock. The number of shares actually issued, if any, varies depending on our stock price at the end of the </span><span style="font-family:Arial;font-size:10pt;color:#000000;text-decoration:none;">three</span><span style="font-family:Arial;font-size:10pt;">-year vesting period compared to pre-established target stock prices. We measure the fair value of the SVA unit on the grant date using a Monte Carlo simulation model. The model utilizes multiple input variables that determine the probability of satisfying the market condition stipulated in the award grant and calculates the fair value of the award. Expected volatilities utilized in the model are based on implied volatilities from traded options on our stock, historical volatility of our stock price, and other factors. Similarly, the dividend yield is based on historical experience and our estimate of future dividend yields. The risk-free interest rate is derived from the U.S. Treasury yield curve in effect at the time of grant. The weighted-average fair values of the SVA units granted during the years ended </span><span style="font-family:Arial;font-size:10pt;color:#000000;text-decoration:none;">December 31, 2018</span><span style="font-family:Arial;font-size:10pt;">, </span><span style="font-family:Arial;font-size:10pt;color:#000000;text-decoration:none;">2017</span><span style="font-family:Arial;font-size:10pt;">, and </span><span style="font-family:Arial;font-size:10pt;color:#000000;text-decoration:none;">2016</span><span style="font-family:Arial;font-size:10pt;"> were </span><span style="font-family:Arial;font-size:10pt;color:#000000;text-decoration:none;"><span>$48.51</span></span><span style="font-family:Arial;font-size:10pt;">, </span><span style="font-family:Arial;font-size:10pt;color:#000000;text-decoration:none;"><span>$66.25</span></span><span style="font-family:Arial;font-size:10pt;">, and </span><span style="font-family:Arial;font-size:10pt;color:#000000;text-decoration:none;"><span>$48.68</span></span><span style="font-family:Arial;font-size:10pt;">, respectively, determined using the following assumptions:</span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"/></tr><tr><td style="width:59%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">(Percents)</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2017</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2016</span></div></td></tr><tr><td style="vertical-align:top;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Expected dividend yield</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>2.50</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">%</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>2.50</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>2.00</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Risk-free interest rate</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>2.31</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>1.38</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>0.92</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Volatility</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>22.26</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>22.91</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>21.68</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Pursuant to this program, approximately </span><span style="font-family:Arial;font-size:10pt;"><span>0.7 million</span></span><span style="font-family:Arial;font-size:10pt;"> shares, </span><span style="font-family:Arial;font-size:10pt;"><span>1.1 million</span></span><span style="font-family:Arial;font-size:10pt;"> shares, and </span><span style="font-family:Arial;font-size:10pt;"><span>1.0 million</span></span><span style="font-family:Arial;font-size:10pt;"> shares were issued during the years ended </span><span style="font-family:Arial;font-size:10pt;">December 31, 2018</span><span style="font-family:Arial;font-size:10pt;">, </span><span style="font-family:Arial;font-size:10pt;">2017</span><span style="font-family:Arial;font-size:10pt;">, and </span><span style="font-family:Arial;font-size:10pt;">2016</span><span style="font-family:Arial;font-size:10pt;">, respectively. Approximately </span><span style="font-family:Arial;font-size:10pt;"><span>1.0 million</span></span><span style="font-family:Arial;font-size:10pt;"> shares are expected to be issued in </span><span style="font-family:Arial;font-size:10pt;color:#000000;text-decoration:none;">2019</span><span style="font-family:Arial;font-size:10pt;">. As of </span><span style="font-family:Arial;font-size:10pt;color:#000000;text-decoration:none;">December 31, 2018</span><span style="font-family:Arial;font-size:10pt;">, the total remaining unrecognized compensation cost related to nonvested SVAs was </span><span style="font-family:Arial;font-size:10pt;color:#000000;text-decoration:none;"><span>$52.2 million</span></span><span style="font-family:Arial;font-size:10pt;">, which will be amortized over the weighted-average remaining requisite service period of </span><span style="font-family:Arial;font-size:10pt;color:#000000;text-decoration:none;"><span>20</span></span><span style="font-family:Arial;font-size:10pt;"> months.</span></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">Restricted Stock Units</span></div><div style="line-height:120%;padding-bottom:16px;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">RSUs are granted to certain employees and are payable in shares of our common stock. RSU shares are accounted for at fair value based upon the closing stock price on the date of grant. The corresponding expense is amortized over the vesting period, typically </span><span style="font-family:Arial;font-size:10pt;color:#000000;text-decoration:none;"><span>three years</span></span><span style="font-family:Arial;font-size:10pt;">. The fair values of RSU awards granted during the years ended </span><span style="font-family:Arial;font-size:10pt;color:#000000;text-decoration:none;">December 31, 2018</span><span style="font-family:Arial;font-size:10pt;">, </span><span style="font-family:Arial;font-size:10pt;color:#000000;text-decoration:none;">2017</span><span style="font-family:Arial;font-size:10pt;">, and </span><span style="font-family:Arial;font-size:10pt;color:#000000;text-decoration:none;">2016</span><span style="font-family:Arial;font-size:10pt;"> were </span><span style="font-family:Arial;font-size:10pt;color:#000000;text-decoration:none;"><span>$70.95</span></span><span style="font-family:Arial;font-size:10pt;">, </span><span style="font-family:Arial;font-size:10pt;color:#000000;text-decoration:none;"><span>$72.47</span></span><span style="font-family:Arial;font-size:10pt;">, and </span><span style="font-family:Arial;font-size:10pt;color:#000000;text-decoration:none;"><span>$71.46</span></span><span style="font-family:Arial;font-size:10pt;">, respectively. The number of shares ultimately issued for the RSU program remains constant with the exception of forfeitures. Pursuant to this program, </span><span style="font-family:Arial;font-size:10pt;color:#000000;text-decoration:none;"><span>1.3 million</span></span><span style="font-family:Arial;font-size:10pt;">, </span><span style="font-family:Arial;font-size:10pt;color:#000000;text-decoration:none;"><span>1.4 million</span></span><span style="font-family:Arial;font-size:10pt;">, and </span><span style="font-family:Arial;font-size:10pt;color:#000000;text-decoration:none;"><span>1.3 million</span></span><span style="font-family:Arial;font-size:10pt;"> shares were granted and approximately </span><span style="font-family:Arial;font-size:10pt;color:#000000;text-decoration:none;"><span>1.0 million</span></span><span style="font-family:Arial;font-size:10pt;">, </span><span style="font-family:Arial;font-size:10pt;color:#000000;text-decoration:none;"><span>0.9 million</span></span><span style="font-family:Arial;font-size:10pt;">, and </span><span style="font-family:Arial;font-size:10pt;color:#000000;text-decoration:none;"><span>0.6 million</span></span><span style="font-family:Arial;font-size:10pt;"> shares were issued during the years ended </span><span style="font-family:Arial;font-size:10pt;color:#000000;text-decoration:none;">December 31, 2018</span><span style="font-family:Arial;font-size:10pt;">, </span><span style="font-family:Arial;font-size:10pt;color:#000000;text-decoration:none;">2017</span><span style="font-family:Arial;font-size:10pt;">, and </span><span style="font-family:Arial;font-size:10pt;color:#000000;text-decoration:none;">2016</span><span style="font-family:Arial;font-size:10pt;">, respectively. Approximately </span><span style="font-family:Arial;font-size:10pt;color:#000000;text-decoration:none;"><span>0.8 million</span></span><span style="font-family:Arial;font-size:10pt;"> shares are expected to be issued in </span><span style="font-family:Arial;font-size:10pt;color:#000000;text-decoration:none;">2019</span><span style="font-family:Arial;font-size:10pt;">. As of </span><span style="font-family:Arial;font-size:10pt;color:#000000;text-decoration:none;">December 31, 2018</span><span style="font-family:Arial;font-size:10pt;">, the total remaining unrecognized compensation cost related to nonvested RSUs was </span><span style="font-family:Arial;font-size:10pt;color:#000000;text-decoration:none;"><span>$99.7 million</span></span><span style="font-family:Arial;font-size:10pt;">, which will be amortized over the weighted-average remaining requisite service period of </span><span style="font-family:Arial;font-size:10pt;"><span>21</span></span><span style="font-family:Arial;font-size:10pt;"> months.</span></div> We recognize the fair value of stock-based compensation as expense over the requisite service period of the individual grantees, which generally equals the vesting period. We provide newly issued shares of our common stock and treasury stock to satisfy the issuance of PA, SVA, and RSU shares. <div style="line-height:120%;padding-top:12px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Stock-based compensation expense and the related tax benefits were as follows:</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:62%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2017</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2016</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Stock-based compensation expense</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>253.5</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>256.3</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>234.9</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Tax benefit</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>53.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>64.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>82.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 253500000 256300000 234900000 53200000 64100000 82200000 53300000 71.63 73.54 72.00 900000 1300000 500000 1200000 57900000 P12M The weighted-average fair values of the SVA units granted during the years ended <span style="font-family:Arial;font-size:10pt;color:#000000;text-decoration:none;">December 31, 2018</span><span style="font-family:Arial;font-size:10pt;">, </span><span style="font-family:Arial;font-size:10pt;color:#000000;text-decoration:none;">2017</span><span style="font-family:Arial;font-size:10pt;">, and </span><span style="font-family:Arial;font-size:10pt;color:#000000;text-decoration:none;">2016</span><span style="font-family:Arial;font-size:10pt;"> were </span><span style="font-family:Arial;font-size:10pt;color:#000000;text-decoration:none;"><span>$48.51</span></span><span style="font-family:Arial;font-size:10pt;">, </span><span style="font-family:Arial;font-size:10pt;color:#000000;text-decoration:none;"><span>$66.25</span></span><span style="font-family:Arial;font-size:10pt;">, and </span><span style="font-family:Arial;font-size:10pt;color:#000000;text-decoration:none;"><span>$48.68</span></span><span style="font-family:Arial;font-size:10pt;">, respectively, determined using the following assumptions:</span><div style="line-height:120%;padding-top:8px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"/></tr><tr><td style="width:59%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">(Percents)</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2017</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2016</span></div></td></tr><tr><td style="vertical-align:top;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Expected dividend yield</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>2.50</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">%</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>2.50</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>2.00</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Risk-free interest rate</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>2.31</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>1.38</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>0.92</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Volatility</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>22.26</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>22.91</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>21.68</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 48.51 66.25 48.68 0.0250 0.0250 0.0200 0.0231 0.0138 0.0092 0.2226 0.2291 0.2168 700000 1100000 1000000.0 1000000.0 52200000 P20M P3Y 70.95 72.47 71.46 1300000 1400000 1300000 1000000.0 900000 600000 800000 99700000 P21M Shareholders' Equity<div style="line-height:120%;padding-top:12px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">During </span><span style="font-family:Arial;font-size:10pt;">2018</span><span style="font-family:Arial;font-size:10pt;">, </span><span style="font-family:Arial;font-size:10pt;">2017</span><span style="font-family:Arial;font-size:10pt;">, and </span><span style="font-family:Arial;font-size:10pt;">2016</span><span style="font-family:Arial;font-size:10pt;">, we repurchased </span><span style="font-family:Arial;font-size:10pt;"><span>$4.15 billion</span></span><span style="font-family:Arial;font-size:10pt;">, </span><span style="font-family:Arial;font-size:10pt;"><span>$359.8 million</span></span><span style="font-family:Arial;font-size:10pt;"> and </span><span style="font-family:Arial;font-size:10pt;"><span>$540.1 million</span></span><span style="font-family:Arial;font-size:10pt;">, respectively, of shares associated with our share repurchase programs. A payment of </span><span style="font-family:Arial;font-size:10pt;"><span>$60.0 million</span></span><span style="font-family:Arial;font-size:10pt;"> was made in 2016 for shares repurchased in 2017. </span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">During 2018, we repurchased </span><span style="font-family:Arial;font-size:10pt;"><span>$2.05 billion</span></span><span style="font-family:Arial;font-size:10pt;"> of shares, which completed the </span><span style="font-family:Arial;font-size:10pt;"><span>$5.00 billion</span></span><span style="font-family:Arial;font-size:10pt;"> share repurchase program announced in October 2013 and our board authorized an </span><span style="font-family:Arial;font-size:10pt;"><span>$8.00 billion</span></span><span style="font-family:Arial;font-size:10pt;"> share repurchase program. </span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">There were </span><span style="font-family:Arial;font-size:10pt;"><span>$2.10 billion</span></span><span style="font-family:Arial;font-size:10pt;"> repurchased under the </span><span style="font-family:Arial;font-size:10pt;"><span>$8.00 billion</span></span><span style="font-family:Arial;font-size:10pt;"> program in 2018. As of December 31, 2018, there were </span><span style="font-family:Arial;font-size:10pt;"><span>$5.90 billion</span></span><span style="font-family:Arial;font-size:10pt;"> of shares remaining under the 2018 program. </span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">We have </span><span style="font-family:Arial;font-size:10pt;color:#000000;text-decoration:none;"><span>5.0 million</span></span><span style="font-family:Arial;font-size:10pt;"> authorized shares of preferred stock. As of </span><span style="font-family:Arial;font-size:10pt;color:#000000;text-decoration:none;">December 31, 2018</span><span style="font-family:Arial;font-size:10pt;"> and </span><span style="font-family:Arial;font-size:10pt;color:#000000;text-decoration:none;">2017</span><span style="font-family:Arial;font-size:10pt;">, </span><span style="font-family:Arial;font-size:10pt;color:#000000;text-decoration:none;"><span>no</span></span><span style="font-family:Arial;font-size:10pt;"> preferred stock was issued.</span></div><div style="line-height:120%;padding-bottom:16px;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">We have an employee benefit trust that held </span><span style="font-family:Arial;font-size:10pt;color:#000000;text-decoration:none;"><span>50.0 million</span></span><span style="font-family:Arial;font-size:10pt;"> shares of our common stock at both </span><span style="font-family:Arial;font-size:10pt;color:#000000;text-decoration:none;">December 31, 2018</span><span style="font-family:Arial;font-size:10pt;"> and </span><span style="font-family:Arial;font-size:10pt;color:#000000;text-decoration:none;">2017</span><span style="font-family:Arial;font-size:10pt;">, to provide a source of funds to assist us in meeting our obligations under various employee benefit plans. The cost basis of the shares held in the trust was </span><span style="font-family:Arial;font-size:10pt;color:#000000;text-decoration:none;"><span>$3.01 billion</span></span><span style="font-family:Arial;font-size:10pt;"> at both </span><span style="font-family:Arial;font-size:10pt;color:#000000;text-decoration:none;">December 31, 2018</span><span style="font-family:Arial;font-size:10pt;"> and </span><span style="font-family:Arial;font-size:10pt;color:#000000;text-decoration:none;">2017</span><span style="font-family:Arial;font-size:10pt;">, and is shown as a reduction of shareholders’ equity. Any dividend transactions between us and the trust are eliminated. Stock held by the trust is not considered outstanding in the computation of EPS. The assets of the trust were not used to fund any of our obligations under these employee benefit plans during the years ended </span><span style="font-family:Arial;font-size:10pt;color:#000000;text-decoration:none;">December 31, 2018</span><span style="font-family:Arial;font-size:10pt;">, </span><span style="font-family:Arial;font-size:10pt;color:#000000;text-decoration:none;">2017</span><span style="font-family:Arial;font-size:10pt;">, and </span><span style="font-family:Arial;font-size:10pt;color:#000000;text-decoration:none;">2016</span><span style="font-family:Arial;font-size:10pt;">.</span></div> 4150000000 359800000 540100000 60000000.0 2050000000.00 5000000000.00 8000000000.00 2100000000 8000000000.00 5900000000 5000000.0 0 50000000.0 3010000000.00 Income Taxes<div style="line-height:120%;padding-top:12px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-style:italic;">2017 Tax Act</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">In December 2017, the President of the U.S. signed into law the 2017 Tax Act. The 2017 Tax Act included significant changes to the U.S. corporate income tax system, such as the reduction in the corporate income tax rate from 35 percent to 21 percent, transition to a territorial tax system, changes to business related exclusions, deductions and credits, and modifications to international tax provisions, including a one-time repatriation transition tax (also known as the ‘Toll Tax’) on unremitted foreign earnings. </span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">GAAP requires that the income tax accounting effects from a change in tax laws or tax rates be recognized in continuing operations in the reporting period that includes the enactment date of the change. These effects include, among other things, re-measuring deferred tax assets and liabilities, evaluating deferred tax assets for valuation allowances, and assessing the impact of the Toll Tax and certain other provisions of the 2017 Tax Act. Our accounting for the tax effects of the enactment of the 2017 Tax Act was not complete as of December 31, 2017; however, in certain cases we made a reasonable estimate. In other cases, we were not able to make a reasonable estimate and continued to account for those items based on our existing accounting model under ASC 740, </span><span style="font-family:Arial;font-size:10pt;font-style:italic;">Income Taxes</span><span style="font-family:Arial;font-size:10pt;">, and the provisions of the tax laws that were in effect immediately prior to enactment. For the items for which we were able to determine a reasonable estimate, we recognized a provisional amount of </span><span style="font-family:Arial;font-size:10pt;"><span>$1.91 billion</span></span><span style="font-family:Arial;font-size:10pt;">, which was included as a component of income tax expense from continuing operations. Our accounting for the effects of the 2017 Tax Act was completed in the current period, and we recorded </span><span style="font-family:Arial;font-size:10pt;"><span>$313.3 million</span></span><span style="font-family:Arial;font-size:10pt;"> of income tax benefit in 2018, mainly attributable to measurement period adjustments to the Toll Tax and the global intangible low-taxed income (GILTI) provision, the new U.S. minimum tax on the earnings of our foreign subsidiaries. Related to GILTI, we elected to establish deferred taxes in the amount of </span><span style="font-family:Arial;font-size:10pt;"><span>$1.74 billion</span></span><span style="font-family:Arial;font-size:10pt;"> for the reversal of temporary items in future years.</span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Subsequent to the enactment of the 2017 Tax Act, additional guidance was issued, including Notices, Proposed Regulations, and Final Regulations. We expect that further guidance will continue to be issued in 2019 which may impact our interpretations of the 2017 Tax Act and could materially affect the estimates used. </span></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Deferred taxes are recognized for the future tax effects of temporary differences between financial and income tax reporting based on enacted tax laws and rates.</span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">We recognize the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by the taxing authorities, based on the technical merits of the position. The tax benefits recognized in the financial statements from such a position are measured based on the largest benefit that has a greater than 50 percent likelihood of being realized upon ultimate resolution.</span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Following is the composition of income tax expense:</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:62%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2017</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2016</span></div></td></tr><tr><td style="vertical-align:top;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Current:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Federal</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>(31.9</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(66.5</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>20.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#dddddd;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Foreign</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>106.8</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>47.5</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>397.0</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">State</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>4.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(5.4</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(134.4</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#dddddd;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">2017 Tax Act</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>201.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>3,247.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Total current tax expense</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>281.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>3,223.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>282.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Deferred:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Federal</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>22.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>732.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>410.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#dddddd;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Foreign</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>248.7</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(230.9</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(136.3</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">State</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>3.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>0.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(4.9</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#dddddd;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">2017 Tax Act</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>(26.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(1,333.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Total deferred tax (benefit) expense</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>248.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(831.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>268.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Income taxes</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>529.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>2,391.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>551.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Significant components of our deferred tax assets and liabilities as of December 31 are as follows:</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.79423868312757%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:75%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:top;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Deferred tax assets:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Purchases of intangible assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>2,627.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>441.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#dddddd;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Compensation and benefits</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>781.6</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>995.3</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Tax credit carryforwards and carrybacks</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>359.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>467.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#dddddd;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Tax loss carryforwards and carrybacks</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>248.2</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>471.3</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Product return reserves</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>95.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>83.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#dddddd;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Other comprehensive loss on hedging transactions</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>68.9</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>68.9</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Debt</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>40.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>53.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#dddddd;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Contingent consideration</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>11.7</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>32.1</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Other</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>680.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>524.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#dddddd;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Total gross deferred tax assets</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>4,913.2</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>3,138.2</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Valuation allowances</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>(574.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(681.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#dddddd;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Total deferred tax assets</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>4,338.4</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>2,456.4</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Deferred tax liabilities:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#dddddd;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Earnings of foreign subsidiaries</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>(1,745.3</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(16.6</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Inventories</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>(681.3</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(649.5</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#dddddd;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Property and equipment</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>(260.9</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(247.5</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Prepaid employee benefits</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>(240.1</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(231.5</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#dddddd;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Intangibles</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>(86.9</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(120.7</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Financial instruments</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>(22.8</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(41.6</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#dddddd;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Total deferred tax liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>(3,037.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(1,307.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Deferred tax assets - net</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>1,301.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>1,149.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Our accounting for the effects of the 2017 Tax Act was completed in the current period; therefore, deferred tax assets and liabilities reflect re-measurement resulting from the 2017 Tax Act.</span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">The deferred tax asset and related valuation allowance amounts for U.S. federal and state net operating losses and tax credits shown above have been reduced for differences between financial reporting and tax return filings.</span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">At </span><span style="font-family:Arial;font-size:10pt;">December 31, 2018</span><span style="font-family:Arial;font-size:10pt;">, based on filed tax returns we have tax credit carryforwards and carrybacks of </span><span style="font-family:Arial;font-size:10pt;"><span>$729.5 million</span></span><span style="font-family:Arial;font-size:10pt;"> available to reduce future income taxes; </span><span style="font-family:Arial;font-size:10pt;"><span>$150.5 million</span></span><span style="font-family:Arial;font-size:10pt;">, if unused, will expire by </span><span style="font-family:Arial;font-size:10pt;">2027</span><span style="font-family:Arial;font-size:10pt;">. The remaining portion of the tax credit carryforwards is related to federal tax credits of </span><span style="font-family:Arial;font-size:10pt;"><span>$122.9 million</span></span><span style="font-family:Arial;font-size:10pt;">, international tax credits of </span><span style="font-family:Arial;font-size:10pt;"><span>$119.3 million</span></span><span style="font-family:Arial;font-size:10pt;">, and state tax credits of </span><span style="font-family:Arial;font-size:10pt;"><span>$336.9 million</span></span><span style="font-family:Arial;font-size:10pt;">, all of which are substantially reserved.</span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">At </span><span style="font-family:Arial;font-size:10pt;">December 31, 2018</span><span style="font-family:Arial;font-size:10pt;">, based on filed tax returns we had net operating losses and other carryforwards for international and U.S. federal income tax purposes of </span><span style="font-family:Arial;font-size:10pt;"><span>$773.2 million</span></span><span style="font-family:Arial;font-size:10pt;">: </span><span style="font-family:Arial;font-size:10pt;"><span>$12.1 million</span></span><span style="font-family:Arial;font-size:10pt;"> will expire by </span><span style="font-family:Arial;font-size:10pt;">2023</span><span style="font-family:Arial;font-size:10pt;">; </span><span style="font-family:Arial;font-size:10pt;"><span>$462.2 million</span></span><span style="font-family:Arial;font-size:10pt;"> will expire between </span><span style="font-family:Arial;font-size:10pt;">2024</span><span style="font-family:Arial;font-size:10pt;"> and </span><span style="font-family:Arial;font-size:10pt;">2038</span><span style="font-family:Arial;font-size:10pt;">; and </span><span style="font-family:Arial;font-size:10pt;"><span>$298.9 million</span></span><span style="font-family:Arial;font-size:10pt;"> of the carryforwards will never expire. Net operating losses and other carryforwards for international and U.S. federal income tax purposes are partially reserved. Deferred tax assets related to state net operating losses of </span><span style="font-family:Arial;font-size:10pt;"><span>$99.7 million</span></span><span style="font-family:Arial;font-size:10pt;"> and other state carryforwards of </span><span style="font-family:Arial;font-size:10pt;"><span>$2.6 million</span></span><span style="font-family:Arial;font-size:10pt;"> are fully reserved.</span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Domestic and Puerto Rican companies contributed approximately </span><span style="font-family:Arial;font-size:10pt;"><span>15 percent</span></span><span style="font-family:Arial;font-size:10pt;">, </span><span style="font-family:Arial;font-size:10pt;"><span>16 percent</span></span><span style="font-family:Arial;font-size:10pt;">, and </span><span style="font-family:Arial;font-size:10pt;"><span>63 percent</span></span><span style="font-family:Arial;font-size:10pt;"> for the years ended </span><span style="font-family:Arial;font-size:10pt;">December 31, 2018</span><span style="font-family:Arial;font-size:10pt;">, </span><span style="font-family:Arial;font-size:10pt;">2017</span><span style="font-family:Arial;font-size:10pt;">, and </span><span style="font-family:Arial;font-size:10pt;">2016</span><span style="font-family:Arial;font-size:10pt;">, respectively, to consolidated income before income taxes. We have a subsidiary operating in Puerto Rico under a tax incentive grant effective through the end of </span><span style="font-family:Arial;font-size:10pt;">2031</span><span style="font-family:Arial;font-size:10pt;">.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">The 2017 Tax Act introduced international tax provisions that fundamentally change the U.S. taxation of foreign earnings. As a result, substantially all of the unremitted earnings of our foreign subsidiaries are considered to not be indefinitely reinvested for continued use in our foreign operations. At December 31, 2018, we have accrued an immaterial amount of foreign withholding taxes and state income taxes that would be owed upon future distributions of unremitted earnings of our foreign subsidiaries that are not indefinitely reinvested. For the amount considered to be indefinitely reinvested, it is not practicable to determine the amount of the related deferred income tax liability due to the complexities in the tax laws and assumptions we would have to make.</span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Cash payments of income taxes were as follows: </span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:62%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2017</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2016</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Cash payments of income taxes</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d8d8d8;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>1,076.7</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d8d8d8;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>221.5</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>686.4</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">The 2017 Tax Act provided an election to taxpayers subject to the Toll Tax to make payments over an eight-year period. We made this election; therefore, we have included Toll Tax payments accordingly.</span></div><div style="line-height:120%;padding-bottom:13px;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Following is a reconciliation of the income tax expense applying the U.S. federal statutory rate to income before income taxes to reported income tax expense:</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:62%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2017</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2016</span></div></td></tr><tr><td style="vertical-align:top;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Income tax at the U.S. federal statutory tax rate</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>772.8</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d8d8d8;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>806.7</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d8d8d8;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>1,146.7</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Add (deduct):</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#d8d8d8;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">International operations, including Puerto Rico</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>(627.1</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(480.8</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(357.2</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">General business credits</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>(87.4</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(66.8</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(57.0</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#d8d8d8;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Non-deductible acquired IPR&D</span><span style="font-family:Arial;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(1)</sup></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>309.9</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>300.1</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">2017 Tax Act</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>175.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>1,914.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#d8d8d8;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Other</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>(14.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d8d8d8;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(82.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d8d8d8;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(181.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d8d8d8;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Income taxes</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>529.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>2,391.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>551.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:8px;padding-left:12px;text-indent:-12px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(1) </sup></span><span style="font-family:Arial;font-size:8pt;">Non-deductible acquired IPR&D was related to ARMO in 2018 and CoLucid in 2017. See Note 3 for additional information related to acquisitions.</span></div><div style="line-height:120%;padding-top:8px;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">A reconciliation of the beginning and ending amount of gross unrecognized tax benefits is as follows:</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:62%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2017</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2016</span></div></td></tr><tr><td style="vertical-align:top;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Beginning balance at January 1</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>1,000.8</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>843.3</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>1,057.2</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Additions based on tax positions related to the current year</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>798.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>133.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>73.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Additions for tax positions of prior years</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>410.9</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>93.8</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>11.0</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Reductions for tax positions of prior years</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>(115.4</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(59.3</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(12.1</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Settlements</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>(33.2</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(2.4</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(171.9</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Lapses of statutes of limitation</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>(20.5</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(19.3</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(110.0</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Changes related to the impact of foreign currency translation</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>(6.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d8d8d8;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>10.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(4.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d8d8d8;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Ending balance at December 31</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>2,034.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>1,000.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>843.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">The total amount of unrecognized tax benefits that, if recognized, would affect our effective tax rate was </span><span style="font-family:Arial;font-size:10pt;"><span>$1.48 billion</span></span><span style="font-family:Arial;font-size:10pt;"> and </span><span style="font-family:Arial;font-size:10pt;"><span>$657.1 million</span></span><span style="font-family:Arial;font-size:10pt;"> at </span><span style="font-family:Arial;font-size:10pt;">December 31, 2018</span><span style="font-family:Arial;font-size:10pt;"> and </span><span style="font-family:Arial;font-size:10pt;">2017</span><span style="font-family:Arial;font-size:10pt;">, respectively.</span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">We file income tax returns in the U.S. federal jurisdiction and various state, local, and non-U.S. jurisdictions. We are no longer subject to U.S. federal, state and local, or non-U.S. income tax examinations in most major taxing jurisdictions for years before 2010.</span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">The U.S. examination of tax years </span><span style="font-family:Arial;font-size:10pt;"><span>2010</span></span><span style="font-family:Arial;font-size:10pt;">-</span><span style="font-family:Arial;font-size:10pt;"><span>2012</span></span><span style="font-family:Arial;font-size:10pt;"> commenced during the fourth quarter of 2013. In December 2015, we executed a closing agreement with the Internal Revenue Service which effectively settled certain matters for tax years </span><span style="font-family:Arial;font-size:10pt;"><span>2010</span></span><span style="font-family:Arial;font-size:10pt;">-</span><span style="font-family:Arial;font-size:10pt;"><span>2012</span></span><span style="font-family:Arial;font-size:10pt;">. Accordingly, we reduced our gross uncertain tax positions by approximately </span><span style="font-family:Arial;font-size:10pt;"><span>$320 million</span></span><span style="font-family:Arial;font-size:10pt;"> in 2015. During 2016, we effectively settled the remaining matters related to tax years </span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>2010</span></span><span style="font-family:Arial;font-size:10pt;">-</span><span style="font-family:Arial;font-size:10pt;"><span>2012</span></span><span style="font-family:Arial;font-size:10pt;">. As a result of this resolution, our gross uncertain tax positions were further reduced by approximately </span><span style="font-family:Arial;font-size:10pt;"><span>$140 million</span></span><span style="font-family:Arial;font-size:10pt;">, and our consolidated results of operations benefited from an immaterial reduction in income tax expense. During 2016, we made cash payments of approximately </span><span style="font-family:Arial;font-size:10pt;"><span>$150 million</span></span><span style="font-family:Arial;font-size:10pt;"> related to tax years </span><span style="font-family:Arial;font-size:10pt;"><span>2010</span></span><span style="font-family:Arial;font-size:10pt;">-</span><span style="font-family:Arial;font-size:10pt;"><span>2012</span></span><span style="font-family:Arial;font-size:10pt;"> after application of available tax credit carryforwards and carrybacks. The U.S. examination of tax years </span><span style="font-family:Arial;font-size:10pt;"><span>2013</span></span><span style="font-family:Arial;font-size:10pt;">-</span><span style="font-family:Arial;font-size:10pt;"><span>2015</span></span><span style="font-family:Arial;font-size:10pt;"> began in 2016, and we believe it is reasonably possible that this examination could reach resolution within the next 12 months for tax years </span><span style="font-family:Arial;font-size:10pt;"><span>2013</span></span><span style="font-family:Arial;font-size:10pt;">-</span><span style="font-family:Arial;font-size:10pt;"><span>2014</span></span><span style="font-family:Arial;font-size:10pt;"> and certain matters under examination for tax year </span><span style="font-family:Arial;font-size:10pt;"><span>2015</span></span><span style="font-family:Arial;font-size:10pt;">, for which the audit remains ongoing. As a result, we currently estimate that gross uncertain tax positions may be reduced by approximately </span><span style="font-family:Arial;font-size:10pt;"><span>$450 million</span></span><span style="font-family:Arial;font-size:10pt;"> within the next 12 months. Additionally, we anticipate up to </span><span style="font-family:Arial;font-size:10pt;"><span>$150 million</span></span><span style="font-family:Arial;font-size:10pt;"> of cash payments will be due upon resolution.</span></div><div style="line-height:120%;padding-bottom:16px;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">We recognize both accrued interest and penalties related to unrecognized tax benefits in income tax expense. We recognized income tax (benefit) expense related to interest and penalties as follows:</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:62%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2017</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2016</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Income tax expense (benefit)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d8d8d8;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>25.1</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d8d8d8;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>22.8</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(63.8</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:16px;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">At </span><span style="font-family:Arial;font-size:10pt;">December 31, 2018</span><span style="font-family:Arial;font-size:10pt;"> and </span><span style="font-family:Arial;font-size:10pt;">2017</span><span style="font-family:Arial;font-size:10pt;">, our accruals for the payment of interest and penalties totaled </span><span style="font-family:Arial;font-size:10pt;"><span>$183.9 million</span></span><span style="font-family:Arial;font-size:10pt;"> and </span><span style="font-family:Arial;font-size:10pt;"><span>$155.0 million</span></span><span style="font-family:Arial;font-size:10pt;">, respectively.</span></div> 1910000000 -313300000 1740000000 <div style="line-height:120%;padding-top:12px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Deferred taxes are recognized for the future tax effects of temporary differences between financial and income tax reporting based on enacted tax laws and rates.</span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">We recognize the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by the taxing authorities, based on the technical merits of the position. The tax benefits recognized in the financial statements from such a position are measured based on the largest benefit that has a greater than 50 percent likelihood of being realized upon ultimate resolution.</span></div> <div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Following is the composition of income tax expense:</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:62%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2017</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2016</span></div></td></tr><tr><td style="vertical-align:top;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Current:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Federal</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>(31.9</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(66.5</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>20.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#dddddd;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Foreign</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>106.8</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>47.5</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>397.0</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">State</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>4.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(5.4</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(134.4</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#dddddd;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">2017 Tax Act</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>201.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>3,247.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Total current tax expense</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>281.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>3,223.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>282.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Deferred:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Federal</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>22.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>732.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>410.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#dddddd;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Foreign</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>248.7</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(230.9</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(136.3</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">State</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>3.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>0.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(4.9</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#dddddd;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">2017 Tax Act</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>(26.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(1,333.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Total deferred tax (benefit) expense</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>248.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(831.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>268.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Income taxes</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>529.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>2,391.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>551.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> -31900000 -66500000 20000000.0 106800000 47500000 397000000.0 4700000 -5400000 -134400000 201500000 3247500000 0 281100000 3223100000 282600000 22500000 732300000 410000000.0 248700000 -230900000 -136300000 3400000 200000 -4900000 -26200000 -1333500000 0 248400000 -831900000 268800000 529500000 2391200000 551400000 <div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Significant components of our deferred tax assets and liabilities as of December 31 are as follows:</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.79423868312757%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:75%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:top;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Deferred tax assets:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Purchases of intangible assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>2,627.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>441.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#dddddd;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Compensation and benefits</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>781.6</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>995.3</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Tax credit carryforwards and carrybacks</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>359.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>467.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#dddddd;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Tax loss carryforwards and carrybacks</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>248.2</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>471.3</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Product return reserves</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>95.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>83.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#dddddd;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Other comprehensive loss on hedging transactions</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>68.9</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>68.9</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Debt</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>40.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>53.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#dddddd;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Contingent consideration</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>11.7</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>32.1</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Other</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>680.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>524.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#dddddd;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Total gross deferred tax assets</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>4,913.2</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>3,138.2</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Valuation allowances</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>(574.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(681.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#dddddd;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Total deferred tax assets</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>4,338.4</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>2,456.4</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Deferred tax liabilities:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#dddddd;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Earnings of foreign subsidiaries</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>(1,745.3</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(16.6</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Inventories</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>(681.3</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(649.5</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#dddddd;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Property and equipment</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>(260.9</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(247.5</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Prepaid employee benefits</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>(240.1</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(231.5</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#dddddd;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Intangibles</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>(86.9</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(120.7</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Financial instruments</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>(22.8</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(41.6</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#dddddd;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Total deferred tax liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>(3,037.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(1,307.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Deferred tax assets - net</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>1,301.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>1,149.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 2627700000 441900000 781600000 995300000 359400000 467500000 248200000 471300000 95300000 83400000 68900000 68900000 40300000 53500000 11700000 32100000 680100000 524300000 4913200000 3138200000 574800000 681800000 4338400000 2456400000 1745300000 16600000 681300000 649500000 260900000 247500000 240100000 231500000 86900000 120700000 22800000 41600000 3037300000 1307400000 1301100000 1149000000.0 729500000 150500000 122900000 119300000 336900000 773200000 12100000 462200000 298900000 99700000 2600000 0.15 0.16 0.63 <div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Cash payments of income taxes were as follows: </span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:62%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2017</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2016</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Cash payments of income taxes</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d8d8d8;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>1,076.7</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d8d8d8;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>221.5</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>686.4</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 1076700000 221500000 686400000 <div style="line-height:120%;padding-bottom:13px;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Following is a reconciliation of the income tax expense applying the U.S. federal statutory rate to income before income taxes to reported income tax expense:</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:62%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2017</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2016</span></div></td></tr><tr><td style="vertical-align:top;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Income tax at the U.S. federal statutory tax rate</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>772.8</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d8d8d8;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>806.7</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d8d8d8;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>1,146.7</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Add (deduct):</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#d8d8d8;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">International operations, including Puerto Rico</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>(627.1</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(480.8</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(357.2</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">General business credits</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>(87.4</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(66.8</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(57.0</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#d8d8d8;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Non-deductible acquired IPR&D</span><span style="font-family:Arial;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(1)</sup></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>309.9</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>300.1</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">2017 Tax Act</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>175.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>1,914.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#d8d8d8;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Other</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>(14.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d8d8d8;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(82.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d8d8d8;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(181.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d8d8d8;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Income taxes</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>529.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>2,391.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>551.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:8px;padding-left:12px;text-indent:-12px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(1) </sup></span><span style="font-family:Arial;font-size:8pt;">Non-deductible acquired IPR&D was related to ARMO in 2018 and CoLucid in 2017. See Note 3 for additional information related to acquisitions.</span></div> 772800000 806700000 1146700000 627100000 480800000 357200000 87400000 66800000 57000000.0 309900000 300100000 0 175300000 1914000000.0 0 -14000000.0 -82000000.0 -181100000 529500000 2391200000 551400000 <div style="line-height:120%;padding-top:8px;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">A reconciliation of the beginning and ending amount of gross unrecognized tax benefits is as follows:</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:62%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2017</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2016</span></div></td></tr><tr><td style="vertical-align:top;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Beginning balance at January 1</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>1,000.8</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>843.3</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>1,057.2</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Additions based on tax positions related to the current year</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>798.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>133.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>73.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Additions for tax positions of prior years</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>410.9</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>93.8</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>11.0</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Reductions for tax positions of prior years</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>(115.4</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(59.3</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(12.1</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Settlements</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>(33.2</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(2.4</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(171.9</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Lapses of statutes of limitation</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>(20.5</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(19.3</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(110.0</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Changes related to the impact of foreign currency translation</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>(6.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d8d8d8;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>10.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(4.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d8d8d8;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Ending balance at December 31</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>2,034.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>1,000.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>843.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:16px;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">We recognize both accrued interest and penalties related to unrecognized tax benefits in income tax expense. We recognized income tax (benefit) expense related to interest and penalties as follows:</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:62%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2017</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2016</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Income tax expense (benefit)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d8d8d8;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>25.1</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d8d8d8;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>22.8</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(63.8</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 1000800000 843300000 1057200000 798200000 133800000 73400000 410900000 93800000 11000000.0 115400000 59300000 12100000 33200000 2400000 171900000 20500000 19300000 110000000.0 6200000 10900000 4300000 2034600000 1000800000 843300000 1480000000 657100000 2010 2012 2010 2012 320000000 2010 2012 140000000 150000000 2010 2012 2013 2015 2013 2014 2015 450000000 150000000 25100000 22800000 -63800000 183900000 155000000.0 Retirement Benefits<div style="line-height:120%;padding-top:12px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">We use a measurement date of December 31 to develop the change in benefit obligation, change in plan assets, funded status, and amounts recognized in the consolidated balance sheets at December 31 for our defined benefit pension and retiree health benefit plans, which were as follows: </span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:53%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Defined Benefit</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Pension Plans</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Retiree Health</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Benefit Plans</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"> </span><span style="font-family:Arial;font-size:8pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2017</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:top;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Change in benefit obligation:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Benefit obligation at beginning of year</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>14,839.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>12,230.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>1,718.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>1,494.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#d8d8d8;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Service cost</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>292.7</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>320.8</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>41.5</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>46.4</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Interest cost</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>458.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>411.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>57.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>52.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#d8d8d8;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Actuarial (gain) loss</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>(1,386.5</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>1,556.0</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>(176.9</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>30.2</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Benefits paid</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>(579.4</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(467.8</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>(82.8</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(60.1</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#d8d8d8;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Plan amendments</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>17.6</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>(14.1</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Curtailment (gain) loss</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>(43.9</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>90.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>2.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>105.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#d8d8d8;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Special termination benefit</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>317.2</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>37.5</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Foreign currency exchange rate changes and other adjustments</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>(171.6</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>380.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>(6.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>12.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#d8d8d8;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Benefit obligation at end of year</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>13,427.1</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>14,839.7</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>1,540.0</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>1,718.7</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:53%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:top;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Change in plan assets:</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Fair value of plan assets at beginning of year</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>11,713.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>10,056.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>2,372.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>1,961.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#d8d8d8;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Actual return on plan assets</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>(360.1</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>1,434.3</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>32.6</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>462.0</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Employer contribution</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>319.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>410.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>75.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>9.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#d8d8d8;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Benefits paid</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>(579.4</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(467.8</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>(82.8</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(60.1</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Foreign currency exchange rate changes and other adjustments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>(159.9</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>280.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>0.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#d8d8d8;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Fair value of plan assets at end of year</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>10,932.6</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>11,713.0</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>2,398.1</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>2,372.4</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:53%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:top;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Funded status</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>(2,494.5</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(3,126.7</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>858.1</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>653.7</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Unrecognized net actuarial loss</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>5,011.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>5,616.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>140.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>182.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Unrecognized prior service (benefit) cost</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>25.0</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>14.5</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>(299.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d8d8d8;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(395.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d8d8d8;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Net amount recognized</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>2,541.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>2,504.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>698.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>440.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:53%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:top;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Amounts recognized in the consolidated balance sheet consisted of:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Sundry</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>193.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>104.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>1,043.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>870.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#d8d8d8;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Other current liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>(64.2</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(64.5</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>(7.3</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(7.1</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Accrued retirement benefits</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>(2,624.0</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(3,166.7</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>(178.2</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(209.3</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#d8d8d8;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Accumulated other comprehensive (income) loss before income taxes</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>5,036.3</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>5,630.9</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>(159.3</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(213.0</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Net amount recognized</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>2,541.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>2,504.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>698.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>440.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">The unrecognized net actuarial loss and unrecognized prior service cost (benefit) have not yet been recognized in net periodic pension costs and are included in accumulated other comprehensive loss at </span><span style="font-family:Arial;font-size:10pt;">December 31, 2018</span><span style="font-family:Arial;font-size:10pt;">.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">In July 2018, we announced that we would amend our defined benefit pension and retiree health benefit plans to freeze or reduce benefits for certain employees effective January 1, 2019. We remeasured the impacted pension and retiree health plans’ benefit obligations as of July 31, 2018, which resulted in a net curtailment gain of </span><span style="font-family:Arial;font-size:10pt;"><span>$28.0 million</span></span><span style="font-family:Arial;font-size:10pt;">, which was recorded in asset impairment, restructuring, and other special charges. Market variables associated with this remeasurement, specifically an increase in the discount rate, were the primary driver for the </span><span style="font-family:Arial;font-size:10pt;"><span>$1.59 billion</span></span><span style="font-family:Arial;font-size:10pt;"> decrease in the benefit obligations in 2018.</span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">The workforce reduction plan initiated in 2017 included a curtailment loss of </span><span style="font-family:Arial;font-size:10pt;"><span>$159.0 million</span></span><span style="font-family:Arial;font-size:10pt;"> and a special termination benefit of </span><span style="font-family:Arial;font-size:10pt;"><span>$354.7 million</span></span><span style="font-family:Arial;font-size:10pt;">, which </span><span style="font-family:Arial;font-size:10pt;"><span>$446.7 million</span></span><span style="font-family:Arial;font-size:10pt;"> was recorded in asset impairment, restructuring, and other special charges and </span><span style="font-family:Arial;font-size:10pt;"><span>$67.0 million</span></span><span style="font-family:Arial;font-size:10pt;"> was recorded in discontinued operations, as a result of a remeasurement as of October 31, 2017. The special termination benefits related to early retirement incentives </span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">offered as part of a voluntary early retirement program for the U.S. plan in the fou</span><span style="font-family:Arial;font-size:10pt;background-color:#ffffff;">rth quarter of 2017. This program allowed certain employees the opportunity to voluntarily leave the Company. Market variables associated with this remeasurement, specifically a decrease in the discount rate, were the primary driver for the</span><span style="font-family:Arial;font-size:10pt;background-color:#ffffff;"> </span><span style="font-family:Arial;font-size:10pt;background-color:#ffffff;"><span>$2.83 billion</span></span><span style="font-family:Arial;font-size:10pt;background-color:#ffffff;"> </span><span style="font-family:Arial;font-size:10pt;background-color:#ffffff;">increase in the benefit obligations in 2017.</span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">The following represents our weighted-average assumptions as of December 31:</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="18"/></tr><tr><td style="width:59%;"/><td style="width:5%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:5%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:5%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:5%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:5%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:5%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"> </span></div></td><td colspan="8" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Defined Benefit</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Pension Plans</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="8" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Retiree Health</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Benefit Plans</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">(Percents)</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2017</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2016</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2017</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2016</span></div></td></tr><tr><td style="vertical-align:top;background-color:#d8d8d8;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Discount rate for benefit obligation</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>4.0</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">%</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>3.4</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>3.9</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>4.4</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">%</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>3.7</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>4.3</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Discount rate for net benefit costs</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>3.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>3.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>4.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>3.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>4.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>4.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#d8d8d8;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Rate of compensation increase for benefit obligation</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>3.4</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>3.4</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>3.4</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Rate of compensation increase for net benefit costs</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>3.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>3.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>3.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#d8d8d8;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Expected return on plan assets for net benefit costs</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>7.4</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>7.4</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>7.4</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>8.0</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>8.0</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>8.0</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">We annually evaluate the expected return on plan assets in our defined benefit pension and retiree health benefit plans. In evaluating the expected rate of return, we consider many factors, with a primary analysis of current and projected market conditions; asset returns and asset allocations; and the views of leading financial advisers and economists. We may also review our historical assumptions compared with actual results, as well as the assumptions and trend rates utilized by similar plans, where applicable. </span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Given the design of our retiree health benefit plans, healthcare-cost trend rates do not have a material impact on our financial condition or results of operations.</span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">The following benefit payments, which reflect expected future service, as appropriate, are expected to be paid as follows:</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="24"/></tr><tr><td style="width:29%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2021</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2022</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2023</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2024-2028</span></div></td></tr><tr><td style="vertical-align:top;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Defined benefit pension plans</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>604.1</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>607.2</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>616.5</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>632.1</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>641.6</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>3,524.7</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Retiree health benefit plans</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>98.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>99.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>100.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>99.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>98.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>505.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Amounts relating to defined benefit pension plans with projected benefit obligations in excess of plan assets were as follows at December 31:</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:77%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:top;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Projected benefit obligation</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>11,584.2</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>12,773.4</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Fair value of plan assets</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>8,895.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>9,542.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Amounts relating to defined benefit pension plans and retiree health benefit plans with accumulated benefit obligations in excess of plan assets were as follows at December 31:</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:53%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Defined Benefit</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Pension Plans</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Retiree Health </span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Benefit Plans</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2017</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:top;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Accumulated benefit obligation</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d8d8d8;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>10,837.8</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d8d8d8;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>11,733.6</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d8d8d8;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>189.4</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d8d8d8;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>225.1</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Fair value of plan assets</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>8,895.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>9,517.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">The total accumulated benefit obligation for our defined benefit pension plans was </span><span style="font-family:Arial;font-size:10pt;color:#000000;text-decoration:none;"><span>$12.57 billion</span></span><span style="font-family:Arial;font-size:10pt;"> and </span><span style="font-family:Arial;font-size:10pt;color:#000000;text-decoration:none;"><span>$13.67 billion</span></span><span style="font-family:Arial;font-size:10pt;"> at </span><span style="font-family:Arial;font-size:10pt;color:#000000;text-decoration:none;">December 31, 2018</span><span style="font-family:Arial;font-size:10pt;"> and </span><span style="font-family:Arial;font-size:10pt;color:#000000;text-decoration:none;">2017</span><span style="font-family:Arial;font-size:10pt;">, respectively.</span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Net pension and retiree health benefit expense included the following components:</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="24"/></tr><tr><td style="width:41%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Defined Benefit</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Pension Plans</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Retiree Health</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Benefit Plans</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"> </span><span style="font-family:Arial;font-size:8pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2017</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2016</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2017</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2016</span></div></td></tr><tr><td style="vertical-align:top;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Components of net periodic (benefit) cost:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Service cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>292.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>320.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>268.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>41.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>46.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>39.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#d8d8d8;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Interest cost</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>458.5</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>411.6</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>419.0</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>57.3</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>52.9</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>53.2</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Expected return on plan assets</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>(842.1</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(773.6</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(748.7</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>(177.9</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(160.7</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(150.2</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#d8d8d8;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Amortization of prior service (benefit) cost</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>4.6</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>5.6</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>11.7</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>(79.5</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(90.0</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(85.8</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Recognized actuarial loss</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>332.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>286.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>284.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>6.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>18.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>19.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#d8d8d8;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Curtailment (gain) loss</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>1.3</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>93.5</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>(29.3</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>65.5</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Special termination benefit</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>317.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>37.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#d8d8d8;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Net periodic (benefit) cost</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#d8d8d8;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>247.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#d8d8d8;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>661.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#d8d8d8;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>235.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#d8d8d8;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>(181.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#d8d8d8;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#d8d8d8;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(30.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#d8d8d8;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#d8d8d8;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(124.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#d8d8d8;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">The following represents the amounts recognized in other comprehensive income (loss) for the years ended </span><span style="font-family:Arial;font-size:10pt;color:#000000;text-decoration:none;">December 31, 2018</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:Arial;font-size:10pt;">2017</span><span style="font-family:Arial;font-size:10pt;">, and </span><span style="font-family:Arial;font-size:10pt;">2016</span><span style="font-family:Arial;font-size:10pt;">:</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="24"/></tr><tr><td style="width:35%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Defined Benefit<br/>Pension Plans</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Retiree Health<br/>Benefit Plans</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2017</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2016</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2017</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2016</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Actuarial gain (loss) arising during period</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>182.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(898.1</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(719.1</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>37.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>261.3</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(132.2</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Plan amendments during period</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>(17.6</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>14.1</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>35.8</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Curtailment gain (loss)</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>45.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>3.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>(31.8</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(39.7</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Amortization of prior service (benefit) cost included in net income</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>4.6</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>5.6</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>11.7</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>(79.5</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(90.0</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(85.8</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Amortization of net actuarial loss included in net income</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>332.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>286.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>284.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>6.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>18.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>19.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Foreign currency exchange rate changes and other</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>47.1</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(108.8</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>72.6</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>(0.1</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(3.3</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>2.5</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Total other comprehensive income (loss) during period</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>594.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(711.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(350.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>(53.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>146.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(160.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">We have defined contribution savings plans that cover our eligible employees worldwide. The purpose of these plans is generally to provide additional financial security during retirement by providing employees with an incentive to save. Our contributions to the plans are based on employee contributions and the level of our match. Expenses under the plans totaled </span><span style="font-family:Arial;font-size:10pt;"><span>$132.6 million</span></span><span style="font-family:Arial;font-size:10pt;">, </span><span style="font-family:Arial;font-size:10pt;color:#000000;text-decoration:none;"><span>$147.0 million</span></span><span style="font-family:Arial;font-size:10pt;">, and </span><span style="font-family:Arial;font-size:10pt;color:#000000;text-decoration:none;"><span>$155.4 million</span></span><span style="font-family:Arial;font-size:10pt;"> for the years ended </span><span style="font-family:Arial;font-size:10pt;color:#000000;text-decoration:none;">December 31, 2018</span><span style="font-family:Arial;font-size:10pt;">, </span><span style="font-family:Arial;font-size:10pt;color:#000000;text-decoration:none;">2017</span><span style="font-family:Arial;font-size:10pt;">, and </span><span style="font-family:Arial;font-size:10pt;color:#000000;text-decoration:none;">2016</span><span style="font-family:Arial;font-size:10pt;">, respectively.</span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">We provide certain other postemployment benefits primarily related to disability benefits and accrue for the related cost over the service lives of employees. Expenses associated with these benefit plans for the years ended </span><span style="font-family:Arial;font-size:10pt;color:#000000;text-decoration:none;">December 31, 2018</span><span style="font-family:Arial;font-size:10pt;">, </span><span style="font-family:Arial;font-size:10pt;color:#000000;text-decoration:none;">2017</span><span style="font-family:Arial;font-size:10pt;">, and </span><span style="font-family:Arial;font-size:10pt;color:#000000;text-decoration:none;">2016</span><span style="font-family:Arial;font-size:10pt;"> were not material.</span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">Benefit Plan Investments</span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Our benefit plan investment policies are set with specific consideration of return and risk requirements in relationship to the respective liabilities. U.S. and Puerto Rico plans represent approximately </span><span style="font-family:Arial;font-size:10pt;"><span>80 percent</span></span><span style="font-family:Arial;font-size:10pt;"> of our global investments. Given the long-term nature of our liabilities, these plans have the flexibility to manage an above-average degree of risk in the asset portfolios. At the investment-policy level, there are no specifically prohibited investments. However, within individual investment manager mandates, restrictions and limitations are contractually set to align with our investment objectives, ensure risk control, and limit concentrations.</span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">We manage our portfolio to minimize concentration of risk by allocating funds within asset categories. In addition, within a category we use different managers with various management objectives to eliminate any significant concentration of risk.</span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Our global benefit plans may enter into contractual arrangements (derivatives) to implement the local investment policy or manage particular portfolio risks. Derivatives are principally used to increase or decrease exposure to a particular public equity, fixed income, commodity, or currency market more rapidly or less expensively than could be accomplished through the use of the cash markets. The plans utilize both exchange-traded and over-the-counter instruments. The maximum exposure to either a market or counterparty credit loss is limited to the carrying value of the receivable, and is managed within contractual limits. We expect all of our counterparties to meet their obligations. The gross values of these derivative receivables and payables are not material to the global asset portfolio, and their values are reflected within the tables below.</span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">The defined benefit pension and retiree health benefit plan allocation for the U.S. and Puerto Rico currently comprises approximately </span><span style="font-family:Arial;font-size:10pt;"><span>70 percent</span></span><span style="font-family:Arial;font-size:10pt;"> growth investments and </span><span style="font-family:Arial;font-size:10pt;"><span>30 percent</span></span><span style="font-family:Arial;font-size:10pt;"> fixed-income investments. The growth investment allocation encompasses U.S. and international public equity securities, hedge funds, private equity-like investments, and real estate. These portfolio allocations are intended to reduce overall risk by providing diversification, while seeking moderate to high returns over the long term.</span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Public equity securities are well diversified and invested in U.S. and international small-to-large companies across various asset managers and styles. The remaining portion of the growth portfolio is invested in private alternative investments.</span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Fixed-income investments primarily consist of fixed-income securities in U.S. treasuries and agencies, emerging market debt obligations, corporate bonds, mortgage-backed securities, commercial mortgage-backed obligations, and any related repurchase agreements.</span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Hedge funds are privately owned institutional investment funds that generally have moderate liquidity. Hedge funds seek specified levels of absolute return regardless of overall market conditions, and generally have low correlations to public equity and debt markets. Hedge funds often invest substantially in financial market instruments (stocks, bonds, commodities, currencies, derivatives, etc.) using a very broad range of trading activities to manage portfolio risks. Hedge fund strategies focus primarily on security selection and seek to be neutral with respect to market moves. Common groupings of hedge fund strategies include relative value, tactical, and event driven. Relative value strategies include arbitrage, when the same asset can simultaneously be bought and sold at different prices, achieving an immediate profit. Tactical strategies often take long and short positions to reduce or eliminate overall market risks while seeking a particular investment opportunity. Event strategy opportunities can evolve from specific company announcements such as mergers and acquisitions, and typically have little correlation to overall market directional movements. Our hedge fund investments are made through limited partnership interests primarily in fund-of-funds structures to ensure diversification across many strategies and many individual managers. Plan holdings in hedge funds are valued based on net asset values (NAVs) calculated by each fund or general partner, as applicable, and we have the ability to redeem these investments at NAV.</span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Private equity-like investment funds typically have low liquidity and are made through long-term partnerships or joint ventures that invest in pools of capital invested in primarily non-publicly traded entities. Underlying investments include venture capital (early stage investing), buyout, and special situation investing. Private equity management firms typically acquire and then reorganize private companies to create increased long term value. Private equity-like funds usually have a limited life of approximately 10-15 years, and require a minimum investment commitment from their limited partners. Our private investments are made both directly into funds and through fund-of-funds structures to ensure broad diversification of management styles and assets across the portfolio. Plan holdings in private equity-like investments are valued using the value reported by the partnership, adjusted for known cash flows and significant events through our reporting date. Values provided by the partnerships are primarily based on analysis of and judgments about the underlying investments. Inputs to these valuations include underlying NAVs, discounted cash flow valuations, comparable market valuations, and may also include adjustments for currency, credit, liquidity and other risks as applicable. The vast majority of these private partnerships provide us with annual audited financial statements including their compliance with fair valuation procedures consistent with applicable accounting standards.</span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Real estate is composed of both public and private holdings. Real estate investments in registered investment companies that trade on an exchange are classified as Level 1 on the fair value hierarchy. Real estate investments in funds measured at fair value on the basis of NAV provided by the fund manager are classified as such. These NAVs are developed with inputs including discounted cash flow, independent appraisal, and market comparable analyses.</span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Other assets include cash and cash equivalents and mark-to-market value of derivatives.</span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">The cash value of the trust-owned insurance contract is primarily invested in investment-grade publicly traded equity and fixed-income securities.</span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Other than hedge funds, private equity-like investments, and real estate, which are discussed above, we determine fair values based on a market approach using quoted market values, significant other observable inputs for identical or comparable assets or liabilities, or discounted cash flow analyses.</span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">The fair values of our defined benefit pension plan and retiree health plan assets as of </span><span style="font-family:Arial;font-size:10pt;color:#000000;text-decoration:none;">December 31, 2018</span><span style="font-family:Arial;font-size:10pt;"> by asset category were as follows:</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="20"/></tr><tr><td style="width:31%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:20px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Fair Value Measurements Using</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Asset Class</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Quoted Prices in Active Markets for<br/>Identical Assets<br/>(Level 1)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Significant<br/>Observable </span></div><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Inputs<br/>(Level 2)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Significant<br/>Unobservable Inputs<br/>(Level 3)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Investments Valued at Net Asset Value</span><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(1)</sup></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">Defined Benefit Pension Plans</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Public equity securities:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#d8d8d8;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">U.S.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>617.7</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>409.1</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>208.6</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">International</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>2,117.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>828.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>1.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>1,287.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Fixed income:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Developed markets</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>2,933.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>17.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>2,173.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>742.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#d8d8d8;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Developed markets - repurchase agreements</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(1,225.5</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-right:20px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(1,225.5</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-right:20px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Emerging markets</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>565.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>3.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>255.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>6.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>299.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Private alternative investments:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Hedge funds</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>2,795.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>2,795.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#d8d8d8;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Equity-like funds</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>1,893.5</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>16.8</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>1,876.7</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Real estate</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>505.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>147.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>358.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Other</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>729.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>213.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>83.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>432.8</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>10,932.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>1,618.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>1,287.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>24.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>8,002.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">Retiree Health Benefit Plans</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Public equity securities:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">U.S.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>59.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>41.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>18.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#d8d8d8;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">International</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>127.0</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>50.5</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>0.2</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>76.3</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Fixed income:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#d8d8d8;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Developed markets</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>69.1</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>61.5</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>7.6</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Emerging markets</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>53.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>25.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>0.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>27.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Private alternative investments:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Hedge funds</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>245.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>245.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#d8d8d8;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Equity-like funds</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>169.2</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>1.7</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>167.5</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Cash value of trust owned insurance contract</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>1,574.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>1,574.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Real estate</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>27.7</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>14.7</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>13.0</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Other</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>71.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>38.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(3.8</span></span></div></td><td style="vertical-align:bottom;padding-right:20px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>36.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d8d8d8;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#d8d8d8;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>2,398.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#d8d8d8;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d8d8d8;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#d8d8d8;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>144.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#d8d8d8;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d8d8d8;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#d8d8d8;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>1,657.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#d8d8d8;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d8d8d8;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#d8d8d8;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>2.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#d8d8d8;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d8d8d8;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#d8d8d8;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>593.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#d8d8d8;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:8px;padding-left:12px;text-indent:-12px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(1) </sup></span><span style="font-family:Arial;font-size:8pt;">Certain investments that are measured at fair value using the NAV per share (or its equivalent) as a practical expedient have not been classified in the fair value hierarchy.</span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">No material transfers between Level 1, Level 2, or Level 3 occurred during the year ended </span><span style="font-family:Arial;font-size:10pt;color:#000000;text-decoration:none;">December 31, 2018</span><span style="font-family:Arial;font-size:10pt;">. The activity in the Level 3 investments during the year ended </span><span style="font-family:Arial;font-size:10pt;">December 31, 2018</span><span style="font-family:Arial;font-size:10pt;"> was not material.</span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">The fair values of our defined benefit pension plan and retiree health plan assets as of </span><span style="font-family:Arial;font-size:10pt;">December 31, 2017</span><span style="font-family:Arial;font-size:10pt;"> by asset category were as follows:</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="20"/></tr><tr><td style="width:31%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Fair Value Measurements Using</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Asset Class</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Quoted Prices in Active Markets for Identical Assets<br/>(Level 1)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Significant Observable Inputs<br/>(Level 2)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Significant Unobservable Inputs<br/>(Level 3)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Investments Valued at Net Asset Value</span><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(1)</sup></span></div></td></tr><tr><td style="vertical-align:top;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">Defined Benefit Pension Plans</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Public equity securities:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#d8d8d8;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">U.S.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>465.4</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>199.0</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>266.4</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">International</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>2,934.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>955.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>1,979.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Fixed income:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Developed markets</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>3,153.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>20.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>2,468.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>664.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#d8d8d8;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Developed markets - repurchase agreements</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(1,372.9</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-right:12px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(1,372.9</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-right:12px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Emerging markets</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>577.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>3.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>251.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>3.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>319.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Private alternative investments:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Hedge funds</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>2,977.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>2,977.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#d8d8d8;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Equity-like funds</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>1,586.9</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>16.8</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>1,570.1</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Real estate</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>543.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>338.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>205.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Other</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>847.4</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>119.1</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>602.7</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>2.2</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>123.4</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>11,713.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>1,635.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>1,949.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>22.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>8,105.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">Retiree Health Benefit Plans</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Public equity securities:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">U.S.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>43.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>19.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>23.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#d8d8d8;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">International</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>182.5</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>61.3</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>121.2</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Fixed income:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#d8d8d8;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Developed markets</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>71.2</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>63.5</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>7.7</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Emerging markets</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>53.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>24.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>0.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>28.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Private alternative investments:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Hedge funds</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>256.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>256.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#d8d8d8;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Equity-like funds</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>137.0</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>1.6</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>135.4</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Cash value of trust owned insurance contract</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>1,524.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>1,524.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Real estate</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>33.0</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>33.0</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Other</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>72.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>15.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>50.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>0.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>6.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d8d8d8;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#d8d8d8;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>2,372.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#d8d8d8;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d8d8d8;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#d8d8d8;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>128.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#d8d8d8;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d8d8d8;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#d8d8d8;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>1,663.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#d8d8d8;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d8d8d8;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#d8d8d8;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>2.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#d8d8d8;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d8d8d8;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#d8d8d8;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>578.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#d8d8d8;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:8px;padding-left:12px;text-indent:-12px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(1) </sup></span><span style="font-family:Arial;font-size:8pt;">Certain investments that are measured at fair value using the NAV per share (or its equivalent) as a practical expedient have not been classified in the fair value hierarchy.</span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">No material transfers between Level 1, Level 2, or Level 3 occurred during the year ended </span><span style="font-family:Arial;font-size:10pt;">December 31, 2017</span><span style="font-family:Arial;font-size:10pt;">. The activity in the Level 3 investments during the year ended </span><span style="font-family:Arial;font-size:10pt;">December 31, 2017</span><span style="font-family:Arial;font-size:10pt;"> was not material.</span></div><div style="line-height:120%;padding-bottom:16px;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">In 2019, we expect to contribute approximately </span><span style="font-family:Arial;font-size:10pt;"><span>$45 million</span></span><span style="font-family:Arial;font-size:10pt;"> to our defined benefit pension plans to satisfy minimum funding requirements for the year. Additional discretionary contributions are not expected to be significant.</span></div> <span style="font-family:Arial;font-size:10pt;">We use a measurement date of December 31 to develop the change in benefit obligation, change in plan assets, funded status, and amounts recognized in the consolidated balance sheets at December 31 for our defined benefit pension and retiree health benefit plans, which were as follows: </span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:53%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Defined Benefit</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Pension Plans</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Retiree Health</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Benefit Plans</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"> </span><span style="font-family:Arial;font-size:8pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2017</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:top;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Change in benefit obligation:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Benefit obligation at beginning of year</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>14,839.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>12,230.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>1,718.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>1,494.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#d8d8d8;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Service cost</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>292.7</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>320.8</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>41.5</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>46.4</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Interest cost</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>458.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>411.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>57.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>52.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#d8d8d8;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Actuarial (gain) loss</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>(1,386.5</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>1,556.0</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>(176.9</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>30.2</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Benefits paid</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>(579.4</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(467.8</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>(82.8</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(60.1</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#d8d8d8;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Plan amendments</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>17.6</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>(14.1</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Curtailment (gain) loss</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>(43.9</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>90.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>2.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>105.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#d8d8d8;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Special termination benefit</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>317.2</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>37.5</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Foreign currency exchange rate changes and other adjustments</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>(171.6</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>380.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>(6.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>12.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#d8d8d8;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Benefit obligation at end of year</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>13,427.1</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>14,839.7</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>1,540.0</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>1,718.7</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div> 14839700000 12230900000 1718700000 1494600000 292700000 320800000 41500000 46400000 458500000 411600000 57300000 52900000 1386500000 -1556000000.0 176900000 -30200000 579400000 467800000 82800000 60100000 -17600000 0 14100000 0 -43900000 90400000 2500000 105200000 0 317200000 0 37500000 -171600000 380600000 -6200000 12000000.0 13427100000 14839700000 1540000000.0 1718700000 <div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:53%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:top;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Change in plan assets:</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Fair value of plan assets at beginning of year</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>11,713.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>10,056.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>2,372.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>1,961.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#d8d8d8;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Actual return on plan assets</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>(360.1</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>1,434.3</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>32.6</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>462.0</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Employer contribution</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>319.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>410.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>75.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>9.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#d8d8d8;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Benefits paid</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>(579.4</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(467.8</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>(82.8</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(60.1</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Foreign currency exchange rate changes and other adjustments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>(159.9</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>280.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>0.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#d8d8d8;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Fair value of plan assets at end of year</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>10,932.6</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>11,713.0</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>2,398.1</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>2,372.4</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div> 11713000000.0 10056000000.0 2372400000 1961200000 -360100000 1434300000 32600000 462000000.0 319000000.0 410400000 75900000 9100000 579400000 467800000 82800000 60100000 -159900000 280100000 0 200000 10932600000 11713000000.0 2398100000 2372400000 <div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:53%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:top;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Funded status</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>(2,494.5</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(3,126.7</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>858.1</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>653.7</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Unrecognized net actuarial loss</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>5,011.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>5,616.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>140.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>182.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Unrecognized prior service (benefit) cost</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>25.0</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>14.5</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>(299.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d8d8d8;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(395.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d8d8d8;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Net amount recognized</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>2,541.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>2,504.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>698.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>440.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div> -2494500000 -3126700000 858100000 653700000 -5011300000 -5616400000 -140600000 -182000000.0 25000000.0 14500000 -299900000 -395000000.0 2541800000 2504200000 698800000 440700000 <div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:53%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:top;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Amounts recognized in the consolidated balance sheet consisted of:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Sundry</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>193.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>104.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>1,043.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>870.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#d8d8d8;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Other current liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>(64.2</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(64.5</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>(7.3</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(7.1</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Accrued retirement benefits</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>(2,624.0</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(3,166.7</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>(178.2</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(209.3</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#d8d8d8;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Accumulated other comprehensive (income) loss before income taxes</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>5,036.3</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>5,630.9</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>(159.3</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(213.0</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Net amount recognized</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>2,541.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>2,504.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>698.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>440.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span> 193700000 104500000 1043600000 870100000 64200000 64500000 7300000 7100000 2624000000.0 3166700000 178200000 209300000 5036300000 5630900000 -159300000 -213000000.0 2541800000 2504200000 698800000 440700000 28000000.0 -1590000000 159000000.0 354700000 446700000 67000000.0 2830000000 <div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">The following represents our weighted-average assumptions as of December 31:</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="18"/></tr><tr><td style="width:59%;"/><td style="width:5%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:5%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:5%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:5%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:5%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:5%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"> </span></div></td><td colspan="8" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Defined Benefit</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Pension Plans</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="8" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Retiree Health</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Benefit Plans</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">(Percents)</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2017</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2016</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2017</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2016</span></div></td></tr><tr><td style="vertical-align:top;background-color:#d8d8d8;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Discount rate for benefit obligation</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>4.0</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">%</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>3.4</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>3.9</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>4.4</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">%</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>3.7</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>4.3</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Discount rate for net benefit costs</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>3.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>3.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>4.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>3.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>4.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>4.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#d8d8d8;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Rate of compensation increase for benefit obligation</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>3.4</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>3.4</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>3.4</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Rate of compensation increase for net benefit costs</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>3.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>3.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>3.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#d8d8d8;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Expected return on plan assets for net benefit costs</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>7.4</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>7.4</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>7.4</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>8.0</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>8.0</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>8.0</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 0.040 0.034 0.039 0.044 0.037 0.043 0.034 0.039 0.043 0.037 0.043 0.045 0.034 0.034 0.034 0.034 0.034 0.034 0.074 0.074 0.074 0.080 0.080 0.080 <div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">The following benefit payments, which reflect expected future service, as appropriate, are expected to be paid as follows:</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="24"/></tr><tr><td style="width:29%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2021</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2022</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2023</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2024-2028</span></div></td></tr><tr><td style="vertical-align:top;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Defined benefit pension plans</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>604.1</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>607.2</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>616.5</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>632.1</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>641.6</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>3,524.7</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Retiree health benefit plans</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>98.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>99.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>100.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>99.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>98.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>505.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 604100000 607200000 616500000 632100000 641600000 3524700000 98000000.0 99100000 100700000 99900000 98500000 505300000 <div style="line-height:120%;padding-top:12px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Amounts relating to defined benefit pension plans with projected benefit obligations in excess of plan assets were as follows at December 31:</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:77%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:top;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Projected benefit obligation</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>11,584.2</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>12,773.4</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Fair value of plan assets</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>8,895.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>9,542.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 11584200000 12773400000 8895600000 9542500000 <div style="line-height:120%;padding-top:12px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Amounts relating to defined benefit pension plans and retiree health benefit plans with accumulated benefit obligations in excess of plan assets were as follows at December 31:</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:53%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Defined Benefit</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Pension Plans</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Retiree Health </span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Benefit Plans</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2017</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:top;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Accumulated benefit obligation</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d8d8d8;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>10,837.8</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d8d8d8;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>11,733.6</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d8d8d8;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>189.4</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d8d8d8;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>225.1</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Fair value of plan assets</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>8,895.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>9,517.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 10837800000 11733600000 189400000 225100000 8895600000 9517600000 0 0 12570000000 13670000000 <div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Net pension and retiree health benefit expense included the following components:</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="24"/></tr><tr><td style="width:41%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Defined Benefit</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Pension Plans</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Retiree Health</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Benefit Plans</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"> </span><span style="font-family:Arial;font-size:8pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2017</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2016</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2017</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2016</span></div></td></tr><tr><td style="vertical-align:top;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Components of net periodic (benefit) cost:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Service cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>292.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>320.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>268.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>41.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>46.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>39.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#d8d8d8;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Interest cost</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>458.5</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>411.6</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>419.0</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>57.3</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>52.9</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>53.2</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Expected return on plan assets</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>(842.1</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(773.6</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(748.7</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>(177.9</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(160.7</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(150.2</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#d8d8d8;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Amortization of prior service (benefit) cost</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>4.6</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>5.6</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>11.7</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>(79.5</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(90.0</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(85.8</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Recognized actuarial loss</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>332.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>286.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>284.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>6.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>18.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>19.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#d8d8d8;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Curtailment (gain) loss</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>1.3</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>93.5</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>(29.3</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>65.5</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Special termination benefit</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>317.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>37.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#d8d8d8;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Net periodic (benefit) cost</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#d8d8d8;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>247.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#d8d8d8;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>661.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#d8d8d8;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>235.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#d8d8d8;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>(181.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#d8d8d8;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#d8d8d8;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(30.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#d8d8d8;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#d8d8d8;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(124.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#d8d8d8;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 292700000 320800000 268400000 41500000 46400000 39100000 458500000 411600000 419000000.0 57300000 52900000 53200000 842100000 773600000 748700000 177900000 160700000 150200000 4600000 5600000 11700000 -79500000 -90000000.0 -85800000 -332500000 -286800000 -284600000 -6100000 -18400000 -19100000 -1300000 -93500000 0 29300000 -65500000 0 0 317200000 0 0 37500000 0 247500000 661900000 235000000.0 -181800000 -30000000.0 -124600000 <div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">The following represents the amounts recognized in other comprehensive income (loss) for the years ended </span><span style="font-family:Arial;font-size:10pt;color:#000000;text-decoration:none;">December 31, 2018</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:Arial;font-size:10pt;">2017</span><span style="font-family:Arial;font-size:10pt;">, and </span><span style="font-family:Arial;font-size:10pt;">2016</span><span style="font-family:Arial;font-size:10pt;">:</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="24"/></tr><tr><td style="width:35%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Defined Benefit<br/>Pension Plans</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Retiree Health<br/>Benefit Plans</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2017</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2016</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2017</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2016</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Actuarial gain (loss) arising during period</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>182.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(898.1</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(719.1</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>37.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>261.3</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(132.2</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Plan amendments during period</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>(17.6</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>14.1</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>35.8</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Curtailment gain (loss)</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>45.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>3.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>(31.8</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(39.7</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Amortization of prior service (benefit) cost included in net income</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>4.6</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>5.6</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>11.7</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>(79.5</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(90.0</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(85.8</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Amortization of net actuarial loss included in net income</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>332.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>286.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>284.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>6.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>18.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>19.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Foreign currency exchange rate changes and other</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>47.1</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(108.8</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>72.6</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>(0.1</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(3.3</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>2.5</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Total other comprehensive income (loss) during period</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>594.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(711.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(350.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>(53.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>146.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(160.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 182800000 -898100000 -719100000 37500000 261300000 -132200000 17600000 0 0 -14100000 0 -35800000 45200000 3200000 0 -31800000 -39700000 0 4600000 5600000 11700000 -79500000 -90000000.0 -85800000 332500000 286800000 284600000 6100000 18400000 19100000 47100000 -108800000 72600000 -100000 -3300000 2500000 -594600000 711300000 350200000 53700000 -146700000 160600000 132600000 147000000.0 155400000 0.80 0.70 0.30 617700000 409100000 0 0 208600000 2117800000 828800000 0 1800000 1287200000 2933400000 17200000 2173300000 0 742900000 -1225500000 0 -1225500000 0 0 565200000 3400000 255800000 6100000 299900000 2795300000 0 0 0 2795300000 1893500000 0 0 16800000 1876700000 505700000 147100000 0 0 358600000 729500000 213000000.0 83700000 0 432800000 10932600000 1618600000 1287300000 24700000 8002000000.0 59900000 41000000.0 0 0 18900000 127000000.0 50500000 0 200000 76300000 69100000 0 61500000 0 7600000 53500000 0 25500000 600000 27400000 245800000 0 0 0 245800000 169200000 0 0 1700000 167500000 1574700000 0 1574700000 0 0 27700000 14700000 0 0 13000000.0 71200000 38100000 -3800000 0 36900000 2398100000 144300000 1657900000 2500000 593400000 <div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">The fair values of our defined benefit pension plan and retiree health plan assets as of </span><span style="font-family:Arial;font-size:10pt;">December 31, 2017</span><span style="font-family:Arial;font-size:10pt;"> by asset category were as follows:</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="20"/></tr><tr><td style="width:31%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Fair Value Measurements Using</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Asset Class</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Quoted Prices in Active Markets for Identical Assets<br/>(Level 1)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Significant Observable Inputs<br/>(Level 2)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Significant Unobservable Inputs<br/>(Level 3)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Investments Valued at Net Asset Value</span><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(1)</sup></span></div></td></tr><tr><td style="vertical-align:top;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">Defined Benefit Pension Plans</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Public equity securities:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#d8d8d8;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">U.S.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>465.4</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>199.0</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>266.4</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">International</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>2,934.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>955.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>1,979.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Fixed income:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Developed markets</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>3,153.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>20.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>2,468.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>664.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#d8d8d8;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Developed markets - repurchase agreements</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(1,372.9</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-right:12px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(1,372.9</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-right:12px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Emerging markets</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>577.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>3.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>251.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>3.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>319.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Private alternative investments:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Hedge funds</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>2,977.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>2,977.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#d8d8d8;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Equity-like funds</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>1,586.9</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>16.8</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>1,570.1</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Real estate</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>543.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>338.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>205.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Other</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>847.4</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>119.1</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>602.7</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>2.2</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>123.4</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>11,713.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>1,635.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>1,949.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>22.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>8,105.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">Retiree Health Benefit Plans</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Public equity securities:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">U.S.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>43.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>19.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>23.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#d8d8d8;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">International</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>182.5</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>61.3</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>121.2</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Fixed income:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#d8d8d8;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Developed markets</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>71.2</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>63.5</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>7.7</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Emerging markets</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>53.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>24.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>0.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>28.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Private alternative investments:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Hedge funds</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>256.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>256.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#d8d8d8;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Equity-like funds</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>137.0</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>1.6</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>135.4</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Cash value of trust owned insurance contract</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>1,524.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>1,524.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Real estate</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>33.0</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>33.0</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Other</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>72.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>15.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>50.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>0.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>6.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d8d8d8;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#d8d8d8;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>2,372.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#d8d8d8;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d8d8d8;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#d8d8d8;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>128.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#d8d8d8;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d8d8d8;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#d8d8d8;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>1,663.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#d8d8d8;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d8d8d8;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#d8d8d8;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>2.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#d8d8d8;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d8d8d8;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#d8d8d8;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>578.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#d8d8d8;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:8px;padding-left:12px;text-indent:-12px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(1) </sup></span><span style="font-family:Arial;font-size:8pt;">Certain investments that are measured at fair value using the NAV per share (or its equivalent) as a practical expedient have not been classified in the fair value hierarchy.</span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">The fair values of our defined benefit pension plan and retiree health plan assets as of </span><span style="font-family:Arial;font-size:10pt;color:#000000;text-decoration:none;">December 31, 2018</span><span style="font-family:Arial;font-size:10pt;"> by asset category were as follows:</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="20"/></tr><tr><td style="width:31%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:20px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Fair Value Measurements Using</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Asset Class</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Quoted Prices in Active Markets for<br/>Identical Assets<br/>(Level 1)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Significant<br/>Observable </span></div><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Inputs<br/>(Level 2)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Significant<br/>Unobservable Inputs<br/>(Level 3)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Investments Valued at Net Asset Value</span><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(1)</sup></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">Defined Benefit Pension Plans</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Public equity securities:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#d8d8d8;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">U.S.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>617.7</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>409.1</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>208.6</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">International</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>2,117.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>828.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>1.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>1,287.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Fixed income:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Developed markets</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>2,933.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>17.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>2,173.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>742.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#d8d8d8;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Developed markets - repurchase agreements</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(1,225.5</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-right:20px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(1,225.5</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-right:20px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Emerging markets</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>565.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>3.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>255.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>6.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>299.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Private alternative investments:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Hedge funds</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>2,795.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>2,795.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#d8d8d8;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Equity-like funds</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>1,893.5</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>16.8</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>1,876.7</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Real estate</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>505.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>147.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>358.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Other</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>729.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>213.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>83.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>432.8</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>10,932.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>1,618.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>1,287.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>24.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>8,002.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">Retiree Health Benefit Plans</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Public equity securities:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">U.S.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>59.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>41.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>18.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#d8d8d8;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">International</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>127.0</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>50.5</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>0.2</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>76.3</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Fixed income:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#d8d8d8;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Developed markets</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>69.1</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>61.5</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>7.6</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Emerging markets</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>53.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>25.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>0.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>27.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Private alternative investments:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Hedge funds</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>245.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>245.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#d8d8d8;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Equity-like funds</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>169.2</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>1.7</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>167.5</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Cash value of trust owned insurance contract</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>1,574.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>1,574.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Real estate</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>27.7</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>14.7</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>13.0</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Other</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>71.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>38.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(3.8</span></span></div></td><td style="vertical-align:bottom;padding-right:20px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>36.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d8d8d8;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#d8d8d8;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>2,398.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#d8d8d8;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d8d8d8;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#d8d8d8;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>144.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#d8d8d8;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d8d8d8;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#d8d8d8;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>1,657.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#d8d8d8;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d8d8d8;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#d8d8d8;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>2.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#d8d8d8;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d8d8d8;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#d8d8d8;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>593.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#d8d8d8;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:8px;padding-left:12px;text-indent:-12px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(1) </sup></span><span style="font-family:Arial;font-size:8pt;">Certain investments that are measured at fair value using the NAV per share (or its equivalent) as a practical expedient have not been classified in the fair value hierarchy.</span></div> 465400000 199000000.0 0 0 266400000 2934200000 955100000 0 0 1979100000 3153000000.0 20500000 2468100000 0 664400000 -1372900000 0 -1372900000 0 0 577500000 3600000 251700000 3100000 319100000 2977800000 0 0 0 2977800000 1586900000 0 0 16800000 1570100000 543700000 338600000 0 0 205100000 847400000 119100000 602700000 2200000 123400000 11713000000.0 1635900000 1949600000 22100000 8105400000 43000000.0 19400000 0 0 23600000 182500000 61300000 0 0 121200000 71200000 0 63500000 0 7700000 53100000 0 24400000 300000 28400000 256000000.0 0 0 0 256000000.0 137000000.0 0 0 1600000 135400000 1524600000 0 1524600000 0 0 33000000.0 33000000.0 0 0 0 72000000.0 15000000.0 50500000 200000 6300000 2372400000 128700000 1663000000.0 2100000 578600000 45000000 Contingencies<div style="line-height:120%;padding-bottom:8px;padding-top:12px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">We are a party to various legal actions and government investigations. The most significant of these are described below. It is not possible to determine the outcome of these matters, and we cannot reasonably estimate the maximum potential exposure or the range of possible loss in excess of amounts accrued for any of these matters; however, we believe that, except as noted below with respect to the Alimta</span><span style="font-family:Arial;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">®</sup></span><span style="font-family:Arial;font-size:10pt;"> patent litigation and administrative proceedings, the resolution of all such matters will not have a material adverse effect on our consolidated financial position or liquidity, but could possibly be material to our consolidated results of operations in any one accounting period.</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Litigation accruals, environmental liabilities, and the related estimated insurance recoverables are reflected on a gross basis as liabilities and assets, respectively, on our consolidated balance sheets. With respect to the product liability claims currently asserted against us, we have accrued for our estimated exposures to the extent they are both probable and reasonably estimable based on the information available to us. We accrue for certain product liability claims incurred but not filed to the extent we can formulate a reasonable estimate of their costs. We estimate these expenses based primarily on historical claims experience and data regarding product usage. Legal defense costs expected to be incurred in connection with significant product liability loss contingencies are accrued when both probable and reasonably estimable.</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">Alimta Patent Litigation and Administrative Proceedings</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">A number of generic manufacturers are seeking approvals in the U.S., Japan, and a number of countries in Europe to market generic forms of Alimta prior to the expiration of our vitamin regimen patents, alleging that those patents are invalid, not infringed, or both. We believe our Alimta vitamin regimen patents are valid and enforceable against these generic manufacturers. However, it is not possible to determine the ultimate outcome of the proceedings, and accordingly, we can provide no assurance that we will prevail. An unfavorable outcome could have a material adverse impact on our future consolidated results of operations, liquidity, and financial position. We expect that a loss of exclusivity for Alimta in one or more of the below jurisdictions would result in a rapid and severe decline in future revenue for the product in the relevant market.</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:12px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-style:italic;text-decoration:underline;">U.S. Patent Litigation and Administrative Proceedings</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:12px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">In the U.S., more than </span><span style="font-family:Arial;font-size:10pt;"><span>10</span></span><span style="font-family:Arial;font-size:10pt;"> Abbreviated New Drug Applications (ANDAs) seeking approval to market generic versions of Alimta prior to the expiration of our vitamin regimen patent (expiring in 2021 plus pediatric exclusivity expiring in 2022) have been filed by a number of companies, including Teva Parenteral Medicines, Inc. (Teva) and APP Pharmaceuticals, LLC (APP) pursuant to procedures set out in the Drug Price Competition and Patent Term Restoration Act of 1984 (the Hatch-Waxman Act). We have received favorable decisions from the U.S. Court of Appeals for the Federal Circuit (affirming the U.S. District Court for the Southern District of Indiana's decisions finding our U.S. vitamin regimen patent valid and infringed) against Teva, APP, and </span><span style="font-family:Arial;font-size:10pt;"><span>two</span></span><span style="font-family:Arial;font-size:10pt;"> other defendants' proposed products, and similar favorable judgments have been entered by the U.S. District Court for the Southern District of Indiana against </span><span style="font-family:Arial;font-size:10pt;"><span>five</span></span><span style="font-family:Arial;font-size:10pt;"> other companies. The remaining ANDA applicants have agreed to a preliminary injunction or stay pending the appeal of the inter partes review (IPR) described in the following sentence. In October 2017, the U.S. Patent and Trademark Office issued written decisions in our favor following IPR of our vitamin regimen patent, finding that the generic company petitioners failed to show that the claims in our patent are unpatentable. A number of these challengers have appealed. A hearing on the appeal was held in the first quarter of 2019, and we expect a decision in the second quarter of 2019. </span></div><div style="line-height:120%;padding-bottom:8px;padding-top:12px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">We also currently have pending lawsuits in the U.S. District Court for the Southern District of Indiana alleging infringement against Actavis LLC (Actavis) and Apotex Inc. in response to their applications to market alternative forms of pemetrexed (the active ingredient in Alimta) products, and we filed a similar lawsuit in the U.S. District Court for the District of Delaware against Eagle Pharmaceuticals, Inc. In June 2018, the U.S. District Court for the Southern District of Indiana ruled in our favor in </span><span style="font-family:Arial;font-size:10pt;"><span>two</span></span><span style="font-family:Arial;font-size:10pt;"> similar cases, finding Dr. Reddy's Laboratories' (Dr. Reddy) and Hospira, Inc.'s (Hospira) proposed products would infringe our patent. Dr. Reddy and Hospira have appealed those rulings. The lawsuit against Actavis has been stayed, pending a decision in Dr. Reddy’s appeal.</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:12px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-style:italic;text-decoration:underline;">European Patent Litigation and Administrative Proceedings</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:12px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">In July 2017, the United Kingdom (U.K.) Supreme Court ruled that commercialization of certain salt forms of pemetrexed by Actavis Group ehf and other Actavis companies directly infringes our vitamin regimen patents in the U.K., Italy, France, and Spain. This litigation in the U.K. is now concluded. </span></div><div style="line-height:120%;padding-bottom:8px;padding-top:12px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Hexal AG, Stada Arzneimittel AG (Stada), and Fresenius Kabi Deutschland GmbH have each challenged the validity of our vitamin regimen patent before the German Federal Patent Court. At a hearing in July 2018, the German Federal Patent Court held that our vitamin regimen patent is invalid. We have appealed this decision. Under German law, the patent remains in force pending appeal. A number of generic competitors have received approval to market generic versions of pemetrexed in Germany. Injunctions are in place against </span><span style="font-family:Arial;font-size:10pt;"><span>four</span></span><span style="font-family:Arial;font-size:10pt;"> of these companies, </span><span style="font-family:Arial;font-size:10pt;background-color:#ffffff;">but in two cases the injunctions have been temporarily suspended pending the validity appeal at the German Supreme Court. Stada</span><span style="font-family:Arial;font-size:10pt;"> has recently launched at risk in Germany and we are seeking an injunction. We are pursuing injunctions against others who have launched or are preparing to launch at </span></div><div style="line-height:120%;padding-bottom:8px;padding-top:12px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">risk. Whether the existing injunctions remain in effect, the suspended injunctions are reinstated pending the appeal or further injunctions are granted, or whether additional generic competitors choose to launch at risk, makes the timing of further generic entry and market erosion in Germany unpredictable. </span></div><div style="line-height:120%;padding-bottom:8px;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Additional legal proceedings are ongoing in various national courts throughout Europe. We are aware that several companies have received approval to market generic versions of pemetrexed in major European markets and that additional generic competitors may choose to launch at risk (including </span><span style="font-family:Arial;font-size:10pt;"><span>one</span></span><span style="font-family:Arial;font-size:10pt;"> generic product currently on the market in France). We will continue to seek to remove any generic pemetrexed products launched at risk in European markets, including Germany, seek damages in respect of such launches, and defend our patents against validity challenges.</span></div><div style="line-height:120%;padding-bottom:8px;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-style:italic;text-decoration:underline;">Japanese Administrative Proceedings</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>Three</span></span><span style="font-family:Arial;font-size:10pt;"> separate sets of demands for invalidation of our </span><span style="font-family:Arial;font-size:10pt;"><span>two</span></span><span style="font-family:Arial;font-size:10pt;"> vitamin regimen patents, involving several companies, have been filed with the Japanese Patent Office (JPO). The JPO rejected a demand for invalidation by Sawai Pharmaceutical Co., Ltd., which was affirmed on appeal in 2017. In July 2018, the JPO issued written decisions dismissing demands brought by Nipro Corporation (Nipro) for invalidation of our </span><span style="font-family:Arial;font-size:10pt;"><span>two</span></span><span style="font-family:Arial;font-size:10pt;"> Japanese vitamin regimen patents. Nipro filed an appeal, and we anticipate decisions by the Japan Intellectual Property High Court in the third quarter of 2019. We anticipate decisions by the JPO with respect to another set of demands, brought by Hospira, in the third quarter of 2019. If upheld through all challenges, these patents would provide intellectual property protection for Alimta until June 2021. Notwithstanding our patents, generic versions of Alimta received regulatory approval in Japan starting in February 2016. We do not currently anticipate that generic versions of Alimta will proceed to pricing approval.</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:12px;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">Cymbalta</span><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">®</sup></span><span style="font-family:Arial;font-size:10pt;font-weight:bold;"> Product Liability Litigation</span></div><div style="line-height:120%;padding-bottom:8px;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">We were named as a defendant in a purported class-action lawsuit in the U.S. District Court for the Central District of California (now called </span><span style="font-family:Arial;font-size:10pt;font-style:italic;">Strafford et al. v. Eli Lilly and Com</span><span style="font-family:Arial;font-size:10pt;">pany) involving Cymbalta. The plaintiffs, purporting to represent a class of all persons within the U.S. who purchased and/or paid for Cymbalta, asserted claims under the consumer protection statutes of four states, California, Massachusetts, Missouri, and New York, and sought declaratory, injunctive, and monetary relief for various alleged economic injuries arising from discontinuing treatment with Cymbalta. The district court denied the plaintiffs' motions for class certification. The district court dismissed the suits and plaintiffs appealed to the U.S. Court of Appeals for the Ninth Circuit. In November 2017, the U.S. Court of Appeals for the Ninth Circuit dismissed the suit. In July 2018, the U.S. District Court for the District of California denied plaintiffs’ motion to reopen the case. Plaintiffs’ appeal of this denial is currently pending before the U.S. Court of Appeals for the Ninth Circuit.</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:12px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">Brazil–Employee Litigation</span></div><div style="line-height:120%;padding-bottom:8px;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Our subsidiary in Brazil, Eli Lilly do Brasil Limitada (Lilly Brasil), is named in a lawsuit brought by the Labor Attorney for the 15th Region in the Labor Court of Paulinia, State of Sao Paulo, Brazil, alleging possible harm to employees and former employees caused by exposure to heavy metals at a former Lilly Brasil manufacturing facility in Cosmopolis, Brazil, operated by the company between 1977 and 2003. In May 2014, the labor court judge ruled against Lilly Brasil, ordering it to undertake several actions of unspecified financial impact, including paying lifetime medical insurance for the employees and contractors who worked at the Cosmopolis facility more than six months during the affected years and their children born during and after this period. We appealed this decision. In July 2018, the appeals court affirmed the labor court's ruling with the total financial impact of the ruling estimated to be approximately </span><span style="font-family:Arial;font-size:10pt;"><span>500.0 million</span></span><span style="font-family:Arial;font-size:10pt;"> Brazilian real (approximately </span><span style="font-family:Arial;font-size:10pt;"><span>$130.0 million</span></span><span style="font-family:Arial;font-size:10pt;"> as of December 31, 2018). The appeals court restricted the broad health coverage awarded by the labor court to health problems that claimants could show arose from exposure to the alleged contamination. We strongly disagree with the appeals court's decision. Lilly Brasil has taken an initial step in the appeal process by filing a Motion for Clarification; a decision on that motion is expected in the first quarter of 2019. </span></div><div style="line-height:120%;padding-bottom:8px;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">We are also named in approximately </span><span style="font-family:Arial;font-size:10pt;"><span>30</span></span><span style="font-family:Arial;font-size:10pt;"> lawsuits filed in the same labor court by individual former employees making similar claims. These lawsuits are each at various stages in the litigation process, with judgments being handed down in approximately half of the lawsuits, nearly all of which are on appeal in the labor courts.</span></div><div style="line-height:120%;padding-bottom:8px;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Lilly Brasil and Elanco Quimica Ltda. have also been named in </span><span style="font-family:Arial;font-size:10pt;"><span>two</span></span><span style="font-family:Arial;font-size:10pt;"> similar lawsuits in the same labor court involving approximately </span><span style="font-family:Arial;font-size:10pt;"><span>410</span></span><span style="font-family:Arial;font-size:10pt;"> individual plaintiffs. As part of the disposition of Elanco, we agreed to indemnify Elanco Quimica Ltda. in this litigation. The plaintiffs’ claims in these lawsuits relate only to mental anguish attributable to the possibility of illness due to alleged exposure to heavy metals or other contaminants. In </span></div><div style="line-height:120%;padding-bottom:8px;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">2017, the labor court dismissed the claims brought by all but the first named plaintiff in each of the lawsuits. The plaintiffs in both lawsuits are appealing.</span></div><div style="line-height:120%;padding-bottom:8px;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">We believe all of these lawsuits are without merit and are defending against them vigorously.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">Adocia, S.A.</span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">We have been named as a respondent in an arbitration filed by Adocia, S.A. (Adocia), with which we entered into agreements for the co-development of an ultra-rapid insulin product. Adocia alleges that we misappropriated and misused Adocia's confidential information and intellectual property and is seeking approximately </span><span style="font-family:Arial;font-size:10pt;"><span>$1.30 billion</span></span><span style="font-family:Arial;font-size:10pt;"> in damages and other specific relief. We have asserted several counterclaims relating to fraudulent misrepresentation and are seeking approximately </span><span style="font-family:Arial;font-size:10pt;"><span>$188.0 million</span></span><span style="font-family:Arial;font-size:10pt;"> in damages. An arbitration hearing was held on Adocia’s claims and our counterclaims in December 2018, and we expect a decision in the third quarter of 2019. We believe Adocia's claims are without merit and have defended against them vigorously.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Throughout the arbitrations described above, Adocia has made statements alleging that Adocia employees should be listed as inventors on </span><span style="font-family:Arial;font-size:10pt;"><span>two</span></span><span style="font-family:Arial;font-size:10pt;"> of our patents related to our ultra-rapid insulin product currently in development. We strongly contest this allegation. While inventorship of these </span><span style="font-family:Arial;font-size:10pt;"><span>two</span></span><span style="font-family:Arial;font-size:10pt;"> patents is not at issue in the arbitrations, in October 2018 we filed a declaratory judgment action against Adocia in the U.S. District Court for the Southern District of Indiana to confirm our inventorship.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">Insulin and Glucagon Pricing Litigation and Proceedings</span></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">We, along with Sanofi and Novo Nordisk, are named as defendants in a consolidated purported class action lawsuit, </span><span style="font-family:Arial;font-size:10pt;font-style:italic;">In re. Insulin Pricing Litigation</span><span style="font-family:Arial;font-size:10pt;">, in the U.S. District Court of New Jersey relating to insulin pricing. Plaintiffs seek damages under various state consumer protection laws and the Federal Racketeer Influenced and Corrupt Organization Act (Federal RICO Act). In February 2019, the court dismissed without prejudice the federal RICO Act claim as well as certain state consumer protection claims. Separately, we, along with Sanofi and Novo Nordisk, are named as defendants in a purported class action lawsuit, </span><span style="font-family:Arial;font-size:10pt;font-style:italic;">MSP Recovery Claims, Series, LLC et al. v. Sanofi Aventis U.S. LLC et al.</span><span style="font-family:Arial;font-size:10pt;">, in the same court, seeking damages under various state consumer protection laws, common law fraud, unjust enrichment, and the federal RICO Act. Finally, the Minnesota Attorney General’s Office filed a complaint against us, Sanofi, and Novo Nordisk, </span><span style="font-family:Arial;font-size:10pt;font-style:italic;">State of Minnesota v. Sanofi-Aventis U.S. LLC et al.,</span><span style="font-family:Arial;font-size:10pt;"> in the U.S. District Court of New Jersey, alleging unjust enrichment, and violations of various Minnesota state consumer protection laws and the Federal RICO Act. We believe these claims are without merit and are defending against them vigorously.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">We have received civil investigative demands from the Offices of the Attorney General from Washington and New Mexico relating to the pricing and sale of our insulin products. We are cooperating with these investigations. The Offices of the Attorney General in Mississippi, Washington D.C., California, Florida, Hawaii, and Nevada have requested information relating to the pricing and sale of our insulin products. We are cooperating with these requests. We received interrogatories from the California Attorney General's Office regarding our competition in the long-acting insulin market. We are cooperating with this investigation. Finally, we received a request from the House of Representatives’ Committee on Oversight and Reform; two requests from its Committee on Energy and Commerce; as well as a request from the Senate Committee on Health, Education, Labor, and Pensions, seeking certain information related to the pricing of insulin products, among other issues</span><span style="font-family:Calibri,sans-serif;font-size:10pt;">.</span><span style="font-family:Arial;font-size:10pt;"> We are cooperating with these investigations.</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">We, along with Novo Nordisk</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:Arial;font-size:10pt;">and various pharmacy benefit managers, are named as defendants in a lawsuit seeking class action status in the U.S. District Court of New Jersey relating to glucagon pricing. The plaintiffs are seeking damages under various state consumer protection laws, the Federal RICO Act, the Sherman Act, and other state and federal laws. We believe this lawsuit is without merit and are defending against it vigorously.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">Product Liability Insurance</span></div>Because of the nature of pharmaceutical products, it is possible that we could become subject to large numbers of additional product liability and related claims in the future. Due to a very restrictive market for product liability insurance, we are self-insured for product liability losses for all our currently marketed products. <div style="line-height:120%;padding-bottom:8px;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Litigation accruals, environmental liabilities, and the related estimated insurance recoverables are reflected on a gross basis as liabilities and assets, respectively, on our consolidated balance sheets. With respect to the product liability claims currently asserted against us, we have accrued for our estimated exposures to the extent they are both probable and reasonably estimable based on the information available to us. We accrue for certain product liability claims incurred but not filed to the extent we can formulate a reasonable estimate of their costs. We estimate these expenses based primarily on historical claims experience and data regarding product usage. Legal defense costs expected to be incurred in connection with significant product liability loss contingencies are accrued when both probable and reasonably estimable.</span></div> 10 2 5 2 4 1 3 2 2 500000000.0 130000000.0 30 2 410 1300000000 188000000.0 2 2 Other Comprehensive Income (Loss)<div style="line-height:120%;padding-top:12px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">The following table summarizes the activity related to each component of other comprehensive income (loss):</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.38271604938271%;border-collapse:collapse;text-align:left;"><tr><td colspan="24"/></tr><tr><td style="width:25%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Continuing Operations</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">(Amounts presented net of taxes)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Foreign Currency Translation Gains (Losses)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Unrealized Net Gains (Losses) on Securities</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Defined Benefit Pension and Retiree Health Benefit Plans</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Effective Portion of Cash Flow Hedges</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Discontinued Operations</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Accumulated Other Comprehensive Loss</span></div></td></tr><tr><td style="vertical-align:top;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;background-color:#d8d8d8;">Beginning balance at January 1, 2016</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(1,315.9</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-right:12px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>10.1</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(2,996.8</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-right:12px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(218.5</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-right:12px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d8d8d8;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(59.6</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-right:12px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(4,580.7</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-right:12px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Other comprehensive income (loss) before reclassifications</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(445.2</span></span></div></td><td style="vertical-align:bottom;padding-right:12px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>206.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(514.3</span></span></div></td><td style="vertical-align:bottom;padding-right:12px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(2.2</span></span></div></td><td style="vertical-align:bottom;padding-right:12px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(140.8</span></span></div></td><td style="vertical-align:bottom;padding-right:12px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(895.8</span></span></div></td><td style="vertical-align:bottom;padding-right:12px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#d8d8d8;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Net amount reclassified from accumulated other comprehensive loss</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>74.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>7.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>159.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>9.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>0.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>250.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Net other comprehensive income (loss)</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(370.7</span></span></div></td><td style="vertical-align:bottom;padding-right:12px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>213.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(355.2</span></span></div></td><td style="vertical-align:bottom;padding-right:12px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>7.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(140.7</span></span></div></td><td style="vertical-align:bottom;padding-right:12px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(645.1</span></span></div></td><td style="vertical-align:bottom;padding-right:12px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Balance at December 31, 2016</span><span style="font-family:Arial;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(1)</sup></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(1,686.6</span></span></div></td><td style="vertical-align:bottom;padding-right:12px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>224.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(3,352.0</span></span></div></td><td style="vertical-align:bottom;padding-right:12px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(210.9</span></span></div></td><td style="vertical-align:bottom;padding-right:12px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(200.3</span></span></div></td><td style="vertical-align:bottom;padding-right:12px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(5,225.8</span></span></div></td><td style="vertical-align:bottom;padding-right:12px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Other comprehensive income (loss) before reclassifications</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>525.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(15.7</span></span></div></td><td style="vertical-align:bottom;padding-right:12px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(532.1</span></span></div></td><td style="vertical-align:bottom;padding-right:12px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>8.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>127.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>114.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#d8d8d8;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Net amount reclassified from accumulated other comprehensive loss</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>8.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(110.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d8d8d8;padding-right:12px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>151.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>9.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>1.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>60.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Net other comprehensive income (loss)</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>533.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(126.3</span></span></div></td><td style="vertical-align:bottom;padding-right:12px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(380.2</span></span></div></td><td style="vertical-align:bottom;padding-right:12px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>18.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>129.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>174.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Reclassifications of stranded tax effects (Note 2)</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(38.8</span></span></div></td><td style="vertical-align:bottom;padding-right:12px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>15.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(579.1</span></span></div></td><td style="vertical-align:bottom;padding-right:12px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(41.5</span></span></div></td><td style="vertical-align:bottom;padding-right:12px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(643.6</span></span></div></td><td style="vertical-align:bottom;padding-right:12px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Balance at December 31, 2017</span><span style="font-family:Arial;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(2)</sup></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(1,191.7</span></span></div></td><td style="vertical-align:bottom;padding-right:12px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>113.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(4,311.3</span></span></div></td><td style="vertical-align:bottom;padding-right:12px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(234.3</span></span></div></td><td style="vertical-align:bottom;padding-right:12px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(71.1</span></span></div></td><td style="vertical-align:bottom;padding-right:12px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(5,694.9</span></span></div></td><td style="vertical-align:bottom;padding-right:12px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Reclassification due to adoption of new accounting standard</span><span style="font-family:Arial;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(3)</sup></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>(128.9</span></span></div></td><td style="vertical-align:bottom;padding-right:12px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>(128.9</span></span></div></td><td style="vertical-align:bottom;padding-right:12px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#d8d8d8;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Other comprehensive income (loss) before reclassifications</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>(378.0</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-right:12px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>24.5</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>250.7</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>(16.3</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-right:12px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>12.2</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>(106.9</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-right:12px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Net amount reclassified from accumulated other comprehensive loss</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>(31.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:12px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>207.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>11.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>2.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>190.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#d8d8d8;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Net other comprehensive income (loss)</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>(378.0</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-right:12px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>(6.7</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-right:12px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>458.6</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>(4.6</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-right:12px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>14.3</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>83.6</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Ending balance at December 31, 2018</span><span style="font-family:Arial;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(4)</sup></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#d8d8d8;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>(1,569.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#d8d8d8;padding-right:12px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#d8d8d8;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>(22.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#d8d8d8;padding-right:12px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#d8d8d8;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>(3,852.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#d8d8d8;padding-right:12px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#d8d8d8;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>(238.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#d8d8d8;padding-right:12px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#d8d8d8;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>(56.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#d8d8d8;padding-right:12px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#d8d8d8;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>(5,740.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#d8d8d8;padding-right:12px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">)</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:8px;padding-left:12px;text-indent:-12px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(1) </sup></span><span style="font-family:Arial;font-size:8pt;">Accumulated other comprehensive loss as of </span><span style="font-family:Arial;font-size:8pt;">December 31, 2016</span><span style="font-family:Arial;font-size:8pt;"> consists of </span><span style="font-family:Arial;font-size:8pt;"><span>$5.27 billion</span></span><span style="font-family:Arial;font-size:8pt;"> of accumulated other comprehensive loss attributable to controlling interest and </span><span style="font-family:Arial;font-size:8pt;"><span>$48.2 million</span></span><span style="font-family:Arial;font-size:8pt;"> of accumulated other comprehensive income attributable to noncontrolling interest. </span></div><div style="line-height:120%;padding-top:8px;padding-left:12px;text-indent:-12px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(2) </sup></span><span style="font-family:Arial;font-size:8pt;">Accumulated other comprehensive loss as of </span><span style="font-family:Arial;font-size:8pt;">December 31, 2017</span><span style="font-family:Arial;font-size:8pt;"> consists of </span><span style="font-family:Arial;font-size:8pt;"><span>$5.72 billion</span></span><span style="font-family:Arial;font-size:8pt;"> of accumulated other comprehensive loss attributable to controlling interest and </span><span style="font-family:Arial;font-size:8pt;"><span>$23.7 million</span></span><span style="font-family:Arial;font-size:8pt;"> of accumulated other comprehensive income attributable to noncontrolling interest. </span></div><div style="line-height:120%;padding-top:8px;padding-left:12px;text-indent:-12px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(3) </sup></span><span style="font-family:Arial;font-size:8pt;">This reclassification consists of </span><span style="font-family:Arial;font-size:8pt;"><span>$105.2 million</span></span><span style="font-family:Arial;font-size:8pt;"> of accumulated other comprehensive loss attributable to controlling interest and </span><span style="font-family:Arial;font-size:8pt;"><span>$23.7 million</span></span><span style="font-family:Arial;font-size:8pt;"> of accumulated other comprehensive loss attributable to noncontrolling interest. Refer to Note 2 for further details regarding the reclassification due to the adoption of Accounting Standards Update 2016-01, </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Financial Instruments - Overall: Recognition and Measurement of Financial Assets and Financial Liabilities.</span></div><div style="line-height:120%;padding-top:8px;padding-left:12px;text-indent:-12px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(4) </sup></span><span style="font-family:Arial;font-size:8pt;">Accumulated other comprehensive loss as of </span><span style="font-family:Arial;font-size:8pt;">December 31, 2018</span><span style="font-family:Arial;font-size:8pt;"> consists of </span><span style="font-family:Arial;font-size:8pt;"><span>$5.73 billion</span></span><span style="font-family:Arial;font-size:8pt;"> of accumulated other comprehensive loss attributable to controlling interest and </span><span style="font-family:Arial;font-size:8pt;"><span>$11.0 million</span></span><span style="font-family:Arial;font-size:8pt;"> of accumulated other comprehensive loss attributable to noncontrolling interest. </span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">The tax effects on the net activity related to each component of other comprehensive income (loss) for the years ended December 31, were as follows:</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:62%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Tax benefit (expense)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2017</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2016</span></div></td></tr><tr><td style="vertical-align:top;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Foreign currency translation gains/losses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>51.6</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>170.8</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(70.6</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-right:12px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Unrealized net gains/losses on securities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>2.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>55.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(89.2</span></span></div></td><td style="vertical-align:bottom;padding-right:12px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Defined benefit pension and retiree health benefit plans</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>(85.3</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-right:12px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>186.6</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>153.3</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Effective portion of cash flow hedges</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>1.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(9.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:12px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(4.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:12px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Benefit/(provision) for income taxes allocated to other comprehensive income (loss) items</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#d8d8d8;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>(30.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#d8d8d8;padding-right:12px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#d8d8d8;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>402.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#d8d8d8;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(10.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#d8d8d8;padding-right:12px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Except for the tax effects of foreign currency translation gains and losses related to our foreign currency-denominated notes, cross-currency interest rate swaps, and other foreign currency exchange contracts designated as net investment hedges (see Note 7), income taxes were not provided for foreign currency translation. Generally, the assets and liabilities of foreign operations are translated into U.S. dollars using the current exchange rate. For those operations, changes in exchange rates generally do not affect cash flows; therefore, resulting translation adjustments are made in shareholders' equity rather than in the consolidated statements of operations.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Reclassifications out of accumulated other comprehensive loss were as follows:</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"/></tr><tr><td style="width:31%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:31%;"/></tr><tr><td rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Details about Accumulated Other </span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Comprehensive Loss Components</span></div></td><td colspan="11" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Year Ended December 31,</span></div></td><td rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Affected Line Item in the Consolidated Statements of Operations</span></div></td></tr><tr><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2017</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2016</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Amortization of retirement benefit items:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Prior service benefits, net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>(74.9</span></span></div></td><td style="vertical-align:bottom;padding-right:12px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(84.4</span></span></div></td><td style="vertical-align:bottom;padding-right:12px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(74.1</span></span></div></td><td style="vertical-align:bottom;padding-right:12px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Other—net, (income) expense</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Actuarial losses</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>338.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>305.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>304.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Other—net, (income) expense</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:12px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Total before tax</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>263.7</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>220.8</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>230.6</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:12px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Tax benefit</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>(55.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d8d8d8;padding-right:12px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(68.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d8d8d8;padding-right:12px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(71.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d8d8d8;padding-right:12px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Income taxes</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:12px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Net of tax</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>207.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>151.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>159.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Unrealized gains/losses on available-for-sale securities:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Realized gains, net</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>(39.5</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-right:12px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(170.2</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-right:12px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(16.1</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-right:12px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Other—net, (income) expense</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Impairment losses</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>27.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Other—net, (income) expense</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:12px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Total before tax</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>(39.5</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-right:12px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(170.2</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-right:12px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>11.2</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:12px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Tax (benefit) expense</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>8.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>59.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(4.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:12px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Income taxes</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:12px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Net of tax</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>(31.2</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-right:12px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(110.6</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-right:12px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>7.2</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Other, net of tax</span><span style="font-family:Arial;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(1)</sup></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>13.8</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>19.2</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>84.4</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Other—net, (income) expense</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Total reclassifications for the period (net of tax)</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>190.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>60.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>250.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:16px;padding-top:8px;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(1) </sup></span><span style="font-family:Arial;font-size:8pt;">Amount for year ended December 31, 2016 included primarily </span><span style="font-family:Arial;font-size:8pt;"><span>$74.5 million</span></span><span style="font-family:Arial;font-size:8pt;"> of foreign currency translation losses.</span></div> <div style="line-height:120%;padding-top:12px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">The following table summarizes the activity related to each component of other comprehensive income (loss):</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.38271604938271%;border-collapse:collapse;text-align:left;"><tr><td colspan="24"/></tr><tr><td style="width:25%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Continuing Operations</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">(Amounts presented net of taxes)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Foreign Currency Translation Gains (Losses)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Unrealized Net Gains (Losses) on Securities</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Defined Benefit Pension and Retiree Health Benefit Plans</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Effective Portion of Cash Flow Hedges</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Discontinued Operations</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Accumulated Other Comprehensive Loss</span></div></td></tr><tr><td style="vertical-align:top;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;background-color:#d8d8d8;">Beginning balance at January 1, 2016</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(1,315.9</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-right:12px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>10.1</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(2,996.8</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-right:12px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(218.5</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-right:12px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d8d8d8;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(59.6</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-right:12px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(4,580.7</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-right:12px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Other comprehensive income (loss) before reclassifications</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(445.2</span></span></div></td><td style="vertical-align:bottom;padding-right:12px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>206.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(514.3</span></span></div></td><td style="vertical-align:bottom;padding-right:12px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(2.2</span></span></div></td><td style="vertical-align:bottom;padding-right:12px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(140.8</span></span></div></td><td style="vertical-align:bottom;padding-right:12px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(895.8</span></span></div></td><td style="vertical-align:bottom;padding-right:12px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#d8d8d8;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Net amount reclassified from accumulated other comprehensive loss</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>74.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>7.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>159.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>9.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>0.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>250.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Net other comprehensive income (loss)</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(370.7</span></span></div></td><td style="vertical-align:bottom;padding-right:12px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>213.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(355.2</span></span></div></td><td style="vertical-align:bottom;padding-right:12px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>7.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(140.7</span></span></div></td><td style="vertical-align:bottom;padding-right:12px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(645.1</span></span></div></td><td style="vertical-align:bottom;padding-right:12px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Balance at December 31, 2016</span><span style="font-family:Arial;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(1)</sup></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(1,686.6</span></span></div></td><td style="vertical-align:bottom;padding-right:12px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>224.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(3,352.0</span></span></div></td><td style="vertical-align:bottom;padding-right:12px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(210.9</span></span></div></td><td style="vertical-align:bottom;padding-right:12px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(200.3</span></span></div></td><td style="vertical-align:bottom;padding-right:12px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(5,225.8</span></span></div></td><td style="vertical-align:bottom;padding-right:12px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Other comprehensive income (loss) before reclassifications</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>525.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(15.7</span></span></div></td><td style="vertical-align:bottom;padding-right:12px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(532.1</span></span></div></td><td style="vertical-align:bottom;padding-right:12px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>8.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>127.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>114.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#d8d8d8;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Net amount reclassified from accumulated other comprehensive loss</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>8.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(110.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d8d8d8;padding-right:12px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>151.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>9.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>1.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>60.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Net other comprehensive income (loss)</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>533.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(126.3</span></span></div></td><td style="vertical-align:bottom;padding-right:12px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(380.2</span></span></div></td><td style="vertical-align:bottom;padding-right:12px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>18.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>129.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>174.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Reclassifications of stranded tax effects (Note 2)</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(38.8</span></span></div></td><td style="vertical-align:bottom;padding-right:12px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>15.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(579.1</span></span></div></td><td style="vertical-align:bottom;padding-right:12px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(41.5</span></span></div></td><td style="vertical-align:bottom;padding-right:12px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(643.6</span></span></div></td><td style="vertical-align:bottom;padding-right:12px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Balance at December 31, 2017</span><span style="font-family:Arial;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(2)</sup></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(1,191.7</span></span></div></td><td style="vertical-align:bottom;padding-right:12px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>113.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(4,311.3</span></span></div></td><td style="vertical-align:bottom;padding-right:12px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(234.3</span></span></div></td><td style="vertical-align:bottom;padding-right:12px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(71.1</span></span></div></td><td style="vertical-align:bottom;padding-right:12px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(5,694.9</span></span></div></td><td style="vertical-align:bottom;padding-right:12px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Reclassification due to adoption of new accounting standard</span><span style="font-family:Arial;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(3)</sup></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>(128.9</span></span></div></td><td style="vertical-align:bottom;padding-right:12px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>(128.9</span></span></div></td><td style="vertical-align:bottom;padding-right:12px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#d8d8d8;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Other comprehensive income (loss) before reclassifications</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>(378.0</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-right:12px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>24.5</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>250.7</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>(16.3</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-right:12px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>12.2</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>(106.9</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-right:12px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Net amount reclassified from accumulated other comprehensive loss</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>(31.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:12px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>207.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>11.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>2.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>190.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#d8d8d8;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Net other comprehensive income (loss)</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>(378.0</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-right:12px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>(6.7</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-right:12px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>458.6</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>(4.6</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-right:12px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>14.3</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>83.6</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Ending balance at December 31, 2018</span><span style="font-family:Arial;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(4)</sup></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#d8d8d8;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>(1,569.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#d8d8d8;padding-right:12px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#d8d8d8;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>(22.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#d8d8d8;padding-right:12px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#d8d8d8;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>(3,852.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#d8d8d8;padding-right:12px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#d8d8d8;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>(238.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#d8d8d8;padding-right:12px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#d8d8d8;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>(56.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#d8d8d8;padding-right:12px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#d8d8d8;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>(5,740.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#d8d8d8;padding-right:12px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">)</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:8px;padding-left:12px;text-indent:-12px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(1) </sup></span><span style="font-family:Arial;font-size:8pt;">Accumulated other comprehensive loss as of </span><span style="font-family:Arial;font-size:8pt;">December 31, 2016</span><span style="font-family:Arial;font-size:8pt;"> consists of </span><span style="font-family:Arial;font-size:8pt;"><span>$5.27 billion</span></span><span style="font-family:Arial;font-size:8pt;"> of accumulated other comprehensive loss attributable to controlling interest and </span><span style="font-family:Arial;font-size:8pt;"><span>$48.2 million</span></span><span style="font-family:Arial;font-size:8pt;"> of accumulated other comprehensive income attributable to noncontrolling interest. </span></div><div style="line-height:120%;padding-top:8px;padding-left:12px;text-indent:-12px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(2) </sup></span><span style="font-family:Arial;font-size:8pt;">Accumulated other comprehensive loss as of </span><span style="font-family:Arial;font-size:8pt;">December 31, 2017</span><span style="font-family:Arial;font-size:8pt;"> consists of </span><span style="font-family:Arial;font-size:8pt;"><span>$5.72 billion</span></span><span style="font-family:Arial;font-size:8pt;"> of accumulated other comprehensive loss attributable to controlling interest and </span><span style="font-family:Arial;font-size:8pt;"><span>$23.7 million</span></span><span style="font-family:Arial;font-size:8pt;"> of accumulated other comprehensive income attributable to noncontrolling interest. </span></div><div style="line-height:120%;padding-top:8px;padding-left:12px;text-indent:-12px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(3) </sup></span><span style="font-family:Arial;font-size:8pt;">This reclassification consists of </span><span style="font-family:Arial;font-size:8pt;"><span>$105.2 million</span></span><span style="font-family:Arial;font-size:8pt;"> of accumulated other comprehensive loss attributable to controlling interest and </span><span style="font-family:Arial;font-size:8pt;"><span>$23.7 million</span></span><span style="font-family:Arial;font-size:8pt;"> of accumulated other comprehensive loss attributable to noncontrolling interest. Refer to Note 2 for further details regarding the reclassification due to the adoption of Accounting Standards Update 2016-01, </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Financial Instruments - Overall: Recognition and Measurement of Financial Assets and Financial Liabilities.</span></div><div style="line-height:120%;padding-top:8px;padding-left:12px;text-indent:-12px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(4) </sup></span><span style="font-family:Arial;font-size:8pt;">Accumulated other comprehensive loss as of </span><span style="font-family:Arial;font-size:8pt;">December 31, 2018</span><span style="font-family:Arial;font-size:8pt;"> consists of </span><span style="font-family:Arial;font-size:8pt;"><span>$5.73 billion</span></span><span style="font-family:Arial;font-size:8pt;"> of accumulated other comprehensive loss attributable to controlling interest and </span><span style="font-family:Arial;font-size:8pt;"><span>$11.0 million</span></span><span style="font-family:Arial;font-size:8pt;"> of accumulated other comprehensive loss attributable to noncontrolling interest. </span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">The tax effects on the net activity related to each component of other comprehensive income (loss) for the years ended December 31, were as follows:</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:62%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Tax benefit (expense)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2017</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2016</span></div></td></tr><tr><td style="vertical-align:top;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Foreign currency translation gains/losses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>51.6</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>170.8</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(70.6</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-right:12px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Unrealized net gains/losses on securities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>2.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>55.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(89.2</span></span></div></td><td style="vertical-align:bottom;padding-right:12px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Defined benefit pension and retiree health benefit plans</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>(85.3</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-right:12px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>186.6</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>153.3</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Effective portion of cash flow hedges</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>1.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(9.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:12px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(4.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:12px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Benefit/(provision) for income taxes allocated to other comprehensive income (loss) items</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#d8d8d8;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>(30.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#d8d8d8;padding-right:12px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#d8d8d8;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>402.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#d8d8d8;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(10.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#d8d8d8;padding-right:12px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> -1315900000 10100000 -2996800000 -218500000 -59600000 -4580700000 -445200000 206700000 -514300000 -2200000 -140800000 -895800000 -74500000 -7200000 -159100000 -9800000 -100000 -250700000 -370700000 213900000 -355200000 7600000 -140700000 -645100000 -1686600000 224000000.0 -3352000000.0 -210900000 -200300000 -5225800000 525600000 -15700000 -532100000 8500000 127700000 114000000.0 -8100000 110600000 -151900000 -9600000 -1500000 -60500000 533700000 -126300000 -380200000 18100000 129200000 174500000 -38800000 15800000 -579100000 -41500000 0 -643600000 -1191700000 113500000 -4311300000 -234300000 -71100000 -5694900000 0 -128900000 0 0 0 -128900000 -378000000.0 24500000 250700000 -16300000 12200000 -106900000 0 31200000 -207900000 -11700000 -2100000 -190500000 -378000000.0 -6700000 458600000 -4600000 14300000 83600000 -1569700000 -22100000 -3852700000 -238900000 -56800000 -5740200000 -5270000000 48200000 -5720000000 23700000 -105200000 -23700000 5730000000 -11000000.0 -51600000 -170800000 70600000 -2100000 -55000000.0 89200000 85300000 -186600000 -153300000 -1300000 9700000 4100000 30300000 -402700000 10600000 <div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"/></tr><tr><td style="width:31%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:31%;"/></tr><tr><td rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Details about Accumulated Other </span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Comprehensive Loss Components</span></div></td><td colspan="11" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Year Ended December 31,</span></div></td><td rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Affected Line Item in the Consolidated Statements of Operations</span></div></td></tr><tr><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2017</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2016</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Amortization of retirement benefit items:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Prior service benefits, net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>(74.9</span></span></div></td><td style="vertical-align:bottom;padding-right:12px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(84.4</span></span></div></td><td style="vertical-align:bottom;padding-right:12px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(74.1</span></span></div></td><td style="vertical-align:bottom;padding-right:12px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Other—net, (income) expense</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Actuarial losses</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>338.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>305.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>304.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Other—net, (income) expense</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:12px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Total before tax</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>263.7</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>220.8</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>230.6</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:12px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Tax benefit</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>(55.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d8d8d8;padding-right:12px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(68.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d8d8d8;padding-right:12px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(71.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d8d8d8;padding-right:12px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Income taxes</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:12px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Net of tax</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>207.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>151.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>159.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Unrealized gains/losses on available-for-sale securities:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Realized gains, net</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>(39.5</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-right:12px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(170.2</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-right:12px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(16.1</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-right:12px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Other—net, (income) expense</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Impairment losses</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>27.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Other—net, (income) expense</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:12px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Total before tax</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>(39.5</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-right:12px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(170.2</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-right:12px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>11.2</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:12px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Tax (benefit) expense</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>8.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>59.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(4.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:12px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Income taxes</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:12px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Net of tax</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>(31.2</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-right:12px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(110.6</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-right:12px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>7.2</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Other, net of tax</span><span style="font-family:Arial;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(1)</sup></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>13.8</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>19.2</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>84.4</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Other—net, (income) expense</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Total reclassifications for the period (net of tax)</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>190.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>60.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>250.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span><div style="line-height:120%;padding-bottom:16px;padding-top:8px;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(1) </sup></span><span style="font-family:Arial;font-size:8pt;">Amount for year ended December 31, 2016 included primarily </span><span style="font-family:Arial;font-size:8pt;"><span>$74.5 million</span></span><span style="font-family:Arial;font-size:8pt;"> of foreign currency translation losses.</span></div> 74900000 84400000 74100000 -338600000 -305200000 -304700000 -263700000 -220800000 -230600000 -55800000 -68900000 -71500000 -207900000 -151900000 -159100000 39500000 170200000 16100000 0 0 -27300000 39500000 170200000 -11200000 8300000 59600000 -4000000.0 31200000 110600000 -7200000 -13800000 -19200000 -84400000 -190500000 -60500000 -250700000 74500000 Other–Net, (Income) Expense<div style="line-height:120%;padding-top:12px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Other–net, (income) expense consisted of the following:</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:62%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2017</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2016</span></div></td></tr><tr><td style="vertical-align:top;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Interest expense</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>242.5</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>225.0</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>185.2</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Interest income</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>(159.3</span></span></div></td><td style="vertical-align:bottom;padding-right:20px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(166.4</span></span></div></td><td style="vertical-align:bottom;padding-right:20px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(107.9</span></span></div></td><td style="vertical-align:bottom;padding-right:20px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Venezuela charge</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>203.9</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Retirement benefit</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>(240.5</span></span></div></td><td style="vertical-align:bottom;padding-right:20px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(249.0</span></span></div></td><td style="vertical-align:bottom;padding-right:20px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(197.1</span></span></div></td><td style="vertical-align:bottom;padding-right:20px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Other (income) expense</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>11.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(111.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d8d8d8;padding-right:20px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(192.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d8d8d8;padding-right:20px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Other–net, (income) expense</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>(145.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-right:20px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(301.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-right:20px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(108.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-right:20px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Due to the financial crisis in Venezuela and the significant deterioration of the bolívar, we changed the exchange rate used to translate the assets and liabilities of our subsidiaries in Venezuela in 2016, which resulted in a charge of </span><span style="font-family:Arial;font-size:10pt;"><span>$203.9 million</span></span><span style="font-family:Arial;font-size:10pt;"> for the year ended December 31, 2016. Prior to this change, we used the Supplementary Foreign Currency Administration System (SICAD) rate; however, this official rate was discontinued in the first quarter of 2016. After considering several factors, including the future uncertainty of the Venezuelan economy, published exchange rates, and the limited amount of foreign currency exchanged, we changed to the Divisa Complementaria (DICOM) rate.</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">As discussed in Note 2, upon adoption of Accounting Standards Update 2017-07, </span><span style="font-family:Arial;font-size:10pt;font-style:italic;">Compensation-Retirement Benefits: Improving the Presentation of Net Periodic Pension Cost and Net Periodic Postretirement Benefit Cost, </span><span style="font-family:Arial;font-size:10pt;">pension and postretirement benefit cost components other than service costs are presented in other–net, (income) expense. Results for the years ended December 31, 2017 and 2016 have been reclassified to reflect the adoption of this standard.</span></div><span style="font-family:Arial;font-size:10pt;">For the years ended December 31, </span><span style="font-family:Arial;font-size:10pt;">2017</span><span style="font-family:Arial;font-size:10pt;">, and </span><span style="font-family:Arial;font-size:10pt;">2016</span>, other income is primarily related to net gains on investments (Note 7). <div style="line-height:120%;padding-top:12px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Other–net, (income) expense consisted of the following:</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:62%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2017</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2016</span></div></td></tr><tr><td style="vertical-align:top;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Interest expense</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>242.5</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>225.0</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>185.2</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Interest income</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>(159.3</span></span></div></td><td style="vertical-align:bottom;padding-right:20px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(166.4</span></span></div></td><td style="vertical-align:bottom;padding-right:20px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(107.9</span></span></div></td><td style="vertical-align:bottom;padding-right:20px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Venezuela charge</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>203.9</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Retirement benefit</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>(240.5</span></span></div></td><td style="vertical-align:bottom;padding-right:20px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(249.0</span></span></div></td><td style="vertical-align:bottom;padding-right:20px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(197.1</span></span></div></td><td style="vertical-align:bottom;padding-right:20px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Other (income) expense</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>11.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(111.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d8d8d8;padding-right:20px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(192.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d8d8d8;padding-right:20px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Other–net, (income) expense</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>(145.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-right:20px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(301.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-right:20px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(108.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-right:20px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 242500000 225000000.0 185200000 159300000 166400000 107900000 0 0 -203900000 240500000 249000000.0 197100000 -11700000 111100000 192900000 145600000 301500000 108800000 -203900000 Segment Information<div style="line-height:120%;padding-top:12px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">On March 11, 2019, we completed the disposition of our remaining </span><span style="font-family:Arial;font-size:10pt;"><span>80.2 percent</span></span><span style="font-family:Arial;font-size:10pt;"> ownership of Elanco common stock through a tax-free exchange offer. As a result, Elanco has been presented as discontinued operations in our consolidated financial statements for all periods presented. Following the completion of the disposition of Elanco, we now operate as a single operating segment engaged in the discovery, development, manufacturing, marketing, and sales of pharmaceutical products worldwide. A global research and development organization and a supply chain organization are responsible for the discovery, development, manufacturing, and supply of our products. Regional commercial organizations market, distribute, and sell the products. The business is also supported by global corporate staff functions. Our determination that we operate as a single segment is consistent with the financial information regularly reviewed by the chief operating decision maker for purposes of evaluating performance, allocating resources, setting incentive compensation targets, and planning and forecasting for future periods.</span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">We lost our compound patent protection for Cialis</span><span style="font-family:Arial;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">®</sup></span><span style="font-family:Arial;font-size:10pt;"> (tadalafil) and Adcirca</span><span style="font-family:Arial;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">®</sup></span><span style="font-family:Arial;font-size:10pt;"> (tadalafil) in major European markets in November 2017, and in the U.S., pediatric exclusivity expired in May 2018. Pursuant to a settlement agreement related to our unit dose patent in the U.S., generic tadalafil entered the U.S. market in September 2018. Entry of generic competition into these markets following the loss of exclusivity will continue to cause a rapid and severe decline in revenue. Our formulation patents for Forteo</span><span style="font-family:Arial;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">® </sup></span><span style="font-family:Arial;font-size:10pt;">expired in December 2018 and use patents will expire in August 2019 in major European markets and the U.S. Both the formulation patent and the use patent expire in 2019 in Japan.</span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Most of our products are distributed through wholesalers that serve pharmacies, physicians and other health care professionals, and hospitals. For the years ended </span><span style="font-family:Arial;font-size:10pt;">December 31, 2018</span><span style="font-family:Arial;font-size:10pt;">, </span><span style="font-family:Arial;font-size:10pt;">2017</span><span style="font-family:Arial;font-size:10pt;">, and </span><span style="font-family:Arial;font-size:10pt;">2016</span><span style="font-family:Arial;font-size:10pt;">, our </span><span style="font-family:Arial;font-size:10pt;"><span>three</span></span><span style="font-family:Arial;font-size:10pt;"> largest wholesalers each accounted for between </span><span style="font-family:Arial;font-size:10pt;"><span>13 percent</span></span><span style="font-family:Arial;font-size:10pt;"> and </span><span style="font-family:Arial;font-size:10pt;"><span>21 percent</span></span><span style="font-family:Arial;font-size:10pt;"> of consolidated total revenue. Further, they each accounted for between </span><span style="font-family:Arial;font-size:10pt;"><span>16 percent</span></span><span style="font-family:Arial;font-size:10pt;"> and </span><span style="font-family:Arial;font-size:10pt;"><span>25 percent</span></span><span style="font-family:Arial;font-size:10pt;"> of accounts receivable as of </span><span style="font-family:Arial;font-size:10pt;color:#000000;text-decoration:none;">December 31, 2018</span><span style="font-family:Arial;font-size:10pt;"> and </span><span style="font-family:Arial;font-size:10pt;color:#000000;text-decoration:none;">2017</span><span style="font-family:Arial;font-size:10pt;">.</span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">We are exposed to the risk of changes in social, political, and economic conditions inherent in foreign operations, and our results of operations and the value of our foreign assets are affected by fluctuations in foreign currency exchange rates.</span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">The following table summarizes our revenue activity:</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="26"/></tr><tr><td style="width:6%;"/><td style="width:9%;"/><td style="width:14%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">U.S.</span><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(1)</sup></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Outside U.S.</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2017</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2016</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2017</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2016</span></div></td></tr><tr><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Revenue—to unaffiliated customers:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Endocrinology:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td colspan="3" style="vertical-align:top;padding-left:60px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-style:italic;">Trulicity</span><span style="font-family:Arial;font-size:10pt;font-style:italic;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">®</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>2,515.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>1,609.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>737.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>683.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>419.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>187.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td colspan="3" style="vertical-align:top;background-color:#d8d8d8;padding-left:60px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-style:italic;">Humalog</span><span style="font-family:Arial;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">®</sup></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>1,787.8</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>1,717.8</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>1,685.2</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>1,208.7</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>1,147.4</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>1,083.6</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td colspan="3" style="vertical-align:top;padding-left:60px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-style:italic;">Humulin</span><span style="font-family:Arial;font-size:10pt;font-style:italic;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">®</sup></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>910.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>884.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>861.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>421.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>450.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>504.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td colspan="3" style="vertical-align:top;background-color:#d8d8d8;padding-left:60px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-style:italic;">Forteo</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>757.9</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>965.2</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>770.5</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>817.7</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>783.8</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>729.4</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td colspan="3" style="vertical-align:top;padding-left:60px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-style:italic;">Basaglar</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>622.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>311.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>15.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>178.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>121.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>70.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td colspan="3" style="vertical-align:top;background-color:#d8d8d8;padding-left:60px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-style:italic;">Jardiance</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>400.2</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>290.4</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>144.5</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>258.1</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>157.0</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>57.4</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td colspan="3" style="vertical-align:top;padding-left:60px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-style:italic;">Trajenta</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>224.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>213.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>165.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>350.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>324.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>270.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td colspan="3" style="vertical-align:top;background-color:#d8d8d8;padding-left:60px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-style:italic;">Other Endocrinology</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>292.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>380.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>450.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>272.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>307.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>347.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td colspan="3" style="vertical-align:top;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Total Endocrinology</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>7,511.6</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>6,373.0</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>4,831.9</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>4,190.5</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>3,712.2</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>3,250.9</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td colspan="3" style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Oncology:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td colspan="3" style="vertical-align:top;background-color:#d8d8d8;padding-left:60px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-style:italic;">Alimta</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>1,131.0</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>1,034.3</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>1,101.0</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>1,001.9</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>1,028.2</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>1,182.3</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td colspan="3" style="vertical-align:top;padding-left:60px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-style:italic;">Erbitux</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>531.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>541.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>581.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>103.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>104.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>105.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td colspan="3" style="vertical-align:top;background-color:#d8d8d8;padding-left:60px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-style:italic;">Cyramza</span><span style="font-family:Arial;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">®</sup></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>291.5</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>278.8</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>270.1</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>529.9</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>479.6</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>344.0</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td colspan="3" style="vertical-align:top;padding-left:60px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-style:italic;">Other Oncology</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>449.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>195.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>22.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>221.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>149.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>114.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td colspan="3" style="vertical-align:top;background-color:#d8d8d8;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Total Oncology</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>2,403.2</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>2,050.4</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>1,975.1</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>1,857.3</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>1,761.6</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>1,746.8</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td colspan="3" style="vertical-align:top;background-color:#d8d8d8;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Cardiovascular:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td colspan="3" style="vertical-align:top;padding-left:60px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-style:italic;">Cialis</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>1,129.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>1,358.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>1,469.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>722.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>964.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>1,002.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td colspan="3" style="vertical-align:top;background-color:#d8d8d8;padding-left:60px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-style:italic;">Effient</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>68.1</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>340.1</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>465.6</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>54.1</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>48.8</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>69.6</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td colspan="3" style="vertical-align:top;padding-left:60px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-style:italic;">Other Cardiovascular</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>158.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>24.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>56.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>121.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>135.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>162.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td colspan="3" style="vertical-align:top;background-color:#d8d8d8;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Total Cardiovascular</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>1,355.7</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>1,722.7</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>1,991.4</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>898.6</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>1,148.5</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>1,234.0</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Neuroscience:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td colspan="3" style="vertical-align:top;padding-left:60px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-style:italic;">Strattera</span><span style="font-family:Arial;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">®</sup></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>89.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>284.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>534.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>361.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>333.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>319.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td colspan="3" style="vertical-align:top;background-color:#d8d8d8;padding-left:60px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-style:italic;">Cymbalta</span><span style="font-family:Arial;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(2)</sup></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>54.3</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>114.9</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>269.3</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>653.7</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>642.2</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>661.2</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td colspan="3" style="vertical-align:top;padding-left:60px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-style:italic;">Zyprexa</span><span style="font-family:Arial;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">®</sup></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>36.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>75.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>69.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>435.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>505.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>655.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td colspan="3" style="vertical-align:top;background-color:#d8d8d8;padding-left:60px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-style:italic;">Other Neuroscience</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>97.2</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>115.7</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>115.9</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>93.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>98.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>93.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td colspan="3" style="vertical-align:top;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Total Neuroscience</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>277.4</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>591.0</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>989.9</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>1,543.3</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>1,580.1</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>1,730.4</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td colspan="3" style="vertical-align:top;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Immunology:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td colspan="3" style="vertical-align:top;background-color:#d8d8d8;padding-left:60px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-style:italic;">Taltz</span><span style="font-family:Arial;font-size:10pt;font-style:italic;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">®</sup></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>738.7</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>486.0</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>110.8</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>198.7</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>73.2</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>2.3</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td colspan="3" style="vertical-align:top;padding-left:60px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-style:italic;">Other Immunology</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>6.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>195.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>45.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td colspan="3" style="vertical-align:top;background-color:#d8d8d8;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Total Immunology</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>745.4</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>486.0</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>110.8</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>394.6</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>119.0</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>2.3</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td colspan="3" style="vertical-align:top;background-color:#d8d8d8;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Other</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>98.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>191.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>247.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>217.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>238.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>201.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Revenue</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>12,391.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>11,414.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>10,147.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>9,101.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>8,559.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>8,165.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:4px;padding-left:12px;text-indent:-12px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Numbers may not add due to rounding.</span></div><div style="line-height:120%;padding-top:4px;padding-left:12px;text-indent:-12px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(1)</sup></span><span style="font-family:Arial;font-size:8pt;"> U.S. revenue includes revenue in Puerto Rico.</span></div><div style="line-height:120%;padding-top:4px;padding-left:12px;text-indent:-12px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(2) </sup></span><span style="font-family:Arial;font-size:8pt;">Cymbalta revenues benefited from reductions to the reserve for expected product returns of approximately </span><span style="font-family:Arial;font-size:8pt;"><span>$175 million</span></span><span style="font-family:Arial;font-size:8pt;"> during the year ended December 31, 2016.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="15"/></tr><tr><td style="width:38%;"/><td style="width:2%;"/><td style="width:21%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2017</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2016</span></div></td></tr><tr><td colspan="3" style="vertical-align:top;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">Geographic Information</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Revenue—to unaffiliated customers</span><span style="font-family:Arial;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(1)</sup></span><span style="font-family:Arial;font-size:10pt;">:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td colspan="3" style="vertical-align:top;background-color:#d8d8d8;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">United States</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>12,391.9</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>11,414.4</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>10,147.0</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td colspan="3" style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Europe</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>3,663.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>3,390.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>3,214.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td colspan="3" style="vertical-align:top;background-color:#d8d8d8;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Japan</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>2,407.4</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>2,339.5</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>2,253.0</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td colspan="3" style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Other foreign countries</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>3,030.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>2,829.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>2,698.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td colspan="3" style="vertical-align:top;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Revenue</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#d8d8d8;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>21,493.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#d8d8d8;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>19,973.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#d8d8d8;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>18,312.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Long-lived assets</span><span style="font-family:Arial;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(2)</sup></span><span style="font-family:Arial;font-size:10pt;">:</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td colspan="3" style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">United States</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>4,344.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>4,408.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>4,520.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td colspan="3" style="vertical-align:top;background-color:#d8d8d8;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Europe</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>2,413.5</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>2,246.4</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>1,864.8</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td colspan="3" style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Japan</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>180.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>153.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>91.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td colspan="3" style="vertical-align:top;background-color:#d8d8d8;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Other foreign countries</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>1,608.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>1,672.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>1,690.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Long-lived assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>8,546.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>8,481.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>8,167.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:4px;padding-left:12px;text-indent:-12px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Numbers may not add due to rounding.</span></div><div style="line-height:120%;padding-top:8px;padding-left:12px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(1) </sup></span><span style="font-family:Arial;font-size:8pt;">Revenue is attributed to the countries based on the location of the customer.</span></div><div style="line-height:120%;padding-top:8px;padding-left:12px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(2) </sup></span><span style="font-family:Arial;font-size:8pt;">Long-lived assets consist of property and equipment, net, and certain sundry assets.</span></div> 0.802 3 0.13 0.21 0.16 0.25 <div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">The following table summarizes our revenue activity:</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="26"/></tr><tr><td style="width:6%;"/><td style="width:9%;"/><td style="width:14%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">U.S.</span><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(1)</sup></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Outside U.S.</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2017</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2016</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2017</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2016</span></div></td></tr><tr><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Revenue—to unaffiliated customers:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Endocrinology:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td colspan="3" style="vertical-align:top;padding-left:60px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-style:italic;">Trulicity</span><span style="font-family:Arial;font-size:10pt;font-style:italic;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">®</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>2,515.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>1,609.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>737.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>683.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>419.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>187.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td colspan="3" style="vertical-align:top;background-color:#d8d8d8;padding-left:60px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-style:italic;">Humalog</span><span style="font-family:Arial;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">®</sup></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>1,787.8</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>1,717.8</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>1,685.2</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>1,208.7</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>1,147.4</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>1,083.6</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td colspan="3" style="vertical-align:top;padding-left:60px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-style:italic;">Humulin</span><span style="font-family:Arial;font-size:10pt;font-style:italic;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">®</sup></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>910.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>884.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>861.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>421.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>450.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>504.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td colspan="3" style="vertical-align:top;background-color:#d8d8d8;padding-left:60px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-style:italic;">Forteo</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>757.9</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>965.2</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>770.5</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>817.7</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>783.8</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>729.4</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td colspan="3" style="vertical-align:top;padding-left:60px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-style:italic;">Basaglar</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>622.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>311.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>15.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>178.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>121.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>70.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td colspan="3" style="vertical-align:top;background-color:#d8d8d8;padding-left:60px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-style:italic;">Jardiance</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>400.2</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>290.4</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>144.5</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>258.1</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>157.0</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>57.4</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td colspan="3" style="vertical-align:top;padding-left:60px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-style:italic;">Trajenta</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>224.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>213.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>165.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>350.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>324.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>270.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td colspan="3" style="vertical-align:top;background-color:#d8d8d8;padding-left:60px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-style:italic;">Other Endocrinology</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>292.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>380.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>450.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>272.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>307.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>347.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td colspan="3" style="vertical-align:top;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Total Endocrinology</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>7,511.6</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>6,373.0</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>4,831.9</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>4,190.5</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>3,712.2</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>3,250.9</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td colspan="3" style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Oncology:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td colspan="3" style="vertical-align:top;background-color:#d8d8d8;padding-left:60px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-style:italic;">Alimta</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>1,131.0</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>1,034.3</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>1,101.0</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>1,001.9</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>1,028.2</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>1,182.3</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td colspan="3" style="vertical-align:top;padding-left:60px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-style:italic;">Erbitux</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>531.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>541.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>581.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>103.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>104.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>105.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td colspan="3" style="vertical-align:top;background-color:#d8d8d8;padding-left:60px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-style:italic;">Cyramza</span><span style="font-family:Arial;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">®</sup></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>291.5</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>278.8</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>270.1</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>529.9</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>479.6</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>344.0</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td colspan="3" style="vertical-align:top;padding-left:60px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-style:italic;">Other Oncology</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>449.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>195.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>22.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>221.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>149.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>114.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td colspan="3" style="vertical-align:top;background-color:#d8d8d8;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Total Oncology</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>2,403.2</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>2,050.4</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>1,975.1</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>1,857.3</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>1,761.6</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>1,746.8</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td colspan="3" style="vertical-align:top;background-color:#d8d8d8;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Cardiovascular:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td colspan="3" style="vertical-align:top;padding-left:60px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-style:italic;">Cialis</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>1,129.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>1,358.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>1,469.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>722.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>964.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>1,002.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td colspan="3" style="vertical-align:top;background-color:#d8d8d8;padding-left:60px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-style:italic;">Effient</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>68.1</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>340.1</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>465.6</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>54.1</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>48.8</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>69.6</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td colspan="3" style="vertical-align:top;padding-left:60px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-style:italic;">Other Cardiovascular</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>158.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>24.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>56.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>121.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>135.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>162.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td colspan="3" style="vertical-align:top;background-color:#d8d8d8;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Total Cardiovascular</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>1,355.7</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>1,722.7</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>1,991.4</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>898.6</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>1,148.5</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>1,234.0</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Neuroscience:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td colspan="3" style="vertical-align:top;padding-left:60px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-style:italic;">Strattera</span><span style="font-family:Arial;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">®</sup></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>89.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>284.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>534.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>361.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>333.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>319.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td colspan="3" style="vertical-align:top;background-color:#d8d8d8;padding-left:60px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-style:italic;">Cymbalta</span><span style="font-family:Arial;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(2)</sup></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>54.3</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>114.9</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>269.3</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>653.7</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>642.2</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>661.2</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td colspan="3" style="vertical-align:top;padding-left:60px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-style:italic;">Zyprexa</span><span style="font-family:Arial;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">®</sup></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>36.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>75.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>69.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>435.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>505.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>655.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td colspan="3" style="vertical-align:top;background-color:#d8d8d8;padding-left:60px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-style:italic;">Other Neuroscience</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>97.2</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>115.7</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>115.9</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>93.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>98.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>93.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td colspan="3" style="vertical-align:top;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Total Neuroscience</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>277.4</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>591.0</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>989.9</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>1,543.3</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>1,580.1</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>1,730.4</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td colspan="3" style="vertical-align:top;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Immunology:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td colspan="3" style="vertical-align:top;background-color:#d8d8d8;padding-left:60px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-style:italic;">Taltz</span><span style="font-family:Arial;font-size:10pt;font-style:italic;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">®</sup></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>738.7</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>486.0</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>110.8</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>198.7</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>73.2</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>2.3</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td colspan="3" style="vertical-align:top;padding-left:60px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-style:italic;">Other Immunology</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>6.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>195.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>45.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td colspan="3" style="vertical-align:top;background-color:#d8d8d8;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Total Immunology</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>745.4</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>486.0</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>110.8</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>394.6</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>119.0</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>2.3</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td colspan="3" style="vertical-align:top;background-color:#d8d8d8;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Other</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>98.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>191.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>247.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>217.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>238.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>201.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Revenue</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>12,391.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>11,414.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>10,147.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>9,101.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>8,559.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>8,165.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:4px;padding-left:12px;text-indent:-12px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Numbers may not add due to rounding.</span></div><div style="line-height:120%;padding-top:4px;padding-left:12px;text-indent:-12px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(1)</sup></span><span style="font-family:Arial;font-size:8pt;"> U.S. revenue includes revenue in Puerto Rico.</span></div><div style="line-height:120%;padding-top:4px;padding-left:12px;text-indent:-12px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(2) </sup></span><span style="font-family:Arial;font-size:8pt;">Cymbalta revenues benefited from reductions to the reserve for expected product returns of approximately </span><span style="font-family:Arial;font-size:8pt;"><span>$175 million</span></span><span style="font-family:Arial;font-size:8pt;"> during the year ended December 31, 2016.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 2515800000 1609800000 737600000 683300000 419900000 187900000 1787800000 1717800000 1685200000 1208700000 1147400000 1083600000 910200000 884600000 861800000 421200000 450700000 504100000 757900000 965200000 770500000 817700000 783800000 729400000 622800000 311100000 15800000 178500000 121000000.0 70300000 400200000 290400000 144500000 258100000 157000000.0 57400000 224200000 213200000 165900000 350500000 324700000 270700000 292700000 380900000 450600000 272500000 307700000 347500000 7511600000 6373000000.0 4831900000 4190500000 3712200000 3250900000 1131000000.0 1034300000 1101000000.0 1001900000 1028200000 1182300000 531600000 541700000 581100000 103800000 104200000 105900000 291500000 278800000 270100000 529900000 479600000 344000000.0 449100000 195600000 22900000 221700000 149600000 114600000 2403200000 2050400000 1975100000 1857300000 1761600000 1746800000 1129200000 1358600000 1469500000 722700000 964500000 1002100000 68100000 340100000 465600000 54100000 48800000 69600000 158400000 24000000.0 56300000 121800000 135200000 162300000 1355700000 1722700000 1991400000 898600000 1148500000 1234000000.0 89700000 284900000 534900000 361100000 333300000 319800000 54300000 114900000 269300000 653700000 642200000 661200000 36200000 75500000 69800000 435100000 505700000 655500000 97200000 115700000 115900000 93400000 98900000 93900000 277400000 591000000.0 989900000 1543300000 1580100000 1730400000 738700000 486000000.0 110800000 198700000 73200000 2300000 6700000 0 0 195900000 45800000 0 745400000 486000000.0 110800000 394600000 119000000.0 2300000 98500000 191300000 247900000 217000000.0 238000000.0 201300000 12391900000 11414400000 10147000000.0 9101400000 8559400000 8165800000 175000000 <div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="15"/></tr><tr><td style="width:38%;"/><td style="width:2%;"/><td style="width:21%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2017</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2016</span></div></td></tr><tr><td colspan="3" style="vertical-align:top;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">Geographic Information</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Revenue—to unaffiliated customers</span><span style="font-family:Arial;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(1)</sup></span><span style="font-family:Arial;font-size:10pt;">:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td colspan="3" style="vertical-align:top;background-color:#d8d8d8;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">United States</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>12,391.9</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>11,414.4</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>10,147.0</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td colspan="3" style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Europe</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>3,663.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>3,390.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>3,214.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td colspan="3" style="vertical-align:top;background-color:#d8d8d8;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Japan</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>2,407.4</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>2,339.5</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>2,253.0</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td colspan="3" style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Other foreign countries</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>3,030.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>2,829.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>2,698.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td colspan="3" style="vertical-align:top;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Revenue</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#d8d8d8;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>21,493.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#d8d8d8;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>19,973.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#d8d8d8;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>18,312.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Long-lived assets</span><span style="font-family:Arial;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(2)</sup></span><span style="font-family:Arial;font-size:10pt;">:</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td colspan="3" style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">United States</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>4,344.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>4,408.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>4,520.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td colspan="3" style="vertical-align:top;background-color:#d8d8d8;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Europe</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>2,413.5</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>2,246.4</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>1,864.8</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td colspan="3" style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Japan</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>180.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>153.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>91.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td colspan="3" style="vertical-align:top;background-color:#d8d8d8;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Other foreign countries</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>1,608.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>1,672.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>1,690.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Long-lived assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>8,546.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>8,481.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>8,167.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:4px;padding-left:12px;text-indent:-12px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Numbers may not add due to rounding.</span></div><div style="line-height:120%;padding-top:8px;padding-left:12px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(1) </sup></span><span style="font-family:Arial;font-size:8pt;">Revenue is attributed to the countries based on the location of the customer.</span></div><div style="line-height:120%;padding-top:8px;padding-left:12px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(2) </sup></span><span style="font-family:Arial;font-size:8pt;">Long-lived assets consist of property and equipment, net, and certain sundry assets.</span></div> 12391900000 11414400000 10147000000.0 3663100000 3390600000 3214400000 2407400000 2339500000 2253000000.0 3030900000 2829300000 2698300000 21493300000 19973800000 18312800000 4344000000.0 4408700000 4520800000 2413500000 2246400000 1864800000 180200000 153400000 91000000.0 1608500000 1672500000 1690400000 8546200000 8481000000.0 8167000000.0 Selected Quarterly Data (unaudited)<div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="17"/></tr><tr><td style="width:56%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Fourth</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Third</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Second</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">First</span></div></td></tr><tr><td style="vertical-align:top;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Revenue</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d8d8d8;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>5,637.6</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d8d8d8;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>5,306.9</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d8d8d8;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>5,585.0</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d8d8d8;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>4,963.8</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Cost of sales</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>1,129.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>1,152.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>1,234.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>1,164.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Operating expenses</span><span style="font-family:Arial;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(1)</sup></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>3,085.5</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>2,738.1</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>2,756.6</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>2,446.2</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Acquired in-process research and development</span><span style="font-family:Arial;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(2)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>329.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>30.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>1,624.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Asset impairment, restructuring, and other special charges</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:middle;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>192.7</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:middle;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>42.9</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:middle;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>(25.5</span></span></div></td><td style="vertical-align:middle;background-color:#d8d8d8;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:middle;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>56.8</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Income before income taxes</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>931.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>1,341.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>41.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>1,365.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Income taxes</span><span style="font-family:Arial;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(3)</sup></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>(189.8</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>247.5</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>273.3</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>198.5</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Net income (loss) from continuing operations</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>1,121.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>1,093.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>(231.6</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>1,167.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Net income (loss) from discontinued operations</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>3.7</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>55.9</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>(28.3</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>50.2</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Net income (loss)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>1,125.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>1,149.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>(259.9</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>1,217.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Earnings (loss) from continuing operations - basic</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>1.11</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>1.07</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>(0.22</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>1.11</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Earnings (loss) from discontinued operations - basic</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>0.06</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>(0.03</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>0.05</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Earnings (loss) per share—basic</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>1.11</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>1.13</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>(0.25</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>1.16</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Earnings (loss) from continuing operations - diluted</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>1.10</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>1.07</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>(0.22</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>1.11</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Earnings (loss) from discontinued operations - diluted</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>0.05</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>(0.03</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>0.05</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Earnings (loss) per share—diluted</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>1.10</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>1.12</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>(0.25</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>1.16</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Dividends paid per share</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>0.5625</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>0.5625</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>0.5625</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>0.5625</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2017</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Fourth</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Third</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Second</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">First</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Revenue</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>5,406.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>4,961.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>5,091.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>4,514.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Cost of sales</span><span style="font-family:Arial;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(4)</sup></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>1,186.4</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>1,163.5</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>1,140.1</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>957.7</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Operating expenses</span><span style="font-family:Arial;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(1)(4)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>3,054.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>2,678.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>2,763.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>2,582.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Acquired in-process research and development</span><span style="font-family:Arial;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(2)</sup></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>50.0</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>205.0</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>857.6</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Asset impairment, restructuring, and other special charges</span><span style="font-family:Arial;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(5)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>830.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>389.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>0.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>111.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Income before income taxes</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>397.0</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>573.1</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>1,249.4</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>85.2</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Income taxes</span><span style="font-family:Arial;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(3)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>1,947.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>29.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>244.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>170.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Net income (loss) from continuing operations</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(1,550.5</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>544.1</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>1,005.1</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(85.1</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Net income (loss) from discontinued operations</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(106.4</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>11.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>2.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(25.7</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Net income (loss)</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(1,656.9</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>555.6</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>1,008.0</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(110.8</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Earnings (loss) from continuing operations - basic</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(1.48</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>0.52</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>0.96</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(0.08</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Earnings (loss) from discontinued operations - basic</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(0.10</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>0.01</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(0.02</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Earnings (loss) per share—basic</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(1.58</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>0.53</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>0.96</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(0.10</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Earnings (loss) from continuing operations - diluted</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(1.48</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>0.52</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>0.95</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(0.08</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Earnings (loss) from discontinued operations - diluted</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(0.10</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>0.01</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(0.02</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Earnings (loss) per share—diluted</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(1.58</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>0.53</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>0.95</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(0.10</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Dividends paid per share</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>0.52</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>0.52</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>0.52</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>0.52</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span><div style="line-height:120%;padding-top:8px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(1) </sup></span><span style="font-family:Arial;font-size:8pt;">Includes research and development and marketing, selling, and administrative expenses.</span></div><div style="line-height:120%;padding-top:8px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(2)</sup></span><span style="font-family:Arial;font-size:8pt;"> Acquired IPR&D charges in the second quarter of 2018 were primarily due to the ARMO acquisition. Acquired IPR&D charges in the first quarter of 2017 were due to the CoLucid acquisition. See Note 3 for further discussion. </span></div><div style="line-height:120%;padding-top:8px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(3) </sup></span><span style="font-family:Arial;font-size:8pt;">Income taxes in the fourth quarter of 2018 were a tax benefit primarily due to adjustments associated with U.S. tax reform. Income taxes in the fourth quarter of 2017 were due to the provisional charge resulting from the 2017 Tax Act. See Note 13 for further discussion.</span></div><div style="line-height:120%;padding-top:8px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(4) </sup></span><span style="font-family:Arial;font-size:8pt;">As discussed in Note 2, upon adoption of Accounting Standards Update 2017-07, </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Compensation-Retirement Benefits: Improving the Presentation of Net Periodic Pension Cost and Net Periodic Postretirement Benefit Cost, </span><span style="font-family:Arial;font-size:8pt;">pension and postretirement benefit cost components other than service costs are presented in other–net, (income) expense. Results for the quarters in 2017 have been reclassified to reflect the adoption of this standard.</span></div><div style="line-height:120%;padding-top:8px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(5) </sup></span><span style="font-family:Arial;font-size:8pt;">Asset impairment, restructuring, and other special charges in the third quarter 2017 were primarily from asset impairments related to lower projected revenue for Posilac (rbST). In the fourth quarter of 2017, restructuring charges were primarily due to severance costs resulting from the U.S. voluntary early retirement program. See Note 5 for further discussion.</span></div><div style="line-height:120%;padding-bottom:16px;padding-top:12px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Our common stock is listed under the ticker symbol LLY on the New York Stock Exchange (NYSE) and the NYSE Euronext.</span></div> <div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="17"/></tr><tr><td style="width:56%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Fourth</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Third</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Second</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">First</span></div></td></tr><tr><td style="vertical-align:top;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Revenue</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d8d8d8;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>5,637.6</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d8d8d8;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>5,306.9</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d8d8d8;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>5,585.0</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d8d8d8;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>4,963.8</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Cost of sales</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>1,129.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>1,152.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>1,234.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>1,164.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Operating expenses</span><span style="font-family:Arial;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(1)</sup></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>3,085.5</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>2,738.1</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>2,756.6</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>2,446.2</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Acquired in-process research and development</span><span style="font-family:Arial;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(2)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>329.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>30.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>1,624.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Asset impairment, restructuring, and other special charges</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:middle;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>192.7</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:middle;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>42.9</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:middle;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>(25.5</span></span></div></td><td style="vertical-align:middle;background-color:#d8d8d8;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:middle;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>56.8</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Income before income taxes</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>931.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>1,341.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>41.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>1,365.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Income taxes</span><span style="font-family:Arial;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(3)</sup></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>(189.8</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>247.5</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>273.3</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>198.5</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Net income (loss) from continuing operations</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>1,121.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>1,093.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>(231.6</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>1,167.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Net income (loss) from discontinued operations</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>3.7</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>55.9</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>(28.3</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>50.2</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Net income (loss)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>1,125.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>1,149.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>(259.9</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>1,217.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Earnings (loss) from continuing operations - basic</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>1.11</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>1.07</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>(0.22</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>1.11</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Earnings (loss) from discontinued operations - basic</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>0.06</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>(0.03</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>0.05</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Earnings (loss) per share—basic</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>1.11</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>1.13</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>(0.25</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>1.16</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Earnings (loss) from continuing operations - diluted</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>1.10</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>1.07</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>(0.22</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>1.11</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Earnings (loss) from discontinued operations - diluted</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>0.05</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>(0.03</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>0.05</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Earnings (loss) per share—diluted</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>1.10</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>1.12</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>(0.25</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>1.16</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Dividends paid per share</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>0.5625</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>0.5625</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>0.5625</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>0.5625</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2017</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Fourth</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Third</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Second</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">First</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Revenue</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>5,406.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>4,961.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>5,091.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>4,514.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Cost of sales</span><span style="font-family:Arial;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(4)</sup></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>1,186.4</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>1,163.5</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>1,140.1</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>957.7</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Operating expenses</span><span style="font-family:Arial;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(1)(4)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>3,054.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>2,678.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>2,763.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>2,582.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Acquired in-process research and development</span><span style="font-family:Arial;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(2)</sup></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>50.0</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>205.0</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>857.6</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Asset impairment, restructuring, and other special charges</span><span style="font-family:Arial;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(5)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>830.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>389.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>0.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>111.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Income before income taxes</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>397.0</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>573.1</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>1,249.4</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>85.2</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Income taxes</span><span style="font-family:Arial;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(3)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>1,947.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>29.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>244.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>170.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Net income (loss) from continuing operations</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(1,550.5</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>544.1</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>1,005.1</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(85.1</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Net income (loss) from discontinued operations</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(106.4</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>11.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>2.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(25.7</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Net income (loss)</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(1,656.9</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>555.6</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>1,008.0</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(110.8</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Earnings (loss) from continuing operations - basic</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(1.48</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>0.52</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>0.96</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(0.08</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Earnings (loss) from discontinued operations - basic</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(0.10</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>0.01</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(0.02</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Earnings (loss) per share—basic</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(1.58</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>0.53</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>0.96</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(0.10</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Earnings (loss) from continuing operations - diluted</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(1.48</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>0.52</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>0.95</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(0.08</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Earnings (loss) from discontinued operations - diluted</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(0.10</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>0.01</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(0.02</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Earnings (loss) per share—diluted</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(1.58</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>0.53</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>0.95</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(0.10</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Dividends paid per share</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>0.52</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>0.52</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>0.52</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>0.52</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span><div style="line-height:120%;padding-top:8px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(1) </sup></span><span style="font-family:Arial;font-size:8pt;">Includes research and development and marketing, selling, and administrative expenses.</span></div><div style="line-height:120%;padding-top:8px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(2)</sup></span><span style="font-family:Arial;font-size:8pt;"> Acquired IPR&D charges in the second quarter of 2018 were primarily due to the ARMO acquisition. Acquired IPR&D charges in the first quarter of 2017 were due to the CoLucid acquisition. See Note 3 for further discussion. </span></div><div style="line-height:120%;padding-top:8px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(3) </sup></span><span style="font-family:Arial;font-size:8pt;">Income taxes in the fourth quarter of 2018 were a tax benefit primarily due to adjustments associated with U.S. tax reform. Income taxes in the fourth quarter of 2017 were due to the provisional charge resulting from the 2017 Tax Act. See Note 13 for further discussion.</span></div><div style="line-height:120%;padding-top:8px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(4) </sup></span><span style="font-family:Arial;font-size:8pt;">As discussed in Note 2, upon adoption of Accounting Standards Update 2017-07, </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Compensation-Retirement Benefits: Improving the Presentation of Net Periodic Pension Cost and Net Periodic Postretirement Benefit Cost, </span><span style="font-family:Arial;font-size:8pt;">pension and postretirement benefit cost components other than service costs are presented in other–net, (income) expense. Results for the quarters in 2017 have been reclassified to reflect the adoption of this standard.</span></div><div style="line-height:120%;padding-top:8px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(5) </sup></span><span style="font-family:Arial;font-size:8pt;">Asset impairment, restructuring, and other special charges in the third quarter 2017 were primarily from asset impairments related to lower projected revenue for Posilac (rbST). In the fourth quarter of 2017, restructuring charges were primarily due to severance costs resulting from the U.S. voluntary early retirement program. See Note 5 for further discussion.</span></div> 5637600000 5306900000 5585000000.0 4963800000 1129900000 1152900000 1234300000 1164600000 3085500000 2738100000 2756600000 2446200000 329400000 30000000.0 1624500000 0 192700000 42900000 -25500000 56800000 931600000 1341100000 41700000 1365700000 -189800000 247500000 273300000 198500000 1121400000 1093600000 -231600000 1167200000 3700000 55900000 -28300000 50200000 1125100000 1149500000 -259900000 1217400000 1.11 1.07 -0.22 1.11 0 0.06 -0.03 0.05 1.11 1.13 -0.25 1.16 1.10 1.07 -0.22 1.11 0 0.05 -0.03 0.05 1.10 1.12 -0.25 1.16 0.5625 0.5625 0.5625 0.5625 5406400000 4961000000.0 5091600000 4514900000 1186400000 1163500000 1140100000 957700000 3054000000.0 2678200000 2763800000 2582500000 50000000.0 205000000.0 0 857600000 830700000 389200000 300000 111400000 397000000.0 573100000 1249400000 85200000 1947500000 29000000.0 244300000 170300000 -1550500000 544100000 1005100000 -85100000 -106400000 11500000 2900000 -25700000 -1656900000 555600000 1008000000.0 -110800000 -1.48 0.52 0.96 -0.08 -0.10 0.01 0 -0.02 -1.58 0.53 0.96 -0.10 -1.48 0.52 0.95 -0.08 -0.10 0.01 0 -0.02 -1.58 0.53 0.95 -0.10 0.52 0.52 0.52 0.52 Discontinued Operations<div style="line-height:120%;padding-bottom:8px;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">On September 24, 2018, Elanco completed its IPO resulting in the issuance of </span><span style="font-family:Arial;font-size:10pt;"><span>72.3 million</span></span><span style="font-family:Arial;font-size:10pt;"> shares of its common stock, which represented </span><span style="font-family:Arial;font-size:10pt;"><span>19.8 percent</span></span><span style="font-family:Arial;font-size:10pt;"> of Elanco's outstanding shares, at </span><span style="font-family:Arial;font-size:10pt;"><span>$24</span></span><span style="font-family:Arial;font-size:10pt;"> per share. Elanco shares began trading on the New York Stock Exchange under the symbol "ELAN" in September 2018.</span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">In connection with the completion of the IPO, through a series of equity and other transactions, we transferred to Elanco the animal health businesses that formed its business. In exchange, Elanco transferred to us</span><span style="font-family:Arial;font-size:10pt;"> </span><span style="font-family:Arial;font-size:10pt;">consideration of approximately </span><span style="font-family:Arial;font-size:10pt;"><span>$4.2 billion</span></span><span style="font-family:Arial;font-size:10pt;">, which consisted primarily of the net proceeds from the IPO and the net proceeds from a </span><span style="font-family:Arial;font-size:10pt;"><span>$2.00 billion</span></span><span style="font-family:Arial;font-size:10pt;"> debt offering and a </span><span style="font-family:Arial;font-size:10pt;"><span>$500.0 million</span></span><span style="font-family:Arial;font-size:10pt;"> </span><span style="font-family:Arial;font-size:10pt;">three</span><span style="font-family:Arial;font-size:10pt;">-year term loan facility entered into by Elanco in August 2018. The consideration that we received was used for debt repayment, dividends, and/or share repurchases. The excess of the net proceeds from the IPO over the net book value of our divested interest was </span><span style="font-family:Arial;font-size:10pt;"><span>$629.2 million</span></span><span style="font-family:Arial;font-size:10pt;"> and was recorded in additional paid-in capital. </span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Through March 11, 2019, we continued to consolidate Elanco, as we retained control over Elanco. The earnings attributable to the divested, noncontrolling interest for the period from the IPO until </span><span style="font-family:Arial;font-size:10pt;">December 31, 2018</span><span style="font-family:Arial;font-size:10pt;"> were not material. As of </span><span style="font-family:Arial;font-size:10pt;">December 31, 2018</span><span style="font-family:Arial;font-size:10pt;">, the noncontrolling interest of </span><span style="font-family:Arial;font-size:10pt;"><span>$1.02 billion</span></span><span style="font-family:Arial;font-size:10pt;"> associated with Elanco was reflected in noncontrolling interests in the consolidated balance sheet. </span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">On March 11, 2019, we completed the disposition of our remaining </span><span style="font-family:Arial;font-size:10pt;"><span>80.2 percent</span></span><span style="font-family:Arial;font-size:10pt;"> ownership of Elanco common stock through a tax-free exchange offer. As a result, in the first quarter of 2019, we recognized a gain related to the disposition of approximately </span><span style="font-family:Arial;font-size:10pt;"><span>$3.7 billion</span></span><span style="font-family:Arial;font-size:10pt;">, and we presented Elanco, including the gain related to the disposition, as discontinued operations in our consolidated condensed financial statements for all periods presented. </span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">The following table sets forth details of revenue and net income (loss) from discontinued operations:</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:55%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2017</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2016</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Revenue from discontinued operations</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>3,062.4</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>2,897.5</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>2,909.3</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Net income (loss) from discontinued operations</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>81.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(117.7</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>12.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">The following table presents the major classes of assets and liabilities from discontinued operations at December 31:</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:58%;"/><td style="width:1%;"/><td style="width:19%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:18%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Inventories</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d8d8d8;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>1,013.7</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d8d8d8;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>1,062.3</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Other current assets</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>1,215.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>1,047.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Current assets of discontinued operations</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#d8d8d8;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>2,229.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#d8d8d8;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>2,110.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Goodwill</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>2,980.9</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>2,992.1</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Other intangibles, net</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>2,453.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>2,674.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Property and equipment, net</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>923.4</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>941.4</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Other assets</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>126.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>60.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Noncurrent assets of discontinued operations</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d8d8d8;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#d8d8d8;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>6,484.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#d8d8d8;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d8d8d8;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#d8d8d8;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>6,668.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#d8d8d8;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Current liabilities of discontinued operations</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#d8d8d8;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>692.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#d8d8d8;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>637.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Long-term debt</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>2,443.3</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>0.5</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Other liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>299.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>351.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Noncurrent liabilities of discontinued operations</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d8d8d8;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#d8d8d8;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>2,742.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#d8d8d8;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d8d8d8;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#d8d8d8;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>351.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#d8d8d8;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Net cash provided by operating activities related to our discontinued operations was approximately </span><span style="font-family:Arial;font-size:10pt;"><span>$500 million</span></span><span style="font-family:Arial;font-size:10pt;">, </span><span style="font-family:Arial;font-size:10pt;"><span>$300 million</span></span><span style="font-family:Arial;font-size:10pt;">, and </span><span style="font-family:Arial;font-size:10pt;"><span>$300 million</span></span><span style="font-family:Arial;font-size:10pt;"> for the years ended December 31, 2018, 2017, and 2016, respectively. Net cash used by investing activities related to our discontinued operations was approximately </span><span style="font-family:Arial;font-size:10pt;"><span>$130 million</span></span><span style="font-family:Arial;font-size:10pt;">, </span><span style="font-family:Arial;font-size:10pt;"><span>$960 million</span></span><span style="font-family:Arial;font-size:10pt;">, and </span><span style="font-family:Arial;font-size:10pt;"><span>$180 million</span></span><span style="font-family:Arial;font-size:10pt;"> for the years ended December 31, 2018, 2017, and 2016, respectively. </span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">We entered into a transitional services agreement (TSA) with Elanco that is designed to facilitate the orderly transfer of various services to Elanco. The TSA relates primarily to administrative services, which are </span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">generally to be provided over </span><span style="font-family:Arial;font-size:10pt;"><span>24 months</span></span><span style="font-family:Arial;font-size:10pt;"> from March 11, 2019, the disposition date. This agreement is not material and does not confer upon us the ability to influence the operating and/or financial policies of Elanco subsequent to the disposition date.</span></div> 72300000 0.198 24 4200000000 2000000000.00 500000000.0 629200000 1020000000.00 0.802 3700000000 <div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">The following table sets forth details of revenue and net income (loss) from discontinued operations:</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:55%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2017</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2016</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Revenue from discontinued operations</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>3,062.4</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>2,897.5</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>2,909.3</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Net income (loss) from discontinued operations</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>81.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(117.7</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>12.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">The following table presents the major classes of assets and liabilities from discontinued operations at December 31:</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:58%;"/><td style="width:1%;"/><td style="width:19%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:18%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Inventories</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d8d8d8;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>1,013.7</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d8d8d8;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>1,062.3</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Other current assets</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>1,215.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>1,047.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Current assets of discontinued operations</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#d8d8d8;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>2,229.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#d8d8d8;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>2,110.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Goodwill</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>2,980.9</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>2,992.1</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Other intangibles, net</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>2,453.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>2,674.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Property and equipment, net</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>923.4</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>941.4</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Other assets</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>126.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>60.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Noncurrent assets of discontinued operations</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d8d8d8;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#d8d8d8;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>6,484.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#d8d8d8;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d8d8d8;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#d8d8d8;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>6,668.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#d8d8d8;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Current liabilities of discontinued operations</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#d8d8d8;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>692.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#d8d8d8;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>637.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Long-term debt</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>2,443.3</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>0.5</span></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Other liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>299.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>351.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Noncurrent liabilities of discontinued operations</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d8d8d8;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#d8d8d8;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;"><span>2,742.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#d8d8d8;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d8d8d8;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d8d8d8;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#d8d8d8;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>351.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#d8d8d8;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 3062400000 2897500000 2909300000 81400000 -117700000 12700000 1013700000 1062300000 1215400000 1047700000 2229100000 2110000000.0 2980900000 2992100000 2453000000.0 2674800000 923400000 941400000 126800000 60400000 6484100000 6668700000 692800000 637500000 2443300000 500000 299000000.0 351100000 2742300000 351600000 500000000 300000000 300000000 -130000000 -960000000 -180000000 P24M Other comprehensive income in 2018 consists of $72.6 million of other comprehensive income attributable to controlling interest and $11.0 million of other comprehensive income attributable to noncontrolling interest. Other comprehensive income in 2017 consists of $199.0 million of other comprehensive income attributable to controlling interest and $24.5 million of other comprehensive loss attributable to noncontrolling interest. Other comprehensive loss in 2016 consists of $693.3 million of other comprehensive loss attributable to controlling interest and $48.2 million of other comprehensive income attributable to noncontrolling interest. XML 59 R45.htm IDEA: XBRL DOCUMENT v3.19.3

Financial Instruments (Tables)
12 Months Ended

Dec. 31, 2018

Derivative Instruments and Hedging Activities Disclosure [Abstract]

Schedule of Derivative Instruments, Effect on Other Comprehensive Income (Loss)
The effective portion of risk-management instruments that was recognized in other comprehensive income (loss) is as follows:

2018

2017

2016
Net investment hedges:

    Foreign currency-denominated notes
$
110.4

$
(361.5
)

$
137.5

    Cross-currency interest rate swaps
96.8

(126.6
)

32.5

    Foreign currency exchange contracts
5.7

—

31.9

Cash flow hedges:

    Forward-starting interest rate swaps
—

13.0

(3.4
)

Fair Value, Liabilities Measured on Recurring and Nonrecurring Basis
The table below summarizes the contractual maturities of our investments in debt securities measured at fair value as of December 31, 2018:

Maturities by Period

Total

Less Than
1 Year

1-5 Years

6-10 Years

More Than 10 Years
Fair value of debt securities
$
943.0

$
86.8

$
604.8

$
97.0

$
154.4

Schedule of Derivatives Instruments Statements of Financial Performance and Financial Position, Location
The following effects of risk-management instruments were recognized in other–net, (income) expense:

2018

2017

2016
Fair value hedges:

Effect from hedged fixed-rate debt
$
(40.9
)

$
(14.1
)

$
(30.8
)
Effect from interest rate contracts
40.9

14.1

30.8

Cash flow hedges:

Effective portion of losses on interest rate contracts reclassified from accumulated other comprehensive loss
14.8

14.8

15.0

Net losses on foreign currency exchange contracts not designated as hedging instruments
100.0

97.9

78.8

Total
$
114.8

$
112.7

$
93.8

Fair Value, Assets Measured on Recurring Basis
The following tables summarize certain fair value information at December 31 for assets and liabilities measured at fair value on a recurring basis, as well as the carrying amount and amortized cost of certain other investments:

Fair Value Measurements Using

Description
Carrying
Amount

Cost⁽¹⁾

Quoted Prices in Active Markets for Identical Assets
(Level 1)

Significant
Other
Observable
Inputs
(Level 2)

Significant
Unobservable
Inputs
(Level 3)

Fair
Value
December 31, 2018

Cash equivalents
$
5,727.1

$
5,727.1

$
5,727.1

$
—

$
—

$
5,727.1

Short-term investments:

U.S. government and agency securities
$
16.9

$
17.1

$
16.9

$
—

$
—

$
16.9

Corporate debt securities
62.2

62.6

—

62.2

—

62.2

Asset-backed securities
7.6

7.7

—

7.6

—

7.6

Other securities
1.5

1.5

—

1.5

—

1.5

Short-term investments
$
88.2

Noncurrent investments:
U.S. government and agency securities
$
149.1

$
153.6

$
149.1

$
—

$
—

$
149.1

Corporate debt securities
568.0

587.8

—

568.0

—

568.0

Mortgage-backed securities
111.4

114.5

—

111.4

—

111.4

Asset-backed securities
27.7

27.9

—

27.7

—

27.7

Other securities
87.8

29.7

—

—

87.8

87.8

Marketable equity securities
357.5

238.3

357.5

—

—

357.5

Equity investments without readily determinable fair values⁽²⁾
414.7

Equity method investments⁽²⁾
289.2

Noncurrent investments
$
2,005.4

December 31, 2017

Cash equivalents
$
4,763.9

$
4,763.9

$
4,712.4

$
51.5

$
—

$
4,763.9

Short-term investments:

U.S. government and agency securities
$
217.8

$
218.2

$
217.8

$
—

$
—

$
217.8

Corporate debt securities
1,182.3

1,183.2

—

1,182.3

—

1,182.3

Asset-backed securities
94.2

94.3

—

94.2

—

94.2

Other securities
3.6

3.6

—

3.6

—

3.6

Short-term investments
$
1,497.9

Noncurrent investments:

U.S. government and agency securities
$
360.0

$
365.0

$
360.0

$
—

$
—

$
360.0

Corporate debt securities
3,464.3

3,473.5

—

3,464.3

—

3,464.3

Mortgage-backed securities
202.4

204.2

—

202.4

—

202.4

Asset-backed securities
653.9

656.0

—

653.9

—

653.9

Other securities
132.1

66.4

—

—

132.1

132.1

Marketable equity securities
281.3

131.0

281.3

—

—

281.3

Cost and equity method investments⁽²⁾
572.5

Noncurrent investments
$
5,666.5

⁽¹⁾For available-for-sale debt securities, amounts disclosed represent the securities' amortized cost.
⁽²⁾Fair value disclosures are not applicable for equity method investments, investments accounted for under the measurement alternative for equity investments, and cost method investments that do not have readily determinable fair values.

Fair Value, Liabilities Measured on Recurring Basis

Fair Value Measurements Using

Description
Carrying
Amount

Quoted Prices in Active Markets for Identical Assets
(Level 1)

Significant
Other
Observable
Inputs
(Level 2)

Significant
Unobservable
Inputs
(Level 3)

Fair
Value
Short-term commercial paper borrowings

December 31, 2018
$
(498.9
)

$
—

$
(497.6
)

$
—

$
(497.6
)
December 31, 2017
(2,696.8
)

—

(2,690.6
)

—

(2,690.6
)

Long-term debt, including current portion

December 31, 2018
$
(9,799.7
)

$
—

$
(9,989.4
)

$
—

$
(9,989.4
)
December 31, 2017
(10,950.3
)

—

(11,529.9
)

—

(11,529.9
)

Fair Value, by Balance Sheet Grouping

Fair Value Measurements Using

Description
Carrying
Amount

Quoted Prices in Active Markets for Identical Assets
(Level 1)

Significant
Other
Observable
Inputs
(Level 2)

Significant
Unobservable
Inputs
(Level 3)

Fair
Value
December 31, 2018

Risk-management instruments

Interest rate contracts designated as fair value hedges:

Sundry
$
4.5

$
—

$
4.5

$
—

$
4.5

Other current liabilities
(22.3
)

—

(22.3
)

—

(22.3
)
Other noncurrent liabilities
(19.0
)

—

(19.0
)

—

(19.0
)
Cross-currency interest rate contracts designated as net investment hedges:

Other receivables
69.2

—

69.2

—

69.2

Sundry
8.2

—

8.2

—

8.2

Other current liabilities
(9.2
)

—

(9.2
)

—

(9.2
)
Cross-currency interest rate contracts not designated as hedging instruments:

Other noncurrent liabilities
(25.8
)

—

(25.8
)

—

(25.8
)
Foreign exchange contracts not designated as hedging instruments:

Other receivables
11.3

—

11.3

—

11.3

Other current liabilities
(16.3
)

—

(16.3
)

—

(16.3
)

December 31, 2017

Risk-management instruments

Interest rate contracts designated as fair value hedges:

Other receivables
$
0.8

$
—

$
0.8

$
—

$
0.8

Sundry
35.1

—

35.1

—

35.1

Other current liabilities
(0.2
)

—

(0.2
)

—

(0.2
)
Other noncurrent liabilities
(10.5
)

—

(10.5
)

—

(10.5
)
Cross-currency interest rate contracts designated as net investment hedges:

    Other current liabilities
(33.4
)

—

(33.4
)

—

(33.4
)
    Other noncurrent liabilities
(26.0
)

—

(26.0
)

—

(26.0
)
Foreign exchange contracts not designated as hedging instruments:

Other receivables
26.8

—

26.8

—

26.8

Other current liabilities
(36.0
)

—

(36.0
)

—

(36.0
)
Contingent consideration liabilities

Other current liabilities
(206.7
)

—

—

(206.7
)

(206.7
)

Available-for-sale Securities
A summary of the fair value of available-for-sale securities in an unrealized gain or loss position and the amount of unrealized gains and losses (pretax) in accumulated other comprehensive loss follows:

2018

2017
Unrealized gross gains
$
0.8

$
184.7

Unrealized gross losses
29.0

47.5

Fair value of securities in an unrealized gain position
84.3

1,434.2

Fair value of securities in an unrealized loss position
858.6

4,692.8

Gain (Loss) on Investments
Activity related to our investment portfolio, substantially all of which related to equity and available-for-sale securities, was as follows:

2018

2017

2016
Proceeds from sales
$
5,668.0

$
5,769.3

$
3,240.5

Realized gross gains on sales
11.8

176.0

30.7

Realized gross losses on sales
51.3

5.8

14.6

X

- Definition
Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-URI http://asc.fasb.org/topic&trid=2196928
+ Details

Name: us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of assets measured at fair value measured on a recurring or nonrecurring basis. Includes, but is not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 820
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 820
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258
+ Details

Name: us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 820
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 820
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258
+ Details

Name: us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=118260190&loc=d3e13467-108611

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 820
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258
+ Details

Name: us-gaap_FairValueByBalanceSheetGroupingTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3). Where the quoted price in an active market for the identical liability is not available, the Level 1 input is the quoted price of an identical liability when traded as an asset.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 820
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 820
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258
+ Details

Name: us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of realized and unrealized gain (loss) on investment in security.
+ References
No definition available.
+ Details

Name: us-gaap_GainLossOnInvestmentsTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of the effective portion of the gains and losses on derivative instruments designated (and non-derivative instruments) designated and qualifying in cash flow hedges and net investment hedges that was recognized in other comprehensive income (loss) during the current period.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4C
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109980867&loc=SL5624171-113959
+ Details

Name: us-gaap_ScheduleOfDerivativeInstrumentsEffectOnOtherComprehensiveIncomeLossTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of derivative instruments (including nonderivative instruments that are designated and qualify as hedging instruments) of (a) the location and amount of gains and losses reported in the statement of financial performance and (b) the location and fair value amounts of the instruments reported in the statement of financial position.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4A
-URI http://asc.fasb.org/extlink&oid=109980867&loc=SL5618551-113959
+ Details

Name: us-gaap_ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 60 R41.htm IDEA: XBRL DOCUMENT v3.19.3

Acquisitions (Tables)
12 Months Ended

Dec. 31, 2018

Business Combinations [Abstract]

Schedule of Research and Development Assets Acquired Other than Through Business Combination
The following table and narrative summarize our asset acquisitions during 2018, 2017, and 2016.
Counterparty
Compound(s),Therapy, or Asset
Acquisition Month

Phase of Development⁽¹⁾

Acquired IPR&D Expense
Sigilon Therapeutics
Encapsulated cell therapies for the potential treatment of type 1 diabetes
April 2018

Pre-clinical

$
66.9

AurKa Pharma, Inc.
AK-01, an Aurora kinase A inhibitor
June 2018

Phase I

81.8

ARMO
Cancer therapy - pegilodecakin
June 2018

Phase III

1,475.8

Anima Biotech
Translation inhibitors for selected neuroscience targets
July 2018

Pre-clinical

30.0

SIGA Technologies, Inc.
Priority Review Voucher
October 2018

Not applicable

80.0

Chugai Pharmaceutical Company
OWL833, an oral non-peptidic GLP-1 receptor agonist
October 2018

Pre-clinical

50.0

NextCure, Inc.
Immuno-oncology cancer therapies
November 2018

Pre-clinical

28.1

Dicerna Pharmaceuticals
Cardio-metabolic disease, neurodegeneration, and pain
December 2018

Pre-clinical

148.7

Hydra Biosciences
TRPA1 antagonists program for the potential treatment of chronic pain syndromes
December 2018

Pre-clinical

22.6

CoLucid Pharmaceuticals, Inc. (CoLucid)
Oral therapy for the acute treatment of migraine - lasmiditan
March 2017

Phase III

857.6

KeyBioscience AG
Multiple molecules for treatment of metabolic disorders
July 2017

Phase II

55.0

Nektar Therapeutics
Immunological therapy - NKTR-358
August 2017

Phase I

150.0

CureVac AG
Cancer vaccines
November 2017

Pre-clinical

50.0

AstraZeneca
Antibody selective for amyloid-beta 42 (Aβ42) - MEDI1814
December 2016

Phase I

30.0

⁽¹⁾The phase of development presented is as of the date of the arrangement and represents the phase of development of the most advanced asset acquired, where applicable.

X

- References
No definition available.
+ Details

Name: us-gaap_BusinessCombinationsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of the nature and amounts of capitalized costs of a research and development nature that were acquired in a transaction other than a business combination, the amount of such assets charged to expense during the period, and identification of the income statement caption in which the charges are included.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 1
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275
+ Details

Name: us-gaap_ScheduleOfResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 61 R20.htm IDEA: XBRL DOCUMENT v3.19.3

Borrowings
12 Months Ended

Dec. 31, 2018

Long-term Debt, Current and Noncurrent [Abstract]

Borrowings Borrowings
Debt at December 31 consisted of the following:

2018

2017
Short-term commercial paper borrowings
$
498.9

$
2,696.8

0.15 to 7.13 percent long-term notes (due 2019-2047)
9,640.8

10,756.7

Other long-term debt
10.1

13.0

Unamortized debt issuance costs
(28.4
)

(49.0
)
Fair value adjustment on hedged long-term notes
177.2

229.0

Total debt
10,298.6

13,646.5

Less current portion
(1,102.2
)

(3,706.5
)
Long-term debt
$
9,196.4

$
9,940.0

The weighted-average effective borrowing rate on outstanding commercial paper at December 31, 2018 was 2.36 percent.
At December 31, 2018, we had a total of $5.42 billion of unused committed bank credit facilities, which consisted primarily of a $3.00 billion credit facility that expires in December 2023 and a $2.00 billion 364-day facility that expires in December 2019, both of which are available to support our commercial paper program. We have not drawn against the $3.00 billion and $2.00 billion facilities. Of the remaining facilities, there was $25.9 million outstanding under the revolving credit facilities as of December 31, 2018, and $6.0 million was outstanding under these facilities as of December 31, 2017. Compensating balances and commitment fees are not material, and there are no conditions that are probable of occurring under which the lines may be withdrawn.
In May 2017, we issued $750.0 million of 2.35 percent fixed-rate notes due in May 2022, $750.0 million of 3.10 percent fixed-rate notes due in May 2027, and $750.0 million of 3.95 percent fixed-rate notes due in May 2047, with interest to be paid semi-annually. We are using the net proceeds of $2.23 billion from the sale of these notes for general corporate purposes, which included the repayment of notes due in 2018 and may include the repayment of notes due in 2019. Prior to such uses, we may temporarily invest the net proceeds in investment securities.
The aggregate amounts of maturities on long-term debt for the next five years are as follows:

2019

2020

2021

2022

2023
Maturities on long-term debt
$
604.5

$
3.5

$
2.3

$
1,439.0

$
0.3

We have converted approximately 25 percent of our long-term fixed-rate notes to floating rates through the use of interest rate swaps. The weighted-average effective borrowing rates based on long-term debt obligations and interest rates at December 31, 2018 and 2017, including the effects of interest rate swaps for hedged debt obligations, were 3.13 percent and 2.65 percent, respectively.
The aggregate amount of cash payments for interest on borrowings, net of capitalized interest, are as follows:

2018

2017

2016
Cash payments for interest on borrowings
$
223.8

$
192.7

$
146.4

In accordance with the requirements of derivatives and hedging guidance, the portion of our fixed-rate debt obligations that is hedged as a fair value hedge is reflected in the consolidated balance sheets as an amount equal to the sum of the debt’s carrying value plus the fair value adjustment representing changes in fair value of the hedged debt attributable to movements in market interest rates subsequent to the inception of the hedge.

X

- Definition
The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-URI http://asc.fasb.org/topic&trid=2208564
+ Details

Name: us-gaap_DebtDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_LongtermDebtCurrentAndNoncurrentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 62 R24.htm IDEA: XBRL DOCUMENT v3.19.3

Retirement Benefits
12 Months Ended

Dec. 31, 2018

Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Abstract]

Retirement Benefits Retirement Benefits
We use a measurement date of December 31 to develop the change in benefit obligation, change in plan assets, funded status, and amounts recognized in the consolidated balance sheets at December 31 for our defined benefit pension and retiree health benefit plans, which were as follows:

Defined Benefit
Pension Plans

Retiree Health
Benefit Plans

2018

2017

2018

2017
Change in benefit obligation:

Benefit obligation at beginning of year
$
14,839.7

$
12,230.9

$
1,718.7

$
1,494.6

Service cost
292.7

320.8

41.5

46.4

Interest cost
458.5

411.6

57.3

52.9

Actuarial (gain) loss
(1,386.5
)

1,556.0

(176.9
)

30.2

Benefits paid
(579.4
)

(467.8
)

(82.8
)

(60.1
)
Plan amendments
17.6

—

(14.1
)

—

Curtailment (gain) loss
(43.9
)

90.4

2.5

105.2

Special termination benefit
—

317.2

—

37.5

Foreign currency exchange rate changes and other adjustments
(171.6
)

380.6

(6.2
)

12.0

Benefit obligation at end of year
13,427.1

14,839.7

1,540.0

1,718.7

Change in plan assets:

Fair value of plan assets at beginning of year
11,713.0

10,056.0

2,372.4

1,961.2

Actual return on plan assets
(360.1
)

1,434.3

32.6

462.0

Employer contribution
319.0

410.4

75.9

9.1

Benefits paid
(579.4
)

(467.8
)

(82.8
)

(60.1
)
Foreign currency exchange rate changes and other adjustments
(159.9
)

280.1

—

0.2

Fair value of plan assets at end of year
10,932.6

11,713.0

2,398.1

2,372.4

Funded status
(2,494.5
)

(3,126.7
)

858.1

653.7

Unrecognized net actuarial loss
5,011.3

5,616.4

140.6

182.0

Unrecognized prior service (benefit) cost
25.0

14.5

(299.9
)

(395.0
)
Net amount recognized
$
2,541.8

$
2,504.2

$
698.8

$
440.7

Amounts recognized in the consolidated balance sheet consisted of:

Sundry
$
193.7

$
104.5

$
1,043.6

$
870.1

Other current liabilities
(64.2
)

(64.5
)

(7.3
)

(7.1
)
Accrued retirement benefits
(2,624.0
)

(3,166.7
)

(178.2
)

(209.3
)
Accumulated other comprehensive (income) loss before income taxes
5,036.3

5,630.9

(159.3
)

(213.0
)
Net amount recognized
$
2,541.8

$
2,504.2

$
698.8

$
440.7

The unrecognized net actuarial loss and unrecognized prior service cost (benefit) have not yet been recognized in net periodic pension costs and are included in accumulated other comprehensive loss at December 31, 2018.
In July 2018, we announced that we would amend our defined benefit pension and retiree health benefit plans to freeze or reduce benefits for certain employees effective January 1, 2019. We remeasured the impacted pension and retiree health plans’ benefit obligations as of July 31, 2018, which resulted in a net curtailment gain of $28.0 million, which was recorded in asset impairment, restructuring, and other special charges. Market variables associated with this remeasurement, specifically an increase in the discount rate, were the primary driver for the $1.59 billion decrease in the benefit obligations in 2018.
The workforce reduction plan initiated in 2017 included a curtailment loss of $159.0 million and a special termination benefit of $354.7 million, which $446.7 million was recorded in asset impairment, restructuring, and other special charges and $67.0 million was recorded in discontinued operations, as a result of a remeasurement as of October 31, 2017. The special termination benefits related to early retirement incentives
offered as part of a voluntary early retirement program for the U.S. plan in the fourth quarter of 2017. This program allowed certain employees the opportunity to voluntarily leave the Company. Market variables associated with this remeasurement, specifically a decrease in the discount rate, were the primary driver for the $2.83 billion increase in the benefit obligations in 2017.
The following represents our weighted-average assumptions as of December 31:

Defined Benefit
Pension Plans

Retiree Health
Benefit Plans
(Percents)
2018

2017

2016

2018

2017

2016
Discount rate for benefit obligation
4.0
%

3.4
%

3.9
%

4.4
%

3.7
%

4.3
%
Discount rate for net benefit costs
3.4

3.9

4.3

3.7

4.3

4.5

Rate of compensation increase for benefit obligation
3.4

3.4

3.4

Rate of compensation increase for net benefit costs
3.4

3.4

3.4

Expected return on plan assets for net benefit costs
7.4

7.4

7.4

8.0

8.0

8.0

We annually evaluate the expected return on plan assets in our defined benefit pension and retiree health benefit plans. In evaluating the expected rate of return, we consider many factors, with a primary analysis of current and projected market conditions; asset returns and asset allocations; and the views of leading financial advisers and economists. We may also review our historical assumptions compared with actual results, as well as the assumptions and trend rates utilized by similar plans, where applicable.
Given the design of our retiree health benefit plans, healthcare-cost trend rates do not have a material impact on our financial condition or results of operations.
The following benefit payments, which reflect expected future service, as appropriate, are expected to be paid as follows:

2019

2020

2021

2022

2023

2024-2028
Defined benefit pension plans
$
604.1

$
607.2

$
616.5

$
632.1

$
641.6

$
3,524.7

Retiree health benefit plans
98.0

99.1

100.7

99.9

98.5

505.3

Amounts relating to defined benefit pension plans with projected benefit obligations in excess of plan assets were as follows at December 31:

2018

2017
Projected benefit obligation
$
11,584.2

$
12,773.4

Fair value of plan assets
8,895.6

9,542.5

Amounts relating to defined benefit pension plans and retiree health benefit plans with accumulated benefit obligations in excess of plan assets were as follows at December 31:

Defined Benefit
Pension Plans

Retiree Health
Benefit Plans

2018

2017

2018

2017
Accumulated benefit obligation
$
10,837.8

$
11,733.6

$
189.4

$
225.1

Fair value of plan assets
8,895.6

9,517.6

—

—

The total accumulated benefit obligation for our defined benefit pension plans was $12.57 billion and $13.67 billion at December 31, 2018 and 2017, respectively.
Net pension and retiree health benefit expense included the following components:

Defined Benefit
Pension Plans

Retiree Health
Benefit Plans

2018

2017

2016

2018

2017

2016
Components of net periodic (benefit) cost:

Service cost
$
292.7

$
320.8

$
268.4

$
41.5

$
46.4

$
39.1

Interest cost
458.5

411.6

419.0

57.3

52.9

53.2

Expected return on plan assets
(842.1
)

(773.6
)

(748.7
)

(177.9
)

(160.7
)

(150.2
)
Amortization of prior service (benefit) cost
4.6

5.6

11.7

(79.5
)

(90.0
)

(85.8
)
Recognized actuarial loss
332.5

286.8

284.6

6.1

18.4

19.1

Curtailment (gain) loss
1.3

93.5

—

(29.3
)

65.5

—

Special termination benefit
—

317.2

—

—

37.5

—

Net periodic (benefit) cost
$
247.5

$
661.9

$
235.0

$
(181.8
)

$
(30.0
)

$
(124.6
)

The following represents the amounts recognized in other comprehensive income (loss) for the years ended December 31, 2018, 2017, and 2016:

Defined Benefit
Pension Plans

Retiree Health
Benefit Plans

2018

2017

2016

2018

2017

2016
Actuarial gain (loss) arising during period
$
182.8

$
(898.1
)

$
(719.1
)

$
37.5

$
261.3

$
(132.2
)
Plan amendments during period
(17.6
)

—

—

14.1

—

35.8

Curtailment gain (loss)
45.2

3.2

—

(31.8
)

(39.7
)

—

Amortization of prior service (benefit) cost included in net income
4.6

5.6

11.7

(79.5
)

(90.0
)

(85.8
)
Amortization of net actuarial loss included in net income
332.5

286.8

284.6

6.1

18.4

19.1

Foreign currency exchange rate changes and other
47.1

(108.8
)

72.6

(0.1
)

(3.3
)

2.5

Total other comprehensive income (loss) during period
$
594.6

$
(711.3
)

$
(350.2
)

$
(53.7
)

$
146.7

$
(160.6
)

We have defined contribution savings plans that cover our eligible employees worldwide. The purpose of these plans is generally to provide additional financial security during retirement by providing employees with an incentive to save. Our contributions to the plans are based on employee contributions and the level of our match. Expenses under the plans totaled $132.6 million, $147.0 million, and $155.4 million for the years ended December 31, 2018, 2017, and 2016, respectively.
We provide certain other postemployment benefits primarily related to disability benefits and accrue for the related cost over the service lives of employees. Expenses associated with these benefit plans for the years ended December 31, 2018, 2017, and 2016 were not material.
Benefit Plan Investments
Our benefit plan investment policies are set with specific consideration of return and risk requirements in relationship to the respective liabilities. U.S. and Puerto Rico plans represent approximately 80 percent of our global investments. Given the long-term nature of our liabilities, these plans have the flexibility to manage an above-average degree of risk in the asset portfolios. At the investment-policy level, there are no specifically prohibited investments. However, within individual investment manager mandates, restrictions and limitations are contractually set to align with our investment objectives, ensure risk control, and limit concentrations.
We manage our portfolio to minimize concentration of risk by allocating funds within asset categories. In addition, within a category we use different managers with various management objectives to eliminate any significant concentration of risk.
Our global benefit plans may enter into contractual arrangements (derivatives) to implement the local investment policy or manage particular portfolio risks. Derivatives are principally used to increase or decrease exposure to a particular public equity, fixed income, commodity, or currency market more rapidly or less expensively than could be accomplished through the use of the cash markets. The plans utilize both exchange-traded and over-the-counter instruments. The maximum exposure to either a market or counterparty credit loss is limited to the carrying value of the receivable, and is managed within contractual limits. We expect all of our counterparties to meet their obligations. The gross values of these derivative receivables and payables are not material to the global asset portfolio, and their values are reflected within the tables below.
The defined benefit pension and retiree health benefit plan allocation for the U.S. and Puerto Rico currently comprises approximately 70 percent growth investments and 30 percent fixed-income investments. The growth investment allocation encompasses U.S. and international public equity securities, hedge funds, private equity-like investments, and real estate. These portfolio allocations are intended to reduce overall risk by providing diversification, while seeking moderate to high returns over the long term.
Public equity securities are well diversified and invested in U.S. and international small-to-large companies across various asset managers and styles. The remaining portion of the growth portfolio is invested in private alternative investments.
Fixed-income investments primarily consist of fixed-income securities in U.S. treasuries and agencies, emerging market debt obligations, corporate bonds, mortgage-backed securities, commercial mortgage-backed obligations, and any related repurchase agreements.
Hedge funds are privately owned institutional investment funds that generally have moderate liquidity. Hedge funds seek specified levels of absolute return regardless of overall market conditions, and generally have low correlations to public equity and debt markets. Hedge funds often invest substantially in financial market instruments (stocks, bonds, commodities, currencies, derivatives, etc.) using a very broad range of trading activities to manage portfolio risks. Hedge fund strategies focus primarily on security selection and seek to be neutral with respect to market moves. Common groupings of hedge fund strategies include relative value, tactical, and event driven. Relative value strategies include arbitrage, when the same asset can simultaneously be bought and sold at different prices, achieving an immediate profit. Tactical strategies often take long and short positions to reduce or eliminate overall market risks while seeking a particular investment opportunity. Event strategy opportunities can evolve from specific company announcements such as mergers and acquisitions, and typically have little correlation to overall market directional movements. Our hedge fund investments are made through limited partnership interests primarily in fund-of-funds structures to ensure diversification across many strategies and many individual managers. Plan holdings in hedge funds are valued based on net asset values (NAVs) calculated by each fund or general partner, as applicable, and we have the ability to redeem these investments at NAV.
Private equity-like investment funds typically have low liquidity and are made through long-term partnerships or joint ventures that invest in pools of capital invested in primarily non-publicly traded entities. Underlying investments include venture capital (early stage investing), buyout, and special situation investing. Private equity management firms typically acquire and then reorganize private companies to create increased long term value. Private equity-like funds usually have a limited life of approximately 10-15 years, and require a minimum investment commitment from their limited partners. Our private investments are made both directly into funds and through fund-of-funds structures to ensure broad diversification of management styles and assets across the portfolio. Plan holdings in private equity-like investments are valued using the value reported by the partnership, adjusted for known cash flows and significant events through our reporting date. Values provided by the partnerships are primarily based on analysis of and judgments about the underlying investments. Inputs to these valuations include underlying NAVs, discounted cash flow valuations, comparable market valuations, and may also include adjustments for currency, credit, liquidity and other risks as applicable. The vast majority of these private partnerships provide us with annual audited financial statements including their compliance with fair valuation procedures consistent with applicable accounting standards.
Real estate is composed of both public and private holdings. Real estate investments in registered investment companies that trade on an exchange are classified as Level 1 on the fair value hierarchy. Real estate investments in funds measured at fair value on the basis of NAV provided by the fund manager are classified as such. These NAVs are developed with inputs including discounted cash flow, independent appraisal, and market comparable analyses.
Other assets include cash and cash equivalents and mark-to-market value of derivatives.
The cash value of the trust-owned insurance contract is primarily invested in investment-grade publicly traded equity and fixed-income securities.
Other than hedge funds, private equity-like investments, and real estate, which are discussed above, we determine fair values based on a market approach using quoted market values, significant other observable inputs for identical or comparable assets or liabilities, or discounted cash flow analyses.
The fair values of our defined benefit pension plan and retiree health plan assets as of December 31, 2018 by asset category were as follows:

Fair Value Measurements Using

Asset Class
Total

Quoted Prices in Active Markets for
Identical Assets
(Level 1)

Significant
Observable
Inputs
(Level 2)

Significant
Unobservable Inputs
(Level 3)

Investments Valued at Net Asset Value⁽¹⁾
Defined Benefit Pension Plans

Public equity securities:

U.S.
$
617.7

$
409.1

$
—

$
—

$
208.6

International
2,117.8

828.8

—

1.8

1,287.2

Fixed income:

Developed markets
2,933.4

17.2

2,173.3

—

742.9

Developed markets - repurchase agreements
(1,225.5
)

—

(1,225.5
)

—

—

Emerging markets
565.2

3.4

255.8

6.1

299.9

Private alternative investments:

Hedge funds
2,795.3

—

—

—

2,795.3

Equity-like funds
1,893.5

—

—

16.8

1,876.7

Real estate
505.7

147.1

—

—

358.6

Other
729.5

213.0

83.7

—

432.8

Total
$
10,932.6

$
1,618.6

$
1,287.3

$
24.7

$
8,002.0

Retiree Health Benefit Plans

Public equity securities:

U.S.
$
59.9

$
41.0

$
—

$
—

$
18.9

International
127.0

50.5

—

0.2

76.3

Fixed income:

Developed markets
69.1

—

61.5

—

7.6

Emerging markets
53.5

—

25.5

0.6

27.4

Private alternative investments:

Hedge funds
245.8

—

—

—

245.8

Equity-like funds
169.2

—

—

1.7

167.5

Cash value of trust owned insurance contract
1,574.7

—

1,574.7

—

—

Real estate
27.7

14.7

—

—

13.0

Other
71.2

38.1

(3.8
)

—

36.9

Total
$
2,398.1

$
144.3

$
1,657.9

$
2.5

$
593.4

⁽¹⁾Certain investments that are measured at fair value using the NAV per share (or its equivalent) as a practical expedient have not been classified in the fair value hierarchy.
No material transfers between Level 1, Level 2, or Level 3 occurred during the year ended December 31, 2018. The activity in the Level 3 investments during the year ended December 31, 2018 was not material.
The fair values of our defined benefit pension plan and retiree health plan assets as of December 31, 2017 by asset category were as follows:

Fair Value Measurements Using

Asset Class
Total

Quoted Prices in Active Markets for Identical Assets
(Level 1)

Significant Observable Inputs
(Level 2)

Significant Unobservable Inputs
(Level 3)

Investments Valued at Net Asset Value⁽¹⁾
Defined Benefit Pension Plans

Public equity securities:

U.S.
$
465.4

$
199.0

$
—

$
—

$
266.4

International
2,934.2

955.1

—

—

1,979.1

Fixed income:

Developed markets
3,153.0

20.5

2,468.1

—

664.4

Developed markets - repurchase agreements
(1,372.9
)

—

(1,372.9
)

—

—

Emerging markets
577.5

3.6

251.7

3.1

319.1

Private alternative investments:

Hedge funds
2,977.8

—

—

—

2,977.8

Equity-like funds
1,586.9

—

—

16.8

1,570.1

Real estate
543.7

338.6

—

—

205.1

Other
847.4

119.1

602.7

2.2

123.4

Total
$
11,713.0

$
1,635.9

$
1,949.6

$
22.1

$
8,105.4

Retiree Health Benefit Plans

Public equity securities:

U.S.
$
43.0

$
19.4

$
—

$
—

$
23.6

International
182.5

61.3

—

—

121.2

Fixed income:

Developed markets
71.2

—

63.5

—

7.7

Emerging markets
53.1

—

24.4

0.3

28.4

Private alternative investments:

Hedge funds
256.0

—

—

—

256.0

Equity-like funds
137.0

—

—

1.6

135.4

Cash value of trust owned insurance contract
1,524.6

—

1,524.6

—

—

Real estate
33.0

33.0

—

—

—

Other
72.0

15.0

50.5

0.2

6.3

Total
$
2,372.4

$
128.7

$
1,663.0

$
2.1

$
578.6

⁽¹⁾Certain investments that are measured at fair value using the NAV per share (or its equivalent) as a practical expedient have not been classified in the fair value hierarchy.
No material transfers between Level 1, Level 2, or Level 3 occurred during the year ended December 31, 2017. The activity in the Level 3 investments during the year ended December 31, 2017 was not material.
In 2019, we expect to contribute approximately $45 million to our defined benefit pension plans to satisfy minimum funding requirements for the year. Additional discretionary contributions are not expected to be significant.

X

- References
No definition available.
+ Details

Name: us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for pension and other postretirement benefits.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-URI http://asc.fasb.org/topic&trid=2235017
+ Details

Name: us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 63 R28.htm IDEA: XBRL DOCUMENT v3.19.3

Segment Information
12 Months Ended

Dec. 31, 2018

Segment Reporting [Abstract]

Segment Information Segment Information
On March 11, 2019, we completed the disposition of our remaining 80.2 percent ownership of Elanco common stock through a tax-free exchange offer. As a result, Elanco has been presented as discontinued operations in our consolidated financial statements for all periods presented. Following the completion of the disposition of Elanco, we now operate as a single operating segment engaged in the discovery, development, manufacturing, marketing, and sales of pharmaceutical products worldwide. A global research and development organization and a supply chain organization are responsible for the discovery, development, manufacturing, and supply of our products. Regional commercial organizations market, distribute, and sell the products. The business is also supported by global corporate staff functions. Our determination that we operate as a single segment is consistent with the financial information regularly reviewed by the chief operating decision maker for purposes of evaluating performance, allocating resources, setting incentive compensation targets, and planning and forecasting for future periods.
We lost our compound patent protection for Cialis^® (tadalafil) and Adcirca^® (tadalafil) in major European markets in November 2017, and in the U.S., pediatric exclusivity expired in May 2018. Pursuant to a settlement agreement related to our unit dose patent in the U.S., generic tadalafil entered the U.S. market in September 2018. Entry of generic competition into these markets following the loss of exclusivity will continue to cause a rapid and severe decline in revenue. Our formulation patents for Forteo^®expired in December 2018 and use patents will expire in August 2019 in major European markets and the U.S. Both the formulation patent and the use patent expire in 2019 in Japan.
Most of our products are distributed through wholesalers that serve pharmacies, physicians and other health care professionals, and hospitals. For the years ended December 31, 2018, 2017, and 2016, our three largest wholesalers each accounted for between 13 percent and 21 percent of consolidated total revenue. Further, they each accounted for between 16 percent and 25 percent of accounts receivable as of December 31, 2018 and 2017.
We are exposed to the risk of changes in social, political, and economic conditions inherent in foreign operations, and our results of operations and the value of our foreign assets are affected by fluctuations in foreign currency exchange rates.
The following table summarizes our revenue activity:

U.S.⁽¹⁾

Outside U.S.

2018

2017

2016

2018

2017

2016
Revenue—to unaffiliated customers:

Endocrinology:

Trulicity^®
$
2,515.8

$
1,609.8

$
737.6

$
683.3

$
419.9

$
187.9

Humalog^®
1,787.8

1,717.8

1,685.2

1,208.7

1,147.4

1,083.6

Humulin^®
910.2

884.6

861.8

421.2

450.7

504.1

Forteo
757.9

965.2

770.5

817.7

783.8

729.4

Basaglar
622.8

311.1

15.8

178.5

121.0

70.3

Jardiance
400.2

290.4

144.5

258.1

157.0

57.4

Trajenta
224.2

213.2

165.9

350.5

324.7

270.7

Other Endocrinology
292.7

380.9

450.6

272.5

307.7

347.5

Total Endocrinology
7,511.6

6,373.0

4,831.9

4,190.5

3,712.2

3,250.9

Oncology:

Alimta
1,131.0

1,034.3

1,101.0

1,001.9

1,028.2

1,182.3

Erbitux
531.6

541.7

581.1

103.8

104.2

105.9

Cyramza^®
291.5

278.8

270.1

529.9

479.6

344.0

Other Oncology
449.1

195.6

22.9

221.7

149.6

114.6

Total Oncology
2,403.2

2,050.4

1,975.1

1,857.3

1,761.6

1,746.8

Cardiovascular:

Cialis
1,129.2

1,358.6

1,469.5

722.7

964.5

1,002.1

Effient
68.1

340.1

465.6

54.1

48.8

69.6

Other Cardiovascular
158.4

24.0

56.3

121.8

135.2

162.3

Total Cardiovascular
1,355.7

1,722.7

1,991.4

898.6

1,148.5

1,234.0

Neuroscience:

Strattera^®
89.7

284.9

534.9

361.1

333.3

319.8

Cymbalta⁽²⁾
54.3

114.9

269.3

653.7

642.2

661.2

Zyprexa^®
36.2

75.5

69.8

435.1

505.7

655.5

Other Neuroscience
97.2

115.7

115.9

93.4

98.9

93.9

Total Neuroscience
277.4

591.0

989.9

1,543.3

1,580.1

1,730.4

Immunology:

Taltz^®
738.7

486.0

110.8

198.7

73.2

2.3

Other Immunology
6.7

—

—

195.9

45.8

—

Total Immunology
745.4

486.0

110.8

394.6

119.0

2.3

Other
98.5

191.3

247.9

217.0

238.0

201.3

Revenue
$
12,391.9

$
11,414.4

$
10,147.0

$
9,101.4

$
8,559.4

$
8,165.8

Numbers may not add due to rounding.
⁽¹⁾ U.S. revenue includes revenue in Puerto Rico.
⁽²⁾Cymbalta revenues benefited from reductions to the reserve for expected product returns of approximately $175 million during the year ended December 31, 2016.

2018

2017

2016
Geographic Information

Revenue—to unaffiliated customers⁽¹⁾:

United States

$
12,391.9

$
11,414.4

$
10,147.0

Europe

3,663.1

3,390.6

3,214.4

Japan

2,407.4

2,339.5

2,253.0

Other foreign countries

3,030.9

2,829.3

2,698.3

Revenue

$
21,493.3

$
19,973.8

$
18,312.8

Long-lived assets⁽²⁾:

United States

$
4,344.0

$
4,408.7

$
4,520.8

Europe

2,413.5

2,246.4

1,864.8

Japan

180.2

153.4

91.0

Other foreign countries

1,608.5

1,672.5

1,690.4

Long-lived assets

$
8,546.2

$
8,481.0

$
8,167.0

Numbers may not add due to rounding.
⁽¹⁾Revenue is attributed to the countries based on the location of the customer.
⁽²⁾Long-lived assets consist of property and equipment, net, and certain sundry assets.

X

- References
No definition available.
+ Details

Name: us-gaap_SegmentReportingAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-URI http://asc.fasb.org/topic&trid=2134510
+ Details

Name: us-gaap_SegmentReportingDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 64 R18.htm IDEA: XBRL DOCUMENT v3.19.3

Goodwill and Other Intangibles
12 Months Ended

Dec. 31, 2018

Goodwill and Intangible Assets Disclosure [Abstract]

Goodwill and Intangible Assets Disclosure Goodwill and Other Intangibles
Goodwill
Goodwill results from excess consideration in a business combination over the fair value of identifiable net assets acquired. Goodwill is not amortized but is reviewed for impairment at least annually and when impairment indicators are present. When required, a comparison of the fair value of the reporting unit to its carrying amount including goodwill is used to determine the amount of any impairment.
No impairments occurred with respect to the carrying value of goodwill for the years ended December 31, 2018, 2017, and 2016.
Other Intangibles
The components of intangible assets other than goodwill at December 31 were as follows:

2018

2017
Description
Carrying
Amount,
Gross

Accumulated
Amortization

Carrying
Amount,
Net

Carrying
Amount,
Gross

Accumulated
Amortization

Carrying
Amount,
Net
Finite-lived intangible assets:

Marketed products
$
2,077.2

$
(1,069.0
)

$
1,008.2

$
4,528.8

$
(3,251.3
)

$
1,277.5

Other
89.5

(29.7
)

59.8

117.1

(40.2
)

76.9

Other intangibles
$
2,166.7

$
(1,098.7
)

$
1,068.0

$
4,645.9

$
(3,291.5
)

$
1,354.4

Marketed products consist of the amortized cost of the rights to assets acquired in business combinations and approved for marketing in a significant global jurisdiction (U.S., Europe, and Japan) and capitalized milestone payments. For transactions other than a business combination, we capitalize milestone payments incurred at or after the product has obtained regulatory approval for marketing.
Other finite-lived intangibles consist primarily of the amortized cost of licensed platform technologies that have alternative future uses in research and development, manufacturing technologies, and customer relationships from business combinations.
Acquired IPR&D consists of the related costs capitalized, adjusted for subsequent impairments, if any. The costs of acquired IPR&D projects acquired directly in a transaction other than a business combination are capitalized if the projects have an alternative future use; otherwise, they are expensed immediately. The fair values of acquired IPR&D projects acquired in business combinations, if any, are capitalized as other intangible assets. As of December 31, 2018 and 2017, we had no acquired IPR&D indefinite-lived intangible assets.
Several methods may be used to determine the estimated fair value of other intangibles acquired in a business combination. We utilize the “income method,” which is a Level 3 fair value measurement and applies a probability weighting that considers the risk of development and commercialization to the estimated future net cash flows that are derived from projected revenues and estimated costs. These projections are based on factors such as relevant market size, patent protection, historical pricing of similar products, and expected industry trends. The estimated future net cash flows are then discounted to the present value using an appropriate discount rate. This analysis is performed for each asset independently. The acquired IPR&D assets are treated as indefinite-lived intangible assets until completion or abandonment of the projects, at which time the assets are tested for impairment and amortized over the remaining useful life or written off, as appropriate.
See Note 4 for additional discussion of recent capitalized milestone payments.
Other indefinite-lived intangible assets are reviewed for impairment at least annually and when impairment indicators are present. Finite-lived intangible assets are reviewed for impairment when an indicator of impairment is present. When required, a comparison of fair value to the carrying amount of assets is performed to determine the amount of any impairment. When determining the fair value of indefinite-lived acquired IPR&D as well as the fair value of finite-lived intangible assets for impairment testing purposes, we utilize the "income method" discussed above. During 2018, we had finite-lived intangible impairment charges of $46.9 million which were recorded in asset impairment, restructuring and other special charges on the consolidated statements of operations. These impairments were primarily related to the sale of the Posilac (rbST) brand. During 2017, we had finite-lived intangible impairment charges of $50.0 million which were recorded in asset impairment, restructuring and other special charges on the consolidated statements of operations. These impairments were related to lower projected revenue for Posilac (rbST). No material impairments occurred with respect to the carrying value of other intangible assets for the year ended December 31, 2016.
Intangible assets with finite lives are capitalized and are amortized over their estimated useful lives, ranging from three to 20 years. As of December 31, 2018, the remaining weighted-average amortization period for finite-lived intangible assets was approximately 10 years.
Amortization expense related to finite-lived intangible assets was as follows:

2018

2017

2016
Amortization expense
$
361.3

$
462.2

$
517.2

The estimated amortization expense for each of the next five years associated with our finite-lived intangible assets as of December 31, 2018 is as follows:

2019

2020

2021

2022

2023
Estimated amortization expense
$
145.4

$
144.0

$
141.6

$
133.8

$
122.6

Amortization expense is included in either cost of sales, marketing, selling, and administrative or research and development depending on the nature of the intangible asset being amortized.

X

- References
No definition available.
+ Details

Name: us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for goodwill and intangible assets.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-URI http://asc.fasb.org/topic&trid=2144416
+ Details

Name: us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 65 R10.htm IDEA: XBRL DOCUMENT v3.19.3

Consolidated Statements of Cash Flows Consolidated Statements of Cash Flows (Parenthetical) - USD ($)
$ in Millions

Dec. 31, 2018

Dec. 31, 2017

Dec. 31, 2016

Dec. 31, 2015

Statement of Cash Flows [Abstract]

Discontinued operations cash $ 677.5 $ 324.4 $ 258.8 $ 460.6

X

- Definition
Amount classified as cash and cash equivalents attributable to disposal group held for sale or disposed of.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5B
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 45
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=109222160&loc=SL51721533-107759

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 45
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=109222160&loc=d3e1107-107759
+ Details

Name: us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_StatementOfCashFlowsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 66 R14.htm IDEA: XBRL DOCUMENT v3.19.3

Collaborations and Other Arrangements
12 Months Ended

Dec. 31, 2018

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Collaborations and Other Arrangements Collaborations and Other Arrangements
We often enter into collaborative and other similar arrangements to develop and commercialize drug candidates. Collaborative activities may include research and development, marketing and selling (including promotional activities and physician detailing), manufacturing, and distribution. These arrangements often require milestone and royalty or profit-share payments, contingent upon the occurrence of certain future events linked to the success of the asset in development, as well as expense reimbursements or payments to the collaboration partner. See Note 1 for amounts of collaboration and other revenue recognized from these types of arrangements.
Operating expenses for costs incurred pursuant to these arrangements are reported in their respective expense line item, net of any payments due to or reimbursements due from our collaboration partners, with such reimbursements being recognized at the time the party becomes obligated to pay. Each collaboration is unique in nature, and our more significant arrangements are discussed below.
Boehringer Ingelheim Diabetes Collaboration
We and Boehringer Ingelheim have a global agreement to jointly develop and commercialize a portfolio of diabetes compounds. Currently, included in the collaboration are Boehringer Ingelheim’s oral diabetes products: Trajenta, Jentadueto^®, Jardiance, Glyxambi^®, and Synjardy^®, as well as our basal insulin: Basaglar^®.
The table below summarizes significant milestones (deferred) capitalized for the compounds included in this collaboration:
Product Family

Milestones
(Deferred) Capitalized⁽¹⁾

Year
Amount
Trajenta⁽²⁾

Cumulative⁽⁴⁾
$
446.4

Jardiance⁽³⁾

Cumulative⁽⁴⁾
289.0

Basaglar

2018
—

2017
—

2016
(187.5
)

Cumulative⁽⁴⁾
(250.0
)

⁽¹⁾In connection with the regulatory approvals of Basaglar in the U.S., Europe, and Japan, milestone payments received were recorded as contract liabilities and are being amortized through the term of the collaboration (2029) to collaboration and other revenue. In connection with the regulatory approvals of Trajenta and Jardiance, milestone payments made were capitalized as intangible assets and are being amortized to cost of sales through the term of the collaboration.
⁽²⁾Jentadueto is included in the Trajenta product family. The collaboration agreement with Boehringer Ingelheim for Trajenta ends upon expiration of the compound patent and any supplementary protection certificates or extensions thereto.
⁽³⁾Glyxambi and Synjardyare included in the Jardiance product family. The collaboration agreement with Boehringer Ingelheim for Jardiance ends upon expiration of the compound patent and any supplementary protection certificates or extensions thereto.
⁽⁴⁾The cumulative amount represents the total amounts that have been (deferred) or capitalized from the start of this collaboration through the end of the reporting period.
In the most significant markets, we and Boehringer Ingelheim share equally the ongoing development costs, commercialization costs, and agreed upon gross margin for any product resulting from the collaboration. We record our portion of the gross margin associated with Boehringer Ingelheim's products as collaboration and other revenue. We record our sales of Basaglar to third parties as net product revenue with the payments made to Boehringer Ingelheim for their portion of the gross margin recorded as cost of sales. For all compounds under this collaboration, we record our portion of the development and commercialization costs as research and development expense and marketing, selling, and administrative expense, respectively. Each company is entitled to potential performance payments depending on the sales of the molecules it contributes to the collaboration. These performance payments result in the owner of the molecule retaining a greater share of the agreed upon gross margin of that product. Subject to achieving these thresholds, in a given period, our reported revenue for Trajenta and Jardiance may be reduced by any performance payments we make related to these products. Similarly, performance payments we may receive related to Basaglar effectively reduce Boehringer Ingelheim's share of the gross margin, which reduces our cost of sales.
The following table summarizes our collaboration and other revenue recognized with respect to the Trajenta and Jardiance families of products and net product revenue recognized with respect to Basaglar:

2018

2017

2016
Basaglar
$
801.2

$
432.1

$
86.1

Jardiance
658.3

447.5

201.9

Trajenta
574.7

537.9

436.6

Erbitux^®
We have several collaborations with respect to Erbitux. The most significant collaborations are or, where applicable, were in Japan, and prior to the transfer of commercialization rights in the fourth quarter of 2015, the U.S. and Canada (Bristol-Myers Squibb Company); and worldwide except the U.S. and Canada (Merck KGaA). Certain rights to Erbitux outside the U.S. and Canada (North America) will remain with Merck KGaA (Merck) upon expiration of that agreement.
The following table summarizes our revenue recognized with respect to Erbitux:

2018

2017

2016
Net product revenue
$
536.1

$
548.2

$
587.0

Collaboration and other revenue
99.2

97.7

100.0

Revenue
$
635.3

$
645.9

$
687.0

Bristol-Myers Squibb Company
Pursuant to commercial agreements with Bristol-Myers Squibb Company and E.R. Squibb (collectively, BMS), we had been co-developing Erbitux in North America exclusively with BMS. On October 1, 2015, BMS transferred their commercialization rights to us with respect to Erbitux in North America pursuant to a modification of our existing arrangement, and we began selling Erbitux at that time. This modification did not affect our rights with respect to Erbitux in other jurisdictions. In connection with the modification of terms, we provided consideration to BMS based upon a tiered percentage of net sales of Erbitux in North America estimated to average 38 percent through September 2018. The transfer of the commercialization rights was accounted for as an acquisition of a business. The consideration to be paid to BMS was accounted for as contingent consideration liability.
Merck KGaA
A development and license agreement granted Merck exclusive rights to market Erbitux outside of North America until December 2018. A separate agreement grants co-exclusive rights among Merck, BMS, and us in Japan and expires in 2032. This agreement was amended in 2015 to grant Merck exclusive commercialization rights in Japan but did not result in any other changes to our rights.
Merck manufactures Erbitux for supply in its territory, including Japan. We receive a royalty on the sales of Erbitux outside of North America, which is included in collaboration and other revenue as the underlying sales occur. Royalties due to third parties are recorded as a reduction of collaboration and other revenue, net of any royalty reimbursements due from third parties.
Olumiant^®
We have a worldwide license and collaboration agreement with Incyte Corporation (Incyte) which provides us the development and commercialization rights to its Janus tyrosine kinase (JAK) inhibitor compound, now known as Olumiant, and certain follow-on compounds, for the treatment of inflammatory and autoimmune diseases. Incyte has the right to receive tiered, double-digit royalty payments on future global sales with rates ranging up to 20 percent if the product is successfully commercialized. The agreement provides Incyte with options to co-develop these compounds on an indication-by-indication basis by funding 30 percent of the associated development costs from the initiation of a Phase IIb trial through regulatory approval in exchange for increased tiered royalties ranging up to percentages in the high twenties. Incyte exercised its option to co-develop Olumiant in rheumatoid arthritis in 2010 and psoriatic arthritis, atopic dermatitis, alopecia areata, and systemic lupus erythematosus (SLE) in 2017. The agreement calls for payments by us to Incyte associated with certain development, success-based regulatory, and sales-based milestones. The following table summarizes our milestones achieved:
Year
Event
Classification
Amount
2018
Regulatory approval in the U.S.
Intangible asset
$
100.0

Began Phase III testing for SLE
R&D Expense
20.0

2017
Regulatory approval in Europe
Intangible asset
65.0

Regulatory approval in Japan
Intangible asset
15.0

Began Phase III testing for atopic dermatitis
R&D expense
30.0

2016
Regulatory submissions in the U.S. and Europe
R&D expense
55.0

As of December 31, 2018, Incyte is eligible to receive up to $130.0 million of additional payments from us contingent upon certain development and success-based regulatory milestones. Incyte is also eligible to receive up to $150.0 million of potential sales-based milestones.
Effient^®
We are in a collaborative arrangement with Daiichi Sankyo Co., Ltd. (Daiichi Sankyo) to develop, market, and promote Effient. Marketing rights for major territories are shown below. We and Daiichi Sankyo each have exclusive marketing rights in certain other territories.
Territory

Marketing Rights

Selling Party
U.S.

Co-promotion

Lilly
Major European markets

Co-promotion

Daiichi Sankyo
Japan

Exclusive

Daiichi Sankyo

The parties share approximately 50/50 in the profits, as well as in the costs of development and marketing in the co-promotion territories. A third party manufactures bulk product, and we produce the finished product for our exclusive and co-promotion territories, including the major European markets.
We record net product revenue in our exclusive and co-promotion territories where we are the selling party. Profit-share payments due to Daiichi Sankyo for co-promotion countries where we are the selling party are recorded as marketing, selling, and administrative expenses. Any profit-share payments due to us from Daiichi Sankyo for the major European markets are recorded as collaboration and other revenue. We also record our share of the expenses in these co-promotion territories as marketing, selling, and administrative expenses. In our exclusive territories, we pay Daiichi Sankyo a royalty specific to these territories. All royalties due to Daiichi Sankyo and the third-party manufacturer are recorded in cost of sales. Generic versions of Effient launched in the U.S. in the third quarter of 2017.
The following table summarizes our revenue recognized with respect to Effient:

2018

2017

2016
Revenue
$
122.2

$
388.9

$
535.2

Tanezumab
We have a collaboration agreement with Pfizer Inc. (Pfizer) to jointly develop and globally commercialize tanezumab for the treatment of osteoarthritis pain, chronic low back pain and cancer pain. Under the agreement, the companies share equally the ongoing development costs and, if successful, in gross margins and certain commercialization expenses. As of December 31, 2018, Pfizer is eligible to receive up to $350.0 million in success-based regulatory milestones and up to $1.23 billion in a series of sales-based milestones, contingent upon the commercial success of tanezumab.

X

- Definition
The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 808
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 808
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 808
-URI http://asc.fasb.org/topic&trid=5833765
+ Details

Name: us-gaap_CollaborativeArrangementDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 67 R37.htm IDEA: XBRL DOCUMENT v3.19.3

Income Taxes (Policies)
12 Months Ended

Dec. 31, 2018

Income Tax Disclosure [Abstract]

Income Tax
Deferred taxes are recognized for the future tax effects of temporary differences between financial and income tax reporting based on enacted tax laws and rates.
We recognize the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by the taxing authorities, based on the technical merits of the position. The tax benefits recognized in the financial statements from such a position are measured based on the largest benefit that has a greater than 50 percent likelihood of being realized upon ultimate resolution.

X

- References
No definition available.
+ Details

Name: us-gaap_IncomeTaxDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 20
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32847-109319

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 954
-SubTopic 740
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6491622&loc=d3e9504-115650

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 17
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32809-109319

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=116657188&loc=SL116659661-227067

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 19
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32840-109319

Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 45
-Paragraph 25
-URI http://asc.fasb.org/extlink&oid=116821951&loc=d3e32247-109318

Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=116821951&loc=d3e32280-109318

Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 30
-Section 05
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=65884525&loc=d3e40913-109327
+ Details

Name: us-gaap_IncomeTaxPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 68 R7.htm IDEA: XBRL DOCUMENT v3.19.3

Consolidated Statements of Shareholders' Equity Statement - USD ($)
shares in Thousands, $ in Millions

Total

Common Stock

Additional Paid-in Capital

Retained Earnings

Employee Benefit Trust

Accumulated Other Comprehensive Loss

Common Stock in Treasury

Noncontrolling Interest

Beginning balance at Dec. 31, 2015 $ 691.3 $ 5,552.1 $ 16,011.8 $ (3,013.2) $ (4,580.7) $ (90.0) $ 19.0

Beginning balance (in shares) at Dec. 31, 2015 1,106,063 796

Increase (Decrease) in Shareholders' Equity [Roll Forward]

Net income (loss) 2,737.6 16.3

Other comprehensive income (loss), net of tax $ (693.3) (693.3) 48.2

Cash dividends declared (2,167.6)

Retirement of treasury shares, shares (7,306) (7,306)

Retirement of treasury shares $ (4.6) (535.5) $ 540.1

Purchase of treasury shares, shares 7,306

Purchase of treasury shares (540.1) (60.0) $ (540.1)

Issuance of stock under employee stock plans, net, shares 2,829 (85)

Issuance of stock under employee stock plans, net $ 1.8 (106.8) $ 9.5

Stock-based compensation 255.3

Other (10.7)

Ending balance (in shares) at Dec. 31, 2016 1,101,586 711

Ending balance at Dec. 31, 2016 $ 688.5 5,640.6 16,046.3 (3,013.2) (5,274.0) $ (80.5) 72.8

Increase (Decrease) in Shareholders' Equity [Roll Forward]

Net income (loss) (204.1) 30.5

Other comprehensive income (loss), net of tax 199.0 199.0 (24.5)

Cash dividends declared (2,234.6)

Retirement of treasury shares, shares (4,390) (4,390)

Retirement of treasury shares $ (2.7) (357.1) $ 359.8

Purchase of treasury shares, shares 4,390

Purchase of treasury shares (359.8) 60.0 $ (359.8)

Issuance of stock under employee stock plans, net, shares 3,476 (47)

Issuance of stock under employee stock plans, net $ 2.1 (164.1) $ 4.7

Stock-based compensation 281.3

Other (3.1)

Ending balance (in shares) at Dec. 31, 2017 1,100,672 664

Ending balance at Dec. 31, 2017 11,667.9 $ 687.9 5,817.8 13,894.1 (3,013.2) (5,718.6) $ (75.8) 75.7

Increase (Decrease) in Shareholders' Equity [Roll Forward]

Net income (loss) 3,232.0 3.7

Other comprehensive income (loss), net of tax 72.6 85.6 (2.0)

Cash dividends declared (2,372.0)

Retirement of treasury shares, shares (45,882) (45,882)

Retirement of treasury shares $ (28.7) (4,122.0) $ 4,150.7

Purchase of treasury shares, shares 45,882

Purchase of treasury shares (4,150.0) $ (4,150.7)

Issuance of stock under employee stock plans, net, shares 2,849 (60)

Issuance of stock under employee stock plans, net $ 1.8 (139.0) $ 6.4

Stock-based compensation 279.5

Sale of Elanco Stock (Note 20) 629.2 9.0 1,017.2

Other (3.9) (14.2)

Ending balance (in shares) at Dec. 31, 2018 1,057,639 604

Ending balance at Dec. 31, 2018 $ 10,909.1 $ 661.0 $ 6,583.6 $ 11,395.9 $ (3,013.2) (5,729.2) $ (69.4) $ 1,080.4

Increase (Decrease) in Shareholders' Equity [Roll Forward]

Reclassification of stranded tax effects and Adoption of new accounting standards (Note 2) $ (105.2)

X

- Definition
Impact on Equity of Sale of Noncontrolling Interest in Subsidiary
+ References
No definition available.
+ Details

Name: lly_ImpactonEquityofSaleofNoncontrollingInterestinSubsidiary

Namespace Prefix: lly_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount after tax of increase (decrease) to equity or (increase) decrease to net assets, resulting from the cumulative effect adjustment of a new accounting principle applied in the period of adoption.
+ References
No definition available.
+ Details

Name: us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of paid and unpaid cash, stock, and paid-in-kind (PIK) dividends declared, for example, but not limited to, common and preferred stock.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 405
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6957935&loc=d3e64057-112817
+ Details

Name: us-gaap_Dividends

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.
+ References
No definition available.
+ Details

Name: us-gaap_IncreaseDecreaseInStockholdersEquityRollForward

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount after tax of other comprehensive income (loss) attributable to parent entity.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=118930883&loc=SL7669625-108580

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 1A
-Subparagraph (c)(3)
-URI http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 45
-Paragraph 20
-URI http://asc.fasb.org/extlink&oid=108774443&loc=SL4569643-111683

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=118930883&loc=SL7669619-108580

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 45
-Paragraph 19
-URI http://asc.fasb.org/extlink&oid=108774443&loc=SL4569616-111683
+ Details

Name: us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118930883&loc=SL7669619-108580

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 1A
-Subparagraph (a)(1)
-URI http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118930883&loc=SL7669625-108580

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 1A
-Subparagraph (c)(1)
-URI http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599

Reference 6: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 55
-Paragraph 4J
-URI http://asc.fasb.org/extlink&oid=116874947&loc=SL4591551-111686

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3000-108585

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 45
-Paragraph 19
-URI http://asc.fasb.org/extlink&oid=108774443&loc=SL4569616-111683

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8933-108599

Reference 10: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 55
-Paragraph 4K
-URI http://asc.fasb.org/extlink&oid=116874947&loc=SL4591552-111686
+ Details

Name: us-gaap_ProfitLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644
+ Details

Name: us-gaap_SharesIssued

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Number of shares issued during the period as a result of an employee stock purchase plan.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644
+ Details

Name: us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5047-113901

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (d)(1)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 45
-Paragraph 16
-URI http://asc.fasb.org/extlink&oid=108774443&loc=SL4568740-111683

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 55
-Paragraph 4I
-URI http://asc.fasb.org/extlink&oid=116874947&loc=SL4590271-111686

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 45
-Paragraph 15
-URI http://asc.fasb.org/extlink&oid=108774443&loc=SL4568447-111683
+ Details

Name: us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
This element represents movements included in the statement of changes in stockholders' equity which are not separately disclosed or provided for elsewhere in the taxonomy.
+ References
No definition available.
+ Details

Name: us-gaap_StockholdersEquityOther

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of decrease of par value, additional paid in capital (APIC) and retained earnings of common and preferred stock retired from treasury when treasury stock is accounted for under the cost method.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770
+ Details

Name: us-gaap_TreasuryStockRetiredCostMethodAmount

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Number of shares that have been repurchased during the period and are being held in treasury.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_TreasuryStockSharesAcquired

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of shares of common and preferred stock retired from treasury during the period.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644
+ Details

Name: us-gaap_TreasuryStockSharesRetired

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 30
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6405813&loc=d3e23239-112655

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770
+ Details

Name: us-gaap_TreasuryStockValueAcquiredCostMethod

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

XML 69 R101.htm IDEA: XBRL DOCUMENT v3.19.3

Discontinued Operations (Discontinued Operations in Financial Statements) (Details) - USD ($)
$ in Millions
3 Months Ended 12 Months Ended

Dec. 31, 2018

Sep. 30, 2018

Jun. 30, 2018

Mar. 31, 2018

Dec. 31, 2017

Sep. 30, 2017

Jun. 30, 2017

Mar. 31, 2017

Dec. 31, 2018

Dec. 31, 2017

Dec. 31, 2016

Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]

Revenue $ 5,637.6 $ 5,306.9 $ 5,585.0 $ 4,963.8 $ 5,406.4 $ 4,961.0 $ 5,091.6 $ 4,514.9 $ 21,493.3 $ 19,973.8 $ 18,312.8

Net Income (loss) from discontinued operations $ 3.7 $ 55.9 $ (28.3) $ 50.2 $ (106.4) $ 11.5 $ 2.9 $ (25.7) 81.4 (117.7) 12.7

Elanco Animal Health Incorporated | Discontinued Operations, Disposed of by Sale

Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]

Revenue $ 3,062.4 $ 2,897.5 $ 2,909.3

X

- Definition
Amount after tax of income (loss) from a discontinued operation including the portion attributable to the noncontrolling interest. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(12))
-URI http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 45
-Paragraph 3B
-URI http://asc.fasb.org/extlink&oid=109222160&loc=SL51721525-107759

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5C
-Subparagraph (b)(2)
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 45
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=109222160&loc=d3e957-107759

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(21))
-URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227

Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 45
-Paragraph 3A
-URI http://asc.fasb.org/extlink&oid=109222160&loc=SL51721523-107759

Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 45
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=109222160&loc=d3e1012-107759
+ Details

Name: us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8933-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(1))
-URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227
+ Details

Name: us-gaap_Revenues

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Details

Name: us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=lly_ElancoAnimalHealthIncorporatedMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_DisposalGroupClassificationAxis=us-gaap_DiscontinuedOperationsDisposedOfBySaleMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 71 R3.htm IDEA: XBRL DOCUMENT v3.19.3

Consolidated Statements of Comprehensive Income (Loss) - USD ($)
$ in Millions
12 Months Ended

Dec. 31, 2018

Dec. 31, 2017

Dec. 31, 2016

Net income (loss) $ 3,232.0 $ (204.1) $ 2,737.6

Other comprehensive income (loss) from continuing operations:

Change in foreign currency translation gains (losses) (429.6) 362.9 (300.0)

Change in net unrealized gains (losses) on securities (8.8) (181.3) 303.0

Change in defined benefit pension and retiree health benefit plans (Note 14) 544.0 (566.8) (508.5)

Change in effective portion of cash flow hedges (6.0) 27.8 11.7

Other comprehensive income (loss) from continuing operations before income taxes 99.6 (357.4) (493.8)

Benefit (provision) for income taxes related to other comprehensive income (loss) from continuing operations (30.3) 402.7 (10.6)

Net other comprehensive income (loss) 83.6 174.5 (645.1)

Comprehensive income (loss) 3,315.6 (29.6) 2,092.5

Continuing Operations

Other comprehensive income (loss) from continuing operations:

Net other comprehensive income (loss) 69.3 45.3 (504.4)

Discontinued Operations

Other comprehensive income (loss) from continuing operations:

Net other comprehensive income (loss) $ 14.3 $ 129.2 $ (140.7)

X

- Definition
Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 55
-Paragraph 4K
-URI http://asc.fasb.org/extlink&oid=116874947&loc=SL4591552-111686

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=118930883&loc=SL7669619-108580

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 45
-Paragraph 19
-URI http://asc.fasb.org/extlink&oid=108774443&loc=SL4569616-111683

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=118930883&loc=SL7669625-108580
+ Details

Name: us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118930883&loc=SL7669619-108580

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(22))
-URI http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118930883&loc=SL7669625-108580

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(18))
-URI http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(20))
-URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585

Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257
+ Details

Name: us-gaap_NetIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount before tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 830
-SubTopic 20
-Section 35
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=118948100&loc=d3e30304-110892

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 830
-SubTopic 30
-Section 45
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=118261656&loc=d3e32022-110900

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 830
-SubTopic 30
-Section 45
-Paragraph 20
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=118930883&loc=d3e637-108580

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 10A
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580
+ Details

Name: us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount before tax, after reclassification adjustments, of appreciation (loss) in value of unsold available-for-sale securities. Excludes amounts related to other than temporary impairment (OTTI) loss.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 10A
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 10A
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=118930883&loc=d3e637-108580
+ Details

Name: us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount before tax, after reclassification adjustments of other comprehensive income (loss).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 45
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=109237563&loc=d3e33775-111570
+ Details

Name: us-gaap_OtherComprehensiveIncomeLossBeforeTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_OtherComprehensiveIncomeLossBeforeTaxPeriodIncreaseDecreaseAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount before tax, after reclassification adjustments, of increase (decrease) in accumulated gain (loss) from derivative instruments designated and qualifying as the effective portion of cash flow hedges and an entity's share of an equity investee's increase (decrease) in deferred hedging gain (loss).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 10A
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580
+ Details

Name: us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesBeforeTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount after tax and reclassification adjustments of other comprehensive income (loss).
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=118930883&loc=SL7669619-108580

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 55
-Paragraph 15
-URI http://asc.fasb.org/extlink&oid=118951672&loc=d3e1436-108581

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=118930883&loc=SL7669625-108580
+ Details

Name: us-gaap_OtherComprehensiveIncomeLossNetOfTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount, before tax, after reclassification adjustment, of (increase) decrease in accumulated other comprehensive income for defined benefit plan.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 10A
-Subparagraph (i-k)
-URI http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=118930883&loc=d3e637-108580
+ Details

Name: us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of tax expense (benefit) allocated to other comprehensive income (loss).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 20
-Section 45
-Paragraph 11
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109238882&loc=d3e39076-109324

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 20
-Section 45
-Paragraph 2
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=109238882&loc=d3e38679-109324

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=118930883&loc=d3e640-108580
+ Details

Name: us-gaap_OtherComprehensiveIncomeLossTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_StatementOperatingActivitiesSegmentAxis=us-gaap_SegmentContinuingOperationsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementOperatingActivitiesSegmentAxis=us-gaap_SegmentDiscontinuedOperationsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 72 R33.htm IDEA: XBRL DOCUMENT v3.19.3

Financial Instruments (Policies)
12 Months Ended

Dec. 31, 2018

Derivative Instruments and Hedging Activities Disclosure [Abstract]

Concentration Risk, Credit Risk
Financial instruments that potentially subject us to credit risk consist principally of trade receivables and interest-bearing investments. Wholesale distributors of life-science products account for a substantial portion of our trade receivables; collateral is generally not required. We seek to mitigate the risk associated with this concentration through our ongoing credit-review procedures and insurance. A large portion of our cash is held by a few major financial institutions. We monitor our exposures with these institutions and do not expect any of these institutions to fail to meet their obligations. Major financial institutions represent the largest component of our investments in corporate debt securities. In accordance with documented corporate risk-management policies, we monitor the amount of credit exposure to any one financial institution or corporate issuer. We are exposed to credit-related losses in the event of nonperformance by counterparties to risk-management instruments but do not expect any counterparties to fail to meet their obligations given their high credit ratings.

Investment
We consider all highly liquid investments with a maturity of three months or less from the date of purchase to be cash equivalents. The cost of these investments approximates fair value.
Our equity investments are accounted for using three different methods depending on the type of equity investment:
•
Investments in companies over which we have significant influence but not a controlling interest are accounted for using the equity method, with our share of earnings or losses reported in other-net, (income) expense.
•
For equity investments that do not have readily determinable fair values, we measure these investments at cost, less any impairment, plus or minus changes resulting from observable price changes in orderly transactions for the identical or similar investment of the same issuer. Any change in recorded value is recorded in other-net, (income) expense.
•
Our public equity investments are measured and carried at fair value. Any change in fair value is recognized in other-net, (income) expense.
We review equity investments other than public equity investments for indications of impairment on a regular basis.

Derivatives
In the normal course of business, our operations are exposed to fluctuations in interest rates which can vary the costs of financing, investing, and operating. We seek to address a portion of these risks through a controlled program of risk management that includes the use of derivative financial instruments. The objective of controlling these risks is to limit the impact of fluctuations in interest rates on earnings. Our primary interest-rate risk exposure results from changes in short-term U.S. dollar interest rates. In an effort to manage interest-rate exposures, we strive to achieve an acceptable balance between fixed- and floating-rate debt and investment positions and may enter into interest rate swaps or collars to help maintain that balance.
Interest rate swaps or collars that convert our fixed-rate debt to a floating rate are designated as fair value hedges of the underlying instruments. Interest rate swaps or collars that convert floating-rate debt to a fixed rate are designated as cash flow hedges. Interest expense on the debt is adjusted to include the payments made or received under the swap agreements. Cash proceeds from or payments to counterparties resulting from the termination of interest rate swaps are classified as operating activities in our consolidated statements of cash flows.
We may enter into forward contracts and designate them as cash flow hedges to limit the potential volatility of earnings and cash flow associated with forecasted sales of available-for-sale securities.
We also may enter into forward-starting interest rate swaps, which we designate as cash flow hedges, as part of any anticipated future debt issuances in order to reduce the risk of cash flow volatility from future changes in interest rates. Upon completion of a debt issuance and termination of the swap, the change in fair value of these instruments is recorded as part of other comprehensive income (loss) and is amortized to interest expense over the life of the underlying debt.
Our derivative activities are initiated within the guidelines of documented corporate risk-management policies and are intended to offset losses and gains on the assets, liabilities, and transactions being hedged. Management reviews the correlation and effectiveness of our derivatives on a quarterly basis.
For derivative instruments that are designated and qualify as fair value hedges, the derivative instrument is marked to market with gains and losses recognized currently in income to offset the respective losses and gains recognized on the underlying exposure. For derivative instruments that are designated and qualify as cash flow hedges, gains and losses are reported as a component of accumulated other comprehensive loss and reclassified into earnings in the same period the hedged transaction affects earnings. For derivative and non-derivative instruments that are designated and qualify as net investment hedges, the foreign currency translation gains or losses due to spot rate fluctuations are reported as a component of accumulated other comprehensive loss. Derivative contracts that are not designated as hedging instruments are recorded at fair value with the gain or loss recognized in earnings during the period of change.
We may enter into foreign currency forward or option contracts to reduce the effect of fluctuating currency exchange rates (principally the euro, British pound, and the Japanese yen). Foreign currency derivatives used for hedging are put in place using the same or like currencies and duration as the underlying exposures. Forward and option contracts are principally used to manage exposures arising from subsidiary trade and loan payables and receivables denominated in foreign currencies. These contracts are recorded at fair value with the gain or loss recognized in other–net, (income) expense. We may enter into foreign currency forward and option contracts and currency swaps as fair value hedges of firm commitments.

X

- Definition
Disclosure of accounting policy for credit risk.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 825
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=108315417&loc=d3e61044-112788
+ Details

Name: us-gaap_ConcentrationRiskCreditRisk

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for its derivative instruments and hedging activities.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109980867&loc=d3e41620-113959

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=109980867&loc=d3e41638-113959

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 1A
-URI http://asc.fasb.org/extlink&oid=109980867&loc=SL5579245-113959

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=109980867&loc=d3e41675-113959

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(n))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=109980867&loc=SL5579240-113959
+ Details

Name: us-gaap_DerivativesPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for investment in financial asset.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (a)(2)
-URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571
+ Details

Name: us-gaap_InvestmentPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 73 R52.htm IDEA: XBRL DOCUMENT v3.19.3

Other Comprehensive Income (Loss) (Tables)
12 Months Ended

Dec. 31, 2018

Equity [Abstract]

Schedule of Amounts Recognized in Other Comprehensive Income (Loss)
Details about Accumulated Other
Comprehensive Loss Components
Year Ended December 31,
Affected Line Item in the Consolidated Statements of Operations
2018

2017

2016
Amortization of retirement benefit items:

Prior service benefits, net
$
(74.9
)

$
(84.4
)

$
(74.1
)
Other—net, (income) expense
Actuarial losses
338.6

305.2

304.7

Other—net, (income) expense
Total before tax
263.7

220.8

230.6

Tax benefit
(55.8
)

(68.9
)

(71.5
)
Income taxes
Net of tax
207.9

151.9

159.1

Unrealized gains/losses on available-for-sale securities:

Realized gains, net
(39.5
)

(170.2
)

(16.1
)
Other—net, (income) expense
Impairment losses
—

—

27.3

Other—net, (income) expense
Total before tax
(39.5
)

(170.2
)

11.2

Tax (benefit) expense
8.3

59.6

(4.0
)
Income taxes
Net of tax
(31.2
)

(110.6
)

7.2

Other, net of tax⁽¹⁾
13.8

19.2

84.4

Other—net, (income) expense
Total reclassifications for the period (net of tax)
$
190.5

$
60.5

$
250.7

⁽¹⁾Amount for year ended December 31, 2016 included primarily $74.5 million of foreign currency translation losses.

Schedule of Accumulated Other Comprehensive Income (Loss)
The following table summarizes the activity related to each component of other comprehensive income (loss):

Continuing Operations

(Amounts presented net of taxes)
Foreign Currency Translation Gains (Losses)

Unrealized Net Gains (Losses) on Securities

Defined Benefit Pension and Retiree Health Benefit Plans

Effective Portion of Cash Flow Hedges

Discontinued Operations

Accumulated Other Comprehensive Loss
Beginning balance at January 1, 2016
$
(1,315.9
)

$
10.1

$
(2,996.8
)

$
(218.5
)

$
(59.6
)

$
(4,580.7
)

Other comprehensive income (loss) before reclassifications
(445.2
)

206.7

(514.3
)

(2.2
)

(140.8
)

(895.8
)
Net amount reclassified from accumulated other comprehensive loss
74.5

7.2

159.1

9.8

0.1

250.7

Net other comprehensive income (loss)
(370.7
)

213.9

(355.2
)

7.6

(140.7
)

(645.1
)

Balance at December 31, 2016⁽¹⁾
(1,686.6
)

224.0

(3,352.0
)

(210.9
)

(200.3
)

(5,225.8
)

Other comprehensive income (loss) before reclassifications
525.6

(15.7
)

(532.1
)

8.5

127.7

114.0

Net amount reclassified from accumulated other comprehensive loss
8.1

(110.6
)

151.9

9.6

1.5

60.5

Net other comprehensive income (loss)
533.7

(126.3
)

(380.2
)

18.1

129.2

174.5

Reclassifications of stranded tax effects (Note 2)
(38.8
)

15.8

(579.1
)

(41.5
)

—

(643.6
)

Balance at December 31, 2017⁽²⁾
(1,191.7
)

113.5

(4,311.3
)

(234.3
)

(71.1
)

(5,694.9
)

Reclassification due to adoption of new accounting standard⁽³⁾
—

(128.9
)

—

—

—

(128.9
)
Other comprehensive income (loss) before reclassifications
(378.0
)

24.5

250.7

(16.3
)

12.2

(106.9
)
Net amount reclassified from accumulated other comprehensive loss
—

(31.2
)

207.9

11.7

2.1

190.5

Net other comprehensive income (loss)
(378.0
)

(6.7
)

458.6

(4.6
)

14.3

83.6

Ending balance at December 31, 2018⁽⁴⁾
$
(1,569.7
)

$
(22.1
)

$
(3,852.7
)

$
(238.9
)

$
(56.8
)

$
(5,740.2
)

⁽¹⁾Accumulated other comprehensive loss as of December 31, 2016 consists of $5.27 billion of accumulated other comprehensive loss attributable to controlling interest and $48.2 million of accumulated other comprehensive income attributable to noncontrolling interest.
⁽²⁾Accumulated other comprehensive loss as of December 31, 2017 consists of $5.72 billion of accumulated other comprehensive loss attributable to controlling interest and $23.7 million of accumulated other comprehensive income attributable to noncontrolling interest.
⁽³⁾This reclassification consists of $105.2 million of accumulated other comprehensive loss attributable to controlling interest and $23.7 million of accumulated other comprehensive loss attributable to noncontrolling interest. Refer to Note 2 for further details regarding the reclassification due to the adoption of Accounting Standards Update 2016-01, Financial Instruments - Overall: Recognition and Measurement of Financial Assets and Financial Liabilities.
⁽⁴⁾Accumulated other comprehensive loss as of December 31, 2018 consists of $5.73 billion of accumulated other comprehensive loss attributable to controlling interest and $11.0 million of accumulated other comprehensive loss attributable to noncontrolling interest.
The tax effects on the net activity related to each component of other comprehensive income (loss) for the years ended December 31, were as follows:
Tax benefit (expense)
2018

2017

2016
Foreign currency translation gains/losses
$
51.6

$
170.8

$
(70.6
)
Unrealized net gains/losses on securities
2.1

55.0

(89.2
)
Defined benefit pension and retiree health benefit plans
(85.3
)

186.6

153.3

Effective portion of cash flow hedges
1.3

(9.7
)

(4.1
)
Benefit/(provision) for income taxes allocated to other comprehensive income (loss) items
$
(30.3
)

$
402.7

$
(10.6
)

X

- References
No definition available.
+ Details

Name: us-gaap_EquityAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of information about items reclassified out of accumulated other comprehensive income (loss).
+ References
No definition available.
+ Details

Name: us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of the components of accumulated other comprehensive income (loss).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 14A
-URI http://asc.fasb.org/extlink&oid=118930883&loc=SL7669686-108580
+ Details

Name: us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 74 R56.htm IDEA: XBRL DOCUMENT v3.19.3

Discontinued Operations (Tables)
12 Months Ended

Dec. 31, 2018

Discontinued Operations and Disposal Groups [Abstract]

Disposal Groups, Including Discontinued Operations
The following table sets forth details of revenue and net income (loss) from discontinued operations:

2018

2017

2016
Revenue from discontinued operations
$
3,062.4

$
2,897.5

$
2,909.3

Net income (loss) from discontinued operations
81.4

(117.7
)

12.7

The following table presents the major classes of assets and liabilities from discontinued operations at December 31:

2018

2017
Inventories
$
1,013.7

$
1,062.3

Other current assets
1,215.4

1,047.7

Current assets of discontinued operations
$
2,229.1

$
2,110.0

Goodwill
$
2,980.9

$
2,992.1

Other intangibles, net
2,453.0

2,674.8

Property and equipment, net
923.4

941.4

Other assets
126.8

60.4

Noncurrent assets of discontinued operations
$
6,484.1

$
6,668.7

Current liabilities of discontinued operations
$
692.8

$
637.5

Long-term debt
$
2,443.3

$
0.5

Other liabilities
299.0

351.1

Noncurrent liabilities of discontinued operations
$
2,742.3

$
351.6

X

- References
No definition available.
+ Details

Name: us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of information related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 3A
-URI http://asc.fasb.org/extlink&oid=109226691&loc=SL51724579-110230

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=109222650&loc=d3e1474-107760

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5D
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721677-107760

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 45
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=109222160&loc=SL51721533-107759

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 3A
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721659-107760

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 4B
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721665-107760

Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230

Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5C
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760

Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760

Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760

Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5A
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721671-107760

Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5B
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760

Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 4A
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721663-107760
+ Details

Name: us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 75 R85.htm IDEA: XBRL DOCUMENT v3.19.3

Income Taxes (Unrecognized benefits) (Details) - USD ($)
$ in Millions
12 Months Ended

Dec. 31, 2018

Dec. 31, 2017

Dec. 31, 2016

Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]

Unrecognized Tax Benefits $ 1,000.8 $ 843.3 $ 1,057.2

Additions based on tax positions related to the current year 798.2 133.8 73.4

Additions for tax positions of prior years 410.9 93.8 11.0

Reductions for tax positions of prior years (115.4) (59.3) (12.1)

Settlements (33.2) (2.4) (171.9)

Lapses of statutes of limitation (20.5) (19.3) (110.0)

Changes related to the impact of foreign currency translation, increase 10.9

Changes related to the impact of foreign currency translation, decrease (6.2) (4.3)

Unrecognized Tax Benefits $ 2,034.6 $ 1,000.8 $ 843.3

X

- Definition
A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.
+ References
No definition available.
+ Details

Name: us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of unrecognized tax benefits.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 45
-Paragraph 10B
-URI http://asc.fasb.org/extlink&oid=116821951&loc=SL37586934-109318

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 15A
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319
+ Details

Name: us-gaap_UnrecognizedTaxBenefits

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of decrease in unrecognized tax benefits resulting from foreign currency translation.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 15A
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319
+ Details

Name: us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromForeignCurrencyTranslation

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of decrease in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 15A
-Subparagraph (a)(1)
-URI http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319
+ Details

Name: us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of decrease in unrecognized tax benefits resulting from settlements with taxing authorities.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 15A
-Subparagraph (a)(3)
-URI http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319
+ Details

Name: us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 15A
-Subparagraph (a)(2)
-URI http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319
+ Details

Name: us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of increase in unrecognized tax benefits resulting from foreign currency translation.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 15A
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319
+ Details

Name: us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromForeignCurrencyTranslation

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 15A
-Subparagraph (a)(1)
-URI http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319
+ Details

Name: us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of decrease in unrecognized tax benefits resulting from lapses of applicable statutes of limitations.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 15A
-Subparagraph (a)(4)
-URI http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319
+ Details

Name: us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

XML 76 R75.htm IDEA: XBRL DOCUMENT v3.19.3

Goodwill and Other Intangibles (Amortization Expense) (Details)
$ in Millions

Dec. 31, 2018

USD ($)

Goodwill and Intangible Assets Disclosure [Abstract]

2019 $ 145.4

2020 144.0

2021 141.6

2022 133.8

2023 $ 122.6

X

- Definition
Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph (a)(3)
-URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275
+ Details

Name: us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph (a)(3)
-URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275
+ Details

Name: us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph (a)(3)
-URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275
+ Details

Name: us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph (a)(3)
-URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275
+ Details

Name: us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph (a)(3)
-URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275
+ Details

Name: us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 77 R71.htm IDEA: XBRL DOCUMENT v3.19.3

Financial Instruments (Investment Portfolio Activity) (Details) - USD ($)
$ in Millions
12 Months Ended

Dec. 31, 2018

Dec. 31, 2017

Dec. 31, 2016

Derivative Instruments and Hedging Activities Disclosure [Abstract]

Proceeds from sales $ 5,668.0 $ 5,769.3 $ 3,240.5

Realized gross gains on sales 11.8 176.0 30.7

Realized gross losses on sales $ 51.3 $ 5.8 $ 14.6

X

- Definition
Available for Sale Securities and Equity Securities, FV-NI, Realized Gain
+ References
No definition available.
+ Details

Name: lly_AvailableforSaleSecuritiesandEquitySecuritiesFVNIRealizedGain

Namespace Prefix: lly_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Available for sale Securities and Equity Securities, FV-NI, Realized Loss
+ References
No definition available.
+ Details

Name: lly_AvailableforsaleSecuritiesandEquitySecuritiesFVNIRealizedLoss

Namespace Prefix: lly_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Proceeds from Sale of Equity and Available for Sale Securities
+ References
No definition available.
+ Details

Name: lly_ProceedsfromSaleofEquityandAvailableforSaleSecurities

Namespace Prefix: lly_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 78 R81.htm IDEA: XBRL DOCUMENT v3.19.3

Shareholders' Equity (Details) - USD ($)
$ in Millions
12 Months Ended

Dec. 31, 2018

Dec. 31, 2017

Dec. 31, 2016

Oct. 31, 2013

Statement [Line Items]

Purchase for treasury $ 4,150.0 $ 359.8 $ 540.1

Purchases of common stock $ 60.0

Preferred stock, shares authorized (in shares) 5,000,000.0

Shares issued (in shares) 0 0

Shares held in employee trust (in shares) 50,000,000.0 50,000,000

Employee benefit trust $ 3,013.2 $ 3,013.2

2013 Share Repurchase Program

Statement [Line Items]

Purchase for treasury 2,050.0

Stock repurchase program, authorized amount $ 5,000.0

2018 Repurchase Program

Statement [Line Items]

Purchase for treasury 2,100.0

Stock repurchase program, authorized amount 8,000.0

Remaining authorized repurchase amount $ 5,900.0

X

- Definition
Payments For Repurchase Of Common Stock In Next Twelve Months
+ References
No definition available.
+ Details

Name: lly_PaymentsForRepurchaseOfCommonStockInNextTwelveMonths

Namespace Prefix: lly_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_ClassOfStockLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Value of common stock issued to a trust (for example, but not limited to, rabbi trust) set up specifically to accumulate stock for the sole purpose of distribution to participating employees.
+ References
No definition available.
+ Details

Name: us-gaap_CommonStockSharesHeldInEmployeeTrust

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Number of common stock held in a trust that has been set up specifically to accumulate stock for the sole purpose of distribution to participating employees but not yet earned.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 40
-Section 25
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=109244457&loc=d3e16701-113920
+ Details

Name: us-gaap_CommonStockSharesHeldInEmployeeTrustShares

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_PreferredStockSharesAuthorized

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_PreferredStockSharesIssued

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Amount of stock repurchase plan authorized.
+ References
No definition available.
+ Details

Name: us-gaap_StockRepurchaseProgramAuthorizedAmount1

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount remaining of a stock repurchase plan authorized.
+ References
No definition available.
+ Details

Name: us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 30
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6405813&loc=d3e23239-112655

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770
+ Details

Name: us-gaap_TreasuryStockValueAcquiredCostMethod

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_ShareRepurchaseProgramAxis=lly_A2013ShareRepurchaseProgramMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ShareRepurchaseProgramAxis=lly_A2018RepurchaseProgramMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 79 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 80 R79.htm IDEA: XBRL DOCUMENT v3.19.3

Borrowings (Debt maturities) (Details)
$ in Millions

Dec. 31, 2018

USD ($)

Debt Disclosure [Abstract]

2019 $ 604.5

2020 3.5

2021 2.3

2022 1,439.0

2023 $ 0.3

X

- References
No definition available.
+ Details

Name: us-gaap_DebtDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing in the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 3
-Subparagraph (SX 210.12-04.(a))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e24072-122690

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6802200&loc=d3e1835-112601
+ Details

Name: us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing in the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 3
-Subparagraph (SX 210.12-04.(a))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e24072-122690

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6802200&loc=d3e1835-112601
+ Details

Name: us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing in the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 3
-Subparagraph (SX 210.12-04.(a))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e24072-122690

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6802200&loc=d3e1835-112601
+ Details

Name: us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing in the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 3
-Subparagraph (SX 210.12-04.(a))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e24072-122690

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6802200&loc=d3e1835-112601
+ Details

Name: us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 3
-Subparagraph (SX 210.12-04.(a))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e24072-122690

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6802200&loc=d3e1835-112601
+ Details

Name: us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

XML 81 R89.htm IDEA: XBRL DOCUMENT v3.19.3

Retirement Benefits (Schedule of Weighted Average Assumptions) (Details)
12 Months Ended

Dec. 31, 2018

Dec. 31, 2017

Dec. 31, 2016

Defined Benefit Pension Plans

Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items] [Line Items]

Discount rate for benefit obligation (in percentage) 4.00% 3.40% 3.90%

Discount rate for net benefit costs (in percentage) 3.40% 3.90% 4.30%

Rate of compensation increase for benefit obligation (in percentage) 3.40% 3.40% 3.40%

Rate of compensation increase for net benefit costs (in percentage) 3.40% 3.40% 3.40%

Expected return on plan assets for net benefit costs (in percentage) 7.40% 7.40% 7.40%

Retiree Health Benefit Plans

Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items] [Line Items]

Discount rate for benefit obligation (in percentage) 4.40% 3.70% 4.30%

Discount rate for net benefit costs (in percentage) 3.70% 4.30% 4.50%

Expected return on plan assets for net benefit costs (in percentage) 8.00% 8.00% 8.00%

X

- Definition
Weighted average rate for present value of future retirement benefits cash flows, used to determine benefit obligation of defined benefit plan.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (k)(1)
-URI http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920
+ Details

Name: us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: instant

X

- Definition
Weighted average rate increase of compensation, used to determine benefit obligation of defined benefit plan. Plan includes, but is not limited to, pay-related defined benefit plan.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (k)(2)
-URI http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920
+ Details

Name: us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: instant

X

- Definition
Weighted average rate for present value of future retirement benefits cash flows, used to determine net periodic benefit cost of defined benefit plan.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (k)(1)
-URI http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920
+ Details

Name: us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
Weighted average rate of return on plan assets, reflecting average rate of earnings expected on existing plan assets and expected contributions, used to determine net periodic benefit cost of defined benefit plan.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (k)(3)
-URI http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920
+ Details

Name: us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
Weighted average rate of compensation increase used to determine net periodic benefit cost of defined benefit plan. Plan includes, but is not limited to, pay-related defined benefit plan.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (k)(2)
-URI http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920
+ Details

Name: us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_RetirementPlanTypeAxis=us-gaap_DefinedBenefitPostretirementHealthCoverageMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 82 R47.htm IDEA: XBRL DOCUMENT v3.19.3

Property and Equipment (Tables)
12 Months Ended

Dec. 31, 2018

Property, Plant and Equipment [Abstract]

Property, Plant and Equipment
At December 31, property and equipment consisted of the following:

2018

2017
Land
$
165.5

$
167.7

Buildings
7,116.6

6,826.9

Equipment
7,792.3

7,684.1

Construction in progress
1,588.6

1,600.6

16,663.0

16,279.3

Less accumulated depreciation
(8,666.9
)

(8,394.2
)
Property and equipment, net
$
7,996.1

$
7,885.1

Schedule of Rent Expense
Depreciation expense related to property and equipment and rental expense for all leases, including contingent rentals (not material), was as follows:

2018

2017

2016
Depreciation expense
$
797.1

$
681.7

$
638.8

Rental expense
175.7

177.4

179.2

Schedule of Future Minimum Rental Payments for Operating Leases
The future minimum rental commitments under non-cancelable operating leases are as follows:

2019

2020

2021

2022

2023

After 2023
Lease commitments
$
130.6

$
107.9

$
75.5

$
64.7

$
49.9

$
281.0

X

- References
No definition available.
+ Details

Name: us-gaap_PropertyPlantAndEquipmentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(13))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229
+ Details

Name: us-gaap_PropertyPlantAndEquipmentTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of future minimum payments required in the aggregate and for each of the five succeeding fiscal years for operating leases having initial or remaining noncancelable lease terms in excess of one year and the total minimum rentals to be received in the future under noncancelable subleases as of the balance sheet date.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 840
-SubTopic 20
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=77902758&loc=d3e41502-112717
+ Details

Name: us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of rental expense from operating leases for each period for which an income statement is presented with separate amounts for minimum rentals, contingent rentals, and sublease rentals. Rental payments under leases with terms of a month or less that were not renewed need not be included.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 840
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=77902758&loc=d3e41499-112717
+ Details

Name: us-gaap_ScheduleOfRentExpenseTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 83 R43.htm IDEA: XBRL DOCUMENT v3.19.3

Asset Impairment, Restructuring, and Other Special Charges (Tables)
12 Months Ended

Dec. 31, 2018

Restructuring and Related Activities [Abstract]

Schedule of Other Operating Cost and Expense, by Component
The components of the charges included in asset impairment, restructuring, and other special charges in our consolidated statements of operations are described below:

2018

2017

2016
Severance
$
127.8

$
601.0

$
85.9

Pension and post-retirement medical charges associated with U.S. voluntary early retirement program (see Note 14)
—

446.7

—

Asset impairment (gains from facility sales) and other special charges
139.1

283.9

(13.0
)
Total asset impairment, restructuring, and other special charges
$
266.9

$
1,331.6

$
72.9

X

- References
No definition available.
+ Details

Name: us-gaap_RestructuringAndRelatedActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of costs incurred for restructuring including, but not limited to, exit and disposal activities, remediation, implementation, integration, asset impairment, and charges against earnings from the write-down of assets.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 420
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB TOPIC 5.P.3)
-URI http://asc.fasb.org/extlink&oid=115931487&loc=d3e140864-122747

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 420
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 420
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB TOPIC 5.P.4)
-URI http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747
+ Details

Name: us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 84 R98.htm IDEA: XBRL DOCUMENT v3.19.3

Segment Information (Details)
$ in Millions
3 Months Ended 12 Months Ended

Dec. 31, 2018

USD ($)

Sep. 30, 2018

USD ($)

Jun. 30, 2018

USD ($)

Mar. 31, 2018

USD ($)

Dec. 31, 2017

USD ($)

Sep. 30, 2017

USD ($)

Jun. 30, 2017

USD ($)

Mar. 31, 2017

USD ($)

Dec. 31, 2018

USD ($)

wholesaler

segment

Dec. 31, 2017

USD ($)

Dec. 31, 2016

USD ($)

Mar. 11, 2019

Segment Reporting Information [Line Items]

Number of operating segments | segment 1

Number of wholesalers | wholesaler 3

Revenue $ 5,637.6 $ 5,306.9 $ 5,585.0 $ 4,963.8 $ 5,406.4 $ 4,961.0 $ 5,091.6 $ 4,514.9 $ 21,493.3 $ 19,973.8 $ 18,312.8

Long-lived assets 8,546.2 8,481.0 8,546.2 8,481.0 8,167.0

United States

Segment Reporting Information [Line Items]

Revenue 12,391.9 11,414.4 10,147.0

Long-lived assets 4,344.0 4,408.7 4,344.0 4,408.7 4,520.8

Outside U.S.

Segment Reporting Information [Line Items]

Revenue 9,101.4 8,559.4 8,165.8

Europe

Segment Reporting Information [Line Items]

Revenue 3,663.1 3,390.6 3,214.4

Long-lived assets 2,413.5 2,246.4 2,413.5 2,246.4 1,864.8

JAPAN

Segment Reporting Information [Line Items]

Revenue 2,407.4 2,339.5 2,253.0

Long-lived assets 180.2 153.4 180.2 153.4 91.0

Other foreign countries

Segment Reporting Information [Line Items]

Revenue 3,030.9 2,829.3 2,698.3

Long-lived assets $ 1,608.5 $ 1,672.5 1,608.5 1,672.5 1,690.4

Endocrinology | Human pharmaceutical products | United States

Segment Reporting Information [Line Items]

Revenue 7,511.6 6,373.0 4,831.9

Endocrinology | Human pharmaceutical products | Outside U.S.

Segment Reporting Information [Line Items]

Revenue 4,190.5 3,712.2 3,250.9

Trulicity | Human pharmaceutical products | United States

Segment Reporting Information [Line Items]

Revenue 2,515.8 1,609.8 737.6

Trulicity | Human pharmaceutical products | Outside U.S.

Segment Reporting Information [Line Items]

Revenue 683.3 419.9 187.9

Humalog | Human pharmaceutical products | United States

Segment Reporting Information [Line Items]

Revenue 1,787.8 1,717.8 1,685.2

Humalog | Human pharmaceutical products | Outside U.S.

Segment Reporting Information [Line Items]

Revenue 1,208.7 1,147.4 1,083.6

Humulin | Human pharmaceutical products | United States

Segment Reporting Information [Line Items]

Revenue 910.2 884.6 861.8

Humulin | Human pharmaceutical products | Outside U.S.

Segment Reporting Information [Line Items]

Revenue 421.2 450.7 504.1

Forteo | Human pharmaceutical products | United States

Segment Reporting Information [Line Items]

Revenue 757.9 965.2 770.5

Forteo | Human pharmaceutical products | Outside U.S.

Segment Reporting Information [Line Items]

Revenue 817.7 783.8 729.4

Basaglar

Segment Reporting Information [Line Items]

Revenue 801.2 432.1 86.1

Basaglar | Human pharmaceutical products | United States

Segment Reporting Information [Line Items]

Revenue 622.8 311.1 15.8

Basaglar | Human pharmaceutical products | Outside U.S.

Segment Reporting Information [Line Items]

Revenue 178.5 121.0 70.3

Jardiance

Segment Reporting Information [Line Items]

Revenue 658.3 447.5 201.9

Jardiance | Human pharmaceutical products | United States

Segment Reporting Information [Line Items]

Revenue 400.2 290.4 144.5

Jardiance | Human pharmaceutical products | Outside U.S.

Segment Reporting Information [Line Items]

Revenue 258.1 157.0 57.4

Trajenta

Segment Reporting Information [Line Items]

Revenue 574.7 537.9 436.6

Trajenta | Human pharmaceutical products | United States

Segment Reporting Information [Line Items]

Revenue 224.2 213.2 165.9

Trajenta | Human pharmaceutical products | Outside U.S.

Segment Reporting Information [Line Items]

Revenue 350.5 324.7 270.7

Other Endocrinology | Human pharmaceutical products | United States

Segment Reporting Information [Line Items]

Revenue 292.7 380.9 450.6

Other Endocrinology | Human pharmaceutical products | Outside U.S.

Segment Reporting Information [Line Items]

Revenue 272.5 307.7 347.5

Oncology: | Human pharmaceutical products | United States

Segment Reporting Information [Line Items]

Revenue 2,403.2 2,050.4 1,975.1

Oncology: | Human pharmaceutical products | Outside U.S.

Segment Reporting Information [Line Items]

Revenue 1,857.3 1,761.6 1,746.8

Alimta | Human pharmaceutical products | United States

Segment Reporting Information [Line Items]

Revenue 1,131.0 1,034.3 1,101.0

Alimta | Human pharmaceutical products | Outside U.S.

Segment Reporting Information [Line Items]

Revenue 1,001.9 1,028.2 1,182.3

Erbitux

Segment Reporting Information [Line Items]

Revenue 635.3 645.9 687.0

Erbitux | Human pharmaceutical products | United States

Segment Reporting Information [Line Items]

Revenue 531.6 541.7 581.1

Erbitux | Human pharmaceutical products | Outside U.S.

Segment Reporting Information [Line Items]

Revenue 103.8 104.2 105.9

Cyramza® | Human pharmaceutical products | United States

Segment Reporting Information [Line Items]

Revenue 291.5 278.8 270.1

Cyramza® | Human pharmaceutical products | Outside U.S.

Segment Reporting Information [Line Items]

Revenue 529.9 479.6 344.0

Other Oncology | Human pharmaceutical products | United States

Segment Reporting Information [Line Items]

Revenue 449.1 195.6 22.9

Other Oncology | Human pharmaceutical products | Outside U.S.

Segment Reporting Information [Line Items]

Revenue 221.7 149.6 114.6

Cardiovascular: | Human pharmaceutical products | United States

Segment Reporting Information [Line Items]

Revenue 1,355.7 1,722.7 1,991.4

Cardiovascular: | Human pharmaceutical products | Outside U.S.

Segment Reporting Information [Line Items]

Revenue 898.6 1,148.5 1,234.0

Cialis | Human pharmaceutical products | United States

Segment Reporting Information [Line Items]

Revenue 1,129.2 1,358.6 1,469.5

Cialis | Human pharmaceutical products | Outside U.S.

Segment Reporting Information [Line Items]

Revenue 722.7 964.5 1,002.1

Effient | Human pharmaceutical products

Segment Reporting Information [Line Items]

Revenue 122.2 388.9 535.2

Effient | Human pharmaceutical products | United States

Segment Reporting Information [Line Items]

Revenue 68.1 340.1 465.6

Effient | Human pharmaceutical products | Outside U.S.

Segment Reporting Information [Line Items]

Revenue 54.1 48.8 69.6

Other Cardiovascular | Human pharmaceutical products | United States

Segment Reporting Information [Line Items]

Revenue 158.4 24.0 56.3

Other Cardiovascular | Human pharmaceutical products | Outside U.S.

Segment Reporting Information [Line Items]

Revenue 121.8 135.2 162.3

Neuroscience: | Human pharmaceutical products | United States

Segment Reporting Information [Line Items]

Revenue 277.4 591.0 989.9

Neuroscience: | Human pharmaceutical products | Outside U.S.

Segment Reporting Information [Line Items]

Revenue 1,543.3 1,580.1 1,730.4

Strattera® | Human pharmaceutical products | United States

Segment Reporting Information [Line Items]

Revenue 89.7 284.9 534.9

Strattera® | Human pharmaceutical products | Outside U.S.

Segment Reporting Information [Line Items]

Revenue 361.1 333.3 319.8

Cymbalta | Human pharmaceutical products | United States

Segment Reporting Information [Line Items]

Revenue 54.3 114.9 269.3

Cymbalta | Human pharmaceutical products | Outside U.S.

Segment Reporting Information [Line Items]

Revenue 653.7 642.2 661.2

Zyprexa® | Human pharmaceutical products | United States

Segment Reporting Information [Line Items]

Revenue 36.2 75.5 69.8

Zyprexa® | Human pharmaceutical products | Outside U.S.

Segment Reporting Information [Line Items]

Revenue 435.1 505.7 655.5

Other Neuroscience | Human pharmaceutical products | United States

Segment Reporting Information [Line Items]

Revenue 97.2 115.7 115.9

Other Neuroscience | Human pharmaceutical products | Outside U.S.

Segment Reporting Information [Line Items]

Revenue 93.4 98.9 93.9

Immunology: | Human pharmaceutical products | United States

Segment Reporting Information [Line Items]

Revenue 745.4 486.0 110.8

Immunology: | Human pharmaceutical products | Outside U.S.

Segment Reporting Information [Line Items]

Revenue 394.6 119.0 2.3

Taltz | Human pharmaceutical products | United States

Segment Reporting Information [Line Items]

Revenue 738.7 486.0 110.8

Taltz | Human pharmaceutical products | Outside U.S.

Segment Reporting Information [Line Items]

Revenue 198.7 73.2 2.3

Other Immunology | Human pharmaceutical products | United States

Segment Reporting Information [Line Items]

Revenue 6.7 0.0 0.0

Other Immunology | Human pharmaceutical products | Outside U.S.

Segment Reporting Information [Line Items]

Revenue 195.9 45.8 0.0

Other | Human pharmaceutical products | United States

Segment Reporting Information [Line Items]

Revenue 98.5 191.3 247.9

Other | Human pharmaceutical products | Outside U.S.

Segment Reporting Information [Line Items]

Revenue $ 217.0 $ 238.0 $ 201.3

Minimum | Sales Revenue, Goods, Net

Segment Reporting Information [Line Items]

Concentration risk, percentage 13.00% 14.00% 13.00%

Minimum | Accounts Receivable

Segment Reporting Information [Line Items]

Concentration risk, percentage 16.00% 16.00%

Maximum | Sales Revenue, Goods, Net

Segment Reporting Information [Line Items]

Concentration risk, percentage 21.00% 21.00% 20.00%

Maximum | Accounts Receivable

Segment Reporting Information [Line Items]

Concentration risk, percentage 25.00% 25.00%

Adjustment to Return Reserve | Cymbalta | Human pharmaceutical products

Segment Reporting Information [Line Items]

Revenue $ 175.0

Elanco Animal Health Incorporated | Discontinued Operations, Disposed of by Sale

Segment Reporting Information [Line Items]

Noncontrolling interest, ownership percentage by parent 80.20%

Revenue $ 3,062.4 $ 2,897.5 $ 2,909.3

X

- Definition
Number of Wholesalers
+ References
No definition available.
+ Details

Name: lly_NumberofWholesalers

Namespace Prefix: lly_

Data Type: xbrli:integerItemType

Balance Type: na

Period Type: duration

X

- Definition
For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 18
-URI http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 20
-URI http://asc.fasb.org/extlink&oid=118260190&loc=d3e13531-108611

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 21
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118260190&loc=d3e13537-108611

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 20
-URI http://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592
+ Details

Name: us-gaap_ConcentrationRiskPercentage1

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
The parent entity's interest in net assets of the subsidiary, expressed as a percentage.
+ References
No definition available.
+ Details

Name: us-gaap_MinorityInterestOwnershipPercentageByParent

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: instant

X

- Definition
Long-lived assets other than financial instruments, long-term customer relationships of a financial institution, mortgage and other servicing rights, deferred policy acquisition costs, and deferred tax assets.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 41
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e9038-108599
+ Details

Name: us-gaap_NoncurrentAssets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.
+ References
No definition available.
+ Details

Name: us-gaap_NumberOfOperatingSegments

Namespace Prefix: us-gaap_

Data Type: xbrli:integerItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8933-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(1))
-URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227
+ Details

Name: us-gaap_Revenues

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_SegmentReportingInformationLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Details

Name: srt_StatementGeographicalAxis=country_US

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_StatementGeographicalAxis=lly_InternationalMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_StatementGeographicalAxis=srt_EuropeMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_StatementGeographicalAxis=country_JP

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_StatementGeographicalAxis=lly_OtherForeignCountriesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_ProductOrServiceAxis=lly_EndocrinologyMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementBusinessSegmentsAxis=lly_HumanPharmaceuticalProductsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_ProductOrServiceAxis=lly_TrulicityMemberMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_ProductOrServiceAxis=lly_HumalogMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_ProductOrServiceAxis=lly_HumulinMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_ProductOrServiceAxis=lly_ForteoMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_ProductOrServiceAxis=lly_BasaglarMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_ProductOrServiceAxis=lly_JardianceMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_ProductOrServiceAxis=lly_TrajentaBIMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_ProductOrServiceAxis=lly_OtherEndocrinologyMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_ProductOrServiceAxis=lly_OncologyMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_ProductOrServiceAxis=lly_AlimtaMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_ProductOrServiceAxis=lly_ErbituxMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_ProductOrServiceAxis=lly_CyramzaMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_ProductOrServiceAxis=lly_OtherOncologyMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_ProductOrServiceAxis=lly_CardiovascularMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_ProductOrServiceAxis=lly_CialisMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_ProductOrServiceAxis=lly_EffientMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_ProductOrServiceAxis=lly_OtherCardiovascularMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_ProductOrServiceAxis=lly_NeuroscienceMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_ProductOrServiceAxis=lly_StratteraMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_ProductOrServiceAxis=lly_CymbaltaMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_ProductOrServiceAxis=lly_ZyprexaMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_ProductOrServiceAxis=lly_OtherNeuroscienceMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_ProductOrServiceAxis=lly_ImmunologyMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_ProductOrServiceAxis=lly_TaltzMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_ProductOrServiceAxis=lly_OtherImmunologyMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_ProductOrServiceAxis=lly_OtherPharmaceuticalsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_RangeAxis=srt_MinimumMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_RangeAxis=srt_MaximumMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_NonrecurringAdjustmentAxis=lly_AdjustmenttoReturnReserveMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=lly_ElancoAnimalHealthIncorporatedMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_DisposalGroupClassificationAxis=us-gaap_DiscontinuedOperationsDisposedOfBySaleMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 85 R68.htm IDEA: XBRL DOCUMENT v3.19.3

Financial Instruments (Short-term and Long-term Classification) (Details) - USD ($)
$ in Millions

Dec. 31, 2018

Dec. 31, 2017

Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]

Short-term commercial paper borrowings $ (498.9) $ (2,696.8)

Carrying Amount

Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]

Long-term debt, including current portion (9,799.7) (10,950.3)

Fair Value

Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]

Long-term debt, including current portion (9,989.4) (11,529.9)

Quoted Prices in Active Markets for Identical Assets (Level 1) | Fair Value

Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]

Long-term debt, including current portion 0.0 0.0

Significant Other Observable Inputs (Level 2) | Fair Value

Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]

Long-term debt, including current portion (9,989.4) (11,529.9)

Significant Unobservable Inputs (Level 3) | Fair Value

Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]

Long-term debt, including current portion 0.0 0.0

Commercial Paper | Carrying Amount

Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]

Short-term commercial paper borrowings (498.9) (2,696.8)

Commercial Paper | Fair Value

Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]

Short-term commercial paper borrowings (497.6) (2,690.6)

Commercial Paper | Quoted Prices in Active Markets for Identical Assets (Level 1) | Fair Value

Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]

Short-term commercial paper borrowings 0.0 0.0

Commercial Paper | Significant Other Observable Inputs (Level 2) | Fair Value

Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]

Short-term commercial paper borrowings (497.6) (2,690.6)

Commercial Paper | Significant Unobservable Inputs (Level 3) | Fair Value

Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]

Short-term commercial paper borrowings $ 0.0 $ 0.0

X

- Definition
Carrying value as of the balance sheet date of short-term borrowings using unsecured obligations issued by banks, corporations and other borrowers to investors. The maturities of these money market securities generally do not exceed 270 days.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(13)(2))
-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(16))
-URI http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(19)(a)(3))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_CommercialPaper

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 4
-Subparagraph (b)(3)
-URI http://asc.fasb.org/extlink&oid=109500613&loc=SL6031897-161870

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(16))
-URI http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(16))
-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(22))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_LongTermDebt

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Details

Name: us-gaap_FairValueByMeasurementBasisAxis=us-gaap_CarryingReportedAmountFairValueDisclosureMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ShortTermDebtTypeAxis=us-gaap_CommercialPaperMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 86 R90.htm IDEA: XBRL DOCUMENT v3.19.3

Retirement Benefits (Schedule of Expected Benefit Payments, Contributions and Expense) (Details) - USD ($)
$ in Millions
1 Months Ended 12 Months Ended

Jul. 31, 2018

Dec. 31, 2018

Dec. 31, 2017

Dec. 31, 2016

Defined Benefit Plan, Pension Plan with Project Benefit Obligation in Excess of Plan Assets [Abstract]

Projected benefit obligation $ 11,584.2 $ 12,773.4

Defined Benefit Plan, Plan with Accumulated Benefit Obligation in Excess of Plan Assets [Abstract]

Fair value of plan assets 8,895.6 9,542.5

Components of net periodic (benefit) cost:

Curtailment (gain) loss $ (28.0)

Other Comprehensive (Income) Loss, Defined Benefit Plan, before Reclassification Adjustment and Tax [Abstract]

Total other comprehensive income (loss) during period 544.0 (566.8) $ (508.5)

Defined Benefit Pension Plans

Defined Benefit Plan, Expected Future Benefit Payment [Abstract]

2019 604.1

2020 607.2

2021 616.5

2022 632.1

2023 641.6

2024-2028 3,524.7

Defined Benefit Plan, Plan with Accumulated Benefit Obligation in Excess of Plan Assets [Abstract]

Accumulated benefit obligation 10,837.8 11,733.6

Fair value of plan assets 8,895.6 9,517.6

Components of net periodic (benefit) cost:

Service cost 292.7 320.8 268.4

Interest cost 458.5 411.6 419.0

Expected return on plan assets (842.1) (773.6) (748.7)

Amortization of prior service (benefit) cost 4.6 5.6 11.7

Recognized actuarial loss 332.5 286.8 284.6

Curtailment (gain) loss 1.3 93.5 0.0

Special termination benefit 0.0 317.2 0.0

Net periodic (benefit) cost 247.5 661.9 235.0

Other Comprehensive (Income) Loss, Defined Benefit Plan, before Reclassification Adjustment and Tax [Abstract]

Actuarial gain (loss) arising during period 182.8 (898.1) (719.1)

Plan amendments during period (17.6) 0.0 0.0

Curtailment gain (loss) 45.2 3.2 0.0

Amortization of prior service (benefit) cost included in net income 4.6 5.6 11.7

Amortization of net actuarial loss included in net income 332.5 286.8 284.6

Foreign currency exchange rate changes and other 47.1 (108.8) 72.6

Total other comprehensive income (loss) during period 594.6 (711.3) (350.2)

Retiree Health Benefit Plans

Defined Benefit Plan, Expected Future Benefit Payment [Abstract]

2019 98.0

2020 99.1

2021 100.7

2022 99.9

2023 98.5

2024-2028 505.3

Defined Benefit Plan, Plan with Accumulated Benefit Obligation in Excess of Plan Assets [Abstract]

Accumulated benefit obligation 189.4 225.1

Fair value of plan assets 0.0 0.0

Components of net periodic (benefit) cost:

Service cost 41.5 46.4 39.1

Interest cost 57.3 52.9 53.2

Expected return on plan assets (177.9) (160.7) (150.2)

Amortization of prior service (benefit) cost (79.5) (90.0) (85.8)

Recognized actuarial loss 6.1 18.4 19.1

Curtailment (gain) loss (29.3) 65.5 0.0

Special termination benefit 0.0 37.5 0.0

Net periodic (benefit) cost (181.8) (30.0) (124.6)

Other Comprehensive (Income) Loss, Defined Benefit Plan, before Reclassification Adjustment and Tax [Abstract]

Actuarial gain (loss) arising during period 37.5 261.3 (132.2)

Plan amendments during period 14.1 0.0 35.8

Curtailment gain (loss) (31.8) (39.7) 0.0

Amortization of prior service (benefit) cost included in net income (79.5) (90.0) (85.8)

Amortization of net actuarial loss included in net income 6.1 18.4 19.1

Foreign currency exchange rate changes and other (0.1) (3.3) 2.5

Total other comprehensive income (loss) during period $ (53.7) $ 146.7 $ (160.6)

X

- Definition
Defined Benefit Plan, Net Periodic Benefit Cost (Credit), Gain (Loss) Due to Special Termination Benefits
+ References
No definition available.
+ Details

Name: lly_DefinedBenefitPlanNetPeriodicBenefitCostCreditGainLossDuetoSpecialTerminationBenefits

Namespace Prefix: lly_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of gain (loss) recognized in net periodic benefit (cost) credit of defined benefit plan.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (h)(4)
-URI http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 55
-Paragraph 17
-URI http://asc.fasb.org/extlink&oid=118257860&loc=d3e4179-114921

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 6
-Subparagraph (a)(4)
-URI http://asc.fasb.org/extlink&oid=118255775&loc=d3e2709-114920
+ Details

Name: us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of prior service cost (credit) recognized in net periodic benefit cost (credit) of defined benefit plan.
+ References
Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 55
-Paragraph 17
-URI http://asc.fasb.org/extlink&oid=118257860&loc=d3e4179-114921

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (h)(5)
-URI http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 6
-Subparagraph (a)(5)
-URI http://asc.fasb.org/extlink&oid=118255775&loc=d3e2709-114920
+ Details

Name: us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount, before tax, after reclassification adjustment, of increase (decrease) in accumulated other comprehensive income from gain (loss) of defined benefit plan.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=118930883&loc=d3e637-108580

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 10A
-Subparagraph (i)
-URI http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (i)
-URI http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920
+ Details

Name: us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_DefinedBenefitPlanEstimatedFutureBenefitPaymentsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of benefits for defined benefit plan expected to be paid in five fiscal years after fifth fiscal year following latest fiscal year.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920
+ Details

Name: us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of benefits for defined benefit plan expected to be paid in next fiscal year following latest fiscal year.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920
+ Details

Name: us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of benefits for defined benefit plan expected to be paid in fifth fiscal year following latest fiscal year.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920
+ Details

Name: us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of benefits for defined benefit plan expected to be paid in fourth fiscal year following latest fiscal year.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920
+ Details

Name: us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of benefits for defined benefit plan expected to be paid in third fiscal year following latest fiscal year.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920
+ Details

Name: us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of benefits for defined benefit plan expected to be paid in second fiscal year following latest fiscal year.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920
+ Details

Name: us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of expected return (loss) recognized in net periodic benefit (cost) credit, calculated based on expected long-term rate of return and market-related value of plan assets of defined benefit plan.
+ References
Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 55
-Paragraph 17
-URI http://asc.fasb.org/extlink&oid=118257860&loc=d3e4179-114921

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (h)(3)
-URI http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 6
-Subparagraph (a)(3)
-URI http://asc.fasb.org/extlink&oid=118255775&loc=d3e2709-114920
+ Details

Name: us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of cost recognized for passage of time related to defined benefit plan.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (h)(2)
-URI http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 55
-Paragraph 17
-URI http://asc.fasb.org/extlink&oid=118257860&loc=d3e4179-114921

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (a)(2)
-URI http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 6
-Subparagraph (a)(2)
-URI http://asc.fasb.org/extlink&oid=118255775&loc=d3e2709-114920
+ Details

Name: us-gaap_DefinedBenefitPlanInterestCost

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of net periodic benefit cost (credit) for defined benefit plan.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 6
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118255775&loc=d3e2709-114920

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 55
-Paragraph 17
-URI http://asc.fasb.org/extlink&oid=118257860&loc=d3e4179-114921

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (h)
-URI http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920
+ Details

Name: us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of accumulated benefit obligation for defined benefit plan with accumulated benefit obligation in excess of plan assets.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 3
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118255775&loc=d3e2417-114920

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 55
-Paragraph 17
-URI http://asc.fasb.org/extlink&oid=118257860&loc=d3e4179-114921

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 3
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=118255775&loc=d3e2417-114920
+ Details

Name: us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of plan asset for defined benefit plan with accumulated benefit obligation in excess of plan assets.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 3
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=118255775&loc=d3e2417-114920

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 55
-Paragraph 17
-URI http://asc.fasb.org/extlink&oid=118257860&loc=d3e4179-114921

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 3
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118255775&loc=d3e2417-114920
+ Details

Name: us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of projected benefit obligation for defined benefit pension plan with accumulated benefit obligation in excess of plan assets.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 3
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118255775&loc=d3e2417-114920

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 55
-Paragraph 17
-URI http://asc.fasb.org/extlink&oid=118257860&loc=d3e4179-114921
+ Details

Name: us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_DefinedBenefitPlanPlansWithBenefitObligationsInExcessOfPlanAssetsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of gain (loss) recognized in net periodic benefit (cost) credit from event reducing expected years of future service of present employees or eliminating accrual of defined benefits for some or all future services of present employees.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (h)(7)
-URI http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 6
-Subparagraph (a)(7)
-URI http://asc.fasb.org/extlink&oid=118255775&loc=d3e2709-114920
+ Details

Name: us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of cost for actuarial present value of benefits attributed to service rendered by employee for defined benefit plan.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (h)(1)
-URI http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 55
-Paragraph 17
-URI http://asc.fasb.org/extlink&oid=118257860&loc=d3e4179-114921

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 6
-Subparagraph (a)(1)
-URI http://asc.fasb.org/extlink&oid=118255775&loc=d3e2709-114920

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (a)(1)
-URI http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920
+ Details

Name: us-gaap_DefinedBenefitPlanServiceCost

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount, before tax, of cost (credit) of benefit change attributable to participants' prior service from plan amendment or plan initiation of defined benefit plan, that has not been recognized in net periodic benefit cost (credit).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (i)
-URI http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 10A
-Subparagraph (j)
-URI http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=118930883&loc=d3e637-108580
+ Details

Name: us-gaap_OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount, before tax, of reclassification adjustment from accumulated other comprehensive (income) loss for prior service cost (credit) of defined benefit plan.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (i)
-URI http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 17A
-URI http://asc.fasb.org/extlink&oid=118930883&loc=SL34724391-108580

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 15
-URI http://asc.fasb.org/extlink&oid=118930883&loc=d3e689-108580

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=118930883&loc=d3e637-108580
+ Details

Name: us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount, before tax, of increase (decrease) to other comprehensive income from settlement and curtailment gain (loss) of defined benefit plan.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 15
-URI http://asc.fasb.org/extlink&oid=118930883&loc=d3e689-108580

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (i)
-URI http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=118930883&loc=d3e637-108580
+ Details

Name: us-gaap_OtherComprehensiveIncomeLossFinalizationOfPensionAndNonPensionPostretirementPlanValuationBeforeTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount before tax, after reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 830
-SubTopic 20
-Section 35
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=118948100&loc=d3e30304-110892

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 10A
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 830
-SubTopic 30
-Section 45
-Paragraph 20
-Subparagraph (b,d)
-URI http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=118930883&loc=d3e637-108580
+ Details

Name: us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsAndTaxAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount, before tax, after reclassification adjustment, of (increase) decrease in accumulated other comprehensive income for defined benefit plan.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 10A
-Subparagraph (i-k)
-URI http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=118930883&loc=d3e637-108580
+ Details

Name: us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount, before tax, of gain (loss) for (increase) decrease in value of benefit obligation for change in actuarial assumptions and increase (decrease) in value of plan assets from experience different from that assumed of defined benefit plan, that has not been recognized in net periodic benefit (cost) credit.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 10A
-Subparagraph (i)
-URI http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=118930883&loc=d3e637-108580

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (i)
-URI http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920
+ Details

Name: us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Details

Name: us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_RetirementPlanTypeAxis=us-gaap_DefinedBenefitPostretirementHealthCoverageMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 87 R60.htm IDEA: XBRL DOCUMENT v3.19.3

Implementation of New Financial Accounting Pronouncements (Details) - USD ($)
$ in Millions
3 Months Ended 12 Months Ended

Dec. 31, 2018

Sep. 30, 2018

Jun. 30, 2018

Mar. 31, 2018

Dec. 31, 2017

Sep. 30, 2017

Jun. 30, 2017

Mar. 31, 2017

Dec. 31, 2018

Dec. 31, 2017

Dec. 31, 2016

Jan. 01, 2019

Jan. 01, 2018

New Accounting Pronouncement, Early Adoption [Line Items]

Retained earnings $ 11,395.9 $ 13,894.1 $ 11,395.9 $ 13,894.1

Deferred tax assets 1,301.1 1,149.0 1,301.1 1,149.0

Accumulated other comprehensive income (loss) 5,729.2 5,718.6 5,729.2 5,718.6

Other income 145.6 301.5 $ 108.8

Cost of sales $ 1,129.9 $ 1,152.9 $ 1,234.3 $ 1,164.6 1,186.4 $ 1,163.5 $ 1,140.1 $ 957.7 4,681.7 4,447.7 4,160.5

Research and development 5,051.2 5,096.2 5,040.0

Marketing, selling, and administrative $ 5,975.1 5,982.4 5,841.9

Accounting Standards Update 2016-01

New Accounting Pronouncement, Early Adoption [Line Items]

Retained earnings $ 105.0

Accumulated other comprehensive income (loss) 105.0

Accounting Standards Update 2016-16

New Accounting Pronouncement, Early Adoption [Line Items]

Retained earnings 700.0

Deferred tax assets 2,500.0

Deferred tax liabilities 1,800.0

Accounting Standards Update 2017-07

New Accounting Pronouncement, Early Adoption [Line Items]

Other income 249.0 197.1

Cost of sales 80.8 54.2

Research and development 75.8 66.4

Marketing, selling, and administrative 92.4 $ 76.5

Accounting Standards Update 2018-02

New Accounting Pronouncement, Early Adoption [Line Items]

Retained earnings 643.6 643.6

Accumulated other comprehensive income (loss) $ 643.6 $ 643.6

Accounting Standards Update 2016-02

New Accounting Pronouncement, Early Adoption [Line Items]

Effect of adopting new accounting standard $ 530.0

Operating lease, liability $ 600.0

Difference between Revenue Guidance in Effect before and after Topic 606 | Accounting Standards Update 2014-09

New Accounting Pronouncement, Early Adoption [Line Items]

Retained earnings $ 5.0

X

- Definition
Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=118930883&loc=d3e637-108580

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 14A
-URI http://asc.fasb.org/extlink&oid=118930883&loc=SL7669686-108580

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 14
-URI http://asc.fasb.org/extlink&oid=118930883&loc=d3e681-108580
+ Details

Name: us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.2(a),(d))
-URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227
+ Details

Name: us-gaap_CostOfGoodsAndServicesSold

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319
+ Details

Name: us-gaap_DeferredTaxAssetsLiabilitiesNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 45
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=116821951&loc=d3e31931-109318

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319
+ Details

Name: us-gaap_DeferredTaxLiabilities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_NewAccountingPronouncementEarlyAdoptionLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.7)
-URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227
+ Details

Name: us-gaap_NonoperatingIncomeExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Present value of lessee's discounted obligation for lease payments from operating lease.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 45
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=77888419&loc=SL77918627-209977
+ Details

Name: us-gaap_OperatingLeaseLiability

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of lessee's right to use underlying asset under operating lease.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 45
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=77888419&loc=SL77918627-209977
+ Details

Name: us-gaap_OperatingLeaseRightOfUseAsset

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 985
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 730
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373
+ Details

Name: us-gaap_ResearchAndDevelopmentExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The cumulative amount of the reporting entity's undistributed earnings or deficit.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30)(a)(3))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(23)(a)(4))
-URI http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770
+ Details

Name: us-gaap_RetainedEarningsAccumulatedDeficit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 330
-SubTopic 10
-Section 30
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=68048583&loc=d3e3636-108311

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.4)
-URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227
+ Details

Name: us-gaap_SellingGeneralAndAdministrativeExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201601Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201616Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201707Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201802Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201602Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis=us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201409Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 88 R64.htm IDEA: XBRL DOCUMENT v3.19.3

Asset Impairment, Restructuring, and Other Special Charges (Narrative) (Details) - USD ($)
$ in Millions
12 Months Ended

Dec. 31, 2018

Dec. 31, 2017

Dec. 31, 2016

Restructuring Cost and Reserve [Line Items]

Severance costs $ 127.8 $ 601.0 $ 85.9

Asset impairment charges 151.5

Impairment of intangibles 50.0

Asset impairment (gains from facility sales) and other special charges $ 139.1 283.9 $ (13.0)

United States

Restructuring Cost and Reserve [Line Items]

Severance costs 368.3

Outside US

Restructuring Cost and Reserve [Line Items]

Severance costs 232.7

PUERTO RICO

Restructuring Cost and Reserve [Line Items]

Asset impairment (gains from facility sales) and other special charges $ 43.4

X

- Definition
Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 45
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=109226348&loc=d3e2420-110228
+ Details

Name: us-gaap_AssetImpairmentCharges

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of an intangible asset (excluding goodwill) to fair value.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 3
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275
+ Details

Name: us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_RestructuringCostAndReserveLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of expenses for special or contractual termination benefits provided to current employees involuntarily terminated under a benefit arrangement associated exit or disposal activities pursuant to an authorized plan. Excludes expenses related to one-time termination benefits, a discontinued operation or an asset retirement obligation.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 420
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 5.P.3)
-URI http://asc.fasb.org/extlink&oid=115931487&loc=d3e140864-122747

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 420
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 5.P.4(b))
-URI http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 420
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585
+ Details

Name: us-gaap_SeveranceCosts1

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The charge against earnings resulting from the aggregate write down of tangible assets from their carrying value to their fair value.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109226691&loc=d3e2921-110230

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760
+ Details

Name: us-gaap_TangibleAssetImpairmentCharges

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: srt_StatementGeographicalAxis=country_US

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_StatementGeographicalAxis=lly_OutsideUnitedStatesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_StatementGeographicalAxis=country_PR

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 89 R94.htm IDEA: XBRL DOCUMENT v3.19.3

Other Comprehensive Income (Loss) (Roll-forward) (Details) - USD ($)
$ in Millions
12 Months Ended

Dec. 31, 2018

Dec. 31, 2017

Dec. 31, 2016

Jan. 01, 2018

Jan. 01, 2017

AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]

Beginning balance $ 11,667.9

Other comprehensive income (loss) before reclassifications (106.9) $ 114.0 $ (895.8)

Net amount reclassified from accumulated other comprehensive loss 190.5 60.5 250.7

Net other comprehensive income (loss) 83.6 174.5 (645.1)

Reclassifications of stranded tax effects (Note 2) (643.6)

Ending balance 10,909.1 11,667.9

Accumulated other comprehensive loss 5,729.2 5,718.6

Accumulated Other Comprehensive Loss

AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]

Beginning balance (5,694.9) (5,225.8) (4,580.7)

Reclassification due to adoption of new accounting standard(3) (128.9)

Ending balance (5,740.2) (5,694.9) (5,225.8)

Accumulated Other Comprehensive Loss

AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]

Beginning balance (5,718.6) (5,274.0) (4,580.7)

Reclassification due to adoption of new accounting standard(3) (105.2) $ (105.2) $ (643.6)

Ending balance (5,729.2) (5,718.6) (5,274.0)

Accumulated other comprehensive loss (5,730.0) 5,720.0 5,270.0

AOCI Attributable to Noncontrolling Interest

AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]

Reclassification due to adoption of new accounting standard(3) (23.7)

Accumulated other comprehensive loss 11.0 (23.7) (48.2)

Continuing Operations

AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]

Net other comprehensive income (loss) 69.3 45.3 (504.4)

Continuing Operations | Foreign Currency Translation Gains (Losses)

AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]

Beginning balance (1,191.7) (1,686.6) (1,315.9)

Reclassification due to adoption of new accounting standard(3) 0.0

Other comprehensive income (loss) before reclassifications (378.0) 525.6 (445.2)

Net amount reclassified from accumulated other comprehensive loss 0.0 8.1 74.5

Net other comprehensive income (loss) (378.0) 533.7 (370.7)

Reclassifications of stranded tax effects (Note 2) (38.8)

Ending balance (1,569.7) (1,191.7) (1,686.6)

Continuing Operations | Unrealized Net Gains (Losses) on Securities

AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]

Beginning balance 113.5 224.0 10.1

Reclassification due to adoption of new accounting standard(3) (128.9)

Other comprehensive income (loss) before reclassifications 24.5 (15.7) 206.7

Net amount reclassified from accumulated other comprehensive loss (31.2) (110.6) 7.2

Net other comprehensive income (loss) (6.7) (126.3) 213.9

Reclassifications of stranded tax effects (Note 2) 15.8

Ending balance (22.1) 113.5 224.0

Continuing Operations | Defined Benefit Pension and Retiree Health Benefit Plans

AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]

Beginning balance (4,311.3) (3,352.0) (2,996.8)

Reclassification due to adoption of new accounting standard(3) 0.0

Other comprehensive income (loss) before reclassifications 250.7 (532.1) (514.3)

Net amount reclassified from accumulated other comprehensive loss 207.9 151.9 159.1

Net other comprehensive income (loss) 458.6 (380.2) (355.2)

Reclassifications of stranded tax effects (Note 2) (579.1)

Ending balance (3,852.7) (4,311.3) (3,352.0)

Continuing Operations | Effective Portion of Cash Flow Hedges

AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]

Beginning balance (234.3) (210.9) (218.5)

Reclassification due to adoption of new accounting standard(3) 0.0

Other comprehensive income (loss) before reclassifications (16.3) 8.5 (2.2)

Net amount reclassified from accumulated other comprehensive loss 11.7 9.6 9.8

Net other comprehensive income (loss) (4.6) 18.1 7.6

Reclassifications of stranded tax effects (Note 2) (41.5)

Ending balance (238.9) (234.3) (210.9)

Discontinued Operations

AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]

Net other comprehensive income (loss) 14.3 129.2 (140.7)

Discontinued Operations | Accumulated Other Comprehensive Loss

AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]

Beginning balance (71.1) (200.3) (59.6)

Reclassification due to adoption of new accounting standard(3) 0.0

Other comprehensive income (loss) before reclassifications 12.2 127.7 (140.8)

Net amount reclassified from accumulated other comprehensive loss 2.1 1.5 0.1

Net other comprehensive income (loss) 14.3 129.2 (140.7)

Reclassifications of stranded tax effects (Note 2) 0.0

Ending balance $ (56.8) $ (71.1) $ (200.3)

X

- Definition
Tax Cuts and Jobs Act, Reclassification from AOCI to Retained Earnings, Tax Effect
+ References
No definition available.
+ Details

Name: lly_TaxCutsandJobsActReclassificationfromAOCItoRetainedEarningsTaxEffect

Namespace Prefix: lly_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=118930883&loc=d3e637-108580

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 14A
-URI http://asc.fasb.org/extlink&oid=118930883&loc=SL7669686-108580

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 14
-URI http://asc.fasb.org/extlink&oid=118930883&loc=d3e681-108580
+ Details

Name: us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount after tax of increase (decrease) to equity or (increase) decrease to net assets, resulting from the cumulative effect adjustment of a new accounting principle applied in the period of adoption.
+ References
No definition available.
+ Details

Name: us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount after tax, before reclassification adjustments of other comprehensive income (loss).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 14A
-URI http://asc.fasb.org/extlink&oid=118930883&loc=SL7669686-108580

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 55
-Paragraph 15
-URI http://asc.fasb.org/extlink&oid=118951672&loc=d3e1436-108581
+ Details

Name: us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount after tax and reclassification adjustments of other comprehensive income (loss).
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=118930883&loc=SL7669619-108580

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 55
-Paragraph 15
-URI http://asc.fasb.org/extlink&oid=118951672&loc=d3e1436-108581

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=118930883&loc=SL7669625-108580
+ Details

Name: us-gaap_OtherComprehensiveIncomeLossNetOfTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount after tax of reclassification adjustments of other comprehensive income (loss).
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 17B
-URI http://asc.fasb.org/extlink&oid=118930883&loc=SL34724394-108580

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 14A
-URI http://asc.fasb.org/extlink&oid=118930883&loc=SL7669686-108580

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 55
-Paragraph 15
-URI http://asc.fasb.org/extlink&oid=118951672&loc=d3e1436-108581
+ Details

Name: us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.
+ References
No definition available.
+ Details

Name: us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 45
-Paragraph 16
-URI http://asc.fasb.org/extlink&oid=108774443&loc=SL4568740-111683

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 55
-Paragraph 4I
-URI http://asc.fasb.org/extlink&oid=116874947&loc=SL4590271-111686

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 45
-Paragraph 15
-URI http://asc.fasb.org/extlink&oid=108774443&loc=SL4568447-111683
+ Details

Name: us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Details

Name: us-gaap_StatementEquityComponentsAxis=us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementEquityComponentsAxis=us-gaap_AociAttributableToNoncontrollingInterestMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementOperatingActivitiesSegmentAxis=us-gaap_SegmentContinuingOperationsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementOperatingActivitiesSegmentAxis=us-gaap_SegmentDiscontinuedOperationsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

JSON 90 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "a20198-kfor201810xkrec.htm ex-991xllyx20181231x10.htm": { "axisCustom": 1, "axisStandard": 40, "contextCount": 890, "dts": { "calculationLink": { "local": [ "lly-20191024_cal.xml" ] }, "definitionLink": { "local": [ "us-gaap-eedm-def-2019-01-31.xml", "srt-eedm1-def-2019-01-31.xml", "lly-20191024_def.xml" ] }, "inline": { "local": [ "a20198-kfor201810xkrec.htm", "ex-991xllyx20181231x10.htm" ] }, "labelLink": { "local": [ "lly-20191024_lab.xml", "dei-doc-2019-01-31.xml", "us-gaap-doc-2019-01-31.xml" ] }, "presentationLink": { "local": [ "lly-20191024_pre.xml" ] }, "referenceLink": { "local": [ "us-gaap-ref-2019-01-31.xml", "dei-ref-2019-01-31.xml" ] }, "schema": { "local": [ "lly-20191024.xsd", "srt-types-2019-01-31.xsd", "xbrl-instance-2003-12-31.xsd", "xbrl-linkbase-2003-12-31.xsd", "xl-2003-12-31.xsd", "xlink-2003-12-31.xsd", "numeric-2009-12-16.xsd", "nonNumeric-2009-12-16.xsd", "ref-2006-02-27.xsd", "srt-2019-01-31.xsd", "xbrldt-2005.xsd", "us-gaap-2019-01-31.xsd", "us-roles-2019-01-31.xsd", "srt-roles-2019-01-31.xsd", "country-2017-01-31.xsd", "us-types-2019-01-31.xsd", "factExplanatory-2009-12-16.xsd", "negated-2009-12-16.xsd", "net-2009-12-16.xsd", "currency-2019-01-31.xsd", "dei-2019-01-31.xsd", "exch-2019-01-31.xsd", "invest-2013-01-31.xsd", "naics-2017-01-31.xsd", "sic-2011-01-31.xsd", "stpr-2018-01-31.xsd", "deprecated-2009-12-16.xsd", "reference-2009-12-16.xsd", "us-parts-codification-2019-01-31.xsd" ] } }, "elementCount": 917, "entityCount": 1, "hidden": { "http://fasb.org/us-gaap/2019-01-31": 57, "http://xbrl.sec.gov/dei/2019-01-31": 5, "total": 62 }, "keyCustom": 49, "keyStandard": 552, "memberCustom": 110, "memberStandard": 82, "nsprefix": "lly", "nsuri": "http://www.lilly.com/20191024", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "a20198-kfor201810xkrec.htm", "contextRef": "D2019Q1", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "0001000 - Document - Cover Page", "role": "http://www.lilly.com/role/CoverPage", "shortName": "Cover Page", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "a20198-kfor201810xkrec.htm", "contextRef": "D2019Q1", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": null, "groupType": "statement", "isDefault": "false", "longName": "1005001 - Statement - Consolidated Statements of Cash Flows Consolidated Statements of Cash Flows (Parenthetical)", "role": "http://www.lilly.com/role/ConsolidatedStatementsOfCashFlowsConsolidatedStatementsOfCashFlowsParenthetical", "shortName": "Consolidated Statements of Cash Flows Consolidated Statements of Cash Flows (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": null }, "R100": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "ex-991xllyx20181231x10.htm", "contextRef": "FI2018Q4", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:MinorityInterest", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2426402 - Disclosure - Discontinued Operations (Details)", "role": "http://www.lilly.com/role/DiscontinuedOperationsDetails", "shortName": "Discontinued Operations (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ex-991xllyx20181231x10.htm", "contextRef": "FD2018Q4YTD", "decimals": "-5", "lang": null, "name": "us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R101": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "ix:continuation", "us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock", "div", "body", "html" ], "baseRef": "ex-991xllyx20181231x10.htm", "contextRef": "FD2018Q4QTD", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:Revenues", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2426403 - Disclosure - Discontinued Operations (Discontinued Operations in Financial Statements) (Details)", "role": "http://www.lilly.com/role/DiscontinuedOperationsDiscontinuedOperationsInFinancialStatementsDetails", "shortName": "Discontinued Operations (Discontinued Operations in Financial Statements) (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R102": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "ex-991xllyx20181231x10.htm", "contextRef": "FI2018Q4", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2426404 - Disclosure - Discontinued Operations (Major Classes of Assets and Liabilities) (Details)", "role": "http://www.lilly.com/role/DiscontinuedOperationsMajorClassesOfAssetsAndLiabilitiesDetails", "shortName": "Discontinued Operations (Major Classes of Assets and Liabilities) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "ex-991xllyx20181231x10.htm", "contextRef": "FI2018Q4_us-gaap_DisposalGroupClassificationAxis_us-gaap_DiscontinuedOperationsDisposedOfBySaleMember_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_lly_ElancoAnimalHealthIncorporatedMember", "decimals": "-5", "lang": null, "name": "us-gaap:DisposalGroupIncludingDiscontinuedOperationInventoryCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ex-991xllyx20181231x10.htm", "contextRef": "FD2018Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2101100 - Disclosure - Summary of Significant Accounting Policies", "role": "http://www.lilly.com/role/SummaryOfSignificantAccountingPolicies", "shortName": "Summary of Significant Accounting Policies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ex-991xllyx20181231x10.htm", "contextRef": "FD2018Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ex-991xllyx20181231x10.htm", "contextRef": "FD2018Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2104100 - Disclosure - Implementation of New Financial Accounting Pronouncements", "role": "http://www.lilly.com/role/ImplementationOfNewFinancialAccountingPronouncements", "shortName": "Implementation of New Financial Accounting Pronouncements", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ex-991xllyx20181231x10.htm", "contextRef": "FD2018Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ex-991xllyx20181231x10.htm", "contextRef": "FD2018Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:MergersAcquisitionsAndDispositionsDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2105100 - Disclosure - Acquisitions", "role": "http://www.lilly.com/role/Acquisitions", "shortName": "Acquisitions", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ex-991xllyx20181231x10.htm", "contextRef": "FD2018Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:MergersAcquisitionsAndDispositionsDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ex-991xllyx20181231x10.htm", "contextRef": "FD2018Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2106100 - Disclosure - Collaborations and Other Arrangements", "role": "http://www.lilly.com/role/CollaborationsAndOtherArrangements", "shortName": "Collaborations and Other Arrangements", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ex-991xllyx20181231x10.htm", "contextRef": "FD2018Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ex-991xllyx20181231x10.htm", "contextRef": "FD2018Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RestructuringImpairmentAndOtherActivitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2107100 - Disclosure - Asset Impairment, Restructuring, and Other Special Charges", "role": "http://www.lilly.com/role/AssetImpairmentRestructuringAndOtherSpecialCharges", "shortName": "Asset Impairment, Restructuring, and Other Special Charges", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ex-991xllyx20181231x10.htm", "contextRef": "FD2018Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RestructuringImpairmentAndOtherActivitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ex-991xllyx20181231x10.htm", "contextRef": "FD2018Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InventoryDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2108100 - Disclosure - Inventories", "role": "http://www.lilly.com/role/Inventories", "shortName": "Inventories", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ex-991xllyx20181231x10.htm", "contextRef": "FD2018Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InventoryDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ex-991xllyx20181231x10.htm", "contextRef": "FD2018Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2109100 - Disclosure - Financial Instruments", "role": "http://www.lilly.com/role/FinancialInstruments", "shortName": "Financial Instruments", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ex-991xllyx20181231x10.htm", "contextRef": "FD2018Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ex-991xllyx20181231x10.htm", "contextRef": "FD2018Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2110100 - Disclosure - Goodwill and Other Intangibles", "role": "http://www.lilly.com/role/GoodwillAndOtherIntangibles", "shortName": "Goodwill and Other Intangibles", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ex-991xllyx20181231x10.htm", "contextRef": "FD2018Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ex-991xllyx20181231x10.htm", "contextRef": "FD2018Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2111100 - Disclosure - Property and Equipment", "role": "http://www.lilly.com/role/PropertyAndEquipment", "shortName": "Property and Equipment", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ex-991xllyx20181231x10.htm", "contextRef": "FD2018Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "ex-991xllyx20181231x10.htm", "contextRef": "FD2018Q4YTD", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:Revenues", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1001000 - Statement - Consolidated Statements of Operations", "role": "http://www.lilly.com/role/ConsolidatedStatementsOfOperations", "shortName": "Consolidated Statements of Operations", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "ex-991xllyx20181231x10.htm", "contextRef": "FD2018Q4YTD", "decimals": "-5", "lang": null, "name": "lly:CostOfSalesOperatingExpensesAndOtherNet", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ex-991xllyx20181231x10.htm", "contextRef": "FD2018Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2112100 - Disclosure - Borrowings", "role": "http://www.lilly.com/role/Borrowings", "shortName": "Borrowings", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ex-991xllyx20181231x10.htm", "contextRef": "FD2018Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ex-991xllyx20181231x10.htm", "contextRef": "FD2018Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2116100 - Disclosure - Stock-Based Compensation", "role": "http://www.lilly.com/role/StockBasedCompensation", "shortName": "Stock-Based Compensation", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ex-991xllyx20181231x10.htm", "contextRef": "FD2018Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ex-991xllyx20181231x10.htm", "contextRef": "FD2018Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2117100 - Disclosure - Shareholders' Equity", "role": "http://www.lilly.com/role/ShareholdersEquity", "shortName": "Shareholders' Equity", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ex-991xllyx20181231x10.htm", "contextRef": "FD2018Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ex-991xllyx20181231x10.htm", "contextRef": "FD2018Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2119100 - Disclosure - Income Taxes", "role": "http://www.lilly.com/role/IncomeTaxes", "shortName": "Income Taxes", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ex-991xllyx20181231x10.htm", "contextRef": "FD2018Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ex-991xllyx20181231x10.htm", "contextRef": "FD2018Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2120100 - Disclosure - Retirement Benefits", "role": "http://www.lilly.com/role/RetirementBenefits", "shortName": "Retirement Benefits", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ex-991xllyx20181231x10.htm", "contextRef": "FD2018Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ex-991xllyx20181231x10.htm", "contextRef": "FD2018Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2121100 - Disclosure - Contingencies", "role": "http://www.lilly.com/role/Contingencies", "shortName": "Contingencies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ex-991xllyx20181231x10.htm", "contextRef": "FD2018Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ex-991xllyx20181231x10.htm", "contextRef": "FD2018Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ComprehensiveIncomeNoteTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2122100 - Disclosure - Other Comprehensive Income (Loss)", "role": "http://www.lilly.com/role/OtherComprehensiveIncomeLoss", "shortName": "Other Comprehensive Income (Loss)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ex-991xllyx20181231x10.htm", "contextRef": "FD2018Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ComprehensiveIncomeNoteTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ex-991xllyx20181231x10.htm", "contextRef": "FD2018Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2123100 - Disclosure - Other-Net, (Income) Expense", "role": "http://www.lilly.com/role/OtherNetIncomeExpense", "shortName": "Other-Net, (Income) Expense", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ex-991xllyx20181231x10.htm", "contextRef": "FD2018Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ex-991xllyx20181231x10.htm", "contextRef": "FD2018Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2124100 - Disclosure - Segment Information", "role": "http://www.lilly.com/role/SegmentInformation", "shortName": "Segment Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ex-991xllyx20181231x10.htm", "contextRef": "FD2018Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ex-991xllyx20181231x10.htm", "contextRef": "FD2018Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:QuarterlyFinancialInformationTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2125100 - Disclosure - Selected Quarterly Data (Unaudited)", "role": "http://www.lilly.com/role/SelectedQuarterlyDataUnaudited", "shortName": "Selected Quarterly Data (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ex-991xllyx20181231x10.htm", "contextRef": "FD2018Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:QuarterlyFinancialInformationTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "ex-991xllyx20181231x10.htm", "contextRef": "FD2018Q4YTD", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1002000 - Statement - Consolidated Statements of Comprehensive Income (Loss)", "role": "http://www.lilly.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss", "shortName": "Consolidated Statements of Comprehensive Income (Loss)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "ex-991xllyx20181231x10.htm", "contextRef": "FD2018Q4YTD", "decimals": "-5", "lang": null, "name": "us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R30": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ex-991xllyx20181231x10.htm", "contextRef": "FD2018Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2126100 - Disclosure - Discontinued Operations (Notes)", "role": "http://www.lilly.com/role/DiscontinuedOperationsNotes", "shortName": "Discontinued Operations (Notes)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ex-991xllyx20181231x10.htm", "contextRef": "FD2018Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ex-991xllyx20181231x10.htm", "contextRef": "FD2018Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InventoryPolicyTextBlock", "reportCount": 1, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2201201 - Disclosure - Summary of Significant Accounting Policies (Policies)", "role": "http://www.lilly.com/role/SummaryOfSignificantAccountingPoliciesPolicies", "shortName": "Summary of Significant Accounting Policies (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "ex-991xllyx20181231x10.htm", "contextRef": "FD2018Q4YTD", "decimals": null, "lang": "en-US", "name": "us-gaap:RevenueRecognitionPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ex-991xllyx20181231x10.htm", "contextRef": "FD2018Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InventoryPolicyTextBlock", "reportCount": 1, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2208201 - Disclosure - Inventories (Policies)", "role": "http://www.lilly.com/role/InventoriesPolicies", "shortName": "Inventories (Policies)", "subGroupType": "policies", "uniqueAnchor": null }, "R33": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "ex-991xllyx20181231x10.htm", "contextRef": "FD2018Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ConcentrationRiskCreditRisk", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2209201 - Disclosure - Financial Instruments (Policies)", "role": "http://www.lilly.com/role/FinancialInstrumentsPolicies", "shortName": "Financial Instruments (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "ex-991xllyx20181231x10.htm", "contextRef": "FD2018Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ConcentrationRiskCreditRisk", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ex-991xllyx20181231x10.htm", "contextRef": "FD2018Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock", "reportCount": 1, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2210201 - Disclosure - Goodwill and Other Intangibles (Policies)", "role": "http://www.lilly.com/role/GoodwillAndOtherIntangiblesPolicies", "shortName": "Goodwill and Other Intangibles (Policies)", "subGroupType": "policies", "uniqueAnchor": null }, "R35": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "ex-991xllyx20181231x10.htm", "contextRef": "FD2018Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock", "reportCount": 1, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2211201 - Disclosure - Property and Equipment (Policies)", "role": "http://www.lilly.com/role/PropertyAndEquipmentPolicies", "shortName": "Property and Equipment (Policies)", "subGroupType": "policies", "uniqueAnchor": null }, "R36": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ex-991xllyx20181231x10.htm", "contextRef": "FD2018Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy", "reportCount": 1, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2216201 - Disclosure - Stock-Based Compensation (Policies)", "role": "http://www.lilly.com/role/StockBasedCompensationPolicies", "shortName": "Stock-Based Compensation (Policies)", "subGroupType": "policies", "uniqueAnchor": null }, "R37": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "ex-991xllyx20181231x10.htm", "contextRef": "FD2018Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxPolicyTextBlock", "reportCount": 1, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2219201 - Disclosure - Income Taxes (Policies)", "role": "http://www.lilly.com/role/IncomeTaxesPolicies", "shortName": "Income Taxes (Policies)", "subGroupType": "policies", "uniqueAnchor": null }, "R38": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "ex-991xllyx20181231x10.htm", "contextRef": "FD2018Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesPolicyTextBlock", "reportCount": 1, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2221201 - Disclosure - Contingencies (Policies)", "role": "http://www.lilly.com/role/ContingenciesPolicies", "shortName": "Contingencies (Policies)", "subGroupType": "policies", "uniqueAnchor": null }, "R39": { "firstAnchor": { "ancestors": [ "us-gaap:RevenueRecognitionPolicyTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ex-991xllyx20181231x10.htm", "contextRef": "FD2018Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2301302 - Disclosure - Summary of Significant Accounting Policies (Tables)", "role": "http://www.lilly.com/role/SummaryOfSignificantAccountingPoliciesTables", "shortName": "Summary of Significant Accounting Policies (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:RevenueRecognitionPolicyTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ex-991xllyx20181231x10.htm", "contextRef": "FD2018Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "span", "span", "link:footnote", "div", "body", "html" ], "baseRef": "ex-991xllyx20181231x10.htm", "contextRef": "FD2018Q4YTD", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1002001 - Statement - Consolidated Statements of Comprehensive Income (Loss) (Parenthetical)", "role": "http://www.lilly.com/role/ConsolidatedStatementsOfComprehensiveIncomeLossParenthetical", "shortName": "Consolidated Statements of Comprehensive Income (Loss) (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "span", "span", "link:footnote", "div", "body", "html" ], "baseRef": "ex-991xllyx20181231x10.htm", "contextRef": "FD2018Q4YTD", "decimals": "-5", "lang": "en-US", "name": "us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R40": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "ex-991xllyx20181231x10.htm", "contextRef": "FD2018Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2304301 - Disclosure - Implementation of New Financial Accounting Pronouncements (Tables)", "role": "http://www.lilly.com/role/ImplementationOfNewFinancialAccountingPronouncementsTables", "shortName": "Implementation of New Financial Accounting Pronouncements (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "ex-991xllyx20181231x10.htm", "contextRef": "FD2018Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R41": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "ex-991xllyx20181231x10.htm", "contextRef": "FD2018Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2305301 - Disclosure - Acquisitions (Tables)", "role": "http://www.lilly.com/role/AcquisitionsTables", "shortName": "Acquisitions (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "ex-991xllyx20181231x10.htm", "contextRef": "FD2018Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R42": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ex-991xllyx20181231x10.htm", "contextRef": "FD2018Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2306301 - Disclosure - Collaborations and Other Arrangements (Tables)", "role": "http://www.lilly.com/role/CollaborationsAndOtherArrangementsTables", "shortName": "Collaborations and Other Arrangements (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ex-991xllyx20181231x10.htm", "contextRef": "FD2018Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R43": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "ex-991xllyx20181231x10.htm", "contextRef": "FD2018Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2307301 - Disclosure - Asset Impairment, Restructuring, and Other Special Charges (Tables)", "role": "http://www.lilly.com/role/AssetImpairmentRestructuringAndOtherSpecialChargesTables", "shortName": "Asset Impairment, Restructuring, and Other Special Charges (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "ex-991xllyx20181231x10.htm", "contextRef": "FD2018Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R44": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "ex-991xllyx20181231x10.htm", "contextRef": "FD2018Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2308302 - Disclosure - Inventories (Tables)", "role": "http://www.lilly.com/role/InventoriesTables", "shortName": "Inventories (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "ex-991xllyx20181231x10.htm", "contextRef": "FD2018Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R45": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "ex-991xllyx20181231x10.htm", "contextRef": "FD2018Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDerivativeInstrumentsEffectOnOtherComprehensiveIncomeLossTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2309302 - Disclosure - Financial Instruments (Tables)", "role": "http://www.lilly.com/role/FinancialInstrumentsTables", "shortName": "Financial Instruments (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "ex-991xllyx20181231x10.htm", "contextRef": "FD2018Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDerivativeInstrumentsEffectOnOtherComprehensiveIncomeLossTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R46": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "ex-991xllyx20181231x10.htm", "contextRef": "FD2018Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2310302 - Disclosure - Goodwill and Other Intangibles (Tables)", "role": "http://www.lilly.com/role/GoodwillAndOtherIntangiblesTables", "shortName": "Goodwill and Other Intangibles (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "ex-991xllyx20181231x10.htm", "contextRef": "FD2018Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R47": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "ex-991xllyx20181231x10.htm", "contextRef": "FD2018Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2311302 - Disclosure - Property and Equipment (Tables)", "role": "http://www.lilly.com/role/PropertyAndEquipmentTables", "shortName": "Property and Equipment (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "ex-991xllyx20181231x10.htm", "contextRef": "FD2018Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R48": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "ex-991xllyx20181231x10.htm", "contextRef": "FD2018Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "lly:ScheduleofAdditionalBorrowingsDisclosuresTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2312301 - Disclosure - Borrowings (Tables)", "role": "http://www.lilly.com/role/BorrowingsTables", "shortName": "Borrowings (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "ex-991xllyx20181231x10.htm", "contextRef": "FD2018Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "lly:ScheduleofAdditionalBorrowingsDisclosuresTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R49": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "ex-991xllyx20181231x10.htm", "contextRef": "FD2018Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "lly:ScheduleofAdditionalStockBasedCompensationDisclosuresTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2316302 - Disclosure - Stock-Based Compensation (Tables)", "role": "http://www.lilly.com/role/StockBasedCompensationTables", "shortName": "Stock-Based Compensation (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "ex-991xllyx20181231x10.htm", "contextRef": "FD2018Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "lly:ScheduleofAdditionalStockBasedCompensationDisclosuresTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "ex-991xllyx20181231x10.htm", "contextRef": "FI2018Q4", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1003000 - Statement - Consolidated Balance Sheets", "role": "http://www.lilly.com/role/ConsolidatedBalanceSheets", "shortName": "Consolidated Balance Sheets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "ex-991xllyx20181231x10.htm", "contextRef": "FI2018Q4", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R50": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "ex-991xllyx20181231x10.htm", "contextRef": "FD2018Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2319302 - Disclosure - Income Taxes (Tables)", "role": "http://www.lilly.com/role/IncomeTaxesTables", "shortName": "Income Taxes (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "ex-991xllyx20181231x10.htm", "contextRef": "FD2018Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R51": { "firstAnchor": { "ancestors": [ "div", "ix:continuation", "body", "html" ], "baseRef": "ex-991xllyx20181231x10.htm", "contextRef": "FD2018Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfChangesInAccumulatedPostemploymentBenefitObligationsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2320301 - Disclosure - Retirement Benefits (Tables)", "role": "http://www.lilly.com/role/RetirementBenefitsTables", "shortName": "Retirement Benefits (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "ix:continuation", "body", "html" ], "baseRef": "ex-991xllyx20181231x10.htm", "contextRef": "FD2018Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfChangesInAccumulatedPostemploymentBenefitObligationsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R52": { "firstAnchor": { "ancestors": [ "div", "ix:continuation", "body", "html" ], "baseRef": "ex-991xllyx20181231x10.htm", "contextRef": "FD2018Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2322301 - Disclosure - Other Comprehensive Income (Loss) (Tables)", "role": "http://www.lilly.com/role/OtherComprehensiveIncomeLossTables", "shortName": "Other Comprehensive Income (Loss) (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "ix:continuation", "body", "html" ], "baseRef": "ex-991xllyx20181231x10.htm", "contextRef": "FD2018Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R53": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "ex-991xllyx20181231x10.htm", "contextRef": "FD2018Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2323301 - Disclosure - Other - Net, (Income) Expense (Tables)", "role": "http://www.lilly.com/role/OtherNetIncomeExpenseTables", "shortName": "Other - Net, (Income) Expense (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "ex-991xllyx20181231x10.htm", "contextRef": "FD2018Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R54": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "ex-991xllyx20181231x10.htm", "contextRef": "FD2018Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2324301 - Disclosure - Segment Information (Tables)", "role": "http://www.lilly.com/role/SegmentInformationTables", "shortName": "Segment Information (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "ex-991xllyx20181231x10.htm", "contextRef": "FD2018Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R55": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "ex-991xllyx20181231x10.htm", "contextRef": "FD2018Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2325301 - Disclosure - Selected Quarterly Data (Unaudited) (Tables)", "role": "http://www.lilly.com/role/SelectedQuarterlyDataUnauditedTables", "shortName": "Selected Quarterly Data (Unaudited) (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "ex-991xllyx20181231x10.htm", "contextRef": "FD2018Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R56": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "ex-991xllyx20181231x10.htm", "contextRef": "FD2018Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2326301 - Disclosure - Discontinued Operations (Tables)", "role": "http://www.lilly.com/role/DiscontinuedOperationsTables", "shortName": "Discontinued Operations (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "ex-991xllyx20181231x10.htm", "contextRef": "FD2018Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R57": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ex-991xllyx20181231x10.htm", "contextRef": "D2018Q3Sept24_dei_LegalEntityAxis_lly_ElancoAnimalHealthIncorporatedMember", "decimals": "3", "first": true, "lang": null, "name": "lly:SaleOfStockPercentageOfStockSold", "reportCount": 1, "unitRef": "number", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2401403 - Disclosure - Summary of Significant Accounting Policies (Acquisitions) (Details)", "role": "http://www.lilly.com/role/SummaryOfSignificantAccountingPoliciesAcquisitionsDetails", "shortName": "Summary of Significant Accounting Policies (Acquisitions) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ex-991xllyx20181231x10.htm", "contextRef": "D2018Q3Sept24_dei_LegalEntityAxis_lly_ElancoAnimalHealthIncorporatedMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember", "decimals": "-5", "lang": null, "name": "us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R58": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "ex-991xllyx20181231x10.htm", "contextRef": "FD2018Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "lly:RevenuefromContractPaymentTermMinimum", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2401404 - Disclosure - Summary of Significant Accounting Policies (Revenue) (Details)", "role": "http://www.lilly.com/role/SummaryOfSignificantAccountingPoliciesRevenueDetails", "shortName": "Summary of Significant Accounting Policies (Revenue) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "ex-991xllyx20181231x10.htm", "contextRef": "FD2018Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "lly:RevenuefromContractPaymentTermMinimum", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R59": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "ex-991xllyx20181231x10.htm", "contextRef": "FI2018Q4", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:ContractWithCustomerLiability", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2401405 - Disclosure - Summary of Significant Accounting Policies (Contract Liabilities) (Details)", "role": "http://www.lilly.com/role/SummaryOfSignificantAccountingPoliciesContractLiabilitiesDetails", "shortName": "Summary of Significant Accounting Policies (Contract Liabilities) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "ex-991xllyx20181231x10.htm", "contextRef": "FI2018Q4", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:ContractWithCustomerLiability", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R6": { "firstAnchor": null, "groupType": "statement", "isDefault": "false", "longName": "1003501 - Statement - Consolidated Balance Sheets (Parenthetical)", "role": "http://www.lilly.com/role/ConsolidatedBalanceSheetsParenthetical", "shortName": "Consolidated Balance Sheets (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": null }, "R60": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "ex-991xllyx20181231x10.htm", "contextRef": "FI2018Q4", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:RetainedEarningsAccumulatedDeficit", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2404402 - Disclosure - Implementation of New Financial Accounting Pronouncements (Details)", "role": "http://www.lilly.com/role/ImplementationOfNewFinancialAccountingPronouncementsDetails", "shortName": "Implementation of New Financial Accounting Pronouncements (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R61": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "ix:continuation", "us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock", "div", "body", "html" ], "baseRef": "ex-991xllyx20181231x10.htm", "contextRef": "FD2018Q4QTD", "decimals": "-5", "first": true, "lang": null, "name": "lly:AcquiredInProcessResearchAndDevelopment", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2405403 - Disclosure - (Narrative) (Details)", "role": "http://www.lilly.com/role/NarrativeDetails", "shortName": "(Narrative) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ex-991xllyx20181231x10.htm", "contextRef": "I2019Q1Feb15_us-gaap_BusinessAcquisitionAxis_lly_LoxoOncologyInc.Member", "decimals": "INF", "lang": null, "name": "us-gaap:BusinessAcquisitionSharePrice", "reportCount": 1, "unique": true, "unitRef": "usdPerShare", "xsiNil": "false" } }, "R62": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "ix:continuation", "us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock", "div", "body", "html" ], "baseRef": "ex-991xllyx20181231x10.htm", "contextRef": "FD2018Q4QTD", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:Revenues", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2406402 - Disclosure - Collaborations and Other Arrangements (Details)", "role": "http://www.lilly.com/role/CollaborationsAndOtherArrangementsDetails", "shortName": "Collaborations and Other Arrangements (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "ex-991xllyx20181231x10.htm", "contextRef": "FD2018Q4YTD_srt_ProductOrServiceAxis_lly_TrajentaBIMember_us-gaap_TypeOfArrangementAxis_lly_MilestonePaymentsDevelopmentandRegulatoryCapitalizedCumulativeMember", "decimals": "-5", "lang": null, "name": "lly:CollaborativeArrangementRightsAndObligationsTerms", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R63": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ex-991xllyx20181231x10.htm", "contextRef": "FD2018Q4YTD", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:SeveranceCosts1", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2407402 - Disclosure - Asset Impairment, Restructuring, and Other Special Charges (Details)", "role": "http://www.lilly.com/role/AssetImpairmentRestructuringAndOtherSpecialChargesDetails", "shortName": "Asset Impairment, Restructuring, and Other Special Charges (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ex-991xllyx20181231x10.htm", "contextRef": "FD2018Q4YTD", "decimals": "-5", "lang": null, "name": "lly:DefinedBenefitPlanNetPeriodicBenefitCostCreditGainLossDuetoCurtailmentandSpecialTerminationBenefits", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R64": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ex-991xllyx20181231x10.htm", "contextRef": "FD2018Q4YTD", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:SeveranceCosts1", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2407403 - Disclosure - Asset Impairment, Restructuring, and Other Special Charges (Narrative) (Details)", "role": "http://www.lilly.com/role/AssetImpairmentRestructuringAndOtherSpecialChargesNarrativeDetails", "shortName": "Asset Impairment, Restructuring, and Other Special Charges (Narrative) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "ix:continuation", "div", "body", "html" ], "baseRef": "ex-991xllyx20181231x10.htm", "contextRef": "FD2017Q4YTD", "decimals": "-5", "lang": null, "name": "us-gaap:TangibleAssetImpairmentCharges", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R65": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ex-991xllyx20181231x10.htm", "contextRef": "FI2018Q4", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:InventoryFinishedGoods", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2408403 - Disclosure - Inventories (Details)", "role": "http://www.lilly.com/role/InventoriesDetails", "shortName": "Inventories (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ex-991xllyx20181231x10.htm", "contextRef": "FI2018Q4", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:InventoryFinishedGoods", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R66": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ex-991xllyx20181231x10.htm", "contextRef": "FD2018Q4YTD", "decimals": "-5", "first": true, "lang": null, "name": "lly:DerivativeInstrumentsGainLossRecognized", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2409403 - Disclosure - Financial Instruments (Effect of Risk Management) (Details)", "role": "http://www.lilly.com/role/FinancialInstrumentsEffectOfRiskManagementDetails", "shortName": "Financial Instruments (Effect of Risk Management) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ex-991xllyx20181231x10.htm", "contextRef": "FD2018Q4YTD", "decimals": "-5", "first": true, "lang": null, "name": "lly:DerivativeInstrumentsGainLossRecognized", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R67": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ex-991xllyx20181231x10.htm", "contextRef": "FI2018Q4", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2409404 - Disclosure - Financial Instruments (Fair Value Measurement) (Details)", "role": "http://www.lilly.com/role/FinancialInstrumentsFairValueMeasurementDetails", "shortName": "Financial Instruments (Fair Value Measurement) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ex-991xllyx20181231x10.htm", "contextRef": "FI2018Q4", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R68": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfDebtTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ex-991xllyx20181231x10.htm", "contextRef": "FI2018Q4", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:CommercialPaper", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2409405 - Disclosure - Financial Instruments (Short-term and Long-term Classification) (Details)", "role": "http://www.lilly.com/role/FinancialInstrumentsShortTermAndLongTermClassificationDetails", "shortName": "Financial Instruments (Short-term and Long-term Classification) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock", "body", "html" ], "baseRef": "ex-991xllyx20181231x10.htm", "contextRef": "FI2018Q4_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_CarryingReportedAmountFairValueDisclosureMember", "decimals": "-5", "lang": null, "name": "us-gaap:LongTermDebt", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R69": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ex-991xllyx20181231x10.htm", "contextRef": "FI2018Q4", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:AvailableForSaleSecuritiesDebtSecurities", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2409406 - Disclosure - Financial Instruments (Contractual Maturities) (Details)", "role": "http://www.lilly.com/role/FinancialInstrumentsContractualMaturitiesDetails", "shortName": "Financial Instruments (Contractual Maturities) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ex-991xllyx20181231x10.htm", "contextRef": "FI2018Q4", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:AvailableForSaleSecuritiesDebtSecurities", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "ex-991xllyx20181231x10.htm", "contextRef": "FI2015Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1004000 - Statement - Consolidated Statements of Shareholders' Equity Statement", "role": "http://www.lilly.com/role/ConsolidatedStatementsOfShareholdersEquityStatement", "shortName": "Consolidated Statements of Shareholders' Equity Statement", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "ex-991xllyx20181231x10.htm", "contextRef": "FI2015Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R70": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ex-991xllyx20181231x10.htm", "contextRef": "FI2018Q4", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2409407 - Disclosure - Financial Instruments (Summary of AFS Unrealized Gain(Loss)) (Details)", "role": "http://www.lilly.com/role/FinancialInstrumentsSummaryOfAfsUnrealizedGainlossDetails", "shortName": "Financial Instruments (Summary of AFS Unrealized Gain(Loss)) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ex-991xllyx20181231x10.htm", "contextRef": "FI2018Q4", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R71": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:GainLossOnInvestmentsTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ex-991xllyx20181231x10.htm", "contextRef": "FD2018Q4YTD", "decimals": "-5", "first": true, "lang": null, "name": "lly:ProceedsfromSaleofEquityandAvailableforSaleSecurities", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2409408 - Disclosure - Financial Instruments (Investment Portfolio Activity) (Details)", "role": "http://www.lilly.com/role/FinancialInstrumentsInvestmentPortfolioActivityDetails", "shortName": "Financial Instruments (Investment Portfolio Activity) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:GainLossOnInvestmentsTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ex-991xllyx20181231x10.htm", "contextRef": "FD2018Q4YTD", "decimals": "-5", "first": true, "lang": null, "name": "lly:ProceedsfromSaleofEquityandAvailableforSaleSecurities", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R72": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ex-991xllyx20181231x10.htm", "contextRef": "FD2018Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AverageRemainingMaturityOfForeignCurrencyDerivatives1", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2409409 - Disclosure - Financial Instruments (Narrative) (Details)", "role": "http://www.lilly.com/role/FinancialInstrumentsNarrativeDetails", "shortName": "Financial Instruments (Narrative) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ex-991xllyx20181231x10.htm", "contextRef": "FD2018Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AverageRemainingMaturityOfForeignCurrencyDerivatives1", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R73": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ex-991xllyx20181231x10.htm", "contextRef": "FI2018Q4", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2410404 - Disclosure - Goodwill and Other Intangibles (Intangibles) (Details)", "role": "http://www.lilly.com/role/GoodwillAndOtherIntangiblesIntangiblesDetails", "shortName": "Goodwill and Other Intangibles (Intangibles) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ex-991xllyx20181231x10.htm", "contextRef": "FI2018Q4", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R74": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ex-991xllyx20181231x10.htm", "contextRef": "FD2018Q4YTD", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:GoodwillImpairmentLoss", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2410405 - Disclosure - Goodwill and Other Intangibles (Narrative) (Details)", "role": "http://www.lilly.com/role/GoodwillAndOtherIntangiblesNarrativeDetails", "shortName": "Goodwill and Other Intangibles (Narrative) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ex-991xllyx20181231x10.htm", "contextRef": "FD2018Q4YTD", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:GoodwillImpairmentLoss", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R75": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ex-991xllyx20181231x10.htm", "contextRef": "FI2018Q4", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2410406 - Disclosure - Goodwill and Other Intangibles (Amortization Expense) (Details)", "role": "http://www.lilly.com/role/GoodwillAndOtherIntangiblesAmortizationExpenseDetails", "shortName": "Goodwill and Other Intangibles (Amortization Expense) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ex-991xllyx20181231x10.htm", "contextRef": "FI2018Q4", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R76": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:PropertyPlantAndEquipmentTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ex-991xllyx20181231x10.htm", "contextRef": "FI2018Q4", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:Land", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2411403 - Disclosure - Property and Equipment (Details)", "role": "http://www.lilly.com/role/PropertyAndEquipmentDetails", "shortName": "Property and Equipment (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:PropertyPlantAndEquipmentTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ex-991xllyx20181231x10.htm", "contextRef": "FI2018Q4", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:Land", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R77": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfDebtTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ex-991xllyx20181231x10.htm", "contextRef": "FI2018Q4", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:CommercialPaper", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2412402 - Disclosure - Borrowings (Long-term Debt) (Details)", "role": "http://www.lilly.com/role/BorrowingsLongTermDebtDetails", "shortName": "Borrowings (Long-term Debt) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfDebtTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ex-991xllyx20181231x10.htm", "contextRef": "FI2018Q4", "decimals": "-5", "lang": null, "name": "us-gaap:NotesPayable", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R78": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ex-991xllyx20181231x10.htm", "contextRef": "FI2018Q4", "decimals": "4", "first": true, "lang": null, "name": "us-gaap:ShortTermDebtWeightedAverageInterestRate", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2412403 - Disclosure - Borrowings (narrative) (Details)", "role": "http://www.lilly.com/role/BorrowingsNarrativeDetails", "shortName": "Borrowings (narrative) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ex-991xllyx20181231x10.htm", "contextRef": "FI2018Q4", "decimals": "4", "first": true, "lang": null, "name": "us-gaap:ShortTermDebtWeightedAverageInterestRate", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R79": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ex-991xllyx20181231x10.htm", "contextRef": "FI2018Q4", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2412404 - Disclosure - Borrowings (Debt maturities) (Details)", "role": "http://www.lilly.com/role/BorrowingsDebtMaturitiesDetails", "shortName": "Borrowings (Debt maturities) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ex-991xllyx20181231x10.htm", "contextRef": "FI2018Q4", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R8": { "firstAnchor": null, "groupType": "statement", "isDefault": "false", "longName": "1004001 - Statement - Consolidated Statements of Shareholders' Equity (Parenthetical)", "role": "http://www.lilly.com/role/ConsolidatedStatementsOfShareholdersEquityParenthetical", "shortName": "Consolidated Statements of Shareholders' Equity (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": null }, "R80": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "lly:ScheduleofAdditionalStockBasedCompensationDisclosuresTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ex-991xllyx20181231x10.htm", "contextRef": "FD2018Q4YTD", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2416403 - Disclosure - Stock-Based Compensation (Details)", "role": "http://www.lilly.com/role/StockBasedCompensationDetails", "shortName": "Stock-Based Compensation (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "lly:ScheduleofAdditionalStockBasedCompensationDisclosuresTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ex-991xllyx20181231x10.htm", "contextRef": "FD2018Q4YTD", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R81": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ex-991xllyx20181231x10.htm", "contextRef": "FD2018Q4YTD", "decimals": "-7", "first": true, "lang": null, "name": "us-gaap:TreasuryStockValueAcquiredCostMethod", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2417401 - Disclosure - Shareholders' Equity (Details)", "role": "http://www.lilly.com/role/ShareholdersEquityDetails", "shortName": "Shareholders' Equity (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ex-991xllyx20181231x10.htm", "contextRef": "FD2016Q4YTD", "decimals": "-5", "lang": null, "name": "lly:PaymentsForRepurchaseOfCommonStockInNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R82": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ex-991xllyx20181231x10.htm", "contextRef": "FD2017Q4YTD", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:TaxCutsAndJobsActOf2017IncompleteAccountingChangeInTaxRateProvisionalIncomeTaxExpenseBenefit", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2419403 - Disclosure - Income Taxes (Narrative) (Details)", "role": "http://www.lilly.com/role/IncomeTaxesNarrativeDetails", "shortName": "Income Taxes (Narrative) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ex-991xllyx20181231x10.htm", "contextRef": "FD2018Q4YTD", "decimals": "-5", "lang": null, "name": "us-gaap:TaxCutsAndJobsActOf2017ChangeInTaxRateIncomeTaxExpenseBenefit", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R83": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ex-991xllyx20181231x10.htm", "contextRef": "FD2018Q4YTD", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:CurrentFederalTaxExpenseBenefit", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2419404 - Disclosure - Income Taxes (Current and Deferred) (Details)", "role": "http://www.lilly.com/role/IncomeTaxesCurrentAndDeferredDetails", "shortName": "Income Taxes (Current and Deferred) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ex-991xllyx20181231x10.htm", "contextRef": "FD2018Q4YTD", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:CurrentFederalTaxExpenseBenefit", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R84": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ex-991xllyx20181231x10.htm", "contextRef": "FI2018Q4", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2419405 - Disclosure - Income Taxes (Deferred tax asset and liabilities) (Details)", "role": "http://www.lilly.com/role/IncomeTaxesDeferredTaxAssetAndLiabilitiesDetails", "shortName": "Income Taxes (Deferred tax asset and liabilities) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ex-991xllyx20181231x10.htm", "contextRef": "FI2018Q4", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R85": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:SummaryOfIncomeTaxContingenciesTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ex-991xllyx20181231x10.htm", "contextRef": "FI2017Q4", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:UnrecognizedTaxBenefits", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2419406 - Disclosure - Income Taxes (Unrecognized benefits) (Details)", "role": "http://www.lilly.com/role/IncomeTaxesUnrecognizedBenefitsDetails", "shortName": "Income Taxes (Unrecognized benefits) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:SummaryOfIncomeTaxContingenciesTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ex-991xllyx20181231x10.htm", "contextRef": "FI2015Q4", "decimals": "-5", "lang": null, "name": "us-gaap:UnrecognizedTaxBenefits", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R86": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ex-991xllyx20181231x10.htm", "contextRef": "FD2018Q4YTD", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2419407 - Disclosure - Income Taxes (Reconciliation of Income Taxes) (Details)", "role": "http://www.lilly.com/role/IncomeTaxesReconciliationOfIncomeTaxesDetails", "shortName": "Income Taxes (Reconciliation of Income Taxes) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ex-991xllyx20181231x10.htm", "contextRef": "FD2018Q4YTD", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R87": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ex-991xllyx20181231x10.htm", "contextRef": "FD2017Q4YTD", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:DefinedBenefitPlanCurtailments", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2420402 - Disclosure - Retirement Benefits (Schedule of Benefit Obligations and Plan Assets) (Details)", "role": "http://www.lilly.com/role/RetirementBenefitsScheduleOfBenefitObligationsAndPlanAssetsDetails", "shortName": "Retirement Benefits (Schedule of Benefit Obligations and Plan Assets) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "us-gaap:ScheduleOfChangesInAccumulatedPostemploymentBenefitObligationsTableTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "ex-991xllyx20181231x10.htm", "contextRef": "FD2018Q4YTD_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember", "decimals": "-5", "lang": null, "name": "us-gaap:DefinedBenefitPlanActuarialGainLoss", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R88": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "ex-991xllyx20181231x10.htm", "contextRef": "FI2018Q4", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2420403 - Disclosure - Retirement Benefits (Schedule of Components in Consolidated Balance Sheets) (Details)", "role": "http://www.lilly.com/role/RetirementBenefitsScheduleOfComponentsInConsolidatedBalanceSheetsDetails", "shortName": "Retirement Benefits (Schedule of Components in Consolidated Balance Sheets) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "us-gaap:ScheduleOfAmountsRecognizedInBalanceSheetTableTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "ex-991xllyx20181231x10.htm", "contextRef": "FI2018Q4_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember", "decimals": "-5", "lang": null, "name": "us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R89": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfAssumptionsUsedTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ex-991xllyx20181231x10.htm", "contextRef": "FI2018Q4_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember", "decimals": "3", "first": true, "lang": null, "name": "us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2420404 - Disclosure - Retirement Benefits (Schedule of Weighted Average Assumptions) (Details)", "role": "http://www.lilly.com/role/RetirementBenefitsScheduleOfWeightedAverageAssumptionsDetails", "shortName": "Retirement Benefits (Schedule of Weighted Average Assumptions) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfAssumptionsUsedTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ex-991xllyx20181231x10.htm", "contextRef": "FI2018Q4_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember", "decimals": "3", "first": true, "lang": null, "name": "us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "ex-991xllyx20181231x10.htm", "contextRef": "FD2018Q4YTD", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1005000 - Statement - Consolidated Statements of Cash Flows", "role": "http://www.lilly.com/role/ConsolidatedStatementsOfCashFlows", "shortName": "Consolidated Statements of Cash Flows", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "ex-991xllyx20181231x10.htm", "contextRef": "FD2018Q4YTD", "decimals": "-5", "lang": null, "name": "us-gaap:DepreciationDepletionAndAmortization", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R90": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ex-991xllyx20181231x10.htm", "contextRef": "FI2018Q4", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2420405 - Disclosure - Retirement Benefits (Schedule of Expected Benefit Payments, Contributions and Expense) (Details)", "role": "http://www.lilly.com/role/RetirementBenefitsScheduleOfExpectedBenefitPaymentsContributionsAndExpenseDetails", "shortName": "Retirement Benefits (Schedule of Expected Benefit Payments, Contributions and Expense) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ex-991xllyx20181231x10.htm", "contextRef": "FI2018Q4", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R91": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "ex-991xllyx20181231x10.htm", "contextRef": "FI2018Q4_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:DefinedBenefitPlanFairValueOfPlanAssets", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2420406 - Disclosure - Retirement Benefits (Fair Value Disclosures) (Details)", "role": "http://www.lilly.com/role/RetirementBenefitsFairValueDisclosuresDetails", "shortName": "Retirement Benefits (Fair Value Disclosures) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "ex-991xllyx20181231x10.htm", "contextRef": "FI2018Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_DefinedBenefitPlanEquitySecuritiesUsMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember", "decimals": "-5", "lang": null, "name": "us-gaap:DefinedBenefitPlanFairValueOfPlanAssets", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R92": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ex-991xllyx20181231x10.htm", "contextRef": "D2018Q3July", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2420407 - Disclosure - Retirement Benefits (Narrative) (Details)", "role": "http://www.lilly.com/role/RetirementBenefitsNarrativeDetails", "shortName": "Retirement Benefits (Narrative) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ex-991xllyx20181231x10.htm", "contextRef": "FD2018Q4YTD", "decimals": "-7", "lang": null, "name": "us-gaap:DefinedBenefitPlanBenefitObligationPeriodIncreaseDecrease", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R93": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ex-991xllyx20181231x10.htm", "contextRef": "I2018Q3july31", "decimals": "INF", "first": true, "lang": null, "name": "lly:NumberofCompanies", "reportCount": 1, "unique": true, "unitRef": "company", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2421402 - Disclosure - Contingencies (Details)", "role": "http://www.lilly.com/role/ContingenciesDetails", "shortName": "Contingencies (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ex-991xllyx20181231x10.htm", "contextRef": "I2018Q3july31", "decimals": "INF", "first": true, "lang": null, "name": "lly:NumberofCompanies", "reportCount": 1, "unique": true, "unitRef": "company", "xsiNil": "false" } }, "R94": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "ex-991xllyx20181231x10.htm", "contextRef": "FI2017Q4", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2422402 - Disclosure - Other Comprehensive Income (Loss) (Roll-forward) (Details)", "role": "http://www.lilly.com/role/OtherComprehensiveIncomeLossRollForwardDetails", "shortName": "Other Comprehensive Income (Loss) (Roll-forward) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "body", "html" ], "baseRef": "ex-991xllyx20181231x10.htm", "contextRef": "FD2018Q4YTD", "decimals": "-5", "lang": null, "name": "us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R95": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "ex-991xllyx20181231x10.htm", "contextRef": "FD2018Q4YTD", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:OtherComprehensiveIncomeLossTax", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2422403 - Disclosure - Other Comprehensive Income (Loss) (Tax effect) (Details)", "role": "http://www.lilly.com/role/OtherComprehensiveIncomeLossTaxEffectDetails", "shortName": "Other Comprehensive Income (Loss) (Tax effect) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "ex-991xllyx20181231x10.htm", "contextRef": "FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember", "decimals": "-5", "lang": null, "name": "us-gaap:OtherComprehensiveIncomeLossTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R96": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ex-991xllyx20181231x10.htm", "contextRef": "FD2018Q4YTD", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:OtherNonoperatingIncomeExpense", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2422404 - Disclosure - Other Comprehensive Income (Loss) (Reclassification) (Details)", "role": "http://www.lilly.com/role/OtherComprehensiveIncomeLossReclassificationDetails", "shortName": "Other Comprehensive Income (Loss) (Reclassification) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "ex-991xllyx20181231x10.htm", "contextRef": "FD2018Q4YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember", "decimals": "-5", "lang": null, "name": "us-gaap:ProfitLoss", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R97": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ex-991xllyx20181231x10.htm", "contextRef": "FD2018Q4YTD", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:InterestExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2423402 - Disclosure - Other - Net, (Income) Expense (Details)", "role": "http://www.lilly.com/role/OtherNetIncomeExpenseDetails", "shortName": "Other - Net, (Income) Expense (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ex-991xllyx20181231x10.htm", "contextRef": "FD2018Q4YTD", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:InterestExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R98": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ex-991xllyx20181231x10.htm", "contextRef": "FD2018Q4YTD", "decimals": "INF", "first": true, "lang": null, "name": "lly:NumberofWholesalers", "reportCount": 1, "unique": true, "unitRef": "wholesaler", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2424402 - Disclosure - Segment Information (Details)", "role": "http://www.lilly.com/role/SegmentInformationDetails", "shortName": "Segment Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ex-991xllyx20181231x10.htm", "contextRef": "FD2018Q4YTD", "decimals": "INF", "first": true, "lang": null, "name": "lly:NumberofWholesalers", "reportCount": 1, "unique": true, "unitRef": "wholesaler", "xsiNil": "false" } }, "R99": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "ix:continuation", "us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock", "div", "body", "html" ], "baseRef": "ex-991xllyx20181231x10.htm", "contextRef": "FD2018Q4QTD", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:Revenues", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2425402 - Disclosure - Selected Quarterly Data (Unaudited) (Details)", "role": "http://www.lilly.com/role/SelectedQuarterlyDataUnauditedDetails", "shortName": "Selected Quarterly Data (Unaudited) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "ix:continuation", "us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock", "div", "body", "html" ], "baseRef": "ex-991xllyx20181231x10.htm", "contextRef": "FD2018Q4QTD", "decimals": "-5", "lang": null, "name": "us-gaap:OperatingExpenses", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R9999": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "ex-991xllyx20181231x10.htm", "contextRef": "I2017Q1Jan1_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "", "isDefault": "false", "longName": "Uncategorized Items - _IXDS", "role": "http://xbrl.sec.gov/role/uncategorizedFacts", "shortName": "Uncategorized Items - _IXDS", "subGroupType": "", "uniqueAnchor": null } }, "segmentCount": 193, "tag": { "country_BR": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "BRAZIL", "terseLabel": "Brazil" } } }, "localname": "BR", "nsuri": "http://xbrl.sec.gov/country/2017-01-31", "presentation": [ "http://www.lilly.com/role/ContingenciesDetails" ], "xbrltype": "domainItemType" }, "country_JP": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "JAPAN", "terseLabel": "JAPAN" } } }, "localname": "JP", "nsuri": "http://xbrl.sec.gov/country/2017-01-31", "presentation": [ "http://www.lilly.com/role/CollaborationsAndOtherArrangementsDetails", "http://www.lilly.com/role/SegmentInformationDetails" ], "xbrltype": "domainItemType" }, "country_PR": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "PUERTO RICO", "terseLabel": "PUERTO RICO" } } }, "localname": "PR", "nsuri": "http://xbrl.sec.gov/country/2017-01-31", "presentation": [ "http://www.lilly.com/role/AssetImpairmentRestructuringAndOtherSpecialChargesNarrativeDetails" ], "xbrltype": "domainItemType" }, "country_US": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "UNITED STATES", "terseLabel": "United States" } } }, "localname": "US", "nsuri": "http://xbrl.sec.gov/country/2017-01-31", "presentation": [ "http://www.lilly.com/role/AssetImpairmentRestructuringAndOtherSpecialChargesNarrativeDetails", "http://www.lilly.com/role/CollaborationsAndOtherArrangementsDetails", "http://www.lilly.com/role/ContingenciesDetails", "http://www.lilly.com/role/SegmentInformationDetails" ], "xbrltype": "domainItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.lilly.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.lilly.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Cover page.", "label": "Cover page." } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "xbrltype": "stringItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus", "terseLabel": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.lilly.com/role/CoverPage" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus", "terseLabel": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.lilly.com/role/CoverPage" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.lilly.com/role/CoverPage" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.lilly.com/role/CoverPage" ], "xbrltype": "submissionTypeItemType" }, "dei_EntitiesTable": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Container to assemble all relevant information about each entity associated with the document instance", "label": "Entities [Table]", "terseLabel": "Entities [Table]" } } }, "localname": "EntitiesTable", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.lilly.com/role/CoverPage" ], "xbrltype": "stringItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.lilly.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.lilly.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.lilly.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.lilly.com/role/CoverPage" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r649" ], "lang": { "en-US": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.lilly.com/role/CoverPage" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.", "label": "Entity [Domain]", "terseLabel": "Entity [Domain]" } } }, "localname": "EntityDomain", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.lilly.com/role/DiscontinuedOperationsDetails", "http://www.lilly.com/role/SummaryOfSignificantAccountingPoliciesAcquisitionsDetails" ], "xbrltype": "domainItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r649" ], "lang": { "en-US": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.lilly.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.lilly.com/role/CoverPage" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.lilly.com/role/CoverPage" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInformationLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Entity Information [Line Items]", "terseLabel": "Entity Information [Line Items]" } } }, "localname": "EntityInformationLineItems", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.lilly.com/role/CoverPage" ], "xbrltype": "stringItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r649" ], "lang": { "en-US": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.lilly.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r649" ], "lang": { "en-US": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.lilly.com/role/CoverPage" ], "xbrltype": "employerIdItemType" }, "dei_LegalEntityAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The set of legal entities associated with a report.", "label": "Legal Entity [Axis]", "terseLabel": "Legal Entity [Axis]" } } }, "localname": "LegalEntityAxis", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.lilly.com/role/DiscontinuedOperationsDetails", "http://www.lilly.com/role/SummaryOfSignificantAccountingPoliciesAcquisitionsDetails" ], "xbrltype": "stringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.lilly.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r646" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer", "terseLabel": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.lilly.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r647" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer", "terseLabel": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.lilly.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r644" ], "lang": { "en-US": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.lilly.com/role/CoverPage" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r645" ], "lang": { "en-US": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.lilly.com/role/CoverPage" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r648" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.lilly.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.lilly.com/role/CoverPage" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r650" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.lilly.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "lly_A1.000NotesDueJune22022Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "1.000% Notes Due June 2, 2022 [Member]", "label": "1.000% Notes Due June 2, 2022 [Member]", "terseLabel": "1.000% Notes Due June 2, 2022" } } }, "localname": "A1.000NotesDueJune22022Member", "nsuri": "http://www.lilly.com/20191024", "presentation": [ "http://www.lilly.com/role/CoverPage" ], "xbrltype": "domainItemType" }, "lly_A1.625NotesDueJune22026Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "1.625% Notes Due June 2, 2026 [Member]", "label": "1.625% Notes Due June 2, 2026 [Member]", "terseLabel": "1.625% Notes Due June 2, 2026" } } }, "localname": "A1.625NotesDueJune22026Member", "nsuri": "http://www.lilly.com/20191024", "presentation": [ "http://www.lilly.com/role/CoverPage" ], "xbrltype": "domainItemType" }, "lly_A2.125NotesDueJune32030Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "2.125% Notes Due June 3, 2030 [Member]", "label": "2.125% Notes Due June 3, 2030 [Member]", "terseLabel": "2.125% Notes Due June 3, 2030" } } }, "localname": "A2.125NotesDueJune32030Member", "nsuri": "http://www.lilly.com/20191024", "presentation": [ "http://www.lilly.com/role/CoverPage" ], "xbrltype": "domainItemType" }, "lly_A2013ShareRepurchaseProgramMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "2013 Share Repurchase Program [Member]", "label": "2013 Share Repurchase Program [Member]", "terseLabel": "2013 Share Repurchase Program" } } }, "localname": "A2013ShareRepurchaseProgramMember", "nsuri": "http://www.lilly.com/20191024", "presentation": [ "http://www.lilly.com/role/ShareholdersEquityDetails" ], "xbrltype": "domainItemType" }, "lly_A2018RepurchaseProgramMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "2018 Repurchase Program [Member]", "label": "2018 Repurchase Program [Member]", "terseLabel": "2018 Repurchase Program" } } }, "localname": "A2018RepurchaseProgramMember", "nsuri": "http://www.lilly.com/20191024", "presentation": [ "http://www.lilly.com/role/ShareholdersEquityDetails" ], "xbrltype": "domainItemType" }, "lly_A6.77NotesDueJanuary12036Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "6.77% Notes Due January 1, 2036 [Member]", "label": "6.77% Notes Due January 1, 2036 [Member]", "terseLabel": "6.77% Notes Due January 1, 2036" } } }, "localname": "A6.77NotesDueJanuary12036Member", "nsuri": "http://www.lilly.com/20191024", "presentation": [ "http://www.lilly.com/role/CoverPage" ], "xbrltype": "domainItemType" }, "lly_A718NotesDueJune12025Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "7 1/8% Notes Due June 1, 2025 [Member]", "label": "7 1/8% Notes Due June 1, 2025 [Member]", "terseLabel": "7 1/8% Notes Due June 1, 2025" } } }, "localname": "A718NotesDueJune12025Member", "nsuri": "http://www.lilly.com/20191024", "presentation": [ "http://www.lilly.com/role/CoverPage" ], "xbrltype": "domainItemType" }, "lly_ACImmuneSAMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "AC Immune SA [Member]", "label": "AC Immune SA [Member]", "terseLabel": "AC Immune SA" } } }, "localname": "ACImmuneSAMember", "nsuri": "http://www.lilly.com/20191024", "presentation": [ "http://www.lilly.com/role/NarrativeDetails" ], "xbrltype": "domainItemType" }, "lly_ARMOBiosciencesInc.Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "ARMO Biosciences, Inc. [Member]", "label": "ARMO Biosciences, Inc. [Member]", "terseLabel": "ARMO" } } }, "localname": "ARMOBiosciencesInc.Member", "nsuri": "http://www.lilly.com/20191024", "presentation": [ "http://www.lilly.com/role/NarrativeDetails" ], "xbrltype": "domainItemType" }, "lly_AccumulatedNetGainLossfromCashFlowHedgesandForeignCurrencyAdjustmentIncludingPortionAttributabletoNoncontrollingInterestMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Accumulated Net Gain (Loss) from Cash Flow Hedges and Foreign Currency Adjustment Including Portion Attributable to Noncontrolling Interest [Member]", "label": "Accumulated Net Gain (Loss) from Cash Flow Hedges and Foreign Currency Adjustment Including Portion Attributable to Noncontrolling Interest [Member]", "terseLabel": "Other, net of tax" } } }, "localname": "AccumulatedNetGainLossfromCashFlowHedgesandForeignCurrencyAdjustmentIncludingPortionAttributabletoNoncontrollingInterestMember", "nsuri": "http://www.lilly.com/20191024", "presentation": [ "http://www.lilly.com/role/OtherComprehensiveIncomeLossReclassificationDetails" ], "xbrltype": "domainItemType" }, "lly_AcquiredInProcessResearchAndDevelopment": { "auth_ref": [], "calculation": { "http://www.lilly.com/role/ConsolidatedStatementsOfCashFlows": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://www.lilly.com/role/ConsolidatedStatementsOfOperations": { "order": 4.0, "parentTag": "lly_CostOfSalesOperatingExpensesAndOtherNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The amount of EXPENSE related to research and development assets that are acquired in a business combination (pre-141R) and/or licensing arrangement that have no alternative future use and are therefore written off in the period of acquisition (INCOME STATEMENT)", "label": "Acquired in-process research and development", "terseLabel": "Acquired in-process research and development", "verboseLabel": "Acquired in-process research and development (Note 3)" } } }, "localname": "AcquiredInProcessResearchAndDevelopment", "nsuri": "http://www.lilly.com/20191024", "presentation": [ "http://www.lilly.com/role/ConsolidatedStatementsOfCashFlows", "http://www.lilly.com/role/ConsolidatedStatementsOfOperations", "http://www.lilly.com/role/NarrativeDetails", "http://www.lilly.com/role/SelectedQuarterlyDataUnauditedDetails" ], "xbrltype": "monetaryItemType" }, "lly_AcquisitionTermsContingentConsiderationMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Acquisition Terms - Contingent Consideration [Member]", "label": "Acquisition Terms - Contingent Consideration [Member]", "terseLabel": "Sales Reported" } } }, "localname": "AcquisitionTermsContingentConsiderationMember", "nsuri": "http://www.lilly.com/20191024", "presentation": [ "http://www.lilly.com/role/CollaborationsAndOtherArrangementsDetails" ], "xbrltype": "domainItemType" }, "lly_AddDeductAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Add (Deduct) [Abstract]", "label": "Add (Deduct) [Abstract]", "terseLabel": "Add (deduct):" } } }, "localname": "AddDeductAbstract", "nsuri": "http://www.lilly.com/20191024", "presentation": [ "http://www.lilly.com/role/IncomeTaxesReconciliationOfIncomeTaxesDetails" ], "xbrltype": "stringItemType" }, "lly_AdjustmenttoReturnReserveMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Adjustment to Return Reserve [Member]", "label": "Adjustment to Return Reserve [Member]", "terseLabel": "Adjustment to Return Reserve" } } }, "localname": "AdjustmenttoReturnReserveMember", "nsuri": "http://www.lilly.com/20191024", "presentation": [ "http://www.lilly.com/role/SegmentInformationDetails" ], "xbrltype": "domainItemType" }, "lly_AdociaS.AMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Adocia S.A [Member]", "label": "Adocia S.A [Member]", "terseLabel": "Adocia S.A" } } }, "localname": "AdociaS.AMember", "nsuri": "http://www.lilly.com/20191024", "presentation": [ "http://www.lilly.com/role/ContingenciesDetails" ], "xbrltype": "domainItemType" }, "lly_AlimtaMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Alimta [Member]", "label": "Alimta [Member]", "terseLabel": "Alimta" } } }, "localname": "AlimtaMember", "nsuri": "http://www.lilly.com/20191024", "presentation": [ "http://www.lilly.com/role/ContingenciesDetails", "http://www.lilly.com/role/SegmentInformationDetails" ], "xbrltype": "domainItemType" }, "lly_AnimaBiotechMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Anima Biotech [Member]", "label": "Anima Biotech [Member]", "terseLabel": "Anima Biotech" } } }, "localname": "AnimaBiotechMember", "nsuri": "http://www.lilly.com/20191024", "presentation": [ "http://www.lilly.com/role/NarrativeDetails" ], "xbrltype": "domainItemType" }, "lly_AnimalHealthProductsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Animal Health Products [Member]", "label": "Animal Health Products [Member]", "terseLabel": "Animal health products", "verboseLabel": "Animal health products" } } }, "localname": "AnimalHealthProductsMember", "nsuri": "http://www.lilly.com/20191024", "presentation": [ "http://www.lilly.com/role/GoodwillAndOtherIntangiblesNarrativeDetails", "http://www.lilly.com/role/SegmentInformationDetails" ], "xbrltype": "domainItemType" }, "lly_AstraZenecaMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "AstraZeneca [Member]", "label": "AstraZeneca [Member]", "terseLabel": "AstraZeneca" } } }, "localname": "AstraZenecaMember", "nsuri": "http://www.lilly.com/20191024", "presentation": [ "http://www.lilly.com/role/NarrativeDetails" ], "xbrltype": "domainItemType" }, "lly_AurkaPharmaMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Aurka Pharma [Member]", "label": "Aurka Pharma [Member]", "terseLabel": "AurKa Pharma, Inc." } } }, "localname": "AurkaPharmaMember", "nsuri": "http://www.lilly.com/20191024", "presentation": [ "http://www.lilly.com/role/NarrativeDetails" ], "xbrltype": "domainItemType" }, "lly_AvailableforSaleSecuritiesandEquitySecuritiesFVNIRealizedGain": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Available for Sale Securities and Equity Securities, FV-NI, Realized Gain", "label": "Available for Sale Securities and Equity Securities, FV-NI, Realized Gain", "terseLabel": "Realized gross gains on sales" } } }, "localname": "AvailableforSaleSecuritiesandEquitySecuritiesFVNIRealizedGain", "nsuri": "http://www.lilly.com/20191024", "presentation": [ "http://www.lilly.com/role/FinancialInstrumentsInvestmentPortfolioActivityDetails" ], "xbrltype": "monetaryItemType" }, "lly_AvailableforsaleSecuritiesandEquitySecuritiesFVNIRealizedLoss": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Available for sale Securities and Equity Securities, FV-NI, Realized Loss", "label": "Available for sale Securities and Equity Securities, FV-NI, Realized Loss", "terseLabel": "Realized gross losses on sales" } } }, "localname": "AvailableforsaleSecuritiesandEquitySecuritiesFVNIRealizedLoss", "nsuri": "http://www.lilly.com/20191024", "presentation": [ "http://www.lilly.com/role/FinancialInstrumentsInvestmentPortfolioActivityDetails" ], "xbrltype": "monetaryItemType" }, "lly_BasaglarMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Basaglar [Member]", "label": "Basaglar [Member]", "terseLabel": "Basaglar" } } }, "localname": "BasaglarMember", "nsuri": "http://www.lilly.com/20191024", "presentation": [ "http://www.lilly.com/role/CollaborationsAndOtherArrangementsDetails", "http://www.lilly.com/role/SegmentInformationDetails" ], "xbrltype": "domainItemType" }, "lly_BuyEuroSellUsDollarMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Foreign Currency Forward Commitment to Buy euro Sell US dollar", "label": "Buy Euro Sell Us Dollar [Member]", "terseLabel": "Buy euro Sell US dollar" } } }, "localname": "BuyEuroSellUsDollarMember", "nsuri": "http://www.lilly.com/20191024", "presentation": [ "http://www.lilly.com/role/FinancialInstrumentsNarrativeDetails" ], "xbrltype": "domainItemType" }, "lly_BuyGBPSellUSDMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Buy GBP Sell USD", "label": "Buy GBP Sell USD [Member]", "terseLabel": "Buy GBP Sell USD" } } }, "localname": "BuyGBPSellUSDMember", "nsuri": "http://www.lilly.com/20191024", "presentation": [ "http://www.lilly.com/role/FinancialInstrumentsNarrativeDetails" ], "xbrltype": "domainItemType" }, "lly_BuySwissfrancsSellUSdollarMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Buy Swiss francs Sell US dollar [Member]", "label": "Buy Swiss francs Sell US dollar [Member]", "terseLabel": "Buy Swiss francs Sell US dollar" } } }, "localname": "BuySwissfrancsSellUSdollarMember", "nsuri": "http://www.lilly.com/20191024", "presentation": [ "http://www.lilly.com/role/FinancialInstrumentsNarrativeDetails" ], "xbrltype": "domainItemType" }, "lly_BuyUSdollarSellBritishpoundMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Buy US dollar Sell British pound [Member]", "label": "Buy US dollar Sell British pound [Member]", "terseLabel": "Buy US dollar Sell British pound" } } }, "localname": "BuyUSdollarSellBritishpoundMember", "nsuri": "http://www.lilly.com/20191024", "presentation": [ "http://www.lilly.com/role/FinancialInstrumentsNarrativeDetails" ], "xbrltype": "domainItemType" }, "lly_BuyUSdollarSellJapaneseYenMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Buy US dollar Sell Japanese Yen [Member]", "label": "Buy US dollar Sell Japanese Yen [Member]", "terseLabel": "Buy USD Sell Japanese Yen" } } }, "localname": "BuyUSdollarSellJapaneseYenMember", "nsuri": "http://www.lilly.com/20191024", "presentation": [ "http://www.lilly.com/role/FinancialInstrumentsNarrativeDetails" ], "xbrltype": "domainItemType" }, "lly_BuyUsdSellEuroMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Buy USD Sell Euro [Member]", "label": "Buy USD Sell Euro [Member]", "terseLabel": "Buy USD Sell Euro" } } }, "localname": "BuyUsdSellEuroMember", "nsuri": "http://www.lilly.com/20191024", "presentation": [ "http://www.lilly.com/role/FinancialInstrumentsNarrativeDetails" ], "xbrltype": "domainItemType" }, "lly_CardiovascularMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Revenue to unaffiliated customers, Cardiovascular", "label": "Cardiovascular [Member]", "terseLabel": "Cardiovascular:" } } }, "localname": "CardiovascularMember", "nsuri": "http://www.lilly.com/20191024", "presentation": [ "http://www.lilly.com/role/SegmentInformationDetails" ], "xbrltype": "domainItemType" }, "lly_CarryforwardMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Tax Carryforward [Member]", "label": "Carryforward [Member]", "terseLabel": "Carryforward" } } }, "localname": "CarryforwardMember", "nsuri": "http://www.lilly.com/20191024", "presentation": [ "http://www.lilly.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "domainItemType" }, "lly_CashFlowHedgeAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Cash Flow Hedge [Abstract]", "label": "Cash Flow Hedge [Abstract]", "terseLabel": "Cash Flow Hedge [Abstract]" } } }, "localname": "CashFlowHedgeAbstract", "nsuri": "http://www.lilly.com/20191024", "presentation": [ "http://www.lilly.com/role/FinancialInstrumentsEffectOfRiskManagementDetails" ], "xbrltype": "stringItemType" }, "lly_ChugaiPharmaceuticalCompanyMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Chugai Pharmaceutical Company [Member]", "label": "Chugai Pharmaceutical Company [Member]", "terseLabel": "Chugai Pharmaceutical Company" } } }, "localname": "ChugaiPharmaceuticalCompanyMember", "nsuri": "http://www.lilly.com/20191024", "presentation": [ "http://www.lilly.com/role/NarrativeDetails" ], "xbrltype": "domainItemType" }, "lly_CialisMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Cialis [Member]", "label": "Cialis [Member]", "terseLabel": "Cialis" } } }, "localname": "CialisMember", "nsuri": "http://www.lilly.com/20191024", "presentation": [ "http://www.lilly.com/role/SegmentInformationDetails" ], "xbrltype": "domainItemType" }, "lly_CoLucidPharmaceuticalsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "CoLucid Pharmaceuticals [Member]", "label": "CoLucid Pharmaceuticals [Member]", "terseLabel": "CoLucid Pharmaceuticals, Inc. (CoLucid)" } } }, "localname": "CoLucidPharmaceuticalsMember", "nsuri": "http://www.lilly.com/20191024", "presentation": [ "http://www.lilly.com/role/NarrativeDetails" ], "xbrltype": "domainItemType" }, "lly_CollaborationandOtherRevenueMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Collaboration and Other Revenue [Member]", "label": "Collaboration and Other Revenue [Member]", "terseLabel": "Collaboration and other revenue" } } }, "localname": "CollaborationandOtherRevenueMember", "nsuri": "http://www.lilly.com/20191024", "presentation": [ "http://www.lilly.com/role/SummaryOfSignificantAccountingPoliciesRevenueDetails" ], "xbrltype": "domainItemType" }, "lly_CollaborativeArrangementRightsAndObligationsPercent": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Description of rights and obligations under the collaborative arrangements, including but not limited to - percent share in various revenues and costs, percent interest earned on related party notes.", "label": "Collaborative Arrangement, Rights and Obligations Percent", "terseLabel": "Collaborative arrangement, rights and obligations percent (in percentage)" } } }, "localname": "CollaborativeArrangementRightsAndObligationsPercent", "nsuri": "http://www.lilly.com/20191024", "presentation": [ "http://www.lilly.com/role/CollaborationsAndOtherArrangementsDetails" ], "xbrltype": "percentItemType" }, "lly_CollaborativeArrangementRightsAndObligationsTerms": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Terms or rights and obligations under collaborative arrangements.", "label": "Collaborative Arrangement, Rights and Obligations, Terms", "terseLabel": "Collaborative arrangement, rights and obligations, terms" } } }, "localname": "CollaborativeArrangementRightsAndObligationsTerms", "nsuri": "http://www.lilly.com/20191024", "presentation": [ "http://www.lilly.com/role/CollaborationsAndOtherArrangementsDetails" ], "xbrltype": "monetaryItemType" }, "lly_ContingentConsiderationLiabilitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Contingent Consideration Liabilities [Abstract]", "label": "Contingent Consideration Liabilities [Abstract]", "terseLabel": "Contingent consideration liabilities:" } } }, "localname": "ContingentConsiderationLiabilitiesAbstract", "nsuri": "http://www.lilly.com/20191024", "presentation": [ "http://www.lilly.com/role/FinancialInstrumentsFairValueMeasurementDetails" ], "xbrltype": "stringItemType" }, "lly_CostOfSalesOperatingExpensesAndOtherNet": { "auth_ref": [], "calculation": { "http://www.lilly.com/role/ConsolidatedStatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Cost of sales, operating expenses, and other-net", "label": "Cost of sales, operating expenses, and other-net", "totalLabel": "Cost of sales, operating expenses, and other-net" } } }, "localname": "CostOfSalesOperatingExpensesAndOtherNet", "nsuri": "http://www.lilly.com/20191024", "presentation": [ "http://www.lilly.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "lly_CureVacAGMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "CureVac AG [Member]", "label": "CureVac AG [Member]", "terseLabel": "CureVac AG" } } }, "localname": "CureVacAGMember", "nsuri": "http://www.lilly.com/20191024", "presentation": [ "http://www.lilly.com/role/NarrativeDetails" ], "xbrltype": "domainItemType" }, "lly_CymbaltaMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Cymbalta [Member]", "label": "Cymbalta [Member]", "terseLabel": "Cymbalta" } } }, "localname": "CymbaltaMember", "nsuri": "http://www.lilly.com/20191024", "presentation": [ "http://www.lilly.com/role/SegmentInformationDetails" ], "xbrltype": "domainItemType" }, "lly_CyramzaMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Cyramza [Member]", "label": "Cyramza [Member]", "terseLabel": "Cyramza\u00ae" } } }, "localname": "CyramzaMember", "nsuri": "http://www.lilly.com/20191024", "presentation": [ "http://www.lilly.com/role/SegmentInformationDetails" ], "xbrltype": "domainItemType" }, "lly_DebtSecuritiesAvailableforsaleUnrealizedGainPosition": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Debt Securities, Available-for-sale, Unrealized Gain Position", "label": "Debt Securities, Available-for-sale, Unrealized Gain Position", "terseLabel": "Fair value of securities in an unrealized gain position" } } }, "localname": "DebtSecuritiesAvailableforsaleUnrealizedGainPosition", "nsuri": "http://www.lilly.com/20191024", "presentation": [ "http://www.lilly.com/role/FinancialInstrumentsSummaryOfAfsUnrealizedGainlossDetails" ], "xbrltype": "monetaryItemType" }, "lly_DeferredTaxAssetFairValueAdjustments": { "auth_ref": [], "calculation": { "http://www.lilly.com/role/IncomeTaxesDeferredTaxAssetAndLiabilitiesDetails": { "order": 8.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Deferred tax asset resulting from fair value adjustments, including on hedged borrowings", "label": "Deferred Tax Asset, Fair Value Adjustments", "terseLabel": "Debt" } } }, "localname": "DeferredTaxAssetFairValueAdjustments", "nsuri": "http://www.lilly.com/20191024", "presentation": [ "http://www.lilly.com/role/IncomeTaxesDeferredTaxAssetAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "lly_DefineBenefitPlanOtherMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Define Benefit Plan, Other [Member]", "label": "Define Benefit Plan, Other [Member]", "terseLabel": "Other" } } }, "localname": "DefineBenefitPlanOtherMember", "nsuri": "http://www.lilly.com/20191024", "presentation": [ "http://www.lilly.com/role/RetirementBenefitsFairValueDisclosuresDetails" ], "xbrltype": "domainItemType" }, "lly_DefinedBenefitPlanEstimatedFutureEmployerContributionsinNextFiscalYearMinimum": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Defined Benefit Plan, Estimated Future Employer Contributions in Next Fiscal Year, Minimum", "label": "Defined Benefit Plan, Estimated Future Employer Contributions in Next Fiscal Year, Minimum", "terseLabel": "Expected contribution" } } }, "localname": "DefinedBenefitPlanEstimatedFutureEmployerContributionsinNextFiscalYearMinimum", "nsuri": "http://www.lilly.com/20191024", "presentation": [ "http://www.lilly.com/role/RetirementBenefitsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "lly_DefinedBenefitPlanNetPeriodicBenefitCostCreditGainLossDuetoCurtailmentandSpecialTerminationBenefits": { "auth_ref": [], "calculation": { "http://www.lilly.com/role/AssetImpairmentRestructuringAndOtherSpecialChargesDetails": { "order": 3.0, "parentTag": "us-gaap_RestructuringSettlementAndImpairmentProvisions", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Defined Benefit Plan, Net Periodic Benefit Cost (Credit), Gain (Loss) Due to Curtailment and Special Termination Benefits", "label": "Defined Benefit Plan, Net Periodic Benefit Cost (Credit), Gain (Loss) Due to Curtailment and Special Termination Benefits", "terseLabel": "Pension and post-retirement medical charges associated with U.S. voluntary early retirement program (see Note 14)" } } }, "localname": "DefinedBenefitPlanNetPeriodicBenefitCostCreditGainLossDuetoCurtailmentandSpecialTerminationBenefits", "nsuri": "http://www.lilly.com/20191024", "presentation": [ "http://www.lilly.com/role/AssetImpairmentRestructuringAndOtherSpecialChargesDetails" ], "xbrltype": "monetaryItemType" }, "lly_DefinedBenefitPlanNetPeriodicBenefitCostCreditGainLossDuetoSpecialTerminationBenefits": { "auth_ref": [], "calculation": { "http://www.lilly.com/role/RetirementBenefitsScheduleOfExpectedBenefitPaymentsContributionsAndExpenseDetails": { "order": 7.0, "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Defined Benefit Plan, Net Periodic Benefit Cost (Credit), Gain (Loss) Due to Special Termination Benefits", "label": "Defined Benefit Plan, Net Periodic Benefit Cost (Credit), Gain (Loss) Due to Special Termination Benefits", "verboseLabel": "Special termination benefit" } } }, "localname": "DefinedBenefitPlanNetPeriodicBenefitCostCreditGainLossDuetoSpecialTerminationBenefits", "nsuri": "http://www.lilly.com/20191024", "presentation": [ "http://www.lilly.com/role/RetirementBenefitsScheduleOfExpectedBenefitPaymentsContributionsAndExpenseDetails" ], "xbrltype": "monetaryItemType" }, "lly_DefinedBenefitPlanPercentageOfGlobalInvestmentsInPlanAssets": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Percentage description of US defined benefit and other postretirement plan assets as compared to the total global investment balance", "label": "Defined Benefit Plan, Percentage of Global Investments in Plan Assets", "terseLabel": "Percentage of global investments in plan assets (in percentage)" } } }, "localname": "DefinedBenefitPlanPercentageOfGlobalInvestmentsInPlanAssets", "nsuri": "http://www.lilly.com/20191024", "presentation": [ "http://www.lilly.com/role/RetirementBenefitsNarrativeDetails" ], "xbrltype": "percentItemType" }, "lly_DerivativeInstrumentsGainLossRecognized": { "auth_ref": [], "calculation": { "http://www.lilly.com/role/FinancialInstrumentsEffectOfRiskManagementDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Derivative Instruments, Gain(loss) Recognized", "label": "Derivative Instruments, Gain (Loss) Recognized", "totalLabel": "Total" } } }, "localname": "DerivativeInstrumentsGainLossRecognized", "nsuri": "http://www.lilly.com/20191024", "presentation": [ "http://www.lilly.com/role/FinancialInstrumentsEffectOfRiskManagementDetails" ], "xbrltype": "monetaryItemType" }, "lly_DescriptionOfDerivativeActivityVolumePercent": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Label: Description of Derivative Activity Volume\nElement ID: us-gaap_DescriptionOfDerivativeActivityVolume\nBalance Type: na\nData Type: PERCENT\nPeriod Type: duration\n---------------------------------------------------------------------\nDefinition: Information that would enable users to understand the volume of the entity's derivative activity.\n\nReference 1: http://www.xbrl.org/2003/role/presentationRef\n -Publisher FASB\n -Name Statement of Financial Accounting Standard (FAS)\n -Number 133\n -Paragraph 44\n -Subparagraph 2", "label": "Description of Derivative Activity Volume Percent", "terseLabel": "Description of derivative activity volume percent" } } }, "localname": "DescriptionOfDerivativeActivityVolumePercent", "nsuri": "http://www.lilly.com/20191024", "presentation": [ "http://www.lilly.com/role/BorrowingsNarrativeDetails" ], "xbrltype": "percentItemType" }, "lly_DesignatedUnusableMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Those operating loss/tax credit carryforwards/carrybacks included that have been designated to be unusable and therefore, is fully reserved.", "label": "Designated Unusable [Member]", "terseLabel": "Designated Unusable" } } }, "localname": "DesignatedUnusableMember", "nsuri": "http://www.lilly.com/20191024", "presentation": [ "http://www.lilly.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "domainItemType" }, "lly_DiabetesCollaborationMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Diabetes Collaboration [Member]", "label": "Diabetes Collaboration [Member]", "terseLabel": "Diabetes Collaboration" } } }, "localname": "DiabetesCollaborationMember", "nsuri": "http://www.lilly.com/20191024", "presentation": [ "http://www.lilly.com/role/CollaborationsAndOtherArrangementsTables" ], "xbrltype": "domainItemType" }, "lly_DicernaPharmaceuticalsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Dicerna Pharmaceuticals [Member]", "label": "Dicerna Pharmaceuticals [Member]", "terseLabel": "Dicerna Pharmaceuticals" } } }, "localname": "DicernaPharmaceuticalsMember", "nsuri": "http://www.lilly.com/20191024", "presentation": [ "http://www.lilly.com/role/NarrativeDetails" ], "xbrltype": "domainItemType" }, "lly_DisposalGroupIncludingDiscontinuedOperationDebtNoncurrent": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Disposal Group, Including Discontinued Operation, Debt, Noncurrent", "label": "Disposal Group, Including Discontinued Operation, Debt, Noncurrent", "terseLabel": "Long-term debt" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationDebtNoncurrent", "nsuri": "http://www.lilly.com/20191024", "presentation": [ "http://www.lilly.com/role/DiscontinuedOperationsMajorClassesOfAssetsAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "lly_DisposalGroupIncludingDiscontinuedOperationTransitionalServicesAgreementTerm": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Disposal Group, Including Discontinued Operation, Transitional Services Agreement, Term", "label": "Disposal Group, Including Discontinued Operation, Transitional Services Agreement, Term", "terseLabel": "Transitional services agreement, term" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationTransitionalServicesAgreementTerm", "nsuri": "http://www.lilly.com/20191024", "presentation": [ "http://www.lilly.com/role/DiscontinuedOperationsDetails" ], "xbrltype": "durationItemType" }, "lly_DomesticandPuertoRicanContributiontoIncomebeforeIncomeTaxes": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Percent contribution of most significant (domestic, including Puerto Rico) areas that contributed to the consolidated income (loss) before income taxes.", "label": "Domestic and Puerto Rican Contribution to Income before Income Taxes", "terseLabel": "Domestic and Puerto Rican companies contribution" } } }, "localname": "DomesticandPuertoRicanContributiontoIncomebeforeIncomeTaxes", "nsuri": "http://www.lilly.com/20191024", "presentation": [ "http://www.lilly.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "percentItemType" }, "lly_DrReddysLabMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Dr Reddy's Lab [Member]", "label": "Dr Reddy's Lab [Member]", "terseLabel": "Dr Reddy's Lab" } } }, "localname": "DrReddysLabMember", "nsuri": "http://www.lilly.com/20191024", "presentation": [ "http://www.lilly.com/role/ContingenciesDetails" ], "xbrltype": "domainItemType" }, "lly_EffectiveIncomeTaxRateReconciliationTaxCutsandJobsActAmount": { "auth_ref": [], "calculation": { "http://www.lilly.com/role/IncomeTaxesReconciliationOfIncomeTaxesDetails": { "order": 6.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Effective Income Tax Rate Reconciliation, Tax Cuts and Jobs Act, Amount", "label": "Effective Income Tax Rate Reconciliation, Tax Cuts and Jobs Act, Amount", "terseLabel": "2017 Tax Act" } } }, "localname": "EffectiveIncomeTaxRateReconciliationTaxCutsandJobsActAmount", "nsuri": "http://www.lilly.com/20191024", "presentation": [ "http://www.lilly.com/role/IncomeTaxesReconciliationOfIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "lly_EffientMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Effient [Member]", "label": "Effient [Member]", "terseLabel": "Effient" } } }, "localname": "EffientMember", "nsuri": "http://www.lilly.com/20191024", "presentation": [ "http://www.lilly.com/role/CollaborationsAndOtherArrangementsDetails", "http://www.lilly.com/role/CollaborationsAndOtherArrangementsTables", "http://www.lilly.com/role/SegmentInformationDetails" ], "xbrltype": "domainItemType" }, "lly_ElancoAnimalHealthIncorporatedMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Elanco Animal Health Incorporated [Member]", "label": "Elanco Animal Health Incorporated [Member]", "terseLabel": "Elanco Animal Health Incorporated" } } }, "localname": "ElancoAnimalHealthIncorporatedMember", "nsuri": "http://www.lilly.com/20191024", "presentation": [ "http://www.lilly.com/role/DiscontinuedOperationsDetails", "http://www.lilly.com/role/DiscontinuedOperationsDiscontinuedOperationsInFinancialStatementsDetails", "http://www.lilly.com/role/DiscontinuedOperationsMajorClassesOfAssetsAndLiabilitiesDetails", "http://www.lilly.com/role/SegmentInformationDetails", "http://www.lilly.com/role/SummaryOfSignificantAccountingPoliciesAcquisitionsDetails" ], "xbrltype": "domainItemType" }, "lly_EmployeeLitigationMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Employee Litigation [Member]", "label": "Employee Litigation [Member]", "terseLabel": "Employee Litigation" } } }, "localname": "EmployeeLitigationMember", "nsuri": "http://www.lilly.com/20191024", "presentation": [ "http://www.lilly.com/role/ContingenciesDetails" ], "xbrltype": "domainItemType" }, "lly_EndocrinologyMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Revenue to unaffiliated customers, Endocrinology", "label": "Endocrinology [Member]", "terseLabel": "Endocrinology" } } }, "localname": "EndocrinologyMember", "nsuri": "http://www.lilly.com/20191024", "presentation": [ "http://www.lilly.com/role/SegmentInformationDetails" ], "xbrltype": "domainItemType" }, "lly_EquityMethodAndOtherInvestmentsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Equity Method and Other Investments [Member]", "label": "Equity Method And Other Investments [Member]", "terseLabel": "Cost and equity method investments" } } }, "localname": "EquityMethodAndOtherInvestmentsMember", "nsuri": "http://www.lilly.com/20191024", "presentation": [ "http://www.lilly.com/role/FinancialInstrumentsFairValueMeasurementDetails" ], "xbrltype": "domainItemType" }, "lly_ErbituxCollaborationandOtherRevenueMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Erbitux, Collaboration and Other Revenue [Member]", "label": "Erbitux, Collaboration and Other Revenue [Member]", "terseLabel": "Erbitux, Collaboration and Other Revenue" } } }, "localname": "ErbituxCollaborationandOtherRevenueMember", "nsuri": "http://www.lilly.com/20191024", "presentation": [ "http://www.lilly.com/role/CollaborationsAndOtherArrangementsDetails" ], "xbrltype": "domainItemType" }, "lly_ErbituxMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Erbitux [Member]", "label": "Erbitux [Member]", "terseLabel": "Erbitux" } } }, "localname": "ErbituxMember", "nsuri": "http://www.lilly.com/20191024", "presentation": [ "http://www.lilly.com/role/CollaborationsAndOtherArrangementsDetails", "http://www.lilly.com/role/CollaborationsAndOtherArrangementsTables", "http://www.lilly.com/role/SegmentInformationDetails" ], "xbrltype": "domainItemType" }, "lly_ErbituxProductMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Erbitux, Product [Member]", "label": "Erbitux, Product [Member]", "terseLabel": "Erbitux, Product" } } }, "localname": "ErbituxProductMember", "nsuri": "http://www.lilly.com/20191024", "presentation": [ "http://www.lilly.com/role/CollaborationsAndOtherArrangementsDetails" ], "xbrltype": "domainItemType" }, "lly_Expiration5to20YearsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Expiration 5 to 20 Years [Member]", "label": "Expiration 5 to 20 Years [Member]", "terseLabel": "Expiration 5 to 20 Years" } } }, "localname": "Expiration5to20YearsMember", "nsuri": "http://www.lilly.com/20191024", "presentation": [ "http://www.lilly.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "domainItemType" }, "lly_Expirationin9YearsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Expiration in 9 Years [Member]", "label": "Expiration in 9 Years [Member]", "terseLabel": "Expiration in 9 Years" } } }, "localname": "Expirationin9YearsMember", "nsuri": "http://www.lilly.com/20191024", "presentation": [ "http://www.lilly.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "domainItemType" }, "lly_Expirationwithin5yearsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Expiration within 5 years [Member]", "label": "Expiration within 5 years [Member]", "terseLabel": "Expiration within 5 years" } } }, "localname": "Expirationwithin5yearsMember", "nsuri": "http://www.lilly.com/20191024", "presentation": [ "http://www.lilly.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "domainItemType" }, "lly_FairValueHedgeAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Fair Value Hedge [Abstract]", "label": "Fair Value Hedge [Abstract]", "terseLabel": "Fair Value Hedge [Abstract]" } } }, "localname": "FairValueHedgeAbstract", "nsuri": "http://www.lilly.com/20191024", "presentation": [ "http://www.lilly.com/role/FinancialInstrumentsEffectOfRiskManagementDetails" ], "xbrltype": "stringItemType" }, "lly_FairValueRetirementBenefitsInvestmentsAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Fair Value, Retirement Benefits, Investments [Axis]", "label": "Fair Value, Retirement Benefits, Investments [Axis]", "terseLabel": "Fair Value, Retirement Benefits, Investments [Axis]" } } }, "localname": "FairValueRetirementBenefitsInvestmentsAxis", "nsuri": "http://www.lilly.com/20191024", "presentation": [ "http://www.lilly.com/role/RetirementBenefitsFairValueDisclosuresDetails" ], "xbrltype": "stringItemType" }, "lly_FairValueRetirementBenefitsInvestmentsDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "[Domain] for Fair Value, Retirement Benefits, Investments [Axis]", "label": "Fair Value, Retirement Benefits, Investments [Domain]", "terseLabel": "Fair Value, Retirement Benefits, Investments [Domain]" } } }, "localname": "FairValueRetirementBenefitsInvestmentsDomain", "nsuri": "http://www.lilly.com/20191024", "presentation": [ "http://www.lilly.com/role/RetirementBenefitsFairValueDisclosuresDetails" ], "xbrltype": "domainItemType" }, "lly_FairValueRetirementBenefitsInvestmentsValuedatNetAssetValueMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Fair Value, Retirement Benefits, Investments Valued at Net Asset Value [Member]\nCertain investments that are measured at fair value using the Net Asset Value per share (or its equivalent) as a practical expedient and are not classified in the fair value heirarchy.", "label": "Fair Value, Retirement Benefits, Investments Valued at Net Asset Value [Member]", "terseLabel": "Fair Value, Retirement Benefits, Investments Valued at Net Asset Value" } } }, "localname": "FairValueRetirementBenefitsInvestmentsValuedatNetAssetValueMember", "nsuri": "http://www.lilly.com/20191024", "presentation": [ "http://www.lilly.com/role/RetirementBenefitsFairValueDisclosuresDetails" ], "xbrltype": "domainItemType" }, "lly_FixedIncomeFundsEmergingMarketsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "An investment that pools funds from many investors to invest in a combination of underlying investments, primarily fixed income investments in EMERGING MARKETS.", "label": "Fixed Income Funds Emerging Markets [Member]", "terseLabel": "Emerging markets" } } }, "localname": "FixedIncomeFundsEmergingMarketsMember", "nsuri": "http://www.lilly.com/20191024", "presentation": [ "http://www.lilly.com/role/RetirementBenefitsFairValueDisclosuresDetails" ], "xbrltype": "domainItemType" }, "lly_FixedIncomeFundsRepurchasedAgreementsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Fixed Income Funds - Repurchased Agreements [Member]", "label": "Fixed Income Funds - Repurchased Agreements [Member]", "terseLabel": "Developed markets - repurchase agreements" } } }, "localname": "FixedIncomeFundsRepurchasedAgreementsMember", "nsuri": "http://www.lilly.com/20191024", "presentation": [ "http://www.lilly.com/role/RetirementBenefitsFairValueDisclosuresDetails" ], "xbrltype": "domainItemType" }, "lly_ForeignCurrencyDenominatedDebtMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Foreign Currency Denominated Debt [Member]", "label": "Foreign Currency Denominated Debt [Member]", "terseLabel": "Foreign Currency Denominated Debt" } } }, "localname": "ForeignCurrencyDenominatedDebtMember", "nsuri": "http://www.lilly.com/20191024", "presentation": [ "http://www.lilly.com/role/FinancialInstrumentsNarrativeDetails" ], "xbrltype": "domainItemType" }, "lly_ForteoMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Forteo [Member]", "label": "Forteo [Member]", "terseLabel": "Forteo" } } }, "localname": "ForteoMember", "nsuri": "http://www.lilly.com/20191024", "presentation": [ "http://www.lilly.com/role/SegmentInformationDetails" ], "xbrltype": "domainItemType" }, "lly_HedgedFixedRateDebtMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Hedged Fixed-Rate Debt [Member]", "label": "Hedged Fixed Rate Debt [Member]", "terseLabel": "Hedged Fixed Rate Debt" } } }, "localname": "HedgedFixedRateDebtMember", "nsuri": "http://www.lilly.com/20191024", "presentation": [ "http://www.lilly.com/role/FinancialInstrumentsEffectOfRiskManagementDetails" ], "xbrltype": "domainItemType" }, "lly_HumalogMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Humalog [Member]", "label": "Humalog [Member]", "terseLabel": "Humalog" } } }, "localname": "HumalogMember", "nsuri": "http://www.lilly.com/20191024", "presentation": [ "http://www.lilly.com/role/SegmentInformationDetails" ], "xbrltype": "domainItemType" }, "lly_HumanPharmaceuticalProductsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Human Pharmaceutical Products [Member]", "label": "Human Pharmaceutical Products [Member]", "terseLabel": "Human pharmaceutical products" } } }, "localname": "HumanPharmaceuticalProductsMember", "nsuri": "http://www.lilly.com/20191024", "presentation": [ "http://www.lilly.com/role/CollaborationsAndOtherArrangementsDetails", "http://www.lilly.com/role/SegmentInformationDetails" ], "xbrltype": "domainItemType" }, "lly_HumulinMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Humulin [Member]", "label": "Humulin [Member]", "terseLabel": "Humulin" } } }, "localname": "HumulinMember", "nsuri": "http://www.lilly.com/20191024", "presentation": [ "http://www.lilly.com/role/SegmentInformationDetails" ], "xbrltype": "domainItemType" }, "lly_HydraBiosciencesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Hydra Biosciences [Member]", "label": "Hydra Biosciences [Member]", "terseLabel": "Hydra Biosciences" } } }, "localname": "HydraBiosciencesMember", "nsuri": "http://www.lilly.com/20191024", "presentation": [ "http://www.lilly.com/role/NarrativeDetails" ], "xbrltype": "domainItemType" }, "lly_ImmunologyMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Immunology [Member]", "label": "Immunology [Member]", "terseLabel": "Immunology:" } } }, "localname": "ImmunologyMember", "nsuri": "http://www.lilly.com/20191024", "presentation": [ "http://www.lilly.com/role/SegmentInformationDetails" ], "xbrltype": "domainItemType" }, "lly_ImpactonEquityofSaleofNoncontrollingInterestinSubsidiary": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Impact on Equity of Sale of Noncontrolling Interest in Subsidiary", "label": "Impact on Equity of Sale of Noncontrolling Interest in Subsidiary", "terseLabel": "Sale of Elanco Stock (Note 20)" } } }, "localname": "ImpactonEquityofSaleofNoncontrollingInterestinSubsidiary", "nsuri": "http://www.lilly.com/20191024", "presentation": [ "http://www.lilly.com/role/ConsolidatedStatementsOfShareholdersEquityStatement" ], "xbrltype": "monetaryItemType" }, "lly_IncomeTaxPaymentAnticipated": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Income Tax Payment, Anticipated", "label": "Income Tax Payment, Anticipated", "terseLabel": "Income tax payment, anticipated" } } }, "localname": "IncomeTaxPaymentAnticipated", "nsuri": "http://www.lilly.com/20191024", "presentation": [ "http://www.lilly.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "lly_IncompleteAccountingProvisionalIncomeTaxExpenseBenefit": { "auth_ref": [], "calculation": { "http://www.lilly.com/role/IncomeTaxesCurrentAndDeferredDetails": { "order": 5.0, "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Incomplete Accounting, Provisional Income Tax Expense (Benefit)", "label": "Incomplete Accounting, Provisional Income Tax Expense (Benefit)", "terseLabel": "2017 Tax Act" } } }, "localname": "IncompleteAccountingProvisionalIncomeTaxExpenseBenefit", "nsuri": "http://www.lilly.com/20191024", "presentation": [ "http://www.lilly.com/role/IncomeTaxesCurrentAndDeferredDetails" ], "xbrltype": "monetaryItemType" }, "lly_InternationalMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "International [Member]", "label": "International [Member]", "terseLabel": "Outside U.S." } } }, "localname": "InternationalMember", "nsuri": "http://www.lilly.com/20191024", "presentation": [ "http://www.lilly.com/role/SegmentInformationDetails" ], "xbrltype": "domainItemType" }, "lly_JapaneseAdministrativeProceedingsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Japanese Administrative Proceedings [Member]", "label": "Japanese Administrative Proceedings [Member]", "terseLabel": "Japanese Administrative Proceedings" } } }, "localname": "JapaneseAdministrativeProceedingsMember", "nsuri": "http://www.lilly.com/20191024", "presentation": [ "http://www.lilly.com/role/ContingenciesDetails" ], "xbrltype": "domainItemType" }, "lly_JardianceMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Jardiance [Member]", "label": "Jardiance [Member]", "terseLabel": "Jardiance" } } }, "localname": "JardianceMember", "nsuri": "http://www.lilly.com/20191024", "presentation": [ "http://www.lilly.com/role/CollaborationsAndOtherArrangementsDetails", "http://www.lilly.com/role/SegmentInformationDetails" ], "xbrltype": "domainItemType" }, "lly_KeyBiosciencesDualAmylinCalcitoninReceptorAgonistsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "KeyBioscience's Dual Amylin Calcitonin Receptor Agonists [Member]", "label": "KeyBioscience's Dual Amylin Calcitonin Receptor Agonists [Member]", "terseLabel": "KeyBioscience AG" } } }, "localname": "KeyBiosciencesDualAmylinCalcitoninReceptorAgonistsMember", "nsuri": "http://www.lilly.com/20191024", "presentation": [ "http://www.lilly.com/role/NarrativeDetails" ], "xbrltype": "domainItemType" }, "lly_LongTermDebtFairValueAdjustment": { "auth_ref": [], "calculation": { "http://www.lilly.com/role/BorrowingsLongTermDebtDetails": { "order": 5.0, "parentTag": "us-gaap_DebtLongtermAndShorttermCombinedAmount", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Fair value adjustment to carrying value of long term debt to arrive at total fair value.", "label": "Long-term Debt, Fair Value Adjustment", "terseLabel": "Fair value adjustment on hedged long-term notes" } } }, "localname": "LongTermDebtFairValueAdjustment", "nsuri": "http://www.lilly.com/20191024", "presentation": [ "http://www.lilly.com/role/BorrowingsLongTermDebtDetails" ], "xbrltype": "monetaryItemType" }, "lly_LossContingencyAmountofClaim": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Loss Contingency, Amount of Claim", "label": "Loss Contingency, Amount of Claim", "terseLabel": "Amount of claim" } } }, "localname": "LossContingencyAmountofClaim", "nsuri": "http://www.lilly.com/20191024", "presentation": [ "http://www.lilly.com/role/ContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "lly_LossContingencyNumberOfLawsuits": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Number of lawsuits in a particular litigation or loss contingency.", "label": "Loss Contingency, Number of Lawsuits", "terseLabel": "Number of lawsuits" } } }, "localname": "LossContingencyNumberOfLawsuits", "nsuri": "http://www.lilly.com/20191024", "presentation": [ "http://www.lilly.com/role/ContingenciesDetails" ], "xbrltype": "integerItemType" }, "lly_LossContingencyNumberOfSimilarLawsuits": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Loss Contingency, Number Of Similar Lawsuits", "label": "Loss Contingency, Number Of Similar Lawsuits", "terseLabel": "Number of similar lawsuits" } } }, "localname": "LossContingencyNumberOfSimilarLawsuits", "nsuri": "http://www.lilly.com/20191024", "presentation": [ "http://www.lilly.com/role/ContingenciesDetails" ], "xbrltype": "integerItemType" }, "lly_LossContingencyNumberofDemands": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Loss Contingency, Number of Demands", "label": "Loss Contingency, Number of Demands", "terseLabel": "Number of demands" } } }, "localname": "LossContingencyNumberofDemands", "nsuri": "http://www.lilly.com/20191024", "presentation": [ "http://www.lilly.com/role/ContingenciesDetails" ], "xbrltype": "integerItemType" }, "lly_LossContingencyNumberofGenericProducts": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Loss Contingency, Number of Generic Products", "label": "Loss Contingency, Number of Generic Products", "terseLabel": "Number of generic products" } } }, "localname": "LossContingencyNumberofGenericProducts", "nsuri": "http://www.lilly.com/20191024", "presentation": [ "http://www.lilly.com/role/ContingenciesDetails" ], "xbrltype": "integerItemType" }, "lly_LoxoOncologyInc.Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Loxo Oncology, Inc. [Member]", "label": "Loxo Oncology, Inc. [Member]", "terseLabel": "Loxo Oncology, Inc." } } }, "localname": "LoxoOncologyInc.Member", "nsuri": "http://www.lilly.com/20191024", "presentation": [ "http://www.lilly.com/role/NarrativeDetails" ], "xbrltype": "domainItemType" }, "lly_MarketableSecuritiesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Marketable Securities [Member]", "label": "Marketable Securities [Member]", "terseLabel": "Marketable equity securities" } } }, "localname": "MarketableSecuritiesMember", "nsuri": "http://www.lilly.com/20191024", "presentation": [ "http://www.lilly.com/role/FinancialInstrumentsFairValueMeasurementDetails" ], "xbrltype": "domainItemType" }, "lly_MaturityDate2019Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Maturity Date, 2019 [Member]", "label": "Maturity Date, 2019 [Member]", "terseLabel": "Maturity Date, 2019" } } }, "localname": "MaturityDate2019Member", "nsuri": "http://www.lilly.com/20191024", "presentation": [ "http://www.lilly.com/role/BorrowingsNarrativeDetails" ], "xbrltype": "domainItemType" }, "lly_MaturityDate2023Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Maturity Date, 2023", "label": "Maturity Date, 2023 [Member]", "terseLabel": "Maturity Date, 2023" } } }, "localname": "MaturityDate2023Member", "nsuri": "http://www.lilly.com/20191024", "presentation": [ "http://www.lilly.com/role/BorrowingsNarrativeDetails" ], "xbrltype": "domainItemType" }, "lly_MilestonePaymentsDevelopmentAndRegulatoryMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Milestone Payments, Development and Regulatory [Member]", "label": "Milestone Payments, Development and Regulatory [Member]", "terseLabel": "Milestone Payments, Development and Regulatory" } } }, "localname": "MilestonePaymentsDevelopmentAndRegulatoryMember", "nsuri": "http://www.lilly.com/20191024", "presentation": [ "http://www.lilly.com/role/CollaborationsAndOtherArrangementsDetails" ], "xbrltype": "domainItemType" }, "lly_MilestonePaymentsDevelopmentandRegulatoryCapitalizedCumulativeMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Milestone Payments, Development and Regulatory, Capitalized, Cumulative [Member]", "label": "Milestone Payments, Development and Regulatory, Capitalized, Cumulative [Member]", "terseLabel": "Milestone Payments, Development and Regulatory, Capitalized, Cumulative [Member]" } } }, "localname": "MilestonePaymentsDevelopmentandRegulatoryCapitalizedCumulativeMember", "nsuri": "http://www.lilly.com/20191024", "presentation": [ "http://www.lilly.com/role/CollaborationsAndOtherArrangementsDetails" ], "xbrltype": "domainItemType" }, "lly_MilestonePaymentsDevelopmentandRegulatoryCapitalizedDeferredMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Milestone Payments, Development and Regulatory, Capitalized [Member]", "label": "Milestone Payments, Development and Regulatory, Capitalized (Deferred) [Member]", "terseLabel": "Milestone Payments, Development and Regulatory, Capitalized (Deferred)" } } }, "localname": "MilestonePaymentsDevelopmentandRegulatoryCapitalizedDeferredMember", "nsuri": "http://www.lilly.com/20191024", "presentation": [ "http://www.lilly.com/role/CollaborationsAndOtherArrangementsDetails" ], "xbrltype": "domainItemType" }, "lly_MilestonePaymentsDevelopmentandRegulatoryCapitalizedMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Milestone Payments, Development and Regulatory, Capitalized [Member]", "label": "Milestone Payments, Development and Regulatory, Capitalized [Member]", "terseLabel": "Milestone Payments, Development and Regulatory, Capitalized" } } }, "localname": "MilestonePaymentsDevelopmentandRegulatoryCapitalizedMember", "nsuri": "http://www.lilly.com/20191024", "presentation": [ "http://www.lilly.com/role/CollaborationsAndOtherArrangementsDetails" ], "xbrltype": "domainItemType" }, "lly_MilestonePaymentsDevelopmentandRegulatoryExpensedMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Milestone Payments, Development and Regulatory, Expensed [Member]", "label": "Milestone Payments, Development and Regulatory, Expensed [Member]", "terseLabel": "Milestone Payments, Development and Regulatory, Expensed" } } }, "localname": "MilestonePaymentsDevelopmentandRegulatoryExpensedMember", "nsuri": "http://www.lilly.com/20191024", "presentation": [ "http://www.lilly.com/role/CollaborationsAndOtherArrangementsDetails" ], "xbrltype": "domainItemType" }, "lly_MilestonePaymentsSalesBasedMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Milestone Payments, Sales-based [Member]", "label": "Milestone Payments, Sales-based [Member]", "terseLabel": "Milestone Payments, Sales-based" } } }, "localname": "MilestonePaymentsSalesBasedMember", "nsuri": "http://www.lilly.com/20191024", "presentation": [ "http://www.lilly.com/role/CollaborationsAndOtherArrangementsDetails" ], "xbrltype": "domainItemType" }, "lly_NektarsPhaseIImmunologicalTherapyMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Nektar's Phase I Immunological Therapy [Member]", "label": "Nektar's Phase I Immunological Therapy [Member]", "terseLabel": "Nektar Therapeutics" } } }, "localname": "NektarsPhaseIImmunologicalTherapyMember", "nsuri": "http://www.lilly.com/20191024", "presentation": [ "http://www.lilly.com/role/NarrativeDetails" ], "xbrltype": "domainItemType" }, "lly_NeuroscienceMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Revenue to unaffiliated customers, Neuroscience", "label": "Neuroscience [Member]", "terseLabel": "Neuroscience:" } } }, "localname": "NeuroscienceMember", "nsuri": "http://www.lilly.com/20191024", "presentation": [ "http://www.lilly.com/role/SegmentInformationDetails" ], "xbrltype": "domainItemType" }, "lly_NextCureInc.Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "NextCure, Inc. [Member]", "label": "NextCure, Inc. [Member]", "terseLabel": "NextCure, Inc." } } }, "localname": "NextCureInc.Member", "nsuri": "http://www.lilly.com/20191024", "presentation": [ "http://www.lilly.com/role/NarrativeDetails" ], "xbrltype": "domainItemType" }, "lly_NoExpirationMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Those operating loss/tax credit carryforwards/carrybacks included that have no expiration.", "label": "No Expiration [Member]", "terseLabel": "No Expiration" } } }, "localname": "NoExpirationMember", "nsuri": "http://www.lilly.com/20191024", "presentation": [ "http://www.lilly.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "domainItemType" }, "lly_NotesDueinMayTwentyTwentySevenMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Notes Due in May Twenty Seven [Member]", "label": "Notes Due in May Twenty Twenty Seven [Member]", "terseLabel": "Notes Due in May 2027" } } }, "localname": "NotesDueinMayTwentyTwentySevenMember", "nsuri": "http://www.lilly.com/20191024", "presentation": [ "http://www.lilly.com/role/BorrowingsNarrativeDetails" ], "xbrltype": "domainItemType" }, "lly_NotesDueinMayTwentyTwentyTwoMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Notes Due in May Twenty Two [Member]", "label": "Notes Due in May Twenty Twenty Two [Member]", "terseLabel": "Notes Due in May 2022" } } }, "localname": "NotesDueinMayTwentyTwentyTwoMember", "nsuri": "http://www.lilly.com/20191024", "presentation": [ "http://www.lilly.com/role/BorrowingsNarrativeDetails" ], "xbrltype": "domainItemType" }, "lly_NotesDueinTwentyFortySevenMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Notes Due in Twenty Forty Seven [Member]", "label": "Notes Due in Twenty Forty Seven [Member]", "terseLabel": "Notes Due in 2047" } } }, "localname": "NotesDueinTwentyFortySevenMember", "nsuri": "http://www.lilly.com/20191024", "presentation": [ "http://www.lilly.com/role/BorrowingsNarrativeDetails" ], "xbrltype": "domainItemType" }, "lly_NumberofCompanies": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Number of Companies", "label": "Number of Companies", "terseLabel": "Number of companies" } } }, "localname": "NumberofCompanies", "nsuri": "http://www.lilly.com/20191024", "presentation": [ "http://www.lilly.com/role/ContingenciesDetails" ], "xbrltype": "integerItemType" }, "lly_NumberofIndividuals": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Number of Individuals", "label": "Number of Individuals", "terseLabel": "Number of individuals" } } }, "localname": "NumberofIndividuals", "nsuri": "http://www.lilly.com/20191024", "presentation": [ "http://www.lilly.com/role/ContingenciesDetails" ], "xbrltype": "integerItemType" }, "lly_NumberofNewApplication": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Number of New Application", "label": "Number of New Application", "terseLabel": "Number of new application" } } }, "localname": "NumberofNewApplication", "nsuri": "http://www.lilly.com/20191024", "presentation": [ "http://www.lilly.com/role/ContingenciesDetails" ], "xbrltype": "integerItemType" }, "lly_NumberofPatents": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Number of Patents", "label": "Number of Patents", "terseLabel": "Number of patents" } } }, "localname": "NumberofPatents", "nsuri": "http://www.lilly.com/20191024", "presentation": [ "http://www.lilly.com/role/ContingenciesDetails" ], "xbrltype": "integerItemType" }, "lly_NumberofWholesalers": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Number of Wholesalers", "label": "Number of Wholesalers", "terseLabel": "Number of wholesalers" } } }, "localname": "NumberofWholesalers", "nsuri": "http://www.lilly.com/20191024", "presentation": [ "http://www.lilly.com/role/SegmentInformationDetails" ], "xbrltype": "integerItemType" }, "lly_OlumiantMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Olumiant [Member]", "label": "Olumiant [Member]", "terseLabel": "Olumiant" } } }, "localname": "OlumiantMember", "nsuri": "http://www.lilly.com/20191024", "presentation": [ "http://www.lilly.com/role/CollaborationsAndOtherArrangementsDetails" ], "xbrltype": "domainItemType" }, "lly_OncologyMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Revenue to unaffiliated customers, Oncology", "label": "Oncology [Member]", "terseLabel": "Oncology:" } } }, "localname": "OncologyMember", "nsuri": "http://www.lilly.com/20191024", "presentation": [ "http://www.lilly.com/role/SegmentInformationDetails" ], "xbrltype": "domainItemType" }, "lly_OtherCardiovascularMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Other Cardiovascular [Member]", "label": "Other Cardiovascular [Member]", "terseLabel": "Other Cardiovascular" } } }, "localname": "OtherCardiovascularMember", "nsuri": "http://www.lilly.com/20191024", "presentation": [ "http://www.lilly.com/role/SegmentInformationDetails" ], "xbrltype": "domainItemType" }, "lly_OtherEndocrinologyMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Other Endocrinology [Member]", "label": "Other Endocrinology [Member]", "terseLabel": "Other Endocrinology" } } }, "localname": "OtherEndocrinologyMember", "nsuri": "http://www.lilly.com/20191024", "presentation": [ "http://www.lilly.com/role/SegmentInformationDetails" ], "xbrltype": "domainItemType" }, "lly_OtherEquitySecuritiesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Other Equity Securities [Member]", "label": "Other Equity Securities [Member]", "terseLabel": "Other securities" } } }, "localname": "OtherEquitySecuritiesMember", "nsuri": "http://www.lilly.com/20191024", "presentation": [ "http://www.lilly.com/role/FinancialInstrumentsFairValueMeasurementDetails" ], "xbrltype": "domainItemType" }, "lly_OtherForeignCountriesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Other Foreign Countries [Member]", "label": "Other Foreign Countries [Member]", "terseLabel": "Other foreign countries" } } }, "localname": "OtherForeignCountriesMember", "nsuri": "http://www.lilly.com/20191024", "presentation": [ "http://www.lilly.com/role/SegmentInformationDetails" ], "xbrltype": "domainItemType" }, "lly_OtherImmunologyMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Other Immunology [Member]", "label": "Other Immunology [Member]", "terseLabel": "Other Immunology" } } }, "localname": "OtherImmunologyMember", "nsuri": "http://www.lilly.com/20191024", "presentation": [ "http://www.lilly.com/role/SegmentInformationDetails" ], "xbrltype": "domainItemType" }, "lly_OtherNeuroscienceMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Other Neuroscience [Member]", "label": "Other Neuroscience [Member]", "terseLabel": "Other Neuroscience" } } }, "localname": "OtherNeuroscienceMember", "nsuri": "http://www.lilly.com/20191024", "presentation": [ "http://www.lilly.com/role/SegmentInformationDetails" ], "xbrltype": "domainItemType" }, "lly_OtherOncologyMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Other Oncology [Member]", "label": "Other Oncology [Member]", "terseLabel": "Other Oncology" } } }, "localname": "OtherOncologyMember", "nsuri": "http://www.lilly.com/20191024", "presentation": [ "http://www.lilly.com/role/SegmentInformationDetails" ], "xbrltype": "domainItemType" }, "lly_OtherPharmaceuticalsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Revenue to unaffiliated customers, Other pharmaceuticals", "label": "Other Pharmaceuticals [Member]", "terseLabel": "Other" } } }, "localname": "OtherPharmaceuticalsMember", "nsuri": "http://www.lilly.com/20191024", "presentation": [ "http://www.lilly.com/role/SegmentInformationDetails" ], "xbrltype": "domainItemType" }, "lly_OutsideUnitedStatesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Outside the United States", "label": "Outside United States [Member]", "terseLabel": "Outside US" } } }, "localname": "OutsideUnitedStatesMember", "nsuri": "http://www.lilly.com/20191024", "presentation": [ "http://www.lilly.com/role/AssetImpairmentRestructuringAndOtherSpecialChargesNarrativeDetails" ], "xbrltype": "domainItemType" }, "lly_PaymentsForRepurchaseOfCommonStockInNextTwelveMonths": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Payments For Repurchase Of Common Stock In Next Twelve Months", "label": "Payments For Repurchase Of Common Stock In Next Twelve Months", "netLabel": "Purchases of common stock" } } }, "localname": "PaymentsForRepurchaseOfCommonStockInNextTwelveMonths", "nsuri": "http://www.lilly.com/20191024", "presentation": [ "http://www.lilly.com/role/ShareholdersEquityDetails" ], "xbrltype": "monetaryItemType" }, "lly_PlaintiffAppealingDecisionofCourtMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Plaintiff Appealing Decision of Court [Member]", "label": "Plaintiff Appealing Decision of Court [Member]", "terseLabel": "Plaintiff Appealing Decision of Court" } } }, "localname": "PlaintiffAppealingDecisionofCourtMember", "nsuri": "http://www.lilly.com/20191024", "presentation": [ "http://www.lilly.com/role/ContingenciesDetails" ], "xbrltype": "domainItemType" }, "lly_ProceedsfromIssuanceorSaleofEquityfromSubsidiary": { "auth_ref": [], "calculation": { "http://www.lilly.com/role/ConsolidatedStatementsOfCashFlows": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Proceeds from Issuance or Sale of Equity from Subsidiary", "label": "Proceeds from Issuance or Sale of Equity from Subsidiary", "terseLabel": "Net proceeds from Elanco initial public offering (Note 20)" } } }, "localname": "ProceedsfromIssuanceorSaleofEquityfromSubsidiary", "nsuri": "http://www.lilly.com/20191024", "presentation": [ "http://www.lilly.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "lly_ProceedsfromSaleofEquityandAvailableforSaleSecurities": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Proceeds from Sale of Equity and Available for Sale Securities", "label": "Proceeds from Sale of Equity and Available for Sale Securities", "terseLabel": "Proceeds from sales" } } }, "localname": "ProceedsfromSaleofEquityandAvailableforSaleSecurities", "nsuri": "http://www.lilly.com/20191024", "presentation": [ "http://www.lilly.com/role/FinancialInstrumentsInvestmentPortfolioActivityDetails" ], "xbrltype": "monetaryItemType" }, "lly_ProfitAndDevelopmentAndMarketingShareMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Share of profits, research and development expenses, and marketing expenses pursuant to the terms of a collaborative arrangement.", "label": "Profit And Development And Marketing Share [Member]", "terseLabel": "Profit And Development And Marketing Share" } } }, "localname": "ProfitAndDevelopmentAndMarketingShareMember", "nsuri": "http://www.lilly.com/20191024", "presentation": [ "http://www.lilly.com/role/CollaborationsAndOtherArrangementsDetails" ], "xbrltype": "domainItemType" }, "lly_PurchasedInProcessResearchAndDevelopment": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The amount of CASH paid for research and development assets that are acquired in a business combination (pre-141R) and/or licensing arrangement that have no alternative future use and are therefore, written off in the period of acquisition (CASH FLOWS).", "label": "Purchased in-process research and development", "terseLabel": "Purchased in-process research and development" } } }, "localname": "PurchasedInProcessResearchAndDevelopment", "nsuri": "http://www.lilly.com/20191024", "presentation": [ "http://www.lilly.com/role/NarrativeDetails" ], "xbrltype": "monetaryItemType" }, "lly_ResearchAndDevelopmentExpMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Share of Research and Development expenses incurred pursuant to a collaborative arrangement. Can be expenses or reimbursement of expenses.", "label": "Research And Development Exp [Member]", "terseLabel": "Research And Development Exp" } } }, "localname": "ResearchAndDevelopmentExpMember", "nsuri": "http://www.lilly.com/20191024", "presentation": [ "http://www.lilly.com/role/CollaborationsAndOtherArrangementsDetails" ], "xbrltype": "domainItemType" }, "lly_RestructuringSettlementAndImpairmentProvisionsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Restructuring, Settlement And Impairment Provisions [Member]", "label": "Restructuring, Settlement And Impairment Provisions [Member]", "terseLabel": "Restructuring, Settlement and Impairment Provisions" } } }, "localname": "RestructuringSettlementAndImpairmentProvisionsMember", "nsuri": "http://www.lilly.com/20191024", "presentation": [ "http://www.lilly.com/role/RetirementBenefitsNarrativeDetails" ], "xbrltype": "domainItemType" }, "lly_RevenuefromContractPaymentTermMaximum": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Revenue from Contract, Payment Term, Maximum", "label": "Revenue from Contract, Payment Term, Maximum", "terseLabel": "Revenue from contract, payment term, maximum (in days)" } } }, "localname": "RevenuefromContractPaymentTermMaximum", "nsuri": "http://www.lilly.com/20191024", "presentation": [ "http://www.lilly.com/role/SummaryOfSignificantAccountingPoliciesRevenueDetails" ], "xbrltype": "durationItemType" }, "lly_RevenuefromContractPaymentTermMinimum": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Revenue from Contract, Payment Term", "label": "Revenue from Contract, Payment Term, Minimum", "terseLabel": "Revenue from contract, payment term, minimum (in days)" } } }, "localname": "RevenuefromContractPaymentTermMinimum", "nsuri": "http://www.lilly.com/20191024", "presentation": [ "http://www.lilly.com/role/SummaryOfSignificantAccountingPoliciesRevenueDetails" ], "xbrltype": "durationItemType" }, "lly_RiskManagementInstrumentsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Risk Management Instruments [Abstract]", "label": "Risk Management Instruments [Abstract]", "terseLabel": "Risk-management instruments" } } }, "localname": "RiskManagementInstrumentsAbstract", "nsuri": "http://www.lilly.com/20191024", "presentation": [ "http://www.lilly.com/role/FinancialInstrumentsFairValueMeasurementDetails" ], "xbrltype": "stringItemType" }, "lly_SIGATechnologiesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "SIGA Technologies [Member]", "label": "SIGA Technologies [Member]", "terseLabel": "SIGA Technologies, Inc." } } }, "localname": "SIGATechnologiesMember", "nsuri": "http://www.lilly.com/20191024", "presentation": [ "http://www.lilly.com/role/NarrativeDetails" ], "xbrltype": "domainItemType" }, "lly_SaleOfStockPercentageOfStockSold": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Sale Of Stock, Percentage Of Stock Sold", "label": "Sale Of Stock, Percentage Of Stock Sold", "terseLabel": "Percentage of stock sold (in percentage)" } } }, "localname": "SaleOfStockPercentageOfStockSold", "nsuri": "http://www.lilly.com/20191024", "presentation": [ "http://www.lilly.com/role/DiscontinuedOperationsDetails", "http://www.lilly.com/role/SummaryOfSignificantAccountingPoliciesAcquisitionsDetails" ], "xbrltype": "percentItemType" }, "lly_SalesRebatesAndDiscounts": { "auth_ref": [], "calculation": { "http://www.lilly.com/role/ConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Sales rebates and discounts", "label": "Sales rebates and discounts", "terseLabel": "Sales rebates and discounts" } } }, "localname": "SalesRebatesAndDiscounts", "nsuri": "http://www.lilly.com/20191024", "presentation": [ "http://www.lilly.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "lly_ScheduleofAdditionalBorrowingsDisclosuresTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Schedule of Additional Borrowings Disclosures [Table Text Block]", "label": "Schedule of Additional Borrowings Disclosures [Table Text Block]", "terseLabel": "Schedule of Additional Borrowings Disclosures" } } }, "localname": "ScheduleofAdditionalBorrowingsDisclosuresTableTextBlock", "nsuri": "http://www.lilly.com/20191024", "presentation": [ "http://www.lilly.com/role/BorrowingsTables" ], "xbrltype": "textBlockItemType" }, "lly_ScheduleofAdditionalIncomeTaxDisclosuresTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Schedule of Additional Income Tax Disclosures [Table Text Block]", "label": "Schedule of Additional Income Tax Disclosures [Table Text Block]", "terseLabel": "Schedule of Additional Income Tax Disclosures" } } }, "localname": "ScheduleofAdditionalIncomeTaxDisclosuresTableTextBlock", "nsuri": "http://www.lilly.com/20191024", "presentation": [ "http://www.lilly.com/role/IncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "lly_ScheduleofAdditionalStockBasedCompensationDisclosuresTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Schedule of Additional Stock-Based Compensation Disclosures [Table Text Block]", "label": "Schedule of Additional Stock-Based Compensation Disclosures [Table Text Block]", "terseLabel": "Schedule of Additional Stock-Based Compensation Disclosures" } } }, "localname": "ScheduleofAdditionalStockBasedCompensationDisclosuresTableTextBlock", "nsuri": "http://www.lilly.com/20191024", "presentation": [ "http://www.lilly.com/role/StockBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "lly_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpectedSharesToBeIssued": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The number of shares expected to be issued in the next twelve months under the plan.", "label": "Share Based Compensation Arrangement by Share-based Payment Award, Expected Shares To Be Issued", "terseLabel": "Shares expected to be issued (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardExpectedSharesToBeIssued", "nsuri": "http://www.lilly.com/20191024", "presentation": [ "http://www.lilly.com/role/StockBasedCompensationDetails" ], "xbrltype": "sharesItemType" }, "lly_SharebasedCompensationAwardsFairValueAssumptionsUsedTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Share-based Compensation Awards, Fair Value Assumptions Used [Table Text Block]", "label": "Share-based Compensation Awards, Fair Value Assumptions Used [Table Text Block]", "terseLabel": "Share-based Compensation Awards, Fair Value Assumptions Used" } } }, "localname": "SharebasedCompensationAwardsFairValueAssumptionsUsedTableTextBlock", "nsuri": "http://www.lilly.com/20191024", "presentation": [ "http://www.lilly.com/role/StockBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "lly_ShareholderValueAwardsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Shareholder Value Awards are granted to officers and management and are payable in shares of common stock at the end of a 3 yr period.", "label": "Shareholder Value Awards [Member]", "terseLabel": "Shareholder Value Awards" } } }, "localname": "ShareholderValueAwardsMember", "nsuri": "http://www.lilly.com/20191024", "presentation": [ "http://www.lilly.com/role/StockBasedCompensationDetails", "http://www.lilly.com/role/StockBasedCompensationTables" ], "xbrltype": "domainItemType" }, "lly_SigilonTherapeuticsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Sigilon Therapeutics [Member]", "label": "Sigilon Therapeutics [Member]", "terseLabel": "Sigilon Therapeutics" } } }, "localname": "SigilonTherapeuticsMember", "nsuri": "http://www.lilly.com/20191024", "presentation": [ "http://www.lilly.com/role/NarrativeDetails" ], "xbrltype": "domainItemType" }, "lly_StratteraMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Strattera [Member]", "label": "Strattera [Member]", "terseLabel": "Strattera\u00ae" } } }, "localname": "StratteraMember", "nsuri": "http://www.lilly.com/20191024", "presentation": [ "http://www.lilly.com/role/SegmentInformationDetails" ], "xbrltype": "domainItemType" }, "lly_SwapSwissFrancsToU.S.DollarsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Swap Swiss Francs To U.S. Dollars [Member]", "label": "Swap Swiss Francs To U.S. Dollars [Member]", "terseLabel": "Swap Swiss Francs to U.S. Dollars" } } }, "localname": "SwapSwissFrancsToU.S.DollarsMember", "nsuri": "http://www.lilly.com/20191024", "presentation": [ "http://www.lilly.com/role/FinancialInstrumentsNarrativeDetails" ], "xbrltype": "domainItemType" }, "lly_TaltzMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Taltz [Member]", "label": "Taltz [Member]", "terseLabel": "Taltz" } } }, "localname": "TaltzMember", "nsuri": "http://www.lilly.com/20191024", "presentation": [ "http://www.lilly.com/role/SegmentInformationDetails" ], "xbrltype": "domainItemType" }, "lly_TanezumabMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Tanezumab [Member]", "label": "Tanezumab [Member]", "terseLabel": "Tanezumab" } } }, "localname": "TanezumabMember", "nsuri": "http://www.lilly.com/20191024", "presentation": [ "http://www.lilly.com/role/CollaborationsAndOtherArrangementsDetails" ], "xbrltype": "domainItemType" }, "lly_TaxCutsandJobsActChangeinTaxRateIncomeTaxExpenseBenefitTotal": { "auth_ref": [], "calculation": { "http://www.lilly.com/role/IncomeTaxesCurrentAndDeferredDetails": { "order": 4.0, "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Tax Cuts and Jobs Act, Change in Tax Rate, Income Tax Expense (Benefit), Total", "label": "Tax Cuts and Jobs Act, Change in Tax Rate, Income Tax Expense (Benefit), Total", "terseLabel": "Tax Cuts and Jobs Act, Change in Tax Rate, Income Tax Expense (Benefit), Total" } } }, "localname": "TaxCutsandJobsActChangeinTaxRateIncomeTaxExpenseBenefitTotal", "nsuri": "http://www.lilly.com/20191024", "presentation": [ "http://www.lilly.com/role/IncomeTaxesCurrentAndDeferredDetails" ], "xbrltype": "monetaryItemType" }, "lly_TaxCutsandJobsActMeasurementPeriodAdjustmentIncomeTaxExpenseBenefit": { "auth_ref": [], "calculation": { "http://www.lilly.com/role/IncomeTaxesCurrentAndDeferredDetails": { "order": 4.0, "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Tax Cuts and Jobs Act, Measurement Period Adjustment, Income Tax Expense (Benefit)", "label": "Tax Cuts and Jobs Act, Measurement Period Adjustment, Income Tax Expense (Benefit)", "terseLabel": "Tax Cuts and Jobs Act, Measurement Period Adjustment, Income Tax Expense (Benefit)" } } }, "localname": "TaxCutsandJobsActMeasurementPeriodAdjustmentIncomeTaxExpenseBenefit", "nsuri": "http://www.lilly.com/20191024", "presentation": [ "http://www.lilly.com/role/IncomeTaxesCurrentAndDeferredDetails" ], "xbrltype": "monetaryItemType" }, "lly_TaxCutsandJobsActReclassificationfromAOCItoRetainedEarningsTaxEffect": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Tax Cuts and Jobs Act, Reclassification from AOCI to Retained Earnings, Tax Effect", "label": "Tax Cuts and Jobs Act, Reclassification from AOCI to Retained Earnings, Tax Effect", "terseLabel": "Reclassifications of stranded tax effects (Note 2)" } } }, "localname": "TaxCutsandJobsActReclassificationfromAOCItoRetainedEarningsTaxEffect", "nsuri": "http://www.lilly.com/20191024", "presentation": [ "http://www.lilly.com/role/OtherComprehensiveIncomeLossRollForwardDetails" ], "xbrltype": "monetaryItemType" }, "lly_TaxCutsandJobsActof2017DeferredTaxAssetGlobalIntangibleLowTaxedIncomeProvision": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Tax Cuts and Jobs Act of 2017, Deferred Tax Asset, Global Intangible Low-Taxed Income Provision", "label": "Tax Cuts and Jobs Act of 2017, Deferred Tax Asset, Global Intangible Low-Taxed Income Provision", "terseLabel": "2017 Tax Act, deferred taxes related to GILTI" } } }, "localname": "TaxCutsandJobsActof2017DeferredTaxAssetGlobalIntangibleLowTaxedIncomeProvision", "nsuri": "http://www.lilly.com/20191024", "presentation": [ "http://www.lilly.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "lly_TaxYears20102012Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Tax Years 2010-2012 [Member]", "label": "Tax Years 2010-2012 [Member]", "terseLabel": "Tax Years 2010-2012" } } }, "localname": "TaxYears20102012Member", "nsuri": "http://www.lilly.com/20191024", "presentation": [ "http://www.lilly.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "domainItemType" }, "lly_TermFacilityMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Term Facility [Member]", "label": "Term Facility [Member]", "terseLabel": "Term Facility" } } }, "localname": "TermFacilityMember", "nsuri": "http://www.lilly.com/20191024", "presentation": [ "http://www.lilly.com/role/DiscontinuedOperationsDetails" ], "xbrltype": "domainItemType" }, "lly_TrajentaBIMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Trajenta (BI) [Member]", "label": "Trajenta (BI) [Member]", "terseLabel": "Trajenta" } } }, "localname": "TrajentaBIMember", "nsuri": "http://www.lilly.com/20191024", "presentation": [ "http://www.lilly.com/role/CollaborationsAndOtherArrangementsDetails", "http://www.lilly.com/role/SegmentInformationDetails" ], "xbrltype": "domainItemType" }, "lly_TrulicityMemberMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Trulicity [Member] [Member]", "label": "Trulicity [Member] [Member]", "terseLabel": "Trulicity" } } }, "localname": "TrulicityMemberMember", "nsuri": "http://www.lilly.com/20191024", "presentation": [ "http://www.lilly.com/role/SegmentInformationDetails" ], "xbrltype": "domainItemType" }, "lly_UnitedStatesandEuropeMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "United States and Europe [Member]", "label": "United States and Europe [Member]", "terseLabel": "United States and Europe [Member]" } } }, "localname": "UnitedStatesandEuropeMember", "nsuri": "http://www.lilly.com/20191024", "presentation": [ "http://www.lilly.com/role/CollaborationsAndOtherArrangementsDetails" ], "xbrltype": "domainItemType" }, "lly_ZyprexaMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Zyprexa [Member]", "label": "Zyprexa [Member]", "terseLabel": "Zyprexa\u00ae" } } }, "localname": "ZyprexaMember", "nsuri": "http://www.lilly.com/20191024", "presentation": [ "http://www.lilly.com/role/SegmentInformationDetails" ], "xbrltype": "domainItemType" }, "srt_EuropeMember": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Europe [Member]", "terseLabel": "Europe" } } }, "localname": "EuropeMember", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.lilly.com/role/CollaborationsAndOtherArrangementsDetails", "http://www.lilly.com/role/SegmentInformationDetails" ], "xbrltype": "domainItemType" }, "srt_LitigationCaseAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Litigation Case [Axis]", "terseLabel": "Litigation Case [Axis]" } } }, "localname": "LitigationCaseAxis", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.lilly.com/role/ContingenciesDetails" ], "xbrltype": "stringItemType" }, "srt_LitigationCaseTypeDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Litigation Case [Domain]", "terseLabel": "Litigation Case Type [Domain]" } } }, "localname": "LitigationCaseTypeDomain", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.lilly.com/role/ContingenciesDetails" ], "xbrltype": "domainItemType" }, "srt_MaximumMember": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Maximum [Member]", "terseLabel": "Maximum" } } }, "localname": "MaximumMember", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.lilly.com/role/BorrowingsNarrativeDetails", "http://www.lilly.com/role/GoodwillAndOtherIntangiblesNarrativeDetails", "http://www.lilly.com/role/IncomeTaxesNarrativeDetails", "http://www.lilly.com/role/PropertyAndEquipmentDetails", "http://www.lilly.com/role/SegmentInformationDetails" ], "xbrltype": "domainItemType" }, "srt_MinimumMember": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Minimum [Member]", "terseLabel": "Minimum" } } }, "localname": "MinimumMember", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.lilly.com/role/BorrowingsNarrativeDetails", "http://www.lilly.com/role/GoodwillAndOtherIntangiblesNarrativeDetails", "http://www.lilly.com/role/PropertyAndEquipmentDetails", "http://www.lilly.com/role/SegmentInformationDetails" ], "xbrltype": "domainItemType" }, "srt_ProductOrServiceAxis": { "auth_ref": [ "r218", "r350", "r352", "r632", "r633" ], "lang": { "en-US": { "role": { "label": "Product and Service [Axis]", "terseLabel": "Product and Service [Axis]" } } }, "localname": "ProductOrServiceAxis", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.lilly.com/role/CollaborationsAndOtherArrangementsDetails", "http://www.lilly.com/role/CollaborationsAndOtherArrangementsTables", "http://www.lilly.com/role/ContingenciesDetails", "http://www.lilly.com/role/SegmentInformationDetails", "http://www.lilly.com/role/SummaryOfSignificantAccountingPoliciesRevenueDetails" ], "xbrltype": "stringItemType" }, "srt_ProductsAndServicesDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Product and Service [Domain]", "terseLabel": "Product and Service [Domain]" } } }, "localname": "ProductsAndServicesDomain", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.lilly.com/role/CollaborationsAndOtherArrangementsDetails", "http://www.lilly.com/role/CollaborationsAndOtherArrangementsTables", "http://www.lilly.com/role/ContingenciesDetails", "http://www.lilly.com/role/SegmentInformationDetails", "http://www.lilly.com/role/SummaryOfSignificantAccountingPoliciesRevenueDetails" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Statistical Measurement [Axis]", "terseLabel": "Statistical Measurement [Axis]" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.lilly.com/role/BorrowingsNarrativeDetails", "http://www.lilly.com/role/GoodwillAndOtherIntangiblesNarrativeDetails", "http://www.lilly.com/role/IncomeTaxesNarrativeDetails", "http://www.lilly.com/role/PropertyAndEquipmentDetails", "http://www.lilly.com/role/SegmentInformationDetails" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Statistical Measurement [Domain]", "terseLabel": "Statistical Measurement [Domain]" } } }, "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.lilly.com/role/BorrowingsNarrativeDetails", "http://www.lilly.com/role/GoodwillAndOtherIntangiblesNarrativeDetails", "http://www.lilly.com/role/IncomeTaxesNarrativeDetails", "http://www.lilly.com/role/PropertyAndEquipmentDetails", "http://www.lilly.com/role/SegmentInformationDetails" ], "xbrltype": "domainItemType" }, "srt_SegmentGeographicalDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Geographical [Domain]", "terseLabel": "Geographical [Domain]" } } }, "localname": "SegmentGeographicalDomain", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.lilly.com/role/AssetImpairmentRestructuringAndOtherSpecialChargesNarrativeDetails", "http://www.lilly.com/role/CollaborationsAndOtherArrangementsDetails", "http://www.lilly.com/role/ContingenciesDetails", "http://www.lilly.com/role/SegmentInformationDetails" ], "xbrltype": "domainItemType" }, "srt_StatementGeographicalAxis": { "auth_ref": [ "r220", "r350", "r353", "r634", "r638", "r642" ], "lang": { "en-US": { "role": { "label": "Geographical [Axis]", "terseLabel": "Geographical [Axis]" } } }, "localname": "StatementGeographicalAxis", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.lilly.com/role/AssetImpairmentRestructuringAndOtherSpecialChargesNarrativeDetails", "http://www.lilly.com/role/CollaborationsAndOtherArrangementsDetails", "http://www.lilly.com/role/ContingenciesDetails", "http://www.lilly.com/role/SegmentInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Accounting Policies [Abstract]" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_AccountingStandardsUpdate201409Member": { "auth_ref": [ "r355" ], "lang": { "en-US": { "role": { "documentation": "Accounting Standards Update 2014-09 Revenue from Contracts with Customers (Topic 606).", "label": "Accounting Standards Update 2014-09 [Member]", "terseLabel": "Accounting Standards Update 2014-09" } } }, "localname": "AccountingStandardsUpdate201409Member", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/ImplementationOfNewFinancialAccountingPronouncementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccountingStandardsUpdate201601Member": { "auth_ref": [ "r552" ], "lang": { "en-US": { "role": { "documentation": "Accounting Standards Update 2016-01 Financial Instruments-Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities.", "label": "Accounting Standards Update 2016-01 [Member]", "terseLabel": "Accounting Standards Update 2016-01" } } }, "localname": "AccountingStandardsUpdate201601Member", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/ImplementationOfNewFinancialAccountingPronouncementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccountingStandardsUpdate201602Member": { "auth_ref": [ "r572" ], "lang": { "en-US": { "role": { "documentation": "Accounting Standards Update 2016-02 Leases (Topic 842).", "label": "Accounting Standards Update 2016-02 [Member]", "terseLabel": "Accounting Standards Update 2016-02" } } }, "localname": "AccountingStandardsUpdate201602Member", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/ImplementationOfNewFinancialAccountingPronouncementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccountingStandardsUpdate201616Member": { "auth_ref": [ "r472", "r473" ], "lang": { "en-US": { "role": { "documentation": "Accounting Standards Update 2016-16 Income Taxes (Topic 740): Intra-Entity Transfers of Assets Other Than Inventory.", "label": "Accounting Standards Update 2016-16 [Member]", "terseLabel": "Accounting Standards Update 2016-16" } } }, "localname": "AccountingStandardsUpdate201616Member", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/ImplementationOfNewFinancialAccountingPronouncementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccountingStandardsUpdate201707Member": { "auth_ref": [ "r411" ], "lang": { "en-US": { "role": { "documentation": "Accounting Standards Update 2017-07 Compensation-Retirement Benefits (Topic 715): Improving the Presentation of Net Periodic Pension Cost and Net Periodic Postretirement Benefit Cost.", "label": "Accounting Standards Update 2017-07 [Member]", "terseLabel": "Accounting Standards Update 2017-07" } } }, "localname": "AccountingStandardsUpdate201707Member", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/ImplementationOfNewFinancialAccountingPronouncementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccountingStandardsUpdate201802Member": { "auth_ref": [ "r127" ], "lang": { "en-US": { "role": { "documentation": "Accounting Standards Update 2018-02 Income Statement-Reporting Comprehensive Income (Topic 220): Reclassification of Certain Tax Effects from Accumulated Other Comprehensive Income.", "label": "Accounting Standards Update 2018-02 [Member]", "terseLabel": "Accounting Standards Update 2018-02" } } }, "localname": "AccountingStandardsUpdate201802Member", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/ImplementationOfNewFinancialAccountingPronouncementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccountsPayableCurrent": { "auth_ref": [ "r77" ], "calculation": { "http://www.lilly.com/role/ConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts Payable, Current", "terseLabel": "Accounts payable" } } }, "localname": "AccountsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsReceivableMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Due from customers or clients for goods or services that have been delivered or sold.", "label": "Accounts Receivable [Member]", "terseLabel": "Accounts Receivable" } } }, "localname": "AccountsReceivableMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/SegmentInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccountsReceivableNetCurrent": { "auth_ref": [ "r31", "r61", "r222", "r223", "r351" ], "calculation": { "http://www.lilly.com/role/ConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.", "label": "Accounts Receivable, after Allowance for Credit Loss, Current", "terseLabel": "Accounts receivable, net of allowances of $24.1 (2018) and $28.9 (2017)" } } }, "localname": "AccountsReceivableNetCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedIncomeTaxesNoncurrent": { "auth_ref": [ "r55", "r589", "r619" ], "calculation": { "http://www.lilly.com/role/ConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesNoncurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all domestic and foreign income tax obligations due beyond one year or the operating cycle, whichever is longer. Alternate captions include income taxes payable, noncurrent.", "label": "Accrued Income Taxes, Noncurrent", "terseLabel": "Long-term income taxes payable (Note 13)" } } }, "localname": "AccruedIncomeTaxesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember": { "auth_ref": [ "r109", "r116", "r119", "r390", "r503" ], "lang": { "en-US": { "role": { "documentation": "Accumulated other comprehensive (income) loss related to defined benefit plans including the portion attributable to the noncontrolling interest.", "label": "Accumulated Defined Benefit Plans Adjustment Including Portion Attributable to Noncontrolling Interest [Member]", "terseLabel": "Defined Benefit Pension and Retiree Health Benefit Plans" } } }, "localname": "AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/OtherComprehensiveIncomeLossReclassificationDetails", "http://www.lilly.com/role/OtherComprehensiveIncomeLossRollForwardDetails", "http://www.lilly.com/role/OtherComprehensiveIncomeLossTaxEffectDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetGainLossIncludingPortionAttributableToNoncontrollingInterestMember": { "auth_ref": [ "r108", "r116", "r119", "r389", "r503" ], "lang": { "en-US": { "role": { "documentation": "Accumulated other comprehensive income (loss) related to gain (loss) component of defined benefit plans including the portion attributable to the noncontrolling interest.", "label": "Accumulated Defined Benefit Plans Adjustment, Net Gain (Loss) Including Portion Attributable to Noncontrolling Interest [Member]", "terseLabel": "Amortization of retirement benefit items:" } } }, "localname": "AccumulatedDefinedBenefitPlansAdjustmentNetGainLossIncludingPortionAttributableToNoncontrollingInterestMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/OtherComprehensiveIncomeLossReclassificationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceIncludingPortionAttributableToNoncontrollingInterestMember": { "auth_ref": [ "r111", "r116", "r119", "r389", "r503" ], "lang": { "en-US": { "role": { "documentation": "Accumulated other comprehensive (income) loss related to prior service cost (credit) component of defined benefit plans including the portion attributable to the noncontrolling interest.", "label": "Accumulated Defined Benefit Plans Adjustment, Net Prior Service Including Portion Attributable to Noncontrolling Interest [Member]", "terseLabel": "Prior service benefits, net" } } }, "localname": "AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceIncludingPortionAttributableToNoncontrollingInterestMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/OtherComprehensiveIncomeLossReclassificationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "auth_ref": [ "r75", "r292" ], "calculation": { "http://www.lilly.com/role/PropertyAndEquipmentDetails": { "order": 2.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.", "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment", "negatedTerseLabel": "Less accumulated depreciation" } } }, "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/PropertyAndEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember": { "auth_ref": [ "r102", "r116", "r119", "r503" ], "lang": { "en-US": { "role": { "documentation": "Accumulated other comprehensive income (loss) resulting from foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, including the portion attributable to the noncontrolling interest.", "label": "Accumulated Foreign Currency Adjustment Including Portion Attributable to Noncontrolling Interest [Member]", "terseLabel": "Foreign Currency Translation Gains (Losses)" } } }, "localname": "AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/OtherComprehensiveIncomeLossReclassificationDetails", "http://www.lilly.com/role/OtherComprehensiveIncomeLossRollForwardDetails", "http://www.lilly.com/role/OtherComprehensiveIncomeLossTaxEffectDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember": { "auth_ref": [ "r103", "r116", "r119", "r503" ], "lang": { "en-US": { "role": { "documentation": "Accumulated other comprehensive income (loss) resulting from gain (loss) from derivative instruments designated and qualifying as the effective portion of cash flow hedges, including the portion attributable to the noncontrolling interest.", "label": "Accumulated Net Gain (Loss) from Cash Flow Hedges Including Portion Attributable to Noncontrolling Interest [Member]", "terseLabel": "Effective Portion of Cash Flow Hedges" } } }, "localname": "AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/OtherComprehensiveIncomeLossRollForwardDetails", "http://www.lilly.com/role/OtherComprehensiveIncomeLossTaxEffectDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember": { "auth_ref": [ "r104", "r105", "r107", "r116", "r119" ], "lang": { "en-US": { "role": { "documentation": "Accumulated unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), including portion attributable to noncontrolling interest.", "label": "AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-sale, Including Noncontrolling Interest [Member]", "terseLabel": "Unrealized Net Gains (Losses) on Securities" } } }, "localname": "AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/OtherComprehensiveIncomeLossReclassificationDetails", "http://www.lilly.com/role/OtherComprehensiveIncomeLossRollForwardDetails", "http://www.lilly.com/role/OtherComprehensiveIncomeLossTaxEffectDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Accumulated Other Comprehensive Income (Loss) [Line Items]", "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Line Items]" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/OtherComprehensiveIncomeLossRollForwardDetails", "http://www.lilly.com/role/OtherComprehensiveIncomeLossTaxEffectDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r113", "r115", "r116" ], "calculation": { "http://www.lilly.com/role/ConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.", "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax", "negatedLabel": "Accumulated other comprehensive loss", "negatedNetLabel": "Accumulated other comprehensive income (loss)", "terseLabel": "Accumulated other comprehensive loss (Note 16)" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/ConsolidatedBalanceSheets", "http://www.lilly.com/role/ImplementationOfNewFinancialAccountingPronouncementsDetails", "http://www.lilly.com/role/OtherComprehensiveIncomeLossRollForwardDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossTable": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about components of accumulated other comprehensive income (loss).", "label": "Accumulated Other Comprehensive Income (Loss) [Table]", "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Table]" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/OtherComprehensiveIncomeLossRollForwardDetails", "http://www.lilly.com/role/OtherComprehensiveIncomeLossTaxEffectDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "auth_ref": [ "r112", "r116", "r119", "r503" ], "lang": { "en-US": { "role": { "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.", "label": "AOCI Attributable to Parent [Member]", "terseLabel": "Accumulated Other Comprehensive Loss" } } }, "localname": "AccumulatedOtherComprehensiveIncomeMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/ConsolidatedStatementsOfShareholdersEquityStatement", "http://www.lilly.com/role/OtherComprehensiveIncomeLossRollForwardDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccumulatedOtherthanTemporaryImpairmentIncludingPortionAttributableToNoncontrollingInterestMember": { "auth_ref": [ "r106", "r116", "r119", "r229", "r503" ], "lang": { "en-US": { "role": { "documentation": "Accumulated other comprehensive loss resulting from other-than-temporary impairments (OTTI) of debt securities if a portion of an other-than-temporary impairment has not been recognized in earnings, including the portion attributable to the noncontrolling interest.", "label": "Accumulated Other-than-Temporary Impairment Including Portion Attributable to Noncontrolling Interest [Member]", "terseLabel": "Impairment losses" } } }, "localname": "AccumulatedOtherthanTemporaryImpairmentIncludingPortionAttributableToNoncontrollingInterestMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/OtherComprehensiveIncomeLossReclassificationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AdditionalPaidInCapital": { "auth_ref": [ "r62" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.", "label": "Additional Paid in Capital", "terseLabel": "Additional paid in capital" } } }, "localname": "AdditionalPaidInCapital", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/DiscontinuedOperationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalCommonStock": { "auth_ref": [ "r62" ], "calculation": { "http://www.lilly.com/role/ConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.", "label": "Additional Paid in Capital, Common Stock", "terseLabel": "Additional paid-in capital" } } }, "localname": "AdditionalPaidInCapitalCommonStock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-in Capital [Member]", "terseLabel": "Additional Paid-in Capital" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/ConsolidatedStatementsOfShareholdersEquityStatement" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsForNewAccountingPronouncementsAxis": { "auth_ref": [ "r180" ], "lang": { "en-US": { "role": { "documentation": "Information by new accounting pronouncement.", "label": "Adjustments for New Accounting Pronouncements [Axis]", "terseLabel": "Adjustments for New Accounting Pronouncements [Axis]" } } }, "localname": "AdjustmentsForNewAccountingPronouncementsAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/ImplementationOfNewFinancialAccountingPronouncementsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Adjustments to Reconcile Net Income (Loss) to Cash Flows from Operating Activities:" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_AllocatedShareBasedCompensationExpense": { "auth_ref": [ "r416", "r427", "r430" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.", "label": "Share-based Payment Arrangement, Expense", "terseLabel": "Stock-based compensation expense" } } }, "localname": "AllocatedShareBasedCompensationExpense", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/StockBasedCompensationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent": { "auth_ref": [ "r67", "r224", "r248" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of allowance for credit loss on accounts receivable, classified as current.", "label": "Accounts Receivable, Allowance for Credit Loss, Current", "terseLabel": "Accounts receivable, allowances" } } }, "localname": "AllowanceForDoubtfulAccountsReceivableCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/ConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "monetaryItemType" }, "us-gaap_AmortizationOfIntangibleAssets": { "auth_ref": [ "r162", "r274", "r282" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.", "label": "Amortization of Intangible Assets", "verboseLabel": "Amortization expense" } } }, "localname": "AmortizationOfIntangibleAssets", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/GoodwillAndOtherIntangiblesIntangiblesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AociAttributableToNoncontrollingInterestMember": { "auth_ref": [ "r112", "r116", "r503" ], "lang": { "en-US": { "role": { "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the noncontrolling interest. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.", "label": "AOCI Attributable to Noncontrolling Interest [Member]", "terseLabel": "AOCI Attributable to Noncontrolling Interest" } } }, "localname": "AociAttributableToNoncontrollingInterestMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/OtherComprehensiveIncomeLossRollForwardDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember": { "auth_ref": [ "r112", "r116", "r119", "r503" ], "lang": { "en-US": { "role": { "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, including the portion attributable to the noncontrolling interest. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.", "label": "AOCI Including Portion Attributable to Noncontrolling Interest [Member]", "terseLabel": "Accumulated Other Comprehensive Loss" } } }, "localname": "AociIncludingPortionAttributableToNoncontrollingInterestMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/OtherComprehensiveIncomeLossRollForwardDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ArrangementsAndNonarrangementTransactionsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]", "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]" } } }, "localname": "ArrangementsAndNonarrangementTransactionsMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/CollaborationsAndOtherArrangementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AssetBackedSecuritiesMember": { "auth_ref": [ "r239", "r377" ], "lang": { "en-US": { "role": { "documentation": "Securities that are primarily serviced by the cash flows of a discrete pool of receivables or other financial assets for example, but not limited to, credit card receivables, car loans, recreational vehicle loans, and mobile home loans.", "label": "Asset-backed Securities [Member]", "terseLabel": "Asset-backed securities" } } }, "localname": "AssetBackedSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/FinancialInstrumentsFairValueMeasurementDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AssetImpairmentCharges": { "auth_ref": [ "r162", "r288" ], "calculation": { "http://www.lilly.com/role/AssetImpairmentRestructuringAndOtherSpecialChargesDetails": { "order": 2.0, "parentTag": "us-gaap_RestructuringSettlementAndImpairmentProvisions", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.", "label": "Asset Impairment Charges", "terseLabel": "Asset impairment (gains from facility sales) and other special charges" } } }, "localname": "AssetImpairmentCharges", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/AssetImpairmentRestructuringAndOtherSpecialChargesDetails", "http://www.lilly.com/role/AssetImpairmentRestructuringAndOtherSpecialChargesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_Assets": { "auth_ref": [ "r211", "r586", "r618" ], "calculation": { "http://www.lilly.com/role/ConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "totalLabel": "Total assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Assets [Abstract]", "terseLabel": "Assets" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r33", "r35", "r99" ], "calculation": { "http://www.lilly.com/role/ConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Current", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Assets, Current [Abstract]", "terseLabel": "Current Assets" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsNoncurrentAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Assets, Noncurrent [Abstract]", "terseLabel": "Other Assets" } } }, "localname": "AssetsNoncurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent": { "auth_ref": [ "r0", "r1", "r20", "r22", "r289", "r296" ], "calculation": { "http://www.lilly.com/role/ConsolidatedBalanceSheets": { "order": 7.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount classified as assets attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.", "label": "Disposal Group, Including Discontinued Operation, Assets, Current", "terseLabel": "Current assets of discontinued operations" } } }, "localname": "AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/ConsolidatedBalanceSheets", "http://www.lilly.com/role/DiscontinuedOperationsMajorClassesOfAssetsAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": { "auth_ref": [ "r232" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax", "terseLabel": "Unrealized gross gains" } } }, "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/FinancialInstrumentsSummaryOfAfsUnrealizedGainlossDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": { "auth_ref": [ "r233" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax", "terseLabel": "Unrealized gross losses" } } }, "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/FinancialInstrumentsSummaryOfAfsUnrealizedGainlossDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Debt Securities, Available-for-sale [Abstract]", "terseLabel": "Noncurrent investments:" } } }, "localname": "AvailableForSaleSecuritiesAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/FinancialInstrumentsFairValueMeasurementDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AvailableForSaleSecuritiesCurrent": { "auth_ref": [], "calculation": { "http://www.lilly.com/role/FinancialInstrumentsFairValueMeasurementDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of investment in debt and equity securities categorized neither as trading securities nor held-to-maturity securities and intended be sold or mature one year or operating cycle, if longer.", "label": "Available-for-sale Securities, Current", "totalLabel": "Short-term investments" } } }, "localname": "AvailableForSaleSecuritiesCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/FinancialInstrumentsFairValueMeasurementDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue": { "auth_ref": [ "r234", "r237", "r607" ], "calculation": { "http://www.lilly.com/role/FinancialInstrumentsContractualMaturitiesDetails": { "order": 3.0, "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in sixth through tenth fiscal year following latest fiscal year. Excludes interim and annual periods when interim period is reported on rolling approach, from latest statement of financial position date.", "label": "Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, after Five Through Ten Years, Fair Value", "terseLabel": "6-10 Years" } } }, "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/FinancialInstrumentsContractualMaturitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue": { "auth_ref": [ "r234", "r236", "r606" ], "calculation": { "http://www.lilly.com/role/FinancialInstrumentsContractualMaturitiesDetails": { "order": 2.0, "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following latest fiscal year. Excludes interim and annual periods when interim period is reported on rolling approach, from latest statement of financial position date.", "label": "Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, after One Through Five Years, Fair Value", "terseLabel": "1-5 Years" } } }, "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/FinancialInstrumentsContractualMaturitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue": { "auth_ref": [ "r234", "r238", "r608" ], "calculation": { "http://www.lilly.com/role/FinancialInstrumentsContractualMaturitiesDetails": { "order": 4.0, "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Fair value of investment in debt security, measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing after tenth fiscal year following latest fiscal year. Excludes interim and annual periods when interim period is reported on rolling approach, from latest statement of financial position date.", "label": "Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, after 10 Years, Fair Value", "terseLabel": "More Than 10 Years" } } }, "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/FinancialInstrumentsContractualMaturitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue": { "auth_ref": [ "r234", "r235", "r605" ], "calculation": { "http://www.lilly.com/role/FinancialInstrumentsContractualMaturitiesDetails": { "order": 1.0, "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), maturing in next fiscal year following latest fiscal year. Excludes interim and annual periods when interim period is reported on rolling approach, from latest statement of financial position date.", "label": "Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, within One Year, Fair Value", "terseLabel": "Less Than 1 Year" } } }, "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/FinancialInstrumentsContractualMaturitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtSecurities": { "auth_ref": [ "r226", "r231", "r254" ], "calculation": { "http://www.lilly.com/role/FinancialInstrumentsContractualMaturitiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-sale", "totalLabel": "Total" } } }, "localname": "AvailableForSaleSecuritiesDebtSecurities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/FinancialInstrumentsContractualMaturitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent": { "auth_ref": [ "r227", "r254" ], "calculation": { "http://www.lilly.com/role/FinancialInstrumentsFairValueMeasurementDetails": { "order": 1.0, "parentTag": "us-gaap_AvailableForSaleSecuritiesCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.", "label": "Debt Securities, Available-for-sale, Current", "terseLabel": "Short-term investments, debt securities" } } }, "localname": "AvailableForSaleSecuritiesDebtSecuritiesCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/FinancialInstrumentsFairValueMeasurementDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent": { "auth_ref": [ "r227", "r254" ], "calculation": { "http://www.lilly.com/role/FinancialInstrumentsFairValueMeasurementDetails": { "order": 1.0, "parentTag": "us-gaap_AvailableForSaleSecuritiesNoncurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as noncurrent.", "label": "Debt Securities, Available-for-sale, Noncurrent", "terseLabel": "Noncurrent investments, debt securities" } } }, "localname": "AvailableForSaleSecuritiesDebtSecuritiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/FinancialInstrumentsFairValueMeasurementDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesEquitySecuritiesNoncurrent": { "auth_ref": [], "calculation": { "http://www.lilly.com/role/FinancialInstrumentsFairValueMeasurementDetails": { "order": 2.0, "parentTag": "us-gaap_AvailableForSaleSecuritiesNoncurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Equity securities categorized neither as held-to-maturity nor trading which are intended be sold more than one year from the balance sheet date or operating cycle, if longer.", "label": "Available-for-sale Securities, Equity Securities, Noncurrent", "terseLabel": "Marketable equity securities" } } }, "localname": "AvailableForSaleSecuritiesEquitySecuritiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/FinancialInstrumentsFairValueMeasurementDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesNoncurrent": { "auth_ref": [], "calculation": { "http://www.lilly.com/role/FinancialInstrumentsFairValueMeasurementDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Investments in debt and equity securities which are categorized neither as held-to-maturity nor trading and which are intended to be sold or mature more than one year from the balance sheet date or operating cycle, if longer. Such securities are reported at fair value; unrealized gains (losses) related to Available-for-sale Securities are excluded from earnings and reported in a separate component of shareholders' equity (other comprehensive income), unless the Available-for-sale security is designated as a hedge or is determined to have had an other than temporary decline in fair value below its amortized cost basis. All or a portion of the unrealized holding gain (loss) of an Available-for-sale security that is designated as being hedged in a fair value hedge is recognized in earnings during the period of the hedge, as are other than temporary declines in fair value below the cost basis for investments in equity securities and debt securities that an entity intends to sell or it is more likely than not that it will be required to sell before the recovery of its amortized cost basis. Other than temporary declines in fair value below the cost basis for debt securities categorized as Available-for-sale that an entity does not intend to sell and for which it is not more likely than not that the entity will be required to sell before the recovery of its amortized cost basis are bifurcated into credit losses and losses related to all other factors. Other than temporary declines in fair value below cost basis related to credit losses are recognized in earnings, and losses related to all other factors are recognized in other comprehensive income.", "label": "Available-for-sale Securities, Noncurrent", "totalLabel": "Available-for-sale Securities, Noncurrent, Total" } } }, "localname": "AvailableForSaleSecuritiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/FinancialInstrumentsFairValueMeasurementDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureOtherPercentageOfNonperformingAssets": { "auth_ref": [ "r242" ], "lang": { "en-US": { "role": { "documentation": "This item represents the percentage of nonperforming assets that the underlying assets in the security represent and which were considered as one of the potential factors in reaching a conclusion that the available-for-sale investments are not other-than-temporarily impaired.", "label": "Available-for-sale, Securities in Unrealized Loss Positions, Qualitative Disclosure, Other, Percentage of Nonperforming Assets", "terseLabel": "Percentage of nonperforming assets (in percentage)" } } }, "localname": "AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureOtherPercentageOfNonperformingAssets", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/FinancialInstrumentsNarrativeDetails" ], "xbrltype": "percentItemType" }, "us-gaap_AverageRemainingMaturityOfForeignCurrencyDerivatives1": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Average period remaining before foreign currency exchange rate derivatives mature or expire, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Average Remaining Maturity of Foreign Currency Derivatives", "terseLabel": "Average remaining maturity of foreign currency derivatives" } } }, "localname": "AverageRemainingMaturityOfForeignCurrencyDerivatives1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/FinancialInstrumentsNarrativeDetails" ], "xbrltype": "durationItemType" }, "us-gaap_AwardTypeAxis": { "auth_ref": [ "r418", "r429" ], "lang": { "en-US": { "role": { "documentation": "Information by type of award under share-based payment arrangement.", "label": "Award Type [Axis]", "terseLabel": "Award Type [Axis]" } } }, "localname": "AwardTypeAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/StockBasedCompensationDetails", "http://www.lilly.com/role/StockBasedCompensationTables" ], "xbrltype": "stringItemType" }, "us-gaap_BuildingMember": { "auth_ref": [ "r291" ], "lang": { "en-US": { "role": { "documentation": "Facility held for productive use including, but not limited to, office, production, storage and distribution facilities.", "label": "Building [Member]", "terseLabel": "Building" } } }, "localname": "BuildingMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/PropertyAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_BuildingsAndImprovementsGross": { "auth_ref": [ "r37", "r291" ], "calculation": { "http://www.lilly.com/role/PropertyAndEquipmentDetails": { "order": 2.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before accumulated depreciation of building structures held for productive use including addition, improvement, or renovation to the structure, including, but not limited to, interior masonry, interior flooring, electrical, and plumbing.", "label": "Buildings and Improvements, Gross", "terseLabel": "Buildings" } } }, "localname": "BuildingsAndImprovementsGross", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/PropertyAndEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessAcquisitionAcquireeDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.", "label": "Business Acquisition, Acquiree [Domain]", "terseLabel": "Business Acquisition, Acquiree [Domain]" } } }, "localname": "BusinessAcquisitionAcquireeDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/NarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_BusinessAcquisitionAxis": { "auth_ref": [ "r482", "r483" ], "lang": { "en-US": { "role": { "documentation": "Information by business combination or series of individually immaterial business combinations.", "label": "Business Acquisition [Axis]", "terseLabel": "Business Acquisition [Axis]" } } }, "localname": "BusinessAcquisitionAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/NarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessAcquisitionLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Business Acquisition [Line Items]", "terseLabel": "Business Acquisition [Line Items]" } } }, "localname": "BusinessAcquisitionLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/NarrativeDetails", "http://www.lilly.com/role/SummaryOfSignificantAccountingPoliciesAcquisitionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessAcquisitionSharePrice": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Price of a single share of a number of saleable stocks paid or offered to be paid in a business combination.", "label": "Business Acquisition, Share Price", "terseLabel": "Share price (usd per share)" } } }, "localname": "BusinessAcquisitionSharePrice", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/NarrativeDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_BusinessCombinationConsiderationTransferred1": { "auth_ref": [ "r486", "r487", "r489" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.", "label": "Business Combination, Consideration Transferred", "terseLabel": "Consideration transferred" } } }, "localname": "BusinessCombinationConsiderationTransferred1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/NarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1": { "auth_ref": [ "r161", "r490" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.", "label": "Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability", "terseLabel": "Change on the fair value of contingent consideration" } } }, "localname": "BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/FinancialInstrumentsFairValueMeasurementDetails", "http://www.lilly.com/role/FinancialInstrumentsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent": { "auth_ref": [ "r485", "r488" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled within one year or the normal operating cycle, if longer.", "label": "Business Combination, Contingent Consideration, Liability, Current", "negatedTerseLabel": "Other current liabilities" } } }, "localname": "BusinessCombinationContingentConsiderationLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/FinancialInstrumentsFairValueMeasurementDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Business Combinations [Abstract]" } } }, "localname": "BusinessCombinationsAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_CarryingReportedAmountFairValueDisclosureMember": { "auth_ref": [ "r548", "r549" ], "lang": { "en-US": { "role": { "documentation": "Measured as reported on the statement of financial position (balance sheet).", "label": "Reported Value Measurement [Member]", "terseLabel": "Carrying Amount" } } }, "localname": "CarryingReportedAmountFairValueDisclosureMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/FinancialInstrumentsFairValueMeasurementDetails", "http://www.lilly.com/role/FinancialInstrumentsShortTermAndLongTermClassificationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r29", "r71", "r164" ], "calculation": { "http://www.lilly.com/role/ConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash and Cash Equivalents, at Carrying Value", "terseLabel": "Cash and cash equivalents (Note 7)" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValueIncludingDiscontinuedOperations": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "For the entity and the disposal group, cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the Entity may deposit additional funds at any time and also effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Compensating balance arrangements that do not legally restrict the withdrawal or usage of cash amounts may be reported as Cash and Cash Equivalents, while legally restricted deposits held as compensating balances against borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits are not generally reported as cash and cash equivalents.", "label": "Cash and Cash Equivalents, at Carrying Value, Including Discontinued Operations", "periodEndLabel": "Cash and Cash Equivalents at End of Year (includes $677.5 (2018), $324.4 (2017), and $258.8 (2016) of discontinued operations)", "periodStartLabel": "Cash and cash equivalents at beginning of year (includes $324.4 (2018), $258.8 (2017), and $460.6 (2016) of discontinued operations)" } } }, "localname": "CashAndCashEquivalentsAtCarryingValueIncludingDiscontinuedOperations", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsFairValueDisclosure": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash and Cash Equivalents, Fair Value Disclosure", "verboseLabel": "Cash equivalents" } } }, "localname": "CashAndCashEquivalentsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/FinancialInstrumentsFairValueMeasurementDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease": { "auth_ref": [], "calculation": { "http://www.lilly.com/role/ConsolidatedStatementsOfCashFlows": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in cash and cash equivalents. Cash and cash equivalents are the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Includes effect from exchange rate changes.", "label": "Cash and Cash Equivalents, Period Increase (Decrease)", "totalLabel": "Net increase in cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsPeriodIncreaseDecrease", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsPeriodIncreaseDecreaseAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Cash and Cash Equivalents, Period Increase (Decrease) [Abstract]", "terseLabel": "Cash and Cash Equivalents, Period Increase (Decrease) [Abstract]" } } }, "localname": "CashAndCashEquivalentsPeriodIncreaseDecreaseAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_CashFlowHedgingMember": { "auth_ref": [ "r515" ], "lang": { "en-US": { "role": { "documentation": "Hedge of the exposure to variability in the cash flows of a recognized asset or liability, or of a forecasted transaction, that is attributable to a particular risk.", "label": "Cash Flow Hedging [Member]", "terseLabel": "Cash flow hedges:" } } }, "localname": "CashFlowHedgingMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/FinancialInstrumentsEffectOfRiskManagementDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations": { "auth_ref": [ "r19", "r157" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow (outflow) of investing activities of discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Cash Provided by (Used in) Investing Activities, Discontinued Operations", "negatedTerseLabel": "Cash used by investing activities, discontinued operations" } } }, "localname": "CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/DiscontinuedOperationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations": { "auth_ref": [ "r19", "r157" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow (outflow) of operating activities of discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Cash Provided by (Used in) Operating Activities, Discontinued Operations", "terseLabel": "Cash provided by operating activities, discontinued operations" } } }, "localname": "CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/DiscontinuedOperationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1": { "auth_ref": [ "r535" ], "calculation": { "http://www.lilly.com/role/FinancialInstrumentsEffectOfRiskManagementDetails": { "order": 2.0, "parentTag": "lly_DerivativeInstrumentsGainLossRecognized", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of gain (loss) from the increase (decrease) in fair value of derivative and nonderivative instruments designated as fair value hedging instruments recognized in the income statement.", "label": "Change in Unrealized Gain (Loss) on Fair Value Hedging Instruments", "terseLabel": "Effect from interest rate contracts" } } }, "localname": "ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/FinancialInstrumentsEffectOfRiskManagementDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1": { "auth_ref": [ "r535" ], "calculation": { "http://www.lilly.com/role/FinancialInstrumentsEffectOfRiskManagementDetails": { "order": 1.0, "parentTag": "lly_DerivativeInstrumentsGainLossRecognized", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of the increase (decrease) in fair value of the hedged item in a fair value hedge recognized in the income statement.", "label": "Change in Unrealized Gain (Loss) on Hedged Item in Fair Value Hedge", "terseLabel": "Effect from hedged fixed-rate debt" } } }, "localname": "ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/FinancialInstrumentsEffectOfRiskManagementDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ClassOfStockDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.", "label": "Class of Stock [Domain]", "terseLabel": "Class of Stock [Domain]" } } }, "localname": "ClassOfStockDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/CoverPage" ], "xbrltype": "domainItemType" }, "us-gaap_ClassOfStockLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Class of Stock [Line Items]", "terseLabel": "Statement [Line Items]" } } }, "localname": "ClassOfStockLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/ShareholdersEquityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CollaborativeArrangementDisclosureTextBlock": { "auth_ref": [ "r492", "r493", "r495" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.", "label": "Collaborative Arrangement Disclosure [Text Block]", "terseLabel": "Collaborations and Other Arrangements" } } }, "localname": "CollaborativeArrangementDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/CollaborationsAndOtherArrangements" ], "xbrltype": "textBlockItemType" }, "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]", "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]" } } }, "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/CollaborationsAndOtherArrangementsDetails", "http://www.lilly.com/role/CollaborationsAndOtherArrangementsTables" ], "xbrltype": "stringItemType" }, "us-gaap_CommercialPaper": { "auth_ref": [ "r49", "r587", "r620" ], "calculation": { "http://www.lilly.com/role/BorrowingsLongTermDebtDetails": { "order": 1.0, "parentTag": "us-gaap_DebtLongtermAndShorttermCombinedAmount", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Carrying value as of the balance sheet date of short-term borrowings using unsecured obligations issued by banks, corporations and other borrowers to investors. The maturities of these money market securities generally do not exceed 270 days.", "label": "Commercial Paper", "negatedLabel": "Short-term commercial paper borrowings", "terseLabel": "Short-term commercial paper borrowings" } } }, "localname": "CommercialPaper", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/BorrowingsLongTermDebtDetails", "http://www.lilly.com/role/FinancialInstrumentsShortTermAndLongTermClassificationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommercialPaperMember": { "auth_ref": [ "r324" ], "lang": { "en-US": { "role": { "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds.", "label": "Commercial Paper [Member]", "terseLabel": "Commercial Paper" } } }, "localname": "CommercialPaperMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/FinancialInstrumentsShortTermAndLongTermClassificationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CommitmentsAndContingencies": { "auth_ref": [ "r87", "r310", "r598", "r625" ], "calculation": { "http://www.lilly.com/role/ConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.", "label": "Commitments and Contingencies", "terseLabel": "Commitments and Contingencies (Note 15)" } } }, "localname": "CommitmentsAndContingencies", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]" } } }, "localname": "CommitmentsAndContingenciesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "auth_ref": [ "r309", "r320" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for commitments and contingencies.", "label": "Commitments and Contingencies Disclosure [Text Block]", "terseLabel": "Contingencies" } } }, "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/Contingencies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommitmentsAndContingenciesPolicyTextBlock": { "auth_ref": [ "r167", "r323", "r639", "r640" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for commitments and contingencies, which may include policies for recognizing and measuring loss and gain contingencies.", "label": "Commitments and Contingencies, Policy [Policy Text Block]", "terseLabel": "Commitments and Contingencies" } } }, "localname": "CommitmentsAndContingenciesPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/ContingenciesPolicies", "http://www.lilly.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonClassAMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Classification of common stock representing ownership interest in a corporation.", "label": "Common Class A [Member]", "terseLabel": "Common Stock (no par value)" } } }, "localname": "CommonClassAMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/CoverPage" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockDividendsPerShareCashPaid": { "auth_ref": [ "r342" ], "lang": { "en-US": { "role": { "documentation": "Aggregate dividends paid during the period for each share of common stock outstanding.", "label": "Common Stock, Dividends, Per Share, Cash Paid", "terseLabel": "Dividends paid per share (usd per share)" } } }, "localname": "CommonStockDividendsPerShareCashPaid", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/SelectedQuarterlyDataUnauditedDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockDividendsPerShareDeclared": { "auth_ref": [ "r342" ], "lang": { "en-US": { "role": { "documentation": "Aggregate dividends declared during the period for each share of common stock outstanding.", "label": "Common Stock, Dividends, Per Share, Declared", "terseLabel": "Cash dividend declared per share (usd per share)" } } }, "localname": "CommonStockDividendsPerShareDeclared", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/ConsolidatedStatementsOfShareholdersEquityParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]", "terseLabel": "Common Stock" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/ConsolidatedStatementsOfShareholdersEquityStatement" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r60" ], "lang": { "en-US": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common Stock, Shares Authorized", "terseLabel": "Authorized shares, shares" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/ConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesHeldInEmployeeTrust": { "auth_ref": [], "calculation": { "http://www.lilly.com/role/ConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_StockholdersEquity", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Value of common stock issued to a trust (for example, but not limited to, rabbi trust) set up specifically to accumulate stock for the sole purpose of distribution to participating employees.", "label": "Common Stock, Shares Held in Employee Trust", "negatedTerseLabel": "Employee benefit trust", "terseLabel": "Employee benefit trust" } } }, "localname": "CommonStockSharesHeldInEmployeeTrust", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/ConsolidatedBalanceSheets", "http://www.lilly.com/role/ShareholdersEquityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommonStockSharesHeldInEmployeeTrustShares": { "auth_ref": [ "r431" ], "lang": { "en-US": { "role": { "documentation": "Number of common stock held in a trust that has been set up specifically to accumulate stock for the sole purpose of distribution to participating employees but not yet earned.", "label": "Common Stock, Shares Held in Employee Trust, Shares", "terseLabel": "Shares held in employee trust (in shares)" } } }, "localname": "CommonStockSharesHeldInEmployeeTrustShares", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/ShareholdersEquityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r60" ], "lang": { "en-US": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common Stock, Shares, Issued", "terseLabel": "Issued shares" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/ConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r60" ], "calculation": { "http://www.lilly.com/role/ConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common Stock, Value, Issued", "terseLabel": "Common stock\u2014no par value Authorized shares: 3,200,000 Issued shares: 1,057,639 (2018) and 1,100,672 (2017)" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CompensationAndRetirementDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Retirement Benefits [Abstract]" } } }, "localname": "CompensationAndRetirementDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Components of Deferred Tax Liabilities [Abstract]", "terseLabel": "Deferred tax liabilities:" } } }, "localname": "ComponentsOfDeferredTaxLiabilitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/IncomeTaxesDeferredTaxAssetAndLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest": { "auth_ref": [ "r122", "r124", "r498", "r507" ], "calculation": { "http://www.lilly.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest", "totalLabel": "Comprehensive income (loss)" } } }, "localname": "ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomeNoteTextBlock": { "auth_ref": [ "r142" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for comprehensive income, which includes, but is not limited to, 1) the amount of income tax expense or benefit allocated to each component of other comprehensive income, including reclassification adjustments, 2) the reclassification adjustments for each classification of other comprehensive income and 3) the ending accumulated balances for each component of comprehensive income.", "label": "Comprehensive Income (Loss) Note [Text Block]", "terseLabel": "Other Comprehensive Income (Loss)" } } }, "localname": "ComprehensiveIncomeNoteTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/OtherComprehensiveIncomeLoss" ], "xbrltype": "textBlockItemType" }, "us-gaap_ConcentrationRiskBenchmarkDomain": { "auth_ref": [ "r202", "r203", "r550", "r551" ], "lang": { "en-US": { "role": { "documentation": "The denominator in a calculation of a disclosed concentration risk percentage.", "label": "Concentration Risk Benchmark [Domain]", "terseLabel": "Concentration Risk Benchmark [Domain]" } } }, "localname": "ConcentrationRiskBenchmarkDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/SegmentInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ConcentrationRiskByBenchmarkAxis": { "auth_ref": [ "r202", "r203", "r550", "r551", "r636" ], "lang": { "en-US": { "role": { "documentation": "Information by benchmark of concentration risk.", "label": "Concentration Risk Benchmark [Axis]", "terseLabel": "Concentration Risk Benchmark [Axis]" } } }, "localname": "ConcentrationRiskByBenchmarkAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/SegmentInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskCreditRisk": { "auth_ref": [ "r201", "r612" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for credit risk.", "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]", "terseLabel": "Concentration Risk, Credit Risk" } } }, "localname": "ConcentrationRiskCreditRisk", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/FinancialInstrumentsPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ConcentrationRiskPercentage1": { "auth_ref": [ "r202", "r203", "r550", "r551" ], "lang": { "en-US": { "role": { "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.", "label": "Concentration Risk, Percentage", "terseLabel": "Concentration risk, percentage" } } }, "localname": "ConcentrationRiskPercentage1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/SegmentInformationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ConstructionInProgressGross": { "auth_ref": [ "r291" ], "calculation": { "http://www.lilly.com/role/PropertyAndEquipmentDetails": { "order": 4.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.", "label": "Construction in Progress, Gross", "terseLabel": "Construction in progress" } } }, "localname": "ConstructionInProgressGross", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/PropertyAndEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock": { "auth_ref": [ "r349" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of contract balances and changes in contract balances.", "label": "Contract with Customer, Asset and Liability [Table Text Block]", "terseLabel": "Schedule of Contract Liabilities" } } }, "localname": "ContractWithCustomerAssetAndLiabilityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/SummaryOfSignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ContractWithCustomerLiability": { "auth_ref": [ "r347", "r348", "r351" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.", "label": "Contract with Customer, Liability", "terseLabel": "Contract liabilities" } } }, "localname": "ContractWithCustomerLiability", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/SummaryOfSignificantAccountingPoliciesContractLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CorporateDebtSecuritiesMember": { "auth_ref": [ "r377", "r410", "r635" ], "lang": { "en-US": { "role": { "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment.", "label": "Corporate Debt Securities [Member]", "terseLabel": "Corporate debt securities" } } }, "localname": "CorporateDebtSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/FinancialInstrumentsFairValueMeasurementDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CostOfGoodsAndServicesSold": { "auth_ref": [ "r136" ], "calculation": { "http://www.lilly.com/role/ConsolidatedStatementsOfOperations": { "order": 1.0, "parentTag": "lly_CostOfSalesOperatingExpensesAndOtherNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.", "label": "Cost of Goods and Services Sold", "terseLabel": "Cost of sales" } } }, "localname": "CostOfGoodsAndServicesSold", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/ConsolidatedStatementsOfOperations", "http://www.lilly.com/role/ImplementationOfNewFinancialAccountingPronouncementsDetails", "http://www.lilly.com/role/SelectedQuarterlyDataUnauditedDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CostsAndExpensesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Costs and Expenses [Abstract]", "terseLabel": "Costs, expenses, and other:" } } }, "localname": "CostsAndExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_CrossCurrencyInterestRateContractMember": { "auth_ref": [ "r377", "r529" ], "lang": { "en-US": { "role": { "documentation": "Derivative instrument whose primary underlying risk is tied to interest rates and foreign exchange rates.", "label": "Cross Currency Interest Rate Contract [Member]", "terseLabel": "Cross-currency interest rate swaps" } } }, "localname": "CrossCurrencyInterestRateContractMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/FinancialInstrumentsEffectOfRiskManagementDetails", "http://www.lilly.com/role/FinancialInstrumentsFairValueMeasurementDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after tax of increase (decrease) to equity or (increase) decrease to net assets, resulting from the cumulative effect adjustment of a new accounting principle applied in the period of adoption.", "label": "Cumulative Effect of New Accounting Principle in Period of Adoption", "terseLabel": "Reclassification due to adoption of new accounting standard(3)", "verboseLabel": "Reclassification of stranded tax effects and Adoption of new accounting standards (Note 2)" } } }, "localname": "CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/ConsolidatedStatementsOfShareholdersEquityStatement", "http://www.lilly.com/role/OtherComprehensiveIncomeLossRollForwardDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CurrencySwapMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Swap involving the exchange of principal and interest in one currency for another currency.", "label": "Currency Swap [Member]", "terseLabel": "Currency Swap" } } }, "localname": "CurrencySwapMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/FinancialInstrumentsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Current Federal, State and Local, Tax Expense (Benefit) [Abstract]", "terseLabel": "Current:" } } }, "localname": "CurrentFederalStateAndLocalTaxExpenseBenefitAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/IncomeTaxesCurrentAndDeferredDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CurrentFederalTaxExpenseBenefit": { "auth_ref": [ "r171", "r469", "r474" ], "calculation": { "http://www.lilly.com/role/IncomeTaxesCurrentAndDeferredDetails": { "order": 1.0, "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of current federal tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Current Federal Tax Expense (Benefit)", "terseLabel": "Federal" } } }, "localname": "CurrentFederalTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/IncomeTaxesCurrentAndDeferredDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CurrentForeignTaxExpenseBenefit": { "auth_ref": [ "r175", "r471" ], "calculation": { "http://www.lilly.com/role/IncomeTaxesCurrentAndDeferredDetails": { "order": 2.0, "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Current Foreign Tax Expense (Benefit)", "terseLabel": "Foreign" } } }, "localname": "CurrentForeignTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/IncomeTaxesCurrentAndDeferredDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CurrentIncomeTaxExpenseBenefit": { "auth_ref": [ "r171", "r469", "r474" ], "calculation": { "http://www.lilly.com/role/IncomeTaxesCurrentAndDeferredDetails": { "order": 1.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.", "label": "Current Income Tax Expense (Benefit)", "totalLabel": "Total current tax expense" } } }, "localname": "CurrentIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/IncomeTaxesCurrentAndDeferredDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CurrentStateAndLocalTaxExpenseBenefit": { "auth_ref": [ "r171", "r469", "r474" ], "calculation": { "http://www.lilly.com/role/IncomeTaxesCurrentAndDeferredDetails": { "order": 3.0, "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of current state and local tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Current State and Local Tax Expense (Benefit)", "terseLabel": "State" } } }, "localname": "CurrentStateAndLocalTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/IncomeTaxesCurrentAndDeferredDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtCurrent": { "auth_ref": [ "r81" ], "calculation": { "http://www.lilly.com/role/BorrowingsLongTermDebtDetailsCalc2": { "order": 1.0, "parentTag": "us-gaap_DebtLongtermAndShorttermCombinedAmount", "weight": 1.0 }, "http://www.lilly.com/role/ConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of short-term debt and current maturity of long-term debt and capital lease obligations due within one year or the normal operating cycle, if longer.", "label": "Debt, Current", "negatedLabel": "Less current portion", "terseLabel": "Short-term borrowings and current maturities of long-term debt (Note 10)" } } }, "localname": "DebtCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/BorrowingsLongTermDebtDetails", "http://www.lilly.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Debt Disclosure [Abstract]" } } }, "localname": "DebtDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_DebtDisclosureTextBlock": { "auth_ref": [ "r331" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.", "label": "Debt Disclosure [Text Block]", "terseLabel": "Borrowings" } } }, "localname": "DebtDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/Borrowings" ], "xbrltype": "textBlockItemType" }, "us-gaap_DebtInstrumentAxis": { "auth_ref": [ "r50", "r52", "r53", "r588", "r591", "r614" ], "lang": { "en-US": { "role": { "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.", "label": "Debt Instrument [Axis]", "terseLabel": "Debt Instrument [Axis]" } } }, "localname": "DebtInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/BorrowingsNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentFaceAmount": { "auth_ref": [ "r565", "r567" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Face (par) amount of debt instrument at time of issuance.", "label": "Debt Instrument, Face Amount", "terseLabel": "Debt instrument, face amount" } } }, "localname": "DebtInstrumentFaceAmount", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/BorrowingsNarrativeDetails", "http://www.lilly.com/role/DiscontinuedOperationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentInterestRateEffectivePercentage": { "auth_ref": [ "r84", "r328", "r565" ], "lang": { "en-US": { "role": { "documentation": "Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.", "label": "Debt Instrument, Interest Rate, Effective Percentage", "terseLabel": "Debt instrument, interest rate, effective percentage (in percentage)" } } }, "localname": "DebtInstrumentInterestRateEffectivePercentage", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/BorrowingsNarrativeDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentInterestRateStatedPercentage": { "auth_ref": [ "r84" ], "lang": { "en-US": { "role": { "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.", "label": "Debt Instrument, Interest Rate, Stated Percentage", "terseLabel": "Stated interest rate (in percentage)" } } }, "localname": "DebtInstrumentInterestRateStatedPercentage", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/BorrowingsNarrativeDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Debt Instrument [Line Items]", "verboseLabel": "Debt Instrument [Line Items]" } } }, "localname": "DebtInstrumentLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/BorrowingsNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentNameDomain": { "auth_ref": [ "r85" ], "lang": { "en-US": { "role": { "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.", "label": "Debt Instrument, Name [Domain]", "terseLabel": "Debt Instrument, Name [Domain]" } } }, "localname": "DebtInstrumentNameDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/BorrowingsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtInstrumentRedemptionPeriodAxis": { "auth_ref": [ "r610" ], "lang": { "en-US": { "role": { "documentation": "Information about timing of debt redemption features under terms of the debt agreement.", "label": "Debt Instrument, Redemption, Period [Axis]", "terseLabel": "Debt Instrument, Redemption, Period [Axis]" } } }, "localname": "DebtInstrumentRedemptionPeriodAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/BorrowingsNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentRedemptionPeriodDomain": { "auth_ref": [ "r610" ], "lang": { "en-US": { "role": { "documentation": "Period as defined under terms of the debt agreement for debt redemption features.", "label": "Debt Instrument, Redemption, Period [Domain]", "terseLabel": "Debt Instrument, Redemption, Period [Domain]" } } }, "localname": "DebtInstrumentRedemptionPeriodDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/BorrowingsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtInstrumentTable": { "auth_ref": [ "r85", "r173", "r336", "r339", "r340", "r341", "r564", "r565", "r567", "r611" ], "lang": { "en-US": { "role": { "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.", "label": "Schedule of Long-term Debt Instruments [Table]", "terseLabel": "Schedule of Long-term Debt Instruments [Table]" } } }, "localname": "DebtInstrumentTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/BorrowingsNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentTerm": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Debt Instrument, Term", "verboseLabel": "Debt instrument, term" } } }, "localname": "DebtInstrumentTerm", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/BorrowingsNarrativeDetails", "http://www.lilly.com/role/DiscontinuedOperationsDetails" ], "xbrltype": "durationItemType" }, "us-gaap_DebtLongtermAndShorttermCombinedAmount": { "auth_ref": [], "calculation": { "http://www.lilly.com/role/BorrowingsLongTermDebtDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.lilly.com/role/BorrowingsLongTermDebtDetailsCalc2": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Represents the aggregate of total long-term debt, including current maturities and short-term debt.", "label": "Debt, Long-term and Short-term, Combined Amount", "totalLabel": "Total debt" } } }, "localname": "DebtLongtermAndShorttermCombinedAmount", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/BorrowingsLongTermDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleSaleAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Debt Securities, Available-for-sale, Sale [Abstract]", "terseLabel": "Short-term investments:" } } }, "localname": "DebtSecuritiesAvailableForSaleSaleAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/FinancialInstrumentsFairValueMeasurementDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock": { "auth_ref": [ "r243" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-sale [Table Text Block]", "terseLabel": "Available-for-sale Securities" } } }, "localname": "DebtSecuritiesAvailableForSaleTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/FinancialInstrumentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition": { "auth_ref": [ "r241", "r256", "r260" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position without allowance for credit loss.", "label": "Debt Securities, Available-for-sale, Unrealized Loss Position", "terseLabel": "Fair value of securities in an unrealized loss position" } } }, "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPosition", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/FinancialInstrumentsSummaryOfAfsUnrealizedGainlossDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible": { "auth_ref": [ "r448" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of decrease reasonably possible in the next twelve months for the unrecognized tax benefit.", "label": "Decrease in Unrecognized Tax Benefits is Reasonably Possible", "terseLabel": "Decrease in unrecognized tax benefits is reasonably possible" } } }, "localname": "DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredFederalIncomeTaxExpenseBenefit": { "auth_ref": [ "r171", "r470", "r474" ], "calculation": { "http://www.lilly.com/role/IncomeTaxesCurrentAndDeferredDetails": { "order": 1.0, "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of deferred federal income tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Deferred Federal Income Tax Expense (Benefit)", "terseLabel": "Federal" } } }, "localname": "DeferredFederalIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/IncomeTaxesCurrentAndDeferredDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Deferred Federal, State and Local, Tax Expense (Benefit) [Abstract]", "terseLabel": "Deferred:" } } }, "localname": "DeferredFederalStateAndLocalTaxExpenseBenefitAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/IncomeTaxesCurrentAndDeferredDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DeferredForeignIncomeTaxExpenseBenefit": { "auth_ref": [ "r171", "r470", "r474" ], "calculation": { "http://www.lilly.com/role/IncomeTaxesCurrentAndDeferredDetails": { "order": 2.0, "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of deferred foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Deferred Foreign Income Tax Expense (Benefit)", "terseLabel": "Foreign" } } }, "localname": "DeferredForeignIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/IncomeTaxesCurrentAndDeferredDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeTaxAssetsNet": { "auth_ref": [ "r463" ], "calculation": { "http://www.lilly.com/role/ConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.", "label": "Deferred Income Tax Assets, Net", "terseLabel": "Deferred tax assets (Note 13)" } } }, "localname": "DeferredIncomeTaxAssetsNet", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeTaxExpenseBenefit": { "auth_ref": [ "r162", "r171", "r470", "r474" ], "calculation": { "http://www.lilly.com/role/IncomeTaxesCurrentAndDeferredDetails": { "order": 2.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Deferred Income Tax Expense (Benefit)", "totalLabel": "Total deferred tax (benefit) expense" } } }, "localname": "DeferredIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/IncomeTaxesCurrentAndDeferredDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeTaxLiabilities": { "auth_ref": [ "r56", "r57", "r459", "r590", "r613" ], "calculation": { "http://www.lilly.com/role/IncomeTaxesDeferredTaxAssetAndLiabilitiesDetails": { "order": 2.0, "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of deferred tax liability attributable to taxable temporary differences.", "label": "Deferred Tax Liabilities, Gross", "negatedTotalLabel": "Total deferred tax liabilities" } } }, "localname": "DeferredIncomeTaxLiabilities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/IncomeTaxesDeferredTaxAssetAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit": { "auth_ref": [ "r171", "r470", "r474" ], "calculation": { "http://www.lilly.com/role/IncomeTaxesCurrentAndDeferredDetails": { "order": 3.0, "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of deferred state and local tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Deferred State and Local Income Tax Expense (Benefit)", "terseLabel": "State" } } }, "localname": "DeferredStateAndLocalIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/IncomeTaxesCurrentAndDeferredDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets": { "auth_ref": [], "calculation": { "http://www.lilly.com/role/IncomeTaxesDeferredTaxAssetAndLiabilitiesDetails": { "order": 2.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from intangible assets including goodwill.", "label": "Deferred Tax Assets, Goodwill and Intangible Assets", "terseLabel": "Purchases of intangible assets" } } }, "localname": "DeferredTaxAssetsGoodwillAndIntangibleAssets", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/IncomeTaxesDeferredTaxAssetAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsGross": { "auth_ref": [ "r460" ], "calculation": { "http://www.lilly.com/role/IncomeTaxesDeferredTaxAssetAndLiabilitiesDetails": { "order": 1.0, "parentTag": "us-gaap_DeferredTaxAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.", "label": "Deferred Tax Assets, Gross", "totalLabel": "Total gross deferred tax assets" } } }, "localname": "DeferredTaxAssetsGross", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/IncomeTaxesDeferredTaxAssetAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsLiabilitiesNet": { "auth_ref": [ "r463" ], "calculation": { "http://www.lilly.com/role/IncomeTaxesDeferredTaxAssetAndLiabilitiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.", "label": "Deferred Tax Assets, Net", "totalLabel": "Deferred tax assets, net", "verboseLabel": "Deferred tax assets" } } }, "localname": "DeferredTaxAssetsLiabilitiesNet", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/ImplementationOfNewFinancialAccountingPronouncementsDetails", "http://www.lilly.com/role/IncomeTaxesDeferredTaxAssetAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsNet": { "auth_ref": [ "r461" ], "calculation": { "http://www.lilly.com/role/IncomeTaxesDeferredTaxAssetAndLiabilitiesDetails": { "order": 1.0, "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.", "label": "Deferred Tax Assets, Net of Valuation Allowance", "totalLabel": "Total deferred tax assets" } } }, "localname": "DeferredTaxAssetsNet", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/IncomeTaxesDeferredTaxAssetAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsNetAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Deferred Tax Assets, Net [Abstract]", "terseLabel": "Deferred tax assets:" } } }, "localname": "DeferredTaxAssetsNetAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/IncomeTaxesDeferredTaxAssetAndLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": { "auth_ref": [ "r437", "r467", "r468" ], "calculation": { "http://www.lilly.com/role/IncomeTaxesDeferredTaxAssetAndLiabilitiesDetails": { "order": 4.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.", "label": "Deferred Tax Assets, Operating Loss Carryforwards", "terseLabel": "Tax loss carryforwards and carrybacks" } } }, "localname": "DeferredTaxAssetsOperatingLossCarryforwards", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/IncomeTaxesDeferredTaxAssetAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal": { "auth_ref": [ "r437", "r467", "r468" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible state and local operating loss carryforwards.", "label": "Deferred Tax Assets, Operating Loss Carryforwards, State and Local", "terseLabel": "Deferred tax assets related to state net operating losses" } } }, "localname": "DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsOther": { "auth_ref": [ "r439", "r467", "r468" ], "calculation": { "http://www.lilly.com/role/IncomeTaxesDeferredTaxAssetAndLiabilitiesDetails": { "order": 9.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.", "label": "Deferred Tax Assets, Other", "terseLabel": "Other" } } }, "localname": "DeferredTaxAssetsOther", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/IncomeTaxesDeferredTaxAssetAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsOtherComprehensiveLoss": { "auth_ref": [ "r439", "r467", "r468", "r476" ], "calculation": { "http://www.lilly.com/role/IncomeTaxesDeferredTaxAssetAndLiabilitiesDetails": { "order": 7.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from unrealized losses in other comprehensive income.", "label": "Deferred Tax Assets, Other Comprehensive Loss", "terseLabel": "Other comprehensive loss on hedging transactions" } } }, "localname": "DeferredTaxAssetsOtherComprehensiveLoss", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/IncomeTaxesDeferredTaxAssetAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsTaxCreditCarryforwards": { "auth_ref": [ "r465", "r467", "r468" ], "calculation": { "http://www.lilly.com/role/IncomeTaxesDeferredTaxAssetAndLiabilitiesDetails": { "order": 3.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, before allocation of a valuation allowances, of deferred tax assets attributable to deductible tax credit carryforwards including, but not limited to, research, foreign, general business, alternative minimum tax, and other deductible tax credit carryforwards.", "label": "Deferred Tax Assets, Tax Credit Carryforwards", "terseLabel": "Tax credit carryforwards and carrybacks" } } }, "localname": "DeferredTaxAssetsTaxCreditCarryforwards", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/IncomeTaxesDeferredTaxAssetAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsOther": { "auth_ref": [ "r465", "r467", "r468" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible tax credit carryforwards, classified as other.", "label": "Deferred Tax Assets, Tax Credit Carryforwards, Other", "terseLabel": "Other state carryforwards" } } }, "localname": "DeferredTaxAssetsTaxCreditCarryforwardsOther", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits": { "auth_ref": [ "r437", "r467", "r468" ], "calculation": { "http://www.lilly.com/role/IncomeTaxesDeferredTaxAssetAndLiabilitiesDetails": { "order": 1.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from compensation and benefits costs.", "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits", "terseLabel": "Compensation and benefits" } } }, "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/IncomeTaxesDeferredTaxAssetAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsContingencies": { "auth_ref": [ "r437", "r467", "r468" ], "calculation": { "http://www.lilly.com/role/IncomeTaxesDeferredTaxAssetAndLiabilitiesDetails": { "order": 5.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from contingent liabilities.", "label": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Contingencies", "terseLabel": "Contingent consideration" } } }, "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsContingencies", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/IncomeTaxesDeferredTaxAssetAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves": { "auth_ref": [ "r437", "r467", "r468" ], "calculation": { "http://www.lilly.com/role/IncomeTaxesDeferredTaxAssetAndLiabilitiesDetails": { "order": 6.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences from reserves, classified as other.", "label": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Reserves", "terseLabel": "Product return reserves" } } }, "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/IncomeTaxesDeferredTaxAssetAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsValuationAllowance": { "auth_ref": [ "r462" ], "calculation": { "http://www.lilly.com/role/IncomeTaxesDeferredTaxAssetAndLiabilitiesDetails": { "order": 2.0, "parentTag": "us-gaap_DeferredTaxAssetsNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.", "label": "Deferred Tax Assets, Valuation Allowance", "negatedLabel": "Valuation allowances" } } }, "localname": "DeferredTaxAssetsValuationAllowance", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/IncomeTaxesDeferredTaxAssetAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxLiabilities": { "auth_ref": [ "r443", "r463" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting.", "label": "Deferred Tax Liabilities, Net", "terseLabel": "Deferred tax liabilities" } } }, "localname": "DeferredTaxLiabilities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/ImplementationOfNewFinancialAccountingPronouncementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedInventoryCosts": { "auth_ref": [ "r438", "r467", "r468" ], "calculation": { "http://www.lilly.com/role/IncomeTaxesDeferredTaxAssetAndLiabilitiesDetails": { "order": 1.0, "parentTag": "us-gaap_DeferredIncomeTaxLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of deferred tax consequences attributable to taxable temporary differences derived from inventory.", "label": "Deferred Tax Liabilities, Inventory", "negatedLabel": "Inventories" } } }, "localname": "DeferredTaxLiabilitiesDeferredExpenseCapitalizedInventoryCosts", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/IncomeTaxesDeferredTaxAssetAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxLiabilitiesDerivatives": { "auth_ref": [ "r467", "r468" ], "calculation": { "http://www.lilly.com/role/IncomeTaxesDeferredTaxAssetAndLiabilitiesDetails": { "order": 5.0, "parentTag": "us-gaap_DeferredIncomeTaxLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from derivatives.", "label": "Deferred Tax Liabilities, Derivatives", "negatedLabel": "Financial instruments" } } }, "localname": "DeferredTaxLiabilitiesDerivatives", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/IncomeTaxesDeferredTaxAssetAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssets": { "auth_ref": [ "r439", "r467", "r468" ], "calculation": { "http://www.lilly.com/role/IncomeTaxesDeferredTaxAssetAndLiabilitiesDetails": { "order": 3.0, "parentTag": "us-gaap_DeferredIncomeTaxLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from intangible assets including goodwill.", "label": "Deferred Tax Liabilities, Goodwill and Intangible Assets", "negatedLabel": "Intangibles" } } }, "localname": "DeferredTaxLiabilitiesGoodwillAndIntangibleAssets", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/IncomeTaxesDeferredTaxAssetAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxLiabilitiesPrepaidExpenses": { "auth_ref": [], "calculation": { "http://www.lilly.com/role/IncomeTaxesDeferredTaxAssetAndLiabilitiesDetails": { "order": 6.0, "parentTag": "us-gaap_DeferredIncomeTaxLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of deferred tax consequences attributable to taxable temporary differences derived from prepaid expenses.", "label": "Deferred Tax Liabilities, Prepaid Expenses", "negatedLabel": "Prepaid employee benefits" } } }, "localname": "DeferredTaxLiabilitiesPrepaidExpenses", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/IncomeTaxesDeferredTaxAssetAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment": { "auth_ref": [ "r439", "r467", "r468" ], "calculation": { "http://www.lilly.com/role/IncomeTaxesDeferredTaxAssetAndLiabilitiesDetails": { "order": 4.0, "parentTag": "us-gaap_DeferredIncomeTaxLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment.", "label": "Deferred Tax Liabilities, Property, Plant and Equipment", "negatedLabel": "Property and equipment" } } }, "localname": "DeferredTaxLiabilitiesPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/IncomeTaxesDeferredTaxAssetAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxLiabilitiesUndistributedForeignEarnings": { "auth_ref": [ "r467" ], "calculation": { "http://www.lilly.com/role/IncomeTaxesDeferredTaxAssetAndLiabilitiesDetails": { "order": 2.0, "parentTag": "us-gaap_DeferredIncomeTaxLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from undistributed earnings of subsidiary and other recognized entity not within country of domicile. Includes, but is not limited to, other basis differences.", "label": "Deferred Tax Liabilities, Undistributed Foreign Earnings", "negatedLabel": "Earnings of foreign subsidiaries" } } }, "localname": "DeferredTaxLiabilitiesUndistributedForeignEarnings", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/IncomeTaxesDeferredTaxAssetAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation": { "auth_ref": [ "r379" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of actuarial present value of benefits attributed to employee service rendered, excluding assumptions about future compensation level.", "label": "Defined Benefit Plan, Accumulated Benefit Obligation", "terseLabel": "Total accumulated benefit obligation for our defined benefit pension plans" } } }, "localname": "DefinedBenefitPlanAccumulatedBenefitObligation", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/RetirementBenefitsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax": { "auth_ref": [ "r110", "r116" ], "calculation": { "http://www.lilly.com/role/RetirementBenefitsScheduleOfComponentsInConsolidatedBalanceSheetsDetails": { "order": 3.0, "parentTag": "us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, before tax, of accumulated other comprehensive (income) loss for defined benefit plan, that has not been recognized in net periodic benefit cost (credit).", "label": "Defined Benefit Plan, Accumulated Other Comprehensive (Income) Loss, before Tax", "terseLabel": "Accumulated other comprehensive (income) loss before income taxes" } } }, "localname": "DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/RetirementBenefitsScheduleOfComponentsInConsolidatedBalanceSheetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax": { "auth_ref": [ "r116", "r390" ], "calculation": { "http://www.lilly.com/role/RetirementBenefitsScheduleOfBenefitObligationsAndPlanAssetsDetails": { "order": 3.0, "parentTag": "us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, before tax, of accumulated other comprehensive income (loss) for gain (loss) of defined benefit plan, that has not been recognized in net periodic benefit (cost) credit.", "label": "Defined Benefit Plan, Accumulated Other Comprehensive Income (Loss), Gain (Loss), before Tax", "negatedTerseLabel": "Unrecognized net actuarial loss" } } }, "localname": "DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/RetirementBenefitsScheduleOfBenefitObligationsAndPlanAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax": { "auth_ref": [ "r116", "r390" ], "calculation": { "http://www.lilly.com/role/RetirementBenefitsScheduleOfBenefitObligationsAndPlanAssetsDetails": { "order": 2.0, "parentTag": "us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, before tax, of accumulated other comprehensive (income) loss for cost (credit) of benefit change attributable to participants' prior service from plan amendment or plan initiation of defined benefit plan, that has not been recognized in net periodic benefit cost (credit).", "label": "Defined Benefit Plan, Accumulated Other Comprehensive (Income) Loss, Prior Service Cost (Credit), before Tax", "terseLabel": "Unrecognized prior service (benefit) cost" } } }, "localname": "DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/RetirementBenefitsScheduleOfBenefitObligationsAndPlanAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets": { "auth_ref": [ "r370", "r410" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in plan assets of defined benefit plan from actual return (loss) determined by change in fair value of plan assets adjusted for contributions, benefit payments, and other expenses.", "label": "Defined Benefit Plan, Plan Assets, Increase (Decrease) for Actual Return (Loss)", "terseLabel": "Actual return on plan assets" } } }, "localname": "DefinedBenefitPlanActualReturnOnPlanAssets", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/RetirementBenefitsScheduleOfBenefitObligationsAndPlanAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanActuarialGainLoss": { "auth_ref": [ "r365" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of gain (loss) from change in actuarial assumptions which (increases) decreases benefit obligation of defined benefit plan. Assumptions include, but are not limited to, interest, mortality, employee turnover, salary, and temporary deviation from substantive plan.", "label": "Defined Benefit Plan, Benefit Obligation, Actuarial Gain (Loss)", "negatedTerseLabel": "Actuarial (gain) loss" } } }, "localname": "DefinedBenefitPlanActuarialGainLoss", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/RetirementBenefitsScheduleOfBenefitObligationsAndPlanAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses": { "auth_ref": [ "r385", "r406", "r410" ], "calculation": { "http://www.lilly.com/role/RetirementBenefitsScheduleOfExpectedBenefitPaymentsContributionsAndExpenseDetails": { "order": 5.0, "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of gain (loss) recognized in net periodic benefit (cost) credit of defined benefit plan.", "label": "Defined Benefit Plan, Amortization of Gain (Loss)", "negatedTerseLabel": "Recognized actuarial loss" } } }, "localname": "DefinedBenefitPlanAmortizationOfGainsLosses", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/RetirementBenefitsScheduleOfExpectedBenefitPaymentsContributionsAndExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit": { "auth_ref": [ "r386", "r407", "r410" ], "calculation": { "http://www.lilly.com/role/RetirementBenefitsScheduleOfExpectedBenefitPaymentsContributionsAndExpenseDetails": { "order": 4.0, "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of prior service cost (credit) recognized in net periodic benefit cost (credit) of defined benefit plan.", "label": "Defined Benefit Plan, Amortization of Prior Service Cost (Credit)", "terseLabel": "Amortization of prior service (benefit) cost" } } }, "localname": "DefinedBenefitPlanAmortizationOfPriorServiceCostCredit", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/RetirementBenefitsScheduleOfExpectedBenefitPaymentsContributionsAndExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet": { "auth_ref": [ "r359", "r374" ], "calculation": { "http://www.lilly.com/role/RetirementBenefitsScheduleOfBenefitObligationsAndPlanAssetsDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.lilly.com/role/RetirementBenefitsScheduleOfComponentsInConsolidatedBalanceSheetsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of asset (liability), recognized in statement of financial position, for defined benefit pension and other postretirement plans.", "label": "Defined Benefit Plan, Amounts for Asset (Liability) Recognized in Statement of Financial Position", "totalLabel": "Net amount recognized" } } }, "localname": "DefinedBenefitPlanAmountsRecognizedInBalanceSheet", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/RetirementBenefitsScheduleOfBenefitObligationsAndPlanAssetsDetails", "http://www.lilly.com/role/RetirementBenefitsScheduleOfComponentsInConsolidatedBalanceSheetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax": { "auth_ref": [ "r108", "r113", "r388" ], "calculation": { "http://www.lilly.com/role/RetirementBenefitsScheduleOfExpectedBenefitPaymentsContributionsAndExpenseDetails": { "order": 5.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, before tax, after reclassification adjustment, of increase (decrease) in accumulated other comprehensive income from gain (loss) of defined benefit plan.", "label": "Other Comprehensive Income (Loss), Defined Benefit Plan, Gain (Loss), after Reclassification Adjustment, before Tax", "terseLabel": "Amortization of net actuarial loss included in net income" } } }, "localname": "DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/RetirementBenefitsScheduleOfExpectedBenefitPaymentsContributionsAndExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent": { "auth_ref": [ "r48", "r359", "r360", "r374", "r585", "r617" ], "calculation": { "http://www.lilly.com/role/RetirementBenefitsScheduleOfComponentsInConsolidatedBalanceSheetsDetails": { "order": 4.0, "parentTag": "us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of asset, recognized in statement of financial position, for overfunded defined benefit pension and other postretirement plans.", "label": "Assets for Plan Benefits, Defined Benefit Plan", "terseLabel": "Sundry" } } }, "localname": "DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/RetirementBenefitsScheduleOfComponentsInConsolidatedBalanceSheetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate": { "auth_ref": [ "r392" ], "lang": { "en-US": { "role": { "documentation": "Weighted average rate for present value of future retirement benefits cash flows, used to determine benefit obligation of defined benefit plan.", "label": "Defined Benefit Plan, Assumptions Used Calculating Benefit Obligation, Discount Rate", "terseLabel": "Discount rate for benefit obligation (in percentage)" } } }, "localname": "DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/RetirementBenefitsScheduleOfWeightedAverageAssumptionsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease": { "auth_ref": [ "r393" ], "lang": { "en-US": { "role": { "documentation": "Weighted average rate increase of compensation, used to determine benefit obligation of defined benefit plan. Plan includes, but is not limited to, pay-related defined benefit plan.", "label": "Defined Benefit Plan, Assumptions Used Calculating Benefit Obligation, Rate of Compensation Increase", "terseLabel": "Rate of compensation increase for benefit obligation (in percentage)" } } }, "localname": "DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/RetirementBenefitsScheduleOfWeightedAverageAssumptionsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate": { "auth_ref": [ "r392" ], "lang": { "en-US": { "role": { "documentation": "Weighted average rate for present value of future retirement benefits cash flows, used to determine net periodic benefit cost of defined benefit plan.", "label": "Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Discount Rate", "terseLabel": "Discount rate for net benefit costs (in percentage)" } } }, "localname": "DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/RetirementBenefitsScheduleOfWeightedAverageAssumptionsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets": { "auth_ref": [ "r394" ], "lang": { "en-US": { "role": { "documentation": "Weighted average rate of return on plan assets, reflecting average rate of earnings expected on existing plan assets and expected contributions, used to determine net periodic benefit cost of defined benefit plan.", "label": "Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Expected Long-term Rate of Return on Plan Assets", "terseLabel": "Expected return on plan assets for net benefit costs (in percentage)" } } }, "localname": "DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/RetirementBenefitsScheduleOfWeightedAverageAssumptionsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease": { "auth_ref": [ "r393" ], "lang": { "en-US": { "role": { "documentation": "Weighted average rate of compensation increase used to determine net periodic benefit cost of defined benefit plan. Plan includes, but is not limited to, pay-related defined benefit plan.", "label": "Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Rate of Compensation Increase", "terseLabel": "Rate of compensation increase for net benefit costs (in percentage)" } } }, "localname": "DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/RetirementBenefitsScheduleOfWeightedAverageAssumptionsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DefinedBenefitPlanBenefitObligation": { "auth_ref": [ "r361" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of actuarial present value of benefits attributed to service rendered by employee for defined benefit plan.", "label": "Defined Benefit Plan, Benefit Obligation", "periodEndLabel": "Benefit obligation at end of year", "periodStartLabel": "Benefit obligation at beginning of year" } } }, "localname": "DefinedBenefitPlanBenefitObligation", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/RetirementBenefitsScheduleOfBenefitObligationsAndPlanAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid": { "auth_ref": [ "r367", "r412" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of payment to participant of defined benefit plan which decreases benefit obligation. For pension plan, payment includes, but is not limited to, pension benefits and death benefits. For other postretirement plan, payment includes, but is not limited to, prescription drug benefits, health care benefits, life insurance benefits, and legal, educational and advisory services.", "label": "Defined Benefit Plan, Benefit Obligation, Benefits Paid", "negatedLabel": "Benefits paid" } } }, "localname": "DefinedBenefitPlanBenefitObligationBenefitsPaid", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/RetirementBenefitsScheduleOfBenefitObligationsAndPlanAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanBenefitObligationPeriodIncreaseDecrease": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in benefit obligation of defined benefit plan.", "label": "Defined Benefit Plan, Benefit Obligation, Period Increase (Decrease)", "terseLabel": "Defined benefit obligation, increase (decrease)" } } }, "localname": "DefinedBenefitPlanBenefitObligationPeriodIncreaseDecrease", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/RetirementBenefitsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis": { "auth_ref": [ "r377", "r378", "r395", "r410" ], "lang": { "en-US": { "role": { "documentation": "Information by defined benefit plan asset investment.", "label": "Defined Benefit Plan, Plan Assets, Category [Axis]", "terseLabel": "Defined Benefit Plan, Plan Assets, Category [Axis]" } } }, "localname": "DefinedBenefitPlanByPlanAssetCategoriesAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/RetirementBenefitsFairValueDisclosuresDetails", "http://www.lilly.com/role/RetirementBenefitsNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Defined Benefit Plan, Change in Benefit Obligation [Roll Forward]", "terseLabel": "Change in benefit obligation:" } } }, "localname": "DefinedBenefitPlanChangeInBenefitObligationRollForward", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/RetirementBenefitsScheduleOfBenefitObligationsAndPlanAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Defined Benefit Plan, Change in Fair Value of Plan Assets [Roll Forward]", "terseLabel": "Defined Benefit Plan, Change in Fair Value of Plan Assets [Roll Forward]" } } }, "localname": "DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/RetirementBenefitsScheduleOfBenefitObligationsAndPlanAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DefinedBenefitPlanContributionsByEmployer": { "auth_ref": [ "r372", "r377", "r378", "r409", "r410" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of contribution received by defined benefit plan from employer which increases plan assets.", "label": "Defined Benefit Plan, Plan Assets, Contributions by Employer", "terseLabel": "Employer contribution" } } }, "localname": "DefinedBenefitPlanContributionsByEmployer", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/RetirementBenefitsScheduleOfBenefitObligationsAndPlanAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanCurtailments": { "auth_ref": [ "r363" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of (increase) decrease in benefit obligation of defined benefit plan from event reducing expected years of future service of present employees or eliminating accrual of benefits for some or all future services of present employees.", "label": "Defined Benefit Plan, Benefit Obligation, (Increase) Decrease for Curtailment", "terseLabel": "Curtailment (gain) loss" } } }, "localname": "DefinedBenefitPlanCurtailments", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/RetirementBenefitsNarrativeDetails", "http://www.lilly.com/role/RetirementBenefitsScheduleOfBenefitObligationsAndPlanAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanDisclosureLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Defined Benefit Plan Disclosure [Line Items]", "terseLabel": "Defined Benefit Plan Disclosure [Line Items]" } } }, "localname": "DefinedBenefitPlanDisclosureLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/RetirementBenefitsNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DefinedBenefitPlanEquitySecuritiesMember": { "auth_ref": [ "r377", "r410" ], "lang": { "en-US": { "role": { "documentation": "Security representing ownership in corporation or other legal entity for which ownership is represented by share of stock, in which defined benefit plan asset is invested. Includes, but is not limited to, common stock, preferred stock, convertible security, stock right and stock warrant.", "label": "Defined Benefit Plan, Equity Securities [Member]", "terseLabel": "Marketable equity securities" } } }, "localname": "DefinedBenefitPlanEquitySecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/RetirementBenefitsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DefinedBenefitPlanEquitySecuritiesNonUsMember": { "auth_ref": [ "r377", "r378", "r410" ], "lang": { "en-US": { "role": { "documentation": "Security representing ownership in corporation or other legal entity, not domiciled in United States of America (US), for which ownership is represented by share of stock; in which defined benefit plan asset is invested. Includes, but is not limited to, common stock, preferred stock, convertible security, stock right and stock warrant.", "label": "Defined Benefit Plan, Equity Securities, Non-US [Member]", "terseLabel": "International" } } }, "localname": "DefinedBenefitPlanEquitySecuritiesNonUsMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/RetirementBenefitsFairValueDisclosuresDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DefinedBenefitPlanEquitySecuritiesUsMember": { "auth_ref": [ "r377", "r378", "r410" ], "lang": { "en-US": { "role": { "documentation": "Security representing ownership in corporation or other legal entity, domiciled in United States of America (US), for which ownership is represented by share of stock; in which defined benefit plan asset is invested. Includes, but is not limited to, common stock, preferred stock, convertible security, stock right and stock warrant.", "label": "Defined Benefit Plan, Equity Securities, US [Member]", "terseLabel": "U.S." } } }, "localname": "DefinedBenefitPlanEquitySecuritiesUsMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/RetirementBenefitsFairValueDisclosuresDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DefinedBenefitPlanEstimatedFutureBenefitPaymentsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Defined Benefit Plan, Expected Future Benefit Payment [Abstract]", "terseLabel": "Defined Benefit Plan, Expected Future Benefit Payment [Abstract]" } } }, "localname": "DefinedBenefitPlanEstimatedFutureBenefitPaymentsAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/RetirementBenefitsScheduleOfExpectedBenefitPaymentsContributionsAndExpenseDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter": { "auth_ref": [ "r380" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of benefits for defined benefit plan expected to be paid in five fiscal years after fifth fiscal year following latest fiscal year.", "label": "Defined Benefit Plan, Expected Future Benefit Payment, Five Fiscal Years Thereafter", "verboseLabel": "2024-2028" } } }, "localname": "DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/RetirementBenefitsScheduleOfExpectedBenefitPaymentsContributionsAndExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths": { "auth_ref": [ "r380" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of benefits for defined benefit plan expected to be paid in next fiscal year following latest fiscal year.", "label": "Defined Benefit Plan, Expected Future Benefit Payment, Next Twelve Months", "terseLabel": "2019" } } }, "localname": "DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/RetirementBenefitsScheduleOfExpectedBenefitPaymentsContributionsAndExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive": { "auth_ref": [ "r380" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of benefits for defined benefit plan expected to be paid in fifth fiscal year following latest fiscal year.", "label": "Defined Benefit Plan, Expected Future Benefit Payment, Year Five", "terseLabel": "2023" } } }, "localname": "DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/RetirementBenefitsScheduleOfExpectedBenefitPaymentsContributionsAndExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour": { "auth_ref": [ "r380" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of benefits for defined benefit plan expected to be paid in fourth fiscal year following latest fiscal year.", "label": "Defined Benefit Plan, Expected Future Benefit Payment, Year Four", "terseLabel": "2022" } } }, "localname": "DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/RetirementBenefitsScheduleOfExpectedBenefitPaymentsContributionsAndExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree": { "auth_ref": [ "r380" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of benefits for defined benefit plan expected to be paid in third fiscal year following latest fiscal year.", "label": "Defined Benefit Plan, Expected Future Benefit Payment, Year Three", "terseLabel": "2021" } } }, "localname": "DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/RetirementBenefitsScheduleOfExpectedBenefitPaymentsContributionsAndExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo": { "auth_ref": [ "r380" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of benefits for defined benefit plan expected to be paid in second fiscal year following latest fiscal year.", "label": "Defined Benefit Plan, Expected Future Benefit Payment, Year Two", "terseLabel": "2020" } } }, "localname": "DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/RetirementBenefitsScheduleOfExpectedBenefitPaymentsContributionsAndExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets": { "auth_ref": [ "r384", "r405", "r410" ], "calculation": { "http://www.lilly.com/role/RetirementBenefitsScheduleOfExpectedBenefitPaymentsContributionsAndExpenseDetails": { "order": 3.0, "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of expected return (loss) recognized in net periodic benefit (cost) credit, calculated based on expected long-term rate of return and market-related value of plan assets of defined benefit plan.", "label": "Defined Benefit Plan, Expected Return (Loss) on Plan Assets", "negatedLabel": "Expected return on plan assets" } } }, "localname": "DefinedBenefitPlanExpectedReturnOnPlanAssets", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/RetirementBenefitsScheduleOfExpectedBenefitPaymentsContributionsAndExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanFairValueOfPlanAssets": { "auth_ref": [ "r369", "r377", "r378", "r410" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of asset segregated and restricted to provide benefit under defined benefit plan. Asset includes, but is not limited to, stock, bond, other investment, earning from investment, and contribution by employer and employee.", "label": "Defined Benefit Plan, Plan Assets, Amount", "netLabel": "Fair value of plan assets", "periodEndLabel": "Fair value of plan assets at end of year", "periodStartLabel": "Fair value of plan assets at beginning of year" } } }, "localname": "DefinedBenefitPlanFairValueOfPlanAssets", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/RetirementBenefitsFairValueDisclosuresDetails", "http://www.lilly.com/role/RetirementBenefitsScheduleOfBenefitObligationsAndPlanAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation": { "auth_ref": [ "r366" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of foreign currency translation gain (loss) which (increases) decreases benefit obligation of defined benefit plan.", "label": "Defined Benefit Plan, Benefit Obligation, Foreign Currency Translation Gain (Loss)", "terseLabel": "Foreign currency exchange rate changes and other adjustments" } } }, "localname": "DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/RetirementBenefitsScheduleOfBenefitObligationsAndPlanAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanFundedStatusOfPlan": { "auth_ref": [ "r359", "r374" ], "calculation": { "http://www.lilly.com/role/RetirementBenefitsScheduleOfBenefitObligationsAndPlanAssetsDetails": { "order": 1.0, "parentTag": "us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of funded (unfunded) status of defined benefit plan, measured as difference between fair value of plan assets and benefit obligation. Includes, but is not limited to, overfunded (underfunded) status.", "label": "Defined Benefit Plan, Funded (Unfunded) Status of Plan", "terseLabel": "Funded status" } } }, "localname": "DefinedBenefitPlanFundedStatusOfPlan", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/RetirementBenefitsScheduleOfBenefitObligationsAndPlanAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanInterestCost": { "auth_ref": [ "r364", "r383", "r404", "r410" ], "calculation": { "http://www.lilly.com/role/RetirementBenefitsScheduleOfExpectedBenefitPaymentsContributionsAndExpenseDetails": { "order": 2.0, "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cost recognized for passage of time related to defined benefit plan.", "label": "Defined Benefit Plan, Interest Cost", "terseLabel": "Interest cost" } } }, "localname": "DefinedBenefitPlanInterestCost", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/RetirementBenefitsScheduleOfBenefitObligationsAndPlanAssetsDetails", "http://www.lilly.com/role/RetirementBenefitsScheduleOfExpectedBenefitPaymentsContributionsAndExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost": { "auth_ref": [ "r381", "r402", "r410" ], "calculation": { "http://www.lilly.com/role/RetirementBenefitsScheduleOfExpectedBenefitPaymentsContributionsAndExpenseDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of net periodic benefit cost (credit) for defined benefit plan.", "label": "Defined Benefit Plan, Net Periodic Benefit Cost (Credit)", "totalLabel": "Net periodic (benefit) cost" } } }, "localname": "DefinedBenefitPlanNetPeriodicBenefitCost", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/RetirementBenefitsScheduleOfExpectedBenefitPaymentsContributionsAndExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Defined Benefit Plan, Net Periodic Benefit Cost (Credit) [Abstract]", "terseLabel": "Components of net periodic (benefit) cost:" } } }, "localname": "DefinedBenefitPlanNetPeriodicBenefitCostAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/RetirementBenefitsScheduleOfExpectedBenefitPaymentsContributionsAndExpenseDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Defined Benefit Plan, Plan with Accumulated Benefit Obligation in Excess of Plan Assets [Abstract]", "terseLabel": "Defined Benefit Plan, Plan with Accumulated Benefit Obligation in Excess of Plan Assets [Abstract]" } } }, "localname": "DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/RetirementBenefitsScheduleOfExpectedBenefitPaymentsContributionsAndExpenseDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation": { "auth_ref": [ "r398", "r399", "r410" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of accumulated benefit obligation for defined benefit plan with accumulated benefit obligation in excess of plan assets.", "label": "Defined Benefit Plan, Plan with Accumulated Benefit Obligation in Excess of Plan Assets, Accumulated Benefit Obligation", "terseLabel": "Accumulated benefit obligation" } } }, "localname": "DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/RetirementBenefitsScheduleOfExpectedBenefitPaymentsContributionsAndExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets": { "auth_ref": [ "r398", "r399", "r410" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of plan asset for defined benefit plan with accumulated benefit obligation in excess of plan assets.", "label": "Defined Benefit Plan, Plan with Accumulated Benefit Obligation in Excess of Plan Assets, Plan Assets", "terseLabel": "Fair value of plan assets" } } }, "localname": "DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/RetirementBenefitsScheduleOfExpectedBenefitPaymentsContributionsAndExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation": { "auth_ref": [ "r398", "r410" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of projected benefit obligation for defined benefit pension plan with accumulated benefit obligation in excess of plan assets.", "label": "Defined Benefit Plan, Pension Plan with Accumulated Benefit Obligation in Excess of Plan Assets, Projected Benefit Obligation", "terseLabel": "Projected benefit obligation" } } }, "localname": "DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/RetirementBenefitsScheduleOfExpectedBenefitPaymentsContributionsAndExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanPlanAmendments": { "auth_ref": [ "r368" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in benefit obligation of defined benefit plan from change in terms of existing plan or initiation of new plan.", "label": "Defined Benefit Plan, Benefit Obligation, Increase (Decrease) for Plan Amendment", "negatedTerseLabel": "Plan amendments" } } }, "localname": "DefinedBenefitPlanPlanAmendments", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/RetirementBenefitsScheduleOfBenefitObligationsAndPlanAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid": { "auth_ref": [ "r373", "r412" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of payment to participant under defined benefit plan which decreases plan assets. For pension plan, payment includes, but is not limited to, pension benefits and death benefits. For other postretirement plan, payment includes, but is not limited to, prescription drug benefits, health care benefits, life insurance benefits, and legal, educational and advisory services.", "label": "Defined Benefit Plan, Plan Assets, Benefits Paid", "negatedLabel": "Benefits paid" } } }, "localname": "DefinedBenefitPlanPlanAssetsBenefitsPaid", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/RetirementBenefitsScheduleOfBenefitObligationsAndPlanAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss": { "auth_ref": [ "r371" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of foreign currency translation gain (loss) which increases (decreases) plan assets of defined benefit plan.", "label": "Defined Benefit Plan, Plan Assets, Foreign Currency Translation Gain (Loss)", "terseLabel": "Foreign currency exchange rate changes and other adjustments" } } }, "localname": "DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/RetirementBenefitsScheduleOfBenefitObligationsAndPlanAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage": { "auth_ref": [ "r376", "r410" ], "lang": { "en-US": { "role": { "documentation": "Percentage of target investment allocation to total plan assets. Includes, but is not limited to, percentage on weighted-average basis if more than one plan.", "label": "Defined Benefit Plan, Plan Assets, Target Allocation, Percentage", "terseLabel": "Plan assets, target allocation (in percentage)" } } }, "localname": "DefinedBenefitPlanPlanAssetsTargetAllocationPercentage", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/RetirementBenefitsNarrativeDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DefinedBenefitPlanPlansWithBenefitObligationsInExcessOfPlanAssetsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Defined Benefit Plan, Pension Plan with Project Benefit Obligation in Excess of Plan Assets [Abstract]", "terseLabel": "Defined Benefit Plan, Pension Plan with Project Benefit Obligation in Excess of Plan Assets [Abstract]" } } }, "localname": "DefinedBenefitPlanPlansWithBenefitObligationsInExcessOfPlanAssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/RetirementBenefitsScheduleOfExpectedBenefitPaymentsContributionsAndExpenseDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DefinedBenefitPlanRealEstateMember": { "auth_ref": [ "r377", "r410" ], "lang": { "en-US": { "role": { "documentation": "Property composed of building, land and land improvement; in which defined benefit plan asset is invested.", "label": "Defined Benefit Plan, Real Estate [Member]", "terseLabel": "Real estate" } } }, "localname": "DefinedBenefitPlanRealEstateMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/RetirementBenefitsFairValueDisclosuresDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments": { "auth_ref": [ "r387", "r408" ], "calculation": { "http://www.lilly.com/role/RetirementBenefitsScheduleOfExpectedBenefitPaymentsContributionsAndExpenseDetails": { "order": 6.0, "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of gain (loss) recognized in net periodic benefit (cost) credit from event reducing expected years of future service of present employees or eliminating accrual of defined benefits for some or all future services of present employees.", "label": "Defined Benefit Plan, Net Periodic Benefit Cost (Credit), Gain (Loss) Due to Curtailment", "negatedLabel": "Curtailment (gain) loss" } } }, "localname": "DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/RetirementBenefitsNarrativeDetails", "http://www.lilly.com/role/RetirementBenefitsScheduleOfExpectedBenefitPaymentsContributionsAndExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanServiceCost": { "auth_ref": [ "r362", "r382", "r403", "r410" ], "calculation": { "http://www.lilly.com/role/RetirementBenefitsScheduleOfExpectedBenefitPaymentsContributionsAndExpenseDetails": { "order": 1.0, "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cost for actuarial present value of benefits attributed to service rendered by employee for defined benefit plan.", "label": "Defined Benefit Plan, Service Cost", "terseLabel": "Service cost", "verboseLabel": "Service cost" } } }, "localname": "DefinedBenefitPlanServiceCost", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/RetirementBenefitsScheduleOfBenefitObligationsAndPlanAssetsDetails", "http://www.lilly.com/role/RetirementBenefitsScheduleOfExpectedBenefitPaymentsContributionsAndExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanSpecialTerminationBenefits": { "auth_ref": [ "r363" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of increase in benefit obligation for benefits provided to employees payable from defined benefit plan or payable upon retirement.", "label": "Defined Benefit Plan, Benefit Obligation, Special and Contractual Termination Benefits", "terseLabel": "Special termination benefit" } } }, "localname": "DefinedBenefitPlanSpecialTerminationBenefits", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/RetirementBenefitsNarrativeDetails", "http://www.lilly.com/role/RetirementBenefitsScheduleOfBenefitObligationsAndPlanAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Abstract]" } } }, "localname": "DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable": { "auth_ref": [ "r396", "r397", "r400", "r401", "r410" ], "lang": { "en-US": { "role": { "documentation": "Disclosures and provisions pertaining to defined benefit pension plans or other postretirement defined benefit plans. The arrangements are generally based on terms and conditions stipulated by the entity, and which contain a promise by the employer to pay certain amounts or awards at designated future dates, including a period after retirement, upon compliance with stipulated requirements. Excludes disclosures pertaining to defined contribution plans.", "label": "Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Table]", "terseLabel": "Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Table]" } } }, "localname": "DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/RetirementBenefitsFairValueDisclosuresDetails", "http://www.lilly.com/role/RetirementBenefitsScheduleOfBenefitObligationsAndPlanAssetsDetails", "http://www.lilly.com/role/RetirementBenefitsScheduleOfComponentsInConsolidatedBalanceSheetsDetails", "http://www.lilly.com/role/RetirementBenefitsScheduleOfExpectedBenefitPaymentsContributionsAndExpenseDetails", "http://www.lilly.com/role/RetirementBenefitsScheduleOfWeightedAverageAssumptionsDetails", "http://www.lilly.com/role/RetirementBenefitsTables" ], "xbrltype": "stringItemType" }, "us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]", "terseLabel": "Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items] [Line Items]" } } }, "localname": "DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/RetirementBenefitsFairValueDisclosuresDetails", "http://www.lilly.com/role/RetirementBenefitsScheduleOfBenefitObligationsAndPlanAssetsDetails", "http://www.lilly.com/role/RetirementBenefitsScheduleOfComponentsInConsolidatedBalanceSheetsDetails", "http://www.lilly.com/role/RetirementBenefitsScheduleOfExpectedBenefitPaymentsContributionsAndExpenseDetails", "http://www.lilly.com/role/RetirementBenefitsScheduleOfWeightedAverageAssumptionsDetails", "http://www.lilly.com/role/RetirementBenefitsTables" ], "xbrltype": "stringItemType" }, "us-gaap_DefinedBenefitPostretirementHealthCoverageMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Plan designed to provide postretirement health benefits to retiree or beneficiary. Includes, but is not limited to, defined benefit and defined contribution plans.", "label": "Postretirement Health Coverage [Member]", "terseLabel": "Retiree Health Benefit Plans" } } }, "localname": "DefinedBenefitPostretirementHealthCoverageMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/RetirementBenefitsFairValueDisclosuresDetails", "http://www.lilly.com/role/RetirementBenefitsScheduleOfBenefitObligationsAndPlanAssetsDetails", "http://www.lilly.com/role/RetirementBenefitsScheduleOfComponentsInConsolidatedBalanceSheetsDetails", "http://www.lilly.com/role/RetirementBenefitsScheduleOfExpectedBenefitPaymentsContributionsAndExpenseDetails", "http://www.lilly.com/role/RetirementBenefitsScheduleOfWeightedAverageAssumptionsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DefinedContributionPlanCostRecognized": { "auth_ref": [ "r413" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cost for defined contribution plan.", "label": "Defined Contribution Plan, Cost", "terseLabel": "Expense under the plans" } } }, "localname": "DefinedContributionPlanCostRecognized", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/RetirementBenefitsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_Depreciation": { "auth_ref": [ "r162", "r290" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.", "label": "Depreciation", "terseLabel": "Depreciation expense" } } }, "localname": "Depreciation", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/PropertyAndEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DepreciationDepletionAndAmortization": { "auth_ref": [ "r162", "r209" ], "calculation": { "http://www.lilly.com/role/ConsolidatedStatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.", "label": "Depreciation, Depletion and Amortization", "terseLabel": "Depreciation and amortization" } } }, "localname": "DepreciationDepletionAndAmortization", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeAssetNotionalAmount": { "auth_ref": [ "r511", "r512", "r514" ], "lang": { "en-US": { "role": { "documentation": "Nominal or face amount used to calculate payments on the derivative asset.", "label": "Derivative Asset, Notional Amount", "terseLabel": "Derivative asset, notional amount" } } }, "localname": "DerivativeAssetNotionalAmount", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/FinancialInstrumentsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeAssetsCurrent": { "auth_ref": [ "r100" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled within one year or normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.", "label": "Derivative Asset, Current", "terseLabel": "Other receivables" } } }, "localname": "DerivativeAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/FinancialInstrumentsFairValueMeasurementDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeAssetsNoncurrent": { "auth_ref": [ "r100" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled after one year or the normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.", "label": "Derivative Asset, Noncurrent", "terseLabel": "Sundry" } } }, "localname": "DerivativeAssetsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/FinancialInstrumentsFairValueMeasurementDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeContractTypeDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset.", "label": "Derivative Contract [Domain]", "terseLabel": "Derivative, Name [Domain]" } } }, "localname": "DerivativeContractTypeDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/FinancialInstrumentsEffectOfRiskManagementDetails", "http://www.lilly.com/role/FinancialInstrumentsFairValueMeasurementDetails", "http://www.lilly.com/role/FinancialInstrumentsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DerivativeInstrumentRiskAxis": { "auth_ref": [ "r519", "r521", "r526", "r530" ], "lang": { "en-US": { "role": { "documentation": "Information by type of derivative contract.", "label": "Derivative Instrument [Axis]", "terseLabel": "Derivative Instrument [Axis]" } } }, "localname": "DerivativeInstrumentRiskAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/FinancialInstrumentsEffectOfRiskManagementDetails", "http://www.lilly.com/role/FinancialInstrumentsFairValueMeasurementDetails", "http://www.lilly.com/role/FinancialInstrumentsNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Derivative Instruments and Hedging Activities Disclosure [Abstract]" } } }, "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis": { "auth_ref": [ "r517", "r519", "r526" ], "lang": { "en-US": { "role": { "documentation": "Information by type of hedging relationship.", "label": "Hedging Relationship [Axis]", "terseLabel": "Hedging Relationship [Axis]" } } }, "localname": "DerivativeInstrumentsGainLossByHedgingRelationshipAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/FinancialInstrumentsEffectOfRiskManagementDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeInstrumentsLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortion": { "auth_ref": [ "r524" ], "calculation": { "http://www.lilly.com/role/FinancialInstrumentsEffectOfRiskManagementDetails": { "order": 3.0, "parentTag": "lly_DerivativeInstrumentsGainLossRecognized", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The effective portion of loss reclassified from accumulated other comprehensive income into income on derivative instruments designated and qualifying as hedging instruments.", "label": "Derivative Instruments, Loss Reclassified from Accumulated OCI into Income, Effective Portion", "terseLabel": "Effective portion of losses on interest rate contracts reclassified from accumulated other comprehensive loss" } } }, "localname": "DerivativeInstrumentsLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortion", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/FinancialInstrumentsEffectOfRiskManagementDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeLiabilitiesCurrent": { "auth_ref": [ "r100" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled within one year or normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.", "label": "Derivative Liability, Current", "negatedTerseLabel": "Other current liabilities" } } }, "localname": "DerivativeLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/FinancialInstrumentsFairValueMeasurementDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeLiabilitiesNoncurrent": { "auth_ref": [ "r100" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled after one year or the normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.", "label": "Derivative Liability, Noncurrent", "negatedTerseLabel": "Other noncurrent liabilities" } } }, "localname": "DerivativeLiabilitiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/FinancialInstrumentsFairValueMeasurementDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeLiabilityNotionalAmount": { "auth_ref": [ "r511", "r512", "r514" ], "lang": { "en-US": { "role": { "documentation": "Nominal or face amount used to calculate payments on the derivative liability.", "label": "Derivative Liability, Notional Amount", "terseLabel": "Derivative liability, notional amount" } } }, "localname": "DerivativeLiabilityNotionalAmount", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/FinancialInstrumentsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Derivative [Line Items]", "terseLabel": "Derivative [Line Items]" } } }, "localname": "DerivativeLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/FinancialInstrumentsEffectOfRiskManagementDetails", "http://www.lilly.com/role/FinancialInstrumentsNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeTable": { "auth_ref": [ "r176", "r510", "r513", "r514", "r517", "r518", "r522", "r526", "r532", "r534", "r536" ], "lang": { "en-US": { "role": { "documentation": "Schedule that describes and identifies a derivative or group of derivatives on a disaggregated basis, such as for individual instruments, or small groups of similar instruments. May include a combination of the type of instrument, risks being hedged, notional amount, hedge designation, related hedged item, inception date, maturity date, or other relevant item.", "label": "Derivative [Table]", "terseLabel": "Derivative [Table]" } } }, "localname": "DerivativeTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/FinancialInstrumentsEffectOfRiskManagementDetails", "http://www.lilly.com/role/FinancialInstrumentsNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativesPolicyTextBlock": { "auth_ref": [ "r167", "r177", "r510", "r513", "r517", "r518", "r533" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for its derivative instruments and hedging activities.", "label": "Derivatives, Policy [Policy Text Block]", "terseLabel": "Derivatives" } } }, "localname": "DerivativesPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/FinancialInstrumentsPolicies", "http://www.lilly.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_DesignatedAsHedgingInstrumentMember": { "auth_ref": [ "r517" ], "lang": { "en-US": { "role": { "documentation": "Derivative instrument designated as hedging instrument under Generally Accepted Accounting Principles (GAAP).", "label": "Designated as Hedging Instrument [Member]", "terseLabel": "Designated as Hedging Instrument" } } }, "localname": "DesignatedAsHedgingInstrumentMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/FinancialInstrumentsEffectOfRiskManagementDetails", "http://www.lilly.com/role/FinancialInstrumentsFairValueMeasurementDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DevelopedTechnologyRightsMember": { "auth_ref": [ "r484" ], "lang": { "en-US": { "role": { "documentation": "Rights to developed technology, which can include the right to develop, use, market, sell, or offer for sale products, compounds, or intellectual property.", "label": "Developed Technology Rights [Member]", "terseLabel": "Marketed products" } } }, "localname": "DevelopedTechnologyRightsMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/GoodwillAndOtherIntangiblesIntangiblesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member": { "auth_ref": [ "r354" ], "lang": { "en-US": { "role": { "documentation": "Effect in current period from application of guidance for revenue from contract with customer compared with guidance for revenue recognition applicable prior to change when using transition method for cumulative effect in period including initial date of application.", "label": "Difference between Revenue Guidance in Effect before and after Topic 606 [Member]", "terseLabel": "Difference between Revenue Guidance in Effect before and after Topic 606" } } }, "localname": "DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/ImplementationOfNewFinancialAccountingPronouncementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DisaggregationOfRevenueLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Disaggregation of Revenue [Line Items]", "terseLabel": "Disaggregation of Revenue [Line Items]" } } }, "localname": "DisaggregationOfRevenueLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/SummaryOfSignificantAccountingPoliciesRevenueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DisaggregationOfRevenueTable": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.", "label": "Disaggregation of Revenue [Table]", "terseLabel": "Disaggregation of Revenue [Table]" } } }, "localname": "DisaggregationOfRevenueTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/SummaryOfSignificantAccountingPoliciesRevenueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DisaggregationOfRevenueTableTextBlock": { "auth_ref": [ "r350" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.", "label": "Disaggregation of Revenue [Table Text Block]", "terseLabel": "Schedule of Revenue Recognized" } } }, "localname": "DisaggregationOfRevenueTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/SummaryOfSignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "auth_ref": [ "r432" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for share-based payment arrangement.", "label": "Share-based Payment Arrangement [Text Block]", "terseLabel": "Stock-Based Compensation" } } }, "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/StockBasedCompensation" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Share-based Payment Arrangement [Abstract]" } } }, "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Discontinued Operations and Disposal Groups [Abstract]" } } }, "localname": "DiscontinuedOperationsAndDisposalGroupsAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_DiscontinuedOperationsDisposedOfBySaleMember": { "auth_ref": [ "r3" ], "lang": { "en-US": { "role": { "documentation": "Component or group of components disposed of by sale and representing a strategic shift that has or will have a major effect on operations and financial results.", "label": "Discontinued Operations, Disposed of by Sale [Member]", "terseLabel": "Discontinued Operations, Disposed of by Sale" } } }, "localname": "DiscontinuedOperationsDisposedOfBySaleMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/DiscontinuedOperationsDetails", "http://www.lilly.com/role/DiscontinuedOperationsDiscontinuedOperationsInFinancialStatementsDetails", "http://www.lilly.com/role/DiscontinuedOperationsMajorClassesOfAssetsAndLiabilitiesDetails", "http://www.lilly.com/role/SegmentInformationDetails", "http://www.lilly.com/role/SummaryOfSignificantAccountingPoliciesAcquisitionsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DisposalGroupClassificationAxis": { "auth_ref": [ "r22" ], "lang": { "en-US": { "role": { "documentation": "Information by disposal group classification.", "label": "Disposal Group Classification [Axis]", "terseLabel": "Disposal Group Classification [Axis]" } } }, "localname": "DisposalGroupClassificationAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/DiscontinuedOperationsDetails", "http://www.lilly.com/role/DiscontinuedOperationsDiscontinuedOperationsInFinancialStatementsDetails", "http://www.lilly.com/role/DiscontinuedOperationsMajorClassesOfAssetsAndLiabilitiesDetails", "http://www.lilly.com/role/SegmentInformationDetails", "http://www.lilly.com/role/SummaryOfSignificantAccountingPoliciesAcquisitionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DisposalGroupClassificationDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Component or group of components disposed of, including but not limited to, disposal group held-for-sale or disposed of by sale, disposed of by means other than sale, and discontinued operations.", "label": "Disposal Group Classification [Domain]", "terseLabel": "Disposal Group Classification [Domain]" } } }, "localname": "DisposalGroupClassificationDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/DiscontinuedOperationsDetails", "http://www.lilly.com/role/DiscontinuedOperationsDiscontinuedOperationsInFinancialStatementsDetails", "http://www.lilly.com/role/DiscontinuedOperationsMajorClassesOfAssetsAndLiabilitiesDetails", "http://www.lilly.com/role/SegmentInformationDetails", "http://www.lilly.com/role/SummaryOfSignificantAccountingPoliciesAcquisitionsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent": { "auth_ref": [ "r0", "r1", "r20", "r22", "r287", "r296" ], "calculation": { "http://www.lilly.com/role/ConsolidatedBalanceSheets": { "order": 8.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount classified as assets attributable to disposal group held for sale or disposed of, expected to be disposed of after one year or the normal operating cycle, if longer.", "label": "Disposal Group, Including Discontinued Operation, Assets, Noncurrent", "terseLabel": "Noncurrent assets of discontinued operations" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/ConsolidatedBalanceSheets", "http://www.lilly.com/role/DiscontinuedOperationsMajorClassesOfAssetsAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents": { "auth_ref": [ "r0", "r1", "r20", "r296" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount classified as cash and cash equivalents attributable to disposal group held for sale or disposed of.", "label": "Disposal Group, Including Discontinued Operation, Cash and Cash Equivalents", "terseLabel": "Discontinued operations cash" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/ConsolidatedStatementsOfCashFlowsConsolidatedStatementsOfCashFlowsParenthetical" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of consideration received or receivable for the disposal of assets and liabilities, including discontinued operation.", "label": "Disposal Group, Including Discontinued Operation, Consideration", "terseLabel": "Consideration received" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationConsideration", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/DiscontinuedOperationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwillNoncurrent": { "auth_ref": [ "r0", "r1", "r20", "r287", "r296" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount classified as goodwill attributable to disposal group held for sale or disposed of, expected to be disposed of after one year or the normal operating cycle, if longer.", "label": "Disposal Group, Including Discontinued Operation, Goodwill, Noncurrent", "terseLabel": "Goodwill" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationGoodwillNoncurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/DiscontinuedOperationsMajorClassesOfAssetsAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent": { "auth_ref": [ "r0", "r1", "r20", "r287", "r296" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount classified as intangible assets, excluding goodwill, attributable to disposal group held for sale or disposed of, expected to be disposed of beyond one year or the normal operating cycle, if longer.", "label": "Disposal Group, Including Discontinued Operation, Intangible Assets, Noncurrent", "terseLabel": "Other intangibles, net" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/DiscontinuedOperationsMajorClassesOfAssetsAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent": { "auth_ref": [ "r0", "r1", "r20", "r289", "r296" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount classified as inventory attributable to disposal group, expected to be disposed of within one year or the normal operating cycle, if longer.", "label": "Disposal Group, Including Discontinued Operation, Inventory, Current", "terseLabel": "Inventories" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationInventoryCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/DiscontinuedOperationsMajorClassesOfAssetsAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentAssets": { "auth_ref": [ "r0", "r1", "r20", "r289", "r296" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount classified as other assets attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.", "label": "Disposal Group, Including Discontinued Operation, Other Assets, Current", "terseLabel": "Other current assets" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationOtherCurrentAssets", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/DiscontinuedOperationsMajorClassesOfAssetsAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentAssets": { "auth_ref": [ "r0", "r1", "r20", "r287", "r296" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount classified as other assets attributable to disposal group held for sale or disposed of, expected to be disposed of after one year or the normal operating cycle, if longer.", "label": "Disposal Group, Including Discontinued Operation, Other Assets, Noncurrent", "terseLabel": "Other assets" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentAssets", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/DiscontinuedOperationsMajorClassesOfAssetsAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities": { "auth_ref": [ "r0", "r1", "r20", "r287", "r296" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount classified as other liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of beyond one year or the normal operating cycle, if longer.", "label": "Disposal Group, Including Discontinued Operation, Other Liabilities, Noncurrent", "terseLabel": "Other liabilities" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/DiscontinuedOperationsMajorClassesOfAssetsAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent": { "auth_ref": [ "r0", "r1", "r20", "r287", "r296" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount classified as property, plant and equipment attributable to disposal group held for sale or disposed of, expected to be disposed of after one year or the normal operating cycle, if longer.", "label": "Disposal Group, Including Discontinued Operation, Property, Plant and Equipment, Noncurrent", "terseLabel": "Property and equipment, net" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/DiscontinuedOperationsMajorClassesOfAssetsAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock": { "auth_ref": [ "r27", "r300" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.", "label": "Disposal Groups, Including Discontinued Operations, Disclosure [Text Block]", "terseLabel": "Disposal Groups, Including Discontinued Operations, Disclosure" } } }, "localname": "DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/DiscontinuedOperationsNotes" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of disposal group.", "label": "Disposal Group Name [Domain]", "terseLabel": "Disposal Group Name [Domain]" } } }, "localname": "DisposalGroupsIncludingDiscontinuedOperationsNameDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/DiscontinuedOperationsDetails", "http://www.lilly.com/role/DiscontinuedOperationsDiscontinuedOperationsInFinancialStatementsDetails", "http://www.lilly.com/role/DiscontinuedOperationsMajorClassesOfAssetsAndLiabilitiesDetails", "http://www.lilly.com/role/SegmentInformationDetails", "http://www.lilly.com/role/SummaryOfSignificantAccountingPoliciesAcquisitionsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_Dividends": { "auth_ref": [ "r342", "r609" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of paid and unpaid cash, stock, and paid-in-kind (PIK) dividends declared, for example, but not limited to, common and preferred stock.", "label": "Dividends", "negatedLabel": "Cash dividends declared" } } }, "localname": "Dividends", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/ConsolidatedStatementsOfShareholdersEquityStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_DividendsPayableCurrent": { "auth_ref": [ "r40", "r82" ], "calculation": { "http://www.lilly.com/role/ConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Carrying value as of the balance sheet date of dividends declared but unpaid on equity securities issued by the entity and outstanding. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Dividends Payable, Current", "terseLabel": "Dividends payable" } } }, "localname": "DividendsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_EarningsPerShareAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Earnings Per Share [Abstract]", "terseLabel": "Earnings (loss) per share:" } } }, "localname": "EarningsPerShareAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareBasic": { "auth_ref": [ "r134", "r181", "r186", "r188", "r189", "r190", "r194", "r603", "r630" ], "lang": { "en-US": { "role": { "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.", "label": "Earnings Per Share, Basic", "terseLabel": "Basic (usd per share)" } } }, "localname": "EarningsPerShareBasic", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/ConsolidatedStatementsOfOperations", "http://www.lilly.com/role/SelectedQuarterlyDataUnauditedDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareDiluted": { "auth_ref": [ "r134", "r181", "r186", "r188", "r189", "r190", "r194", "r603", "r630" ], "lang": { "en-US": { "role": { "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Earnings Per Share, Diluted", "terseLabel": "Diluted (usd per share)" } } }, "localname": "EarningsPerShareDiluted", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/ConsolidatedStatementsOfOperations", "http://www.lilly.com/role/SelectedQuarterlyDataUnauditedDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerSharePolicyTextBlock": { "auth_ref": [ "r167", "r191", "r192", "r193" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.", "label": "Earnings Per Share, Policy [Policy Text Block]", "terseLabel": "Earnings Per Share" } } }, "localname": "EarningsPerSharePolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents": { "auth_ref": [ "r557" ], "calculation": { "http://www.lilly.com/role/ConsolidatedStatementsOfCashFlows": { "order": 4.0, "parentTag": "us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) from the effect of exchange rate changes on cash and cash equivalent balances held in foreign currencies.", "label": "Effect of Exchange Rate on Cash and Cash Equivalents", "terseLabel": "Effect of exchange rate changes on cash and cash equivalents" } } }, "localname": "EffectOfExchangeRateOnCashAndCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeRelatedLiabilitiesCurrent": { "auth_ref": [ "r82" ], "calculation": { "http://www.lilly.com/role/ConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Employee-related Liabilities, Current", "terseLabel": "Employee compensation" } } }, "localname": "EmployeeRelatedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": { "auth_ref": [ "r428" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.", "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount", "terseLabel": "Total compensation cost not yet recognized" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/StockBasedCompensationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": { "auth_ref": [ "r428" ], "lang": { "en-US": { "role": { "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition", "terseLabel": "Period for recognition of the compensation cost not yet recognized (in months)" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/StockBasedCompensationDetails" ], "xbrltype": "durationItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense": { "auth_ref": [ "r427" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of tax benefit for recognition of expense of award under share-based payment arrangement.", "label": "Share-based Payment Arrangement, Expense, Tax Benefit", "terseLabel": "Tax benefit" } } }, "localname": "EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/StockBasedCompensationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EquipmentMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Tangible personal property used to produce goods and services.", "label": "Equipment [Member]", "terseLabel": "Equipment" } } }, "localname": "EquipmentMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/PropertyAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EquityAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Equity [Abstract]" } } }, "localname": "EquityAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r335" ], "lang": { "en-US": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.", "label": "Equity Component [Domain]", "terseLabel": "Equity Component [Domain]" } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/ConsolidatedStatementsOfShareholdersEquityStatement", "http://www.lilly.com/role/OtherComprehensiveIncomeLossReclassificationDetails", "http://www.lilly.com/role/OtherComprehensiveIncomeLossRollForwardDetails", "http://www.lilly.com/role/OtherComprehensiveIncomeLossTaxEffectDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EquityFundsMember": { "auth_ref": [ "r377" ], "lang": { "en-US": { "role": { "documentation": "An investment that pools funds from many investors to invest in a combination of underlying investments, primarily equity investments.", "label": "Equity Funds [Member]", "terseLabel": "Equity-like funds" } } }, "localname": "EquityFundsMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/RetirementBenefitsFairValueDisclosuresDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EquitySecuritiesFvNi": { "auth_ref": [ "r545" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).", "label": "Equity Securities, FV-NI", "terseLabel": "Equity Securities, FV-NI" } } }, "localname": "EquitySecuritiesFvNi", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/FinancialInstrumentsFairValueMeasurementDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EquitySecuritiesFvNiGainLoss": { "auth_ref": [ "r245" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of unrealized and realized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).", "label": "Equity Securities, FV-NI, Gain (Loss)", "negatedTerseLabel": "Unrealized losses from equity securities" } } }, "localname": "EquitySecuritiesFvNiGainLoss", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/FinancialInstrumentsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EquitySecuritiesMember": { "auth_ref": [ "r45", "r51", "r243", "r597", "r615", "r637" ], "lang": { "en-US": { "role": { "documentation": "Ownership interest or right to acquire or dispose of ownership interest in corporations and other legal entities for which ownership interest is represented by shares of common or preferred stock, convertible securities, stock rights, or stock warrants.", "label": "Equity Securities [Member]", "terseLabel": "Marketable equity securities" } } }, "localname": "EquitySecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/FinancialInstrumentsFairValueMeasurementDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount": { "auth_ref": [ "r244" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of investment in equity security without readily determinable fair value.", "label": "Equity Securities without Readily Determinable Fair Value, Amount", "terseLabel": "Equity investments without readily determinable fair values" } } }, "localname": "EquitySecuritiesWithoutReadilyDeterminableFairValueAmount", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/FinancialInstrumentsFairValueMeasurementDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EstimateOfFairValueFairValueDisclosureMember": { "auth_ref": [ "r547" ], "lang": { "en-US": { "role": { "documentation": "Measured as an estimate of fair value.", "label": "Estimate of Fair Value Measurement [Member]", "terseLabel": "Fair Value" } } }, "localname": "EstimateOfFairValueFairValueDisclosureMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/FinancialInstrumentsFairValueMeasurementDetails", "http://www.lilly.com/role/FinancialInstrumentsShortTermAndLongTermClassificationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock": { "auth_ref": [ "r539", "r540" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of assets measured at fair value measured on a recurring or nonrecurring basis. Includes, but is not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2.", "label": "Fair Value, Assets Measured on Recurring and Nonrecurring Basis [Table Text Block]", "terseLabel": "Fair Value, Liabilities Measured on Recurring and Nonrecurring Basis" } } }, "localname": "FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/FinancialInstrumentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock": { "auth_ref": [ "r539", "r540" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).", "label": "Fair Value, Assets Measured on Recurring Basis [Table Text Block]", "terseLabel": "Fair Value, Assets Measured on Recurring Basis" } } }, "localname": "FairValueAssetsMeasuredOnRecurringBasisTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/FinancialInstrumentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]", "terseLabel": "Statement [Line Items]" } } }, "localname": "FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/FinancialInstrumentsFairValueMeasurementDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByBalanceSheetGroupingTable": { "auth_ref": [ "r539", "r548", "r549" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities.", "label": "Fair Value, by Balance Sheet Grouping [Table]", "terseLabel": "Fair Value, by Balance Sheet Grouping [Table]" } } }, "localname": "FairValueByBalanceSheetGroupingTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/FinancialInstrumentsFairValueMeasurementDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByBalanceSheetGroupingTextBlock": { "auth_ref": [ "r539", "r548" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities.", "label": "Fair Value, by Balance Sheet Grouping [Table Text Block]", "terseLabel": "Fair Value, by Balance Sheet Grouping" } } }, "localname": "FairValueByBalanceSheetGroupingTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/FinancialInstrumentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "auth_ref": [ "r377", "r378", "r410", "r540", "r577" ], "lang": { "en-US": { "role": { "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.", "label": "Fair Value Hierarchy and NAV [Axis]", "terseLabel": "Fair Value Hierarchy and NAV [Axis]" } } }, "localname": "FairValueByFairValueHierarchyLevelAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/FinancialInstrumentsFairValueMeasurementDetails", "http://www.lilly.com/role/FinancialInstrumentsShortTermAndLongTermClassificationDetails", "http://www.lilly.com/role/RetirementBenefitsFairValueDisclosuresDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByMeasurementBasisAxis": { "auth_ref": [ "r539", "r544" ], "lang": { "en-US": { "role": { "documentation": "Information by measurement basis.", "label": "Measurement Basis [Axis]", "terseLabel": "Measurement Basis [Axis]" } } }, "localname": "FairValueByMeasurementBasisAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/FinancialInstrumentsFairValueMeasurementDetails", "http://www.lilly.com/role/FinancialInstrumentsShortTermAndLongTermClassificationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosureItemAmountsDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Measurement basis, for example, but not limited to, reported value, fair value, portion at fair value, portion at other than fair value.", "label": "Fair Value Measurement [Domain]", "terseLabel": "Fair Value Measurement [Domain]" } } }, "localname": "FairValueDisclosureItemAmountsDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/FinancialInstrumentsFairValueMeasurementDetails", "http://www.lilly.com/role/FinancialInstrumentsShortTermAndLongTermClassificationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueDisclosuresTextBlock": { "auth_ref": [ "r542" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.", "label": "Fair Value Disclosures [Text Block]", "terseLabel": "Financial Instruments" } } }, "localname": "FairValueDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/FinancialInstruments" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueInputsLevel1Member": { "auth_ref": [ "r377", "r378", "r410", "r540", "r578" ], "lang": { "en-US": { "role": { "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.", "label": "Fair Value, Inputs, Level 1 [Member]", "terseLabel": "Quoted Prices in Active Markets for Identical Assets (Level 1)" } } }, "localname": "FairValueInputsLevel1Member", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/FinancialInstrumentsFairValueMeasurementDetails", "http://www.lilly.com/role/FinancialInstrumentsShortTermAndLongTermClassificationDetails", "http://www.lilly.com/role/RetirementBenefitsFairValueDisclosuresDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel2Member": { "auth_ref": [ "r377", "r378", "r410", "r540", "r579" ], "lang": { "en-US": { "role": { "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.", "label": "Fair Value, Inputs, Level 2 [Member]", "terseLabel": "Significant Other Observable Inputs (Level 2)" } } }, "localname": "FairValueInputsLevel2Member", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/FinancialInstrumentsFairValueMeasurementDetails", "http://www.lilly.com/role/FinancialInstrumentsShortTermAndLongTermClassificationDetails", "http://www.lilly.com/role/RetirementBenefitsFairValueDisclosuresDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel3Member": { "auth_ref": [ "r377", "r378", "r410", "r540", "r580" ], "lang": { "en-US": { "role": { "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Inputs, Level 3 [Member]", "terseLabel": "Significant Unobservable Inputs (Level 3)" } } }, "localname": "FairValueInputsLevel3Member", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/FinancialInstrumentsFairValueMeasurementDetails", "http://www.lilly.com/role/FinancialInstrumentsShortTermAndLongTermClassificationDetails", "http://www.lilly.com/role/RetirementBenefitsFairValueDisclosuresDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock": { "auth_ref": [ "r539", "r540" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3). Where the quoted price in an active market for the identical liability is not available, the Level 1 input is the quoted price of an identical liability when traded as an asset.", "label": "Fair Value, Liabilities Measured on Recurring Basis [Table Text Block]", "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis" } } }, "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/FinancialInstrumentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]", "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]" } } }, "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/FinancialInstrumentsShortTermAndLongTermClassificationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable": { "auth_ref": [ "r541", "r543" ], "lang": { "en-US": { "role": { "documentation": "Schedule of information required and determined to be provided for purposes of reconciling beginning and ending balances of fair value measurements of liabilities using significant unobservable inputs (level 3). Separately presenting changes during the period, attributable to: (1) total gains or losses for the period (realized and unrealized) and location reported in the statement of income (or activities); (2) purchases, sales, issuances, and settlements (net); (3) transfers in and/or out of Level 3.", "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]", "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]" } } }, "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/FinancialInstrumentsShortTermAndLongTermClassificationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.", "label": "Fair Value Hierarchy and NAV [Domain]", "terseLabel": "Fair Value Hierarchy and NAV [Domain]" } } }, "localname": "FairValueMeasurementsFairValueHierarchyDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/FinancialInstrumentsFairValueMeasurementDetails", "http://www.lilly.com/role/FinancialInstrumentsShortTermAndLongTermClassificationDetails", "http://www.lilly.com/role/RetirementBenefitsFairValueDisclosuresDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FinancialInstrumentAxis": { "auth_ref": [ "r249", "r250", "r251", "r252", "r253", "r257", "r258", "r259", "r260" ], "lang": { "en-US": { "role": { "documentation": "Information by type of financial instrument.", "label": "Financial Instrument [Axis]", "terseLabel": "Schedule of Available-for-sale Securities, Major Types of Debt and Equity Securities [Axis]" } } }, "localname": "FinancialInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/FinancialInstrumentsFairValueMeasurementDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetUsefulLife": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Finite-Lived Intangible Asset, Useful Life", "terseLabel": "Finite-lived intangible asset, useful life (in years)" } } }, "localname": "FiniteLivedIntangibleAssetUsefulLife", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/GoodwillAndOtherIntangiblesNarrativeDetails" ], "xbrltype": "durationItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": { "auth_ref": [ "r281" ], "calculation": { "http://www.lilly.com/role/GoodwillAndOtherIntangiblesIntangiblesDetails": { "order": 2.0, "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Accumulated Amortization", "negatedLabel": "Accumulated Amortization" } } }, "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/GoodwillAndOtherIntangiblesIntangiblesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": { "auth_ref": [ "r283" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Finite-Lived Intangible Assets, Amortization Expense, Next Twelve Months", "terseLabel": "2019" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/GoodwillAndOtherIntangiblesAmortizationExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of amortization expense of assets, excluding financial assets, that lack physical substance, having a limited useful life.", "label": "Finite-lived Intangible Assets Amortization Expense [Table Text Block]", "terseLabel": "Finite-lived Intangible Assets Amortization Expense" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/GoodwillAndOtherIntangiblesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive": { "auth_ref": [ "r283" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Finite-Lived Intangible Assets, Amortization Expense, Year Five", "terseLabel": "2023" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFive", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/GoodwillAndOtherIntangiblesAmortizationExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": { "auth_ref": [ "r283" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Finite-Lived Intangible Assets, Amortization Expense, Year Four", "terseLabel": "2022" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/GoodwillAndOtherIntangiblesAmortizationExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": { "auth_ref": [ "r283" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Finite-Lived Intangible Assets, Amortization Expense, Year Three", "terseLabel": "2021" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/GoodwillAndOtherIntangiblesAmortizationExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": { "auth_ref": [ "r283" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Finite-Lived Intangible Assets, Amortization Expense, Year Two", "terseLabel": "2020" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/GoodwillAndOtherIntangiblesAmortizationExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": { "auth_ref": [ "r275", "r277", "r281", "r284", "r583" ], "lang": { "en-US": { "role": { "documentation": "Information by major type or class of finite-lived intangible assets.", "label": "Finite-Lived Intangible Assets by Major Class [Axis]", "terseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]" } } }, "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/GoodwillAndOtherIntangiblesIntangiblesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsGross": { "auth_ref": [ "r281", "r583" ], "calculation": { "http://www.lilly.com/role/GoodwillAndOtherIntangiblesIntangiblesDetails": { "order": 1.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Gross", "terseLabel": "Carrying Amount, Gross" } } }, "localname": "FiniteLivedIntangibleAssetsGross", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/GoodwillAndOtherIntangiblesIntangiblesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Finite-Lived Intangible Assets [Line Items]", "terseLabel": "Finite-lived intangible assets:" } } }, "localname": "FiniteLivedIntangibleAssetsLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/GoodwillAndOtherIntangiblesIntangiblesDetails", "http://www.lilly.com/role/GoodwillAndOtherIntangiblesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": { "auth_ref": [ "r275", "r280" ], "lang": { "en-US": { "role": { "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.", "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]", "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]" } } }, "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/GoodwillAndOtherIntangiblesIntangiblesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FiniteLivedIntangibleAssetsNet": { "auth_ref": [ "r281" ], "calculation": { "http://www.lilly.com/role/GoodwillAndOtherIntangiblesIntangiblesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Net", "totalLabel": "Carrying Amount, Net" } } }, "localname": "FiniteLivedIntangibleAssetsNet", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/GoodwillAndOtherIntangiblesIntangiblesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Remaining amortization period of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Finite-Lived Intangible Assets, Remaining Amortization Period", "terseLabel": "Remaining amortization period (in years)" } } }, "localname": "FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/GoodwillAndOtherIntangiblesNarrativeDetails" ], "xbrltype": "durationItemType" }, "us-gaap_FixedIncomeFundsMember": { "auth_ref": [ "r377" ], "lang": { "en-US": { "role": { "documentation": "Investment that pools funds from investors to invest in a combination of underlying investments, primarily fixed income investments.", "label": "Fixed Income Funds [Member]", "terseLabel": "Developed markets" } } }, "localname": "FixedIncomeFundsMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/RetirementBenefitsFairValueDisclosuresDetails", "http://www.lilly.com/role/RetirementBenefitsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ForeignCountryMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Designated tax departments of governments entitled to levy and collect income taxes from the entity outside the entity's country of domicile.", "label": "Foreign Tax Authority [Member]", "terseLabel": "Foreign Tax Authority" } } }, "localname": "ForeignCountryMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ForeignCurrencyTransactionGainLossRealized": { "auth_ref": [ "r554", "r555", "r556" ], "calculation": { "http://www.lilly.com/role/OtherNetIncomeExpenseDetails": { "order": 5.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount before tax of foreign currency transaction realized gain (loss) recognized in the income statement.", "label": "Foreign Currency Transaction Gain (Loss), Realized", "negatedTerseLabel": "Venezuela charge" } } }, "localname": "ForeignCurrencyTransactionGainLossRealized", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/OtherNetIncomeExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": { "auth_ref": [ "r167", "r556", "r562" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.", "label": "Foreign Currency Transactions and Translations Policy [Policy Text Block]", "terseLabel": "Foreign Currency Translation" } } }, "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ForeignExchangeContractMember": { "auth_ref": [ "r377", "r528" ], "lang": { "en-US": { "role": { "documentation": "Derivative instrument whose primary underlying risk is tied to foreign exchange rates.", "label": "Foreign Exchange Contract [Member]", "terseLabel": "Foreign Exchange Contract" } } }, "localname": "ForeignExchangeContractMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/FinancialInstrumentsEffectOfRiskManagementDetails", "http://www.lilly.com/role/FinancialInstrumentsFairValueMeasurementDetails" ], "xbrltype": "domainItemType" }, "us-gaap_GainContingencyUnrecordedAmount": { "auth_ref": [ "r319" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The amount or range of possible amounts of gain that could be realized upon the resolution of a contingency.", "label": "Gain Contingency, Unrecorded Amount", "terseLabel": "Gain contingency, unrecorded amount" } } }, "localname": "GainContingencyUnrecordedAmount", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/ContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments": { "auth_ref": [ "r519", "r525" ], "calculation": { "http://www.lilly.com/role/FinancialInstrumentsEffectOfRiskManagementDetails": { "order": 4.0, "parentTag": "lly_DerivativeInstrumentsGainLossRecognized", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of gain (loss) recognized in earnings in the period from the increase (decrease) in fair value of foreign currency derivatives not designated as hedging instruments.", "label": "Gain (Loss) on Foreign Currency Derivative Instruments Not Designated as Hedging Instruments", "terseLabel": "Net losses on foreign currency exchange contracts not designated as hedging instruments" } } }, "localname": "GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/FinancialInstrumentsEffectOfRiskManagementDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GainLossOnInvestmentsTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of realized and unrealized gain (loss) on investment in security.", "label": "Gain (Loss) on Securities [Table Text Block]", "terseLabel": "Gain (Loss) on Investments" } } }, "localname": "GainLossOnInvestmentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/FinancialInstrumentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_GainLossOnSaleOfBusiness": { "auth_ref": [ "r162", "r504" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of gain (loss) from sale and disposal of integrated set of activities and assets capable of being conducted and managed for purpose of providing return in form of dividend, lower cost, or other economic benefit to investor, owner, member and participant.", "label": "Gain (Loss) on Disposition of Business", "terseLabel": "Gain on disposition of business" } } }, "localname": "GainLossOnSaleOfBusiness", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/DiscontinuedOperationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GainsLossesOnExtinguishmentOfDebt": { "auth_ref": [ "r162", "r329", "r330" ], "calculation": { "http://www.lilly.com/role/OtherNetIncomeExpenseDetails": { "order": 3.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.", "label": "Gain (Loss) on Extinguishment of Debt", "negatedTerseLabel": "Retirement benefit" } } }, "localname": "GainsLossesOnExtinguishmentOfDebt", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/OtherNetIncomeExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_Goodwill": { "auth_ref": [ "r267", "r269" ], "calculation": { "http://www.lilly.com/role/ConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill", "terseLabel": "Goodwill (Note 8)" } } }, "localname": "Goodwill", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Goodwill and Intangible Assets Disclosure [Abstract]" } } }, "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock": { "auth_ref": [ "r286" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for goodwill and intangible assets.", "label": "Goodwill and Intangible Assets Disclosure [Text Block]", "terseLabel": "Goodwill and Intangible Assets Disclosure" } } }, "localname": "GoodwillAndIntangibleAssetsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/GoodwillAndOtherIntangibles" ], "xbrltype": "textBlockItemType" }, "us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock": { "auth_ref": [ "r167", "r271", "r278" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for goodwill and intangible assets. This accounting policy also may address how an entity assesses and measures impairment of goodwill and intangible assets.", "label": "Goodwill and Intangible Assets, Policy [Policy Text Block]", "terseLabel": "Goodwill and Intangible Assets" } } }, "localname": "GoodwillAndIntangibleAssetsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/GoodwillAndOtherIntangiblesPolicies", "http://www.lilly.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_GoodwillImpairmentLoss": { "auth_ref": [ "r162", "r268", "r270", "r272" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill, Impairment Loss", "terseLabel": "Goodwill, impairment loss" } } }, "localname": "GoodwillImpairmentLoss", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/GoodwillAndOtherIntangiblesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_HedgeFundsMember": { "auth_ref": [ "r377" ], "lang": { "en-US": { "role": { "documentation": "Investments in registered hedge funds.", "label": "Hedge Funds [Member]", "terseLabel": "Hedge funds" } } }, "localname": "HedgeFundsMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/RetirementBenefitsFairValueDisclosuresDetails" ], "xbrltype": "domainItemType" }, "us-gaap_HedgingDesignationAxis": { "auth_ref": [ "r517", "r531" ], "lang": { "en-US": { "role": { "documentation": "Information by designation of purpose of derivative instrument.", "label": "Hedging Designation [Axis]", "terseLabel": "Hedging Designation [Axis]" } } }, "localname": "HedgingDesignationAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/FinancialInstrumentsEffectOfRiskManagementDetails", "http://www.lilly.com/role/FinancialInstrumentsFairValueMeasurementDetails" ], "xbrltype": "stringItemType" }, "us-gaap_HedgingDesignationDomain": { "auth_ref": [ "r517" ], "lang": { "en-US": { "role": { "documentation": "Designation of purpose of derivative instrument.", "label": "Hedging Designation [Domain]", "terseLabel": "Hedging Designation [Domain]" } } }, "localname": "HedgingDesignationDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/FinancialInstrumentsEffectOfRiskManagementDetails", "http://www.lilly.com/role/FinancialInstrumentsFairValueMeasurementDetails" ], "xbrltype": "domainItemType" }, "us-gaap_HedgingRelationshipDomain": { "auth_ref": [ "r517" ], "lang": { "en-US": { "role": { "documentation": "Nature or intent of a hedge.", "label": "Hedging Relationship [Domain]", "terseLabel": "Hedging Relationship [Domain]" } } }, "localname": "HedgingRelationshipDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/FinancialInstrumentsEffectOfRiskManagementDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IPOMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "First sale of stock by a private company to the public.", "label": "IPO [Member]", "terseLabel": "IPO" } } }, "localname": "IPOMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/SummaryOfSignificantAccountingPoliciesAcquisitionsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill": { "auth_ref": [ "r162", "r285" ], "calculation": { "http://www.lilly.com/role/GoodwillAndOtherIntangiblesNarrativeDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of an intangible asset (excluding goodwill) to fair value.", "label": "Impairment of Intangible Assets (Excluding Goodwill)", "terseLabel": "Impairment of intangibles", "totalLabel": "Impairment of intangibles" } } }, "localname": "ImpairmentOfIntangibleAssetsExcludingGoodwill", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/AssetImpairmentRestructuringAndOtherSpecialChargesNarrativeDetails", "http://www.lilly.com/role/GoodwillAndOtherIntangiblesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ImpairmentOfIntangibleAssetsFinitelived": { "auth_ref": [ "r162", "r285" ], "calculation": { "http://www.lilly.com/role/GoodwillAndOtherIntangiblesNarrativeDetails": { "order": 1.0, "parentTag": "us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of a finite-lived intangible asset to fair value.", "label": "Impairment of Intangible Assets, Finite-lived", "terseLabel": "Impairment of finite-lived intangible" } } }, "localname": "ImpairmentOfIntangibleAssetsFinitelived", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/GoodwillAndOtherIntangiblesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill": { "auth_ref": [ "r162", "r285" ], "calculation": { "http://www.lilly.com/role/GoodwillAndOtherIntangiblesNarrativeDetails": { "order": 2.0, "parentTag": "us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of impairment loss resulting from write-down of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit to fair value.", "label": "Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill)", "terseLabel": "Impairment of indefinite-lived intangibles" } } }, "localname": "ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/GoodwillAndOtherIntangiblesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ImpairmentOfInvestments": { "auth_ref": [ "r228" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The amount by which the fair value of an investment is less than the amortized cost basis or carrying amount of that investment at the balance sheet date and the decline in fair value is deemed to be other than temporary, before considering whether or not such amount is recognized in earnings or other comprehensive income.", "label": "Other than Temporary Impairment Losses, Investments", "terseLabel": "Other-than-temporary impairment losses recognized during the year" } } }, "localname": "ImpairmentOfInvestments", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/FinancialInstrumentsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "auth_ref": [ "r131", "r181", "r584", "r600", "r631" ], "calculation": { "http://www.lilly.com/role/ConsolidatedStatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 }, "http://www.lilly.com/role/OtherComprehensiveIncomeLossReclassificationDetails": { "order": 1.0, "parentTag": "us-gaap_ProfitLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.", "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest", "negatedTerseLabel": "Total before tax", "totalLabel": "Income before income taxes" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/ConsolidatedStatementsOfOperations", "http://www.lilly.com/role/OtherComprehensiveIncomeLossReclassificationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments": { "auth_ref": [ "r174" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments.", "label": "Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest", "terseLabel": "Income before income taxes" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/SelectedQuarterlyDataUnauditedDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest": { "auth_ref": [ "r498" ], "calculation": { "http://www.lilly.com/role/ConsolidatedStatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after tax of income (loss) from continuing operations including portion attributable to the noncontrolling interest.", "label": "Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest", "totalLabel": "Net income (loss) from continuing operations" } } }, "localname": "IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/ConsolidatedStatementsOfOperations", "http://www.lilly.com/role/SelectedQuarterlyDataUnauditedDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromContinuingOperationsPerBasicShare": { "auth_ref": [ "r128", "r134", "r186", "r188", "r189", "r599", "r601", "r603", "r627" ], "lang": { "en-US": { "role": { "documentation": "The amount of net income (loss) from continuing operations per each share of common stock or unit outstanding during the reporting period.", "label": "Income (Loss) from Continuing Operations, Per Basic Share", "terseLabel": "Earnings (loss) from continuing operations - basic (usd per share)" } } }, "localname": "IncomeLossFromContinuingOperationsPerBasicShare", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/ConsolidatedStatementsOfOperations", "http://www.lilly.com/role/SelectedQuarterlyDataUnauditedDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare": { "auth_ref": [ "r128", "r134", "r186", "r188", "r189", "r190", "r603", "r627", "r630" ], "lang": { "en-US": { "role": { "documentation": "The amount of net income (loss) derived from continuing operations during the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Income (Loss) from Continuing Operations, Per Diluted Share", "terseLabel": "Earnings (loss) from continuing operations - diluted (usd per share)" } } }, "localname": "IncomeLossFromContinuingOperationsPerDilutedShare", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/ConsolidatedStatementsOfOperations", "http://www.lilly.com/role/SelectedQuarterlyDataUnauditedDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax": { "auth_ref": [ "r7", "r8", "r9", "r10", "r11", "r23", "r134", "r628" ], "calculation": { "http://www.lilly.com/role/ConsolidatedStatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after tax of income (loss) from a discontinued operation including the portion attributable to the noncontrolling interest. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.", "label": "Income (Loss) from Discontinued Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest", "terseLabel": "Net Income (loss) from discontinued operations (Note 20)", "verboseLabel": "Net Income (loss) from discontinued operations" } } }, "localname": "IncomeLossFromDiscontinuedOperationsNetOfTax", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/ConsolidatedStatementsOfOperations", "http://www.lilly.com/role/DiscontinuedOperationsDiscontinuedOperationsInFinancialStatementsDetails", "http://www.lilly.com/role/SelectedQuarterlyDataUnauditedDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare": { "auth_ref": [ "r132", "r134", "r187", "r188", "r189", "r603", "r628", "r630" ], "lang": { "en-US": { "role": { "documentation": "Per basic share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation and gain (loss) from the disposal of the discontinued operation.", "label": "Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Basic Share", "terseLabel": "Earnings (loss) from discontinued operations - basic (usd per share)" } } }, "localname": "IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/ConsolidatedStatementsOfOperations", "http://www.lilly.com/role/SelectedQuarterlyDataUnauditedDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare": { "auth_ref": [ "r187", "r188", "r189", "r508" ], "lang": { "en-US": { "role": { "documentation": "Per diluted share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation and gain (loss) from the disposal of the discontinued operation.", "label": "Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Diluted Share", "terseLabel": "Earnings (loss) from discontinued operations - diluted (usd per share)" } } }, "localname": "IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/ConsolidatedStatementsOfOperations", "http://www.lilly.com/role/SelectedQuarterlyDataUnauditedDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Income Statement [Abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by name of disposal group.", "label": "Disposal Group Name [Axis]", "terseLabel": "Disposal Group Name [Axis]" } } }, "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/DiscontinuedOperationsDetails", "http://www.lilly.com/role/DiscontinuedOperationsDiscontinuedOperationsInFinancialStatementsDetails", "http://www.lilly.com/role/DiscontinuedOperationsMajorClassesOfAssetsAndLiabilitiesDetails", "http://www.lilly.com/role/SegmentInformationDetails", "http://www.lilly.com/role/SummaryOfSignificantAccountingPoliciesAcquisitionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]", "terseLabel": "Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]" } } }, "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/DiscontinuedOperationsDetails", "http://www.lilly.com/role/DiscontinuedOperationsDiscontinuedOperationsInFinancialStatementsDetails", "http://www.lilly.com/role/DiscontinuedOperationsMajorClassesOfAssetsAndLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable": { "auth_ref": [ "r1", "r13", "r14", "r15", "r16", "r17", "r18", "r21", "r24", "r25", "r26", "r298", "r299" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.", "label": "Disposal Groups, Including Discontinued Operations [Table]", "terseLabel": "Disposal Groups, Including Discontinued Operations [Table]" } } }, "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/DiscontinuedOperationsDetails", "http://www.lilly.com/role/DiscontinuedOperationsDiscontinuedOperationsInFinancialStatementsDetails", "http://www.lilly.com/role/DiscontinuedOperationsMajorClassesOfAssetsAndLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationAxis": { "auth_ref": [ "r295" ], "lang": { "en-US": { "role": { "documentation": "Information by location in the income statement.", "label": "Income Statement Location [Axis]", "terseLabel": "Income Statement Location [Axis]" } } }, "localname": "IncomeStatementLocationAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/RetirementBenefitsNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Location in the income statement.", "label": "Income Statement Location [Domain]", "terseLabel": "Income Statement Location [Domain]" } } }, "localname": "IncomeStatementLocationDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/RetirementBenefitsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxAuthorityAxis": { "auth_ref": [ "r449" ], "lang": { "en-US": { "role": { "documentation": "Information by tax jurisdiction.", "label": "Income Tax Authority [Axis]", "terseLabel": "Income Tax Authority [Axis]" } } }, "localname": "IncomeTaxAuthorityAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxAuthorityDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.", "label": "Income Tax Authority [Domain]", "terseLabel": "Income Tax Authority [Domain]" } } }, "localname": "IncomeTaxAuthorityDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Income Tax Disclosure [Abstract]" } } }, "localname": "IncomeTaxDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxDisclosureTextBlock": { "auth_ref": [ "r480" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.", "label": "Income Tax Disclosure [Text Block]", "terseLabel": "Income Taxes" } } }, "localname": "IncomeTaxDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/IncomeTaxes" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxExaminationYearUnderExamination": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Tax year being audited in the income tax examination, in CCYY format.", "label": "Income Tax Examination, Year under Examination", "terseLabel": "Year under examination" } } }, "localname": "IncomeTaxExaminationYearUnderExamination", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "gYearListItemType" }, "us-gaap_IncomeTaxExpenseBenefit": { "auth_ref": [ "r171", "r210", "r477" ], "calculation": { "http://www.lilly.com/role/ConsolidatedStatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest", "weight": -1.0 }, "http://www.lilly.com/role/IncomeTaxesCurrentAndDeferredDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.lilly.com/role/IncomeTaxesReconciliationOfIncomeTaxesDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.lilly.com/role/OtherComprehensiveIncomeLossReclassificationDetails": { "order": 2.0, "parentTag": "us-gaap_ProfitLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Income Tax Expense (Benefit)", "negatedLabel": "Tax (benefit) expense", "terseLabel": "Income taxes (Note 13)", "totalLabel": "Income taxes" } } }, "localname": "IncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/ConsolidatedStatementsOfOperations", "http://www.lilly.com/role/IncomeTaxesCurrentAndDeferredDetails", "http://www.lilly.com/role/IncomeTaxesReconciliationOfIncomeTaxesDetails", "http://www.lilly.com/role/OtherComprehensiveIncomeLossReclassificationDetails", "http://www.lilly.com/role/SelectedQuarterlyDataUnauditedDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxPolicyTextBlock": { "auth_ref": [ "r125", "r167", "r441", "r442", "r457", "r458", "r464", "r479", "r641" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.", "label": "Income Tax, Policy [Policy Text Block]", "terseLabel": "Income Tax" } } }, "localname": "IncomeTaxPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/IncomeTaxesPolicies", "http://www.lilly.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate": { "auth_ref": [ "r170", "r444", "r445" ], "calculation": { "http://www.lilly.com/role/IncomeTaxesReconciliationOfIncomeTaxesDetails": { "order": 1.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.", "label": "Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount", "verboseLabel": "Income tax at the U.S. federal statutory tax rate" } } }, "localname": "IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/IncomeTaxesReconciliationOfIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment": { "auth_ref": [ "r444", "r445" ], "calculation": { "http://www.lilly.com/role/IncomeTaxesReconciliationOfIncomeTaxesDetails": { "order": 4.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible research and development expense.", "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Amount", "verboseLabel": "Non-deductible acquired IPR&D" } } }, "localname": "IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/IncomeTaxesReconciliationOfIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxReconciliationOtherAdjustments": { "auth_ref": [ "r444" ], "calculation": { "http://www.lilly.com/role/IncomeTaxesReconciliationOfIncomeTaxesDetails": { "order": 5.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.", "label": "Effective Income Tax Rate Reconciliation, Other Adjustments, Amount", "verboseLabel": "Other" } } }, "localname": "IncomeTaxReconciliationOtherAdjustments", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/IncomeTaxesReconciliationOfIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxReconciliationTaxCredits": { "auth_ref": [ "r444", "r445" ], "calculation": { "http://www.lilly.com/role/IncomeTaxesReconciliationOfIncomeTaxesDetails": { "order": 3.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax credits. Including, but not limited to, research credit, foreign tax credit, investment tax credit, and other tax credits.", "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Amount", "negatedLabel": "General business credits" } } }, "localname": "IncomeTaxReconciliationTaxCredits", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/IncomeTaxesReconciliationOfIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxReconciliationTaxCreditsForeign": { "auth_ref": [ "r444", "r445" ], "calculation": { "http://www.lilly.com/role/IncomeTaxesReconciliationOfIncomeTaxesDetails": { "order": 2.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to foreign tax credit.", "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Foreign, Amount", "negatedLabel": "International operations, including Puerto Rico" } } }, "localname": "IncomeTaxReconciliationTaxCreditsForeign", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/IncomeTaxesReconciliationOfIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxesPaid": { "auth_ref": [ "r159", "r166" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.", "label": "Income Taxes Paid", "terseLabel": "Cash payments of income taxes" } } }, "localname": "IncomeTaxesPaid", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables": { "auth_ref": [ "r161" ], "calculation": { "http://www.lilly.com/role/ConsolidatedStatementsOfCashFlows": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The increase (decrease) during the reporting period in the amount due from customers for the credit sale of goods and services; includes accounts receivable and other types of receivables.", "label": "Increase (Decrease) in Accounts and Other Receivables", "negatedLabel": "Receivables\u2014(increase) decrease" } } }, "localname": "IncreaseDecreaseInAccountsAndOtherReceivables", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": { "auth_ref": [ "r161" ], "calculation": { "http://www.lilly.com/role/ConsolidatedStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.", "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities", "terseLabel": "Accounts payable and other liabilities\u2014increase (decrease)" } } }, "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable": { "auth_ref": [ "r161" ], "calculation": { "http://www.lilly.com/role/ConsolidatedStatementsOfCashFlows": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The increase (decrease) during the period in the amount due for taxes based on the reporting entity's earnings or attributable to the entity's income earning process (business presence) within a given jurisdiction.", "label": "Increase (Decrease) in Income Taxes Payable", "terseLabel": "Income taxes payable\u2014increase (decrease)" } } }, "localname": "IncreaseDecreaseInAccruedIncomeTaxesPayable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInDeferredIncomeTaxes": { "auth_ref": [ "r161" ], "calculation": { "http://www.lilly.com/role/ConsolidatedStatementsOfCashFlows": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The increase (decrease) during the reporting period in the account that represents the temporary difference that results from Income or Loss that is recognized for accounting purposes but not for tax purposes and vice versa.", "label": "Increase (Decrease) in Deferred Income Taxes", "negatedLabel": "Change in deferred income taxes" } } }, "localname": "IncreaseDecreaseInDeferredIncomeTaxes", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInInventories": { "auth_ref": [ "r161" ], "calculation": { "http://www.lilly.com/role/ConsolidatedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.", "label": "Increase (Decrease) in Inventories", "negatedLabel": "Inventories\u2014(increase) decrease" } } }, "localname": "IncreaseDecreaseInInventories", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Increase (Decrease) in Operating Capital [Abstract]", "terseLabel": "Other changes in operating assets and liabilities, net of acquisitions and divestitures:" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInOtherOperatingAssets": { "auth_ref": [ "r161" ], "calculation": { "http://www.lilly.com/role/ConsolidatedStatementsOfCashFlows": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in operating assets classified as other.", "label": "Increase (Decrease) in Other Operating Assets", "negatedLabel": "Other assets\u2014(increase) decrease" } } }, "localname": "IncreaseDecreaseInOtherOperatingAssets", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "terseLabel": "Increase (Decrease) in Shareholders' Equity [Roll Forward]" } } }, "localname": "IncreaseDecreaseInStockholdersEquityRollForward", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/ConsolidatedStatementsOfShareholdersEquityStatement" ], "xbrltype": "stringItemType" }, "us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis": { "auth_ref": [ "r354" ], "lang": { "en-US": { "role": { "documentation": "Information about effect of transition method for cumulative effect in initial period of application.", "label": "Initial Application Period Cumulative Effect Transition [Axis]", "terseLabel": "Initial Application Period Cumulative Effect Transition [Axis]" } } }, "localname": "InitialApplicationPeriodCumulativeEffectTransitionAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/ImplementationOfNewFinancialAccountingPronouncementsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Effect of transition method for cumulative effect in initial period of application.", "label": "Initial Application Period Cumulative Effect Transition [Domain]", "terseLabel": "Initial Application Period Cumulative Effect Transition [Domain]" } } }, "localname": "InitialApplicationPeriodCumulativeEffectTransitionDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/ImplementationOfNewFinancialAccountingPronouncementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IntangibleAssetsGrossExcludingGoodwill": { "auth_ref": [], "calculation": { "http://www.lilly.com/role/GoodwillAndOtherIntangiblesIntangiblesDetails": { "order": 1.0, "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before accumulated amortization of intangible assets, excluding goodwill.", "label": "Intangible Assets, Gross (Excluding Goodwill)", "terseLabel": "Other Intangibles, gross" } } }, "localname": "IntangibleAssetsGrossExcludingGoodwill", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/GoodwillAndOtherIntangiblesIntangiblesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IntangibleAssetsNetExcludingGoodwill": { "auth_ref": [ "r273", "r279" ], "calculation": { "http://www.lilly.com/role/ConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_Assets", "weight": 1.0 }, "http://www.lilly.com/role/GoodwillAndOtherIntangiblesIntangiblesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.", "label": "Intangible Assets, Net (Excluding Goodwill)", "terseLabel": "Other intangibles, net (Note 8)", "totalLabel": "Other intangibles, net" } } }, "localname": "IntangibleAssetsNetExcludingGoodwill", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/ConsolidatedBalanceSheets", "http://www.lilly.com/role/GoodwillAndOtherIntangiblesIntangiblesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestExpense": { "auth_ref": [ "r129", "r208", "r563", "r566", "r604" ], "calculation": { "http://www.lilly.com/role/OtherNetIncomeExpenseDetails": { "order": 4.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.", "label": "Interest Expense", "terseLabel": "Interest expense" } } }, "localname": "InterestExpense", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/OtherNetIncomeExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestPaidNet": { "auth_ref": [ "r155", "r158", "r166" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.", "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities", "terseLabel": "Cash payments for interest on borrowings" } } }, "localname": "InterestPaidNet", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/BorrowingsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestRateCashFlowHedgeGainLossToBeReclassifiedDuringNext12MonthsNet": { "auth_ref": [ "r538" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The estimated net amount of unrealized gains or losses on interest rate cash flow hedges as of the balance sheet date expected to be reclassified to earnings within the next twelve months.", "label": "Interest Rate Cash Flow Hedge Gain (Loss) to be Reclassified During Next 12 Months, Net", "negatedLabel": "Losses expected to be reclassified in the next 12 months" } } }, "localname": "InterestRateCashFlowHedgeGainLossToBeReclassifiedDuringNext12MonthsNet", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/FinancialInstrumentsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestRateContractMember": { "auth_ref": [ "r377", "r527" ], "lang": { "en-US": { "role": { "documentation": "Derivative instrument whose primary underlying risk is tied to the right to receive or pay a sum of money at a given interest rate.", "label": "Interest Rate Contract [Member]", "terseLabel": "Interest Rate Contract" } } }, "localname": "InterestRateContractMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/FinancialInstrumentsEffectOfRiskManagementDetails", "http://www.lilly.com/role/FinancialInstrumentsFairValueMeasurementDetails" ], "xbrltype": "domainItemType" }, "us-gaap_InterestRateSwapMember": { "auth_ref": [ "r527" ], "lang": { "en-US": { "role": { "documentation": "Forward based contracts in which two parties agree to swap periodic payments that are fixed at the outset of the swap contract with variable payments based on a market interest rate (index rate) over a specified period.", "label": "Interest Rate Swap [Member]", "terseLabel": "Interest rate swap" } } }, "localname": "InterestRateSwapMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/FinancialInstrumentsEffectOfRiskManagementDetails", "http://www.lilly.com/role/FinancialInstrumentsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_InternalRevenueServiceIRSMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Designated tax department of the United States of America government entitled to levy and collect income taxes from the entity.", "label": "Internal Revenue Service (IRS) [Member]", "terseLabel": "Internal Revenue Service (IRS)" } } }, "localname": "InternalRevenueServiceIRSMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_InventoryDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Inventory Disclosure [Abstract]" } } }, "localname": "InventoryDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_InventoryDisclosureTextBlock": { "auth_ref": [ "r265" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.", "label": "Inventory Disclosure [Text Block]", "terseLabel": "Inventories" } } }, "localname": "InventoryDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/Inventories" ], "xbrltype": "textBlockItemType" }, "us-gaap_InventoryFinishedGoods": { "auth_ref": [ "r92" ], "calculation": { "http://www.lilly.com/role/InventoriesDetails": { "order": 1.0, "parentTag": "us-gaap_InventoryGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.", "label": "Inventory, Finished Goods, Gross", "terseLabel": "Finished products" } } }, "localname": "InventoryFinishedGoods", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/InventoriesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryGross": { "auth_ref": [ "r95" ], "calculation": { "http://www.lilly.com/role/InventoriesDetails": { "order": 1.0, "parentTag": "us-gaap_InventoryNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Gross amount, as of the balance sheet date, of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.", "label": "Inventory, Gross", "totalLabel": "Total (approximates replacement cost)" } } }, "localname": "InventoryGross", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/InventoriesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryLIFOReserve": { "auth_ref": [ "r97" ], "calculation": { "http://www.lilly.com/role/InventoriesDetails": { "order": 2.0, "parentTag": "us-gaap_InventoryNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount by which inventory stated at last-in first-out (LIFO) is less than (in excess of) inventory stated at other inventory cost methods.", "label": "Inventory, LIFO Reserve", "negatedTerseLabel": "Increase (reduction) to LIFO cost" } } }, "localname": "InventoryLIFOReserve", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/InventoriesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryNet": { "auth_ref": [ "r30", "r95", "r262" ], "calculation": { "http://www.lilly.com/role/ConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 }, "http://www.lilly.com/role/InventoriesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.", "label": "Inventory, Net", "terseLabel": "Inventories (Note 6)", "totalLabel": "Inventories" } } }, "localname": "InventoryNet", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/ConsolidatedBalanceSheets", "http://www.lilly.com/role/InventoriesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryPolicyTextBlock": { "auth_ref": [ "r41", "r96", "r167", "r197", "r263", "r264" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.", "label": "Inventory, Policy [Policy Text Block]", "terseLabel": "Inventory" } } }, "localname": "InventoryPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/InventoriesPolicies", "http://www.lilly.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_InventoryRawMaterials": { "auth_ref": [ "r94" ], "calculation": { "http://www.lilly.com/role/InventoriesDetails": { "order": 3.0, "parentTag": "us-gaap_InventoryGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer.", "label": "Inventory, Raw Materials, Gross", "terseLabel": "Raw materials and supplies" } } }, "localname": "InventoryRawMaterials", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/InventoriesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryWorkInProcess": { "auth_ref": [ "r93" ], "calculation": { "http://www.lilly.com/role/InventoriesDetails": { "order": 2.0, "parentTag": "us-gaap_InventoryGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer.", "label": "Inventory, Work in Process, Gross", "terseLabel": "Work in process" } } }, "localname": "InventoryWorkInProcess", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/InventoriesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentIncomeInterest": { "auth_ref": [ "r139", "r207" ], "calculation": { "http://www.lilly.com/role/OtherNetIncomeExpenseDetails": { "order": 2.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.", "label": "Investment Income, Interest", "negatedLabel": "Interest income" } } }, "localname": "InvestmentIncomeInterest", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/OtherNetIncomeExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentPolicyTextBlock": { "auth_ref": [ "r247" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for investment in financial asset.", "label": "Investment, Policy [Policy Text Block]", "terseLabel": "Investment" } } }, "localname": "InvestmentPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/FinancialInstrumentsPolicies", "http://www.lilly.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_LIFOInventoryAmount": { "auth_ref": [ "r41" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The amount of LIFO (last in first out) inventory present at the reporting date when inventory is also valued using different valuation methods.", "label": "LIFO Inventory Amount", "terseLabel": "LIFO Inventory Amount" } } }, "localname": "LIFOInventoryAmount", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/InventoriesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_Land": { "auth_ref": [ "r36", "r74" ], "calculation": { "http://www.lilly.com/role/PropertyAndEquipmentDetails": { "order": 1.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before accumulated depletion of real estate held for productive use, excluding land held for sale.", "label": "Land", "terseLabel": "Land" } } }, "localname": "Land", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/PropertyAndEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LeaseAndRentalExpense": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of rent expense incurred for leased assets, including but not limited to, furniture and equipment, that is not directly or indirectly associated with the manufacture, sale or creation of a product or product line.", "label": "Operating Leases, Rent Expense", "terseLabel": "Rental expense" } } }, "localname": "LeaseAndRentalExpense", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/PropertyAndEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r66", "r593", "r623" ], "calculation": { "http://www.lilly.com/role/ConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities and Equity", "totalLabel": "Total liabilities and equity" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Liabilities and Equity [Abstract]", "terseLabel": "Liabilities and Equity" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r83" ], "calculation": { "http://www.lilly.com/role/ConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities, Current", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Liabilities, Current [Abstract]", "terseLabel": "Current Liabilities" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesNoncurrent": { "auth_ref": [ "r42", "r43", "r44", "r53", "r54" ], "calculation": { "http://www.lilly.com/role/ConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of obligation due after one year or beyond the normal operating cycle, if longer.", "label": "Liabilities, Noncurrent", "totalLabel": "Total other liabilities" } } }, "localname": "LiabilitiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesNoncurrentAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Liabilities, Noncurrent [Abstract]", "terseLabel": "Other Liabilities" } } }, "localname": "LiabilitiesNoncurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent": { "auth_ref": [ "r0", "r1", "r20", "r22", "r289", "r296" ], "calculation": { "http://www.lilly.com/role/ConsolidatedBalanceSheets": { "order": 8.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount classified as liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.", "label": "Disposal Group, Including Discontinued Operation, Liabilities, Current", "terseLabel": "Current liabilities of discontinued operations" } } }, "localname": "LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/ConsolidatedBalanceSheets", "http://www.lilly.com/role/DiscontinuedOperationsMajorClassesOfAssetsAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent": { "auth_ref": [ "r0", "r1", "r20", "r22", "r287", "r296" ], "calculation": { "http://www.lilly.com/role/ConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_LiabilitiesNoncurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount classified as liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of beyond one year or the normal operating cycle, if longer.", "label": "Disposal Group, Including Discontinued Operation, Liabilities, Noncurrent", "terseLabel": "Noncurrent liabilities of discontinued operations" } } }, "localname": "LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/ConsolidatedBalanceSheets", "http://www.lilly.com/role/DiscontinuedOperationsMajorClassesOfAssetsAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LineOfCreditFacilityFairValueOfAmountOutstanding": { "auth_ref": [ "r547" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Fair value of the amount outstanding under the credit facility.", "label": "Line of Credit Facility, Fair Value of Amount Outstanding", "terseLabel": "Line of credit facility, outstanding" } } }, "localname": "LineOfCreditFacilityFairValueOfAmountOutstanding", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/BorrowingsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": { "auth_ref": [ "r79" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.", "label": "Line of Credit Facility, Maximum Borrowing Capacity", "terseLabel": "Line of credit facility, maximum borrowing capacity" } } }, "localname": "LineOfCreditFacilityMaximumBorrowingCapacity", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/BorrowingsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity": { "auth_ref": [ "r79" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of borrowing capacity currently available under the credit facility (current borrowing capacity less the amount of borrowings outstanding).", "label": "Line of Credit Facility, Remaining Borrowing Capacity", "terseLabel": "Line of credit facility, remaining borrowing capacity" } } }, "localname": "LineOfCreditFacilityRemainingBorrowingCapacity", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/BorrowingsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LitigationStatusAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by status of pending, threatened, or settled litigation.", "label": "Litigation Status [Axis]", "terseLabel": "Litigation Status [Axis]" } } }, "localname": "LitigationStatusAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/ContingenciesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LitigationStatusDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Status of pending, threatened, or settled litigation.", "label": "Litigation Status [Domain]", "terseLabel": "Litigation Status [Domain]" } } }, "localname": "LitigationStatusDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/ContingenciesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LongTermDebt": { "auth_ref": [ "r53", "r327", "r591", "r620" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.", "label": "Long-term Debt", "negatedLabel": "Long-term debt, including current portion", "terseLabel": "Long-term debt" } } }, "localname": "LongTermDebt", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/FinancialInstrumentsNarrativeDetails", "http://www.lilly.com/role/FinancialInstrumentsShortTermAndLongTermClassificationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths": { "auth_ref": [ "r179", "r325" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing in the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Long-term Debt, Maturities, Repayments of Principal in Next Twelve Months", "terseLabel": "2019" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/BorrowingsDebtMaturitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive": { "auth_ref": [ "r179", "r325" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing in the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Long-term Debt, Maturities, Repayments of Principal in Year Five", "terseLabel": "2023" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/BorrowingsDebtMaturitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour": { "auth_ref": [ "r179", "r325" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing in the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Long-term Debt, Maturities, Repayments of Principal in Year Four", "terseLabel": "2022" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/BorrowingsDebtMaturitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree": { "auth_ref": [ "r179", "r325" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing in the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Long-term Debt, Maturities, Repayments of Principal in Year Three", "terseLabel": "2021" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/BorrowingsDebtMaturitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo": { "auth_ref": [ "r179", "r325" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Long-term Debt, Maturities, Repayments of Principal in Year Two", "terseLabel": "2020" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/BorrowingsDebtMaturitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtNoncurrent": { "auth_ref": [ "r85" ], "calculation": { "http://www.lilly.com/role/BorrowingsLongTermDebtDetailsCalc2": { "order": 2.0, "parentTag": "us-gaap_DebtLongtermAndShorttermCombinedAmount", "weight": 1.0 }, "http://www.lilly.com/role/ConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesNoncurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.", "label": "Long-term Debt, Excluding Current Maturities", "terseLabel": "Long-term debt (Note 10)", "verboseLabel": "Long-term debt" } } }, "localname": "LongTermDebtNoncurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/BorrowingsLongTermDebtDetails", "http://www.lilly.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtPercentageBearingVariableInterestRate": { "auth_ref": [ "r84" ], "lang": { "en-US": { "role": { "documentation": "The interest rate applicable to the portion of the carrying amount of long-term borrowings outstanding as of the balance sheet date, including current maturities, which accrues interest at a rate subject to change from time to time.", "label": "Long-term Debt, Percentage Bearing Variable Interest, Percentage Rate", "terseLabel": "Variable rate (in percentage)" } } }, "localname": "LongTermDebtPercentageBearingVariableInterestRate", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/FinancialInstrumentsNarrativeDetails" ], "xbrltype": "percentItemType" }, "us-gaap_LongTermInvestments": { "auth_ref": [ "r72" ], "calculation": { "http://www.lilly.com/role/ConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The total amount of investments that are intended to be held for an extended period of time (longer than one operating cycle).", "label": "Long-term Investments", "terseLabel": "Investments (Note 7)" } } }, "localname": "LongTermInvestments", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/ConsolidatedBalanceSheets", "http://www.lilly.com/role/FinancialInstrumentsFairValueMeasurementDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongtermDebtCurrentAndNoncurrentAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Long-term Debt, Current and Noncurrent [Abstract]" } } }, "localname": "LongtermDebtCurrentAndNoncurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_LongtermDebtTypeAxis": { "auth_ref": [ "r85" ], "lang": { "en-US": { "role": { "documentation": "Information by type of long-term debt.", "label": "Long-term Debt, Type [Axis]", "terseLabel": "Long-term Debt, Type [Axis]" } } }, "localname": "LongtermDebtTypeAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/DiscontinuedOperationsDetails", "http://www.lilly.com/role/FinancialInstrumentsNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LongtermDebtTypeDomain": { "auth_ref": [ "r85", "r326" ], "lang": { "en-US": { "role": { "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.", "label": "Long-term Debt, Type [Domain]", "terseLabel": "Long-term Debt, Type [Domain]" } } }, "localname": "LongtermDebtTypeDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/DiscontinuedOperationsDetails", "http://www.lilly.com/role/FinancialInstrumentsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LossContingenciesLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Loss Contingencies [Line Items]", "terseLabel": "Loss Contingencies [Line Items]" } } }, "localname": "LossContingenciesLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/ContingenciesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LossContingenciesTable": { "auth_ref": [ "r310", "r311", "r312", "r314", "r315", "r316", "r318", "r321", "r322" ], "lang": { "en-US": { "role": { "documentation": "Discloses the specific components (such as the nature, name, and date) of the loss contingency and gives an estimate of the possible loss or range of loss, or states that a reasonable estimate cannot be made. Excludes environmental contingencies, warranties and unconditional purchase obligations.", "label": "Loss Contingencies [Table]", "terseLabel": "Loss Contingencies [Table]" } } }, "localname": "LossContingenciesTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/ContingenciesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LossContingencyClaimsSettledAndDismissedNumber": { "auth_ref": [ "r313" ], "lang": { "en-US": { "role": { "documentation": "The number of claims settled and dismissed during the period.", "label": "Loss Contingency, Claims Settled and Dismissed, Number", "terseLabel": "Claims settled and dismissed" } } }, "localname": "LossContingencyClaimsSettledAndDismissedNumber", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/ContingenciesDetails" ], "xbrltype": "integerItemType" }, "us-gaap_LossContingencyDamagesAwardedValue": { "auth_ref": [ "r310", "r313", "r317" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of damages awarded to the plaintiff in the legal matter.", "label": "Loss Contingency, Damages Awarded, Value", "terseLabel": "Damages awarded, value" } } }, "localname": "LossContingencyDamagesAwardedValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/ContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LossContingencyNumberOfDefendants": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Number of defendants named in a legal action.", "label": "Loss Contingency, Number of Defendants", "terseLabel": "Number of defendants" } } }, "localname": "LossContingencyNumberOfDefendants", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/ContingenciesDetails" ], "xbrltype": "integerItemType" }, "us-gaap_MachineryAndEquipmentGross": { "auth_ref": [ "r37", "r291" ], "calculation": { "http://www.lilly.com/role/PropertyAndEquipmentDetails": { "order": 3.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before accumulated depreciation of tangible personal property used to produce goods and services, including, but is not limited to, tools, dies and molds, computer and office equipment.", "label": "Machinery and Equipment, Gross", "terseLabel": "Equipment" } } }, "localname": "MachineryAndEquipmentGross", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/PropertyAndEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_MaximumRemainingMaturityOfForeignCurrencyDerivatives1": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Maximum amount of time remaining before foreign currency exchange rate derivatives mature or expire, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Maximum Remaining Maturity of Foreign Currency Derivatives", "terseLabel": "Maximum remaining maturity of foreign currency derivatives (in days)" } } }, "localname": "MaximumRemainingMaturityOfForeignCurrencyDerivatives1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/FinancialInstrumentsNarrativeDetails" ], "xbrltype": "durationItemType" }, "us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock": { "auth_ref": [ "r27", "r491" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for business combinations, including leverage buyout transactions (as applicable), and divestitures. This may include a description of a business combination or divestiture (or series of individually immaterial business combinations or divestitures) completed during the period, including background, timing, and assets and liabilities recognized and reclassified or sold. This element does not include fixed asset sales and plant closings.", "label": "Mergers, Acquisitions and Dispositions Disclosures [Text Block]", "terseLabel": "Acquisitions" } } }, "localname": "MergersAcquisitionsAndDispositionsDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/Acquisitions" ], "xbrltype": "textBlockItemType" }, "us-gaap_MinorityInterest": { "auth_ref": [ "r91", "r592", "r622" ], "calculation": { "http://www.lilly.com/role/ConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).", "label": "Stockholders' Equity Attributable to Noncontrolling Interest", "terseLabel": "Noncontrolling interests" } } }, "localname": "MinorityInterest", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/ConsolidatedBalanceSheets", "http://www.lilly.com/role/DiscontinuedOperationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_MinorityInterestOwnershipPercentageByParent": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The parent entity's interest in net assets of the subsidiary, expressed as a percentage.", "label": "Noncontrolling Interest, Ownership Percentage by Parent", "terseLabel": "Noncontrolling interest, ownership percentage by parent" } } }, "localname": "MinorityInterestOwnershipPercentageByParent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/DiscontinuedOperationsDetails", "http://www.lilly.com/role/SegmentInformationDetails", "http://www.lilly.com/role/SummaryOfSignificantAccountingPoliciesAcquisitionsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_MortgageBackedSecuritiesMember": { "auth_ref": [ "r230", "r377", "r378", "r410", "r635" ], "lang": { "en-US": { "role": { "documentation": "Securities collateralized by mortgage loans.", "label": "Collateralized Mortgage Backed Securities [Member]", "terseLabel": "Mortgage-backed securities" } } }, "localname": "MortgageBackedSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/FinancialInstrumentsFairValueMeasurementDetails" ], "xbrltype": "domainItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r157" ], "calculation": { "http://www.lilly.com/role/ConsolidatedStatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Net Cash Provided by (Used for) Financing Activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]", "terseLabel": "Cash Flows from Financing Activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r157" ], "calculation": { "http://www.lilly.com/role/ConsolidatedStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Net Cash Provided by (Used in) Investing Activities", "totalLabel": "Net Cash Provided by (Used for) Investing Activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]", "terseLabel": "Cash Flows from Investing Activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r157", "r160", "r163" ], "calculation": { "http://www.lilly.com/role/ConsolidatedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease", "weight": 1.0 } }, "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "Net Cash Provided by Operating Activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Net Cash Provided by Operating Activities [Abstract]" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract]", "terseLabel": "Cash Flows from Operating Activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r120", "r123", "r133", "r163", "r192", "r602", "r629" ], "calculation": { "http://www.lilly.com/role/ConsolidatedStatementsOfCashFlows": { "order": 11.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://www.lilly.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss": { "order": 1.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 }, "http://www.lilly.com/role/ConsolidatedStatementsOfOperations": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net Income (Loss) Attributable to Parent", "terseLabel": "Net income (loss)", "totalLabel": "Net income (loss)" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/ConsolidatedStatementsOfCashFlows", "http://www.lilly.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss", "http://www.lilly.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetInvestmentHedgingMember": { "auth_ref": [ "r516" ], "lang": { "en-US": { "role": { "documentation": "Hedges of a net investment in a foreign operation.", "label": "Net Investment Hedging [Member]", "terseLabel": "Net investment hedges:" } } }, "localname": "NetInvestmentHedgingMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/FinancialInstrumentsEffectOfRiskManagementDetails" ], "xbrltype": "domainItemType" }, "us-gaap_NewAccountingPronouncementEarlyAdoptionLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "New Accounting Pronouncement, Early Adoption [Line Items]", "terseLabel": "New Accounting Pronouncement, Early Adoption [Line Items]" } } }, "localname": "NewAccountingPronouncementEarlyAdoptionLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/ImplementationOfNewFinancialAccountingPronouncementsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_NewAccountingPronouncementEarlyAdoptionTable": { "auth_ref": [ "r180", "r182" ], "lang": { "en-US": { "role": { "documentation": "Schedule detailing the financial statement line items and the effect of the guidance on financial statement line items by guidance implemented if the entity elects earlier application.", "label": "New Accounting Pronouncement, Early Adoption [Table]", "terseLabel": "New Accounting Pronouncement, Early Adoption [Table]" } } }, "localname": "NewAccountingPronouncementEarlyAdoptionTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/ImplementationOfNewFinancialAccountingPronouncementsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "New Accounting Pronouncements and Changes in Accounting Principles [Abstract]" } } }, "localname": "NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock": { "auth_ref": [ "r183" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure of changes in accounting principles, including adoption of new accounting pronouncements, that describes the new methods, amount and effects on financial statement line items.", "label": "New Accounting Pronouncements and Changes in Accounting Principles [Text Block]", "terseLabel": "Implementation of New Financial Accounting Pronouncements" } } }, "localname": "NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/ImplementationOfNewFinancialAccountingPronouncements" ], "xbrltype": "textBlockItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "terseLabel": "New Accounting Pronouncements, Policy" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_NoncontrollingInterestMember": { "auth_ref": [ "r496" ], "lang": { "en-US": { "role": { "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest.", "label": "Noncontrolling Interest [Member]", "terseLabel": "Noncontrolling Interest" } } }, "localname": "NoncontrollingInterestMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/ConsolidatedStatementsOfShareholdersEquityStatement" ], "xbrltype": "domainItemType" }, "us-gaap_NoncurrentAssets": { "auth_ref": [ "r219" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Long-lived assets other than financial instruments, long-term customer relationships of a financial institution, mortgage and other servicing rights, deferred policy acquisition costs, and deferred tax assets.", "label": "Long-Lived Assets", "terseLabel": "Long-lived assets" } } }, "localname": "NoncurrentAssets", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/SegmentInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NondesignatedMember": { "auth_ref": [ "r517" ], "lang": { "en-US": { "role": { "documentation": "Derivative instrument not designated as hedging instrument under Generally Accepted Accounting Principles (GAAP).", "label": "Not Designated as Hedging Instrument [Member]", "terseLabel": "Not Designated as Hedging Instrument" } } }, "localname": "NondesignatedMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/FinancialInstrumentsEffectOfRiskManagementDetails", "http://www.lilly.com/role/FinancialInstrumentsFairValueMeasurementDetails" ], "xbrltype": "domainItemType" }, "us-gaap_NonoperatingIncomeExpense": { "auth_ref": [ "r140" ], "calculation": { "http://www.lilly.com/role/ConsolidatedStatementsOfOperations": { "order": 6.0, "parentTag": "lly_CostOfSalesOperatingExpensesAndOtherNet", "weight": -1.0 }, "http://www.lilly.com/role/OtherNetIncomeExpenseDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).", "label": "Nonoperating Income (Expense)", "negatedLabel": "Other\u2014net, (income) expense (Note 17)", "negatedTotalLabel": "Other\u2013net, (income) expense", "terseLabel": "Other income" } } }, "localname": "NonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/ConsolidatedStatementsOfOperations", "http://www.lilly.com/role/ImplementationOfNewFinancialAccountingPronouncementsDetails", "http://www.lilly.com/role/OtherNetIncomeExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NonoperatingIncomeExpenseAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Nonoperating Income (Expense) [Abstract]" } } }, "localname": "NonoperatingIncomeExpenseAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_NonrecurringAdjustmentAxis": { "auth_ref": [ "r481" ], "lang": { "en-US": { "role": { "documentation": "Information about material and nonrecurring adjustment directly attributable to the business combination(s) included in the reported pro forma revenue and earnings (supplemental pro forma information).", "label": "Nonrecurring Adjustment [Axis]", "terseLabel": "Nonrecurring Adjustment [Axis]" } } }, "localname": "NonrecurringAdjustmentAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/SegmentInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_NonrecurringAdjustmentDomain": { "auth_ref": [ "r481" ], "lang": { "en-US": { "role": { "documentation": "Material, nonrecurring adjustment(s) allocated (included) to (in) reported pro forma revenue and earnings (supplemental pro forma information).", "label": "Nonrecurring Adjustment [Domain]", "terseLabel": "Nonrecurring Adjustment [Domain]" } } }, "localname": "NonrecurringAdjustmentDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/SegmentInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_NotesPayable": { "auth_ref": [ "r53", "r591", "r620" ], "calculation": { "http://www.lilly.com/role/BorrowingsLongTermDebtDetails": { "order": 2.0, "parentTag": "us-gaap_DebtLongtermAndShorttermCombinedAmount", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Including the current and noncurrent portions, aggregate carrying amount of all types of notes payable, as of the balance sheet date, with initial maturities beyond one year or beyond the normal operating cycle, if longer.", "label": "Notes Payable", "terseLabel": "0.15 to 7.13 percent long-term notes (due 2019-2047)" } } }, "localname": "NotesPayable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/BorrowingsLongTermDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NumberOfOperatingSegments": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.", "label": "Number of Operating Segments", "terseLabel": "Number of operating segments" } } }, "localname": "NumberOfOperatingSegments", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/SegmentInformationDetails" ], "xbrltype": "integerItemType" }, "us-gaap_OperatingExpenses": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.", "label": "Operating Expenses", "terseLabel": "Operating expenses" } } }, "localname": "OperatingExpenses", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/SelectedQuarterlyDataUnauditedDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiability": { "auth_ref": [ "r574" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.", "label": "Operating Lease, Liability", "terseLabel": "Operating lease, liability" } } }, "localname": "OperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/ImplementationOfNewFinancialAccountingPronouncementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAsset": { "auth_ref": [ "r573" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's right to use underlying asset under operating lease.", "label": "Operating Lease, Right-of-Use Asset", "netLabel": "Effect of adopting new accounting standard" } } }, "localname": "OperatingLeaseRightOfUseAsset", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/ImplementationOfNewFinancialAccountingPronouncementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent": { "auth_ref": [ "r568", "r570" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Operating Leases, Future Minimum Payments Due, Next Twelve Months", "terseLabel": "2019" } } }, "localname": "OperatingLeasesFutureMinimumPaymentsDueCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/PropertyAndEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears": { "auth_ref": [ "r568", "r570" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Operating Leases, Future Minimum Payments, Due in Five Years", "terseLabel": "2023" } } }, "localname": "OperatingLeasesFutureMinimumPaymentsDueInFiveYears", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/PropertyAndEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears": { "auth_ref": [ "r568", "r570" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Operating Leases, Future Minimum Payments, Due in Four Years", "terseLabel": "2022" } } }, "localname": "OperatingLeasesFutureMinimumPaymentsDueInFourYears", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/PropertyAndEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasesFutureMinimumPaymentsDueInRollingAfterYearFive": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due after the fifth rolling twelve months following the latest balance sheet. For interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Operating Leases, Future Minimum Payments, Due in Rolling after Year Five", "terseLabel": "After 2023" } } }, "localname": "OperatingLeasesFutureMinimumPaymentsDueInRollingAfterYearFive", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/PropertyAndEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears": { "auth_ref": [ "r568", "r570" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Operating Leases, Future Minimum Payments, Due in Three Years", "terseLabel": "2021" } } }, "localname": "OperatingLeasesFutureMinimumPaymentsDueInThreeYears", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/PropertyAndEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears": { "auth_ref": [ "r568", "r570" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Operating Leases, Future Minimum Payments, Due in Two Years", "terseLabel": "2020" } } }, "localname": "OperatingLeasesFutureMinimumPaymentsDueInTwoYears", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/PropertyAndEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLossCarryforwards": { "auth_ref": [ "r465" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.", "label": "Operating Loss Carryforwards", "terseLabel": "Operating loss carryforwards" } } }, "localname": "OperatingLossCarryforwards", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLossCarryforwardsLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Operating Loss Carryforwards [Line Items]", "terseLabel": "Operating Loss Carryforwards [Line Items]" } } }, "localname": "OperatingLossCarryforwardsLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingLossCarryforwardsTable": { "auth_ref": [ "r466" ], "lang": { "en-US": { "role": { "documentation": "Schedule reflecting pertinent information, such as tax authority, amounts, and expiration dates, of net operating loss carryforwards, including an assessment of the likelihood of utilization.", "label": "Operating Loss Carryforwards [Table]", "terseLabel": "Operating Loss Carryforwards [Table]" } } }, "localname": "OperatingLossCarryforwardsTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": { "auth_ref": [ "r28", "r509" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.", "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]", "terseLabel": "Summary of Significant Accounting Policies" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/SummaryOfSignificantAccountingPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_OtherAssetsNoncurrent": { "auth_ref": [ "r76" ], "calculation": { "http://www.lilly.com/role/ConsolidatedBalanceSheets": { "order": 6.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of noncurrent assets classified as other.", "label": "Other Assets, Noncurrent", "terseLabel": "Sundry" } } }, "localname": "OtherAssetsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax": { "auth_ref": [ "r111", "r113", "r388" ], "calculation": { "http://www.lilly.com/role/RetirementBenefitsScheduleOfExpectedBenefitPaymentsContributionsAndExpenseDetails": { "order": 2.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, before tax, of cost (credit) of benefit change attributable to participants' prior service from plan amendment or plan initiation of defined benefit plan, that has not been recognized in net periodic benefit cost (credit).", "label": "Other Comprehensive (Income) Loss, Defined Benefit Plan, Prior Service Cost (Credit), before Tax", "negatedTerseLabel": "Plan amendments during period" } } }, "localname": "OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/RetirementBenefitsScheduleOfExpectedBenefitPaymentsContributionsAndExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax": { "auth_ref": [ "r101", "r113", "r553", "r558", "r560" ], "calculation": { "http://www.lilly.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss": { "order": 4.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossBeforeTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount before tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.", "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Gain (Loss), before Reclassification and Tax", "terseLabel": "Change in foreign currency translation gains (losses)" } } }, "localname": "OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax": { "auth_ref": [ "r113", "r117", "r118", "r388" ], "calculation": { "http://www.lilly.com/role/RetirementBenefitsScheduleOfExpectedBenefitPaymentsContributionsAndExpenseDetails": { "order": 4.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, before tax, of reclassification adjustment from accumulated other comprehensive (income) loss for prior service cost (credit) of defined benefit plan.", "label": "Other Comprehensive (Income) Loss, Defined Benefit Plan, Prior Service Cost (Credit), Reclassification Adjustment from AOCI, before Tax", "terseLabel": "Amortization of prior service (benefit) cost included in net income" } } }, "localname": "OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/RetirementBenefitsScheduleOfExpectedBenefitPaymentsContributionsAndExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax": { "auth_ref": [ "r104", "r105", "r113" ], "calculation": { "http://www.lilly.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss": { "order": 3.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossBeforeTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount before tax, after reclassification adjustments, of appreciation (loss) in value of unsold available-for-sale securities. Excludes amounts related to other than temporary impairment (OTTI) loss.", "label": "Other Comprehensive Income (Loss), Securities, Available-for-sale, Adjustment, before Tax", "terseLabel": "Change in net unrealized gains (losses) on securities" } } }, "localname": "OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax": { "auth_ref": [ "r116", "r126" ], "calculation": { "http://www.lilly.com/role/OtherComprehensiveIncomeLossRollForwardDetails": { "order": 1.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after tax, before reclassification adjustments of other comprehensive income (loss).", "label": "Other Comprehensive Income (Loss), before Reclassifications, Net of Tax", "terseLabel": "Other comprehensive income (loss) before reclassifications" } } }, "localname": "OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/OtherComprehensiveIncomeLossRollForwardDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossBeforeTax": { "auth_ref": [ "r246" ], "calculation": { "http://www.lilly.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss": { "order": 1.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount before tax, after reclassification adjustments of other comprehensive income (loss).", "label": "Other Comprehensive Income (Loss), before Tax", "totalLabel": "Other comprehensive income (loss) from continuing operations before income taxes" } } }, "localname": "OtherComprehensiveIncomeLossBeforeTax", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossBeforeTaxPeriodIncreaseDecreaseAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Other Comprehensive Income (Loss), before Tax [Abstract]", "terseLabel": "Other comprehensive income (loss) from continuing operations:" } } }, "localname": "OtherComprehensiveIncomeLossBeforeTaxPeriodIncreaseDecreaseAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss" ], "xbrltype": "stringItemType" }, "us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesBeforeTax": { "auth_ref": [ "r103" ], "calculation": { "http://www.lilly.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss": { "order": 1.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossBeforeTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount before tax, after reclassification adjustments, of increase (decrease) in accumulated gain (loss) from derivative instruments designated and qualifying as the effective portion of cash flow hedges and an entity's share of an equity investee's increase (decrease) in deferred hedging gain (loss).", "label": "Other Comprehensive Income (Loss), Derivatives Qualifying as Hedges, before Tax", "terseLabel": "Change in effective portion of cash flow hedges" } } }, "localname": "OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesBeforeTax", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossFinalizationOfPensionAndNonPensionPostretirementPlanValuationBeforeTax": { "auth_ref": [ "r113", "r117", "r388" ], "calculation": { "http://www.lilly.com/role/RetirementBenefitsScheduleOfExpectedBenefitPaymentsContributionsAndExpenseDetails": { "order": 6.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, before tax, of increase (decrease) to other comprehensive income from settlement and curtailment gain (loss) of defined benefit plan.", "label": "Other Comprehensive Income (Loss), Defined Benefit Plan, Settlement and Curtailment Gain (Loss), before Tax", "terseLabel": "Curtailment gain (loss)" } } }, "localname": "OtherComprehensiveIncomeLossFinalizationOfPensionAndNonPensionPostretirementPlanValuationBeforeTax", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/RetirementBenefitsScheduleOfExpectedBenefitPaymentsContributionsAndExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax": { "auth_ref": [ "r101", "r113", "r553", "r561" ], "calculation": { "http://www.lilly.com/role/RetirementBenefitsScheduleOfExpectedBenefitPaymentsContributionsAndExpenseDetails": { "order": 3.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount before tax, after reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.", "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, before Tax", "terseLabel": "Foreign currency exchange rate changes and other" } } }, "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/RetirementBenefitsScheduleOfExpectedBenefitPaymentsContributionsAndExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r121", "r124", "r126", "r335" ], "calculation": { "http://www.lilly.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss": { "order": 2.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 }, "http://www.lilly.com/role/OtherComprehensiveIncomeLossRollForwardDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss).", "label": "Other Comprehensive Income (Loss), Net of Tax", "totalLabel": "Net other comprehensive income (loss)" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss", "http://www.lilly.com/role/OtherComprehensiveIncomeLossRollForwardDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest": { "auth_ref": [ "r121", "r124", "r498", "r499", "r502" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount after tax of other comprehensive income (loss) attributable to noncontrolling interests.", "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Noncontrolling Interest", "terseLabel": "Other comprehensive income (loss), non-controlling interest" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/ConsolidatedStatementsOfComprehensiveIncomeLossParenthetical" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent": { "auth_ref": [ "r121", "r124", "r498", "r499", "r502" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after tax of other comprehensive income (loss) attributable to parent entity.", "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent", "terseLabel": "Other comprehensive income (loss), attributed to parent", "verboseLabel": "Other comprehensive income (loss), net of tax" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/ConsolidatedStatementsOfComprehensiveIncomeLossParenthetical", "http://www.lilly.com/role/ConsolidatedStatementsOfShareholdersEquityStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsAndTaxAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Other Comprehensive (Income) Loss, Defined Benefit Plan, before Reclassification Adjustment and Tax [Abstract]", "terseLabel": "Other Comprehensive (Income) Loss, Defined Benefit Plan, before Reclassification Adjustment and Tax [Abstract]" } } }, "localname": "OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsAndTaxAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/RetirementBenefitsScheduleOfExpectedBenefitPaymentsContributionsAndExpenseDetails" ], "xbrltype": "stringItemType" }, "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax": { "auth_ref": [ "r110", "r113" ], "calculation": { "http://www.lilly.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss": { "order": 2.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossBeforeTax", "weight": -1.0 }, "http://www.lilly.com/role/RetirementBenefitsScheduleOfExpectedBenefitPaymentsContributionsAndExpenseDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, before tax, after reclassification adjustment, of (increase) decrease in accumulated other comprehensive income for defined benefit plan.", "label": "Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, before Tax", "negatedLabel": "Change in defined benefit pension and retiree health benefit plans (Note 14)", "negatedTotalLabel": "Total other comprehensive income (loss) during period" } } }, "localname": "OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss", "http://www.lilly.com/role/RetirementBenefitsScheduleOfExpectedBenefitPaymentsContributionsAndExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax": { "auth_ref": [ "r108", "r113", "r388" ], "calculation": { "http://www.lilly.com/role/RetirementBenefitsScheduleOfExpectedBenefitPaymentsContributionsAndExpenseDetails": { "order": 1.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, before tax, of gain (loss) for (increase) decrease in value of benefit obligation for change in actuarial assumptions and increase (decrease) in value of plan assets from experience different from that assumed of defined benefit plan, that has not been recognized in net periodic benefit (cost) credit.", "label": "Other Comprehensive Income (Loss), Defined Benefit Plan, Gain (Loss) Arising During Period, before Tax", "terseLabel": "Actuarial gain (loss) arising during period" } } }, "localname": "OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/RetirementBenefitsScheduleOfExpectedBenefitPaymentsContributionsAndExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossTax": { "auth_ref": [ "r114", "r476", "r478" ], "calculation": { "http://www.lilly.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss": { "order": 2.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of tax expense (benefit) allocated to other comprehensive income (loss).", "label": "Other Comprehensive Income (Loss), Tax", "negatedLabel": "Benefit/(provision) for income taxes allocated to other comprehensive income (loss) items", "negatedNetLabel": "Benefit (provision) for income taxes related to other comprehensive income (loss) from continuing operations" } } }, "localname": "OtherComprehensiveIncomeLossTax", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss", "http://www.lilly.com/role/OtherComprehensiveIncomeLossTaxEffectDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodBeforeTax": { "auth_ref": [ "r103", "r113", "r537" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount before tax of increase (decrease) in accumulated gain (loss) from derivative instruments designated and qualifying as the effective portion of cash flow hedges and an entity's share of an equity investee's increase (decrease) in deferred hedging gain (loss).", "label": "Other Comprehensive Income (Loss), Unrealized Gain (Loss) on Derivatives Arising During Period, before Tax", "terseLabel": "Effective portion of risk-management instruments that was recognized in other comprehensive income (loss) is" } } }, "localname": "OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodBeforeTax", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/FinancialInstrumentsEffectOfRiskManagementDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherContractMember": { "auth_ref": [ "r377", "r529" ], "lang": { "en-US": { "role": { "documentation": "Derivative instrument whose primary underlying risk is classified as other.", "label": "Other Contract [Member]", "terseLabel": "Cash value of trust owned insurance contract" } } }, "localname": "OtherContractMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/RetirementBenefitsFairValueDisclosuresDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OtherDebtSecuritiesMember": { "auth_ref": [ "r240", "r255", "r377", "r542" ], "lang": { "en-US": { "role": { "documentation": "Investments in debt securities classified as other.", "label": "Other Debt Obligations [Member]", "terseLabel": "Other securities" } } }, "localname": "OtherDebtSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/FinancialInstrumentsFairValueMeasurementDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock": { "auth_ref": [ "r356", "r433" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for other income or other expense items (both operating and nonoperating). Sources of nonoperating income or nonoperating expense that may be disclosed, include amounts earned from dividends, interest on securities, profits (losses) on securities, net and miscellaneous other income or income deductions.", "label": "Other Income and Other Expense Disclosure [Text Block]", "terseLabel": "Other - Net, (Income) Expense" } } }, "localname": "OtherIncomeAndOtherExpenseDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/OtherNetIncomeExpense" ], "xbrltype": "textBlockItemType" }, "us-gaap_OtherIntangibleAssetsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Intangible assets classified as other.", "label": "Other Intangible Assets [Member]", "terseLabel": "Other" } } }, "localname": "OtherIntangibleAssetsMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/GoodwillAndOtherIntangiblesIntangiblesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OtherLiabilitiesCurrent": { "auth_ref": [ "r38", "r39", "r82" ], "calculation": { "http://www.lilly.com/role/ConsolidatedBalanceSheets": { "order": 7.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.", "label": "Other Liabilities, Current", "terseLabel": "Other current liabilities" } } }, "localname": "OtherLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherLiabilitiesNoncurrent": { "auth_ref": [ "r86" ], "calculation": { "http://www.lilly.com/role/ConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_LiabilitiesNoncurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.", "label": "Other Liabilities, Noncurrent", "terseLabel": "Other noncurrent liabilities" } } }, "localname": "OtherLiabilitiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherLongTermInvestments": { "auth_ref": [ "r72", "r626" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of long-term investments classified as other.", "label": "Other Long-term Investments", "terseLabel": "Cost and equity method investments" } } }, "localname": "OtherLongTermInvestments", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/FinancialInstrumentsFairValueMeasurementDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNonoperatingIncomeExpense": { "auth_ref": [ "r141" ], "calculation": { "http://www.lilly.com/role/OtherNetIncomeExpenseDetails": { "order": 1.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.", "label": "Other Nonoperating Income (Expense)", "negatedLabel": "Other (income) expense", "negatedTerseLabel": "Other, net (income) expense" } } }, "localname": "OtherNonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/OtherComprehensiveIncomeLossReclassificationDetails", "http://www.lilly.com/role/OtherNetIncomeExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNotesPayable": { "auth_ref": [ "r53", "r591", "r620" ], "calculation": { "http://www.lilly.com/role/BorrowingsLongTermDebtDetails": { "order": 3.0, "parentTag": "us-gaap_DebtLongtermAndShorttermCombinedAmount", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of long-term notes payable classified as other.", "label": "Other Notes Payable", "terseLabel": "Other long-term debt" } } }, "localname": "OtherNotesPayable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/BorrowingsLongTermDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherOperatingActivitiesCashFlowStatement": { "auth_ref": [], "calculation": { "http://www.lilly.com/role/ConsolidatedStatementsOfCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Other cash or noncash adjustments to reconcile net income to cash provided by (used in) operating activities that are not separately disclosed in the statement of cash flows (for example, cash received or cash paid during the current period for miscellaneous operating activities, net change during the reporting period in other assets or other liabilities).", "label": "Other Operating Activities, Cash Flow Statement", "terseLabel": "Other non-cash operating activities, net" } } }, "localname": "OtherOperatingActivitiesCashFlowStatement", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherReceivables": { "auth_ref": [ "r98" ], "calculation": { "http://www.lilly.com/role/ConsolidatedBalanceSheets": { "order": 6.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount due from parties in nontrade transactions, classified as other.", "label": "Other Receivables", "terseLabel": "Other receivables" } } }, "localname": "OtherReceivables", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsForProceedsFromOtherInvestingActivities": { "auth_ref": [ "r145", "r149", "r178" ], "calculation": { "http://www.lilly.com/role/ConsolidatedStatementsOfCashFlows": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of cash (inflow) outflow from investing activities classified as other.", "label": "Payments for (Proceeds from) Other Investing Activities", "negatedLabel": "Other investing activities, net" } } }, "localname": "PaymentsForProceedsFromOtherInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsForProceedsFromShortTermInvestments": { "auth_ref": [ "r143", "r146", "r165" ], "calculation": { "http://www.lilly.com/role/ConsolidatedStatementsOfCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The net amount paid (received) by the reporting entity through acquisition or sale and maturities of short-term investments with an original maturity that is three months or less which qualify for treatment as an investing activity based on management's intention and intended by management to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.", "label": "Payments for (Proceeds from) Short-term Investments", "negatedLabel": "Purchases of short-term investments" } } }, "localname": "PaymentsForProceedsFromShortTermInvestments", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsForRepurchaseOfCommonStock": { "auth_ref": [ "r152" ], "calculation": { "http://www.lilly.com/role/ConsolidatedStatementsOfCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow to reacquire common stock during the period.", "label": "Payments for Repurchase of Common Stock", "negatedTerseLabel": "Purchases of common stock" } } }, "localname": "PaymentsForRepurchaseOfCommonStock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsOfDividends": { "auth_ref": [ "r152" ], "calculation": { "http://www.lilly.com/role/ConsolidatedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Cash outflow in the form of capital distributions and dividends to common shareholders, preferred shareholders and noncontrolling interests.", "label": "Payments of Dividends", "negatedLabel": "Dividends paid" } } }, "localname": "PaymentsOfDividends", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired": { "auth_ref": [ "r147" ], "calculation": { "http://www.lilly.com/role/ConsolidatedStatementsOfCashFlows": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.", "label": "Payments to Acquire Businesses, Net of Cash Acquired", "negatedLabel": "Cash paid for acquisitions, net of cash acquired (Note 3 and 20)", "verboseLabel": "Cash paid for acquisitions, net of cash acquired" } } }, "localname": "PaymentsToAcquireBusinessesNetOfCashAcquired", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/ConsolidatedStatementsOfCashFlows", "http://www.lilly.com/role/DiscontinuedOperationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment": { "auth_ref": [ "r147" ], "calculation": { "http://www.lilly.com/role/ConsolidatedStatementsOfCashFlows": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflows from the purchase of net carrying value allocated to in-process research and development costs and materials acquired in a business combination.", "label": "Payments to Acquire in Process Research and Development", "negatedTerseLabel": "Purchases of in-process research and development" } } }, "localname": "PaymentsToAcquireInProcessResearchAndDevelopment", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireOtherInvestments": { "auth_ref": [ "r149" ], "calculation": { "http://www.lilly.com/role/ConsolidatedStatementsOfCashFlows": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of cash outflow to acquire investments classified as other.", "label": "Payments to Acquire Other Investments", "negatedLabel": "Purchases of noncurrent investments" } } }, "localname": "PaymentsToAcquireOtherInvestments", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireOtherPropertyPlantAndEquipment": { "auth_ref": [ "r148" ], "calculation": { "http://www.lilly.com/role/ConsolidatedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of cash outflow from the acquisition of or improvements to long-lived, physical assets used to produce goods and services and not intended for resale, classified as other.", "label": "Payments to Acquire Other Property, Plant, and Equipment", "negatedLabel": "Purchases of property and equipment" } } }, "localname": "PaymentsToAcquireOtherPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock": { "auth_ref": [ "r414" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for pension and other postretirement benefits.", "label": "Pension and Other Postretirement Benefits Disclosure [Text Block]", "terseLabel": "Retirement Benefits" } } }, "localname": "PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/RetirementBenefits" ], "xbrltype": "textBlockItemType" }, "us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities": { "auth_ref": [ "r52", "r359", "r360", "r374" ], "calculation": { "http://www.lilly.com/role/RetirementBenefitsScheduleOfComponentsInConsolidatedBalanceSheetsDetails": { "order": 1.0, "parentTag": "us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of liability, recognized in statement of financial position, for defined benefit pension and other postretirement plans, classified as current.", "label": "Liability, Defined Benefit Plan, Current", "negatedLabel": "Other current liabilities" } } }, "localname": "PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/RetirementBenefitsScheduleOfComponentsInConsolidatedBalanceSheetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent": { "auth_ref": [ "r55", "r359", "r360", "r374" ], "calculation": { "http://www.lilly.com/role/ConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesNoncurrent", "weight": 1.0 }, "http://www.lilly.com/role/RetirementBenefitsScheduleOfComponentsInConsolidatedBalanceSheetsDetails": { "order": 2.0, "parentTag": "us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of liability, recognized in statement of financial position, for defined benefit pension and other postretirement plans, classified as noncurrent.", "label": "Liability, Defined Benefit Plan, Noncurrent", "negatedNetLabel": "Accrued retirement benefits", "terseLabel": "Accrued retirement benefits (Note 14)" } } }, "localname": "PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/ConsolidatedBalanceSheets", "http://www.lilly.com/role/RetirementBenefitsScheduleOfComponentsInConsolidatedBalanceSheetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PensionPlansDefinedBenefitMember": { "auth_ref": [ "r357", "r396", "r397", "r413" ], "lang": { "en-US": { "role": { "documentation": "Plan designed to provide participant with pension benefits. Includes, but is not limited to, defined benefit and defined contribution plans. Excludes other postretirement benefits.", "label": "Pension Plan [Member]", "terseLabel": "Defined Benefit Pension Plans" } } }, "localname": "PensionPlansDefinedBenefitMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/RetirementBenefitsFairValueDisclosuresDetails", "http://www.lilly.com/role/RetirementBenefitsScheduleOfBenefitObligationsAndPlanAssetsDetails", "http://www.lilly.com/role/RetirementBenefitsScheduleOfComponentsInConsolidatedBalanceSheetsDetails", "http://www.lilly.com/role/RetirementBenefitsScheduleOfExpectedBenefitPaymentsContributionsAndExpenseDetails", "http://www.lilly.com/role/RetirementBenefitsScheduleOfWeightedAverageAssumptionsDetails", "http://www.lilly.com/role/RetirementBenefitsTables" ], "xbrltype": "domainItemType" }, "us-gaap_PerformanceSharesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Share-based payment arrangement awarded for meeting performance target.", "label": "Performance Shares [Member]", "terseLabel": "Performance Shares" } } }, "localname": "PerformanceSharesMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/StockBasedCompensationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PlanAssetCategoriesDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Defined benefit plan asset investment.", "label": "Defined Benefit Plan, Plan Assets, Category [Domain]", "terseLabel": "Defined Benefit Plan, Plan Assets, Category [Domain]" } } }, "localname": "PlanAssetCategoriesDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/RetirementBenefitsFairValueDisclosuresDetails", "http://www.lilly.com/role/RetirementBenefitsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PortionAtFairValueFairValueDisclosureMember": { "auth_ref": [ "r546" ], "lang": { "en-US": { "role": { "documentation": "Measured at fair value for financial reporting purposes.", "label": "Portion at Fair Value Measurement [Member]", "terseLabel": "Portion at Fair Value Measurement" } } }, "localname": "PortionAtFairValueFairValueDisclosureMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/FinancialInstrumentsFairValueMeasurementDetails", "http://www.lilly.com/role/FinancialInstrumentsShortTermAndLongTermClassificationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PortionAtOtherThanFairValueFairValueDisclosureMember": { "auth_ref": [ "r546" ], "lang": { "en-US": { "role": { "documentation": "Not measured at fair value.", "label": "Portion at Other than Fair Value Measurement [Member]", "terseLabel": "Portion at Other than Fair Value Measurement" } } }, "localname": "PortionAtOtherThanFairValueFairValueDisclosureMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/FinancialInstrumentsFairValueMeasurementDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PreferredStockSharesAuthorized": { "auth_ref": [ "r59" ], "lang": { "en-US": { "role": { "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.", "label": "Preferred Stock, Shares Authorized", "terseLabel": "Preferred stock, shares authorized (in shares)" } } }, "localname": "PreferredStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/ShareholdersEquityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesIssued": { "auth_ref": [ "r59" ], "lang": { "en-US": { "role": { "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.", "label": "Preferred Stock, Shares Issued", "terseLabel": "Shares issued (in shares)" } } }, "localname": "PreferredStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/ShareholdersEquityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_PrepaidExpenseCurrent": { "auth_ref": [ "r32", "r34", "r266" ], "calculation": { "http://www.lilly.com/role/ConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.", "label": "Prepaid Expense, Current", "terseLabel": "Prepaid expenses and other" } } }, "localname": "PrepaidExpenseCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfDebt": { "auth_ref": [ "r150" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt.", "label": "Proceeds from Issuance of Debt", "terseLabel": "Proceeds from issuance of debt" } } }, "localname": "ProceedsFromIssuanceOfDebt", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/DiscontinuedOperationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfLongTermDebt": { "auth_ref": [ "r150" ], "calculation": { "http://www.lilly.com/role/ConsolidatedStatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.", "label": "Proceeds from Issuance of Long-term Debt", "terseLabel": "Proceeds from issuance of long-term debt" } } }, "localname": "ProceedsFromIssuanceOfLongTermDebt", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfSecuredDebt": { "auth_ref": [ "r150" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The cash inflow from amounts received from issuance of long-term debt that is wholly or partially secured by collateral. Excludes proceeds from tax exempt secured debt.", "label": "Proceeds from Issuance of Secured Debt", "terseLabel": "Proceeds from issuance of secured debt" } } }, "localname": "ProceedsFromIssuanceOfSecuredDebt", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/BorrowingsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromPaymentsForOtherFinancingActivities": { "auth_ref": [ "r151", "r154", "r178" ], "calculation": { "http://www.lilly.com/role/ConsolidatedStatementsOfCashFlows": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities classified as other.", "label": "Proceeds from (Payments for) Other Financing Activities", "terseLabel": "Other financing activities, net" } } }, "localname": "ProceedsFromPaymentsForOtherFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromRepaymentsOfShortTermDebt": { "auth_ref": [ "r178" ], "calculation": { "http://www.lilly.com/role/ConsolidatedStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The net cash inflow or outflow for borrowing having initial term of repayment within one year or the normal operating cycle, if longer.", "label": "Proceeds from (Repayments of) Short-term Debt", "terseLabel": "Net change in short-term borrowings" } } }, "localname": "ProceedsFromRepaymentsOfShortTermDebt", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments": { "auth_ref": [ "r145" ], "calculation": { "http://www.lilly.com/role/ConsolidatedStatementsOfCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The cash inflow associated with the sale and maturity (principal being due) of other investments, prepayment and call (request of early payment) of other investments not otherwise defined in the taxonomy.", "label": "Proceeds from Sale and Maturity of Other Investments", "terseLabel": "Proceeds from sales of noncurrent investments" } } }, "localname": "ProceedsFromSaleAndMaturityOfOtherInvestments", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromSaleOfOtherPropertyPlantAndEquipment": { "auth_ref": [ "r144" ], "calculation": { "http://www.lilly.com/role/ConsolidatedStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow for the sale of long-lived, physical assets used to produce goods and services and not intended for resale, classified as other.", "label": "Proceeds from Sale of Other Property, Plant, and Equipment", "terseLabel": "Proceeds from disposals of property and equipment" } } }, "localname": "ProceedsFromSaleOfOtherPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromSaleOfShortTermInvestments": { "auth_ref": [ "r145" ], "calculation": { "http://www.lilly.com/role/ConsolidatedStatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The cash inflow from sales of all investments, including securities and other assets, having ready marketability and intended by management to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.", "label": "Proceeds from Sale of Short-term Investments", "terseLabel": "Proceeds from sales and maturities of short-term investments" } } }, "localname": "ProceedsFromSaleOfShortTermInvestments", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProductMember": { "auth_ref": [ "r352" ], "lang": { "en-US": { "role": { "documentation": "Article or substance produced by nature, labor or machinery.", "label": "Product [Member]", "terseLabel": "Net product revenue" } } }, "localname": "ProductMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/SummaryOfSignificantAccountingPoliciesRevenueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ProfitLoss": { "auth_ref": [ "r120", "r123", "r156", "r211", "r217", "r498", "r500", "r501", "r506", "r507" ], "calculation": { "http://www.lilly.com/role/OtherComprehensiveIncomeLossReclassificationDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.", "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest", "negatedTotalLabel": "Net of tax", "terseLabel": "Net income (loss)" } } }, "localname": "ProfitLoss", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/ConsolidatedStatementsOfShareholdersEquityStatement", "http://www.lilly.com/role/OtherComprehensiveIncomeLossReclassificationDetails", "http://www.lilly.com/role/SelectedQuarterlyDataUnauditedDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Property, Plant and Equipment [Abstract]" } } }, "localname": "PropertyPlantAndEquipmentAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "auth_ref": [ "r75", "r293" ], "lang": { "en-US": { "role": { "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.", "label": "Property, Plant and Equipment, Type [Axis]", "terseLabel": "Property, Plant and Equipment by Type [Axis]" } } }, "localname": "PropertyPlantAndEquipmentByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/PropertyAndEquipmentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": { "auth_ref": [ "r300" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, accounting policies and methodology, roll forwards, depreciation, depletion and amortization expense, including composite depreciation, accumulated depreciation, depletion and amortization expense, useful lives and method used, income statement disclosures, assets held for sale and public utility disclosures.", "label": "Property, Plant and Equipment Disclosure [Text Block]", "terseLabel": "Property and Equipment" } } }, "localname": "PropertyPlantAndEquipmentDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/PropertyAndEquipment" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentGross": { "auth_ref": [ "r74", "r291" ], "calculation": { "http://www.lilly.com/role/PropertyAndEquipmentDetails": { "order": 1.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Gross", "totalLabel": "Property and equipment, gross" } } }, "localname": "PropertyPlantAndEquipmentGross", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/PropertyAndEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Property, Plant and Equipment [Line Items]", "terseLabel": "Property, Plant and Equipment [Line Items]" } } }, "localname": "PropertyPlantAndEquipmentLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/PropertyAndEquipmentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentNet": { "auth_ref": [ "r46", "r47", "r293", "r624" ], "calculation": { "http://www.lilly.com/role/ConsolidatedBalanceSheets": { "order": 7.0, "parentTag": "us-gaap_Assets", "weight": 1.0 }, "http://www.lilly.com/role/PropertyAndEquipmentDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Net", "terseLabel": "Property and equipment, net (Note 9)", "totalLabel": "Property and equipment, net" } } }, "localname": "PropertyPlantAndEquipmentNet", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/ConsolidatedBalanceSheets", "http://www.lilly.com/role/PropertyAndEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": { "auth_ref": [ "r73", "r167", "r293" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, basis of assets, depreciation and depletion methods used, including composite deprecation, estimated useful lives, capitalization policy, accounting treatment for costs incurred for repairs and maintenance, capitalized interest and the method it is calculated, disposals and impairments.", "label": "Property, Plant and Equipment, Policy [Policy Text Block]", "terseLabel": "Property, Plant and Equipment" } } }, "localname": "PropertyPlantAndEquipmentPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/PropertyAndEquipmentPolicies", "http://www.lilly.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentTextBlock": { "auth_ref": [ "r46", "r293" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Property, Plant and Equipment [Table Text Block]", "terseLabel": "Property, Plant and Equipment" } } }, "localname": "PropertyPlantAndEquipmentTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/PropertyAndEquipmentTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "auth_ref": [ "r46", "r291" ], "lang": { "en-US": { "role": { "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.", "label": "Property, Plant and Equipment, Type [Domain]", "terseLabel": "Property, Plant and Equipment, Type [Domain]" } } }, "localname": "PropertyPlantAndEquipmentTypeDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/PropertyAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PropertyPlantAndEquipmentUsefulLife": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.", "label": "Property, Plant and Equipment, Useful Life", "terseLabel": "Estimated useful life (in years)" } } }, "localname": "PropertyPlantAndEquipmentUsefulLife", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/PropertyAndEquipmentDetails" ], "xbrltype": "durationItemType" }, "us-gaap_QuarterlyFinancialInformationDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Quarterly Financial Information Disclosure [Abstract]" } } }, "localname": "QuarterlyFinancialInformationDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_QuarterlyFinancialInformationTextBlock": { "auth_ref": [ "r200" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for quarterly financial data. Includes, but is not limited to, tabular presentation of financial information for fiscal quarters, effect of year-end adjustments, and an explanation of matters or transactions that affect comparability of the information.", "label": "Quarterly Financial Information [Text Block]", "terseLabel": "Selected Quarterly Data (Unaudited)" } } }, "localname": "QuarterlyFinancialInformationTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/SelectedQuarterlyDataUnaudited" ], "xbrltype": "textBlockItemType" }, "us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]", "terseLabel": "Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]" } } }, "localname": "ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/OtherComprehensiveIncomeLossReclassificationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax": { "auth_ref": [ "r116", "r119", "r126" ], "calculation": { "http://www.lilly.com/role/OtherComprehensiveIncomeLossRollForwardDetails": { "order": 2.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount after tax of reclassification adjustments of other comprehensive income (loss).", "label": "Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax", "negatedTerseLabel": "Net amount reclassified from accumulated other comprehensive loss" } } }, "localname": "ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/OtherComprehensiveIncomeLossRollForwardDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]", "terseLabel": "AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]" } } }, "localname": "ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/OtherComprehensiveIncomeLossRollForwardDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by item reclassified out of accumulated other comprehensive income (loss).", "label": "Reclassification out of Accumulated Other Comprehensive Income [Axis]", "terseLabel": "Reclassification out of Accumulated Other Comprehensive Income [Axis]" } } }, "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/OtherComprehensiveIncomeLossReclassificationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Item reclassified out of accumulated other comprehensive income (loss).", "label": "Reclassification out of Accumulated Other Comprehensive Income [Domain]", "terseLabel": "Reclassification out of Accumulated Other Comprehensive Income [Domain]" } } }, "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/OtherComprehensiveIncomeLossReclassificationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Identifies item reclassified out of accumulated other comprehensive income (loss).", "label": "Reclassification out of Accumulated Other Comprehensive Income [Member]", "terseLabel": "Reclassification out of Accumulated Other Comprehensive Income" } } }, "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/OtherComprehensiveIncomeLossReclassificationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about items reclassified out of accumulated other comprehensive income (loss).", "label": "Reclassification out of Accumulated Other Comprehensive Income [Table]", "terseLabel": "Reclassification out of Accumulated Other Comprehensive Income [Table]" } } }, "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/OtherComprehensiveIncomeLossReclassificationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of information about items reclassified out of accumulated other comprehensive income (loss).", "label": "Reclassification out of Accumulated Other Comprehensive Income [Table Text Block]", "terseLabel": "Schedule of Amounts Recognized in Other Comprehensive Income (Loss)" } } }, "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/OtherComprehensiveIncomeLossTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock": { "auth_ref": [ "r213", "r215" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the reconciliation of profit (loss) from reportable segments to the consolidated income (loss) before income tax expense (benefit) and discontinued operations. Includes, but is not limited to, reconciliation after income tax if income tax is allocated to the reportable segment.", "label": "Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table Text Block]", "terseLabel": "Reconciliation of Operating Profit (Loss) from Segments to Consolidated" } } }, "localname": "ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/SegmentInformationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]", "terseLabel": "Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]" } } }, "localname": "ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/IncomeTaxesUnrecognizedBenefitsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RepaymentsOfLongTermDebt": { "auth_ref": [ "r153" ], "calculation": { "http://www.lilly.com/role/ConsolidatedStatementsOfCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.", "label": "Repayments of Long-term Debt", "negatedLabel": "Repayments of long-term debt" } } }, "localname": "RepaymentsOfLongTermDebt", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpense": { "auth_ref": [ "r434", "r643" ], "calculation": { "http://www.lilly.com/role/ConsolidatedStatementsOfOperations": { "order": 2.0, "parentTag": "lly_CostOfSalesOperatingExpensesAndOtherNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.", "label": "Research and Development Expense", "terseLabel": "Research and development" } } }, "localname": "ResearchAndDevelopmentExpense", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/CollaborationsAndOtherArrangementsDetails", "http://www.lilly.com/role/ConsolidatedStatementsOfOperations", "http://www.lilly.com/role/ImplementationOfNewFinancialAccountingPronouncementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpensePolicy": { "auth_ref": [ "r167", "r434" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.", "label": "Research and Development Expense, Policy [Policy Text Block]", "terseLabel": "Research and Development Expense" } } }, "localname": "ResearchAndDevelopmentExpensePolicy", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_RestrictedStockUnitsRSUMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.", "label": "Restricted Stock Units (RSUs) [Member]", "terseLabel": "Restricted Stock Units (RSUs)" } } }, "localname": "RestrictedStockUnitsRSUMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/StockBasedCompensationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RestructuringAndRelatedActivitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Restructuring and Related Activities [Abstract]" } } }, "localname": "RestructuringAndRelatedActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_RestructuringCostAndReserveLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Restructuring Cost and Reserve [Line Items]", "terseLabel": "Restructuring Cost and Reserve [Line Items]" } } }, "localname": "RestructuringCostAndReserveLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/AssetImpairmentRestructuringAndOtherSpecialChargesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RestructuringImpairmentAndOtherActivitiesDisclosureTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The entire disclosure of costs incurred for restructuring including, but not limited to, exit and disposal activities, remediation, implementation, integration, asset impairment, and charges against earnings from the write-down of assets.", "label": "Restructuring, Impairment, and Other Activities Disclosure [Text Block]", "terseLabel": "Asset Impairment, Restructuring, And Other Special Charges" } } }, "localname": "RestructuringImpairmentAndOtherActivitiesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/AssetImpairmentRestructuringAndOtherSpecialCharges" ], "xbrltype": "textBlockItemType" }, "us-gaap_RestructuringSettlementAndImpairmentProvisions": { "auth_ref": [ "r137" ], "calculation": { "http://www.lilly.com/role/AssetImpairmentRestructuringAndOtherSpecialChargesDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.lilly.com/role/ConsolidatedStatementsOfOperations": { "order": 5.0, "parentTag": "lly_CostOfSalesOperatingExpensesAndOtherNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of restructuring charges, remediation cost, and asset impairment loss.", "label": "Restructuring, Settlement and Impairment Provisions", "terseLabel": "Asset impairment, restructuring, and other special charges (Note 5)", "totalLabel": "Asset impairment, restructuring, and other special charges" } } }, "localname": "RestructuringSettlementAndImpairmentProvisions", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/AssetImpairmentRestructuringAndOtherSpecialChargesDetails", "http://www.lilly.com/role/ConsolidatedStatementsOfOperations", "http://www.lilly.com/role/SelectedQuarterlyDataUnauditedDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r63", "r342", "r621" ], "calculation": { "http://www.lilly.com/role/ConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings (Accumulated Deficit)", "terseLabel": "Retained earnings" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/ConsolidatedBalanceSheets", "http://www.lilly.com/role/ImplementationOfNewFinancialAccountingPronouncementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings [Member]", "terseLabel": "Retained Earnings" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/ConsolidatedStatementsOfShareholdersEquityStatement" ], "xbrltype": "domainItemType" }, "us-gaap_RetirementPlanTypeAxis": { "auth_ref": [ "r357", "r358", "r396", "r397", "r413" ], "lang": { "en-US": { "role": { "documentation": "Information by type of retirement benefit plan. Includes, but is not limited to, retirement benefit arrangement for defined benefit pension and other postretirement plans, retirement benefit arrangement for defined contribution pension and other postretirement plans, and special and contractual termination benefits payable upon retirement.", "label": "Retirement Plan Type [Axis]", "terseLabel": "Retirement Plan Type [Axis]" } } }, "localname": "RetirementPlanTypeAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/RetirementBenefitsFairValueDisclosuresDetails", "http://www.lilly.com/role/RetirementBenefitsScheduleOfBenefitObligationsAndPlanAssetsDetails", "http://www.lilly.com/role/RetirementBenefitsScheduleOfComponentsInConsolidatedBalanceSheetsDetails", "http://www.lilly.com/role/RetirementBenefitsScheduleOfExpectedBenefitPaymentsContributionsAndExpenseDetails", "http://www.lilly.com/role/RetirementBenefitsScheduleOfWeightedAverageAssumptionsDetails", "http://www.lilly.com/role/RetirementBenefitsTables" ], "xbrltype": "stringItemType" }, "us-gaap_RetirementPlanTypeDomain": { "auth_ref": [ "r357", "r358", "r396", "r397", "r413" ], "lang": { "en-US": { "role": { "documentation": "Type of plan designed to provide participants with retirement benefits. Includes, but is not limited to, retirement benefit arrangement for defined benefit pension and other postretirement plans, retirement benefit arrangement for defined contribution pension and other postretirement plans, and special and contractual termination benefits payable upon retirement.", "label": "Retirement Plan Type [Domain]", "terseLabel": "Retirement Plan Type [Domain]" } } }, "localname": "RetirementPlanTypeDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/RetirementBenefitsFairValueDisclosuresDetails", "http://www.lilly.com/role/RetirementBenefitsScheduleOfBenefitObligationsAndPlanAssetsDetails", "http://www.lilly.com/role/RetirementBenefitsScheduleOfComponentsInConsolidatedBalanceSheetsDetails", "http://www.lilly.com/role/RetirementBenefitsScheduleOfExpectedBenefitPaymentsContributionsAndExpenseDetails", "http://www.lilly.com/role/RetirementBenefitsScheduleOfWeightedAverageAssumptionsDetails", "http://www.lilly.com/role/RetirementBenefitsTables" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueRecognitionPolicyTextBlock": { "auth_ref": [ "r168", "r169" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.", "label": "Revenue [Policy Text Block]", "terseLabel": "Revenue Recognition" } } }, "localname": "RevenueRecognitionPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_Revenues": { "auth_ref": [ "r130", "r205", "r206", "r216" ], "calculation": { "http://www.lilly.com/role/ConsolidatedStatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).", "label": "Revenues", "terseLabel": "Revenue" } } }, "localname": "Revenues", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/CollaborationsAndOtherArrangementsDetails", "http://www.lilly.com/role/ConsolidatedStatementsOfOperations", "http://www.lilly.com/role/DiscontinuedOperationsDiscontinuedOperationsInFinancialStatementsDetails", "http://www.lilly.com/role/SegmentInformationDetails", "http://www.lilly.com/role/SelectedQuarterlyDataUnauditedDetails", "http://www.lilly.com/role/SummaryOfSignificantAccountingPoliciesRevenueDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RoyaltyAgreementTermsMember": { "auth_ref": [ "r435", "r436" ], "lang": { "en-US": { "role": { "documentation": "Terms of the royalty agreement under research and development arrangements.", "label": "Royalty Agreement Terms [Member]", "terseLabel": "Royalty Payments Received" } } }, "localname": "RoyaltyAgreementTermsMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/CollaborationsAndOtherArrangementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RoyaltyMember": { "auth_ref": [ "r352" ], "lang": { "en-US": { "role": { "documentation": "Money for usage-based right to asset.", "label": "Royalty [Member]", "terseLabel": "Royalty" } } }, "localname": "RoyaltyMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/SummaryOfSignificantAccountingPoliciesRevenueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SaleOfStockNameOfTransactionDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.", "label": "Sale of Stock [Domain]", "terseLabel": "Sale of Stock [Domain]" } } }, "localname": "SaleOfStockNameOfTransactionDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/SummaryOfSignificantAccountingPoliciesAcquisitionsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.", "label": "Sale of Stock, Number of Shares Issued in Transaction", "terseLabel": "Initial public offering (in shares)" } } }, "localname": "SaleOfStockNumberOfSharesIssuedInTransaction", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/DiscontinuedOperationsDetails", "http://www.lilly.com/role/SummaryOfSignificantAccountingPoliciesAcquisitionsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_SaleOfStockPricePerShare": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.", "label": "Sale of Stock, Price Per Share", "terseLabel": "Sale of stock, price per share (usd per share)" } } }, "localname": "SaleOfStockPricePerShare", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/DiscontinuedOperationsDetails", "http://www.lilly.com/role/SummaryOfSignificantAccountingPoliciesAcquisitionsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_SalesRevenueNetMember": { "auth_ref": [ "r202" ], "lang": { "en-US": { "role": { "documentation": "Revenue from sale of product and rendering of service and other sources of income, when it serves as benchmark in concentration of risk calculation.", "label": "Revenue Benchmark [Member]", "terseLabel": "Sales Revenue, Goods, Net" } } }, "localname": "SalesRevenueNetMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/SegmentInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ScheduleOfAccumulatedBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock": { "auth_ref": [ "r398", "r399", "r410" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of benefit obligation and plan assets of defined benefit plan with accumulated benefit obligation in excess of plan assets.", "label": "Defined Benefit Plan, Plan with Accumulated Benefit Obligation in Excess of Plan Assets [Table Text Block]", "terseLabel": "Schedule of Accumulated Benefit Obligations in Excess of Fair Value of Plan Assets" } } }, "localname": "ScheduleOfAccumulatedBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/RetirementBenefitsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock": { "auth_ref": [ "r116" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the components of accumulated other comprehensive income (loss).", "label": "Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]", "terseLabel": "Schedule of Accumulated Other Comprehensive Income (Loss)" } } }, "localname": "ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/OtherComprehensiveIncomeLossTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAllocationOfPlanAssetsTableTextBlock": { "auth_ref": [ "r375" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the major categories of plan assets of pension plans and/or other employee benefit plans. This information may include, but is not limited to, the target allocation of plan assets, the fair value of each major category of plan assets, and the level within the fair value hierarchy in which the fair value measurements fall.", "label": "Schedule of Allocation of Plan Assets [Table Text Block]", "terseLabel": "Schedule of Allocation of Plan Assets" } } }, "localname": "ScheduleOfAllocationOfPlanAssetsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/RetirementBenefitsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAmountsRecognizedInBalanceSheetTableTextBlock": { "auth_ref": [ "r374" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the amounts that are recognized in the balance sheet (or statement of financial position) for pension plans and/or other employee benefit plans, showing separately the assets and current and noncurrent liabilities (if applicable) recognized.", "label": "Schedule of Amounts Recognized in Balance Sheet [Table Text Block]", "terseLabel": "Schedule of Amounts Recognized in Balance Sheet" } } }, "localname": "ScheduleOfAmountsRecognizedInBalanceSheetTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/RetirementBenefitsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock": { "auth_ref": [ "r388" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the net gain (loss) and net prior service cost or credit recognized in other comprehensive income (loss) for the period for pension plans and/or other employee benefit plans, and reclassification adjustments of other comprehensive income (loss) for the period, as those amounts, including amortization of the net transition asset or obligation, are recognized as components of net periodic benefit cost.", "label": "Schedule of Amounts Recognized in Other Comprehensive Income (Loss) [Table Text Block]", "terseLabel": "Schedule of Amounts Recognized in Other Comprehensive Income (Loss)" } } }, "localname": "ScheduleOfAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/RetirementBenefitsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAssumptionsUsedTableTextBlock": { "auth_ref": [ "r391" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of assumption used to determine benefit obligation and net periodic benefit cost of defined benefit plan. Includes, but is not limited to, discount rate, rate of compensation increase, expected long-term rate of return on plan assets and interest crediting rate.", "label": "Defined Benefit Plan, Assumptions [Table Text Block]", "terseLabel": "Schedule of Assumptions Used" } } }, "localname": "ScheduleOfAssumptionsUsedTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/RetirementBenefitsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock": { "auth_ref": [ "r398", "r410" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of benefit obligation and plan assets for defined benefit pension plan with projected benefit obligation in excess of plan assets.", "label": "Defined Benefit Plan, Plan with Projected Benefit Obligation in Excess of Plan Assets [Table Text Block]", "terseLabel": "Schedule of Benefit Obligations in Excess of Fair Value of Plan Assets" } } }, "localname": "ScheduleOfBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/RetirementBenefitsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": { "auth_ref": [ "r482", "r483" ], "lang": { "en-US": { "role": { "documentation": "Schedule reflecting each material business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities.", "label": "Schedule of Business Acquisitions, by Acquisition [Table]", "terseLabel": "Schedule of Business Acquisitions, by Acquisition [Table]" } } }, "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/NarrativeDetails", "http://www.lilly.com/role/SummaryOfSignificantAccountingPoliciesAcquisitionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfChangesInAccumulatedPostemploymentBenefitObligationsTableTextBlock": { "auth_ref": [ "r361" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the change in the accumulated postemployment benefit obligation from the beginning to the end of the period, showing separately, if applicable, the effects of the following: service cost, interest cost, contributions by plan participants, actuarial gains and losses, foreign currency exchange rate changes, benefits paid, plan amendments, business combinations, divestitures, curtailments, settlements, and special and contractual termination benefits.", "label": "Schedule of Changes in Accumulated Postemployment Benefit Obligations [Table Text Block]", "terseLabel": "Schedule of Changes in Accumulated Postemployment Benefit Obligations" } } }, "localname": "ScheduleOfChangesInAccumulatedPostemploymentBenefitObligationsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/RetirementBenefitsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfChangesInFairValueOfPlanAssetsTableTextBlock": { "auth_ref": [ "r369" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the reconciliation of beginning and ending balances of the fair value of plan assets of pension plans and/or other employee benefit plans showing separately, if applicable, the effects during the period attributable to each of the following: actual return on plan assets, foreign currency exchange rate changes, contributions by the employer, contributions by plan participants, benefits paid, business combinations, divestitures, and settlements.", "label": "Schedule of Changes in Fair Value of Plan Assets [Table Text Block]", "terseLabel": "Schedule of Changes in Fair Value of Plan Assets" } } }, "localname": "ScheduleOfChangesInFairValueOfPlanAssetsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/RetirementBenefitsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": { "auth_ref": [ "r494" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]", "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]" } } }, "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/CollaborationsAndOtherArrangementsDetails", "http://www.lilly.com/role/CollaborationsAndOtherArrangementsTables" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock": { "auth_ref": [ "r494" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table Text Block]", "terseLabel": "Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions" } } }, "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/CollaborationsAndOtherArrangementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": { "auth_ref": [ "r471" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.", "label": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]", "terseLabel": "Schedule of Components of Income Tax Expense (Benefit)" } } }, "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/IncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDebtTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation.", "label": "Schedule of Debt [Table Text Block]", "terseLabel": "Schedule of Debt" } } }, "localname": "ScheduleOfDebtTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/BorrowingsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": { "auth_ref": [ "r463" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.", "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]", "terseLabel": "Schedule of Deferred Tax Assets and Liabilities" } } }, "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/IncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable": { "auth_ref": [ "r396", "r397", "r400", "r401", "r410" ], "lang": { "en-US": { "role": { "documentation": "Disclosures about an individual defined benefit pension plan or an other postretirement defined benefit plan. It may be appropriate to group certain similar plans. Also includes schedule for fair value of plan assets by major categories of plan assets by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets or liabilities (Level 1), Significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).", "label": "Schedule of Defined Benefit Plans Disclosures [Table]", "terseLabel": "Schedule of Defined Benefit Plans Disclosures [Table]" } } }, "localname": "ScheduleOfDefinedBenefitPlansDisclosuresTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/RetirementBenefitsNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfDerivativeInstrumentsEffectOnOtherComprehensiveIncomeLossTableTextBlock": { "auth_ref": [ "r523" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the effective portion of the gains and losses on derivative instruments designated (and non-derivative instruments) designated and qualifying in cash flow hedges and net investment hedges that was recognized in other comprehensive income (loss) during the current period.", "label": "Schedule of Derivative Instruments, Effect on Other Comprehensive Income (Loss) [Table Text Block]", "terseLabel": "Schedule of Derivative Instruments, Effect on Other Comprehensive Income (Loss)" } } }, "localname": "ScheduleOfDerivativeInstrumentsEffectOnOtherComprehensiveIncomeLossTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/FinancialInstrumentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock": { "auth_ref": [ "r520" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of derivative instruments (including nonderivative instruments that are designated and qualify as hedging instruments) of (a) the location and amount of gains and losses reported in the statement of financial performance and (b) the location and fair value amounts of the instruments reported in the statement of financial position.", "label": "Schedule of Derivatives Instruments Statements of Financial Performance and Financial Position, Location [Table Text Block]", "terseLabel": "Schedule of Derivatives Instruments Statements of Financial Performance and Financial Position, Location" } } }, "localname": "ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/FinancialInstrumentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock": { "auth_ref": [ "r1", "r13", "r14", "r15", "r16", "r17", "r18", "r21", "r24", "r25", "r26", "r298", "r299" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of information related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.", "label": "Disposal Groups, Including Discontinued Operations [Table Text Block]", "terseLabel": "Disposal Groups, Including Discontinued Operations" } } }, "localname": "ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/DiscontinuedOperationsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": { "auth_ref": [ "r444" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.", "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]", "terseLabel": "Schedule of Effective Income Tax Rate Reconciliation" } } }, "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/IncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfExpectedBenefitPaymentsTableTextBlock": { "auth_ref": [ "r380" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of benefits expected to be paid by pension plans and/or other employee benefit plans in each of the next five fiscal years and in the aggregate for the five fiscal years thereafter.", "label": "Schedule of Expected Benefit Payments [Table Text Block]", "terseLabel": "Schedule of Expected Benefit Payments" } } }, "localname": "ScheduleOfExpectedBenefitPaymentsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/RetirementBenefitsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": { "auth_ref": [ "r275", "r280" ], "lang": { "en-US": { "role": { "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Schedule of Finite-Lived Intangible Assets [Table]", "terseLabel": "Schedule of Finite-Lived Intangible Assets by Major Class [Table]" } } }, "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/GoodwillAndOtherIntangiblesIntangiblesDetails", "http://www.lilly.com/role/GoodwillAndOtherIntangiblesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": { "auth_ref": [ "r275", "r280" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.", "label": "Schedule of Finite-Lived Intangible Assets [Table Text Block]", "terseLabel": "Schedule of Intangible Assets and Goodwill" } } }, "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/GoodwillAndOtherIntangiblesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock": { "auth_ref": [ "r571" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of future minimum payments required in the aggregate and for each of the five succeeding fiscal years for operating leases having initial or remaining noncancelable lease terms in excess of one year and the total minimum rentals to be received in the future under noncancelable subleases as of the balance sheet date.", "label": "Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]", "terseLabel": "Schedule of Future Minimum Rental Payments for Operating Leases" } } }, "localname": "ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/PropertyAndEquipmentTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": { "auth_ref": [ "r41", "r68", "r69", "r70" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.", "label": "Schedule of Inventory, Current [Table Text Block]", "terseLabel": "Schedule of Inventory" } } }, "localname": "ScheduleOfInventoryCurrentTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/InventoriesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock": { "auth_ref": [ "r325" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the combined aggregate amount of maturities and sinking fund requirements for all long-term borrowings for each of the five years following the date of the latest balance sheet date presented.", "label": "Schedule of Maturities of Long-term Debt [Table Text Block]", "terseLabel": "Schedule of Maturities of Long-term Debt" } } }, "localname": "ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/BorrowingsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfNetBenefitCostsTableTextBlock": { "auth_ref": [ "r381" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the components of net benefit costs for pension plans and/or other employee benefit plans including service cost, interest cost, expected return on plan assets, gain (loss), prior service cost or credit, transition asset or obligation, and gain (loss) recognized due to settlements or curtailments.", "label": "Schedule of Net Benefit Costs [Table Text Block]", "terseLabel": "Schedule of Net Benefit Costs" } } }, "localname": "ScheduleOfNetBenefitCostsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/RetirementBenefitsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfNetFundedStatusTableTextBlock": { "auth_ref": [ "r374" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of net funded status of pension plans and/or other employee benefit plans.", "label": "Schedule of Net Funded Status [Table Text Block]", "terseLabel": "Schedule of Net Funded Status" } } }, "localname": "ScheduleOfNetFundedStatusTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/RetirementBenefitsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock": { "auth_ref": [ "r180", "r182", "r195", "r196", "r199" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of changes in accounting principles, including adoption of new accounting pronouncements, that describes the new methods, amount and effects on financial statement line items.", "label": "Schedule of New Accounting Pronouncements and Changes in Accounting Principles [Table Text Block]", "terseLabel": "Schedule of New Accounting Pronouncements and Changes in Accounting Principles" } } }, "localname": "ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/ImplementationOfNewFinancialAccountingPronouncementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the components of non-operating income or non-operating expense that may include amounts earned from dividends, interest on securities, gains (losses) on securities sold, equity earnings of unconsolidated affiliates, net gain (loss) on sales of business, interest expense and other miscellaneous income or expense items.", "label": "Schedule of Other Nonoperating Income (Expense) [Table Text Block]", "terseLabel": "Schedule of Other Nonoperating Income (Expense)" } } }, "localname": "ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/OtherNetIncomeExpenseTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": { "auth_ref": [ "r75", "r293" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Property, Plant and Equipment [Table]", "terseLabel": "Property, Plant and Equipment [Table]" } } }, "localname": "ScheduleOfPropertyPlantAndEquipmentTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/PropertyAndEquipmentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock": { "auth_ref": [ "r198" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of quarterly financial data. Includes, but is not limited to, financial information for fiscal quarters, cumulative effect of a change in accounting principle and earnings per share data.", "label": "Quarterly Financial Information [Table Text Block]", "terseLabel": "Schedule of Quarterly Financial Information" } } }, "localname": "ScheduleOfQuarterlyFinancialInformationTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/SelectedQuarterlyDataUnauditedTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfRentExpenseTableTextBlock": { "auth_ref": [ "r569" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of rental expense from operating leases for each period for which an income statement is presented with separate amounts for minimum rentals, contingent rentals, and sublease rentals. Rental payments under leases with terms of a month or less that were not renewed need not be included.", "label": "Schedule of Rent Expense [Table Text Block]", "terseLabel": "Schedule of Rent Expense" } } }, "localname": "ScheduleOfRentExpenseTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/PropertyAndEquipmentTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationTextBlock": { "auth_ref": [ "r276" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the nature and amounts of capitalized costs of a research and development nature that were acquired in a transaction other than a business combination, the amount of such assets charged to expense during the period, and identification of the income statement caption in which the charges are included.", "label": "Schedule of Research and Development Assets Acquired Other than Through Business Combination [Table Text Block]", "terseLabel": "Schedule of Research and Development Assets Acquired Other than Through Business Combination" } } }, "localname": "ScheduleOfResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/AcquisitionsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfRestructuringAndRelatedCostsTable": { "auth_ref": [ "r303", "r304", "r306" ], "lang": { "en-US": { "role": { "documentation": "Table presenting the description of the restructuring costs, such as the expected cost; the costs incurred during the period; the cumulative costs incurred as of the balance sheet date; the income statement caption within which the restructuring charges recognized for the period are included; and the amount of and periodic changes to an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost by type of restructuring.", "label": "Schedule of Restructuring and Related Costs [Table]", "terseLabel": "Schedule of Restructuring and Related Costs [Table]" } } }, "localname": "ScheduleOfRestructuringAndRelatedCostsTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/AssetImpairmentRestructuringAndOtherSpecialChargesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock": { "auth_ref": [ "r303", "r304", "r306" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of costs incurred for restructuring including, but not limited to, exit and disposal activities, remediation, implementation, integration, asset impairment, and charges against earnings from the write-down of assets.", "label": "Restructuring and Related Costs [Table Text Block]", "terseLabel": "Schedule of Other Operating Cost and Expense, by Component" } } }, "localname": "ScheduleOfRestructuringAndRelatedCostsTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/AssetImpairmentRestructuringAndOtherSpecialChargesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock": { "auth_ref": [ "r135", "r220" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of information concerning material long-lived assets (excluding financial instruments, customer relationships with financial institutions, mortgage and other servicing rights, deferred policy acquisition costs, and deferred taxes assets) located in identified geographic areas and/or the amount of revenue from external customers attributed to that country from which revenue is material. An entity may also provide subtotals of geographic information about groups of countries.", "label": "Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas [Table Text Block]", "terseLabel": "Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas" } } }, "localname": "ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/SegmentInformationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": { "auth_ref": [ "r204", "r211", "r212", "r214", "r271" ], "lang": { "en-US": { "role": { "documentation": "A table disclosing the profit or loss and total assets for each reportable segment of the entity. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.", "label": "Schedule of Segment Reporting Information, by Segment [Table]", "terseLabel": "Schedule of Segment Reporting Information, by Segment [Table]" } } }, "localname": "ScheduleOfSegmentReportingInformationBySegmentTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/SegmentInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "auth_ref": [ "r418", "r429" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about share-based payment arrangement.", "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]", "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]" } } }, "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/StockBasedCompensationDetails", "http://www.lilly.com/role/StockBasedCompensationTables" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfStockByClassTable": { "auth_ref": [ "r88", "r172", "r332", "r333", "r334", "r336", "r337", "r338", "r339", "r340", "r341", "r342" ], "lang": { "en-US": { "role": { "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.", "label": "Schedule of Stock by Class [Table]", "terseLabel": "Schedule of Stock by Class [Table]" } } }, "localname": "ScheduleOfStockByClassTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/ShareholdersEquityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock": { "auth_ref": [ "r280" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.", "label": "Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]", "terseLabel": "Schedule of Finite-Lived Intangible Assets, Future Amortization Expense" } } }, "localname": "ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/GoodwillAndOtherIntangiblesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_SegmentContinuingOperationsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Component of an entity expected to operate in the foreseeable future.", "label": "Continuing Operations [Member]", "terseLabel": "Continuing Operations" } } }, "localname": "SegmentContinuingOperationsMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss", "http://www.lilly.com/role/OtherComprehensiveIncomeLossRollForwardDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SegmentDiscontinuedOperationsMember": { "auth_ref": [ "r2", "r4", "r5", "r6" ], "lang": { "en-US": { "role": { "documentation": "Component or group of components disposed of or classified as held-for-sale and representing a strategic shift that has or will have a major effect on operations and financial results. Includes a business or nonprofit activity on acquisition classified as held-for-sale.", "label": "Discontinued Operations [Member]", "terseLabel": "Discontinued Operations" } } }, "localname": "SegmentDiscontinuedOperationsMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss", "http://www.lilly.com/role/OtherComprehensiveIncomeLossRollForwardDetails", "http://www.lilly.com/role/RetirementBenefitsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SegmentDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.", "label": "Segments [Domain]", "terseLabel": "Segments [Domain]" } } }, "localname": "SegmentDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/CollaborationsAndOtherArrangementsDetails", "http://www.lilly.com/role/GoodwillAndOtherIntangiblesNarrativeDetails", "http://www.lilly.com/role/SegmentInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SegmentOperatingActivitiesDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Operations of an entity including continuing and discontinued operations.", "label": "Operating Activities [Domain]", "terseLabel": "Operating Activities [Domain]" } } }, "localname": "SegmentOperatingActivitiesDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss", "http://www.lilly.com/role/OtherComprehensiveIncomeLossRollForwardDetails", "http://www.lilly.com/role/RetirementBenefitsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SegmentReportingAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Segment Reporting [Abstract]" } } }, "localname": "SegmentReportingAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_SegmentReportingDisclosureTextBlock": { "auth_ref": [ "r221" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.", "label": "Segment Reporting Disclosure [Text Block]", "terseLabel": "Segment Information" } } }, "localname": "SegmentReportingDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/SegmentInformation" ], "xbrltype": "textBlockItemType" }, "us-gaap_SegmentReportingInformationLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Segment Reporting Information [Line Items]", "terseLabel": "Segment Reporting Information [Line Items]" } } }, "localname": "SegmentReportingInformationLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/SegmentInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SellingGeneralAndAdministrativeExpense": { "auth_ref": [ "r138", "r261" ], "calculation": { "http://www.lilly.com/role/ConsolidatedStatementsOfOperations": { "order": 3.0, "parentTag": "lly_CostOfSalesOperatingExpensesAndOtherNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.", "label": "Selling, General and Administrative Expense", "terseLabel": "Marketing, selling, and administrative" } } }, "localname": "SellingGeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/ConsolidatedStatementsOfOperations", "http://www.lilly.com/role/ImplementationOfNewFinancialAccountingPronouncementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SeveranceCosts1": { "auth_ref": [ "r162", "r301", "r305", "r307" ], "calculation": { "http://www.lilly.com/role/AssetImpairmentRestructuringAndOtherSpecialChargesDetails": { "order": 1.0, "parentTag": "us-gaap_RestructuringSettlementAndImpairmentProvisions", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of expenses for special or contractual termination benefits provided to current employees involuntarily terminated under a benefit arrangement associated exit or disposal activities pursuant to an authorized plan. Excludes expenses related to one-time termination benefits, a discontinued operation or an asset retirement obligation.", "label": "Severance Costs", "terseLabel": "Severance", "verboseLabel": "Severance costs" } } }, "localname": "SeveranceCosts1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/AssetImpairmentRestructuringAndOtherSpecialChargesDetails", "http://www.lilly.com/role/AssetImpairmentRestructuringAndOtherSpecialChargesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r161" ], "calculation": { "http://www.lilly.com/role/ConsolidatedStatementsOfCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of noncash expense for share-based payment arrangement.", "label": "Share-based Payment Arrangement, Noncash Expense", "terseLabel": "Stock-based compensation expense" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": { "auth_ref": [ "r419" ], "lang": { "en-US": { "role": { "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period", "terseLabel": "Award vesting period (in years)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/StockBasedCompensationDetails" ], "xbrltype": "durationItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "auth_ref": [ "r422" ], "lang": { "en-US": { "role": { "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period", "terseLabel": "Grants in period (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/StockBasedCompensationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r422" ], "lang": { "en-US": { "role": { "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Weighted average grant date fair value (in usd per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/StockBasedCompensationDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": { "auth_ref": [ "r425" ], "lang": { "en-US": { "role": { "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate", "terseLabel": "Expected dividend yield (in percentage)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/StockBasedCompensationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": { "auth_ref": [ "r424" ], "lang": { "en-US": { "role": { "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate", "terseLabel": "Volatility (in percentage)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/StockBasedCompensationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": { "auth_ref": [ "r426" ], "lang": { "en-US": { "role": { "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate", "terseLabel": "Risk-free interest rate (in percentage)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/StockBasedCompensationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/StockBasedCompensationDetails", "http://www.lilly.com/role/StockBasedCompensationTables" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": { "auth_ref": [ "r429" ], "lang": { "en-US": { "role": { "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant", "terseLabel": "Number of shares available for grant (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/StockBasedCompensationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod": { "auth_ref": [ "r429" ], "lang": { "en-US": { "role": { "documentation": "Number of shares issued under share-based payment arrangement.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period", "terseLabel": "Shares issued in period (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/StockBasedCompensationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "auth_ref": [ "r415", "r420" ], "lang": { "en-US": { "role": { "documentation": "Award under share-based payment arrangement.", "label": "Award Type [Domain]", "terseLabel": "Award Type [Domain]" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/StockBasedCompensationDetails", "http://www.lilly.com/role/StockBasedCompensationTables" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": { "auth_ref": [ "r167", "r418", "r421" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.", "label": "Share-based Payment Arrangement [Policy Text Block]", "terseLabel": "Share-based Compensation, Option and Incentive Plans" } } }, "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/StockBasedCompensationPolicies", "http://www.lilly.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ShareRepurchaseProgramAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by share repurchase program.", "label": "Share Repurchase Program [Axis]", "terseLabel": "Share Repurchase Program [Axis]" } } }, "localname": "ShareRepurchaseProgramAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/ShareholdersEquityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareRepurchaseProgramDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the share repurchase program.", "label": "Share Repurchase Program [Domain]", "terseLabel": "Share Repurchase Program [Domain]" } } }, "localname": "ShareRepurchaseProgramDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/ShareholdersEquityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SharesIssued": { "auth_ref": [ "r335" ], "lang": { "en-US": { "role": { "documentation": "Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.", "label": "Shares, Issued", "periodEndLabel": "Ending balance (in shares)", "periodStartLabel": "Beginning balance (in shares)" } } }, "localname": "SharesIssued", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/ConsolidatedStatementsOfShareholdersEquityStatement" ], "xbrltype": "sharesItemType" }, "us-gaap_ShortTermDebtTypeAxis": { "auth_ref": [ "r80" ], "lang": { "en-US": { "role": { "documentation": "Information by type of short-term debt arrangement.", "label": "Short-term Debt, Type [Axis]", "terseLabel": "Short-term Debt, Type [Axis]" } } }, "localname": "ShortTermDebtTypeAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/FinancialInstrumentsShortTermAndLongTermClassificationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShortTermDebtTypeDomain": { "auth_ref": [ "r77" ], "lang": { "en-US": { "role": { "documentation": "Type of short-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing.", "label": "Short-term Debt, Type [Domain]", "terseLabel": "Short-term Debt, Type [Domain]" } } }, "localname": "ShortTermDebtTypeDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/FinancialInstrumentsShortTermAndLongTermClassificationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShortTermDebtWeightedAverageInterestRate": { "auth_ref": [ "r78" ], "lang": { "en-US": { "role": { "documentation": "Weighted average interest rate of short-term debt outstanding calculated at point in time.", "label": "Short-term Debt, Weighted Average Interest Rate, at Point in Time", "terseLabel": "Weighted average interest rate (in percentage)" } } }, "localname": "ShortTermDebtWeightedAverageInterestRate", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/BorrowingsNarrativeDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShortTermInvestments": { "auth_ref": [ "r51", "r594", "r595", "r597", "r616" ], "calculation": { "http://www.lilly.com/role/ConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.", "label": "Short-term Investments", "terseLabel": "Short-term investments (Note 7)" } } }, "localname": "ShortTermInvestments", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_StateAndLocalJurisdictionMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Designated tax department of a state or local government entitled to levy and collect income taxes from the entity.", "label": "State and Local Jurisdiction [Member]", "terseLabel": "State and Local Jurisdiction" } } }, "localname": "StateAndLocalJurisdictionMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_StatementBusinessSegmentsAxis": { "auth_ref": [ "r12", "r211", "r271", "r297", "r302", "r308", "r632" ], "lang": { "en-US": { "role": { "documentation": "Information by business segments.", "label": "Segments [Axis]", "terseLabel": "Segments [Axis]" } } }, "localname": "StatementBusinessSegmentsAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/CollaborationsAndOtherArrangementsDetails", "http://www.lilly.com/role/GoodwillAndOtherIntangiblesNarrativeDetails", "http://www.lilly.com/role/SegmentInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StatementClassOfStockAxis": { "auth_ref": [ "r58", "r59", "r60", "r335" ], "lang": { "en-US": { "role": { "documentation": "Information by the different classes of stock of the entity.", "label": "Class of Stock [Axis]", "terseLabel": "Class of Stock [Axis]" } } }, "localname": "StatementClassOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/CoverPage" ], "xbrltype": "stringItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r90", "r335" ], "lang": { "en-US": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]", "terseLabel": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/ConsolidatedStatementsOfShareholdersEquityStatement", "http://www.lilly.com/role/OtherComprehensiveIncomeLossReclassificationDetails", "http://www.lilly.com/role/OtherComprehensiveIncomeLossRollForwardDetails", "http://www.lilly.com/role/OtherComprehensiveIncomeLossTaxEffectDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]", "terseLabel": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss", "http://www.lilly.com/role/ConsolidatedStatementsOfShareholdersEquityStatement" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Statement of Financial Position [Abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Statement of Comprehensive Income [Abstract]" } } }, "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfOtherComprehensiveIncomeAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Statement of Other Comprehensive Income [Abstract]" } } }, "localname": "StatementOfOtherComprehensiveIncomeAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Statement of Stockholders' Equity [Abstract]" } } }, "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOperatingActivitiesSegmentAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by continuing and discontinuing operations.", "label": "Operating Activities [Axis]", "terseLabel": "Operating Activities [Axis]" } } }, "localname": "StatementOperatingActivitiesSegmentAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss", "http://www.lilly.com/role/OtherComprehensiveIncomeLossRollForwardDetails", "http://www.lilly.com/role/RetirementBenefitsNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]", "terseLabel": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss", "http://www.lilly.com/role/ConsolidatedStatementsOfShareholdersEquityStatement" ], "xbrltype": "stringItemType" }, "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": { "auth_ref": [ "r59", "r60", "r335", "r342" ], "lang": { "en-US": { "role": { "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan.", "label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans", "terseLabel": "Issuance of stock under employee stock plans, net, shares" } } }, "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/ConsolidatedStatementsOfShareholdersEquityStatement" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan": { "auth_ref": [ "r59", "r60", "r335", "r342" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.", "label": "Stock Issued During Period, Value, Employee Stock Purchase Plan", "netLabel": "Issuance of stock under employee stock plans, net" } } }, "localname": "StockIssuedDuringPeriodValueEmployeeStockPurchasePlan", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/ConsolidatedStatementsOfShareholdersEquityStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": { "auth_ref": [ "r59", "r60", "r342", "r417", "r423" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).", "label": "Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture", "terseLabel": "Stock-based compensation" } } }, "localname": "StockIssuedDuringPeriodValueShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/ConsolidatedStatementsOfShareholdersEquityStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockRepurchaseProgramAuthorizedAmount1": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of stock repurchase plan authorized.", "label": "Stock Repurchase Program, Authorized Amount", "terseLabel": "Stock repurchase program, authorized amount" } } }, "localname": "StockRepurchaseProgramAuthorizedAmount1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/ShareholdersEquityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount remaining of a stock repurchase plan authorized.", "label": "Stock Repurchase Program, Remaining Authorized Repurchase Amount", "terseLabel": "Remaining authorized repurchase amount" } } }, "localname": "StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/ShareholdersEquityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r60", "r64", "r65", "r225" ], "calculation": { "http://www.lilly.com/role/ConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "Stockholders' Equity Attributable to Parent", "totalLabel": "Total Eli Lilly and Company shareholders' equity" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": { "auth_ref": [ "r496", "r497", "r505" ], "calculation": { "http://www.lilly.com/role/ConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.", "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest", "periodEndLabel": "Ending balance", "periodStartLabel": "Beginning balance", "totalLabel": "Total equity" } } }, "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/ConsolidatedBalanceSheets", "http://www.lilly.com/role/ConsolidatedStatementsOfShareholdersEquityStatement", "http://www.lilly.com/role/OtherComprehensiveIncomeLossRollForwardDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]", "terseLabel": "Eli Lilly and Company Shareholders' Equity (Notes 11 and 12)" } } }, "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityNoteAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Stockholders' Equity Note [Abstract]" } } }, "localname": "StockholdersEquityNoteAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "auth_ref": [ "r346" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.", "label": "Stockholders' Equity Note Disclosure [Text Block]", "terseLabel": "Shareholders' Equity" } } }, "localname": "StockholdersEquityNoteDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/ShareholdersEquity" ], "xbrltype": "textBlockItemType" }, "us-gaap_StockholdersEquityOther": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "This element represents movements included in the statement of changes in stockholders' equity which are not separately disclosed or provided for elsewhere in the taxonomy.", "label": "Stockholders' Equity, Other", "negatedTerseLabel": "Other" } } }, "localname": "StockholdersEquityOther", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/ConsolidatedStatementsOfShareholdersEquityStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_SubsidiarySaleOfStockAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by type of sale of the entity's stock.", "label": "Sale of Stock [Axis]", "terseLabel": "Sale of Stock [Axis]" } } }, "localname": "SubsidiarySaleOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/SummaryOfSignificantAccountingPoliciesAcquisitionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SummaryOfIncomeTaxContingenciesTextBlock": { "auth_ref": [ "r447", "r456", "r458" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure for tax positions taken in the tax returns filed or to be filed for which it is more likely than not that the tax position will not be sustained upon examination by taxing authorities and other income tax contingencies. Includes, but is not limited to, interest and penalties, reconciliation of unrecognized tax benefits, unrecognized tax benefits that would affect the effective tax rate, tax years that remain subject to examination by tax jurisdictions, and information about positions for which it is reasonably possible that amounts unrecognized will significantly change within 12 months.", "label": "Summary of Income Tax Contingencies [Table Text Block]", "terseLabel": "Summary of Income Tax Contingencies" } } }, "localname": "SummaryOfIncomeTaxContingenciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/IncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_TangibleAssetImpairmentCharges": { "auth_ref": [ "r11", "r294" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The charge against earnings resulting from the aggregate write down of tangible assets from their carrying value to their fair value.", "label": "Tangible Asset Impairment Charges", "terseLabel": "Asset impairment charges" } } }, "localname": "TangibleAssetImpairmentCharges", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/AssetImpairmentRestructuringAndOtherSpecialChargesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_TaxCreditCarryforwardAmount": { "auth_ref": [ "r465" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.", "label": "Tax Credit Carryforward, Amount", "terseLabel": "Tax credit carryforward" } } }, "localname": "TaxCreditCarryforwardAmount", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_TaxCreditCarryforwardAxis": { "auth_ref": [ "r466" ], "lang": { "en-US": { "role": { "documentation": "Information by specific tax credit related to an unused tax credit.", "label": "Tax Credit Carryforward [Axis]", "terseLabel": "Tax Credit Carryforward [Axis]" } } }, "localname": "TaxCreditCarryforwardAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_TaxCreditCarryforwardNameDomain": { "auth_ref": [ "r466" ], "lang": { "en-US": { "role": { "documentation": "The name of the tax credit carryforward.", "label": "Tax Credit Carryforward, Name [Domain]", "terseLabel": "Tax Credit Carryforward, Name [Domain]" } } }, "localname": "TaxCreditCarryforwardNameDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TaxCutsAndJobsActOf2017ChangeInTaxRateIncomeTaxExpenseBenefit": { "auth_ref": [ "r471" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of income tax expense (benefit) for remeasurement of deferred tax from change in tax rate pursuant to Tax Cuts and Jobs Act.", "label": "Tax Cuts and Jobs Act, Change in Tax Rate, Income Tax Expense (Benefit)", "negatedLabel": "2017 Tax Act benefit" } } }, "localname": "TaxCutsAndJobsActOf2017ChangeInTaxRateIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_TaxCutsAndJobsActOf2017IncompleteAccountingChangeInTaxRateProvisionalIncomeTaxExpenseBenefit": { "auth_ref": [ "r475" ], "calculation": { "http://www.lilly.com/role/IncomeTaxesReconciliationOfIncomeTaxesDetails": { "order": 7.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of reasonable estimate for income tax expense (benefit) for which accounting for tax effect for remeasurement of deferred tax from change in tax rate is incomplete pursuant to Tax Cuts and Jobs Act.", "label": "Tax Cuts and Jobs Act, Incomplete Accounting, Change in Tax Rate, Provisional Income Tax Expense (Benefit)", "terseLabel": "2017 Tax Act", "verboseLabel": "2017 Tax Act provision" } } }, "localname": "TaxCutsAndJobsActOf2017IncompleteAccountingChangeInTaxRateProvisionalIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/IncomeTaxesNarrativeDetails", "http://www.lilly.com/role/IncomeTaxesReconciliationOfIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_TaxCutsAndJobsActOf2017IncompleteAccountingProvisionalIncomeTaxExpenseBenefit": { "auth_ref": [ "r475" ], "calculation": { "http://www.lilly.com/role/IncomeTaxesCurrentAndDeferredDetails": { "order": 5.0, "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of reasonable estimate for income tax expense (benefit) for which accounting for tax effect is incomplete pursuant to Tax Cuts and Jobs Act.", "label": "Tax Cuts and Jobs Act, Incomplete Accounting, Provisional Income Tax Expense (Benefit)", "terseLabel": "2017 Tax Act" } } }, "localname": "TaxCutsAndJobsActOf2017IncompleteAccountingProvisionalIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/IncomeTaxesCurrentAndDeferredDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_TaxPeriodAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information about the period subject to enacted tax laws.", "label": "Tax Period [Axis]", "terseLabel": "Tax Period [Axis]" } } }, "localname": "TaxPeriodAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_TaxPeriodDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Identified tax period.", "label": "Tax Period [Domain]", "terseLabel": "Tax Period [Domain]" } } }, "localname": "TaxPeriodDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TaxesPayableCurrent": { "auth_ref": [ "r81" ], "calculation": { "http://www.lilly.com/role/ConsolidatedBalanceSheets": { "order": 6.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Taxes Payable, Current", "terseLabel": "Income taxes payable (Note 13)" } } }, "localname": "TaxesPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_TransferOfFinancialAssetsAccountedForAsSalesAmountDerecognized": { "auth_ref": [ "r581" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of derecognized financial assets from transactions which comprise an initial transfer and an agreement entered into in contemplation of the initial transfer resulting in retention of substantially all of the exposure to the economic return throughout the term of the transaction, at the date of derecognition.", "label": "Transfer of Financial Assets Accounted for as Sales, Amount Derecognized", "terseLabel": "Amount derecognized" } } }, "localname": "TransferOfFinancialAssetsAccountedForAsSalesAmountDerecognized", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/FinancialInstrumentsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": { "auth_ref": [ "r582" ], "lang": { "en-US": { "role": { "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.", "label": "Financial Instruments [Domain]", "terseLabel": "Financial Instruments [Domain]" } } }, "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/FinancialInstrumentsFairValueMeasurementDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTax": { "auth_ref": [ "r559" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, after tax, of cumulative translation adjustment attributable to gain (loss) on foreign currency derivatives that are designated as, and are effective as, economic hedges of a net investment in a foreign entity.", "label": "Derivatives used in Net Investment Hedge, Net of Tax", "terseLabel": "Foreign currency-denominated notes, designated as hedge" } } }, "localname": "TranslationAdjustmentForNetInvestmentHedgeNetOfTax", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/FinancialInstrumentsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_TreasuryStockMember": { "auth_ref": [ "r89", "r344" ], "lang": { "en-US": { "role": { "documentation": "Shares of an entity that have been repurchased by the entity. This stock has no voting rights and receives no dividends. Note that treasury stock may be recorded at its total cost or separately as par (or stated) value and additional paid in capital. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.", "label": "Treasury Stock [Member]", "terseLabel": "Common Stock in Treasury" } } }, "localname": "TreasuryStockMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/ConsolidatedStatementsOfShareholdersEquityStatement" ], "xbrltype": "domainItemType" }, "us-gaap_TreasuryStockRetiredCostMethodAmount": { "auth_ref": [ "r60", "r335", "r343" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of decrease of par value, additional paid in capital (APIC) and retained earnings of common and preferred stock retired from treasury when treasury stock is accounted for under the cost method.", "label": "Treasury Stock, Retired, Cost Method, Amount", "negatedTerseLabel": "Retirement of treasury shares" } } }, "localname": "TreasuryStockRetiredCostMethodAmount", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/ConsolidatedStatementsOfShareholdersEquityStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_TreasuryStockSharesAcquired": { "auth_ref": [ "r60", "r335", "r342" ], "lang": { "en-US": { "role": { "documentation": "Number of shares that have been repurchased during the period and are being held in treasury.", "label": "Treasury Stock, Shares, Acquired", "terseLabel": "Purchase of treasury shares, shares" } } }, "localname": "TreasuryStockSharesAcquired", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/ConsolidatedStatementsOfShareholdersEquityStatement" ], "xbrltype": "sharesItemType" }, "us-gaap_TreasuryStockSharesRetired": { "auth_ref": [ "r60", "r335", "r342" ], "lang": { "en-US": { "role": { "documentation": "Number of shares of common and preferred stock retired from treasury during the period.", "label": "Treasury Stock, Shares, Retired", "negatedTerseLabel": "Retirement of treasury shares, shares" } } }, "localname": "TreasuryStockSharesRetired", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/ConsolidatedStatementsOfShareholdersEquityStatement" ], "xbrltype": "sharesItemType" }, "us-gaap_TreasuryStockValue": { "auth_ref": [ "r89", "r344", "r345" ], "calculation": { "http://www.lilly.com/role/ConsolidatedBalanceSheets": { "order": 6.0, "parentTag": "us-gaap_StockholdersEquity", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.", "label": "Treasury Stock, Value", "negatedLabel": "Cost of common stock in treasury" } } }, "localname": "TreasuryStockValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_TreasuryStockValueAcquiredCostMethod": { "auth_ref": [ "r335", "r342", "r344" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method.", "label": "Treasury Stock, Value, Acquired, Cost Method", "negatedTerseLabel": "Purchase of treasury shares", "terseLabel": "Purchase for treasury" } } }, "localname": "TreasuryStockValueAcquiredCostMethod", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/ConsolidatedStatementsOfShareholdersEquityStatement", "http://www.lilly.com/role/ShareholdersEquityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_TrustForBenefitOfEmployeesMember": { "auth_ref": [ "r395", "r575", "r576" ], "lang": { "en-US": { "role": { "documentation": "Trust created by the entity that exists for the benefit of its employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of the entity's management.", "label": "Trust for Benefit of Employees [Member]", "terseLabel": "Employee Benefit Trust" } } }, "localname": "TrustForBenefitOfEmployeesMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/ConsolidatedStatementsOfShareholdersEquityStatement" ], "xbrltype": "domainItemType" }, "us-gaap_TypeOfAdoptionMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Adoption and early adoption of sources of change to generally accepted accounting principles (GAAP) in the United States. The FASB released the FASB Accounting Standards Codification as the authoritative source of literature effective for interim and annual periods ending after September 15, 2009. As part of the Codification process, the FASB issues Accounting Standards Updates to amend the Codification but otherwise the Accounting Standards Updates are not authoritative in their own right. All previous accounting standards (such as FASB Statements of Financial Accounting Standards, FASB Interpretations, FASB Staff Positions, Emerging Issues Task Force Consensuses, other pronouncements of the FASB or other designated bodies, or other forms of GAAP are considered accounting pronouncements) were superseded upon the adoption of the Codification. For an interim period, references to the superseded standards are included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.", "label": "Type of Adoption [Domain]", "terseLabel": "Type of Adoption [Domain]" } } }, "localname": "TypeOfAdoptionMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/ImplementationOfNewFinancialAccountingPronouncementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TypeOfArrangementAxis": { "auth_ref": [ "r494" ], "lang": { "en-US": { "role": { "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]", "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]" } } }, "localname": "TypeOfArrangementAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/CollaborationsAndOtherArrangementsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_USGovernmentAgenciesDebtSecuritiesMember": { "auth_ref": [ "r377", "r596" ], "lang": { "en-US": { "role": { "documentation": "Debentures, notes, and other debt securities issued by US government agencies, for example, but not limited to, Government National Mortgage Association (GNMA or Ginnie Mae). Excludes US treasury securities and debt issued by government-sponsored Enterprises (GSEs), for example, but is not limited to, Federal Home Loan Mortgage Corporation (FHLMC or Freddie Mac), Federal National Mortgage Association (FNMA or Fannie Mae), and the Federal Home Loan Bank (FHLB).", "label": "US Government Agencies Debt Securities [Member]", "terseLabel": "U.S. government and agency securities" } } }, "localname": "USGovernmentAgenciesDebtSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/FinancialInstrumentsFairValueMeasurementDetails" ], "xbrltype": "domainItemType" }, "us-gaap_UnamortizedDebtIssuanceExpense": { "auth_ref": [ "r76" ], "calculation": { "http://www.lilly.com/role/BorrowingsLongTermDebtDetails": { "order": 4.0, "parentTag": "us-gaap_DebtLongtermAndShorttermCombinedAmount", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The remaining balance of debt issuance expenses that were capitalized and are being amortized against income over the lives of the respective bond issues. This does not include the amounts capitalized as part of the cost of the utility plant or asset.", "label": "Unamortized Debt Issuance Expense", "negatedLabel": "Unamortized debt issuance costs" } } }, "localname": "UnamortizedDebtIssuanceExpense", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/BorrowingsLongTermDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefits": { "auth_ref": [ "r440", "r450" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of unrecognized tax benefits.", "label": "Unrecognized Tax Benefits", "periodEndLabel": "Unrecognized Tax Benefits", "periodStartLabel": "Unrecognized Tax Benefits" } } }, "localname": "UnrecognizedTaxBenefits", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/IncomeTaxesUnrecognizedBenefitsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromForeignCurrencyTranslation": { "auth_ref": [ "r450" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of decrease in unrecognized tax benefits resulting from foreign currency translation.", "label": "Unrecognized Tax Benefits, Decrease Resulting from Foreign Currency Translation", "negatedLabel": "Changes related to the impact of foreign currency translation, decrease" } } }, "localname": "UnrecognizedTaxBenefitsDecreasesResultingFromForeignCurrencyTranslation", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/IncomeTaxesUnrecognizedBenefitsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions": { "auth_ref": [ "r451" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of decrease in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.", "label": "Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions", "negatedLabel": "Reductions for tax positions of prior years" } } }, "localname": "UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/IncomeTaxesUnrecognizedBenefitsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities": { "auth_ref": [ "r453" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of decrease in unrecognized tax benefits resulting from settlements with taxing authorities.", "label": "Unrecognized Tax Benefits, Decrease Resulting from Settlements with Taxing Authorities", "negatedLabel": "Settlements", "terseLabel": "Settlements" } } }, "localname": "UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/IncomeTaxesNarrativeDetails", "http://www.lilly.com/role/IncomeTaxesUnrecognizedBenefitsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued": { "auth_ref": [ "r446" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.", "label": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued", "terseLabel": "Accruals for the payment of interest and penalties" } } }, "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense": { "auth_ref": [ "r446" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of expense for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.", "label": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense", "terseLabel": "Income tax expense (benefit)" } } }, "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions": { "auth_ref": [ "r452" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.", "label": "Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions", "terseLabel": "Additions based on tax positions related to the current year" } } }, "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/IncomeTaxesUnrecognizedBenefitsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromForeignCurrencyTranslation": { "auth_ref": [ "r450" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of increase in unrecognized tax benefits resulting from foreign currency translation.", "label": "Unrecognized Tax Benefits, Increase Resulting from Foreign Currency Translation", "terseLabel": "Changes related to the impact of foreign currency translation, increase" } } }, "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromForeignCurrencyTranslation", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/IncomeTaxesUnrecognizedBenefitsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions": { "auth_ref": [ "r451" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.", "label": "Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions", "terseLabel": "Additions for tax positions of prior years" } } }, "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/IncomeTaxesUnrecognizedBenefitsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations": { "auth_ref": [ "r454" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of decrease in unrecognized tax benefits resulting from lapses of applicable statutes of limitations.", "label": "Unrecognized Tax Benefits, Reduction Resulting from Lapse of Applicable Statute of Limitations", "negatedLabel": "Lapses of statutes of limitation" } } }, "localname": "UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/IncomeTaxesUnrecognizedBenefitsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate": { "auth_ref": [ "r455" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The total amount of unrecognized tax benefits that, if recognized, would affect the effective tax rate.", "label": "Unrecognized Tax Benefits that Would Impact Effective Tax Rate", "terseLabel": "Unrecognized tax benefits that would impact effective tax rate" } } }, "localname": "UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "auth_ref": [ "r185", "r190" ], "lang": { "en-US": { "role": { "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.", "label": "Weighted Average Number of Shares Outstanding, Diluted", "terseLabel": "Diluted (shares)" } } }, "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]", "terseLabel": "Shares used in calculation of earnings (loss) per share:" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "auth_ref": [ "r184", "r190" ], "lang": { "en-US": { "role": { "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.", "label": "Weighted Average Number of Shares Outstanding, Basic", "terseLabel": "Basic (shares)" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.lilly.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "sharesItemType" } }, "unitCount": 20 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=d3e1107-107759" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=SL51721533-107759" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=d3e1012-107759" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a),(b),(c)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(i),(j),(k)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(i-k)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(j)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=d3e637-108580" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=d3e640-108580" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=d3e681-108580" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "14A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669686-108580" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=d3e689-108580" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "17A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL34724391-108580" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "17B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL34724394-108580" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669619-108580" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669619-108580" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669619-108580" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669625-108580" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669625-108580" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116657188&loc=SL116659661-227067" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118951672&loc=d3e1436-108581" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116657190&loc=SL116659633-172590" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(13))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868656-224227" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(210.5-03(11))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(1))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(10))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(14))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(21))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.1)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.2(a),(d))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.3)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7(b))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=d3e1474-107760" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.9)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r142": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "220", "URI": "http://asc.fasb.org/topic&trid=2134417" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3179-108585" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3179-108585" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3179-108585" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3213-108585" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3213-108585" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3213-108585" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3213-108585" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "3A", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721659-107760" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3255-108585" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3255-108585" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3291-108585" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3291-108585" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3291-108585" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3367-108585" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3000-108585" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3521-108585" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3536-108585" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3536-108585" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721663-107760" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3536-108585" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3044-108585" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3098-108585" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4297-108586" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18823-107790" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18823-107790" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721665-107760" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h)(2))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(d),(e))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(e),(f))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(h)(1)(i))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(h))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(n)(2))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(n))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-04(a))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e24072-122690" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-04.(a))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e24072-122690" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "5A", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721671-107760" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794" }, "r183": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "250", "URI": "http://asc.fasb.org/topic&trid=2122394" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=d3e1448-109256" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=d3e1505-109256" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=d3e1252-109256" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=d3e1278-109256" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=SL5780133-109256" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=d3e1337-109256" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "5B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3630-109257" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "52", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=117327953&loc=d3e4984-109258" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "270", "URI": "http://asc.fasb.org/extlink&oid=116846552&loc=d3e725-108305" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "270", "URI": "http://asc.fasb.org/extlink&oid=116846552&loc=d3e765-108305" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "270", "URI": "http://asc.fasb.org/extlink&oid=116846552&loc=d3e543-108305" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "270", "URI": "http://asc.fasb.org/extlink&oid=118952077&loc=d3e1280-108306" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.10-01.(b)(6))", "Topic": "270", "URI": "http://asc.fasb.org/extlink&oid=27015980&loc=d3e46468-122699" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=SL51721491-107759" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "5B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760" }, "r200": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "270", "URI": "http://asc.fasb.org/topic&trid=2126967" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8721-108599" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "5B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8813-108599" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8906-108599" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8906-108599" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8924-108599" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8933-108599" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8933-108599" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e9031-108599" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e9038-108599" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "5C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(2)", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e9038-108599" }, "r221": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "280", "URI": "http://asc.fasb.org/topic&trid=2134510" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=118952595&loc=d3e4428-111522" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=118952595&loc=d3e4531-111522" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=118936363&loc=d3e5074-111524" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=118954083&loc=d3e26610-111562" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=118954083&loc=d3e26626-111562" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "8A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=118954083&loc=SL6284422-111562" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "9A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=118954083&loc=SL6284427-111562" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "5C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=SL6283291-111563" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(aa)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27161-111563" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27161-111563" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27161-111563" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27161-111563" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27198-111563" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27198-111563" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27198-111563" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27198-111563" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27232-111563" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "5C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27290-111563" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27290-111563" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27290-111563" }, "r243": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "320", "URI": "http://asc.fasb.org/topic&trid=2196928" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "321", "URI": "http://asc.fasb.org/extlink&oid=116654751&loc=SL75117539-209714" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "321", "URI": "http://asc.fasb.org/extlink&oid=116654751&loc=SL75117546-209714" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=109237563&loc=d3e33775-111570" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=118955202&loc=SL82895884-210446" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=119407570&loc=SL82919244-210447" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "5D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721677-107760" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=119407570&loc=SL82919249-210447" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=119407570&loc=SL82919253-210447" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=119407570&loc=SL82919258-210447" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=119407570&loc=SL82919230-210447" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=118942338&loc=SL82898722-210454" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=118955579&loc=SL82922888-210455" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=118955579&loc=SL82922888-210455" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=118955579&loc=SL82922888-210455" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=118955579&loc=SL82922895-210455" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=118955579&loc=SL82922900-210455" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=118942371&loc=SL82922954-210456" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "30", "SubTopic": "10", "Topic": "330", "URI": "http://asc.fasb.org/extlink&oid=68048583&loc=d3e3636-108311" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "330", "URI": "http://asc.fasb.org/extlink&oid=116846819&loc=d3e3927-108312" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "330", "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4492-108314" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "330", "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4556-108314" }, "r265": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "330", "URI": "http://asc.fasb.org/topic&trid=2126998" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Topic": "340", "URI": "http://asc.fasb.org/extlink&oid=68074540&loc=d3e5879-108316" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13777-109266" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=77989000&loc=SL49117168-202975" }, "r27": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/subtopic&trid=2122178" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=108376223&loc=d3e13816-109267" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=108376223&loc=d3e13816-109267" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=108376223&loc=d3e13854-109267" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "((a)(1),(b))", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r28": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "205", "URI": "http://asc.fasb.org/topic&trid=2122149" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(2)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(3)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275" }, "r286": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "350", "URI": "http://asc.fasb.org/topic&trid=2144416" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226348&loc=d3e2510-110228" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226348&loc=d3e2420-110228" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226348&loc=d3e2473-110228" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2921-110230" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "3A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=SL51724579-110230" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=SL51721494-107759" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765" }, "r300": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "360", "URI": "http://asc.fasb.org/topic&trid=2155823" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 5.P.3)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140864-122747" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.3)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140864-122747" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 5.P.4)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.4(b))", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.4(d))", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747" }, "r309": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "http://asc.fasb.org/topic&trid=2144648" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=118942415&loc=d3e14326-108349" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=118942415&loc=d3e14615-108349" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=118942415&loc=d3e14394-108349" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=118942415&loc=d3e14435-108349" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=118942415&loc=d3e14435-108349" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=118942415&loc=d3e14453-108349" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=118942415&loc=d3e14472-108349" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=118942415&loc=d3e14557-108349" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=118942415&loc=d3e14557-108349" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=6397426&loc=d3e17499-108355" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765" }, "r320": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "450", "URI": "http://asc.fasb.org/topic&trid=2127136" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "460", "URI": "http://asc.fasb.org/extlink&oid=118943654&loc=d3e12021-110248" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "460", "URI": "http://asc.fasb.org/extlink&oid=118943654&loc=d3e12053-110248" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "460", "URI": "http://asc.fasb.org/extlink&oid=68068213&loc=d3e12565-110249" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "12A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=99376301&loc=SL5988623-112600" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=6802200&loc=d3e1835-112601" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=6802200&loc=SL6230698-112601" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=109500613&loc=SL6031897-161870" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=109500613&loc=SL6036836-161870" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "40", "SubTopic": "50", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=117329964&loc=d3e12317-112629" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "40", "SubTopic": "50", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=117329964&loc=d3e12355-112629" }, "r331": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "470", "URI": "http://asc.fasb.org/topic&trid=2208564" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(CFRR 211.02)", "Topic": "480", "URI": "http://asc.fasb.org/extlink&oid=65877616&loc=d3e177068-122764" }, "r333": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21553-112644" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21475-112644" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21484-112644" }, "r338": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21488-112644" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21506-112644" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6787-107765" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21521-112644" }, "r341": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21538-112644" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770" }, "r343": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770" }, "r344": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=6405813&loc=d3e23239-112655" }, "r345": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=6405834&loc=d3e23315-112656" }, "r346": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "505", "URI": "http://asc.fasb.org/topic&trid=2208762" }, "r347": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=118944033&loc=SL49130531-203044" }, "r348": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=118944033&loc=SL49130532-203044" }, "r349": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=118956577&loc=SL49130551-203045" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6801-107765" }, "r350": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=118956577&loc=SL49130545-203045" }, "r351": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=118956577&loc=SL49130549-203045" }, "r352": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=118944142&loc=SL49130690-203046-203046" }, "r353": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=118944142&loc=SL49130690-203046-203046" }, "r354": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(i)(1)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=113356391&loc=SL49131195-203048" }, "r355": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=113356391&loc=SL49131195-203048" }, "r356": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "610", "URI": "http://asc.fasb.org/topic&trid=49130413" }, "r357": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "15", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "712", "URI": "http://asc.fasb.org/extlink&oid=6410066&loc=d3e79218-111664" }, "r358": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "15", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "712", "URI": "http://asc.fasb.org/extlink&oid=6410066&loc=d3e79218-111664" }, "r359": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=109237824&loc=d3e1703-114919" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6812-107765" }, "r360": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=109237824&loc=d3e1731-114919" }, "r361": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r362": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(1)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r363": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(10)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r364": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(2)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r365": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(4)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r366": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(5)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r367": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(6)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r368": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(7)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r369": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6812-107765" }, "r370": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r371": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r372": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r373": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(5)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r374": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r375": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(5)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r376": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(i)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r377": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r378": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r379": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6904-107765" }, "r380": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r381": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r382": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)(1)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r383": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)(2)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r384": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)(3)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r385": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)(4)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r386": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)(5)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r387": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)(7)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r388": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(i)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r389": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(i),(j)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6911-107765" }, "r390": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(j)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r391": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(k)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r392": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(k)(1)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r393": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(k)(2)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r394": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(k)(3)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r395": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(n)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r396": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r397": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2410-114920" }, "r398": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2417-114920" }, "r399": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2417-114920" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=SL51721494-107759" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6935-107765" }, "r400": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2417-114920" }, "r401": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2439-114920" }, "r402": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2709-114920" }, "r403": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(1)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2709-114920" }, "r404": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(2)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2709-114920" }, "r405": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(3)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2709-114920" }, "r406": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(4)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2709-114920" }, "r407": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(5)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2709-114920" }, "r408": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(7)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2709-114920" }, "r409": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2709-114920" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766" }, "r410": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118257860&loc=d3e4179-114921" }, "r411": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118136717&loc=SL108413206-114923" }, "r412": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "60", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=6414203&loc=d3e39716-114964" }, "r413": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "70", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=49170846&loc=d3e28014-114942" }, "r414": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "715", "URI": "http://asc.fasb.org/topic&trid=2235017" }, "r415": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5047-113901" }, "r416": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5047-113901" }, "r417": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5047-113901" }, "r418": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5047-113901" }, "r419": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 201.5-02(24))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r420": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a),(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r421": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b),(f)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r422": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r423": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r424": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r425": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r426": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iv)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r427": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r428": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r429": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 201.5-02(25))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r430": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.F)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809" }, "r431": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "25", "SubTopic": "40", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109244457&loc=d3e16701-113920" }, "r432": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "718", "URI": "http://asc.fasb.org/topic&trid=2228938" }, "r433": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "720", "URI": "http://asc.fasb.org/topic&trid=2122503" }, "r434": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "730", "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373" }, "r435": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "730", "URI": "http://asc.fasb.org/extlink&oid=6420387&loc=d3e23199-108380" }, "r436": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "730", "URI": "http://asc.fasb.org/extlink&oid=6420387&loc=d3e23221-108380" }, "r437": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=117330534&loc=d3e28680-109314" }, "r438": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=117330534&loc=d3e28680-109314" }, "r439": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=117330534&loc=d3e28680-109314" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 201.5-02(26))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r440": { "Name": "Accounting Standards Codification", "Paragraph": "10B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116821951&loc=SL37586934-109318" }, "r441": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116821951&loc=d3e32247-109318" }, "r442": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116821951&loc=d3e32280-109318" }, "r443": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116821951&loc=d3e31931-109318" }, "r444": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32687-109319" }, "r445": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32698-109319" }, "r446": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32718-109319" }, "r447": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32718-109319" }, "r448": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32718-109319" }, "r449": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32718-109319" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(12))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r450": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319" }, "r451": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319" }, "r452": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319" }, "r453": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319" }, "r454": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(4)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319" }, "r455": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319" }, "r456": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319" }, "r457": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32809-109319" }, "r458": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32840-109319" }, "r459": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(13))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r460": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319" }, "r461": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b),(c)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319" }, "r462": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319" }, "r463": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319" }, "r464": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32847-109319" }, "r465": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32559-109319" }, "r466": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32559-109319" }, "r467": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32621-109319" }, "r468": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32632-109319" }, "r469": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(14))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r470": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319" }, "r471": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319" }, "r472": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=117331771&loc=SL96870463-158277" }, "r473": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=117331771&loc=SL96870463-158277" }, "r474": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.7)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817" }, "r475": { "Name": "Accounting Standards Codification", "Paragraph": "2A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.EE.Q2(b))", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=SL116722634-122817" }, "r476": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=109238882&loc=d3e39076-109324" }, "r477": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=109238882&loc=d3e38679-109324" }, "r478": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=109238882&loc=d3e38679-109324" }, "r479": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "05", "SubTopic": "30", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=65884525&loc=d3e40913-109327" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(17))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r480": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "740", "URI": "http://asc.fasb.org/topic&trid=2144680" }, "r481": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(4)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463" }, "r482": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463" }, "r483": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463" }, "r484": { "Name": "Accounting Standards Codification", "Paragraph": "38", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=77890550&loc=d3e5504-128473" }, "r485": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "25", "SubTopic": "30", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=6911189&loc=d3e6408-128476" }, "r486": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "30", "SubTopic": "30", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=116859721&loc=d3e6578-128477" }, "r487": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "30", "SubTopic": "30", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=116859721&loc=d3e6613-128477" }, "r488": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "35", "SubTopic": "30", "Subparagraph": "b", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=116859824&loc=d3e6819-128478" }, "r489": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(19)(a)(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r490": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=35744584&loc=d3e7008-128479" }, "r491": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "805", "URI": "http://asc.fasb.org/topic&trid=2303972" }, "r492": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "808", "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434" }, "r493": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "808", "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434" }, "r494": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "808", "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434" }, "r495": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "808", "URI": "http://asc.fasb.org/topic&trid=5833765" }, "r496": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4568447-111683" }, "r497": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4568740-111683" }, "r498": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569616-111683" }, "r499": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569643-111683" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=SL51721501-107759" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(19))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r500": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r501": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r502": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(3)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r503": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c),(3)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r504": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4582445-111684" }, "r505": { "Name": "Accounting Standards Codification", "Paragraph": "4I", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116874947&loc=SL4590271-111686" }, "r506": { "Name": "Accounting Standards Codification", "Paragraph": "4J", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116874947&loc=SL4591551-111686" }, "r507": { "Name": "Accounting Standards Codification", "Paragraph": "4K", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116874947&loc=SL4591552-111686" }, "r508": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.E)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116822174&loc=d3e355146-122828" }, "r509": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "810", "URI": "http://asc.fasb.org/topic&trid=2197479" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(2))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r510": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5579240-113959" }, "r511": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5579245-113959" }, "r512": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5579245-113959" }, "r513": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5579245-113959" }, "r514": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5580258-113959" }, "r515": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)(ii)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=d3e41620-113959" }, "r516": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)(iii)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=d3e41620-113959" }, "r517": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=d3e41620-113959" }, "r518": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=d3e41638-113959" }, "r519": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5618551-113959" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(20))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r520": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5618551-113959" }, "r521": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624163-113959" }, "r522": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624163-113959" }, "r523": { "Name": "Accounting Standards Codification", "Paragraph": "4C", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624171-113959" }, "r524": { "Name": "Accounting Standards Codification", "Paragraph": "4C", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624171-113959" }, "r525": { "Name": "Accounting Standards Codification", "Paragraph": "4C", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624171-113959" }, "r526": { "Name": "Accounting Standards Codification", "Paragraph": "4C", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624171-113959" }, "r527": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624177-113959" }, "r528": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624177-113959" }, "r529": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(6)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624177-113959" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(22))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r530": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624177-113959" }, "r531": { "Name": "Accounting Standards Codification", "Paragraph": "4E", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624181-113959" }, "r532": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=d3e41641-113959" }, "r533": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=d3e41675-113959" }, "r534": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=d3e41678-113959" }, "r535": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "25", "Subparagraph": "(a)(1)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109977999&loc=d3e76258-113986" }, "r536": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "25", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109977999&loc=d3e76258-113986" }, "r537": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109978405&loc=d3e80720-113993" }, "r538": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=112277219&loc=d3e80748-113994" }, "r539": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(23))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r540": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r541": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r542": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r543": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19279-110258" }, "r544": { "Name": "Accounting Standards Codification", "Paragraph": "6A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=SL6742756-110258" }, "r545": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=99377092&loc=SL75136599-209740" }, "r546": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=116690757&loc=d3e13220-108610" }, "r547": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=118260190&loc=d3e13433-108611" }, "r548": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=118260190&loc=d3e13467-108611" }, "r549": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=118260190&loc=d3e13476-108611" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(24))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r550": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=118260190&loc=d3e13531-108611" }, "r551": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=118260190&loc=d3e13537-108611" }, "r552": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=117336053&loc=SL75039408-165497" }, "r553": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "35", "SubTopic": "20", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118948100&loc=d3e30304-110892" }, "r554": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=109240200&loc=d3e30690-110894" }, "r555": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=109240200&loc=d3e30700-110894" }, "r556": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=6450222&loc=d3e30840-110895" }, "r557": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=98513438&loc=d3e33268-110906" }, "r558": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32022-110900" }, "r559": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(26)(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r560": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r561": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b,d)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r562": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901" }, "r563": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391" }, "r564": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=114775744&loc=d3e28541-108399" }, "r565": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=114775744&loc=d3e28551-108399" }, "r566": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=114775744&loc=d3e28555-108399" }, "r567": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400" }, "r568": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(Note 3)", "Topic": "840", "URI": "http://asc.fasb.org/extlink&oid=82846649&loc=d3e38371-112697" }, "r569": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "840", "URI": "http://asc.fasb.org/extlink&oid=77902758&loc=d3e41499-112717" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(26)(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r570": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "840", "URI": "http://asc.fasb.org/extlink&oid=77902758&loc=d3e41502-112717" }, "r571": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "840", "URI": "http://asc.fasb.org/extlink&oid=77902758&loc=d3e41502-112717" }, "r572": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=119364159&loc=SL77916155-209984" }, "r573": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918627-209977" }, "r574": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918627-209977" }, "r575": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r576": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864" }, "r577": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=118948506&loc=d3e107207-111719" }, "r578": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=118948506&loc=d3e107207-111719" }, "r579": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=118948506&loc=d3e107207-111719" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(27))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r580": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=118948506&loc=d3e107207-111719" }, "r581": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=118948506&loc=SL51823488-111719" }, "r582": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746" }, "r583": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "340", "Topic": "928", "URI": "http://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004" }, "r584": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "940", "URI": "http://asc.fasb.org/extlink&oid=68072869&loc=d3e41242-110953" }, "r585": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(10))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r586": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r587": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(13)(2))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r588": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(13))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r589": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(15)(1))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r590": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(15)(2))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r591": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(16))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r592": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(22))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r593": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r594": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(4))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r595": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(5))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r596": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(6)(a)(1))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r597": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(6))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r598": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.17)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r599": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(19))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=SL51721503-107759" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r600": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(15))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260" }, "r601": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(20))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260" }, "r602": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260" }, "r603": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(23))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260" }, "r604": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04.9)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260" }, "r605": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "320", "Subparagraph": "(a)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=75019621&loc=d3e62586-112803" }, "r606": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "320", "Subparagraph": "(b)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=75019621&loc=d3e62586-112803" }, "r607": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "320", "Subparagraph": "(c)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=75019621&loc=d3e62586-112803" }, "r608": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "320", "Subparagraph": "(d)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=75019621&loc=d3e62586-112803" }, "r609": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "405", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6957935&loc=d3e64057-112817" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r610": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "470", "Subparagraph": "e", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=75038535&loc=d3e64711-112823" }, "r611": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "470", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=75038535&loc=d3e64711-112823" }, "r612": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "825", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=108315417&loc=d3e61044-112788" }, "r613": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(15)(b)(2))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r614": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(16))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r615": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(1)(b))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r616": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(1)(g))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r617": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(10))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r618": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r619": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(15)(b)(1))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r620": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(16))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r621": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r622": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(24))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r623": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r624": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r625": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.(a),19)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r626": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.1(f))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r627": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(11))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263" }, "r628": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(12))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263" }, "r629": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r630": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(19))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263" }, "r631": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(8))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263" }, "r632": { "Name": "Accounting Standards Codification", "Paragraph": "4H", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438" }, "r633": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=117419784&loc=SL117783719-158441" }, "r634": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(b)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=117419784&loc=SL117783719-158441" }, "r635": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(e)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=117420044&loc=d3e19393-158473" }, "r636": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "825", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=99380617&loc=SL75241803-196195" }, "r637": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15)", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=50485924&loc=d3e611379-123010" }, "r638": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "310", "Subparagraph": "(SX 210.12-29(Footnote 4))", "Topic": "948", "URI": "http://asc.fasb.org/extlink&oid=6589523&loc=d3e617274-123014" }, "r639": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "450", "Topic": "954", "URI": "http://asc.fasb.org/extlink&oid=6491354&loc=d3e6049-115624" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r640": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "450", "Topic": "954", "URI": "http://asc.fasb.org/extlink&oid=6491354&loc=d3e6052-115624" }, "r641": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "740", "Topic": "954", "URI": "http://asc.fasb.org/extlink&oid=6491622&loc=d3e9504-115650" }, "r642": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Footnote 2))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=6590653&loc=d3e638233-123024" }, "r643": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "985", "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756" }, "r644": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r645": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r646": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r647": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r648": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r649": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r650": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(4)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=d3e957-107759" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(c))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.1)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.12)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.13(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.13)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.14)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.17)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(b),22(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "3A", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=SL51721523-107759" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19,20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.24)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.25)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.28,29)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29,30)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "3B", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=SL51721525-107759" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.31)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(a)(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(a)(4))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(c))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.8)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.9)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" } }, "version": "2.1" } XML 92 R22.htm IDEA: XBRL DOCUMENT v3.19.3

Shareholders' Equity
12 Months Ended

Dec. 31, 2018

Stockholders' Equity Note [Abstract]

Shareholders' Equity Shareholders' Equity
During 2018, 2017, and 2016, we repurchased $4.15 billion, $359.8 million and $540.1 million, respectively, of shares associated with our share repurchase programs. A payment of $60.0 million was made in 2016 for shares repurchased in 2017.
During 2018, we repurchased $2.05 billion of shares, which completed the $5.00 billion share repurchase program announced in October 2013 and our board authorized an $8.00 billion share repurchase program.
There were $2.10 billion repurchased under the $8.00 billion program in 2018. As of December 31, 2018, there were $5.90 billion of shares remaining under the 2018 program.
We have 5.0 million authorized shares of preferred stock. As of December 31, 2018 and 2017, no preferred stock was issued.
We have an employee benefit trust that held 50.0 million shares of our common stock at both December 31, 2018 and 2017, to provide a source of funds to assist us in meeting our obligations under various employee benefit plans. The cost basis of the shares held in the trust was $3.01 billion at both December 31, 2018 and 2017, and is shown as a reduction of shareholders’ equity. Any dividend transactions between us and the trust are eliminated. Stock held by the trust is not considered outstanding in the computation of EPS. The assets of the trust were not used to fund any of our obligations under these employee benefit plans during the years ended December 31, 2018, 2017, and 2016.

X

- References
No definition available.
+ Details

Name: us-gaap_StockholdersEquityNoteAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-URI http://asc.fasb.org/topic&trid=2208762
+ Details

Name: us-gaap_StockholdersEquityNoteDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 93 R26.htm IDEA: XBRL DOCUMENT v3.19.3

Other Comprehensive Income (Loss)
12 Months Ended

Dec. 31, 2018

Equity [Abstract]

Other Comprehensive Income (Loss) Other Comprehensive Income (Loss)
The following table summarizes the activity related to each component of other comprehensive income (loss):

Continuing Operations

(Amounts presented net of taxes)
Foreign Currency Translation Gains (Losses)

Unrealized Net Gains (Losses) on Securities

Defined Benefit Pension and Retiree Health Benefit Plans

Effective Portion of Cash Flow Hedges

Discontinued Operations

Accumulated Other Comprehensive Loss
Beginning balance at January 1, 2016
$
(1,315.9
)

$
10.1

$
(2,996.8
)

$
(218.5
)

$
(59.6
)

$
(4,580.7
)

Other comprehensive income (loss) before reclassifications
(445.2
)

206.7

(514.3
)

(2.2
)

(140.8
)

(895.8
)
Net amount reclassified from accumulated other comprehensive loss
74.5

7.2

159.1

9.8

0.1

250.7

Net other comprehensive income (loss)
(370.7
)

213.9

(355.2
)

7.6

(140.7
)

(645.1
)

Balance at December 31, 2016⁽¹⁾
(1,686.6
)

224.0

(3,352.0
)

(210.9
)

(200.3
)

(5,225.8
)

Other comprehensive income (loss) before reclassifications
525.6

(15.7
)

(532.1
)

8.5

127.7

114.0

Net amount reclassified from accumulated other comprehensive loss
8.1

(110.6
)

151.9

9.6

1.5

60.5

Net other comprehensive income (loss)
533.7

(126.3
)

(380.2
)

18.1

129.2

174.5

Reclassifications of stranded tax effects (Note 2)
(38.8
)

15.8

(579.1
)

(41.5
)

—

(643.6
)

Balance at December 31, 2017⁽²⁾
(1,191.7
)

113.5

(4,311.3
)

(234.3
)

(71.1
)

(5,694.9
)

Reclassification due to adoption of new accounting standard⁽³⁾
—

(128.9
)

—

—

—

(128.9
)
Other comprehensive income (loss) before reclassifications
(378.0
)

24.5

250.7

(16.3
)

12.2

(106.9
)
Net amount reclassified from accumulated other comprehensive loss
—

(31.2
)

207.9

11.7

2.1

190.5

Net other comprehensive income (loss)
(378.0
)

(6.7
)

458.6

(4.6
)

14.3

83.6

Ending balance at December 31, 2018⁽⁴⁾
$
(1,569.7
)

$
(22.1
)

$
(3,852.7
)

$
(238.9
)

$
(56.8
)

$
(5,740.2
)

⁽¹⁾Accumulated other comprehensive loss as of December 31, 2016 consists of $5.27 billion of accumulated other comprehensive loss attributable to controlling interest and $48.2 million of accumulated other comprehensive income attributable to noncontrolling interest.
⁽²⁾Accumulated other comprehensive loss as of December 31, 2017 consists of $5.72 billion of accumulated other comprehensive loss attributable to controlling interest and $23.7 million of accumulated other comprehensive income attributable to noncontrolling interest.
⁽³⁾This reclassification consists of $105.2 million of accumulated other comprehensive loss attributable to controlling interest and $23.7 million of accumulated other comprehensive loss attributable to noncontrolling interest. Refer to Note 2 for further details regarding the reclassification due to the adoption of Accounting Standards Update 2016-01, Financial Instruments - Overall: Recognition and Measurement of Financial Assets and Financial Liabilities.
⁽⁴⁾Accumulated other comprehensive loss as of December 31, 2018 consists of $5.73 billion of accumulated other comprehensive loss attributable to controlling interest and $11.0 million of accumulated other comprehensive loss attributable to noncontrolling interest.
The tax effects on the net activity related to each component of other comprehensive income (loss) for the years ended December 31, were as follows:
Tax benefit (expense)
2018

2017

2016
Foreign currency translation gains/losses
$
51.6

$
170.8

$
(70.6
)
Unrealized net gains/losses on securities
2.1

55.0

(89.2
)
Defined benefit pension and retiree health benefit plans
(85.3
)

186.6

153.3

Effective portion of cash flow hedges
1.3

(9.7
)

(4.1
)
Benefit/(provision) for income taxes allocated to other comprehensive income (loss) items
$
(30.3
)

$
402.7

$
(10.6
)

Except for the tax effects of foreign currency translation gains and losses related to our foreign currency-denominated notes, cross-currency interest rate swaps, and other foreign currency exchange contracts designated as net investment hedges (see Note 7), income taxes were not provided for foreign currency translation. Generally, the assets and liabilities of foreign operations are translated into U.S. dollars using the current exchange rate. For those operations, changes in exchange rates generally do not affect cash flows; therefore, resulting translation adjustments are made in shareholders' equity rather than in the consolidated statements of operations.
Reclassifications out of accumulated other comprehensive loss were as follows:
Details about Accumulated Other
Comprehensive Loss Components
Year Ended December 31,
Affected Line Item in the Consolidated Statements of Operations
2018

2017

2016
Amortization of retirement benefit items:

Prior service benefits, net
$
(74.9
)

$
(84.4
)

$
(74.1
)
Other—net, (income) expense
Actuarial losses
338.6

305.2

304.7

Other—net, (income) expense
Total before tax
263.7

220.8

230.6

Tax benefit
(55.8
)

(68.9
)

(71.5
)
Income taxes
Net of tax
207.9

151.9

159.1

Unrealized gains/losses on available-for-sale securities:

Realized gains, net
(39.5
)

(170.2
)

(16.1
)
Other—net, (income) expense
Impairment losses
—

—

27.3

Other—net, (income) expense
Total before tax
(39.5
)

(170.2
)

11.2

Tax (benefit) expense
8.3

59.6

(4.0
)
Income taxes
Net of tax
(31.2
)

(110.6
)

7.2

Other, net of tax⁽¹⁾
13.8

19.2

84.4

Other—net, (income) expense
Total reclassifications for the period (net of tax)
$
190.5

$
60.5

$
250.7

⁽¹⁾Amount for year ended December 31, 2016 included primarily $74.5 million of foreign currency translation losses.

X

- Definition
The entire disclosure for comprehensive income, which includes, but is not limited to, 1) the amount of income tax expense or benefit allocated to each component of other comprehensive income, including reclassification adjustments, 2) the reclassification adjustments for each classification of other comprehensive income and 3) the ending accumulated balances for each component of comprehensive income.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-URI http://asc.fasb.org/topic&trid=2134417
+ Details

Name: us-gaap_ComprehensiveIncomeNoteTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_EquityAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 94 R46.htm IDEA: XBRL DOCUMENT v3.19.3

Goodwill and Other Intangibles (Tables)
12 Months Ended

Dec. 31, 2018

Goodwill and Intangible Assets Disclosure [Abstract]

Schedule of Intangible Assets and Goodwill
The components of intangible assets other than goodwill at December 31 were as follows:

2018

2017
Description
Carrying
Amount,
Gross

Accumulated
Amortization

Carrying
Amount,
Net

Carrying
Amount,
Gross

Accumulated
Amortization

Carrying
Amount,
Net
Finite-lived intangible assets:

Marketed products
$
2,077.2

$
(1,069.0
)

$
1,008.2

$
4,528.8

$
(3,251.3
)

$
1,277.5

Other
89.5

(29.7
)

59.8

117.1

(40.2
)

76.9

Other intangibles
$
2,166.7

$
(1,098.7
)

$
1,068.0

$
4,645.9

$
(3,291.5
)

$
1,354.4

Finite-lived Intangible Assets Amortization Expense
Amortization expense related to finite-lived intangible assets was as follows:

2018

2017

2016
Amortization expense
$
361.3

$
462.2

$
517.2

Schedule of Finite-Lived Intangible Assets, Future Amortization Expense
The estimated amortization expense for each of the next five years associated with our finite-lived intangible assets as of December 31, 2018 is as follows:

2019

2020

2021

2022

2023
Estimated amortization expense
$
145.4

$
144.0

$
141.6

$
133.8

$
122.6

X

- Definition
Tabular disclosure of amortization expense of assets, excluding financial assets, that lack physical substance, having a limited useful life.
+ References
No definition available.
+ Details

Name: us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275
+ Details

Name: us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275
+ Details

Name: us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 95 R42.htm IDEA: XBRL DOCUMENT v3.19.3

Collaborations and Other Arrangements (Tables)
12 Months Ended

Dec. 31, 2018

Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]

Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions The following table summarizes our milestones achieved:
Year
Event
Classification
Amount
2018
Regulatory approval in the U.S.
Intangible asset
$
100.0

Began Phase III testing for SLE
R&D Expense
20.0

2017
Regulatory approval in Europe
Intangible asset
65.0

Regulatory approval in Japan
Intangible asset
15.0

Began Phase III testing for atopic dermatitis
R&D expense
30.0

2016
Regulatory submissions in the U.S. and Europe
R&D expense
55.0

Diabetes Collaboration

Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]

Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions
The following table summarizes our collaboration and other revenue recognized with respect to the Trajenta and Jardiance families of products and net product revenue recognized with respect to Basaglar:

2018

2017

2016
Basaglar
$
801.2

$
432.1

$
86.1

Jardiance
658.3

447.5

201.9

Trajenta
574.7

537.9

436.6

The table below summarizes significant milestones (deferred) capitalized for the compounds included in this collaboration:
Product Family

Milestones
(Deferred) Capitalized⁽¹⁾

Year
Amount
Trajenta⁽²⁾

Cumulative⁽⁴⁾
$
446.4

Jardiance⁽³⁾

Cumulative⁽⁴⁾
289.0

Basaglar

2018
—

2017
—

2016
(187.5
)

Cumulative⁽⁴⁾
(250.0
)

⁽¹⁾In connection with the regulatory approvals of Basaglar in the U.S., Europe, and Japan, milestone payments received were recorded as contract liabilities and are being amortized through the term of the collaboration (2029) to collaboration and other revenue. In connection with the regulatory approvals of Trajenta and Jardiance, milestone payments made were capitalized as intangible assets and are being amortized to cost of sales through the term of the collaboration.
⁽²⁾Jentadueto is included in the Trajenta product family. The collaboration agreement with Boehringer Ingelheim for Trajenta ends upon expiration of the compound patent and any supplementary protection certificates or extensions thereto.
⁽³⁾Glyxambi and Synjardyare included in the Jardiance product family. The collaboration agreement with Boehringer Ingelheim for Jardiance ends upon expiration of the compound patent and any supplementary protection certificates or extensions thereto.
⁽⁴⁾The cumulative amount represents the total amounts that have been (deferred) or capitalized from the start of this collaboration through the end of the reporting period.

Erbitux

Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]

Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions
The following table summarizes our revenue recognized with respect to Erbitux:

2018

2017

2016
Net product revenue
$
536.1

$
548.2

$
587.0

Collaboration and other revenue
99.2

97.7

100.0

Revenue
$
635.3

$
645.9

$
687.0

Effient

Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]

Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions
The following table summarizes our revenue recognized with respect to Effient:

2018

2017

2016
Revenue
$
122.2

$
388.9

$
535.2

We are in a collaborative arrangement with Daiichi Sankyo Co., Ltd. (Daiichi Sankyo) to develop, market, and promote Effient. Marketing rights for major territories are shown below. We and Daiichi Sankyo each have exclusive marketing rights in certain other territories.
Territory

Marketing Rights

Selling Party
U.S.

Co-promotion

Lilly
Major European markets

Co-promotion

Daiichi Sankyo
Japan

Exclusive

Daiichi Sankyo

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 808
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434
+ Details

Name: us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Details

Name: srt_ProductOrServiceAxis=lly_DiabetesCollaborationMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_ProductOrServiceAxis=lly_ErbituxMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_ProductOrServiceAxis=lly_EffientMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 96 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 97 R91.htm IDEA: XBRL DOCUMENT v3.19.3

Retirement Benefits (Fair Value Disclosures) (Details) - USD ($)
$ in Millions

Dec. 31, 2018

Dec. 31, 2017

Dec. 31, 2016

Defined Benefit Pension Plans

Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items] [Line Items]

Fair value of plan assets $ 10,932.6 $ 11,713.0 $ 10,056.0

Retiree Health Benefit Plans

Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items] [Line Items]

Fair value of plan assets 2,398.1 2,372.4 $ 1,961.2

U.S. | Defined Benefit Pension Plans

Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items] [Line Items]

Fair value of plan assets 617.7 465.4

U.S. | Retiree Health Benefit Plans

Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items] [Line Items]

Fair value of plan assets 59.9 43.0

International | Defined Benefit Pension Plans

Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items] [Line Items]

Fair value of plan assets 2,117.8 2,934.2

International | Retiree Health Benefit Plans

Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items] [Line Items]

Fair value of plan assets 127.0 182.5

Developed markets | Defined Benefit Pension Plans

Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items] [Line Items]

Fair value of plan assets 2,933.4 3,153.0

Developed markets | Retiree Health Benefit Plans

Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items] [Line Items]

Fair value of plan assets 69.1 71.2

Developed markets - repurchase agreements | Defined Benefit Pension Plans

Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items] [Line Items]

Fair value of plan assets (1,225.5) (1,372.9)

Emerging markets | Defined Benefit Pension Plans

Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items] [Line Items]

Fair value of plan assets 565.2 577.5

Emerging markets | Retiree Health Benefit Plans

Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items] [Line Items]

Fair value of plan assets 53.5 53.1

Hedge funds | Defined Benefit Pension Plans

Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items] [Line Items]

Fair value of plan assets 2,795.3 2,977.8

Hedge funds | Retiree Health Benefit Plans

Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items] [Line Items]

Fair value of plan assets 245.8 256.0

Equity-like funds | Defined Benefit Pension Plans

Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items] [Line Items]

Fair value of plan assets 1,893.5 1,586.9

Equity-like funds | Retiree Health Benefit Plans

Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items] [Line Items]

Fair value of plan assets 169.2 137.0

Cash value of trust owned insurance contract | Retiree Health Benefit Plans

Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items] [Line Items]

Fair value of plan assets 1,574.7 1,524.6

Real estate | Defined Benefit Pension Plans

Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items] [Line Items]

Fair value of plan assets 505.7 543.7

Real estate | Retiree Health Benefit Plans

Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items] [Line Items]

Fair value of plan assets 27.7 33.0

Other | Defined Benefit Pension Plans

Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items] [Line Items]

Fair value of plan assets 729.5 847.4

Other | Retiree Health Benefit Plans

Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items] [Line Items]

Fair value of plan assets 71.2 72.0

Significant Unobservable Inputs (Level 3) | Defined Benefit Pension Plans

Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items] [Line Items]

Fair value of plan assets 24.7 22.1

Significant Unobservable Inputs (Level 3) | Retiree Health Benefit Plans

Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items] [Line Items]

Fair value of plan assets 2.5 2.1

Significant Unobservable Inputs (Level 3) | U.S. | Defined Benefit Pension Plans

Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items] [Line Items]

Fair value of plan assets 0.0 0.0

Significant Unobservable Inputs (Level 3) | U.S. | Retiree Health Benefit Plans

Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items] [Line Items]

Fair value of plan assets 0.0 0.0

Significant Unobservable Inputs (Level 3) | International | Defined Benefit Pension Plans

Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items] [Line Items]

Fair value of plan assets 1.8 0.0

Significant Unobservable Inputs (Level 3) | International | Retiree Health Benefit Plans

Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items] [Line Items]

Fair value of plan assets 0.2 0.0

Significant Unobservable Inputs (Level 3) | Developed markets | Defined Benefit Pension Plans

Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items] [Line Items]

Fair value of plan assets 0.0 0.0

Significant Unobservable Inputs (Level 3) | Developed markets | Retiree Health Benefit Plans

Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items] [Line Items]

Fair value of plan assets 0.0 0.0

Significant Unobservable Inputs (Level 3) | Developed markets - repurchase agreements | Defined Benefit Pension Plans

Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items] [Line Items]

Fair value of plan assets 0.0 0.0

Significant Unobservable Inputs (Level 3) | Emerging markets | Defined Benefit Pension Plans

Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items] [Line Items]

Fair value of plan assets 6.1 3.1

Significant Unobservable Inputs (Level 3) | Emerging markets | Retiree Health Benefit Plans

Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items] [Line Items]

Fair value of plan assets 0.6 0.3

Significant Unobservable Inputs (Level 3) | Hedge funds | Defined Benefit Pension Plans

Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items] [Line Items]

Fair value of plan assets 0.0 0.0

Significant Unobservable Inputs (Level 3) | Hedge funds | Retiree Health Benefit Plans

Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items] [Line Items]

Fair value of plan assets 0.0 0.0

Significant Unobservable Inputs (Level 3) | Equity-like funds | Defined Benefit Pension Plans

Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items] [Line Items]

Fair value of plan assets 16.8 16.8

Significant Unobservable Inputs (Level 3) | Equity-like funds | Retiree Health Benefit Plans

Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items] [Line Items]

Fair value of plan assets 1.7 1.6

Significant Unobservable Inputs (Level 3) | Cash value of trust owned insurance contract | Retiree Health Benefit Plans

Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items] [Line Items]

Fair value of plan assets 0.0 0.0

Significant Unobservable Inputs (Level 3) | Real estate | Defined Benefit Pension Plans

Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items] [Line Items]

Fair value of plan assets 0.0 0.0

Significant Unobservable Inputs (Level 3) | Real estate | Retiree Health Benefit Plans

Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items] [Line Items]

Fair value of plan assets 0.0 0.0

Significant Unobservable Inputs (Level 3) | Other | Defined Benefit Pension Plans

Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items] [Line Items]

Fair value of plan assets 0.0 2.2

Significant Unobservable Inputs (Level 3) | Other | Retiree Health Benefit Plans

Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items] [Line Items]

Fair value of plan assets 0.0 0.2

Significant Other Observable Inputs (Level 2) | Defined Benefit Pension Plans

Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items] [Line Items]

Fair value of plan assets 1,287.3 1,949.6

Significant Other Observable Inputs (Level 2) | Retiree Health Benefit Plans

Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items] [Line Items]

Fair value of plan assets 1,657.9 1,663.0

Significant Other Observable Inputs (Level 2) | U.S. | Defined Benefit Pension Plans

Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items] [Line Items]

Fair value of plan assets 0.0 0.0

Significant Other Observable Inputs (Level 2) | U.S. | Retiree Health Benefit Plans

Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items] [Line Items]

Fair value of plan assets 0.0 0.0

Significant Other Observable Inputs (Level 2) | International | Defined Benefit Pension Plans

Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items] [Line Items]

Fair value of plan assets 0.0 0.0

Significant Other Observable Inputs (Level 2) | International | Retiree Health Benefit Plans

Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items] [Line Items]

Fair value of plan assets 0.0 0.0

Significant Other Observable Inputs (Level 2) | Developed markets | Defined Benefit Pension Plans

Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items] [Line Items]

Fair value of plan assets 2,173.3 2,468.1

Significant Other Observable Inputs (Level 2) | Developed markets | Retiree Health Benefit Plans

Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items] [Line Items]

Fair value of plan assets 61.5 63.5

Significant Other Observable Inputs (Level 2) | Developed markets - repurchase agreements | Defined Benefit Pension Plans

Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items] [Line Items]

Fair value of plan assets (1,225.5) (1,372.9)

Significant Other Observable Inputs (Level 2) | Emerging markets | Defined Benefit Pension Plans

Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items] [Line Items]

Fair value of plan assets 255.8 251.7

Significant Other Observable Inputs (Level 2) | Emerging markets | Retiree Health Benefit Plans

Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items] [Line Items]

Fair value of plan assets 25.5 24.4

Significant Other Observable Inputs (Level 2) | Hedge funds | Defined Benefit Pension Plans

Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items] [Line Items]

Fair value of plan assets 0.0 0.0

Significant Other Observable Inputs (Level 2) | Hedge funds | Retiree Health Benefit Plans

Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items] [Line Items]

Fair value of plan assets 0.0 0.0

Significant Other Observable Inputs (Level 2) | Equity-like funds | Defined Benefit Pension Plans

Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items] [Line Items]

Fair value of plan assets 0.0 0.0

Significant Other Observable Inputs (Level 2) | Equity-like funds | Retiree Health Benefit Plans

Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items] [Line Items]

Fair value of plan assets 0.0 0.0

Significant Other Observable Inputs (Level 2) | Cash value of trust owned insurance contract | Retiree Health Benefit Plans

Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items] [Line Items]

Fair value of plan assets 1,574.7 1,524.6

Significant Other Observable Inputs (Level 2) | Real estate | Defined Benefit Pension Plans

Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items] [Line Items]

Fair value of plan assets 0.0 0.0

Significant Other Observable Inputs (Level 2) | Real estate | Retiree Health Benefit Plans

Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items] [Line Items]

Fair value of plan assets 0.0 0.0

Significant Other Observable Inputs (Level 2) | Other | Defined Benefit Pension Plans

Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items] [Line Items]

Fair value of plan assets 83.7 602.7

Significant Other Observable Inputs (Level 2) | Other | Retiree Health Benefit Plans

Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items] [Line Items]

Fair value of plan assets (3.8) 50.5

Quoted Prices in Active Markets for Identical Assets (Level 1) | Defined Benefit Pension Plans

Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items] [Line Items]

Fair value of plan assets 1,618.6 1,635.9

Quoted Prices in Active Markets for Identical Assets (Level 1) | Retiree Health Benefit Plans

Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items] [Line Items]

Fair value of plan assets 144.3 128.7

Quoted Prices in Active Markets for Identical Assets (Level 1) | U.S. | Defined Benefit Pension Plans

Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items] [Line Items]

Fair value of plan assets 409.1 199.0

Quoted Prices in Active Markets for Identical Assets (Level 1) | U.S. | Retiree Health Benefit Plans

Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items] [Line Items]

Fair value of plan assets 41.0 19.4

Quoted Prices in Active Markets for Identical Assets (Level 1) | International | Defined Benefit Pension Plans

Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items] [Line Items]

Fair value of plan assets 828.8 955.1

Quoted Prices in Active Markets for Identical Assets (Level 1) | International | Retiree Health Benefit Plans

Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items] [Line Items]

Fair value of plan assets 50.5 61.3

Quoted Prices in Active Markets for Identical Assets (Level 1) | Developed markets | Defined Benefit Pension Plans

Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items] [Line Items]

Fair value of plan assets 17.2 20.5

Quoted Prices in Active Markets for Identical Assets (Level 1) | Developed markets | Retiree Health Benefit Plans

Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items] [Line Items]

Fair value of plan assets 0.0 0.0

Quoted Prices in Active Markets for Identical Assets (Level 1) | Developed markets - repurchase agreements | Defined Benefit Pension Plans

Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items] [Line Items]

Fair value of plan assets 0.0 0.0

Quoted Prices in Active Markets for Identical Assets (Level 1) | Emerging markets | Defined Benefit Pension Plans

Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items] [Line Items]

Fair value of plan assets 3.4 3.6

Quoted Prices in Active Markets for Identical Assets (Level 1) | Emerging markets | Retiree Health Benefit Plans

Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items] [Line Items]

Fair value of plan assets 0.0 0.0

Quoted Prices in Active Markets for Identical Assets (Level 1) | Hedge funds | Defined Benefit Pension Plans

Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items] [Line Items]

Fair value of plan assets 0.0 0.0

Quoted Prices in Active Markets for Identical Assets (Level 1) | Hedge funds | Retiree Health Benefit Plans

Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items] [Line Items]

Fair value of plan assets 0.0 0.0

Quoted Prices in Active Markets for Identical Assets (Level 1) | Equity-like funds | Defined Benefit Pension Plans

Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items] [Line Items]

Fair value of plan assets 0.0 0.0

Quoted Prices in Active Markets for Identical Assets (Level 1) | Equity-like funds | Retiree Health Benefit Plans

Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items] [Line Items]

Fair value of plan assets 0.0 0.0

Quoted Prices in Active Markets for Identical Assets (Level 1) | Cash value of trust owned insurance contract | Retiree Health Benefit Plans

Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items] [Line Items]

Fair value of plan assets 0.0 0.0

Quoted Prices in Active Markets for Identical Assets (Level 1) | Real estate | Defined Benefit Pension Plans

Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items] [Line Items]

Fair value of plan assets 147.1 338.6

Quoted Prices in Active Markets for Identical Assets (Level 1) | Real estate | Retiree Health Benefit Plans

Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items] [Line Items]

Fair value of plan assets 14.7 33.0

Quoted Prices in Active Markets for Identical Assets (Level 1) | Other | Defined Benefit Pension Plans

Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items] [Line Items]

Fair value of plan assets 213.0 119.1

Quoted Prices in Active Markets for Identical Assets (Level 1) | Other | Retiree Health Benefit Plans

Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items] [Line Items]

Fair value of plan assets 38.1 15.0

Fair Value, Retirement Benefits, Investments Valued at Net Asset Value | Defined Benefit Pension Plans

Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items] [Line Items]

Fair value of plan assets 8,002.0 8,105.4

Fair Value, Retirement Benefits, Investments Valued at Net Asset Value | Retiree Health Benefit Plans

Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items] [Line Items]

Fair value of plan assets 593.4 578.6

Fair Value, Retirement Benefits, Investments Valued at Net Asset Value | U.S. | Defined Benefit Pension Plans

Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items] [Line Items]

Fair value of plan assets 208.6 266.4

Fair Value, Retirement Benefits, Investments Valued at Net Asset Value | U.S. | Retiree Health Benefit Plans

Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items] [Line Items]

Fair value of plan assets 18.9 23.6

Fair Value, Retirement Benefits, Investments Valued at Net Asset Value | International | Defined Benefit Pension Plans

Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items] [Line Items]

Fair value of plan assets 1,287.2 1,979.1

Fair Value, Retirement Benefits, Investments Valued at Net Asset Value | International | Retiree Health Benefit Plans

Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items] [Line Items]

Fair value of plan assets 76.3 121.2

Fair Value, Retirement Benefits, Investments Valued at Net Asset Value | Developed markets | Defined Benefit Pension Plans

Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items] [Line Items]

Fair value of plan assets 742.9 664.4

Fair Value, Retirement Benefits, Investments Valued at Net Asset Value | Developed markets | Retiree Health Benefit Plans

Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items] [Line Items]

Fair value of plan assets 7.6 7.7

Fair Value, Retirement Benefits, Investments Valued at Net Asset Value | Developed markets - repurchase agreements | Defined Benefit Pension Plans

Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items] [Line Items]

Fair value of plan assets 0.0 0.0

Fair Value, Retirement Benefits, Investments Valued at Net Asset Value | Emerging markets | Defined Benefit Pension Plans

Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items] [Line Items]

Fair value of plan assets 299.9 319.1

Fair Value, Retirement Benefits, Investments Valued at Net Asset Value | Emerging markets | Retiree Health Benefit Plans

Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items] [Line Items]

Fair value of plan assets 27.4 28.4

Fair Value, Retirement Benefits, Investments Valued at Net Asset Value | Hedge funds | Defined Benefit Pension Plans

Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items] [Line Items]

Fair value of plan assets 2,795.3 2,977.8

Fair Value, Retirement Benefits, Investments Valued at Net Asset Value | Hedge funds | Retiree Health Benefit Plans

Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items] [Line Items]

Fair value of plan assets 245.8 256.0

Fair Value, Retirement Benefits, Investments Valued at Net Asset Value | Equity-like funds | Defined Benefit Pension Plans

Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items] [Line Items]

Fair value of plan assets 1,876.7 1,570.1

Fair Value, Retirement Benefits, Investments Valued at Net Asset Value | Equity-like funds | Retiree Health Benefit Plans

Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items] [Line Items]

Fair value of plan assets 167.5 135.4

Fair Value, Retirement Benefits, Investments Valued at Net Asset Value | Cash value of trust owned insurance contract | Retiree Health Benefit Plans

Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items] [Line Items]

Fair value of plan assets 0.0 0.0

Fair Value, Retirement Benefits, Investments Valued at Net Asset Value | Real estate | Defined Benefit Pension Plans

Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items] [Line Items]

Fair value of plan assets 358.6 205.1

Fair Value, Retirement Benefits, Investments Valued at Net Asset Value | Real estate | Retiree Health Benefit Plans

Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items] [Line Items]

Fair value of plan assets 13.0 0.0

Fair Value, Retirement Benefits, Investments Valued at Net Asset Value | Other | Defined Benefit Pension Plans

Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items] [Line Items]

Fair value of plan assets 432.8 123.4

Fair Value, Retirement Benefits, Investments Valued at Net Asset Value | Other | Retiree Health Benefit Plans

Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items] [Line Items]

Fair value of plan assets $ 36.9 $ 6.3

X

- Definition
Amount of asset segregated and restricted to provide benefit under defined benefit plan. Asset includes, but is not limited to, stock, bond, other investment, earning from investment, and contribution by employer and employee.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (d)(iv)(01)
-URI http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (d)(iv)(01)
-URI http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (d)(ii)
-URI http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920

Reference 4: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 55
-Paragraph 17
-URI http://asc.fasb.org/extlink&oid=118257860&loc=d3e4179-114921

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920

Reference 6: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (d)(ii)
-URI http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920
+ Details

Name: us-gaap_DefinedBenefitPlanFairValueOfPlanAssets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_RetirementPlanTypeAxis=us-gaap_DefinedBenefitPostretirementHealthCoverageMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_DefinedBenefitPlanEquitySecuritiesUsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_DefinedBenefitPlanEquitySecuritiesNonUsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_FixedIncomeFundsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=lly_FixedIncomeFundsRepurchasedAgreementsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=lly_FixedIncomeFundsEmergingMarketsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_HedgeFundsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_EquityFundsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_OtherContractMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_DefinedBenefitPlanRealEstateMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=lly_DefineBenefitPlanOtherMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: lly_FairValueRetirementBenefitsInvestmentsAxis=lly_FairValueRetirementBenefitsInvestmentsValuedatNetAssetValueMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 98 R61.htm IDEA: XBRL DOCUMENT v3.19.3

(Narrative) (Details)
$ / shares in Units, SFr in Millions, $ in Millions
1 Months Ended 3 Months Ended 12 Months Ended

Feb. 15, 2019

USD ($)

$ / shares

Jan. 31, 2019

CHF (SFr)

Jan. 31, 2019

USD ($)

Dec. 31, 2018

USD ($)

Nov. 30, 2018

USD ($)

Oct. 31, 2018

USD ($)

Jul. 31, 2018

USD ($)

Jun. 30, 2018

USD ($)

Apr. 30, 2018

USD ($)

Nov. 30, 2017

USD ($)

Aug. 31, 2017

USD ($)

Jul. 31, 2017

USD ($)

Mar. 31, 2017

USD ($)

Dec. 31, 2016

USD ($)

Dec. 31, 2018

USD ($)

Sep. 30, 2018

USD ($)

Jun. 30, 2018

USD ($)

Mar. 31, 2018

USD ($)

Dec. 31, 2017

USD ($)

Sep. 30, 2017

USD ($)

Jun. 30, 2017

USD ($)

Mar. 31, 2017

USD ($)

Dec. 31, 2018

USD ($)

Dec. 31, 2017

USD ($)

Dec. 31, 2016

USD ($)

Business Acquisition [Line Items]

Acquired in-process research and development $ 329.4 $ 30.0 $ 1,624.5 $ 0.0 $ 50.0 $ 205.0 $ 0.0 $ 857.6 $ 1,983.9 $ 1,112.6 $ 30.0

Loxo Oncology, Inc.

Business Acquisition [Line Items]

Share price (usd per share) | $ / shares $ 235

Consideration transferred $ 8,000.0

AC Immune SA

Business Acquisition [Line Items]

Acquired in-process research and development $ 96.9

Purchased in-process research and development SFr 80.0 $ 50.0

Sigilon Therapeutics

Business Acquisition [Line Items]

Acquired in-process research and development $ 66.9

AurKa Pharma, Inc.

Business Acquisition [Line Items]

Acquired in-process research and development $ 81.8

ARMO

Business Acquisition [Line Items]

Acquired in-process research and development $ 1,475.8

Anima Biotech

Business Acquisition [Line Items]

Acquired in-process research and development $ 30.0

SIGA Technologies, Inc.

Business Acquisition [Line Items]

Acquired in-process research and development $ 80.0

Chugai Pharmaceutical Company

Business Acquisition [Line Items]

Acquired in-process research and development $ 50.0

NextCure, Inc.

Business Acquisition [Line Items]

Acquired in-process research and development $ 28.1

Dicerna Pharmaceuticals

Business Acquisition [Line Items]

Acquired in-process research and development $ 148.7

Hydra Biosciences

Business Acquisition [Line Items]

Acquired in-process research and development $ 22.6

CoLucid Pharmaceuticals, Inc. (CoLucid)

Business Acquisition [Line Items]

Acquired in-process research and development $ 857.6

KeyBioscience AG

Business Acquisition [Line Items]

Acquired in-process research and development $ 55.0

Nektar Therapeutics

Business Acquisition [Line Items]

Acquired in-process research and development $ 150.0

CureVac AG

Business Acquisition [Line Items]

Acquired in-process research and development $ 50.0

AstraZeneca

Business Acquisition [Line Items]

Acquired in-process research and development $ 30.0

X

- Definition
The amount of EXPENSE related to research and development assets that are acquired in a business combination (pre-141R) and/or licensing arrangement that have no alternative future use and are therefore written off in the period of acquisition (INCOME STATEMENT)
+ References
No definition available.
+ Details

Name: lly_AcquiredInProcessResearchAndDevelopment

Namespace Prefix: lly_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The amount of CASH paid for research and development assets that are acquired in a business combination (pre-141R) and/or licensing arrangement that have no alternative future use and are therefore, written off in the period of acquisition (CASH FLOWS).
+ References
No definition available.
+ Details

Name: lly_PurchasedInProcessResearchAndDevelopment

Namespace Prefix: lly_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_BusinessAcquisitionLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Price of a single share of a number of saleable stocks paid or offered to be paid in a business combination.
+ References
No definition available.
+ Details

Name: us-gaap_BusinessAcquisitionSharePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 30
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=116859721&loc=d3e6613-128477

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 30
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=116859721&loc=d3e6578-128477
+ Details

Name: us-gaap_BusinessCombinationConsiderationTransferred1

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Details

Name: us-gaap_BusinessAcquisitionAxis=lly_LoxoOncologyInc.Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_BusinessAcquisitionAxis=lly_ACImmuneSAMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_BusinessAcquisitionAxis=lly_SigilonTherapeuticsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_BusinessAcquisitionAxis=lly_AurkaPharmaMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_BusinessAcquisitionAxis=lly_ARMOBiosciencesInc.Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_BusinessAcquisitionAxis=lly_AnimaBiotechMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_BusinessAcquisitionAxis=lly_SIGATechnologiesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_BusinessAcquisitionAxis=lly_ChugaiPharmaceuticalCompanyMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_BusinessAcquisitionAxis=lly_NextCureInc.Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_BusinessAcquisitionAxis=lly_DicernaPharmaceuticalsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_BusinessAcquisitionAxis=lly_HydraBiosciencesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_BusinessAcquisitionAxis=lly_CoLucidPharmaceuticalsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_BusinessAcquisitionAxis=lly_KeyBiosciencesDualAmylinCalcitoninReceptorAgonistsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_BusinessAcquisitionAxis=lly_NektarsPhaseIImmunologicalTherapyMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_BusinessAcquisitionAxis=lly_CureVacAGMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_BusinessAcquisitionAxis=lly_AstraZenecaMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 99 R65.htm IDEA: XBRL DOCUMENT v3.19.3

Inventories (Details) - USD ($)
$ in Millions

Dec. 31, 2018

Dec. 31, 2017

Inventory Disclosure [Abstract]

Finished products $ 577.8 $ 759.4

Work in process 2,057.8 2,117.7

Raw materials and supplies 426.1 418.4

Total (approximates replacement cost) 3,061.7 3,295.5

Increase (reduction) to LIFO cost 36.4 100.5

Inventories 3,098.1 3,396.0

LIFO Inventory Amount $ 1,370.0 $ 1,330.0

X

- References
No definition available.
+ Details

Name: us-gaap_InventoryDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.6(a)(1))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_InventoryFinishedGoods

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Gross amount, as of the balance sheet date, of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.6(a))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_InventoryGross

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount by which inventory stated at last-in first-out (LIFO) is less than (in excess of) inventory stated at other inventory cost methods.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.6(c))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_InventoryLIFOReserve

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 330
-SubTopic 10
-Section 35
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=116846819&loc=d3e3927-108312

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.6(a))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_InventoryNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.6(a)(4))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_InventoryRawMaterials

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.6(a)(3))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_InventoryWorkInProcess

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
The amount of LIFO (last in first out) inventory present at the reporting date when inventory is also valued using different valuation methods.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766
+ Details

Name: us-gaap_LIFOInventoryAmount

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

XML 100 R95.htm IDEA: XBRL DOCUMENT v3.19.3

Other Comprehensive Income (Loss) (Tax effect) (Details) - USD ($)
$ in Millions
12 Months Ended

Dec. 31, 2018

Dec. 31, 2017

Dec. 31, 2016

Accumulated Other Comprehensive Income (Loss) [Line Items]

Benefit/(provision) for income taxes allocated to other comprehensive income (loss) items $ (30.3) $ 402.7 $ (10.6)

Foreign Currency Translation Gains (Losses)

Accumulated Other Comprehensive Income (Loss) [Line Items]

Benefit/(provision) for income taxes allocated to other comprehensive income (loss) items 51.6 170.8 (70.6)

Unrealized Net Gains (Losses) on Securities

Accumulated Other Comprehensive Income (Loss) [Line Items]

Benefit/(provision) for income taxes allocated to other comprehensive income (loss) items 2.1 55.0 (89.2)

Defined Benefit Pension and Retiree Health Benefit Plans

Accumulated Other Comprehensive Income (Loss) [Line Items]

Benefit/(provision) for income taxes allocated to other comprehensive income (loss) items (85.3) 186.6 153.3

Effective Portion of Cash Flow Hedges

Accumulated Other Comprehensive Income (Loss) [Line Items]

Benefit/(provision) for income taxes allocated to other comprehensive income (loss) items $ 1.3 $ (9.7) $ (4.1)

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of tax expense (benefit) allocated to other comprehensive income (loss).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 20
-Section 45
-Paragraph 11
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109238882&loc=d3e39076-109324

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 20
-Section 45
-Paragraph 2
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=109238882&loc=d3e38679-109324

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=118930883&loc=d3e640-108580
+ Details

Name: us-gaap_OtherComprehensiveIncomeLossTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 101 R99.htm IDEA: XBRL DOCUMENT v3.19.3

Selected Quarterly Data (Unaudited) (Details) - USD ($)
$ / shares in Units, $ in Millions
3 Months Ended 12 Months Ended

Dec. 31, 2018

Sep. 30, 2018

Jun. 30, 2018

Mar. 31, 2018

Dec. 31, 2017

Sep. 30, 2017

Jun. 30, 2017

Mar. 31, 2017

Dec. 31, 2018

Dec. 31, 2017

Dec. 31, 2016

Quarterly Financial Information Disclosure [Abstract]

Revenue $ 5,637.6 $ 5,306.9 $ 5,585.0 $ 4,963.8 $ 5,406.4 $ 4,961.0 $ 5,091.6 $ 4,514.9 $ 21,493.3 $ 19,973.8 $ 18,312.8

Cost of sales 1,129.9 1,152.9 1,234.3 1,164.6 1,186.4 1,163.5 1,140.1 957.7 4,681.7 4,447.7 4,160.5

Operating expenses 3,085.5 2,738.1 2,756.6 2,446.2 3,054.0 2,678.2 2,763.8 2,582.5

Acquired in-process research and development 329.4 30.0 1,624.5 0.0 50.0 205.0 0.0 857.6 1,983.9 1,112.6 30.0

Asset impairment, restructuring, and other special charges (Note 5) 192.7 42.9 (25.5) 56.8 830.7 389.2 0.3 111.4 266.9 1,331.6 72.9

Income before income taxes 931.6 1,341.1 41.7 1,365.7 397.0 573.1 1,249.4 85.2

Income taxes (Note 13) (189.8) 247.5 273.3 198.5 1,947.5 29.0 244.3 170.3 529.5 2,391.2 551.4

Net income (loss) from continuing operations 1,121.4 1,093.6 (231.6) 1,167.2 (1,550.5) 544.1 1,005.1 (85.1) 3,150.6 (86.4) 2,724.9

Net Income (loss) from discontinued operations 3.7 55.9 (28.3) 50.2 (106.4) 11.5 2.9 (25.7) $ 81.4 $ (117.7) $ 12.7

Net income (loss) $ 1,125.1 $ 1,149.5 $ (259.9) $ 1,217.4 $ (1,656.9) $ 555.6 $ 1,008.0 $ (110.8)

Earnings (loss) from continuing operations - basic (usd per share) $ 1.11 $ 1.07 $ (0.22) $ 1.11 $ (1.48) $ 0.52 $ 0.96 $ (0.08) $ 3.07 $ (0.08) $ 2.57

Earnings (loss) from discontinued operations - basic (usd per share) 0 0.06 (0.03) 0.05 (0.10) 0.01 0 (0.02) 0.07 (0.11) 0.02

Basic (usd per share) 1.11 1.13 (0.25) 1.16 (1.58) 0.53 0.96 (0.10) 3.14 (0.19) 2.59

Earnings (loss) from continuing operations - diluted (usd per share) 1.10 1.07 (0.22) 1.11 (1.48) 0.52 0.95 (0.08) 3.05 (0.08) 2.57

Earnings (loss) from discontinued operations - diluted (usd per share) 0 0.05 (0.03) 0.05 (0.10) 0.01 0 (0.02) 0.08 (0.11) 0.01

Diluted (usd per share) 1.10 1.12 (0.25) 1.16 (1.58) 0.53 0.95 (0.10) $ 3.13 $ (0.19) $ 2.58

Dividends paid per share (usd per share) $ 0.5625 $ 0.5625 $ 0.5625 $ 0.5625 $ 0.52 $ 0.52 $ 0.52 $ 0.52

X

- Definition
The amount of EXPENSE related to research and development assets that are acquired in a business combination (pre-141R) and/or licensing arrangement that have no alternative future use and are therefore written off in the period of acquisition (INCOME STATEMENT)
+ References
No definition available.
+ Details

Name: lly_AcquiredInProcessResearchAndDevelopment

Namespace Prefix: lly_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Aggregate dividends paid during the period for each share of common stock outstanding.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770
+ Details

Name: us-gaap_CommonStockDividendsPerShareCashPaid

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.2(a),(d))
-URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227
+ Details

Name: us-gaap_CostOfGoodsAndServicesSold

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(19))
-URI http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=117326831&loc=d3e1337-109256

Reference 3: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 55
-Paragraph 52
-URI http://asc.fasb.org/extlink&oid=117327953&loc=d3e4984-109258

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(21))
-URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=117326831&loc=d3e1252-109256

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(23))
-URI http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=117326831&loc=SL5780133-109256
+ Details

Name: us-gaap_EarningsPerShareBasic

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.
+ References
Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 55
-Paragraph 52
-URI http://asc.fasb.org/extlink&oid=117327953&loc=d3e4984-109258

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=117326831&loc=d3e1252-109256

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(23))
-URI http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=117326831&loc=d3e1337-109256

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(21))
-URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=117326831&loc=SL5780133-109256

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(19))
-URI http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263
+ Details

Name: us-gaap_EarningsPerShareDiluted

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(h)(1)(i))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690
+ Details

Name: us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount after tax of income (loss) from continuing operations including portion attributable to the noncontrolling interest.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 45
-Paragraph 19
-URI http://asc.fasb.org/extlink&oid=108774443&loc=SL4569616-111683
+ Details

Name: us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The amount of net income (loss) from continuing operations per each share of common stock or unit outstanding during the reporting period.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(19))
-URI http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(11))
-URI http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(21))
-URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=117326831&loc=d3e1337-109256

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=117326831&loc=SL5780133-109256

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=117326831&loc=d3e1252-109256

Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(20))
-URI http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260

Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(23))
-URI http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260

Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-03(13))
-URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868656-224227
+ Details

Name: us-gaap_IncomeLossFromContinuingOperationsPerBasicShare

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
The amount of net income (loss) derived from continuing operations during the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=117326831&loc=d3e1337-109256

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=117326831&loc=d3e1252-109256

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(23))
-URI http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(11))
-URI http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-03(13))
-URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868656-224227

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=117326831&loc=SL5780133-109256

Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(19))
-URI http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263

Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(21))
-URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227
+ Details

Name: us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount after tax of income (loss) from a discontinued operation including the portion attributable to the noncontrolling interest. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(12))
-URI http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 45
-Paragraph 3B
-URI http://asc.fasb.org/extlink&oid=109222160&loc=SL51721525-107759

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5C
-Subparagraph (b)(2)
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 45
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=109222160&loc=d3e957-107759

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(21))
-URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227

Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 45
-Paragraph 3A
-URI http://asc.fasb.org/extlink&oid=109222160&loc=SL51721523-107759

Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 45
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=109222160&loc=d3e1012-107759
+ Details

Name: us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Per basic share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation and gain (loss) from the disposal of the discontinued operation.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=117326831&loc=SL5780133-109256

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(23))
-URI http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=117326831&loc=d3e1278-109256

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(19))
-URI http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(12))
-URI http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=117326831&loc=d3e1337-109256

Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(21))
-URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227

Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(14))
-URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227
+ Details

Name: us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
Per diluted share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation and gain (loss) from the disposal of the discontinued operation.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=117326831&loc=d3e1337-109256

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section S99
-Paragraph 5
-Subparagraph (SAB Topic 5.E)
-URI http://asc.fasb.org/extlink&oid=116822174&loc=d3e355146-122828

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=117326831&loc=SL5780133-109256

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=117326831&loc=d3e1278-109256
+ Details

Name: us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (h)
-URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(h))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 20
-Section 45
-Paragraph 2
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109238882&loc=d3e38679-109324
+ Details

Name: us-gaap_IncomeTaxExpenseBenefit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.
+ References
No definition available.
+ Details

Name: us-gaap_OperatingExpenses

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118930883&loc=SL7669619-108580

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 1A
-Subparagraph (a)(1)
-URI http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118930883&loc=SL7669625-108580

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 1A
-Subparagraph (c)(1)
-URI http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599

Reference 6: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 55
-Paragraph 4J
-URI http://asc.fasb.org/extlink&oid=116874947&loc=SL4591551-111686

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3000-108585

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 45
-Paragraph 19
-URI http://asc.fasb.org/extlink&oid=108774443&loc=SL4569616-111683

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8933-108599

Reference 10: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 55
-Paragraph 4K
-URI http://asc.fasb.org/extlink&oid=116874947&loc=SL4591552-111686
+ Details

Name: us-gaap_ProfitLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_QuarterlyFinancialInformationDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of restructuring charges, remediation cost, and asset impairment loss.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.3)
-URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227
+ Details

Name: us-gaap_RestructuringSettlementAndImpairmentProvisions

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8933-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(1))
-URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227
+ Details

Name: us-gaap_Revenues

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

XML 102 R69.htm IDEA: XBRL DOCUMENT v3.19.3

Financial Instruments (Contractual Maturities) (Details)
$ in Millions

Dec. 31, 2018

USD ($)

Derivative Instruments and Hedging Activities Disclosure [Abstract]

Total $ 943.0

Less Than 1 Year 86.8

1-5 Years 604.8

6-10 Years 97.0

More Than 10 Years $ 154.4

X

- Definition
Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in sixth through tenth fiscal year following latest fiscal year. Excludes interim and annual periods when interim period is reported on rolling approach, from latest statement of financial position date.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=118939692&loc=d3e27161-111563

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=118939692&loc=d3e27198-111563

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 320
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=75019621&loc=d3e62586-112803
+ Details

Name: us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following latest fiscal year. Excludes interim and annual periods when interim period is reported on rolling approach, from latest statement of financial position date.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=118939692&loc=d3e27198-111563

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 320
-Section 50
-Paragraph 3
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=75019621&loc=d3e62586-112803

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=118939692&loc=d3e27161-111563
+ Details

Name: us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Fair value of investment in debt security, measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing after tenth fiscal year following latest fiscal year. Excludes interim and annual periods when interim period is reported on rolling approach, from latest statement of financial position date.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=118939692&loc=d3e27198-111563

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=118939692&loc=d3e27161-111563

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 320
-Section 50
-Paragraph 3
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=75019621&loc=d3e62586-112803
+ Details

Name: us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), maturing in next fiscal year following latest fiscal year. Excludes interim and annual periods when interim period is reported on rolling approach, from latest statement of financial position date.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118939692&loc=d3e27198-111563

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=118939692&loc=d3e27161-111563

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 320
-Section 50
-Paragraph 3
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=75019621&loc=d3e62586-112803
+ Details

Name: us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 326
-SubTopic 30
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=118942338&loc=SL82898722-210454

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-SubTopic 10
-Section 45
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=118954083&loc=d3e26610-111562

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (aa)
-URI http://asc.fasb.org/extlink&oid=118939692&loc=d3e27161-111563
+ Details

Name: us-gaap_AvailableForSaleSecuritiesDebtSecurities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 103 R23.htm IDEA: XBRL DOCUMENT v3.19.3

Income Taxes
12 Months Ended

Dec. 31, 2018

Income Tax Disclosure [Abstract]

Income Taxes Income Taxes
2017 Tax Act
In December 2017, the President of the U.S. signed into law the 2017 Tax Act. The 2017 Tax Act included significant changes to the U.S. corporate income tax system, such as the reduction in the corporate income tax rate from 35 percent to 21 percent, transition to a territorial tax system, changes to business related exclusions, deductions and credits, and modifications to international tax provisions, including a one-time repatriation transition tax (also known as the ‘Toll Tax’) on unremitted foreign earnings.
GAAP requires that the income tax accounting effects from a change in tax laws or tax rates be recognized in continuing operations in the reporting period that includes the enactment date of the change. These effects include, among other things, re-measuring deferred tax assets and liabilities, evaluating deferred tax assets for valuation allowances, and assessing the impact of the Toll Tax and certain other provisions of the 2017 Tax Act. Our accounting for the tax effects of the enactment of the 2017 Tax Act was not complete as of December 31, 2017; however, in certain cases we made a reasonable estimate. In other cases, we were not able to make a reasonable estimate and continued to account for those items based on our existing accounting model under ASC 740, Income Taxes, and the provisions of the tax laws that were in effect immediately prior to enactment. For the items for which we were able to determine a reasonable estimate, we recognized a provisional amount of $1.91 billion, which was included as a component of income tax expense from continuing operations. Our accounting for the effects of the 2017 Tax Act was completed in the current period, and we recorded $313.3 million of income tax benefit in 2018, mainly attributable to measurement period adjustments to the Toll Tax and the global intangible low-taxed income (GILTI) provision, the new U.S. minimum tax on the earnings of our foreign subsidiaries. Related to GILTI, we elected to establish deferred taxes in the amount of $1.74 billion for the reversal of temporary items in future years.
Subsequent to the enactment of the 2017 Tax Act, additional guidance was issued, including Notices, Proposed Regulations, and Final Regulations. We expect that further guidance will continue to be issued in 2019 which may impact our interpretations of the 2017 Tax Act and could materially affect the estimates used.
Deferred taxes are recognized for the future tax effects of temporary differences between financial and income tax reporting based on enacted tax laws and rates.
We recognize the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by the taxing authorities, based on the technical merits of the position. The tax benefits recognized in the financial statements from such a position are measured based on the largest benefit that has a greater than 50 percent likelihood of being realized upon ultimate resolution.
Following is the composition of income tax expense:

2018

2017

2016
Current:

Federal
$
(31.9
)

$
(66.5
)

$
20.0

Foreign
106.8

47.5

397.0

State
4.7

(5.4
)

(134.4
)
2017 Tax Act
201.5

3,247.5

—

Total current tax expense
281.1

3,223.1

282.6

Deferred:

Federal
22.5

732.3

410.0

Foreign
248.7

(230.9
)

(136.3
)
State
3.4

0.2

(4.9
)
2017 Tax Act
(26.2
)

(1,333.5
)

—

Total deferred tax (benefit) expense
248.4

(831.9
)

268.8

Income taxes
$
529.5

$
2,391.2

$
551.4

Significant components of our deferred tax assets and liabilities as of December 31 are as follows:

2018

2017
Deferred tax assets:

Purchases of intangible assets
$
2,627.7

$
441.9

Compensation and benefits
781.6

995.3

Tax credit carryforwards and carrybacks
359.4

467.5

Tax loss carryforwards and carrybacks
248.2

471.3

Product return reserves
95.3

83.4

Other comprehensive loss on hedging transactions
68.9

68.9

Debt
40.3

53.5

Contingent consideration
11.7

32.1

Other
680.1

524.3

Total gross deferred tax assets
4,913.2

3,138.2

Valuation allowances
(574.8
)

(681.8
)
Total deferred tax assets
4,338.4

2,456.4

Deferred tax liabilities:

Earnings of foreign subsidiaries
(1,745.3
)

(16.6
)
Inventories
(681.3
)

(649.5
)
Property and equipment
(260.9
)

(247.5
)
Prepaid employee benefits
(240.1
)

(231.5
)
Intangibles
(86.9
)

(120.7
)
Financial instruments
(22.8
)

(41.6
)
Total deferred tax liabilities
(3,037.3
)

(1,307.4
)
Deferred tax assets - net
$
1,301.1

$
1,149.0

Our accounting for the effects of the 2017 Tax Act was completed in the current period; therefore, deferred tax assets and liabilities reflect re-measurement resulting from the 2017 Tax Act.
The deferred tax asset and related valuation allowance amounts for U.S. federal and state net operating losses and tax credits shown above have been reduced for differences between financial reporting and tax return filings.
At December 31, 2018, based on filed tax returns we have tax credit carryforwards and carrybacks of $729.5 million available to reduce future income taxes; $150.5 million, if unused, will expire by 2027. The remaining portion of the tax credit carryforwards is related to federal tax credits of $122.9 million, international tax credits of $119.3 million, and state tax credits of $336.9 million, all of which are substantially reserved.
At December 31, 2018, based on filed tax returns we had net operating losses and other carryforwards for international and U.S. federal income tax purposes of $773.2 million: $12.1 million will expire by 2023; $462.2 million will expire between 2024 and 2038; and $298.9 million of the carryforwards will never expire. Net operating losses and other carryforwards for international and U.S. federal income tax purposes are partially reserved. Deferred tax assets related to state net operating losses of $99.7 million and other state carryforwards of $2.6 million are fully reserved.
Domestic and Puerto Rican companies contributed approximately 15 percent, 16 percent, and 63 percent for the years ended December 31, 2018, 2017, and 2016, respectively, to consolidated income before income taxes. We have a subsidiary operating in Puerto Rico under a tax incentive grant effective through the end of 2031.
The 2017 Tax Act introduced international tax provisions that fundamentally change the U.S. taxation of foreign earnings. As a result, substantially all of the unremitted earnings of our foreign subsidiaries are considered to not be indefinitely reinvested for continued use in our foreign operations. At December 31, 2018, we have accrued an immaterial amount of foreign withholding taxes and state income taxes that would be owed upon future distributions of unremitted earnings of our foreign subsidiaries that are not indefinitely reinvested. For the amount considered to be indefinitely reinvested, it is not practicable to determine the amount of the related deferred income tax liability due to the complexities in the tax laws and assumptions we would have to make.
Cash payments of income taxes were as follows:

2018

2017

2016
Cash payments of income taxes
$
1,076.7

$
221.5

$
686.4

The 2017 Tax Act provided an election to taxpayers subject to the Toll Tax to make payments over an eight-year period. We made this election; therefore, we have included Toll Tax payments accordingly.
Following is a reconciliation of the income tax expense applying the U.S. federal statutory rate to income before income taxes to reported income tax expense:

2018

2017

2016
Income tax at the U.S. federal statutory tax rate
$
772.8

$
806.7

$
1,146.7

Add (deduct):

International operations, including Puerto Rico
(627.1
)

(480.8
)

(357.2
)
General business credits
(87.4
)

(66.8
)

(57.0
)
Non-deductible acquired IPR&D⁽¹⁾
309.9

300.1

—

2017 Tax Act
175.3

1,914.0

—

Other
(14.0
)

(82.0
)

(181.1
)
Income taxes
$
529.5

$
2,391.2

$
551.4

⁽¹⁾Non-deductible acquired IPR&D was related to ARMO in 2018 and CoLucid in 2017. See Note 3 for additional information related to acquisitions.
A reconciliation of the beginning and ending amount of gross unrecognized tax benefits is as follows:

2018

2017

2016
Beginning balance at January 1
$
1,000.8

$
843.3

$
1,057.2

Additions based on tax positions related to the current year
798.2

133.8

73.4

Additions for tax positions of prior years
410.9

93.8

11.0

Reductions for tax positions of prior years
(115.4
)

(59.3
)

(12.1
)
Settlements
(33.2
)

(2.4
)

(171.9
)
Lapses of statutes of limitation
(20.5
)

(19.3
)

(110.0
)
Changes related to the impact of foreign currency translation
(6.2
)

10.9

(4.3
)
Ending balance at December 31
$
2,034.6

$
1,000.8

$
843.3

The total amount of unrecognized tax benefits that, if recognized, would affect our effective tax rate was $1.48 billion and $657.1 million at December 31, 2018 and 2017, respectively.
We file income tax returns in the U.S. federal jurisdiction and various state, local, and non-U.S. jurisdictions. We are no longer subject to U.S. federal, state and local, or non-U.S. income tax examinations in most major taxing jurisdictions for years before 2010.
The U.S. examination of tax years 2010-2012 commenced during the fourth quarter of 2013. In December 2015, we executed a closing agreement with the Internal Revenue Service which effectively settled certain matters for tax years 2010-2012. Accordingly, we reduced our gross uncertain tax positions by approximately $320 million in 2015. During 2016, we effectively settled the remaining matters related to tax years
2010-2012. As a result of this resolution, our gross uncertain tax positions were further reduced by approximately $140 million, and our consolidated results of operations benefited from an immaterial reduction in income tax expense. During 2016, we made cash payments of approximately $150 million related to tax years 2010-2012 after application of available tax credit carryforwards and carrybacks. The U.S. examination of tax years 2013-2015 began in 2016, and we believe it is reasonably possible that this examination could reach resolution within the next 12 months for tax years 2013-2014 and certain matters under examination for tax year 2015, for which the audit remains ongoing. As a result, we currently estimate that gross uncertain tax positions may be reduced by approximately $450 million within the next 12 months. Additionally, we anticipate up to $150 million of cash payments will be due upon resolution.
We recognize both accrued interest and penalties related to unrecognized tax benefits in income tax expense. We recognized income tax (benefit) expense related to interest and penalties as follows:

2018

2017

2016
Income tax expense (benefit)
$
25.1

$
22.8

$
(63.8
)

At December 31, 2018 and 2017, our accruals for the payment of interest and penalties totaled $183.9 million and $155.0 million, respectively.

X

- References
No definition available.
+ Details

Name: us-gaap_IncomeTaxDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-URI http://asc.fasb.org/topic&trid=2144680
+ Details

Name: us-gaap_IncomeTaxDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 104 R27.htm IDEA: XBRL DOCUMENT v3.19.3

Other-Net, (Income) Expense
12 Months Ended

Dec. 31, 2018

Nonoperating Income (Expense) [Abstract]

Other - Net, (Income) Expense Other–Net, (Income) Expense
Other–net, (income) expense consisted of the following:

2018

2017

2016
Interest expense
$
242.5

$
225.0

$
185.2

Interest income
(159.3
)

(166.4
)

(107.9
)
Venezuela charge
—

—

203.9

Retirement benefit
(240.5
)

(249.0
)

(197.1
)
Other (income) expense
11.7

(111.1
)

(192.9
)
Other–net, (income) expense
$
(145.6
)

$
(301.5
)

$
(108.8
)

Due to the financial crisis in Venezuela and the significant deterioration of the bolívar, we changed the exchange rate used to translate the assets and liabilities of our subsidiaries in Venezuela in 2016, which resulted in a charge of $203.9 million for the year ended December 31, 2016. Prior to this change, we used the Supplementary Foreign Currency Administration System (SICAD) rate; however, this official rate was discontinued in the first quarter of 2016. After considering several factors, including the future uncertainty of the Venezuelan economy, published exchange rates, and the limited amount of foreign currency exchanged, we changed to the Divisa Complementaria (DICOM) rate.
As discussed in Note 2, upon adoption of Accounting Standards Update 2017-07, Compensation-Retirement Benefits: Improving the Presentation of Net Periodic Pension Cost and Net Periodic Postretirement Benefit Cost, pension and postretirement benefit cost components other than service costs are presented in other–net, (income) expense. Results for the years ended December 31, 2017 and 2016 have been reclassified to reflect the adoption of this standard.
For the years ended December 31, 2017, and 2016, other income is primarily related to net gains on investments (Note 7).

X

- References
No definition available.
+ Details

Name: us-gaap_NonoperatingIncomeExpenseAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for other income or other expense items (both operating and nonoperating). Sources of nonoperating income or nonoperating expense that may be disclosed, include amounts earned from dividends, interest on securities, profits (losses) on securities, net and miscellaneous other income or income deductions.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 720
-URI http://asc.fasb.org/topic&trid=2122503

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 610
-URI http://asc.fasb.org/topic&trid=49130413
+ Details

Name: us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 105 R11.htm IDEA: XBRL DOCUMENT v3.19.3

Summary of Significant Accounting Policies
12 Months Ended

Dec. 31, 2018

Accounting Policies [Abstract]

Summary of Significant Accounting Policies Summary of Significant Accounting Policies
Basis of presentation
The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (GAAP). The accounts of all wholly-owned and majority-owned subsidiaries are included in the consolidated financial statements. Where our ownership of consolidated subsidiaries is less than 100 percent, the noncontrolling shareholders’ interests are reflected as a separate component of equity. All intercompany balances and transactions have been eliminated.
The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues, expenses, and related disclosures at the date of the financial statements and during the reporting period. Actual results could differ from those estimates. We issued our financial statements by filing with the Securities and Exchange Commission (SEC) and have evaluated subsequent events up to the time of the filing of our Form 10-K.
On September 24, 2018, Elanco Animal Health Incorporated (Elanco), one of our subsidiaries, completed its initial public offering (IPO) of 72.3 million shares of its common stock, which represents 19.8 percent of Elanco's outstanding shares, at $24 per share. On March 11, 2019, we completed the disposition of our remaining 80.2 percent ownership of Elanco common stock through a tax-free exchange offer. As a result, in the first quarter of 2019, we presented Elanco as discontinued operations in our consolidated condensed financial statements for all periods presented. Accordingly, all prior periods have been recast to conform to this presentation.
Certain reclassifications have been made to prior periods in the consolidated financial statements and accompanying notes to conform with the current presentation.
All per-share amounts, unless otherwise noted in the footnotes, are presented on a diluted basis.
Adoption of Revenue Accounting Standard
Effective January 1, 2018, we adopted Accounting Standards Update 2014-09, Revenue from Contracts with Customers and other related updates (see Note 2 for additional discussion). The new standard has been applied to contracts for which performance was not substantially complete as of the date of adoption. For those contracts that were modified prior to the date of adoption, we reflected the aggregate effect of those modifications when determining the appropriate accounting under the new standard. We don’t believe the effect of applying this practical expedient resulted in material differences. Revenue presented for periods prior to 2018 was accounted for under previous standards and has not been adjusted. Revenue and net income for 2018 do not differ materially from amounts that would have resulted from application of the previous standards.
The following table summarizes our revenue recognized in our consolidated statements of operations:

2018

2017

2016
Net product revenue
$
19,866.4

$
18,776.5

$
17,480.0

Collaboration and other revenue⁽¹⁾
1,626.9

1,197.3

832.8

Revenue
$
21,493.3

$
19,973.8

$
18,312.8

⁽¹⁾Collaboration and other revenue associated with prior year transfers of intellectual property was $303.2 million, $144.9 million, and $145.3 million during the years ended 2018, 2017, and 2016, respectively.
We recognize revenue primarily from two different types of contracts, product sales to customers (net product revenue) and collaborations and other arrangements. Revenue recognized from collaborations and other arrangements will include our share of profits from the collaboration, as well as royalties, upfront and milestone payments we receive under these types of contracts. See Note 4 for additional information related to our collaborations and other arrangements. Collaboration and other revenue disclosed above includes the revenue from the Trajenta^® and Jardiance^® families of products resulting from our collaboration with
Boehringer Ingelheim discussed in Note 4. Substantially all of the remainder of collaboration and other revenue is related to contracts accounted for as contracts with customers.
Net Product Revenue
Revenue from sales of products is recognized at the point where the customer obtains control of the goods and we satisfy our performance obligation, which generally is at the time we ship the product to the customer. Payment terms differ by jurisdiction and customer, but payment terms in most of our major jurisdictions typically range from 30 to 70 days from date of shipment. Revenue for our product sales has not been adjusted for the effects of a financing component as we expect, at contract inception, that the period between when we transfer control of the product and when we receive payment will be one year or less. Any exceptions are either not material or we collect interest for payments made after the due date. Provisions for rebates and discounts, and returns are established in the same period the related sales are recognized. We generally ship product shortly after orders are received; therefore, we generally only have a few days of orders received but not yet shipped at the end of any reporting period. Shipping and handling activities are considered to be fulfillment activities and are not considered to be a separate performance obligation. We exclude from the measurement of the transaction price all taxes assessed by a governmental authority that are imposed on our sales of product and collected from a customer.
Significant judgments must be made in determining the transaction price for our sales of products related to anticipated rebates and discounts and returns. The following describe the most significant of these judgments:
Sales Rebates and Discounts - Background and Uncertainties
•
Most of our products are sold to wholesalers that serve pharmacies, physicians and other health care professionals, and hospitals. We initially invoice our customers at contractual list prices. Contracts with direct and indirect customers may provide for various rebates and discounts that may differ in each contract. As a consequence, to determine the appropriate transaction price for our product sales at the time we recognize a sale to a direct customer, we must estimate any rebates or discounts that ultimately will be due to the direct customer and other customers in the distribution chain under the terms of our contracts. Significant judgments are required in making these estimates.
•
The rebate and discount amounts are recorded as a deduction to arrive at our net product revenue. Sales rebates and discounts that require the use of judgment in the establishment of the accrual include managed care, Medicare, Medicaid, chargebacks, long-term care, hospital, patient assistance programs, and various other programs. We estimate these accruals using an expected value approach.
•
The largest of our sales rebate and discount amounts are rebates associated with sales covered by managed care, Medicare, Medicaid, and chargeback contracts in the United States (U.S.) In determining the appropriate accrual amount, we consider our historical rebate payments for these programs by product as a percentage of our historical sales as well as any significant changes in sales trends (e.g., patent expiries and product launches), an evaluation of the current contracts for these programs, the percentage of our products that are sold via these programs, and our product pricing. Although we accrue a liability for rebates related to these programs at the time we record the sale, the rebate related to that sale is typically paid up to six months later. Because of this time lag, in any particular period our rebate adjustments may incorporate revisions of accruals for several periods.
•
Most of our rebates outside the U.S. are contractual or legislatively mandated and are estimated and recognized in the same period as the related sales. In some large European countries, government rebates are based on the anticipated budget for pharmaceutical payments in the country. An estimate of these rebates, updated as governmental authorities revise budgeted deficits, is recognized in the same period as the related sale.
Sales Returns - Background and Uncertainties
•
When product sales occur, to determine the appropriate transaction price for our sales, we estimate a reserve for future product returns related to those sales using an expected value approach. This estimate is based on several factors, including: historical return rates, expiration date by product (on average, approximately 24 months after the initial sale of a product to our customer), and estimated levels of inventory in the wholesale and retail channels, as well as any other specifically-identified anticipated returns due to known factors such as the loss of patent exclusivity, product recalls and
discontinuances, or a changing competitive environment. We maintain a returns policy that allows U.S. customers to return product for dating issues within a specified period prior to and subsequent to the product's expiration date. Following the loss of exclusivity for a patent-dependent product, we expect to experience an elevated level of product returns as product inventory remaining in the wholesale and retail channels expires. Adjustments to the returns reserve have been and may in the future be required based on revised estimates to our assumptions. We record the return amounts as a deduction to arrive at our net product revenue. Once the product is returned, it is destroyed; we do not record a right of return asset. Our returns policies outside the U.S. are generally more restrictive than in the U.S. as returns are not allowed for reasons other than failure to meet product specifications in many countries. Our reserve for future product returns for product sales outside the U.S. is not material.
•
As a part of our process to estimate a reserve for product returns, we regularly review the supply levels of our significant products sold to major wholesalers in the U.S. and in major markets outside the U.S., primarily by reviewing periodic inventory reports supplied by our major wholesalers and available prescription volume information for our products, or alternative approaches. We attempt to maintain U.S. wholesaler inventory levels at an average of approximately one month or less on a consistent basis across our product portfolio. Causes of unusual wholesaler buying patterns include actual or anticipated product-supply issues, weather patterns, anticipated changes in the transportation network, redundant holiday stocking, and changes in wholesaler business operations. In the U.S., the current structure of our arrangements provides us with data on inventory levels at our wholesalers; however, our data on inventory levels in the retail channel is more limited. Wholesaler stocking and destocking activity historically has not caused any material changes in the rate of actual product returns.
•
Actual product returns have been less than 2 percent of our net revenue over each of the past three years and have not fluctuated significantly as a percentage of revenue, although fluctuations are more likely in periods following loss of patent exclusivity for major products in the U.S. market.
Adjustments to Revenue
Adjustments to revenue recognized as a result of changes in estimates for the judgments described above during 2018 for product shipped in previous years were approximately 1 percent of revenue.
Disaggregation of Revenue
Our disaggregated revenue is disclosed in Note 18.
Collaborations and Other Arrangements
We recognize several types of revenue from our collaborations and other arrangements, which we discuss in general terms immediately below and more specifically in Note 4 for each of our material collaborations and other arrangements. Our collaborations and other arrangements are not contracts with customers but are evaluated to determine whether any aspects of the arrangements are contracts with customers.
•
Revenue related to products we sell pursuant to these arrangements is included in net product revenue, while other sources of revenue (e.g., royalties and profit sharing from our partner) are included in collaboration and other revenue.
•
Initial fees and developmental milestones we receive in collaborative and other similar arrangements from the partnering of our compounds under development are generally deferred and amortized into income through the expected product approval date.
•
Profit-sharing due from our collaboration partners, which is based upon gross margins reported to us by our partners, is recognized as collaboration and other revenue as earned.
•
Royalty revenue from licensees, which is based on sales to third-parties of licensed products and technology, is recorded when the third-party sale occurs and the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). This royalty revenue is included in collaboration and other revenue.
•
For arrangements involving multiple goods or services (e.g., research and development, marketing and selling, manufacturing, and distribution), each required good or service is evaluated to determine whether it is distinct. If a good or service does not qualify as distinct, it is combined with the other non-distinct goods or services within the arrangement and these combined goods or services are
treated as a single performance obligation for accounting purposes. The arrangement's transaction price is then allocated to each performance obligation based on the relative standalone selling price of each performance obligation. For arrangements that involve variable consideration where we have sold intellectual property, we recognize revenue based on estimates of the amount of consideration we believe we will be entitled to receive from the other party, subject to a constraint. These estimates are adjusted to reflect the actual amounts to be collected when those facts and circumstances become known.
•
Significant judgments must be made in determining the transaction price for our sales of intellectual property. Because of the risk that products in development will not receive regulatory approval, we generally do not recognize any contingent payments that would be due to us upon or after regulatory approval.
•
We have entered into arrangements whereby we transferred rights to products and committed to supply for a period of time. For those arrangements for which we concluded that the obligations were not distinct, any amounts received upfront are being amortized to revenue as net product revenue over the period of the supply arrangement as the performance obligation is satisfied.
Contract Liabilities
Our contract liabilities result from arrangements where we have received payment in advance of performance under the contract and do not include sales rebates, discounts, and returns. Changes in contract liabilities are generally due to either receipt of additional advance payments or our performance under the contract.
We have the following amounts recorded for contract liabilities:

2018

2017
Contract liabilities
$
294.9

$
330.9

The contract liabilities amount disclosed above as of December 31, 2018 and 2017, are primarily related to:
•
The remaining license period of symbolic intellectual property, and
•
Obligations to supply product for a defined period of time.
Revenue recognized from contract liabilities as of January 1, 2018, during the year ended December 31, 2018 was not material. Revenue expected to be recognized in the future from contract liabilities as the related performance obligations are satisfied is not expected to be material in any one year.
Research and development expenses and acquired in-process research and development
Research and development expenses include the following:
•
Research and development costs, which are expensed as incurred.
•
Milestone payment obligations incurred prior to regulatory approval of the product, which are accrued when the event requiring payment of the milestone occurs.
Acquired in-process research and development (IPR&D) expense includes the initial costs of IPR&D projects, acquired directly in a transaction other than a business combination, that do not have an alternative future use.
Earnings per share
We calculate basic earnings per share (EPS) based on the weighted-average number of common shares outstanding and incremental shares from potential participating securities. We calculate diluted EPS based on the weighted-average number of common shares outstanding, including incremental shares from our stock-based compensation programs.
Foreign Currency Translation
Operations in our subsidiaries outside the U.S. are recorded in the functional currency of each subsidiary which is determined by a review of the environment where each subsidiary primarily generates and expends cash. The results of operations for our subsidiaries outside the U.S. are translated from functional currencies into U.S. dollars using the weighted average currency rate for the period. Assets and liabilities are translated
using the period end exchange rates. The U.S. dollar effects that arise from translating the net assets of these subsidiaries are recorded in other comprehensive income (loss).
Other significant accounting policies
Our other significant accounting policies are described in the remaining appropriate notes to the consolidated financial statements.

X

- References
No definition available.
+ Details

Name: us-gaap_AccountingPoliciesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-URI http://asc.fasb.org/topic&trid=2122149

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-URI http://asc.fasb.org/topic&trid=2197479
+ Details

Name: us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 106 R15.htm IDEA: XBRL DOCUMENT v3.19.3

Asset Impairment, Restructuring, and Other Special Charges
12 Months Ended

Dec. 31, 2018

Restructuring and Related Activities [Abstract]

Asset Impairment, Restructuring, And Other Special Charges Asset Impairment, Restructuring, and Other Special Charges
The components of the charges included in asset impairment, restructuring, and other special charges in our consolidated statements of operations are described below:

2018

2017

2016
Severance
$
127.8

$
601.0

$
85.9

Pension and post-retirement medical charges associated with U.S. voluntary early retirement program (see Note 14)
—

446.7

—

Asset impairment (gains from facility sales) and other special charges
139.1

283.9

(13.0
)
Total asset impairment, restructuring, and other special charges
$
266.9

$
1,331.6

$
72.9

Severance costs recognized during the years ended December 31, 2018, 2017 and 2016 were incurred as a result of actions taken to reduce our cost structure. Severance costs recognized in 2017 were associated with the U.S. voluntary early retirement program. During 2017, severance costs recognized in the U.S. and outside the U.S. were $368.3 million and $232.7 million, respectively. Substantially all of the severance costs incurred in 2016 and 2017 have been paid. Of the severance costs incurred during the year ended December 31, 2018, approximately half will be paid in 2019 and half will be paid in 2020.
Asset impairment and other special charges recognized during the year ended December 31, 2018 resulted primarily from asset impairment and other special charges related to the sale of the Posilac^® (rbST) brand and the associated Augusta, Georgia manufacturing site.
Asset impairment and other special charges recognized during the year ended December 31, 2017 resulted primarily from asset impairments related to lower projected revenue for Posilac (rbST). The assets associated with Posilac (rbST) were written down to their fair values, which were determined based upon a discounted cash flow valuation. Impairment charges were recorded for the associated fixed assets and intangible asset of $151.5 million and $50.0 million, respectively (refer to Note 8 for further detail relating to intangible asset impairments). In addition, we incurred approximately $43.4 million of costs associated with the temporary shut down of our Puerto Rico facility following Hurricane Maria.

X

- References
No definition available.
+ Details

Name: us-gaap_RestructuringAndRelatedActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure of costs incurred for restructuring including, but not limited to, exit and disposal activities, remediation, implementation, integration, asset impairment, and charges against earnings from the write-down of assets.
+ References
No definition available.
+ Details

Name: us-gaap_RestructuringImpairmentAndOtherActivitiesDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 107 R19.htm IDEA: XBRL DOCUMENT v3.19.3

Property and Equipment
12 Months Ended

Dec. 31, 2018

Property, Plant and Equipment [Abstract]

Property and Equipment Property and Equipment
Property and equipment is stated on the basis of cost. Provisions for depreciation of buildings and equipment are computed generally by the straight-line method at rates based on their estimated useful lives (12 to 50 years for buildings and three to 25 years for equipment). We review the carrying value of long-lived assets for potential impairment on a periodic basis and whenever events or changes in circumstances indicate the carrying value of an asset may not be recoverable. Impairment is determined by comparing projected undiscounted cash flows to be generated by the asset to its carrying value. If an impairment is identified, a loss is recorded equal to the excess of the asset’s net book value over its fair value, and the cost basis is adjusted.
At December 31, property and equipment consisted of the following:

2018

2017
Land
$
165.5

$
167.7

Buildings
7,116.6

6,826.9

Equipment
7,792.3

7,684.1

Construction in progress
1,588.6

1,600.6

16,663.0

16,279.3

Less accumulated depreciation
(8,666.9
)

(8,394.2
)
Property and equipment, net
$
7,996.1

$
7,885.1

Depreciation expense related to property and equipment and rental expense for all leases, including contingent rentals (not material), was as follows:

2018

2017

2016
Depreciation expense
$
797.1

$
681.7

$
638.8

Rental expense
175.7

177.4

179.2

The future minimum rental commitments under non-cancelable operating leases are as follows:

2019

2020

2021

2022

2023

After 2023
Lease commitments
$
130.6

$
107.9

$
75.5

$
64.7

$
49.9

$
281.0

Capitalized interest costs were not material for the years ended December 31, 2018, 2017, and 2016.
Assets under capital leases included in property and equipment, net on the consolidated balance sheets, capital lease obligations entered into, and future minimum rental commitments are not material.

X

- References
No definition available.
+ Details

Name: us-gaap_PropertyPlantAndEquipmentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, accounting policies and methodology, roll forwards, depreciation, depletion and amortization expense, including composite depreciation, accumulated depreciation, depletion and amortization expense, useful lives and method used, income statement disclosures, assets held for sale and public utility disclosures.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-URI http://asc.fasb.org/topic&trid=2155823
+ Details

Name: us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 108 R36.htm IDEA: XBRL DOCUMENT v3.19.3

Stock-Based Compensation (Policies)
12 Months Ended

Dec. 31, 2018

Share-based Payment Arrangement [Abstract]

Share-based Compensation, Option and Incentive Plans We recognize the fair value of stock-based compensation as expense over the requisite service period of the individual grantees, which generally equals the vesting period. We provide newly issued shares of our common stock and treasury stock to satisfy the issuance of PA, SVA, and RSU shares.

X

- References
No definition available.
+ Details

Name: us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (b),(f)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5047-113901
+ Details

Name: us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 109 R6.htm IDEA: XBRL DOCUMENT v3.19.3

Consolidated Balance Sheets (Parenthetical) - USD ($)
$ in Millions

Dec. 31, 2018

Dec. 31, 2017

Statement of Financial Position [Abstract]

Accounts receivable, allowances $ 24.1 $ 28.9

Issued shares 1,057,639,000 1,100,672,000

Authorized shares, shares 3,200,000,000 3,200,000,000

X

- Definition
Amount of allowance for credit loss on accounts receivable, classified as current.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(4)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=118936363&loc=d3e5074-111524

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 326
-SubTopic 20
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=118955202&loc=SL82895884-210446
+ Details

Name: us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
The maximum number of common shares permitted to be issued by an entity's charter and bylaws.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_CommonStockSharesAuthorized

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_CommonStockSharesIssued

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_StatementOfFinancialPositionAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 110 R100.htm IDEA: XBRL DOCUMENT v3.19.3

Discontinued Operations (Details) - USD ($)
$ in Millions
1 Months Ended 3 Months Ended 12 Months Ended

Mar. 11, 2019

Sep. 24, 2018

Aug. 31, 2018

Mar. 31, 2019

Dec. 31, 2018

Dec. 31, 2017

Dec. 31, 2016

Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]

Noncontrolling interests $ 1,080.4 $ 75.7

Cash paid for acquisitions, net of cash acquired 0.0 882.1 $ 45.0

Cash provided by operating activities, discontinued operations 500.0 300.0 300.0

Cash used by investing activities, discontinued operations 130.0 $ 960.0 $ 180.0

Elanco Animal Health Incorporated

Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]

Consideration received $ 4,200.0

Additional paid in capital $ 629.2

Noncontrolling interests $ 1,020.0

Elanco Animal Health Incorporated | Discontinued Operations, Disposed of by Sale

Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]

Noncontrolling interest, ownership percentage by parent 80.20%

Gain on disposition of business $ 3,700.0

Transitional services agreement, term 24 months

Elanco Animal Health Incorporated

Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]

Percentage of stock sold (in percentage) 19.80%

Proceeds from issuance of debt $ 2,000.0

Term Facility | Elanco Animal Health Incorporated

Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]

Debt instrument, face amount $ 500.0

Debt instrument, term 3 years

X

- Definition
Disposal Group, Including Discontinued Operation, Transitional Services Agreement, Term
+ References
No definition available.
+ Details

Name: lly_DisposalGroupIncludingDiscontinuedOperationTransitionalServicesAgreementTerm

Namespace Prefix: lly_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Sale Of Stock, Percentage Of Stock Sold
+ References
No definition available.
+ Details

Name: lly_SaleOfStockPercentageOfStockSold

Namespace Prefix: lly_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30)(a)(1))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_AdditionalPaidInCapital

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of cash inflow (outflow) of investing activities of discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 24
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3521-108585

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5B
-Subparagraph (c)(1)
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760
+ Details

Name: us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of cash inflow (outflow) of operating activities of discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 24
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3521-108585

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5B
-Subparagraph (c)(1)
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760
+ Details

Name: us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Face (par) amount of debt instrument at time of issuance.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=114775744&loc=d3e28551-108399

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 55
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400
+ Details

Name: us-gaap_DebtInstrumentFaceAmount

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.
+ References
No definition available.
+ Details

Name: us-gaap_DebtInstrumentTerm

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of consideration received or receivable for the disposal of assets and liabilities, including discontinued operation.
+ References
No definition available.
+ Details

Name: us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of gain (loss) from sale and disposal of integrated set of activities and assets capable of being conducted and managed for purpose of providing return in form of dividend, lower cost, or other economic benefit to investor, owner, member and participant.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 1B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109239629&loc=SL4582445-111684
+ Details

Name: us-gaap_GainLossOnSaleOfBusiness

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(24))
-URI http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.31)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(22))
-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878
+ Details

Name: us-gaap_MinorityInterest

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
The parent entity's interest in net assets of the subsidiary, expressed as a percentage.
+ References
No definition available.
+ Details

Name: us-gaap_MinorityInterestOwnershipPercentageByParent

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: instant

X

- Definition
The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 13
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3213-108585
+ Details

Name: us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 14
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3255-108585
+ Details

Name: us-gaap_ProceedsFromIssuanceOfDebt

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=lly_ElancoAnimalHealthIncorporatedMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_DisposalGroupClassificationAxis=us-gaap_DiscontinuedOperationsDisposedOfBySaleMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: dei_LegalEntityAxis=lly_ElancoAnimalHealthIncorporatedMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_LongtermDebtTypeAxis=lly_TermFacilityMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 111 R2.htm IDEA: XBRL DOCUMENT v3.19.3

Consolidated Statements of Operations - USD ($)
shares in Thousands, $ in Millions
12 Months Ended

Dec. 31, 2018

Dec. 31, 2017

Dec. 31, 2016

Income Statement [Abstract]

Revenue $ 21,493.3 $ 19,973.8 $ 18,312.8

Costs, expenses, and other:

Cost of sales 4,681.7 4,447.7 4,160.5

Research and development 5,051.2 5,096.2 5,040.0

Marketing, selling, and administrative 5,975.1 5,982.4 5,841.9

Acquired in-process research and development (Note 3) 1,983.9 1,112.6 30.0

Asset impairment, restructuring, and other special charges (Note 5) 266.9 1,331.6 72.9

Other—net, (income) expense (Note 17) (145.6) (301.5) (108.8)

Cost of sales, operating expenses, and other-net 17,813.2 17,669.0 15,036.5

Income before income taxes 3,680.1 2,304.8 3,276.3

Income taxes (Note 13) 529.5 2,391.2 551.4

Net income (loss) from continuing operations 3,150.6 (86.4) 2,724.9

Net Income (loss) from discontinued operations (Note 20) 81.4 (117.7) 12.7

Net income (loss) $ 3,232.0 $ (204.1) $ 2,737.6

Earnings (loss) per share:

Earnings (loss) from continuing operations - basic (usd per share) $ 3.07 $ (0.08) $ 2.57

Earnings (loss) from discontinued operations - basic (usd per share) 0.07 (0.11) 0.02

Basic (usd per share) 3.14 (0.19) 2.59

Earnings (loss) from continuing operations - diluted (usd per share) 3.05 (0.08) 2.57

Earnings (loss) from discontinued operations - diluted (usd per share) 0.08 (0.11) 0.01

Diluted (usd per share) $ 3.13 $ (0.19) $ 2.58

Shares used in calculation of earnings (loss) per share:

Basic (shares) 1,027,721 1,052,023 1,058,324

Diluted (shares) 1,033,667 1,052,023 1,061,825

X

- Definition
The amount of EXPENSE related to research and development assets that are acquired in a business combination (pre-141R) and/or licensing arrangement that have no alternative future use and are therefore written off in the period of acquisition (INCOME STATEMENT)
+ References
No definition available.
+ Details

Name: lly_AcquiredInProcessResearchAndDevelopment

Namespace Prefix: lly_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Cost of sales, operating expenses, and other-net
+ References
No definition available.
+ Details

Name: lly_CostOfSalesOperatingExpensesAndOtherNet

Namespace Prefix: lly_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.2(a),(d))
-URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227
+ Details

Name: us-gaap_CostOfGoodsAndServicesSold

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_CostsAndExpensesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_EarningsPerShareAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(19))
-URI http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=117326831&loc=d3e1337-109256

Reference 3: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 55
-Paragraph 52
-URI http://asc.fasb.org/extlink&oid=117327953&loc=d3e4984-109258

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(21))
-URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=117326831&loc=d3e1252-109256

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(23))
-URI http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=117326831&loc=SL5780133-109256
+ Details

Name: us-gaap_EarningsPerShareBasic

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.
+ References
Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 55
-Paragraph 52
-URI http://asc.fasb.org/extlink&oid=117327953&loc=d3e4984-109258

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=117326831&loc=d3e1252-109256

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(23))
-URI http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=117326831&loc=d3e1337-109256

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(21))
-URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=117326831&loc=SL5780133-109256

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(19))
-URI http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263
+ Details

Name: us-gaap_EarningsPerShareDiluted

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 940
-SubTopic 20
-Section 25
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=68072869&loc=d3e41242-110953

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(10))
-URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(8))
-URI http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(15))
-URI http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260
+ Details

Name: us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount after tax of income (loss) from continuing operations including portion attributable to the noncontrolling interest.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 45
-Paragraph 19
-URI http://asc.fasb.org/extlink&oid=108774443&loc=SL4569616-111683
+ Details

Name: us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The amount of net income (loss) from continuing operations per each share of common stock or unit outstanding during the reporting period.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(19))
-URI http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(11))
-URI http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(21))
-URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=117326831&loc=d3e1337-109256

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=117326831&loc=SL5780133-109256

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=117326831&loc=d3e1252-109256

Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(20))
-URI http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260

Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(23))
-URI http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260

Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-03(13))
-URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868656-224227
+ Details

Name: us-gaap_IncomeLossFromContinuingOperationsPerBasicShare

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
The amount of net income (loss) derived from continuing operations during the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=117326831&loc=d3e1337-109256

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=117326831&loc=d3e1252-109256

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(23))
-URI http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(11))
-URI http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-03(13))
-URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868656-224227

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=117326831&loc=SL5780133-109256

Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(19))
-URI http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263

Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(21))
-URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227
+ Details

Name: us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount after tax of income (loss) from a discontinued operation including the portion attributable to the noncontrolling interest. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(12))
-URI http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 45
-Paragraph 3B
-URI http://asc.fasb.org/extlink&oid=109222160&loc=SL51721525-107759

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5C
-Subparagraph (b)(2)
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 45
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=109222160&loc=d3e957-107759

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(21))
-URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227

Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 45
-Paragraph 3A
-URI http://asc.fasb.org/extlink&oid=109222160&loc=SL51721523-107759

Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 45
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=109222160&loc=d3e1012-107759
+ Details

Name: us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Per basic share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation and gain (loss) from the disposal of the discontinued operation.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=117326831&loc=SL5780133-109256

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(23))
-URI http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=117326831&loc=d3e1278-109256

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(19))
-URI http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(12))
-URI http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=117326831&loc=d3e1337-109256

Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(21))
-URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227

Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(14))
-URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227
+ Details

Name: us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
Per diluted share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation and gain (loss) from the disposal of the discontinued operation.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=117326831&loc=d3e1337-109256

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section S99
-Paragraph 5
-Subparagraph (SAB Topic 5.E)
-URI http://asc.fasb.org/extlink&oid=116822174&loc=d3e355146-122828

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=117326831&loc=SL5780133-109256

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=117326831&loc=d3e1278-109256
+ Details

Name: us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_IncomeStatementAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (h)
-URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(h))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 20
-Section 45
-Paragraph 2
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109238882&loc=d3e38679-109324
+ Details

Name: us-gaap_IncomeTaxExpenseBenefit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118930883&loc=SL7669619-108580

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(22))
-URI http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118930883&loc=SL7669625-108580

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(18))
-URI http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(20))
-URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585

Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257
+ Details

Name: us-gaap_NetIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.7)
-URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227
+ Details

Name: us-gaap_NonoperatingIncomeExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 985
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 730
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373
+ Details

Name: us-gaap_ResearchAndDevelopmentExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of restructuring charges, remediation cost, and asset impairment loss.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.3)
-URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227
+ Details

Name: us-gaap_RestructuringSettlementAndImpairmentProvisions

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8933-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(1))
-URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227
+ Details

Name: us-gaap_Revenues

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 330
-SubTopic 10
-Section 30
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=68048583&loc=d3e3636-108311

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.4)
-URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227
+ Details

Name: us-gaap_SellingGeneralAndAdministrativeExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 16
-URI http://asc.fasb.org/extlink&oid=117326831&loc=d3e1505-109256
+ Details

Name: us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=117326831&loc=d3e1448-109256

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257
+ Details

Name: us-gaap_WeightedAverageNumberOfSharesOutstandingBasic

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

XML 112 R32.htm IDEA: XBRL DOCUMENT v3.19.3

Inventories (Policies)
12 Months Ended

Dec. 31, 2018

Inventory Disclosure [Abstract]

Inventory We use the last-in, first-out (LIFO) method for the majority of our inventories located in the continental U.S. Other inventories are valued by the first-in, first-out (FIFO) method. FIFO cost approximates current replacement cost.

X

- References
No definition available.
+ Details

Name: us-gaap_InventoryDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 330
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=116847112&loc=d3e4556-108314

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 270
-SubTopic 10
-Section 45
-Paragraph 6
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=116846552&loc=d3e543-108305

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 330
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=116847112&loc=d3e4492-108314

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.6(b))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_InventoryPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 113 R53.htm IDEA: XBRL DOCUMENT v3.19.3

Other - Net, (Income) Expense (Tables)
12 Months Ended

Dec. 31, 2018

Nonoperating Income (Expense) [Abstract]

Schedule of Other Nonoperating Income (Expense)
Other–net, (income) expense consisted of the following:

2018

2017

2016
Interest expense
$
242.5

$
225.0

$
185.2

Interest income
(159.3
)

(166.4
)

(107.9
)
Venezuela charge
—

—

203.9

Retirement benefit
(240.5
)

(249.0
)

(197.1
)
Other (income) expense
11.7

(111.1
)

(192.9
)
Other–net, (income) expense
$
(145.6
)

$
(301.5
)

$
(108.8
)

X

- References
No definition available.
+ Details

Name: us-gaap_NonoperatingIncomeExpenseAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of the components of non-operating income or non-operating expense that may include amounts earned from dividends, interest on securities, gains (losses) on securities sold, equity earnings of unconsolidated affiliates, net gain (loss) on sales of business, interest expense and other miscellaneous income or expense items.
+ References
No definition available.
+ Details

Name: us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 114 R57.htm IDEA: XBRL DOCUMENT v3.19.3

Summary of Significant Accounting Policies (Acquisitions) (Details) - $ / shares
shares in Millions

Sep. 24, 2018

Mar. 11, 2019

Elanco Animal Health Incorporated

Business Acquisition [Line Items]

Percentage of stock sold (in percentage) 19.80%

IPO | Elanco Animal Health Incorporated

Business Acquisition [Line Items]

Initial public offering (in shares) 72.3

Sale of stock, price per share (usd per share) $ 24

Elanco Animal Health Incorporated | Discontinued Operations, Disposed of by Sale

Business Acquisition [Line Items]

Noncontrolling interest, ownership percentage by parent 80.20%

X

- Definition
Sale Of Stock, Percentage Of Stock Sold
+ References
No definition available.
+ Details

Name: lly_SaleOfStockPercentageOfStockSold

Namespace Prefix: lly_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_BusinessAcquisitionLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The parent entity's interest in net assets of the subsidiary, expressed as a percentage.
+ References
No definition available.
+ Details

Name: us-gaap_MinorityInterestOwnershipPercentageByParent

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: instant

X

- Definition
The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.
+ References
No definition available.
+ Details

Name: us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.
+ References
No definition available.
+ Details

Name: us-gaap_SaleOfStockPricePerShare

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Details

Name: dei_LegalEntityAxis=lly_ElancoAnimalHealthIncorporatedMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=lly_ElancoAnimalHealthIncorporatedMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_DisposalGroupClassificationAxis=us-gaap_DiscontinuedOperationsDisposedOfBySaleMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

EXCEL 115 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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�EL*:H8K/ -CELG4\6L@]<><-O!^?F/_Z,0; M,4>JX%FPGW6IJ\Q?^UX))WIA^D5TGV 0E/C>H/X+7($9N*W$Y"@$4^[K%1>E M!1]83"F:QXLX)5=+-&#V/2:ZPR3K$4(,_9@CPG+LHW_C-WA\C-88 MN_CX78T+G&"!$BP
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end XML 116 R78.htm IDEA: XBRL DOCUMENT v3.19.3

Borrowings (narrative) (Details) - USD ($)
$ in Millions
1 Months Ended 12 Months Ended

May 31, 2017

Dec. 31, 2018

Dec. 31, 2017

Dec. 31, 2016

Debt Instrument [Line Items]

Weighted average interest rate (in percentage) 2.36%

Line of credit facility, remaining borrowing capacity $ 5,420.0

Line of credit facility, outstanding $ 25.9 $ 6.0

Proceeds from issuance of secured debt $ 2,230.0

Description of derivative activity volume percent 25.00%

Debt instrument, interest rate, effective percentage (in percentage) 3.13% 2.65%

Cash payments for interest on borrowings $ 223.8 $ 192.7 $ 146.4

Notes Due in May 2022

Debt Instrument [Line Items]

Debt instrument, face amount $ 750.0

Stated interest rate (in percentage) 2.35%

Notes Due in May 2027

Debt Instrument [Line Items]

Debt instrument, face amount $ 750.0

Stated interest rate (in percentage) 3.10%

Notes Due in 2047

Debt Instrument [Line Items]

Debt instrument, face amount $ 750.0

Stated interest rate (in percentage) 3.95%

Minimum

Debt Instrument [Line Items]

Stated interest rate (in percentage) 0.15%

Maximum

Debt Instrument [Line Items]

Stated interest rate (in percentage) 7.13%

Maturity Date, 2023

Debt Instrument [Line Items]

Line of credit facility, maximum borrowing capacity $ 3,000.0

Maturity Date, 2019

Debt Instrument [Line Items]

Line of credit facility, maximum borrowing capacity $ 2,000.0

Debt instrument, term 364 days

X

- Definition
Label: Description of Derivative Activity Volume Element ID: us-gaap_DescriptionOfDerivativeActivityVolume Balance Type: na Data Type: PERCENT Period Type: duration --------------------------------------------------------------------- Definition: Information that would enable users to understand the volume of the entity's derivative activity. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 133 -Paragraph 44 -Subparagraph 2
+ References
No definition available.
+ Details

Name: lly_DescriptionOfDerivativeActivityVolumePercent

Namespace Prefix: lly_

Data Type: num:percentItemType

Balance Type: na

Period Type: instant

X

- Definition
Face (par) amount of debt instrument at time of issuance.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=114775744&loc=d3e28551-108399

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 55
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400
+ Details

Name: us-gaap_DebtInstrumentFaceAmount

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 6
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109500613&loc=SL6036836-161870

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=114775744&loc=d3e28551-108399

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.22(a)(1))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_DebtInstrumentInterestRateEffectivePercentage

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: instant

X

- Definition
Contractual interest rate for funds borrowed, under the debt agreement.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.22(a)(1))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_DebtInstrumentInterestRateStatedPercentage

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: instant

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_DebtInstrumentLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.
+ References
No definition available.
+ Details

Name: us-gaap_DebtInstrumentTerm

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=98513485&loc=d3e4297-108586

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 17
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3367-108585

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 25
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3536-108585
+ Details

Name: us-gaap_InterestPaidNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Fair value of the amount outstanding under the credit facility.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=118260190&loc=d3e13433-108611
+ Details

Name: us-gaap_LineOfCreditFacilityFairValueOfAmountOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.19(b),22(b))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of borrowing capacity currently available under the credit facility (current borrowing capacity less the amount of borrowings outstanding).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.19(b),22(b))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
The cash inflow from amounts received from issuance of long-term debt that is wholly or partially secured by collateral. Excludes proceeds from tax exempt secured debt.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 14
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3255-108585
+ Details

Name: us-gaap_ProceedsFromIssuanceOfSecuredDebt

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Weighted average interest rate of short-term debt outstanding calculated at point in time.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.19(b))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_ShortTermDebtWeightedAverageInterestRate

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: instant

X

- Details

Name: us-gaap_DebtInstrumentAxis=lly_NotesDueinMayTwentyTwentyTwoMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_DebtInstrumentAxis=lly_NotesDueinMayTwentyTwentySevenMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_DebtInstrumentAxis=lly_NotesDueinTwentyFortySevenMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_RangeAxis=srt_MinimumMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_RangeAxis=srt_MaximumMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_DebtInstrumentRedemptionPeriodAxis=lly_MaturityDate2023Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_DebtInstrumentRedemptionPeriodAxis=lly_MaturityDate2019Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 117 R88.htm IDEA: XBRL DOCUMENT v3.19.3

Retirement Benefits (Schedule of Components in Consolidated Balance Sheets) (Details) - USD ($)
$ in Millions

Dec. 31, 2018

Dec. 31, 2017

Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items] [Line Items]

Accrued retirement benefits $ (2,802.2) $ (3,376.0)

Defined Benefit Pension Plans

Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items] [Line Items]

Sundry 193.7 104.5

Other current liabilities (64.2) (64.5)

Accrued retirement benefits (2,624.0) (3,166.7)

Accumulated other comprehensive (income) loss before income taxes 5,036.3 5,630.9

Net amount recognized 2,541.8 2,504.2

Retiree Health Benefit Plans

Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items] [Line Items]

Sundry 1,043.6 870.1

Other current liabilities (7.3) (7.1)

Accrued retirement benefits (178.2) (209.3)

Accumulated other comprehensive (income) loss before income taxes (159.3) (213.0)

Net amount recognized $ 698.8 $ 440.7

X

- Definition
Amount, before tax, of accumulated other comprehensive (income) loss for defined benefit plan, that has not been recognized in net periodic benefit cost (credit).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 10A
-Subparagraph (i-k)
-URI http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 14A
-URI http://asc.fasb.org/extlink&oid=118930883&loc=SL7669686-108580
+ Details

Name: us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of asset (liability), recognized in statement of financial position, for defined benefit pension and other postretirement plans.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109237824&loc=d3e1703-114919
+ Details

Name: us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of asset, recognized in statement of financial position, for overfunded defined benefit pension and other postretirement plans.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 45
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=109237824&loc=d3e1731-114919

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109237824&loc=d3e1703-114919

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(17))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(10))
-URI http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(10))
-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878
+ Details

Name: us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of liability, recognized in statement of financial position, for defined benefit pension and other postretirement plans, classified as current.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109237824&loc=d3e1703-114919

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(20))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 45
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=109237824&loc=d3e1731-114919

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920
+ Details

Name: us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of liability, recognized in statement of financial position, for defined benefit pension and other postretirement plans, classified as noncurrent.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109237824&loc=d3e1703-114919

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 45
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=109237824&loc=d3e1731-114919

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(24))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Details

Name: us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_RetirementPlanTypeAxis=us-gaap_DefinedBenefitPostretirementHealthCoverageMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 118 R84.htm IDEA: XBRL DOCUMENT v3.19.3

Income Taxes (Deferred tax asset and liabilities) (Details) - USD ($)
$ in Millions

Dec. 31, 2018

Dec. 31, 2017

Deferred tax assets:

Purchases of intangible assets $ 2,627.7 $ 441.9

Compensation and benefits 781.6 995.3

Tax credit carryforwards and carrybacks 359.4 467.5

Tax loss carryforwards and carrybacks 248.2 471.3

Product return reserves 95.3 83.4

Other comprehensive loss on hedging transactions 68.9 68.9

Debt 40.3 53.5

Contingent consideration 11.7 32.1

Other 680.1 524.3

Total gross deferred tax assets 4,913.2 3,138.2

Valuation allowances (574.8) (681.8)

Total deferred tax assets 4,338.4 2,456.4

Deferred tax liabilities:

Earnings of foreign subsidiaries (1,745.3) (16.6)

Inventories (681.3) (649.5)

Property and equipment (260.9) (247.5)

Prepaid employee benefits (240.1) (231.5)

Intangibles (86.9) (120.7)

Financial instruments (22.8) (41.6)

Total deferred tax liabilities (3,037.3) (1,307.4)

Deferred tax assets, net $ 1,301.1 $ 1,149.0

X

- Definition
Deferred tax asset resulting from fair value adjustments, including on hedged borrowings
+ References
No definition available.
+ Details

Name: lly_DeferredTaxAssetFairValueAdjustments

Namespace Prefix: lly_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of deferred tax liability attributable to taxable temporary differences.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(26)(b))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(15)(b)(2))
-URI http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(15)(2))
-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(26)(a))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319
+ Details

Name: us-gaap_DeferredIncomeTaxLiabilities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from intangible assets including goodwill.
+ References
No definition available.
+ Details

Name: us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319
+ Details

Name: us-gaap_DeferredTaxAssetsGross

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319
+ Details

Name: us-gaap_DeferredTaxAssetsLiabilitiesNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (b),(c)
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319
+ Details

Name: us-gaap_DeferredTaxAssetsNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_DeferredTaxAssetsNetAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32621-109319

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32632-109319

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 25
-Paragraph 20
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=117330534&loc=d3e28680-109314
+ Details

Name: us-gaap_DeferredTaxAssetsOperatingLossCarryforwards

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 25
-Paragraph 20
-URI http://asc.fasb.org/extlink&oid=117330534&loc=d3e28680-109314

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32632-109319

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32621-109319
+ Details

Name: us-gaap_DeferredTaxAssetsOther

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from unrealized losses in other comprehensive income.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 20
-Section 45
-Paragraph 11
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109238882&loc=d3e39076-109324

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 25
-Paragraph 20
-URI http://asc.fasb.org/extlink&oid=117330534&loc=d3e28680-109314

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32621-109319

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32632-109319
+ Details

Name: us-gaap_DeferredTaxAssetsOtherComprehensiveLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount, before allocation of a valuation allowances, of deferred tax assets attributable to deductible tax credit carryforwards including, but not limited to, research, foreign, general business, alternative minimum tax, and other deductible tax credit carryforwards.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32632-109319

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32559-109319

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32621-109319
+ Details

Name: us-gaap_DeferredTaxAssetsTaxCreditCarryforwards

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from compensation and benefits costs.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32621-109319

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32632-109319

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 25
-Paragraph 20
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=117330534&loc=d3e28680-109314
+ Details

Name: us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from contingent liabilities.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 25
-Paragraph 20
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=117330534&loc=d3e28680-109314

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32632-109319

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32621-109319
+ Details

Name: us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsContingencies

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences from reserves, classified as other.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32632-109319

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 25
-Paragraph 20
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=117330534&loc=d3e28680-109314

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32621-109319
+ Details

Name: us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319
+ Details

Name: us-gaap_DeferredTaxAssetsValuationAllowance

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of deferred tax consequences attributable to taxable temporary differences derived from inventory.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32632-109319

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 25
-Paragraph 20
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=117330534&loc=d3e28680-109314

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32621-109319
+ Details

Name: us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedInventoryCosts

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of deferred tax liability attributable to taxable temporary differences from derivatives.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32621-109319

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32632-109319
+ Details

Name: us-gaap_DeferredTaxLiabilitiesDerivatives

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of deferred tax liability attributable to taxable temporary differences from intangible assets including goodwill.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32632-109319

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32621-109319

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 25
-Paragraph 20
-URI http://asc.fasb.org/extlink&oid=117330534&loc=d3e28680-109314
+ Details

Name: us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of deferred tax consequences attributable to taxable temporary differences derived from prepaid expenses.
+ References
No definition available.
+ Details

Name: us-gaap_DeferredTaxLiabilitiesPrepaidExpenses

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 25
-Paragraph 20
-URI http://asc.fasb.org/extlink&oid=117330534&loc=d3e28680-109314

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32621-109319

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32632-109319
+ Details

Name: us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of deferred tax liability attributable to taxable temporary differences from undistributed earnings of subsidiary and other recognized entity not within country of domicile. Includes, but is not limited to, other basis differences.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32621-109319
+ Details

Name: us-gaap_DeferredTaxLiabilitiesUndistributedForeignEarnings

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

XML 119 R74.htm IDEA: XBRL DOCUMENT v3.19.3

Goodwill and Other Intangibles (Narrative) (Details) - USD ($)
$ in Millions
12 Months Ended

Dec. 31, 2018

Dec. 31, 2017

Dec. 31, 2016

Finite-lived intangible assets:

Goodwill, impairment loss $ 0.0 $ 0.0 $ 0.0

Impairment of intangibles 50.0

Impairment of finite-lived intangible $ 46.9

Impairment of indefinite-lived intangibles 50.0

Remaining amortization period (in years) 10 years

Animal health products

Finite-lived intangible assets:

Impairment of intangibles $ 68.9 135.5

Impairment of finite-lived intangible 55.9 97.5

Impairment of indefinite-lived intangibles $ 13.0 $ 38.0

Minimum

Finite-lived intangible assets:

Finite-lived intangible asset, useful life (in years) 3 years

Maximum

Finite-lived intangible assets:

Finite-lived intangible asset, useful life (in years) 20 years

X

- Definition
Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.
+ References
No definition available.
+ Details

Name: us-gaap_FiniteLivedIntangibleAssetUsefulLife

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_FiniteLivedIntangibleAssetsLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Remaining amortization period of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.
+ References
No definition available.
+ Details

Name: us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 50
-Paragraph 2
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=108376223&loc=d3e13854-109267

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=108376223&loc=d3e13816-109267

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=99380562&loc=d3e13777-109266
+ Details

Name: us-gaap_GoodwillImpairmentLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of an intangible asset (excluding goodwill) to fair value.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 3
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275
+ Details

Name: us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of a finite-lived intangible asset to fair value.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 3
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275
+ Details

Name: us-gaap_ImpairmentOfIntangibleAssetsFinitelived

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of impairment loss resulting from write-down of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit to fair value.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 3
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585
+ Details

Name: us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_StatementBusinessSegmentsAxis=lly_AnimalHealthProductsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_RangeAxis=srt_MinimumMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_RangeAxis=srt_MaximumMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 120 R70.htm IDEA: XBRL DOCUMENT v3.19.3

Financial Instruments (Summary of AFS Unrealized Gain(Loss)) (Details) - USD ($)
$ in Millions

Dec. 31, 2018

Dec. 31, 2017

Derivative Instruments and Hedging Activities Disclosure [Abstract]

Unrealized gross gains $ 0.8 $ 184.7

Unrealized gross losses 29.0 47.5

Fair value of securities in an unrealized gain position 84.3 1,434.2

Fair value of securities in an unrealized loss position $ 858.6 $ 4,692.8

X

- Definition
Debt Securities, Available-for-sale, Unrealized Gain Position
+ References
No definition available.
+ Details

Name: lly_DebtSecuritiesAvailableforsaleUnrealizedGainPosition

Namespace Prefix: lly_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=118939692&loc=d3e27161-111563
+ Details

Name: us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=118939692&loc=d3e27161-111563
+ Details

Name: us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position without allowance for credit loss.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-SubTopic 10
-Section 50
-Paragraph 6
-Subparagraph (a)(1)
-URI http://asc.fasb.org/extlink&oid=118939692&loc=d3e27290-111563

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 326
-SubTopic 30
-Section 50
-Paragraph 4
-Subparagraph (a)(1)
-URI http://asc.fasb.org/extlink&oid=118955579&loc=SL82922888-210455

Reference 3: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 326
-SubTopic 30
-Section 55
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=118942371&loc=SL82922954-210456
+ Details

Name: us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 121 R80.htm IDEA: XBRL DOCUMENT v3.19.3

Stock-Based Compensation (Details) - USD ($)
$ / shares in Units, shares in Millions, $ in Millions
12 Months Ended

Dec. 31, 2018

Dec. 31, 2017

Dec. 31, 2016

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Stock-based compensation expense $ 253.5 $ 256.3 $ 234.9

Tax benefit $ 53.2 $ 64.1 $ 82.2

Number of shares available for grant (in shares) 53.3

Performance Shares

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Award vesting period (in years) 2 years

Weighted average grant date fair value (in usd per share) $ 71.63 $ 73.54 $ 72.00

Shares issued in period (in shares) 0.9 1.3 0.5

Shares expected to be issued (in shares) 1.2

Total compensation cost not yet recognized $ 57.9

Period for recognition of the compensation cost not yet recognized (in months) 12 months

Shareholder Value Awards

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Award vesting period (in years) 3 years

Weighted average grant date fair value (in usd per share) $ 48.51 $ 66.25 $ 48.68

Shares issued in period (in shares) 0.7 1.1 1.0

Shares expected to be issued (in shares) 1.0

Total compensation cost not yet recognized $ 52.2

Period for recognition of the compensation cost not yet recognized (in months) 20 months

Expected dividend yield (in percentage) 2.50% 2.50% 2.00%

Risk-free interest rate (in percentage) 2.31% 1.38% 0.92%

Volatility (in percentage) 22.26% 22.91% 21.68%

Restricted Stock Units (RSUs)

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Award vesting period (in years) 3 years

Weighted average grant date fair value (in usd per share) $ 70.95 $ 72.47 $ 71.46

Shares issued in period (in shares) 1.0 0.9 0.6

Shares expected to be issued (in shares) 0.8

Total compensation cost not yet recognized $ 99.7

Period for recognition of the compensation cost not yet recognized (in months) 21 months

Grants in period (in shares) 1.3 1.4 1.3

X

- Definition
The number of shares expected to be issued in the next twelve months under the plan.
+ References
No definition available.
+ Details

Name: lly_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpectedSharesToBeIssued

Namespace Prefix: lly_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5047-113901

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 14.F)
-URI http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (h)(1)(i)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_AllocatedShareBasedCompensationExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of cost not yet recognized for nonvested award under share-based payment arrangement.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (i)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (i)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of tax benefit for recognition of expense of award under share-based payment arrangement.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (h)(1)(i)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (a)(1)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(iii)(1)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(iii)(1)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(iii)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(ii)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
The risk-free interest rate assumption that is used in valuing an option on its own shares.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(iv)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Number of shares issued under share-based payment arrangement.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_AwardTypeAxis=lly_ShareholderValueAwardsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

Goodwill and Other Intangibles (Policies)	12 Months Ended
Goodwill and Other Intangibles (Policies)	Dec. 31, 2018
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill and Intangible Assets	For transactions other than a business combination, we capitalize milestone payments incurred at or after the product has obtained regulatory approval for marketing. Goodwill results from excess consideration in a business combination over the fair value of identifiable net assets acquired. Goodwill is not amortized but is reviewed for impairment at least annually and when impairment indicators are present. When required, a comparison of the fair value of the reporting unit to its carrying amount including goodwill is used to determine the amount of any impairment. The costs of acquired IPR&D projects acquired directly in a transaction other than a business combination are capitalized if the projects have an alternative future use; otherwise, they are expensed immediately. The fair values of acquired IPR&D projects acquired in business combinations, if any, are capitalized as other intangible assets. As of December 31, 2018 and 2017, we had no acquired IPR&D indefinite-lived intangible assets. Several methods may be used to determine the estimated fair value of other intangibles acquired in a business combination. We utilize the “income method,” which is a Level 3 fair value measurement and applies a probability weighting that considers the risk of development and commercialization to the estimated future net cash flows that are derived from projected revenues and estimated costs. These projections are based on factors such as relevant market size, patent protection, historical pricing of similar products, and expected industry trends. The estimated future net cash flows are then discounted to the present value using an appropriate discount rate. This analysis is performed for each asset independently. The acquired IPR&D assets are treated as indefinite-lived intangible assets until completion or abandonment of the projects, at which time the assets are tested for impairment and amortized over the remaining useful life or written off, as appropriate. Other indefinite-lived intangible assets are reviewed for impairment at least annually and when impairment indicators are present. Finite-lived intangible assets are reviewed for impairment when an indicator of impairment is present. When required, a comparison of fair value to the carrying amount of assets is performed to determine the amount of any impairment. When determining the fair value of indefinite-lived acquired IPR&D as well as the fair value of finite-lived intangible assets for impairment testing purposes, we utilize the "income method" discussed above.

Discontinued Operations (Major Classes of Assets and Liabilities) (Details) - USD ($) $ in Millions	Dec. 31, 2018	Dec. 31, 2017
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Current assets of discontinued operations	$ 2,229.1	$ 2,110.0
Noncurrent assets of discontinued operations	6,484.1	6,668.7
Current liabilities of discontinued operations	692.8	637.5
Noncurrent liabilities of discontinued operations	2,742.3	351.6
Elanco Animal Health Incorporated \| Discontinued Operations, Disposed of by Sale
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Inventories	1,013.7	1,062.3
Other current assets	1,215.4	1,047.7
Current assets of discontinued operations	2,229.1	2,110.0
Goodwill	2,980.9	2,992.1
Other intangibles, net	2,453.0	2,674.8
Property and equipment, net	923.4	941.4
Other assets	126.8	60.4
Noncurrent assets of discontinued operations	6,484.1	6,668.7
Current liabilities of discontinued operations	692.8	637.5
Long-term debt	2,443.3	0.5
Other liabilities	299.0	351.1
Noncurrent liabilities of discontinued operations	$ 2,742.3	$ 351.6

Contingencies (Policies)	12 Months Ended
Contingencies (Policies)	Dec. 31, 2018
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Litigation accruals, environmental liabilities, and the related estimated insurance recoverables are reflected on a gross basis as liabilities and assets, respectively, on our consolidated balance sheets. With respect to the product liability claims currently asserted against us, we have accrued for our estimated exposures to the extent they are both probable and reasonably estimable based on the information available to us. We accrue for certain product liability claims incurred but not filed to the extent we can formulate a reasonable estimate of their costs. We estimate these expenses based primarily on historical claims experience and data regarding product usage. Legal defense costs expected to be incurred in connection with significant product liability loss contingencies are accrued when both probable and reasonably estimable.

Property and Equipment (Details) - USD ($) $ in Millions	12 Months Ended
Property and Equipment (Details) - USD ($) $ in Millions	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Property, Plant and Equipment [Abstract]
Land	$ 165.5	$ 167.7
Buildings	7,116.6	6,826.9
Equipment	7,792.3	7,684.1
Construction in progress	1,588.6	1,600.6
Property and equipment, gross	16,663.0	16,279.3
Less accumulated depreciation	(8,666.9)	(8,394.2)
Property and equipment, net	7,996.1	7,885.1
Depreciation expense	797.1	681.7	$ 638.8
Rental expense	175.7	$ 177.4	$ 179.2
Property, Plant and Equipment [Line Items]
2019	130.6
2020	107.9
2021	75.5
2022	64.7
2023	49.9
After 2023	$ 281.0
Building \| Minimum
Property, Plant and Equipment [Line Items]
Estimated useful life (in years)	12 years
Building \| Maximum
Property, Plant and Equipment [Line Items]
Estimated useful life (in years)	50 years
Equipment \| Minimum
Property, Plant and Equipment [Line Items]
Estimated useful life (in years)	3 years
Equipment \| Maximum
Property, Plant and Equipment [Line Items]
Estimated useful life (in years)	25 years

Financial Instruments (Narrative) (Details) € in Millions, ¥ in Millions, £ in Millions, SFr in Millions, $ in Millions	12 Months Ended
	Dec. 31, 2018 USD ($)	Dec. 31, 2017 USD ($)	Dec. 31, 2016 USD ($)	Dec. 31, 2018 EUR (€)	Dec. 31, 2018 CHF (SFr)	Dec. 31, 2018 GBP (£)	Dec. 31, 2018 USD ($)	Dec. 31, 2018 JPY (¥)
Derivative [Line Items]
Average remaining maturity of foreign currency derivatives	12 months
Maximum remaining maturity of foreign currency derivatives (in days)	30 days
Foreign currency-denominated notes, designated as hedge		$ 3,700.0					$ 2,650.0
Variable rate (in percentage)				25.00%	25.00%	25.00%	25.00%	25.00%
Losses expected to be reclassified in the next 12 months							$ 15.0
Change on the fair value of contingent consideration	$ 199.7	203.1
Unrealized losses from equity securities	20.1
Other-than-temporary impairment losses recognized during the year	$ 0.0	0.0	$ 53.0
Percentage of nonperforming assets (in percentage)	55.00%
Amount derecognized		723.2					696.2
Buy USD Sell Euro
Derivative [Line Items]
Derivative liability, notional amount							785.5
Derivative asset, notional amount \| €				€ 685.3
Buy euro Sell US dollar
Derivative [Line Items]
Derivative liability, notional amount \| €				€ 2,050.0
Derivative asset, notional amount							2,350.0
Buy USD Sell Japanese Yen
Derivative [Line Items]
Derivative liability, notional amount							435.1
Derivative asset, notional amount \| ¥								¥ 48,850
Buy Swiss francs Sell US dollar
Derivative [Line Items]
Derivative liability, notional amount \| SFr					SFr 255.6
Derivative asset, notional amount							259.7
Buy US dollar Sell British pound
Derivative [Line Items]
Derivative liability, notional amount							388.3
Derivative asset, notional amount \| £						£ 306.7
Buy GBP Sell USD
Derivative [Line Items]
Derivative liability, notional amount \| £						£ 354.0
Derivative asset, notional amount							448.1
Currency Swap
Derivative [Line Items]
Derivative liability, notional amount							2,460.0
Swap Swiss Francs to U.S. Dollars
Derivative [Line Items]
Derivative liability, notional amount							754.0
Interest rate swap
Derivative [Line Items]
Derivative asset, notional amount							350.0
Foreign Currency Denominated Debt
Derivative [Line Items]
Long-term debt		$ 3,700.0					$ 3,400.0

Income Taxes (Narrative) (Details) - USD ($) $ in Millions	12 Months Ended
Income Taxes (Narrative) (Details) - USD ($) $ in Millions	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2010
Operating Loss Carryforwards [Line Items]
2017 Tax Act provision		$ 1,914.0	$ 0.0
2017 Tax Act benefit	$ 313.3
2017 Tax Act, deferred taxes related to GILTI	$ 1,740.0
Domestic and Puerto Rican companies contribution	15.00%	16.00%	63.00%
Unrecognized tax benefits that would impact effective tax rate	$ 1,480.0	$ 657.1
Year under examination				2015	2014	2013	2012	2010
Settlements	33.2	2.4	$ 171.9
Cash payments of income taxes	1,076.7	221.5	686.4
Decrease in unrecognized tax benefits is reasonably possible	450.0
Income tax payment, anticipated	150.0
Income tax expense (benefit)	25.1	22.8	(63.8)
Accruals for the payment of interest and penalties	183.9	$ 155.0
Carryforward
Operating Loss Carryforwards [Line Items]
Tax credit carryforward	729.5
Operating loss carryforwards	773.2
Expiration in 9 Years
Operating Loss Carryforwards [Line Items]
Tax credit carryforward	150.5
Designated Unusable \| Internal Revenue Service (IRS)
Operating Loss Carryforwards [Line Items]
Tax credit carryforward	122.9
Designated Unusable \| Foreign Tax Authority
Operating Loss Carryforwards [Line Items]
Tax credit carryforward	119.3
Designated Unusable \| State and Local Jurisdiction
Operating Loss Carryforwards [Line Items]
Tax credit carryforward	336.9
Deferred tax assets related to state net operating losses	99.7
Other state carryforwards	2.6
Expiration within 5 years
Operating Loss Carryforwards [Line Items]
Operating loss carryforwards	12.1
Expiration 5 to 20 Years
Operating Loss Carryforwards [Line Items]
Operating loss carryforwards	462.2
No Expiration
Operating Loss Carryforwards [Line Items]
Operating loss carryforwards	$ 298.9
Tax Years 2010-2012
Operating Loss Carryforwards [Line Items]
Settlements				$ 320.0
Cash payments of income taxes			150.0
Maximum
Operating Loss Carryforwards [Line Items]
Decrease in unrecognized tax benefits is reasonably possible			$ 140.0

Summary of Significant Accounting Policies (Contract Liabilities) (Details) - USD ($) $ in Millions	Dec. 31, 2018	Dec. 31, 2017
Accounting Policies [Abstract]
Contract liabilities	$ 294.9	$ 330.9

Property and Equipment (Policies)	12 Months Ended
Property and Equipment (Policies)	Dec. 31, 2018
Property, Plant and Equipment [Abstract]
Property, Plant and Equipment	Property and equipment is stated on the basis of cost. Provisions for depreciation of buildings and equipment are computed generally by the straight-line method at rates based on their estimated useful lives (12 to 50 years for buildings and three to 25 years for equipment). We review the carrying value of long-lived assets for potential impairment on a periodic basis and whenever events or changes in circumstances indicate the carrying value of an asset may not be recoverable. Impairment is determined by comparing projected undiscounted cash flows to be generated by the asset to its carrying value. If an impairment is identified, a loss is recorded equal to the excess of the asset’s net book value over its fair value, and the cost basis is adjusted.

Consolidated Balance Sheets - USD ($) $ in Millions	Dec. 31, 2018	Dec. 31, 2017
Current Assets
Cash and cash equivalents (Note 7)	$ 7,320.7	$ 6,211.8
Short-term investments (Note 7)	88.2	1,497.9
Accounts receivable, net of allowances of $24.1 (2018) and $28.9 (2017)	4,593.9	3,977.0
Other receivables	1,182.9	689.5
Inventories (Note 6)	3,098.1	3,396.0
Prepaid expenses and other	2,036.7	1,319.9
Current assets of discontinued operations	2,229.1	2,110.0
Total current assets	20,549.6	19,202.1
Other Assets
Investments (Note 7)	2,005.4	5,666.5
Goodwill (Note 8)	1,366.6	1,378.0
Other intangibles, net (Note 8)	1,068.0	1,354.4
Deferred tax assets (Note 13)	2,613.7	1,216.9
Sundry	1,824.9	1,609.3
Property and equipment, net (Note 9)	7,996.1	7,885.1
Noncurrent assets of discontinued operations	6,484.1	6,668.7
Total assets	43,908.4	44,981.0
Current Liabilities
Short-term borrowings and current maturities of long-term debt (Note 10)	1,102.2	3,706.5
Accounts payable	1,207.1	1,206.9
Employee compensation	955.6	911.8
Sales rebates and discounts	4,849.5	4,310.1
Dividends payable	650.8	590.6
Income taxes payable (Note 13)	393.4	522.5
Other current liabilities	2,036.7	2,650.0
Current liabilities of discontinued operations	692.8	637.5
Total current liabilities	11,888.1	14,535.9
Other Liabilities
Long-term debt (Note 10)	9,196.4	9,940.0
Accrued retirement benefits (Note 14)	2,802.2	3,376.0
Long-term income taxes payable (Note 13)	3,700.0	3,747.0
Other noncurrent liabilities	2,670.3	1,362.6
Noncurrent liabilities of discontinued operations	2,742.3	351.6
Total other liabilities	21,111.2	18,777.2
Commitments and Contingencies (Note 15)
Eli Lilly and Company Shareholders' Equity (Notes 11 and 12)
Common stock—no par value Authorized shares: 3,200,000 Issued shares: 1,057,639 (2018) and 1,100,672 (2017)	661.0	687.9
Additional paid-in capital	6,583.6	5,817.8
Retained earnings	11,395.9	13,894.1
Employee benefit trust	(3,013.2)	(3,013.2)
Accumulated other comprehensive loss (Note 16)	(5,729.2)	(5,718.6)
Cost of common stock in treasury	(69.4)	(75.8)
Total Eli Lilly and Company shareholders' equity	9,828.7	11,592.2
Noncontrolling interests	1,080.4	75.7
Total equity	10,909.1	11,667.9
Total liabilities and equity	$ 43,908.4	$ 44,981.0

Cover Page	Oct. 24, 2019
Entity Information [Line Items]
Document Type	8-K
Document Period End Date	Oct. 24, 2019
Entity Registrant Name	Lilly Eli & Co
Entity Incorporation, State or Country Code	IN
Entity File Number	001-06351
Entity Tax Identification Number	35-0470950
Entity Address, Address Line One	Lilly Corporate Center
Entity Address, City or Town	Indianapolis
Entity Address, State or Province	IN
Entity Address, Postal Zip Code	46285
City Area Code	317
Local Phone Number	276-2000
Written Communications	false
Soliciting Material	false
Pre-commencement Tender Offer	false
Pre-commencement Issuer Tender Offer	false
Entity Emerging Growth Company	false
Entity Central Index Key	0000059478
Amendment Flag	false
Document Fiscal Period Focus	FY
Document Fiscal Year Focus	2018
Common Stock (no par value)
Entity Information [Line Items]
Title of 12(b) Security	Common Stock (no par value)
Trading Symbol	LLY
Security Exchange Name	NYSE
1.000% Notes Due June 2, 2022
Entity Information [Line Items]
Title of 12(b) Security	1.000% Notes Due June 2, 2022
Trading Symbol	LLY22
Security Exchange Name	NYSE
7 1/8% Notes Due June 1, 2025
Entity Information [Line Items]
Title of 12(b) Security	7 1/8% Notes Due June 1, 2025
Trading Symbol	LLY25
Security Exchange Name	NYSE
1.625% Notes Due June 2, 2026
Entity Information [Line Items]
Title of 12(b) Security	1.625% Notes Due June 2, 2026
Trading Symbol	LLY26
Security Exchange Name	NYSE
2.125% Notes Due June 3, 2030
Entity Information [Line Items]
Title of 12(b) Security	2.125% Notes Due June 3, 2030
Trading Symbol	LLY30
Security Exchange Name	NYSE
6.77% Notes Due January 1, 2036
Entity Information [Line Items]
Title of 12(b) Security	6.77% Notes Due January 1, 2036
Trading Symbol	LLY36
Security Exchange Name	NYSE

Borrowings (Long-term Debt) (Details) - USD ($) $ in Millions	Dec. 31, 2018	Dec. 31, 2017
Debt Disclosure [Abstract]
Short-term commercial paper borrowings	$ 498.9	$ 2,696.8
0.15 to 7.13 percent long-term notes (due 2019-2047)	9,640.8	10,756.7
Other long-term debt	10.1	13.0
Unamortized debt issuance costs	(28.4)	(49.0)
Fair value adjustment on hedged long-term notes	177.2	229.0
Total debt	10,298.6	13,646.5
Less current portion	(1,102.2)	(3,706.5)
Long-term debt	$ 9,196.4	$ 9,940.0

Label	Element	Value
Retained Earnings [Member]
Cumulative Effect of New Accounting Principle in Period of Adoption	us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption	$ 643,600,000
Cumulative Effect of New Accounting Principle in Period of Adoption	us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption	$ 763,800,000

Retirement Benefits (Narrative) (Details) - USD ($) $ in Millions	1 Months Ended	12 Months Ended
	Jul. 31, 2018	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Defined Benefit Plan Disclosure [Line Items]
Curtailment (gain) loss	$ (28.0)
Defined benefit obligation, increase (decrease)		$ (1,590.0)	$ 2,830.0
Curtailment (gain) loss			159.0
Special termination benefit			354.7
Total accumulated benefit obligation for our defined benefit pension plans		12,570.0	13,670.0
Expense under the plans		$ 132.6	147.0	$ 155.4
Percentage of global investments in plan assets (in percentage)		80.00%
Expected contribution		$ 45.0
Marketable equity securities
Defined Benefit Plan Disclosure [Line Items]
Plan assets, target allocation (in percentage)		70.00%
Developed markets
Defined Benefit Plan Disclosure [Line Items]
Plan assets, target allocation (in percentage)		30.00%
Discontinued Operations
Defined Benefit Plan Disclosure [Line Items]
Special termination benefit			67.0
Restructuring, Settlement and Impairment Provisions
Defined Benefit Plan Disclosure [Line Items]
Special termination benefit			$ 446.7

Collaborations and Other Arrangements (Details) - USD ($) $ in Millions		1 Months Ended	3 Months Ended								12 Months Ended			36 Months Ended
	Oct. 01, 2015	Dec. 31, 2009	Dec. 31, 2018	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018	Dec. 31, 2017	Sep. 30, 2017	Jun. 30, 2017	Mar. 31, 2017	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2018
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Revenue			$ 5,637.6	$ 5,306.9	$ 5,585.0	$ 4,963.8	$ 5,406.4	$ 4,961.0	$ 5,091.6	$ 4,514.9	$ 21,493.3	$ 19,973.8	$ 18,312.8
Research and development											5,051.2	5,096.2	5,040.0
Europe
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Revenue											3,663.1	3,390.6	3,214.4
JAPAN
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Revenue											2,407.4	2,339.5	2,253.0
United States
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Revenue											12,391.9	11,414.4	10,147.0
Trajenta
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Revenue											574.7	537.9	436.6
Trajenta \| United States \| Human pharmaceutical products
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Revenue											224.2	213.2	165.9
Trajenta \| Milestone Payments, Development and Regulatory, Capitalized, Cumulative [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Collaborative arrangement, rights and obligations, terms											446.4
Jardiance
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Revenue											658.3	447.5	201.9
Jardiance \| United States \| Human pharmaceutical products
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Revenue											400.2	290.4	144.5
Jardiance \| Milestone Payments, Development and Regulatory, Capitalized, Cumulative [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Collaborative arrangement, rights and obligations, terms											289.0
Basaglar
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Revenue											801.2	432.1	86.1
Basaglar \| United States \| Human pharmaceutical products
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Revenue											622.8	311.1	15.8
Basaglar \| Milestone Payments, Development and Regulatory, Capitalized, Cumulative [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Collaborative arrangement, rights and obligations, terms														$ (250.0)
Basaglar \| Milestone Payments, Development and Regulatory, Capitalized
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Collaborative arrangement, rights and obligations, terms											0.0	0.0	(187.5)
Erbitux
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Revenue											635.3	645.9	687.0
Erbitux \| United States \| Human pharmaceutical products
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Revenue											531.6	541.7	581.1
Erbitux \| Sales Reported
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Collaborative arrangement, rights and obligations percent (in percentage)	38.00%
Erbitux, Product
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Revenue											536.1	548.2	587.0
Erbitux, Collaboration and Other Revenue
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Revenue											99.2	97.7	100.0
Effient \| Human pharmaceutical products
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Revenue											122.2	388.9	535.2
Effient \| United States \| Human pharmaceutical products
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Revenue											$ 68.1	340.1	465.6
Effient \| Profit And Development And Marketing Share
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Collaborative arrangement, rights and obligations percent (in percentage)											50.00%
Olumiant \| Research And Development Exp
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Collaborative arrangement, rights and obligations percent (in percentage)		30.00%
Olumiant \| Milestone Payments, Development and Regulatory, Expensed
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Research and development											$ 20.0	30.0
Olumiant \| Milestone Payments, Development and Regulatory, Expensed \| United States and Europe [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Research and development													$ 55.0
Olumiant \| Milestone Payments, Development and Regulatory, Capitalized (Deferred) \| Europe
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Collaborative arrangement, rights and obligations, terms												65.0
Olumiant \| Milestone Payments, Development and Regulatory, Capitalized (Deferred) \| JAPAN
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Collaborative arrangement, rights and obligations, terms												$ 15.0
Olumiant \| Milestone Payments, Development and Regulatory, Capitalized (Deferred) \| United States
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Collaborative arrangement, rights and obligations, terms											100.0
Olumiant \| Milestone Payments, Development and Regulatory
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Collaborative arrangement, rights and obligations, terms											130.0
Olumiant \| Royalty Payments Received
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Collaborative arrangement, rights and obligations percent (in percentage)		20.00%
Olumiant \| Milestone Payments, Sales-based
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Collaborative arrangement, rights and obligations, terms											150.0
Tanezumab \| Milestone Payments, Development and Regulatory
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Collaborative arrangement, rights and obligations, terms											350.0
Tanezumab \| Milestone Payments, Sales-based
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Collaborative arrangement, rights and obligations, terms											$ 1,230.0

Consolidated Statements of Cash Flows Consolidated Statements of Cash Flows (Parenthetical) - USD ($) $ in Millions	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Statement of Cash Flows [Abstract]
Discontinued operations cash	$ 677.5	$ 324.4	$ 258.8	$ 460.6

Income Taxes (Policies)	12 Months Ended
Income Taxes (Policies)	Dec. 31, 2018
Income Tax Disclosure [Abstract]
Income Tax	Deferred taxes are recognized for the future tax effects of temporary differences between financial and income tax reporting based on enacted tax laws and rates. We recognize the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by the taxing authorities, based on the technical merits of the position. The tax benefits recognized in the financial statements from such a position are measured based on the largest benefit that has a greater than 50 percent likelihood of being realized upon ultimate resolution.

Consolidated Statements of Shareholders' Equity Statement - USD ($) shares in Thousands, $ in Millions	Total	Common Stock	Additional Paid-in Capital	Retained Earnings	Employee Benefit Trust	Accumulated Other Comprehensive Loss	Common Stock in Treasury	Noncontrolling Interest
Beginning balance at Dec. 31, 2015		$ 691.3	$ 5,552.1	$ 16,011.8	$ (3,013.2)	$ (4,580.7)	$ (90.0)	$ 19.0
Beginning balance (in shares) at Dec. 31, 2015		1,106,063					796
Increase (Decrease) in Shareholders' Equity [Roll Forward]
Net income (loss)				2,737.6				16.3
Other comprehensive income (loss), net of tax	$ (693.3)					(693.3)		48.2
Cash dividends declared				(2,167.6)
Retirement of treasury shares, shares		(7,306)					(7,306)
Retirement of treasury shares		$ (4.6)		(535.5)			$ 540.1
Purchase of treasury shares, shares							7,306
Purchase of treasury shares	(540.1)		(60.0)				$ (540.1)
Issuance of stock under employee stock plans, net, shares		2,829					(85)
Issuance of stock under employee stock plans, net		$ 1.8	(106.8)				$ 9.5
Stock-based compensation			255.3
Other	(10.7)
Ending balance (in shares) at Dec. 31, 2016		1,101,586					711
Ending balance at Dec. 31, 2016		$ 688.5	5,640.6	16,046.3	(3,013.2)	(5,274.0)	$ (80.5)	72.8
Increase (Decrease) in Shareholders' Equity [Roll Forward]
Net income (loss)				(204.1)				30.5
Other comprehensive income (loss), net of tax	199.0					199.0		(24.5)
Cash dividends declared				(2,234.6)
Retirement of treasury shares, shares		(4,390)					(4,390)
Retirement of treasury shares		$ (2.7)		(357.1)			$ 359.8
Purchase of treasury shares, shares							4,390
Purchase of treasury shares	(359.8)		60.0				$ (359.8)
Issuance of stock under employee stock plans, net, shares		3,476					(47)
Issuance of stock under employee stock plans, net		$ 2.1	(164.1)				$ 4.7
Stock-based compensation			281.3
Other	(3.1)
Ending balance (in shares) at Dec. 31, 2017		1,100,672					664
Ending balance at Dec. 31, 2017	11,667.9	$ 687.9	5,817.8	13,894.1	(3,013.2)	(5,718.6)	$ (75.8)	75.7
Increase (Decrease) in Shareholders' Equity [Roll Forward]
Net income (loss)				3,232.0				3.7
Other comprehensive income (loss), net of tax	72.6					85.6		(2.0)
Cash dividends declared				(2,372.0)
Retirement of treasury shares, shares		(45,882)					(45,882)
Retirement of treasury shares		$ (28.7)		(4,122.0)			$ 4,150.7
Purchase of treasury shares, shares							45,882
Purchase of treasury shares	(4,150.0)						$ (4,150.7)
Issuance of stock under employee stock plans, net, shares		2,849					(60)
Issuance of stock under employee stock plans, net		$ 1.8	(139.0)				$ 6.4
Stock-based compensation			279.5
Sale of Elanco Stock (Note 20)			629.2			9.0		1,017.2
Other				(3.9)				(14.2)
Ending balance (in shares) at Dec. 31, 2018		1,057,639					604
Ending balance at Dec. 31, 2018	$ 10,909.1	$ 661.0	$ 6,583.6	$ 11,395.9	$ (3,013.2)	(5,729.2)	$ (69.4)	$ 1,080.4
Increase (Decrease) in Shareholders' Equity [Roll Forward]
Reclassification of stranded tax effects and Adoption of new accounting standards (Note 2)						$ (105.2)

Goodwill and Other Intangibles (Amortization Expense) (Details) $ in Millions	Dec. 31, 2018 USD ($)
Goodwill and Intangible Assets Disclosure [Abstract]
2019	$ 145.4
2020	144.0
2021	141.6
2022	133.8
2023	$ 122.6

Shareholders' Equity (Details) - USD ($) $ in Millions	12 Months Ended
Shareholders' Equity (Details) - USD ($) $ in Millions	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016	Oct. 31, 2013
Statement [Line Items]
Purchase for treasury	$ 4,150.0	$ 359.8	$ 540.1
Purchases of common stock			$ 60.0
Preferred stock, shares authorized (in shares)	5,000,000.0
Shares issued (in shares)	0	0
Shares held in employee trust (in shares)	50,000,000.0	50,000,000
Employee benefit trust	$ 3,013.2	$ 3,013.2
2013 Share Repurchase Program
Statement [Line Items]
Purchase for treasury	2,050.0
Stock repurchase program, authorized amount				$ 5,000.0
2018 Repurchase Program
Statement [Line Items]
Purchase for treasury	2,100.0
Stock repurchase program, authorized amount	8,000.0
Remaining authorized repurchase amount	$ 5,900.0

Borrowings (Debt maturities) (Details) $ in Millions	Dec. 31, 2018 USD ($)
Debt Disclosure [Abstract]
2019	$ 604.5
2020	3.5
2021	2.3
2022	1,439.0
2023	$ 0.3

Segment Information (Details) $ in Millions	3 Months Ended								12 Months Ended
Segment Information (Details) $ in Millions	Dec. 31, 2018 USD ($)	Sep. 30, 2018 USD ($)	Jun. 30, 2018 USD ($)	Mar. 31, 2018 USD ($)	Dec. 31, 2017 USD ($)	Sep. 30, 2017 USD ($)	Jun. 30, 2017 USD ($)	Mar. 31, 2017 USD ($)	Dec. 31, 2018 USD ($) wholesaler segment	Dec. 31, 2017 USD ($)	Dec. 31, 2016 USD ($)	Mar. 11, 2019
Segment Reporting Information [Line Items]
Number of operating segments \| segment									1
Number of wholesalers \| wholesaler									3
Revenue	$ 5,637.6	$ 5,306.9	$ 5,585.0	$ 4,963.8	$ 5,406.4	$ 4,961.0	$ 5,091.6	$ 4,514.9	$ 21,493.3	$ 19,973.8	$ 18,312.8
Long-lived assets	8,546.2				8,481.0				8,546.2	8,481.0	8,167.0
United States
Segment Reporting Information [Line Items]
Revenue									12,391.9	11,414.4	10,147.0
Long-lived assets	4,344.0				4,408.7				4,344.0	4,408.7	4,520.8
Outside U.S.
Segment Reporting Information [Line Items]
Revenue									9,101.4	8,559.4	8,165.8
Europe
Segment Reporting Information [Line Items]
Revenue									3,663.1	3,390.6	3,214.4
Long-lived assets	2,413.5				2,246.4				2,413.5	2,246.4	1,864.8
JAPAN
Segment Reporting Information [Line Items]
Revenue									2,407.4	2,339.5	2,253.0
Long-lived assets	180.2				153.4				180.2	153.4	91.0
Other foreign countries
Segment Reporting Information [Line Items]
Revenue									3,030.9	2,829.3	2,698.3
Long-lived assets	$ 1,608.5				$ 1,672.5				1,608.5	1,672.5	1,690.4
Endocrinology \| Human pharmaceutical products \| United States
Segment Reporting Information [Line Items]
Revenue									7,511.6	6,373.0	4,831.9
Endocrinology \| Human pharmaceutical products \| Outside U.S.
Segment Reporting Information [Line Items]
Revenue									4,190.5	3,712.2	3,250.9
Trulicity \| Human pharmaceutical products \| United States
Segment Reporting Information [Line Items]
Revenue									2,515.8	1,609.8	737.6
Trulicity \| Human pharmaceutical products \| Outside U.S.
Segment Reporting Information [Line Items]
Revenue									683.3	419.9	187.9
Humalog \| Human pharmaceutical products \| United States
Segment Reporting Information [Line Items]
Revenue									1,787.8	1,717.8	1,685.2
Humalog \| Human pharmaceutical products \| Outside U.S.
Segment Reporting Information [Line Items]
Revenue									1,208.7	1,147.4	1,083.6
Humulin \| Human pharmaceutical products \| United States
Segment Reporting Information [Line Items]
Revenue									910.2	884.6	861.8
Humulin \| Human pharmaceutical products \| Outside U.S.
Segment Reporting Information [Line Items]
Revenue									421.2	450.7	504.1
Forteo \| Human pharmaceutical products \| United States
Segment Reporting Information [Line Items]
Revenue									757.9	965.2	770.5
Forteo \| Human pharmaceutical products \| Outside U.S.
Segment Reporting Information [Line Items]
Revenue									817.7	783.8	729.4
Basaglar
Segment Reporting Information [Line Items]
Revenue									801.2	432.1	86.1
Basaglar \| Human pharmaceutical products \| United States
Segment Reporting Information [Line Items]
Revenue									622.8	311.1	15.8
Basaglar \| Human pharmaceutical products \| Outside U.S.
Segment Reporting Information [Line Items]
Revenue									178.5	121.0	70.3
Jardiance
Segment Reporting Information [Line Items]
Revenue									658.3	447.5	201.9
Jardiance \| Human pharmaceutical products \| United States
Segment Reporting Information [Line Items]
Revenue									400.2	290.4	144.5
Jardiance \| Human pharmaceutical products \| Outside U.S.
Segment Reporting Information [Line Items]
Revenue									258.1	157.0	57.4
Trajenta
Segment Reporting Information [Line Items]
Revenue									574.7	537.9	436.6
Trajenta \| Human pharmaceutical products \| United States
Segment Reporting Information [Line Items]
Revenue									224.2	213.2	165.9
Trajenta \| Human pharmaceutical products \| Outside U.S.
Segment Reporting Information [Line Items]
Revenue									350.5	324.7	270.7
Other Endocrinology \| Human pharmaceutical products \| United States
Segment Reporting Information [Line Items]
Revenue									292.7	380.9	450.6
Other Endocrinology \| Human pharmaceutical products \| Outside U.S.
Segment Reporting Information [Line Items]
Revenue									272.5	307.7	347.5
Oncology: \| Human pharmaceutical products \| United States
Segment Reporting Information [Line Items]
Revenue									2,403.2	2,050.4	1,975.1
Oncology: \| Human pharmaceutical products \| Outside U.S.
Segment Reporting Information [Line Items]
Revenue									1,857.3	1,761.6	1,746.8
Alimta \| Human pharmaceutical products \| United States
Segment Reporting Information [Line Items]
Revenue									1,131.0	1,034.3	1,101.0
Alimta \| Human pharmaceutical products \| Outside U.S.
Segment Reporting Information [Line Items]
Revenue									1,001.9	1,028.2	1,182.3
Erbitux
Segment Reporting Information [Line Items]
Revenue									635.3	645.9	687.0
Erbitux \| Human pharmaceutical products \| United States
Segment Reporting Information [Line Items]
Revenue									531.6	541.7	581.1
Erbitux \| Human pharmaceutical products \| Outside U.S.
Segment Reporting Information [Line Items]
Revenue									103.8	104.2	105.9
Cyramza® \| Human pharmaceutical products \| United States
Segment Reporting Information [Line Items]
Revenue									291.5	278.8	270.1
Cyramza® \| Human pharmaceutical products \| Outside U.S.
Segment Reporting Information [Line Items]
Revenue									529.9	479.6	344.0
Other Oncology \| Human pharmaceutical products \| United States
Segment Reporting Information [Line Items]
Revenue									449.1	195.6	22.9
Other Oncology \| Human pharmaceutical products \| Outside U.S.
Segment Reporting Information [Line Items]
Revenue									221.7	149.6	114.6
Cardiovascular: \| Human pharmaceutical products \| United States
Segment Reporting Information [Line Items]
Revenue									1,355.7	1,722.7	1,991.4
Cardiovascular: \| Human pharmaceutical products \| Outside U.S.
Segment Reporting Information [Line Items]
Revenue									898.6	1,148.5	1,234.0
Cialis \| Human pharmaceutical products \| United States
Segment Reporting Information [Line Items]
Revenue									1,129.2	1,358.6	1,469.5
Cialis \| Human pharmaceutical products \| Outside U.S.
Segment Reporting Information [Line Items]
Revenue									722.7	964.5	1,002.1
Effient \| Human pharmaceutical products
Segment Reporting Information [Line Items]
Revenue									122.2	388.9	535.2
Effient \| Human pharmaceutical products \| United States
Segment Reporting Information [Line Items]
Revenue									68.1	340.1	465.6
Effient \| Human pharmaceutical products \| Outside U.S.
Segment Reporting Information [Line Items]
Revenue									54.1	48.8	69.6
Other Cardiovascular \| Human pharmaceutical products \| United States
Segment Reporting Information [Line Items]
Revenue									158.4	24.0	56.3
Other Cardiovascular \| Human pharmaceutical products \| Outside U.S.
Segment Reporting Information [Line Items]
Revenue									121.8	135.2	162.3
Neuroscience: \| Human pharmaceutical products \| United States
Segment Reporting Information [Line Items]
Revenue									277.4	591.0	989.9
Neuroscience: \| Human pharmaceutical products \| Outside U.S.
Segment Reporting Information [Line Items]
Revenue									1,543.3	1,580.1	1,730.4
Strattera® \| Human pharmaceutical products \| United States
Segment Reporting Information [Line Items]
Revenue									89.7	284.9	534.9
Strattera® \| Human pharmaceutical products \| Outside U.S.
Segment Reporting Information [Line Items]
Revenue									361.1	333.3	319.8
Cymbalta \| Human pharmaceutical products \| United States
Segment Reporting Information [Line Items]
Revenue									54.3	114.9	269.3
Cymbalta \| Human pharmaceutical products \| Outside U.S.
Segment Reporting Information [Line Items]
Revenue									653.7	642.2	661.2
Zyprexa® \| Human pharmaceutical products \| United States
Segment Reporting Information [Line Items]
Revenue									36.2	75.5	69.8
Zyprexa® \| Human pharmaceutical products \| Outside U.S.
Segment Reporting Information [Line Items]
Revenue									435.1	505.7	655.5
Other Neuroscience \| Human pharmaceutical products \| United States
Segment Reporting Information [Line Items]
Revenue									97.2	115.7	115.9
Other Neuroscience \| Human pharmaceutical products \| Outside U.S.
Segment Reporting Information [Line Items]
Revenue									93.4	98.9	93.9
Immunology: \| Human pharmaceutical products \| United States
Segment Reporting Information [Line Items]
Revenue									745.4	486.0	110.8
Immunology: \| Human pharmaceutical products \| Outside U.S.
Segment Reporting Information [Line Items]
Revenue									394.6	119.0	2.3
Taltz \| Human pharmaceutical products \| United States
Segment Reporting Information [Line Items]
Revenue									738.7	486.0	110.8
Taltz \| Human pharmaceutical products \| Outside U.S.
Segment Reporting Information [Line Items]
Revenue									198.7	73.2	2.3
Other Immunology \| Human pharmaceutical products \| United States
Segment Reporting Information [Line Items]
Revenue									6.7	0.0	0.0
Other Immunology \| Human pharmaceutical products \| Outside U.S.
Segment Reporting Information [Line Items]
Revenue									195.9	45.8	0.0
Other \| Human pharmaceutical products \| United States
Segment Reporting Information [Line Items]
Revenue									98.5	191.3	247.9
Other \| Human pharmaceutical products \| Outside U.S.
Segment Reporting Information [Line Items]
Revenue									$ 217.0	$ 238.0	$ 201.3
Minimum \| Sales Revenue, Goods, Net
Segment Reporting Information [Line Items]
Concentration risk, percentage									13.00%	14.00%	13.00%
Minimum \| Accounts Receivable
Segment Reporting Information [Line Items]
Concentration risk, percentage									16.00%	16.00%
Maximum \| Sales Revenue, Goods, Net
Segment Reporting Information [Line Items]
Concentration risk, percentage									21.00%	21.00%	20.00%
Maximum \| Accounts Receivable
Segment Reporting Information [Line Items]
Concentration risk, percentage									25.00%	25.00%
Adjustment to Return Reserve \| Cymbalta \| Human pharmaceutical products
Segment Reporting Information [Line Items]
Revenue											$ 175.0
Elanco Animal Health Incorporated \| Discontinued Operations, Disposed of by Sale
Segment Reporting Information [Line Items]
Noncontrolling interest, ownership percentage by parent												80.20%
Revenue									$ 3,062.4	$ 2,897.5	$ 2,909.3

Financial Instruments (Short-term and Long-term Classification) (Details) - USD ($) $ in Millions	Dec. 31, 2018	Dec. 31, 2017
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Short-term commercial paper borrowings	$ (498.9)	$ (2,696.8)
Carrying Amount
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Long-term debt, including current portion	(9,799.7)	(10,950.3)
Fair Value
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Long-term debt, including current portion	(9,989.4)	(11,529.9)
Quoted Prices in Active Markets for Identical Assets (Level 1) \| Fair Value
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Long-term debt, including current portion	0.0	0.0
Significant Other Observable Inputs (Level 2) \| Fair Value
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Long-term debt, including current portion	(9,989.4)	(11,529.9)
Significant Unobservable Inputs (Level 3) \| Fair Value
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Long-term debt, including current portion	0.0	0.0
Commercial Paper \| Carrying Amount
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Short-term commercial paper borrowings	(498.9)	(2,696.8)
Commercial Paper \| Fair Value
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Short-term commercial paper borrowings	(497.6)	(2,690.6)
Commercial Paper \| Quoted Prices in Active Markets for Identical Assets (Level 1) \| Fair Value
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Short-term commercial paper borrowings	0.0	0.0
Commercial Paper \| Significant Other Observable Inputs (Level 2) \| Fair Value
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Short-term commercial paper borrowings	(497.6)	(2,690.6)
Commercial Paper \| Significant Unobservable Inputs (Level 3) \| Fair Value
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Short-term commercial paper borrowings	$ 0.0	$ 0.0

Shareholders' Equity	12 Months Ended
Shareholders' Equity	Dec. 31, 2018
Stockholders' Equity Note [Abstract]
Shareholders' Equity	Shareholders' Equity During 2018, 2017, and 2016, we repurchased $4.15 billion, $359.8 million and $540.1 million, respectively, of shares associated with our share repurchase programs. A payment of $60.0 million was made in 2016 for shares repurchased in 2017. During 2018, we repurchased $2.05 billion of shares, which completed the $5.00 billion share repurchase program announced in October 2013 and our board authorized an $8.00 billion share repurchase program. There were $2.10 billion repurchased under the $8.00 billion program in 2018. As of December 31, 2018, there were $5.90 billion of shares remaining under the 2018 program. We have 5.0 million authorized shares of preferred stock. As of December 31, 2018 and 2017, no preferred stock was issued. We have an employee benefit trust that held 50.0 million shares of our common stock at both December 31, 2018 and 2017, to provide a source of funds to assist us in meeting our obligations under various employee benefit plans. The cost basis of the shares held in the trust was $3.01 billion at both December 31, 2018 and 2017, and is shown as a reduction of shareholders’ equity. Any dividend transactions between us and the trust are eliminated. Stock held by the trust is not considered outstanding in the computation of EPS. The assets of the trust were not used to fund any of our obligations under these employee benefit plans during the years ended December 31, 2018, 2017, and 2016.

(Narrative) (Details) $ / shares in Units, SFr in Millions, $ in Millions		1 Months Ended													3 Months Ended								12 Months Ended
	Feb. 15, 2019 USD ($) $ / shares	Jan. 31, 2019 CHF (SFr)	Jan. 31, 2019 USD ($)	Dec. 31, 2018 USD ($)	Nov. 30, 2018 USD ($)	Oct. 31, 2018 USD ($)	Jul. 31, 2018 USD ($)	Jun. 30, 2018 USD ($)	Apr. 30, 2018 USD ($)	Nov. 30, 2017 USD ($)	Aug. 31, 2017 USD ($)	Jul. 31, 2017 USD ($)	Mar. 31, 2017 USD ($)	Dec. 31, 2016 USD ($)	Dec. 31, 2018 USD ($)	Sep. 30, 2018 USD ($)	Jun. 30, 2018 USD ($)	Mar. 31, 2018 USD ($)	Dec. 31, 2017 USD ($)	Sep. 30, 2017 USD ($)	Jun. 30, 2017 USD ($)	Mar. 31, 2017 USD ($)	Dec. 31, 2018 USD ($)	Dec. 31, 2017 USD ($)	Dec. 31, 2016 USD ($)
Business Acquisition [Line Items]
Acquired in-process research and development															$ 329.4	$ 30.0	$ 1,624.5	$ 0.0	$ 50.0	$ 205.0	$ 0.0	$ 857.6	$ 1,983.9	$ 1,112.6	$ 30.0
Loxo Oncology, Inc.
Business Acquisition [Line Items]
Share price (usd per share) \| $ / shares	$ 235
Consideration transferred	$ 8,000.0
AC Immune SA
Business Acquisition [Line Items]
Acquired in-process research and development			$ 96.9
Purchased in-process research and development		SFr 80.0	$ 50.0
Sigilon Therapeutics
Business Acquisition [Line Items]
Acquired in-process research and development									$ 66.9
AurKa Pharma, Inc.
Business Acquisition [Line Items]
Acquired in-process research and development								$ 81.8
ARMO
Business Acquisition [Line Items]
Acquired in-process research and development								$ 1,475.8
Anima Biotech
Business Acquisition [Line Items]
Acquired in-process research and development							$ 30.0
SIGA Technologies, Inc.
Business Acquisition [Line Items]
Acquired in-process research and development						$ 80.0
Chugai Pharmaceutical Company
Business Acquisition [Line Items]
Acquired in-process research and development						$ 50.0
NextCure, Inc.
Business Acquisition [Line Items]
Acquired in-process research and development					$ 28.1
Dicerna Pharmaceuticals
Business Acquisition [Line Items]
Acquired in-process research and development				$ 148.7
Hydra Biosciences
Business Acquisition [Line Items]
Acquired in-process research and development				$ 22.6
CoLucid Pharmaceuticals, Inc. (CoLucid)
Business Acquisition [Line Items]
Acquired in-process research and development													$ 857.6
KeyBioscience AG
Business Acquisition [Line Items]
Acquired in-process research and development												$ 55.0
Nektar Therapeutics
Business Acquisition [Line Items]
Acquired in-process research and development											$ 150.0
CureVac AG
Business Acquisition [Line Items]
Acquired in-process research and development										$ 50.0
AstraZeneca
Business Acquisition [Line Items]
Acquired in-process research and development														$ 30.0

Inventories (Details) - USD ($) $ in Millions	Dec. 31, 2018	Dec. 31, 2017
Inventory Disclosure [Abstract]
Finished products	$ 577.8	$ 759.4
Work in process	2,057.8	2,117.7
Raw materials and supplies	426.1	418.4
Total (approximates replacement cost)	3,061.7	3,295.5
Increase (reduction) to LIFO cost	36.4	100.5
Inventories	3,098.1	3,396.0
LIFO Inventory Amount	$ 1,370.0	$ 1,330.0

Financial Instruments (Contractual Maturities) (Details) $ in Millions	Dec. 31, 2018 USD ($)
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Total	$ 943.0
Less Than 1 Year	86.8
1-5 Years	604.8
6-10 Years	97.0
More Than 10 Years	$ 154.4

Stock-Based Compensation (Policies)	12 Months Ended
Stock-Based Compensation (Policies)	Dec. 31, 2018
Share-based Payment Arrangement [Abstract]
Share-based Compensation, Option and Incentive Plans	We recognize the fair value of stock-based compensation as expense over the requisite service period of the individual grantees, which generally equals the vesting period. We provide newly issued shares of our common stock and treasury stock to satisfy the issuance of PA, SVA, and RSU shares.

Consolidated Balance Sheets (Parenthetical) - USD ($) $ in Millions	Dec. 31, 2018	Dec. 31, 2017
Statement of Financial Position [Abstract]
Accounts receivable, allowances	$ 24.1	$ 28.9
Issued shares	1,057,639,000	1,100,672,000
Authorized shares, shares	3,200,000,000	3,200,000,000

Discontinued Operations (Details) - USD ($) $ in Millions			1 Months Ended	3 Months Ended	12 Months Ended
Discontinued Operations (Details) - USD ($) $ in Millions	Mar. 11, 2019	Sep. 24, 2018	Aug. 31, 2018	Mar. 31, 2019	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Noncontrolling interests					$ 1,080.4	$ 75.7
Cash paid for acquisitions, net of cash acquired					0.0	882.1	$ 45.0
Cash provided by operating activities, discontinued operations					500.0	300.0	300.0
Cash used by investing activities, discontinued operations					130.0	$ 960.0	$ 180.0
Elanco Animal Health Incorporated
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Consideration received		$ 4,200.0
Additional paid in capital		$ 629.2
Noncontrolling interests					$ 1,020.0
Elanco Animal Health Incorporated \| Discontinued Operations, Disposed of by Sale
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Noncontrolling interest, ownership percentage by parent	80.20%
Gain on disposition of business				$ 3,700.0
Transitional services agreement, term	24 months
Elanco Animal Health Incorporated
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Percentage of stock sold (in percentage)		19.80%
Proceeds from issuance of debt		$ 2,000.0
Term Facility \| Elanco Animal Health Incorporated
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Debt instrument, face amount			$ 500.0
Debt instrument, term			3 years

Inventories (Policies)	12 Months Ended
Inventories (Policies)	Dec. 31, 2018
Inventory Disclosure [Abstract]
Inventory	We use the last-in, first-out (LIFO) method for the majority of our inventories located in the continental U.S. Other inventories are valued by the first-in, first-out (FIFO) method. FIFO cost approximates current replacement cost.